"1","04-02-17","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2","04-02-12","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM RIVA-AMIODARONE","MODIFICATION DU NOM DU PRODUIT DE RIVA-AMIODARONE","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"3","04-02-06","TRANSKARYOTIC THERAPIES INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE SUBSTITUTION ENZYMATIQUE","",""
"4","04-01-23","GENZYME CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"5","04-01-23","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER","TROUBLE DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ","",""
"6","04-01-19","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION: 70MG/75ML (FOR THE APPROVED INDICATION: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND IN MEN)","NOUVELLE FORMULE : 70MG/75ML (POUR L'INDICATION APPROUVÉE : TRAITEMENT DE L'OSTÉOPOROSE CHEZ LES FEMMES POSTMÉNOPAUSIQUES ET CHEZ LES HOMMES)","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7","04-01-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORETIC","ZENECA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"8","04-01-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORETIC","ZENECA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"9","04-01-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"10","04-03-15","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT, ANTIPARKISONIAN AGENT","ANTIVIRAL, ANTIPARKINSONIEN","",""
"11","04-03-15","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"12","04-03-09","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST, ELEVATED INTRAOCULAR PRESSURE THERAPY","AGONISTE ALPHA2-ADRÉNORÉCEPTEUR RELATIVEMENT SÉLECTIF, THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"13","04-03-02","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"14","04-02-12","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM BACLOFEN","MODIFICATION DU NOM DU PRODUIT DE BACLOFEN","MUSCLE RELAXANT ANTISPASTIC AGENT","RELAXANT MUSCULAIRE - ANTIPASMODIQUE","",""
"15","04-01-29","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DRUG PRODUCT MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","IMMUNOSUPPRESSANT","AGENT IMMUNOSUPPRESSEUR","",""
"16","04-03-10","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BERLEX CANADA INC.","CANADA","CANADA","1","CHANGE IN FORMULATION AND MANUFACTURING PROCESS","CHANGEMENT À LA FORMULATION ET AU PROCÉDÉ DE FABRICATION","ANTIANDROGEN","ANTIANDROGÈNE","",""
"17","04-03-03","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEACHAM INC.","CANADA","CANADA","1","","","Congestive heart failure agent","Agent pour l'insuffisance cardiaque congestive","",""
"18","03-12-17","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"19","04-03-03","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"20","03-12-09","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","ADDITION OF NEW STRENGTH","ADDITION D'UNE NOUVELLE CONCENTRATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"21","03-11-04","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN","SMITHKLINE BEECHAM PHARMACEUTICALS","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIBIOTIC AND B-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE B-LACTAMASES","",""
"22","03-10-24","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH TO INCLUDE THE INDICATION FOR REDUCING RISK OF A FIRST NON-FATAL MYOCARDIAL INFARCTION IN THE INFORMATION FOR THE CONSUMER SECTION","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SECTION RENSEIGNEMENTS AU CONSOMMATEUR, POUR INCLURE L'INDICATION DE RÉDUCTON DU RISQUE D'UN PREMIER INFARCTUS NON MORTEL DU MYOCARDE","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"23","03-10-17","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON-STÉROÏDIEN","",""
"24","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"25","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"26","03-09-29","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1, RECEPTOR AGONIST - MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 - ANTIMIGRAINEUX","",""
"27","03-09-11","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"28","03-09-03","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYCLOCORT 0.1% CREAM","STIEFEL CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","COTICOSTÉROÏDE TOPIQUE","",""
"29","03-08-27","GILEAD SCIENCES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"30","04-03-03","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"31","04-02-26","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"32","04-02-18","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPROBAY","BAYER AG","GERMANY","ALLEMAGNE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"33","04-02-18","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC., HEALTHCARE DIVISION","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"34","04-02-18","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC., HEALTHCARE DIVISION","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"35","04-02-18","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"36","04-02-18","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"37","03-08-25","ORBUS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"38","04-02-18","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"39","04-02-18","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"40","04-02-18","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"41","04-02-18","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC., HEALTHCARE DIVISION","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"42","04-02-18","DR REDDYS LABORATORIES INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"43","04-02-12","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"44","04-02-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"45","04-02-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"46","04-02-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"47","04-01-29","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"48","03-08-13","SANGSTAT MEDICAL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING PROCESS","EXPANSION DU PROCÉDÉ DE FABRICATION","IMMUMOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"49","04-01-28","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE PRODUCT MONOGRAPH RE: FIRST-LINE TREATMENT","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT POUR LE TRAITEMENT DE PREMIÈRE LIGNE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER & ANGIOTENSIN II AT1 RECEPTOR BLOCKER + DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II & ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II + DIURÉTIQUE","",""
"50","04-01-26","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"51","04-01-23","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"52","04-01-23","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"53","04-01-19","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"54","04-01-14","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"55","04-01-12","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"56","03-08-11","CHIRON CANADA ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REGULATORY RELIEF FROM IN-PROCESS AND FINAL PRODUCT RELEASE TESTING AND MODIFICATIONS TO LOT RELEASE PROTOCOL","MODIFICATION DE LA MÉTHODE DE FABRICATION","IMMUNOMODULATOR","AGENT IMMUNOMODULATEUR","",""
"57","04-03-15","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"58","04-03-03","STERIMAX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"59","04-03-15","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HORMONE REPLACEMENT THERAPY","TRAITEMENT HORMONAL SUBSTITUTIF","",""
"61","04-03-09","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: 2MG/PAD, 5.7MG/PAD; NEW INDICATION: FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS, 3.8MG/PAD, 5.7MG/PAD, 7.6MG/PAD","NOUVELLES CONCENTRATIONS : 2MG/PAD, 5.7MG/PAD; NOUVELLE INDICATION : POUR LA PRÉVENTION DE L'OSTÉOPOROSE POSTMÉNOPAUSIQUE, 3.8MG/PAD, 5.7MG/PAD, 7.6MG/PAD","ESTROGEN","OESTROGÈNE","",""
"62","04-03-01","SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN","OESTROGÈNE","",""
"63","04-02-03","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HAIR GROWTH INHIBITOR","INHIBITEUR DE LA POUSSE DES CHEVEUX","",""
"64","04-01-28","VETOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"65","04-01-20","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDRONEL","PROCTER AND GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR, ANTI-PAGETIC AGENT, ANTI-HYPERCALCEMIC AGENT","RÉGULATEUR DU MÉTABOLISME OSSEUX, AGENT ANTIPAGÉTIQUE, AGENT ANTIHYPERCALCÉMIQUE","",""
"66","04-01-08","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: PSORIATIC ARTHRITIS","NOUVELLE INDICATION : POLYARTHRITE PSORIASIQUE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"67","04-03-15","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC, ADJUNCT TO ANESTHESIA","ANALGÉSIQUE NARCOTIQUE, ADJUVANT ANESTHÉSIQUE","",""
"68","03-06-20","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE","BAYER INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVEAU DOSAGE","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION  INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"69","04-03-15","ORGANON SANOFI-SYNTHELABO CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE ACTION AND CLINICAL PHARMACOLOGY SECTION OF THE PRODUCT MONOGRAPH WITH REGARDS TO EXTENDED PROPHYLAXIS OF THROMBOEMBOLIC EVENTS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY","MISE À JOUR À LA RUBRIQUE PHARMACOLOGIE DE LA MONOGRAPHIE DU PRODUIT POUR INCLURE LE TRAITEMENT PROLONGÉ DE TROUBLES THROMBOEMBOLIQUES CHEZ LES PERSONNES SUBISSANT UNE CHIRURGIE POUR FRACTURE DE LA HANCHE","SYNTHETIC ANTITHROMBOTIC","ANTITHROMBOTIQUE SYNTHÉTIQUE","",""
"70","03-07-21","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"71","04-03-10","ORPHAN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ALCOHOL DEHYDROGENASE INHIBITOR","INHIBITEUR SYNTHÉTIQUE DE L'ALCOOL","",""
"72","04-02-27","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"73","04-02-26","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER S.C.A.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"74","04-02-17","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONAGONIST ESTROGEN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES OESTROGÈNES SANS EFFET AGONISTE CONNUS","",""
"75","04-02-12","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"76","03-06-11","INTERMUNE, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"77","04-02-03","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN INJECTION","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"78","04-01-15","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOFRACORT","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANTIBIOTIC, CORTICOSTEROID","ANTIBIOTIQUE, CORTICOSTÉROÏDE","",""
"79","03-05-20","CLONMEL HEALTHCARE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"80","04-01-14","NORBROOK LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","BANAMINE INJECTION","SCHERING CANADA INC.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"81","03-05-12","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"82","03-05-02","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCESS","MODIFICATION DE LA FABRICATION","IMMUNOMODULATORY AGENT","AGENT IMMUNOMODULATEUR","",""
"83","03-08-25","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH TO ALLOW A FLEXIBLE STARTING DOSE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT POUR PERMETTRE UNE DOSE DE DÉPART FLEXIBLE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"84","03-04-25","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CIE., MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"85","03-04-14","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFIBRINOLYTIC AGENT","INHIBITEUR DE LA FIBRINOLYSE","",""
"86","03-04-09","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE","BAYER INC.","CANADA","CANADA","1","NEW INDICATION","NOUVELLE INDICATION","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"87","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"88","03-03-20","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACRIUM","BURROUGHS WELLCOME INC.","CANADA","CANADA","1","","","INTRAVENOUS SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE ADMINISTRÉ PAR VOIE INTRAVEINEUSE","",""
"89","03-02-25","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ZENECA PHARMA","CANADA","CANADA","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"90","04-03-09","LG LIFE SCIENCES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"91","04-02-17","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS, DIVISION OF WARNER LAMBERT CO. CANADA INC.","CANADA","CANADA","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"92","03-02-17","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"93","04-01-27","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR CONTRAST-ENHANCED MAGNETIC RESONANCE ANGIOGRAPHY (CE-MRA)","NOUVELLE INDICATION : AUGMENTATION DE CONTRASTE DE L'ANGIOGRAPHIE PAR RÉSONANCE MAGNÉTIQUE","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"94","04-03-05","STERIMAX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"95","04-01-27","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RECTAL ANTI-INFLAMMATORY CORTICOSTEROID FOAM","ANTI-INFLAMMATOIRE RECTAL CORTICOSTÉROÏDE","",""
"96","03-02-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"97","04-03-04","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MANUFACTURER NAME CHANGE","MODIFICATION DU NOM DU FABRICANT","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"98","03-02-11","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYCLOCORT 0.1% CREAM","STIEFEL CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"99","04-03-01","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"100","04-03-01","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"101","04-03-01","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"102","04-02-16","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"103","04-02-16","BAYER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"104","04-02-10","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXPANSION OF INDICATION FOR CROHN'S DISEASE","EXPANSION DE L'INDICATION POUR LA MALADIE DE CROHN","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"105","04-01-29","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"106","04-01-14","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"107","04-01-09","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT NASAL","",""
"108","04-01-08","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SOURCE OF HUMAN ALBUMIN","SOURCE D'ALBUMINE HUMAINE ALTERNATIVE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"109","04-01-12","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 0.4%; NEW NAME: ACULAR LS; NEW INDICATION: FOR THE REDUCTION OF OCULAR PAIN AND OCULAR SYMPTOMS OF FOREIGN BODY SENSATION, BURNING/STINGING, TEARING, AND PHOTOPHOBIA FOLLOWING REFRACTIVE SURGERY","NOUVELLE CONCENTRATION : 0.4%; NOUVEAU NOM : ACULAR LS; NOUVELLE INDICATION : RÉDUCTION DE LA DOULEUR OCULAIRE ET DES SYMPTÔMES OCULAIRES DE SENSATION DE PRÉSENCE DE CORPS ÉTRANGER DE BRÛLURE/PICOTEMENT, LARMOIEMENT ET DE PHOTOPHOBIE SUITE À UNE CHIRURGIE RÉFRINGENTE","TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY AGENT","AGENT ANTI-INFLAMMATOIRE NON-STÉROÏDIEN TOPIQUE","",""
"110","04-03-02","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE REGIMEN: 750MG ONCE DAILY FOR FIVE DAYS IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA (CAP)","RÉVISION À LA POSOLOGIE : 750MG UNE FOIS PAR JOUR POUR 5 JOURS POUR LE TRAITEMENT DE LA PNEUMONIE COMMUNAUTAIRE ACQUISE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"111","04-03-02","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF CHRONIC BACTERIAL PROSTATITIS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE LA PROSTATITE BACTÉRIENNE CHRONIQUE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"112","03-01-21","GLADES, DIVISION OF STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"113","03-01-06","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME FROM ATENOLOL","MODIFICATION DU NOM DU PRODUIT DE ATENOLOL","ß-Adrenergic Receptor Blocking Agent","Inhibiteur des récepteurs ß-adrénergiques","",""
"114","03-01-03","RATIOPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE B-LACTAMASES","",""
"115","04-02-23","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 30MG","NOUVELLE CONCENTRATION : 30MG","LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"116","04-02-11","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"117","04-02-06","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF NOSOCOMIAL PNEUMONIA USING A ONCE DAILY 750 MG DOSE FOR 7 TO 14 DAYS","NOUVELLE INDICATION : TRAITEMENT DE LA PNEUMONIE NOSOCOMIALE UTILISANT UNE DOSE DE 750 MG POUR UNE DURÉE DE 7 À 14 JOURS","ANTI-BACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"118","04-01-29","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"119","04-01-29","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF EROSIVE AND NON-EROSIVE GERD IN CHILDREN AGED 1-17 YEARS","NOUVELLE INDICATION : POUR LE TRAITEMENT DU REFLUX GASTROOESOPHAGIEN PATHOLOGIQUE ÉROSIF ET NON-ÉROSIF CHEZ LES ENFANTS ÂGÉS DE 1 À 17 ANS","H+, K+ -ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+ -ATPASE","",""
"120","03-12-23","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"121","04-01-02","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PREMIX PRESENTATIONS","AJOUT DE PRÉMÉLANGES","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"122","04-03-19","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF A NEW STRENGTH","AJOUT D'UNE NOUVELLE CONCENTRATION","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"123","04-03-03","STERIMAX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT","ANOREXIGÈNE","",""
"124","04-02-26","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN AND MINERAL SUPPLEMENT","SUPPLÉMENT DE VITAMINES ET MINÉRAUX","",""
"125","03-12-09","ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"126","04-02-26","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN AND MINERAL SUPPLEMENT","SUPPLÉMENT DE VITAMINES ET MINÉRAUX","",""
"127","04-02-03","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"128","04-01-14","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYTOTEC","SEARLE CANADA","CANADA","CANADA","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"129","04-01-14","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"130","04-02-23","GALEN (CHEMICALS) LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN-PROGESTIN COMBINATION","ASSOCIATION OESTROGROGESTATIVE","",""
"131","04-01-28","NORBROOK LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","LIQUAMYCIN LP","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"132","06-01-04","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRA PHARMA INC.","CANADA","CANADA","1","","","H+, K+ -ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+ -ATPASE","",""
"133","04-01-23","VALEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"134","04-01-12","NORBROOK LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"135","03-11-19","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 400/12 MCG PER DOSE","NOUVELLE CONCENTRATION: 400/12 MCG PER DOSE","CORTICOSTEROID AND BRONCHODILATOR FOR INHALATION","CORTICOSTÉROÏDE ET BRONCHODILATATEUR POUR INHALATION","",""
"136","04-01-05","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SANDOSTATIN","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"137","04-03-12","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","HEMATOPOIETIC AGENT","HÉMATOPOÏÉTIQUE","",""
"138","04-03-09","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"139","04-03-09","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"140","04-02-17","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PIPRACIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"141","04-02-12","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER) THERAPY, POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLITIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"142","04-02-12","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"143","04-02-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAXOL INJECTION","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"144","03-11-19","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCAL ANALGESIC","ANALGÉSIQUE LOCAL","",""
"145","04-02-05","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER) THERAPY, POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"146","04-01-29","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW REDIPEN DELIVERY SYSTEM","NOUVELLE PRÉSENTATION (REDIPEN)","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"147","04-01-27","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"148","04-01-23","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE DRUG PRODUCT MANUFACTURING SITE, REFORMULATION OF DRUG PRODUCT","SITE ALTERNATIF DE FABRICATION DU PRODUIT MÉDICAMENTEUX, REFORMULATION DU PRODUIT MÉDICAMENTEUX","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"149","04-01-14","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"150","04-01-09","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE","",""
"151","03-11-04","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ELEVATED INTRAOCULAR PRESSURE THERAPY (RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST)","THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE (AGONISTE ALPHA2-ADRÉNORÉCEPTEUR RELATIVEMENT SÉLECTIF)","",""
"152","04-01-09","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"153","04-03-15","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR","INHIBITEUR DE LA PROLACTINE","",""
"154","04-02-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXOWELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"155","03-09-05","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: TABLET 24 MG","NOUVEAU DOSAGE: COMPRIMÉ DE 24 MG","ANTI-VERTIGO AGENT","ANTIVERTIGINEUX","",""
"156","04-02-12","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH BASED ON THE 2003 GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE","CHANGEMENTS À LA RUBRIQUE POSOLOGIE ET ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT POUR TENIR COMPTE DES LIGNES DIRECTRICES DE 2003 SUR LA GESTION DE LA DYSLIPIDÉMIE ET LA PRÉVENTION DES MALADIES CARDIOVASCULAIRES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"157","04-02-09","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXOWELLCOME INC.","CANADA","CANADA","1","REVISION TO LABEL CLAIM","RÉVISION À LA RÉCLAME SUR L'ÉTIQUETTE","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"158","04-01-23","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH TO INCLUDE STATEMENT RE THE MANAGEMENT OF PATIENTS AT INCREASED RISK OF CARDIOVASCULAR EVENTS","MONOGRAPHIE RÉVISÉE DU PRODUIT INCLUANT UN ÉNONCÉ SUR LA GESTION DES PERSONNES PRÉSENTANT UN RISQUE ÉLEVÉ DE TROUBLES CARDIOVASCULAIRES","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"159","04-01-15","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"160","04-03-19","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"161","04-03-08","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS REGARDING SAFETY OF SILDENAFIL IN SUBJECTS WITH TREATED HYPERTENSION, CORONARY ARTERY DISEASE AND STABLE ANGINA","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT RELATIVEMENT À L'INNOCUITÉ DU SILDÉNAFIL CHEZ LES PERSONNES TRAITÉES POUR HYPERTENSION, INSUFFISANCE CORONAIRE ET ANGOR STABLE","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE GMPC","",""
"162","03-09-05","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM HELICIDE","MODIFICATION DU NOM DU PRODUIT DE HELICIDE","HELICOBACTER PYLORI ERADICATION THERAPY IN CONJUNCTION WITH OMEPRAZOLE","TRAITEMENT D'ÉRADICATION DE L'HELICOBACTER PYLORI EN UTILISANT PARALLÈLEMENT L'OMÉPRAZOLE","",""
"163","04-03-02","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES RÉCEPTEURS ß2-ADRÉNERGIQUES)","",""
"164","04-03-02","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","INCORPORATE RELEVANT CLINICAL TRIAL INFORMATION INTO THE PRODUCT MONOGRAPH","INCLURE À LA MONOGRAPHIE DU PRODUIT LES RENSEIGNEMENTS PERTINENTS AUX ESSAIS CLINIQUES","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"165","04-02-17","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW CONTAINER CLOSURE SYSTEM: NUTROPIN AQ PEN CARTRIDGE","NOUVEAU DISPOSITIF DE FERMETURE DES CONTENANTS : NUTROPIN AQ PEN CARTRIDGE","GROWTH HORMONE","HORMONE DE CROISSANCE","",""
"166","04-02-12","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","0","","","DIAGNOSTIC ULTRASOUND CONTRAST AGENT","AGENT DE CONTRASTE POUR L'ÉCHOGRAPHIE","",""
"167","03-08-22","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING AREA","ZONE DE FABRICATION ADDITIONNELLE","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYTIQUE NEUROMUSCULAIRE","",""
"168","04-02-10","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","THERAPEUTIC RADIOPHARMACEUTICAL","THÉRAPEUTIQUE RADIOPHARMACEUTIQUE","",""
"169","04-02-02","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRO-DUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRO-DUODÉNAL","",""
"170","04-03-18","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION WITH IMPROVED STABILITY AT AMBIENT CONDITIONS","CHANGEMENT À LA COMPOSITION AVEC STABILITÉ AMÉLIORÉE AUX CONDITIONS AMBIANTES","ANDROGEN","ANDROGÈNE","",""
"171","03-08-22","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING AREA","ZONE DE FABRICATION ADDITIONNELLE","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYTIQUE NEUROMUSCULAIRE","",""
"172","04-02-26","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM TRAZODONE","MODIFICATION DU NOM DU PRODUIT DE TRAZODONE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"173","04-04-01","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"174","03-07-21","ESP PHARMA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"175","04-02-25","VETOQUINOL N.-A. INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","TRIVETRIN INJECTION","SCHERING CANADA INC.","CANADA","CANADA","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"176","04-02-23","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR TREATMENT OF RHEUMATOID ARTHRITIS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ARTHRITE RHUMATOÏDE","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"177","04-01-23","JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","COMEDOLYTIC AGENT","AGENT COMÉDOLYTIQUE","",""
"178","04-01-23","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"179","04-01-20","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","REAGENT FOR PREPARATION OF A RADIODIAGNOSTIC AGENT","RÉACTIF POUR LA PRÉPARATION D'UN AGENT RADIODIAGNOSTIQUE","",""
"180","04-01-20","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"181","04-01-19","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH CORRESPONDING TO THE LATEST CHANGES OF THE INNOVATOR","MISE À JOUR À LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'INNOCUITÉ RELATIVEMENT AUX DERNIERS CHANGEMENTS DE L'INNOVATEUR","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"182","04-01-14","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"183","04-03-17","BAYER INC., HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DU GMP CYCLIQUE","",""
"184","04-03-15","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"185","04-02-26","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN SOLID ORGAN TRANSPLANT PATIENTS AT RISK","NOUVELLE INDICATION : COMME PRÉVENTION DE L'INFECTION AU CYTOMÉGALOVIRUS CHEZ LES RÉCIPIENDAIRES DE GREFFES D'ORGANES SOLIDES ET QUI SONT VULNÉRABLES À L'INFECTION","ANTIVIRAL AGENT","ANTIVIRAL","",""
"186","04-02-12","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR THE REDUCTION OF TRANSMISSION OF GENITAL HERPES","NOUVELLE INDICATION : POUR LA RÉDUCTION DE LA TRANSMISSION DE L'HERPÈS GÉNITAL","ANTIVIRAL AGENT","ANTIVIRAL","",""
"187","04-03-02","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: NASAL SPRAY","NOUVELLE FORME POSOLOGIQUE : VAPORISATEUR NASAL","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"188","02-12-16","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACRIUM","BURROUGHS WELLCOME","CANADA","CANADA","1","","","INTRAVENOUS SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE","",""
"189","02-12-16","ENZON, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"190","02-11-28","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"191","02-11-20","SANGSTAT MEDICAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","AGENT IMMUNOSUPPRESSEUR","",""
"192","02-11-20","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","BURROUGHS WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"193","02-11-05","AVENTIS BEHRING LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTI-HEMOPHILIC FACTOR (HUMAN)","FACTEUR ANTIHÉMOPHILIQUE (HUMAINE)","",""
"194","02-11-04","PANGEO HEALTH SCIENCES DIV. OF/DE PANGEO PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTICOAGULANT","ANTICOAGULANT ORAL","",""
"195","02-11-01","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"196","02-10-24","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"197","02-10-15","ELAN PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"198","02-09-30","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"199","02-08-29","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"200","02-08-20","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ACCELERATED DOSING IN PEDIATRIC PATIENTS FOR ACUTE OTITIS MEDIA: 30 MG/KG SINGLE DOSE FOR 1 DAY, 10 MG/KG ONCE DAILY FOR 3 DAYS, PRODUCT MONOGRAPH REVISIONS","POSOLOGIE ACCÉLÉRÉE POUR L'OTITE MOYENNE AIGÜE CHEZ LES PATIENTS PÉDIATRIQUES : 1 DOSE UNIQUE DE 30 MG/KG POUR UNE JOURNÉE, DOSE DE 10 MG/KG UNE FOIS PAR JOUR POUR 3 JOURS, RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"201","02-07-30","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"202","02-07-30","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"203","02-07-19","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - PEDIATRIC USE","NOUVELLE INDICATION : POUR L'USAGE EN PÉDIATRIE","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"204","02-05-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE PROPHYLAXIS OF PLASMODIUM FALCIPARUM MALARIA","NOUVELLE INDICATION : PROPHYLAXIE DE LA MALARIA À PLASMODIUM FALCIPARUM","ANTIMALARIAL AGENT","ANTIPALUDÉEN","",""
"205","02-05-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE, INHIBITEUR DE ß-LACTAMASES","",""
"206","02-05-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"207","02-05-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"208","02-05-15","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"209","02-05-15","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESIVE AGENT","IMMUNOSUPPRESSEUR","",""
"210","02-04-16","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARHYTHMIQUE","",""
"211","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"212","02-04-16","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN-875","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"213","02-04-03","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","AGENT ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"214","02-03-20","WAMPOLE BRANDS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT, PLATELET AGGREGATION INHIBITOR","ANTI-INFLAMMATOIRE, NON-STÉROÏDIEN, ANALGÉSIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"215","02-06-26","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR REDUCING THE RISK OF A FIRST NON-FATAL MYOCARDIAL INFARCTION IN INDIVIDUALS DEEMED TO BE AT SUFFICIENT RISK OF SUCH AN EVENT BY THEIR PHYSICIAN","NOUVELLE INDICATION : POUR RÉDUIRE LE RISQUE D'UN PREMIER INFARCTUS DU MYOCARDE NON FATAL CHEZ LES INDIVIDUS QUI, SELON L'ESTIMATION DU MÉDECIN, PRÉSENTENT UN RISQUE SUFFISANT D'UN TEL PROBLÈME","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"216","02-03-11","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE INTRAVENOUS","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"217","02-02-21","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"218","02-02-20","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE INTRAVENOUS","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARHYTHMIQUE","",""
"219","02-02-19","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"220","02-02-19","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: RAISES HDL-CHOLESTEROL AND THEREFORE LOWERS THE LDL-C/HDL-C AND TOTAL-C/HDL-C RATIOS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND COMBINED (MIXED) HYPERLIPIDEMIA (FREDRICKSON TYPE IIA AND IIB DYSLIPIDEMIA)","NOUVELLE INDICATION : AUGMENTE LE LDL CHOLESTÉROL ET, PAR CONSÉQUENT, RÉDUIT LES RAPPORTS CDL-C/HDL-C ET C/HDL-C TOTAL CHEZ LES PATIENTS PRÉSENTANT UNE HYPERCHOLESTÉROLÉMIE PRIMAIRE ET HYPERLIPIDÉMIE COMBINÉE MIXTE (DYSLIPIDÉMIE DE TYPE IIA ET IIB DE FREDRICKSON)","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"221","02-02-13","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN-125F AND CLAVULIN-250F","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","ANTIBIOTIC AND ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"222","03-07-15","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: SEPARATE PRODUCT MONOGRAPH FOR SENCORCAINE FORTE FROM THAT OF THE OTHER SENSORCAINE PRODUCTS","MONOGRAPHIE RÉVISÉE: MONOGRAPHIE DU PRODUIT SENSORCAINE FORTE SÉPARÉE DES AUTRES PRODUITS SENSORCAINE","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"223","02-02-04","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 70MG; NEW DOSING REGIMEN: ONCE WEEKLY; FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND IN MEN","NOUVELLE CONCENTRATION : 70MG; NOUVEAU SCHÉMA POSOLOGIQUE : UNE FOIS PAR SEMAINE; POUR LE TRAITEMENT DE L'OSTÉOPOROSE CHEZ LES FEMMES POSTMÉNOPAUSÉES ET LES HOMMES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"224","03-04-25","3M PHARMACEUTICALS, A DIVISION OF 3M CANADA COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROPHYLACTIC MANAGEMENT OF STEROID-RESPONSIVE BRONCHIAL ASTHMA IN PEDIATRIC PATIENTS BETWEEN 5 AN 11 YEARS OLD","NOUVELLE INDICATION: GESTION PROPHYLACTIQUE DE L'ASTHME BRONCHIQUE RÉCEPTIF AUX STÉROÏDES CHEZ LES PATIENTS PÉDIATRIQUES DE 5 À 11 ANS","CORTICOSTEROID FOR ORAL INHALATION","CORTICOSTÉROÏDE POUR INHALATION","",""
"225","03-04-23","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","CRYSTAAL A DIVISION OF BIOVAIL CORPORATION CANADA","CANADA","CANADA","1","","","B-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"226","03-04-02","ORYX PHARMACEUTICALS INC., A SUBSIDIARY OF FILIALE D'ARROW PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIRECT THROMBIN INHIBITOR","INHIBITEUR DIRECT DE LA THROMBINE","",""
"227","02-02-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHISTAMINIC, ANTI-INFLAMMATORY, LEUKOTRIENE INHIBITOR AGENT","ANTI-HISTAMINIQUE, ANTI-INFLAMMATOIRE, AGENT INHIBITEUR DE LEUCOTRIÈNE","",""
"228","02-02-04","WELLSPRING PHARMACEUTICAL CANADA CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MUCOLYTIC, ANTIDOTE FOR ACETAMINOPHEN POISONING","MUCOLYTIQUE, ANTIDOTE CONTRE LES INTOXICATIONS PAR L'ACÉTAMINOPHÈNE","",""
"229","03-03-14","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HELICOBACTER PYLORI ERADICATION THERAPY IN CONJUNCTION WITH OMEPRAZOLE","TRAITEMENT D'ÉRADICATION DE L'HELICOBACTER PYLORI EN UTILISANT PARALLÈLEMENT L'OMÉPRAZOLE","",""
"230","02-01-14","DENTSPLY CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC FOR DENTAL USE","ANESTHÉSIQUE LOCAL POUR SOINS DENTAIRES","",""
"231","03-03-14","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM WELLBUTRIN SR","CHANGEMENT DU NOM DU PRODUIT DE WELLBUTRIN SR","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"232","03-03-14","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ZYBAN","CHANGEMENT DU NOM DU PRODUIT DE ZYBAN","SMOKING CESSATION AID","AIDE ANTITABAGIQUE","",""
"233","03-03-14","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"234","02-01-02","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW-DOSE 81MG","BAYER INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM SAFEWAY COATED DAILY LOW-DOSE ASA","MODIFICATION DU NOM DU PRODUIT DE SAFEWAY COATED DAILY LOW-DOSE ASA","ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"235","03-03-14","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE ANTITABAGIQUE","",""
"236","02-01-02","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT, ANTIPARKINSONIAN AGENT","AGENT ANTIVIRAL, AGENT ANTIPARKINSONIEN","",""
"237","02-10-25","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING PROCEDURE","CHANGEMENT À LA PROCÉDURE DE FABRICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"238","02-09-10","DRAXIMAGE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING SITE","CHANGEMENT DE SITE DE FABRICATION","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"239","02-09-06","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"240","02-08-28","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC AGENT AID","AGENT POUR USAGE DIAGNOSTIQUE","",""
"241","02-07-25","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","INTRAVENOUS ULTRASOUND CONTRAST MEDIUM","AGENT DE CONTRASTE INTRAVEINEUX PAR ULTRASON","",""
"242","02-06-06","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","INTRAVENOUS ULTRASOUND CONTRAST MEDIUM","MILIEU DE CONTRASTE INTRAVEINEUX POUR ULTRASON","",""
"243","02-05-24","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","IMMUNOMODULATORY AGENT","AGENT D'IMMUNOMODULATEUR","",""
"244","02-05-10","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT (TISSUE PLASMINOGEN ACTIVATOR)","AGENT FIBRINOLYTIQUE (ACTIVATEUR DU PLASMINOGÈNE TISSULAIRE)","",""
"245","02-01-23","WELLSPRING PHARMACEUTICAL CANADA CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"246","03-12-23","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM TAZIDIME","CHANGEMENT DU NOM DU PRODUIT DE TAZIDIME","ANTIBIOTIC","ANTIBIOTIQUE","",""
"247","03-12-22","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE VULGARIS THERAPY","TRAITEMENT DE L'ACNÉ VULGAIRE","",""
"248","03-12-19","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"249","03-11-28","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C CAPSULES","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"250","03-11-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOESCHT MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"251","03-11-12","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"252","03-10-17","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"253","03-10-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE ANTI-INFLAMMATOIRE","",""
"254","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VAGINAL ANTIBACTERIAL PREPARATION","AGENT ANTIBACTÉRIEN","",""
"255","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"256","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"257","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"258","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"259","03-09-19","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DOPAMINE RECEPTOR AGONIST","AGONISTE DES RÉCEPTEURS DE LA DOPAMINE","",""
"260","03-09-19","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"261","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERCHOLESTEROLEMIC","ANTIHYPERCHOLESTÉROLÉMIQUE ORAL","",""
"262","03-09-15","LUNDBECK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: ADDITION OF STATEMENTS TO THE DOSAGE AND ADMINISTRATION SECTION","MONOGRAPHIE RÉVISÉE DU PRODUIT: AJOUT D'ÉNONCÉS À LA RUBRIQUE POSOLOGIE ET ADMINISTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"263","03-10-08","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML)","NOUVELLE INDICATION: DIAGNOSTIC RÉCENT DE LEUCÉMIE CHRONIQUE MYÉLOÏDE","PROTEIN TYROSINE-KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"264","03-12-05","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AZAPEPTIDE INHIBITOR OF HIV-1 PROTEASE","INHIBITEUR AZAPEPTIDE DE LA PROTÉASE VIH-1","",""
"265","03-12-02","DENTSPLY CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC FOR DENTAL USE","ANESTHÉSIQUE LOCAL","",""
"266","03-09-16","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"267","03-08-05","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW 500 MG TABLET STRENGTH AND NEW DOSING REGIMEN (THREE DAY TREATMENT) FOR ACUTE BACTERIAL EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN ADULTS","NOUVEAU COMPRIMÉ DE 500 MG ET NOUVELLE POSOLOGIE (TRAITEMENT D'UNE DURÉE DE TROIS JOURS) POUR EXACERBATIONS BACTÉRIENNES AIGUES DE LA BRONCHOPNEUMOPATHIE CHRONIQUE OBSTRUCTIVE CHEZ L'ADULTE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"268","03-09-05","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION FOR 500MG TABLET","NOUVELLE FORMULATION POUR LES COMPRIMÉS DE 500MG","ANTIBIOTIC","ANTIBIOTIQUE","",""
"269","03-09-05","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"270","03-09-05","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"271","03-09-04","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"272","03-09-03","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"273","04-03-23","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"274","04-03-22","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"275","04-03-26","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO UPDATE THE INDICATIONS IN THE PRODUCT MONOGRAPH","MISE À JOUR DES INDICATIONS DE LA MONOGRAPHIE DU PRODUIT","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"276","04-03-26","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF A NEW 80 MG STRENGTH AND REVISED DOSAGE RECOMMENDATIONS","AJOUT D'UNE NOUVELLE CONCENTRATION DE 80 MG ET RÉVISION AUX RECOMMENDATIONS RELATIVES À LA POSOLOGIE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"277","04-03-23","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","KNOLL PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"278","04-03-23","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN PATIENTS AT HIGH RISK OF CORONARY EVENTS REGARDLESS OF LIPID STATUS","NOUVELLE INDICATION : CHEZ LES PATIENTS À RISQUE ÉLEVÉ DE MANIFESTATIONS CORONAIRES, SANS ÉGARD AU TAUX DES LIPIDES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"279","04-03-25","QLT INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PRESUMED OCULAR HISTOPLASMOSIS","NOUVELLE INDICATION : HISTOPLASMOSE OCCULAIRE PRÉSUMÉE","PHOTOSENSITIZING AGENT FOR AGE-RELATED MACULAR DEGENERATION AND PATHOLOGIC MYOPIA","AGENT PHOTOSENSIBILISANT POUR LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE ET POUR LA MYOPIE PATHOLOGIQUE","",""
"280","04-03-24","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"281","04-03-24","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"282","04-03-24","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"283","04-03-25","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC AGENT","HYPNOTIQUE","",""
"284","04-03-22","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: 80 MG EXTENDED RELEASE TABLET","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉ À ACTION PROLONGÉE DE 80 MG","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"285","04-03-22","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ANEXATE","HOFFMAN-LA ROCHE LIMITED","CANADA","CANADA","1","","","BENZODIAZEPINE ANTAGONIST","ANTAGONISTE DES BENZODIAZÉPINES","",""
"286","04-03-24","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"287","04-03-24","ALPHARMA APS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"288","04-03-23","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antileukemic Agent","Antileucémique","",""
"289","04-03-23","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"290","04-03-26","BAYER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING PROCEDURE","MODIFICATION À LA MÉTHODE DE FABRICATION","COAGULATION FACTOR","AGENT DE COAGULATION","",""
"291","04-03-25","WYETH CONSUMER HEALTHCARE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM: SOLUTION IN GELATIN CAPSULE","NOUVELLE FORME POSOLOGIQUE : SOLUTION DANS UNE CAPSULE EN GÉLATINE","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT","",""
"292","04-03-31","ACTELION PHARMACEUTICALS LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOSYCERAMIDE SYNTHASE INHIBITOR","INHIBITEUR DE LA GLUCOSYCERAMIDE SYNTHASE","",""
"293","04-03-29","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DILANTIN","PARKE-DAVIS DIVISION WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"294","04-03-29","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION AND INDICATION: SUSTAINED-RELEASE CAPSULES TO PROLONG THE TIME TO RECURRENCE OF SYMPTOMATIC ATRIAL ARRHYTHMIAS IN PATIENTS WITHOUT SIGNIFICANT STRUCTURAL HEART DISEASE AND WITH A HISTORY OF SYMPTOMATIC ATRIAL FIBRILLATION","NOUVELLE FORMULE ET INDICATION : CAPSULES À LIBÉRATION SOUTENUE POUR PROLONGER LE TEMPS DE RÉCURRENCE DE L'ARYTHMIE AURICULAIRE SYMPTOMATIQUE CHEZ LES PERSONNES QUI NE PRÉSENTENT PAS DE MALADIE CARDIAQUE STRUCTURELLE IMPORTANTE ET AYANT UNE HISTOIRE DE FIBRILLATION AURICULAIRE SYMPTOMATIQUE","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"295","04-03-29","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"296","04-03-29","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER S.A.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"297","04-04-01","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORALLY DISINTEGRATING TABLET","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉ À DISSOLUTION ORALE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"298","04-04-01","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT AGENT","ANTIDÉPRESSEUR","",""
"299","04-03-31","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"300","04-03-29","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REFORMULATION OF TABLETS","REFORMULATION DES COMPRIMÉS","5-HT1, RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"301","04-03-31","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"302","04-03-30","NOVO NORDISK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HORMONE REPLACEMENT THERAPY","TRAITEMENT HORMONAL SUSTITUTIF","",""
"303","04-03-29","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: FOR RELIEF OF MIGRAINES","NOUVELLE INDICATION : POUR LE SOULAGEMENT DES MIGRAINES","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"304","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"305","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"306","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"307","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"308","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"309","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"310","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"311","04-04-01","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"312","04-04-01","AVENTIS PASTEUR SA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"313","02-12-09","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"314","02-11-25","ASTRAZENECA CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","0","NEW INDICATION: FOR IMMEDIATE THERAPY IN SOME PATIENTS WITH LOCALIZED (T1-T2) PROSTATE CANCER WHO ARE INAPPROPRIATE FOR SURGERY OR RADIOTHERAPY; NEW STRENGTH: 150MG","NOUVELLE INDICATION : POUR LE TRAITEMENT IMMÉDIAT DES PATIENTS QUI PRÉSENTENT UN CANCER LOCALISÉ (T1-T2) DE LA PROSTATE ET POUR QUI LA CHIRURGIE OU LA RADIOTHÉRAPIE SERAIT INAPPROPRIÉE; NOUVEAU DOSAGE : 150 MG","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"315","02-10-09","THE MEDICINES COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIRECT THROMBIN INHIBITOR","INHIBITEUR DIRECT DE LA THROMBINE","",""
"316","02-07-30","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST, ELEVATED INTRAOCULAR PRESSURE THERAPY","STIMULANT DES RÉCEPTEURS ALPHA2-ADRÉNERGIQUES RELATIVEMENT SÉLECTIF, THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"317","02-07-29","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST, ELEVATED INTRAOCULAR PRESSURE THERAPY","STIMULANT DES RÉCEPTEURS ALPHA2-ADRÉNERGIQUES RELATIVEMENT SÉLECTIF, THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"318","02-07-29","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST, ELEVATED INTRAOCULAR PRESSURE THERAPY","STIMULANT DES RÉCEPTEURS ALPHA2-ADRÉNERGIQUES RELATIVEMENT SÉLECTIF, THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"319","02-07-19","ALCON CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","Elevated Intraocular Pressure Therapy","Thérapie pour réduire la pression intra-oculaire","",""
"320","02-06-17","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Relatively Selective Alpha2-Adrenoceptor Agonist, Elevated Intraocular Pressure Therapy","Stimulant des récepteurs Alpha2-adrénergiques relativement sélectif, Thérapie pour réduire la pression intra-oculaire","",""
"321","02-06-10","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: NEW SAFETY INFORMATION ON USE IN PATIENTS WITH LIVER OR RENAL IMPAIRMENT","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT : NOUVELLE MISE EN GARDE POUR LE TRAITEMENT DES PATIENTS PRÉSENTANT UN TROUBLE DE LA FONCTION HÉPATIQUE OU RÉNALE","SMOKING CESSATION AID","AIDE ANTITABAGIQUE","",""
"322","02-05-31","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"323","02-05-30","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYERS SQUIBB CANADA LTD.","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"324","02-05-30","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Muscle Relaxant, Antispastic Agent","Relaxant Musculaire, Antispasmodique","",""
"325","02-05-24","ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY, PROSTAMIDE ANALOGUE","TRAITEMENT DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE, PROSTAMIDE ANALOGUE","",""
"326","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCALLY ACTING ANALGESIC AGENT","ANALGÉSIQUE LOCAL","",""
"327","02-04-29","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPROSALIC LOTION","SCHERING CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID AND KERATOLYTIC","CORTICOSTÉROÏDE TOPIQUE ET KÉRATOLYTIQUE","",""
"328","02-03-01","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE PRODUCT MONOGRAPH: NEW DOSING RECOMMENDATIONS FOR USE IN PATIENTS WITH LIVER OR RENAL IMPAIRMENT","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT : NOUVELLES RECOMMENDATIONS PORTANT SUR LA POSOLOGIE POUR LE TRAITEMENT DES PATIENTS SOUFFRANT D'INSUFFISANCE RÉNALE OU HÉPATIQUE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"329","03-09-03","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIACALCIN NS","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"330","02-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID AND BRONCHODILATOR FOR INHALATION","CORTICOSTÉROÏDE ET BRONCHODILATATEUR POUR INHALATION","",""
"331","03-08-27","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA","NOUVELLE INDICATION: POUR LE TRAITEMENT DE LA PNEUMONIE ACQUISE DANS LA COMMUNAUTÉ","ANTIBIOTIC","ANTIBIOTIQUE","",""
"332","02-12-13","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"333","02-07-12","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCESS, NEW MANUFACTURING FACILITY","CHANGEMENT DANS LE PROCÉDÉ DE FABRICATION; NOUVEL ÉTABLISSEMENT DE FABRICATION","LUNG SURFACTANT (BOVINE)","SURFACTANT PULMONAIRE (BOVIN)","",""
"334","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"335","03-08-13","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE AND CHANGES TO THE DOSAGE AND ADMINISTRATION SECTION TO REFLECT THE MAINTENANCE DOSING SCHEDULE FOR ADULT PATIENTS WITH RENAL IMPAIRMENT","MISE À JOUR À LA MONOGRAPHIE DU PRODUIT ET MODIFICATIONS APPORTÉES À LA RUBRIQUE POSOLOGIE POUR INCLURE UN SCHÉMA POSOLOGIQUE CHEZ LES PATIENTS DONT LA FONCTION RÉNALE EST ANORMALE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"336","02-12-11","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"337","03-08-13","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GNRH ANTAGONIST","GNRH (ANTAGONISTE)","",""
"338","02-12-09","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"339","02-11-08","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY AND COMPANY","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"340","03-08-12","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","HOFFMANN-LAROCHE LIMITED","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"341","02-10-15","ORYX PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"342","02-10-08","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSING REGIMEN: STARTING DOSE OF 16MG ONCE DAILY WHEN USED AS MONOTHERAPY, AND A MAXIMUM DAILY DOSE OF 32MG","NOUVELLE POSOLOGIE : COMMENÇANT À 16MG UNE FOIS PAR JOUR EN MONOTHÉRAPIE, AVEC DOSE MAXIMALE QUOTIDIENNE DE 32MG","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"343","02-09-19","ORBUS PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"344","02-09-04","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BERLEX CANADA INC.","CANADA","CANADA","1","","","ANTI-ANDROGEN","ANTIANDROGÈNE","",""
"345","02-08-27","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","RÉVISIONS À LA RUBRIQUE DOSAGE ET ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"346","02-08-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"347","03-08-07","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLOZARIL","NOVARTIS CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"348","02-08-02","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","E.R. SQUIBB & SONS, INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"349","02-07-30","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"350","02-07-30","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"351","02-07-18","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEORAL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"352","02-06-17","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","RELAXANT MUSCULAIRE SQUELETTIQUE","",""
"353","02-06-17","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"354","02-06-13","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ACUTE OTITIS EXTERNA; NEW ROUTE OF ADMINISTRATION: OTIC","NOUVELLE INDICATION : OTITE AIGUË EXTERNE; NOUVELLE VOIE D'ADMINISTRATION : OTIQUE","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"355","02-06-04","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"356","02-05-28","PHARMACIA CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","0","NEW INDICATION: TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS","NOUVELLE INDICATION : TRAITEMENT DE LA POLYPOSE ADÉNOMATEUSE FAMILIALE","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"357","03-08-07","BAYER INC., HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"358","02-05-15","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL, ANTIFUNGAL AGENT WITH TOPICAL CORTICOSTEROID","ANTIBACTÉRIEN, ANTIFONGIQUE, CORTICOSTÉROÏDE TOPIQUE","",""
"359","02-05-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"360","03-08-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA DIVISION OF SMITHKLINE BEECHAM INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"361","03-08-01","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA DIVISION OF SMITHKLINE BEECHAM INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"362","02-05-13","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"363","02-05-10","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR EN MATIÈRE D'INNOCUITÉ DE LA MONOGRAPHIE DU PRODUIT","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"364","02-05-08","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"365","02-05-08","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"366","02-05-01","ABIOGEN PHARMA S.P.A","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"367","02-05-01","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"368","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Anti-Inflammatory Steroid","Corticostéroïde anti-inflammatoire topique","",""
"369","03-07-22","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"370","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"371","03-07-11","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLOZARIL","NOVARTIS CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"372","03-07-11","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE TREATMENT OF ESOPHAGEAL CANDIDIASIS","NOUVELLE INDICATION POUR LE TRAITEMENT DE LA CANDIDIASE OESOPHAGIENNE","ANTIFUNGAL","ANTIFONGIQUE","",""
"373","03-07-11","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE TREATMENT OF INVASIVE CANDIDIASIS","NOUVELLE INDICATION POUR LE TRAITEMENT DE LA CANDIDIASE ENVAHISSANTE","ANTIFUNGAL","ANTIFONGIQUE","",""
"374","03-07-07","PHARMACIA CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","0","NEW STRENGTH: 400 MG - FOR THE TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS (FAP)","NOUVELLE CONCENTRATION: 400 MG - POUR LE TRAITEMENT DE LA POLYPOSE ADÉNOMATEUSE FAMILIALE","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"375","03-06-20","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION; CHANGE IN METHOD OF MANUFACTURING","MODIFICATION DE LA PRÉPARATION; MODIFICATION DE LA MÉTHODE DE FABRICATION","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"376","03-06-17","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CLARIFICATION OF MONITORING FREQUENCY WHEN SWITCHING CLOZAPINE BRANDS","CLARIFICATION À LA FRÉQUENCE DU SUIVI LORS D'UN CHANGEMENT DE MARQUE DE LA CLOZAPINE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"377","02-04-19","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CALCIJEX","ABBOTT LABORATORIES, LIMITED","CANADA","CANADA","1","","","VITAMIN D3 METABOLITE","MÉTABOLITE DE LA VITAMINE D3","",""
"378","02-04-10","GUILFORD PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"379","03-06-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CLARIFICATION OF MONITORING FREQUENCY WHEN SWITCHING CLOZAPINE BRANDS","CLARIFICATION À LA FRÉQUENCE DU SUIVI LORS DU CHANGEMENT DE MARQUE DE COMMERCE DE LA CLOZAPINE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"380","02-04-10","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: REDUCTION OF ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES, UNSTABLE ANGINA OR NON-Q-WAVE MYOCARDIAL INFARCTION, WITHOUT ST SEGMENT ELEVATION","NOUVELLE INDICATION : RÉDUCTION DES ACCIDENTS DE THROMBOSE ATHÉROSCLÉREUSE CHEZ LES PATIENTS QUI PRÉSENTENT DES SYNDRÔMES CORONAIRES AIGUS, DE L'ANGINE INSTABLE OU UN INFARCTUS DU MYOCARDE SANS ONDE Q, ET QUI NE PRÉSENTENT PAS D'AUGMENTATION DU SEGMENT ST","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"381","02-04-10","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF SEVERE HEART FAILURE","NOUVELLE INDICATION : TRAITEMENT DE L'INSUFFISANCE CARDIAQUE GRAVE","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"382","02-03-20","LEO PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN THE DOSING REGIMEN TO ONCE DAILY","CHANGEMENT AU SCHÉMA POSOLOGIQUE À UNE FOIS PAR JOUR","TOPICAL ANTIPSORIATIC AGENT, VITAMIN D ANALOGUE, CORTICOSTEROID","AGENT ANTIPSORIASIQUE TOPIQUE, ANALOGUE DE LA VITAMIN D, CORTICOSTÉROÏDE","",""
"383","03-06-13","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"384","03-05-16","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"385","02-03-11","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1","",""
"386","02-02-21","TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"387","02-02-19","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"388","02-02-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"389","02-02-04","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME FROM PMS-CARBAMAZEPINE","MODIFICATION DU NOM DU PRODUIT DE PMS-CARBAMAZEPINE","ANTICONVULSANT, SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA, ANTIMANIC","ANTICONVULSIVANT, SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU, ANTIMANIAQUE","",""
"390","02-02-04","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"391","02-02-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"392","02-01-28","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C CAPSULES","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"393","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"394","02-09-30","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST, SYMPATHOMIMETIC AMINE","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE, AMINE SYMPATHOMIMÉTIQUE","",""
"395","02-08-15","DRAXIMAGE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING SITE","CHANGEMENT DE SITE DE FABRICATION","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"396","02-06-14","MEDIMMUNE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FRACTIONATION SITE","NOUVEAU SITE DE FRACTIONNEMENT","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"397","03-05-14","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLOZARIL","SANDOZ CANADA INC.","CANADA","CANADA","1","CLARIFICATION OF MONITORING FREQUENCY WHEN SWITCHING CLOZAPINE BRANDS","ÉCLAIRCISSEMENTS À LA FRÉQUENCE DES ACTIVITÉS DE SUIVI, AU COURS D'UN CHANGEMENT DE MARQUE DE CLOZAPINE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"398","02-05-31","DRAXIMAGE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVEAU SITE DE FABRICATION","DIAGNOSTIC IMAGING AGENT","AGENT D'IMAGERIE DIAGNOSTIQUE","",""
"399","02-05-02","BERNA BIOTECH LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"400","02-03-22","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","PROPHYLACTIC VACCINE","VACCIN PROPHYLACTIQUE","",""
"401","03-04-08","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR IX","FACTEUR IX ANTIHÉMORRAGIQUE DE COAGULATION SANGUINE","",""
"402","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"403","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"404","03-04-03","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CLONAZEPAM","MODIFICATION DU NOM DU PRODUIT DE CLONAZEPAM","ANTICONVULSANT","ANTICONVULSIVANT","",""
"405","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"406","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"407","02-03-08","CYTOGEN CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"408","03-04-03","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGENIC HORMONES / PROGESTIN","HORMONES OESTROGÈNES / PROGESTATIF","",""
"409","02-12-24","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DESFERAL","NOVARTIS CANADA INC.","CANADA","CANADA","1","","","IRON AND ALUMINUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"410","02-12-10","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMITOTIC, ANTIBIOTIC","ANTIMITOTIQUE, ANTIBIOTIQUE","",""
"411","03-11-25","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGENIC HORMONES, PROGESTIN","HORMONES OESTROGÈNES, PROGESTATIF","",""
"412","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGENIC HORMONES / PROGESTIN","HORMONES OESTROGÈNES / PROGESTATIF","",""
"413","02-10-17","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC AGENT AID","AGENT POUR USAGE DIAGNOSTIQUE","",""
"414","02-10-17","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"415","02-09-23","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DTIC","BAYER INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"416","02-08-27","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN COMBINATION WITH XELODA (CAPECITABINE) FOR THE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING CHEMOTHERAPY","NOUVELLE INDICATION : CONJOINTEMENT AU XELODA (CAPÉCITABINE) POUR LE TRAITEMENT DES PATIENTS ATTEINTS D'UN CANCER AVANCÉ OU MÉTASTATIQUE DU SEIN APRÈS ÉCHEC D'UNE CHIMIOTHÉRAPIE INCLUANT L'ANTHRACYCLINE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"417","02-08-01","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVASCULAR X-RAY CONTRAST MEDIUM-MD-60, IONIC, WATER SOLUBLE RADIOPAQUE CONTRAST MEDIUM FOR INTRAVASCULAR USE-MD-76","AGENT DE CONTRASTE RADIOLOGIQUE INTRAVASCULAIRE-MD-60, AGENT IONIQUE DE CONTRASTE RADIO-OPAQUE HYDROSOLUBLE POUR USAGE INTRAVASCULAIRE-MD-76","",""
"418","02-07-30","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PRSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"419","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"420","03-03-26","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL","ANTIFONGIQUE TOPIQUE","",""
"421","03-02-13","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"422","03-02-21","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOECHST MARION ROUSSEL INC.","CANADA","CANADA","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"423","03-02-20","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"424","03-02-20","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"425","03-02-19","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLOZARIL","SANDOZ CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"426","03-02-17","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"427","03-02-13","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"428","03-02-13","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"429","03-02-04","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CARBAMAZEPINE CR","MODIFICATION DU NOM DU PRODUIT DE CARBAMAZEPINE CR","ANTICONVULSANT, SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA, ANTIMANIC","ANTICONVULSIVANT, SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU, ANTIMANIAQUE","",""
"430","03-01-31","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT / SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA","ANTICONVULSIVANT / SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU","",""
"431","03-01-31","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"432","03-01-03","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1","",""
"433","03-11-25","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"434","03-10-28","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERSANTINE","BOEHRINGER INGELHEIM CANADA","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM DIPYRIDAMOLE FOR INJECTION","MODIFICATION DU NOM DU PRODUIT DE DIPYRIDAMOLE FOR INJECTION","CORONARY VASODILATOR","VASODILATATEUR CORONARIEN","",""
"435","03-10-17","BAXTER CORPORATION-CLINTEC NUTRITION DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN DEXTROSE QUICKMIX","MODIFICATION DU NOM DU PRODUIT DE TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN DEXTROSE QUICKMIX","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"436","02-07-16","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"437","02-06-20","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","RADIOPAQUE CONTRAST MEDIA","AGENT DE CONTRASTE OPACIFIANT","",""
"438","02-06-20","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","RADIOPAQUE CONTRAST MEDIA","AGENT DE CONTRASTE OPACIFIANT","",""
"439","02-06-10","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE AND ADMINISTRATION FOR POST-OPERATIVE INITIATION OF THROMBOPROPHYLAXIS IN PATIENTS UNDERGOING ELECTIVE HIP SURGERY AT HIGHER RISK OF PERIOPERATIVE BLEEDING","DOSAGE ET ADMINISTRATION RÉVISÉS POUR L'AMORCE POST-OPÉRATOIRE DE LA THROMBOPROPHYLAXIE CHEZ LES PATIENTS QUI SUBISSENT UNE CHIRURGIE ÉLECTIVE DE LA HANCHE ET QUI PRÉSENTENT UN RISQUE HÉMORRAGIQUE POST-OPÉRATOIRE ACCRU","ANTICOAGULANT, ANTITHROMBOTIC AGENT","ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"440","02-06-06","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"441","02-06-06","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST MEDIUM","AGENT DE CONTRASTE","",""
"442","03-10-17","BAXTER CORPORATION-CLINTEC NUTRITION DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN DEXTROSE QUICKMIX","MODIFICATION DU NOM DU PRODUIT DE TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN DEXTROSE QUICKMIX","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"443","02-06-06","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF PROSTATIC CARCINOMA","THÉRAPIE DU CARCINOME PROSTATIQUE","",""
"444","02-05-24","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VITAL ENTRY BLOCKING AGENT","AGENT BLOQUANT D'ENTRÉE VIRALE","",""
"445","02-05-22","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIAZEM CD","HOECHST MARION ROUSSEL CANADA","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","AGENT ANTIHYPERTENSEUR, AGENT ANTIANGINEUX","",""
"446","02-05-08","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"447","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"448","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"449","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"450","02-02-19","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MONOTHERAPY IN THE TREATMENT OF PARIENTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF A PREVIOUS CHEMOTHERAPY REGIMEN","NOUVELLE INDICATION : MONOTHÉRAPIE POUR LE TRAITEMENT OU RÉCIDIVE DE L'ÉPITHÉLIOME ÉPIDERMOÏDE MÉTASTATIQUE DE LA TÊTE ET DU COU, SUITE À L'ÉCHEC DU TRAITEMENT PAR CHIMIOTHÉRAPIE","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"451","03-10-17","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN D ANALOGUE","ANALOGUE DE LA VITAMINE D","",""
"452","02-01-10","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTIANGINAL AGENT","AGENT ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"453","02-08-02","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE DE L'ÉRYTHROPOÏÈSE","",""
"454","03-10-10","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIOPROTECTIVE AGENT","AGENT CARDIOPROTECTEUR","",""
"455","02-04-19","DRAXIMAGE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURER","CHANGEMENT DU FABRICANT","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"456","02-11-29","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"457","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"458","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"459","02-09-20","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"460","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"461","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"462","03-09-22","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"463","03-09-19","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-DIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"464","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT WITH A MUCOSAL PROTECTIVE AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE, AGENT PROTECTEUR DE LA MUQUEUSE","",""
"465","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT / ANTITHROMBOTIC AGENT","ANTICOAGULANT / ANTITHROMBOTIQUE","",""
"466","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"467","03-09-10","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"468","03-09-05","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"469","03-09-04","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPICORT","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"470","03-09-04","AXXESS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BENZODIAZEPINE","BENZODIAZÉPINES","",""
"471","03-08-25","AXXESS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL AGENT FOR SCLERODERMA TREATMENT","TRAITEMENT DE LA SCLÉRODERMIE","",""
"472","03-08-13","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"473","03-08-11","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"474","03-07-30","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE PRODUCT MONOGRAPH BASED ON RESULTS FROM FOUR STUDIES","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT BASÉE SUR LES RÉSULTATS DE QUATRE ÉTUDES","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"475","03-07-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TYPE I AND II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE TYPE I ET II DE LA 5-ALPHA RÉDUCTASE","",""
"476","03-07-21","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DRUG PRODUCT MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"477","03-07-11","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"478","03-06-09","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AS MONOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER, WHERE THERE IS AN INCREASED CARDIAC RISK","NOUVELLE INDICATION: EN MONOTHÉRAPIE CHEZ LES PATIENTS PRÉSENTANT UN CANCER DU SEIN AVEC MÉTASTASES, ET À RISQUE ACCRU DE TROUBLE CARDIAQUE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"479","03-05-16","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT FOR BOOSTER VACCINATION","AGENT D'IMMUNISATION ACTIF POUR LE RAPPEL DE VACCINATION","",""
"480","03-04-23","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, RELAXANT","ANXIOLYTIQUE, SÉDATIF","",""
"481","03-04-02","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: ALLERGIC RHINITIS","NOUVELLE INDICATION: RHINITE ALLERGIQUE","ANTIHISTAMINE H1 - RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"482","03-03-28","DIMETHAID HEALTH CARE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY - ANALGESIC","ANTI-INFLAMMATOIRE TOPIQUE - ANALGÉSIQUE","",""
"483","03-03-24","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","HISTAMINE H1 - RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"484","03-03-14","IVAX PHARMACEUTICALS INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INOTROPIC","INOTROPE","",""
"485","03-03-11","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","COLLAGENASE INHIBITOR FOR PERIODONTAL USE","INHIBITEUR DE LA COLLAGÉNASE POUR USAGE PÉRIODONTIQUE","",""
"486","03-02-13","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC / RELAXANT","ANXIOLYTIQUE / RELAXANT","",""
"487","03-01-31","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTITHROMBOTIC PROFIBRINOLYTIC ANTI-INFLAMMATORY ENZYME","ENZYME ANTITHROMBOTIQUE PROFIBRINOLYTIQUE ANTI-INFLAMMATOIRE","",""
"488","03-01-22","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM DOMPERIDONE","CHANGEMENT DU NOM DU PRODUIT DE DOMPERIDONE","Modifier of Upper Gastrointestinal Motility","Modificateur de la motilité des voies digestives supérieures","",""
"489","02-07-04","BRISTOL-MYERS SQUIBB PHARMA. GROUP, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS; PRODUCT MONOGRAPH UPDATE: REVISED DOSING OF THE CAPSULES AND TABLETS TO RECOMMEND TAKING ON AN EMPTY STOMACH","NOUVELLES CONCENTRATIONS; MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT : FORMULATION RÉVISÉE DES CAPSULES ET COMPRIMÉS POUR RECOMMANDER DE LES INGÉRER À JEUN","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"490","02-06-03","MILLENNIUM PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL INDICATION AND A NEW DOSING REGIMEN IN THE TREATMENT OF PATIENTS UNDERGOING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY","INDICATION ADDITIONNELLE ET NOUVEAU SCHÉMA POSOLOGIQUE POUR LE TRAITEMENT DES PATIENTS QUI SUBISSENT UNE ANGIOPLASTIE TRANSLUMINAIRE PERCUTANÉE","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"491","02-04-03","MILLENNIUM PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"492","02-04-03","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 25MCG/DAY","NOUVELLE CONCENTRATION : 25MCG/JOUR","ESTROGEN","OESTROGÈNE","",""
"493","02-12-24","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF FIVE-YEAR CLINICAL DATA TO PRODUCT MONOGRAPH","AJOUT DE DONNÉES CLINIQUES DE CINQ ANS À LA MONOGRAPHIE DU PRODUIT","TYPE II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"494","02-12-20","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC, ADJUNCT TO ANESTHESIA","ANALGÉSIQUE NARCOTIQUE, ADJUVANT ANESTHÉSIQUE","",""
"495","02-12-06","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN 150","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"496","02-11-28","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, AGENT ANTIOBSESSIONNEL","",""
"497","02-10-23","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN-150","PFIZER CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU RPODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"498","02-09-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROPHYLACTIC MANAGEMENT OF STEROID-RESPONSIVE BRONCHIAL ASTHMA IN PEDIATRIC PATIENTS (12 MONTHS TO 16 YEARS)","NOUVELLE INDICATION : GESTION PROPHYLACTIQUE DES PATIENTS PÉDIATRIQUES ÂGÉS DE 12 MOIS À 16 ANS ATTEINTS D'ASTHME BRONCHIQUE RÉAGISSANT BIEN À L'ADMINISTRATION DE STÉROÏDES","CORTICOSTEROID FOR ORAL INHALATION","CORTICOSTÉROÏDE POUR INHALATION ORALE","",""
"499","02-09-25","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN 150","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"500","02-08-29","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE DOSING REGIMEN OF 200MCG TWICE DAILY FOR CHILDREN AGED 4 YEARS AND ABOVE WHO REQUIRE A HIGHER DOSE TO CONTROL ASTHMA","SCHÉMA POSOLOGIQUE ALTERNATIF DE 200MCG PAR JOUR POUR LES ENFANTS ÂGÉS DE 4 ANS ET PLUS QUI ONT BESOIN D'UNE DOSE PLUS ÉLEVÉE POUR CONTRÔLER LEUR ASTHME","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE","",""
"501","02-08-29","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID I.V.","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUE H2","",""
"502","02-08-20","SQUIBB CANADA INC., A DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO THE DOSAGE & ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH REGARDING ELDERLY AND POOR RISK PATIENTS","CHANGEMENTS À LA RUBRIQUE POSOLOGIE DE LA MONOGRAPHIE DU PRODUIT POUR LES PERSONNES ÂGÉES ET LES INDIVIDUS À PAUVRE RISQUE","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"503","02-08-20","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: 10MG TABLETS","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉS DE 10MG","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"504","02-07-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SIBELIUM","JANSSEN PHAMACEUTICA","CANADA","CANADA","1","","","SELECTIVE CALCIUM-ENTRY BLOCKER","INHIBITEUR CALCIQUE SÉLECTIF","",""
"505","02-07-02","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"506","02-06-19","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GRANULOCYTE COLONY STIMULATING FACTOR, HAEMATOPOIETIC AGENT","FACTEUR STIMULANT DE COLONIES DE GRANULOCYTES, AGENT HÉMATOPOÏÉTIQUE","",""
"507","03-12-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN","OESTROGÈNE","",""
"508","02-06-13","ORGANON SANOFI-SYNTHELABO CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC ANTITHROMBOTIC","ANTITHROMBOTIQUE SYNTHÉTIQUE","",""
"509","02-06-06","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN 150","PFIZER CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"510","02-06-05","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN-150","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"511","02-06-05","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN 100 MG","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"512","02-06-05","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"513","02-05-24","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"514","03-12-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN","OESTROGÈNE","",""
"515","03-12-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN-PROGESTIN","OESTROGÈNE-PROGESTÉRONE","",""
"516","03-12-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","PROGESTIN-ESTROGEN","PROGESTÉRONE-OESTROGÈNE","",""
"517","03-11-19","MILLENNIUM PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR TREATMENT OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION","NOVELLES INDICATIONS POUR LE TRAITEMENT DES PATIENTS SUBISSANT UNE INTERVENTION CORONAIRE","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"518","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"519","03-09-22","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"520","04-04-08","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"521","04-04-05","DUSA PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOTODYNAMIC THERAPY PHOTOSENSITIZER","SENSIBILISATEUR POUR THÉRAPIE PHOTODYNAMIQUE","",""
"522","04-04-08","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN + PROGESTIN","OESTROGÈNE + PROGESTATIF","",""
"523","04-04-07","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"524","04-04-05","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES","PREGESTIN","PROGESTATIF","",""
"525","04-04-05","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARUTHMIQUE","",""
"526","04-04-05","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","FOR THE TREATMENT OF HYPOTHYROIDISM","POUR LE TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"527","04-04-05","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","FOR THE TREATMENT OF HYPOTHYROIDISM","POUR LE TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"528","04-04-05","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","FOR THE TREATMENT OF HYPOTHYROIDISM","POUR LE TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"529","04-04-05","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","FOR THE TREATMENT OF HYPOTHYROIDISM","POUR LE TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"530","04-04-05","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","FOR THE TREATMENT OF HYPOTHYROIDISM","POUR LE TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"531","03-09-19","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"532","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AROMATASE INACTIVATOR / ANTI-TUMOR AGENT","INACTIVATEUR DE L'AROMATASE / ANTITUMORAL","",""
"533","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"534","03-09-04","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISIONS TO PRODUCT MONOGRAPH - PHARMACOKINETICS AND HIGH DOSE","RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT - PHARMACOCINÉTIQUE ET DOSE ÉLEVÉE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"535","03-09-04","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - EARLY RHEUMATOID ARTHRITIS","NOUVELLE INDICATION - STADE INITIAL DE DÉVELOPPEMENT DE L'ARTHRITE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"536","03-08-01","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"537","03-07-29","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION -JUVENILE RHEUMATOID ARTHRITIS","NOUVELLE INDICATION - ARTHRITE RHUMATOÏDE JUVÉNILE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"538","03-07-14","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"539","02-05-24","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"540","02-05-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"541","03-06-03","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDRONEL","PROCTOR & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR, ANTI-PAGETIC AGENT, ANTI-HYPERCALCEMIC AGENT","RÉGULATEUR DU MÉTABOLISME OSSEUX, AGENT ANTI PAGETIQUE, AGENT ANTIHYPERCALCÉMIQUE","",""
"542","02-05-24","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"543","02-05-10","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID I.V.","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"544","02-05-08","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID WITH ANTIBACTERIAL, ANTIFUNGAL AGENT","CORTICOSTÉROÏDE TOPIQUE, ANTIBACTÉRIEN, ANTIFONGIQUE","",""
"545","02-05-08","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID WITH ANTIBACTERIAL, ANTIFUNGAL AGENT FOR AURAL USE","CORTICOSTÉROÏDE TOPIQUE, ANTIBACTÉRIEN, ANTIFONGIQUE POUR USAGE AURICULAIRE","",""
"546","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"547","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK SHARP & DOHME","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"548","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"549","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant, Antiobsessional Agent","Antidépresseur, Agent Antiobsessionnel","",""
"550","02-04-02","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID I.V.","MERCK FROSST CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"551","02-04-02","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","Histamine H2 Receptor Antagonist","Antagoniste des récepteurs histaminiques H2","",""
"552","02-03-11","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"553","02-02-19","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTISPASMODIC","ANTISPASMODIQUE AGISSANT SUR LES VOIES URINAIRES","",""
"554","02-02-14","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL ANTIBOULIMIQUE","",""
"555","02-01-31","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT : MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"556","02-01-31","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT : MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"557","02-01-11","ORYX PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"558","02-06-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"559","02-10-10","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","HUMAN GONADOTROPIN","GONADOTROPHINE HUMAINE","",""
"560","02-12-10","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM GABAPENTIN","MODIFICATION DU NOM DU PRODUIT DE GABAPENTIN","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"561","02-10-24","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"562","02-07-30","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS INC.","CANADA","CANADA","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"563","02-07-16","FIRST HORIZON PHARMACEUTICAL CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC","ANTICHOLINERGIQUE","",""
"564","02-05-27","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT ORAL","",""
"565","02-05-27","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PARAMAGNETIC, INTRAVASCULAR CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","PARAMAGNÉTIQUE, AGENT DE CONTRASTE INTRAVASCULAIRE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE (IRM)","",""
"566","02-05-27","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL AGENT","AGENT RADIOPHARMACEUTIQUE DE DIAGNOSTIC","",""
"567","02-05-01","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"568","02-05-01","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GONADOTROPIN-RELEASING HORMONE (GNRH) ANTAGONIST","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE (GNRH)","",""
"569","02-04-16","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: 5-DAY TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS","NOUVELLE INDICATION : TRAITEMENT DE 5 JOURS DE LA BRONCHITE CHRONIQUE EN POUSSÉE ÉVOLUTIVE","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"570","02-03-20","TEVA PHARMACEUTICALS USA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORMAT: PRE-FILLED SYRINGE","NOUVELLE FORME POSOLOGIQUE : SERINGUE PRÉREMPLIE","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"571","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - FOR DIAGNOSTIC USE","AGENT RADIOPHARMACEUTIQUE - POUR USAGE DIAGNOSTIQUE","",""
"572","02-01-25","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HUPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIQUE ORAL (SULFONYLUREA)","",""
"573","02-01-21","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE USE IN COMBINATION WITH CISPLATIN FOR PATIENTS WITH STAGE IV (LOCALLY ADVANCED OR METASTATIC) TRANSITIONAL CELL CARCINOMA (TCC) OF THE BLADDER","NOUVELLE INDICATION : À ÊTRE UTILISÉ CONJOINTEMENT À LA CISPLASTINE POUR LE TRAITEMENT DU CARCINOME DE LA VESSIE DE TYPE TRANSITIONNEL PHASE IV","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"574","02-01-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON TABLETS 80MG","SERVIER CANADA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC AGENT","AGENT HYPOGLYCÉMIANT ORAL","",""
"575","02-12-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAQUENIL","SANOFI CANADA INC.","CANADA","CANADA","1","","","ANTI-RHEUMATIC, ANTIMALARIAL","ANTI-INFLAMMATOIRE, ANTIPALUDÉEN","",""
"576","02-12-04","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DOSING SCHEDULE (ADULT PRESENTATION)","PLAN POSOLOGIQUE ALTERNATIF (PRÉSENTATION ADULTE)","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"577","02-10-18","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"578","02-10-18","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","INJECTABLE VACCINE","VACCIN INJECTABLE","",""
"579","02-07-08","BIOTIME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLASMA VOLUME EXPANDER","EXPANSION DU VOLUME DE PLASMA","",""
"580","02-05-30","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: IMMEDIATE RELEASE TABLETS","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉS À LIBÉRATION IMMÉDIATE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"581","02-05-28","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PURIFICATION AND FORMULATION FACILITY, THIMEROSAL-FREE FORMULATION - 10MCG/ML (ADULT PRESENTATION) - 40MCG/ML (DIALYSIS FORMULATION)","NOUVEAU SITE DE FORMULATION DE PURIFICATION, FORMULATION SANS THIMÉROSAL - 10MCG/ML (PRÉSENTATION ADULTE) - 40MCG/ML (FORMULATION POUR LA DIALYSE)","VACCINE FOR IMMUNIZATION - HEPATITIS B","VACCIN POUR L'IMMUNISATION CONTRE L'HÉPATITE B","",""
"582","02-05-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"583","02-05-02","BERNA BIOTECH LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"584","02-04-16","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DOSING SCHEDULE AND BOOSTER WORDING","NOUVEAU PLAN POSOLOGIQUE ET PERSISTANCE DE L'EFFICACITÉ","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"585","02-04-16","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SOURCE OF INGREDIENT","DIFFÉRENTE SOURCE DE L'INGRÉDIENT","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"586","02-03-22","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","PROPHYLACTIC VACCINE","VACCIN PROPHYLACTIQUE","",""
"587","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"588","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"589","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"590","02-01-10","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST HEPATITIS A VIRUS","AGENT D'IMMUNISATION ACTIVE CONTRE LE VIRUS DE L'HÉPATITE A","",""
"591","02-12-10","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","DIAGNOSTIC AGENT FOR THE DELINEATION OF LYMPHATIC VESSELS","AGENT DIGNOSTIQUE POUR LA DÉLINÉATION DES VAISSEAUX LUMPHATIQUE","",""
"592","02-11-05","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS AND RENAL DISEASE TO REDUCE THE RATE OF PROGRESSION OF NEPHROPATHY","NOUVELLE INDICATION : TRAITEMENT DES PATIENTS HYPERTENSIFS QUI SOUFFRENT DE DIABÈTE MELLITUS TYPE 2 ET DE MALADIE RÉNAL DANS LE BUT DE RÉDUIRE LE TAUX DE PROGRESSION DE LA NÉPHROPATHIE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"593","02-10-17","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTHS","NOUVELLE FORME POSOLOGIQUE ET NOUVELLES CONCENTRATIONS","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"594","02-10-16","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IFEX","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"595","02-09-13","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"596","02-09-10","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","REAGENT FOR PREPARATION OF A RADIODIAGNOSTIC AGENT","RÉACTIF POUR LA PRÉPARATION D'AGENTS RADIODIAGNOSTIQUES","",""
"597","02-08-21","BIOGEN CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CONVERSION FROM SINGLE PRODUCT FACILITY TO MULTI-PRODUCT FACILITY","CONVERSION D'UNE INSTALLATION À PRODUIT UNIQUE À UNE INSTALLATION MULTI-PRODUITS","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"598","02-08-09","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: INTRAVENOUS CONTRAST ENHANCEMENT IN COMPUTED TOMOGRAPHY OF THE BODY IN ADULTS - ISOVUE 370 (76%) INJECTION; NEW DOSAGE FOR INTRAVENOUS CONTRAST ENHANCEMENT IN COMPUTED TOMOGRAPHY OF THE BODY IN ADULTS: 100-150ML ADMINISTRED BY RAPID INTRAVENOUS BOLUS INJECTION OR INFUSION - ISOVUE 300 (61%) INJECTION","NOUVELLE INDICATION : AMÉLIORATION DU CONTRASTE INTRAVEINEUX POUR LA TOMOGRAPHIE PAR ORDINATEUR DU CORPS CHEZ L'ADULTE - INJECTION INTRAVEINEUSE D'ISOVUE 370 (76%); NOUVEAU DOSAGE POUR L'AMÉLIORATION DU CONTRASTE INTRAVEINEUX POUR LA TOMOGRAPHIE PAR ORDINATEUR DU CORPS CHEZ L'ADULTE : 100-150ML ADMINISTRÉ PAR INJECTION INTRAVEINEUSE BOLUS RAPIDE OU PAR PERFUSION - INJECTION D'ISOVUE 300 (61%)","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","AGENT DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"599","02-08-07","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"600","02-07-10","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMBIVENT","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","BRONCHODILATATOR","BRONCHODILATATEUR","",""
"601","02-07-10","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATROVENT","BOEHRINGER INGELHEIM (CANADA) INC.","CANADA","CANADA","1","","","TOPICAL ANTICHOLINERGIQUE","ANTICHOLINERGIQUE TOPIQUE","",""
"602","02-07-04","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN HIV-INFECTED PEDIATRIC PATIENTS; REVISED FORMULATION OF THE 100MG CAPSULES","NOUVELLE INDICATION : POUR LES PATIENTS PÉDIATRIQUES INFECTÉS AU VIH; FORMULATION RÉVISÉE DES CAPSULES DE 100MG","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"603","02-07-02","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC RADIOGRAPHIC CONTRAST MEDIUM","AGENT DE CONTRASTE RADIOLOGIQUE NON IONIQUE","",""
"604","02-07-02","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVASCULAR X-RAY CONTRAST MEDIUM","SUBSTANCE DE CONTRASTE DE RADIOGRAPHIE INTRAVASCULAIRE","",""
"605","02-06-25","BIOGEN CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CONVERSION FROM SINGLE PRODUCT FACILITY TO MULTI PRODUCT FACILITY","CONVERSION D'UNE INSTALLATION À PRODUIT UNIQUE À UNE INSTALLATION MULTI-PRODUITS","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"606","02-06-19","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"607","02-06-19","VITA HEALTH PRODUCTS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"608","02-06-17","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"610","02-05-14","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"611","03-05-26","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS REGARDING THE ADMINISTRATION OF DISPERSED TABLETS THROUGH NASO-GASTRIC TUBES","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT RELATIVEMENT À L'ADMINISTRATION DES COMPRIMÉS DISPERSÉS PAR TUBES NASO-GASTRIQUES","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"612","02-05-14","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","ADDITION OF 400MG CAPLET AS A NON-PRESCRIPTION PRODUCT","AJOUT D'UN COMPRIMÉ DE 400MG COMME PRODUIT SANS ORDONNANCE","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"613","02-05-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"614","02-05-02","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","ANTICHOLINERGIQUE TOPIQUE ADMINISTRÉ PAR VOIE NASALE","",""
"615","02-05-01","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"616","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Nonsteroidal Anti-Inflammatory Analgesic Agent","Analgésique anti-inflammatoire non stéroïdien","",""
"617","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"618","02-04-30","MCNEIL CONSUMER HEALTHCARE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT NASAL","",""
"619","02-04-16","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITION OF ALTERNATE MANUFACTURING SITE","AJOUT D'UN AUTRE SITE DE FABRICATION","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"620","03-05-12","MERCK FROSST/SCHERING PHARMA GP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLESTEROL ABSORPTION INHIBITOR","INHIBITEUR DE L'ABSORPTION DU CHOLESTÉROL","",""
"621","02-04-03","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"622","02-02-14","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"623","02-02-04","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"624","02-01-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","","","DIURETIC, ANTIHYPERTENSIVE AGENT","AGENT DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"625","02-01-18","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN LABELS TO INCLUDE DOSING FOR CHILDREN LESS THAN 24 MONTHS AND CHANGE TO PRODUCT MONOGRAPH TO INCLUDE DOSING FOR CHILDREN LESS THAN SIX MONTHS","MODIFICATION À L'ÉTIQUETAGE POUR INCLURE LA POSOLOGIE POUR LES ENFANTS DE MOINS DE 24 MOIS ET MODIFICATION À LA MONOGRAPHIE DU PRODUIT POUR INCLURE LA POSOLOGIE POUR LES ENFANTS DE MOINS DE 6 MOIS","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"626","03-05-12","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"627","02-11-27","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KETALAR","PFIZER CANADA INC.","CANADA","CANADA","1","","","GENERAL ANESTHETIC","ANESTHÉSIQUE GÉNÉRAL","",""
"628","02-11-04","PANGEO HEALTH SCIENCES DIV. OF/DE PANGEO PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PEDIATRIC ASTHMA PROPHYLACTIC, ANTIALLERGIC AGENT","AGENT PROPHYLACTIQUE DE L'ASTHME INFANTILE, AGENT ANTIALLERGIQUE","",""
"629","02-05-27","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: OPHTHALMIC SOLUTION","NOUVELLE FORME POSOLOGIQUE : SOLUTION OPHTALMIQUE","TOPICAL ANTI-INFLAMMATORY AGENT","AGENT ANTI-INFLAMMATOIRE TOPIQUE","",""
"630","02-04-03","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NIZORAL CREAM","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"631","03-04-14","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIVELLE 100","CIBA PHARMACEUTICALS, CIBA GEIGY CANADA LTD.","CANADA","CANADA","1","","","ESTROGEN THERAPY","THÉRAPIE D'OESTROGÈNE","",""
"632","02-12-20","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"633","03-02-28","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH INCLUDING REDUCED DOSAGE REGIMEN FOR PATIENTS WITH SEVERE RENAL IMPAIRMENT","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT INCLUANT UNE POSOLOGIE RÉDUITE POUR LES PERSONNES ATTEINTES DE DÉFICIENCE RÉNALE GRAVE","ANTICOAGULANT, ANTITHROMBOTIC AGENT","ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"634","02-12-11","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION (TABLETS 250MG, 500MG, 750MG; INJECTION 25MG/ML, 5MG/ML IN 5% DEXTROSE): COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (MILD TO MODERATE), EXCLUDING BURNS, DUE TO ENTEROCOCCUS FAECALIS, METHICILLIN-SENSITIVE STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PYOGENES, PROTEUS MIRABILIS, OR STREPTOCOCCUS AGALACTIAE; NEW DOSING REGIMEN OF 750MG ONCE DAILY FOR TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"635","02-12-11","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW TABLET STRENGTH 750MG","NOUVELLE CONCENTRATION DU COMPRIMÉ 750MG","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"636","02-12-10","RATIOPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"637","03-12-09","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"638","02-10-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN F2A ANALOGUE AND BETA-ADRENERGIC RECEPTOR BLOCKER","ANALOGUE DE LA PROSTAGLANDINE F2A ET INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"639","02-09-11","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme lipidique","",""
"640","03-11-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"641","02-08-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"642","02-07-12","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"643","02-06-28","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTITHROMBOTIC","AGENT ANTITHROMBOTIQUE","",""
"644","02-05-22","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK SHARP AND DOHME","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"645","03-11-06","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK FROSST CANADA AND COMPANY","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"646","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"647","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Glaucoma Therapy, Noncardioselective Beta-Adrenoceptor Blocking Agent","Traitement du glaucome, Inhibiteur non cardiosélectif des récepteurs Bêta-Adrénergiques","",""
"648","03-09-19","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANDROGENIC - ANABOLIC STEROID","ANDROGÈNE - STÉROÏDE ANABOLISANT","",""
"649","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"650","02-04-16","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC-SEDATIVE","ANXIOLYTIQUE-SÉDATIF","",""
"651","02-03-20","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"652","02-03-11","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"653","03-09-19","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION AND FILL-BY-MASS","NOUVELLE FORMULATION ET REMPLISSAGE BASÉ SUR LA MASSE","GONADOTROPHIN","GONADOTROPHINE","",""
"654","02-02-27","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTITHROMBOTIC","ANTITHROMBOTIQUE","",""
"655","02-02-27","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"656","03-09-16","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"657","03-09-16","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"658","02-02-19","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: TOPICAL ANALGESIA ON INTACT SKIN PRIOR TO VACCINATION WITH VACCINES THAT HAVE BEEN SHOWN NOT TO INTERACT WITH EMLA IN CLINICAL TRIALS","NOUVELLE INDICATION : ANALGÉSIE TOPIQUE AVENT LA VACCINATION AVEC DES VACCINS, QUI LORS DES ESSAIS CLINIQUES, N'ONT PAS DÉMONTRÉ D'INTERACTION ANTAGONISTE AVEC L'EMLA","TOPICAL ANESTHETIC FOR DERMAL ANALGESIA","ANESTHÉSIQUE TOPIQUE POUR ANALGÉSIE DERMIQUE","",""
"659","02-02-14","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"660","02-02-06","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM: CAPLETS","NOUVELLE FORME POSOLOGIOQUE : CAPLETS","ORAL ANTIDIARRHEAL, ANTIFLATULENT","ANTIDIARRHÉIQUE ORAL, ANTIFLATULENT","",""
"661","02-01-21","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN >= 14 YEARS OF AGE","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ACNÉ VULGAIRE MODÉRÉ CHEZ LES FEMMES DE 14 ANS ET PLUS","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"662","03-09-11","LABORATOIRES FOURNIER S.A.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXTEND THE CLINICAL INDICATION TO INCLUDE ADULT PATIENTS WITH TYPE 2 DIABETES, WHO ARE AT RISK OF CORONARY ATHEROSCLEROSIS","AJOUTER AUX INDICATIONS CLINIQUES LE TRAITEMENT DES ADULTES SOUFFRANT DE DIABÈTE DE TYPE 2 AVEC RISQUE D'ATHÉROSCLÉROSE CORONARIENNE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"663","03-09-05","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"664","02-12-16","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERGLYCEMIC","ANTIHYPERGLYCÉMIANT","",""
"665","02-12-10","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"666","02-12-06","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","","","PROGESTAGEN","PROGESTATIF","",""
"667","02-09-20","DRAXIMAGE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING SITE","CHANGEMENT DE SITE DE FABRICATION","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"668","02-10-24","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"669","02-10-17","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"670","02-10-09","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","","","PROGESTAGEN","PROGESTATIF","",""
"671","02-10-09","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANITMETABOLITE/ANTIRHEUMATIC","ANTIMÉTABOLITE/ANTIRHUMATISMALE","",""
"672","02-09-26","METHAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","CHOLINERGIC/DIAGNOSTIC AID (BRONCHIAL ASTHMA)","CHOLINERGIQUE/AUXILIAIRE DIAGNOSTIQUE (ASTHME BRONCHIQUE)","",""
"673","02-09-25","ORBUS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"674","02-09-19","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOVANTRONE","WYETH AYERST CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"675","02-07-19","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF NEW STRENGTH","ADDITION D'UNE NOUVELLE CONCENTRATION","BETA-ADRENOCEPTOR AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"676","02-07-02","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","IONIC, WATER SOLUBLE RADIOPAQUE CONTRAST MEDIUM FOR INTRAVASCULAR USE","IONIQUE, SUBSTANCE DE CONTRASTE RADIO-OPAQUE HYDROSOLUBLE POUR USAGE INTRAVASCULAIRE","",""
"677","02-06-26","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVASCULAR X-RAY CONTRAST MEDIUM","AGENT DE CONTRASTE RADIOLOGIQUE INTRAVASCULAIRE","",""
"678","02-06-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERIE CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"679","02-06-21","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL RADIOPAQUE CONTRAST MEDIUM FOR DILUTION","AGENT DE CONTRASTE RADIOLOGIQUE ORAL","",""
"680","02-06-20","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","RETROGRADE CYSTOGRAPHY AND CYSTOURETHROGRAPHY X-RAY CONTRAST","AGENT DE CONTRASTE RADIOLOGIQUE CYSTOGRAPHIE RÉTROGRADE ET CYSTOURÉTROGRAPHIE","",""
"681","02-06-13","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REFORMULATION OF THE 2MG TABLET; NEW DRUG PRODUCT MANUFACTURING SITE; NEW DRUG SUBSTANCE MANUFACTURING SITE","REFORMULATION DU COMPRIMÉ DE 2 MG; NOUVEAU SITE DE FABRICATION DU PRODUIT; NOUVEAU SITE DE FABRICATION DE LA SUBSTANCE MÉDICAMENTEUSE","ANTINEOPLASTIC (ALKYLATING) AGENT","ANTINÉOPLASIQUE","",""
"682","02-05-28","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR VIII","FACTEUR VIII DE COAGULATION ANTIHÉMORRAGIQUE","",""
"683","02-05-28","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEPTAZANE","WYETH-AYERST CANADA","CANADA","CANADA","1","","","CARBONIC ANHYDRASE INHIBITOR","INHIBITEUR DE L'ANHYDRASE CARBONIQUE","",""
"684","02-05-15","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CONVERSION TO MULTI-PRODUCT FAMILY","CONVERSION À UN ÉTABLISSEMENT MULTI-PRODUITS","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"685","02-05-15","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE","",""
"686","02-05-10","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"687","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MS CONTIN","PURDUE FREDERICK","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"688","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","HOECHST MARION ROUSSEL CANADA","CANADA","CANADA","1","","","ORAL ANTIHYPERGYLCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"689","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"690","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"691","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"692","02-03-08","GALDERMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AGENT FOR THE TREATMENT OF SOLAR LENTIGINES AND RELATED HYPERPIGMENTED LESIONS","AGENT POUR LE TRAITEMENT DES LENTIGINES SOLAIRES ET LÉSIONS CONNEXES DE PIGMENTATION EXCESSIVE","",""
"693","02-03-07","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPO-MEDROL","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"694","02-02-27","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"695","02-02-27","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"696","02-02-04","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","UROPROTECTOR","UROPROTECTEUR","",""
"697","02-02-04","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ROSACEA AGENT","AGENT ANTIROSACÉE","",""
"698","02-01-22","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"699","02-01-07","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"700","02-01-07","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","RADIODIAGNOSTIC AGENT (HEPATOBILIARY IMAGING)","AGENT RADIODIAGNOSTIQUE (IMAGE HÉPATOBILIAIRE)","",""
"701","02-12-24","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION: ADDITION OF 20MG ONCE DAILY DOSE FOR THE INITIATION OF THERAPY IN MILD TO MODERATE ESSENTIAL HYPERTENSION PATIENTS","RÉVISION DE LA MONOGRAPHIE DU PRODUIT: AJOUT D'UNE DOSE DE 20 MG PAR JOUR POUR LA THÉRAPIE INITIALE DE L'HYPERTENSION ESSENTIELLE LÉGÈRE OU MOYENNE","ANTIANGINAL, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"702","02-12-10","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM NEFAZODONE","MODIFICATION DU NOM DU PRODUIT DE NEFAZODONE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"703","02-12-09","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK SHARP & DOHME CANADA","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"704","02-12-06","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL MYERS SQUIBB","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"705","02-11-29","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC AGENT FOR THE RELIEF OF SELECTED SYMPTOMS IN PATIENTS WITH ORGANIC BRAIN SYNDROME/PERIPHERAL VASODILATOR","AGENT SYMPATHICOMIMÉTIQUE POUR LE SOULAGEMENT DE SYMPTÔMES PRÉCIS CHEZ LES PERSONNES PRÉSENTANT UN SYNDROME CÉRÉBRAL ORGANIQUE/VASODILATATEUR PÉRIPHÉRIQUE","",""
"706","02-11-13","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - ENTERIC COATED TABLETS","NOUVELLE FORM POSOLOGIQUE - COMPRIMÉS GASTRO-RÉSISTANTS","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"707","02-09-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK SHARP & DOHME CANADA","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"708","02-09-09","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"709","02-08-20","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HORMONAL CONTRACEPTIVE","CONTRACEPTIF HORMONAL","",""
"710","02-08-07","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"711","02-07-30","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"712","02-07-10","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AXID","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"713","02-06-20","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"714","02-05-27","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVENTYL","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"715","02-05-08","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AND ANTIHYPERTENSIVE AGENT","ANTIANGINEUX ET ANTIHYPERTENSEUR","",""
"716","02-05-02","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"717","02-04-10","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"718","02-03-07","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"719","02-02-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE ORAL","",""
"720","02-02-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"721","02-02-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"722","02-01-25","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"723","02-01-25","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"724","02-01-23","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"725","02-01-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOGADON","ICN CANADA LIMITED","CANADA","CANADA","1","","","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE ET ANTICONVULSIVANT","",""
"726","02-01-18","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"727","02-12-16","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL STRENGTH","DOSAGE ADDITIONNEL","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"728","02-07-10","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"729","02-05-15","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"730","02-05-10","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"731","02-03-11","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND INDICATION - POWDER FOR ORAL SUSUPENSION TO BE USED IN THE TREATMENT OF PEDIATRIC PATIENTS ONE YEAR AND OLDER","NOUVELLE PRÉSENTATION ET INDICATION - POUDRE POUR SUSPENSION ORALE POUR LE TRAITEMENT DES ENFANTS ÂGÉSDE UN AN ET PLUS","ANTIVIRAL AGENT","ANTIVIRAL","",""
"732","02-02-21","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"733","02-02-08","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN COMBINATION WITH ANTI-DIABETIC AGENTS TO IMPROVE BLOOD GLUCOSE CONTROL IN OVERWEIGHT OR OBESE TYPE 2 DIABETES PATIENTS","NOUVELLE INDICATION: POUR ÊTRE UTILISÉ EN ASSOCIATION AVEC DES AGENTS ANTI-DIABÉTIQUES POUR AMÉLIORER LE CONTRÔLE DU GLUCOSE SANGUIN CHEZ LES SUJETS OBÈSES OU QUI PRÉSENTENT UN DIABÈTE DE TYPE 2","ANTI-OBESITY AGENT/GASTROINTESTINAL LIPASE INHIBITOR","AGENT ANTIOBÉSITÉ/INHIBITEUR DES LIPASES GASTRO-INTESTINALES","",""
"734","02-02-04","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"735","02-11-28","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PSYCHOTROPIC AGENT","PSYCHOTROPE","",""
"736","02-11-08","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"737","02-11-05","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PIPRACIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"738","03-09-04","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: ADVERSE EFFECTS FOLLOWING DISCONTINUATION OF TREATMENT","MONOGRAPHIE RÉVISÉE DU PRODUIT: EFFETS INDÉSIRABLES SUITE À L'ABANDON DU TRAITEMENT","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, AGENT ANTIOBSESSIONNEL","",""
"739","02-11-04","PANGEO HEALTH SCIENCES DIV. OF/DE PANGEO PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASCULAR HEADACHE PROPHYLAXIS","PROPHYLAXIE DES CÉPHALÉES VASCULAIRES","",""
"740","02-10-18","SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE/DIURÉTIQUE","",""
"741","02-10-18","SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE/DIURÉTIQUE","",""
"742","02-10-16","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 8MG TABLET","NOUVELLE CONCENTRATION: COMPRIMÉ DE 8MG","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"743","02-10-09","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"744","02-09-27","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"745","03-09-04","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"746","02-09-10","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","TROUSSE RADIODIAGNOSTIQUE","",""
"747","02-09-03","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","NEUROLEPTIQUE","",""
"748","02-08-29","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION","NOUVELLE INDICATION: POUR LE TRAITEMENT DE L'HYPERTENSION ESSENTIELLE LÉGÈRE À MODÉRÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"749","02-08-20","ALTANA PHARMA AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"750","02-07-30","ALTANA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"751","02-07-16","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"752","01-12-31","GLAXOSMITHKLINE SHIRE BIOCHEM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"753","02-07-12","MM THERAPEUTICS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"754","02-07-10","SQUIBB CANADA INC., A DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF A CAUTIONARY STATEMENT TO THE DOSAGE & ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","AJOUT D'UNE MISE EN GARDE SOUS LES RUBRIQUES POSOLOGIE ET MODE D'ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"755","02-06-19","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE REGARDING USE IN PATIENTS WITH HEPATIC IMPAIRMENT AND/OR RENAL INSUFFICIENCY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT POUR LE TRAITEMENT DES PATIENTS PRÉSENTANT UN PROBLÈME DE LA FONCTION HÉPATIQUE ET/OU INFUFFISANCE RÉNALE","CHOLINOMIMETIC AGENT","AGENT CHOLINOMIMÉTIQUE","",""
"757","02-05-31","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER PLUS ANTIVIRAL AGENT","MODULATEUR DES RÉACTIONS BIOLOGIQUES, ANTIVIRAL","",""
"758","01-12-20","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ALTI-AMOXI CLAV 125F AND ALTI-AMOXI CLAV 250F","MODIFICATION DU NOM DU PRODUIT DE ALTI-AMOXI CLAV 125F ET ALTI-AMOXI CLAV 250F","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"759","02-05-30","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","VASOACTIVE AGENT","AGENT VASO-ACTIF","",""
"760","01-11-30","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"761","01-11-22","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT, ANTIPARKINSONIAN AGENT","ANTIVIRAL, ANTIPARKINSONIEN","",""
"762","02-05-17","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE USE IN THE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA","NOUVELLE INDICATION: POUR LE TRAITEMENT DU SARCOME DE KAPOSI RELIÉ AU SIDA","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"763","02-05-15","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT (HUMANIZED MONOCLONAL ANTIBODY)","AGENT D'IMMUNISATION PASSIVE (ANTICORPS MONOCLONAUX HUMANISÉE)","",""
"764","01-11-21","GLAXOSMITHKLINE INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"765","02-05-01","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLYCOSAMINOGLYCAN SUBSTITUTE","SUCCÉDANÉ DE GLYCOSAMINOGLYCANNE","",""
"766","02-04-19","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SYMPTOMATIC TREATMENT OF POSTTRAUMATIC STRESS DISORDER","NOUVELLE INDICATION: TRAITEMENT SYMPTOMATIQUE DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","ANTIDEPRESSANT-ANTIOBSESSIONAL-ANTIPANIC-ANXIOLYTIC AGENT-SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER)-POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE D'ANXIÉTÉ SOCIALE), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"767","02-03-22","SIGMA-TAU PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"768","02-03-08","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEDIAPRED","RHÔNE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","GLUCOCORTICOID/ANTI-INFLAMMATORY","GLUCOCORTICOÏDE, ANTI-INFLAMMATOIRE","",""
"769","02-03-07","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"770","02-02-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ORAP","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC","NEUROLEPTIQUE","",""
"771","02-02-15","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST INFECTIONS CAUSED BY PNEUMOCCI","AGENT D'IMMUNISATION ACTIVE CONTRE LES INFECTIONS SYSTÉMIQUES À PNEUMOCOQUES","",""
"772","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRAST ENHANCING IMAGING AGENT","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE","",""
"773","02-02-04","BLES BIOCHEMICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","LUNG SURFACTANT (BOVINE)","SURFACTANT PULMONAIRE (BOVINE)","",""
"774","02-01-11","DENTSPLY CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"775","02-01-11","DENTSPLY CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"776","02-12-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"777","02-12-09","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 35MG FILM-COATED TABLETS; NEW DOSING REGIMEN: ONCE A WEEK FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS","NOUVELLE CONCENTRATION: COMPRIMÉS DE 35MG ENROBÉS D'UNE PELLICULE; NOUVELLE POSOLOGIE: UNE FOIS PAR SEMAINE POUR LE TRAITEMENT DE L'OSTÉOPOROSE POST-MÉNOPAUSIQUE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"778","02-11-06","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION - FOR USE IN THE TREATMENT OF PATIENTS WITH CD20 POSITIVE, DIFFUSE LARGE B-CELL NOON-HODGKIN'S LYMPHOMA COMBINATION WITH CHOP CHEMOTHERAPY","NOUVELLE INDICATION: POUR LE TRAITEMENT DES PATIENTS AVEC LYMPHOME NON HODGKINIEN DIFFUS À GRANDES CELLULES DE PHÉNOTYPE B CD20-POSITIVES EN COMBINATIONS AVEC LE TRAITEMENT CHIMIOTHÉRAPEUTIQUE CHOP","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"779","02-08-27","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"780","02-08-13","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"781","02-08-13","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"782","02-06-26","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"783","02-03-11","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","NEW PRODUCT NAME","NOUVEAU NOM DU PRODUIT","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"784","02-02-06","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORAL SOLUTION","NOUVELLE FORME POSOLOGIQUE: SOLUTION ORALE","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"785","02-01-23","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH AND LABEL REVISIONS","RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT ET DE L'ÉTIQUETTE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"786","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"787","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL-FOR DIAGNOSTIC USE","RADIOPHARMACEUTIQUE-POUR USAGE DIAGNOSTIQUE","",""
"788","02-12-09","RATIOPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","HYPNOTIC","HYPNOTIQUE","",""
"789","02-05-27","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"790","02-08-07","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF BONE METASTASES DUE TO PROSTATE CANCER IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY","NOUVELLE INDICATION: TRAITEMENT DES MÉTASTASES OSSEUSES SECONDAIRES À UN CANCER DE LA PROSTATE CONJOINTEMENT À UNE THÉRAPIE UNIFORME ANTINÉOPLASIQUE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"791","02-07-30","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","HYPNOTIC AGENT","HYPNOTIQUE","",""
"792","02-04-19","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC AGENT","AGENT HYPNOTIQUE","",""
"793","02-01-31","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION: SAFETY UPDATE - INCREASE IN THE INFUSION DILUTION VOLUMEFROM 50 TO 100 ML","RÉVISION À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ - AUGMENTATIONDU VOLUME DE DILUTION DE L'INFUSION DE 50 À 100 ML","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"794","02-05-01","LINSON PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTICOAGULANT","ANTICOAGULANT","",""
"795","02-04-16","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT PHARMA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLES CONCENTRATION","ANTICOAGULANT","ANTICOAGULANT","",""
"796","02-01-02","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"797","03-09-04","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIDEX OINTMENT, TOPSYN GEL","SYNTEX CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"798","02-12-13","AMERSHAM HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE TO IN-PROCESS CONTROL","MODIFICATION DES CONTRÔLES EN COURS DE PRODUCTION","DIAGNOSTIC RADIOPHARMACEUTICAL","PRODUIT RADIOPHARMACEUTIQUE À USAGE DIAGNOSTIQUE","",""
"799","01-11-21","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"800","02-11-29","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC","NEUROLEPTIQUE","",""
"801","01-11-13","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO REINSTATE 50MG/VIAL INJECTION WHICH WAS ORIGINALLY CLEARED MARCH 24, 1974 BUT NEVER SOLD IN CANADA","RÉTABLIR LE VIAL DE 50 MG POUR INJECTION QUI AVAIT ÉTÉ APPROUVÉ INITIALEMENT LE 24 MARS 1974 MAIS QUI N'A JAMAIS ÉTÉ COMMERCIALISÉ AU CANADA","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"802","02-11-28","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPRURITIC/ANTIHISTAMINIC","ANTIPRURIGINEUX/ANTIHISTAMINIQUE","",""
"803","02-11-20","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"804","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"805","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"806","02-10-23","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISIONS TO PRODUCT MONOGRAPH-CHANGE IN AGE INDICATION FROM AGED 12 TO 54 YEARS TO READ AGED 11 TO 54 YEARS; THE SAFETY OF ADACEL WHEN CONCURRENTLY ADMINISTERED WITH HEPATITIS B VACCINE","RÉVISIONS À LA MONOGRAPHIE DE PRODUIT: -MODIFICATION DE L'ÂGE D'INDICATION DE ÂGÉ DE 12 À 54 ANS À ÂGÉ DE 11 À 54 ANS; SÉCURITÉ D'ADACEL LORSQU'ADMINISTRÉ CONJOINTEMENT AVEC LE VACCIN DE L'HÉPATITE B","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"807","02-10-15","ORYX PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"808","02-10-15","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC","MERCK FROSST","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"809","01-10-17","GLAXO WELLCOME BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"810","02-10-04","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYKLOKAPRON","PHARMACIA AND UPJOHN INC.","CANADA","CANADA","1","","","ANTIFIBRINOLYTIC AGENT","AGENT ANTIFIBRINOLYTIQUE","",""
"811","01-10-12","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"812","01-10-12","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"813","02-09-09","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","CHOLESTATIC LIVER DISEASES","MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"814","02-06-19","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 500MG","NOUVELLE CONCENTRATION: 500MG","CHOLESTATIC LIVER DISEASES","MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"815","01-10-09","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVEAUX DOSAGES","ANTIBIOTIC & BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"816","02-04-03","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY, DOCOSANOID","TRAITEMENT D'UNE PRESSION INTRAOCULAIRE ÉLEVÉE, DOCOSANOÏDE","",""
"817","02-12-11","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"818","03-09-03","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"819","02-11-29","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"820","02-11-29","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"821","03-09-03","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"822","02-11-04","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"823","01-09-21","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MAINTENANCE OF REMISSION OF MILD TO MODERATE ULCERATIVE COLITIS","NOUVELLE INDICATION : MAINTIEN DE LA RÉMISSION DE LA COLITE ULCÉREUSE BÉNIGNE À MODÉRÉE","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DE LA PARTIE BASSE DU TUBE DIGESTIF","",""
"824","03-08-25","AXXESS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"825","02-06-19","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FULLY REFRIGERATOR-STABLE VACCINE","RÉFRIGÉRATEUR-VACCIN STABLE","ACTIVE IMMUNIZING AGENT AGAINST VARICELLA","AGENT D'IMMUNISATION ACTIVE CONTRE LA VARICELLE","",""
"826","02-05-31","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","SEARLE CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"827","02-05-15","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"828","03-08-12","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"829","02-05-03","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"830","02-04-10","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"831","02-04-16","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING PROCESS","NOUVEAU PROCÉDÉ DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"832","03-07-21","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"833","02-10-04","UNITED THERAPEUTICS CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASODILATOR","VASODILATATEUR","",""
"834","01-09-10","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REPLACES THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON JUNE 4, 1999","REMPLACE L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 4 JUIN 1999","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"835","02-09-09","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT/SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"836","01-09-10","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REPLACES THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON JUNE 4, 1999","REMPLACE L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 4 JUIN 1999","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"837","01-09-10","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REPLACES THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON JUNE 4, 1999","REMPLACE L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 4 JUIN 1999","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"838","02-07-25","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","AGENT RADIODIAGNOSTIQUE","",""
"839","02-06-20","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADIITION OF A NEW STRENGTH","ADDITION D'UNE NOUVELLE CONCENTRATION","TESTOSTERONE REPLACEMENT THERAPY","TRAITEMENT DE REMPLACEMENT DE LA TESTOSTÉRONE","",""
"840","02-06-06","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE (LH-RH)","",""
"841","02-06-05","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF PHOTODAMAGED SKIN","NOUVELLE INDICATION: POUR LE TRAITEMENT DE LA PEAU ENDOMMAGÉE SUITE À UNE EXPOSITION AU SOLEIL OU À LA LUMIÈRE ULTRAVIOLETTE","ANTI-PSORIASIS AGENT, ANTI-ACNE AGENT, AGENT FOR THE TREATMENT OF PHOTODAMAGED SKIN","ANTIPSORIASIQUE, ANTIACNÉ, AGENT POUR LE TRAITEMENT DE LA PEAU ENDOMMAGÉE SUITE À UNE EXPOSITION AU SOLEIL OU À LA LUMIÈRE ULTRAVIOLETTE","",""
"842","02-05-31","GENZYME CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","THYROID STIMULATING HORMONE","HORMONE STIMULATRICE DE LA THYROÏDE","",""
"843","02-05-15","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TOPICAL TREATMENT OF ACNE VULGARIS","NOUVELLE INDICATION: POUR LE TRAITEMENT TOPIQUE DE L'ACNÉ SIMPLE","ANTI-PSORIASIS AGENT, ANTI-ACNE AGENT","ANTIPSORIASIQUE, ANTIACNÉ","",""
"844","02-05-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"845","02-05-08","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"846","02-05-02","BERNA BIOTECH LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"847","01-08-28","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","USE OF PARAMETRIC RELEASE INSTEAD OF STERILITY TESTING FOR FINISHED PRODUCT TESTING","USAGE DE LA DIFFUSION PARAMÉTRIQUE PLUTÔT QUE DE L'ÉPREUVE DE STÉRILITÉ POUR UN TEST DE PRODUIT COMPLÉTÉ","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"848","02-05-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RESTORIL","NOVARTIS PHARMA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"849","02-04-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBREX","ALCON CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"850","02-04-16","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MODULIN","AXCAN PHARMA INC.","CANADA","CANADA","1","","","LOWER GASTROINTESTINAL TRACT MOTILITY REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"851","02-03-14","SWISS SERUM & VACCINE INSTITUTE BERNE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW GELATIN CAPSULE MANUFACTURER","NOUVEAU FABRICANT DE GÉLATINE EN CAPSULE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"852","02-03-13","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"853","02-03-12","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT4 RECEPTOR PARTIAL AGONIST","RÉCEPTEUR AGONISTE PARTIEL 5-HT4","",""
"854","02-03-11","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"855","02-02-28","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGING PRODUCT NAME FROM DETROL SR TO UNIDEL. ALSO INVOLVES SPLITTING OF APPROVED PRODUCT MONOGRAPH FOR DETROL AND DETROL SR","MODIFICATION DU PRODUIT DE DETROL SR À UNIDET. DE PLUS, IMPLIQUE LA SÉPARATION DE LA MONOGRAPHIE APPROUVÉE DU PRODUIT POUR DETROL ET DETROL SR","ANTICHOLINERGIC-ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"856","02-02-27","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"857","02-02-21","MEDI PHYSICS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"858","02-02-19","ELAN PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","ANTIPASTIC AGENT","AGENT ANTISPASMODIQUE","",""
"859","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (MYOCARDIAL IMAGING)","AGENT RADIODIAGNOSTIQUE DE L'INFARCTUS MYOCARDIQUE","",""
"860","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL-DIAGNOSTIC AGENT","RADIOPHARMACEUTIQUE-AGENT DIAGNOSTIQUE","",""
"861","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (BREAST IMAGING)","AGENT RADIODIAGNOSTIQUE POUR L'IMAGE DU SEIN","",""
"862","02-02-06","SOLVAY PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANDROGENIC HORMONE","HORMONE ANDROGÉNIQUE","",""
"863","02-12-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA CO.","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme lipidique","",""
"864","02-11-15","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","NEW INDICATIONS: FOR THE TREATMENT OF PANIC DISORDER AND OBESSESIVE COMPULSIVE DISORDER","NOUVELLES INDICATIONS: POUR LE TRAITEMENT DES TROUBLES PANIQUE ET OBSESSIVO-COMPULSIF","ANTIDEPRESSANT, ANTIPANIC, AND ANTIOBSESSIONAL AGENT","ANTIDÉRESSEUR, ANTIPANIQUE ET ANTIOBSESSIONAL","",""
"865","02-12-13","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"866","02-11-28","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"867","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"868","02-11-05","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"869","02-10-31","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"870","02-10-31","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (LIVER AND SPLEEN IMAGING)","AGENT RADIODIAGNOSTIQUE (POUR L'IMAGE DU FOIE ET DE LA RATE)","",""
"871","02-10-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES)","",""
"872","02-10-01","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","RÉVISIONS AU DOSAGE ET À LA SECTION DE L'ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"873","02-09-10","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL AGENT","AGENT RADIODIAGNOSTIQUE","",""
"874","02-10-09","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"875","02-09-06","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"876","02-09-06","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"877","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL AGENT","ANTIPALUDÉEN","",""
"878","01-08-17","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"879","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE-OXYDASE","",""
"880","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"881","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPROTOZOAL AGENT","AGENT ANTIPROTOZOAIRE","",""
"882","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"883","01-08-03","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"884","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"885","01-07-11","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASE","",""
"886","01-06-20","DRAXIS HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOTODYNAMIC THERAPY PHOTOSENSITIZER","SENSIBILISATEUR POUR THÉRAPIE PHOTODYNAMIQUE","",""
"887","01-06-13","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"888","02-03-01","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE WHERE THE USE OF A COMBINATION PRODUCT IS CONSIDERED TO BE APPROPRIATE","NOUVELLE INDICATION: POUR UNE THÉRAPIE D'ENTRETIEN DE L'ASTHME CHEZ LES PATIENTS QUI PRÉSENTENT UNE OBSTRUCTION RÉVERSIBLE DES VOIES RESPIRATOIRES CHEZ QUI UN PRODUIT MIXTE EST JUGÉ ADÉQUAT","BRONCHODILATOR AND CORTICOSTEROID FOR ORAL INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE EN INHALATION","",""
"889","03-07-11","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID I.V.","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"890","02-08-01","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","BRONCHODILATOR/BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR/STIMULANT DES RÉCEPTEURS BÊTA2-ADRÉNERGIQUES","",""
"891","02-07-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CALCIMAR","RHÔNE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","SYNTHETIC SALMON CALCITONIN","CALCITONINE DE SAUMON SYNTHÉTIQUE","",""
"892","02-07-16","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR/BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES BETA2-ADRÉNERGIQUE","",""
"893","02-05-30","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bronchodilator/Beta2-Adrenergic Stimulant","Bronchodilatateur/Stimulant des Beta2-adrénergique","",""
"894","03-05-08","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"895","02-06-04","AVENTIS BEHRING GMBH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"896","01-06-07","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","NEW DOSAGE FORM (POWDER FOR SUSPENSION)","NOUVELLE FORME POSOLOGIQUE","ANTIBIOTIC, ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE, INHIBITEUR DE ß-LACTAMASES","",""
"897","02-05-31","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"898","02-05-31","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"899","01-06-07","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: FOR REDUCING THE RISK OF VASCULAR MORTALITY IN PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL INFARCTION","NOUVELLE INDICATION : POUR RÉDUIRE LE RISQUE DE MORTALITÉ VASCULAIRE CHEZ LES PATIENTS SUSPECTS D'INFARCTUS AIGÜE DU MYOCARDE","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"900","03-04-25","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH - UPDATED TO CONFORM TO INNOVATOR","RÉVISION À LA MONOGRAPHIE DU PRODUIT - POUR ÊTRE CONFORME À L'INNOVATEUR","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"901","02-05-28","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"902","03-04-23","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"903","01-06-04","TEXAS BIOTECHNOLOGY CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHROMBOTIC","ANTITHROMBOTIQUE","",""
"904","02-05-10","IVAX PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES)","",""
"905","01-05-30","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"906","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"907","02-05-08","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF INFLAMMATORY BOWEL DISEASE, ULCERATIVE COLITIS, CROHN'S DISEASE AND RHEUMATOID ARTHRITIS","TRAITEMENT DE LA MALADIE INTESTINALE INFLAMMATOIRE, DE LA COLITE ULCÉREUSE, DE LA MALADIE DE CROHN ET DE L'ARTHRITE RHUMATOÏDE","",""
"908","02-05-01","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"909","02-05-01","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"910","01-05-17","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","ADDITION OF 325 MG DAILY IN THE RECOMMENDED DOSAGE FOR UNSTABLE ANGINA OR PREVIOUS MYOCARDIAL INFARCTION.  REVISED INDICATION FOR REDUCING THE RISK OF RECURRENT TRANSIENT ISCHEMIC ATTACKS AND FOR SECONDARY PREVENTION OF ATHEROTHROMBOTIC CEREBRAL INFARCTION TO INCLUDE WOMEN AS WELL AS MEN","AJOUT D'UNE DOSE DE 325 MG PAR JOUR À LA DOSE RECOMMANDÉE DANS LE CAS D'ANGOR INSTABLE AVEC ANTÉCÉDENTS D'INFARCTUS DU MYOCARDE.  INDICATION RÉVISÉ POUR LA RÉDUCTION DU RISQUE D'ACCIDENTS ISCHÉMIQUES TRANSITOIRES ET POUR LA PRÉVENTION SECONDAIRE D'INFARCTUS CÉRÉBRAL ATHÉROTHROMBOTIQUE CHEZ LA FEMME AUSSI BIEN QUE CHEZ L'HOMME","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT, PLATELET AGGREGATION INHIBITOR","ANTI-INFLAMMATOIRE NON STÉROÏDIEN, ANALGÉSIQUE, ANTIANGRÉGANT PLAQUETTAIRE","",""
"911","01-05-11","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"912","02-03-21","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR/BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES","",""
"913","01-05-11","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"914","02-02-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL-DIAGNOSTIC AGENT","RADIOPHARMACEUTIQUE-AGENT DIAGNOSTIQUE","",""
"915","03-04-23","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"916","02-01-28","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"917","03-03-28","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"918","02-01-23","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"919","01-04-27","BAXTER HEALTHCARE CORPORATION, HYLAND IMMUNO","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DRUG SUBSTANCE MANUFACTURING SUITE","NOUVELLE SUITE DE FABRICATION POUR LES SUBSTANCES MÉDICALES","ANTIHEMOPHILIC","ANTIHÉMOPHILIQUE","",""
"920","03-03-04","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"921","03-02-27","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"922","03-02-17","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"923","02-08-29","DENTSPLY CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC FOR DENTAL USE","ANESTHÉSIQUE LOCAL","",""
"924","03-01-22","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM FLUOXETINE","CHANGEMENT DU NOM DU PRODUIT DE FLUOXETINE","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"925","03-12-17","ASTRAZENECA CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITOR","INHIBITEUR DE L'ACTIVITÉ TYROSINE KINASE DU RÉCEPTEUR DE FACTEUR DE CROISSANCE ÉPIDERMIQUE","",""
"926","03-12-05","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: PREVENTION AND TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING","NOUVELLES INDICATIONS: LA PRÉVENTION ET LE TRAITEMENT DE LA NAUSÉE POST-OPÉRATOIRE ET DU VOMISSEMENT","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"927","03-11-19","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS DIVISION OF WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"928","03-11-14","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON TABLETS 80MG","SERVIER CANADA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"929","03-11-06","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE PRODUCT MONOGRAPH REGARDING THE POTENTIAL FOR INTERACTIONS WITH OPIOID ANALGESICS","MISES À JOUR DE LA MONOGRAPHIE EN MATIÈRE D'INTERACTION POSSIBLE AVEC LES ANALGÉSIQUES OPIOÏDES","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"930","03-11-03","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS OF WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"931","03-10-02","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"932","00-12-21","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR CONCENTRATE","FACTEUR DE COAGULATION CONCENTRÉ","",""
"933","00-12-19","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"934","00-12-11","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANTI-HISTAMINIC, LEUKOTRIENE INHIBITOR AGENT","ANTI-INFLAMMATOIRE, ANTI-HISTAMINIQUE, INHIBITEUR DE LEUCOTRIÈNE","",""
"935","00-12-11","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MUCOMYST","ROBERTS PHARMACEUTICAL CANADA INC.","CANADA","CANADA","1","","","MUCOLYTIC, ANTIDOTE FOR ACETAMINOPHEN POISONING","AGENT MUCOLYTIQUE, ANTIDOTE CONTRE LES INTOXICATIONS PAR L'ACÉTAMINOPHÈNE","",""
"936","00-12-08","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"937","00-12-05","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"938","00-12-01","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"939","00-11-28","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMIKIN","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"940","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"941","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIHEMORRHAGIC","ANTIHÉMORRAGIQUE","",""
"942","00-11-10","JOHNSON & JOHNSON - MERCK CONSUMER PHARMACEUTICALS OF CANADA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTI-PYRETIC & PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE & INHIBIEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"943","00-10-27","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTIPLATELET ANTIBODY","ANTICORPS ANTIPLAQUETTAIRE","",""
"944","00-10-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","AGENT ANTILEUCÉMIQUE","",""
"945","00-10-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"946","00-09-11","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"947","00-08-02","HANSAMED LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"948","00-08-02","HANSAMED LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"949","00-07-27","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"950","03-08-01","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC","HYPOGLYCÉMIANT ORAL","",""
"951","00-07-24","BAYER INC., HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"952","00-07-21","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SECONDARY HYPERPARATHYROIDISM","NOUVELLE INDICATION: HYPERPARATHYROÏDE SECONDAIRE","VITAMIN D ANALOGUE","ANALOGUE DE LA VITAMIN D","",""
"953","00-07-21","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: SOLUTION FOR INJECTION 2MCG/ML","NOUVELLE FORM POSOLOGIQUE: SOLUTION POUR INJECTION","VITAMIN D ANALOGUE","ANALOGUE DE LA VITAMIN D","",""
"954","00-07-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYEST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHIQUE","",""
"955","00-07-04","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"956","00-06-16","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"957","00-06-12","CHIRON CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING-INCREASE IN FINAL PRODUCT LOT SIZE, -CHANGE IN STABILITY TESTING PROGRAMME","CHANGEMENT DANS LA FABRICATION - AUGMENTATION DE LA QUANTITÉ DU PRODUIT FINAL - CHANGEMENT AU NIVEAU DU PROGRAMME D'ÉTUDES DE STABILITÉ","IMMUNOMODULATOR","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"958","00-06-12","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE INTRAVENOUS","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"959","00-05-29","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: HORMONAL TREATMENT OF ADVANCED BREAST CANCER IN POST MENOPAUSAL WOMEN","NOUVELLE INDICATION : TRAITEMENT HORMONAL POUR LE CANCER DU SEIN À UN STAGE AVANCÉ CHEZ LES FEMMES MÉNOPAUSÉES","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"960","00-05-26","CATALYTICA PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE-OXYDASE","",""
"961","00-05-19","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"962","00-04-26","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING -NEW SITE FOR PRODUCTION OF DRUG SUBSTANCE","MODIFICATION DE LA MÉTHODE DE FABRICATION - NOUVEL EMPLACEMENT POUR LA FABRICATION DE LA SUBSTANCE MÉDICAMENTEUSE","ANTIHEMOPHILIC FACTOR","FACTEUR ANTIHÉMOPHILIQUE","",""
"963","00-04-26","SEQUUS PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"964","00-04-20","MEDIMMUNE ONCOLOGY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR","",""
"965","00-04-20","MEDIMMUNE ONCOLOGY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"966","00-04-19","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"967","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"968","00-04-11","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"969","00-04-11","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"970","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC-ANTIHYPERTENSIVE","DIURÉTIQUE-ANTIHYPERTENSEUR","",""
"971","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC-SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"972","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"973","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT DI'IMMUNISATION ACTIVE","",""
"974","00-03-30","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"975","00-03-30","ZIMMER OF CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"976","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNE AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"977","00-03-10","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"978","00-03-03","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET-REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"979","00-02-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL DENTAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"980","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"981","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"982","00-02-11","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSTINE VR STERILE SOLUTION","PHARMACIA & UPJOHN","CANADA","CANADA","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"983","00-02-09","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Intravenous Skeletal Neuromuscular Blocking Agent","Inhibiteur neuromusculaire squelettique intraveineuse","",""
"984","00-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON-STÉROÏDIEN","",""
"985","00-01-24","ROBERTS PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF THROMBOCYTHEMIA SECONDARY TO MYELOPROLIFERATIVE DISORDERS","NOUVELLE INDICATION : TRAITEMENT DE LA THROMBOCYTHÉMIE SECONDAIRE AUX TROUBLES MYÉLOPROLIFÉRATIFS","PLATELET-REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"986","00-01-19","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"987","00-11-10","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST, ELEVEATED INTRAOCULAR PRESSURE THERAPY","AGONISTE DES RÉCEPTEURS 2-ADRÉNERGIQUES RELATIVEMENT SÉLECTIF - THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"988","00-10-05","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"989","00-09-01","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"990","00-08-01","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STADOL NS","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANALGESIC","ANALGÉSIQUE","",""
"991","00-06-30","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","SMOKING CESSATION AID","AIDE ANTITABAGIQUE","",""
"992","00-06-30","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"993","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"994","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH ANALOGUE)","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"995","00-04-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"996","00-04-20","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASMODIQUE","",""
"997","00-04-19","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE AGENT","ANXIOLYTIQUE, SÉDATIF","",""
"998","00-04-19","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"999","00-04-13","3M PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"1000","00-03-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1001","00-03-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1002","00-03-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1003","00-03-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1004","00-03-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1005","03-05-02","STERIMAX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GARASONE","SCHERING CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID AND ANTIBIOTIC","CORTICOSTÉROÏDE TOPIQUE ET ANTIBIOTIQUE","",""
"1006","00-03-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1007","00-03-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1008","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1009","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1010","00-03-08","BIOCHEM PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1011","03-04-08","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS DIVISION OF WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE FORME POSOLOGIQUE ET CONCENTRATION","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"1012","00-02-29","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1013","00-02-24","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","PREMEDICANT-SEDATIVE-ANAESTHETIC","PRÉMÉDICATION-SÉDATIF-ANESTHÉSIQUE","",""
"1014","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"1015","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1016","00-02-07","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1017","03-03-19","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ADJUVANT THERAPY IN PRE- AND PERIMENOPAUSAL WOMEN WITH EARLY BREAST CANCER, WHOSE TUMOUR CONTAINS ESTROGEN AND/OR PROGESTERONE RECEPTORS","NOUVELLE INDICATION: THÉRAPEUTIQUE AUXILIAIRE CHEZ LA FEMME PRÉ OU PÉRI-MÉNOPAUSALE AVEC CANCER PRIMAIRE DU SEIN DONT LA TUMEUR CONTIENT DES RÉCEPTEURS D'OESTROGÈNE ET/OU DE PROGESTÉRONE","LUTEINIZING HORMONE - RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉOSTIMULINE","",""
"1018","00-01-28","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOSTEROID","GLUCOCORITCOSTÉROÏDE","",""
"1019","00-01-28","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1020","00-01-28","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1021","03-03-19","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSING RECOMMENDATIONS FOR HEPATIC AND RENAL IMPAIRMENT","RECOMMANDATIONS MODIFIÉES À LA POSOLOGIE POUR LE TRAITEMENT DE LA DÉFICIENCE HÉPATIQUE ET RÉNALE","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"1022","00-12-28","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH; PRODUCT MONOGRAPH UPDATED","NOUVEAU DOSAGE; MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1023","03-03-04","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE (IRM)","",""
"1024","00-12-19","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC","NEUROLEPTIQUE","",""
"1025","00-12-11","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"1026","00-12-01","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"1027","00-11-28","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"1028","00-11-01","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"1029","00-11-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIALLERGENIC AGENT","ANTIALLERGIQUE","",""
"1030","00-10-27","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1031","00-10-17","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: CONTROLLED RELEASE TABLETS","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉ À ACTION CONTRÔLÉE","ANTICONVULSANT","ANTICONVULSIVANT","",""
"1032","00-10-16","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGENIC HORMONES/PROGESTIN","HORMONES OESTROGÈNES/PROGESTATIF","",""
"1033","00-09-27","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-ACNE","TRAITEMENT DE L'ACNÉ","",""
"1034","00-09-12","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1035","00-09-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"1036","00-09-06","ZYMCAN PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1037","00-09-06","NU-PHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1038","00-08-31","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM RHO-CLONAZEPAM","MODIFICATION DU NOM DE RHO-CLONAZEPAM","ANTICONVULSANT","ANTICONVULSIVANT","",""
"1039","03-12-19","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STERILE FILLING FACILITY","NOUVEL ÉTABLISSEMENT POUR LE REMPLISSAGE STÉRILE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1040","00-08-15","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1042","00-08-01","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AN ADJUNCT IN THE MANAGEMENT OF OSTEOLYSIS RESULTING FROM BONE METASTASES OF MALIGNANT TUMORS","NOUVELLE INDICATION : ADJUVANT À LA GESTION DE L'OSTÉOLYSE RÉSULTANT DES MÉTASTASES OSSEUSES DE TUMEURS MALIGNES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"1043","00-07-24","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF DIAPER RASH INFECTED WITH CANDIDA ALBICANS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ÉRYTHÈME FESSIER INFECTÉ PAR C.ALBICANS","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1044","00-07-17","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FIRST LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER","NOUVELLE INDICATION : TRAITEMENT DE PREMIÈRE LIGNE DES PATIENTS ATTEINTS D'UN CANCER COLO-RECTAL MÉTASTATIQUE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1045","00-07-05","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW MANUFACTURING SITE, REVISED FORMULATION","NOUVEL EMPLACEMENT DE FABRICATION, FORMULATION REVISÉE","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"1046","00-06-30","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DOPAMINE RECEPTOR AGONIST","AGONISTE DU RÉCEPTEUR DOPAMINERGIQUE","",""
"1047","00-06-28","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OVULATORY AGENT","AGENT OVULATOIRE","",""
"1048","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1049","00-06-12","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN","UPJOHN CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1050","00-06-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERIDEX ORAL RINSE","PROCTER & GAMBLE INC.","CANADA","CANADA","1","","","ANTIGINGIVITIS","ANTIGINGIVITE","",""
"1051","00-04-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANDROGEN","ANTIANDROGÈNE","",""
"1052","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1053","00-08-04","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION:  ADJUNCTIVE TREATMENT TO ANTIBIOTICS FOR ACUTE EPISODES OF SINUSITIS IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER","NOUVELLE INDICATION : TRAITMENT ADJUVANT AUX ANTIBIOTIQUES POUR LES ÉPISODES AIGUËS DE SINUSITE CHEZ LES ADULTES ET LES ENFANTS DE 12 ANS ET PLUS","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"1054","00-04-12","SMITHKLINE BEECHAM CONSUMER HEALTHCARE, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH - NEW STRENGTH FOR THE TREATMENT OF HEARTBURN","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE - NOUVELLE CONCENTRATION POUR SOULAGER LES BRÛLURES D'ESTOMAC","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1055","03-12-04","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1056","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"1057","00-04-11","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1058","00-04-11","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1059","00-04-04","LEO PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE REGIMEN REVISED INDICATION: TREATMENT OF PSORIASIS NEW INDICATION: COMBINATION THERAPY - USE WITH TOPICAL CORTICOSTEROIDS, CYCLOSPRORIN A, ACITRETIN AND/OR PHOTOTHERAPY (PUVA OR UVB)","SCHÉMA POSOLOGIQUE RÉVISÉ; INDICATION RÉVISÉE : TRAITEMENT DU PSORIASIS. NOUVELLE INDICATION : TRAITEMENT D'ASSOCIATION UTILISÉ AVE I) CORTICOSTÉROÏDES TOPIQUES II) CYCLOSPORINE A, ACITRÉTINE III) PHOTOTHÉRAPIE (PUVA THÉRAPIE ET LES RAYONS UVB)","TOPICAL NON-STEROIDAL, ANTIPSORIATIC AGENT","AGENT ANTIPSORIASIQUE TOPIQUE NON STÉROÏDIEN","",""
"1060","03-09-18","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYDREA","SQUIBB CANADA INC., DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1061","03-09-03","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WESTCORT","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1062","03-09-02","DUCHESNAY INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RECTAL ANTI-INFLAMMATORY FOAM","TRAITEMENT ANORECTAL","",""
"1063","03-03-24","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1064","00-04-04","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT DES MUSCLES SQUELETTIQUES","",""
"1065","00-03-28","CHX TECHNOLOGIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMICROBIAL","ANTIBACTÉRIEN","",""
"1066","00-03-21","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE - FOR USE DURING CORONARY ARTERY BYPASS GRAFT SURGERY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT - UTILISER LORS DE PONTAGE AORTOCORONARIEN","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"1067","00-03-15","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEGRETOL CR","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT - FOR SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA - ANTIMANIC","ANTICONVULSIVANT - SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU - ANTIMANIAQUE","",""
"1068","00-03-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1069","00-03-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1070","00-03-07","ASTA MEDICA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1071","00-02-25","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZINACEF","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1072","00-02-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"1073","00-02-16","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN","UPJOHN CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1074","00-02-09","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1075","00-02-08","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION (NEW SALT - CISAPRIDE TARTRATE)","NOUVELLE FORMULATION (NOUVEAU SEL - TARTRATE DE CISAPRIDE)","GASTROINTESTINAL PROKINETIC AGENT","AGENT FAVORISANT LA MOTILITÉ GASTRO-INTESTINALE","",""
"1076","00-02-03","PRO-DENTEC CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-GINGIVITIS ORAL RINSE","BAIN DE BOUCHE CONTRE LA GINGIVITE","",""
"1077","00-01-28","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUEUR DU RÉCEPTEUR AT1 DE L'ANGIOTENSINE II","",""
"1078","00-01-17","TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1079","00-12-22","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT - ANTIANGINAL AGENT","ANTIHYPERTENSEUR - ANTIANGINEUX","",""
"1080","00-12-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1081","00-12-05","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)","NOUVELLE INDICATION POUR THROMBOCYTOPÉNIE INDUITE PAR L'HÉPARINE","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1082","00-11-24","EDWARDS LIFESCIENCES RESEARCH MEDICAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF INTERSTITIAL CYSTITIS","TRAITEMENT DE LA CYSTITE INTERSTITIELLE","",""
"1083","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1084","00-11-10","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL STEROID","STÉROÏDE TOPIQUE","",""
"1085","00-10-24","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PITUITARY GONADOTROPIN INHIBITOR","INHIBITEUR DE LA GONADOTROPHINE HYPOPHYSAIRE","",""
"1086","00-10-20","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR (ANTI-HYPERCALCEMIA AGENT)","RÉGULATEUR DE MÉTABOLISME OSSEUX (AGENT ANTIHYPERCALCÉMIQUE)","",""
"1087","00-10-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOESCHT MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"1088","00-10-05","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMITOTIC - ANTIBIOTIC","ANTIMITOTIQUE - ANTIBIOTIQUE","",""
"1089","00-09-18","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AGENT(CARDIZEM, CARDIZEM SR, CARDIZEM CD), ANTIHYPERTENSIVE AGENT (CARDIZEM SR, CARDIZEM CD)","ANTIANGINEUX, ANTIANGINEUX - ANTIHYPERTENSEUR, ANTIANGINEUX - ANTIHYPERTENSEUR","",""
"1090","00-09-18","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTMIQUE","",""
"1091","00-09-18","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"1092","00-09-14","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF NOCTURNAL ENURESIS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ÉNURÉSIE NOCTURNE","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"1093","00-09-06","BIOVAIL LABORATORIES INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, ANTIANGIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"1094","00-08-31","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-1","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR - TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"1095","00-08-24","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW INTEGRATED PRODUCTION FACILITY - NEW CONTINUOUS FLOW CENTRIFUGATION STEP","MODIFICATION À L'EMPLACEMENT DE FABRICATION ET MODIFICATION DE LA MÉTHODE DE FABRICATION","SPECIFIC ANTIBODY FOR DIGOXIN","ANTICORPS SPÉCIFIQUE DE LA DIGOXINE","",""
"1096","00-08-23","GILEAD SCIENCES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1097","00-08-17","SKYEPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF ACTINIC KERATOSES","TRAITEMENT DES KÉRATOSES D'ORIGINE ACTINIQUE","",""
"1098","00-08-15","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1099","00-08-15","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN MONOTHERAPY OR IN COMBINATION WITH PLATINUM DERIVATIVES","INDICATION RÉVISÉE : TRAITEMENT DES PATIENTS ATTEINTS D'UN CANCER PULMONAIRE NON À PETITES CELLULES (CPNPC) AU STADE LOCAL AVANCÉ OU MÉTASTATIQUE, EN MONOTHÉRAPIE OU ASSOCIÉ À BASE DE PLATINE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1100","00-07-28","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT","ANOREXIGÈNE","",""
"1101","00-07-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1102","00-07-18","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DDAVP SPRAY","FERRING INC.","CANADA","CANADA","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"1103","00-07-07","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1104","00-07-05","ATRIX LABORATORIES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMICROBIAL AGENT FOR PERIODONTITIS","ANTIMICROBIEN POUR LA PÉRIODONTITE","",""
"1105","00-06-16","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"1106","00-06-12","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST; MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"1107","00-06-06","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATES","MONOGRAPHIES RÉVISÉES","CHOHLINESTERASE INHIBITOR","INHIBITEUR DE CHOLINESTÉRASE","",""
"1108","00-05-29","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZATION","AGENT D'IMMUNISATION ACTIVE","",""
"1109","00-05-29","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROPINE","ALLEGRAN INC.","CANADA","CANADA","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"1110","00-04-25","AGOURON PHARMACEUTICALS CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1111","00-04-25","UNIMED CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF WEIGHT LOSS ASSOCIATED WITH WASTING SYNDROME","NOUVELLE INDICATION : TRAITEMENT DE LA PERTE DE POIDS ASSOCIÉ À LA CACHEXIE","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"1112","00-04-19","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1113","00-04-13","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPLATELET AGENT","INHIBITEUR DE L'ADHÉSION ET DE L'AGRÉGATION PLAQUETTAIRE","",""
"1114","00-04-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IRON AND ALUMINUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"1115","00-04-04","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DOBUTREX","ELI LILLY","CANADA","CANADA","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"1116","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1117","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1118","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1119","00-04-04","BAXTER RESEARCH MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GENITOURINARY DISORDERS","MALADIES GÉNITO-URINAIRES","",""
"1120","00-03-17","DUMEX-ALPHARMA A/S","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"1121","00-03-15","TARO PHARMACEUTICALS INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPICORT","HOECHST CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM: GEL","NOUVELLE PRÉSENTATION : GEL","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1122","00-03-07","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1123","00-03-03","ASTA MEDICA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF PROSTATIC CARCINOMA","THÉRAPIE DU CARCINOME PROSTATIQUE","",""
"1124","00-02-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-Depolarizing Skeletal Neuromuscular Blocking Agent","Inhibiteur neuromusculaire squelettique nondépolarisant intraveineux","",""
"1125","00-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT, ALPHA 1 ANTAGONIST","ANTIHYPERTENSEUR, ALPHA 1-BLOQUANT ADRÉNERGIQUE","",""
"1126","00-02-07","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DESFERAL","NOVARTIS","CANADA","CANADA","1","","","IRON AND ALUMINIUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"1127","00-01-13","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DTIC","BAYER INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1128","00-01-04","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISANT ACTIF","",""
"1129","00-01-04","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSANT","",""
"1130","00-12-22","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ADJUVANT TREATMENT OF EARLY STAGE BREAST CANCER FOR PRE- AND PERI-MENOPAUSAL WOMEN","NOUVELLE INDICATION : TRAITEMENT ADJUVANT DU CANCER PRÉCOCE DU SEIN CHEZ LES FEMMES EN PRÉ ET PÉRIMÉNOPAUSE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1131","00-12-22","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ADJUVANT TREATMENT OF EARLY STAGE BREAST CANCER FOR PRE- AND PERI-MENOPAUSAL WOMEN","NOUVELLE INDICATION : TRAITEMENT ADJUVANT DU CANCER PRÉCOCE DU SEIN CHEZ LES FEMMES EN PRÉ- ET PÉRIMÉNOPAUSE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1132","00-12-19","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1133","00-12-19","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1134","00-12-01","IMMUNEX CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"1135","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"1136","00-10-12","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTRADOL","PROCTER & GAMBLE PHARMACEUTICALS","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE","",""
"1137","00-10-05","FOURNIER PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: 7.5MG/PAD, 15MG/PAD","NOUVELLES CONCENTRATIONS : 7.5MG/PAD, 15MG/PAD","ESTROGEN","OESTROGÈNE","",""
"1138","00-09-20","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ÉRYTHROPOÏÈSE","",""
"1139","00-09-11","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE, DIURÉTIQUE","",""
"1140","00-08-17","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AROMATASE INACTIVATOR; ANTI-TUMOUR AGENT","INACTIVATEUR DE L'AROMATASE; AGENT ANTINÉOPLASIQUE","",""
"1141","00-08-15","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTICOAGULANT/ANTITHROMBOTIC AGENT (LOW MOLECULAR WEIGHT HEPARIN FRAGMENT)","ANTICOAGULANT/ANTITHROMBOTIQUE (FRAGMENT D'HÉPARINE DE BAS POIDS MOLÉCULAIRE (HBPM))","",""
"1142","00-05-09","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTRADOL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"1143","00-02-29","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"1144","00-12-28","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","HÉMOSTATIQUE","",""
"1145","00-12-28","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","HÉMOSTATIQUE","",""
"1146","00-12-28","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","HÉMOSTATIQUE","",""
"1147","00-12-28","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","HÉMOSTATIQUE","",""
"1148","00-12-19","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","COMBINATION: HISTAMINE H2-RECEPTOR ANTAGONIST AND ANTACID","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2 ET ANTACIDE","",""
"1149","00-12-01","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE","INDICATION RÉVISÉE : TRAITEMENT DE L'ASTHME CHEZ LES PATIENTS DE 6 ANS ET PLUS ATTEINTS D'OBSTRUCTION RÉVERSIBLE DES VOIES RESPIRATOIRES","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1150","00-11-30","ORPHAN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC ALCOHOL DEHYDROGENASE INHIBITOR","INHIBITEUR SYNTHÉTIQUE DE L'ALCOOL-DÉHYDROGÉNASE","",""
"1151","00-11-28","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1152","00-11-01","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","GONADOTROPHIN","GONADOTROPHINE","",""
"1153","00-09-14","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIDEPRESSANT, ANTIOBESESSIONAL, ANTIBULLMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"1154","00-09-14","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"1155","00-08-17","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID WITH ANTIBACTERIAL - ANTIFUNGAL AGENT","CORTICOSTÉROÏDE TOPIQUE AVEC ANTIBACTÉRIEN-ANTIFONGIQUE","",""
"1156","00-08-17","GALDERMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC CORTICOSTEROID","CORTICOSTÉROÏDE SYNTHÉTIQUE","",""
"1157","00-08-17","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PROUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1158","00-08-17","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1159","00-08-15","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - PEDIATRIC DOSING FOR CHILDREN 6 YEARS AND OLDER","NOUVELLE INDICATION : POSOLOGIE POUR ENFANTS DE 6 ANS ET PLUS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1160","00-08-15","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"1161","00-08-15","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"1162","00-07-27","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1163","00-06-30","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLUANXOL DEPOT INJECTION","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1164","00-06-23","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1165","00-06-13","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW LIQUID FORMULATION AND THREE NEW STRENGTHS","NOUVELLE FORMULATION DE LIQUIDE ET TROIS NOUVELLES CONCENTRATIONS","HUMAN GONADOTROPIN","GONADOTROPHINE HUMAINE","",""
"1166","00-06-12","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","COMBINATION: HISTAMINE H2-RECEPTOR ANTAGONIST AND ANTACID","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUE H2, ANTIACIDE","",""
"1167","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1168","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST/SYMPATHOMIMETIC AGENT","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE, AMINE-SYMPATHOMIMÉTIQUE","",""
"1169","00-06-06","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK SHARP & DOHME","CANADA","CANADA","1","","","HISTAMINE H2 RECETOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"1170","00-05-03","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"1171","00-05-01","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"1172","00-04-20","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1173","00-03-30","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MODECATE CONCENTRATE","SQUIBB","CANADA","CANADA","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1174","00-03-15","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM, NEW STRENGTH","NOUVELLE PRÉSENTATION, NOUVELLE CONCENTRATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1175","00-03-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1176","00-03-02","LABORATOIRES FOURNIER S.C.A.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM, NEW FORMULATION","NOUVELLE PRÉSNETATION, NOUVELLE FORMULATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1177","00-02-23","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM, NEW INDICATION: USE OF FLONASE NASAL DROPS FOR THE REGULAR TREATMENT OF NASAL POLYPS AND ASSOCIATED SYMPTOMS OF NASAL OBSTRUCTION","NOUVELLE FORME POSOLOGIQUE, NOUVELLE INDICATION : UTILISATION DES GOUTTES NASALES FLONASE POUR LE TRAITEMENT DES POLYPES NASAUX ET DES SYMPTÔMES ASSOCIÉS À L'OBSTRUCTION NASALE","CORTICOSTEROID FOR INTRANASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"1178","00-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1179","00-02-03","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"1180","00-01-13","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"1181","00-12-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT ORAL","",""
"1182","00-12-11","MALLINCKRODT MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE","",""
"1183","00-11-24","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN METHOD OF MANUFACTURE","MODIFICATION DE LA MÉTHODE DE FABRICATION","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1184","00-11-24","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM/STRENGTH, REVISED DOSING","NOUVELLE FORME POSOLOGIQUE/CONCENTRATION, POSOLOGIE RÉVISÉE","HYPOGLYCEMIC SULFONYLUREA-ORAL ANTIDIABETIC AGENT","HYPOGLYCÉMIANT SULFONYLURÉE - ANTIDIABÉTIQUE ORAL","",""
"1185","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCULAR RELAXANT","RELAXANT MUSCULAIRE","",""
"1186","00-08-15","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GARAMYCIN INJECTABLE","SCHERING","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1187","00-07-18","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"1188","00-06-30","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT","",""
"1189","00-06-16","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION OF THE DOSAGE FORM","CHANGEMENT DE LA PRÉPARATION DE LA FORME POSOLOGIQUE","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1190","00-06-12","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1191","00-05-09","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LUTEINIZING HORMONE - RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE LA LH-RH","",""
"1192","00-04-20","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1193","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT ORAL","",""
"1194","00-03-15","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN THE HORMONAL MANAGEMENT OF ENDOIMETRIOSIS, INCLUDING PAIN RELIEF AND REDUCTION OF ENDOMETRIOTIC LESIONS","NOUVELLE INDICATION : POUR L'HORMONOTHÉRAPIE DE L'ENDOMÉTRIOSE, Y COMPRIS LE SOULAGEMENT DE LA DOULEUR ET LA RÉDUCTION DE LA DIMENSION ET LE NOMBRE DES PLAQUES D'ENDOMÉTRIOSE","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉLINOSTIMULINE (ANALOGUE DE LA LH-RH)","",""
"1195","00-03-15","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSING INTERVAL","INTERVALLE POSOLOGIQUE RÉVISÉE","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉLINOSTIMULINE (ANALOGUE DE LA LH-RH)","",""
"1196","00-02-16","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1197","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE (ANALOGUE DE LA LH-RH)","",""
"1198","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE (ANALOGUE DE LA LH-RH)","",""
"1199","00-02-03","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1200","00-12-19","PURDUE PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"1201","00-11-17","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WESTCORT CREAM & OINTMENT","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1202","00-11-10","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATIONS","NOUVELLES INDICATIONS","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1203","00-11-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITUSSIVE, ANTIHISTAMINE","ANTITUSSIF, ANTIHISTAMINIQUE","",""
"1204","00-10-17","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYDREA","SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1205","00-10-10","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY (BUILDING ABIS SUD)","NOUVEL EMPLACEMENT DE FABRICATION (BUILDING ABIS SUD)","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1206","00-09-27","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HALDOL LA","MCNEIL","CANADA","CANADA","1","NAME CHANGE FROM HALOPERIDOL DECANOATE INJECTION","MODIFICATION DU NOM DE HALOPERIDOL DECANOATE INJECTION","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1207","00-09-27","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HALDOL LA","MCNEIL","CANADA","CANADA","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1208","00-08-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: PREVENTION OF HEPATITIS B INFECTION IN PATIENTS WITH CHRONIC LIVER DISEASE, INTRODUCTION OF RAPID IMMUNIZATION SCHEDULE, PRODUCT MONOGRAPH REVISIONS","NOUVELLE INDICATION, NOUVEAU SCHÉMA POSOLOGIQUE, MONOGRAPHIE RÉVISÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1209","00-06-22","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: INJECTABLE","NOUVELLE FORME POSOLOGIQUE: INJECTABLE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1210","00-06-12","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEPATITIS B VACCINE","VACCIN CONTRE L'HÉPATITE B","",""
"1211","00-04-11","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID/NSAID COMBINATION ANALGESIC","ANALGÉSIQUE AINS/OPIOÏDE","",""
"1212","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1213","00-03-14","AVENTIS PASTEUR SA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1214","00-12-28","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1215","00-10-27","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1216","00-10-12","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION FOR MIGRAINE PAIN RELIEF","NOUVELLE INDICATION POUR LE SOULAGEMENT DES DOULEURS DUES AUX MIGRAINES","ANALGESIC, ANITPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1217","00-09-29","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1218","00-09-18","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"1219","00-08-17","MALLINCKRODT MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE METHOD FOR SYNTHESIS OF LOVERSOL (ASI)","AUTRE MÉTHODE DE SYNTHÈSE L'IOVERSOL","RADIOPAQUE CONTRAST MEDIUM","AGENT DE CONTRASTE RADIOLOGIQUE","",""
"1220","00-07-21","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCENTRATION ET FORME POSOLOGIQUE","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1221","00-07-14","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1222","00-06-22","D.C. LABS LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANTIPYRETIC AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANTIPYRÉTIQUE","",""
"1223","00-06-13","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW FORMULATION AND TWO NEW FLAVOURED LINE EXTENSIONS","NOUVELLE PRÉPARATION ET EXTENSION DE GAMME : DEUX NOUVELLES SAVEURS","ANALGESIC, ANTIPYRETIC AGENT - FOR CHILDREN","ANALGÉSIQUE, ANTIPYRÉTIQUE, POUR ENFANTS","",""
"1224","00-05-26","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"1225","00-05-11","WARNER LAMBERT CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD & SINUS","WHITEHALL-ROBINS INC.","CANADA","CANADA","1","","","ANALGESIC/ANTIPYRETIC/NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT","",""
"1226","00-04-20","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"1227","00-04-20","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC-ANTIHYPERTENSIVE AGENT","DIURÉTIQUE - ANTIHYPERTENSIF","",""
"1228","00-04-19","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW PRODUCT NAME","NOUVEAU NOM DU PRODUIT","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","AGENT DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"1229","00-04-19","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW PRODUCT NAME","NOUVEAU NOM DU PRODUIT","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","AGENT DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"1230","00-03-07","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1231","00-02-29","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER - DIURETIC","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II - DIURÉTIQUE","",""
"1232","00-02-23","GENZYME CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYME","",""
"1233","00-02-16","BIOGEN","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1234","00-02-03","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1235","00-01-04","GENZYME CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - EXTENSION OF HARVEST PHASE","MODIFICATION DE LA FABRICATION","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"1236","00-12-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1237","00-11-30","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANGALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1238","00-05-29","CIBA VISION CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ALLERGY AGENT","AGENT ANTIALLERGIQUE","",""
"1239","00-05-01","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","ANALGÉSIQUE - AINS","",""
"1240","00-12-21","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A CHANGE IN FINISHED PRODUCT SPECIFICATION","MODIFICATION DE LA SPÉCIFICATION DU PRODUIT FINI","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1241","00-12-21","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING SITE, CHANGE IN FORMULATION","NOUVEL EMPLACEMENT DE FABRICATION, MODIFICATION DE LA PRÉPARATION","ANXIOLYTIC-SEDATIVE","ANXIOLYTIQUE-SÉDATIF","",""
"1242","00-11-24","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTOGEN","PROGESTATIF","",""
"1243","00-11-17","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EMERGENCY CONTRACEPTIVE","CONTRACEPTIF D'URGENCE","",""
"1244","00-11-10","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE","TOPICAL ANESTHETIC FOR DERMAL ANALGESIA","ANESTHÉSIQUE TOPIQUE POUR ANALGÉSIE DERMIQUE","",""
"1245","00-11-01","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-PARKINSON AGENT","ANTIPARKINSONIEN","",""
"1246","03-12-23","BAYER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STERILE FILLING FACILITY","NOUVEL ÉTABLISSEMENT POUR LE REMPLISSAGE STÉRILE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1247","00-11-01","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM RHO-LOPERAMIDE","CHANGEMENT DU NOM DU PRODUIT DE RHO-LOPERAMIDE","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"1248","00-10-24","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOXAPAC","LEDERLE-CYANAMID","CANADA","CANADA","1","NEW STRENGTH 2.5MG TABLETS","NOUVEAU DOSAGE: COMPRIMÉS DE 2.5MG","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1249","00-10-05","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"1250","00-09-20","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1251","00-09-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARBOLITH","ICN CANADA LTD.","CANADA","CANADA","1","","","ANTIMANIC AGENT","AGENT ANTIMANIAQUE","",""
"1252","00-08-15","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE REGIMEN FOR THE TRIPLE THERAPY","SCHÉMA POSOLOGIQUE RÉVISÉ DE LA TRIPLE THÉRAPIE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1253","00-08-15","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MONOGRAPHIE REVISÉE","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"1254","00-07-06","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH - ADDITION OF NEW INDICATION - FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION","MISE À JOUR DE LA MONOGRAPHIE - AJOUT D'UNE NOUVELLE INDICATION - POUR LE TRAITEMENT DE L'INFARCTUS AIGU DU MYOCARDE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1255","00-07-05","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1256","00-06-16","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXPANDED INDICATION: COMMUNITY ACQUIRED PNEUMONIA DUE TO STREPTOCOCCUS PNEUMONIAE INCLUDING PENICILLIN-RESISTANT STRAINS","INDICATION RÉVISÉE : PNEUMONIE EXTRA-HOSPITALIÈRE DUE À S. PNEUMONIAE INCLUANT LES SOUCHES PÉNICILLORÉSISTANTES","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1257","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTITHROMBOTIC","ANTITHROMBOTIQUE","",""
"1258","00-05-11","GLAXO WELLCOME BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1259","00-05-09","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANESTHETIC","ANESTHÉSIQUE TOPIQUE","",""
"1260","03-12-19","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STERILE FILLING FACILITY","NOUVEL ÉTABLISSEMENT POUR LE REMPLISSAGE STÉRILE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1261","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1262","00-03-16","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRHEUMATIC AGENT","AGENT ANTIRHUMATISANT","",""
"1263","00-03-09","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1264","00-03-03","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EMERGENCY CONTRACEPTIVE","CONTRACEPTIF D'URGENCE","",""
"1265","00-02-25","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1266","00-02-21","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"1267","00-02-16","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"1268","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE/DIURÉTIQUE","",""
"1269","00-02-09","WOMENS CAPITAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EMERGENCY CONTRACEPTION","CONTRACEPTIF ORAL","",""
"1270","00-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1271","00-02-07","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"1272","03-12-19","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, NASAL DECONGESTANT AND ANTIHISTAMINE","ANALGÉSIQUE, DÉCONGESTIONNANT NASAL, ANTIHISTAMINIQUE","",""
"1273","00-01-13","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1274","00-12-28","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX-OTC","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","HAIR REGROWTH TREATMENT FOR MEN","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"1275","00-12-22","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SNC","",""
"1276","00-12-11","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR TEH PROPYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC HEPATIC TRANSPLANTS","NOUVELLE INDICATION: POUR LE TRAITEMENT DE LA RÉJECTION D'ORGANES CHEZ LES PATIENTS QUIE REÇOIVENT DES GREFFES HÉPATIQUES ALLOGÉNIQUES","IMMUNOSUPPRESSANT AGENT","IMMUNOSUPPRESSEUR","",""
"1277","00-12-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC/ANTIHYPERTENSIVE","DIURÉTIQUE - ANTIHYPERTENSEUR","",""
"1278","00-11-24","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"1279","00-11-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VITAMIN SUPPLEMENT","SUPPLÉMENT VITAMINIQUE","",""
"1280","00-11-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","THERAPEUTIC MULTIVITAMIN","MULTIVITAMINE THÉRAPEUTIQUE","",""
"1281","00-11-17","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1282","00-11-17","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1283","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC","NEUROLEPTIQUE","",""
"1284","00-10-27","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL - ANTIPROTOZOAL","ANTIBACTÉRIEN, ANTIPROTOZOAIRE","",""
"1285","00-10-24","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM MOBIC","CHANGEMENT DU NOM DU PRODUIT DE MOBIC","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"1286","00-10-24","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ROSACEA","AGENT ANTIROSACÉE","",""
"1287","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICHOMONACIDE-MONILIACIDE","TRICHOMONACIDE-MONILIACIDE","",""
"1288","00-10-24","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMAN LA ROCHE","CANADA","CANADA","1","","","PREMEDICANT/SEDATIVE/ANAESTHETIC AGENT","PRÉMÉDICATION, SÉDATIF, ANESTHÉSIQUE","",""
"1289","00-10-24","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INOTROPE - VASODILATOR","AGENT INOTROPE - VASODILATATEUR","",""
"1290","03-12-05","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC AND NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT","",""
"1291","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"1292","00-10-19","BAYER INC., HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1293","00-09-14","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM; REVISED DOSAGE REGIMEN","NOUVELLE FORME POSOLOGIQUE; SHCHÉMA POSOLOGIQUE RÉVISÉ","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"1294","00-09-07","LABORATOIRE RIVA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1295","00-09-07","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM RHO-METFORMIN","MODIFICATION DU NOM DE RHO-METFORMIN","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1296","00-09-06","ZYMCAN PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1297","00-08-31","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANIT-INFLAMMATORY ANALGESIC AGENT","AGENT ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"1298","00-08-15","DOMINION PHARMACAL","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1299","00-08-15","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE","CANADA","CANADA","1","","","PREMEDICANT/SEDATIVE/ANAESTHETIC AGENT","PRÉMÉDICATION, SÉDATIF, ANESTHÉSIQUE","",""
"1300","03-11-06","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED INDICATION AND DOSING INSTRUCTIONS","INSTRUCTIONS RÉVISÉES EN MATIÈRE D'INDICATIONS ET POSOLOGIE","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1301","00-07-27","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GONADOTROPIN","GONADOTROPHINE","",""
"1302","03-10-24","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH: 400 MG CAPSULES","NOUVELLE CONCENTRATION: 400 MG CAPSULES","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1303","00-07-27","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION (500MG) AND NEW STRENGTH (850MG)","NOUVELLE FORMULATION (500MG) ET NOUVELLE CONCENTRATION (850MG)","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1304","00-07-18","PURDUE FREDERICK","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSING","POSOLOGIE RÉVISÉE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"1305","00-07-12","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"1306","00-07-12","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RX À OTC","ANTIEMETIC AGENT","ANTIÉMÉTIQUE","",""
"1307","00-06-28","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"1308","00-06-19","STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"1310","00-06-19","STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"1311","00-06-06","SEARLE CANADA - UNIT OF MONSANTO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"1312","00-05-19","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","GONADOTROPINS","GONADOTROPHINES","",""
"1313","00-05-09","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","IMMUNOSUPPRESSENT AGENT","IMMUNOSUPPRESSEUR","",""
"1314","00-05-03","FAULDING (CANADA) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"1315","00-05-03","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT FOR MEN","STIMULANT POUR LA POUSSE DES CHEVEUX POUR LES HOMMES","",""
"1316","00-05-03","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH - 1000MG","NOUVELLE CONCENTRAION - 1000MG","LOWER GASTROINTESTINAL TRACT ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"1317","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"1318","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"1319","00-04-26","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1320","00-04-19","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1321","00-04-11","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTAGEN","PROGESTATIF","",""
"1322","00-04-04","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1323","00-04-04","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1324","00-03-16","AVENTIS PASTEUR SA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1325","00-03-14","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (HEPATOBILIARY IMAGING)","AGENT RADIODIAGNOSTIC (IMAGE HÉPATOBILIAIRE)","",""
"1326","00-03-07","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1327","00-03-07","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM FLAGYL","MODIFICATION DU NOM DE FLAGYL","ANTIBACTERIAL - ANTIPROTOZOAL","ANTIBACTÉRIEN - ANTIPROTOZOAIRE","",""
"1328","00-02-24","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOPRESSOR","VASOPRESSEUR","",""
"1329","00-02-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-Depolarizing Skeletal Neuromuscular Blocking Agent","Inhibiteur neuromusculaire squelettique nondépolarisant","",""
"1330","00-02-09","NYCOMED IMAGING A.S.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE","",""
"1331","00-02-08","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"1332","03-10-20","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC REAGENT","AGENT RADIODIAGNOSTIQUE","",""
"1333","00-02-08","PHARMACIA & UPJOHN COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","HAIR REGROWTH TREATMENT FOR MEN","STIMULANT POUR LA POUSSE DES CHEVEUX POUR HOMMES","",""
"1334","00-12-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHIAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE BRONCHIQUE","",""
"1335","00-11-24","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM RHO-NITRAZEPAM","MODIFICATION DU NOM DE RHO-NITRAZEPAM","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE ET ANTICONVULSIVANT","",""
"1336","00-11-21","AGOURON PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"1337","00-11-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"1338","00-11-09","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1339","00-11-01","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"1340","00-11-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"1341","00-10-17","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"1342","00-10-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASODILATOR/PERIPHERAL","VASODILATATEUR, PÉRIPHÉRIQUE","",""
"1343","00-10-02","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"1344","00-08-25","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIALLERGIC","ANTIALLERGIQUE","",""
"1345","00-07-28","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN-PROGESTIN COMBINATION","ASSOCIATION OESTROPROGESTATIVE","",""
"1346","00-07-24","ELAN PHARMACEUTICAL RESEARCH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC DES PROPRIÉTÉS ANALGÉSIQUES ET ANTIPYRÉTIQUES","",""
"1347","00-06-12","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTIANDROGEN","AGENT ANTIANDROGÈNE NON STÉROÏDIEN","",""
"1348","00-05-26","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","ANTIANGINAL, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"1349","00-04-20","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC AGENT","ANTIÉMÉTIQUE","",""
"1350","00-03-30","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","ANTIANGINAL/ANTIHYPERTENSIVE AGENT","ANTIANGINEUX - ANTIHYPERTENSEUR","",""
"1351","00-03-21","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"1352","00-03-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN-ESTROGEN","ASSOCIATION OESTRO-PROGESTATIVE","",""
"1353","00-03-10","SANOFI CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW CONDITION OF USE: TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCATION","NOUVELLE CONDITION D'EMPLOI : TRAITEMENT DE L'ANGINE INSTABLE ET INFARCTUS SOUS-ENDOCARDIQUE SANS ONDES","ANTICOAGULANT/ANTITHROMBOTIC","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1354","00-02-24","FC PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1355","00-02-07","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME FROM SERZONE","MODIFICATION DU NOM DE SERZONE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1356","00-01-05","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH 150MG","NOUVELLE CONCENTRATION 150MG","NONSTEROIDAL ANTIANDROGEN","AGENT ANTIANDROGÈNE NON STÉROÏDIEN","",""
"1357","00-01-04","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK SHARP & DOHME","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1358","00-12-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC - ANTISPASMODIC AGENT","ANTICHOLINERGIQUE - AGENT ANTISPASMODIQUE","",""
"1359","00-12-01","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORALLY DISINTEGRATING TABLET","NOUVELLE FORME D'ADMINISTRATION : COMPRIMÉS SE DÉSINTÉGRANT ORALEMENT","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1360","00-11-10","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1361","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1362","00-10-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1363","00-10-24","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE","ANTI-ALLERGY AGENT","AGENT ANTIALLERGIQUE","",""
"1364","00-07-27","DAIICHI PHARMACEUTICAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1365","00-07-18","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DITROPAN","MARION MERRELL DOW INC.","CANADA","CANADA","1","","","ANTICHOINERGIC/ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE, AGENT ANTISPASMODIQUE","",""
"1366","00-07-11","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: A MULTIPLE UNIT PELLET SYSTEM (MUPS) TABLETS","NOUVELLE FORME POSOLOGIQUE : MULTIPLE UNIT PELLET SYSTEME (MUPS) TABLETS (ENSEMBLE DE COMPRIMÉS À GRANULES)","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1367","00-04-11","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC - ANTISPASMODIC AGENT","ANTICHOLINERGIQUE - ANTISPASMODIQUE","",""
"1368","00-04-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1369","00-03-16","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DITROPAN","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTICHOLINERGIC - ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE - AGENT ANTISPASMODIQUE","",""
"1370","00-02-03","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1371","00-12-28","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRAST ENHANCING IMAGING AGENT","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE","",""
"1372","03-09-25","BAYER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STERILE FILLING FACILITY","NOUVEL ÉTABLISSEMENT POUR LE REMPLISSAGE STÉRILE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1373","00-12-22","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOACTIVE AGENT","AGENT VASOACTIF","",""
"1374","00-12-08","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1375","00-11-24","STIEFEL LABORATORIES (IRELAND) LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMITOTIC AGENT","AGENT ANTIMITOTIQUE","",""
"1376","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARASITIC AGENT","ANTIPARASITAIRE","",""
"1377","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC - ANTIEMETIC","ANTIPSYCHOTIQUE - ANTIÉMÉTIQUE","",""
"1378","00-11-02","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"1379","00-11-01","DRAXIS HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AS EARLY THERAPY IN THE TREATMENT OF PARKINSON'S DISEASE, WITHOUT CONCOMITANT LEVODOPA THERAPY","NOUVELLE INDICATION : THÉRAPIE PRÉCOCE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON SANS TRAITEMENT CONCOMITANT À LA LÉVODOPA","DOPAMINE AGONIST","AGONISTE DE LA DOPAMINE","",""
"1380","00-10-27","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PSYCHOTROPIC AGENT","PSYCHOTROPE","",""
"1381","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1382","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1383","00-10-24","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1385","00-10-24","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1386","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID/ANTI-INFLAMMATORY","GLUCOCORTICOÏDE - ANTI-INFLAMMATOIRE","",""
"1387","00-10-20","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"1388","00-10-10","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT","ANOREXIGÈNE","",""
"1389","04-04-20","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1390","00-09-22","ZIMMER OF CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1391","03-09-16","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTMIQUE","",""
"1392","00-09-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1393","00-09-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOACTIVE AGENT","AGENT VASO-ACTIF","",""
"1394","04-04-14","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CLARITIN LIBERATOR","MODIFICATION DU NOM DU PRODUIT DE CLARITIN LIBERATOR","HISTAMINE H1 RECEPTOR ANTAGONIST, SYMPATHOMIMETIC AMINE","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE, AMINE SYMPATHOMIMÉTIQUE","",""
"1395","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1396","04-04-16","ELAN PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","NEUROMUSCULAR BLOCKING AGENT","AGENT BLOQUANT NEUROMUSCULAIRE","",""
"1397","04-04-16","SHIRE BIOLOGICS, A DIVISION OF SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN DOSAGE","CHANGEMENT DANS LA POSOLOGIE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1398","03-08-26","BIOGEN CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","CHANGE TO LABELLING: EXPANSION OF INDICATION","CHANGEMENT DE L'ÉTIQUETAGE: EXPANSION DE L'INDICATION","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1399","00-08-25","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1400","04-04-21","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY FOR DRUG SUBSTANCE","NOUVLE EMPLACEMENT DE FABRICATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"1401","04-04-21","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY FOR DRUG SUBSTANCE","NOUVEL EMPLACEMENT DE FABRICATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"1402","03-08-11","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"1403","00-08-15","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC THYROTROPIN-RELEASING HORMONE","HORMONE RÉGULATRICE DE LA THYRÉOTROPHINE SYNTHÉTIQUE","",""
"1404","00-08-17","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-DIABETIC AGENT","AGENT ANTI-DIABÉTIQUE","",""
"1405","00-06-22","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1406","00-06-22","LINSON PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: NEW INDICATIONS RELATED TO THE PREVENTION OF SECONDARY CARDIOVASCULAR EVENTS","MISE À JOUR DE LA MONOGRAPHIE : NOUVELLE INDICATION ASSOCIÉE À LA PRÉVENTION DES MANIFESTATIONS CARDIOVASCULAIRES SECONDAIRES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1407","00-06-12","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC PHOTOSENSITIZING AGENT","PHOTOSENSIBILISANT ANTINÉOPLASIQUE","",""
"1408","00-06-12","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"1409","00-05-01","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1410","00-04-26","BAKER NORTON PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1411","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANAESTHETIC - SEDATIVE","ANESTHÉSIQUE - SÉDATIF","",""
"1412","00-04-26","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1413","00-04-13","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD COMBINATION THERAPY","NOUVELLE INDICATION : AU COURS DU TRAITEMENT ADJUVANT DU CANCER DU SEIN À NOEUDS POSITIFS, ADMINISTRÉS SÉQUENTIELLEMENT À LA THÉRAPIE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1414","00-04-06","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1415","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1416","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1417","00-03-17","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1418","00-03-16","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1419","00-03-10","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 20MG NEW INDICATION: MAINTENANCE TREATMENT OF PATIENTS WITH REFLUX ESOPHAGITIS","NOUVEAU DOSAGE : 20MG NOUVELLE INDICATION : TRAITEMENT D'ENTRETIEN CHEZ LES PATIENTS ATTEINTS D'OESOPHAGITE PAR REFLUX GASTRO-OESOPHAGIEN","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1420","00-03-10","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN COMBINATION WITH APPROPRIATE ANTIBIOTICS, ERADICATION OF H. PYLORI INFECTION ASSOCIATED WITH AN ACTIVE DUODENAL ULCER","NOUVELLE INDICATION : EN ASSOCIATION AVEC DES ANTIBIOTIQUES APPROPRIÉS, ÉRADICATION D'INFECTION À H. PYLORI ASSOCIÉE À UN ULCÈRE DUODÉNAL ÉVOLUTIF","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1421","00-03-02","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AS SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS","NOUVELLE INDICATION : COMME PRÉVENTION SECONDAIRE DES ACCIDENTS CARDIO-VASCULAIRES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1422","00-02-24","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL POUR INFILTRATION ET BLOCAGE NERVEUX","",""
"1423","00-02-09","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ELECTROLYTE REPLENISHER","RÉAPPROVISIONNEMENT D'ÉLECTROLYTE","",""
"1424","00-02-08","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPARKINSONIAN AGENT/DOPAMINE AGONIST","ANTIPARKINSONIEN - AGONISTE DOPAMINERGIQUE","",""
"1425","00-01-17","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPRIVAN","ZENECA PHARMA","CANADA","CANADA","1","","","ANESTHETIC/SEDATIVE","ANESTHÉSIQUE/SÉDATIF","",""
"1426","00-01-17","DEY, L.P.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","LUNG SURFACTANT (PORCINE)","SURFACTANT PULMONAIRE (PORCINE)","",""
"1427","00-12-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1428","00-08-15","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1429","00-04-19","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1430","00-02-08","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1431","00-07-21","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GONADOTROPIN","GONADOTROPHINE","",""
"1432","03-07-02","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION: CHANGE OF PROPELLANT FROM CFC TO HFA","NOUVELLE FORMULATION: CHANGEMENT DU PROPULSEUR DE CFC À HFA","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1433","03-05-28","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"1434","03-05-21","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE FOR PRE-FILLED SYRINGES","NOUVEL EMPLACEMENT DE FABRICATION POUR LES SERINGUES PRÉ-REMPLIES","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1435","00-11-28","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","1. IN THORACIC EPIDURAL BLOCK FOR ACUTE PAIN MANAGEMENT - 2MG/ML SOLUTION CONTINUOUS INFUSION FOR UP TO 72 HOURS; 2. IN THORACIC EPIDURAL BLOCK FOR SURGICAL ANESTHESIA - 5 AND 7.5 MG/ML SOLUTION; 3. IN MAJOR NERVE BLOCK FOR SURGICAL ANESTHESIA - 7.5MG/ML","1. DANS LE BLOC ÉPIDURAL THORACIQUE, POUR GESTION DE LA DOULEUR AIGUË - ERFUSION CONTINUE JUSQU'À 72 HEURES; 2. DANS LE BLOC ÉPIDURAL THORACIQUE POUR ANESTHÉSIE CHIRURGICALE; 3. DANS LE BLOC NERVEUX MAJEUR POUR ANESTHÉSIE CHIRURGICALE","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1436","03-05-13","WATSON LABORATORIES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH AND THE ADDITIONAL CONDITION OF UNDILUTED ADMINISTRATION","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT ET À LA CONDITION SUPPLÉMENTAIRE D'ADMINISTRATION NON DILUÉE","HEMATINIC","HÉMATINIQUE","",""
"1437","00-10-10","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1438","03-05-12","ORBUS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1439","00-09-27","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITUBERCULOUS ANTIBIOTIC","ANTIBIOTIQUE ANTITUBERCULEUX","",""
"1440","00-09-21","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH AND ADDITION OF NEW STRENGTH","MONOGRAPHIE RÉVISÉE ET NOUVELLE CONCENTRATION","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1441","00-09-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1442","00-08-30","AVENTIS PHARMA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGLUTAMATE","ANTIGLUTAMATE","",""
"1443","00-08-09","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1444","00-07-17","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT AND PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS, NEW STRENGTH","NOUVELLE INIDICATION : TRAITEMENT ET PRÉVENTION DE L'OSTÉOPOROSE POSTMÉNOPAUSIQUE, NOUVELLE CONCENTRATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"1445","00-05-17","FC PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1446","00-05-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN COMBINATION WITH SULFONYLUREA","NOUVELLE INDICATION : UTILISER EN ASSOCIATION AVEC LES SULFONYLURÉES","ANTIDIABETIC AGENT, INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE, AGENT DE RÉDUCTION POUR LA RÉSISTANCE À L'INSULINE","",""
"1447","00-05-08","CENTOCOR","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN FINAL PRODUCT FORMULATION","MODIFICATION À LA FORMULATION","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"1448","03-05-01","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH AND LABELS","MONOGRAPHIE DU PRODUIT ET ÉTIQUETTES RÉVISÉES","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1449","00-04-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"1450","00-03-21","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIABETIC AGENT, INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE, AGENT DE RÉDUCTION POUR LA RÉSISTANCE À L'INSULINE","",""
"1451","03-04-25","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"1452","00-03-17","AVENTIS PASTEUR SA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNE AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1453","00-03-17","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1454","03-04-23","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC RADIOGRAPHIC CONTRAST MEDIUM","AGENT DIAGNOSTIQUE OPACIFIANT NON IONIQUE","",""
"1455","00-02-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID COMPONENT TO ANAESTHESIA","COMPOSANTE OPIOÏDE POUR L'ANESTHÉSIE","",""
"1456","00-03-02","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOTHERAPEUTIC AGENT (PASSIVE IMMUNIZATION)","AGENT IMMUNOTHÉRAPEUTIQUE (IMMUNISATION PASSIVE)","",""
"1457","00-02-23","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1458","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1459","00-02-15","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1460","00-01-19","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN","NOUVELLE INDICATION: TRAITEMENT DE L'OSTÉOPOROSE CHEZ LES FEMMES POSTMÉNOPAUSÉES","SELECTIVE ESTROGEN RECEPTOR MODULATOR","MODULATEUR SÉLECTIF DES RÉCEPTEURS OESTROGÉNIQUES","",""
"1461","00-12-28","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT/ANTIOBESITY AGENT","ANOREXIANT/ANTIOBÉSITÉ","",""
"1462","00-12-12","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: TREATMENT OF TURNER'S SYNDROME","NOUVELLE INDICATION : TRAITEMENT DU SYNDROME DE TURNER","HUMAN GROWTH HORMONE","STIMULANT DE LA CROISSANCE","",""
"1463","00-12-12","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1464","00-12-08","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM SEVORANE","MODIFICATION DU NOM DE SEVORANE","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"1465","00-11-30","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: DISKUS","NOUVELLE FORME POSOLOGIQUE : DISKUS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1466","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1467","00-11-14","SMITH & NEPHEW INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIBACTERIAL AGENT","ANTIBACTÉRIEN TOPIQUE","",""
"1468","00-11-10","3M PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF EXERCISE-INDUCED ASTHMA IN PEDIATRIC PATIENTS BETWEEN 6 AND 11 YEARS OLD","NOUVELLE INDICATION : PRÉVENTION DE L'ASTHME D'EFFORT CHEZ LES ENFANTS DE 6 À 11 ANS","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES","",""
"1469","00-11-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1470","00-10-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CALCIUM REGULATOR","RÉGULATEUR DE CALCIUM","",""
"1471","00-10-12","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: REGULAR TREATMENT OF REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE, INCLUDING ASTHMA, IN CHILDREN 4-11 YEARS","NOUVELLE INDICATION : TRAITEMENT RÉGULIER DE L'OBSTRUCTION RÉVERSIBLE DES VOIES AÉRIENNES, Y COMPRIS L'ASTHME, CHEZ LES ENFANTS DE 4 À 11 ANS","BRONCHODILATOR AND CORTICOSTEROID FOR INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"1472","03-04-09","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (FOR RADIOLABELLING AUTOLOGOUS LEUKOCYTES)","AGENT RADIODIAGNOSTIQUE (POUR RADIOMARQUER DES LEUCOCYTES AUTOLOGUES)","",""
"1473","00-10-10","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM RHO-SOTALOL","MODIFICATION DU NOM DE RHO-SOTALOL","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1474","00-08-17","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MEDICAL TREATMENT OF OSTOSPONGIOSIS","TRAITEMENT DE L'OTOSPONGIOSE","",""
"1475","00-08-16","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1476","00-07-24","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1477","00-06-28","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRO-DUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRODUODÉNAL","",""
"1478","00-02-24","GENZYME CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOSPHATE BINDER","AGENT D'AGGLUTINATION DU PHOSPHATE","",""
"1479","00-04-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1480","00-04-19","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1481","03-04-09","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW FORMULATION AND FLAVOURED LINE EXTENSIONS","NOUVELLE FORMULATION ET EXTENSIONS DE LA LIGNE AROMATISÉE","ANALGESIC, ANTIPYRETIC AGENT - FOR CHILDREN","ANALGÉSIQUE, ANTIPYRÉTIQUE - POUR ENFANTS","",""
"1482","00-03-30","ZIMMER OF CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"1483","00-03-16","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1484","00-03-14","AVENTIS PASTEUR SA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1485","00-03-10","LEVER PONDS, A DIVISION OF U L CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTICARIES TOOTHPASTE","DENTIFRICE ANTICARIES","",""
"1486","00-01-19","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1487","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"1488","00-01-17","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME","CANADA","CANADA","1","","","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES","",""
"1489","03-02-25","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","","","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"1490","00-01-12","RIVA LABORATORY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1491","00-12-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT PHARMA","CANADA","CANADA","1","","","ANTI-COAGULANT","ANTICOAGULANT","",""
"1492","00-10-05","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT PHARMA INC.","CANADA","CANADA","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"1493","03-02-18","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","","","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"1494","00-08-09","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT PHARMA INC.","CANADA","CANADA","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"1495","03-02-04","D.C. LABS LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1496","00-11-17","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - ORALLY DISPERSIBLE TABLETS","NOUVELLE FORME POSOLOGIQUE -  COMPRIMÉS SE DISSOLVANT ORALEMENT","5-HT RECEPTOR AGONIST - MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT, ANTIMIGRAINEUX","",""
"1497","00-10-05","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1498","00-08-21","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"1499","00-07-05","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHÔNE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1500","03-01-22","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","IONIC, LOW OSMOLALITY, WATER SOLUBLE RADIOPAQUE CONTRAST MEDIUM FOR INTRAVENOUS USE","PRODUIT DE CONTRASTE RADIO-OPAQUE HYDROSOLUBLE, IONIQUE, À FAIBLE OSMOLALITÉ POUR USAGE INTRAVEINEUX","",""
"1501","00-05-11","SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1502","00-02-03","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR DES LEUCOTRIÈNES","",""
"1503","00-01-28","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MIGRAINE THERAPY","TRAITEMENT DES MIGRAINES","",""
"1504","00-09-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILIEPTIC","ANTIÉPILEPTIQUE","",""
"1505","00-08-23","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: EXTENDED-RELEASE TABLETS","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉS À ACTION PROLONGÉE","ANTICONVULSANT","ANTICONVULSIVANT","",""
"1507","00-07-04","ANTHRA PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CYTOTOXIC ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE CYTOTOXIQUE","",""
"1508","03-09-03","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NIZORAL CREAM","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"1509","00-05-31","QLT INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOTOSENSITIZING AGENT FOR AGE-RELATED MACULAR DEGENERATION","PHOTOSENSIBILISANT POUR LA DÉGÉNÉRESCENCE MACULAIRE ASSOCIÉE À L'ÂGE","",""
"1510","00-03-15","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"1511","03-04-14","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY AGENT","AGENT ANTI-INFLAMMATOIRE TOPIQUE","",""
"1512","00-03-14","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VANCOCIN","ELI LILLY","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1513","00-03-07","SWISS SERUM & VACCINE INSTITUTE BERNE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1514","03-11-13","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1515","00-01-28","ABBOTT LABORATORIES, LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORCURON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEUROMUSCULAIRE NON DÉPOLARISANT","",""
"1516","00-12-22","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROLOPRIM","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"1517","00-12-21","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"1518","03-11-12","CARTER-HORNER CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"1519","00-12-13","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","DIAGNOSTIC RADIOPHARMACEUTICAL FOR MYOCARDIAL INFARCTION","AGENT RADIODIAGNOSTIQUE DE L'INFARCTUS MYOCARDIQUE","",""
"1520","00-12-07","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","DIAGNOSTIC RADIOPHARMACEUTICAL FOR BREAST IMAGING","AGENT RADIODIAGNOSTIQUE","",""
"1521","00-12-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICYCLIC ANTIDEPRESSANT","ANTIDÉPRESSEUR TRICYCLIQUE","",""
"1522","00-12-01","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1523","00-11-30","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1524","00-11-30","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR THE TREATMENT OF BRONCHIAL ASTHMA","CORTICOSTÉROÏDE POUR LE TRAITEMENT DE L'ASTHME BRONCHIQUE","",""
"1525","00-11-29","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TESTOSTERONE REPLACEMENT THERAPY","THÉRAPIE DESTINÉE À REMPLACER LE TESTOSTÉRONE","",""
"1526","00-10-02","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TESTOSTERONE REPLACEMENT THERAPY","THÉRAPHIE DESTINÉE À REMPLACER LE TESTOSTÉRONE","",""
"1527","00-11-16","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1528","00-11-16","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1529","00-11-16","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1530","03-11-07","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: CONTROLLED RELEASE TABLETS","NOUVELLE FORME POSOLOGIQUE: COMPRIMÉ À ACTION CONTRÔLÉE","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"1531","00-11-14","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPRURITIC-ANTIHISTAMINIC","ANTIPRURIGINEUX, ANTIHISTAMINIQUE","",""
"1532","00-11-10","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RESTORIL","NOVARTIS PHARMA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1533","00-10-05","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC","NEUROLEPTIQUE","",""
"1534","03-11-06","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ANALOG","ANALOGUE DE LA LHRH","",""
"1535","00-10-05","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRANQUILLIZER - ANTIPSYCHOTIC","TRANQUILLISANT - ANTIPSYCHOTIQUE","",""
"1536","00-09-27","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"1537","00-08-17","LIFEHEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MONOAMINE DEPLETING AGENT","AGENT DE DÉPLÉTION DE MONOAMINES","",""
"1538","00-06-13","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: GEL FORMING SOLUTION","NOUVELLE FORME POSOLOGIQUE : SOLUTION GÉLIFIANTE","ELEVATE INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"1539","00-06-12","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1540","00-05-16","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1541","00-05-09","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1542","00-05-01","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW REFILL PACKAGE","NOUVEL EMBALLAGE DE RECHARGE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1543","00-05-01","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1544","00-05-01","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1545","00-04-26","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARYTHMIQUE","",""
"1546","00-04-20","MEDIMMUNE ONCOLOGY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPROTOZOAL AGENT","AGENT ANTIPROTOZOAIRE","",""
"1547","00-03-16","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"1548","00-03-03","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1549","00-02-29","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1550","00-02-29","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBREX","ALCON CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1551","00-02-16","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC","MERCK FROSST","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"1552","00-02-15","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC","MERCK FROSST","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"1553","00-01-24","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW RAW MATERIAL SUPPLIER, ALTERNATE FORMULATION (UNCOATED TABLETS) AND AN ADDITIONAL MANUFACTURING SITE","NOUVELLE MATIÈRE PREMIÈRE, AUTRE FORME PHARMACEUTIQUE (COMPRIMÉS NON ENROBÉS) ET UN LIEU DE FABRICATION SUPPLÉMENTAIRE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1554","03-10-24","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: CHANGES TO DOSAGE & ADMINISTRATION AND WARNINGS SECTIONS WITH REGARDS TO RHABDOMYOLYSIS","MONOGRAPHIE RÉVISÉE DU PRODUIT: CHANGEMENTS AUX RUBRIQUES POSOLOGIE ET MISES EN GARDE RELATIVEMENT À LA RHABDOMYOLISE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1555","99-12-10","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR USE IN PAEDIATRIC PATIENTS WITH PARAOXYSMAL SUPERAVENTRICULAR TACHYCARDIA (PSVT)","POUR L'UTILISATION CHEZ LES ENFANTS ATTEINTS DE TACHYCARDIE PAROXYSTIQUE SUPRAVENTRICULAIRE","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"1556","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN F2ALPHA ANALOGUE","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA","",""
"1557","03-09-22","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1558","99-11-17","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRHEUMATIC AGENT","ANTIRHUMATISMAL","",""
"1559","03-09-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"1560","99-11-08","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DES VOIES GASTRO-INTESTINALES INFÉRIEURES","",""
"1561","99-11-08","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"1562","99-11-08","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"1563","99-10-29","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"1564","99-10-18","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"1565","99-10-01","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH AYERST","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"1566","99-10-01","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT AND MANUFACTURER'S NAME","MODIFICATION DU NOM DU PRODUIT ET DU FABRICANT","ANTIBIOTIC & BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE - INHIBITEUR DE B-LACTAMASES","",""
"1567","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1568","99-09-28","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SYMPTOMATIC RELIEF OF ANXIETY IN PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD)","NOUVELLE INDICATION : SOULAGEMENT SYMPTOMATIQUE DE L'ANXIÉTÉ CHEZ LES PATIENTS SOUFFRANT DU TROUBLE D'ANXIÉTÉ GÉNÉRALISÉE","ANTIDEPRESSANT/ANXIOLYTIC","ANTIDÉPRESSEUR/ANXIOLYTIQUE","",""
"1569","99-09-21","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC KIT FOR THE PREPARATION OF TECHNETIUM TC 99M ALBUMIN AGGREGATED","TROUSSE DIAGNOSTIQUE POUR LA PRÉPARATION DE TECHNÉTIUM 99M TC ALBUMINE AGRÉGÉ","",""
"1570","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN F2ALPHA ANALOGUE AND BETA-ADRENERGIC RECEPTOR BLOCKER","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA ET INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"1571","99-09-02","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE OXYDASE","",""
"1572","03-09-05","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH CHRONIC ANGLE-CLOSURE GLAUCOMA WHO UNDERWENT PERIPHERAL IRIDOTOMY OR LASER IRIDOPLASTY","NOUVELLE INDICATION - RÉDUCTION DE LA PRESSION INTRA-OCULAIRE CHEZ LES PATIENTS QUI SOUFFRENT DE GLAUCOME PAR FERMETURE DE L'ANGLE ET QUI ONT SUBI UNE IRIDOTOMIE PÉRIPHÉRIQUE OU UNE IRIDOPLASTIE AU LASER","PROSTAGLANDIN F2ALPHA ANALOGUE","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA","",""
"1573","99-09-01","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL ANTIBIOTIC","ANTIBACTÉRIEN ANTIBIOTIQUE","",""
"1574","99-08-18","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR USE IN COMBINATION WITH METFORMIN OR INSULIN IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS","POUR L'UTILISATION EN ASSOCIATION AVEC METFORMIN OU INSULIN POUR LE TRAITEMENT DES PATIENTS ATTEINTS DE DIABÈTE SUCRÉ DE TYPE 2","ORAL ANTIDIABETIC AGENT, ALPHA-GLUCOSIDASE INHIBITOR","ANTIDIABÉTIQUE ORAL, INHIBITEUR DES ALPHA-GLUCOSIDASES","",""
"1575","99-08-03","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1576","99-07-02","IMMUNOMEDICS,INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","SCALE-UP IN MANUFACTURING PROCESS AND NEW MANUFACTURING SITE","CHANGEMENT DE FABRICATION ET NOUVEL EMPLACEMENT DE FABRICATION","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSITQUE","",""
"1577","03-08-26","GLAXOSMITHKLINE SHIRE BIOCHEM","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND NEW 300 MG ONCE DAILY DOSING REGIMEN","NOUVELLE CONCENTRATION ET NOUVELLE POSOLOGIE DE 300 MG UNE FOIS PAR JOUR","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1578","99-06-16","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACRIUM","BURROUGHS WELLCOME","CANADA","CANADA","1","","","INTRAVENOUS SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE","",""
"1579","99-06-16","LEO PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","VITAMIN D ANALOGUE","MÉTABOLITE DE LA VITAMINE D3","",""
"1580","99-03-26","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARON","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1581","99-06-11","LIGAND PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"1582","99-06-04","GLAXO WELLCOME INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1583","99-05-20","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","HAEMATOPOIETIC AGENT","AGENT HÉMATOPOÏÉTIQUE","",""
"1584","99-03-04","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1585","99-03-04","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","BURROUGHS WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"1586","99-03-04","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","AGENT ANTIHYPERTENSEUR - ANTIANGINEUX","",""
"1587","99-03-04","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","AGENT ANTIHYPERTENSEUR - ANTIANGINEUX","",""
"1588","99-03-04","FC PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"1589","99-05-05","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1590","99-04-15","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW DOSAGE FORM","FOURNIS POUR UNE NOUVELLE PRÉSENTATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1591","99-03-04","CHIRON CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN CELL BANKS AND USE OF DIFFERENT CELL GROWTH MEDIUM","NOUVELLES BANQUES CELLULAIRES ET UN NOUVEAU MILIEU DE CROISSANCE","IMMUNOMODULATOR","AGENT D'IMMUNOMODULATION","",""
"1592","99-02-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HISMANAL TABLETS","JANSSEN PHARMACEUTICA INC.","CANADA","CANADA","1","","","HISTAMINE H1-ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE - ANTAGONISTE","",""
"1593","99-02-16","HOFFMANN-LA ROCHE LIMITED","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION FOR MANAGEMENT OF ACUTE ISCHEMIC STROKE","NOUVELLE INDICATION : POUR LA GESTION DES ATTAQUES D'APOPLEXIE AIGUS ET ISCHÉMIQUES","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"1594","99-02-12","FC PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ZENECA PHARMA","CANADA","CANADA","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"1595","99-02-02","MALLINCKRODT MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","INTRAVENOUS ULTRASOUND CONTRAST MEDIUM","MILIEU DE CONTRASTE INTRAVEINEUX POUR ULTRASON","",""
"1596","99-01-14","LEO PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","VITAMIN D ANALOGUE","VITAMINE D ANALOGUE","",""
"1597","99-01-12","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: AS AN ADJUNCT TO DIET FOR THE REDUCTION OF ELEVATED TOTAL CHOLESTEROL IN DYSBETALIPOPROTEINEMIA (TYPE III), HYPERTRIGLYCERIDEMIA (TYPE IV), AND HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA","NOUVELLE INDICATION : ADJUVANT À LA DIÈTE POUR LA RÉDUCTION DU TAUX DE CHOLESTÉROL DANS LA DYSBÊTALIPOPROTÉINÉMIE, L'HYPERTRIGLYCÉRIDÉMIE ET L'HYPERCHOLESTÉROLÉMIE FAMILIALE HOMOZYGOTE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1598","99-12-22","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BECONASE AQ","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"1599","99-11-18","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RHINOCORT AQUA","ASTRA PHARMA","CANADA","CANADA","1","","","CORTICOSTEROID","CORITCOSTÉROÏDE","",""
"1600","99-11-08","CRYSTAAL CORPORATION, A DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","B-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"1601","99-10-15","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RHINOCORT AQ NASAL SPRAY","ASTRA PHARMA","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"1602","99-09-02","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE STRENGTH","NOUVELLE CONCENTRATION","LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"1603","99-08-27","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","MAINTENANCE DOSING: TREATMENT WITH ZYBAN FOR UP TO 1 YEAR TO PREVENT RELAPSE","DOSE D'ENTRETIEN : TRAITEMENT AVEC ZYBAN JUSQU'À 1 AN AFIN DE PRÉVENIR UNE RECHUTE","SMOKING CESSATION AID","AIDE POUR ARRÊTER DE FUMER","",""
"1604","99-08-25","HOECHST-ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"1605","99-08-06","SOLVAY PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-VERTIGO AGENT","ANTIVERTIGINEUX","",""
"1606","99-08-06","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR CHANGES TO THE PRODUCT MONOGRAPH AND LABELLING","PRODUIT POUR LES MODIFICATIONS À LA MONOGRAPHIE ET À L'ÉTIQUETAGE","ANTI-VERTIGO AGENT","ANTIVERTIGINEUX","",""
"1607","99-08-06","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TANTUM","3M PHARMCEUTICALS","CANADA","CANADA","1","","","BENZYDAMINE MOUTHWASH, BP","BENZYDAMINE (BAIN DE BOUCHE), BP","",""
"1608","99-07-22","ORPHAN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1609","99-07-07","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: TREATMENT OF EQUINUS FOOT DEFORMITY DUE TO SPASTICITY IN PEDIATRIC CEREBRAL PALSY PATIENTS","NOUVELLE INDICATION : TRAITEMENT DE LA DÉFORMATION EN PIED ÉQUIN SECONDAIRE À LA SPASTICITE CHEZ LES ENFANTS ATTEINTS DE PARALYSIE CÉRÉBRALE","NEUROMUSCULAR PARALYTIC AGENT","AGENT NEUROMUSCULAIRE PARALYSANT","",""
"1610","99-06-21","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","PREMEDICANT - SEDATIVE - ANAESTHETIC AGENT","PRÉMÉDICATION - SÉDATIF - ANESTHÉSIQUE","",""
"1611","99-06-16","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BEZALIP","BOEHRINGER MANNHEIM CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1612","99-05-14","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW FACILITY, UPGRADES TO PRODUCTION PROCESS","MODIFICATION DE LA MÉTHODE DE FABRICATION - NOUVEL EMPLACEMENT DE FABRICATION, MODIFICATION DE LA MÉTHODE DE FABRICATION","NEUROMUSCULAR PARALYTIC AGENT","AGENT NEUROMUSCULAIRE PARALYSANT","",""
"1613","99-05-10","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETOPTIC OPHTHALMIC SOLUTION","ALCON CANADA INC.","CANADA","CANADA","1","","","ANTIGLAUCOMA AGENT (OPHTHALMIC)","AGENT POUR LE TRAITEMENT DU GLAUCOME (OPHTHALMIQUE)","",""
"1614","99-05-05","MEDICAN TECHNOLOGIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SCABICIDE","SCABICIDE","",""
"1615","99-01-28","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTHS - 0.75%; NEW INDICATION - SENSORCAINE 0.75% WITH/WITHOUT EPINEPHRINE FOR RETROBULBAR BLOCK","NOUVELLES CONCENTRATIONS 0.75%, NOUVELLE INDICATION - SENSORCAINE 0.75% AVEC/SANS ÉPINÉPHRINE POUR BLOC RÉTROBULBAIRE","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"1616","99-01-25","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCAL ANALGESIC","ANALGÉSIQUE LOCAL","",""
"1617","99-12-22","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1618","99-11-17","SKYEPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1619","99-10-18","BAXTER AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC","HÉMOSTATIQUE","",""
"1620","04-04-13","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","WITHDRAWAL OF INDICATION: TREATMENT OF LOCALIZED PROSTATE CANCER; AND WITHDRAWAL OF STRENGTH: 150MG","RETRAIT DE L'INDICATION : POUR LE TRAITEMENT DU CANCER LOCALISÉ DE LA PROSTATE; ET RETRAIT DE LA CONCENTRATION DE 150MG","NON-STEROIDAL ANTI-ANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"1621","04-04-14","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"1622","99-10-07","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"1623","04-04-14","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM RIVA-INDAPAMIDE","MODIFICATION DU NOM DU PRODUIT DE RIVA-INDAPAMIDE","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"1624","99-09-28","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1625","04-04-14","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1626","99-09-21","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1627","04-04-14","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM RIVA-SOTALOL","MODIFICATION DU NOM DU PRODUIT DE RIVA-SOTALOL","ANTIARRHYTHMIC","ANTIAHYTHMIQUE","",""
"1628","99-08-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"1629","04-04-14","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM TERAZOSIN","MODIFICATION DU NOM DU PRODUIT DE TERAZOSIN","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"1630","04-04-14","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1631","04-04-15","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF INDICATION: FOR UNCOMPLICATED CYSTITIS AND COMPLICATED URINARY TRACT INFECTIONS","RETRAIT DE L'INDICATION : POUR LE TRAITEMENT DE LA CYSTITE NON COMPLIQUÉE ET DES INFECTIONS URINAIRES COMPLIQUÉES","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1632","04-04-16","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN","OESTROGÈNE","",""
"1633","04-04-19","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"1634","99-08-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURICEF","BRISTOL-MYERS SQUIBB INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1635","04-04-20","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","REVISED PRODUCT MONOGRAPH AS REQUESTED IN TPD LETTER REGARDING WORKING PAPER FOR PRODUCT MONOGRAPHS OF NON-CONTRACEPTIVE ESTROGEN AND ESTROGEN/PROGESTIN PRODUCTS","MODIFICATION À LA MONOGRAPHIE DU PRODUIT COMME DEMANDÉ DANS LA LETTRE DE LA DPT RELATIVEMENT AU WORKING PAPER FOR PRODUCT MONOGRAPHS OF NON-CONTRACEPTIVE ESTROGEN AND ESTROGEN/PROGESTIN PRODUCTS","PROGESTIN","PROGESTATIF","",""
"1636","04-04-23","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH AS REQUESTED IN TPD LETTER REGARDING WORKING PAPER FOR PRODUCT MONOGRAPHS OF NON-CONTRACEPTIVE ESTROGEN AND ESTROGEN/PROGESTIN PRODUCTS","MODIFICATION À LA MONOGRAPHIE DU PRODUIT COMME DEMANDÉ DANS LA LETTRE DE LA DPT RELATIVEMENT AU WORKING PAPER FOR PRODUCT MONOGRAPHS OF NON-CONTRACEPTIVE ESTROGEN AND ESTROGEN/PROGESTIN PRODUCTS","PROGESTAGEN, PROGESTATIONAL STEROID","PROGESTOGÈNE, HORMONE STÉROÏDE PROGESTATIVE","",""
"1637","99-07-30","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"1638","99-07-26","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURICEF","BRISTOL-MYERS SQUIBB INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1639","04-04-20","NABI BIOPHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOSPHATE BINDER","AGGLOMÉRANT PHOSPHATE","",""
"1640","99-07-13","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERIDEX","PROCTER & GAMBLE INC.","CANADA","CANADA","1","","","ANTIGINGIVITIS ORAL RINSE","ANTIGINGIVITE","",""
"1641","04-04-20","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1642","99-07-13","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"1643","04-04-20","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1644","99-07-07","GERMIPHENE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGINGIVITIS ORAL RINSE","BAIN DE BOUCHE CONTRE LA GINGIVITE","",""
"1645","04-04-21","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","PROGESTIN","PROGESTATIF","",""
"1646","99-06-29","A.R. MEDICOM CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGINGIVITIS ORAL RINSE","BAIN DE BOUCHE CONTRE LA GINGIVITE","",""
"1647","99-06-09","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC/CORTICOSTEROID","ANTIBIOTIQUE/CORTICOSTÉROÏDE","",""
"1648","99-06-03","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1649","99-06-03","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1650","04-04-22","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE PRODUCT MONOGRAPH WITH NEW CLINICAL TRIAL INFORMATION","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT POUR INCLURE DE NOUVEAUX RENSEIGNEMENTS SUR LES ESSAIS CLINIQUES","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1651","99-05-28","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1652","04-04-26","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OCUFLOX","ALLERGAN INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1653","04-04-26","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1654","04-04-28","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"1655","99-05-10","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLEXERIL","MERCK FROSST CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","SKELETAL MUSCLE RELAXANT","RELAXANT DES MUSCLES SQUELETTIQUES","",""
"1656","04-04-30","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RESTORIL","NOVARTIS PHARMA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1657","99-05-06","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL/CORTICOSTEROID","ANTIBACTÉRIEN/CORTICOSTÉROÏDE","",""
"1658","04-04-30","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK SHARP & DOHME","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1659","99-04-14","SEARLE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","AGENT ANALGÉSIQUE ANTI-INFLAMMATOIRE","",""
"1660","04-04-30","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVENOUS NUTRIENT SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"1661","99-04-12","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1662","04-04-30","GMD DISTRIBUTING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTALITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"1663","99-02-23","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1664","04-04-30","GMD DISTRIBUTING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"1665","99-02-05","LUNDBECK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1666","99-02-05","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1667","99-01-28","NYCOMED AMERSHAM PLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"1668","99-01-05","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","VITAMIN D3 METABOLITE","MÉTABOLITE DE LA VITAMINE D3","",""
"1669","99-12-31","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"1670","99-11-22","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM","HOECHST MARION ROUSSEL","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1671","99-11-17","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN","GEIGY (CANADA)","CANADA","CANADA","1","","","ANTI-INFLAMMATORY -ANALGESIC","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1672","99-11-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1673","99-11-04","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","5-HT1 RECEPTOR AGONIST","AGONISTE SUR LE RÉCEPTEUR 5-HT1","",""
"1674","99-10-07","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-2","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1675","99-10-01","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-2","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1676","99-08-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","CIBA GEIGY CANADA LTD., GEIGY PHARMACEUTICALS","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1677","99-08-25","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1678","99-07-22","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-2","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","AGENT ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"1679","01-05-08","MEDIMMUNE ONCOLOGY, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TO REDUCE THE INCIDENCE AND SEVERITY OF RADIATION-INDUCED XEROSTOMIA, IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK","NOUVELLE INDICATION : POUR RÉDUIRE L'INCIDENCE ET LA SÉVÉRITÉ DE LA XÉROSTOMIE RADIO-INDUITE CHEZ LES PATIENTS ATTEINTS DE CANCER ÉPIDERMOÏDE DE LA TÊTE ET DU COU","CYTOPROTECTRIVE AGENT","AGENT CYTOPROTECTEUR","",""
"1680","01-04-30","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"1681","01-04-30","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"1682","01-04-26","CHIRON CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BIOLOGIC RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"1683","01-04-20","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DE PLAQUETTES","",""
"1684","01-04-20","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DE PLAQUETTE","",""
"1685","01-04-20","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DE PLAQUETTES","",""
"1686","01-04-09","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN THE TREATMENT OF OSTEOPOROSIS IN MEN","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'OSTÉOPOROSE CHEZ LES HOMMES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"1687","01-04-09","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"1688","01-04-06","THE LIPOSOME COMPANY INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: FOR THE TREATMENT OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WHO ARE REFRACTORY TO OR INTOLERANT OF CONVENTIONAL AMPHOTERICIN B THERAPY","INDICATION RÉVISÉE : POUR LE TRAITEMENT D'INFECTIONS FONGIQUES ENVAHISSANTES CHEZ LES PATIENTS QUI SOUFFRENT D'INTOLÉRANCE OU QUI SONT RÉFRACTAIRES À LA THÉRAPIE À AMPHOTÉRICINE B","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1689","01-03-29","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"1690","01-03-01","GLAXO WELLCOME INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1691","01-02-23","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","","","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"1692","01-02-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADENOCARD","FUJISAWA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"1693","01-02-15","MGI PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"1694","01-02-01","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"1695","01-01-31","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1696","01-01-25","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"1697","01-01-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1698","01-01-18","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1699","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1700","01-01-09","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"1701","01-11-30","ACTELION PHARMACEUTICALS LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ENDOTHELIN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"1702","01-11-21","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC","ANTILEUCÉMIQUE","",""
"1703","01-11-13","BIOVAIL PHARMACEUTICALS, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"1704","01-10-30","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC AGENT FOR BLADDER INSTILLATION","ANTINÉOPLASIQUE","",""
"1705","01-10-24","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: MANAGEMENT OF FOCAL SPASTICITY, INCLUDING THE TREATMENT OF UPPER LIMB SPASTICITY ASSOCIATED WITH STROKE IN ADULTS","NOUVELLE INDICATION : TRAITEMENT DE LA SPASTICITÉ FOCALE INCLUANT LA SPASTICITÉ DES MEMBRES SUPÉRIEURS CAUSÉE PAR UN ACCIDENT VASCULAIRE CÉRÉBRAL CHEZ L'ADULTE","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYTIQUE NEUROMUSCULAIRE","",""
"1706","01-10-12","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR, GROWTH HORMONE SUPPRESSANT IN ACROMEGALY, ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, MÉDICAMENT ADJUVANT UTILISÉ DANS LA MALADIE DE PARKINSON","",""
"1707","01-10-12","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASMODIQUE","",""
"1708","99-07-16","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-2","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"1709","03-08-13","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTILEUKEMIC AGENT","AGENT ANTI-LEUCÉMIQUE","",""
"1710","03-08-01","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1712","03-05-16","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINEMET","MERCK SHARP & DOHME FOR DUPONT PHARMA","CANADA","CANADA","1","","","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"1713","03-05-14","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE: REVISIONS TO THE CLINICAL PHARMACOLOGY SECTION","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT: RÉVISIONS À LA RUBRIQUE PHARMACOLOGIE CLINIQUE","ANTIRHEUMATIC AGENT","ANTIRHUMATISMAL","",""
"1714","03-04-30","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1715","03-04-25","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR FIRST LINE THERAPY","POURVOIR AU TRAITEMENT DE PREMIÈRE LIGNE","PROSTAGLANDIN F2ALPHA ANALOGUE","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA","",""
"1716","03-04-07","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1717","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1718","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"1719","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"1720","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1721","01-09-21","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STADOL NS","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANALGESIC","ANALGÉSIQUE","",""
"1722","01-09-21","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION OF THE 100MG TABLET","MODIFICATION DE LA PRÉPARATION DES COMPRIMÉS DE 100MG","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1723","01-08-31","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: TREATMENT OF HYPERHIDROSIS OF THE AXILLA","NOUVELLE INDICATION : TRAITEMENT DE L'HYPERHIDROSE DES AISSELLES","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYTIQUE NEUROMUSCULAIRE","",""
"1724","01-08-24","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TANTUM","3M PHARMACEUTICALS","CANADA","CANADA","1","","","LOCAL ANALGESIC","ANALGÉSIQUE LOCAL","",""
"1725","01-08-22","SCHERING-PLOUGH HEALTHCARE PRODUCTS CANADA, A DIVISION OF SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1726","03-03-14","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: RENAL PROTECTION IN TYPE 2 DIABETES WITH PROTEINURIA","NOUVELLE INDICATION: PROTECTION RÉNALE POUR LE DIABÈTE DE TYPE 2 AVEC PROTÉINURIE","ANGIOTENSIN II RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II","",""
"1727","01-07-19","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE ANTITABAGIQUE","",""
"1728","01-07-18","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1729","03-03-06","UCB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1730","01-07-18","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BCG MANUFACTURING FACILITY","NOUVELLE INSTALLATION DE FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1731","03-02-26","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK SHARP AND DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1732","01-07-18","SHIRE BIOLOGICS, A DIVISION OF SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"1733","01-05-30","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC, ANTIPARKINSON AGENT","AGENT ANTICHOLINERGIQUE, ANTIPARKINSONIEN","",""
"1734","01-05-22","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-VERTIGO AGENT","ANTIVERTIGINEUX","",""
"1735","01-04-04","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: FOR THE TREATMENT OF GLABELLAR LINES ASSOCIATED WITH CORRUGATOR AND/OR PROCERUS MUSCLE ACTIVITY","NOUVELLE INDICATION - POUR LE TRAITEMENT DES RIDES GLABELLAIRES RELIÉES À L'ACTIVITÉ DU MUSCLE CORRUGATOR ET/OU DU PROCERUS","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYTIQUE NEUROMUSCULAIRE","",""
"1736","03-02-20","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE TO CLINICAL STUDIES AND ADVERSE REACTIONS SECTIONS","MISE À JOUR AUX RUBRIQUES ÉTUDES CLINIQUES ET RÉACTIONS INDÉSIRABLES DE LA MONOGRAPHIE DU PRODUIT","NON-STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESIS; ANTITUMOR AGENT","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN; INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES; ANTINÉOPLASIQUE","",""
"1737","01-02-16","N.V. ORGANON","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1738","03-02-18","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"1739","99-06-16","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION FOR A PRIMARY VACCINE SERIES (2, 4 AND 6 MONTHS)","NOUVELLE INIDICATION IMMUNISATION (2,4 et 6 MOIS)","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1740","01-12-28","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: XELODA IN COMBINATION WITH DOCETAXEL FOR HTE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING CHEMOTHERAPY","NOUVELLE INDICATION : XELODA COMBINÉ AU DOCETAXEL POUR LE TRAITEMENT DU CANCER DU SEIN MÉTASTATIQUE RÉSISTANT À UN TRAITEMENT PRÉALABLE À L'ANTHRACYCLINE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1741","03-02-17","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1742","01-12-21","TOBA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1743","03-02-06","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1744","01-11-21","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1745","99-05-10","MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"1746","01-11-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"1747","03-01-22","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1748","01-11-19","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1749","01-11-13","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGGRÉGATION PLAQUETTAIRE","",""
"1750","03-01-14","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRYPTAN","ICN CANADA LTD.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","ADJUVANT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"1751","99-05-06","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INIDICATION: TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CARCINOMA AFTER FAILURE OF A PREVIOUS CHEMOTHERAPY REGIMEN","INDICATION RÉVISÉE : TRAITEMENT DES PATIENTS ATTEINTS D'UN CANCER MÉTASTATIQUE DU SEIN OU LOCALEMENT AVANCÉ QUI N'ONT PAS RÉPONDU AU SCHÉMA CHIMIOTHÉRAPIQUE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1752","99-05-06","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: OVARIAN CANCER","NOUVELLE INDICATION : CANCER OVARIEN","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1753","99-05-05","ELAN PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BENZODIAZEPINE ANTICONVULSANT","BENZODIAZÉPINE ANTICONVULSIVANT","",""
"1754","99-05-05","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1755","99-03-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","AGENT ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1756","99-01-12","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","GEIGY PHARMACEUTICALS, CIBA GEIGY CANADA LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","AGENT ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1757","99-12-10","NOVO NORDISK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"1758","99-11-10","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1759","99-10-07","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTRADOL","PROCTOR AND GAMBLE PHARMACEUTICALS","CANADA","CANADA","1","","","NON-STEROIDAL, ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE","",""
"1760","99-08-25","SOLVAY PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR (AT1) ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIONTENSINE II","",""
"1761","99-08-19","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ERYTHROPORISE","",""
"1762","99-08-18","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF SECONDARY PULMONARY HYPERTENSION DUE TO SCLERODERMA DUE TO SCLERODERMA SPECTRUM OF DISEASES (SSD)","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'HYPERTENSION PULMONAIRE SECONDAIRE DUE À DES MALADIES DE TYPE SCLÉRODERMIQUE","VASODILATOR","VASODILATATEUR","",""
"1763","99-07-07","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR (AT1) ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR AT1 DE L'ANGIOTENSIVE II","",""
"1764","99-06-11","COR THERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"1765","99-05-28","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1766","99-03-19","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"1768","99-01-25","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIALLERGIC AGENT","ANTIALLERGIQUE","",""
"1769","99-01-12","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTRADOL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT","AGENT NON STÉROÏDIEN ANTI-INFLAMMOATOIRE - ANALGÉSIQUE","",""
"1770","99-05-05","ULTRAPHARM 2000 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORITCOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"1771","99-05-05","ULTRAPHARM 2000 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE POUR INHALATION","",""
"1772","99-03-09","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING PRODUCT MONOGRAPH AND LABELLING","MONOGRAPHIE ET ÉTIQUETTE RÉVISÉE","ANTIFUNGAL AGENT","AGENT ANTIFONGIQUE","",""
"1773","03-12-19","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORALLY DISINTEGRATING TABLET","NOUVELLE FORME POSOLOGIQUE: COMPRIMÉ SE DÉSINTÉGRANT PAR VOIE ORALE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1774","99-12-22","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","UPDATING PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"1775","99-12-09","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE EN AÉROSOL","",""
"1776","99-12-08","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1777","99-12-07","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"1778","03-12-17","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MUSCLE RELAXANT, ANALGESIC","RELAXANT MUSCULAIRE, ANALGÉSIQUE","",""
"1779","99-11-25","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: RELIEF OF SYMPTOMS ASSOCIATED WITH PERENNIAL ALLERGIC RHINITIS","NOUVELLE INDICATION : SOULAGEMENT DES SYMPTÔMES ASSOCIÉS AVEC LA RHINITE ALLERGIQUE NON-SAISONNIÈRE","HISTAMINE H1 RECEPTOR ANTAGONIST","ANAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"1780","99-11-22","RIVA LABORATORY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"1781","99-11-22","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1782","99-11-18","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","UPDATE LABELLING - TO REDUCE AND CONTROL STOMACH ACID IN THE NIGHT","MISE À JOUR DE L'ÉTIQUETAGE - POUR RÉDUIRE ET CONTRÔLER L'ACIDE GASTRIQUE DURANT LA NUIT","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"1783","99-11-17","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE","PRÉSENTATION RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1784","03-12-12","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1785","99-11-08","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","MODIFICATION OF PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIDEPRESSANT, ANTIOBSESSIVE, ANTIBULIMIC AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"1786","99-11-08","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1787","03-12-05","GALDERMA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTI-ROSACEA AGENT","AGENT ANTI-ROSACÉE","",""
"1788","99-10-21","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORITCOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE EN AÉROSOL","",""
"1789","03-12-05","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE AND ANTIRHEUMATIC","ANTIMÉTABOLITE ET ANTIRHUMATISMAL","",""
"1790","03-12-02","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"1791","99-10-07","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATORIES FOURNIER","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1792","99-09-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"1793","99-08-13","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF RECURRENT EPISODES OF MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-INFECTED PATIENTS","NOUVELLE INDICATION : TRAITEMENT D'ÉPISODES RÉCURRENTS D'INFECTIONS MUCOCUTANÉES À HERPES SIMPLEX CHEZ LES PATIENTS ATTEINTS D'UNE INFECTION AU VIH","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"1794","99-08-06","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: PROVIDES LONG-TERM USE IN PATIENTS SUFFERING FROM DEPRESSSION. PRODUCT MONOGRAPH REVISIONS","INDICATION RÉVISÉE : FOURNIT POUR L'UTILISATION À LONG TERME DES PATIENTS SOUFFRANT DE DÉPRESSION. MONOGRAPHIE RÉVISÉE","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"1795","99-07-30","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"1796","99-07-13","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"1797","99-07-06","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FENTANYL CITRATE INJECTION","ABBOTT LABORATORIES","CANADA","CANADA","1","","","OPIOID ANALGESIC - ADJUNCT TO ANAESTHESIA","ANALGÉSIQUE OPIOÏDE - MÉDICAMENT D'APPOINT À L'ANESTHÉSIE","",""
"1798","99-06-29","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE POUR INHALATION","",""
"1799","03-12-02","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"1800","99-06-29","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"1801","03-11-06","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"1802","99-06-21","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"1803","99-06-16","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1804","03-11-06","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"1805","99-06-09","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1806","99-06-09","PURDUE FREDERICK","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1807","99-04-12","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"1808","99-04-12","ZAMBON CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1809","03-10-28","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIDIABETIC AGENT, ALPHA-GUCOSIDASE INHIBITOR","ANTIDIABÉTIQUE ORAL, INHIBITEUR DES ALPHA-GLUCOSIDASES","",""
"1810","99-03-26","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1-RECEPTOR ANTAGONIST/SYMPATHOMIMETIC AMINE","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE/AMINE SYMPATHOMIMÉTIQUE","",""
"1811","99-03-16","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1812","99-02-12","OMEGA LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1813","03-10-24","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ELOCOM 0.1% OINTMENT","SCHERING CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"1814","99-01-25","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"1815","99-05-26","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATORIES FOURNIER","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1816","03-10-24","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO THE PRODUCT MONOGRAPH RE: DISCONTINUATION SYMPTOMS AND THE MANAGEMENT OF THESE SYMPTOMS","CHANGEMENTS À LA MONOGRAPHIE DU PRODUIT RELATIVEMENT À L'INTERRUPTION DES SYMPTÔMES ET À LA GESTION DE CES DERNIERS","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1817","99-03-17","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSING SCHEDULE","PROGRAMME DE POSOLOGIE RÉVISÉE","ANTI-INFLAMMATORY STEROID","ANTI-INFLAMMATOIRE STÉROÏDE","",""
"1818","99-03-26","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATORIES FOURNIER S.C.A.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1819","99-04-15","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR/AGENT ANTIOBSESSIONNEL","",""
"1820","99-08-25","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR - AGENT ANTIOBSESSIONNEL","",""
"1821","99-09-13","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR/AGENT ANTIOBSESSIONNEL","",""
"1822","03-10-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"1823","99-12-17","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL","",""
"1824","03-10-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID, ANTIBIOTIC","GLUCOCORTICOÏDE, ANTIBIOTIQUE","",""
"1825","99-12-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH FRACTIONATED ABDOMINAL IRRADIATION OR TOTAL BODY IRRADIATION","POUR LA PRÉVENTION DES NAUSÉES ET VOMISSEMENTS ASSOCIÉS À L'IRRADIATION ABDOMINALE FRACTIONNÉE OU L'IRRADIATION CORPORELLE TOTALE","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"1826","99-11-30","PHARMACYCLICS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE (IRM)","",""
"1827","03-10-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"1828","03-10-17","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT FOR MEN","STIMULANT POUR LA REPOUSSE DES CHEVEUX POUR HOMMES","",""
"1829","99-11-08","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE (IRM)","",""
"1830","99-08-25","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1831","99-08-19","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN COMIBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER","NOUVELLE INDICATION : EN ASSOCIATION AVEC CISPLATIN POUR LE TRAITEMENT DES PATIENTS ATTEINTS D'UN CANCER PULMONAIRE NON À PETITES CELLULES (CPNPC) AU STADE LOCAL AVANCÉ OU MÉTASTATIQUE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1832","99-08-18","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN COMBINATION WITH A NON-STEROIDAL ANTIANDROGEN FOR THE MANAGEMENT OF LOCALLY ADVANCED, BULKY STAGE T2B, T2C, T3 AND T4 CARCINOMA OF THE PROSTATE","NOUVELLE INDICATION : POUR L'UTILISATION EN ASSOCIATION À UN ANTIANDROGÈNE NON STÉROÏDIEN POUR LE TRAITEMENT DE VOLUMINEUX CANCERS LOCALISÉS DE LA PROSTATE AU STADE T2B, T2C, T3 ET T4","LUTEINIZING HORMONE - RELEASING HORMONE ANALOG","ANALOGUE DE LA LH-RH","",""
"1833","99-08-18","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE AS ADJUVANT HORMONE THERAPY TO EXTERNAL BEAM IRRADIATION FOR PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER (STAGE T3-T4)","NOUVELLE INDICATION : POUR L'UTILISATION COMME HORMONOTHÉRAPIE ADJUVANTE À LA RADIOTHÉRAPIE EXTERNE CHEZ LES PATIENTS ATTEINTS D'UN CANCER LOCALISÉ AVANCÉ DE LA PROSTATE (STADE T3-T4)","LUTEINIZING HORMONE - RELEASING HORMONE ANALOG","ANALOGUE DE LA LH-RH","",""
"1834","99-07-02","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, REVISED SPECIFICATIONS, ALTERNATE MANUFACTURING SITE, MANUFACTURING CHANGES, PRODUCT MONOGRAPH REVISIONS","NOUVELLE CONCENTRATION, SPÉCIFICATIONS RÉVISÉES, AUTRE EMPLACEMENT DE FABRICATION, MODIFICATION DE LA MÉTHODE DE FABRICATION, MONOGRAPHIE RÉVISÉE","ANTIVIRAL AGENT","ANTIVIRAL","",""
"1835","99-06-29","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSAGE REGIMEN","SCHÉMA POSOLOGIQUE RÉVISÉ","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1836","99-04-15","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCENTRATION ET PRÉSENTATION","ANTIHYPERLIPIDEMIC AGENT","HYPLIPIDÉMIANT","",""
"1837","99-04-06","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"1838","99-03-16","TEVA PHARMACEUTICALS USA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1839","99-02-25","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIEPILEPTIC AGENT","AGENT ANTIÉPILEPTIQUE","",""
"1840","99-11-17","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN DOSAGE - ALTERNATE TWO-DOSE REGIMEN IN ADOLESCENTS","NOUVEAU SCHÉMA POSOLOGIQUE - ALTERNATION POUR LES ADOLESCENTS DE LA POSOLOGIE À DEUX DOSES","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1841","99-08-30","SWISS SERUM & VACCINE INSTITUTE BERNE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXPANDED MANUFACTURING FACILITIES","MODIFICATION DE L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"1842","99-07-12","CONNAUGHT LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1843","99-04-06","BAXTER CORPORATION-CLINTEC NUTRITION DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"1844","99-04-06","SWISS SERUM & VACCINE INSTITUTE BERNE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGETN D'IMMUNISATION ACTIF","",""
"1845","99-02-12","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HALDOL LA","MCNEIL","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1846","99-12-20","GENZYME CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"1847","99-12-17","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOVUE","BRACCO DIAGNOSTIC","CANADA","CANADA","1","","","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","AGENT DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"1848","99-12-09","ASTA MEDICA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1849","99-12-08","HALOCARBON LABORATORIES, A DIVISION OF HALOCARBON PRODUCTS CORP.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FORANE","ZENECA","CANADA","CANADA","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"1850","99-11-01","MEDICAN PHARMA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGE PRESENTATION","NOUVELLE PRÉSENTATION D'EMBALLAGE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1851","99-11-01","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"1852","99-10-07","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-HYPERTENSIVE/DIURETIC","ANTIHYPERTENSEUR/DIURÉTIQUE","",""
"1853","99-10-05","COOK IMAGING CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONIONIC CONTRAST AGENT","AGENT DE CONTRASTE NON IONIQUE","",""
"1854","99-09-17","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PERITONEAL DIALYSIS SOLUTION","SOLUTION DE DIALYSE PÉRITONÉALE","",""
"1855","99-09-02","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE; NEW DOSAGE REGIMEN: 'ONCE-EVERY-THREE-WEEK' DOSAGE SCHEDULE","MONOGRAPHIE RÉVISÉE; NOUVEAU SCHÉMA POSOLOGIQUE : UNE FOIS TOUTES LES TROIS SEMAINES","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"1856","99-08-13","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","THREE NEW STRENGTHS FOR SOLUTION IN MULTI-DOSE PEN - ALBUMIN (HUMAN) FREE","TROIS NOUVELLES CONCENTRATIONS DANS STYLO MULTI-DOSE - SANS ALBUMINE (HUMAIN)","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"1857","99-07-16","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANALGESIC, ANTIPYRETIC AGENT - FOR CHILDREN","ANALGÉSIQUE, ANTIPYRÉTIQUE - POUR ENFANTS","",""
"1858","99-06-30","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION - TREATMENT OF PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS","NOUVELLE INDICATION : TRAITEMENT DES PATEINTS ATTEINTS DE SCLÉROSE EN PLAQUES SECONDAIRE PROGRESSIVE","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"1859","99-06-29","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","ANTICHOLINERGIQUE TOPIQUE POUR L'ADMINISTRATION NASALE","",""
"1860","03-10-14","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"1861","99-06-29","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE PRÉSENTATION ET CONCENTRATION","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","ANTICHOLINERGIQUE TOPIQUE POUR L'ADMINISTRATION NASALE","",""
"1862","99-06-03","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","FORMULATION CHANGE","NOUVELLE FORMULATION","ANTI-DIABETIC AGENT","ANTIDIABÉTIQUE","",""
"1863","99-05-10","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCNETRATION","DIURETIC/ANTIHYPERTENSIVE AGENT","DIURÉTIQUE - ANTIHYPERTENSEUR","",""
"1864","03-10-10","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID WITH LOCAL ANAESTHETIC","GLUCOCORTICOÏDE AVEC ANESTHÉSIQUE LOCAL","",""
"1865","03-10-03","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1866","99-05-05","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","BRONCHODILATATEUR","",""
"1867","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"1868","99-04-20","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW MASTER CELL BANK - NEW MANUFACTURING FACILITY","MODIFICATION DE LA MÉTHODE DE FABRICATION : NOUVELLE BANQUE DE CELLULES PRIMAIRES, NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"1869","99-04-06","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","","","DIURETIC/ANTIHYPERTENSIVE AGENT","DIURÉTIQUE/ANTIHYPERTENSIF","",""
"1870","99-03-16","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A REVISED INDICATION","FOURNIS POUR UNE INDICATION RÉVISÉE","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"1871","99-03-09","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"1872","99-02-12","MALLINCKRODT MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIO-DIAGNOSTIQUE","",""
"1873","99-02-12","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","","","DIURETIC/ANTIHYPERTENSIVE AGENT","DIURÉTIQUE/ANTIHYPERTENSEUR","",""
"1874","99-02-12","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE PRÉSENTATION ET CONCENTRATION","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","ANTICHOLINERGIQUE TOPIQUE POUR ADMINISTRATION NASALE","",""
"1875","99-01-28","NYCOMED AMERSHAM PLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"1876","99-01-28","NYCOMED AMERSHAM PLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"1877","99-01-25","3M PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE IMMUNITAIRE","",""
"1878","99-10-15","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN II RECEPTOR ANTAGONIST AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II - DIURÉTIQUE","",""
"1879","99-10-13","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1880","99-10-01","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTITHROMBOTIC","ANTITHROMBOTIQUE","",""
"1881","99-09-28","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1882","99-08-25","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"1883","99-08-13","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: GASTROESOPHAGEAL REFLUX DISEASE (GERD), TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD","NOUVELLE INDICATION : REFLUX GASTRO-OESOPHAGIEN, TRAITEMENT DES BRÛLURES D'ESTOMAC ET AUTRES SYMPTÔMES ASSOCIÉS AU REFLUX GASTRO-OESOPHAGIEN","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1884","99-07-26","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATED PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","CHOLESTEROL LOWERING AGENT","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1885","99-07-22","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1886","99-07-07","ROBERTS PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRACEPTIVE AGENT","CONTRACEPTIF ORAL","",""
"1887","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID ACNE COMPOUND","CORTICOSTÉROÏDE TOPIQUE POUR LE TRAITEMENT DE L'ACNÉ","",""
"1888","99-07-02","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRYPTAN","ICN CANADA LTD.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"1889","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"1890","99-07-02","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: UNCOMPLICATED URINARY TRACT INFECTIONS (MILD TO MODERATE) DUE TO ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE OR STAPHYLOCOCCUS SAPROPHYTICUS.","NOUVELLE INDICATION : INFECTIONS DES VOIES URINAIRES SIMPLES (DOUCES ET MODÉRÉES) DUES À ESCHERICHIA COLI, PNEUMONIE KLEBSIELLA OU STAPHYLOCOQUE SAPROPHYTE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1891","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"1892","99-06-18","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUPRON","TAP PHARMACEUTICALS","CANADA","CANADA","1","","","GONADOTROPIN RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"1893","99-06-18","WESTCAN PHARMACEUTICALS LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"1894","99-06-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-MANIC AGENT","ANTIMANIAQUE","",""
"1895","99-06-07","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION, CHANGE IN TABLET SIZE","MODIFICATION DE LA PRÉPARATION ET DE LA TAILLE DES COMPRIMÉS","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1897","99-05-28","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION AND REVISED DOSAGE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE","INDICATION ET PRÉSENTATION RÉVISÉES POUR LE TRAITEMENT DE LA DÉFAILLANCE CARDIAQUE CONGESTIVE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"1898","99-05-18","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION: CHEWABLE/DISPERSIBLE TABLET","NOUVELLE FORMULATION: COMPRIMÉ À MÂCHER/DISPERSER","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1899","99-05-18","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AS ADJUNCTIVE THERAPY FOR THE MANAGEMENT OF THE SEIZURE ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN ADULTS AND CHILDREN","NOUVELLE INDICATION : ADJUVANT POUR LE TRAITEMENT DES CRISES ASSOCIÉES AU SYNDROME DE LENNOX-GASTAUT CHEZ LES ADULTES ET LES ENFANTS","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"1900","99-04-20","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1901","99-04-20","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"1902","99-04-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"1903","99-03-26","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH; PRODUCT MONOGRAPH REVISION","NOUVELLE CONCENTRATION, MONOGRAPHIE RÉVISÉE","GONADOTROPIN-RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"1904","99-03-26","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","GONADOTROPIN-RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"1905","99-03-16","GYNETICS LTD/LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EMERGENCY CONTRACEPTIVE","CONTRACEPTIF D'URGENCE","",""
"1906","99-02-16","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","NON-STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESIS; ANTITUMOUR AGENT","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN; INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES; AGENT ANTI-TUMEUR","",""
"1907","99-01-25","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"1908","99-11-04","CORIXA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","IMMUNOSTIMULATING AGENT","AGENT IMMUNOSTIMULANT","",""
"1909","99-02-25","METHAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINERGIC/DIAGNOSTIC AID (BRONCHIAL ASTHMA)","DIAGNOSTIC CHOLINERGIQUE (ASTHME BRONCHIQUE)","",""
"1910","99-12-17","ASTA MEDICA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"1911","99-11-22","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CYANAMIDE","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1912","99-10-14","METHAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","CHOLINERGIC, DIAGNOSTIC AID","CHOLINERGIQUE, AUXILIAIRE DIAGNOSTIQUE","",""
"1913","99-09-28","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EDITORIAL CHANGES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","MODIFICATION À LA SECTION POSOLOGIE DE LA MONOGRAPHIE DU PRODUIT","PROGERSTOGEN, ANTINEOPLASTIC, ANTIANOREXIC, ANTICACHECTIC/ANTIANOREXIC, ANTICACHECTIC","PROGESTATIF, ANTINÉOPLASIQUE, ANTIANOREXIQUE, ANTICACHECTIQUE/ANTIANOREXIQUE, ANTICACHECTIQUE","",""
"1914","99-09-28","PRO DOC LIMITÉE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1915","99-09-21","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC KIT FOR THE PREPARATION OF TECHNETIUM TC 99M MEDRONATE","TROUSSE DIAGNOSTIQUE POUR LA PRÉPARATION DE TECHNÉTIUM 99M TC","",""
"1916","99-08-27","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1917","99-08-25","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1918","99-08-23","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PEDIATRIC INDICATION: FOR USE IN CHILDREN BETWEEN THE AGES OF 3 AND 11 YEARS TO TREAT THE SYMPTOMS OF SEASONAL OR PERENNIAL ALLERGIC RHINITIS","NOUVELLE INDICATION PÉDIATRIQUE : POUR L'UTILISATION CHEZ LES ENFANTS DE 3 À 11 ANS POUR TRAITER LES SYMPTÔMES DE RHINITE ALLERGIQUE SAISONNIÈRE ET NON SAISONNIÈRE","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"1919","99-08-19","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"1920","99-07-12","CONNAUGHT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1921","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"1922","99-07-12","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1923","99-06-21","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","IMMUNOSUPPRESSANT AGENT","IMMUNOSUPPRESSEUR","",""
"1924","03-09-22","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"1925","99-05-13","CONNAUGHT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MODIFICATION DE LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1926","99-05-10","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CYANAMID CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1927","99-04-12","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","FAT EMULSION FOR INTRAVENOUS NUTRITION","ÉMULSION LIPIDIQUE POUR ALIMENTATION PAR VOIE INTRAVEINEUSE","",""
"1928","99-03-16","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PONSTAN","PARKE-DAVIS","CANADA","CANADA","1","","","ANALGESIC","ANALGÉSIQUE","",""
"1929","99-03-12","FOURNIER PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY","CANADA","CANADA","1","","","PROGESTAGEN","PROGESTATIF","",""
"1930","99-03-09","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"1931","99-03-09","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1932","99-03-08","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"1933","99-02-26","DRAXIS HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CNS STIMULANT","STIMULANT DU SNC","",""
"1934","99-02-23","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DES VOIES GASTRO-INTESTINALES","",""
"1935","99-02-23","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CYANAMID CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"1936","99-02-16","PROCTER & GAMBLE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DE LA PARTIE BASE DU TUBE DIGESTIF","",""
"1937","99-02-05","MCNEIL CONSUMER PRODUCTS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"1938","99-02-03","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PATIENT PACKAGE INSERT","RÉVISIONS DU PAQUET D'INSERTION DU PATIENT","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DES VOIES GASTROINTESTINALES INFÉRIEURES","",""
"1939","99-01-14","MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW SUPPLIER OF ALBUMIN (HUMAN)","CHANGEMENT DANS LE PROCESSUS DE FABRICATION - UTILISATION D'UN NOUVEAU FOURNISSEUR D'ALBUMINE (HUMAINE)","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1940","99-01-14","MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - NEW SUPPLIER OF ALBUMIN (HUMAN)","CHANGEMENT DANS LE PROCESSUS DE FABRICATION - UTILISATION D'UN NOUVEAU FOURNISSEUR D'ALBUMINE (HUMAINE)","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1941","99-01-12","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIDIABETIC AGENT - ALPHA-GLUCOSIDASE INHIBITOR","ANTIDIABÉTIQUE ORAL - INHIBITEUR DES ALPHA GLUCOSIDASES","",""
"1942","99-12-17","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","ANTIALLERGIC","ANTIALLERGIQUE","",""
"1943","99-12-03","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"1945","99-10-15","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAPROSYN E 500MG TABLETS","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTI-PYRETIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE - ANTIPYRÉTIQUE","",""
"1946","99-09-28","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM (CANADA) INC.","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"1947","99-09-07","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVENTYL","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"1948","99-09-01","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC, ANTI-INFLAMMATORY AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"1949","99-08-27","SABEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME ONLY","MODIFICATION DU NOM DU PRODUIT SEULEMENT","ANTI-INFLAMMATORY AGENT, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"1950","99-08-27","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE ET ANTIPYRÉTIQUE","",""
"1951","99-08-18","ICN CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE - ANTICONVULSIVANT","",""
"1952","99-08-11","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"1953","99-07-23","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AXID","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTATGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"1954","99-07-22","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","PROPRIÉTÉS ANTI-INFLAMMATOIRE, ANALGÉSIQUE ET ANTIPYRÉTIQUE","",""
"1955","99-06-09","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1956","99-06-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1957","99-06-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1958","99-06-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1959","99-06-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1960","99-06-04","SANOFI CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND NEW DOSAGE REGIMEN","NOUVELLE CONCENTRATION ET NOUVEAU SCHÉMA POSOLOGIQUE","ANTICOAGULANT/ANTITHROMBOTIC","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"1961","99-05-28","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1962","99-05-04","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCNETRATION ET PRÉSENTATION","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE - ANTIPYRÉTIQUE","",""
"1963","99-05-04","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING PRODUCT MONOGRAPH AND LABELLING","MONOGRAPHIE ET ÉTIQUETTE RÉVISÉES","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE - ANTIPYRÉTIQUE","",""
"1964","99-04-06","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANALGESIC, ANTI-INFLAMMATORY AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"1965","99-02-23","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","AGENT ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"1966","99-02-12","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1967","99-02-12","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"1968","99-01-25","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE ET ANTICONVULSIVANT","",""
"1969","99-01-25","ALZA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"1970","99-01-25","ALZA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"1971","99-12-23","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"1972","99-12-02","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF DYSPEPSIA","NOUVELLE INDICATION: TRAITEMENT DE DYSPEPSIE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1973","99-06-04","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO PRODUCT MONOGRAPH","MONOGRAHIE RÉVISÉE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1974","99-11-22","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"1975","99-08-26","MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STORAGE CONDITIONS; PRODUCT NAME CHANGE; COMPANY NAME CHANGE","NOUVELLE CONDITIONS DE STOCKAGE, CHANGEMENTS DANS LE NOM DU FABRICANT ET DU PRODUIT","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1976","99-08-06","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTICHOLINERGIC/ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE - AGENT ANTISPASMODIQUE","",""
"1977","99-06-03","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-OBESITY AGENT/GASTROINTESTINAL LIPASE INHIBITOR","AGENT ANTI-OBÉSITÉ/INHIBITEUR DE LIPASE GASTRO-INTESTINAL","",""
"1978","99-05-18","PURDUE FREDERICK","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"1979","99-04-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: TREATMENT OF SYMPTOMS ASSOCIATED WITH CARCINOID TUMORS AND VASOACTIVE INTESTINAL PEPTIDE TUMORS (VIPOMAS)","NOUVELLSE INDICATIONS : TRAITEMENT DES SYMPTÔMES ASSOCIÉS AVEC : LES TUMEURS CARCINOÏDES ET LES TUMEURS PEPTIDES INTESTINALES VASOACTIVES (VIPOMAS)","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDES SYNTHÉTIQUES ANALOGUE DE LA SOMATOSTATINE","",""
"1980","99-04-06","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1981","99-12-10","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"1982","99-09-28","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"1983","99-10-21","COLUMBIA LABORATORIES (UK) LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"1984","99-10-05","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN METHOD OF MANUFACTURE","MODIFICATION DE LA MÉTHODE DE FABRICATION","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER) THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, THÉRAPIE (TROUBLES D'ANXIÉTÉ SOCIAL) DE PHOBIE SOCIALE","",""
"1985","99-09-07","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED FORMULATION TO ALLOW EMBOSSING OF THE TABLETS","PRÉPARATION RÉVISÉE POUR PERMETTRE LE BOSSELAGE DES COMPRIMÉS","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"1986","99-08-25","PASTEUR MERIEUX SERUM & VACCIN","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1987","99-08-12","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES OSSEUX","",""
"1988","99-08-03","PROCTER & GAMBLE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","DIETARY FIBRE SUPPLEMENT, BULK FORMING LAXATIVE, CHOLESTEROL LOWERING AGENT","SUPPLÉMENT DE FIBRE ALIMENTAIRE, LAXATIF, BAISSE DU CHOLESTÉROL","",""
"1989","99-07-26","MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DRUG IDENTIFICATION NUMBER FOR 5 DOSE VIAL","NOUVELLE IDENTIFICATION NUMÉRIQUE DE DROGUE POUR FIOLE DE 5 DOSE","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"1990","99-07-16","QLT PHOTOTHERAPEUTICS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TO ALLOW FOR THE USE OF PHOTODYNAMIC THERAPY WITH PHOTOFIRN IN THE REDUCTION OF OBSTRUCTION AND PALLATIVE TREATMENT OF PATIENTS WITH OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER AND IN THE TREATMENT OF SUPERFICIAL ENDOBRONCHIAL NSCLC IN PATIENTS WHO ARE NOT ELIGIBLE FOR SURGERY OR RADIOTHERAPY","NOUVELLE INDICATION : THÉRAPIE PHOTODYNAMIQUE AVEC PHOTOPHRIN POUR DIMINUER L'OBSTRUCTION ET TRAITEMENT PALLIATIF DES PATIENTS ATTEINTS D'UN CANCER ENDOBRONCHIQUE OBSTRUCTIF À NON-PETITES CELLULES (NSCLC) ET TRAITEMENT D'UN CANCER PULMONAIRE SUPERFICIEL À NON-PETITES CELLULES (NSCLC)","ANTINEOPLASTIC PHOTOSENSITIZING AGENT","PHOTOSENSIBILISANT ANTINÉOPLASIQUE","",""
"1991","99-07-13","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAHIE RÉVISÉE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"1992","99-07-12","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"1993","99-06-16","V.I. TECHNOLOGIES INC. (VITEX)","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","POOLED BLODD COMPONENT/DERIVATIVE","COMPOSANTS DU SANG/PRODUITS DÉRIVÉS DU SANG","",""
"1994","99-05-12","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED FORMULATION","FORMULATION RÉVISÉE","INTRAVENOUS EMULSION - ANAESTHETIC - SEDATIVE","ÉMULSION I.V. - ANESTHÉSIQUE - SÉDATIF","",""
"1995","99-04-15","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: THE TREATMENT OF SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA","NOUVELLE INDICATION : TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE D'ANXIÉTÉ SOCIALE)","ANTIDEPRESSANT - ANTIOBSESSIONAL - ANTIPANIC AGENT- SOCIAL PHOBIA","ANTIDÉPRESSEUR, ANTIOBESSIONNEL, ANTIPANIQUE, THÉRAPIE (TROUBLES D'ANXIÉTÉ SOCIAL) DE PHOBIE SOCIALE","",""
"1996","99-04-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"1997","99-03-26","SQUIBB CANADA INC., A DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"1998","99-03-17","RJR PHARMA INTERNATIONAL SERVICES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMTOIRE - ANALGÉSIQUE","",""
"1999","99-03-16","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ORAP","MCNEIL PHARMACEUTICALS CANADA LTD.","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"2000","99-03-02","CRYSTAAL CORPORATION, A DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","ANALGÉSIQUE AINS","",""
"2001","99-02-17","BYK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2002","99-02-02","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2003","99-01-25","LEO LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2004","99-01-25","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2005","99-12-17","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE","ABBOTT LABORATORIES","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2006","99-12-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2007","99-10-29","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2008","99-09-01","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORCURON","ORGANON","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEUROMUSCULAIRE NON DÉPOLARISANT","",""
"2009","99-06-16","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2010","99-06-07","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","SEARLE CANADA","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2011","99-05-05","RHODIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE","ABBOTT LABORATORIES","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2012","99-03-23","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2013","99-03-08","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2014","99-03-08","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN","SEARLE CANADA","CANADA","CANADA","1","","","ANTIANGINAL/ANTIARRHYTHMIC/ANTIHYPERTENSIVE AGENT","AGENT ANTIANGINEUX/ANTIARYTHMIQUE/ANTIHYPERTENSEUR","",""
"2015","99-01-15","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2016","99-05-21","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTICOAGULANT","ANTICOAGULANT","",""
"2017","99-11-02","GLAXO WELLCOME INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2018","99-09-01","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC AGENT","HYPNOTIQUE","",""
"2019","99-08-03","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHÔNE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC AGENT","HYPNOTIQUE","",""
"2020","99-03-04","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"2021","99-12-23","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"2022","99-12-17","STANLEY PHARMACEUTICALS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC 75","GLAXO WELLCOME","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2023","99-11-17","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGE FORMAT INCORPORATING REBETRON MULTI-DOSE PEN","NOUVEL EMBALLAGE CONTENANT LE STYLO MULTI-DOSE REBETRON","ANTIVIRAL AGENT PLUS BIOLOGICAL RESPONSE MODIFIER","ANTIVIRAL/MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2024","99-11-10","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC 75","GLAXO WELLCOME INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2025","99-10-25","MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2026","99-08-25","PASTEUR MERIEUX SERUM & VACCIN","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2027","99-08-18","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2028","99-07-29","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: TABLETS (0.25MG & 0.5MG); NEW INDICATION: FOR USE IN SEVERE DEMENTIA FOR THE SHORT-TERM SYMPTOMATIC MANAGEMENT OF INAPPROPRIATE BEHAVIOUR DUE TO AGRESSSION AND/OR PSYCHOSIS","NOUVELLES CONCENTRATIONS : TAB (0.25MG & 0.5MG); NOUVELLE INDICATION : L'UTILISATION POUR LA DÉMENCE GRAVE DANS LA GESTION SYMPTOMATIQUE À COURT TERME DU COMPORTEMENT INAPPROPRIÉ RÉSULTANT DE L'AGRESSION ET/OU LA PSYCHOSE","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"2029","99-07-28","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIPARKINSONIAN AGENT/DOPAMINE AGONIST","ANTIPARKINSONIEN/AGONISTE DOPAMINERGIQUE","",""
"2030","99-07-16","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST","AGONISTE DES RÉCEPTEURS 5-HT1","",""
"2031","99-04-22","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY","TRAITEMENT DE L'HÉPATITE C CHRONIQUE CHEZ LES PATIENTS ANTÉRIEUREMENT NON TRAITÉS À LA THÉRAPIE DE L'INTERFÉRON ALPHA","ANTIVIRAL AGENT PLUS BIOLOGICAL RESPONSE MODIFIER","AGENT ANTIVIRAL ET MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2032","99-04-06","NOVO NORDISK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"2033","99-02-26","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT PLUS BIOLOGICAL RESPONSE MODULATOR","AGENT ANTIVIRAL ET MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2034","99-02-12","WARNER LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTIHISTAMINIQUE SPÉCIFIQUE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2035","99-02-12","NOVO NORDISK CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"2036","99-12-14","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 4 YEARS OF AGE AND OLDER","NOUVELLE INDICATION : TRAITEMENT D'ENTRETIEN DE L'ASTHME CHEZ LES PATIENTS DE 4 ANS ET PLUS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2037","99-10-25","3M PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","BRONCHODILATOR","BRONCHODILATEUR","",""
"2038","99-09-01","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2039","99-08-12","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT AGENT","ANTIDÉPRESSEUR","",""
"2040","99-02-25","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO PROVIDE FOR ADDITIONAL WORDING UNDER CLINICAL TRIALS-OBSESSIVE COMPULSIVE DISORDER SECTION OF THE PM TO INCLUDE PEDIATRIC AND ADOLESCENT EXPERIENCE","POUR L'ADDITION, À LA SECTION TROUBLE OBSESSIONNEL COMPULSIF DE LA MONOGRPHIE, D'INFORMATION SUPPLÉMENTAIRE CONCERNANT LES ÉTUDES CLINIQUES CHEZ LES ENFANTS ET LES ADOLESCENTS","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","AGENT ANTIDÉPRESSEUR, ANTIPANIQUE ET ANTIOBSESSIONNEL","",""
"2041","99-09-02","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATIONS: 1. REDUCE THE RISK OF FATAL PLUS NON-FATAL CEREBROVASCULAR EVENTS (STROKE AND TRANSIENT ISCHEMIC ATTACKS); 2. REDUCE THE RISK OF MAJOR CORONARY EVENTS IN HYPERCHOLESTEROLEMIC PATIENTS WITH DIABETES MELLITUS","INDICATIONS RÉVISÉES : RÉDUIT LE RISQUE DES INCIDENTS CÉRÉBROVASCULAIRE MORTEL ET NON-MORTEL (ATTAQUE ET CRISE ISCHÉMIQUE TRANSITOIRE); RÉDUIT LE RISQUE DES INCIDENTS CORONAIRES MAJEURS SUR LES PATIENTS ATTEINTS DE HYPERCHOLESTÉROLÉMIE AYANT LE DIABÈTE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2042","99-09-03","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR AND CORTICOSTEROID FOR INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"2043","99-09-21","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC KIT FOR THE PREPARATION OF TECHNETIUM TC 99M PYROPHOSPHATE","TROUSSE DIAGNOSTIQUE POUR LA PRÉPARATION DE TECHNÉTIUM 99M TC PYROPHOSPHATE","",""
"2044","99-09-01","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR THE TREATMENT OF POST MENOPAUSAL OSTEOPOROSIS IN FEMALES GREATER THAN FIVE YEARS POSTMENOPAUSE WITH LOW BONE MASS (FOR PATIENTS WHO REFUSE OR CANNOT TOLERATE TREATMENT WITH ESTROGENS OR IN WHOM ESTROGENS ARE CONTRAINDICATED)","POUR LE TRAITEMENT DE L'OESTÉOPOROSES POST-MÉNOPAUSALE POUR LES FEMMES AYANT PLUS DE CINQ ANS DE POST-MÉNOPAUSE AVEC UNE FAIBLE MASSE OSSEUSE (POUR LES PATIENTES QUI REFUSENT OU QUI NE PEUVENT TOLÉRER LE TRAITEMENT AVEC DES OESTROGÈNES OU CELLES OÙ LES OESTROGÈNES LEUR SONT CONTREINDIQUÉES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2045","99-08-19","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE TO PRODUCT NAME; RX TO OTC SWITCH","CHANGEMENT DE NOM DE PRODUIT, RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","SEASONAL ALLERGIC RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"2046","99-07-12","CONNAUGHT LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW BLENDING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"2047","99-06-29","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2048","99-06-29","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2049","99-05-05","ULTRAPHARM 2000 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2050","99-05-05","ULTRAPHARM 2000 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2051","99-06-21","MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH; REVISED INDICATION: TO INCLUDE THE REDUCTION OF ELEVATED LEVELS OF APOLIPOPROTEIN B AND TRIGLYCERIDES; REVISED DOSAGE","NOUVELLE CONCENTRATION; INDICATION REVISÉE : POUR INCLURE LA RÉDUCTION DES NIVEAUX ÉLEVÉS D'APOLOPROTÉINE B ET DES TRIGLYCÉRIDES; PRÉSENTATION REVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2052","99-05-18","FRESENIUS KABI AB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","FAT EMULSIONS FOR INTRAVENOUS NUTRITION","ÉMULSION DE GRAS, ALIMENTATION I.V.","",""
"2053","99-04-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRODUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRODUODÉNAL","",""
"2054","99-03-08","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR","GMPC-INHIBITEUR SPÉCIFIQUE DE LA PHOSPHODIESTÉRASE DE TYPE 5","",""
"2055","99-03-04","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN SOURCE OF BULK DRUG SUBSTANCE AND FINISHED DRUG PRODUCT","NOUVELLE SOURCE DE SUBSTANCE BIOLOGIQUE ET PRODUIT FINAL","GROWTH STIMULANT","STIMULANT DE CROISSANCE","",""
"2056","99-02-22","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OPTICROM","FISONS CORPORATION LTD.","CANADA","CANADA","1","","","ANTIALLERGIC AGENT","AGENT ANTIALLERGIQUE","",""
"2057","99-01-14","BAUSCH & LOMB SURGICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2058","99-01-12","TECHNILAB PHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE - NEW STRENGTHS","MONOGRAPHIE RÉVISÉE - NOUVELLES CONCENTRATIONS","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BÊTA2-ADRÉNERGIQUES","",""
"2059","99-12-17","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF CLOTTING IN INDWELLING INTRAVENOUS LINES DURING HAEMODIALYSIS AND EXTRACORPOREAL CIRCULATION","NOUVELLE INDICATION : POUR PRÉVENIR LA COAGULATION DANS LES LIGNES DE PERFUSION I.V. À DEMEURE DURANT L'HÉMODIALYSE ET LA CIRCULATION EXTRACORPORELLE","ANTICOAGULANT/ANTITHROMBOTIC AGENT","AGENT ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"2060","99-12-01","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2061","99-06-16","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN RECOMMENDED DOSAGE FOR LIVER TRANSPLANTATION","MODIFICATION DE LA POSOLOGIE RECOMMANDÉE POUR LA GREFFE DU FOIE","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2062","99-11-18","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","HOFFMANN-LA ROCHE","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"2063","99-11-10","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEBCIN","ELI LILLY","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2064","99-10-25","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2065","99-10-07","SABEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"2066","99-10-01","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TWO NEW STRENGTHS","DEUX NOUVELLES CONCENTRATIONS","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2067","99-09-02","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC/ANTIHYPERTENSIVE","DIURÉTIQUE/ANTIHYPERTENSEUR","",""
"2068","99-08-27","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2069","99-08-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2070","99-08-26","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUEUR DU RÉCEPTEUR AT1 DE L'ANGIOTENSINE II","",""
"2071","99-08-19","MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"2072","99-08-13","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2073","99-07-28","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","NEW MANUFACTURING FACILITY, CHANGE IN MANUFACTURING PROCESS, NEW STRENGTH, NEW INDICATION-USE IN SPECT IMAGING","NOUVEL EMPLACEMENT DE FABRICATION, MODIFICATION DE LA FABRICATION, NOUVELLE CONCENTRATION, NOUVELLE INDICATION-UTILISATION DANS L'IMAGE SPECT","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"2074","99-06-29","ELAN PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTISPASTIC AGENT","AGENT ANTISPASTIQUE","",""
"2075","99-06-16","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","POLYTRIM OPHTHALMIC SOLUTION","ALLERGAN INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2076","99-06-16","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PHARMACEUTICAL FORM AND NEW STRENGTH","NOUVELLE PRÉSENTATION PHARMACEUTIQUE ET NOUVELLE CONCENTRATION","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"2077","99-05-28","HEXAL PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC","MERCK FROSST","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","MAÎTRISE DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"2078","99-05-20","CONNAUGHT LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2079","99-05-20","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - SPRINKLE CAPSULE FORMULATION","NOUVELLE PRÉSENTATION - FORMULATION D'UNE CAPSULE À SAUPOUDRER","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2080","99-05-20","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PEDIATRIC USE IN PARTIAL ONSET SEIZURES","NOUVELLE INDICATION : POUR L'USAGE EN PÉDIATRIE À L'APPROCHE D'ATTAQUES PARTIELLES","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2081","99-05-06","DEBIO RECHERCHE PHARMACEUTIQUE S.A.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE (LH-RH)","",""
"2082","99-03-19","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM (GEL)","NOUVELLE PRÉSENTATION (GEL)","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2083","99-03-15","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF RECURRENT SMALL CELL LUNG CANCER","NOUVELLE INDICATION : POUR LE TRAITEMENT DE FRÉQUENTE PETITE CELLULE DU CANCER DU POUMON","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"2084","99-03-04","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"2085","99-02-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TESTOSTERONE REPLACEMENT THERAPY","THÉRAPIE DESTINÉE À REMPLACER LE TESTOSTÉRONE","",""
"2086","99-02-16","PATHOGENISIS CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RESPIRATORY ANTIBIOTIC","RESPIRATOIRE ANTIBIOTIQUE","",""
"2087","99-02-02","ORTHO DERMATOLOGICAL, DIVISION OF JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","COMEDOLYTIC AGENT","AGENT COMÉDOLYTIQUE","",""
"2088","99-01-28","NYCOMED AMERSHAM PLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"2089","99-01-25","ATHENA NEUROSCIENCES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTISPASTIC AGENT","AGENT ANTISPASTIQUE","",""
"2090","99-01-12","CROWNPHARMA CANADA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC","MERCK SHARP & DOHME","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","THÉRAPIE ÉLEVÉE DE LA PRESSION INTRAOCULAIRE","",""
"2091","99-08-19","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL","ANTIDÉPRESSEUR/AGENT ANTIOBSESSIONNEL","",""
"2092","01-11-02","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","SEASONAL ALLERGIC RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"2093","01-11-02","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIALLERGIC AGENT","ANTIALLERGIQUE","",""
"2094","01-10-26","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2095","01-10-31","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW EXTENDED RELEASE FORMULATION","NOUVELLE FORMULATION À ACTION PROLONGÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2096","01-10-24","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOECHST MARION ROUSSEL INC.","CANADA","CANADA","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTIVONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"2097","01-10-24","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR IX","FACTEUR IX ANTIHÉMORRAGIQUE DE COAGULATION SANGUINE","",""
"2098","01-10-24","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AND CORTICOSTEROID AGENT","ANTIFONGIQUE - CORTICOSTÉROÏDE TOPIQUE","",""
"2099","01-10-16","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"2100","01-09-21","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REFORMULATION OF THE 125MG/5ML CLARITHROMYCIN FOR ORAL SUSPENSION","REFORMULATION DU CLARITHROMYCIN","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2101","01-09-21","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2102","01-09-10","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINEMET","MERCK SHARP & DOHME","CANADA","CANADA","1","","","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"2103","01-08-31","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC LUNG SURFACTANT","SURFACTANT PULMONAIRE SYNTHÉTIQUE","",""
"2104","01-08-31","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2105","01-08-28","TARO PHARMACEUTICALS INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEGRETOL CHEWTABS","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE FORME POSOLOGIQUE ET CONCENTRATION","ANTICONVULSANT, FOR SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA, ANTIMANIC","ANTICONVULSIVANT, SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU, ANTIMANIAQUE","",""
"2106","01-08-27","CHX TECHNOLOGIES INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CHLORZOIN","MODIFICATION DU NOM DU PRODUIT DE CHLORZOIN","ANTIMICROBIAL AGENT","ANTIBACTÉRIEN","",""
"2107","01-08-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERCHOLESTEROLEMIC","ANTIHYPERCHOLESTÉROLÉMIQUE ORAL","",""
"2108","01-08-24","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZINACEF","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2109","01-08-24","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFTIN","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2110","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR H2 DE L'HISTAMINE","",""
"2111","01-08-17","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2112","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2113","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2114","01-08-24","ALZA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"2115","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2116","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2117","01-08-07","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR H2 DE L'HISTAMINE","",""
"2118","01-08-07","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR H2 DE L'HISTAMINE","",""
"2119","01-08-07","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR H2 DE L'HISTAMINE","",""
"2120","01-07-19","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"2121","01-07-11","LEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIPSORIATIC AGENT, VITAMIN D ANALOGUE, CORTICOSTEROID","AGENT ANTIPSORIASIQUE TOPIQUE, ANALOGUE DE LA VITAMINE D, CORTICOSTÉROÏDE TOPIQUE","",""
"2122","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"2123","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2124","01-06-18","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER + DIURETIC","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"2125","01-06-07","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2126","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2127","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VAGINAL ANTIBACTERIAL PREPARATION","AGENT ANTIBACTÉRIEN POUR ADMINISTRATION VAGINALE","",""
"2128","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2129","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2130","01-05-08","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"2131","01-05-08","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE TO PRODUCT MONOGRAPH","MODIFICATION DE LA MONOGRAPHIE DU PRODUIT","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2132","01-05-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","INTAL NEBULIZER SOLUTION","FISONS CORP. LTD.","CANADA","CANADA","1","","","ASTHMA PROPHYLAXIS","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"2133","01-04-24","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEORAL","NOVARTIS PHARMACEUTICALS","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"2134","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2135","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2136","01-04-17","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ION EXCHANGE RESIN","RÉSINE ÉCHANGEUSE D'IONS","",""
"2137","01-04-06","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2138","01-04-04","AVENTIS BEHRING LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BLOOD COAGULATION PRODUCT","PRODUIT DE COAGULATION DE SANG","",""
"2139","01-03-29","GLADES, DIVISION OF STIEFEL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN T","UPJOHN COMPANY","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2140","01-03-07","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DOPAMINE RECEPTOR AGONIST","AGONISTE DU RÉCEPTEUR DOPAMINERGIQUE","",""
"2141","01-02-15","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT, ANTIMANIC, SYMPTOMATIC RELIEF OF TRIGERMINAL NEURALGIA","ANTICONVULSIVANT, ANTIMANIAQUE, SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRAGE DU TRIJUMEAU","",""
"2142","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2143","01-02-08","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE - BIAXIN TO BIAXIN BID","MODIFICATION DU NOM DU PRODUIT - BIAXIN À BIAXIN BID","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2144","01-02-01","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL - ANTIPARASITIC","ANTIPALUDÉEN - PARASITICIDE","",""
"2145","01-01-31","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"2146","01-01-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2147","01-01-18","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2148","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2149","01-01-11","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGENIC HORMONES/PROGESTIN","HORMONE OESTROGÈNES, PROGESTATIF","",""
"2150","01-01-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAGAMET","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2151","01-01-05","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"2152","01-01-05","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"2153","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2154","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2155","01-08-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2156","01-08-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIPROTECTIVE AGENT","AGENT CARDIOPROTECTEUR","",""
"2157","01-08-15","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR/ANTI-PAGETIC AGENT/ANTI-HYPERCALCEMIC AGENT","RÉGULATEUR DU MÉTABOLISME OSSEUX, AGENT ANTIPAGÉTIQUE, AGENT ANTIHYPERCALCÉMIQUE","",""
"2158","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","SPECIFIC ANTIBODY FOR DIGOXIN","ANTICORPS SPÉCIFIQUES DE LA DIGOXINE","",""
"2159","01-08-01","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2160","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2161","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2162","01-07-06","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"2163","01-07-06","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"2164","01-06-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2165","01-06-04","ALZA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"2166","01-05-29","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2167","01-04-30","DRAXIS HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN D ANALOGUE","ANALOGUE DE LA VITAMIN D","",""
"2168","01-04-17","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"2169","01-03-29","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"2170","01-03-02","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CARCINOMA","NOUVELLE INDICATION: TRAITEMENT DES PATIENTS SOUFFRANT DU CANCER DU SEIN AVANCÉ LOCALISÉ OU MÉTASTATIQUE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2171","01-02-22","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTRAN RAPIDE","CIBA-GEIGY CANADA LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2172","01-02-16","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2173","01-02-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT, ANTITHROMBIC AGENT","ANTICOAGULANT, ANTITHROMGBOTIQUE","",""
"2174","01-02-15","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM","HOECHST MARION ROUSSEL","CANADA","CANADA","1","","","ANTIHYPERTENSIVE - ANTIANGINAL AGENT","ANTIHYPERTENSEUR - ANTIANGINEUX","",""
"2175","01-02-13","CRYSTAAL, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AGENT, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"2176","01-02-13","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","IRON AND ALUMINUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"2177","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT WITH A PROTECTIVE MUCOSAL AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE - AGENT PROTECTEUR DE LA MUQUEUSE","",""
"2178","01-02-06","CRYSTAAL, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"2179","04-05-05","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC AGENT","SYMPATHOMIMÉTIQUE","",""
"2180","04-05-03","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION: THE ADDITION OF 3 NEW EXCIPIENTS TO IMPROVE THE TASTE","CHANGEMENT DANS LA COMPOSITION : AJOUT DE 3 NOUVEAUX EXCIPIENTS POUR AMÉLIORER LE GOÛT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2181","04-05-03","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORCURON","ORGANON CANADA INC.","CANADA","CANADA","1","","","NON DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"2182","04-05-03","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"2183","04-05-03","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2184","04-05-04","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"2185","04-05-04","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"2186","01-02-06","CRYSTAAL, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"2187","04-05-04","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"2188","01-01-24","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPICORT","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2189","04-05-03","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"2190","01-01-22","DEPARTMENT OF NATIONAL DEFENCE, CANADIAN FORCES MEDICAL GROUP HEADQUARTERS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"2191","01-01-18","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RIMSO-50 USP","ROBERTS PHARMACEUTICAL CANADA INC.","CANADA","CANADA","1","","","INTRAVESICAL INSTILLATION FOR THE TREATMENT OF INTERSTITIAL CYSTITIS","MALADIES GÉNITO-URINAIRES","",""
"2192","01-01-18","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANIHYPERTENSIVE AGENT; SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR; TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"2193","01-12-21","THE LIPOSOME COMPANY INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2194","01-12-21","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF CHRONIC IDIOPATHIC URTICARIA","NOUVELLE INDICATION: POUR LE TRAITEMENT DE L'URTICAIRE CHRONIQUE IDIOPATHIQUE","HISTAMINE H1-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2195","01-12-05","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"2196","01-11-22","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERSANTINE","BOEHRINGER INGELHEIM CANADA INC.","CANADA","CANADA","1","","","CORONARY VASODILATOR AND INHIBITOR OF PLATELET ADHESION AND AGGREGATION","VASODILATATEUR CORONARIEN ET INHIBITEUR DE L'ADHÉSION ET L'AGRÉGATION PLAQUETTAIRES","",""
"2197","01-11-21","BIOVAIL PHARMACEUTICALS, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AGENT, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"2198","01-11-13","BIOVAIL PHARMACEUTICALS, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE/ANTIANGINAL AGENT","ANTIHYPETENSEUR, ANTIANGINEUX","",""
"2199","01-11-13","XCEL PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BENZODIAZEPINE ANTICONVULSANT","BENZODIAZÉPINE, ANTICONVULSIVANT","",""
"2200","01-10-16","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NIGTHTIME SLEEP-AID","ADIE-SOMMEIL","",""
"2201","01-10-12","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM INJECTABLE","HOECHST MARION ROUSSEL","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"2202","01-10-12","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-DIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"2203","01-10-09","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERSANTINE","BOEHRINGER INGELHEIM","CANADA","CANADA","1","","","CORONARY VASODILATOR","VASODILATATEUR CORANARIEN","",""
"2204","01-10-09","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","CORTICOSTÉROÏDE TOPIQUE","",""
"2205","01-10-04","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO GAIN APPROVAL FOR A NEW ENCAPSULATED ENTERIC-COATED BEADLET FORMULATION AS WELL AS A ONCE-DAILY DOSAGE ADMINISTRATION","PERMETTRE L'AJOUT D'UNE PRÉSENTATION À ENROBAGE ENTÉROSOLUBLE ET L'ADMINISTRATION D'UNE DOSE PAR JOUR","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2206","01-09-21","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-4","ASTRA PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE","",""
"2207","01-12-28","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2208","01-12-05","BRISTOL-MYERS SQUIBB PHARMA. GROUP, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"2209","01-10-30","BAXTER CORPORATION-CLINTEC NUTRITION DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"2210","04-05-03","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK SHARP & DOHME","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2211","04-05-03","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC., HEALTHCARE DIVISION","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2212","04-05-03","GMD DISTRIBUTING INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL MYERS SQUIBB CANADA","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2213","04-05-05","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","ESTROGEN","OESTROGÈNE","",""
"2214","04-05-03","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2215","04-05-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR","SANOFI SYNTHELABO CANADA INC.","CANADA","CANADA","1","","","Inotrope, Vasodilator","Inotrope, Vasodilatateur","",""
"2216","04-05-06","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING PROCESS","CHANGEMENT AU PROCESSUS DE FABRICATION","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"2217","04-05-06","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISION TO PRODUCT MONOGRAPH","RÉVISION À LA MONOGRAPHIE DU PRODUIT","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2218","04-05-06","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGES TO MANUFACTURING PROCESS","CHANGEMENT AU PROCESSUS DE FABRICATION","DIAGNOSTIC RADIOPHARMACEUTICAL AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"2219","01-08-24","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2220","01-08-17","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"2221","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VASODILATOR","VASODILATATEUR","",""
"2222","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2223","01-06-06","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE OF VASOTEC IN HYPETENSIVE PEDIATRIC PATIENTS","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2224","01-06-06","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2225","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2226","01-05-24","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN II RECEPTOR (AT1) ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR (AT1) DE L'ANGIOTENSINE II","",""
"2227","01-05-10","WESTWOOD-SQUIBB COLTON HOLDINGS PARTNERSHIP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HAIR GROWTH INHIBITOR","INHIBITEUR DE LA POUSSE DE POILS","",""
"2228","01-05-08","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUNCT TO LEVODOPA AND DDC INHIBITOR/COMT-INHIBITOR","TRAITEMENT D'APPOINT À LA LÉVODOPA ET INHIBITEUR DE LA DDC/COMT","",""
"2229","01-05-08","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTICOAGULANT/ANTITHROMBOTIC AGENT (LOW MOLECULAR WEIGHT HEPARIN FRAGMENT)","ANTICOAGULANT/ANTITHROMBOTIQUE (FRAGMENT D'HÉPARINE DE BAS POIDS MOLÉCULAIRE)","",""
"2230","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AROMATASE INACTIVATOR; ANTI-TUMOR AGENT","INACTIVATEUR DE L'AROMATASE, AGENT ANTINÉOPLASIQUE","",""
"2231","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2232","01-04-12","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2233","01-04-04","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2234","01-04-04","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"2235","01-03-20","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) IN MEDICAL PATIENTS BEDRIDDEN DUE TO ACUTE CARDIAC INSUFFICIENCY, ACUTE RESPIRATORY FAILURE AND ACUTE RESPIRATORY INFECTIONS (EXCLUDING SEPTIC SHOCK)","INDICATION RÉVISÉE: PRÉVENTION DES THROMBOSES VEINEUSES PROFONDES (TVP) CHEZ LES PATIENTS ALITÉS EN RAISON D'UNE INSUFFISANCE CARDIAQUE AIGÜE, D'UNE INSUFFISACE RESPIRATOIRE AIGÜE ET D'INFECTIONS RESPIRATOIRES AIGÜES (EXCLUANT LE CHOC SEPTIQUE)","ANTICOAGULANT/ANTITHROMBOTIC AGENT (LOW MOLECULAR WEIGHT HEPARIN FRAGMENT)","ANTICOAGULANT/ANTITHROMBOTIQUE (FRAGMENT D'HÉPARINE DE BAS POIDS MOLÉCULAIRE)","",""
"2236","01-02-23","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN-ESTROGEN","ASSOCIATION OESTRO-PROGESTATIVE","",""
"2237","01-01-25","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2238","01-02-22","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN PREVENTION OF OSTEOPOROSIS","NOUVLLE INDICATION:  USAGE DANS LA PRÉVENTION DE L'OSTÉOPOROSE","ESTROGEN","OESTROGÈNE","",""
"2239","01-02-22","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ESTROGEN","OESTROGÈNE","",""
"2240","01-01-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2241","01-12-21","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2242","01-12-13","DR REDDYS LABORATORIES INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","MANUFACTURER NAME CHANGE","MODIFICATION DU NOM DU FABRICANT","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2243","01-12-10","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2244","01-12-10","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2245","01-12-10","PREMPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2246","01-12-04","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK FROSST CANADA INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH SAFETY UPDATE","MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2247","01-12-04","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINNIQUES H2","",""
"2248","01-11-30","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINNIQUES H2","",""
"2249","01-11-30","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISAMINIQUES H2","",""
"2250","01-11-19","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MANAGEMENT OF SINUS PAIN AND PRESSURE ASSOCIATED WITH ALLERGIC RHINITIS","NOUVELLE INDICATION: GESTION DE LA DOULEUR ET PRESSION SINUSALES RELIÉS À LA RHINITE ALLERGIQUE","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"2251","01-11-16","REDDY-CHEMINOR, INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2252","01-11-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IDARAC","SANOFI WINTHROP","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2253","01-11-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTI-SPASMODIC","ANTISPASMODIQUE AGISSANT SUR LES VOIES URINAIRES","",""
"2254","01-11-05","RHOXALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS: SAFETY UPDATE","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT: MISE À JOUR EN MATIÈRE D'INNOCUITÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2255","01-11-05","ORPHAN MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AN ANTIDOTE FOR METHANOL POISONING","NOUVELLE INDICATION: UN ANTIDOTE À L'EMPOISONNEMENT AU MÉTHANOL","SYNTHETIC ALCOHOL DEHYDROGENASE INHIBITOR","INHIBITEUR SYNTHÉTIQUE DE L'ALCOOL DÉSHYDROGÉNASE","",""
"2256","01-10-30","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE USE IN THE TREATMENT OF LOW-GRADE NON-HODGKIN'S LYMPHOMA (LG-NHL) IN PATIENTS WHO HAVE FAILED OTHER CONVENTIONAL TREATMENT","NOUVELLE INDICATION : COMME TRAITEMENT DU LYMPHOME PEU AVANCÉ NON-HODGKINIEN CHEZ LES PATIENTS RÉFRACTAIRES AUX TRAITEMENTS CONVENTIONNELS","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2257","01-10-12","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR VOIE NASALE","",""
"2258","01-10-09","DR REDDYS LABORATORIES INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2259","01-10-09","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","GONADOTROPHIN","GONADOTROPHINE","",""
"2260","01-10-04","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITION OF A NEW CLAIM","AJOUT D'UNE NOUVELLE INDICATION","GONADOTROPHIN","GONADOTROPHINE","",""
"2261","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE","",""
"2262","01-07-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MODECATE","SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"2263","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2264","01-07-19","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXPANSION OF THE INDICATION FROM MANAGEMENT OF CHRONIC CANCER PAIN TO CHRONIC PAIN","ÉLARGISSEMENT DE L'INDICATION DE GESTION DE LA DOULEUR CHRONIQUE RELIÉE AU CANCER À LA DOULEUR CHRONIQUE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2265","01-07-18","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR ORAL INHALATION","CORTICOSTÉROÏDE POUR INHALATION ORALE","",""
"2266","01-07-18","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2267","01-07-06","REDDY-CHEMINOR, INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"2268","01-06-22","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANDROGENIC-ANABOLIC STEROID","ANDROGÈNE, STÉROÏDE ANABOLISANT","",""
"2269","01-05-30","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"2270","01-05-24","LEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL OPHTHALMIC ANTIBIOTIC","ANTIBIOTIQUE","",""
"2271","01-05-11","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MULTIPLE DOSE PRESENTATION","NOUVELLE PRESENTATION À DOSE MULTIPLE","HUMAN GONADOTROPIN","GONADOTROPHINE HUMAINE","",""
"2272","01-04-26","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2273","01-04-17","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF MILD TO MODERATE ACTUTE EXACERBATIONS OF ASTHMA IN CHILDREN 4-16 YEARS OF AGE. NEW DOSAGE FORM: NEBULES","NOUVELLE INDICATION : POUR LE TRAITEMENT DES EXACERBATIONS LÉGÈRES AIGUES DE L'ASTHME CHEZ LES ENFANTS DE 4 À 16 ANS. NOUVELLE FORME POSOLOGIQUE : NÉBULES","CORTICOSTEROID FOR INHALATION","CORTICOSTÉROÏDE","",""
"2274","01-04-17","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIHYPERLIPIDEMIC AGENT","AGENT ANTIHYPOLIPIDÉMIANT","",""
"2275","01-04-02","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2276","01-03-29","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: PREVENTION OF NOCTURNAL SYMPTOMS ASSOCIATED WITH THE EVENING MEAL AND EXPECTED TO CAUSE SLEEP DISTURBANCE","NOUVELLE INDICATION: PRÉVENTION DES SYMPTÔMES NOCTURNES ASSOCIÉS AU REPAS DU SOIR ET DE NATURE À CAUSER DES TROUBLES DU SOMMEIL","H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2277","01-03-29","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","FOURNIER PHARMA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2278","01-02-22","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"2279","01-01-31","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIDEX OINTMENT, TOPSYN GEL","SYNTEX CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2280","01-01-31","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2281","01-01-25","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2282","01-01-24","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ALLEGRA","MODIFICATION DU NOM DU PRODUIT DE ALLEGRA","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2283","01-01-18","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2284","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"2285","01-01-12","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN: ON-DEMAND (PRN) DOSIND IN PATIENTS 12 YEARS OF AGE AND OLDER","NOUVEAU SCHÉMA POSOLOGIQUE: ADMINISTRATION SUR DEMANDE (PRN) CHEZ LES PATIENTS DE 12 ANS ET PLUS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2286","01-01-11","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: TREATMENT AND PREVENTION OF SYMPTOMS OF REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE INLCUDING ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER. NEW INDICATION: TREATMENT AND PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 6 YEARS OF AGE AND OLDER.","INDICATION RÉVISÉE : TRAITEMENT ET PRÉVENTION DE MALADIE OBSTRUCTIVE RÉVERSIBLE DES VOIES RESPIRATOIRES COMPRENANT L'ASTHME CHEZ LES PATIENTS DE 6 ANS ET PLUS.  NOUVELLE INDICATION : TRAITEMENT ET PRÉVENTION DE LA BRONCHOCONSTRICTION DÉCLENCHÉE PAR L'EXERCICE CHEZ LES PATIENTS DE 6 ANS ET PLUS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2287","01-01-11","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATORIES FOURNIER S.C.A.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2288","01-01-11","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: LONG-TERM TREATMENT OF ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","NOUVELLE INDICATION : SOINS À LONG TERME DES ADULTES ATTEINTS DE BRONCHO-PNEUMONIE CHRONIQUE OBSTRUCTIVE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2289","01-09-21","TEVA PHARMACEUTICALS USA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO PROVIDE FOR ADDITIONAL WORDING UNDER CLINICAL STUDIES TO INCLUDE RESULTS FROM A MRI-MONITORED STUDY","FOURNIR L'AJOUT, SOUS ÉTUDES CLINIQUES, DES RÉSULTATS D'UNE ÉTUDE MESURÉE PAR IRM","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"2290","01-09-21","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"2291","01-08-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2292","01-07-31","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"2293","01-04-30","BIOMET ORTHOPEDICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2294","01-04-04","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN HEAD AND NECK","NOUVELLE INDICATION: POUR REHAUSSER LE CONTRASTE DANS LES EXAMENS IRM CHEZ L'ADULTE ET POUR AMÉLIORER LA DÉTECTION DES LÉSIONS DE LA TÊTE ET DU COU","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","PRODUIT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"2295","01-04-04","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"2296","01-02-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"2297","01-02-13","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"2298","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"2299","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"2300","01-01-11","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","HYPERGLYCEMIC AGENT","AGENT HYPERGLYCÉMIANT","",""
"2301","01-01-09","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2302","01-12-20","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","INJECTABLE VACCINE","VACCIN INJECTABLE","",""
"2303","01-11-06","SABEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2304","01-10-16","PRECISION PHARMA SERVICES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","POOLED BLOOD COMPONENT/DERIVATIVE","COMPSANTS DU SANG/PRODUITS DÉRIVÉE DU SANG","",""
"2305","01-10-16","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RECTAL ANTI-INFLAMMATORY CORTICOSTEROID FOAM","ANTI-INFLAMMATOIRE RECTAL","",""
"2306","01-10-16","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RECTAL ANTI-INFLAMMATORY FOAM","TRAITEMENT ANORECTAL","",""
"2307","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2308","01-07-19","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2309","01-07-19","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"2310","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST INFECTION BY HEPATITIS A VIRUS","AGETN D'IMMUNISATION ACTIVE CONTRE L'INFECTION PAR LE VIRUS DE L'HÉPATITE A","",""
"2311","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2312","01-06-14","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2313","01-06-13","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID/NSAID COMBINATION ANALGESIC","OPIOÏDES, ANALGÉSIQUE AINS","",""
"2314","01-04-06","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW 80 ANTIGEN UNIT FORMULATION FOR PEDIATRIC USE","NOUVELLE FORMULATION DE 80 UNITÉS D'ANTIGÈNE POUR USAGE PÉDIATRIQUE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2315","01-03-29","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2316","01-03-16","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION (PRESERVATIVE-FREE)","NOUVELLE FORMULATION (SANS AGENTS DE CONSERVATION)","VACCINE FOR IMMUNIZATION","VACCIN","",""
"2317","01-02-01","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING PROCESS","MODIFICATION DU PROCESSUS DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2318","01-01-25","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY/ANTIMALARIAL","ANTI-INFLAMMATOIRE - ANTIPALUDÉEN","",""
"2319","01-01-24","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WESTCORT CREAM","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2320","01-01-24","OPTIMAPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WESTCORT OINTMENT","WESTWOOD SQUIBB","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2321","01-12-27","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","AUTRE SITE DE FABRICATION","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"2322","01-12-21","BIOGEN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SUPPLIER FOR HSA AS EXCIPIENT","FOURNISSEUR ALTERNATIF DE ASH","IMMUNODULATOR","IMMUNODULATEUR","",""
"2323","01-12-17","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","FACILITY CHANGES","MODIFICATION À L'EMPLACEMENT DE FABRICATION","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"2324","01-12-17","NOVO NORDISK A/S","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DELIVERY DEVICE","NOUVEAU SYSTÈME D'ADMINISTRATION","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"2325","01-11-23","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCEDURE","MODIFICATION DES PROCÉDURES DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2326","01-11-23","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCEDURE","MODIFICATION DES PROCÉDURES DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2327","01-11-14","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SUPPLIER FOR HSA USED AS EXCIPIENT IN MANUFACTURE OF BETASERON","FOURNISSEUR ADDITIONEL DE L'ASH UTILISÉE COMME EXCIPIENT DANS LA FABRICATION DE BETASERON","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"2328","01-10-12","INTERMUNE, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"2329","01-09-27","CENTOCOR INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER (ADDITIONAL INDICATION: RHEUMATOID ARTHRITIS)","MODULATEUR DES RÉACTIONS BIOLOGIQUES (INDICATION ADDITIONNELLE: RHUMATISME ARTICULAIRE)","",""
"2330","01-08-28","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FORANE","ZENECA PHARMA INC.","CANADA","CANADA","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"2331","01-08-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"2332","01-09-20","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"2333","01-07-25","WATSON LABORATORIES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HEMATINIC","HÉMATINIQUE","",""
"2334","01-07-18","NOVO NORDISK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"2335","01-06-18","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANALGESI/ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"2336","01-06-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATROVENT UDV","BOEHRINGER INGELHEIM INC.","CANADA","CANADA","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2337","01-06-06","CENTOCOR INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"2338","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2339","01-05-29","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATROVENT UDV","BOEHRINGER INGELHEIM","CANADA","CANADA","1","NEW STRENGTH","NOUVEAU DOSAGE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2340","01-05-11","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2341","01-04-20","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRNCHODILATATEUR","",""
"2342","01-04-17","LUITPOLD PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HEMATINIC","HÉMATINIQUE","",""
"2343","01-04-02","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ACCUTANE","MODIFICATION DU NOM DU PRODUIT DE ACCUTANE","NODULAR/INFLAMMATORY AND CONGLOBATE ACNE THERAPY","TRAITEMENT DE L'ACNÉ NODULAIRE/INFLAMMATOIRE ET DE L'ACNE CONGLOBATA","",""
"2344","01-02-28","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM INDICATION: FOR THE TREATMENT OF THE FOLLOWING SYSTEMIC FUNGAL INFECTIONS IN IMMUNOCOMPROMISED AND NON-IMMUNOCOMPROMISED PATIENTS: 1.BLASTOMYCOSIS 2.CHRONIC PULMONARY HISTOPLASMOSIS 3.INVASIVE AND NON-INVASIVE PULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY","NOUVELLE FORME POSOLOGIQUE INDICATION : POUR LE TRAITEMENT DES INFECTIONS FONGIQUES SYSTÉMIQUES SUIVANTES CHEZ LES INDIVIDUS IMMUNODÉPRIMÉS OU NON : 1. BLASTOMYCOSE 2. HISTOPLASMOSE PULMONAIRE CHRONIQUE 3. ASPERGILLOSE PULMONAIRE ENVAHISSANTE ET NON-ENVAHISSANTE CHEZ LES PERSONNES QUI PRÉSENTENT UNE INTOLÉRANCE OU QUI SONT RÉFRACTAIRES À UN TRAITEMENT À L'AMPHOTÉRICINE B","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2345","01-02-28","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE USE IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVORIN AS FIRST-LINE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER","NOUVELLE INDICATION:  POUR UTILISATION EN COMBINAISON AVEC 5-FLUOROURACILE ET LEUCOVORINE COMME THÉRAPIE DE PREMIÈRE LIGNE POUR LES PATIENTS SOUFFRANT D'UN CANCER MÉTASTATIQUE DU CÔLON OU DU RECTUM","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2346","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2347","01-02-08","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM: CHEWABLE TABLET","NOUVELLE FORME POSOLGIQUE","ANALGESIC/ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"2348","01-02-02","GENZYME CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"2349","01-01-30","R & D LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HEMATINIC","HÉMATIQUE","",""
"2350","01-01-18","LABORATOIRE CHAUVIN S.A.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"2351","01-01-18","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT NASAL","",""
"2352","01-11-30","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TORADOL IM","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"2353","01-06-04","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORM POSOLOGIQUE","NSAID ANALAGESIC AGENT","ANALGÉSIQUE AINS","",""
"2354","01-03-20","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2355","01-02-16","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIALLERGY AGENT","AGENT ANTIALLERGIQUE","",""
"2356","01-01-24","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2357","01-01-24","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"2358","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PARENTERAL GENERAL ANESTHETIC","ANESTHÉSIQUE GÉNÉRAL PARENTÉRAL","",""
"2359","01-12-21","GLAXOSMITHKLINE SHIRE BIOCHEM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2360","01-12-21","GLAXOSMITHKLINE SHIRE BIOCHEM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2361","01-12-21","GLAXOSMITHKLINE SHIRE BIOCHEM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2362","01-12-18","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCENTRATION ET NOUVELLE FORME POSOLOGIQUE","HISTAMINE H1 RECEPTOR ANTAGONIST/SYMPATHOMIMETIC AMINE","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE, AMINE SYMPATHOMIMÉTIQUE","",""
"2363","01-12-06","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: HEALING OF NSAID-ASSOCIATED GASTRIC ULCER AND REDUCTION OF RISK OF NSAID-ASSOCIATED GASTRIC ULCER","NOUVELLES INDICATIONS : CICATRISATION DE L'ULCÈRE GASTRIQUE RELIÉ À L'USAGE DES AINS ET RÉDUCTION DU RISQUE D'ULCÈRE GASTRIQUE RELIÉ À L'USAGE DES AINS","K+, H+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2364","01-11-19","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTION IN FEBRIL, NEUTROPENIC PATIENTS, AND TREATMENT OF CRYPTOCOCCAL MENINGITIS IN IMMUNOCOMPROMISED PATIENTS","NOUVELLE INDICATION : TRAITEMENT EMPIRIQUE DES PATIENTS EN ÉTAT DE NEUTROPÉNIE ET DE FÉBRILITÉ ET TRAITEMENT DE LA MÉNINGITE À CRYPTOCOQUE CHEZ LES PATIENTS QUI PRÉSENTENT UN DÉFICIT IMMUNITAIRE","ANTIFUNGAL","ANTIFONGIQUE","",""
"2365","01-11-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRANDATE","ROBERTS PHARMACEUTICAL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2366","01-10-12","VITA HEALTH PRODUCTS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2367","01-10-12","VITA HEALTH PRODUCTS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2368","01-10-12","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLES CONCENTRATION ET FORME POSOLOGIQUE","TOPICAL ANTICHOLINERGIC FOR NASAL ADMINISTRATION","ANTICHOLINERGIQUE TOPIQUE","",""
"2369","01-08-31","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","TWO ALTERNATIVE DOSING SCHEDULES AND A SEROLOGIC CORRELATE OF PROTECTION","DEUX NOUVEAUX PLANS POSOLOGIQUES ET UNE CORRÉLATION SÉROLOGIQUE PROTECTRICE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2370","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2371","01-07-20","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2372","01-07-18","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2373","01-07-06","D.C. LABS LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"2374","01-06-11","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2375","01-06-06","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2376","01-05-11","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FIRST-LINE THERAPY IN POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER","NOUVELLE INDICATION: THÉRAPIE DE PREMIÈRE LIGNE CHEZ LA FEMME ATTEINTE DE CANCER AVANCÉ DU SEIN ET EN ÉTAT POSTMÉNOPAUSIQUE","NON-STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESIS; ANTITUMOUR AGENT","INHIBITEUR DE L'AROMATASE NON-STÉROÏDIEN; INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES; ANTINÉOPLASIQUE","",""
"2377","01-04-30","SIGMA-TAU PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS","NOUVELLE INDICATION: POUR LA PRÉVENTION ET LE TRAITEMENT DU DÉFICIT EN CARNITINE CHEZ LES PATIENTS EN INSUFFISANCE RÉNALE TERMINALE QUI REÇOIVENT DES TRAITEMENTS DE DIALYSE","REPLENISHER (CARNITINE)","AGENT DE RECHARGE EN CARNITINE","",""
"2378","01-04-04","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING SITE, CHANGE IN FORMULATION","NOUVEL EMPLACEMENT DE FABRICATION ET MODIFICATION DE LA PRÉPARATION","ANXIOLYTIC-SEDATIVE","ANXIOLYTIQUE-SÉDATIF","",""
"2379","01-04-02","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2380","01-03-09","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Human Immunodeficiency Virus (HIV) Protease Inhibitor","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH)","",""
"2381","01-03-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRANDATE","ROBERTS PHARMACEUTICAL INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2382","01-02-23","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED LABELLING: REMOVAL OF DUAL THERAPY IN THE TREATMENT OF H. PYLORI INFECTION","ÉTIQUETTE RÉVISÉE: RETRAIT DE LA BITHÉRAPIE DANS LE TRAITEMENT DE L'INFECTION À H.PYLORI","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2383","01-02-22","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2384","01-02-15","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW METHOD OF ADMINISTRATION: INGESTION OF INTACT GRANULES","NOUVELLE MÉTHODE D'ADMINISTRATION: INGESTION DE GRANULES ENTIERS","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2385","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN F2 ANALOGUE","ANALOGUE DE LA PROSTAGLANDINE F2","",""
"2386","01-02-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2387","01-01-25","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATIVAN","WYETH AYERST CANADA INC.","CANADA","CANADA","1","","","ANXIOLYTIC SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"2388","01-01-24","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2389","01-01-17","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"2390","01-05-07","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: CHEWABLE/DISPERSIBLE TABLET","NOUVEAU DOSAGE; COMPRIMÉ À MÂCHER/DISPERSABLE","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2391","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2392","01-12-31","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"2393","01-12-21","BAXTER CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","PREMEDICANT/SEDATIVE/ANESTHETIC AGENT","PRÉMÉDICATION, SÉDATIF, ANESTHÉSIQUE","",""
"2394","01-12-18","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL VIRAL BULK MANUFACTURING FACILITY","NOUVEL ÉTABLISSEMENT DE FABRICATION EN VRAC DU VIRUS","PROPHYLACTIC VACCINE","VACCIN PROPHYLACTIQUE","",""
"2395","01-12-18","SHIRE BIOLOGICS, A DIVISION OF SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2396","01-12-06","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","UROMITEXAN","BRISTO-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","UROPROTECTOR","AGENT UROPROTECTEUR","",""
"2397","01-12-05","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"2398","01-12-05","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"2399","01-11-19","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR","SANOFI WINTHROP","CANADA","CANADA","1","","","INOTROPE/VASODILATOR","AGENT INOTROPE, VASODILATATEUR","",""
"2400","01-11-13","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MS CONTIN","PURDUE FREDERICK","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2401","01-11-06","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR","SANOFI WINTHROP","CANADA","CANADA","1","","","INOTROPE/VASODILATOR","AGENT INOTROPE, VASODILATATEUR","",""
"2402","01-11-02","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","PROGESTIN","PROGESTATIF","",""
"2403","01-10-24","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VITAMIN SUPPLEMENT FOR TOTAL PARENTERAL NUTRITION","SUPPLÉMENT VITAMINIQUE POUR NUTRITION PARENTÉRALE TOTALE","",""
"2404","01-10-24","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SOURCE OF HSA","SOURCE D'ALBUMINE (HUMAINE) ALTERNATIVE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2405","01-10-24","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"2406","01-10-16","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","B-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"2407","01-10-16","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"2408","01-10-12","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST INFECTION BY MEASLES, MUMPS AND RUBELLA","AGENT D'IMMUNISATION ACTIVE","",""
"2409","01-10-09","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR","SANOFI WINTHROP","CANADA","CANADA","1","","","INOTROPE/VASODILATOR","AGENT INOTROPE/VASODILATATEUR","",""
"2410","01-10-01","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOVANTRONE","WYETH-AYERST","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2411","01-09-21","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AND ANTIPROTOZOAL AGENT","ANTIBACTÉRIEN ET ANTIPROTOZOAIRE","",""
"2412","01-09-19","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST MENINGOCOCCAL MENINGITIS CAUSED BY GROUPS A AND C","AGENT D'IMMUNISATION ACTIVE CONTRE LA MÉNINGITE À MÉNINGOCOQUE CAUSÉE PAR LES GROUPES A ET C","",""
"2413","01-08-31","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LARIAM","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANTIMALARIAL","ANTIPALUDIQUE","",""
"2414","01-08-28","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC (ALKYLATING) AGENT","ANTINÉOPLASIQUE","",""
"2415","01-08-27","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2416","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC","ANTILEUCÉMIQUE","",""
"2417","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"2418","01-08-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"2419","01-08-09","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"2420","01-08-09","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"2421","01-08-09","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2422","01-07-30","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF OPIOID DEPENDENCE","TRAITEMENT DE LA DÉPENDANCE AUX OPIACÉS","",""
"2423","01-07-30","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF THE INDICATION TREATMENT OF OPIOID DEPENDENCE","RETRAIT DE L'INDICATION TRAITEMENT DE LA DÉPENDENCE AUX OPIACÉS","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2424","01-07-20","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","PREMEDICANT/SEDATIVE/ANESTHETIC AGENT","PRÉMÉDICATION, SÉDATIF, ANESTHÉSIQUE","",""
"2425","01-07-19","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHYROID AGENT","ANTITHYROÏDIEN","",""
"2426","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT FOR MEN","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"2427","01-07-18","WHITEHALL-ROBINS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VITAMIN AND MINERAL SUPPLEMENT","SUPPLÉMENT DE VITAMINES ET MINÉRAUX","",""
"2428","01-07-11","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2429","01-06-26","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"2430","01-06-22","METHAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","CHOLINERGIC/DIAGNOSTIC AID (BRONCHIAL ASTHMA)","CHOLINERGIQUE, AUXILIAIRE DIAGNOSTIQUE (ASTHME BRONCHIQUE)","",""
"2431","01-06-22","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID - ANTIBIOTIC","GLUCOCORTICOÏDE, ANTIBIOTIQUE","",""
"2432","01-06-20","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYTOTEC","SEARLE CANADA","CANADA","CANADA","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"2433","01-06-11","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYTOTEC","SEARLE CANADA","CANADA","CANADA","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"2434","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID ACNE COMPOUND","TRAITEMENT DE L'ACNÉ","",""
"2435","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"2436","01-05-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"2437","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID WITH LOCAL ANAESTHETIC","GLUCOCORTICOÏDE AVEC ANESTHÉSIQUE LOCAL","",""
"2438","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"2439","01-05-18","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2440","01-04-24","CHIRON S.P.A.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2441","01-04-20","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT - VACCINE FOR IMMUNIZATION AGAINST MEASLES, MUMPS AND RUBELLA","AGENT D'IMMUNISATION ACTIF - VACCIN POUR L'IMMUNISATION CONTRE LA ROUGEOLE, LES OREILLONS ET LA RUBÉOLE","",""
"2442","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUTICORTICOID","GLUCOCORTICOÏDE","",""
"2443","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"2444","01-04-09","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","VACCINE FOR IMMUNIZATION AGAINTS MUMPS","PROPHYLAXIE CONTRE LES OREILLONS","",""
"2445","01-03-20","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REGLAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIEMETIC, MODIFIER OF UPPER GASTROINTESTINAL TRACT MOTILITY","ANTIÉMÉTIQUE, MODIFICATEUR DE LA MOTILITÉ DE VOIES DIGESTIVES SUPÉRIEURES","",""
"2446","01-03-09","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE STRENGTH AND NEW INDICATION: FOR USE IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER FOR THE PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA","NOUVEAU DOSAGE INDICATION RÉVISÉE: CHEZ LES ADULTES ET LES ENFANTS DE 2 ANS ET PLUS POUR LA PRÉVENTION ET LE TRAITEMENT À LONG TERME DE L'ASTHME","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"2447","01-03-02","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"2448","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTOGEN","PROGESTATIF","",""
"2449","01-02-01","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2450","01-01-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","Premedicant, Sedative, Anesthetic Agent","Prémédication, Sédatif, Anesthésique","",""
"2451","01-01-24","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHYROID AGENT","ANTITHYROÏDIEN","",""
"2452","01-01-24","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","ROCHE CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2453","01-01-23","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","URINARY ANTIBACTERIAL","ANTI-INFECTIEUX DES VOIES URINAIRES","",""
"2454","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"2455","01-01-17","WESTWOOD-SQUIBB, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AGENT FOR THE TREATMENT OF SOLAR LENTIGINES AND RELATED HYPERPIGMENTATED LESIONS","AGENT POUR LE TRAITEMENT DES LENTIGINES SOLAIRES ET LÉSIONS CONNEXES DE PIGMENTATION EXCESSIVE","",""
"2456","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2457","01-01-09","LABORATOIRE RIVA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","RX TO OTC","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","HAIR REGROWTH TREATMENT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"2458","01-01-08","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2459","01-01-05","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","ROCHE CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2460","01-12-28","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GONADOTROPIN RELEASING HORMONE (GNRH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE (GNRH)","",""
"2461","01-12-04","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2462","01-11-22","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANTAGONIST","ANTAGONISTE DES OPIOÏDES","",""
"2463","01-11-22","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANTAGONIST","ANTAGONISTE DES NARCOTIQUES","",""
"2464","01-11-22","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"2465","01-11-22","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"2466","01-10-26","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"2467","01-10-12","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2468","01-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"2469","01-08-27","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2470","01-08-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2471","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST; MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"2472","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"2473","01-07-19","METRO PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"2474","01-06-04","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"2475","01-05-08","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"2476","01-04-30","BIOENHANCE MEDICINES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2477","01-04-26","LINSON PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2478","01-04-20","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"2479","01-03-13","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2480","01-03-09","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","NITROLINGUAL SPRAY","RHÔNE-POULENC RORER INC.","CANADA","CANADA","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"2481","01-03-09","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAPROSYN E","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTI-INFLAMMATORY, ANALGESIC, ANTI-PYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"2482","01-02-23","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ENTERIC COATED TABLET","NOUVELLE FORME POSOLOGIQUE: COMPRIMÉ GASTRO-RÉSISTANT","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"2483","01-02-13","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL - ANTIHYPERTENSIVE AGENT","ANTIANGINEUX - ANTIHYPERTENSEUR","",""
"2484","01-02-06","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT - ANTITHROMBOTIC","ANTICOAGULANT - ANTITHROMBOTIQUE","",""
"2485","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2486","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN-PROGESTIN COMBINATION","ASSOCIATION OESTROPROGESTATIVE","",""
"2487","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"2488","01-01-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTATIONAL AGENT","AGENT PROGESTATIF","",""
"2489","01-01-11","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2490","01-10-12","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2491","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT3 RECEPTOR ANTAGONIST","ANTIÉMÉTIQUE","",""
"2492","01-05-24","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE POUR LE TRACTUS GASTRO-INTESTINAL INFÉRIEUR","",""
"2493","01-05-24","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DAYPRO","SEARLE CANADA","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2494","01-05-24","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOXIN","ORTHO-MCNEIL INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2495","01-05-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DAYPRO","SEARLE CANADA","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2496","01-04-20","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"2497","01-01-30","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2498","01-01-30","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR-EXPECTORANT","BRONCHODILATATEUR-EXPECTORANT","",""
"2499","01-01-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2500","01-03-02","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: DYSPEPSIA","NOUVELLE INDICATION: DYSPEPSIE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2501","01-12-17","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCEDURE","MODIFICATION DANS LA MÉTHODE DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2502","01-11-22","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLASMA VOLUME EXPANDER","EXPANSEUR DU VOLUME PLASMATIQUE","",""
"2503","01-11-21","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTISPASMODIC AGENT","ANTIPARKINSONIEN","",""
"2504","01-11-14","PRECISION PHARMA SERVICES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING METHOD","MODIFICATION DE LA MÉTHODE DE FABRICATION","PLASMA COMPONENT/DERIVATIVE","COMPOSANTS DU SANG/PRODUITS DÉRIVÉS DU SANG","",""
"2505","01-10-16","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL PEDICULICIDE AND OVICIDE","AGENT PÉDICULICIDE ET OVICIDE TOPIQUE","",""
"2506","01-10-16","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL SCABICIDE","SCABICIDE TOPIQUE","",""
"2507","01-10-12","CHIESI FARMACEUTICI, S.P.A","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","LUNG SURFACTANT (PORCINE)","SURFACTANT PULMONAIRE (PROCINE)","",""
"2508","01-10-02","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPRIVAN","ZENECA PHARMA INC.","CANADA","CANADA","1","","","INTRAVENOUS EMULSION - ANAESTHETIC - SEDATIVE","ÉMULSION I.V. - ANESTHÉSIQUE - SÉDATIF","",""
"2509","01-10-01","BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2510","01-08-31","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: THE TREATMENT OF GENERALIZED ANXIETY DISORDER (GAD)","NOUVELLE INDICATION : TRAITEMENT D'UN TROUBLE D'ANXIÉTÉ GÉNÉRALISÉ","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT SOCIAL PHOBI (SOCIAL ANXIETY DISORDER) THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIAL","",""
"2511","01-08-31","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLSIME OSSEUX","",""
"2512","01-08-27","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2513","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2514","01-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL SCABICIDE","SCABICIDE TOPIQUE","",""
"2515","01-08-22","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE STRENGTH","NOUVELLE CONCENTRATION","GLUCOCORTICOID/ANTI-INFLAMMATORY","GLUCOCORTICOÏDE, ANTI-INFLAMMATOIRE","",""
"2516","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL","ANTIMALARIQUE","",""
"2517","01-08-01","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN MILD TO MODERATE CONGESTIVE HEART FAILURE","NOUVELLE INDICATION: UTILISATION DANS LE CAS DE DÉFAILLANCE CARDIAQUE CONGESTIVE LÉGÈRE À MODÉRÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2518","01-07-30","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINOMIMETIC AGENT","AGENT CHOLINOMIMÉTIQUE","",""
"2519","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER) THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, TRAITEMENT DE LA PHOBIE SOCIALE","",""
"2520","01-06-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2521","01-06-07","BIOVAIL LABORATORIES INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRENTAL","HOECHST MARION ROUSSEL INC.","CANADA","CANADA","1","","","VASOACTIVE AGENT","AGENT VASO-ACTIF","",""
"2522","01-05-30","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"2523","01-05-07","BYK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2524","01-04-30","BIOENHANCE MEDICINES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2525","01-04-20","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"2526","01-04-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"2527","01-04-02","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL","ANTIPALUDÉEN","",""
"2528","01-03-09","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"2529","01-03-02","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF SYMPTOMATIC GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), SUCH AS, ACID REGURGITATION AND HEARTBURN","NOUVELLE INDICATION: TRAITEMENT DES SYMPTÔMES ASSOCIÉS AU REFLUX GASTRO-OESOPHAGIEN TELS QUE RÉGURGITATION ACIDE ET PYROSIS","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2530","01-02-27","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2531","01-02-08","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"2532","01-02-01","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2533","01-02-01","IPSEN BIOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIHEMOPHILIC FACTOR","FACTEUR ANTIHÉMOPHILIQUE","",""
"2534","01-02-01","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PEDICULICIDE - OVICIDE","AGENT PÉDICULICIDE - OVICIDE","",""
"2535","01-01-26","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2536","01-01-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2537","01-01-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"2538","01-01-18","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2539","01-01-18","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF ADVANCED OVARIAN CANCER FOLLOWING FAILURE OF STANDARD FIRST-LINE THERAPY","NOUVELLE INDICATION: TRAITEMENT DU CANCER OVARIEN AVANCÉ SUITE À L'ÉCHEC DU TRAITEMENT NORMAL DE PREMIÈRE LIGNE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2540","01-06-20","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"2541","01-01-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE, DIURÉTIQUE","",""
"2542","01-01-09","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"2543","01-10-19","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT AND PREVENTION OF GULCOCORTICOID-INDUCED OSTEOPOROSIS","NOUVELLE INDICATION: LE TRAITEMENT ET LA PRÉVENTION DE L'OSTÉOPOROSE PROVOQUÉE PAR L'USAGE DES GLUCOCORTICOÏDES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2544","01-10-09","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2545","01-08-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2546","01-07-25","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO PRODUCT MONOGRAPH","MODIFICATIONS DE LA MONOGRAPHIE DU PRODUIT","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2547","01-07-19","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DE RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2548","01-07-19","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MANAGEMENT OF PATIENTS AT INCREASED RISK OF CARDIOVASCULAR EVENTS","NOUVELLE INDICATION : GESTION DES PATIENTS À RISQUE ÉLEVÉ D'ACCIDENTS CARDIOVASCULAIRES","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2549","01-07-18","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIABETIC AGENT; INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE, AGENT INSULINOSENSIBILISATEUR","",""
"2550","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT, DOPAMINE AGONIST","ANTIPARKINSONIEN, AGONISTE DOPAMINERGIQUE","",""
"2551","01-06-18","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIPARKINSONIAN AGENT/DOPAMINE AGONIST","ANTIPARKINSONIEN, AGONISTE DOPAMINERGIQUE","",""
"2552","01-06-13","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT - ANTITHROMBOTIC AGENT","ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"2553","01-05-29","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION, MODIFIED MANUFACTURING PROCESS, AND REVISION TO DRUG PRODUCT SPECIFICATIONS AND METHODS","MODIFICATION APPORTÉE À LA FORMULATION, PROCESSUS DE FABRICATION MODIFIÉ ET RÉVISION DES SPÉCIFICATIONS ET MÉTHODES DU PRODUIT MÉDICAMENTEUX","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"2554","01-05-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"2555","01-04-04","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"2556","01-03-06","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM PEPTIC RELIEF","MODIFICATION DU NOM DU PRODUIT DE PEPTIC RELIEF","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2557","01-02-15","BAYER INC., HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"2558","01-02-13","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MANAGEMENT OF PATIENTS AT INCREASED RISK OF CARDIOVASCULAR EVENTS","NOUVELLE INDICATION: GESTION DES PATIENTS À RISQUE ACCRÛ D'INCIDENTS CARDIOVASCULAIRES","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEURS DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2559","01-01-31","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"2560","01-01-17","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2561","01-01-11","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2562","01-01-08","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2563","01-07-18","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST: MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 ANTI-MIGRAINEUX","",""
"2564","01-08-27","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"2565","01-08-28","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"2566","01-12-21","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: INHALATION AEROSOL","NOUVELLE FORME POSOLOGIQUE","BRONCHOLDILATOR AND CORTICOSTEROID FOR ORAL INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE EN INHALATION","",""
"2567","01-12-21","TOBA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"2568","01-11-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF INDICATION: FOR USE OF ADJUNCTIVE BORNCHODILATOR TREATMENT FOR  PATIENTS WHO HAVE INADEQUATE RELIEF OF SYMPTOMS WITH SHORT-ACTING BRONCHODILATORS; PRODUCT MONOGRAPH REVISIONS","RETRAIT DE L'INDICATION: COMME TRAITEMENT BORNCHODILATATEUR D'APPOINT CHEZ LE PATIENTS QUI N'OBTIENNENT PAS UN SOULAGEMENT ADÉQUAT DE LEURS SYMPTÔMES AVEC LES BRONCHODILATATEURS À COURTE DURÉE D'ACTION; RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (RÉCEPTEURS BETA2-ADRÉNERGIQUES)","",""
"2569","01-10-26","ALTIMED PHARMA INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES B2-ADRÉNERGIQUES)","",""
"2570","01-08-31","GENZYME CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTHS","NOUVELLE FORME POSOLOGIQUE ET CONCENTRATIONS","PHOSPHATE BINDER","AGENT D'AGGLUTINATION DU PHOSPHATE","",""
"2571","01-08-27","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"2572","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES)","",""
"2573","01-08-22","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ALDOSTERONE ANTAGONIST WITH A DIURETIC","ANTAGONISTE DE L'ALDOSTÉRONE, DIURÉTIQUE","",""
"2574","01-08-17","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ALDOSTERONE ANTAGONIST","ANTAGONISTE DE L'ALDOSTÉRONE","",""
"2575","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2576","01-07-27","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"2577","01-07-26","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SUFENTA","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC/ADJUNCT TO ANAESTHESIA","ANALGÉSIQUE OPIOÏDE, ADJUVANT ANESTHÉSIQUE","",""
"2578","01-07-20","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"2579","01-07-19","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2580","01-06-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR AND CORTICOSTEROID FOR INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE EN INHALATION","",""
"2581","01-06-22","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS; NEW ROUTE; NEW INDICATION - THERAPEUTIC USE OF NEW STRENGTHS AND ROUTE FOR TREATMENT OF IDIOPATHIC GROWTH HORMONE DEFICIENCY IN CHILDREN WITH GROWTH FAILURE","NOUVELLES CONCENTRATIONS; NOUVELLE VOIE D'ADMINISTRATION; NOUVELLE INDICATION - USAGE THÉRAPEUTIQUE DE NOUVELLES FORCES CONCENTRATIONS ET VOIE D'ADMINISTRATION POUR LE TRAITEMENT DE L'INSUFFISANCE IDIOPATHIQUE DE L'HORMONE DE CROISSANCE CHEZ LES ENFANTS QUI PRÉSENTENT DES TROUBLES DE CROISSANCE","GROWTH HORMONE RELEASING HORMONE - THERAPEUTIC AGENT","HORMONE LIBÉRATRICE D'HORMONE DE CROISSANCE, AGENT THÉRAPEUTIQUE","",""
"2582","01-06-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"2583","01-06-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO CANADA INC.","CANADA","CANADA","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2584","01-05-30","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT/ANTIOBESITY AGENT","ANOREXIANT, ANTIOBÉSITÉ","",""
"2585","01-05-30","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIBACTERIAL AGENT","ANTIBACTÉRIEN TOPIQUE","",""
"2586","01-05-11","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVEAU DOSAGE","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"2587","01-05-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME","CANADA","CANADA","1","","","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"2588","01-04-20","BIOENHANCE MEDICINES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"2589","01-04-04","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: GROWTH FAILURE IN CHILDREN DUE TO CHRONIC RENAL FAILURE","NOUVELLE INDICATION : LE TRAITEMENT DU RETARD DE CROISSANCE CHEZ LES ENFANTS ATTRIBUABLE À UNE INSUFFISANCE RÉNALE CHRONIQUE","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"2590","01-03-29","COLGATE-PALMOLIVE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM COLGATE SENSATION FRESH/COOL MINT TOOTHPASTE","MODIFICATION DU NOM DU PRODUIT DE COLGATE SENSATION FRESH/COOL MINT TOOTHPASTE","ANTICARIES TOOTHPASTE","DENTIFRICE ANTICARIES","",""
"2591","01-02-13","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM FORTOVASE","MODIFICATION DU NOM DU PRODUIT DE FORTOVASE","ANTIRETROVIRAL - HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH - ANTIRÉTROVIRAL","",""
"2592","01-01-30","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2593","01-01-25","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV-1 INFECTION","INDICATION RÉVISÉE: POUR ADMINISTRATION CONCOMITANTE À D'AUTRES AGENTS ANTIRÉTROVIRAUX POUR LE TRAITEMENT DE L'INFECTION AU VIH-1","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2594","01-01-24","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CATION-EXCHANGE RESIN","RÉSINE POUR ÉCHANGE CATONIQUE","",""
"2595","01-01-18","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"2596","01-01-11","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"2597","01-01-05","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","AGENT IMMUNODÉPRESSEUR","",""
"2598","01-01-30","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF INDICATION FOR GALLSTONE DISSOLUTION","RETRAIT DE L'INDICATION POUR LA DISSOLUTION DU CALCUL BILIAIRE","CHOLESTATIC LIVER DISEASES","MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"2599","01-12-10","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT MERCK PHARMA","CANADA","CANADA","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"2600","01-12-04","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"2601","01-12-20","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","HYPNOTIC","HYPNOTIQUE","",""
"2602","01-11-19","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO UPDATE THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","5-HT1 RECEPTOR AGONIST MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 ANTIMIGRAINEUX","",""
"2603","01-08-14","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2604","01-02-15","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE POULENC RORER","CANADA","CANADA","1","NEW DOSAGE STRENGTH","NOUVELLE CONCENTRATION","HYPNOTIC","HYPNOTIQUE","",""
"2605","01-11-19","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"2606","01-08-24","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORCURON","ORGANON CANADA INC.","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEURO-MUSCULAIRE NON DÉPOLARISANT","",""
"2607","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2608","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"2609","01-07-25","QLT INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXTENSION OF THE INDICATION: TO INCLUDE THE TREATMENT OF PATHOLOGIC MYOPIA IN PATIENTS WITH PREDOMINANTLY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION (CNV)","ÉLARGISSEMENT DE L'INDICATION : POUR INCLURE LE TRAITEMENT DE LA MYOPIE PATHOLOGIQUE CHEZ LES PATIENTS QUI PRÉSENTENT UNE NÉOVASCULARISATION CHOROÏDIENNE SUBFOVÉALE","PHOTOSENSITIZING AGENT FOR AGE-RELATED MACULAR DEGENERATION AND PATHOLOGIC MYOPIA","AGENT PHOTOSENSIBILISANT POUR LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGEET POUR LA MYOPIE PATHOLOGIQUE","",""
"2610","01-06-22","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"2611","01-06-22","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL/ANTIARRHYTHMIC/ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIARYTHMIQUE, ANTIHYPERTENSEUR","",""
"2612","01-05-18","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2613","01-04-17","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED FORMULATION","FORMULATION RÉVISÉE","ANTIANGINAL/ANTIHYPERTENSIVE/ANTIARRHYTHMIC AGENT","ANTIANGINEUX/ANTIHYPERTENSEUR/ANTIARHYTHMIQUE","",""
"2614","01-03-15","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","UPGRADES TO THE PRODUCTION PROCESS","MISE À JOUR AU PROCESSUS DE PRODUCTION","ACTIVE IMMUNIZING AGENT AGAINST VARICELLA","AGENT D'IMMUNISATION ACTIVE","",""
"2615","01-02-15","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR - ANTIGANGINEUX","",""
"2616","01-02-06","ANTHRA PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FORM VALSTAR","MODIFICATION DU NOM DU PRODUIT DE VALSTAR","CYTOTOXIC ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE CYTOTOXIQUE","",""
"2617","01-01-18","CANGENE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"2618","01-12-28","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"2619","01-11-16","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","SYNTEX INC. (HOFFMANN-LA ROCHE LTD.)","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","INHIBITEUR DE LA FONCTION PLAQUETTAIRE","",""
"2620","01-11-09","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY - PROSTAGLANDIN F2 ANALOGUE","TRAITEMENT DE LA PRESSION INTRAOCULAIRE ÉLEVÉE - PROSTAGLANDINE F2 ANALOGUE","",""
"2621","01-10-23","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE PRÉSENTATION ET CONCENTRATION","ANTICHOLINERGIC  - ANTISPASMODIC AGENT","ANTICHOINERGIQUE - ANTISPASMODIQUE","",""
"2622","01-10-17","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"2623","01-10-16","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"2624","01-09-06","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"2625","01-08-31","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2626","01-08-24","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEBCIN","ELI LILLY INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2627","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE BETA-LACTAMASES","",""
"2629","01-08-17","SHIRE BIOLOGICS, A DIVISION OF SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","TETANUS VACCINE","VACCIN CONTRE LE TÉTANOS","",""
"2630","01-08-15","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER/DIURETIC","INHIBITEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II, DIURÉTIQUE","",""
"2631","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"2632","01-08-15","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2633","01-08-07","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFIBRINOLYTIC ACID","AGENT ANTIFIBRINOLYTIQUE","",""
"2634","01-08-07","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2635","01-07-31","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","COMPATIBILITY OF AGGRASTAT WITH INTRAVENOUS MEDICATION WHICH MAY OR MAY NOT BE CO-ADMINISTERED","COMPATIBILITÉ D'AGGRASTAT AVEC UNE MÉDICATION INTRAVEINEUSE QUI PEUT OU NE PEUT ÊTRE ADMINISTRÉ CONJOINTEMENT","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"2636","01-06-25","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL IMMUNOMODULATOR","IMMUNOSUPPRESSEUR","",""
"2637","01-07-11","ORTHO DERMATOLOGICAL, DIVISION OF JOHNSON & JOHNSON INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","COMEDOLYTIC AGENT","AGENT COMÉDOLYTIQUE","",""
"2638","01-06-22","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2639","01-06-13","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2640","01-05-30","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTI-PSORIASIS AGENT","ANTIPSORIASIQUE","",""
"2641","01-05-24","DEBIO RECHERCHE PHARMACEUTIQUE SA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LUTEINIZING HORMONE RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LA LUTÉINOSTIMULINE (ANALOGUE DE LA LH-RH)","",""
"2642","01-03-29","DEBIO RECHERCHE PHARMACEUTIQUE SA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE MANAGEMENT AND RELIEF OF CHRONIC PAIN ASSOCIATED WITH ENDOMETRIOSIS","NOUVELLE INDICATION: POUR LA GESTION ET LE SOULAGEMENT DE LA DOULEUR CHRONIGUQ RELIÉE À L'ENDOMÉTRIOSE","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE  DE LA LUTÉINOSTIMULINE (ANALOGUEDE LA LH-RH)","",""
"2643","01-05-11","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"2644","01-05-07","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","ROCHE CANADA INC.","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"2645","01-04-09","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT/BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR/TRAITEMENT SYMPTOMATIQUE DEL'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"2646","01-04-06","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT AND FOLIC ACID DERIVATIVE","ANTINÉOPLASIQUE ET DÉRIVÉ D'ACIDE FOLIQUE","",""
"2647","01-04-04","CHIRON CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RESPIRATORY ANTIBIOTIC","ANTIBIOTIQUE RESPIRATOIRE","",""
"2648","01-03-29","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HYPNOTIC AGENT","HYPNOTIQUE","",""
"2649","01-03-19","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","ROCHE CANADA LIMITED","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"2650","01-03-09","THERAMED CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIVIRAL AGENT","ANTIVIRAL TOPIQUE","",""
"2651","01-02-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT/BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR - TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"2652","01-02-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","ROCHE CANADA INC.","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"2653","01-02-16","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBREX","ALCON INC.","CANADA","CANADA","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"2654","01-02-13","PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC - ANTISPASMODIC AGENT","ANTICHOLINERGIQUE - ANTISPASMODIQUE","",""
"2655","01-01-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE","",""
"2656","01-01-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE","",""
"2657","01-01-18","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","COTICOSTEROID","CORTICOSTÉROÏDE","",""
"2658","01-01-08","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATIONS","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2659","98-12-04","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2660","98-11-20","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"2661","98-11-20","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"2662","98-11-12","B. BRAUN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","3% AMINO ACID AND 3% GLYCERIN INJECTION WITH ELECTROLYTES","3% ACIDES AMINÉS ET 3% INJECTION DE GLYCÉRINE AVEC ÉLECTROLYTES","",""
"2663","98-11-09","B. BRAUN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"2664","98-11-06","CHIRON CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN BATCH SIZE AND CHANGES IN PRODUCT TESTING","MODIFICATION À LA GRANDEUR DE LÔT ET AUX MÉTHODES D'ANALYSE POUR LE PRODUIT","IMMUNOMODULATING AGENT","AGENT D'IMMUNOMODULATEUR","",""
"2665","98-11-01","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN","NOUVELLE INDICATION :  TRAITEMENT ET PRÉCAUTIONS DE L'ENDUIT DE GLUCOCORTICOÏDE OSTÉOPOROSE POUR HOMMES ET FEMMES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2666","98-11-01","B. BRAUN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"2667","98-10-28","CENTOCOR","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION: ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION AND STABILIZATION OF UNSTABLE ANGINA PATIENTS","NOUVELLE INDICATION : AGENT ADJOINT À L'INTERVENTION CORONAIRE PERCUTANÉE ET POUR LA STABILISATION DES PATIENTS AVEC L'ANGINE INSTABLE","ANTIPLATELET ANTIBODY","ANTICORPS ANTIPLAQUETTE","",""
"2668","98-10-28","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DES VOIES GASTRO-INTESTINALES INFÉRIEURES","",""
"2669","98-10-13","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN, NEW STRENGTH","NOUVEAU SCHÉMA POSOLOGIQUE, NOUVELLES CONCENTRATIONS","ANTIBIOTIC & BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE - INHIBITEUR DE BETA-LACTAMASES","",""
"2670","98-10-07","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ZENECA PHARMA","CANADA","CANADA","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"2671","98-08-13","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"2672","98-08-06","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"2673","98-08-06","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF RELAPSE OF CROHN'S DISEASE IN PATIENTS FOLLOWING BOWEL RESECTION","NOUVELLE INDICATION : POUR LA PRÉVENTION DES RECHUTES DE LA MALADIE DE CROHN CHEZ LES PERSONNES AYANT SUBI UNE RÉSECTION INTESTINALE","LOWER GASTROINTESTINAL TRACT ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE POUR LE TRACTUS GASTRO INTESTINAL INFÉRIEUR","",""
"2674","98-08-06","FTP PHARMACAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"2675","98-07-30","TAP PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC H+, K+-ATPASE","ANTIBIOTIQUE H+, K+-ATPASE","",""
"2676","98-07-30","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2677","98-07-30","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR/ANTIANGINEUX","",""
"2678","98-07-14","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2679","98-07-13","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2680","98-07-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL, ANTIPARKINSONIAN","ANTIVIRAL, ANTIPARKINSONIEN","",""
"2681","98-07-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE, ANTIANGINAL","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2682","98-06-22","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL AGENT","ANTIMALARIAL","",""
"2683","98-06-17","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2684","98-06-01","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2685","98-06-01","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"2686","98-05-27","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2687","98-05-11","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC-ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"2690","98-04-15","OSTERREICHISCHES INSTITUT","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"2691","98-04-06","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2692","98-03-25","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","CHANGE IN PRODUCT NAME AND IN MANUFACTURING","MODIFICATION DU NOM ET DE LA MÉTHODE DE FABRICATION","ANTICOAGULANT","ANTICOAGULANT","",""
"2693","98-03-24","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE TO DOSAGE REGIMEN","MODIFICATION DU SCHÉMA POSOLOGIQUE","ORAL ANTIDIABETIC AGENT","ANTIDIABÉTIQUE ORAL","",""
"2694","98-03-23","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"2695","98-03-04","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2696","98-03-04","FUJISAWA CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2697","98-03-04","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2698","98-02-11","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"2699","98-02-05","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"2700","98-02-05","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"2701","98-02-05","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2702","98-01-22","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2703","98-12-30","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","WOUND HEALING GROWTH FACTOR","AGENT CURATIF POUR LES BLESSURES","",""
"2704","98-12-14","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BECONASE AQ","GLAXO WELLCOME","CANADA","CANADA","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR L'USAGE NASAL","",""
"2705","98-12-04","DUPONT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"2706","98-11-16","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE-ANTISPASMODIQUE","",""
"2707","98-11-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TANTUM","3M PHARMACEUTICALS","CANADA","CANADA","1","","","ORAL RINSE AND GARGLE","RINSE BOUCHE ET GARGARISME","",""
"2708","98-11-03","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2710","98-10-23","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","MAÎTRISE DE LA PRESSION INTRA-OCULAIRE","",""
"2711","98-10-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BECONASE AQ","GLAXO-WELLCOME","CANADA","CANADA","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASALE","",""
"2712","98-10-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID AND ANTIBIOTIC","CORTICOSTÉROÏDE - ANTIBIOTIQUE TOPIQUE","",""
"2713","98-10-06","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID AND ANTIBIOTIC","CORTICOSTÉROÏDE - ANTIBIOTIQUE TOPIQUE","",""
"2714","98-09-25","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TANTUM","3M PHARMACEUTICALS","CANADA","CANADA","1","","","LOCALLY ACTING ANALGESIC AGENT","ANALGÉSIQUE À ACTION LOCALE","",""
"2715","98-08-21","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR - GROWTH HORMONE SUPPRESSANT IN ACROMEGALY - ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, MÉDICAMENT ADJUVANT DANS LA MALADIE DE PARKINSON","",""
"2716","98-08-13","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BECONASE AQ","GLAXO WELLCOME","CANADA","CANADA","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"2717","98-08-13","PENTAPHARM LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2718","98-07-30","ORPHAN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-HOMOCYSTEINE AGENT","AGENT ANTIHOMOCYSTIQUE","",""
"2719","98-07-30","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGLAUCOMA AGENT","AGENT POUR LE TRAITEMENT DU GLAUCOME","",""
"2720","98-07-30","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","AUXILIAIRE POUR CESSER DE FUMER","",""
"2721","98-07-27","FTP PHARMACAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT ANTISPASTIC AGENT","RELAXANT MUSCULAIRE ET AGENT ANTISPASTIQUE","",""
"2722","98-07-27","FTP PHARMACAL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYER SQUIBB LTD.","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2723","98-06-19","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR - GROWTH HORMONE SUPPRESSANT IN ACROMEGALY - ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, MÉDICAMENT ADJUVANT UTILISÉ DANS LA MALADIE DE PARKINSON","",""
"2724","98-06-08","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2725","98-04-30","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYERS SQUIBB CANADA LTD.","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2726","98-04-28","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"2727","98-03-05","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"2728","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTOGEN","PROGESTATIF","",""
"2729","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"2731","03-08-07","RATIOPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2732","03-07-21","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOPRESSOR","VASOPRESSEUR","",""
"2733","03-07-15","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"2734","98-02-11","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"2735","98-02-11","B.D.H. INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYERS CANADA INC.","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2736","98-02-11","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"2737","98-01-16","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA MÉTHODE DE FABRICATION","NEUROMUSCULAR PARALYTIC AGENT","AGENT NEUROMUSCULAIRE PARALYSANT","",""
"2738","98-12-14","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTROINTESTINAL PROKINETIC AGENT","AGENT FAVORISANT LA MOTILITÉ GASTRO-INTESTINALE","",""
"2739","98-12-04","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2740","98-11-27","PRO DOC LIMITÉE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","APR-CLONIDINE","APOTEX","CANADA","CANADA","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"2741","98-11-20","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN 11 AT1 RECEPTOR BLOCKER","BLOQUEUR DU RÉCEPTEUR AT1 DE L'ANGIOTENSINE II","",""
"2742","98-11-20","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2743","98-11-20","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - ORAL SUSPENSION","NOUVELLE PRÉSENTATION - SUSPENSION ORALE","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2744","98-11-06","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2745","98-11-01","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2746","98-10-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1","",""
"2747","98-10-15","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2748","98-10-07","SANOFI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGGRÉGATION PLAQUETTAIRE","",""
"2749","98-09-30","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT ADJUNCTIVE THERAPY","ANTICONVULSIVANT POUR THÉRAPIE ADJUNCTIF","",""
"2750","98-09-09","BALLARD MEDICAL PRODUCTS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"2751","98-09-09","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","GASTROINTESTINAL PROKINETIC AGENT","AGENT FAVORISANT LA MOTILITÉ GASTRO-INTESTINALE","",""
"2752","98-08-31","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2753","98-08-21","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR SYMPTOMATIC RELIEF OF TRIGERMINAL NEURALGIA - ANTIMANIC","ANTICONVULSIVANT - SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU - ANTIMANIAQUE","",""
"2754","98-08-21","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"2755","98-08-12","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: PEDIATRIC USAGE IN UTI, SKIN AND SKIN STRUCTURE INFECTIONS, LRTI (NOSOCOMIAL AND COMMUNITY ACQUIRED PNEUMONIA) AND FEBRILE NEUTROPENIA","NOUVELLES INDICATIONS : USAGE PÉDIATRIQUE DANS LES CAS D'INFECTION DES VOIES URINAIRES, DE LA PEAU ET DES STRUCTURES DERMIQUES, INFECTIONS NOSOCOMIALES ET ACQUISES DANS LA COMMUNAUTÉ, ET NEUTROPÉNIE FÉBRILE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2756","98-08-06","SABEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2757","98-07-30","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2758","03-07-11","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: 1MG, 5MG, 10MG, 25MG TABLETS","NOUVELLE FORME POSOLOGIQUE: 1MG, 5MG, 10MG, 25MG COMPRIMÉS","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2759","98-07-30","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2760","98-07-30","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2761","98-07-30","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"2762","98-07-27","FTP PHARMACAL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2763","98-07-22","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H1","",""
"2764","98-07-22","NU-PHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"2765","98-07-14","LABORATOIRES PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFACLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2766","98-07-14","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","COMPETITIVE HISTAMINE H2 - RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR H2 DE L'HISTAMINE","",""
"2767","98-07-14","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2768","98-07-13","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANCEF","SMITHKLINE BEECHAM","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2769","98-07-13","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2770","98-07-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOECHST-ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2771","98-06-19","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR SYMPTMATIC RELIEF OF TRIGEMINAL NEURALGIA/ANTIMANIC","ANTICONVULSIVANT - SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU / ANTIMANIAQUE","",""
"2772","98-06-18","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2773","98-06-18","TECHNILAB PHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2774","98-06-17","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2775","98-06-15","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH - LABELLING ONLY","RX À OTC","SEASONAL ALLERGIC RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"2776","98-06-10","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONGESTIVE HEART FAILURE AGENT","INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"2777","98-06-10","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2778","98-06-08","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2779","98-06-05","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR PEDIATRIC USE","NOUVELLE INDICATION POUR USAGE PÉDIATRIQUE","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2780","98-06-05","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","UPDATING PM FROM RX TO OTC","MONOGRAPHIE RÉVISÉE - RX À OTC","SEASONAL ALLERGIC RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"2781","98-05-27","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TOPICAL TREATMENT OF MILD TO MODERATE PSORIASIS IN CHILDREN AGED 2 YEARS AND OLDER","NOUVELLE INDICATION : TRAITEMENT TOPIQUE DU PSORIASIS BÉNIN À MODÉRÉ POUR LES ENFANTS ÂGÉS DE DEUX ANS ET PLUS","TOPICAL NON-STEROIDAL ANTIPSORIATIC AGENT","AGENT ANTIPSORIASIQUE TOPIQUE NON STÉROÏDIEN","",""
"2782","98-05-22","ALPHA THERAPEUTIC CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","HÉMOSTATIQUE","",""
"2783","98-05-11","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR TRIPLE THERAPY (CLARITHROMYCIN/OMEPRAZOLE/AMOXICILLIN) REGIMEN FOR THE ERADICATION OF H.PYLORI","NOUVELLE INDICATION : TRI-THÉRAPIE (CLARITHROMYCINE/OMÉPRAZOLE/AMOXICILLINE) RÉGIME D'ÉRADICATION DE H.PYLORI","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2784","98-05-06","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEGRETOL CR","CIBA GEIGY CANADA","CANADA","CANADA","1","","","ANTICONVULSANT, FOR SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA, ANTIMANIC","ANTICONVULSIVANT - SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU, ANTIMANIQUE","",""
"2785","98-05-04","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VAGINAL ANTIBACTERIAL PREPARATION","ANTIBACTÉRIEN","",""
"2786","98-04-23","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZINACEF","GLAXO WELLCOME","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2787","98-04-06","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY AND COMPANY","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2788","98-03-30","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2789","98-03-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"2790","98-03-23","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"2791","98-03-23","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA IN AIDS PATIENTS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE LA PNEUMNIE À PNEUMOCYSTIS CARINII CHEZ LES PERSONNES ATTEINTES DU SIDA","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2792","98-03-13","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE DOSAGE FORM","AUTRE MÉTHODE DE PRÉSENTATION","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"2793","98-03-06","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM AND STRENGTHS","NOUVELLE PRÉSENTATION ET CONCENTRATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2794","98-03-06","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2795","98-03-06","MEDICAN PHARMA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SEASONAL RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"2796","98-03-06","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"2797","98-03-05","ZILA PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGINGIVITIS ORAL RINSE","RINCE-BOUCHE ANTIGINGIVITE","",""
"2798","98-02-18","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2799","01-11-30","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GARASONE","SCHERING CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID - ANTIBIOTIC","CORTICOSTÉROÏDE TOPIQUE - ANTIBIOTIQUE","",""
"2800","98-02-18","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW NONPRESCRIPTION STRENGTH","NOUVELLE CONCENTRATION","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"2801","98-02-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2802","98-02-11","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2803","98-02-11","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2804","98-02-11","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RIVOTRIL","HOFFMANN LA ROCHE","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"2805","98-02-11","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLEXERIL","MERCK FROSST","CANADA","CANADA","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"2806","98-02-11","B.D.H. INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BERLEX CANADA","CANADA","CANADA","1","","","ANTIANDROGEN","ANTIANDROGÈNE","",""
"2807","98-02-11","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BERLEX CANADA","CANADA","CANADA","1","","","ANTIANDROGEN","ANTIANDROGEN","",""
"2808","98-02-05","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2809","98-01-28","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2810","98-01-28","FUJISAWA CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANCEF","SMITHKLINE BEECHAM","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2811","98-01-22","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH AND LABELLING","MONOGRAPHIE ET ÉTIQUETTE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2812","98-01-19","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"2813","98-12-16","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE REVISÉE","ANTICOAGULANT/ANTITHROMBOTIC AGENT","AGENT ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"2814","98-11-20","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL-DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"2815","98-11-16","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPICORT","HOECHST CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"2816","98-10-23","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATED PRODUCT MONOGRAPH","MONOGRAPHIE REVISÉE","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR - TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"2817","98-09-24","ATHENA NEUROSCIENCES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BENZODIAZEPINE ANTICONVULSANT","ANTICONVULSIVANT - BENZODIAZÉPINES","",""
"2818","98-08-24","BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF CHRONIC STABLE ANGINA PECTORIS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ANGINE STABLE CHRONIQUE","ANTI-HYPERTENSIVE, ANTI-ANGINAL","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2819","98-08-17","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"2820","98-08-07","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN UNSTABLE CORONARY ARTERY DISEASE","NOUVELLE INDICATION : USAGE DANS LA MALADIE CORONARIENNE NON-STABLE","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"2821","98-08-06","RATIOPHARM CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2822","98-08-04","ALCON CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN OPHTHA","CIBA VISION","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTI-INFLAMMATORY/ANALGESIC AGENT","ANTI-INFLAMMATOIRE/ANALGÉSIQUE","",""
"2823","98-07-27","FTP PHARMACAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFIE LA MOTILITÉ GASTRO-INTESTINALE","",""
"2824","98-07-22","PHARMACIA & UPJOHN INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2825","98-07-20","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2826","98-07-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE MOTILITÉ GASTROINTESTINAL","",""
"2827","98-07-13","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE MOTILITÉ GASTROINTESTINAL","",""
"2828","98-06-10","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"2829","98-05-06","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIHEMORRHAGIC","ANTIHÉMORRAGIQUE","",""
"2830","98-05-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLAUCOMA THERAPY AGENT","TRAITEMENT DU GLAUCOME","",""
"2831","98-04-30","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIOPROTECTIVE AGENT","AGENT CARDIOPROTECTEUR","",""
"2832","98-04-09","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN","CIBA-GEIGY CANADA LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY AND ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUES","",""
"2833","03-07-11","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: 1MG, 5MG, 10MG, 25MG TABLETS","NOUVELLE FORME POSOLOGIQUE: 1MG, 5MG, 10MG, 25MG COMPRIMÉS","TREATMENT OF OPIOID DEPENDENCE","TRAITEMENT DE LA DÉPENDANCE AUX OPIACÉS","",""
"2834","98-02-13","MEDICAN PHARMA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIHYPERTENSIVE AGENT, ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2835","98-02-11","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"2836","98-02-05","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE/ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"2837","98-11-12","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: 1. PREVENTION OF BONE LOSS IN POSTMENOPAUSAL WOMEN WHO ARE AT RISK OF DEVELOPING OSTEOPOROSIS; 2. PREVENTION OF CORTICOSTEROID INDUCED OSTEOPOROSIS","NOUVELLES INDICATIONS: 1. EMPÊCHEMENT DE LA PERTE DES OS POUR LES FEMMES POSTMÉNOPAUSÉES QUI SONT À RISQUES DE DÉVELOPPER L'OSTÉOPOROSE. 2. EMPÊCHEMENT DU CORTICOSTÉROÏDE INDUIT D'OSTÉOPOROSE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2838","03-07-11","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"2839","03-07-09","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC","ANTILEUCÉMIQUE","",""
"2840","03-07-02","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2841","03-07-02","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GONADOTROPINS FOR INFERTILITY","GONADOTROPHINES POUR L'INFERTILITÉ","",""
"2842","99-05-18","FRESENIUS KABI AB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE AND ELECTROLYTE SUPPLEMENTS FOR INTRAVENOUS INFUSION","SUPPLÉMENT NUTRITIF ET ÉLECTROLYTIQUES POUR PERFUSION I.V.","",""
"2843","03-06-26","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 1MG/ML SOLUTION","NOUVELLE CONCENTRATION: 1 MG/ML SOLUTION","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"2844","03-06-26","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CNS STIMULANT","STIMULANT DU SNC","",""
"2846","99-11-18","NOVARTIS CONSUMER HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"2847","03-06-20","MAYNE PHARMA (CANADA) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM METHOTREXATE SODIUM INJECTION USP","MODIFICATION DU NOM DE METHOTREXATE SODIUM INJECTION USP","ANTIMETABOLITE, ANTIRHEUMATIC","ANTIMÉTABOLITE, ANTIRHUMASTISMAL","",""
"2848","03-06-18","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: LIQUID FOR INTRAVENOUS ADMINISTRATION FOR COMMUNITY ACQUIRED PNEUMONIA IN HOSPITALIZED PATIENTS","NOUVELLE FORME POSOLOGIQUE: LIQUIDE POUR ADMINISTRATION INTRAVEINEUSE POUR LA PNEUMONIE COMMUNAUTAIRE CHEZ LES PERSONNES HOSPITALISÉES","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2849","03-06-09","CHIRON S.P.A.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2850","03-05-12","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","","","PROGESTAGEN","PROGESTATIF","",""
"2851","99-04-15","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TORADOL","HOFFMANN LAROCHE LIMITED","CANADA","CANADA","1","","","NSAID ANALGESIC AGENT","ANALGÉSIQUE AINS","",""
"2852","03-04-02","WHITEHALL-ROBINS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MUSCLE RELAXANT / ANALGESIC","RELAXANT MUSCULAIRE / ANALGÉSIQUE","",""
"2853","98-09-15","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2854","98-09-04","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR D'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"2855","98-07-30","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS AND NEW DOSAGE FORM: PREFILLED SYRINGES","NOUVELLES INIDCATIONS ET NOUVELLE CONCENTRATION : SERINGUES PRÉREMPLIES","ANTICOAGULANT/ANTITHROMBOTIC AGENT","AGENT ANTICOAGULANT ET ANTITHROMBOTIQUE","",""
"2856","98-07-27","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW ALBUMIN (HUMAN)-FREE FORMULATION FOR PRE-FILLED SYRINGES","NOUVELLE FORMULE SANS ALBUMINE (HUMAINE) POUR SERINGUES PRÉREMPLIES","ERYTHROPOIESIS REGULATING HOMRONE","HORMONE RÉGULATRICE D'ÉRYTHROPOÏÈSE","",""
"2857","03-04-07","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"2858","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2859","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTAGEN - PROGESTATIONAL STEROID","STÉROÏDE PROGESTAGÈNE - PROGESTATIONAL","",""
"2860","98-11-12","PROCTER & GAMBLE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: 1. PREVENTION  OF BONE LOSS IN POSTMENOPAUSAL WOMEN WHO ARE AT RISK OF DEVELOPING OSTEOPOROSIS; 2. PREVENTION OF CORTICOSTEROID INDUCED OSTEOPOROSIS","NOUVELLES INDICATIONS: 1) EMPÊCHEMENT DE LA PERTE DES OS POUR LES FEMMES POSTMÉNOPAUSÉES QUI SONT À RISQUES DE DÉVELOPPER L'OSTÉOPOROSE. 2) EMPÊCHEMENT DU CORTICOSTÉROÏDE INDUIT D'OSTÉOPOROSE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES OSSEUX","",""
"2861","03-03-31","BAXTER CORPORATION-CLINTEC NUTRITION DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN PRODUCT NAME FROM CRITILIP 20%","MODIFICATION DU NOM DE CRITILIP 20%","FAT EMULSION FOR INTRAVENOUS NUTRITION","ÉMULSION LIPIDIQUE POUR ALIMENTATION PAR VOIE INTRAVEINEUSE","",""
"2862","03-03-11","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR VIII","FACTEUR VIII DE COAGULATION ANTIHÉMORRAGIQUE","",""
"2863","98-05-04","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2864","04-05-10","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL, CORTICOSTEROID (OTIC)","ANTIBACTÉRIEN, CORTICOSTÉROÏDE (OTIQUE)","",""
"2865","98-05-04","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2866","03-03-04","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2867","98-05-04","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2868","04-05-14","DENTSPLY CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CITANEST DENTAL (WITH EPINEPHRINE 1:200,000)","MODIFICATION DU NOM DU PRODUIT DE CITANEST DENTAL (WITH EPINEPHRINE 1:200,000)","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"2869","98-04-28","FOURNIER PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"2870","04-05-14","DENTSPLY CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CITANEST DENTAL","MODIFICATION DU NOM DU RPRODUIT DE CITANEST DENTAL","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"2871","98-04-15","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ETHRANE","ZENECA","CANADA","CANADA","1","","","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"2872","04-05-13","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","PROGESTIN","PROGESTATIF","",""
"2873","04-05-13","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM IMITREX","MODIFICATION DU NOM DU PRODUIT DE IMITREX","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"2874","04-05-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","PROGESTIN","PROGESTATIF","",""
"2875","98-04-15","IPSEN LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","CYTOSTATIC","AGENT CYTOSTATIQUE","",""
"2876","98-03-25","PHARMACHEMIE B.V.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2877","98-02-16","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIALLERGIC AGENT","ANTIALLERGIQUE","",""
"2878","04-05-13","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","PROGESTIN","PROGESTATIF","",""
"2879","98-02-16","PROCTER & GAMBLE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","ESTROGÈNE","",""
"2880","04-05-11","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRACEPTIVE VAGINAL RING","ANNEAU VAGINAL CONTRACEPTIF","",""
"2881","04-05-13","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"2882","98-12-30","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EUFLEX","SCHERING CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"2883","04-05-13","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRA[HIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","PROGESTIN","PROGESTATIF","",""
"2884","98-12-21","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"2885","04-05-13","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE DE LA SANTÉ DES FEMMES (WHI)","PROGESTIN","PROGESTATIF","",""
"2886","04-05-11","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"2887","98-12-16","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - PAEDIATRIC ONCOLOGY PATIENTS","NOUVELLE INDICATION: POUR LE TRAITEMENT DES PATIENTS PÉDIATRIQUES CANCÉREUX","HAEMATOPOIETIC AGENT","AGENT HÉMATOPÉTIQUE","",""
"2888","04-05-14","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","CHANGEMENT AU PROCESSUS DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"2889","98-11-20","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EUFLEX","SCHERING CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"2890","98-11-09","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"2891","03-03-03","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMATOPOIETIC GROWTH FACTOR","FACTEUR DE CROISSANCE HÉMATOPOÏÉTIQUE","",""
"2892","98-11-12","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION","INDICATION RÉVISÉE","TYPE 11 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE","",""
"2893","98-10-27","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2894","98-10-09","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"2895","98-10-07","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"2896","98-10-07","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EUFLEX","SCHERING CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"2897","98-09-24","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN DOSING INSTRUCTIONS","NOUVEAU SCHÉMA POSOLOGIQUE","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"2898","03-03-03","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MANUFACTURING CHANGE","CHANGEMENT DE FABRICATION","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR VIII","FACTEUR VIII DE COAGULATION ANTIHÉMORRAGIQUE","",""
"2899","98-09-09","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH CHANGES","MONOGRAPHIE RÉVISÉE","SELECTIVE CALCIUM-ENTRY BLOCKER","INHIBITEUR CALCIQUE SÉLECTIF","",""
"2900","03-02-28","SHIRE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","VASOPRESSOR","VASOPRESSEUR","",""
"2901","98-08-13","LEO LABORATORIES CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIBIOTIC/CORTICOSTEROID","ANTIBIOTIQUE, CORTICOSTÉROÏDES TOPIQUES","",""
"2902","03-02-25","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2903","04-05-14","BAYER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","CHANGEMENT AU PROCESSUS DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"2904","03-02-13","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"2905","98-08-06","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORITCOSTEROID","CORTICOSTÉROÏDE","",""
"2906","98-07-30","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTISPASMODIC","ANTISPASMODIQUE AGISSANT SUR LES VOIES URINAIRES","",""
"2907","98-07-27","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SUPPRESSION GENITAL HERPES IN IMMUNIOCOMPETENT ADULTS","NOUVELLE INDICATION : SUPPRESSION DE L'HERPÈS GÉNITAL CHEZ L'ADULTE IMMUNOCOMPÉTENT","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"2908","98-07-22","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2909","98-07-15","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: ACUTE MYELOID LEUKEMIA","NOUVELLE INDICATION","HAEMATOPOIETIC AGENT","HÉMATOPOÏÉTIQUE","",""
"2910","98-06-26","MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TYPE II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR 5-ALPHA RÉDUCATASE DU TYPE II","",""
"2911","98-06-17","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"2912","98-06-17","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"2913","98-05-15","CARTER-HORNER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"2914","98-05-11","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"2915","98-05-11","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"2916","98-05-04","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2917","98-05-04","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FROBEN SR","ORGANON CANADA LTD.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2918","98-04-23","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"2919","98-03-30","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","SELECTIVE CALCIUM-ENTRY BLOCKER","INHIBITEUR CALCIQUE SÉLECTIF","",""
"2920","98-03-25","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING, NEW SITE FOR FORMULATION AND FILLING","MODIFICATION DE LA MÉTHODE DE FABRICATION, NOUVEL EMPLACEMENT DE FABRICATION","ANTIHEMOPHILIC FACTOR","FACTEUR ANTIHÉMOPHILIQUE","",""
"2921","98-03-23","J.C.P. LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H1","",""
"2922","98-03-06","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH COROANRY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS.","NOUVELLE INDICATION POUR RALENTIR LA PROGRESSION DE L'ATHÉROSCLÉROSE CORONARIENNE CHEZ LES PATIENTS PRÉSENTANT UNE INSUFFISANCE CORONAIRE DANS UNE STRATÉGIE DE TRAITEMENT POUR RÉDUIRE LES NIVEAUX CIBLES DE CHOLESTÉROL TOTAL ET LIPOPROTÉINE DE FAIBLE DENSITÉ (LDL)","LIPID METABOLISM REGULATOR","RÉULATEUR DU MÉTABOLISME DES LIPIDES","",""
"2923","98-03-01","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"2924","98-02-23","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUE H2","",""
"2925","98-02-18","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2926","98-02-11","J.C.P. LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 À L'HISTAMINE","",""
"2927","98-02-11","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","CORTICOSTEROID FOR INAHALATION","CORTICOSTÉROÏDE PAR VOIE NASALE","",""
"2928","98-02-05","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2929","98-01-28","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"2930","98-01-23","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SUBLIMAZE INJ.","JANSSEN PHARMA INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC ADJUNCT FTO ANESTHESIA","ANALGÉSIQUE NARCOTIQUE - ADJUVANT ANESTHÉSIQUE","",""
"2931","98-01-22","STANLEY PHARMACEUTICALS LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUE H2","",""
"2932","98-01-19","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW TABLET SIZE","NOUVELLE TAILLE DE COMPRIMÉ","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUE H2","",""
"2933","98-01-16","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"2934","98-12-04","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - FOR DIAGNOSTIC USE","AGENT RADIOPHARMACEUTIQUE - POUR USAGE DIAGNOSTIQUE","",""
"2935","98-08-26","OMNI LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"2936","98-06-17","NYCOMED IMAGING A.S.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR APPROVAL FOR THE USE OF OMNISCAN FOR BODY IMAGING","APPROBATION DE L'UTILISATION D'OMNISCAN DESTINÉ À L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"2937","98-06-05","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON","SERVIER CANADA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORALE","",""
"2938","98-04-09","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"2939","98-04-09","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"2940","98-04-08","PHARMACYCLICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","PRÉPARATION DE CONTRASTE DESTINÉ À L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE","",""
"2941","98-04-08","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE PALLATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN WHOSE TUMOR CONTAINS ESTROGEN AND/OR PROGESTERONE RECEPTORS","NOUVELLE INDICATION : POUR LE TRAITEMENT PALLIATIF DU CANCER AVANCÉ DU SEIN CHEZ LA FEMME EN PÉRIODE DE PRÉ OU PÉRI-MÉNOPAUSE DONT LES TUMEURS CONTIENNENT DE L'ESTROGÈNE ET OU DES RÉCEPTEURS DE PROGESTÉRONE","LUTEINIZING HORMONE - RELEASING HORMONE ANALOG","ANALOGUE DE LA LH-RH","",""
"2942","98-02-19","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN THE TREATMENT OF PANCREATIC CANCER","NOUVELLE INDICATION : TRAITEMENT DU CANCER PANCRÉATIQUE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"2943","04-05-18","WYETH CONSUMER HEALTHCARE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ADVIL ALLERGY SINUS CAPLETS TO ADVIL COLD AND SINUS PLUS","MODIFICATION DU NOM DU PRODUIT DE ADVIL ALLERGY SINUS CAPLETS À ADVIL COLD AND SINUS PLUS","ANALGESIC, NASAL DECONGESTANT, ANTIHISTAMINE","ANALGÉSIQUE, DÉCONGESTIONNANT NASAL, ANTIHISTAMINIQUE","",""
"2944","04-05-21","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARYTHMIQUE","",""
"2945","04-05-21","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"2946","04-05-20","PFIZER CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","0","","","ANTI-INFLAMMATORY ANALGESIC AGENT, FAMILIAL ADENOMATOUS POLYPOSIS","ANTI-INFLAMMATOIRE ANALGÉSIQUE, POLYPOSE ADÉNOMATEUSE FAMILIALE","",""
"2947","04-05-18","AMPHASTAR PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADRENOCORTICAL INSUFFICIENCY DIAGNOSTIC AGENT","HORMONE ADRÉNOCORTICOTROPE","",""
"2948","04-05-17","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION: ADDITION OF A PHOSPHATE BUFFER","NOUVELLE COMPOSITION : AJOUT D'UN TAMPON DE PHOSPHATE","CONTRAST ENHANCING IMAGING AGENT","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE","",""
"2949","04-05-20","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC-SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"2950","04-05-18","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2951","04-05-18","GMD DISTRIBUTING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"2952","04-05-21","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAQUENIL","SANOFI-WINTHROP CANADA INC.","CANADA","CANADA","1","","","ANTI-RHEUMATIC, ANTIMALARIAL","ANTIRHUMATISMAL, ANTIPALUDÉEN","",""
"2953","04-05-17","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"2954","04-05-21","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARYTHMIQUE","",""
"2955","04-05-18","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"2956","04-05-21","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"2957","04-05-20","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"2958","98-02-18","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ULTRASOUND CONTRAST AGENT","AGENT DE CONTRASTE POUR ULTRASON","",""
"2959","98-02-11","MEDICAN PHARMA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOPID","PARKE-DAVIS (CANADA) INC.","CANADA","CANADA","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPOLIPIDÉMIANT","",""
"2960","98-02-05","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT ORAL","",""
"2961","98-12-04","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"2962","98-11-27","PRO DOC LIMITÉE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYDRALAZINE","APOTEX","CANADA","CANADA","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"2963","98-11-12","MERCK, SHARP AND DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - SCALE UP AND NEW BUILDING","NOUVEL IMMEUBLE ET AUGMENTATION PROPORTIONNELLEMENT AU PROCESSUS DE FABRICATION","VACCINE","VACCIN","",""
"2966","98-08-06","RATIOPHARM CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"2967","98-07-14","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE PRODUCT MONOGRAPH AND LABELLING","MONOGRAPHIE ET ÉTIQUETTE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"2968","98-04-08","CONNAUGHT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"2969","98-03-06","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH AND NEW DOSAGE REGIMEN FOR INFANTS, CHILDREN AND ADOLESCENTS 1 THROUGH 18 YEARS OF AGE","NOUVELLE CONCENTRATION ET NOUVEAU SCHÉMA POSOLOGIQUE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"2970","98-12-04","TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","AGENT ANTI-INFLAMMATOIRE ANALGÉSIQUE NON STÉROÏDIEN","",""
"2971","98-12-04","TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","AGENT ANTI-INFLAMMATOIRE ANALGÉSIQUE NON STÉROÏDIEN","",""
"2972","98-12-04","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW MULTIDOSE SOLUTION","FOURNIS POUR UNE NOUVELLE SOLUTION MULTIDOSE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2973","98-11-20","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","AGENT ANTIANGINEUX","",""
"2974","98-11-16","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2975","98-11-13","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE FILTRATION STEP","ÉTAPE DE FILTRAGE ALTERNATIF","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"2976","98-11-12","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2977","98-09-21","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING - ALTERNATE FILTRATION SEPARATION STEP","MODIFICATION DE LA MÉTHODE DE FABRICATION","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPHIE PASSIVE","",""
"2978","01-08-22","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUVANT THERAPY IN GASTROINTESTINAL DISORDERS","TRAITEMENT D'APPOINT DE TROUBLES GASTO-INTESTINAUX","",""
"2979","98-09-08","MCNEIL CONSUMER PRODUCTS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANALGESIC, ANTIPYRETIC AGENT - FOR CHILDREN","ANALGÉSIQUE, ANTIPYRÉTIQUE - POUR LES ENFANTS","",""
"2980","98-08-20","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","TWO NEW STRENGTHS FOR READY-TO-USE SOLUTION - ALBUMIN (HUMAN) FREE","NOUVELLE CONCENTRATIONS D'UNE NOUVELLE FORMULATION SANS ALBUMINE (HUMAINE)","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2981","98-07-30","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC-ANTIPYRETIC","ANALGÉSIQUE/ANTIPYRÉTIQUE","",""
"2982","98-07-27","FTP PHARMACAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","AGENT ANALGÉSIQUE ET ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"2983","98-07-27","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN TEST SPECIFICATION","SPÉCIFICATION RÉVISÉE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2984","98-07-13","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ISOVUE","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"2985","98-06-08","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"2986","98-06-08","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - CHRONIC HEPATITIS C INFECTION PLUS ADDITIONAL REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION - INFECTION CHRONIQUE DE L'HÉPATITE C, MONOGRAPHIE RÉVISÉE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"2987","98-06-01","SANOFI WINTHROP CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE II","",""
"2988","98-04-30","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-INFLAMMTORY/ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"2989","98-04-15","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FORANE","ZENECA PHARMA","CANADA","CANADA","1","","","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"2990","98-04-06","BIOGEN CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOMODULATOR","IMMUNOMODULATION","",""
"2991","98-03-30","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2992","98-03-24","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN TEST SPECIFICATIONS","SPÉCIFICATIONS RÉVISÉES","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2993","98-03-05","UNITED STATES SURGICAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","DIAGNOSTIC AGENT FOR THE DELINEATION OF LYMPHATIC VESSELS","AGENT DIAGNOSTIQUE POUR LA DÉLINÉATION DES VAISSEAUX LYMPHATIQUES","",""
"2994","98-02-11","ABBOTT LABORATORIES, LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ISOVUE","BRACCO DIAGNOSTICS","CANADA","CANADA","1","","","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON IONIQUE","",""
"2995","98-02-05","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC/ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"2996","98-02-05","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"2997","98-01-28","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATROVENT INHALATION SOLUTION","BEORHINGER INGELHEIM","CANADA","CANADA","1","NEW DOSAGE FORM: STERULES","NOUVELLE PRÉSENTATION : STÉRULES","BRONCHODILATOR","BRONCHODILATATEUR","",""
"2998","98-01-27","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"2999","98-01-21","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVELLE EMPLACEMENT DE FABRICATION","ANTI-DIABETIC AGENT","ANTIDIABÉTIQUE","",""
"3000","98-11-20","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"3001","98-11-16","MALLINCKRODT MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","NEW INDICATION FOR USE IN PEDIATRIC PATIENTS","NOUVELLE INDICATION - POUR L'UTILISATION AVEC LES PATIENTS PÉDIATRIQUES","DIAGNOSTIC RADIOPHARMACEUTICAL AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"3002","98-11-12","TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN ANALGÉSIQUE","",""
"3003","98-06-22","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","AINS ANALGÉSIQUE","",""
"3004","98-06-22","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","AINS ANALGÉSIQUE","",""
"3005","98-06-22","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","AINS ANALGÉSIQUE","",""
"3006","98-05-04","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3007","98-01-29","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3008","98-01-29","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3009","98-01-29","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3010","98-01-28","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3011","98-01-16","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT, TUMOR IMAGING AGENT","AGENT RADIODIAGNOSTIQUE, AGENT POUR L'IMAGERIE DES CANCERS","",""
"3012","98-12-30","ICN CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"3013","98-12-14","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING OF CURRENT APPROVED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3014","98-12-03","GLAXO WELLCOME BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"3015","98-12-02","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"3016","98-11-27","GLAXO WELLCOME BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"3017","98-11-23","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"3018","98-09-21","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"3019","98-06-25","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOXAPAC","LEDERLE-CYANAMID CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"3020","98-06-22","CYTOGEN CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL","RADIOPHARMACEUTICAL","",""
"3021","98-06-17","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"3022","98-06-15","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3023","98-06-15","LABORATOIRES TRIANON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"3024","98-06-10","MCNEIL CONSUMER PRODUCTS COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ORAL ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE ORAL","",""
"3025","98-06-03","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK SHARP & DOHME","CANADA","CANADA","1","NEW INDICATION, REVISED PRODUCT MONOGRAPH","NOUVELLE INDICATION, MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3026","98-05-22","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","GLAUCOMA THERAPY AGENT","TRAITEMENT DU GLAUCOME","",""
"3027","98-05-04","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR USE OF THE NON-STERILE CREAM FOR LEG ULCERS AND CHANGE IN FREQUENCY OF TREATMENT","POUR USAGE SUR ULCÈRES (JAMBES) ET CHANGEMENT DE POSOLOGIE","TOPICAL ANESTHETIC FOR DERMAL ANLAGESIA","ANESTHÉSIQUE TOPIQUE POUR ANALGÉSIE DERMIQUE","",""
"3028","98-04-07","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR TRIPLE THERAPY AND DUAL THERAPY REGIMENS FOR THE ERADICATION OF H.PYLORI","NOUVELLE INDICATION : TRI-THÉAPIE ET BI-THÉRAPIE RÉGIME D'ÉRADICATION DE H. PYLORI","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"3029","98-04-06","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"3030","98-03-24","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOXAPAC","LEDERLE-CYANAMID CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"3031","98-03-06","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOXAPAC","LEDERLE-CYANAMID CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"3032","98-02-23","PALADIN LABS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMANIAC AGENT","ANTIMANIQUE","",""
"3033","98-02-05","MCNEIL CONSUMER PRODUCTS COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL ANTIDIARRHEAL/ANTIFLATULENT AGENT","ANTIDIARRHÉIQUE ORAL, AGENT ANTIFLATULENT","",""
"3034","98-02-05","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"3035","98-12-14","ICN CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"3036","98-12-14","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE-CYANAMID CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3037","98-12-04","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"3038","98-11-27","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","PROGESTOGEN/ANTINEOPLASTIC/ANTIANOREXIC/ANTICACHECTIC","PROGESTATIF/ANTINÉOPLASIQUE/ANTIANOREXIQUE/ANTICACHECTIQUE","",""
"3039","98-11-16","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC","ANTIHYPERGLYCÉMIANT","",""
"3040","98-10-15","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC","ANTILEUCÉMIQUE","",""
"3041","98-10-07","ROBERTS PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TO ATTENUATE SYMPTOMS OF CHRONIC ORTHOSTATIC HYPOTENSION DUE TO AUTONOMIC FAILURE IN PATIENTS WITH DIABETES MELLITUS DISEASE AND PARKINSON'S DISEASE","NOUVELLE INDICATION : POUR ATTÉNUER LES SYMPTÔMES D'HYPOTENSION CHRONIQUE ORTHOSTATIQUE CAUSÉS PAR UNE FÉFAILLANCE AUTOMATIQUE CHEZ LES PERSONNES SOUFFRANT DE DIABÈTE MELLITUS ET DE MALADIE DE PARKINSON","VASOPRESSOR","VASOPRESSEUR","",""
"3042","98-10-06","LABORATOIRES CONFAB INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"3043","98-09-28","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CANADA","CANADA","CANADA","1","","","ANTIBACTERIAL ANTIBIOTIC","AGENT ANTIBACTÉRIEN, ANTIBIOTIQUE","",""
"3044","98-09-02","RJR PHARMA INTERNATIONAL SERVICES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3045","98-08-06","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"3046","98-07-27","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"3047","98-07-22","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","PROGESTOGEN/ANTINEOPLASTIC/ANTIANOREXIC/ANTICACHECTIC","AGENT PROGESTATIF/ANTINÉOPLASIQUE/ANTI-ANORÉXIQUE/ANTICACHETIQUE","",""
"3048","98-07-22","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIDIABETIC AGENT, ALPHA-GLUCOSIDASE INHIBITOR","ANTIDIABÉTIQUE ORAL/INHIBITEUR DES ALPHA GLUCOSIDASES","",""
"3049","98-07-22","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"3050","98-06-17","MERCK SHARP & DOHME CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE LEUKOTRIÈNE","",""
"3051","98-05-25","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: CARDIAC TRANSPLATATION","NOUVELLE INDICATION : GREFFE CARDIAQUE","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"3052","98-05-04","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-HYPERTENSIVE","ANTI-HYPERTENSEUR","",""
"3053","98-05-04","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3054","98-04-30","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PONSTAN","PARKE-DAVIS","CANADA","CANADA","1","","","ANALGESIC","ANALGÉSIQUE","",""
"3056","98-03-30","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID WITH LOCAL ANESTHETIC","GLUCOCORTICOÏDE AVEC ANESTHÉSIQUE LOCAL","",""
"3057","98-03-23","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"3058","98-03-30","PURDUE FREDERICK INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF CHRONIC NAUSEA IN CANCER PATIENTS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE LA NAUSÉE CHRONIQUE CHEZ LES PERSONNES CANCÉREUSES","ANTINAUSEANT","ANTINAUSÉEUX","",""
"3059","98-03-23","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALUPENT","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ß2-ADRENERGIC STIMULANT BRONCHODILATOR","BRONCHODILATATEUR-STIMULANT DES RÉCEPTEURS ß2-ADRÉNERGIQUES","",""
"3060","98-03-05","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"3061","98-03-05","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCENTRATION ET PRÉSENTATION","IMMUNOSUPPRESSANT AGENT","IMMUNOSUPPRESSEUR","",""
"3062","98-02-23","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"3063","98-02-23","HEXAL PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3064","98-02-19","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3065","98-02-11","3M PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"3066","98-02-11","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HAIR GROWTH STIMULANT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"3067","98-01-19","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3068","98-08-19","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK, SHARP & DOHME CANADA","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3069","98-12-09","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"3070","98-12-22","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK, SHARP & DOHME CANADA","CANADA","CANADA","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"3071","98-11-10","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"3072","98-09-04","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL","ANTIRÉTROVIRAL","",""
"3073","98-09-28","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"3074","98-09-30","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIANGINAL, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"3075","98-08-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"3076","04-05-28","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM: ORAL SOLUTION","NOUVELLE PRÉSENTATION : SOLUTION ORALE","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3077","04-05-28","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM : INJECTION","NOUVELLE PRÉSENTATION : INJECTION","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3078","04-05-27","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"3079","04-05-25","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3080","98-08-21","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANTAGONIST","ANTAGONISTE DES OPIACÉS","",""
"3081","04-05-28","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO DOSAGE REGIMEN TO INCLUDE RAPAMUNE MAINTENANCE REGIMEN","RÉVISION À LA POSOLOGIE DU PRODUIT RAPAMUNE POUR INCLURE UN SCHÉMA POSOLOGIQUE DE MAINTIEN","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"3082","98-08-13","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A CHANGE IN INITIAL DOSING, PM UPDATE","NOUVEAU SCHÉMA POSOLOGIQUE, MONOGRAPHIE RÉVISÉE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3083","98-08-11","AGOURON PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"3084","98-07-16","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3085","98-07-16","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3086","98-07-14","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"3087","98-07-14","SANOFI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"3088","98-06-19","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"3089","98-06-01","NOVARTIS CONSUMER HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC","RX À OTC","SMOKING CESSATION AID","AUXILIAIRE POUR CESSER DE FUMER","",""
"3090","98-06-01","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RX À OTC","SMOKING CESSATION AID","AUXILIAIRE POUR CESSER DE FUMER","",""
"3091","98-06-01","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RX À OTC","STOP SMOKING AID","AUXILIAIRE POUR CESSER DE FUMER","",""
"3092","98-06-01","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RX À OTC","SMOKING CESSATION AID","AUXILIAIRE POUR CESSER DE FUMER","",""
"3093","98-05-20","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC","RX À OTC","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3094","98-05-06","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION OF PRODUCT MONOGRAPH - CLINICAL TRIALS SECTION","MONOGRAPHIE RÉVISÉE","CALCIUM CHANNEL BLOCKING AGENT; ADJUNCT IN MANAGEMENT OF SUBARACHNOID HEMMORRAGE","INHIBITEUR DES CANAUX CALCIQUES - TRAITEMENT D'APPOINT DE L'HÉMORRAGIE SOUS-ARACHONOÏDIENNE","",""
"3095","98-04-28","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MIGRAINE THERAPY","TRAITEMENT DES MIGRAINES","",""
"3096","98-04-23","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO PROVIDE CLINICIANS WITH GREATER DOSING FLEXIBILITY WITHIN THE DOSAGE RANGE","POUR OFFRIR UNE PLUS GRANDE FLEXIBILITÉ DANS LA POSOLOGIE","ANTIANGINAL/ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"3097","98-03-25","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH FOR USE AS INITIAL DOSING IN SELECT PATIENT POPULATIONS","NOUVELLE CONCENTRATION COMME DOSE INITIALE AUPRÈS DE CERTAINES CATÉGORIES DE PATIENTS","ANTI-HYPERTENSIVE","ANTIHYPERTENSEUR","",""
"3098","98-03-05","ORTHO PHARMACEUTICAL CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ACNÉ SIMPLE CHEZ LES FEMELLES SANS CONTRE-INDICATION CONNUE À UNE THÉRAPIE CONTRACEPTIVE ORALE","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3099","98-02-19","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3100","98-02-19","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3101","98-02-06","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - FOR JUVENILE RHEUMATOID ARTHRITIS","NOUVELLE INDICATION","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC PROPRIÉTÉS ANALGÉSIQUES ET ANTIPYRÉTIQUES","",""
"3102","98-12-23","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - MICROSPHERES FOR SUSPENSION","NOUVELLE PRÉSENTATION -  MICROSPHÈRE POUR SUSPENSION","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"3103","98-12-23","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","5-HT3 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS 5-HT3","",""
"3104","98-11-20","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"3105","98-11-09","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"3106","98-07-20","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"3107","98-07-14","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3108","98-03-23","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR THE TREATMENT AND MAINTENANCE OF SYMPTOMATIC GERD (HEARTBURN AND REGURGITATION)","NOUVELLE INDICATION : POUR LE TRAITEMENT ET LE MAINTIEN DU REFLUX GASTOOESOPHAGIEN PATHOLOGIQUE SYMPTOMATIQUE (GERD) - BRÛLEMENT D'ESTOMAC ET RÉGURGITATION","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"3109","98-03-23","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR NEW INDICATION: USE OF OMEPRAZOLE IN PATIENTS WITH OR AT RISK OF NSAID-ASSOCIATED GASTRIC AND DUODENAL ULCERS","NOUVELLE INDICATION : USAGE DE L'OMÉPRAZOLE CHEZ LES PATIENTS ATTEINTS OU À RISQUE D'ULCÈRE GASTRIQUE ET DUODÉNAL RELIÉ À L'USAGE D'ANTI-INFLAMMATOIRES NON STÉROÏDIENS","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+. K+-ATPASE","",""
"3110","98-03-23","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR NEW INDICATION: LOSEC IN COMBINATION WITH TWO ANTIMICROBRIALS TO TREAT PEPTIC ULCER DISEASE BY ERADICATING H. PYLORI","NOUVELLE INDICATION : LOSEC EN ASSOCIATION AVEC 2 ANTIMICROBIENS POUR LE TRAITEMENT DE L'ULCÈRE GASTRODUODÉNAL PAR ÉRADICATION DE L'H. PYLORI","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"3111","98-03-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO OBTAIN APPROVAL FOR THE USE OF SANDOSTATIN IN EMERGENCY MANAGEMENT TO STOP BLEEDING AND TO PROTECT FROM REBLEEDING OWING TO GASTRO-OESOPHAGEL VARICES IN PATIENTS WITH CIRRHOSIS, NEW ROUTE OF ADMINISTRATION - CONTINUOUS IV INFUSION","ARRÊTER ET PRÉVENTIR LE SAIGNEMENT - VARICES GASTRO-OESOPHAGIEN, NOUVELLE VOIE D'ADMINISTRATION","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"3112","98-02-03","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3113","96-06-06","ALBERT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"3114","98-11-27","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR AN ALTERNATE MANUFACTURING METHOD FOR THE DRUG SUBSTANCE","FOURNIS POUR UNE MÉTHODE DE FABRICATION ALTERNATIVE POUR LES SUBSTANCES MÉDICINALES","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3115","98-11-27","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"3116","98-10-06","ALZA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLYCOSAMINOGLYCAN SUBSTITUTE","SUCCÉDANÉ GLYCOSAMINOGLYCANNE","",""
"3117","98-10-06","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","DECONGESTANT","DÉCONGESTIONNANT","",""
"3118","98-08-21","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLASMA VOLUME EXPANDER","EXPANSEUR DU VOLUME PLASMATIQUE","",""
"3119","98-07-30","DRAXIS HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DOPAMINE AGONIST","AGONISTE DE LA DOPAMINE","",""
"3120","98-07-30","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC PROPRIÉTÉS ANALGÉSIQUE","",""
"3121","98-07-30","RATIOPHARM CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"3122","98-07-20","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER","NOUVELLE INDICATION : POUR LE TRAITEMENT DU CANCER PULMONAIRE AUTRE QU'À PETITES CELLULES","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"3123","98-07-13","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"3124","98-06-08","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE/ANTIANGINAL AGENT","ANTIHYPERTENSEUR/ANTIANGINEUX","",""
"3125","98-05-22","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FELDENE","PFIZER CANADA INC.","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC AND ANTIPYRETIC AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"3126","98-04-17","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PSYCHOTROPIC AGENT","PSYCHOTROPE","",""
"3127","98-04-08","CONNAUGHT LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: USE TO RECONSTITUTE ACT-HIB","NOUVELLE INDICATION : UTILISATION COMMME RECONSTITUANT POUR L'ACT-HIB","IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"3128","98-04-08","CONNAUGHT LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: USE TO RECONSTITUTE ACT-HIB","NOUVELLE INDICATION : UTILISATION COMME RECONSTITUANT POUR L'ACT-HIB","IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"3129","98-03-13","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH AND LABELLING","MONOGRAPHIE ET ÉTIQUETTE RÉVISÉES","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"3130","98-02-13","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"3131","98-02-05","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOACTIVE AGENT","AGENT VASOACTIF","",""
"3132","98-02-05","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC PROPRIÉTÉS ANALGÉSIQUES","",""
"3133","98-01-29","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT/DOPAMINE AGONIST","AGENT ANTIPARKINSONIEN, DOPAMINE AGONIST","",""
"3134","98-01-19","ALZA CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLYCOSAMINOGLYCAN SUBSTITUTE","SUCCÉDANÉ DE GLYCOSAMINOGLYCANNE","",""
"3135","98-01-21","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"3136","98-03-01","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE/DIURÉTIQUE","",""
"3137","98-12-10","CHIRON CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: TREATMENT OF PATIENTS WITH METATSTIC MALIGNANT MELANOMA","NOUVELLE INDICATION : TRAITEMENT DES PATIENTS AVEC MÉLANOME MÉTASTATIQUE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"3138","98-11-27","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR THE TREATMENT OF PEDIATRIC PATIENTS, PRODUCT MONOGRAPH REVISIONS","NOUVELLE INDICATION : FOURNIS POUR LE TRAITEMENT DES PATIENTS EN PÉDIATRIE, MONOGRAPHIE RÉVISÉE","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"3139","98-11-20","CENTOCOR","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"3140","98-11-16","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANGICOAGULANT/ANTITHROMBOTIC AGENT","AGENT ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"3141","98-11-06","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SELECTIVE ESTROGEN RECEPTOR MODULATOR","MODULATEUR SÉLECTIF DU RÉCEPTEUR D'OESTROGÈNES","",""
"3142","98-10-27","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","REVISED LABELLING AND PRODUCT MONOGRAPH (RX TO OTC)","ÉTIQUETTE ET MONOGRAPHIE RÉVISÉES - RX À OTC","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3143","98-10-15","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2","",""
"3144","98-09-25","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"3145","98-08-06","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR: PRODUCT MONOGRAPH REVISION AND MODIFICATION TO DOSING SCHEDULE FOR RENAL IMPAIRED PATIENTS","RÉVISION DE LA MONOGRAPHIE DU PRODUIT ET CHANGEMENT À LA POSOLOGIE CHEZ LES PATIENTS ATTENITS DE TROUBLES DE LA FONCTION RÉNALE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"3146","98-04-28","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","NEW NON-PRESCRIPTION STRENGTH","NOUVELLE CONCENTRATION","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"3147","98-04-17","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"3148","98-02-23","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: PREVENTION OF MEAL INDUCED HEARTBURN","NOUVELLE INDICATION","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"3149","98-02-18","GLAXO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: 12 HOUR DURATION OF ACID CONTROL","NOUVELLE INDICATION","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"3150","98-08-07","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES","",""
"3151","98-02-16","CANGENE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA MÉTHODE DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"3152","98-02-11","PASTEUR MERIEUX SERUM & VACCIN","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"3153","98-11-01","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW DOSAGE FORM, CHANGE IN PRODUCT NAME FROM URSOFALK TO URSO","NOUVELLE PRÉSENTATION, MODIFICATION DU NOM DU PRODUIT DE URSOFALK À URSO","LITHOLYTIC AGENT, CHOLESTATIC LIVER DISEASES","AGENT LITHOLYTIQUE, MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"3154","98-12-23","PRO DOC LIMITÉE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE SYRUP","ABBOTT LABORATORIES","CANADA","CANADA","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE PRÉSENTATION ET CONCENTRATION","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3155","98-12-04","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL INDICATION FOR THE SUPPRESSION OF RECURRENT GENITAL HERPES AND FOR A NEW TABLET STRENGTH","INDICATION ADDITIONNELLE POUR LA SUPPRESSION DE L'HERPÈS GÉNITAL RÉCURRENT ET POUR UNE NOUVELLE CONCENTRATION DU COMPRIMÉ","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"3156","98-12-02","MERCK SHARP & DOHME","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"3157","98-10-06","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE SYRUP","ABBOTT LABORATORIES","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3158","98-07-30","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3159","98-07-30","RATIOPHARM CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN","KNOLL PHARMACEUTICALS","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"3160","98-07-27","FTP PHARMACAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3161","98-07-15","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3162","98-07-14","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE SYRUP","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3163","98-07-03","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","SEARLE CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","AGENT ANTIHYPERTENSEUR","",""
"3164","98-06-25","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE SYRUP","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3165","98-06-15","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE SYRUP","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3166","98-06-01","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE","ABBOTT LABS LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3167","98-05-27","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE SYRUP","ABBOTT LABORATORIES INC. CANADA","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3168","98-05-11","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN","SEARLE CANADA","CANADA","CANADA","1","","","ANTIANGINAL/ANTIARRHYTHMIC/ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIARHYTHMIQUE, ANTIHYPERTENSEUR","",""
"3169","98-04-23","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE","ABBOTT LABORATORIES LIMITED CANADA","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3170","98-04-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","SEARLE CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"3171","98-02-16","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - EXTENDED RELEASE CAPSULES","NOUVELLE PRÉSENTATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3172","98-08-31","PASTEUR MERIEUX SERUM & VACCIN","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"3173","98-08-13","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"3174","98-02-05","DU PONT MERCK PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR: PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","ANTICOAGULANT","ANTICOAGULANT","",""
"3175","98-12-04","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - FOR DIAGNOSTIC USE","AGENT RADIOPHARMACEUTIQUE - POUR USAGE DIAGNOSTIQUE","",""
"3176","98-03-05","MDS NORDION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF HEPATIC NEOPLASIA","TRAITEMENT POUR LES NÉOPLASIES HÉPATIQUES","",""
"3177","98-09-09","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM; NEW DOSAGE REGIMEN","NOUVELLE PRÉSENTATION ET NOUVEAU SCHÉMA POSOLOGIQUE","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"3178","98-08-24","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST MIGRAINE THERAPY","AGONISTE DE RÉCEPTEUR 5-HT1 POUR LE TRAITEMENT DES MIGRAINES","",""
"3179","98-08-12","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHÔNE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"3180","98-07-14","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT TRACE MULTIPLE","",""
"3181","98-07-13","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT TRACE MULTIPLE","",""
"3182","98-05-11","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"3183","98-12-02","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY - ANALGESIC","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"3184","98-11-20","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE","NOUVELLE INDICATION : TRAITEMENT DE LA MALADIE OBSTRUCTIVE PULMONAIRE CHRONIQUE","BRONCHODILATOR (ß2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT ß2-ADRÉNERGIQUES)","",""
"3185","98-11-20","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HIV PROTEASE INHIBITOR/ANTIRETROVIRAL AGENT","INHIBITEUR DE LA PROTÉASE DU VIH - AGENT ANTIRÉTROVIRAL","",""
"3186","98-11-20","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE - RADIOPHARMACEUTIQUE","",""
"3187","98-11-20","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE - RADIOPHARMACEUTIQUE","",""
"3188","98-11-09","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - DIAGNOSTIC AGENT","AGENT RADIOPHARMACEUTIQUE - POUR USAGE DIAGNOSTIQUE","",""
"3189","98-11-06","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"3190","98-11-01","COLGATE-PALMOLIVE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTICARIES TOOTHPASTE","DENTIFRICE ANTICARIES","",""
"3191","98-10-06","FTP PHARMACAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR AGENT","BRONCHODILATATEUR","",""
"3192","98-09-30","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH CHANGES","MONOGRAPHIE RÉVISÉE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"3193","98-09-28","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"3194","98-09-21","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"3195","98-08-21","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"3196","98-08-13","FTP PHARMACAL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"3197","98-07-27","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ELDEPRYL","DRAXIS HEALTH INC.","CANADA","CANADA","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"3198","98-07-15","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ELDEPRYL","DRAXIS HEALTH INC.","CANADA","CANADA","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKISONIEN","",""
"3199","98-07-14","TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL-MYERS SQUIBB INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"3200","98-07-13","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TRACE ELEMENT","ÉLÉMENT TRACE","",""
"3201","98-07-06","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"3202","98-06-19","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRODUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRO-DUODENAL","",""
"3203","98-06-15","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH - LABELLING ONLY","RX À OTC","SEASONAL ALLERGIC RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"3204","98-06-03","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ELDEPRYL","DRAXIS HEALTH INC.","CANADA","CANADA","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"3205","98-05-20","HYAL PHARMACEUTICAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF ACTINIC KERATOSES","TRAITEMENT DES KÉRATOSES ACTINIQUES","",""
"3206","98-05-13","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING, NEW STRENGTH","MODIFICATION DE LA MÉTHODE DE FABRICATION, NOUVELLE CONCENTRATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE","",""
"3207","98-05-13","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITIES & NEW STRENGTH","NOUVEL EMPLACEMENT DE FABRICATION & NOUVELLE CONCENTRATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE","",""
"3208","98-05-11","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC SALMON CALCITONIN","CALCITONINE SAUMON SYNTHÉTIQUE","",""
"3209","98-04-06","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR NEW INDICATION: TREATMENT OF OBSESSIVE COMPULSIVE DISORDER","NOUVELLE INDICATION : TRAITEMENT DU TROUBLE OBSESSIVO-COMPULSIF","ANTIDEPRESSANT/ANTIPANIC/ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONEL","",""
"3210","98-03-05","MEDICAN PHARMA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BRONCHODILATOR","BRONCHODILATATEUR","",""
"3211","98-02-11","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"3212","98-02-05","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRYTHMIC","ANTIARYTHMIQUE","",""
"3213","98-02-05","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"3214","98-01-19","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"3215","98-12-30","ORTHO DERMATOLOGICAL, DIVISION OF JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AGENT FOR THE TREATMENT OF PHOTODAMAGED SKIN","AGENT POUR LE TRAITEMENT DE LA PEAU ENDOMMAGÉE PAR LE SOLEIL","",""
"3216","98-12-23","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"3217","98-12-16","ALCON CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","POLYTRIM OPHTHALMIC SOLUTION","ALLERGAN INC.","CANADA","CANADA","1","","","Antibacterial Agent","Agent Antibactérien","",""
"3218","98-12-14","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"3219","98-12-10","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHIBITOR OF PLATELET FUNCTION","INHIBITEUR DE LA FONCTION PLAQUETTAIRE","",""
"3220","98-12-04","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"3221","98-12-02","BAUSCH & LOMB CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBREX","ALCON CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3222","98-11-20","PHARMACIA & UPJOHN COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC, ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"3223","98-11-12","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"3224","98-10-15","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3225","98-09-30","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"3226","98-09-30","SANKYO U.S.A. CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH 300MG, NEW INDICATION: CONCOMITANT USE WITH SULFONYLURE AS IN PATIENTS WITH TYPE 2 DIABETES","NOUVELLE CONCENTRATION DE 300 MG ET NOUVELLE INDICATION : THÉRAPIE CONCOMITANTE AU SULFONYLURE COMME CHEZ LES PATIENTS ATTEINTS DE DIABÈTE DE TYPE 2","ANTIDIABETIC AGENT, INSULIN REDUCING AGENT","ANTIDIABÉTIQUE, AGENT POUR LA MODÉRATION DE LA RÉSISTANCE À L'INSULINE","",""
"3227","98-09-28","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","MAÎTRISE DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"3228","98-09-15","CIBA VISION CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBREX","ALCON","CANADA","CANADA","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"3229","98-09-15","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3230","98-09-15","LEO LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PULMONARY EMBOLISM","NOUVELLE INDICATION","ANTICOAGULANT/ANTITHROMBOTIC AGENT","AGENT ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"3231","98-09-15","CROWNPHARMA CANADA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBREX","ALCON","CANADA","CANADA","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"3232","98-09-09","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL - FOR DIAGNOSTIC USE","AGENT RADIODIAGNOSTIQUE","",""
"3233","98-08-21","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC/ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"3234","98-08-13","MALLINCKRODT MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL AGENT","AGENT DIAGNOSTIQUE RADIOPHARMCEUTIQUE","",""
"3235","98-07-13","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","A NEW METERED DOSE FORMULATION","NOUVELLE PRÉPARATION","CORITCOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"3236","98-06-10","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC - ANTIHYPERTENSIVE","DIURÉTIQUE - ANTIHYPERTENSEUR","",""
"3237","98-06-05","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"3238","98-06-01","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SELECTIVE ADRENERGIC RECEPTOR ANTAGONIST","ANTAGONISTE SÉLECTIF DES RÉCEPTEURS ADRÉNERGIQUES","",""
"3239","98-05-06","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"3240","98-04-06","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: CONCOMITATNT USE WITH SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES - NEW STRENGTH","NOUVELLE INDICATION ET NOUVELLE CONCENTRATION","ANTIDIABETIC AGENT, INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE, AGENT POUR LA MODÉRATION DE LA RÉSISTANCE À L'INSULINE","",""
"3241","98-03-25","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL INDICATION: LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION","INDICATION COMPLÉMENTAIRE : DYSFONCTIONNEMENT DU VENTRICULE GAUCHE SUITE À UN INFARCTUS DU MYOCARDE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"3242","98-03-23","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"3243","98-03-23","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"3244","98-03-13","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"3245","98-03-05","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3246","98-02-16","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW TABLET STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3247","98-03-05","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BHP)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"3248","98-02-16","SWISS SERUM & VACCINE INSTITUTE BERNE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION À LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"3249","98-02-11","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"3250","98-02-05","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-HYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE","",""
"3251","98-02-05","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"3252","98-03-30","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHIBITOR OF PLATELET FUNCTION","INHIBITEUR DE LA FONCTION DES PLAQUETTES","",""
"3253","97-04-17","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN COMBINATION WITH SULFONYLUREA","NOUVELLE INDICATION : EN ASSOCIATION AVEC LA SULFONYLURÉE","ORAL ANTIDIABETIC AGENT, ALPHA-GLUCOSIDASE INHIBITOR","ANTIDIABÉTIQUE/INHIBITEUR ALPHA GLUCOSIDASE","",""
"3254","97-05-12","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, TRAITEMENT DE L'ANGINE","",""
"3255","97-01-08","RJR PHARMA INTERNATIONAL SERVICES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTI-ANGINEUX","",""
"3256","97-01-08","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADMINISTRATIVE NAME CHANGE","CHANGEMENT DE NOM ADMINISTRATIF","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"3257","97-12-03","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC/ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"3258","97-08-21","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"3259","97-06-04","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3260","97-05-29","SANOFI WINTHROP","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3261","97-05-26","ABBOTT LABORATORIES, LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME","CANADA","CANADA","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3262","97-06-24","GALDERMA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW DOSAGE FORM: CREAM","NOUVELLE PRÉSENTATION : CRÈME","ACNE THERAPY","TRAITEMENT ANTIACNÉIQUE","",""
"3263","97-01-31","MALLINCKRODT MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","INTRAVENOUS ULTRASOUND CONTRAST MEDIUM","AGENT DE CONTRASTE POUR ULTRASON INTRAVEINEUX","",""
"3264","97-09-10","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND NEW 5MG TABLET STRENGTH","NOUVELLE INDICATION POUR LA PRÉVENTION DE L'OSTÉOPOROSE CHEZ LES FEMMES POST-MÉNOPAUSÉES ET NOUVEAU COMPRIMÉ D'UNE CONCENTRATION DE 5 MG","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"3265","97-09-10","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR PREVENTION OF FRACTURES IN POSTMENOPAUSAL WOMEN TREATED FOR OSTEOPOROSIS","NOUVELLE INDICATION POUR LA PRÉVENTION DE FRACTURES CHEZ LES FEMMES POST-MÉNOPAUSÉES TRAITÉES POUR OSTÉOPOROSE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"3267","97-04-24","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC/ADJUNCT TO ANAESTHESIA","ANALGÉSIQUE NARCOTIQUE/APPOINT À L'ANESTHÉSIE","",""
"3268","97-11-17","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE OXIDASE","",""
"3269","04-05-10","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER + ANTIVIRAL AGENT","AGENT D'IMMUNOMODULATION + AGENT ANTIVIRAL","",""
"3270","97-03-06","PREMPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANXIOLYTIC - ANTIPANIC","ANXIOLYTIQUE - ANTIPANIQUE","",""
"3271","97-10-06","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"3272","97-11-10","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING","MODIFICATION DE LA FABRICATION","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"3273","97-05-12","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC - ANTIHYPERTENSIVE","DIURÉTIQUE - ANTIHYPERTENSEUR","",""
"3275","97-02-27","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PERITONEAL DIALYSIS SOLUTION","SOLUTION DIALYSE PÉRITONÉAL","",""
"3277","97-11-26","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"3278","97-08-01","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE - ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"3279","97-09-11","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3280","97-02-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3281","97-06-24","THE LIPOSOME COMPANY INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3282","97-11-19","ROBERTS PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET REDUCING AGENT","AGENT POUR LA RÉDUCTION DES PLAQUETTES","",""
"3283","97-04-15","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR D'AROMATASE NON-STÉROÏDIEN","",""
"3284","97-09-16","OSTERREICHISCHES INSTITUT","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MANUFACTURING CHANGES; CHANGE IN MANUFACTURING SITE","MODIFICATION DE LA FABRICATION, NOUVEL EMPLACEMENT DE FABRICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"3285","97-09-16","IMMUNOMEDICS,INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"3286","97-06-11","RJR PHARMA INTERNATIONAL SERVICES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTI-ANGINEUX","",""
"3287","97-09-09","RHODIAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"3288","97-07-16","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA ADRÉNERGIQUES","",""
"3289","97-02-19","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"3290","97-10-10","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACRIUM","BURROUGHS WELLCOME INC.","CANADA","CANADA","1","","","INTRAVENOUS SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE INTRAVEINEUSE","",""
"3291","97-04-10","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INTRAVENOUS SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE INTRAVEINEUSE","",""
"3292","97-11-14","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACRIUM","BURROUGHS WELLCOME INC.","CANADA","CANADA","1","","","SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE","",""
"3293","97-12-08","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRHEUMATIC AGENT","ANTIRHUMATISMAL","",""
"3294","97-11-10","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"3295","97-11-14","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"3296","97-06-24","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"3297","97-06-18","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"3298","97-10-06","B.D.H. INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"3299","97-04-17","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF DISSEMINATED MAC DISEASE AND A NEW STRENGTH","NOUVELLE INDICATION : PRÉVENTION DE L'INFECTION DISSÉMINÉE À M. AVIUM-INTRACELLULAIRE (MAI) ET NOUVELLE CONCENTRATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3300","97-06-27","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA DUE TO MYCOPLASMA PNEUMONIAE AND CHLAMYDIA PNEUMONIAE","NOUVELLE INDICATION : POUR LE TRAITEMENT DE LA PNEUMONIE ACQUISE DANS LA COMMUNAUTEÉ CAUSÉE PAR LE MYCOPLASMA PNEUMONIAE ET LE CHLAMYDIA PNEUMONIAE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3301","97-11-17","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR TREATMENT IN PEDIATRIC PATIENTS OF COMMUNITY ACQUIRED PNEUMONIA DUE TO CHLAMYDIA PNEUMONIAE HAEMOPHILUS INFLUENZAE, MYCOPLASMA PNEUMONIAE OR STREPTOCOCCUS PNEUMONIAE","NOUVELLE INDICATION : POUR LE TRAITEMENT DES MALADES PÉDIATRIQUES DE LA PNEUMONIE ACQUISE DANS LA COMMUNAUTÉ CAUSÉE PAR LE CHLAMYDIA PNEUMONIAE, L'HAEMOPHILUS INFLUENZAE, LE MYCOPLASMA PNEUMONIAE OU LE STREPTOCOCCUS PNEUMONIAE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3302","97-08-13","BIOCHEM VACCINES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"3303","97-12-03","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASTIQUE","",""
"3304","97-10-17","TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASTIQUE","",""
"3305","97-06-27","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASMODIQUE","",""
"3306","97-11-17","TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASTIQUE","",""
"3307","97-05-15","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"3308","97-06-27","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"3309","97-12-03","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION AU PROCESSUS DE FABRICATION","NATURAL SURFACTANT FROM BOVINE LUNG","SURFACTANT PULMONAIRE D'ORIGINE BOVINE","",""
"3310","97-11-26","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIGLAUCOMA AGENT","AGENT POUR LE TRAITEMENT DU GLAUCOME","",""
"3311","97-10-08","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETOPTIC","ALCON CANADA","CANADA","CANADA","1","","","ANTIGLAUCOMA AGENT","AGENT POUR LE TRAITEMENT DU GLAUCOME","",""
"3312","97-02-06","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGLAUCOMA AGENT","ANTIGLAUCOME","",""
"3313","97-08-07","BRISTOL LABORATORIES OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF MALIGNANT PLEURAL EFFUSION","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ÉPANCHEMENT PLEURAL MALIN","ANTINEOPLASTIC, ANTIBIOTIC","ANTINÉOPLASIQUE, ANTIBIOTIQUE","",""
"3314","97-06-06","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3315","97-11-24","ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY (RELATIVELY SELECTIVE ALPHA 2-ADRENORECEPTOR AGONIST)","MAÎTRISE DE LA PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"3316","97-01-31","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"3317","97-02-28","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"3318","97-02-04","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE AGENT","ANXIOLYTIQUE, SÉDATIF","",""
"3319","97-08-26","PENTAPHARM LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE AGENT","ANXIOLYTIQUE, SÉDATIF","",""
"3320","97-01-08","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCENTRATION ET PRÉSENTATION","PROLACTIN INHIBITOR, GROWTH HORMONE SUPPRESSANT IN ACROMEGALY, ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, TRAITEMENT ADJUVANT DANS LA MALADIE DE PARKINSON","",""
"3321","97-03-06","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","PROLACTIN INHIBITOR, GROWTH HORMONE SUPPRESSANT IN ACROMEGALY ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, TRAITEMENT ADJUVANT DANS LA MALADIE DE PARKINSON","",""
"3322","97-02-25","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR/GROWTH HORMONE SUPPRESSANT IN ACROMEGALY ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, TRAITEMENT ADJUVANT DANS LA MALADIE DE PARKINSON","",""
"3323","97-08-12","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR","INHIBITEUR PROLACTINE","",""
"3324","97-12-03","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCENTRATION ET PRÉSENTATION","PROLACTIN INHIBITOR, GROWTH HORMONE SUPPRESSANT IN ACROMEGALY, ADJUNCTIVE MEDICATION IN PARKISON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, MÉDICAMENT ADJUVANT UTILISÉ DANS LA MALADIE DE PARKINSON","",""
"3325","97-07-14","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR, GROWTH HORMONE SUPPRESSANT IN ACROMEGALY, ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, DANS L'ACROMÉGALIE, MÉDICAMENT ADJUVANT UTILISÉ DANS LA MALADIE DE PARKINSON","",""
"3326","97-02-11","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RHINOCORT AQUA","ASTRA PHARMA","CANADA","CANADA","1","","","GLUCOCORTICOTEROID","GLUCOCORTICOSTÉROÏDE","",""
"3327","97-08-01","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS AND NEW DOSAGE REGIMEN: LOWER RECOMMENDED AND MAXIMUM DOSE","NOUVELLES CONCENTRATIONS ET NOUVELLE POSOLOGIE : RECOMMANDATIONS POUR DOSE MOINDRE ET DOSE MAXIMALE","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"3328","97-09-30","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDING FOR THE ENDOCRINE TREATMENT OF PATIENTS WITH ENDOMETRIOSIS","POUR LE TRAITEMENT ENDOCRINIEN DES PATIENTES SOUFFRANT D'ENDOMÉTRIOSE","LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE (LH-RH)","",""
"3329","97-04-15","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"3330","97-04-03","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"3331","97-08-26","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"3332","97-03-18","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"3333","97-03-06","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"3334","97-06-18","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"3335","97-04-15","PENEDERM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"3336","97-09-09","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PAGET'S DISEASE THERAPY - HYPERCALCEMIA TREATMENT","TRAITEMENT DE LA MALADIE DE PAGET - TRAITEMENT DE L'HYPERCALCÉMIE","",""
"3337","97-03-26","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"3338","97-07-08","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA/ANTIMANIC","ANTICONVULSIVANT - SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU, ANTIMANIAQUE","",""
"3339","97-06-24","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","UTEROTONIC AGENT","UTEROTONIQUE","",""
"3340","97-07-02","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA/ANTIMANIC","ANTICONVULSIVANT - SOULAGEMENT SYMPTOMATIQUE DE LA NÉURALGIE DU TRIJUMEAU, ANTIMANIAQUE","",""
"3341","97-05-29","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticonvulsant, Symptomatic Relief of Trigenal Neuragia, Antimanic","Anticonvulsivant, Soulagement symptomatique de la névralgie du trijumeau, Antimaniaque","",""
"3342","97-01-17","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"3343","97-07-29","BOEHRINGER MANNHEIM CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONGESTIVE HEART FAILURE AGENT","INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"3344","97-01-17","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3345","97-10-24","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3346","97-07-09","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3347","97-10-06","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3348","97-09-22","TEVA PHARMACEUTICALS INDUSTRIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3349","97-08-11","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN THE TREATMENT OF FEBRILE NEUTROPENIA","NOUVELLE INDICATION : POUR LE TRAITEMENT DE LA NEUTROPÉNIE FÉBRILE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3351","03-12-09","NORBROOK LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SUBCUTANEOUS ROUTE OF ADMINISTRATION IN CATTLE","NOUVELLE VOIE D'ADMINISTRATION SOUS-CUTANÉE CHEZ LES BOVINS","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3352","03-12-09","NORBROOK LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW DMAC-FREE FORMULATION","NOUVELLE FORMULATION DÉPOURVUE DE N,N-DIMÉTHYLACÉTAMIDE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3353","03-11-25","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3354","03-11-14","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","RESPIRATORY STIMULANT","STIMULANT RESPIRATOIRE","",""
"3355","03-11-14","VETOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3356","03-11-14","VETOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3357","03-11-13","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC (IVERMECTIN) POUR-ON FOR CATTLE","MERIAL CANADA INC","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3358","03-11-04","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES: CHICKEN AND TURKEY","AUTRES ESPÈCES : POULETS ET DINDONS","ANTIBIOTIC, ANTICOCCIDIAL","ANTIBIOTIQUE, ANTICOCCIDIEN","",""
"3359","03-01-28","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CYANAMID CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3360","03-01-14","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"3361","03-11-04","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES: CATTLE","AUTRE ESPÈCE : BOVINS","ANTIBIOTIC, ANTICOCCIDIAL","ANTIBIOTIQUE, ANTICOCCIDIEN","",""
"3362","03-01-08","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS (2 TO 18 YEARS) RECEIVING ALLOGENEIC RENAL TRANSPLANTS IN COMBINATION WITH CYCLOSPORINE AND CORTICOSTEROIDS","NOUVELLE INDICATION: PROPHYLAXIE DU REJET D'ORGANES CHEZ LES PATIENTS PÉDIATRIQUES DE 2 À 18 ANS QUI REÇOIVENT DES TRANSPLANTATIONS RÉNALES ALLOGÉNIQUES EN ASSOCIATION AVEC LA CYCLOSPORINE ET LES CORTICOSTÉROÏDES","IMMUNOSUPPRESSANT AGENT","IMMUNOSUPPRESSEUR","",""
"3363","03-12-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES","PROGESTIN-ESTROGEN","PROGESTÉRONE/OESTROGÈNE","",""
"3364","03-12-30","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 625MG TABLETS","NOUVELLE CONCENTRATION : COMPRIMÉS 625MG","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"3365","03-11-19","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW MANUFACTURING SITE FOR THE DRUG PRODUCT","NOUVEL EMPLACEMENT DE FABRICATION","HORMONAL CONTRACEPTION","CONTRACEPTIF HORMONAL","",""
"3366","03-10-31","COIN PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"3367","03-10-27","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"3368","03-10-23","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"3369","03-10-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3370","03-10-15","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"3371","03-10-28","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3372","03-10-14","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3373","03-10-28","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3374","03-10-28","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3375","03-10-06","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GONADOTROPIN RELEASING HORMONE (GNRH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE (GNRH)","",""
"3376","03-09-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3377","03-10-28","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3378","03-10-28","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3379","03-10-28","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3380","03-10-28","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3381","03-10-28","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3382","03-10-28","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3383","03-10-28","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3384","03-10-23","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"3385","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"3386","03-09-03","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH : CONCOMITANT USE OF LOW DOSES OF ADALAT XL & ENALAPRIL FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION","MONOGRAPHIE RÉVISÉE DU PRODUIT: USAGE CONCOMITANT DE FAIBLES DOSES D'ADALAT XL & D'ENALAPRIL POUR LE TRAITEMENT DE L'HYPERTENSION ESSENTIELLE LÉGÈRE OU MODÉRÉE","ANTIANGINAL, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"3387","03-08-12","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","LABELLING REVISION","RÉVISION DE L'ÉTIQUETAGE","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"3388","03-07-21","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE: ACTION & CLINICAL PHARMACOLOGY SECTION UPDATED WITH THE RESULTS OF THE INSIGHT STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT: RUBRIQUE ACTION ET PHARMACOLOGIE CLINIQUE COMPTE TENU DES RÉSULTATS DE L'ÉTUDE INSIGHT","ANTIANGINAL, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"3389","03-06-14","GALEN (CHEMICALS) LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN-PROGESTIN COMBINATION","ASSOCIATION OESTROPROGESTATIVE","",""
"3390","03-07-09","GALEN (CHEMICALS) LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3391","03-07-08","GALEN (CHEMICALS) LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3392","03-05-13","DURAMED PHARMACEUTICALS, INC. SUBSIDIARY OF BARR LABORATORIES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANTAGONIST","ANTAGONISTE DES OPIOÏDES","",""
"3393","03-10-23","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"3394","03-10-23","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"3395","03-10-21","VETOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"3396","03-10-09","BIONICHE ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"3397","03-10-06","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","CARDIOVASCULAR (MYOCARDIAL STIMULANT)","CARDIOVASCULAIRE (STIMULANT DU MYOCARDE)","",""
"3398","03-10-02","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES - CATS","AUTRE ESPÈCE - CHATS","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"3399","03-09-30","VETOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3400","03-09-30","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3401","03-09-19","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","CARDIOVASCULAR (MYOCARDIAL STIMULANT)","CARDIOVASCULAIRE (STIMULANT DU MYOCARDE)","",""
"3402","03-09-19","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","CARDIOVASCULAR (MYOCARDIAL STIMULANT)","CARDIOVASCULAIRE (STIMULANT DU MYOCARDE)","",""
"3403","03-05-08","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3404","03-04-14","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGES FROM NICORETTE AND NICORETTE PLUS","MODIFICATION DU NOM DU PRODUIT DE NICORETTE ET NICORETTE PLUS","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"3405","03-04-09","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3406","03-04-02","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3407","03-09-12","NORBROOK LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC (IVERMECTIN) DRENCH FOR SHEEP","MERIAL CANADA INC.","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3408","03-09-09","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3409","03-02-26","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERZONE","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3410","03-08-26","LEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL, ANTIFUNGAL, ANTI-INFLAMMATORY","ANTIBACTÉRIEN, ANTIFONGIQUE, ANTI-INFLAMMATOIRE","",""
"3411","03-08-25","NORBROOK LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC (IVERMECTIN) POUR-ON FOR CATTLE","MERIAL CANADA INC.","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3412","03-08-14","LEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3413","03-01-22","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE DURING TEMPORARY ABSTINENCE FROM SMOKING","NOUVELLE INDICATION: UTILISATION DURANT UNE ABSTINENCE TEMPORAIRE DE L'USAGE DU TABAC","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"3414","03-08-14","LEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC, ANTI-INFLAMMATORY","ANTIBIOTIQUE, ANTI-INFLAMMATOIRE","",""
"3415","03-01-06","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3416","03-12-23","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR PREVENTION OF INFLUENZA IN ADULT AND ADOLESCENTS 13 YEARS AND OLDER","NOUVELLE INDICATION: POUR LA PRÉVENTION DE LA GRIPPE CHEZ L'ADULTE ET L'ADOLESCENT DE 13 ANS ET PLUS","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3417","03-08-14","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3418","03-11-14","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OCUFLOX","ALLERGAN INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3419","03-08-14","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE CONCURRENT USE OF BMD 110G PREMIX, AT 55 PPM BACITRACIN FOR PREVENTION OF NECROTIC ENTERITIS, WITH MONTEBAN 70 PREMIX (ELANCO), AT 70 PPM NARASIN FOR THE PREVENTION OF COCCIDIOSIS, IN BROILER CHICKENS","EN VUE D'HOMOLOGATION D'UN USAGE CONCOMITANT DE 55 PPM DE BACITRACINE, POUR LA PRÉVENTION DE L'ENTÉRITE NÉCROTIQUE, AVEC MONTEBAN 70 PREMIX (ELANCO), CONTENANT UNE CONCENTRATION DE 70 PPM DE NARASINE, POUR LA PRÉVENTION DE LA COCCIDIOSE, CHEZ LES POULETS DE GRIL","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3420","03-10-09","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"3421","03-07-28","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3422","03-09-25","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: TO CLARIFY INDICATION TO SPECIFY RELIEF OF MODERATE TO SEVERE PAIN REQUIRING THE CONTINUOUS USE OF AN OPIOID ANALGESIC PREPARATION FOR SEVERAL DAYS OR MORE","INDICATION RÉVISÉE: CLARIFIER L'INDICATION POUR PRÉCISER LE SOULAGEMENT DES DOULEURS MODÉRÉES À INTENSES NÉCESSITANT L'EMPLOI PROLONGÉ D'UNE PRÉPARATION ANALGÉSIQUE OPIOÏDE POUR PLUSIEURS JOURS OU PLUS","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"3423","03-09-22","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE POUR LE TRACTUS GASTRO-INTESTINAL INFÉRIEUR","",""
"3424","03-07-23","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3425","03-09-08","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ZYPREXA IM","MODIFICATION DU NOM DU PRODUIT DE ZYPREXA IM","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"3426","03-07-18","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3427","03-06-05","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ANTICHOLINERGIC, ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"3428","03-03-26","ALCON CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OCUFLOX","ALLERGAN INC.","CANADA","CANADA","1","","","Antibacterial Agent","Antibactérien","",""
"3429","03-07-09","VETOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3430","03-03-19","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: INTRAMUSCULAR INJECTION FOR THE RAPID CONTROL OF AGITATION","NOUVELLE FORME POSOLOGIQUE: INJECTION INTRAMUSCULAIRE POUR LE CONTRÔLE RAPIDE DE L'AGITATION","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"3431","03-03-17","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF ACUTE BIPOLAR MANIA","NOUVELLE INDICATION: POUR LE TRAITEMENT DE LA MANIE BIPOLAIRE AIGUE","ANTIPSYCHOTIC/ANTIMANIC AGENT","ANTIPSYCHOTIQUE/ANTIMANIAQUE","",""
"3432","03-07-09","LES PRODUITS AGRO-B INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"3433","03-02-13","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"3434","03-12-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF SOCIAL ANXIETY DISORDER","NOUVELLE INDICATION: TRAITEMENT DU TROUBLE ANXIEUX SOCIAL","SELECTIVE SEROTONIN REUPTAKE INHIBITOR","INHIBITEUR SÉLECTIF DE LA RECAPTURE DE LA SÉROTONINE","",""
"3435","03-07-08","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3436","03-07-08","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3437","03-12-19","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIDEPRESSANT-ANTIOBSESSIONAL-ANTIPANIC-ANXIOLYTIC AGENT SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER)-POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"3438","03-12-09","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"3439","03-12-09","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"3440","03-07-08","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"3441","03-07-08","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3442","03-07-08","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3443","03-07-08","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3444","03-07-08","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3445","03-07-02","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3446","03-11-27","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: CONTROLLED RELEASE TABLETS FOR THE SYMPTOMATIC TREATMENT OF DEPRESSION AND PANIC DISORDER","NOUVELLE FORME POSOLOGIQUE: COMPRIMÉS À LIBÉRATION CONTRÔLÉE POUR LE SOULAGEMENT SYMPTOMATIQUE DU TROUBLE PANIQUE ET DE LA DÉPRESSION","SELECTIVE SEROTONIN REUPTAKE INHIBITOR","INHIBITEUR SÉLECTIF DE LA RECAPTURE DE LA SÉROTONINE","",""
"3447","03-07-02","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR ADDITIONAL INDICATIONS FOR THE NEW DRUG AND TO MODIFY THE STATEMENT REGARDING SUSTAINED EFFICACY UNDER ADVERSE WEATHER CONDITIONS (RAIN)","POUR AJOUTER CERTAINES INDICATIONS AU PRODUIT ET MODIFIER LES RECOMMENDATIONS RELATIVES À SON ADMINISTRATION AVANT OU APRÈS UN ÉPISODE TYPIQUE DE PLUIE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3448","03-11-06","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","0","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"3449","03-10-28","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","Antidepressant, Antiobsessional, Antipanic Agent, Anxiolytic Agent, Social Phobia (Social Anxiety Disorder), Posttraumatic Stress Disorder Therapy","Antidépresseur, Antiobsessionnel, Antipanique, Anxiolytique, Traitement de la Phobie Sociale (Trouble Anxieux Social), Traitement de l'état de Stress Post-traumatique","",""
"3450","03-10-27","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DOPAMINE AGONIST","AGONISTE DE LA DOPAMINE","",""
"3451","03-10-23","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER) THERAPY, POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"3453","03-10-09","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"3454","03-10-08","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE","",""
"3455","03-09-25","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPRIVAN","ZENECA PHARMA CANADA INC.","CANADA","CANADA","1","","","ANAESTHETIC-SEDATIVE","ANESTHÉSIQUE-SÉDATIF","",""
"3456","03-09-15","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"3457","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINOMIMETIC AGENT","AGENT CHOLINOMIMÉTIQUE","",""
"3458","03-08-13","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"3459","03-08-07","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL MYERS SQUIBB","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"3460","03-08-05","ALTANA PHARMA AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF GASTROINTESTINAL LESIONS INDUCED BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN PATIENTS WITH A NEED FOR CONTINUOUS NSAID TREATMENT","NOUVELLE INDICATION: PRÉVENTION DES LÉSIONS GASTROINTESTINALES CAUSÉES PAR L'USAGE DES MÉDICAMENTS ANTI-INFLAMMATOIRE NON STÉROÏDIENS CHEZ LES PATIENTS NÉCESSITANT UN TRAITEMENT CONTINU AUX AINS","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"3461","03-07-02","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3462","03-07-21","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA INC., A DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"3463","03-07-16","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME FROM BIPREL","MODIFICATION DU NOM DU PRODUIT DE BIPREL","ANGIOTENSIN CONVERTING ENZYME INHIBITOR/DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE/DIURÉTIQUE","",""
"3464","03-07-09","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"3465","03-06-18","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAXOL INJECTION","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3466","03-05-20","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC, ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE, INHIBITEUR DE ß-LACTAMASE","",""
"3467","03-05-12","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENERGIC RECEPTOR BLOCKING AGENT","AGENT BLOQUEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"3468","03-04-30","INSIGHT PHARMACEUTICALS CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PEDICULOCIDE, OVICIDE","AGENT PÉDICULOCIDE, OVICIDE TOPIQUE","",""
"3469","03-04-07","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3470","03-04-04","LINSON PHARMA CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: TO BE CONSISTENT WITH THE PRAVACHOL PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE: POUR ÊTRE COMPATIBLE AVEC LA MONOGRAPHIE DU PRODUIT PRAVACHOL","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"3471","03-03-19","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ASCOMYCIN MACROLACTAM DERIVATIVE","MACROLACTAME DÉRIVÉ DE L'ASCOMYCINE","",""
"3472","03-03-14","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ABLATION OF HIGH-GRADE DYSPLASIA (HGD) IN BARRETT'S ESOPHAGUS (BE) IN PATIENTS WHO REFUSE ESOPHAGECTOMY AND ARE IN OVERALL GOOD HEALTH","NOUVELLE INDICATION: ABLATION DE LA DYSPLASIE GRAVE DE L'OESOPHAGE DE BARRETT CHEZ LES PATIENTS QUI REFUSENT L'OESOPHAGECTOMIE ET DONT L'ÉTAT DE SANTÉ EST PAR AILLEURS BON","ANTINEOPLASTIC PHOTOSENSITIZING AGENT","PHOTOSENSIBILISANT ANTINÉOPLASIQUE","",""
"3473","03-03-07","TRITON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, NEUROLEPTIC","ANTIDÉPRESSEUR, NEUROLEPTIQUE","",""
"3474","03-02-21","MAYNE PHARMA (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARASITIC AGENT","ANTIPARASITAIRE","",""
"3475","03-02-13","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL SCABICIDE","SCABICIDE TOPIQUE","",""
"3476","03-02-13","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: COMBINATION THERAPY (WITH A SULFONYLUREA OR METFORMIN) IN PATIENTS WITH TYPE 2 DIABETES","NOUVELLE INDICATION: POLYTHÉRAPIE (AVEC SUFONYLURÉE OU METFORMINE) POUR LE TRAITEMENT DU DIABÈTE DE TYPE 2","ANTI-DIABETIC AGENT, INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE, AGENT RÉDUCTEUR DE RÉSISTANCE À L'INSULINE","",""
"3477","03-01-31","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE INDICATIONS SECTION OF THE PRODUCT MONOGRAPH: DELETED PERINDOPRIL SHOULD NORMALLY BE USED IN THOSE PATIENTS IN WHOM TREATMENT WITH A DIURETIC OR BETA-BLOCKER WAS FOUND TO BE INEFFECTIVE OR HAS BEEN ASSOCIATED WITH UNACCEPTABLE ADVERSE EFFECTS. TO BE CONSISTENT WITH THE PRODUCT MONOGRAPH FOR COVERSYL","MISE À JOUR À LA RUBRIQUE INDICATION DE LA MONOGRAPHIE DU PRODUIT: PARTIE SUIVANTE SUPPRIMÉE CONFOMÉMENT À LA MONOGRAPHIE DU PRODUIT POUR COVERSYL: LE PERINDOPRIL DEVRAIT NORMALEMENT ÊTRE UTILISÉ CHEZ LES INDIVIDUS CHEZ QUI LE TRAITEMENT AVEC UN DIURÉTIQUE OU UN BÊTABLOQUANT S'EST AVÉRÉ INEFFICACE OU A ÉTÉ RELIÉ À DES EFFETS SECONDAIRES INACCEPTABLES","ANGIOTENSIN CONVERTING ENZYME INHIBITOR, DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE, DIURÉTIQUE","",""
"3478","03-01-31","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","POTASSIUM SUPPLEMENT","SUPPLÉMENT POTASSIQUE","",""
"3479","03-01-17","AMERSHAM HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING PROCESS","MODIFICATION DE LA FABRICATION","DIAGNOSTIC RADIOPHARMACEUTICAL","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"3480","03-01-14","ALTANA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF CONDITIONS WHERE A RAPID REDUCTION OF GASTRIC SECRETION IS REQUIRED, SUCH AS PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SYNDROME IN HOSPITALIZED PATIENTS WHO CANNOT TOLERATE ORAL MEDICATION","NOUVELLE INDICATION: TRAITEMENT DES AFFECTIONS EXIGEANT UNE BAISSE RAPIDE DE LA SÉCRÉTION GASTRIQUE TELLE L'HYPERSÉCRÉTION RELIÉE AU SYNDROME ZOLLINGER-ELLISON CHEZ LES PATIENTS HOSPITALISÉS QUI NE PEUVENT PRENDRE DES MÉDICAMENTS PAR VOIE ORALE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"3481","03-01-14","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DE MÉTABOLISME LIPIDIQUE","",""
"3482","03-07-02","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR ADDITIONAL INDICATION FOR THE NEW DRUG AND TO MODIFY THE STATEMENT REGARDING SUSTAINED EFFICACY UNDER ADVERSE WEATHER CONDITIONS (RAIN)","POUR AJOUTER CERTAINES INDICATIONS AU PRODUIT ET MODIFIER LES RECOMMENDATIONS RELATIVES À SON ADMINISTRATION AVANT OU APRÈS UN ÉPISODE TYPIQUE DE PLUIE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3483","03-07-02","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTITUSSIVE","ANTITUSSIF","",""
"3484","03-07-02","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTITUSSIVE","ANTITUSSIF","",""
"3485","03-01-10","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","PRODUCT NAME CHANGE FROM PEG-INTRON","MODIFICATION DU NOM DU PRODUIT DE PEG-INTRON","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"3486","03-07-02","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTITUSSIVE","ANTITUSSIF","",""
"3487","03-06-27","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3488","03-06-27","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3489","03-06-18","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3490","03-06-11","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3491","03-01-08","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB COMPANY","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"3492","03-06-02","IVY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENT LE GAIN PONDÉRAL","",""
"3493","03-10-21","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH - REVISED DOSAGE RECOMMENDATIONS FOR POPULATIONS AT RISK; INTERACTION STUDY WITH RIFAMPIN","CHANGEMENTS À LA MONOGRAPHIE DU PRODUIT: RECOMMENDATIONS MODIFIÉES À LA POSOLOGIE POUR LES POPULATIONS À RISQUE; ÉTUDE DE L'INTERACTION AVEC LE RIFAMPIN","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3494","03-10-02","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATES WITH REGARDS TO WEIGHT CHANGE AND USE IN PATIENTS WITH MILD HEPATIC IMPAIRMENT","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT EN MATIÈRE DE MODIFICATION DU POIDS ET EMPLOI CHEZ LES PERSONNES PRÉSENTANT UN TROUBLE LÉGER DE LA FONCTION HÉPATIQUE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"3495","03-12-24","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOWELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3496","03-12-19","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STERILE FILLING FACILITY","NOUVEL ÉTABLISSEMENT POUR LE REMPLISSAGE STÉRILE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"3497","03-12-19","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STERILE FILLING FACILITY","NOUVEL ÉTABLISSEMENT POUR LE REMPLISSAGE STÉRILE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"3498","03-12-19","BAYER INC., HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STERILE FILLING FACILITY","NOUVEL ÉTABLISSEMENT POUR LE REMPLISSAGE STÉRILE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"3500","03-11-21","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: 2MG/1000MG AND 4MG/1000MG","NOUVELLES CONCENTRATIONS: 2MG/1000MG ET 4MG/1000MG","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"3501","03-11-10","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEUR H2 DE L'HISTAMINE","",""
"3502","03-11-06","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE ACTION AND CLINICAL PHARMACOLOGY SECTION OF THE PRODUCT MONOGRAPH WITH REGARDS TO MANAGEMENT OF PATIENTS WITH INCREASED RISK OF CARDIOVASCULAR EVENTS","MISE À JOUR DE LA RUBRIQUE ACTION ET PHARMACOLOGIE DE LA MONOGRAPHIE DU PRODUIT POUR CE QUI EST DE LA GESTION DES PATIENTS PRÉSENTANT UN RISQUE AGGRAVÉ DE TROUBLES CARDIOVASCULAIRES","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"3503","03-06-02","IVY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"3504","03-10-29","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","URICOLYTIC AGENT","AGENT URICOLYTIQUE","",""
"3505","03-10-23","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ERADICATION OF HELICOBACTER PYLORI ASSOCIATED WITH DUODENAL ULCER DISEASE (IN CONJUCTION WITH CERTAIN ANTIBIOTICS)","NOUVELLE INDICATION: ÉRADICATION DE L'HELICOBACTER PYLORI RELIÉ À L'ULCÈRE DUODÉNAL (AVEC LE CONCOURS DE CERTAINS ANTIBIOTIQUES)","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"3506","03-06-02","IVY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"3507","03-10-14","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3508","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3509","03-09-18","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"3510","03-09-05","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","SELECTIVE ESTROGEN RECEPTOR MODULATOR","MODULATEUR SÉLECTIF DES RÉCEPTEURS ESTROGÉNIQUES","",""
"3511","03-06-18","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORALLY DISINTEGRATING TABLETS","NOUVELLE FORME POSOLOGIQUE: COMPRIMÉS SE DÉSINTÉGRANT DANS LA BOUCHE","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"3512","03-06-17","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"3513","03-05-27","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: LONG-TERM MAINTENANCE OF THERAPEUTIC RESPONSE IN SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS","NOUVELLE INDICATION: MAINTIEN À LONG TERME DE LA RÉPONSE THÉRAPEUTIQUE DANS LE TRAITEMENT DE LA SCHIZOPHRÉNIE ET TROUBLES PSYCHOTIQUES CONNEXES","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"3514","03-05-12","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM PMS-RANITIDINE","MODIFICATION DU NOM DU PRODUIT DE PMS-RANITIDINE","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3515","03-04-30","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3516","03-06-02","IVY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"3517","03-04-14","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM ZANTAC 75","MODIFICATION DU NOM DU PRODUIT DE ZANTAC 75","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3518","03-03-28","NORBROOK LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3519","03-04-03","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ACUTE AND CHRONIC TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS","NOUVELLE INDICATION: TRAITEMENT AIGU ET CHRONIQUE DES SIGNES ET SYMPTÔMES DE LA POLYARTHRITE RHUMATOÏDE CHEZ L'ADULTE","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"3520","03-03-26","BIONICHE ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"3521","03-03-10","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","MODIFICATION OF THE ADULT DOSAGE STATEMENT ON CARTON LABELS","CHANGEMENT SUR L'ÉTIQUETTE AUX INSTRUCTIONS DE DOSAGE CHEZ L'ADULTE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"3522","03-02-17","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"3523","03-02-16","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"3524","03-02-13","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"3525","03-02-17","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANABOLIC STEROID","STÉROÏDE ANABOLISANT","",""
"3526","03-12-15","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE PRODUCT MONOGRAPH TO INCLUDE A STATEMENT THAT ADMINISTRATION OF VALSARTAN TO PATIENTS WITH TYPE II DIABETES AND MICROALBUMINURIA HAS RESULTED IN SIGNIFICANT REDUCTION OF URINARY ALBUMIN EXCRETION","MISE À JOUR À LA MONOGRAPHIE DU PRODUIT INDIQUANT QUE L'ADMINISTRATION DE VALSARTAN AUX PATIENTS PRÉSENTANT UN DIABÈTE DE TYPE II AVEC MICROALBUMINUERIE A DÉMONTRÉ UNE RÉDUCTION APPRÉCIABLE D'EXCRÉTION D'ALBUMINE DANS L'URINE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"3527","03-02-13","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"3528","03-10-09","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR THE SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV INFECTED INDIVIDUALS","NOUVELLE INDICATION: POUR LA SUPPRESSION DE L'HERPÈS GÉNITAL RÉCURRENT CHEZ LES PATIENTS ATTEINTS DU VIH","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3529","03-10-09","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR THE TREATMENT OF AN INITIAL EPISODE OF GENITAL HERPES","NOUVELLE INDICATION: POUR LE TRAITEMENT D'UN ÉPISODE INITIAL D'HERPÈS GÉNITAL","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3530","03-10-09","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED DOSING REGIMEN FOR THE TREATMENT OF RECURRENT GENITAL HERPES","RÉVISION AU DOSAGE POUR LE TRAITEMENT DE L'HERPÈS GÉNITAL RÉCURRENT","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3531","03-02-13","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","AN ADDITIONAL FEED MANUFACTURER, BLUE ROCK MINERALS (2002) INC.","UN CONSTRUCTEUR CANADIEN SUPPLÉMENTAIRE D'ALIMENTATION, BLUE ROCK MINERALS (2002) INC.","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3532","03-02-10","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","PROMOTEUR DE CROISSANCE","",""
"3533","03-09-18","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3534","03-09-18","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3535","03-09-16","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTI-ANGINEUX","",""
"3536","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC ANTI-INFLAMMATORY AGENT","ANALGÉSIQUE ANTI-INFLAMMATOIRE","",""
"3537","03-07-22","QLT INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","PHOTOSENSITIZING AGENT FOR AGE-RELATED MACULAR DEGENERATION AND PATHOLOGIC MYOPIA","AGENT PHOTOSENSIBILISANT POUR LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE ET POUR LA MYOPIE PATHOLOGIQUE","",""
"3538","03-06-13","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER)","NOUVELLE INDICATION: PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL)","ANTIDEPRESSANT, ANXIOLYTIC","ANTIDÉPRESSEUR, ANXIOLYTIQUE","",""
"3539","03-05-06","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR THE TREATMENT OF COLD SORES (HERPES LABIALIS)","NOUVELLE INDICATION: POUR LE TRAITEMENT DES BOUTONS DE FIÈVRE (HERPES LABIALIS)","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3540","03-04-25","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION: FOR MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER","NOUVELLE INDICATION: THÉRAPHIE D'ENTRETIEN D'UN TROUBLE DÉPRESSIF IMPORTANT","ANTIDEPRESSANT, ANXIOLYTIC","ANTIDÉPRESSEUR, ANXIOLYTIQUE","",""
"3541","03-03-14","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANXIOLYTIC","ANTIDÉPRESSEUR, ANXIOLYTIQUE","",""
"3542","03-02-21","SBL VACCIN AB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"3543","03-02-20","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","KNOLL PHARMA INC.","CANADA","CANADA","1","NEW DOSAGE FORM - SUSTAINED RELEASE TABLETS","NOUVELLE FORME POSOLOGIQUE: COMPRIMÉS À LIBÉRATION PROLONGÉE","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"3544","03-01-03","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 160MG/25MG","NOUVELLE CONCENTRATION: 160MG/25MG","ANGIOTENSIN II AT1 RECEPTOR BLOCKER AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"3545","03-12-05","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: CONCENTRATE SOLUTION","NOUVELLE FORME POSOLOGIQUE: SOLUTION CONCENTRÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"3546","03-10-07","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE POULENC RORER","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"3547","03-09-12","SANOFI-SYNTHELABO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AGENT","AGENT HYPNOTIQUE","",""
"3548","03-09-04","LOREX PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATES FOR THE ADDITION OF INFORMATION FROM CLINICAL TRIALS TO DESCRIBE THE EFFICACY OF ZOLPIDEM AND FOR THE RE-LOCATION OF STATEMENTS ON THE INDICATIONS SECTION TO THE WARNINGS SECTION","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT POUR L'AJOUT DE RENSEIGNEMENTS SUR LES ESSAIS CLINIQUES DÉCRIVANT L'EFFICACITÉ DU ZOLPIDEM ET POUR LA RE-LOCALISATION DES ÉNONCÉS DE LA RUBRIQUE INDICATIONS À LA RUBRIQUE MISES EN GARDE","HYPNOTIC AGENT","HYPNOTIQUE","",""
"3549","03-08-26","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NOTICE OF COMPLIANCE TO REPLACE THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED FEBRUARY 13, 2003","AVIS DE CONFORMITÉ QUI REMPLACE L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 13 FÉVRIER 2003","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3550","03-08-26","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TREATMENT OF INFLUENZA IN PAEDIATRICS 7 YEARS AND OLDER","TRAITEMENT DE L'INFLUENZA CHEZ LES ENFANTS DE 7 ANS ET PLUS","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3551","03-02-13","GLAXOSMITHKLINE INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3552","03-07-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO WORDING OF THE SOLID TUMORS INDICATION","RÉVISION RELATIVE À L'INDICATION DES TUMEURS SOLIDES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"3553","03-02-04","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF PATIENTS WITH DOCUMENTED BONE METASTASES FROM SOLID TUMORS AND PATIENTS WITH OSTEOLYTIC LESIONS OF MULTIPLE MYELOMA IN CONJUCTION WITH STANDARD CARE IN ORDER TO PREVENT OR DELAY POTENTIAL COMPLICATIONS FROM THE BONE LESIONS","NOUVELLE INDICATION: POUR LE TRAITEMENT DES MÉTASTASES OSSEUSES PROVENANT DE TUMEURS SOLIDES ET LE TRAITEMENT DE L'OSTÉOLYSE DU MYÉLOME MULTIPLE, DE CONCERT AVEC UN TRAITEMENT DE BASE POUR PRÉVENIR OU RETARDER LES COMPLICATIONS POSSIBLES PROVENANT DE LÉSIONS OSSEUSES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"3554","03-12-12","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY FOR DRUG PRODUCT","NOUVEL EMPLACEMENT DE FABRICATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"3555","03-12-12","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY FOR DRUG PRODUCT","NOUVEL EMPLACEMENT DE FABRICATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"3556","03-12-11","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: REGARDING USE IN PATIENTS WITH RENAL IMPAIRMENT, DRUG INTERACTIONS AND SYMPTOMS AND TREATMENT OF OVERDOSE","MONOGRAPHIE RÉVISÉE DU PRODUIT: RELATIVEMENT AUX PATIENTS PRÉSENTANT UNE DÉFICIENCE DE LA FONCTION RÉNALE, AUX INTERACTIONS MÉDICAMENTEUSES AVEC SYMPTÔMES ET TRAITEMENT DE SURDOSE","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"3557","03-11-19","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","NEW INDICATIONS: ANTIPANIC, ANTIOBSESSIONAL AGENT","NOUVELLES INDICATIONS: ANTIPANIQUE, ANTIOBSESSIONNEL","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"3558","03-11-19","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM RIVA SERTRALINE  NEW INDICATIONS: ANTIPANIC, ANTIOBSESSIONAL AGENT","MODIFICATION DU NOM DU PRODUIT DE RIVA SERTRALINE, NOUVELLES INDICATIONS: ANTIPANIQUE, ANTIOBSESSIONNEL","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"3559","03-11-14","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH WITH REGARDS TO GREATER IMPROVEMENT IN PULMONARY FUNCTION AND SYMPTOM CONTROL THAN EITHER FLUTICASONE OR SALMETEROL USED ALONE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT EN CE QUI A TRAIT À UNE AMÉLIORATION PLUS MARQUÉE DE LA FONCTION PULMONAIRE ET DU CONTRÔLE DES SYMPTÔMES QUE L'UTILISATION SIMPLE SOIT DU FLUTICASONE OU DE SALMÉTÉROL","BRONCHODILATOR AND CORTICOSTEROID FOR ORAL INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE EN INHALATION","",""
"3560","03-11-13","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3561","03-11-04","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"3562","03-10-29","AVENTIS PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"3563","03-10-10","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3564","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"3565","03-09-25","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3566","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ALDOSTERONE ANTAGONIST","ANTAGONISTE DE L'ALDOSTÉRONE","",""
"3567","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ALDOSTERONE ANTAGONIST WITH A DIURETIC","ANTAGONISTE DE L'ALDOSTÉRONE DIURÉTIQUE","",""
"3568","03-09-05","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: EXTENDED RELEASE CAPSULES; REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE FORME POSOLOGIQUE: CAPSULES À ACTION PROLONGÉE; RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"3569","03-08-12","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH ADDITION OF DISCONTINUATION SYMPTOMES AND THEIR MANAGEMENT","AJOUT À LA MONOGRAPHIE DU PRODUIT POUR RÉFLETER LES SYMPTÔMES RELIÉS À L'ABANDON ET À LEUR GESTION","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"3570","03-07-09","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3571","03-06-02","RATIOPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","ADDITION OF TWO NEW INDICATIONS: FOR THE SYMPTOMATIC RELIEF OF PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA AND OBSESSIVE COMPULSIVE DISORDER","AJOUT DE DEUX NOUVELLES INDICATIONS: POUR LE SOULAGEMENT DES SYMPTÔMES RELIÉS AU TROUBLE PANIQUE ACCOMPAGNÉ OU NON D'AGORAPHOBIE ET DE TROUBLE OBSESSIVO-COMPULSIF","Antidepressant, Antipanic, Antiobsessional Agent","Antidépresseur, Antipanique, Antiobsessionnel","",""
"3572","03-05-28","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORAL LIQUID","NOUVELLE FORME POSOLOGIQUE: LIQUIDE ORAL","BRONCHODILATOR","BRONCHODILATATEUR","",""
"3573","03-05-20","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: PANIC DISORDER AND OBSESSIVE COMPULSIVE DISORDER","NOUVELLES INDICATIONS: TROUBLE PANIQUE ET TROUBLE OBSESSIVO-COMPULSIF","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBESSIONNEL","",""
"3574","03-05-07","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","NEW INDICATION: PANIC DISORDER AND OBSESSIVE COMPULSIVE DISORDER","NOUVELLE INDICATION: TROUBLE PANIQUE ET TROUBLE OBSESSIVO-COMPULSIF","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"3575","03-05-01","RHOXALPHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","NEW INDICATIONS: FOR THE SYMPTOMATIC RELIEF OF PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA AND OBESSIVE COMPULSIVE DISORDER","NOUVELLES INDICATIONS: POUR LE SOULAGEMENT DES SYMPTÔMES RELIÉS AU TROUBLE PANIQUE AVEC OU SANS PRÉSENCE DU TROUBLE OBSESSIVO-COMPULSIF DE L'AGORAPHOBIE","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"3576","03-04-30","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3577","03-04-23","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)","NOUVELLE INDICATION: POUR LA THÉRAPIE D'ENTRETIEN DE LA BRONCHOPNEUMOPATHIE CHRONIQUE OBSTRUCTIVE","BRONCHODILATOR AND CORTICOSTEROID FOR ORAL INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE EN INHALATION","",""
"3578","03-04-15","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","NEW INDICATIONS: FOR THE SYMPTOMATIC RELIEF OF PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA AND OBSESSIVE COMPULSIVE DISORDER","NOUVELLES INDICATIONS: POUR LE SOULAGEMENT SYMPTOMATIQUE DU TROUBLE PANIQUE, AVEC OU SANS AGORAPHOBIE ET DU TROUBLE OBSESSIVO-COMPULSIF","ANTIDEPRESSANT, ANTIPANIC, ANTI-OBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTI-OBSESSIONNEL","",""
"3579","03-04-08","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"3580","03-03-10","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"3581","03-03-04","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3582","03-03-03","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"3583","03-02-17","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3584","03-02-14","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"3585","03-02-10","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: TABLETS; NEW STRENGTH: 1 MG","NOUVELLE FORME POSOLOGIQUE: COMPRIMÉS; NOUVELLE CONCENTRATION: 1 MG","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"3586","03-01-15","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3587","03-01-15","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3588","03-01-15","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3589","03-01-15","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3590","03-12-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRYPTAN","ICN CANADA LTD.","CANADA","CANADA","1","","","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"3591","03-12-09","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIROPTIC","THERAMED CORPORATION","CANADA","CANADA","1","","","TOPICAL ANTIVIRAL AGENT","ANTIVIRAL TOPIQUE","",""
"3592","03-12-02","ALLERGAN INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBREX","ALCON","CANADA","CANADA","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"3593","03-10-31","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIROPTIC","BURROUGHS WELLCOME INC.","CANADA","CANADA","1","","","TOPICAL ANTIVIRAL AGENT","ANTIVIRAL TOPIQUE","",""
"3594","03-10-20","AMERSHAM HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (MEASUREMENT OF BILE ACID POOL LOSS)","AGENT RADIODIAGNOSTIQUE (MESURE DE LA PERTE DES RÉSERVES D'ACIDE BILIAIRE)","",""
"3595","03-10-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3596","03-10-03","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINEOPLASIQUE","",""
"3597","03-09-29","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉOSTIMULINE","",""
"3598","03-09-22","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"3599","03-09-18","PHARMACIA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO PRODUCT MONOGRAPH CORRESPONDING TO THE LATEST CHANGES OF THE INNOVATOR","MISE À JOUR À LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'INNOCUITÉ RELATIVEMENT AUX DERNIERS CHANGEMENT DE L'INNOVATEUR","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3600","03-09-17","LILLY ICOS LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE LA GMPC","",""
"3601","03-09-15","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO PRODUCT MONOGRAPH CORRESPONDING TO THE LATEST CHANGES OF THE INNOVATOR","MISE À JOUR À LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'INNOCUITÉ RELATIVEMENT AUX DERNIERS CHANGEMENTS DE L'INNOVATEUR","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3602","03-09-15","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO PRODUCT MONOGRAPH CORRESPONDING TO THE LATEST CHANGES OF THE INNOVATOR","MISE À JOUR À LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'INNOCUITÉ RELATIVEMENT AUX DERNIERS CHANGEMENTS DE L'INNOVATEUR","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3603","03-09-15","DOMINION PHARMACAL","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO PRODUCT MONOGRAPH CORRESPONDING TO THE LATEST CHANGES OF THE INNOVATOR","MISE À JOUR À LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'INNOCUITÉ RELATIVEMENT AUX DERNIERS CHANGEMENTS DE L'INNOVATEUR","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3604","03-09-15","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFIBRINOLYTIC AGENT","AGENT ANTIFIBRINOLYTIQUE","",""
"3605","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC, ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"3606","03-09-11","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC, ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"3607","03-09-11","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO PRODUCT MONOGRAPH CORRESPONDING TO THE LATEST CHANGES OF THE INNOVATOR","MISE À JOUR À LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'INNOCUITÉ RELATIVEMENT AUX DERNIERS CHANGEMENTS DE L'INNOVATEUR","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3608","03-09-11","PREMPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO PRODUCT MONOGRAPH CORRESPONDING TO THE LATEST CHANGES OF THE INNOVATOR","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'INNOCUITÉ RELATIVEMENT AUX DERNIERS CHANGEMENTS DE L'INNOVATEUR","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3609","03-09-11","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO PRODUCT MONOGRAPH CORRESPONDING TO THE LATEST CHANGES OF THE INNOVATOR","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'INNOCUITÉ RELATIVEMENT AUX DERNIERS CHANGEMENTS DE L'INNOVATEUR","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3610","03-09-04","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO PRODUCT MONOGRAPH CORRESPONDING TO THE LATEST CHANGES OF THE INNOVATOR","MISE À JOUR À LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'INNOCUITÉ RELATIVEMENT AUX DERNIERS CHANGEMENTS DE L'INNOVATEUR","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"3611","03-09-04","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REWORDING OF INDICATION AND SAFETY UPDATE AS PER LETTER DATED JULY 31, 2002 FROM THE THERAPEUTIC DIRECTORATE AND THE MARKETED HEALTH PRODUCTS DIRECTORATE","REFORMULATION DE LA MISE À JOUR AUX RUBRIQUES INDICATION ET INNOCUITÉ POUR TENIR COMPTE DE LA LETTRE DU 31 JUILLET 2002 DE LA DIRECTION DES PRODUITS THÉRAPEUTIQUES ET DE LA DIRECTION DES PRODUITS DE SANTÉ COMMERCIALISÉS","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3612","03-07-15","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW VIAL SIZE","NOUVEAU FORMAT DE FIOLE","ANTIBIOTIC AND ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"3613","03-06-11","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TERAZOLE 7","JANSSEN-ORTHO","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3614","03-05-28","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3615","03-04-30","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3616","03-04-28","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"3617","03-04-23","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CYTOTOXIC AGENT","AGENT CYTOTOXIQUE","",""
"3618","03-01-24","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","AS AN AID IN THE TREATMENT OF NECROTIC ENTERITIS CAUSED BY CLOSTRIDIUM PERFRINGENS IN BROILER CHICKENS","ADJUVANT AU TRAITEMENT DE L'ENTÉRITE NÉCROTIQUE CAUSÉE PAR CLOSTRIDIUM PERFRINGENS CHEZ LES POULETS À GRILLER","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3619","03-04-08","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE: PRECAUTIONARY INFORMATION FOR PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT: MISE EN GARDE POUR LES PATIENTS QUI PRÉSENTENT UNE DÉFICIENCE RÉNALE OU HÉPATIQUE","ELEVATE INTRAOCULAR PRESSURE THERAPY - PROSTAGLANDIN F2ALPHA ANALOGUE","TRAITEMENT DE L'HYPERTENSION OCULAIRE ÉLEVÉ, ANALOGUE DE LA PROSTAGLANDINE F2ALPHA","",""
"3620","03-01-17","VETOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"3621","03-03-18","GILEAD SCIENCES, INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"3622","03-01-03","SOLVAY PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"3623","03-01-13","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIN: FOR THE CONTROL OF PERIOPERATIVE PAIN AND INFLAMMATION FOLLOWING ORTHOPEDIC AND SOFT TISSUE SURGERY","POUR MAÎTRISER LA DOULEUR PÉRIOPÉRATOIRE ET L'INFLAMMATION APRÈS UNE CHIRURGIE ORTHOPÉDIQUE OU DES TISSUS","NON STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"3624","03-01-06","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES: CATTLE","ESPÈCES ADDITIONNELLES : BOVINS","ANTI-INFLAMMATORY, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"3625","03-12-19","SABEX 2002 INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALFENTA","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC; ADJUNCT TO ANESTHESIA","ANALGÉSIQUE OPIOÏDE; ADJUVANT À L'ANESTHÉSIE","",""
"3626","03-01-06","VETOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SYMPATHOMIMETIC AGENT","AGENT SYMPATHOMIMÉTIQUE","",""
"3627","03-01-06","BIONICHE ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC","ANESTHÉSIQUE","",""
"3628","04-05-19","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3629","04-05-19","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3630","04-05-19","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3631","04-05-19","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE, TRANQUILIZER","SÉDATIF, TRANQUILLISANT","",""
"3632","04-05-19","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMYCOTIC","ANTIMYCOSIQUE","",""
"3633","04-02-12","BAYER INC. - AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"3634","97-06-16","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW INDICATION: TREATMENT OF ACUTE SINUSITIS","NOUVELLE INDICATION : TRAITEMENT DE LA SINUSITE AIGUË","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3635","04-05-19","VETOQUINOL N.-A. INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","FERROFORTE INJECTION","BIMEDA-MTC ANIMAL HEALTH INC.","CANADA","CANADA","1","","","IRON DEFICIENCY ANAEMIA","CARENCE EN FER","",""
"3636","04-05-19","A.P.A., DIVISION OF VÉTOQUINOL N.-A. INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","FERROFORTE INJECTION","BIMEDA-MTC ANIMAL HEALTH INC.","CANADA","CANADA","1","","","IRON DEFICIENCY ANAEMIA","CARENCE EN FER","",""
"3637","04-04-30","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC (IVERMECTIN) INJECTION FOR CATTLE AND SWINE","MERIAL CANADA INC.","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3638","04-05-19","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEROTOININ S2 RECEPTOR ANTAGONIST","ANTISÉROTONINE (RÉCEPTEUR S2)","",""
"3639","04-03-02","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3640","04-03-02","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGES TO THE WITHDRAWAL PERIOD","CHANGEMENT À LA PÉRIODE DE RETRAIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3641","04-02-26","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGES TO THE WITHDRAWAL PERIOD","CHANGEMENT À LA PÉRIODE DE RETRAIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3642","04-02-26","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3643","04-02-26","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGES TO THE WITHDRAWAL PERIOD","CHANGEMENT À LA PÉRIODE DE RETRAIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3644","04-02-26","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3645","04-05-19","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIFUNGAL, ANTIBACTERIAL, ANTI-INFLAMMATORY","ANTIFONGIQUE, ANTIBACTÉRIEN, ANTI-INFLAMMATOIRE","",""
"3646","04-05-19","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"3647","04-02-20","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3648","04-03-15","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIULCER","ANTIULCÉREUX","",""
"3649","04-01-14","EUROVET ANIMAL HEALTH B.V.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","LIQUAMYCIN LA 200 INJECTION","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3650","04-03-10","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HYPOKALEMIA","HYPOKALIÉMIE","",""
"3651","04-03-10","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HYPOKALEMIA","HYPOKALIÉMIE","",""
"3652","04-03-09","BAYER INC. - AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"3653","04-02-18","VETOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"3654","97-09-30","SWISS SERUM & VACCINE INSTITUTE BERNE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"3655","97-04-07","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIARRHEAL AND ANTIHYPERCHOLESTEROLEMIC","ANTIDIARRHÉIQUE ET ANTIHYPERCHOLESTÉROLÉMIANT","",""
"3656","97-12-03","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERCHOLESTEROLEMIC AND ANTIDIARRHEAL","ANTIHYPERCHOLESTÉROLÉMIANT, ANTIDIARRHÉIQUE","",""
"3657","97-05-12","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTES DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3658","97-12-15","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"3659","97-11-19","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR NEW INDICATION: EMPIRIC THERAPY OF FEBRILE NEURTOPENIC PATIENTS","NOUVELLE INDICATION : EMPIRIQUE, TRAITEMENT DES MALADES NEUTROPÉNIQUES FÉBRILES","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"3660","97-04-17","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALLOWS FOR NEW INDICATION: ACUTE SINUSITIS","NOUVELLE INDICATION : SINUSITE AIGUË","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"3661","97-08-14","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL INDICATIONS - BACTERIAL PROSTATITIS","INDICATIONS ADDITIONNELLES : PROSTATITE BACTÉRIENNE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3662","97-11-04","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","GASTROINTESTINAL PROKINETIC AGENT","AGENT FAVORISANT LA MOTILITÉ GASTRO-INTESTINALE","",""
"3663","97-10-06","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC/CHEMOTHERAPEUTIC AGENT","AGENT ANTINÉOPLASIQUE, CHIMIOTHÉRAPIQUE","",""
"3664","97-06-03","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW INDICATION - PREVENTION OF DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX DISEASE IN PATIENTS WITH ADVANCED HIV INFECTION","NOUVELLE INDICATION : PRÉVENTION DU COMPLEXE MYCOBACTERIUM AVIUM (MAC) CHEZ LES PERSONNES ATTEINTES DE L'INFECTION AVANCÉE À VIH","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3665","97-11-10","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3666","97-09-30","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3667","97-11-10","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3669","97-08-26","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY STEROID","STÉROÏDE ANTI-INFLAMMATOIRE TOPIQUE","",""
"3670","97-08-18","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"3671","97-05-15","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL","",""
"3672","97-07-08","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"3673","97-07-08","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL","",""
"3674","97-01-31","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3675","97-10-06","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3676","97-12-03","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3677","97-03-20","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RIVOTRIL","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3678","97-09-30","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3679","97-01-16","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW COMBINATION","NOUVELLE COMBINAISON","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3680","97-10-29","TARO PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3681","97-08-27","RJR PHARMA INTERNATIONAL SERVICES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"3682","97-01-31","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3683","97-08-14","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"3684","97-07-14","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"3685","97-03-21","GENETICS INSTITUTE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR IX","FACTEUR DE COAGULATION ANTIHÉMORRHAGIQUE DE SANG IX","",""
"3686","97-12-11","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERCHOLESTEROLEMIC","ANTIHYPERCHOLESTÉROLÉMIANT ORALE","",""
"3687","97-06-18","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADRENOCORTICOTROPIC HORMONE","HORMONE ADRÉNOCORTICOTROPE","",""
"3688","97-07-23","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SEASONAL RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"3689","97-06-16","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INTAL NEBULIZER SOL.","FISONS CORP. LTD.","CANADA","CANADA","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"3690","97-12-11","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SEASONAL RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"3691","97-11-26","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","SEASONAL RHINITIS PROPHYLAXIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"3692","97-07-23","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INTAL NEBULIZER SOL.","FISONS CORP. LTD.","CANADA","CANADA","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE RHINITIQUE SAISONAL","",""
"3693","97-05-26","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYNACROM","FISONS CORP. LTD.","CANADA","CANADA","1","","","SEASONAL RHINITIS PROPHYLAXIS","PROPHYLAXIE RHINITIQUE SAISONNIÈRE","",""
"3694","97-04-15","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","RELAXANT DES MUSCLES SQUELETTIQUES","",""
"3695","97-07-08","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"3696","97-07-08","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"3697","97-10-21","TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"3698","97-11-17","TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","RELAXANT DES MUSCLES SQUELETTIQUES","",""
"3699","97-05-21","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLEXERIL","MERCK FROSST CANADA INC.","CANADA","CANADA","1","","","SKELETAL MUSCLE RELAXANT","RELAXANT DES MUSCLES SQUELETTIQUES","",""
"3700","97-09-17","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE THERAPY","TRAITEMENT ANTIACNÉIQUE","",""
"3701","97-08-28","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANDROGEN","ANTIANDROGÈNE","",""
"3702","97-08-12","PHARMACIA & UPJOHN COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC","ANTILEUCÉMIQUE","",""
"3703","97-08-01","MEDIMMUNE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"3704","97-04-16","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHROMBOTIC AGENT","ANTITHROMBOTIQUE","",""
"3705","97-04-22","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR MULTIDOSE VIAL WITH PRESERVATIVE AND A NEW ONCE DAILY TREATMENT REGIMEN IN THE TREATMENT OF DEEP VEIN THROMBOSIS","FLACON À DOSES MULTIPLES AVEC AGENT DE CONSERVATION ET NOUVEAU SCHÉMA THÉRAPEUTIQUE D'UNE FOIS PAR JOUR POUR LE TRAITEMENT DE LA THROMBOSE VEINEUSE PROFONDE","ANTITHROMBOTIC AGENT","ANTITHROMOBOTIQUE","",""
"3706","97-05-29","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CERUBIDINE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","ANTIMITOTIC, ANTIBIOTIC","ANTIMITOTIQUE, ANTIBIOTIQUE","",""
"3707","97-06-27","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IRON AND ALUMINIUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"3708","97-12-03","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3709","97-08-26","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3710","97-02-06","ORTHO PHARMACEUTICAL CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION OF NON-MEDICINALS AND NEW MANUFACTURING SITE","MODIFICATION DE LA PRÉPARATION / NOUVEL EMPLACEMENT DE FABRICATION","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3711","97-11-26","MEDISAN PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS AGENT","AGENT PROPHYLAXIE","",""
"3712","97-09-30","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC-SEDATIVE","ANXIOLYTIQUE-SÉDATIF","",""
"3713","97-05-15","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"3714","97-07-08","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"3715","97-06-27","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"3716","97-10-24","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN","CIBA-GEIGY CANADA LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"3717","97-11-10","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR REVISED INDICATION: THE TREATMENT OF HIV INFECTION WHEN ANTIRETROVIRAL THERAPY IS WARRANTED","INDICATION RÉVISÉE : POUR LE TRAITEMENT DE L'INFECTION À VIH LORSQUE LA THÉRAPIE ANTIRÉTROVIRALE EST INDIQUÉE","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"3718","97-05-07","MERRELL PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS - RESTRICTION IN INDICATION - NEW WARNING","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT : RESTRICTION AUX INDICATIONS - NOUVELLE MISE EN GARDE","ANOREXIANT","ANOREXIGÈNE","",""
"3719","97-07-04","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST/MIGRAINE THERAPY","ANTAGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT DE LA MIGRAINE","",""
"3720","97-05-29","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"3721","97-03-26","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIHYPERTENSIVE AGENT/ANTIANGINAL AGENT","ANTIHYPERTENSEUR/ANTIANGINEUX","",""
"3722","97-01-30","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: CONTROLLED DELIVERY CAPSULES","NOUVELLE FORME POSOLOGIQUE : CAPSULES À LIBÉRATION CONTRÔLÉE","ANTIANGINAL AGENT/ANTIHYPERTENSIVE AGENT","ANTIANGINEUX/ANTIHYPERTENSEUR","",""
"3723","97-06-27","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"3724","97-07-16","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE PRÉSENTATION, NOUVELLE CONCENTRATION","ANTIHYPERTENSIVE AGENT, ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"3725","97-03-11","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIHYPERTENSIVE AGENT, ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"3726","97-04-24","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIHYPERTENSIVE AGENT/ANTIANGINAL AGENT","ANTIHYPERTENSEUR/ANTIANGINEUX","",""
"3727","97-11-10","CRYSTAAL CORPORATION, A DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"3728","97-04-15","BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"3729","97-03-20","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","ANTICONVULSANT","ANTICONVULSIVANT","",""
"3730","97-11-10","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","INOTROPIC","INOTROPE","",""
"3731","97-05-21","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"3732","97-09-17","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"3733","97-11-17","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"3734","97-09-17","TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"3735","97-09-17","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"3736","97-09-17","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"3737","97-10-21","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTIINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"3738","97-04-07","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"3739","97-08-12","PHARMACIA & UPJOHN COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"3740","97-09-16","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"3741","97-09-04","PHARMACIA & UPJOHN COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"3742","97-08-12","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"3743","97-09-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"3744","97-04-09","LEIRAS OY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DOBUTREX","ELI LILLY","CANADA","CANADA","1","","","INOTROPIC AGENT","INTROPIQUE","",""
"3745","97-08-12","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTERASE","",""
"3746","97-07-23","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE TO COMMERCIAL PACKAGING FOR PHYSICIAN STARTER KIT","MODIFICATION À L'EMBALLAGE COMMERCIAL POUR LA TROUSSE DE DÉMARRAGE DU MÉDECIN","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"3747","97-12-03","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3748","97-08-12","PHARMACIA & UPJOHN COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"3749","04-06-08","SOLVAY PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR (AT1) ANTAGONIST AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"3750","97-09-04","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3751","04-06-08","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"3752","04-06-10","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT SUITE À L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI)","PROGESTIN","PROGESTATIF","",""
"3753","97-07-29","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BROAD SPECTRUM ANTIBIOTIC","ANTIBIOTIQUE À LARGE SPECTRE","",""
"3754","97-04-03","RJR PHARMA INTERNATIONAL SERVICES INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3755","97-08-18","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INAPSINE","JANSSEN PHARMA.","CANADA","CANADA","1","","","NEUROLEPTIC ANTIEMETIC","NEUROLEPTIC, ANTIÉMÉTIQUE","",""
"3756","97-02-27","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3757","04-06-08","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TO REDUCE THE RISK OF MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH CHD WHO HAVE UNDERGONE PERCUTANEOUS INTERVENTION PROCEDURES","NOUVELLE INDICATION : RÉDUCTION DU RISQUE D'IMPORTANTS TROUBLES CARDIAQUES INDÉSIRABLES CHEZ LES PERSONNES ATTEINTES DE CORONOPATHIE QUI ONT SUBI DES PROCÉDURES D'INTERVENTIONS PERCUTANÉES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉRABOLISME LIPIDIQUE","",""
"3758","97-11-26","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR NEW PRESENTATION: 40MG/0.4ML PREFILLED SYRINGES AND ADDITIONAL INDICATIONS: PROPHYLAXIS OF THROMBOEMBOLIC DISORDERS IN PATIENTS UNDERGOING HIGH RISK ABDOMINAL, GYNECOLOGICAL OR UROLOGICAL SURGERIES; COLORECTAL SURGERY","NOUVELLE PRÉSENTATION : SERINGUES PRÉREMPLIES DE 40MG/0.4ML ET INDICATIONS ADDITIONNELLES : TRAITEMENT DE TROUBLES THROMBOEMBOLIQUES CONSÉCUTIFS AUX INTERVENTIONS CHIRURGICALES À RISQUE ÉLEVÉ DE L'ABDOMEN, AU SYSTÈME GYNÉCOLOGIQUE OU UROLOGIQUE; CHIRURGIE COLORECTALE","ANTITHROMBOTIC AGENT","ANTITHROMBOTIQUE","",""
"3759","97-05-29","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3760","97-03-26","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3761","04-06-11","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE INDICATIONS AND CLINICAL USE SECTION OF THE PRODUCT MONOGRAPH FOR THE USE OF VALSARTAN AS FIRST-LINE THERAPY","RÉVISIONS À LA RUBRIQUE INDICATIONS ET USAGE CLINIQUE DE LA MONOGRAPHIE DU PRODUIT POUR INCLURE L'USAGE DU VALSARTAN COMME THÉRAPIE DE PREMIÈRE LIGNE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L;ANGIOTENSINE II ET DIURÉTIQUE","",""
"3762","97-02-12","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PRE-FILLED SYRINGE PRESENTATION","NOUVELLE PRÉSENTATION","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ÉRYTHROPOÏÈSE","",""
"3763","04-06-11","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE INDICATIONS AND CLINICAL USE SECTION OF THE PRODUCT MONOGRAPH FOR THE USE OF VALSARTAN AS FIRST-LINE THERAPY","RÉVISIONS À LA RUBRIQUE INDICATIONS ET USAGE CLINIQUE DE LA MONOGRAPHIE DU PRODUIT POUR INCLURE L'USAGE DU VALSARTAN COMME THÉRAPIE DE PREMIÈRE LIGNE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"3764","04-06-10","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH - REVISED INDICATION AND SAFETY INFORMATION","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT - RÉVISIONS AUX INDICATIONS ET MISES EN GARDE","PITUITARY GONADOTROPIN INHIBITOR","INHIBITEUR DE LA GONADOTROPHINE HYPOPHYSAIRE","",""
"3765","97-05-21","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","SUBCUTANEOUS ADMINISTRATION IN HEMODIALYSIS PATIENTS","ADMINISTRATION SOUS-CUTANÉE CHEZ LES PATIENTS QUI SONT EN HÉMODIALYSE","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ÉRYTHROPOÏÈSE","",""
"3766","97-03-27","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION IN VIAL PRESENTATION","MODIFICATION DE LA PRÉPARATION","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ÉRYTHROPOÏÈSE","",""
"3767","97-03-06","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VASODILATOR","VASODILATATEUR","",""
"3768","04-06-08","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE WITH ELECTROLYTE SUPPLEMENTS FOR INTRAVENOUS INFUSION","NUTRITIF AVEC SUPPLÉMENTS HYDRO-ÉLECTROLYTIQUES POUR INFUSION INTRAVEINEUSE","",""
"3769","04-06-08","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE WITH ELECTROLYTE SUPPLEMENTS FOR INTRAVENOUS INFUSION","NUTRITIF AVEC SUPPLÉMENTS HYDRO-ÉLECTROLYTIQUES POUR INFUSION INTRAVEINEUSE","",""
"3770","97-04-10","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW CLAIM: FOR CONTINUOUS, LONG-TERM USE","NOUVELLE RÉCLAME : POUR USAGE  CONTINU, À LONG TERME","ESTROGEN","OESTROGÈNE","",""
"3771","97-06-16","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"3772","97-06-27","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN-PROGESTIN","ASSOCIATION OESTRO-PROGESTATIVE","",""
"3773","04-06-08","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE WITH ELECTROLYTE SUPPLEMENTS FOR INTRAVENOUS INFUSION","NUTRITIF AVEC SUPPLÉMENTS HYDRO-ÉLECTROLYTIQUES POUR INFUSION INTRAVEINEUSE","",""
"3774","04-06-08","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE WITH ELECTROLYTE SUPPLEMENTS FOR INTRAVENOUS INFUSION","NUTRITIF AVEC SUPPLÉMENTS HYDRO-ÉLECTROLYTIQUES POUR INFUSION INTRAVEINEUSE","",""
"3775","97-06-18","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"3776","04-06-08","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE SUPPLEMENT FOR INTRAVENOUS INFUSION","SUPPLÉMENT NUTRITIF POUR INFUSION INTRAVEINEUSE","",""
"3777","04-06-08","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE SUPPLEMENT FOR INTRAVENOUS INFUSION","SUPPLÉMENT NUTRITIF POUR INFUSION INTRAVEINEUSE","",""
"3778","04-06-08","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE SUPPLEMENT FOR INTRAVENOUS INFUSION","SUPPLÉMENT NUTRITIF POUR INFUSION INTRAVEINEUSE","",""
"3779","04-06-08","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVENOUS NUTRITIVE SUPPLEMENTS","SUPPLÉMENTS NUTRITIFS INTRAVEINEUX","",""
"3780","04-06-10","SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"3781","97-08-18","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE","",""
"3782","97-10-29","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE","",""
"3783","97-08-11","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTRADOL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE","",""
"3784","97-08-29","PROCTER & GAMBLE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - FOR THE SHORT-TERM TREATMENT OF MILD TO MODERATE PAIN","NOUVELLE INDICATION - POUR LE TRAITEMENT À COURT TERME DE LA DOULEUR LÉGÈRE À MODÉRÉE","NON-STEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"3785","97-04-07","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"3786","97-12-31","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"3787","97-06-11","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC","RX À OTC","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"3788","97-08-07","WAMPOLE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"3789","97-05-30","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"3790","97-01-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"3791","97-05-30","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"3792","97-09-22","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"3793","97-09-22","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"3794","97-04-22","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW TABLET SIZE","NOUVEL EMBALLAGE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"3795","97-05-21","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION: RESTRICTION IN INDICATION, NEW WARNING","RÉVISION À LA MONOGRAPHIE DU PRODUIT : RESTRICTION DES INDICATIONS, NOUVELLE MISE EN GARDE","ANOREXIANT","ANOREXIGÈNE","",""
"3796","97-06-18","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIANT","",""
"3797","97-06-23","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL","JOUVEINAL INC.","CANADA","CANADA","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIANT","",""
"3798","97-07-23","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3799","97-04-07","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"3800","97-06-11","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H1","",""
"3801","97-01-14","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA FABRICATION","HAEMATOPOIETIC AGENT","HÉMOTOPOÏÉTIQUE","",""
"3802","97-10-06","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - ADJUNCTIVE THERAPY IN PATIENTS WITH HIV INFECTION","NOUVELLE INDICATION - TRAITEMENT COMPLÉMENTAIRE CHEZ LES PATIENTS ATTEINTS D'INFECTION À VIH","HAEMATOPOIETIC AGENT","AGENT HÉMATOPOÏÉTIQUE","",""
"3803","97-01-16","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING FACILITY, INCLUDING MULTI-USE ACTIVITIES","CHANGEMENTS À L'ÉTABLISSEMENT DE FABRICATION, INCLUANT DES ACTIVITÉS À USAGE MULTIPLE","HAEMATOPOIETIC AGENT","HÉMOTOPOÏÉTIQUE","",""
"3804","97-12-03","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTISPASMODIC","ANTISPASMODIQUE AGISSANT SUR LES VOIES URINAIRES","",""
"3805","97-10-17","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SELECTIVE CALCIUM-ENTRY BLOCKER","INHIBITEUR CALCIQUE SÉLECTIF","",""
"3806","97-04-07","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"3807","97-11-24","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORITICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"3808","97-12-08","TARO PHARMACEUTICALS INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIDEX OINTMENT, TOPSYN GEL","SYNTEX CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORMS - OINTMENT AND GEL","NOUVELLE PRÉSENTATION : ONGUENT ET GEL","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"3809","97-09-19","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE TOPIQUE","",""
"3810","97-06-06","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC AGENT","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"3811","97-05-01","NU-PHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC AGENT","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"3812","97-02-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"3813","97-09-16","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"3814","97-09-04","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"3815","97-03-06","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"3816","97-08-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3817","97-05-12","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"3818","97-10-29","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"3819","97-04-29","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY KINGSWOOD INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"3820","97-06-06","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","GONADOTROPHIN","GONADOTROPHINE","",""
"3821","97-07-02","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","HUMAN GONADOTROPIN","GONADOTROPHINE HUMAINE","",""
"3822","97-06-27","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESIS; ANTITUMOUR AGENT","INHIBITEUR DE L'AROMATASE STÉROÏDIEN, INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES, ANTINÉOPLASIQUES","",""
"3823","97-03-06","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"3824","97-04-24","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR USE IN PATIENTS WITH SYMPTOMATIC CONGESTIVE HEART FAILURE","POUR TRAITEMENT DEL'INSUFFISANCE CARDIAQUE CONGESTIVE SYMPTOMATIQUE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"3825","97-03-20","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"3826","97-07-28","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF CYTOMEGALOVIRUS DISEASE (CMV) IN SOLID ORGAN TRANSPLANT RECIPIENTS AT RISK OF DEVELOPING CMV DISEASE","NOUVELLE INDICATION : PRÉVENTION DE L'INFECTION AU CYTOMÉGALOVIRUS (CMV) CHEZ LES RECEVEURS DE GREFFES D'ORGANES PLEINS RISQUANT D'AVOIR DES MALADIES À CMV","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"3827","97-09-04","CHIRON CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"3828","97-01-30","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIQUE","",""
"3829","97-04-24","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIQUE","",""
"3830","97-01-14","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOPID","PARKE-DAVIS (CANADA) INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIANT","",""
"3831","97-09-04","TEVA PHARMACEUTICALS USA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"3832","97-12-31","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ORAL HYPOGLYCEMIC","HYPOGLYCÉMIANT ORAL","",""
"3833","97-10-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"3834","97-06-06","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"3835","97-10-21","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"3836","97-10-29","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"3837","97-03-20","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE OF ZOLADEX AS AN ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION","NOUVELLE INDICATION : USAGE DE ZOLADEX COMME AGENT RÉDUCTEUR DU TISSU ENDOMÉTRIAL AVANT L'ABLATION DE L'ENDOMÈTRE","LUTEINIZING HORMONE-RELEASING HORMONE ANALOG","ANALOGUE DE LA LH-RH","",""
"3838","97-09-30","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DOSAGE FORM AND NEW FORMULATION","NOUVELLE PRÉSENTATION, NOUVELLE PRÉPARATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"3840","97-05-12","CONNAUGHT LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"3841","97-02-12","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HALDOL LA","MCNEIL","CANADA","CANADA","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"3842","97-11-17","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HALDOL LA","MCNEIL","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"3843","97-03-27","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","USE IN CHILDREN AND ADOLESCENTS FROM 1 YEAR UP TO AND INCLUDING 18 YEARS OF AGE, NEW PRESENTATION","POUR L'ENFANT ET L'ADOLESCENT DE 1 À 18 ANS INCLUSIVEMENT, NOUVELLE PRÉSENTATION","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"3844","97-07-08","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","AN ALTERNATE SITE FOR PRODUCTION OF CONCENTRATED STERILE BULK, SCALE UP OF MANUFACTURING PROCESS","SITE ALTERNATIF POUR LA PRODUCTION DE PRODUIT EN VRAC STÉRILE CONCENTRÉ, MISE À L'ÉCHELLE DU PROCÉDÉ DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"3845","97-11-10","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","VACCINE","VACCIN","",""
"3846","97-05-29","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE TEST SPECIFICATIONS AND METHODS","MODIFICATIONS AUX SPÉCIFICATIONS ET MÉTHODES ANALYTIQUES","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"3847","97-05-21","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SITE OF ADSORPTION / FORMULATION AND FILLING OF ALL PRESENTATIONS","SITE ALTERNATIF D'ADSORPTION/FORMULE ET REMPLISSAGE DE TOUTES LES PRÉSENTATIONS","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"3848","97-11-10","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","VACCINE","VACCIN","",""
"3849","97-02-12","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"3850","97-01-23","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"3851","97-07-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"3852","97-04-24","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC-ANTIHYPERTENSIVE","DIURÉTIQUE-ANTIHYPERTENSEUR","",""
"3853","97-08-27","BOEHRINGER MANNHEIM CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"3854","97-02-04","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW GELATIN COATED CAPLET","NOUVEAU COMPRIMÉ-CAPSULE ENROBÉ DE GÉLATINE","ANALGESIC/ANTIPYRETIC","ANALGÉSIQUE/ANTIPYRÉTIQUE","",""
"3855","97-09-05","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE PRÉSENTATION ET CONCENTRATION","ANALGESIC/ANTIPYRETIC","ANALGÉSIQUE/ANTIPYRÉTIQUE","",""
"3856","97-11-27","MCNEIL CONSUMER PRODUCTS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"3857","97-03-26","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"3858","97-02-12","GENZYME CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYME","",""
"3859","97-01-23","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"3860","97-04-10","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"3861","97-05-29","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - PROPHYLAXIS OF INFECTIONS IN CHILDREN WITH HIV INFECTION","NOUVELLE INDICATION : TRAITEMENT D'INFECTIONS CHEZ L'ENFANT INFECTÉ AU VIH","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPIE PASSIVE","",""
"3862","97-11-04","BAYER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - PROPHYLAXIS OF INFECTIONS IN CHILDREN WITH HIV INFECTION","NOUVELLE INDICATION - TRAITEMENT DES INFECTIONS CHEZ L'ENFANT ATTEINT DU VIH","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPHIE PASSIVE","",""
"3863","97-02-17","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"3864","97-06-11","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","REPLACEMENT THERAPY FOR IMMUNODEFICIENCIES","THÉRAPIE DE REPLACEMENT","",""
"3865","97-04-29","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC/ANTIHYPERTENSIVE AGENT","DIURÉTIQUE/ANTIHYPERTENSEUR","",""
"3866","97-02-28","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC/ANTIHYPERTENSIVE AGENT","DIURÉTIQUE/ANTIHYPERTENSEUR","",""
"3867","97-07-30","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY - ANALGESIC","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"3868","97-08-18","SABEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"3870","97-12-24","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - MULTIPLE MYELOMA, REVISED PRODUCT MONOGRAPH, INCLUDING REVISIONS FROM NOTIFIABLE CHANGE # 043070","NOUVELLE INDICATION - MYÉLOME MULTIPLE, RÉVISION À LA MONOGRAPHIE DU PRODUIT INCLUANT DES RÉVISIONS AU CHANGEMENT DEVANT ÊTRE OBLIGATOIREMENT DÉCLARÉ # 043070","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"3871","97-07-02","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","THREE NEW STRENGTHS","TROIS NOUVELLES CONCENTRATIONS","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"3872","97-06-06","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE, CHANGE IN MANUFACTURING","AUTRE EMPLACEMENT DE FABRICATION, MODIFICATION DE LA FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"3873","97-06-06","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW 2ND GENERATION PROCESS FOR DRUG SUBSTANCE","NOUVEAU PROCÉDÉ DE 2IÈME GÉNÉRATION DE LA SUBSTANCE MÉDICAMENTEUSE","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"3874","97-09-02","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PRESENTATION: PRE-FILLED SYRINGES FOR SELF-ADMINISTRATION","NOUVELLE PRÉSENTATION : SERINGUES PRÉ-REMPLIES POUR AUTO-ADMINISTRATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"3875","97-06-16","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE FOR ALBUMIN (HUMAN) FREE FORMULATION, TWO NEW STRENGTHS OF ALBUMIN (HUMAN) FREE FORMULATION","SITE ALTERNATIF DE FABRICATION POUR POUR LA PRÉSENTATION SANS ALBUMINE HUMAINE, 2 NOUVELLES CONCENTRATIONS POUR LA PRÉSENTATION SANS ALBUMINE HUMAINE","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"3876","97-05-06","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ISOVUE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"3877","97-05-06","FUJISAWA CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ISOVUE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"3878","97-07-23","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"3879","97-06-23","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATROVENT INHALATION SOLUTION","BOEHRINGER INGELHEIM","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","BRONCHODILATOR","BRONCHODILATATEUR","",""
"3880","97-07-08","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: IN PLASTIC SINGLE DOSE UNITS","NOUVELLE FORME POSOLOGIQUE : FLACONS MONODOSES EN PLASTIQUE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"3881","97-12-11","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"3882","97-08-13","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATROVENT INH. SOL.","BOEHRINGER INGELHEIM","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","BRONCHODILATOR","BRONCHODILATATEUR","",""
"3883","97-04-25","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"3884","97-07-04","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"3885","97-01-08","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"3886","97-09-11","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FORANE","ZENECA PHARMA","CANADA","CANADA","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"3887","97-05-21","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - ONYCHOMYCOSIS","NOUVELLE INDICATION - ONYCHOMYCOSIS","ANTIFUNGAL","ANTIFONGIQUE","",""
"3888","97-08-07","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE DOSAGE RECOMMENDATION IN DERMATOMYCOSES","RECOMMANDATION DE DOSE ALTERNATIVE POUR LES DERMATOMYCOSES","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3889","97-05-20","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIFUNGAL","ANTIFONGIQUE","",""
"3890","97-08-18","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3891","97-12-15","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","NON-STÉROÏDIEN, ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"3892","97-05-12","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIENS (AINS), ANALGÉSIQUE","",""
"3893","97-03-10","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PEDIATRIC ASTHMA PROPHYLACTIC AND ANTIALLERGIC AGENT","PROPHYLAXIE DE L'ASTHME INFANTILE ET AGENT ANTI-ALLERGIQUE","",""
"3894","97-02-21","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","PEDIATRIC ASTHMA PROPHYLACTIC & ANTIALLERGIC AGENT","PROPHYLAXIE DE L'ASTHME INFANTILE ET AGENT ANTI-ALLERGIQUE","",""
"3895","97-07-08","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PEDIATRIC ASTHMA PROPHYLACTIC, ANTIALLERGIC AGENT","AGENT PROPHYLACTIQUE DE L'ASTHME INFANTILE, AGENT ANTIALLERGIQUE","",""
"3896","97-08-12","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PEDIATRIC ASTHMA PROPHYLACTIC AND ANTIALLERGIC AGENT","AGENT PROPHYLACTIQUE DE L'ASTHME INFANTILE, AGENT ANTIALLERGIQUE","",""
"3897","97-09-30","CENTOCOR","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"3898","97-07-14","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRANDATE","ROBERTS PHARMACEUTICAL CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"3899","97-04-22","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR USE AS MONOTHERAPY FOLLOWING WITHDRAWAL OF CONCOMITANT ANTIEPILEPTIC DRUG","COMME MONOTHÉRAPIE APRÈS LE RETRAIT DES ANTIÉPILEPTIQUES ADMINISTRÉS EN CONCOMITANCE","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"3900","97-12-15","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","H, K-ATPASE INHIBITOR","INHIBITEUR DE L'H, K-ATPASE","",""
"3901","97-05-29","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR THE FOLLOWING ADDITIONAL INDICATIONS: 1. MAINTENANCE OF HEALED DUODENAL ULCER 2. MAINTENANCE OF HEALED REFLUX ESOPHAGITIS 3. LONG TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROM","NOUVELLES INDICATIONS : MAINTIEN D'UN ULCÈRE DUODÉNAL CICATRISÉ 2. MAINTIEN DU REFLUX GASTRO-OESOPHAGIEN GUÉRI 3. TRAITEMENT À LONG TERME D'ÉTATS PATHOLOGIQUES D'HYPERSÉCRÉTION, INCLUANT LE SYNDROME DE ZOLLINGER-ELLISON","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"3902","97-06-16","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN F2-ANALOGUE","ANALOGUE DE LA PROSTAGLANDINE F2","",""
"3903","97-03-10","SIGMA-TAU PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","REPLENISHER","RÉGÉNÉRATEUR","",""
"3904","97-05-21","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESES; ANTITUMOUR AGENT","INHIBITEUR D'AROMATASE NON-STÉROÏDIEN; INHIBITEUR DE LA BIOSYNTHÈSE DE L'ESTROGÈNE; AGENT ANTITUMORAL","",""
"3905","97-06-03","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","GONADOTROPIN-RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"3906","97-09-30","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ERGAMISOL","JANSSEN PHARMACEUTICA INC.","CANADA","CANADA","1","","","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"3907","97-07-14","BAUSCH & LOMB CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"3908","97-11-04","ALCON CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"3909","97-11-14","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3910","97-12-03","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3911","97-06-27","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR THE TREATMENT FOLLOWING ACUTE MYOCARDIAL INFARCTION","TRAITEMENT SUITE À UN INFARCTUS AIGU DU MYOCARDE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"3912","97-06-24","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR THE TREATMENT FOLLOWING ACUTE MYOCARDIAL INFARCTION","TRAITEMENT SUITE À UN INFARCTUS AIGU DU MYOCARDE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"3913","97-05-29","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMANIC AGENT","ANTIMANIAQUE","",""
"3914","97-12-11","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMANIC AGENT","AGENT ANTIMANIAQUE","",""
"3915","97-01-31","MCNEIL CONSUMER PRODUCTS COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ORAL ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE ORAL","",""
"3916","97-09-30","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"3917","97-12-03","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"3918","97-02-28","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"3919","97-03-26","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"3920","97-09-22","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"3921","97-07-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3922","97-05-15","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS-RESTRICTION IN INDICATION, NEW WARNING","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT - RESTRICTION AUX INDICATIONS, NOUVELLE MISE EN GARDE","ANOREXIANT","ANOREXIGÈNE","",""
"3923","97-08-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT","ANOREXIGÈNE","",""
"3924","97-08-28","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"3926","97-09-02","CONNAUGHT LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"3927","97-02-25","CLINTEC NUTRITION COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","FAT EMULSION FOR INTRAVENOUS NUTRITION","ÉMULSION DE GRAISSE POUR NUTRITION INTRAVÉINEUSE","",""
"3928","97-05-29","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTROGEN","AGENT PROSGESTATIF","",""
"3929","97-04-03","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: CONTRACEPTION NEW PACKAGING: PRE-FILLED SYRINGE","NOUVEL EMBALLAGE : SERINGE PRÉ-REMPLIE, NOUVELLE INDICATION : CONTRACEPTION","PROGESTOGEN","PROGESTROGÈNE","",""
"3930","97-07-23","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTAGEN","PROGESTATIF","",""
"3931","97-01-30","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"3932","97-04-29","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PONSTAN","PARKE DAVIS","CANADA","CANADA","1","","","ANALGESIC","ANALGÉSIQUE","",""
"3933","97-12-18","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR PRODUCT MONOGRAPH REVISIONS: - MODIFICATIONS TO THE CURRENT MEFLOQUINE TREATMENT RECOMMENDATIONS FOR CHILDREN - MEFLOQUINE LOADING DOSE OPTION FOR MALARIA PROPHYLAXIS","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT : CHANGEMENTS AUX RECOMMENDATIONS DE TRAITEMENT À LA MÉFLOQUINE CHEZ L'ENFANT - OPTION DE DOSE D'ATTAQUE DE MÉFLOQUINE POUR LE TRAITEMENT DU PALUDISME","ANTIMALARIAL","ANTIPALUDIQUE","",""
"3934","97-05-29","LINSON PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","PROGESTOGEN/ANTINEOPLASTIC/ANTIANOREXIC/ANTICACHECTIC","PROGESTOGÈNE/ANTINÉOPLASIQUE/ANTIANOREXIANT/ANTICACHEXIQUE","",""
"3935","97-02-06","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN CANCER AS AN ANTIANOREXIC AND ANTICACHECTIC","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ANOREXIE ET DE LA CACHEXIE INDUITES PAR UN CANCER","PROGESTOGEN/ANTINEOPLASTIC/ANTIANOREXIC/ANTICACHETIC","PROGESTROGÈNE/ANTINÉOPLASIQUE/ANTIANOREXIANT/ANTICACHECTIQUE","",""
"3936","97-10-24","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF ANTIANOREXIC AND ANTICACHECTIC TO THE THERAPEUTIC CLASSIFICATION OF THE PRODUCT","AJOUT À LA CLASSIFICATION THÉRAPEUTIQUE DU PRODUIT POUR INCLURE ANTIANOREXIQUE ET ANTICACHECTIQUE","PROGESTOGEN/ANTINEOPLASTIC/ANTIANOREXIC/ANTICACHECTIC","PROGESTATIF/ANTINÉOPLASIQUE/ANTIANOREXIQUE/ANTICACHECTIQUE","",""
"3937","97-06-27","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR NEW PEDIATRIC INDICATIONS","NOUVELLE INDICATION: PÉDIATRIQUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3938","97-02-28","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"3939","97-01-30","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"3940","97-01-14","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND NEW SOURCE OF FINISHED PRODUCT","NOUVELLE CONCENTRATION, NOUVELLE SOURCE DU PRODUIT FINI","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"3941","97-05-29","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"3942","97-09-30","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"3943","97-08-27","FAULDING (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOLU-MEDROL","PHARMACIA & UPJOHN CAN. LTD.","CANADA","CANADA","1","","","GLUCOCORTICOID/ANTI-INFLAMMATORY","GLUCOCORTICOÏDE, ANTI-INFLAMMATOIRE","",""
"3944","97-07-30","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOLU-MEDROL STERILE POWDER","UPJOHN CANADA LTD.","CANADA","CANADA","1","","","GLUCOCORTICOID/ANTI-INFLAMMATORY","GLUCOCORTICOÏDE/ANTI-INFLAMMATOIRE","",""
"3945","97-01-08","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC, MODIFIER OF UPPER GASTROINTESTINAL TRACT MOTILITY","ANTIÉMÉTIQUE, MODIFICATEUR DE MOTILITÉ GASTROINTESTINAL","",""
"3946","97-04-24","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"3947","97-01-08","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"3948","97-08-26","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"3949","97-03-10","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"3950","97-03-10","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"3951","97-07-04","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ß-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"3952","97-04-22","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A CHANGE IN DOSAGE: FROM TWICE DAILY, TO ONCE OR TWICE DAILY","CHANGEMENT À LA POSOLOGIE : DE 2 FOIS PAR JOUR À 1 OU DEUX FOIS PAR JOUR","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"3953","97-07-14","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRYTHMIC AGENT","AGENT ANTIARYTHMIQUE","",""
"3954","97-04-17","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MONISTAT CREAM 2%","ORTHO PHARMACEUTICAL (CANADA) LTD.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"3955","97-06-20","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN PEDIATRICS","NOUVELLE INDICATION : POUR USAGE PÉDIATRIQUE","PREMEDICANT/SEDATIVE/ANAESTHETIC AGENT","PRÉMÉDICATION, SÉDATIF, ANESTHÉSIQUE","",""
"3956","97-04-07","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3957","97-03-26","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3958","97-02-21","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3960","97-02-17","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"3961","97-09-17","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3962","97-03-10","SCHERING CANADA INC./NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","HEMATOPOIETIC GROWTH FACTOR","FACTEUR DE CROISSANCE HÉMOTOPOÏÉTIQUE","",""
"3963","97-02-06","PURDUE FREDERICK","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH - 5MG TABLETS","NOUVELLE CONCENTRATION - COMPRIMÉS DE 5MG","OPIOID ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"3965","97-11-03","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW ROUTE OF ADMINISTRATION AND NEW INDICATION","NOUVELLE VOIE D'ADMINISTRATION ET NOUVELLE INDICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"3966","97-05-21","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE PRÉSENTATION ET CONCENTRATION","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"3967","97-03-26","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AND ANTI-HYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"3968","97-11-27","SANOFI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT/ANTITHROMBOTIC","ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"3969","97-08-01","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"3970","97-04-15","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE/ANALGÉSIQUE/ANTIPYRÉTIQUE","",""
"3971","97-07-28","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC PROPRIÉTÉS ANALGÉSIQUE ET ANTIPYRÉTIQUE","",""
"3972","97-03-26","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC, ANTI-INFLAMMATORY AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"3973","97-01-30","ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIALLERGIC","ANTIALLERGIQUE","",""
"3974","97-01-31","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHIAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE BRONCHIQUE","",""
"3975","97-11-10","CONNAUGHT LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW SITE FOR PURIFICATION","NOUVEL EMPLACEMENT POUR LA PURIFICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"3976","97-09-11","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"3977","97-06-27","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","AUXILIAIRE POUR CESSER DE FUMER","",""
"3978","97-08-18","PHARMACIA & UPJOHN COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","AUXILIAIRE POUR CESSER DE FUMER","",""
"3979","97-09-15","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RX À OTC","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"3980","97-10-29","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"3981","97-10-08","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"3982","97-04-07","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL/ANTIHYPERTENSIVE AGENT","ANTIANGINEUX/ANTIHYPERTENSEUR","",""
"3983","97-04-22","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE, ANTICONVULSIVANT","",""
"3984","97-09-30","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE, ANTICONVULSIVANT","",""
"3985","97-04-17","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY TRACT ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"3986","97-06-13","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR A NEW CHOLOROFLUOROCARBON-FREE FORMULATION","NOUVELLE FORMULATION SANS CHLOROFLUOROCARBONE","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"3987","97-06-18","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL","ANTIANGINEUX","",""
"3988","97-03-10","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"3989","97-04-30","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEURS H2 DE L'HISTAMINE","",""
"3990","97-02-04","DISPENSAPHARM","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"3991","97-07-14","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICYCLIC ANTIDEPRESSANT","ANTIDÉPRESSEUR TRICYCLIQUE","",""
"3992","97-07-28","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"3993","97-08-18","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"3994","97-07-14","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW INDICATION: USE IN THE PREVENTION OF COMPLICATIONS FOLLOWING PANCREATIC SURGERY IN PATIENTS UNDERGOING HIGH RISK PROCEDURES","NOUVELLE INDICATION : POUR PRÉVENIR LES COMPLICATIONS CHEZ LES PATIENTS AYANT SUBI UNE CHIRURGIE PANCRÉATIQUE À HAUT RISQUE","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"3995","97-09-16","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIALLERGY AGENT","ANTIALLERGIQUE","",""
"3996","97-10-17","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE POUR LE TRACTUS GASTRO-INTESTINAL INFÉRIEUR","",""
"3997","97-02-21","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","H+, K+-ATPASE INHIBITOR","INHIBITEUR H+, K+-ATPASE","",""
"3998","97-10-17","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALUPENT","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ß2-ADRENERGIC STIMULANT BRONCHODILATOR","BRONCHODILATATEUR-STIMULANT DES RÉCEPTEURS ß2-ADRÉNERGIQUES","",""
"3999","97-01-08","STIEFEL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"4000","97-11-10","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß2-ADRENERGIC STIMULANT BRONCHODILATOR","BRONCHODILATATEUR-STIMULANT DES RÉCEPTEURS ß2-ADRÉNERGIQUES","",""
"4001","97-04-22","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"4002","97-03-26","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"4003","97-03-18","NU-PHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DITROPAN","MARION LABORATORIES INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"4005","97-08-01","PURDUE FREDERICK","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"4006","97-07-02","IMMUNEX CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4007","96-12-31","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE AS FIRST-LINE TREATMENT OF OVARIAN CANCER","NOUVELLE INDICATION","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4008","97-06-20","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"4009","97-11-19","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4010","97-01-14","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOACTIVE AGENT","AGENT VASOACTIF","",""
"4011","97-01-14","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOACTIVE AGENT","AGENT VASOACTIF","",""
"4012","97-01-30","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOACTIVE AGENT","AGENT VASOACTIF","",""
"4013","97-06-16","BLOCK DRUG COMPANY (CANADA) LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION AND DOSAGE FORM","NOUVELLE INDICATION, NOUVELLE PRÉSENTATION","TOPICAL PEDICULICIDE AND OVICIDE","PÉDICULICIDE ET OVICIDE TOPIQUE","",""
"4014","97-05-21","REED & CARNICK, DIVISION OF BLOCK DRUG COMPANY (CANADA) LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL SCABICIDE","SCABICIDE TOPIQUE","",""
"4015","97-03-20","CONNAUGHT LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4016","97-06-11","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION: RESTRICTION IN INDICATION AND NEW WARNING","RÉVISION A LA MONOGRAPHIE DU PRODUIT : RESTRICTION AUX INDICATIONS ET NOUVELLE MISE EN GARDE","ANOREXIANT","ANOREXIGÈNE","",""
"4017","97-05-21","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION: RESTRICTION IN INDICATION, NEW WARNING","RÉVISION À LA MONOGRAPHIE DU PRODUIT : RESTRICTION AUX INDICATIONS ET NOUVELLE MISE EN GARDE","ANOREXIANT","ANOREXIGÈNE","",""
"4018","97-10-06","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT","ANOREXIGÈNE","",""
"4019","97-01-08","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINOMIMETIC AGENT","CHOLINOMIMÉTIQUE","",""
"4020","97-07-28","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW INDICATION: FOR THE TREATMENT OF SJÖGREN'S SYNDROME","NOUVELLE INDICATION : POUR LE TRAITEMENT DU SYNDROME DE SJÖGREN","CHOLINOMIMETIC AGENT","CHOLINOMIMÉTIQUE","",""
"4021","97-02-12","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE STRENGTH","NOUVELLE CONCENTRATION","GASTROINTESTINAL CALCIUM ANTAGONIST","ANTAGONISTE DE CALCIUM GASTROINTESTINAL","",""
"4022","97-07-08","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE/ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4023","97-03-06","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4024","97-06-27","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE/ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4025","97-08-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE/ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4026","97-08-12","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-HYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4027","97-10-24","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"4028","97-08-26","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC PROPRIÉTES ANALGÉSIQUES","",""
"4029","97-05-15","RJR PHARMA INTERNATIONAL SERVICES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4030","97-04-29","CONNAUGHT LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4031","97-04-29","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4032","97-11-10","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","VACCINE","VACCIN","",""
"4033","97-10-17","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"4034","97-03-07","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"4035","97-05-01","RJR PHARMA INTERNATIONAL SERVICES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"4036","97-02-06","HOECHST-ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM, NEW INDICATION (PEDIATRIC USE)","NOUVELLE PRÉSENTATION, NOUVELLE INDICATION : USAGE PÉDIATRIQUE","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"4037","97-02-04","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID/ANTI-INFLAMMATORY","GLUCOCORTICOÏDE/ANTI-INFLAMMATOIRE","",""
"4038","97-11-27","ABBOTT LABORATORIES, LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPRIVAN","ZENECA PHARMA INC.","CANADA","CANADA","1","","","ANAESTHETIC SEDATIVE","ANESTHÉSIQUE - SÉDATIF","",""
"4039","97-12-02","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"4040","97-12-15","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4041","97-06-16","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4042","97-02-12","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"4043","96-12-31","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL INDICATION: TREATMENT FOLLOWING ACUTE MYOCARDIAL INFARCTION","NOUVELLE INDICATION : TRAITEMENT À LA SUITE D'UN INFARCTUS AIGU DU MYOCARDE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4044","97-07-23","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR WITH HELICOBACTER SUPPRESSIVE ACTIVITY","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE DOTÉ D'UN POUVOIR SUPPRESSIF À L'ÉGARD DE HELICOBACTER PYLORI","",""
"4045","97-09-15","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","RX À OTC","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"4046","97-08-20","MEDIMMUNE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"4047","97-08-29","BOEHRINGER MANNHEIM CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"4048","97-05-12","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"4049","97-01-08","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"4050","97-12-03","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"4051","97-08-19","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"4052","97-12-31","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR, ß2-ADRENERGIC STIMULANT","BRONCHODILATATEUR - STIMULANT DES RÉCEPTEURS ß2-ADRÉNERGIQUES","",""
"4053","97-05-06","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","INTRAVENOUS NUTRIENT SUPPLEMENT (FAT EMULSION)","SUPPLÉMENT NUTRITIF INTRAVEINEUX - (ÉMULSION DE GRAS)","",""
"4054","97-12-04","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4055","97-08-20","3M PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR, ß2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS ß2-ADRÉNERGIQUES","",""
"4056","97-01-14","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR, ß2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT ß2-ADRÉNERGIQUE","",""
"4057","97-07-08","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO WELLCOME","CANADA","CANADA","1","NEW STRENGTH UNIT DOSE FORMULATION","NOUVELLE FORMULATION DE MONODOSE","BRONCHODILATOR, ß2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS ß2-ADRÉNERGIQUES","",""
"4058","97-06-23","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO CANADA","CANADA","CANADA","1","NEW STRENGTH, NAME CHANGE FROM APO-SALVENT NEBULES TO APO-SALVENT STERULES","NOUVELLE CONCENTRATION, MODIFICATION DU NOM DU PRODUIT DE APO-SALVENT NEBULES À APO-SALVENT STERULES","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4059","97-06-11","TECHNILAB PHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO CANADA","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4060","97-09-09","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4061","97-07-29","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES P.F.","GLAXO CANADA","CANADA","CANADA","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","BRONCHODILATOR, ß2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES RÉCEPTEURS ß2-ADRÉNERGIQUES","",""
"4062","97-11-10","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4063","97-10-29","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"4064","97-02-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"4065","97-04-09","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"4066","97-03-20","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"4067","97-03-26","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"4068","97-11-10","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"4069","97-06-18","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"4070","97-04-22","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","CHANGEMENT DE PRESCRIPTION À VENTE LIBRE","ANTIALLERGIC AGENT","ANTIALLERGIQUE","",""
"4071","97-02-12","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIALLERGIC AGENT","ANTIALLERGIQUE","",""
"4072","97-09-09","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIALLERGIC AGENT","ANTIALLERGIQUE","",""
"4073","97-05-15","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYNACROM","FISONS CORP. LTD.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","SEASONAL RHINITIS PROPHYLAXIS","PROPHYLAXIE DE L'ASTHME","",""
"4074","97-04-22","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC","CHANGEMENT DE PRESCRIPTION À VENTE LIBRE","ANTIALLERGIC","ANTIALLERGIQUE","",""
"4075","97-07-31","ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIALLERGIC","ANTIALLERGIQUE","",""
"4076","97-02-21","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIALLERGIC AGENT","ANTIALLERGIQUE","",""
"4077","97-10-06","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"4078","97-02-25","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SEASONAL RHINITIS PROPHYLAXIS","PROPHYLAXIS RHINITIQUE SAISONNIER","",""
"4079","97-04-22","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DELIVERY SYSTEM - MULTI-DOSE POWDER INHALER","NOUVEAU SYSTÈME DE PERFUSION - INHALEUR À DOSES MULTIPLES","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4080","97-07-31","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","CHANGEMENT DE PRESCRIPTION À VENTE LIBRE","SEASONAL ALLERGIC RHINITIS PROPHYLAXIS","TRAITEMENT DE LA RHINITE ALLERGIQUE SAISONNIÈRE","",""
"4081","97-07-31","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","OTC SWITCH","RX À OTC","ANTIALLERGIC AGENT","ANTIALLERGIQUE","",""
"4082","97-06-20","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GROWTH HORMONE","HORMONE DE CROISSANCE","",""
"4083","97-12-19","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: REPLACEMENT THERAPY IN GROWH HORMONE DEFICIENT ADULTS","NOUVELLE INDICATION : TRAITEMENT SUBSTITUTIF CHEZ L'ADULTE PRÉSENTANT UN DÉFICIT DE L'HORMONE DE CROISSANCE","GROWTH STIMULANT","STIMULANT DE LA CROISSANCE","",""
"4085","97-03-26","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"4086","97-04-24","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARRHYTHMIQUE","",""
"4087","97-09-30","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ARRHYTHMIC","ANTIARYTHMIQUE","",""
"4088","97-02-06","ICN CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL LABORATORIES OF CANADA","CANADA","CANADA","1","","","ANTI-ARRHYTHMIC","ANTIARYTHMIQUE","",""
"4089","97-11-17","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"4090","97-11-17","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","FAT EMULSIONS FOR INTRAVENOUS NUTRITION","ÉMULSIONS DE GRAS POUR ALIMENTATION INTRAVÉNEUSE","",""
"4091","97-04-15","PROCTER & GAMBLE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIGINGIVITIS - ANTICARIES","ANTIGINGIVITE - ANTICARIES","",""
"4092","97-12-15","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR NEW DOSAGE FORM AND NEW PEDIATRIC INDICATION","NOUVELLE PRÉSENTATION ET NOUVELLE INDICATION POUR PÉDIATRIQUES","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"4093","97-01-08","PHARMACIA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION DE LA FABRICATION","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"4094","97-04-22","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC/ADJUNCT TO ANAESTHESIA","ANALGÉSIQUE NARCOTIQUE/APPOINT À L'ANÉSTHESIE","",""
"4095","97-11-17","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"4096","97-05-12","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMTORY AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIENS (AINS)","",""
"4097","97-12-03","TRI-MED SPECIALTIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"4098","97-08-12","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LITHOLYTIC AGENT, CHOLESTATIC LIVER AGENT","AGENT LITHOLYTIQUE, MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"4099","97-10-21","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS LEUKOTRIÈNE","",""
"4100","97-04-24","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"4101","97-04-15","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"4102","97-01-30","LUNDBECK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"4103","97-06-16","TECHNILAB PHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4104","97-04-24","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4105","97-02-28","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4106","97-05-15","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4107","97-11-14","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE SYRUP","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4108","97-02-21","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4109","97-11-10","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4110","97-11-03","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","INHIBITEUR DES RÉCEPTEURS DE L'ANGIOTENSINE II AT1","",""
"4111","97-05-06","MASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"4112","97-02-12","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORCURON","ORGANON","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON-DÉPOLARISANT","",""
"4113","97-11-27","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL/ANTIARRYTHMIC/ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIARYTHMIQUE, ANTIHYPERTENSEUR","",""
"4114","97-07-07","SEARLE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4115","97-11-10","CONNAUGHT LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SITE FOR PURIFICATION","NOUVEL EMPLACEMENT POUR LA PURIFICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"4116","97-10-21","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-SYSTEMIC GLUCO-MINERALOCORTICOID","GLUCOMINÉRALOCORTICOÏDE NON SYSTÉMIQUE","",""
"4117","97-11-10","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4118","97-10-17","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"4119","97-10-24","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL TRACT MOTILITY REGULATOR","RÉGULATEUR DE LA MOTILITÉ DU TRACTUS GASTRO-INTESTINAL INFÉRIEUR","",""
"4120","97-09-16","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROPHYLAXIS OF KIDNEY REJECTION AND FOR THE TREATMENT OF REFRACTORY REJECTION IN PATIENTS RECEIVING AN ALLOGENIC KIDNEY","NOUVELLE INDICATION : PROPHYLAXIE DU REJET DE REIN ET DU REJET RÉFRACTAIRE CHEZ LES RECEVEURS D'ALLOGREFFE RÉNALE","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"4121","97-08-27","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4122","97-02-25","ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-PSORIATIC, ANTI-ACNE","ANTIPSORIASIQUE, ANTI-ACNÉ","",""
"4123","97-04-22","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4124","97-10-10","PHARMACIA & UPJOHN INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOLVADEX","ZENECA PHARMA INC.","CANADA","CANADA","1","PROVIDES FOR REVISIONS TO THE PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTINEOPLASTIC (NON-STEROIDAL ANTIESTROGEN) AGENT","ANTINÉOPLASIQUE (ANTI-OESTROGÈNES NON STÉROÏDIEN)","",""
"4125","97-03-06","PHARMACHEMIE B.V.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4126","97-02-21","MEDICAN PHARMA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE REVISÉE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4127","97-02-21","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE REVISÉE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4128","97-02-21","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE REVISÉE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4129","97-02-21","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE REVISÉE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4130","97-03-27","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE REVISÉE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4131","97-08-20","DU PONT MERCK PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","NEW INDICATION: AS A SECOND LINE DIAGNOSTIC AID TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS FOR WHOM MAMMOGRAPHY CANNOT EXCLUDE MALIGNANCY, NEW TRADE NAME FOR THIS INDICATION","NOUVELLE INDICATION : COMME AIDE DIAGNOSTIQUE DE DEUXIÈME LIGNE POUR L'ÉVALUATION DES LÉSIONS DU SEIN CHEZ LES PERSONNES POUR QUI LA MAMMOGRAPHIE NE POUVAIT EXCLURE UNE MALIGNITÉ; NOUVELLE APPELLATION COMMERCIALE POUR CETTE INDICATION","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"4132","97-07-02","MEDI PHYSICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"4133","97-07-08","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4134","97-08-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4135","97-04-24","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4136","97-02-21","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4137","97-05-29","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4138","97-01-24","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4139","97-04-24","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4140","97-09-22","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-HYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"4141","97-09-22","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE (BPH)","",""
"4142","97-02-06","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW REGIMEN: ONE WEEK DOSING REGIMEN IN THE TREATMENT OF T. CORPORIS/CRURIS AND C.ALBICANS","NOUVELLE POSOLOGIE : DURÉE DE TRAITEMENT D'UNE SEMAINE POUR LE TRAITEMENT DE L'INFECTION À T. CORPORIS/CRURIS ET À C. ALBICANS","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4143","97-08-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4144","97-02-12","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"4145","97-07-08","PROCTER & GAMBLE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC IMPREGNATED FILAMENT FOR TOPICAL APPLICATION","FILAMENT INDUIT D'ANTIBIOTIQUE POUR APPLICATION TOPIQUE","",""
"4146","97-04-24","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY/ANALGESIC","ANTI-INFLAMMATOIRE/ANALGÉSIQUE","",""
"4147","97-05-12","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY/ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4148","97-02-28","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SURGAM","HOECHST-ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY/ANALGESIC","ANTI-INFLAMMATOIRE/ANALGÉSIQUE","",""
"4149","97-04-24","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHIBITOR OF PLATELET FUNCTION","INHIBITEUR DE LA FONCTION DES PLAQUETTES","",""
"4150","97-02-06","SANOFI WINTHROP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"4151","97-10-06","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ELEVATED INTRAOCULAR PRESSURE THERAPY","MAÎTRISE DE LA PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"4152","97-02-28","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE LA PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"4154","97-02-06","SCHEIN PHARMACEUTICAL CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEBCIN","ELI LILLY","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4155","97-10-08","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT/COMT-INHIBITOR","ANTIPARKINSONIEN/COMT-INHIBITEUR","",""
"4156","97-05-29","ORTHO PHARMACEUTICAL, DIVISION OF JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO FACILITATE DOSAGE ADJUSTMENT","POUR FACILITER L'AJUSTEMENT À LA DOSE","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"4157","97-03-06","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"4158","97-04-15","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4159","97-06-11","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4160","97-05-15","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4161","97-03-26","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4162","97-07-14","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4163","97-08-26","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4164","97-12-03","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4165","97-08-20","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR USE IN PEDIATRICS AGE 4 TO 12","NOUVELLE INDICATION POUR USAGE CHEZ LES ENFANTS DE 4 À 12 ANS","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"4166","97-07-14","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4167","97-08-27","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4168","97-12-11","SANKYO U.S.A. CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INSULIN RESISTANCE REDUCING AGENT","AGENTS DIMINUANT LA RÉSISTANCE À L'INSULINE","",""
"4169","97-05-09","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIABETIC AGENT, INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE, AGENT RÉDUISANT L'INSULINORÉSISTANCE","",""
"4170","97-05-12","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"4171","97-05-15","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"4172","97-12-03","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"4173","97-09-16","OSTERREICHISCHES INSTITUT","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE FROM BOVINE THROMBIN TO HUMAN THROMBIN; CHANGE IN MANUFACTURING SITE; REVISED LABELLING AND PRODUCT MONOGRAPH","CHANGEMENT DE LA THROMBINE BOVINE À LA THROMBINE HUMAINE; CHANGEMENT AU SITE DE FABRICATION; RÉVISION À L'ÉTIQUETTE ET À LA MONOGRAPHIE DU PRODUIT","HEMOSTATIC AGENT","HÉMOSTATIQUE","",""
"4174","97-06-20","SWISS SERUM & VACCINE INSTITUTE BERNE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW LIQUID FORMULATION","NOUVELLE PRÉPARATION LIQUIDE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"4175","96-07-04","CENTOCOR","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ANTIPLATELET ANTIBODY","ANTICORPS ANTIPLAQUETTAIRE","",""
"4176","96-01-04","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE, ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTI-ANGINEUX","",""
"4177","96-03-29","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4178","96-03-01","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR REDUCING THE RISK OF MORBIDITY AND DEATH IN PATIENTS WITH UNSTABLE ANGINA AND IN THOSE WITH PREVIOUS MYOCARDIAL INFARCTION","INDIQUÉ POUR ABAISSER LE RISQUE DE MORBIDITÉ ET D'ISSUE FATALE LIÉ À L'ANGOR INSTABLE ET AUX ANTÉCÉDENTS D'INFARCTUS DU MYOCARDE","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC, PLATELET AGGREGATION INHIBITOR","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE, INHIBITEUR D'AGGRÉGATION PLAQUETTAIRE","",""
"4180","96-10-15","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"4181","96-11-20","FABRIGEN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES IN MANUFACTURING, REVISED SPECIFICATIONS","MODIFICATIONS DE LA FABRICATION, SPÉCIFICATIONS RÉVISÉES","ANTIVIRAL AGENT","ANTIVIRAL","",""
"4182","96-12-03","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"4183","96-04-15","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR D'OXIDASE XANTHINE","",""
"4184","96-06-25","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ALPHA1-ANTITRYPSIN REPLENISHER","RECHARGEUR ALPHA1-ANTITRYPSINE","",""
"4185","96-08-19","LABORATOIRES TRIANON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"4186","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"4187","96-10-25","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"4188","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"4191","96-07-23","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"4192","96-09-09","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"4193","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT, ANTIVIRAL AGENT","ANTIPARKINSONIEN, ANTIVIRAL","",""
"4194","96-04-25","U.S. BIOSCIENCE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CYTOPROTECTIVE AGENT","CYTOPROTECTEUR","",""
"4199","96-07-04","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE GASTROINTESTINAL","",""
"4200","96-08-15","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE GASTROINTESTINAL","",""
"4201","96-08-21","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE GASTROINTESTINAL","",""
"4202","96-09-23","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4203","96-12-19","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE, PRODUCT NAME CHANGE","MONOGRAPHIE RÉVISÉE, MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4204","96-08-01","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR D'AROMATASE NON-STÉROÏDIEN","",""
"4205","96-06-06","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"4206","96-07-04","ROBERTS PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"4207","96-08-28","ROBERTS PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"4208","96-03-11","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE FERMENTATION AND PURIFICATION SITE","AUTRE EMPLACEMENT DE LA FABRICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"4209","96-03-26","CENTEON L.L.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BLOOD COAGULATION PRODUCT","PRODUIT DE COAGULATION DU SANG","",""
"4210","96-04-23","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"4211","96-09-30","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"4212","96-12-11","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULANT","COAGULANT","",""
"4213","96-11-29","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ULTRACAINE","HOECHST CANADA INC.","CANADA","CANADA","1","","","LOCAL ANESTHETIC FOR DENTAL USE","ANESTHÉSIQUE LOCAL POUR USAGE DENTAIRE","",""
"4214","96-10-08","JOHNSON & JOHNSON - MERCK CONSUMER PHARMACEUTICALS OF CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1-ANTAGONIST","ANTAGONISTE H1 DE L'HISTAMINE","",""
"4215","96-08-19","LABORATOIRES TRIANON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET AGENT ANTI-ANGINEUX","",""
"4216","96-09-16","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"4217","96-10-02","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"4218","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTI-ANGINEUX","",""
"4219","96-04-04","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORAL SUSPENSION","NOUVELLE PRÉSENTATION: SUSPENSION ORALE","ANTIPROTOZOAL","ANTIPROTOZOAIRE","",""
"4220","96-04-10","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPROTOZOAL AGENT","AGENT ANTIPROTOZOAIRE","",""
"4221","96-04-10","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INTRAVENOUS SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE PAR VOIE INTRAVEINEUSE","",""
"4222","96-02-21","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4223","96-06-24","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR POWDER FOR ORAL SUSPENSION 100MG/5ML AND 200MG/5ML AFTER RECONSTITUTION","NOUVELLE FORME POSOLOGIQUE (SUSPENSION ORALE): 100MG/5ML ET 200MG/5ML APRÈS RECONSTITUTION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4224","96-11-19","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4225","96-11-19","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: 1GM UNIPAK POWDER FOR SOLUTION","NOUVELLE PRÉSENTATION: 1GM UNIPAK PWS","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4226","96-08-02","ORGANON TEKNIKA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4227","96-11-04","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASTIQUE","",""
"4228","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTICITY AGENT","RELAXANT MUSCULAIRE, ANTISPASTIQUE","",""
"4229","96-03-07","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID INHALATION FOR THE TREATMENT OF BRONCHIAL ASTHMA","CORTICOSTÉROÏDE EN INHALATION POUR LE TRAITEMENT DE L'ASTHME BRONCHIQUE","",""
"4230","96-03-12","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR THE TREATMENT OF BRONCHIAL ASTHMA","CORTICOSTÉROÏDE POUR LE TRAITEMENT DE L'ASTHME BRONCHIQUE","",""
"4231","96-03-12","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"4232","96-03-20","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR THE TREATMENT OF BRONCHIAL ASTHMA","CORTICOSTÉROÏDE EN INHALATION POUR LE TRAITEMENT DE L'ASTHME BRONCHIQUE","",""
"4233","96-11-01","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"4234","96-12-24","RIVA LABORATORY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE EN INHALATION","",""
"4235","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE EN INHALALATION","",""
"4236","96-07-16","SUN PHARMACEUTICAL INDUSTRIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCALLY ACTING ANALGESIC AGENT","AGENT ANALGÉSIQUE LOCAL","",""
"4237","96-10-25","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCAL ANALGESIC","ANALGÉSIQUE LOCAL","",""
"4238","96-10-21","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCAL ANALGESIC","ANALGÉSIQUE LOCAL","",""
"4239","96-12-03","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCAL ACTING ANALGESIC AGENT","ANALGÉSIQUE LOCAL","",""
"4240","96-06-05","SOLVAY KINGSWOOD INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVERTIGO","ANTIVERTIGE","",""
"4241","96-10-23","SOLVAY PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVERTIGO","ANTIVERTIGE","",""
"4242","96-01-04","BOEHRINGER MANNHEIM CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE PRÉPARATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"4243","96-11-15","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SCABICIDE","SCABICIDE","",""
"4244","96-09-19","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","NEUROMUSCULAR PARALYTIC AGENT","AGENT NEUROMUSCULAIRE PARALYSANT","",""
"4245","96-05-24","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"4246","96-08-19","LABORATOIRES TRIANON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"4247","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"4248","96-05-16","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","GLUCOCORTICOSTEROID FOR THE TREATMENT OF BRONCHIAL ASTHMA","GLUCOCORTICOSTÉROÏDE POUR LE TRAITEMENT DE L'ASTHME BRONCHIQUE","",""
"4249","96-08-12","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND PRODUCT MONOGRAPH REVISION","NOUVELLE CONCENTRATION, MONOGRAPHIE RÉVISÉE","GLUCOCORTICOSTEROID FOR THE TREATMENT OF BRONCHIAL ASTHMA","GLUCOCORTICOSTÉROÏDE POUR LE TRAITEMENT DE L'ASTHME BRONCHIQUE","",""
"4250","96-08-15","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION AND NEW DOSAGE FORM","NOUVELLE INDICATION ET NOUVELLE PRÉSENTATION","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"4251","96-10-25","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","DIURETIC","DIURÉTIQUE","",""
"4252","96-07-17","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE ANALOG","ANALOGUE DE LA LH-RH","",""
"4253","96-08-12","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","LUTEINIZING HORMONE-RELEASING HORMONE ANALOGUE","ANALOGUE DE LA LH-RH","",""
"4254","96-01-18","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"4255","96-02-28","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"4256","96-06-10","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"4257","96-03-07","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4258","96-10-23","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC, VAGINAL ANTIBACTERIAL PREPARATION","ANTIBIOTIQUE, PRÉPARATION ANTIBACTÉRIENNE VAGINALE","",""
"4259","96-06-05","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"4260","96-10-28","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"4261","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"4262","96-10-02","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"4263","96-12-17","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANAFRANIL","GEIGY PHARMACEUTICALS","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"4264","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"4265","96-01-09","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4266","96-05-24","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4267","96-07-02","DOMINION PHARMACAL","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4268","96-12-24","ICN CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RIVOTRIL","HOFFMANN-LA ROCHE","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4269","04-06-03","RATIOPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","Antibiotic and Beta-Lactamase Inhibitor","Antibiotique et inhibiteur de ß-Lactamases","",""
"4270","04-06-04","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEUROMUSCULAIRE NON-DÉPOLARISANT","",""
"4271","04-06-02","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: TABLETS","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉS","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"4272","96-02-26","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR REVISED PRODUCT MONOGRAPH: CHANGE IN BLOOD MONITORING FREQUENCY REQUIREMENTS","MONOGRAPHIE RÉVISÉE: CHANGEMENT AUX EXIGENCES DE LA FRÉQUENCE DES ANALYSES HÉMATOLOGIQUES","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"4273","96-09-30","CENTEON L.L.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BLOOD COAGULATION PRODUCT","PRODUIT DE COAGULATION DU SANG","",""
"4274","04-06-04","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE SUPPLEMENTS FOR INTRAVENOUS INFUSION","SUPPLÉMENTS NUTRITIFS POUR INFUSION INTRAVEINEUSE","",""
"4275","96-12-24","PURDUE FREDERICK","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"4276","96-04-10","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC LUNG SURFACTANT","SURFACTANT SYNTHÉTIQUE PULMONAIRE","",""
"4277","04-06-04","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE WITH AND WITHOUT ELECTROLYTE SUPPLEMENTS FOR INTRAVENOUS INFUSION","NUTRITIF AVEC OU SANS SUPPLÉMENTS HYDRO-ÉLECTROLYTIQUES POUR INFUSION INTRAVEINEUSE","",""
"4278","96-07-10","CONNAUGHT LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4279","96-12-13","CONNAUGHT LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4280","04-06-04","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE WITH AND WITHOUT ELECTROLYTE SUPPLEMENTS FOR INTRAVENOUS INFUSION","NUTRITIF AVEC OU SANS SUPPLÉMENTS HYDRO-ÉLECTROLYTIQUES POUR INFUSION INTRAVEINEUSE","",""
"4281","96-02-26","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","RELAXANT DES MUSCLES SQUELETTIQUES","",""
"4282","04-05-28","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"4283","96-06-05","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","RELAXANT DES MUSCLES SQUELETTIQUES","",""
"4284","96-05-23","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS","NOUVELLES INDICATIONS","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"4285","96-12-03","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"4286","04-06-03","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","BONE FORMATION AGENT","AGENT DE FORMATION DE CELLULES OSSEUSES","",""
"4287","96-09-23","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANDROGEN","ANTIANDROGÈNE","",""
"4288","96-10-15","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BERLEX CANADA","CANADA","CANADA","1","","","ANTIANDROGEN","ANTIANDROGÈNE","",""
"4289","96-09-19","BRAINTREE LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOSPHATE BINDER","AGGLOMÉRANT PHOSPHATE","",""
"4290","04-05-31","GENZYME CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"4291","96-04-25","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4292","04-06-11","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTER","PROMOTEUR DE CROISSANCE","",""
"4293","04-05-31","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4294","04-05-31","BIONICHE ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"4295","96-04-25","SYNCARE PHARMACEUTICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4296","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4297","96-12-24","LABORATOIRES TRIANON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4298","96-01-26","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"4299","96-09-30","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"4300","96-07-17","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4301","96-08-06","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4302","96-03-07","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4303","96-11-20","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PROVIDES FOR USE IN ADULTS WITH ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB)","NOUVELLE INDICATION: TRAITEMENT POUR ADULTES AVEC AECB","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4304","96-01-26","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A REDUCED RECONSTITUTION VOLUME FOR INTRAMUSCULAR ADMINISTRATION","NOUVEL EMBALLAGE: VOLUME RÉDUIT DE SOLUTION RECONSTITUÉE POUR ADMINISTRATION INTRAMUSCULAIRE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4305","96-02-26","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4306","96-03-12","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4307","96-09-23","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4308","96-03-25","UCB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"4309","96-07-11","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"4310","96-01-12","COLGATE ORAL PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGINGIVITIS ORAL RINSE","ANTIGINGIVITE","",""
"4311","96-01-26","GERMIPHENE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGINGIVITIS ORAL RINSE","ANTIGINGIVITE","",""
"4312","96-09-09","SWISS SERUM & VACCINE INSTITUTE BERNE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4313","96-01-10","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ANTIHYPERCHOLESTEROLEMIC, ANTIDIARRHEAL","ANTIHYPERCHOLESTÉROLÉMIANT, ANTIDIARRHÉIQUE","",""
"4314","96-06-05","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","AGENT ANTIFONGIQUE TOPIQUE","",""
"4315","96-01-09","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR NEW INDICATION: IN THE TREATMENT OF CONGESTIVE HEART FAILURE","NOUVELLE INDICATION: TRAITEMENT DE L'INSUFFISANCE CARDIAQUE CONGESTIVE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4316","96-02-02","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - INJECTION","NOUVELLE PRÉSENTATION - INJECTION","H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2","",""
"4317","96-05-27","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW OTC STRENGTH","NOUVELLE CONCENTRATION","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4318","96-08-28","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4319","96-12-24","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4320","96-01-09","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"4321","96-04-19","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR AN ADDITIONAL USE: CHRONIC BACTERIAL PROSTATITIS","NOUVELLE INDICATION: TRAITEMENT DE LA PROSTATITE BACTÉRIENNE CHRONIQUE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"4322","96-05-16","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR ADDITIONAL INDICATION: COMPLICATED INTRA-ABDOMINAL INFECTIONS","NOUVELLE INDICATION: INFECTIONS INTRA-ABDOMINALES COMPLIQUÉES","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"4323","96-12-18","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOQUAGE NEUROMUSCULAIRE NON-DÉPOLARISANT","",""
"4324","96-02-02","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR THE ERADICATION OF HELICOBACTER PYLORI THAT MAY RESULT IN DECREASED RECURRENCE OF DUODENAL ULCER","INDIQUÉ POUR L'ÉRADICATION DE H. PYLORI EN VUE DE RÉDUIRE LE RISQUE DE RÉCURRENCE DE L'ULCÈRE DUODÉNAL","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4325","96-07-04","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW INDICATION: IN THE TREATMENT OF CHILDREN WITH DISSEMINATED MYCOBACTERIAL INFECTIONS DUE TO MYCOBACTERIUM AVIUM AND MYCOBACTERIUM INTRACELLULARE","NOUVELLE INDICATION: POUR LE TRAITEMENT DES ENFANTS SOUFFRANT D'INFECTIONS MYCOBACTÉRIENNES DISSÉMINÉES À MYCOBACTÉRIUM AVIUM ET À MYCOBACTÉRIUM INTRACELLULARE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4326","96-03-07","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR ADDITIONAL INDICATIONS: LOWER RESPIRATORY INFECTIONS, SKIN AND SKIN STRUCTURE INFECTIONS, GYNECOLOGICAL INFECTIONS, INTRA-ABDOMINAL INFECTIONS, SEPTICEMIA AND BONE & JOINT INFECTIONS","NOUVELLES INDICATIONS: INFECTIONS RESPIRATOIRES INFÉRIEURES, INFECTIONS DE LA PEAU ET D'AUTRES STRUCTURES CUTANÉES, INFECTIONS GYNÉCOLOGIQUES, INFECTIONS INTRA-ABDOMINALES, SEPTICÉMIES ET INFECTIONS OSSEUSES ET ARTICULAIRES","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4327","96-12-03","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"4328","96-03-20","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4329","96-02-21","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4330","96-06-10","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4331","96-06-18","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4332","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4333","96-08-22","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"4334","96-06-10","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL STEROID","STÉROÏDE TOPIQUE","",""
"4335","96-12-24","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATED PRODUCT MONOGRAPH WITH NEW SAFETY INFORMATION","MONOGRAPHIE RÉVISÉE AVEC NOUVELLE INFORMATION EN MATIÈRE D'INNOCUITÉ","ANOREXIANT","ANOREXIGÈNE","",""
"4336","96-07-09","SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT","ANOREXIGÈNE","",""
"4337","96-06-18","DISPENSAPHARM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT WITH A MUCOSAL PROTECTIVE AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE AVEC AGENT PROTECTEUR DE LA MUQUEUSE","",""
"4338","96-07-04","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4339","96-10-25","SEARLE CANADA - UNIT OF MONSANTO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY, ANALGESIC AGENT, MUCOSAL PROTECTIVE AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, AGENT PROTECTEUR DE LA MUQUEUSE","",""
"4340","96-09-26","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4341","96-10-04","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4342","96-03-26","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR REFORMULATION OF 100MG AND 150MG TABLETS - REDUCED MASS","MODIFICATION DE LA PRÉPARATION - MASSE RÉDUITE (COMPRIMÉS DE 100MG ET 150MG)","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"4343","96-09-12","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","SPECIFIC ANTIBODY FOR DIGOXIN","ANTICORPS SPÉCIFIQUE DE LA DIGOXINE","",""
"4344","96-10-04","SANDOZ CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MIGRAINE THERAPY","ANTIMIGRAINEUX","",""
"4345","96-06-07","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM SR","NORDIC LABORATORIES INC.","CANADA","CANADA","1","NEW STRENGTHS AND NEW DOSAGE FORM","NOUVELLES CONCENTRATIONS ET NOUVELLE PRÉSENTATION","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4346","96-10-25","ALBERT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4347","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"4348","96-12-19","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM","HOECHST MARION ROUSSEL","CANADA","CANADA","1","PROVIDES FOR NEW DOSAGE FORM","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"4349","96-11-07","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4350","96-09-16","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM","NOUVELLE CONCENTRATION ET NOUVELLE PRÉSENTATION","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4351","96-07-25","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL AGENT, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"4352","96-09-12","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM IN DUAL CHAMBERED SYRINGE","NOUVELLE PRÉSENTATION","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"4353","96-08-06","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4354","96-08-28","LABORATOIRES TRIANON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"4355","96-09-16","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTIANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"4356","96-10-02","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"4357","96-08-19","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIHYPERTENSIVE, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4358","96-05-03","DISPENSAPHARM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-DIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"4359","96-12-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"4361","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"4363","96-03-29","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4364","96-03-29","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4365","96-05-27","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERSANTINE 100MG SC TABLETS","BOEHRINGER INGELHEIM LTD.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","INHIBITOR OF PLATELET ADHESION AND AGGREGATION","INHIBITEUR DE L'ADHÉSION ET L'AGRÉGATION DES PLAQUETTES","",""
"4366","96-04-25","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXTENSIVE REVISION TO PRODUCT MONOGRAPH INCLUDING INDICATIONS FOR USE","RÉVISION IMPORTANTE DE LA MONOGRAPHIE DU PRODUIT INCLUANT LES INDICATIONS D'UTILISATION","INHIBITOR OF PLATELET ADHESION AND AGGREGATION","INHIBITEUR DE L'ADHÉSION ET L'AGRÉGATION DES PLAQUETTES","",""
"4367","96-04-25","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXTENSIVE REVISION TO PRODUCT MONOGRAPH INCLUDING INDICATIONS FOR USE","RÉVISION IMPORTANTE DE LA MONOGRAPHIE DU PRODUIT INCLUANT LES INDICATIONS D'UTILISATION","INHIBITOR OF PLATELET ADHESION AND AGGREGATION","INHIBITEUR DE L'ADHÉSION ET L'AGRÉGATION DES PLAQUETTES","",""
"4368","96-09-16","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHIBITOR OF PLATELET ADHESION AND AGGREGATION","INHIBITEUR DE L'ADHÉSION ET L'AGRÉGATION PLAQUETTAIRES","",""
"4369","96-10-28","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4371","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"4372","96-08-30","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DOBUTREX","ELI LILLY","CANADA","CANADA","1","","","INOTROPIC","INOTROPIQUE","",""
"4374","96-06-06","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DOBUTREX","ELI LILLY","CANADA","CANADA","1","","","INOTROPIC AGENT","AGENT INOTROPIQUE","",""
"4375","96-02-02","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"4376","96-06-13","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","AN ENZYME THAT CLEAVES DNA","ENZYME PERMETTANT LE CLIVAGE DE L'ADN","",""
"4377","96-04-25","MERCK SHARP & DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"4378","96-04-15","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INTRAVENOUS NONDEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NONDÉPOLARISANT INTRAVEINEUX","",""
"4379","96-08-19","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"4380","96-10-25","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"4381","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT AND ANXIOLYTIC","ANTIDÉPRESSEUR ET ANXIOLYTIQUE","",""
"4382","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4383","96-02-19","ORTHO-MCNEIL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH - PRESERVED WITH BENZYL ALCOHOL","NOUVELLE CONCENTRATION - CONSERVÉ AVEC DE L'ALCOOL BENZYLIQUE","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ÉRYTHROPOÏÈSE","",""
"4384","96-07-09","ORTHO-MCNEIL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: SURGERY PATIENTS - TO TREAT PATIENTS WHO ARE UNDERGOING MAJOR, ELECTIVE SURGERY AND HAVE A PRETREATMENT HEMOGLOBIN OF >100 TO <130 G/L; TO REDUCE ALLOGENEIC BLOOD TRANSFUSIONS AND HASTEN ERYTHROID RECOVERY IN THESE PATIENTS","NOUVELLE INDICATION: FUTUR OPÉRÉS - POUR DIMINUER LE NOMBRE D'ALLOTRANSFUSIONS ET ACCÉLÉRER LA RÉCUPÉRATION ÉRYTHROCYTAIRE CHEZ LES SUJETS QUI DOIVENT SUBIR UNE GROSSE OPÉRATION NON URGENTE ET DONT LE TAUX D'HÉMOGLOBINE AVANT TRAITEMENT EST >100 G/L MAIS <130 G/L; POUR RÉDUIRE L'EXPOSITION AU SANG ALLOGÉNIQUE DE CES PATIENTS","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ÉRYTHROPOÏÈSE","",""
"4385","96-07-09","ORTHO-MCNEIL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: SURGERY PATIENTS IN AN AUTOLOGOUS BLOOD DONATION (ABD) PROGRAM - TO FACILITATE AUTOLOGOUS BLOOD COLLECTION WITHIN A PREDEPOSIT PROGRAM AND MAY DECRESE THE RISK OF RECEIVING ALLOGENEIC BLOOD TRANSFUSIONS IN PATIENTS WITH HEMATOCRITS OF 33-39% WHO ARE SCHEDULED FOR MAJOR ELECTIVE SURGERY AND ARE EXPECTED TO REQUIRE MORE BLOOD THAN THAT WHICH CAN BE OBTAINED THROUGH AUTOLOGOUS BLOOD COLLECTION TECHNIQUES IN THE ABSENCE OF EPOETIN ALFA","NOUVELLE INDICATION: EN ASSOCIATION AVEC L'AUTOTRANSFUSION: POUR FACILITER LE PRÉLÈVEMENT DE SANG DANS LE CADRE D'UN PROGRAMME D'AUTOTRANSFUSION ET PEUT DIMINUER LE RISQUE D'ALLOTRANSFUSIONS CHEZ LES SUJETS DONT L'HÉMATOCRITE EST DE 33 À 39%, QUI DOIVENT SUBIR UNE GROSSE OPÉRATION NON URGENTE ET QUI AURONT VRAISEMBLABLEMENT BESOIN D'UN PLUS GRAND VOLUME DE SANG QU'ILS NE PEUVENT FOURNIR EN L'ABSENCE D'ÉPOTÉINE ALFA","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ÉRYTHROPOÏÈSE","",""
"4386","96-07-04","DERMIK LABORATORIES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"4387","96-08-21","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"4388","96-07-10","ROBERTS PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ESTROGEN","OESTROGÈNE","",""
"4389","96-01-04","CIBA PHARMACEUTICALS, DIVISION OF CIBA GEIGY CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"4390","96-11-20","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4392","96-08-06","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4393","96-05-03","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4394","96-05-16","AMERSHAM CORPORATION LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ADDITION OF STABILIZER","MODIFICATION DE LA PRÉPARATION","REAGENT FOR PREPARATION OF A RADIODIAGNOSTIC AGENT","RÉAGENT POUR LA PRÉPARATION D'UNE AGENT RADIODIAGNOSTIQUE","",""
"4395","96-08-15","SMITHKLINE BEECHAM PHARMA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION-RECURRENT EPISODES OF GENITAL HERPES, NEW STRENGTHS","NOUVELLE INDICATION - RÉCIDIVES D'HERPÈS GÉNITAL. NOUVELLES CONCENTRATIONS","ANTIVIRAL","AGENT ANTIVIRAL","",""
"4396","96-02-14","FROSST, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","RX TO OTC SWITCH","SUBSTITUTION DE SOUS ORDONNANCE À VENTE LIBRE","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4397","96-06-06","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4398","96-12-18","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PACKAGING","NOUVEL EMBALLAGE","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"4399","96-12-20","LABORATOIRES FOURNIER S.C.A.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"4400","96-08-06","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIQUE","",""
"4401","96-11-01","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIQUE","",""
"4402","96-07-04","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIQUE","",""
"4403","96-03-15","MALLINCKRODT MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING","PRÉPARATION DE CONTRASTE ORALE DESTINÉ À L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE","",""
"4404","96-12-31","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - FOR CANCER PATIENTS UNDERGOING PERIPHERAL BLOOD PROGENITOR CELL (PBPC) COLLECTION AND THERAPY","NOUVELLE INDICATION: PATIENTS CANCÉREUX SUBISSANT UN PRÉLÈVEMENT DE CELLULES SOUCHES DU SANG PÉRIPHÉRIQUE SUIVI D'UN TRAITEMENT","HAEMATOPOIETIC AGENT","HÉMATOPOÏÉTIQUE","",""
"4405","96-03-11","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - TO REDUCE THE DURATION OF NEUTROPENIA AND NEUTROPENIA-RELATED CLINICAL SEQUELAE, IN PATIENTS UNDERGOING MYELOABLATIVE THERAPY FOLLOWED BY BONE MARROW TRANSPLANTATION","NOUVELLE INDICATION: POUR RÉDUIRE LA DURÉE DE LA NEUTROPÉNIE ET LES SÉQUELLES CLINIQUES LIÉES À LA NEUTROPÉNIE CHEZ LES PATIENTS RECEVANT UNE THÉRAPIE MYÉLOABLATIVE SUIVIE D'UNE GREFFE DE LA MOELLE OSSEUSE","HAEMATOPOIETIC AGENT","HÉMATOPOÏÉTIQUE","",""
"4406","96-08-06","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE","",""
"4407","96-08-21","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"4408","96-03-21","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"4409","96-03-21","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"4410","96-03-21","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"4411","96-12-11","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SELECTIVE CALCIUM-ENTRY BLOCKER","INHIBITEUR CALCIQUE SÉLECTIF","",""
"4412","96-12-03","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"4413","96-06-18","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"4414","96-07-04","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"4415","96-02-28","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"4416","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4417","96-04-11","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"4418","96-11-20","SOLVAY PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"4419","96-01-17","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"4420","96-06-18","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"4421","96-09-27","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - TREATMENT OF LOCALLY CONFINED PROSTATIC CARCINOMA","NOUVELLE INDICATION: TRAITEMENT DU CANCER LOCALISÉ DE LA PROSTATE","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"4422","96-11-20","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"4423","96-11-25","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"4424","96-03-07","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"4425","96-03-07","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR INHALATION","CORSTICOSTÉROÏDE POUR INHALATION","",""
"4426","96-05-31","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"4427","96-10-16","NYCOMED IMAGING A.S.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR USE IN PEDIATRIC ENHANCEMENT IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM","NOUVELLE INDICATION: CHEZ LES ENFANTS AFIN D'OBTENIR UN REHAUSSEMENT DU CONTRASTE LORS D'ÉPREUVES D'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE DU SYSTÈME NERVEUX CENTRAL","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"4428","96-12-23","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4429","96-12-23","OMNI LABORATORIES DIVISION, WARNER-LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIQUE","",""
"4430","96-12-03","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR MRI SCANNING IN CHILDREN","NOUVELLE INDICATION: POUR LES EXAMENS IRM CHEZ L'ENFANT","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"4431","96-08-19","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT PREPARATION FOR MAGNETIC RESONANCE IMAGING","PRODUIT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE","",""
"4432","96-10-02","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIQUE","",""
"4433","96-12-03","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIQUE","",""
"4434","96-07-17","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4435","96-09-10","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"4436","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"4437","96-10-02","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC","HYPOGLYCÉMIANT ORAL","",""
"4438","96-08-28","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR BLISTER PACKAGING","NOUVEL EMBALLAGE","ORAL HYPOGLYCEMIC","HYPOGLYCÉMIANT ORAL","",""
"4439","96-08-19","LABORATOIRES TRIANON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"4440","96-02-14","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE RÉVISÉE","LUTEINIZING HORMONE-RELEASING HORMONE ANALOG","ANALOGUE DE LA LH-RH","",""
"4441","96-07-10","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","LUTEINIZING HORMONE - RELEASING HORMONE ANALOG","ANALOGUE DE LA LH-RH","",""
"4442","96-05-03","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4443","96-12-02","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4444","96-10-10","RJR PHARMA INTERNATIONAL SERVICES INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"4445","96-03-07","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"4446","96-12-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","CHANGEMENT DE LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4447","96-03-19","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW 5 ML MULTI-DOSE VIAL","NOUVEL EMBALLAGE","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4448","96-03-07","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DOSAGE REGIMEN, REVISED PRODUCT MONOGRAPH, REVISED LABELLING","NOUVEAU SCHÉMA POSOLOGIQUE, MONOGRAPHIE RÉVISÉE, ÉTIQUETTE RÉVISÉE","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4449","96-03-26","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"4450","96-09-30","MERCK MANUFACTURING DIVISION, DIVISION OF MERCK & CO., INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4451","96-04-01","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"4452","96-07-24","PURDUE FREDERICK","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - IMMEDIATE RELEASE","NOUVELLE PRÉSENTATION: LIBÉRATION IMMÉDIATE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"4453","96-10-29","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSCOPAN","BOEHRINGER INGELHEIM","CANADA","CANADA","1","","","ANTISPASMODIC","ANTISPASMODIQUE","",""
"4454","96-03-05","STANLEY PHARMACEUTICALS LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4455","96-01-18","RJR PHARMA INTERNATIONAL SERVICES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"4456","96-10-28","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4457","96-03-01","RH PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - IMMUNE THROMBOCYTOPENIC PURPURA (ITP)","NOUVELLE INDICATION","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"4458","96-05-03","OSTERREICHISCHES INSTITUT","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURE","CHANGEMENT DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"4459","96-04-23","CANGENE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"4460","96-03-01","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"4461","96-05-03","OSTERREICHISCHES INSTITUT FUR HAEMODERIVATE GES M.B.H.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC","HÉMOSTATIQUE","",""
"4462","96-08-06","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"4463","96-11-07","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"4464","96-07-04","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC ,ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, AGENT ANTIHYPERTENSEUR","",""
"4465","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"4466","96-08-06","PROVAL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"4467","96-09-13","MERCK SHARP & DOHME","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR VIH PROTÉASE","",""
"4468","96-05-03","CHAUVIN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"4471","96-03-19","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MODIFIED DOSING RECOMMENDATIONS FOR CHRONIC HEPATITIS NON-A NON-B/C","NOUVEAU SCHÉMA POSOLOGIQUE POUR L'HÉPATITE NON A, NON B DE TYPE C CHRONIQUE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"4472","96-03-29","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW ALBUMIN (HUMAN) FREE FORMULATION","NOUVELLE PRÉPARATION SANS ALBUMINE HUMAINE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"4473","96-03-26","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","USE OF SWISS RED CROSS ALBUMIN (HUMAN) IN THE FORMULATION","NOUVELLE SOURCE DE PRINCIPE ACTIF","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"4474","96-02-28","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","BIOLOGIC RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"4475","96-02-26","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"4476","96-12-24","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION FOR THE TREATMENT OF  CHRONIC HEPATITIS B INFECTION","NOUVELLE INDICATION: TRAITEMENT DE L'INFECTION CHRONIQUE DE L'HÉPATITE B","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"4477","96-09-09","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"4478","96-04-01","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4479","96-02-02","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4480","96-05-31","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HAEMATINIC - IRON SUPPLEMENT","HÉMATINIQUE - SUPPLÉMENT DE FER","",""
"4481","96-05-03","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NODULAR/INFLAMMATORY AND CONGLOBATE ACNE THERAPY","TRAITEMENT DE L'ACNÉ NODULAIRE/INFLAMMATOIRE ET DE L'ACNE CONGLOBATA","",""
"4482","96-01-30","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR THE TREATMENT OF DERMATOMYCOSES DUE TO TINEA CORPORIS, TINEA CRURIS, TINEA PEDIS AND PITYRIASIS VERSICOLOR","INDIQUÉ POUR LE TRAITEMENT DES DERMATOMYCOSES DUES À TINEA CORPORIS, TINEA CRURIS, TINEA PEDIS ET PITYRIASIS VERSICOLOR","ANTIFUNGAL","ANTIFONGIQUE","",""
"4483","96-08-19","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-IONIC, WATER SOLUBLE CONTRAST AGENT","AGENT DE CONTRASTE NON-IONIQUE SOLUBLE","",""
"4484","96-07-10","MALLINCKRODT MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: FOR SUBARACHNOID ADMINISTRATION IN ADULTS FOR LUMBAR, THORACIC AND CERVICAL MYELOGRAPHY","NOUVELLE INDICATION: EN INJECTION SOUS-ARACHNOÏDIENNE CHEZ L'ADULTE POUR LA MYÉLOGRAPHIE LOMBAIRE, THORACIQUE ET CERVICALE","RADIOPAQUE CONTRAST MEDIUM","AGENT DE CONTRASTE RADIO-OPAQUE","",""
"4485","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4486","96-11-01","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4487","96-08-19","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4488","96-01-09","LUITPOLD PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HAEMATINIC - IRON SUPPLEMENT","HÉMATINIQUE - SUPPLÉMENT DE FER","",""
"4489","96-06-13","LUITPOLD PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","HAEMATINIC - IRON SUPPLEMENT","HÉMATINIQUE - SUPPLÉMENT DE FER","",""
"4490","96-01-30","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NODULAR/INFLAMMATORY AND CONGLOBATE ACNE THERAPY","TRAITEMENT DE L'ACNÉ NODULAIRE/INFLAMMATOIRE ET DE L'ACNE CONGLOBATA","",""
"4491","96-12-13","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4492","96-06-05","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PEDIATRIC ASTHMA PROPHYLACTIC AND ANTIALLERGIC AGENT","PROPHYLAXIE DE L'ASTHME INFANTILE ET AGENT ANTI-ALLERGIQUE","",""
"4493","96-05-03","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PEDIATRIC ASTHA PROPHYLACTIC AND ANTIALLERGIC AGENT","PROPHYLAXIE DE L'ASTHME INFANTILE ET AGENT ANTI-ALLERGIQUE","",""
"4494","96-02-12","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4495","98-09-28","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4496","98-11-01","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL FOR MYOCARDIAL PERFUSION IMAGING","AGENT RADIOPHARMACEUTIQUE POUR L'IMAGE DE LA PERFUSION MYOCARDIAQUE","",""
"4497","98-11-01","DUPONT PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL FOR BREAST IMAGING","AGENT RADIOPHARMACEUTIQUE POUR L'IMAGE DU SEIN","",""
"4498","96-12-11","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRYPTAN","ICN CANADA LTD.","CANADA","CANADA","1","","","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"4499","96-03-12","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4500","96-04-10","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"4501","96-12-13","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH & NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE, NOUVELLE CONCENTRATION","GONADOTROPIN RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"4502","96-10-02","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLAUCOMA THERAPY, NONCARDIOSELECTIVE BETA-ADRENOCEPTOR BLOCKING AGENT","TRAITEMENT DU GLAUCOME, INHIBITEUR NON CARDIOSÉLECTIF DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"4503","96-06-18","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","AGENT ANTIPARKINSONIEN","",""
"4504","96-02-02","ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"4505","96-07-31","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ULTRASOUND CONTRAST AGENT","AGENT DE CONTRASTE POUR ULTRASON","",""
"4506","96-04-25","NEXSTAR PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4507","96-10-18","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4508","96-10-18","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4509","96-11-12","MERCK SHARP & DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF HYPERTENSION AND CONGESTIVE HEART FAILURE","NOUVELLE INDICATION: TRAITEMENT DE L'HYPERTENSION ET DE L'INSUFFISANCE CARDIAQUE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4510","96-03-26","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMANIC AGENT","ANTIMANIAQUE","",""
"4511","96-10-02","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","MODIFICATION OF INDICATION: MANAGEMENT OF SYPTOMATIC CONGESTIVE HEART FAILURE AS ADJUNCTIVE TREATMENT WITH DIURETICS AND WHERE APPROPRIATE DIGITALIS","NOUVELLE INDICATION: POUR LA PRISE EN CHARGE DE L'INSUFFISANCE CARDIAQUE CONGESTIVE SYPMTOMATIQUE EN TANT QUE TRAITEMENT D'APPOINT AVEC DES DIURÉTIQUES ET LORSQUE APPROPRIÉ, LA DIGITALINE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4512","96-05-24","WAMPOLE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL ANTIDIARRHEAL AGENT","AGENT ANTIDIARRHÉIQUE ORAL","",""
"4513","96-02-26","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE ORAL","",""
"4514","96-07-17","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL ANTIDIARRHEAL AGENT","AGENT ANTIDIARRHÉIQUE ORAL","",""
"4515","96-02-26","FRANK W. HORNER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"4516","96-08-19","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL ANTIDIARRHEAL AGENT","AGENT ANTIDIARRHÉIQUE ORAL","",""
"4517","96-08-02","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"4518","96-08-02","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","Oral Antidiarrheal Agent","Antidiarrhéique oral","",""
"4519","96-09-16","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"4520","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL ANTIDIARRHEAL AGENT","AGENT ANTIDIARRHÉIQUE ORAL","",""
"4521","96-11-15","MERCK SHARP & DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST AND DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE II, DIURÉTIQUE","",""
"4522","96-02-19","DU PONT MERCK PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4523","96-06-24","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"4524","96-12-11","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"4525","96-08-28","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING AND REVISED PRODUCT MONOGRAPH","MODIFICATION DE LA FABRICATION, MONOGRAPHIE RÉVISÉE","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"4526","96-12-24","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW 10 DOSE PRESENTATION","NOUVELLE CONCENTRATION","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4527","96-02-26","SWISS SERUM & VACCINE INSTITUTE BERNE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4528","96-05-31","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","","","PROGESTAGEN","PROGESTATIF","",""
"4529","96-02-21","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTAGEN-PROGESTATIONAL STEROID","STÉROÏDE PROGESTATIF","",""
"4530","96-10-04","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"4531","96-11-15","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTAGEN-PROGESTATIONAL STEROID","STÉROÏDE PROGESTATIF","",""
"4532","96-09-20","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","CHANGE TO PRODUCT MONOGRAPH, NEW INDICATION","MONOGRAPHIE RÉVISÉE, NOUVELLE INDICATION","PROGESTAGEN","PROGESTATIF","",""
"4533","96-10-25","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"4534","96-09-16","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"4535","96-06-10","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL PROGESTOGEN, ANTINEOPLASTIC","PROGESTATIF ORAL, ANTINÉOPLASIQUE","",""
"4536","96-04-15","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC (ALKYLATING) AGENT","ANTINÉOPLASIQUE (ALKYLANT)","",""
"4538","96-11-15","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ORAL ANTIHYPERGLYCEMIC TABLETS","COMPRIMÉS ANTIHYPERGLYCÉMIANTS ORAUX","",""
"4539","96-09-30","ASTA MEDICA AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","UROPROTECTOR","UROPROTECTEUR","",""
"4540","96-11-20","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC","ANTIHYPERGLYCÉMIANT","",""
"4541","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"4542","96-09-30","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"4543","96-06-18","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"4544","96-09-09","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"4545","96-06-10","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"4546","96-09-10","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","MARION MERRELL DOW CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"4547","96-07-04","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC","ANTIHYPERGLYCÉMIANT","",""
"4548","96-12-31","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"4549","96-08-21","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA ADRÉNERGIQUES","",""
"4550","96-07-18","GALDERMA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-ROSACEA AGENT","AGENT ANTIROSACÉE","",""
"4551","96-12-24","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARHYTHMIQUE","",""
"4552","96-12-20","MCNEIL CONSUMER PRODUCTS COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4553","96-05-03","TECHNILAB INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4554","96-12-20","SANOFI WINTHROP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL STRENGTH","NOUVELLE CONCENTRATION","INOTROPE/VASODILATOR","INOTROPE/VASODILATATEUR","",""
"4555","96-12-20","SANOFI WINTHROP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SHORT-TERM MANAGEMENT OF SEVERE CONGESTIVE HEART FAILURE INCLUDING LOW OUTPUT STATES FOLLOWING CARDIAC SURGERY","NOUVELLE INDICATION: TRAITEMENT À COURT TERME DE L'INSUFFISANCE CARDIAQUE GLOBALE SÉVÈRE Y COMPRIS LES ÉTATS DE FAIBLE DÉBIT APRÈS UNE CHIRURGIE CARDIAQUE","INOTROPE/VASODILATOR","INOTROPE/VASODILATATEUR","",""
"4556","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR GROWTH STIMULANT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"4557","96-11-01","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR GROWTH STIMULANT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"4558","96-08-22","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR GROWTH STIMULANT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"4559","96-04-10","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONDEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NONDÉPOLARISANT","",""
"4560","96-05-03","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4561","96-07-10","FAULDING (CANADA) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A CHANGE IN DOSAGE","NOUVEAU SCHÉMA POSOLOGIQUE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"4562","96-03-12","DISPENSAPHARM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GONADOTROPIN RELEASING HORMONE (GNRH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"4563","96-11-06","OHMEDA PHARMACEUTICAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANTAGONIST","ANTAGONISTE NARCOTIQUE","",""
"4564","96-12-18","ABBOTT LABORATORIES, LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NARCAN","DUPONT PHARMA","CANADA","CANADA","1","","","NARCOTIC ANTAGONIST","ANTAGONISTE NARCOTIQUE","",""
"4565","96-02-28","DU PONT MERCK PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","MODIFICATION DE LA PRÉPARATION","OPIOID ANTAGONIST","ANTAGONISTE NARCOTIQUE","",""
"4566","96-08-02","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE REVISÉE","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE/ANALGÉSIQUE/ANTIPYRÉTIQUE","",""
"4567","96-09-26","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIALLERGIC","ANTIALLERGIQUE","",""
"4568","96-05-13","FISONS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR USE IN CHILDREN","NOUVELLE INDICATION: USAGE AVEC ENFANTS","BRONCHIAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE BRONCHIQUE","",""
"4569","96-02-27","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-HYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4570","96-07-11","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","SOUTIEN À L'ARRÊT DE FUMER","",""
"4571","96-06-18","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","SOUTIEN À L'ARRÊT DE FUMER","",""
"4572","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"4573","96-04-22","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4574","96-02-27","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4575","96-09-27","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE ET ANTICONVULSIVANT","",""
"4576","96-02-20","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE CONCENTRATION","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4577","96-06-05","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"4578","96-02-27","KEY PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR AN ADDITIONAL STRENGTH","NOUVELLE CONCENTRATION","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"4579","96-04-25","DISPENSAPHARM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"4580","96-03-12","DISPENSAPHARM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"4581","96-05-03","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"4582","96-03-29","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"4583","96-08-19","ORTHO PHARMACEUTICAL, DIVISION OF JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"4584","96-08-19","ORTHO PHARMACEUTICAL, DIVISION OF JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"4585","96-06-18","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"4586","96-06-07","NU-PHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVENTYL","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4587","96-12-24","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICYCLIC ANTIDEPRESSANT","ANTIDÉPRESSEUR TRICYCLIQUE","",""
"4588","96-06-27","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4589","96-11-07","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4590","96-03-07","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"4591","96-08-28","ORTHO PHARMACEUTICAL, DIVISION OF JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"4592","96-10-28","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"4593","96-08-22","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF SYMPTOMS ASSOCIATED WITH GASTROESOPHAGEAL REFLUX DISEASE (IE. HEARTBURN AND REGURGITATION)","NOUVELLE INDICATION: POUR LE TRAITEMENT DES SYMPTÔMES RELIÉS AU REFLUX GASTROOESOPHAGIEN PATHOLOGIQUE (I.E. BRÛLEMENT D'ESTOMAC ET RÉGURGITATION)","H+, K+-ATPASE INHIBITOR","INHIBITEUR H+, K+-ATPASE","",""
"4594","96-09-10","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF HELICOBACTER PYLORI-ASSOCIATED PEPTIC ULCER DISEASE","NOUVELLE INDICATION: POUR LE TRAITEMENT DE L'HELICOBACTER PYLORI - RELIÉ À L'ULCÈRE GASTRODUODÉNAL","H+, K+-ATPASE INHIBITOR","INHIBITEUR H+, K+-ATPASE","",""
"4595","96-10-10","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICAITON: TREATMENT OF PATIENTS WITH ACTIVE DUODENAL ULCER INVOLVING HELICOBACTER PYLORI INFECTION","NOUVELLE INDICATION:  POUR LE TRAITEMENT DES PERSONNES QUI PRÉSENTENT UN ULCÈRE DUODÉNAL ACTIF RELIÉ À L'INFECTION À L'HELICOBACTER PYLORI","H+, K+-ATPASE INHIBITOR","INHIBITEUR H+, K+-ATPASE","",""
"4596","96-01-12","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW DOSAGE FORM DELAYED RELEASE TABLETS","NOUVELLE PRÉSENTATION","H+, K+-ATPASE INHIBITOR","INHIBITEUR H+, K+-ATPASE","",""
"4597","96-09-26","GLAXO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"4598","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4599","96-10-29","TECHNILAB PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4600","96-06-10","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC AGENT","ANTICHOLINERGIQUE","",""
"4601","96-12-24","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE - ANTISPASMODIQUE","",""
"4602","98-02-05","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"4603","96-06-18","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"4604","96-05-08","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC - ANTISPASMODIC AGENT","ANTICHOLINERGIQUE - ANTISPASMODIQUE","",""
"4605","96-01-04","PURDUE FREDERICK","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"4606","96-06-25","SANDOZ CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR","INHIBITEUR DE LA PROLACTINE","",""
"4607","96-05-27","CIBA-GEIGY CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: LYSTIC BONE METASTASES AND MULTIPLE MYELOMA","NOUVELLE INDICATION: MÉTASTASIS LYSTIQUE OSSEUX ET MYÉLOMA MULTIPLE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"4608","96-07-05","BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"4609","96-10-21","CIBA-GEIGY CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","DOSAGE CHANGE AND PRODUCT MONOGRAPH REVISION","NOUVEAU SCHÉMA POSOLOGIQUE, MONOGRAPHIE REVISÉE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"4610","96-02-19","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOQUAGE NEUROMUSCULAIRE NON-DÉPOLARISANT","",""
"4611","96-08-06","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOQUAGE NEUROMUSCULAIRE NON-DÉPOLARISANT","",""
"4612","96-09-23","SOLVAY KINGSWOOD INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"4613","96-10-08","SOLVAY PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"4614","96-06-10","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOACTIVE AGENT","AGENT VASOACTIF","",""
"4615","96-09-26","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL PEDICULICIDE AND OVICIDE","PÉDICULICIDE ET OVICIDE TOPIQUE","",""
"4616","96-10-15","SOLVAY PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTROINTESTINAL CALCIUM ANTAGONIST","ANTAGONISTE DE CALCIUM GASTROINTESTINAL","",""
"4617","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC PROPRIÉTÉS ANALGÉSIQUE","",""
"4618","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC PROPRIÉTÉS ANALGÉSIQUES","",""
"4619","96-04-25","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC PROPRIÉTÉS ANALGÉSIQUES","",""
"4620","96-03-01","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BLOOD VOLUME SUPPORTER","","",""
"4621","96-08-02","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4622","96-12-02","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4623","96-06-07","SQUIBB CANADA INC., A DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION AND ADDITION OF A NEW STRENGTH","MODIFICATION DE LA PRÉPARATION, NOUVELLE CONCENTRATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"4624","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"4625","96-08-12","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"4626","96-01-04","SQUIBB CANADA INC., A DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PACKAGING MATERIAL, ALTERNATE MANUFACTURING SITE, CHANGE IN FORMULATION","MODIFICATION DU MATÉRIEL D'EMBALLAGE, AUTRE EMPLACEMENT DE FABRICATION, MODIFICATION DE LA PRÉPARATION","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"4627","96-07-19","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INDERAL","WYETH-AYERST","CANADA","CANADA","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"4628","96-09-12","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4629","96-06-05","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4630","96-03-07","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4631","96-03-07","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4632","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4633","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4634","96-12-24","LABORATOIRES TRIANON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4635","96-01-30","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4636","96-06-18","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4637","96-12-24","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID COMPONENT TO ANAESTHESIA","COMPOSANT NARCOTIQUE D'ANÉSTHÉSIQUE","",""
"4638","96-09-10","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHROMBOTIC AGENT","ANTITHROMBOTIQUE","",""
"4639","96-12-23","CANGENE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"4640","96-12-31","CANGENE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING, CHANGE IN TRADE NAME","MODIFICATION DE LA FABRICATION, MODIFICATION DU NOM","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"4641","96-12-23","CANGENE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION","MODIFICATION DE LA PRÉPARATION","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"4642","96-07-04","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITUBERCULOSIS ANTIBIOTIC","ANTIBIOTIQUE ANTITUBERCULEUX","",""
"4643","96-01-17","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORITICOSTEROID","CORTICOSTÉROÏDE","",""
"4644","96-04-04","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A ONCE A DAY DOSING REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"4645","96-02-14","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR REVISED PRODUCT MONOGRAPH","MONOGRAPHIE REVISÉE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"4646","96-08-14","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR VIH PROTÉASE","",""
"4647","96-12-24","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANÉSTHÉSIQUE LOCALE","",""
"4648","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4649","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT BÊTA2-ADRÉNERGIQUE","",""
"4650","96-04-19","DOMINION PHARMACAL","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR NEW STRENGTHS","NOUVELLES CONCENTRATIONS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4651","96-03-07","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT BÊTA2-ADRENERGIQUE","",""
"4652","96-03-12","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT BETA2-ADRÉNERGIQUE","",""
"4653","96-01-26","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR NEW STRENGTHS","NOUVELLES CONCENTRATIONS","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4654","96-07-04","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4655","96-08-28","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4656","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF INFLAMMATORY BOWEL DISEASE, ULCERATIVE COLITIS, CROHN'S DISEASE AND RHEUMATOID ARTHRITIS","AGENT DANS LE TRAITEMENT DE MALADIES INTESTINALES INFLAMMATOIRES, DE LA COLITE ULCÉREUSE, DE LA MALADIE DE CROHN ET DE LA POLYARTHRITE RHUMATOÏDE","",""
"4657","96-10-02","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR (B2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT B2-ADRÉNERGIQUE)","",""
"4658","96-03-22","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HIV PROTEASE INHIBITOR/ANTIRETROVIRAL","INHIBITEUR VIH PROTÉASE/ANTIRÉTROVIRAL","",""
"4659","96-05-03","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMATOPOIETIC GROWTH FACTOR","FACTEUR DE CROISSANCE HÉMOTOPOÏÉTIQUE","",""
"4660","96-12-31","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION IN TREATMENT OF PANIC DISORDER","NOUVELLE INDICATION: TRAITEMENT DE PANIQUE","ANTIDEPRESSANT - ANTIPANIC AGENT","ANTIDÉPRESSEUR - ANTIPANIQUE","",""
"4661","96-04-19","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR PATIENTS WITH CORONARY HEART DISEASE","NOUVELLE INDICATION: TRAITEMENT DE CARDIOPATHIE ISCHÉMIQUE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"4662","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME","",""
"4663","96-05-28","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INTAL","FISONS","CANADA","CANADA","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME","",""
"4664","96-06-13","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GROWTH STIMULANT","STIMULANT DE LA CROISSANCE","",""
"4665","96-09-13","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","GROWTH STIMULANT","STIMULANT DE LA CROISSANCE","",""
"4666","96-09-30","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","THREE NEW STRENGTHS IN A CARTRIDGE PRESENTATION FOR USE WITH HUMATRO-PEN II","MONOGRAPHIE REVISÉE, NOUVELLE PRÉSENTATION: CARTRIDGE, NOUVELLES CONCENTRATIONS","GROWTH STIMULANT","STIMULANT DE LA CROISSANCE","",""
"4667","96-07-24","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GROWTH HORMONE","HORMONE DE LA CROISSANCE","",""
"4668","96-10-15","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","GROWTH HORMONE","HORMONE DE LA CROISSANCE","",""
"4669","96-03-29","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HUMAN GROWTH HORMONE - GROWTH STIMULANT","STIMULANT DE LA CROISSANCE","",""
"4670","96-11-29","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING","MODIFICATION DE LA FABRICATION","HUMAN GROWTH HORMONE - GROWTH STIMULANT","STIMULANT DE LA CROISSANCE","",""
"4671","96-02-02","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"4672","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"4673","96-06-05","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"4674","96-10-21","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"4675","96-03-14","PHARMACIA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR A NEW STRENGTH: A MORE CONCENTRATED PRODUCT","NOUVELLE CONCENTRATION","FAT EMULSION FOR INTRAVENOUS NUTRITION","EMULSION DE GRAS POUR ALIMENTATION IV","",""
"4676","96-03-26","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"4677","96-06-18","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"4678","96-11-20","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"4679","96-09-26","CARTER-HORNER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRODUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRO-DUODENAL","",""
"4680","96-07-04","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRO-DUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRO-DUODENAL","",""
"4681","96-12-24","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","5-HT RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS 5-HT","",""
"4682","96-03-07","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST/MIGRAINE THERAPY","ANTAGONISTE DES RÉCEPTEURS 5-HT1/THÉRAPIE MIGRAINE","",""
"4683","96-01-26","FERTIN A/S","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","FOR THE SUBJECTIVE RELIEF OF XEROSTOMIA AND FOR THE NEUTRALIZING DENTAL PLAQUE ACIDS TAHT CAN CAUSE TOOTH DECAY","SOULAGEMENT SUBJECTIF DE LA XÉROSTOMIE, NEUTRALISATION DES ACIDES DE LA PLAQUE DENTAIRE","",""
"4684","96-09-27","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","GONADOTROPIN","GONADOTROPHINE","",""
"4685","96-08-01","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MANUFACTURING CHANGES","MODIFICATION DE LA FABRICATION","GONADOTROPIN","GONADOTROPHINE","",""
"4686","96-03-11","JOUVEINAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR THE MANAGEMENT OF CHOLESTATIC LIVER DISEASES SUCH AS PRIMARY BILIARY CIRRHOSIS","NOUVELLE INDICATION","LITHOLYTIC AGENT & CHOLESTATIC LIVER DISEASES","LITHOLYTIQUE","",""
"4687","96-05-24","DU PONT MERCK PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISIONS","MONOGRAPHIE REVISÉE","ANTICOAGULANT","ANTICOAGULANT","",""
"4688","96-10-25","DU PONT MERCK PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTICOAGULANT","ANTICOAGULANT","",""
"4689","96-06-10","PHARMACHEMIE B.V.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4690","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4691","96-06-07","DU PONT MERCK PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","VIAL CLOSURE CHANGE","NOUVEL EMBALLAGE","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"4692","96-06-07","DU PONT MERCK PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN FACILITY AND MANUFACTURING PROCESS","MODIFICATION DE LA FABRICATION","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"4693","96-05-24","MALLINCKRODT MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","MODIFICATION OF PACKAGING SYSTEM","NOUVEL EMBALLAGE","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"4694","96-12-11","MEDI PHYSICS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING AND REVISED PRODUCT MONOGRAPH","MODIFICATION DE LA FABRICATION ET MONOGRAPHIE REVISÉE","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"4695","96-08-06","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AGENT","HYPNOTIQUE","",""
"4696","96-11-07","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4697","96-11-07","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AGENT","HYPNOTIQUE","",""
"4698","96-11-25","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4699","96-07-04","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AGENT","HYPNOTIQUE","",""
"4700","96-09-16","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4701","96-10-25","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HYPNOTIC","HYPNOTIQUE","",""
"4702","96-04-25","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT/SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR/TRAITEMENT DES SYMPTÔMES DE L'HYPERTROPHIE DE LA PROSTATE","",""
"4703","96-03-12","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT/SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR/TRAITEMENT DES SYMPTÔMES DE L'HYPERTROPHIE DE LA PROSTATE","",""
"4704","96-03-29","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4705","96-03-29","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4706","96-11-18","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4707","96-06-10","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4708","96-12-20","LEO LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN FOR HIP AND KNEE SURGERY","NOUVEAU SCHÉMA POSOLOGIQUE","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"4709","96-09-09","LEO LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF DEEP VENOUS THROMBOSIS","NOUVELLE INDICATION","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"4710","96-09-09","LEO LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTICOAGULANT/ANTITHROMBOTIC AGENT","ANTICOAGULANT/ANTITHROMOBTIQUE","",""
"4712","96-04-22","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4713","96-04-01","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4714","96-04-22","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4715","96-12-18","ICN CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4716","96-06-27","JANSSEN PHARMACEUTICA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AGENT FOR THE TREATMENT OF PHOTODAMAGED SKIN","TRAITEMENT DE LA PEAU PHOTOALTÉRÉE","",""
"4717","96-02-28","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"4718","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4719","96-10-25","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4720","96-09-12","SWISS SERUM & VACCINE INSTITUTE BERNE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING AND REVISED PRODUCT MONOGRAPH","MODIFICATION DE LA PRÉPARATION, MONOGRAPHIE REVISÉE","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4721","96-05-01","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL","ANTIVIRAL","",""
"4722","96-10-08","BURROUGHS WELLCOME","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL INDICATION: RECURRENT GENITAL HERPES","NOUVELLE INDICATION","ANTIVIRAL AGENT","ANTIVIRAL","",""
"4723","96-09-26","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4724","96-12-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4725","96-11-01","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4726","96-04-04","TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4727","96-04-25","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4728","96-02-21","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4729","96-10-02","PENTAPHARM LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiarrhythmic, Antianginal, Antihypertensive Agent","Antiarhythmique, Antiangineux, Antihypertenseur","",""
"4730","96-10-08","ALTIMED PHARMACEUTICAL COMPANY INC., DIVISION OF TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL/ANTIARRHYTHMIC/ANTIHYPERTENSIVE AGENT","ANTIARHYTHMIQUE/ANTIANGINEUX/ANTIHYPERTENSEUR","",""
"4731","96-05-27","RJR PHARMA INTERNATIONAL SERVICES INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN","KNOLL PHARMACEUTICAL","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARHYTHMIQUE","",""
"4732","96-02-12","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4733","96-11-13","HOECHST MARION ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AS INITIAL MONOTHERAPY FOR THE MANAGEMENT OF INFANTILE SPASMS (WEST SYNDROME)","NOUVELLE INDICATION","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"4734","96-07-04","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"4735","96-04-10","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4736","96-01-30","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR THE USE OF THE DRUG IN MONOTHERAPY","MONOTHÉRAPIE","ANTIRETROVIRAL","ANTIRÉTROVIRAL","",""
"4737","96-04-15","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"4738","96-11-20","LOREX PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AGENT","HYPNOTIQUE","",""
"4739","96-06-18","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNTOIC","HYPNOTIQUE","",""
"4740","96-05-03","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4741","96-08-19","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4742","96-12-23","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HYPNOTIC","HYPNOTIQUE","",""
"4743","96-03-01","RHODIAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"4744","96-06-27","HOECHST MARION ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"4745","96-03-07","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4746","96-03-07","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY STEROID","STÉROÏDE ANTI-INFLAMMATOIRE TOPIQUE","",""
"4747","95-01-27","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC/ANTI-PYRETIC","ANALGÉSIQUE/ANTIPYRÉTIQUE","",""
"4748","95-01-16","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC-ANTIPANIC","ANXIOLYTIQUE/ANTIPANIQUE","",""
"4749","95-01-19","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE/ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR/ANTI-ANGINEUX","",""
"4750","95-01-24","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4751","95-01-16","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT/ANTISPASTICITY AGENT","RELAXANT MUSCULAIRE/ANTISPASTIQUE","",""
"4752","95-01-27","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT/ANTISPASTICITY AGENT","RELAXANT MUSCULAIRE/ANTISPASMODIQUE","",""
"4753","95-01-19","SIGMA-TAU PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","REPLENISHES CARNITINE","RÉAPPROVISIONNEMENT EN CARNITINE","",""
"4754","95-01-16","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-DEPRESSANT - ANTIOBSESSIONAL","ANTIDÉPRESSEUR - ANTI-OBSESSIONNEL","",""
"4755","95-01-24","GALDERMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"4756","95-01-24","GALDERMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"4757","95-01-06","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ASTHMA PROPHYLAXIS","PROPHYLAXIE DE L'ASTHME","",""
"4758","95-01-24","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT - ANXIOLYTIC","ANTIDÉPRESSEUR - ANXIOLYTIQUE","",""
"4759","95-01-12","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4760","04-06-14","TRITON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"4761","04-06-17","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM RIVA-OXYBUTYNIN","MODIFICATION DU NOM DU PRODUIT DE RIVA-OXYBUTYNIN","ANTICHOLINERGIC, ANTIPASMODIC AGENT","AGENT ANTICHOLONERGIQUE, ANTIPASMODIQUE","",""
"4762","04-06-14","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM LOXAPINE","MODIFICATION DU NOM DU PRODUIT DE LOXAPINE","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"4763","04-06-14","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"4764","04-06-14","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4765","04-06-14","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIDAMOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","ANTIKALIURETIC AGENT WITH DIURETIC PROPERTIES","ANTIKALIURÉTIQUE, DIURÉTIQUE","",""
"4766","04-06-17","GENZYME CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYME","",""
"4767","04-06-21","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"4768","04-06-21","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"4769","04-06-21","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"4770","04-06-22","WATSON LABORATORIES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPASMODIC, ANTICHOLINERGIC AGENT","AGENT ANTISPASMODIQUE, ANTICHOLINERGIQUE","",""
"4771","04-06-21","ORBUS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"4772","04-06-21","ORBUS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIKALIURETIC AGENT WITH DIURETIC PROPERTIES","ANTIKALIURÉTIQUE, DIURÉTIQUE","",""
"4773","04-06-24","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VITAMIN AND MINERAL SUPPLEMENT","SUPPLÉMENT DE VITAMINES ET MINÉRAUX","",""
"4774","04-06-22","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDIABETIC AGENT, INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE, AGENT INSULINOSENSIBILISATEUR","",""
"4775","04-06-22","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"4776","04-06-24","3M PHARMACEUTICALS, A DIVISION OF 3M CANADA COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF ACTINIC KERATOSIS IN ADULTS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE LA KÉRATOSE ACTINIQUE CHEZ L'ADULTE","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE IMMUNITAIRE","",""
"4777","04-06-25","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4778","04-06-30","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO EXTEND THE ACUTE TREATMENT EFFICACY CLAIM TO A LONGER TERM TREATMENT OF UP TO ONE YEAR","POUR ÉLARGIR LA RÉCLAME DE L'EFFICACITÉ DU TRAITEMENT D'URGENCE À UN TRAITEMENT À PLUS LONG TERME ALLANT JUSQU'À UN AN","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4779","04-06-30","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE FOR TEST ON FINISHED PRODUCT","CHANGEMENT AU TEST POUR LE PRODUIT ACHEVÉ","PERITONEAL DIALYSIS SOLUTION","PÉRITONÉALE","",""
"4780","04-06-30","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH - 27MG","NOUVELLE CONCENTRATION - 27MG","CNS STIMULANT","STIMULANT DU SNC","",""
"4781","04-06-30","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER","NOUVELLE INDICATION : POUR LE TRAITEMENT ADJUVANT DE LA FEMME POSTMÉNOPAUSIQUE AVEC CANCER DU SEIN PRÉCOCE POSITIF À L'HORMONE RÉCEPTEUR","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"4782","04-06-30","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIXARIT","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","VASCULAR STABILIZER FOR TREATMENT OF MENOPAUSAL FLUSHING","STABILISATEUR VASCULAIRE POUR LE TRAITEMENT DES BOUFFÉES DE CHALEUR DE LA MÉNOPAUSE","",""
"4783","04-07-05","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN-150","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4784","04-07-05","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOGADON","ICN CANADA LIMITED","CANADA","CANADA","1","","","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE ET ANTICONVULSIVANT","",""
"4785","04-07-05","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSANT, ANTIOBSESSIONNEL","",""
"4786","04-07-05","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ZENECA PHARMA","CANADA","CANADA","1","","","BETA ADRENERGIC-RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"4787","04-07-05","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REPLACES THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED MARCH 1ST, 2001","REMPLACE L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 1ER MARS 2001","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"4788","04-07-07","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR VIII","FACTEUR VIII DE COAGULATION ANTIHÉMORRAGIQUE","",""
"4789","04-07-08","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"4790","04-07-20","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM UNIDET","MODIFICATION DU NOM DU PRODUIT DE UNIDET","ANTICHOLINERGIC, ANTISPASMODIC","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"4791","04-07-22","VITA HEALTH PRODUCTS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"4792","04-07-20","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"4793","04-07-20","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING AREA","NOUVELLE ZONE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"4794","04-07-20","AVENTIS PASTEUR SA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING AREA","NOUVELLE ZONE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"4795","04-07-20","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING AREA","NOUVELLE ZONE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"4796","04-07-20","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING AREA","NOUVELLE ZONE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"4797","04-07-16","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF SYMPTOMS IN SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD), ALSO CALLED NON-EROSIVE REFLUX DISEASE (NERD)","NOUVELLE INDICATION : POUR LE TRAITEMENT DES SYMPTÔMES DU REFLUX GASTROOESOPHAGIEN PATHOLOGIQUE, AUSSI APPELÉ REFLUX GASTROOESOPHAGIEN PATHILOGIQUE NON-ÉROSIF","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"4798","04-07-15","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW ADMINISTRATION: MEDICAL THERAPY OF PROSTATE SYMPTOMS (MTOPS).  COMBINAISON OF PROSCAR AND DOXAZOSIN TO REDUCE THE RISK OF SYMPTOMATIC PROGRESSION OF BPH","NOUVELLE ADMINISTRATION : THÉRAPIE MÉDICALE DES SYMPTÔMES RELIÉS À LA PROSTATE.  ASSOCIATION DE PROSCAR ET DOXAZOSIN POUR RÉDUIRE LE RISQUE DE PROGRESSION SYMPTÔMATIQUE DE L'HYPERTROPHIE BÉNIGNE DE LA PROSTATE","TYPE II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"4799","04-07-16","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: POWDER FOR INJECTABLE PROLONGED-RELEASE SUSPENSION","NOUVELLE POSOLOGIE : POUDRE POUR SUSPENSION À LIBÉRATION PROLONGÉE INJECTABLE","ANTIPSYCHOTIQUE AGENT","AGENT ANTIPSYCHOTIQUE","",""
"4800","04-07-15","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4801","04-07-15","DURAMED PHARMACEUTICALS, INC., A SUBSIDIARY OF BARR PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EMERGENCY CONTRACEPTION","CONTRACEPTIF D'URGENCE","",""
"4802","04-07-15","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4803","04-07-15","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4804","04-07-15","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"4805","04-07-15","AVEVA DRUG DELIVERY SYSTEMS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"4806","95-12-28","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ALPHA1 - ANTITRYPSIN REPLENISHER","INHIBITEUR DE PROTÉINASE - ALPHA1","",""
"4807","95-12-28","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","TWO ADDITIONAL FILL SIZES - 100ML AND 200ML, REVISIONS TO THE METHOD OF MANUFACTURING FOR ALL FILL SIZES","MODIFICATION DE LA FABRICATION","HEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"4808","95-12-19","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN/ANTIVIRAL AGENT","ANTIPARKINSONIEN/ANTIVIRAL","",""
"4809","95-12-18","MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DE MÉTABOLISME OSSEUX","",""
"4810","95-11-30","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ALPHA1 - ANTITRYPSIN REPLENISHER","RECHARGEUR ALPHA1 - ANTITRYPSINE","",""
"4811","95-11-29","GENENTECH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DOSING REGIMEN, MODIFICATION TO CLAIMS","MONOGRAPHIE RÉVISÉE, NOUVEAU SCHÉMA POSOLOGIQUE ET ALLÉGATION : INFUSION ACCÉLÉRÉE LORS DE L'INFARCTUS DU MYOCARDE À LA PHASE AIGUE","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"4812","95-11-29","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISION TO THE PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"4813","95-11-29","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"4814","95-11-29","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"4815","04-07-27","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSING SCHEDULE FOR RENALLY IMPAIRED PATIENTS AND UNCOMPLICATED URINARY TRACT INFECTION","NOUVELLE POSOLOGIE POUR LES PERSONNES QUI PRÉSENTENT DES TROUBLES DE LA FONCTION RÉNALE ET POUR L'INFECTION NON-COMPLIQUÉE DU SYSTÈME URINAIRE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"4816","04-07-28","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"4817","04-07-28","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS DIVISION OF WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM AND STRENGTHS","NOUVELLE FORME POSOLOGIQUE ET NOUVELLES CONCENTRATIONS","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"4818","04-07-29","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"4819","04-07-29","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: 70MG ONCE WEEKLY DOSING REGIMEN FOR THE TREATMENT OF OSTEOPOROSIS IN MEN","NOUVELLE INDICATION : 70MG UNE FOIS PAR SEMAINE POUR LE TRAITEMENT DE L'OSTÉOPOROSE CHEZ L'HOMME","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"4820","04-07-29","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY CORTICOSTEROID","CORTICOSTÉROÏDE ANTI-INFLAMMATOIRE TOPIQUE","",""
"4821","04-07-29","GALDERMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"4822","04-07-29","GALDERMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"4823","04-07-29","ICN CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 0.5MG CAPSULES","NOUVELLE CONCENTRATION : 0.5MG CAPSULES","ANTIEMETIC AGENT","ANTIÉMÉTIQUE","",""
"4824","04-07-27","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"4825","04-07-30","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","BIOVAIL PHARMACEUTICALS","CANADA","CANADA","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"4826","04-07-29","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN THE DRUG SUBSTANCE SOURCE, STANDARD AND FINAL PRODUCT TESTING.  CHANGE IN THE DRUG PRODUCT MANUFACTURING SITE, EXPIRY DATING TO 30 MONTHS AND PACKAGING","CHANGEMENT DE LA SOURCE, DE LA NORME ET DE L'ANALYSE DU PRODUIT FINAL POUR LA PRÉPARATION PHARMACEUTIQUE; CHANGEMENT DU SITE DE FABRICATION, DE LA DATE D'EXPIRATION À 30 MOIS ET DE L'EMBALLAGE POUR LE PRODUIT PHARMACEUTIQUE","ANESTHETIC","ANESTHÉSIQUE","",""
"4827","04-07-27","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","GONADOTROPINS","GONADOTROPHINES","",""
"4828","04-07-30","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING PROCESS","NOUVELLE MÉTHODE DE FABRICATION","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"4829","04-08-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE AS MONOTHERAPY IN CHILDREN WITH PARTIAL SEIZURES AND BETWEEN 6-16 YEARS OF AGE","NOUVELLE INDICATION : COMME MONOTHÉRAPIE CHEZ LES ENFANTS DE 6 À 16 ANS QUI PRÉSENTENT DES CRISES CONVULSIVES PARTIELLES","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"4830","04-08-12","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4831","04-08-09","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CALCIMIMETIC AGENT","AGENT CALCIMIMÉTIQUE","",""
"4832","04-08-13","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIINFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE NON-STÉROÏDIEN","",""
"4833","04-08-13","ORBUS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"4834","04-08-10","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE - ANTI-INFLAMMATOIRE","",""
"4835","04-08-13","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM","HOECHST MARION ROUSSEL","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4836","04-08-13","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","WARNER-LAMBERT","CANADA","CANADA","1","","","ANTI-EPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"4837","04-08-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4838","04-08-13","BAKER CUMMINS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, AGENT ANTIOBSESSIONNEL","",""
"4839","04-08-13","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION: REDUCED MASS/FILM COATED TABLET","NOUVELLE FORMULE :","ANGIOTENSIN II AT1 RECEPTOR BLOCKER, DIURETIC","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II, DIURÉTIQUE","",""
"4840","04-08-13","ORBUS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIKALIURETIC AGENT WITH DIURETIC PROPERTIES","ANTIKALIURÉTIQUE, DIURÉTIQUE","",""
"4841","04-08-10","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"4842","04-08-10","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","HUMAN GONADOTROPIN","GONADOTROPHINE HUMAINE","",""
"4843","04-08-09","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"4844","04-08-09","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONNAL MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"4845","04-08-09","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING PROCEDURE","NOUVELLE MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"4846","04-08-05","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"4847","04-08-05","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","CHANGEMENTS AUX RUBRIQUES POSOLOGIE ET ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT","ANGIOTENSIN II RECEPTOR (AT1) ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR AT1 DE L'ANGIOTENSINE II","",""
"4848","04-08-05","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MIGRAINE THERAPY","ANTIMIGRAINEUX","",""
"4849","04-08-04","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOWELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"4850","95-11-17","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"4851","95-11-15","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIDIABETIC AGENT, ALPHA-GLUCOSIDASE INHIBITOR","ANTIDIABÉTIQUE, INHIBITEUR ALPHA GLUCOSIDASE","",""
"4852","95-11-06","CIBA-GEIGY CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A PRODUCT MONOGRAPH REVISION","MONOGRAPHIE RÉVISÉE","ADRENAL SUPPRESSANT, REVERSIBLE INHIBITOR OF PERIPHERAL ESTROGEN SYNTHESIS","INHIBITEUR SURRÉNALIEN, INHIBITEUR RÉVERSIBLE DE LA SYNTHÈSE PÉRIPHÉRIQUE DES OESTROGÈNES","",""
"4853","95-11-03","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC & BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE BETA-LACTAMASE","",""
"4854","95-10-31","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR / ANTI-ANGINEUX","",""
"4855","95-10-31","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC & BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE BETA-LACTAMASE","",""
"4856","95-10-03","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"4857","95-10-03","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"4858","95-09-18","MCNEIL CONSUMER PRODUCTS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 - ANTAGONIST","ANTAGONISTE DES HISTAMINIQUES H1","",""
"4859","95-09-15","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4860","95-08-04","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTICOAGULANT","ANTICOAGULANT","",""
"4861","95-08-04","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"4862","95-08-04","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"4863","95-06-29","TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"4864","95-06-21","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL, ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DE LA PARTIE BASSE DU TUBE DIGESTIF","",""
"4865","95-06-19","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"4866","95-05-02","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4867","95-05-01","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: IV","NOUVELLE PRÉSENTATION : IV","ANTIARRHYTHMIC AGENT","AGENT ANTIARYTHMIQUE","",""
"4868","95-04-26","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR / ANTI-ANGINEUX","",""
"4869","95-04-19","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"4870","95-03-29","CLINTEC NUTRITION COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"4871","95-03-09","MCGAW INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"4872","95-02-27","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME, REVISED LABELLING","MODIFICATION DU NOM, ÉTIQUETTE RÉVISÉE","LOWER GASTRO INTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE GASTROINTESTINAL INFÉRIEUR","",""
"4873","95-01-24","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"4874","95-01-19","GENENTECH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"4875","95-01-16","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE / ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR / ANTIANGINEUX","",""
"4876","95-11-17","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH: 81MG/VIAL PLUS 3ML/VIAL DILUENT","NOUVELLE CONCENTRATION : 81MG/VIAL PLUS 3ML DILUENT","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4877","95-11-10","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"4878","95-11-02","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"4879","95-10-10","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4880","95-09-22","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"4881","95-07-31","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"4882","95-07-26","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"4883","95-07-19","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 2MG","NOUVELLE CONCENTRATION : 2MG","DIURETIC","DIURÉTIQUE","",""
"4884","95-07-07","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"4885","95-06-26","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"4886","95-06-22","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","B-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS B-ADRÉNERGIQUES","",""
"4887","95-05-26","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"4888","95-05-15","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","GLUCOCORTICOSTEROID FOR THE TREATMENT OF BRONCHIAL ASTHMA","GLUCOCORTICOSTÉROÏDE POUR LE TRAITEMENT DEL'ASTHME BRONCHIQUE","",""
"4889","95-05-06","ORGANON TEKNIKA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4890","95-05-04","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"4891","95-04-27","SYNCARE PHARMACEUTICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: REMOVAL OF THE INDICATION OF INHIBITION OF LACTATIM","MONOGRAPHIE RÉVISÉE : RETRAIT DE L'INDICATION - INHIBITION DE LACTATIM","PROALCTIN INHIBITOR, GROWTH HORMONE SUPPRESSANT IN ACROMEGALY, ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, MÉDICAMENT ADJUVANT DANS LA MALADIE DE PARKINSON","",""
"4892","95-03-29","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION, NEW PACKAGING","MODIFICATION DE LA PRÉPARATION, NOUVEL EMBALLAGE","ANTIGLAUCOMA AGENT","ANTIGLAUCOME","",""
"4893","95-03-29","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED PRODUCT MONOGRAPH, NEW INDICATION: TO REDUCE THE SUBJECTIVE SYMPTOMS AND OBJECTIVE  SIGNS OF CERVICAL DYSTONIA (SPASMODIC TORTICOLLIS) IN ADULTS","MONOGRAPHIE REVISÉE, NOUVELLE INDICATION: POUR RÉDUIRE LES SYMPTÔMES SUBJECTIFS ET LES SIGNES OBJECTIFS DE DYSTOMIE CERVICALE (TORTICOLIS SPASMODIQUE) CHEZ L'ADULTE","NEUROMUSCULAR PARALYTIC AGENT","AGENT NEUROMUSCULAIRE PARALYSANT","",""
"4894","95-03-29","CIBA-GEIGY CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / TIAZIDE DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE DE THIAZINE","",""
"4895","95-02-28","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","NATURAL SURFACTANT","SURFACTANT NATUREL","",""
"4896","95-02-15","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","NATURAL SURFACTANT","SURFACTANT NATUREL","",""
"4897","95-02-15","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR, GROWTH HORMONE SUPPRESSANT IN ACROMEGALY ADJUNCTIVE, MEDICATION IN  PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, TRAITEMENT ADJUVANT DANS LA MALADIE DE PARKINSON","",""
"4898","95-02-09","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4899","95-02-07","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"4900","95-12-28","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: OPHTHALMIC OINTMENT","NOUVELLE PRÉSENTATION : ONGUENT OPHTALMIQUE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"4901","95-12-19","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","VITAMIN D3 METABOLITE","MÉTABOLITE DE LA VITAMINE D3","",""
"4902","95-12-08","GLAXO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4903","04-08-16","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY AND MANUFACTURING CHANGES","SITE DE FABRICATION SUPPLÉMENTAIRE ET CHANGEMENTS À LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"4904","04-08-19","SOLSTICE NEUROSCIENCES, LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","NEUROMUSCULAR BLOCKING AGENT","AGENT BLOQUANT NEUROMUSCULAIRE","",""
"4905","04-08-16","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY AND MANUFACTURING CHANGES","SITE DE FABRICATION SUPPLÉMENTAIRE ET CHANGEMENTS À LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"4906","04-08-19","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYCLOCORT","STIEFEL CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM: OINTMENT","NOUVELLE FORME POSOLOGIQUE : ONGUENT","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"4907","04-08-17","BAKER CUMMINS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ZENECA PHARMA","CANADA","CANADA","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"4908","04-08-17","BAKER CUMMINS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"4909","04-08-19","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"4910","04-08-20","RAINBOW PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"4911","04-08-16","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4912","04-08-18","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"4913","04-08-17","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE, ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4914","04-08-17","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"4915","04-08-20","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4916","04-08-24","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"4917","04-08-24","GENZYME CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","PHOSPHATE BINDER","CHÉLATEUR DE PHOSPHATES","",""
"4918","04-08-24","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"4919","04-08-27","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAVELBINE","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4920","04-08-23","AMERSHAM HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA MÉTHODE DE FABRICATION","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"4921","04-08-23","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY AND PROCESS","NOUVEL EMPLACEMENT DE FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"4922","95-11-29","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4923","95-11-29","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","AGENT ANTIPARKINSONIEN","",""
"4924","95-11-15","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSGE FORM: SCALP SOLUTION","NOUVELLE PRÉSENTATION : SOLUTION POUR LE CUIR CHEVELU","NON-STEROIDAL ANTIPSORIATIC AGENT","ANTIPSORIASIQUE NON-STÉROÏDIEN","",""
"4925","95-11-15","CIBA-GEIGY CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR ORAL SUSPENSION","NOUVELLE PRÉSENTATION : SUSPENSION ORALE","ANTICONVULSANT, FOR SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA, ANTIMANIC","ANTICONVULSIVANT","",""
"4926","95-11-08","KENRAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4927","95-11-03","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","ANTIHYPERCHOLESTEROLEMIC, ANTIDIARRHEAL","ANTIHYPERCHOLESTÉROLEMIQUE, ANTIDIARRHÉIQUE","",""
"4928","95-11-02","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR USE IN PEDIATRIC PATIENTS (OVER 1 YEAR OF AGE)","NOUVELLE INDICATION : USAGE EN PÉDIATRIE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"4929","95-11-02","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"4930","95-10-31","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTI-OBSESSIONNEL","",""
"4931","95-10-10","HOECHST-ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","TOPICAL ANTI-ACNE","ANTI-ACNÉ TOPIQUE","",""
"4932","95-09-22","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4933","95-09-22","SQUIBB CANADA INC., A DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN DIABETIC NEPHROPATHY","NOUVELLE INDICATION : USAGE LORS DE NÉPHROPATHIE DIABÉTIQUE","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4934","95-09-12","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR, DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE, DIURÉTIQUE","",""
"4935","95-09-12","SCHERING-PLOUGH HEALTHCARE PRODUCTS CANADA, A DIVISION OF SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4936","95-09-12","SCHERING-PLOUGH HEALTHCARE PRODUCTS CANADA, A DIVISION OF SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4937","95-09-05","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"4938","95-09-05","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4939","95-08-25","STCC INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4940","95-08-23","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4941","95-08-22","HOECHST-ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4942","95-08-22","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"4943","95-08-18","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4944","95-08-17","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, NEW FORMULATION","NOUVELLE PRÉPARATION, NOUVELLE CONCENTRATION","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4945","95-08-09","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"4946","95-07-31","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4947","95-07-31","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4948","95-07-31","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"4949","95-07-31","SQUIBB CANADA INC., A DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN POST-MI","NOUVELLE INDICATION : EMPLOYÉ EN POST-IM","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITOR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4950","95-07-13","NEOLAB INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE FROM PRESCRIPTION TO NON-PRESCRIPTION","CHANGEMENT DE PRESCRIPTION À VENTE LIBRE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4951","95-07-13","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"4952","95-07-07","BOEHRINGER MANNHEIM (CANADA) LTEE/LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN: 1500 MG - SINGLE INFUSION","NOUVEAU SCHÉMA POSOLOGIQUE : 1500 MG - PERFUSION UNIQUE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"4953","95-07-07","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"4954","95-06-26","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"4955","95-06-26","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"4956","95-06-22","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4957","95-06-13","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PROTEOLYTIC ENZYME","ENZYME PROTÉOLYTIQUE","",""
"4958","95-06-02","PURDUE FREDERICK","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"4959","95-06-02","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4960","95-05-25","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","AGENT ANTILEUCÉMIQUE","",""
"4961","95-05-09","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4962","95-04-24","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4963","95-04-24","TARO PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","OTC SALE","POUR VENTE SANS ORDONNANCE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"4964","95-04-19","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE, ANTI-ANGINAL","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"4965","95-04-18","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CICATRISING AGENT","AGENT CICATRISANT","",""
"4966","95-04-18","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"4967","95-03-31","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4968","95-03-31","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: CONVENIENT DOSE TABLETS: 375MG AND 500MG","NOUVELLE PRÉSENTATION : COMPRIMÉS PRATIQUES DOSE DE 375MG ET 500MG","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4969","95-02-28","STCC INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4970","95-02-27","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERCHOLESTEROLEMIC AND ANTIDIARRHEAL","ANTIHYPERCHOLESTÉROLÉMIANT ET ANTIDIARRHÉIQUE","",""
"4971","95-02-27","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"4972","95-02-22","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-FUNGAL","ANTIFONGIQUE","",""
"4973","95-02-27","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4974","95-02-27","BOEHRINGER MANNHEIM (CANADA) LTEE/LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4975","95-02-08","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4976","95-02-07","LEO LABORATORIES CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIPSORIATIC AGENT","AGENT ANTIPSORIASIQUE","",""
"4977","95-02-01","UCB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1","",""
"4978","95-01-19","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4979","95-01-13","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"4980","95-12-28","CONNAUGHT LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4981","95-12-06","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"4982","95-12-05","RHODIAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM","ANTIBIOTIC","ANTIBIOTIQUE","",""
"4983","95-11-30","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"4984","95-11-22","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","SPECIFIC ANTIBODY FOR DIGOXIN","ANTICORPS SPÉCIFIQUES POUR LA DIGOXIME","",""
"4985","95-11-17","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4986","95-10-11","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA","NOUVELLE INDICATION : TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE DE LA PROSTATE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"4987","95-09-22","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: ORAL SOLUTION 2MG/ML","NOUVELLE PRÉSENTATION : SOLUTION ORALE 2MG/ML","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4988","95-09-08","CANADA PHARMACAL CO.(1975) LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"4989","95-08-28","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TO IMPROVE URINARY FLOW & SYMPTOMS OF BENIGN PROSTATIC HYPERLASIA (BPH)","NOUVELLE INDICATION : AMÉLIORATION DU DÉBIT URINAIRE ET DES SYMPTÔMES DE L'HYPERTROPHIE DE LA PROSTATE","ALPHA-ADRENOCEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS ALPHA-ADRÉNERGIQUE","",""
"4990","95-08-28","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4991","95-08-04","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: 100MG 150MG","NOUVELLES CONCENTRATIONS : 100MG 150MG","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"4992","95-07-31","CIBA-GEIGY CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","IRON AND ALUMINUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"4993","95-07-21","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4994","95-07-13","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4995","95-06-13","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPOLIPIDEMIC THYROACTIVE AGENT","AGENT TYRÉOACTIF HYPOLIPIDÉMIQUE","",""
"4996","95-05-15","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC, ANTIEMETIC","NEUROLEPTIQUE, ANTIÉMÉTIQUE","",""
"4997","95-04-18","DAVID BULL LABORATORIES (PTY) LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"4998","95-03-30","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"4999","95-03-15","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","CORONARY VASODILATOR","VASODILATATEUR CORONARIEN","",""
"5000","95-03-13","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5001","95-03-09","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"5002","95-03-09","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5003","95-02-07","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIOPROTECTIVE AGENT","AGENT CARDIOPROTECTEUR","",""
"5004","95-01-31","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"5005","95-01-16","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTI-ANGINEUX","",""
"5006","95-11-06","ORTHO-MCNEIL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: AMENIA IN CANCER PATIENTS","NOUVELLE INDICATION : ANÉMIE CHEZ LES CONCÉREUX","ERYTGROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ÉRYTHROPOÏÈSE","",""
"5007","95-10-31","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","AGENT BÉTA-BLOQUANT","",""
"5008","95-10-31","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONDEPOLARIZING NEUROMUSCULAR ANTAGONIST","ANTAGONISTE NEUROMUSCULAIRE NON-DÉPOLARISANT","",""
"5009","95-10-31","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"5010","95-07-19","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISM OSSEUX","",""
"5011","95-06-02","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","ESTROGÈNE","",""
"5012","95-02-08","GALDERMA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","TREATMENT FOR ACNE VULGARIS","TRAITEMENT DE L'ACNÉ VULGAIRE","",""
"5013","95-01-24","OHMEDA PHARMACEUTICAL PRODUCTS, DIVISION OF BOC CANADA LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PACKAGING","NOUVEL EMBALLAGE","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA ADRÉNERGIQUES","",""
"5014","95-01-16","ROBERTS PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"5015","95-11-22","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"5016","95-10-23","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"5017","95-09-22","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE OF THE DRUG IN PEDIATRIC PATIENTS","NOUVELLE INDICATION : EMPLOI EN PÉDIATRIE","ANTIFUNGAL","ANTIFONGIQUE","",""
"5018","95-09-18","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5019","95-08-22","MERCK SHARP & DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","5-ALPHA-REDUCTASE INHIBITOR","INHIBITEUR 5-ALPHA RÉDUCTASE","",""
"5020","95-08-18","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTI-OBSESSIONNEL, ANTIBOULIMIQUE","",""
"5021","95-08-18","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTI-OBSESSIONNEL, ANTIBOULIMIQUE","",""
"5022","95-07-31","SMITHKLINE BEECHAM PHARMA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"5023","95-07-31","GLAXO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALED CORTICOSTEROID FOR THE TREATMENT","CORTICOSTÉROÏDE EN INHALATION POUR LE TRAITEMENT DE L'ASTHME BRONCHIQUE","",""
"5024","95-04-19","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"5025","95-04-18","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"5026","95-04-18","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"5027","95-03-06","LUNDBECK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTISPYCHOTIC","ANTIPSYCHOTIQUE","",""
"5028","95-03-06","LUNDBECK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"5029","95-02-28","STCC INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTI-OBSESSIONNEL, ANTIBOULIMIQUE","",""
"5030","95-01-03","LABORATOIRES FOURNIER S.C.A.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, CHANGE IN FORMULATION","NOUVELLE CONCENTRATION, MODIFICATION DE LA PRÉPARATION","LIPID METABOLISM REGULATORS","RÉGULATEURS DU MÉTABOLISME LIPIDIQUE","",""
"5031","95-11-02","QUEST VITAMIN SUPPLIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","MODULATION OF PHYSICAL ACTIVITY","MODULATION DE L'ACTIVITÉ PHYSIQUE","",""
"5032","95-10-19","SMITHKLINE BEECHAM PHARMA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW ROUTE OF ADMINISTRATION, NEW DOSAGE FORM","NOUVELLE VOIE D'ADMINISTRATION, NOUVELLE PRÉSENTATION","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"5033","95-10-10","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"5034","95-09-27","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"5035","95-07-26","NYCOMED IMAGING A.S.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MRI","AGENT DE REHAUSSEMENT DE CONTRASTE POUR IRM","",""
"5036","95-04-26","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"5037","95-03-06","PROVAL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT","",""
"5038","95-01-16","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPOGLYCEMIC AGENT","AGENT HYPOGLYCÉMIANT","",""
"5039","95-12-28","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL STEROID, EMOLLIENT CREAM","STÉROÏDE TOPIQUE, CRÈME ÉMOLLIENTE","",""
"5040","95-11-23","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"5041","95-10-16","SMITHKLINE BEECHAM PHARMA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DOSAGE REGIMEN, NEW STRENGTH","NOUVEAU SCHÉMA POSOLOGIQUE, NOUVELLE CONCENTRATION","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"5042","95-07-13","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"5043","95-03-29","SMITHKLINE BEECHAM PHARMA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL AGENT","ANTIMALARIA","",""
"5044","95-03-29","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"5045","95-01-12","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS, REVISED PRODUCT MONOGRAPH","NOUVELLE CONCENTRATIONS, MONOGRAPHIE RÉVISÉE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"5046","95-01-12","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS, REVISED PRODUCT MONOGRAPH","NOUVELLES CONCENTRATIONS, MONOGRAPHIE RÉVISÉE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"5047","95-12-29","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5048","95-12-28","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC RADIOCONTRAST AGENT","RADIOCONTRASTANT NON-IONIQUE","",""
"5049","95-10-31","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"5050","95-10-31","LABORATOIRES TRIANON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"5051","95-10-19","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: CHRONIC HEPATITIS C","NOUVELLE INDICATION : HÉPATITE C CHRONIQUE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5052","95-10-04","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC RADIOCONTRAST AGENT","RADIOCONTRASTANT NON-IONIQUE","",""
"5053","95-10-03","BAYER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"5054","95-10-02","MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-STEROIDAL ANALGESIC AND ANTIPYRETIC AGENT","ANALGÉSIQUE NON-STÉROÏDIEN ET ANTIPYRÉTIQUE","",""
"5055","95-08-29","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH: 6 MILLION UNITS/VIAL","NOUVELLE CONCENTRATION : 6 MILLION UNITÉS/VIAL","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5056","95-08-29","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5057","95-08-16","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 1.25MG TAB","NOUVELLE CONCENTRATION : 1.25MG TAB","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"5058","95-08-09","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"5059","95-08-04","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATIONS FOR 10 MILLION IU/VIAL: NON-HODGKIN'S LYMPHOMA / CONDYLOMATA ACUMINATA","NOUVELLE INDICATION POUR 10 MILLIONS UI/VIAL: LYMPHOME NON DE HODGKIN / CONDYLOME ACUMINÉ","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5060","95-08-04","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION FOR 3 AND 5 MILLION IU/VIAL: NON-HODGKIN'S LYMPHOMA","NOUVELLE INDICATION POUR 3 ET 5 MILLIONS UI/VIAL: LYMPHOME NON DE HODGKIN","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5061","95-08-04","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"5062","95-07-31","NYCOMED IMAGING A.S.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC RADIOGRAPHIC CONTRAST MEDIUM","AGENT DE CONTRASTE RADIOLOGIQUE NON-IONIQUE","",""
"5063","95-07-19","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"5064","95-07-07","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5065","95-07-07","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5066","95-06-21","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: CUTANEOUS T-CELL LYMPHOMA","NOUVELLE INDICATION : LYMPHOME CUTANÉ LYMPHOCYTE-T","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5067","95-06-21","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING AND PACKAGING","MODIFICATION DE LA FABRICATION ET L'EMBALLAGE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5068","95-05-09","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC AGENT","ANTICHOLINERGIQUE","",""
"5069","95-05-02","PHARMACIA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: CAPSULES 5MG, 10MG, 25MG","NOUVELLE PRÉSENTATION : CAPSULES 5MG, 10MG, 25MG","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5070","95-04-07","KENRAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH OR FOR THE THERAPY OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE","NOUVELLE INDICATION : THÉRAPIE D'ENTRETIEN LORS DE BRONCHOSPASMES ASSOCIÉ AVEC, OU POUR LE TRAITEMENT DE POUSSÉES ÉVALUATIVES LORS DE BRONCHOPULMOPATHIE CHRONIQUE OBSTRUCTIVE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5071","95-03-27","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH: 5 MEGA UNITS/ML","NOUVELLE CONCENTRATION : 5 MÉGA UNITÉS/ML","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"5072","95-03-13","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"5074","95-02-15","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5075","95-02-15","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE AGENT","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"5076","95-01-12","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANALGÉSIQUE ANTI-INFLAMMATOIRE","",""
"5077","95-01-03","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5078","95-12-19","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","ANALGÉSIQUE AINS","",""
"5079","95-12-19","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5080","95-09-18","MCNEIL CONSUMER PRODUCTS COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"5081","95-09-14","RHO-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5082","95-07-19","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PEDIATRIC ASTHMA PROPHYLACTIC AND ANTIALLETGIC AGENT","PROPHYLAXIE DE L'ASTHME INFANTILE ET AGENT ANTI-ALLERGIQUE","",""
"5083","95-06-29","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"5085","95-06-16","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: 1MG/ML, NEW INDICATION: USE IN CHILDREN FROM 6 MONTHS TO 3 YEARS OLD","NOUVELLE PRÉSENTATION: 1MG/M;, NOUVELLE INDICATION: EMPLOYÉ CHEZ LES ENFANTS DE 6 MOIS À 3 ANS","PEDIATRIC ASTHMA PROPHYLACTIC AND ANTIALLERGIC AGENT","PROPHYLAXIE DE L'ASTHME INFANTILE ET ANTI-ALLERGIQUE","",""
"5086","95-05-15","TECHNILAB INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE","",""
"5087","95-04-19","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID ANALGESIC AGENT","AINS ANALGÉSIQUE","",""
"5088","95-02-28","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5089","95-02-01","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"5090","95-01-24","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","NON-STEROIDAL, ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, NON-STÉROÏDIEN, ANALGÉSIQUE","",""
"5091","95-01-16","SYNTEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","NSAID / ANALGESIC AGENT","AINS / ANALGÉSIQUE","",""
"5092","95-12-08","GLAXO WELLCOME BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"5095","95-11-29","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"5096","94-12-02","BURROUGHS WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE-OXYDASE","",""
"5097","95-11-27","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"5098","94-11-15","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORONARY VASODILATOR","VASODILATATEUR CORONARIEN","",""
"5099","94-11-04","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT / ANTIVIRAL AGENT","ANTIPARKINSONIEN / ANTIVIRAL","",""
"5100","94-11-10","CLINTEC NUTRITION COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"5101","94-10-21","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - ANTIPANIC","ANXIOLYTIQUE - ANTIPANIQUE","",""
"5102","94-10-17","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC - ANTIPYRETIC","ANALGÉSIQUE - ANTIPYRÉTIQUE","",""
"5103","95-10-31","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTI-ANGINEUX","",""
"5104","94-10-13","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5105","95-09-28","MERCK SHARP & DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST","ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II","",""
"5106","95-09-18","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"5107","95-08-22","MERCK SHARP & DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"5108","95-07-17","TEVA PHARMACEUTICALS INDUSTRIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉE DE L'ACIDE FOLIQUE","",""
"5109","95-07-13","STANLEY PHARMACEUTICALS LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"5110","95-06-29","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"5111","95-05-16","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: STERILE CREAM","NOUVELLE PRÉSENTATION : CRÈME STÉRILE","ANESTHETIC FOR DERMAL ANALGESIA","ANESTHÉSIQUE POUR ANALGÉSIE DERMIQUE","",""
"5112","95-05-12","TAP PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"5113","95-04-28","STANLEY PHARMACEUTICALS LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"5114","94-09-27","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE OXYDASE","",""
"5115","95-04-18","KENRAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME, NEW DOSAGE FORM","MODIFICATION DU NOM DU PRODUIT, NOUVELLE PRÉSENTATION","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"5116","95-03-30","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTI-ALLERGY AGENT","AGENT CONTRE LES ALLERGIES","",""
"5117","94-09-15","CHIRON CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5118","95-03-23","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: POWDER FOR ORAL SUSPENSION (100MG/5ML, 200MG/5ML)","NOUVELLE PRÉSENTATION : POUDRE POUR SUSPENSION ORALE (100MG/5ML, 20MG/5ML)","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5119","95-03-15","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL-CHOLESTEROL TO TARGET LEVELS","NOUVELLE INDICATION : POUR RALENTIR LA PROGRESSION DE L'ARTHÉROSCLÉROSE CORONARIENNE CHEZ LES MALADES AYANT UNE CARDIAPATHIE ISCHÉMIQUE; CECI FAISANT PARTIE DE LA STRATÉGIE DE TRAITEMENT POUR DIMINUER LE CHOLESTÉROL TOTAL ET LDL AUX NIVEAUX CIBLÉS","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"5120","94-09-13","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN / ANTIVIRAL AGENT","ANTIPARKINSONIEN / ANTIVIRAL","",""
"5121","95-02-27","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION, NEW STRENGTH","NOUVELLE INDICATION, NOUVELLE CONCENTRATION","GONADOTROPIN RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"5122","95-02-27","TAP PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION, NEW STRENGTH","NOUVELLE INDICATION, NOUVELLE CONCENTRATION","GONADOTROPIN RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"5123","95-02-27","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antidiarrheal Agent","Antidiarrhéique","",""
"5124","94-09-08","GENENTECH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"5125","95-12-28","BIONICHE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL TRACT MOTILITY, ANTIEMETIC","MODIFICATEUR DE LA MOTILITÉ DE LA PARTIE SUPÉRIEURE DU TRACTUS GASTRO-INTESTINAL, ANTIÉMÉTIQUE","",""
"5126","95-11-29","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL PROGESTOGEN, ANTINEOPLASTIC","PROGESTATIF ORAL, ANTINÉOPLASIQUE","",""
"5127","95-11-15","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"5128","95-11-15","TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5129","95-10-31","LABORATOIRES TRIANON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC","ANTI-HYPERGLYCÉMIANT","",""
"5130","95-10-02","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"5131","95-10-02","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTOGEN, ANTINEOPLASTIC","PROGESTATIF, ANTINÉOPLASIQUE","",""
"5132","95-09-28","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"5133","95-09-18","LAVAL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL TRACT ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"5134","95-09-18","DISPENSAPHARM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUCOSAL PROTECTIVE AGENT","AGENT PROTECTEUR DE LA MUQUEUSE","",""
"5135","95-09-14","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","UPPER G.I. MOTILITY MODIFIER, ANTIEMETIC","MODIFICATEUR DE LA MOTILITÉ DE LA PARTIE SUPÉRIEUR DU TRACTUS G.I., ANTIÉMÉTIQUE","",""
"5136","95-08-16","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","NONDEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NONDÉPOLARISANT","",""
"5137","95-07-31","SEARLE CANADA - UNIT OF MONSANTO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN THE TREATMENT AND PREVENTION OF NSAID-INDUCED GASTRODUODENAL ULCERS","NOUVELLE INDICATION : POUR LA PRÉVENTION ET LE TRAITEMENT DES ULCÈRES GASTROINTESTINAUX ASSOCIÉS AUX AINS","MUCOSAL PROTECTIVE AGENT","PROTECTEUR DE LA MUQUEUSE","",""
"5138","95-07-31","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"5139","95-07-31","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"5140","95-07-26","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"5141","95-07-26","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTOGEN, ANTINEOPLASTIC","PROGESTATIF, ANTINÉOPLASIQUE","",""
"5142","95-07-17","STANLEY PHARMACEUTICALS LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5143","95-07-13","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"5144","95-07-07","RHONE-POULENC RORER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ROSACEA AGENT","AGENT ANTIROSACÉ","",""
"5145","95-06-22","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRHEUMATIC","ANTIRHUMATISMAL","",""
"5146","95-06-08","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM, NEW INDICATION","NOUVELLE PRÉSENTATION, NOUVELLE INDICATION","ANTIANOREXIC, ANTICACHEXIC","ANTIANOREXIQUE, ANTICACHEXIQUE","",""
"5147","95-06-02","PURDUE FREDERICK","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINAUSEANT","ANTIÉMÉTIQUE","",""
"5148","95-05-19","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"5149","95-05-17","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5150","95-04-07","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","AGENT ANTIHYPERGLYCÉMIANT","",""
"5151","95-03-29","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"5152","95-03-23","THE UPJOHN COMPANY OF CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"5153","95-03-09","PURDUE FREDERICK","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"5154","95-03-09","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5155","95-02-28","TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE, ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTI-ANGINEUX","",""
"5156","95-02-16","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5157","95-01-24","KENRAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE, REVISED PRODUCT MONOGRAPH","MODIFICATION DU NOM DU PRODUIT, MONOGRAPHIE RÉVISÉE","PROGESTIN","PROGESTATIF","",""
"5158","95-01-19","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","AGENT ANTIHYPERGLYCÉMIANT","",""
"5159","95-01-03","KENRAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","HAIR GROWTH STIMULANT","STIMULANT DE LA POUSSE DES CHEVEUX","",""
"5160","95-01-03","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROIBTESTINAL MOTILITY ANTIEMETIC","ANTIÉMÉTIQUE ET MODIFICATEUR DE LA MOTILITÉ DU TRACTUS GASTROINTESTINAL SUPÉRIEUR","",""
"5161","95-01-03","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"5162","94-08-31","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE GASTRO-INTESTINAL INFERIEUR","",""
"5163","94-08-25","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"5164","94-08-25","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"5165","94-08-09","U.S. BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5166","94-08-09","SEPTODONT SPECIALTIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANAESTHETIC FOR DENTAL USE","ANESTHÉSIQUE LOCAL POUR USAGE DENTAIRE","",""
"5167","94-07-26","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIRHEUMATIC AGENT","AGENT ANTIRHUMATISMAL","",""
"5168","94-06-28","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE GASTRO-INTESTINAL","",""
"5169","94-06-23","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF FINISHED PRODUCT","AUTRE SOURCE DU PRODUIT FINI","NARCOTIC ANALGESIC / ADJUNCT TO ANAESTHESIA","ANALGÉSIQUE NARCOTIQUE / ADJUVANT À L'ANESTHÉSIE","",""
"5170","95-12-20","DU PONT MERCK PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF ALCOHOL DEPENDENCE","NOUVELLE INDICATION : TRAITEMENT DE LA DÉPENDANCE À L'ACOHOL","OPIOID ANTAGONIST","ANTAGONISTE OPIOÏDE","",""
"5171","95-12-19","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE ET ANTICONVULSIVANT","",""
"5172","95-12-05","DISPENSAPHARM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"5173","95-11-29","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND NEW STRENGTH","NOUVELLE PRÉSENTATION ET NOUVELLE CONCENTRATION","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5174","95-11-02","MILES CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIANGINAL, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSIF","",""
"5175","95-10-31","SEARLE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"5176","95-10-31","SEARLE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"5177","95-10-31","SEARLE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GONADOTROPIN-RELEASING HORMONE ANALOGUE","ANALOGUE DE L'HORMONE NATURELLE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"5178","95-10-31","SEARLE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"5179","95-09-22","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HITAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"5180","95-09-18","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASODILATOR","VASODILATATEUR","",""
"5181","95-09-05","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SRTENGTH","NOUVELLE CONCENTRATION","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5182","95-08-25","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5183","95-08-25","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"5184","95-08-23","3M PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL","ANTIANGINEUX","",""
"5185","95-08-22","HOECHST-ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","NONSTEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"5186","95-08-18","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5187","95-06-05","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANALGÉSIQUE ET ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE","",""
"5188","95-04-24","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC, ANTI-INFLAMMATORY AGENT","ANALGÉSIQUE ANTI-INFLAMMATOIRE","",""
"5189","95-04-19","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"5190","95-04-19","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AND ANTI-HYPERTENSIVE AGENT","ANTI-ANGINEUX ET ANTIHYPERTENSEUR","",""
"5191","95-04-19","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"5192","95-04-19","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GONADOTROPIN RELEASING HORMONE ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"5193","95-04-19","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"5194","95-04-18","ALLERGAN HERBERT","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW CLAIM: USE OF THE TERM CURES IN CONJUNCTION WITH ACCEPTED INDICATIONS","NOUVELLE RÉCLAME : EMPLOI DU MOT CURE CONJOINTEMENT AVEC LES INDICATIONS ACCEPTÉES","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5195","95-03-23","DUPONT MERCK PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANTAGONIST","ANTAGONIST OPIOÏDE","",""
"5196","95-02-28","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AGENT, ANTIHYPERTENSIVE AGENT","ANTI-ANGINEUX, ANTIHYPERTENSEUR","",""
"5197","95-02-28","STCC INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"5198","95-02-28","STCC INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5199","95-02-27","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AGENT, ANTIHYPERTENSIVE AGENT, ANTIANGINAL AND ANTI-HYPERTENSIVE AGENT","ANTI-ANGINEUX, ANTIHYPERTENSEUR, ANTI-ANGINEUX ET ANTI-HYPERTENSEUR","",""
"5200","95-02-27","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUNCT IN THE MANAGEMENT OF SUBARACHNOID HEMORRHAGE, CALCIUM CHANNEL BLOCKING AGENT","TRAITEMENT D'APPOINT DE L'HÉMORRAGIE SOUS-ARACHNOÏDIENNE, INHIBITEUR DES CANAUX CLACIQUES","",""
"5201","95-02-01","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANTAGONIST","ANTAGONISTE OPIOÏDE","",""
"5202","95-12-28","ORTHO-MCNEIL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF ACUTE PELVIC INFLAMMATORY DISEASE OF MILD TO MODERATE SEVERITY APPROPRIATE FOR OUTPATIENT MANAGEMENT","NOUVELLE INDICATION : TRAITEMENT DE LA SALPINGITE AIGÜE D'INTENSITÉ FAIBLE À MODÉRÉ CHEZ LES PATIENTS EXTERNES","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"5203","95-11-02","TANTA PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5204","95-07-21","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF ACROMEGALY","NOUVELLE INDICATION : TRAITEMENT DE L'ACROMÉGALIE","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE AU SOMATOSTATIN","",""
"5205","95-04-18","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANABOLIC AGENT","ANABOLISANT","",""
"5206","95-04-18","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC AGENT","ANTICHOLINERGIQUE","",""
"5207","95-03-09","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC AGENT","ANTICHOLINERGIQUE","",""
"5208","95-01-27","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5209","95-11-09","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS","NOUVELLES INDICATIONS","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE","",""
"5210","95-11-09","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS","NOUVELLES INDICATIONS","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE","",""
"5211","95-09-18","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARASITIC AGENT","ANTIPARASITAIRE","",""
"5212","95-09-12","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"5213","95-08-23","REED & CARNICK, DIVISION OF BLOCK DRUG COMPANY (CANADA) LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ABDOMINAL PAIN AND BLOATING RELIEF AGENT","POUR LE SOULAGEMENT DE LA DOULEUR ET GONFLEMENT ABDOMINAUX","",""
"5214","95-08-22","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN CARDIAC SURGERY","NOUVELLE INDICATION : EMPLOYÉ EN CHIRURGIE CARDIAQUE","ANAESTHETIC, SEDATIVE","ANESTHÉSIQUE, SÉDATIF","",""
"5215","95-07-31","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5216","95-07-13","QLT PHOTOTHERAPEUTICS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: REDUCTION OF OBSTRUCTION AND PALLIATION OF DYSPHAGIA IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ESOPHAGEAL CANCER","NOUVELLE INDICATION : RÉDUCTION DE L'OBSTRUCTION ET PALLIATIF DE LA DIPHAGIE CHEZ LES PATIENTS AYANT UNE OBSTRUCTION PARTIELLE OU COMPLÈTE","ANTINEOPLASTIC PHOTOSENSITIZING AGENT","ANTINÉOPLASIQUE PHOTOSENSIBLE","",""
"5217","95-07-13","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC PROPRIÉTÉS ANALGÉSIQUES","",""
"5218","95-07-07","SQUIBB CANADA INC., DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: REDUCE THE RATE OF PROGRESSION OF ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL LDL-CHOLESTEROL TO TARGET LEVELS","NOUVELLE INDICATION : RÉDUIT LA PROGRESSION DE L'ATHÉRIOSCLÉROSE CHEZ LES PATIENTS SOUFFRANT DE CARDIOPATHIE ISCHÉMIQUE.  CETTE STRATÉGIE VISE À DIMINUER LE CHOLESTÉROL TOTAL ET LDL AU NIVEAU DÉSIRÉ","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"5219","95-06-22","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC, ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE, INHIBITEUR DE ß-LACTAMASE","",""
"5220","95-06-08","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSEPOLARIZING NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOQUAGE NEUROMUSCULAIRE NON-DÉPOLARISANT","",""
"5221","95-05-15","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"5222","95-04-19","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN NEUROSURGERY","NOUVELLE INDICATION : EMPLOI EN NEUROCHIRURGIE","INTRAVENOUS EMULSION, ANESTHETIC, SEDATIVE","EMULSION IV, ANESTHÉSIQUE, SÉDATIF","",""
"5223","95-03-30","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"5224","95-03-30","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE TO MANUFACTURING","MODIFICTION DE LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"5225","95-03-30","SQUIBB CANADA INC., DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DE SLIPIDES","",""
"5226","95-02-27","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","INTRAVENOUS EMULSION, ANESTHETIC, SEDATIVE","EMULSION INTRAVEINEUSE, ANESTHÉSIQUE, SÉDATIF","",""
"5227","95-02-22","SPEYWOOD BIOPHARM LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIHEMOPHILIC FACTOR","FACTEUR ANTIHÉMOPHILE","",""
"5228","95-02-16","PASTEUR MÉRIEUX SERUMS ET VACCINS, S.A.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"5229","95-02-15","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE AYANT DES PROPRIÉTÉS ANALGÉSIQUES","",""
"5230","95-01-26","FISONS CORPORATION LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID, ANTI-INFLAMMATORY","GLUCOCORTICOÏDE, ANTI-INFLAMMATOIRE","",""
"5231","95-02-07","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIARRHYTHMIC, ANTIMALARIAL","ANTI-ARHYTHMIQUE, ANTIPALUDÉEN","",""
"5232","95-01-12","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITUBERCULOUS, ANTIBIOTIC","ANTITUBERCULEUX, ANTIBIOTIQUE","",""
"5233","95-12-28","GENENTECH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DISAGE REGIMEN (DAILY), NEW ROUTE OF ADMINISTRATION (SUBCUTANEOUS)","NOUVEAU SCHÉMA POSOLOGIQUE (QUOTIDIEN), NOUVELLE VOIE D'ADMINISTRATION (SOUS-CUTANÉE)","GROWTH STIMULANT","STIMULANT DE LA CROISSANCE","",""
"5234","95-12-28","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ASTHMA PROPHYLAXIS","PROPYLAXIE DE L'ASTHME","",""
"5235","95-12-19","FROSST, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"5236","95-12-14","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"5237","95-10-16","DRAXIS HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"5238","95-10-11","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ANTIARRHYTHMIC","NOUVELLE INDICATION : ANTI-ARYTHMIQUE","ANTIARRHYTHMIC","ANTI-ARYTHMIQUE","",""
"5239","95-10-11","3M PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"5240","95-09-18","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANAESTHETIC","ANESTHÉSIQUE","",""
"5241","95-08-04","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ENZYMATIC DEBRIDING AGENT","DÉBRIDANT ENZYMATIQUE","",""
"5242","95-07-31","SYNCARE PHARMACEUTICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ANTIARRHYTHMIC","NOUVELLE INDICATION : ANTIARYTHMIQUE","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"5243","95-07-21","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ANTIARRHYTHMIC","NOUVELLE INDICATION : ANTIARYTHMIQUE","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"5244","95-07-19","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5245","95-07-13","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"5246","95-06-13","LINSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"5247","95-06-13","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"5248","95-06-08","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIAGNOSTIC AGENT","AGENT DE DIAGNOSTIC","",""
"5249","95-05-19","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL, ANTI-HYPERTENSIVE","ANTI-ANGINEUX, ANTIHYPERTENSEUR","",""
"5250","95-04-26","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5251","95-04-19","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5252","95-04-18","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL, ANTI-HYPERTENSIVE","ANTI-ANGINEUX, ANTIHYPERTENSEUR","",""
"5253","95-03-31","GLAXO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH, NEW STRENGTH: 50 MG TABLETS FOR HEPATIC PATIENTS","MONOGRAPHIE RÉVISÉE, NOUVELLE CONCENTRATION COMPRIMÉS DE 50 MG POUR MALADES HÉPATIQUES","5-HT1 RECEPTOR AGONIST","RÉCEPTEUR AGONISTE 5-HT1","",""
"5254","95-02-24","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR, B2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT DES B2-ADRÉNERGIQUES","",""
"5255","95-02-16","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5256","95-01-12","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5257","95-01-03","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN SUPPLEMENT","SUPPLÉMENT VITAMINIQUE","",""
"5258","95-12-29","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MONOAMINE DEPLETING AGENT","DÉPLÉTION DE MONOAMINE","",""
"5259","95-12-19","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5260","95-12-19","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"5261","95-12-06","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"5262","95-11-17","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHIBITOR OF PLATELET FUNCTION","INHIBITEUR DE LA FONCTION PLAQUETTAIRE","",""
"5263","95-11-15","STIEFEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AGENT FOR THE TREATMENT OF PHOTODAMAGED SKIN","TRAITEMENT DE LA PEAU PHOTOALTÉRÉE","",""
"5264","95-10-31","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5265","95-09-22","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DISAGE FORM: ORAL SOLUTION","NOUVELLE PRÉSENTATION : SOLUTION ORALE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5266","95-09-12","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5267","95-08-17","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5268","95-08-14","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRACE LELEMENT SUPPLEMENT","SUPPLÉMENT D'OLIGO-ÉLÉMENTS","",""
"5269","95-07-19","LEIRAS OY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLAUCOMA THERAPY","TRAITEMENT DE GLAUCOME","",""
"5270","95-06-26","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR A COMBINATION PACK OF THE CREAM AND OVULE","EMBALLAGE COMBINÉ DE LA CRÈME ET DES OVULES","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5271","95-06-26","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR A COMBINATION PACK OF CREAM AND OINTMENT","EMBALLAGE COMBINÉ DE CRÈME ET D'ONGUENT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5272","95-06-22","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"5273","95-06-21","MERCK SHARP & DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: LONG ACTING GELLAN SOLUTION","NOUVELLE PRÉSENTATION : SOLUTION GELLAN À ACTION PROLONGÉE","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE LA PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"5274","95-05-24","LEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT / ANTITHROMBOTIC AGENT","ANTICOAGULANT / ANTITHROMBOTIQUE","",""
"5275","95-05-06","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"5276","95-04-26","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5277","95-04-11","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHIBITOR OF PLATELET FUNCTION","INHIBITEUR DE LA FONCTION PLAQUETTAIRE","",""
"5278","95-03-30","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5279","95-03-16","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5280","95-02-28","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5281","95-02-28","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5282","95-02-15","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5283","95-02-08","ALBERT PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5284","95-02-08","ORTHO-MCNEIL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AGENT FOR THE TREATMENT OF PHOTODAMAGED SKIN","TRAITEMENT DE LA PEAU PHOTOLÉSÉE","",""
"5285","95-01-16","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM, NEW STRENGTH","NOUVELLE PRÉSENTATION, NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5286","95-01-16","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5287","95-01-12","B.D.H. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","MAÎTRISE DE LA PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"5288","95-02-22","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","GONADOTROPIN","GONADOTROPHINE","",""
"5289","95-09-18","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5290","95-09-18","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5291","95-09-15","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"5292","95-09-08","DISPENSAPHARM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL, ANTIARRHYTHMIC, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIARYTHMIQUE, ANTIHYPERTENSEUR","",""
"5293","95-08-09","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TO TREAT PATIENTS WITH METASTATIC BREAST CANCER WHO HAVE FAILED STANDARD CHEMOTHERAPY","NOUVELLE INDICATION : TRAITEMENT DES PATIENTS AYANT DES MÉTASTASES AUX SEINS POUR QUI LA CHÉMIOTHÉRAPIE CONVENTIONNELLE A ÉCHOUÉE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5294","95-07-07","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"5295","95-06-02","SYNCARE PHARMACEUTICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5296","95-05-06","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"5297","95-03-23","SEARLE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5298","95-01-03","SEARLE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5299","95-01-03","SEARLE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5300","95-02-01","ENDO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"5301","95-04-24","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"5302","95-04-24","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"5303","95-04-24","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"5304","95-03-23","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"5305","95-01-12","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"5306","94-06-22","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE REVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5307","94-06-22","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTI-HYPERTENSIVE, ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"5308","94-06-20","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE REVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5309","94-06-20","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5310","94-05-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5311","04-09-03","VERNALIS DEVELOPMENT LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HTI RECEPTOR SUBTYPE AGONIST, MIGRAINE THERAPY","AGONISTE SOUS-TYPE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"5312","04-08-31","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS, DIVISION OF WARNER LAMBERT CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE FORME POSOLOGIQUE ET NOUVELLE CONCENTRATION","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"5313","04-09-02","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISE PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5314","04-08-30","ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"5315","04-08-31","PHARMETICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"5316","04-09-03","GENZYME CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"5317","04-09-08","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANRIRHEUMATIC AGENT","ANTIRHUMATISMAL","",""
"5318","04-09-08","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE SHORT TERM (<= 7 DAYS) MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN IN ADULTS","NOUVELLE INDICATION POUR LE TRAITEMENT À COURT TERME (<= 7 JOURS) DE LA DOULEUR MODÉRÉ À AIGÜE CHEZ L'ADULTE","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"5319","04-09-10","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO PROVIDE FOR A REVISION OF THE DOSAGE RECOMMENDATIONS FOR PATIENTS WITH RENAL IMPAIRMENT IN THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","RÉVISION À LA RUBRIQUE POSOLOGIE DE LA MONOGRAPHIE DU PRODUIT POUR INCLURE UN SCHÉMA POUR LES PERSONNES ATTEINTES DE TROUBLE DE LA FONCTION RÉNALE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5320","04-09-09","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","KETASET","AYERST VETERINARY LABORATORIES","CANADA","CANADA","1","","","GENERAL ANESTHETIC","ANESTHÉSIQUE GÉNÉRAL","",""
"5321","04-08-31","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"5322","04-08-31","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"5323","04-08-31","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM FOR SWINE: AS AN AID IN THE TREATMENT OF PORCINE PROLIFERATIVE ENTEROPATHY (PPE) OR ILEITIS ASSOCIATED WITH LAWSONIA INTRACELLULARIS","INDICATION ADDITIONNELLE CHEZ LE PORC : COMME ADJUVANT AU TRAITEMENT DE L'ENTÉROPATHIE PROLIFÉRATIVE PORCINE, OU ILÉITE, CAUSÉE PAR LAWSONIA INTRACELLULARIS","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5324","94-05-13","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"5325","94-05-13","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","SPECIFIC ANTIDOTE","ANTIDOTE SPÉCIFIQUE","",""
"5326","94-04-27","FUJISAWA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIARRYTHMIC","ANTIARYTHMIQUE","",""
"5327","94-04-07","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH, REVISED LABELLING","MONOGRAPHIE RÉVISÉE, ÉTIQUETTE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5328","94-03-18","TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC / ANTIHYPERTENSIVE","DIURÉTIQUE / ANTIHYPERTENSEUR","",""
"5329","94-03-18","TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC / SEDATIVE","ANXIOLYTIQUE / SÉDATIF","",""
"5330","94-03-10","FABRIGEN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"5331","94-03-01","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, NEW INDICATION","NOUVELLE CONCENTRATION, NOUVELLE INDICATION","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"5332","94-02-10","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","KERATINIZATION DISORDER THERAPY","TRAITEMENT DES TROUBLES DE LA KÉRATINISATION","",""
"5333","94-02-01","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"5334","94-01-26","NU-PHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5335","94-01-14","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"5336","94-01-14","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"5337","94-03-01","WYETH-AYERST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCE OF FINISHED PRODUCT","NOUVELLE SOURCE DU PRODUIT FINI","ANTIARRHYTMIC AGENT","ANTIARYTHMIQUE","",""
"5338","94-01-14","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"5339","94-01-14","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5340","94-01-14","FAULDING PHARMS, DIVISION OF FH FAULDING CO LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHROMBOTIC THERAPY AFTER HEART VALVE REPLACEMENT","TRAITEMENT ANTITHROMBIQUE SUITE AU REMPLACEMENT D'UNE VALVE CARDIAQUE","",""
"5341","94-01-14","FAULDING PHARMS, DIVISION OF FH FAULDING CO LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR DE L'AGRÉGATION DES PLAQUETTES","",""
"5343","03-09-05","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF DOSING INFORMATION FOR GERIATRIC PATIENTS AND PEDIATRIC PATIENTS 2 WEEKS TO <8 MONTHS OF AGE.  REVISIONS TO THE PRODUCT MONOGRAPH","AJOUT AUX RENSEIGNEMENTS POSOLOGIQUES POUR LES PATIENTS GÉRIATRIQUES ET LES PATIENTS PÉDIATRIQUES ÂGÉS DE 2 SEMAINES À <8 MOIS. RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"5344","03-02-07","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"5345","03-07-22","AGOURON PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REPLACES THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON APRIL 25, 2000","REMPLACE L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 25 AVRIL 2000","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"5346","03-07-22","AGOURON PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REPLACES THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON APRIL 25, 2000","REMPLACE L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 25 AVRIL 2000","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"5347","03-03-28","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING PROCEDURE","NOUVELLE MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"5348","03-06-17","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING FACILITY AND PROCESS FOR PRE-FILLED SYRINGES","MODIFICATION À L'EMPLACEMENT DE FABRICATION ET MODIFICATION DE LA MÉTHODE DE FABRICATION DES SERINGUES PRÉREMPLIES","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE D'ERYTHROPOIESE","",""
"5349","04-09-13","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SPECIES: SWINE - TREATMENT OF SWINE RESPIRATORY DISEASE ASSOCIATED WITH ACTINOBACILLUS PLEUROPNEUMONIAE AND PASTEURELLA MULTOCIDA","NOUVELLES ESPÈCES : PORCS - TRAITEMENT DES MALADIES RESPIRATOIRES PORCINES ASSOCIÉES À ACTINOBACILLUS PLEUROPNEUMONIA ET PASTEURELLA MULTOCIDA","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"5350","04-09-17","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","POLYPEPTIDE PROTEINASE INHIBITOR / HEMOSTATIC AGENT","POLYPEPTIDE INHIBITEUR DE PROTÉINASES, AGENT HÉMOSTATIQUE","",""
"5351","04-09-16","PREMPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","HYPNOTIC","HYPNOTIQUE","",""
"5352","04-09-13","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REPLACES THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON SEPTEMBER 4, 1998","REMPLACE L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 4 SEPTEMBRE 1998","ANTIRETROVIRAL AGENT, NON0NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR WITH ACTIVITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)","ANTIRÉTROVIRAL, INHIBITEUR NON-NUCLÉOSIDE DE LA REVERSE-TRANSCRIPTASE CONTRE LE VIRUS DE L'IMMUNODÉFICIENCE HUMAINE DE TYPE 1 (VIH-1)","",""
"5353","04-09-13","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"5354","04-09-14","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITUBERCULOSIS AGENT","AGENT ANTITUBERCULEUX","",""
"5355","04-09-15","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"5356","04-09-17","CHX TECHNOLOGIES INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE REDUCTION OF ROOT CARIES IN ADULTS AT HIGH RISK OF DENTAL CARIES","NOUVELLE INDICATION POUR LA RÉDUCTION DE LA CARIE DU CÉMENT CHEZ L'ADULTE QUI PRÉSENTE UN RISQUE ÉLEVÉ DE CARIE DENTAIRE","ANTIMICROBIAL AGENT","AGENT ANTIMICROBIEN","",""
"5357","04-09-17","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"5358","04-09-13","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5359","04-09-13","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH RE: NAUSEA REDUCTION","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT CONCERNANT LA RÉDUCTION DE LA NAUSÉE","ANTIDEPRESSANT, ANXIOLYTIC","ANTIDÉPRESSEUR, ANXIOLYTIQUE","",""
"5360","04-09-13","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS, DIVISION OF WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM AND STRENGTH","NOUVELLE FORME POSOLOGIQUE ET NOUVELLE CONCENTRATION","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"5362","94-11-09","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL/ANTI-INFLAMMATORY/ANALGESIC","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN/ANALGÉSIQUE","",""
"5363","94-10-25","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5364","94-03-28","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTI-INFLAMMATORY / ANALGESIC AGENT","ANTI-INFLAMMATOIRE / ANALGÉSIQUE","",""
"5365","94-01-14","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR SALE AS A NONPRESCRIPTION DRUG","PERMET LA VENTE SANS ORDONNANCE MÉDICALE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5366","95-12-22","MERCK SHARP & DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"5367","94-11-21","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"5368","94-11-09","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"5369","94-09-13","CIBA VISION CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1-ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"5370","94-08-12","ENDO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"5371","94-07-26","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1-ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"5372","94-06-20","ZENECA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"5373","94-06-20","MERCK SHARP & DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"5374","94-06-20","LEDERLE-CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","FOLIC ACID DERIVATIVE","DÉRIVÉDE L'ACIDE FOLIQUE","",""
"5375","94-05-11","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS","NOUVELLES INDICATIONS","TOPICAL ANESTHETIC FOR DERMAL ANALGESIA","ANESTHÉSIQUE TOPIQUE POUR ANALGÉSIE DERMIQUE","",""
"5376","94-04-27","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"5377","94-04-27","LEDERLE-CYANAMID CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"5378","94-03-16","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMANIAC AGENT","ANTIMANIAQUE","",""
"5379","94-01-14","LEDERLE-CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED SPECIFICATION","SPÉCIFICATION RÉVISÉE","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"5380","94-11-02","MALLINCKRODT MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","RADIOPAQUE CONTRAST MEDIUM","AGENT DE CONSTRATE","",""
"5381","94-10-26","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5382","94-10-12","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5383","94-09-08","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","PROGESTIN","PROGESTÉRONE","",""
"5384","94-09-01","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5385","94-08-25","GALDERMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ROSACEA AGENT","ANTI-ROSACÉE","",""
"5386","94-08-12","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"5387","94-08-12","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR NONPRESCRIPTION SALE","POUR VENTE SASN ORDONNANCE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5388","94-08-09","DELTA WEST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"5389","94-07-19","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PACKAGING","NOUVEL EMBALLAGE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5390","94-07-15","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL TRACT ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DU TRACTUS GASTOINTESTINAL INFÉRIEUR","",""
"5391","94-07-15","AXCAN PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL TRACT ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DU TRACTUS GASTROINTESTINAL INFÉRIEUR","",""
"5392","94-06-22","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTIPLE VITAMIN FOR TOTAL PARENTERAL NUTRITION","VITAMINES MULTIPLES POUR ALIMENTATION PARENTÉRALE TOTALE","",""
"5393","94-06-20","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","GLUCOCORTICOID","CLUCOCORTICOÏDE","",""
"5394","94-06-09","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING, REVISED PRODUCT MONOGRAPH","MODIFICATION DE LA FABRICATION, MONOGRAPHIE RÉVISÉE","ACTIVE IMMUNIZING AGENT","IMMUNISANT ACTIF","",""
"5395","94-06-08","BRISTOL LABORATORIES OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED SPECIFICATION","SPÉCIFICATION RÉVISÉE","UROPROTECTOR","UROPROTECTEUR","",""
"5396","94-06-08","CYANAMID CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5397","94-06-02","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"5398","94-05-11","ABIC LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"5399","94-05-09","LEDERLE-CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"5400","94-04-27","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONDEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEURO-MUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"5401","94-04-27","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FINAL DOSAGE FORM AND FORMULATION","MODIFICATION DE LA PRÉPARATION ET PRÉSENTATION","NARCOTIC ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"5402","94-04-27","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, NEW DOSAGE FORM (KIT)","NOUVELLE CONCENTRATION, NOUVELLE PRÉSENTATION (TROUSSE)","ANTINEOPLASTIC (ALKYLATING) AGENT","ANTINÉOPLASIQUE (ALKYLANT)","",""
"5403","03-08-27","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"5404","03-10-15","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF GASTROINTESTINAL LESIONS INDUCED BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN PATIENTS WITH A NEED FOR CONTINUOUS NSAID THERAPY","NOUVELLE INDICATION: PRÉVENTION DES LÉSIONS GASTRO-INTESTINALES CAUSÉES PAR L'USAGE DES MÉDICAMENTS ANTI-INFLAMMATOIRE NON STÉROÏDIENS CHEZ LES PATIENTS NÉCESSITANT UN TRAITEMENT CONTINU AUX AINS","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"5405","04-09-21","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INFORMATION FOR USE IN CHILDREN AND NEONATES, CHANGE IN DOSING RECOMMENDATIONS FOR CHILDREN 2 TO 13 YEARS OF AGE","NOUVEAUX RENSEIGNEMENTS POUR L'UTILISATION CHEZ L'ENFANT ET LE NOUVEAU-NÉ, CHANGEMENTS AUX RECOMMENDATIONS RELATIVES À LA POSOLOGIE CHEZ LES ENFANTS ÂGÉS DE 2 À 13 ANS","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"5406","04-09-23","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 5MG TABLETS","NOUVELLE CONCENTRATION : COMPRIMÉS DE 5MG","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"5407","04-09-21","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC, ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"5408","04-09-21","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE ET ANTICONVULSIVANT","",""
"5409","04-09-23","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC, ANTICONVULSANT","HYPNOTIQUE, ANTICONVULSIVANT","",""
"5410","04-09-21","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"5411","04-09-23","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT, ANTITHROMBOTIC","ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"5412","03-12-05","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH REGARDING CEREBROVASCULAR ADVERSE EVENTS IN DEMENTIA TRIALS OF RISPERIDONE IN ELDERLY PATIENTS","MISES À JOUR À LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'ÉVÉNEMENTS CÉRÉBROVASCULAIRES INDÉSIRABLES DANS LES ESSAIS SUR LA DÉMENCE DE LA RISPÉRIDONE CHEZ LES PERSONNES ÂGÉES","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"5413","04-09-21","OSCIENT PHARMACEUTICAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5414","04-09-23","RAINBOW PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: NASAL SPRAY","NOUVELLE FORME POSOLOGIQUE : VAPORISATEUR NASAL","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"5415","04-09-21","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC AGENT","ANTIÉMÉTIQUE","",""
"5416","04-09-23","ORGANON SANOFI-SYNTHELABO CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH AND NEW INDICATION FOR THE TREATMENT OF ACUTE DEEP VEIN THROMBOSIS (DVT) AND ACUTE PULMONARY EMBOLISM (PE)","NOUVELLE CONCENTRATION ET NOUVELLE INDICATION POUR LE TRAITEMENT DE LA THROMBOSE VEINEUSE PROFONDE AIGUE ET DE L'EMBOLIE PULMONAIRE AIGUE","SYNTHETIC ANTITHROMBOTIC","ANTITHROMBOTIQUE SYNTHÉTIQUE","",""
"5417","04-09-23","VITA HEALTH PRODUCTS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM LOPERACAP","MODIFICATION DU NOM DU PRODUIT DE LOPERACAP","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"5418","04-09-24","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5419","04-09-21","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE PRODUCT MONOGRAPH","MODIFICATION À LA MONOGRAPHIE DU PRODUIT","ANTI-DIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"5420","04-09-22","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL MANUFACTURING SITE FOR THE MEDICINAL INGREDIENT","FABRICANT SUPPLÉMENTAIRE POUR L'INGRÉDIENT ACTIF","MUCOLYTIC/EXPECTORANT","MUCOLYTIQUE/EXPECTORANT","",""
"5421","94-04-11","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5422","94-04-11","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5423","94-03-31","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5424","94-03-16","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY ANTIEMETIC","MODIFICATEUR DE LA MOTILITÉ DU TRACTUS GASTRO-INTESTINAL SUPÉRIEUR","",""
"5425","94-03-01","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANALGESIC","ANALGÉSIQUE","",""
"5426","94-03-01","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5427","94-02-23","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","PREMEDICANT / SEDATIVE / ANAESTHETIC AGENT","PRÉMÉDICATION / SÉDATIF / ANESTHÉTIQUE","",""
"5428","94-02-23","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTIMALARIAL AGENT","ANTIPALUDÉEN","",""
"5429","94-01-14","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HAIR GROWTH STIMULANT","STIMULANT POUR LA POUSSE DES CHEVEUX","",""
"5430","94-01-12","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCE OF FINISHED PRODUCT, NEW PACKAGING","NOUVELLE SOURCE DE PRODUIT FINI, NOUVEL EMBALLAGE","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"5431","94-01-12","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCE OF FINISHED PRODUCT, NEW PACKAGING","NOUVELLE SOURCE DE PRODUIT FINI, NOUVEL EMBALLAGE","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"5432","94-12-15","FISONS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PACKAGING","NOUVEL EMBALLAGE","BRONCHIAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE BRONCHIQUE","",""
"5433","94-12-13","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VASODILATOR","VASODILATATEUR","",""
"5434","94-11-25","SYNTEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5435","94-11-25","SYNTEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"5436","94-11-21","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"5437","94-11-09","DAVID BULL LABORATORIES (PTY) LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANTAGONIST","ANTAGONISTE NARCOTIQUE","",""
"5438","94-09-30","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL, ANTIHYPERTENSIVE AGENT","ANTI-ANGINEUX, ANTIHYPERTENSEUR","",""
"5439","94-08-25","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"5440","94-08-25","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5441","94-05-11","MILES CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","ANTIANGINAL, ANTIHYPERTENSIVE","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"5442","94-05-09","MERRELL DOW PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW EXPIRATION DATE, REVISED SPECIFICATIONS","NOUVELLE DATE LIMITE D'UTILISATION, SPÉCIFICATIONS RÉVISÉES","SMOKING CESSATION AID","SOUTIEN À L'ARRÊT DE FUMER","",""
"5443","94-04-27","SYNTEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING OF ACTIVE INGREDIENT","MODIFICATION DE LA FABRICATION DU PRINCIPE ACTIF","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC PROPRIÉTÉS ANALGÉSIQUES ET ANTIPYRÉTIQUES","",""
"5444","94-04-27","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5445","94-04-11","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"5446","94-03-18","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"5447","94-03-16","SYNTEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","GONADOTROPIN RELEASING HORMONE ANALOGUE","ANALOGUE AGONISTE DE L'HORMONE NATURELLE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"5448","94-01-25","KEY PHARMACEUTICALS, DIVISION OF SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"5449","94-01-19","SEARLE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTIPYRETIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC PROPRIÉTÉS ANALGÉSIQUES ET ANTIPYRÉTIQUES","",""
"5450","94-01-14","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","AUXILLIAIRE POUR CESSER DE FUMER","",""
"5451","94-12-13","LEDERLE-CYANAMID CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DE RÉCEPTEUR ß-ADRÉNERGIQUE","",""
"5453","94-11-10","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","PROLACTIN INHIBITOR, GROWTH HORMONE SUPPRESSANT IN ACROMEGALY, ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, MÉDICAMENT ADJUVANT DANS LA MALADIE DE PARKINSON","",""
"5454","94-11-25","ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"5455","94-11-25","GLAXO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"5456","94-11-09","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASTIQUE","",""
"5457","94-07-15","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, NEW INDICATION","NOUVELLE CONCENTRATION, NOUVELLE INDICATION","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"5458","94-04-07","ORTHO-MCNEIL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"5459","94-11-04","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASMODIQUE","",""
"5460","94-02-10","SEARLE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT, CHANGE IN FORMULATION, CHANGE IN MANUFACTURING","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF, MODIFICATION DE LA PRÉPARATION, MODIFICATION DE LA FABRICATION","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5461","94-01-12","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE GASTROINTESTINAL INFÉRIEUR","",""
"5462","94-12-12","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"5463","94-12-12","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5464","94-11-25","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5465","94-11-24","GEIGY PHARMACEUTICALS, CIBA-GEIGY CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"5466","94-11-21","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5467","94-11-09","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"5468","94-10-17","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"5469","94-10-12","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASTIQUE","",""
"5470","94-09-26","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"5471","94-09-21","SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5472","94-09-13","LEDERLE-CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIC, B-LACTAMASE INHIBITOR","ANTIBIOTIQUE, INHIBITEUR DE B-LACTAMASE","",""
"5473","94-08-25","LEDERLE-CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIC, B-LACTAMASE INHIBITOR","ANTIBIOTIQUE, INHIBITEUR DE B-LACTAMASE","",""
"5474","94-08-12","DRAXIS HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DOPAMINE AGONIST","AGONISTE DE LA DOPAMINE","",""
"5475","94-08-09","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCE OF ACTIVE INGREDIENT","NOUVELLE SOURCE DE PRINCIPE ACTIF","HYPOTENSIVE AGENT","HYPOTENSEUR","",""
"5476","94-06-22","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTIHYPERTENSIVE, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"5477","94-05-31","CONPHARM AB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMITOTIC AGENT","ANTIMITOTIQUE","",""
"5478","94-05-11","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","REVISION TO FORMULATION AND MANUFACTURING PROCEDURES","RÉVISION DE LA FORMULE ET DES PROCÉDÉS DE FABRICATION","TOPICAL PEDICULICIDE AND OVICIDE","PÉDICULICIDE TOPIQUE ET OVICIDE","",""
"5479","94-05-09","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"5480","94-05-09","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"5481","94-04-20","DEPRENYL RESEARCH LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DOPAMINE AGONIST","AGONISTE DE LA DOPAMINE","",""
"5482","94-04-07","LEDERLE-CYANAMID CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC, B-LACTAMASE INHIBITOR","ANTIBIOTIQUE, INHIBITEUR DE B-LACTAMASE","",""
"5483","94-03-28","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE, ANTI-ANGINAL","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"5484","94-03-18","TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"5485","94-03-11","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEUROMUSCULAIRE NON DÉPOLARISANT","",""
"5486","94-10-25","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5487","94-09-30","HOECHST-ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5488","94-09-27","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEUROMUSCULAIRE SQUELETTIQUE NON-DÉPOLARISANT","",""
"5489","94-03-11","GLAXO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES-H2","",""
"5490","94-02-15","ORTHO-MCNEIL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","HAEMATOPOIETIC AGENT","HÉMATOPÏÉTIQUE","",""
"5491","94-01-26","KENRAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"5492","94-01-14","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"5493","94-07-29","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GONADOTROPIN","GONADOTROPHINE","",""
"5494","94-07-20","BLOCK DRUG COMPANY (CANADA) LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","FOR THE SUBJECTIVE RELIEF OF XEROSTOMIA AND FOR NEUTRALIZING DENTAL PLAQUE ACIDS","SOULAGEMENT SUBJECTIF DE LA XÉROSTOMIE ET NEUTRALISATION DES ACIDES DE LA PLAQUE DENTAIRE","",""
"5495","94-09-21","DUPONT MERCK PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"5496","94-12-22","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN SUPPLEMENT","SUPPLÉMENT VITAMINIQUE","",""
"5497","94-12-14","PASTEUR MÉRIEUX SERUMS ET VACCINS, S.A.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"5498","94-12-07","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, ALTERNATE MANUFACTURING SITE","NOUVELLE CONCENTRATION, AUTRE EMPLACEMENT DE FABRICATION","SYNTHETIC SALMON CALCITONIN","CALCITONINE SAUMON SYNTHÉTIQUE","",""
"5499","94-11-24","FRANK W HORNER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRODUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRODUODÉNAL","",""
"5500","94-11-21","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"5501","94-11-21","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TRACE ELEMENT ADDITIVE","OLIGO-ÉLÉMENT ADDITIF","",""
"5502","94-11-09","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5503","94-10-25","GLAXO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5504","94-10-13","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY / ANTIBACTERIAL AGENT","ANTI-INFLAMMATOIRE / ANTIBACTÉRIEN","",""
"5505","94-10-05","HOECHST-ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","FIBRINOLYTIC AGENT","FIBRINOLYTIQUE","",""
"5506","94-09-30","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPHTHALMIC NONSTEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"5507","94-09-27","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF ACUTE VARICEAL BLEEDING","TRAITEMENT DES HÉMORRAGIES VARIQUEUSES AIGUËS","",""
"5508","94-09-27","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5509","94-09-27","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRO-DIODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRO-DUODENAL","",""
"5510","94-09-27","RECKITT & COLMAN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"5511","94-09-13","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRO-DUODENAL CYTOPROTECTIVE AGENT","AGENT CYTO-PROTECTEUR GASTRO-DUODÉNAL","",""
"5512","94-08-25","GENENTECH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","GROWTH STIMULANT","STIMULANT DE LA CROISSANCE","",""
"5513","94-09-21","CIBA-GEIGY CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, ANTISPASTIQUE","",""
"5514","94-08-25","GLAXO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","BRONCHDILATOR","BRONCHODILATATEUR","",""
"5515","94-08-12","DRAXIS HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"5516","94-08-09","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRO-DUODENAL CYTOPROTECTIVE AGENT","CYTOPROTECTEUR GASTRO-DUODÉNAL","",""
"5517","94-09-08","IAF BIOVAC INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5518","94-06-23","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF FINISHED PRODUCT","","NARCOTIC ANALGESIC / ADJUNCT TO ANESTHESIA","ANALGÉSIQUE NARCOTIQUE / ADJUVANT À L'ANESTHÉSIE","",""
"5519","94-06-23","HOECHST-ROUSSEL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","HEMATOPOIETIC GROWTH FACTOR","FACTEUR DE CROISSANCE HÉMOTOPÏÉTIQUE","",""
"5520","94-09-30","DAVID BULL LABORATORIES (PTY) LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5521","94-06-22","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE CONCENTRATION","GASTRO-DUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRODUODÉNAL","",""
"5522","94-07-07","BRISTOL-MYERS SQUIBB CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"5523","94-06-15","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GASTRO-DUODENAL CYTOPROTECTIVE AGENT","AGENT CYTOPROTECTEUR GASTRODUODÉNAL","",""
"5524","94-05-24","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROLACTIN INHIBITOR, GROWTH HORMONE SUPPRESSANT IN ACROMEGALY, ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, MÉDICAMENT ADJUVANT DANS LA MALADIE DE PARKINSON","",""
"5525","94-04-22","BRISTOL LABORATORIES OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"5526","94-04-22","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5527","94-04-27","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"5528","94-04-11","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"5529","94-04-11","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5530","94-03-28","NEOLAB INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5531","94-04-27","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","MUSCLE RELAXANT, ANTISPASTICITY AGENT","RELAXANT MUSCULAIRE, ANTISPASTIQUE","",""
"5532","94-03-18","TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET INHIBITOR AGENT / URICOSURIC AGENT","AGENT ANTIPLAQUETTAIRE, AGENT URICORUSIQUE","",""
"5533","94-01-25","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5534","94-01-21","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF INFLAMMATORY BOWEL DISEASE, ULCERATIVE COLITIS AND CROHN'S DISEASE","TRAITEMENT DE MALADIES INTESTINALES INFLAMMATOIRES, RECTOCOLITE HÉMORRAGIQUE ET MALADIE DE CROHN","",""
"5535","94-01-14","GLAXO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BRONCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATATEUR, STIMULANT BETA2-ADRÉNERGIQUE","",""
"5536","94-01-14","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5537","94-01-14","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FAT EMULSION FOR INTRAVENOUS NUTRITION","ÉMULSION DE GRAS POUR ALIMENTATION INTRAVEINEUSE","",""
"5538","94-01-14","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT","ANTIPARKINSONIEN","",""
"5539","94-01-12","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"5540","94-01-12","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","NSAID","AINS","",""
"5541","04-09-28","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTICHOLINERGIC AGENT","ANXIOLYTIQUE, ANTICHOLINERGIQUE","",""
"5542","04-10-01","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF A NEW FORMULATION THAT IS PRESERVATIVE-FREE","AJOUT D'UNE NOUVELLE CONCENTRATION SANS AGENT DE CONSERVATION","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"5543","04-09-30","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATES TO THE CLINICAL TRIALS SECTION","MISES À JOUR À LA RUBRIQUE DES ESSAIS CLINIQUES DE LA MONOGRAPHIE DU PRODUIT","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"5544","04-10-06","BIOGEN IDEC CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","SELECTIVE IMMUNOMODULATING AGENT","AGENT IMMUNOMODULATEUR SÉLECTIF","",""
"5545","04-10-06","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXTENSION DATA TO SUPPORT LONG TERM USE IN THE TREATMENT OF BONE METASTASES OF SOLID TUMOURS AND OSTEOLYTIC LESIONS OF MULTIPLE MYELOMA","DONNÉES PLUS POUSSÉES POUR APPUYER LE TRAITEMENT À LONG TERME DES MÉTASTASES OSSEUSES DE TUMEURS SOLIDES ET DES LÉSIONS OSTÉOLYTIQUES DU MYÉLOME MULTIPLE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"5546","04-10-06","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","0","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"5547","04-10-05","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION IN ADULT HYPERTENSIVE PATIENTS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE, BUT WITH AT LEAST THREE ADDITIONAL RISK FACTORS FOR CORONARY HEART DISEASE","NOUVELLE INDICATION : RÉDUCTION DU RISQUE D'INFARCTUS DU MYOCARDE CHEZ L'ADULTE SOUFFRANT D'HYPERTENSION SANS MALADIE CORONARIENNE ÉVIDENTE CLINIQUEMENT, MAIS AYANT AU MOINS 3 AUTRES FACTEURS DE RISQUE DE MALADIE CORONARIENNE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"5548","04-10-07","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION FOR THE TREATMENT OF ESSENTIAL HYPERTENSION","NOUVELLE INDICATION POUR LE TRAITEMENT DE L'HYPERTENSION ESSENTIELLE","ANGIOTENSIN II RECEPTOR ANTAGONIST & DIURETIC","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"5549","04-10-07","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM TO PREVENT RECURRENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER","NOUVELLE INDICATION : TRAITEMENT DE LA THROMBO-EMBOLIE VEINEUSE SYMPTOMATIQUE POUR PRÉVENIR LA RÉCIDIVE DE THROMBO-EMBOLIE CHEZ LES PERSONNES ATTEINTES DE CANCER","ANTICOAGULANT, ANTITHROMBOTIC AGENT","ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"5550","04-10-07","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","SALURETIC-DIURETIC AGENT","SALIDIURÉTIQUE","",""
"5551","04-10-07","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION FOR THE TREATMENT OF ESSENTIAL HYPERTENSION","NOUVELLE INDICATION POUR LE TRAITEMENT DE L'HYPERTENSION ESSENTIELLE","ANGIOTENSIN II RECEPTOR ANTAGONISTE","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II","",""
"5552","04-10-13","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","ADJUVANT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"5553","04-10-12","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW COMBINATION PRODUCT WITH LESS ETHINYL ESTRADIOL LEVELS THAN THE CURRENTLY APPROVED TRI-CYCLEN (0.025MG VS 0.035MG)","NOUVEAU PRODUIT MIXTE REFLÉTANT UN NIVEAU D'ÉTHINYLOESTRADIOL MOINS ÉLEVÉ QUE CELUI DÉJÀ APPROUVÉ POUR LE PRODUIT TRI-CYCLEN (0.025MG VS 0.035MG)","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"5554","04-10-12","PENDOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTICOAGULANT","ANTICOAGULANT ORAL","",""
"5555","04-10-13","RATIOPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","ADJUVANT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"5556","04-10-12","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MELANIN REPIGMENTATION, PHOTOCHEMOTHERAPY OF PSORIASIS AND ATOPIC DERMATITIS, REPIGMENTATION IN VITILIGO, TO INCREASE TOLERANCE TO SOLAR EXPOSURE","REPIGMENTATION DE LA MÉLANINE, PHOTOCHIMIOTHÉRAPIE DU PSORIASIS ET DES DERMATOSES ATOPIQUES, REPIGMENTATION IN VITILIGO, AUGMENTATION DE LA TOLÉRANCE À L'EXPOSITION AU SOLEIL","",""
"5557","04-10-12","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMYASTHENIC, CHOLINERGIC","ANTIMYASTHÉNIQUE, CHOLINERGIQUE","",""
"5558","04-10-12","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITUBERCULOSIS AGENT","AGENT ANTITUBERCULEUX","",""
"5559","04-10-12","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES PF","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES)","",""
"5560","04-10-12","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CYANAMID CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5561","04-10-12","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"5562","04-10-12","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5563","04-10-12","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CECLOR","ELI LILLY & CO.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5564","04-10-12","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","E.R. SQUIBB & SONS INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5565","04-10-12","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMANIC AGENT","ANTIMANIAQUE","",""
"5566","04-10-12","BAKER CUMMINS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES PF","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES RÉCEPTEURS B2-ADRÉNERGIQUES)","",""
"5567","04-10-12","BAKER CUMMINS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","E.R. SQUIBB & SONS INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5568","04-10-12","ID BIOMEDICAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5569","04-10-12","ID BIOMEDICAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BACTERIAL VACCINE","VACCIN BACTÉRIEN","",""
"5570","04-10-12","VETOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"5571","94-04-11","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"5572","94-04-07","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"5573","94-03-28","BOEHRINGER MANNHEIM (CANADA) LTEE/LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"5574","94-03-28","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTICITY AGENT","RELAXANT MUSCULAIRE, ANTISPASTIQUE","",""
"5575","94-03-07","PHARMACO CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"5576","94-03-07","PHARMACO CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"5577","94-01-14","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT ANTISPASTIC AGENT","RELAXANT MUSCULAIRE ANTISPASMODIQUE","",""
"5578","94-12-22","GLAXO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PACKAGING, REVISED PRODUCT MONOGRAPH","NOUVEL EMBALLAGE, MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5579","94-12-20","KENRAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5580","94-12-15","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","VASCULAR STABILIZER FOR THE TREATMENT OF MENOPAUSAL FLUSHING","STABILISANT VASCULAIRE POUR SOULAGER LES BOUFFÉES DE CHALEUR DE LA MÉNOPAUSE","",""
"5581","94-12-15","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5582","94-12-12","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"5583","94-11-21","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5584","94-11-15","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTI-ANGINAL, ANTI-ARRHYTHMIC, ANTIHYPERTENSIVE AGENT","ANTI-ANGINEUX, ANTI-ARYTHMIQUE, ANTIHYPERTENSEUR","",""
"5585","94-11-09","BOEHRINGER MANNHEIM (CANADA) LTEE/LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"5586","94-11-04","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTI-OBSESSIONNEL","",""
"5587","94-11-02","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIARRHEAL, ANTIHYPERCHOLESTEROLEMIC","ANTIDIARRHÉIQUE, ANTIHYPERCHOLESTÉROLÉMIANT","",""
"5588","94-10-28","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATON","NOUVELLE INDICATION","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"5589","94-12-22","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIFFERENTIATION INDUCING AGENT","INDUCTEUR DE DIFFÉRENTIATION","",""
"5590","94-12-07","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5591","94-10-17","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5592","94-10-14","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5593","94-10-13","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"5594","94-09-27","BOEHRINGER MANNHEIM (CANADA) LTEE/LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"5595","94-09-15","ORTHO-MCNEIL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5596","94-09-13","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H1","",""
"5597","94-08-29","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5598","94-08-25","SWISS SERUM & VACCINE INSTITUTE BERNE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ACTIVE IMMUNISING AGENT","AGENT IMMUNISANT ACTIF","",""
"5599","94-08-09","PENEDERM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ACNE THERAPY","TRAITEMENT TOPIQUE DE L'ACNÉ","",""
"5600","94-07-29","CIBA VISION CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","MAÎTRISE DE LA PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"5601","94-07-12","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5602","94-06-23","PENEDERM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","TOPICAL ACNE THERAPY","TRAITEMENT TOPIQUE DE L'ACNÉ","",""
"5603","94-06-20","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE PRÉPARATION","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE L'HYPERTENSION INTRA-OCULAIRE","",""
"5604","94-06-20","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 - RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H1","",""
"5605","94-05-26","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"5606","94-05-24","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR NONPRESCRIPTION SALE","POUR VENTE SANS ORDONNANCE MÉDICALE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5607","94-05-24","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR NONPRESCRIPTION SALE","POUR VENTE SANS ORDONNANCE MÉDICALE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5608","94-05-24","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR NONPRESCRIPTION SALE","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5609","94-10-19","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","ANTIBIOTIC, CORTICOSTEROID","ANTIBIOTIQUE, CORTICOSTÉROÏDE","",""
"5610","94-05-19","KEY PHARMACEUTICALS, DIVISION OF SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5611","94-04-27","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE OF PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5612","94-04-22","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5613","94-04-11","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"5614","94-04-05","COLGATE-PALMOLIVE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION (NEW CLAIM)","NOUVELLE INDICATION (NOUVELLE RÉCLAME)","ANTICARIES, ANTIPLAQUE, ANTIGINGIVITIS, ANTICALCULUS","ANTICARIES, ANTIPLAQUE, ANTIGINGIVITE, ANTICALCULS","",""
"5615","94-04-05","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE L'HYPERTENSION INTRA-OCULAIRE","",""
"5616","94-03-28","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE L'HYPERTENSION INTRA-OCULAIRE","",""
"5617","94-03-28","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5618","94-03-28","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"5619","94-03-18","TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICYCLIC ANTIDEPRESSANT","ANTIDÉPRESSEUR TRICYCLIQUE","",""
"5620","94-03-18","TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"5621","94-03-14","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIHYPERTENSIVE AGENT, SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA","ANTIHYPERTENSEUR, TRAITEMENT SYMPTOMATIQUE DE L'HYPERTROPHIE DE LA PROSTATE","",""
"5622","94-02-23","ICN CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"5623","94-01-26","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","TRICYCLIC ANTIDEPRESSANT","ANTIDÉPRESSEUR TRICYCLIQUE","",""
"5624","94-01-25","PENEDERM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ACNE THERAPY","TRAITEMENT DE L'ACNÉ TOPIQUE","",""
"5625","94-01-14","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5626","94-01-14","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCE OF ACTIVE INGREDIENT","NOUVELLE SOURCE DE PRINCIPE ACTIF","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"5627","94-12-12","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5628","94-11-25","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5629","94-11-09","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIF","",""
"5630","94-09-30","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTIANGINAL, ANTIARRHYTHMIC, ANTIHYPERTENSIVE AGENT","ANTI-ANGINEUX, ANTI-ARYTHMIQUE, ANTI-HYPERTENSEUR","",""
"5631","94-07-18","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5632","94-06-20","ELAN PHARMACEUTICAL RESEARCH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5633","94-05-26","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5634","94-05-10","BURROUGHS WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5635","94-03-16","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5636","94-03-01","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"5637","94-01-14","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"5638","94-12-01","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-RACE ELEMENT","OLIGO-ÉLÉMENTS","",""
"5639","94-11-25","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TRACE ELEMENT","OLIGO-ÉLÉMENTS","",""
"5640","94-11-25","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TRACE ELEMENTS","OLIGO-ÉLÉMENTS","",""
"5641","94-10-13","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"5642","94-08-09","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HYPNOTIC","HYPNOTIQUE","",""
"5643","94-05-09","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT MULTI TRACES","",""
"5644","94-05-09","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT MULTI-TRACES","",""
"5645","94-05-09","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT MULTI TRACES","",""
"5646","94-10-17","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERCHOLESTEROLEMIC , ANTIDIARRHEAL","ANTIHYPERCHOLESTÉROLÉMIANT, ANTIDIARRHÉIQUE","",""
"5647","94-05-09","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT MULTI TRACES","",""
"5648","94-09-30","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTI-OBSESSIONNEL","",""
"5649","94-09-30","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5650","04-10-19","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","AS AN AID IN THE MANAGEMENT OF CHRONIC RENAL INSUFFICIENCY ASSOCIATED WITH PROTEINURIA IN CATS","COMME ADJUVANT DANS LE TRAITEMENT DE L'INSUFFISANCE RÉNALE CHRONIQUE ASSOCIÉE À LA PROTÉINURIE CHEZ LE CHAT","ACE (ANGIOTENSIN CONVERTING ENZYME) INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE (ECA)","",""
"5651","04-10-18","OPI SAS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTILEUKEMIC AGENT","AGENT ANTILEUCÉMIQUE","",""
"5652","04-10-20","OVATION PHARMACEUTICALS, INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-EPILEPTIC","ANTI-ÉPILEPTIQUE","",""
"5653","04-10-22","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","N.V. ORGANON OSS.","NETHERLANDS","PAYS-BAS","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5654","04-10-22","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 15 MG EXTENDED RELEASE TABLETS","NOUVELLE CONCENTRATION : 15 MG COMPRIMÉS À ACTION PROLONGÉE","ANTICHOLINERGIC, ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"5655","04-10-21","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"5656","04-10-20","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC ANTITHROMBOTIC","ANTITHROMBOTIQUE SYNTHÉTIQUE","",""
"5657","04-10-22","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAPAZOLE","PALADIN LABORATORIES INC.","CANADA","CANADA","1","","","ANTI-THYROID AGENT","ANTITHYROÏDIEN","",""
"5658","94-09-30","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANTIHYPERCHOLESTEROLEMIC","ANTIHYPERCHOLESTÉROLÉMIQUE","",""
"5659","94-09-30","MILES CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"5660","94-09-26","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR SALE WITHOUT PRESCRIPTION","POUR VENTE SANS ORDONNANCE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5661","94-09-26","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR SALE WITHOUT PRESCRIPTION","POUR VENTE SANS ORDONNANCE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5662","94-09-22","FAULDING (CANADA) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW ROUTE OF ADMINISTRATION","NOUVELLE VOIE D'ADMINISTRATION","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"5663","94-09-22","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5664","94-09-21","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR NONPRESCRIPTION SALE","POUR VENTE SANS ORDONNANCE MÉDICALE","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H1","",""
"5665","94-09-15","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5666","94-09-15","KENRAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME, REVISED PRODUCT MONOGRAPH","MODIFICATION DU NOM DU PRODUIT, MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5667","94-09-13","KENRAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME, REVISED PRODUCT MONOGRAPH, REVISED LABELLING","MODIFICATION DU NOM DU PRODUIT, MONOGRAPHIE RÉVISÉE, ÉTIQUETTE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5668","94-09-13","KENRAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME, REVISED PRODUCT MONOGRAPH","MODIFICATION DU NOM DU PRODUIT, MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5669","94-09-01","MILES CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR NONPRESCRIPTION SALE","POUR VENTE SANS ORDONNANCE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5670","94-09-01","MILES CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR NONPRESCRIPTION SALE","POUR VENTE SANS ORDONNANCE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5671","94-09-01","MILES CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR NONPRESCRIPTION SALE","POUR VENTE SANS ORDONNANCE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5672","94-12-20","NYCOMED IMAGING A.S.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC RADIOGRAPHIC CONTRAST MEDIUM","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON IONIQUE","",""
"5673","94-12-05","TECHNILAB PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE","",""
"5674","94-11-25","NEOLAB INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTIINFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE","",""
"5675","94-10-25","SANOFI WINTHROP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-IONIC RADIOGRAPHIC CONTRAST MEDIUM","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"5676","94-09-30","MCNEIL CONSUMER PRODUCTS COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"5677","94-09-08","MERCK SHARP & DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING, CHANGE IN FORMULATION","MODIFICATION DE LA FABRICATION, MODIFICATION DE LA PRÉPARATION","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"5678","94-09-08","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"5679","94-09-01","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5680","94-08-12","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5681","94-08-09","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH, REVISED PRODUCT MONOGRAPH","NOUVELLE CONCENTRATION, MONOGRAPHIE RÉVISÉE","ANTI-ANGINAL AGENT","ANTI-ANGINEUX","",""
"5682","94-07-19","NOVO NORDISK A/S","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PACKAGE SIZE, REVISED PRODUCT MONOGRAPH","NOUVEAU FORMAT D'EMBALLAGE, MONOGRAPHIE RÉVISÉE","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"5683","94-06-20","MALLINCKRODT MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","RADIOPAQUE CONTRAST MEDIUM FOR INTRAVASCULAR USE","AGENT DE CONTRASTE RADIOLOGIQUE POUR USAGE INTRAVASCULAIRE","",""
"5684","94-06-17","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"5685","94-06-09","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED LABELLING, REVISED SPECIFICATION, REVISED PRODUCT MONOGRAPH","ÉTIQUETTE RÉVISÉE, SPÉCIFICATION RÉVISÉE, MONOGRAPHIE RÉVISÉE","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5686","94-06-09","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5687","94-06-02","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5688","94-06-02","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5689","94-04-07","MERCK SHARP & DOHME CANADA, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","NSAID","AINS","",""
"5690","94-04-05","WHITEHALL-ROBINS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT NASAL","",""
"5691","94-03-16","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC IODINATED RADIOGRAPHIC CONTRAST MEDIUM","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON IONIQUE IODÉE","",""
"5692","94-03-11","MALLINCKRODT MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","RADIOPAQUE CONTRAST MEDIUM FOR INTRAVASCULAR USE","AGENT DE CONTRASTE RADIOLOGIQUE POUR USAGE INTRAVASCULAIRE","",""
"5693","94-03-07","PROCTER & GAMBLE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT NASAL","",""
"5694","94-02-23","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","INHALATION ANAESTHETIC","ANESTHÉSIQUE EN INHALATION","",""
"5695","94-01-14","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5696","94-12-01","HAEMACURE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CICATRIZING AGENT","CICATRISANT","",""
"5697","94-10-27","LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"5698","94-09-21","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"5699","94-08-09","PURDUE FREDERICK","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"5700","94-08-09","DAVID BULL LABORATORIES (PTY) LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"5701","94-06-17","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"5702","94-05-09","KNOLL PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","NARCOTIC ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"5703","94-03-10","LABORATOIRES PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5704","94-02-23","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING, CHANGE IN MANUFACTURING","NOUVEL EMBALLAGE, MODIFICATION DE LA FABRICATION","ANTICOAGULANT","ANTICOAGULANT","",""
"5705","94-01-14","PASTEUR MÉRIEUX SERUMS ET VACCINS, S.A.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"5706","94-12-28","QUEST VITAMINS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN FORMULATION, NEW PACKAGE SIZE","MODIFICATION DE LA PRÉPARATION, NOUVEL EMBALLAGE","MODULATION OF PHYSICAL ACTIVITY","MODULATION DE L'ACTIVITÉ PHYSIQUE","",""
"5707","94-12-15","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5708","94-11-25","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPÉDÉMIANT","",""
"5709","94-10-05","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","ANTIHYPERLIPIDÉMIQUE","",""
"5710","94-09-08","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE","",""
"5711","94-07-14","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"5712","94-05-18","SANOFI WINTHROP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT D'AMÉLIORATION DU CONTRASTE POUR LA RÉSONANCE MAGNÉTIQUE NUCLÉAIRE","",""
"5713","94-04-27","SYNTEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"5714","94-04-07","SQUIBB DIAGNOSTICS CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","CONTRAST ENHANCEMENT PREPARATION FOR MAGNETIC RESONANCE IMAGING","PRÉPARATION DE CONTRASTE DESTINÉ À L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE","",""
"5715","94-04-07","PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"5716","94-04-05","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"5717","94-03-31","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCES OF ACTIVE INGREDIENT","NOUVELLES SOURCES DE PRINCIPE ACTIF","ORAL HYPOGLYCEMIC","HYPOGLYCÉMIANT ORAL","",""
"5718","94-03-16","SQUIBB DIAGNOSTICS CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCE OF FINISHED PRODUCT","NOUVELLE SOURCE DU PRODUIT FINI","CONTRAST ENHANCEMENT PREPARATION FOR MAGNETIC RESONANCE IMAGING","PRÉPARATION DE CONTRASTE DESTINÉ À L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE","",""
"5719","04-10-28","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING PROCEDURE","NOUVELLE MÉTHODE DE FABRICATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"5720","04-10-28","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING PROCEDURE","NOUVELLE MÉTHODE DE FABRICATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"5721","04-10-20","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MONOTHERAPY MAINTENANCE TREATMENT IN BIPOLAR PATIENTS WITH MANIC OR MIXED EPISODES","NOUVELLE INDICATION : TRAITEMENT DE MAINTIEN DE LA MONOTHÉRAPIE CHEZ LES PERSONNES BIPOLAIRES PRÉSENTANT DES ÉPISODES DE TROUBLES MANIAQUES OU DES ÉPISODES DE TROUBLES MIXTES","ANTIPSYCHOTIC, ANTIMANIC AGENT","ANTIPSYCHOTIQUE, ANTIMANIAQUE","",""
"5722","04-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5723","04-10-28","PENDOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLACTIC MANAGEMENT OF VASCULAR HEADACHES","TRAITEMENT PROPHYLACTIQUE DES CÉPHALÉES VASCULAIRES","",""
"5724","04-10-28","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AGRYLIN","SHIRE CANADA INC.","CANADA","CANADA","1","","","PLATELET-REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"5725","04-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5726","04-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5727","04-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5728","04-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5729","04-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ANGINAL AND ANTI-HYPERTENSIVE AGENT","ANTIANGINEUX ET ANTIHYPERTENSEUR","",""
"5730","04-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5731","94-02-23","MALLINCKRODT MEDICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS","NOUVELLES INDICATIONS","RADIOPAQUE CONTRAST MEDIUM FOR INTRAVASULAR USE","AGENT DE CONTRASTE RADIO-OPAQUE POUR USAGE INTRAVASCULAIRE","",""
"5732","94-11-21","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"5733","94-11-10","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM, NEW INDICATION","NOUVELLE PRÉSENTATION, NOUVELLE INDICATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5734","94-11-02","GLAXO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"5735","94-10-28","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"5736","94-10-17","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"5737","94-10-17","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"5738","94-10-13","FRANK W HORNER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"5739","94-10-13","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"5740","94-09-30","ASTRA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"5741","94-09-21","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIFUNGAL","ANTIFONGIQUE","",""
"5742","94-09-08","HILL DERMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC CORTICOSTEROID WITH ANTI-INFLAMMATORY, ANTIPRURITIC AND VASOCONSTRICTIVE PROPERTIES","CORTICOSTÉROÏDE SYNTHÉTIQUE AYANT DES PROPRIÉTÉS ANTI-INFLAMMATOIRES, ANTIPRURITIQUES ET VASOCONSTRICTRICES","",""
"5743","94-08-29","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"5744","94-08-25","GEIGY PHARMACEUTICALS, CIBA-GEIGY CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","STEROIDAL AROMATASE INHIBITOR, INHIBITOR OF ESTROGEN BIOSYNTHESIS, ANTITUMOUR AGENT","INHIBITEUR D'AROMATASE STÉROÏDIEN, INHIBITEUR DE LA BIOSYNTHÈSE OESTROGÉNIQUE, ANTITUMEUR","",""
"5745","94-08-25","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTI-OBSESSIONEL, ANTIBOULIMIQUE","",""
"5746","94-08-25","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"5747","94-08-12","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"5748","94-06-23","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF FINISHED PRODUCT","AUTRE SOURCE DU PRODUIT FINI","NARCOTIC ANALGESIC, ADJUNCT TO ANAESTHESIA","ANALGÉSIQUE NARCOTIQUE, ADJUVANT À L'ANESTHÉSIE","",""
"5749","94-06-08","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"5750","94-05-19","BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5751","94-05-09","GLAXO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY STEROID","STÉROÏDE ANTI-INFLAMMATOIRE TOPIQUE","",""
"5752","94-03-25","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONEL, ANTIBOULIMIQUE","",""
"5753","94-03-16","SYNTEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED SPECIFICATIONS","SPÉCIFICATIONS RÉVISÉES","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"5754","94-03-16","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"5755","94-02-01","HOECHST-ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5756","94-01-27","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"5757","94-01-27","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"5758","94-01-14","NU-PHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'HISTAMINE H2","",""
"5759","94-12-22","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE","",""
"5760","94-12-07","BRISTOL LABS, DIVISION OF BRISTOL-MYERS SQUIBB","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5761","94-10-13","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","HYPNOTIC","HYPNOTIQUE","",""
"5762","94-09-30","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION, CHANGE IN MANUFACTURING SITE","MODIFICATION DE LA PRÉPARATION, NOUVEL EMPLACEMENT DE FABRICATION","HYPNOTIC","HYPNOTIQUE","",""
"5763","94-08-25","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELECTROLYTE AND TRACE ELEMENT SUPPLEMENT","ÉLECTROLYTE ET SUPPLÉMENT D'OLIGO-ÉLÉMENTS","",""
"5764","04-11-01","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC","ANTI-INFLAMMATOIRE NON STÉROÏDIEN ANALGÉSIQUE","",""
"5765","04-11-02","SKRETTING","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"5766","04-11-05","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5767","04-11-02","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5768","04-11-01","RHOXALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"5769","04-11-02","AMERSHAM HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"5770","04-11-01","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW 400G TIN AND ADDITIONAL FORMULATION (LEMON-LIME FLAVOUR)","NOUVEL EMPAQUETAGE DE 400G ET AJOUT D'UNE PRÉPARATION SUPPLÉMENTAIRE À SAVEUR DE CITRON/LIME","ANTIHYPERCHOLESTEROLEMIC AND ANTIDIARRHEAL","HYPOCHOLESTÉROLÉMIANT ET ANTIDIARRHÉIQUE","",""
"5771","04-11-01","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CHOLESTYRAMINE","CHANGEMENT DU NOM DU PRODUIT DE CHOLESTYRAMINE","ANTIHYPERCHOLESTEROLEMIC AND ANTIDIARRHEAL","HYPOCHOLESTÉROLÉMIANT ET ANTIDIARRHÉQUE","",""
"5772","04-11-01","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5773","04-11-01","LABORATOIRE RIVA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS DIVISION, WARNER LAMBERT CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM AND STRENGTHS","NOUVELLE FORME POSOLOGIQUE ET NOUVELLES CONCENTRATIONS","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"5774","04-11-05","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MONOTHERAPY FOR THE ACUTE MANAGEMENT OF MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER","NOUVELLE INDICATION : MONOTHÉRAPIE POUR LA GESTION DES CRISES DE MANIE RELIÉES AU TROUBLE BIPOLAIRE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"5775","04-11-01","PENDOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PEDIATRIC ASTHMA PROPHYLACTIC AND ANTIALLERGIC AGENT","AGENT PROPHYLACTIQUE DE L'ASTHME INFANTILE ET ANTIALLERGIQUE","",""
"5776","94-08-09","BRISTOL LABS, DIVISION OF BRISTOL-MYERS SQUIBB","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5777","94-07-29","ALLERGAN HERBERT SKIN CARE DIVISION OF ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-ACNE","TRAITEMENT TOPIQUE DE L'ACNÉ","",""
"5778","94-07-29","ALLERGAN HERBERT SKIN CARE DIVISION OF ALLERGAN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-ACNE","TRAITEMENT TOPIQUE DE L'ACNÉ","",""
"5779","94-06-23","FROSST, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5780","94-06-22","CIBA PHARMACEUTICALS, DIVISION OF CIBA GEIGY CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN - PROGESTIN","OESTROGÈNE - PROGESTÉRONE","",""
"5781","94-05-09","PHARMACIA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED SPECIFICATIONS, NEW PACKAGING","SPÉCIFICATIONS RÉVISÉES, NOUVEL EMBALLAGE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5782","94-05-09","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PACKAGING","NOUVEL EMBALLAGE","INHALATION ANAESTHETIC","ANESTHÉSIQUE EN INHALATION","",""
"5783","94-04-27","FROSST, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5784","94-03-18","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE","",""
"5785","94-03-11","GALDERMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-ACNE PREPARATION","PRÉPARATION TOPIQUE CONTRE L'ACNÉ","",""
"5786","94-03-07","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5787","94-02-15","ABIC LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5788","94-02-10","BRISTOL LABS, DIVISION OF BRISTOL-MYERS SQUIBB","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION, NEW PACKAGING","NOUVELLE INDICATION, NOUVEL EMBALLAGE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5789","94-02-01","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5790","94-02-10","BRISTOL LABS, DIVISION OF BRISTOL-MYERS SQUIBB","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION, NEW PACKAGING","NOUVELLE INDICATION, NOUVEL EMBALLAGE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5791","94-11-10","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM, NEW INDICATION","NOUVELLE PRÉSENTATION, NOUVELLE INDICATION","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5792","94-01-14","FROSST, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5793","94-01-14","FROSST, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5794","94-01-14","CIBA-GEIGY CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCE OF ACTIVE INGREDIENT","NOUVELLE SOURCE DE PRINCIPE ACTIF","ESTROGEN THERAPY","TRAITEMENT À L'OESTROGÈNE","",""
"5795","94-01-14","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5796","94-01-12","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5797","94-05-09","PHARMACIA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED SPECIFICATIONS, NEW PACKAGING","SPÉCIFICATIONS RÉVISÉES, NOUVEL EMBALLAGE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5798","94-04-27","FROSST, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5799","94-12-20","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5800","94-12-12","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANXIOLYTIC","ANTIDÉPRESSEUR, ANXIOLYTIQUE","",""
"5801","94-11-25","GENDERM CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Antipruritic","Antiprurigineux","",""
"5802","04-11-08","PENDOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT, PLATELET AGGREGATION INHIBITOR","ANTI-INFLAMMATOIRE NON STÉROÏDIEN, ANALGÉSIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"5803","04-11-10","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANAFLEX","ELAN PHARMACEUTICALS INC.","CANADA","CANADA","1","","","ANTISPASTIC AGENT","ANTISPASMODIQUE","",""
"5804","04-11-08","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"5805","04-11-08","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5806","04-11-08","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5807","04-11-08","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CLONAZEPAM-R","CHANGEMENT DU NOM DU PRODUIT DE CLONAZEPAM-R","ANTICONVULSANT","ANTICONVULSIVANT","",""
"5808","04-11-08","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE SYRUP","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM VALPROIC ACID SYRUP","PRODUCT NAME CHANGE FROM VALPROIC ACID SYRUP","ANTICONVULSANT","ANTICONVULSIVANT","",""
"5809","94-11-25","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5810","94-11-21","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","SPECIFIC ANTIBODY FOR DIGOXIN","ANTICORPS SPÉCIFIQUE DE LA DIGOXINE","",""
"5811","94-11-09","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANXIOLYTIC","ANTIDÉPRESSEUR, ANXIOLYTIQUE","",""
"5812","94-10-17","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"5813","94-10-05","ORGANON CANADA LTD./LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-THROMBOTIC AGENT","ANTITHROMBOTIQUE","",""
"5814","94-09-22","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ALLERGIC AGENT, SEASONAL RHINITIS PROPHYLAXIS","ANTIALLERGIQUE, PROPHYLAXIE DE LA RHINITE SAISONNIÈRE","",""
"5815","94-09-30","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHROMBOTIC AGENT","ANTITHROMBOTIQUE","",""
"5816","94-12-13","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"5817","94-09-13","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5818","94-09-13","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC, ANTI-INFLAMMATORY AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"5819","94-09-08","GENENTECH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ENZYME","ENZYME","",""
"5820","94-08-25","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTICONVULSANT","ANTICONVULSIVANT","",""
"5821","94-08-09","RHONE-POULENC RORER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"5822","94-07-29","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"5823","94-07-26","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5824","94-07-14","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","NEUROLEPTIC","NEUROLEPTIQUE","",""
"5825","94-06-30","GALDERMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"5826","94-06-20","CIBA VISION CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING, NEW FORMULATION","NOUVEL EMBALLAGE, NOUVELLE PRÉSENTATION","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5827","94-06-15","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"5828","94-06-15","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5829","94-06-08","RIVA LABORATORIES INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5830","94-06-02","MARION MERRELL DOW (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTMIC","ANTIARYTHMIQUE","",""
"5831","94-06-02","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"5832","94-06-02","MARION MERRELL DOW (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL, ANTIHYPERTENSIVE AGENT","ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"5833","94-06-02","VERANE PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5834","94-05-19","GALDERMA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"5835","94-05-09","TECHNILAB INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5836","94-04-29","CYANAMID CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"5837","94-02-07","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"5838","98-02-16","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"5839","94-02-07","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"5840","98-06-18","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5841","98-06-18","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5842","98-06-18","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5843","94-02-01","STIEFEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"5844","98-06-18","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"5845","98-06-18","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"5846","98-06-18","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"5847","98-06-18","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"5848","94-01-26","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5849","94-01-19","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5850","94-01-12","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"5851","98-06-18","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"5852","98-06-18","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"5853","98-06-18","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"5854","98-06-18","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"5855","94-01-12","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS AGENT","PROPHYLACTIQUE","",""
"5856","94-08-25","CIBA-GEIGY CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTICONVULSANT, ANTIMANIC, SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA","ANTICONVULSIVANT, ANTIMANIAQUE, SOULAGEMENT DE LA NEURALGIE DU TRIJUMEAU","",""
"5857","94-08-25","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5858","94-08-25","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5859","94-08-25","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"5860","94-08-17","SCHERING-PLOUGH HEALTHCARE PRODUCTS CANADA, A DIVISION OF SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5861","94-08-17","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5862","94-08-17","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5863","94-08-16","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5864","94-08-16","DAVID BULL LABORATORIES (PTY) LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW ROUTE OF ADMINISTRATION, CHANGE IN MANUFACTURING","NOUVELLE VOIE D'ADMINISTRATION, MODIFICATION DE LA FABRICATION","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"5865","94-08-12","GLAXO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION, NEW PACKAGING","MODIFICATION DE LA PRÉPARATION, NOUVEL EMBALLAGE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5866","94-08-12","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5867","94-08-12","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5868","94-08-12","KENRAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"5869","94-08-12","FAULDING (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5870","94-08-09","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY CORTICOSTEROID","CORTICOSTÉROÏDE ANTI-INFLAMMATOIRE TOPIQUE","",""
"5871","94-08-09","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"5872","94-07-29","LEDERLE-CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5873","94-07-14","SQUIBB CANADA INC., DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING SITE, CHANGE IN MANUFACTURING","NOUVEL EMPLACEMENT DE FABRICATION, MODIFICATION DE LA FABRICATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"5874","94-06-23","DAVID BULL LABORATORIES (PTY) LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"5875","94-06-15","SYNCARE PHARMACEUTICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"5876","94-06-08","MILES CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, NEW INDICATION","NOUVELLE CONCENTRATION, NOUVELLE INDICATION","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"5877","94-06-08","MILES CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, NEW INDICATION","NOUVELLE CONCENTRATION, NOUVELLE INDICATION","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"5878","94-05-19","ABIC LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"5879","94-05-11","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY STEROID","STÉROÏDE ANTI-INFLAMMATOIRE TOPIQUE","",""
"5880","94-05-09","MILES CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS","NOUVELLES INDICATIONS","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"5881","94-05-09","BOOTS PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCE OF ACTIVE INGREDIENT, NEW EXPIRATION DATE","NOUVELLE SOURCE DE PRINCIPE ACTIF, NOUVELLE DATE LIMITE D'UTILISATION","PROTEOLYTIC ENZYME","ENZYME PROTÉOLYTIQUE","",""
"5882","94-05-09","BOOTS PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCE OF ACTIVE INGREDIENT, NEW EXPIRATION DATE","NOUVELLE SOURCE DE PRINCIPE ACTIF, NOUVELLE DATE LIMITE D'UTILISATION","PROTEOLYTIC ENZYME","ENZYME PROTÉOLYTIQUE","",""
"5883","94-04-05","ORTHO BIOTECH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCE OF FINISHED PRODUCT","NOUVELLE SOURCE DU PRODUIT FINI","ANTINEOPLASTIC, CHEMOTHERAPEUTIC AGENT","ANTINÉOPLASIQUE, AGENT CHIMIOTHÉRAPIQUE","",""
"5884","94-03-28","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"5885","94-03-28","MEDICAN PHARMA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"5886","94-03-25","KNOLL PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ENZYMATIC DEBRIDING AGENT","TRAITEMENT FIBRINOLYTIQUE PAR ENZYMES","",""
"5887","94-03-18","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","MYORELAXANT","",""
"5888","94-03-16","BRISTOL LABS, DIVISION OF BRISTOL-MYERS SQUIBB","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTIDIARRHEAL AND ANTIHYPERCHOLESTEROLEMIC","ANTIDIARRHÉIQUE, ANTIHYPERCHOLESTÉROLÉMIANT","",""
"5889","94-02-23","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN, CHANGE IN FORMULATION","NOUVEAU SCHÉMA POSOLOGIQUE, MODIFICATION DE LA PRÉPARATION","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"5890","94-02-23","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN, CHANGE IN FORMULATION","NOUVEAU SCHÉMA POSOLOGIQUE, MODIFICATION DE LA PRÉPARATION","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"5891","94-02-23","SANDOZ CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN, CHANGE IN FORMULATION","NOUVEAU SCHÉMA POSOLOGIQUE, MODIFICATION DE LA PRÉPARATION","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"5892","94-02-21","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5893","94-02-10","SQUIBB CANADA INC., DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF RAW MATERIAL, CHANGE IN MANUFACTURING","AUTRE SOURCE ÉQUIVALENTE DE MATIÈRE PREMIÈRE, MODIFICATION DE LA FABRICATION","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5894","94-01-20","SYNCARE PHARMACEUTICAL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5895","94-01-14","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5896","94-08-25","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"5897","94-03-31","MILES CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"5898","94-03-01","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, NEW INDICATION","NOUVELLE CONCENTRATION, NOUVELLE INDICATION","GLAUCOMA THERAPY","TRAITEMENT DU GLAUCOME","",""
"5899","94-01-14","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NUTRITIVE AND ELECTROLYTE SUPPLEMENTS","SUPPLÉMENTS NUTRITIFS ET ÉLECTROLYTES","",""
"5900","04-11-15","ID BIOMEDICAL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZATION AGAINST TETANUS","IMMUNISATION ACTIVE CONTRE LE TÉTANOS","",""
"5901","04-11-18","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","IGE-NEUTRALIZING ANTIBODY","ANTICORPS NEUTRALISANT D'IGE","",""
"5902","04-11-17","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5903","04-11-17","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR ADJUCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"5904","04-11-17","ENDO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR SUBTYPE AGONIST, MIGRAINE THERAPY","AGONISTE SOUS-TYPE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"5905","04-11-17","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FORM NIZATIDINE","CHANGEMENT DU NOM DU PRODUIT DE NIZATIDINE","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"5906","04-11-17","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW TABLET STRENGTH AND NEW DOSAGE FORM","NOUVELLE CONCENTRATION (COMPRIMÉ) ET NOUVELLE FORME POSOLOGIQUE","ANTICHOLINERGIC, ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"5907","04-11-17","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FORM RIVA-RANITIDINE","CHANGEMENT DU NOM DU PRODUIT DE RIVA-RANITIDINE","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"5908","04-11-17","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"5909","04-11-17","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"5910","04-11-17","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS DIVISION OF WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"5911","04-11-17","ODAN LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC THYROTROPIN-RELEASING HORMONE","HORMONE RÉGULATRICE DE LA THYRÉOTROPHINE SYNTHÉTIQUE","",""
"5912","04-11-14","ODAN LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5913","04-11-17","KODAK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANAESTHETIC FOR DENTAL USE","ANESTHÉSIQUE LOCAL","",""
"5914","04-11-26","AMERSHAM HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING PROCESS","CHANGEMENT AU PROCESSUS DE FABRICATION","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"5915","04-11-26","AMERSHAM HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCESS","CHANGEMENT AU PROCESSUS DE FABRICATION","THERAPEUTIC PHARMACEUTICAL","RADIOPHARMACEUTIQUE THÉRAPEUTIQUE","",""
"5916","04-11-26","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING AREA","NOUVELLE ZONE DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER PLUS ANTIVIRAL AGENT","MODULATEUR DES RÉACTIONS BIOLOGIQUES ET AGENT ANTIVIRAL","",""
"5917","04-11-23","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - ADULT GROWTH HORMONE DEFICIENCY","NOUVELLE INDICATION - ANOMALIE DE L'HORMONE DE CROISSANCE ADULTE","HUMAN GROWTH HROMONE","HORMONE DE CROISSANCE HUMAINE","",""
"5918","04-11-26","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING AREA","NOUVELLE ZONE DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"5919","04-11-24","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5920","04-11-26","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR A CHANGE IN THE NON-MEDICINAL INGREDIENTS","EN VUE DE L'HOMOLOGATION SUITE À UN CHANGEMENT AU NIVEAU DES INGRÉDIENTS NON-MÉDICINAUX","DIURETIC","DIURÉTIQUE","",""
"5921","04-11-23","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"5922","04-11-23","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"5923","04-11-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"5924","04-11-25","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5925","04-11-23","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DENTAL CORTICOSTEROID","CORTICOSTÉROÏDE DENTAIRE","",""
"5926","04-11-23","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5927","04-11-26","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: DOSAGE AND ADMINISTRATION SECTION, THE USE OF 60 MG DOSE FOR PATIENTS WHO ARE CLOSE TO THEIR THERAPEUTIC TARGET WHEN USED AS A MONOTHERAPY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT (RUBRIQUE POSOLOGIE) POUR INCLURE L'USAGE DE LA DOSE DE 60 MG CHEZ LES PATIENTS PROCHES DE LEUR CIBLE THÉRAPEUTIQUE, LORSQUE LE PRODUIT EST UTILISÉ EN MONOTHÉRAPIE","ORAL ANTIDIABETIC AGENT","ANTIDIABÉTIQUE ORAL","",""
"5928","94-09-13","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"5929","94-08-25","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"5930","04-12-01","ORYX PHARMACEUTICALS INC., A SUBSIDIARY OF FILIALE D'ARROW PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"5931","04-11-29","ALLERGAN INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC","MERCK SHARPE & DOHME","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"5932","04-12-01","SANDOZ INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IRON AND ALUMINUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"5933","04-12-03","GILEAD SCIENCES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE FOR ADDITIONAL CLINICAL DATA","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT POUR INCLURE DES DONNÉES CLINIQUES ADDITIONNELLES","ANTIVIRAL","ANTIVIRAL","",""
"5934","04-11-29","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"5935","04-11-29","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PHL TO THE PRODUCT NAME","AJOUT DE PHL AU NOM DU PRODUIT","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5936","04-11-29","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5937","04-12-02","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"5938","04-11-30","TAP PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR AN ADDITIONAL DOSAGE FORM: GRANULES FOR DELAYED RELEASE ORAL SUSPENSION","ADDITION D'UNE PRÉSENTATION : GRANULES POUR SUSPENSION ORALE À LIBÉRATION RETARDÉE","H+, K+-ATPASE INHIBITOR","INHBITEUR DE L'H+, K+-ATPASE","",""
"5939","04-11-30","TAP PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"5940","04-12-03","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"5941","04-11-29","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"5942","04-12-01","SANDOZ INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"5943","04-12-01","SANDOZ INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT, SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA, ANTIMANIC","ANTICONVULSIVANT, SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU, ANTIMANIAQUE","",""
"5944","04-12-03","SANDOZ INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-inflammatory, Analgesic Agent","Anti-inflammatoire, analgésique","",""
"5945","04-12-01","SANDOZ INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5946","04-12-01","SANDOZ INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"5947","04-11-29","AMERSHAM HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","DIAGNOSTIC RADIOPHARMACEUTICAL","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"5948","04-11-30","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PRODUCTION LINE","NOUVELLE CHAÎNE DE PRODUCTION","REPLACEMENT THERAPY FOR IMMUNODEFICIENCIES","THÉRAPIE DE REMPLACEMENT POUR IMMUNODÉFICIENCES","",""
"5949","04-12-02","MDS NORDION, A DIVISION OF MDS (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","N/A","S/O","",""
"5950","04-12-01","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"5951","94-12-22","BURROUGHS WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"5952","94-11-21","FUJISAWA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTMIC","ANTIARYTHMIQUE","",""
"5953","98-04-17","RHODIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICHOMONACIDE - MONILIACIDE","TRICHOMONACIDE - MONILIACIDE","",""
"5954","94-11-25","CLINTEC NUTRITION COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"5955","94-11-21","CLINTEC NUTRITION COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"5956","94-04-20","KABI PHARMACIA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NUTRITIVE AND ELECTROLYTE SUPPLEMENTS","SUPPLÉMENTS NUTRITIFS ET ÉLECTROLYTES","",""
"5957","94-11-25","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"5958","94-09-30","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION, REVISED PRODUCT MONOGRAPH","NOUVELLE PRÉPARATION, MONOGRAPHIE RÉVISÉE","ANTIHYPERCHOLESTEROLEMIC","ANTIHYPERCHOLESTÉROLÉMIQUE","",""
"5959","94-09-30","THE UPJOHN COMPANY OF CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION, REVISED PRODUCT MONOGRAPH","NOUVELLE PRÉPARATION, MONOGRAPHIE RÉVISÉE","ANTIHYPERCHOLESTEROLEMIC","ANTIHYPERCHOLESTÉROLÉMIQUE","",""
"5960","94-09-13","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"5961","94-09-01","MILES CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR NONPRESCRIPTION SALE","POUR VENTE SANS ORDONNANCE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5962","94-09-01","MILES CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PROVIDES FOR NONPRESCRIPTION SALE","POUR VENTE SANS ORDONNANCE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5963","94-06-20","KNOWELL THERAPEUTICS TECHNOLOGIES INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTIMICROBIAL AGENT","ANTIMICROBIEN","",""
"5964","94-05-24","SQUIBB CANADA INC., DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR, DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE, DIURÉTIQUE","",""
"5965","94-05-19","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH, NEW EXPIRATION DATE","MONOGRAPHIE RÉVISÉE, NOUVELLE DATE LIMITE D'UTILISATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5966","94-07-07","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"5967","94-01-14","HOECHST-ROUSSEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5968","94-01-14","ASTRA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE RÉVISÉE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"5969","98-04-30","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","PROSTAGLANDIN","PROSTAGLANDINE","",""
"5970","98-04-30","PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE PRÉSENTATION","PROSTAGLANDIN","PROSTAGLANDINE","",""
"5971","98-08-31","CONNAUGHT LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"5972","98-08-31","CONNAUGHT LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNIZING AGENT","AGENT D'IMMUNISATION","",""
"5973","98-06-18","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"5974","94-03-16","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5975","94-03-16","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5976","94-03-16","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PACKAGING","NOUVEL EMBALLAGE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5977","94-03-16","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME","MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"5978","04-12-10","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"5979","04-12-08","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM AND NEW DOSING REGIMEN","NOUVELLE FORME POSOLOGIQUE ET NOUVEAU SCHÉMA POSOLOGIQUE","ANTIBACTERIAL (OPHTHALMIC)","ANTIBACTÉRIEN (OPHTALMIQUE)","",""
"5980","04-12-10","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"5981","04-12-10","SANDOZ INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"5982","04-12-09","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","BETA-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"5983","04-12-10","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANTIRHEUMATIC AGENT","ANTIRHUMATISMAL","",""
"5984","04-12-10","SOPHERION THERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"5985","04-12-08","BAXTER CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER INC.","CANADA","CANADA","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"5986","04-12-10","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","DESCRIPTION OF CLINICAL TRIAL IN THE TREATMENT OF SOCIAL ANXIETY DISORDER FOR UP TO SIX MONTHS","DESCRIPTION DE L'ESSAI CLINIQUE DANS LE TRAITEMENT JUSQU'À SIX MOIS DU TROUBLE D'ANGOISSE SOCIALE","ANTIDEPRESSANT, ANXIOLYTIC","ANTIDÉPRESSEUR, ANXIOLYTIQUE","",""
"5987","04-12-08","LUNDBECK CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE LA N-MÉTHYLE-D-ASPARTATE (NMDA)","",""
"5988","04-12-08","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS","NOUVELLE INDICATION : THÉRAPIE EMPIRIQUE POUR LE TRAITEMENT DES INFECTIONS FONGIQUES PRÉSUMÉES CHEZ LES PATIENTS FIÉVREUX, NEUTROPÉNIQUES","ANTIFUNGAL","ANTIFONGIQUE","",""
"5989","04-12-06","NOVARTIS CONSUMER HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","TO REDUCE THE TOTAL DURATION OF USE FROM 9-12 WEEKS TO 8 WEEKS","POUR LA RÉDUCTION DE LA DURÉE TOTALE D'USAGE, DE 9-12 SEMAINES À 8 SEMAINES","SMOKING CESSATION AID","AIDE POUR CESSER DE DUMER","",""
"5990","04-12-06","AVENTIS BEHRING GMBH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING, NEW INDICATION","CHANGEMENT À LA FABRICATION, NOUVELLE INDICATION","THROMBOLYTIC","THROMBOLYTIQUE","",""
"5991","04-12-17","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTI-OBESITY AGENT, GASTROINTESTINAL LIPASE INHIBITOR","AGENT ANTIOBÉSITÉ, INHIBITEUR DES LIPASES GASTRO-INTESTINALES","",""
"5992","04-12-17","RHOXALPHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIVELLE 100","CIBA PHARMACEUTICALS, CIBA GEIGY CANADA LTD.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE AS REQUESTED IN TPD LETTER DATED APRIL 3, 2003 RESULTING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) STUDY","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT, CONFORMÉMENT À LA DEMANDE DE LA DPT DANS SA LETTRE DU 3 AVRIL 2003, RÉSULTANT DE L'ÉTUDE SUR LA SANTÉ DES FEMMES","ESTROGEN THERAPY","OESTROGÈNE","",""
"5993","04-12-13","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPRIVAN","ZENECA PHARMA","CANADA","CANADA","1","","","ANAESTHETIC, SEDATIVE","ANESTHÉSIQUE, SÉDATIF","",""
"5994","04-12-13","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRYPTAN","ICN CANADA INC.","CANADA","CANADA","1","","","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"5995","04-12-13","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PHL TO THE PRODUCT NAME","ADDITION DE PHL AU NOM DU PRODUIT","ADJUNCT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DES TROUBLES AFFECTIFS","",""
"5996","04-12-13","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PHL TO PRODUCT NAME","ADDITION DE PHL AU NOM DU PRODUIT","ANTIMANIC AGENT","ANTIMANIAQUE","",""
"5997","04-12-16","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PHL TO PRODUCT NAME","ADDITION DE PHL AU NOM DU PRODUIT","BRONCHODILATOR","BRONCHODILATATEUR","",""
"5998","04-12-16","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL","",""
"5999","04-12-13","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PHL TO PRODUCT NAME","ADDITION DE PHL AU NOM DU PRODUIT","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"6000","04-12-16","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIPARKINSONIAN AGENT, ANTIVIRAL AGENT","ANTIPARKINSONIEN, ANTIVIRAL","",""
"6001","04-12-16","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PHL TO THE PRODUCT NAME","ADDITION DE PHL AU NOM DU PRODUIT","ANTIPARKINSONIAN AGENT, ANTIVIRAL AGENT","ANTIPARKINSONIEN, ANTIVIRAL","",""
"6002","04-12-13","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","TESTOSTERONE REPLACEMENT THERAPY","TRAITEMENT DE REMPLACEMENT DE LA TESTOSTÉRONE","",""
"6003","04-12-14","BAXTER HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR VIII","FACTEUR VIII DE COAGULATION","",""
"6004","04-12-16","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN DOSING ADVICE","CHANGEMENT DE CONSEIL POSOLOGIQUE","HUMAN GONADOTROPIN","GONADOTROPHINE HUMAINE","",""
"6005","04-12-16","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","GONADOTROPIN","GONADOTROPHINE","",""
"6006","04-12-14","BAXTER HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIHEMOPHILIA THERAPY","TRAITEMENT ANTI-HÉMOPHILIQUE","",""
"6007","04-12-16","BIOGEN IDEC CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"6008","04-12-24","LUNDBECK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"6009","04-12-24","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"6010","04-12-24","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE TOPIQUE","",""
"6011","04-12-24","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM PALLADONE.IR","MODIFICATION DU NOM DU PRODUIT DE PALLADONE.IR","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"6012","04-12-22","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR TREATMENT OF ACUTE SINUSITIS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE LA SINUSITE AIGUË","ANTI-BACTERIAL AGENT","ANTIBACTÉRIEN","",""
"6013","04-12-24","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"6014","04-12-24","AVENTIS PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6015","04-12-21","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE RAPID CONTROL OF AGITATION IN PATIENTS WITH BIPOLAR MANIA","NOUVELLE INDICATION : POUR LE CONTRÔLE RAPIDE DE L'AGITATION CHEZ LES PERSONNES ATTEINTES DE MANIE BIPOLAIRE","ANTIPSYCHOTIC, ANTIMANIC AGENT","ANTISPYCHOTIQUE, ANTIMANIAQUE","",""
"6016","04-12-21","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"6017","04-12-21","ORYX PHARMACEUTICALS INC., A SUBSIDIARY OF FILIALE D'ARROW PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","INDICATION EXTENDED TO INCLUDE USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) AND A NEW INDICATION FOR PATIENTS WITH OR AT RISK OF HIT/HITTS UNDERGOING PCI","INDICATION COMPLÉMENTAIRE POUR INCLURE L'USAGE COMME ANTICOAGULANT CHEZ LES PATIENTS SUBISSANT UNE INTERVENTION CORONAIRE PERCUTANÉE (ICP) ET UNE NOUVELLE INDICATION POUR LES PATIENTS SUBISSANT UNE ICP ET À RISQUE DE THROMBOCYTOPÉNIE SOUS HÉPARINE/SYNDROME THROMBOTIQUE","DIRECT THROMBIN INHIBITOR","INHIBITEUR DE LA THROMBINE","",""
"6018","04-12-24","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR","INHIBITEUR SÉLECTIF DE RECAPTAGE DE LA NORÉPINÉPHRINE","",""
"6019","04-12-23","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"6020","04-12-24","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CLARITIN EXTRA","MODIFICATION DU NOM DU PRODUIT DE CLARITIN EXTRA","HISTAMINE H1 RECEPTOR ANTAGONIST, SYMPATHOMIMETIC AMINE","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE, AMINE SYMPATHOMIMÉTIQUE","",""
"6021","04-12-24","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM LIBERATOR","MODIFICATION DU NOM DU PRODUIT DE LIBERATOR","HISTAMINE H1 RECEPTOR ANTAGONIST, SYMPATHOMIMETIC AMINE","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE, AMINE SYMPATHOMIMÉTIQUE","",""
"6022","97-04-07","LEO LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ALSO USED FOR PATIENTS WITH RENAL FAILURE WHO DO NOT YET REQUIRE DIALYSIS","NOUVELLE INDICATION : ÉGALEMENT UTILISÉ POUR LES PATIENTS QUI PRÉSENTENT DE TROUBLE DE LA FONCTION RÉNALE MAIS QUI NE REQUIÈRENT PAS ENCORE DE TRAITEMENT PAR DIALYSE","VITAMIN D ANALOGUE","ANALOGUE DE LA VITAMINE D","",""
"6023","97-09-04","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NUTRITIVE AND ELECTROLYTE SUPPLEMENTS FOR INTRAVENOUS INFUSION","SUPPLÉMENTS NUTRITIFS ET ÉLECTROLYTIQUES POUR PERFUSION INTRAVEINEUX","",""
"6024","97-09-04","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NUTRITIVE AND ELECTROLYTES SUPPLEMENTS FOR INTRAVENOUS INFUSION","SUPPLÉMENTS NUTRITIFS ET ÉLECTROLYTIQUES POUR PERFUSION INTRAVIENEUX","",""
"6025","97-01-17","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN-C PHOSPHATE","UPJOHN CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6026","97-08-20","CONNAUGHT LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW SITE FOR PURIFICATION","NOUVEL EMPLACEMENT POUR LA PURIFICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"6027","97-09-16","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW 3.0ML CARTRIDGE PRESENTATION TO BE USED WITH HUMAJECT INJECTOR","NOUVEL EMBALLAGE - CARTOUCHE DE 3.0ML POUR USAGE AVEC L'INJECTEUR HUMAJECT","ANTI-DIABETIC AGENT","ANTIDIABÉTIQUE","",""
"6028","97-11-10","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE TO MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","VACCINE","VACCIN","",""
"6029","97-01-08","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"6030","97-08-20","MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE TO MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"6031","04-12-29","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AS AN ADJUNCTIVE THERAPY WITH CATHETERIZATION FOR ACUTE URINARY RETENTION (AUR) IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA","NOUVELLE INDICATION : COMME TRAITEMENT AUXILIAIRE À LA CATHÉTÉRISATION DANS LES CAS DE RÉTENTION URINAIRE AIGUË CHEZ LES PERSONNES PRÉSENTANT UNE HYPERPLASIE BÉNIGNE PROSTATIQUE","SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE","",""
"6032","04-12-29","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE FOR NEW CLINICAL DATA FOR 2ND LINE CHRONIC MYELOID LEUKEMIA (CML)","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT RELATIVEMENT AUX NOUVELLES DONNÉES CLINIQUES POUR LA LEUCÉMIE MYÉLOÏDE CHRONIQUE (LMC) DE DEUXIÈME LIGNE","PROTEIN TYROSINE-KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"6033","04-12-29","3M PHARMACEUTICALS, A DIVISION OF 3M CANADA COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA IN ADULTS","NOUVELLE INDICATION : POUR LE TRAITEMENT DU CARCINOME BASOCELLULAIRE SUPERFICIEL CHEZ L'ADULTE","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE IMMUNITAIRE","",""
"6034","96-08-09","SOLVAY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANABOLIC STEROID","STÉROÏDE ANABOLISANT","",""
"6035","97-12-19","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: TREATMENT OF SHORT STATURE ASSOCIATED WITH TURNER SYNDROME","NOUVELLE INDICATION : TRAITEMENT DE LA PETITE TAILLE CHEZ LES PATIENTS ATTEINTS DU SYNDROME DE TURNER","GROWTH STIMULANT","STIMULANT DE LA CROISSANCE","",""
"6036","97-12-04","LABORATOIRES PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC/ANTISPASMODIC AGENT","ANTICHOLINERGIQUE/ANTISPASMODIQUE","",""
"6037","97-03-27","OSTERREICHISCHES INSTITUT","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE SOURCE OF APROTININ","SOURCE ALTERNATIVE D'APROTININE","HAEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"6038","05-01-06","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE - 48 WEEK DATA AND SAFETY DATA","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT - DONNÉES DE 48 SEMAINES ET DONNÉES RELATIVES À L'INNOCUITÉ","ANTIVIRAL AGENT","ANTIVIRAL","",""
"6039","05-01-07","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOWELLCOME INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"6040","05-01-06","WESTFALIA-SURGE, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"6041","05-01-06","WESTFALIA-SURGE, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"6042","96-01-30","CLINTEC NUTRITION COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH, NEW PACKAGING","MONOGRAPHIE RÉVISÉE, NOUVEL EMBALLAGE","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"6043","96-01-30","CLINTEC NUTRITION COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH, NEW PACKAGING","MONOGRAPHIE RÉVISÉE, NOUVEL EMBALLAGE","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"6044","02-12-10","WESTFALIA-SURGE, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"6045","02-12-05","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","VITAMIN AND MINERAL SUPPLEMENT","SUPPLÉMENT DE VITAMINES ET DE MINÉRAUX","",""
"6046","02-12-05","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"6047","02-12-02","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6048","02-11-19","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6049","02-11-12","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6050","02-11-12","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6051","02-11-05","A&L LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"6052","02-11-04","BIONICHE ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6053","02-10-31","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6054","02-10-28","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL, ANTIMYCOTIC","ANTIBACTÉRIEN, ANTIMYCOTIQUE","",""
"6055","02-10-28","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR ADDITIONAL EFFICACY CLAIMS AGAINST ROUNDWORM INFECTIONS (TOXOCARA CANIS) AND TICK INFESTATIONS (RHIPICEPHALUS SANGUINEUS, DERMACENTOR VARIABILIS) IN DOGS, AND FLEA LARVAE (CTENOCEPHALIDES CANIS, C. FELIS) IN THE IMMEDIATE ENVIRONMENT OF THE INTENDED SPECIES","POUR AJOUTER CERTAINES INDICATIONS RELATIVES AUX INFECTIONS D'ASCARIDES (TOXOCARA CANIS) ET AUX INFESTATIONS DE TIQUES (RHIPICEPHALUS SANGUINEUS, DERMACENTOR VARIABILIS) CHEZ LE CHIEN AINSI QU'AUX LARVES DE PUCES (CTENOCEPHALIDES CANIS, C. FELIS) PRÉSENTES DANS L'ENVIRONNEMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6056","02-10-28","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR ADDITIONAL EFFICACY CLAIMS AGAINST ROUNDWORM INFECTIONS (TOXOCARA CANIS) AND TICK INFESTATIONS (RHIPICEPHALUS SANGUINEUS, DERMACENTOR VARIABILIS) IN DOGS, AND FLEA LARVAE (CTENOCEPHALIDES CANIS, C. FELIS) IN THE IMMEDIATE ENVIRONMENT OF THE INTENDED SPECIES","POUR AJOUTER CERTAINES INDICATIONS RELATIVES AUX INFECTIONS D'ASCARIDES (TOXOCARA CANIS) ET AUX INFESTATIONS DE TIQUES (RHIPICEPHALUS SANGUINEUS, DERMACENTOR VARIABILIS) CHEZ LE CHIEN, AINSI QU'AUX LARVES DE PUCES (CTENOCEPHALIDES CANIS, C. FELIS) PRÉSENTES DANS L'ENVIRONNEMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6057","02-10-28","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR ADDITIONAL EFFICACY CLAIMS AGAINST ROUNDWORM INFECTIONS (TOXOCARA CANIS) AND TICK INFESTATIONS (RHIPICEPHALUS SANGUINEUS, DERMACENTOR VARIABILIS) IN DOGS, AND FLEA LARVAE (CTENOCEPHALIDES CANIS, C. FELIS) IN THE IMMEDIATE ENVIRONMENT OF THE INTENDED SPECIES","POUR AJOUTER CERTAINES INDICATIONS RELATIVES AUX INFECTIONS D'ASCARIDES (TOXOCARA CANIS) ET AUX INFESTATIONS DE TIQUES (RHIPICEPHALUS SANGUINEUS, DERMACENTOR VARIABILIS) CHEZ LE CHIEN, AINSI QU'AUX LARVES DE PUCES (CTENOCEPHALIDES CANIS, C. FELIS) PRÉSENTES DANS L'ENVIRONNEMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6058","02-10-28","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL EFFICACY CLAIM AGAINST FLEA LARVAE (CTENOCEPHALIDES CANIS, C. FELIS) IN THE IMMEDIATE ENVIRONMENT OF THE INTENDED SPECIES (CATS)","POUR AJOUTER UNE INDICATION RELATIVE AUX LARVES DE PUCES (CTENOCEPHALIDES CANIS, C. FELIS) PRÉSENTES DANS L'ENVIRONNEMENT DES CHATS","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6059","02-10-28","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR ADDITIONAL EFFICACY CLAIMS AGAINST ROUNDWORM INFECTIONS (TOXOCARA CANIS) AND TICK INFESTATIONS (RHIPICEPHALUS SANGUINEUS, DERMACENTOR VARIABILIS) IN DOGS, AND FLEA LARVAE (CTENOCEPHALIDES CANIS, C. FELIS) IN THE IMMEDIATE ENVIRONMENT OF THE INTENDED SPECIES","POUR AJOUTER CERTAINES INDICATIONS RELATIVES AUX INFECTIONS D'ASCARIDES (TOXOCARA CANIS) ET AUX INFESTATIONS DE TIQUES (RHIPICEPHALUS SANGUINEUS, DERMACENTOR VARIABILIS) CHEZ LE CHIEN, AINSI QU'AUX LARVES DE PUCES (CTENOCEPHALIDES CANIS, C. FELIS) PRÉSENTES DANS L'ENVIRONNEMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6061","02-10-21","BIONICHE ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6062","02-10-21","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6063","02-10-02","BIONICHE ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SUPEROVULATORY AGENT","AGENT SUPEROVULATOIRE","",""
"6064","02-09-27","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL FEED MANUFACTURER, FEED-RITE, TO PREPARE A MINERAL-VITAMIN MIX MEDICATED WITH BOVATEC MEDICATED PREMIX","POUR PRÉVOIR UN CONSTRUCTEUR CANADIEN SUPPLÉMENTAIRE D'ALIMENTATION, FEED-RITE, POUR PRÉPARER UN MÉLANGE DE MINÉRAL-VITAMINE MÉDICAMENTÉ AVEC LE PRÉMÉLANGE MÉDICAMENTÉ DE BOVATEC","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6065","02-09-16","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"6066","02-09-16","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"6067","02-09-16","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"6068","02-09-11","WESTFALIA-SURGE, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"6069","02-08-08","PHIBRO ANIMAL HEALTH LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE CONCURRENT OF POSISTAC 6% PREMIX WITH MGA 100 PREMIX IN FEEDLOT HEIFERS FOR IMPROVED GROWTH RATE AND FEED EFFICIENCY, AND AS AN AID IN SUPPRESSION OF ESTRUS IN HEIFERS BEING FED FOR SLAUGHTER","POUR PRÉVOIR L'UTILISATION SIMULTANÉE DE POSISTAC PRÉMÉLANGE À 6% AVEC MGA 100 PRÉMÉLANGE DANS LES GÉNISSES EN PARC D'ENGRAISSEMENT POUR AVOIR UN TAUX DE CROISSANCE AMÉLIORÉ ET PLUS L'EFFICACITÉ DANS L'ALIMENTATION, ET AUSSI COMME UNE AIDE DANS L'OESTRUS DANS DES GÉNISSES ÉTANT ALIMENTÉES POUR L'ABBATAGE","ANTIBIOTIC, GROWTH PROMOTANT","ANTIBIOTIQUE, PROMOTANT DE CROISSANCE","",""
"6070","02-07-30","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-BLOAT SURFACTANT","SURFACTANT CONTRE LE BALLONNEMENT","",""
"6071","02-07-24","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM: FOR THE TREATMENT OF CHRONIC SUPERFICIAL KERATITIS (CSK) IN DOGS","INDICATION ADDITIONNELLE : POUR LE TRAITEMENT DE LA KÉRATITE SUPERFICIELLE CHRONIQUE (CSK) CHEZ LE CHIEN","LACRIMOMIMETIC-ANTI-INFLAMMATORY","LACRIMOMIMÉTIQUE-ANTI-INFLAMMATOIRE","",""
"6072","02-07-24","BIO AGRI MIX 1998 INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW CLAIMS/SPECIES: FOR THE TREATMENT OF INFECTIONS IN SWINE CAUSED BY PENICILLIN SUSCEPTIBLE STREPTOCOCCUS SUIS","NOUVELLE ALLÉGATION/ESPÈCE : POUR LE TRAITEMENT D'INFECTIONS CAUSÉES PAR STREPTOCOCCUS SUIS SENSIBLE À LA PÉNICILLINE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6073","02-07-24","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","PROMOTANT DE CROISSANCE","",""
"6074","02-07-22","PHIBRO ANIMAL HEALTH LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO ALLOW THE CONCURRENT USE OF AVIAX 5% PREMIX (SEMDURAMICIN 25 PPM) AND STAFAC (VIRGINIAMYCIN 11 PPM) IN MEDICATED FEEDS INTENDED FOR BROILER CHICKENS","POUR PERMETTRE L'ADMINISTRATION DE AVIAX 5% PREMIX (SEMDURAMICIN 25 PPM) ET DE STAFAC (VIRGINIAMYCIN 11 PPM) DANS LES MOULÉES MÉDICAMENTEUSES DESTINÉES AUX POULETS DE GRIL","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6075","96-01-30","CLINTEC NUTRITION COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH, NEW PACKAGING","MONOGRAPHIE RÉVISÉE, NOUVEL EMBALLAGE","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"6076","96-01-30","CLINTEC NUTRITION COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH, NEW PACKAGING","MONOGRAPHIE RÉVISÉE, NOUVEL EMBALLAGE","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"6077","02-07-22","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6078","02-07-17","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6079","02-07-08","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6080","02-07-05","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: TREATMENT OF BOVINE INTERDIGITAL PHLEGMON (FOOT ROT, INTERDIGITAL NECROBACILLOSIS, INFECTIOUS PODODERMATITIS) ASSOCIATED WITH FUSOBACTERIUM NECROPHORUM AND BACTEROIDES MELANINOGENICUS","NOUVELLE INDICATION : TRAITEMENT DU PHLEGMON DE L'ESPACE INTERDIGITÉ (PIÉTIN, PANARIS INTERDIGITÉ AIGU, PODODERMATITE INFECTIEUSE) ASSOCIÉ À FUSOBACTERIUM NECROPHORUM ET BACTEROIDES MELANINOGENICUS","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6081","02-07-05","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: TREATMENT OF INFECTIOUS BOVINE KERATOCONJUNCTIVITIS (IBK, PINKEYE) CAUSED BY MORAXELLA BOVIS","NOUVELLE INDICATION : TRAITEMENT DE LA KÉRATO-CONJONCTIVITE INFECTIEUSE DES BOVINS (KÉRATITE CONTAGIEUSE DES BOVINS OU KÉRATITE D'ÉTÉ DES BOVINS) ASSOCIÉE À MORAXELLA BOVIS","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6082","02-06-25","BIO AGRI MIX 1998 INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW ZERO-DAY WITHDRAWAL TIME WHEN FED TO SWINE AT 110 MG TYLOSIN PER KG OF COMPLETE FEED (IN THE ABSENCE OF CONCURRENT TYLOSIN USE IN DRINKING WATER)","NOUVELLE PÉRIODE DE RETRAIT DE ZÉRO JOUR QUAND ADMINISTRÉ À RAISON DE 110 MG DE TYLOSINE PAR KG D'ALIMENT COMPLET (EN L'ABSENCE DE TRAITEMENT CONCOMITANT À LA TYLOSINE DANS L'EAU DE BOISSON)","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6083","02-06-25","BIO AGRI MIX 1998 INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW ZERO-DAY WITHDRAWAL TIME WHEN FED TO SWINE AT 110 MG TYLOSIN PER KG OF COMPLETE FEED (IN THE ABSENCE OF CONCURRENT TYLOSIN USE IN DRINKING WATER)","NOUVELLE PÉRIODE DE RETRAIT DE ZÉRO JOUR QUAND ADMINISTRÉ À RAISON DE 110 MG DE TYLOSINE PAR KG D'ALIMENT COMPLET (EN L'ABSENCE DE TRAITEMENT CONCOMITANT À LA TYLOSINE DANS L'EAU DE BOISSON)","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6084","02-06-20","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6085","02-06-21","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGES IN MANUFACTURING","MODIFICATIONS DE LA FABRICATION","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6086","02-06-21","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGES IN MANUFACTURING","MODIFICATIONS DE LA FABRICATION","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6087","02-06-05","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6088","02-06-04","ALSTOE LTD ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HAEMATINIC","HÉMATINIQUE","",""
"6089","02-06-03","PHARMACIA ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF THE ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6090","02-05-30","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE. ANTIPYRÉTIQUE","",""
"6091","02-05-30","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE. ANTIPYRÉTIQUE","",""
"6092","02-05-30","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6093","02-05-30","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6094","02-05-30","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6095","02-05-22","BIO AGRI MIX 1998 INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES: CATTLE","ESPÈCE ADDITIONELLE : BOVINS","IONOPHORE ANTIBIOTIC","ANTIBIOTIQUE IONOPHORE","",""
"6096","02-05-21","IVY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT AND ANTIBACTERIAL","AUGMENTE LE GAIN PONDÉRAL ET ANTIBACTÉRIEN","",""
"6097","02-05-21","IVY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT AND ANTIBACTERIAL","AUGMENTE LE GAIN PONDÉRAL ET ANTIBACTÉRIEN","",""
"6098","02-05-21","IVY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT AND ANTIBACTERIAL","AUGMENTE LE GAIN PONDÉRAL ET ANTIBACTÉRIEN","",""
"6099","02-05-21","IVY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT AND ANTIBACTERIAL","AUGMENT LE GAIN PONDÉRAL ET ANTIBACTÉRIEN","",""
"6100","02-05-21","IVY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT AND ANTIBACTERIAL","AUGMENTE LE GAIN PONDÉRAL ET ANTIBACTÉRIEN","",""
"6101","02-05-14","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL FEED MANUFACTURER, TO PREPARE A MINERAL-VITAMIN MIX MEDICATED WITH BOVATEC MEDICATED PREMIX","POUR PRÉVOIR UN CONSTRUCTEUR SUPPLÉMENTAIRE D'ALIMENTATION, POUR PRÉPARER UN MÉLANGE DE MINÉRAL-VITAMINE MÉDICAMENTÉ AVEC LE PRÉMÉLANGE MÉDICAMENTÉ DE BOVATEC","IONOPHORE ANTIBIOTIC","ANTIBIOTIQUE IONOPHORE","",""
"6102","02-05-13","MOORE-CLARK","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6103","02-05-03","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE APPROVAL OF A NEW DOSAGE REGIMEN (4.4MG/KG OF BODY WEIGHT ONCE DAILY) FOR THE RELIEF OF PAIN AND INFLAMMATION ASSOCIATED WITH OSTEOARTHRITIS IN DOGS","DANS LE BUT D'OBTENIR L'APPROBATION D'UNE NOUVELLE POSOLOGIE (4,4MG PAR KG DE POIDS CORPOREL UNE FOIS PAR JOUR) POUR LE SOULAGEMENT DE LA DOULEUR ET DE L'INFLAMMATION ASSOCIÉE À L'ARTHROSE CHEZ LE CHIEN","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"6104","02-05-03","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE APPROVAL OF A NEW DOSAGE REGIMEN (4.4MG/KG OF BODY WEIGHT ONCE DAILY) FOR THE RELIEF OF PAIN AND INFLAMMATION ASSOCIATED WITH OSTEOARTHRITIS IN DOGS","DANS LE BUT D'OBTENIR L'APPROBATION D'UNE NOUVELLE POSOLOGIE (4,4MG PAR KG DE POIDS CORPOREL UNE FOIS PAR JOUR) POUR LE SOULAGEMENT DE LA DOULEUR ET DE L'INFLAMMATION ASSOCIÉE À L'ARTHROSE CHEZ LE CHIEN","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"6105","02-05-03","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE APPROVAL OF A NEW DOSAGE REGIMEN (4.4MG/KG OF BODY WEIGHT ONCE DAILY) FOR THE RELIEF OF PAIN AND INFLAMMATION ASSOCIATED WITH OSTEOARTHRITIS IN DOGS","DANS LE BUT D'OBTENIR L'APPROBATION D'UNE NOUVELLE POSOLOGIE (4,4MG PAR KG DE POIDS CORPOREL UNE FOIS PAR JOUR) POUR LE SOULAGEMENT DE LA DOULEUR ET DE L'INFLAMMATION ASSOCIÉE À L'ARTHROSE CHEZ LE CHIEN","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"6106","96-12-04","VETOQUINOL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOCALCAEMIC CONDITIONS","TRAITEMENT DES CONDITIONS HYPOCALCÉMIQUES","",""
"6107","02-05-02","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6108","02-05-02","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6109","02-05-01","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6110","02-05-01","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6111","02-05-01","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6112","02-04-29","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","FOR THE TREATMENT OF GINGIVITIS ASSOCIATED WITH PERIODONTAL INFECTIONS IN DOGS","POUR LE TRAITEMENT DE LA GINGIVITE ASSOCIÉE AUX INFECTIONS PÉRIODONTIQUES","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6113","02-04-23","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6114","02-04-23","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6115","02-04-23","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6116","02-04-23","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6117","02-04-23","VETOQUINOL N.-A. INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES: CATS","ESPÈCE ADDITIONNELLE : CHATS","ANALGESIC, ANTIPYRETIC, NON-STEROIDAL ANTI-INFLAMMATORY","ANALGÉSIQUE, ANTIPYRÉTIQUE, ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"6118","02-04-17","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTITUSSIVE","ANTITUSSIF","",""
"6119","02-04-17","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTITUSSIVE","ANTITUSSIF","",""
"6120","02-04-17","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTITUSSIVE","ANTITUSSIF","",""
"6121","02-04-17","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIMS: FOR THE TREATMENT OF PARASITIC INFECTIONS CAUSED BY THE ADULT STAGE OF STRONGYLOIDES PAPILLOSUS AND TRICHOSTRONGYLUS LONGISPICULARIS IN CATTLE","ALLÉGATIONS SUPPLÉMENTAIRES : POUR LE TRAITEMENT DES INFECTIONS PARASITAIRES ATTRIBUABLES À LA FORME ADULTE DE STRONGYLOIDES PAPILLOSUS ET DE TRICHOSTRONGYLUS LONGISPICULARIS CHEZ LES BOVINS","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6122","02-04-10","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6123","02-04-04","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR ADDITIONAL EFFICACY CLAIMS AGAINST CERTAIN LARGE STRONGYLES (GENERA: CRATEROSTOMUN AND TRIODONTOPHORUS) AND SMALL STRONGYLES (GENERA: CORONOCYCLUS, PARAPOTERIOSTOMUM AND POTERIOSTOMUN) IN HORSES","POUR AJOUTER CERTAINES INDICATIONS RELATIVES AUX GRANDS STRONGLES (GENRES : CRATEROSTOMUN ET TRIODONTOPHORUS) ET AUX PETITS STRONGLES (GENRES : CORONOCYCLUS, PARAPOTERIOSTOMUM ET POTERIOSTOMUN) CHEZ LES CHEVAUX","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6124","02-03-01","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION, CHANGE(S) IN MANUFACTURING","MODIFICATION DE LA COMPOSITION, MODIFICATION(S) DE LA FABRICATION","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6125","02-02-27","PEPTECH ANIMAL HEALTH PTY LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","OVULATORY INDUCTION AGENT","AGENT D'INDUCTION DE L'OVULATION","",""
"6126","02-02-22","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6127","02-02-19","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6128","02-02-19","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6129","02-02-19","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6130","02-02-18","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6131","02-02-18","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6132","02-02-08","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6133","02-01-30","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6134","02-01-22","JANSSEN","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6135","02-01-22","JANSSEN","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6136","02-01-22","JANSSEN","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6137","02-01-22","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT, SUPPRESSION OF ESTRUS","PROMOTEUR DE CROISSANCE, SUPPRESSION DE L'OESTRUS","",""
"6138","02-01-22","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6139","02-01-21","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6140","02-01-18","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6141","02-01-15","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6142","02-01-14","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANAESTHETIC","ANESTHÉSIQUE","",""
"6143","02-01-14","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANAESTHETIC","ANESTHÉSIQUE","",""
"6144","02-01-14","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6145","02-01-09","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6146","02-01-09","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6147","02-01-09","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6148","01-12-05","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROGESTOGEN","PROGESTOGÈNE","",""
"6149","01-11-30","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC ANTI-INFLAMMATORY","ANTIBIOTIQUE ANTI-INFLAMMATOIRE","",""
"6150","01-11-30","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6151","01-11-30","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6152","01-11-30","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6153","01-11-30","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANABOLIC STEROID","STÉROÏDE ANABOLISANT","",""
"6154","01-11-23","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANABOLIC STEROID","STÉROÏDE ANABOLISANT","",""
"6155","01-11-23","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6156","01-11-23","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6157","01-11-23","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"6158","01-11-20","SYNDEL LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC / SEDATIVE","ANESTHÉSIQUE, SÉDATIF","",""
"6159","01-11-20","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6160","01-11-15","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6161","01-11-13","SABEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","DIURETIC, SALURETIC","DIURÉTIQUE, SALIDIURÉTIQUE","",""
"6162","01-11-05","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","FOR THE PREVENTION OF NECROTIC ENTERITIS IN BROILER CHICKENS","POUR LA PRÉVENTION DE L'ENTÉRITE NÉCROTIQUE CHEZ LES POULETS À GRILLER","ANTIBIOTIC, ANTICOCCIDIAL","ANTIBIOTIQUE, ANTICOCCIDIEN","",""
"6163","01-11-05","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TREATMENT OF EQUINE LARVAL CYATHOSTOMOSIS INDUCED BY ENCYSTED LARVAE (THIRD AND FOURTH STAGE) OF CYATHOSTOMES","POUR LE TRAITEMENT DE LA CYATHOSTOMOSE LARVAIRE ÉQUINE CAUSÉE PAR LES LARVES ENKYSTÉES (DU TROISIÈME ET QUATRIÈME STADE) DE CYATHOSTOMES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6164","01-10-24","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"6165","01-10-24","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6166","01-10-22","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6167","01-10-11","NORBROOK LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR SUBCUTANEOUS ADMINISTRATION TO CATTLE","VOIE D'ADMINISTRATION ADDITIONNELLE CHEZ LES BOVINS : SOUS-CUTANÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6168","01-10-09","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6169","05-01-12","CHURCH & DWIGHT CANADA CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"6170","05-01-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CILOXAN","ALCON CANADA INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"6171","05-01-12","DOMINION PHARMACAL","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"6172","05-01-12","SANDOZ INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"6173","05-01-12","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6174","05-01-12","PHARMEL INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"6175","05-01-12","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"6176","05-01-12","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"6177","05-01-12","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: THE USE OF TOPAMAX IN ADULTS FOR PROPHYLAXIS OF MIGRAINE HEADACHE IN PATIENTS EXPERIENCING 4 OR MORE MIGRAINES A MONTH WHO FAIL TO RESPOND TO, OR HAVE CONTRA-INDICATIONS TO, AVAILABLE ABORTIVE TREATMENTS","NOUVELLE INDICATION : POUR LE TRAITEMENT DES ADULTES PRÉSENTANT 4 ÉPISODES DE MIGRAINES PAR MOIS OU PLUS ET DONT L'ÉTAT N'EST PAS MAÎTRISÉ DE FAÇON SATISFAISANTE PAR LES TRAITEMENTS ABORTIFS DISPONIBLES OU ENCORE DONT L'ÉTAT EST CONTRE-INDIQUÉ À CES TRAITEMENTS ABORTIFS","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"6178","01-10-09","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6179","01-10-09","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6180","01-10-09","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6181","01-10-09","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6182","01-10-04","PHARMACIA & UPJOHN ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES: CATTLE. FOR INTRAMUSCULAR OR SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF BOVINE RESPIRATORY DISEASE (BRD, SHIPPING FEVER, PNEUMONIA) ASSOCIATED WITH PASTEURELLA HAEMOLYTICA, P. MULTOCIDA AND HAEMOPHILUS SOMNUS AND ACUTE BOVINE INTERDIGITAL NECROBACILLOSIS (FOOT ROT, PODODERMATITIS) ASSOCIATED WITH FUSOBACTERIUM NECROPHORUM AND BACTEROIDES MELANINOGENICUS","ESPÈCE ADDITIONNELLE : BOVINS.  POUR ADMINISTRATION INTRAMUSCULAIRE OU SOUS-CUTANÉE POUR LE TRAITEMENT DES MALADIES RESPIRATOIRES BOVINES (FIÈVRE DES TRANSPORTS, PNEUMONIE) ASSOCIÉES À PASTEURELLA HAEMOLYTICA, P. MULTOCIDA ET HAEMOPHILUS SOMNUS ET POUR LE TRAITEMENT DE LA NÉCROBACILLOSE INTERDIGITÉE (PIÉTIN, PODODERMATITE) ASSOCIÉE À FUSOBACTERIUM NECROPHORUM ET BACTEROIDES MELANINOGENICUS","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6183","01-10-04","IVY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTER","PROMOTEUR DE CROISSANCE","",""
"6184","01-10-01","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6185","01-10-01","PHARMACIA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6186","01-09-25","LEO VET, DIVISION OF/DE LEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC, ANTI-INFLAMMATORY","ANTIBIOTIQUE, ANTI-INFLAMMATOIRE","",""
"6187","01-09-25","ABBOTT LABORATORIES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC","ANESTHÉSIQUE","",""
"6188","01-09-19","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE USE OF THIS PRODUCT IN A THIXOTROPE LIQUID SUPPLEMENT MANUFACTURED BY PROMOLAS, DIV. TATE & LYLE N.A. SUGARS LTD.","FAIRE APPROUVER L'USAGE DE CE PRODUIT SOUS FORME DE SUPPLÉMENT LIQUIDE THIXOTROPE FABRIQUÉ PAR PROMOLAS, DIV. TATE & LYLE N.A. SUGARS LTD.","ANTICOCCIDIAL, GROWTH PROMOTANT","ANTICOCCIDIEN, AUGMENTE LE GAIN PONDÉRAL","",""
"6189","01-09-19","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE USE OF THIS PRODUCT IN A THIXOTROPE LIQUID SUPPLEMENT MANUFACTURED BY HCS, NUTRENA FEEDS, CARGILL LTD. AND BY PROMOLAS, DIV. OF TATE & LYLE N.A. SUGARS LTD.","FAIRE APPROUVER L'USAGE DE CE PRODUIT SOUS FORME DE SUPPLÉMENT LIQUIDE THIXOTROPE FABRIQUÉ PAR HCS, NUTRENA FEEDS, CARGILL LTD. ET PAR PROMOLAS, DIV. DE TATE & LYLE N.A. SUGARS LTD.","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6190","01-09-19","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE USE OF THIS PRODUCT IN A THIXOTROPE LIQUID SUPPLEMENT MANUFACTURED BY HCS, NUTRENA FEEDS, CARGILL LTD. AND BY PROMOLAS, DIV. OF TATE & LYLE N.A. SUGARS LTD.","FAIRE APPROUVER L'USAGE DE CE PRODUIT SOUS FORME DE SUPPLÉMENT LIQUIDE THIXOTROPE FABRIQUÉ PAR BY HCS, NUTRENA FEEDS, CARGILL LTD. ET PAR PROMOLAS, DIV. DE TATE & LYLE N.A. SUGARS LTD.","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6191","01-08-02","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTITUSSIVE","ANTITUSSIF","",""
"6192","01-08-02","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTITUSSIVE","ANTITUSSIF","",""
"6193","01-08-02","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTITUSSIVE","ANTITUSSIF","",""
"6194","01-08-02","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL CANADIAN FEED MANUFACTURER, CONCENTRÉS SCIENTIFIQUES BELISLE INC., TO PREPARE PK100012GS MINERAL - PATURAGE BOVATEC PASTURE MINERAL, A MINERAL-VITAMIN MIX MEDICATED WITH BOVATEC MEDICATED PREMIX","POUR PRÉVOIR UN CONSTRUCTEUR CANADIEN SUPPLÉMENTAIRE D'ALIMENTATION, CONCENTRÉS SCIENTIFIQUES BELISLE INC., POUR PRÉPARER PK100012GS MINERAL - PATURAGE BOVATEC PASTURE MINERAL, UN MÉLANGE DE MINÉRAL-VITAMINE MÉDICAMENTÉ AVEC LE PRÉMÉLANGE MÉDICAMENTÉ DE BOVATEC","IONOPHORE ANTIBIOTIC","ANTIBIOTIQUE IONOPHORE","",""
"6195","01-07-17","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"6196","01-07-16","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL, GROWTH PROMOTANT","ANTIBACTÉRIEN, AUGMENTE LE GAIN PONDÉRAL","",""
"6197","01-07-16","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL, GROWTH PROMOTANT","ANTIBACTÉRIEN, AUGMENTE LE GAIN PONDÉRAL","",""
"6198","01-07-16","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTHIC","ANTHELMINTHIQUE","",""
"6199","01-06-29","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"6200","01-06-29","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","DIURETIC","DIURÉTIQUE","",""
"6201","01-06-13","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SYNTHETIC PROGESTIN (HORMONE)","PROGESTIF SYNTHÉTIQUE (HORMONE)","",""
"6202","01-05-24","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6203","01-05-24","CAN-VET ANIMAL HEALTH SUPPLIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTIQUE","",""
"6204","05-01-17","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTIDIABÉTIQUE AGENT","AGENT ANTIDIABÉTIQUE","",""
"6205","05-01-17","IMMUNOMEDICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"6206","05-01-19","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVENOUS NUTRIENT SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"6207","05-01-19","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"6208","05-01-19","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER","NOUVELLE INDICATION : TRAITEMENT DU TROUBLE DYSPHORIQUE PRÉMENSTRUEL","SELECTIVE SEROTONIN REUPTAKE INHIBITOR","INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA SÉROTONINE","",""
"6209","05-01-21","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIATE AGONIST/ANTAGONIST: FOR SUBSTITUTION TREATMENT IN OPIOID DRUG DEPENDENCE IN ADULTS THROUGH SUBUTEX NATIONAL EDUCATION PROGRAM","AGONISTE/ANTAGONISTE DES OPIACÉS : POUR TRAITEMENT DE SUBSTITUTION DANS LES CAS DE DÉPENDANCES AUX OPIACÉS CHEZ L'ADULTE PAR L'ENTREMISE DU PROGRAMME D'ÉDUCATION NATIONALE SUR LE SUBUTEX","",""
"6210","05-01-19","BAUSCH & LOMB INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"6211","05-01-17","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6212","05-01-17","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASIRAIRE","",""
"6213","05-01-17","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6214","05-01-17","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6215","05-01-17","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6216","05-01-17","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6217","05-01-27","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITION OF DOSING FOR ADULT PATIENTS","AJOUT DE DOSAGE CHEZ L'ADULTE","GROWTH HORMONE","HORMONE DE CROISSANCE","",""
"6218","05-01-27","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","HIGHER DOSE FOR PUBERTAL PATIENTS","DOSAGE PLUS ÉLEVÉ POUR LES SUJETS PUBERTAIRES","GROWTH HORMONE","HORMONE DE CROISSANCE","",""
"6219","05-01-27","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DOSING REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE DE L'ÉRYTHROPOÏÈSE","",""
"6220","05-01-26","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NOTICE OF COMPLIANCE TO REPLACE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON FEBRUARY 16, 1999 FOR ACUTE ISCHEMIC STROKE","AVIS DE CONFORMITÉ POUR REMPLACER L'AVIS DE CONFORMITÉ CONDITIONNEL ÉMIS LE 16 FÉVRIER 1999 POUR LE TRAITEMENT DE L'ACCIDENT ISCHÉMIQUE CÉRÉBRAL AIGU","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"6221","05-01-27","JANSSEN-ORTHO INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"6222","05-01-27","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH RE: USE IN CHILDREN 4 TO 12 YEARS OF AGE","MISES À JOUR À LA MONOGRAPHIE DU PRODUIT RELATIVEMENT À L'USAGE CHEZ LES ENFANTS ÂGÉS DE 4 À 12 ANS","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"6223","05-01-27","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE DE L'ÉRYTHROPOÏÈSE","",""
"6224","05-01-28","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVOCHOLINE","METHAPHARM INC.","CANADA","CANADA","1","","","CHOLINERGIC, DIAGNOSTIC AID (BRONCHIAL ASTHMA)","CHOLINERGIQUE, AUXILIAIRE DIAGNOSTIQUE (ASTHME BRONCHIQUE)","",""
"6225","05-01-25","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXY-IR","PURDUE PHARMA INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"6226","05-02-03","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"6227","05-02-04","PENDOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC AGENT, PLATELET AGGREGATION INHIBITOR","ANTI-INFLAMMATOIRE NON STÉROÏDIEN, ANALGÉSIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"6228","05-02-04","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"6229","05-01-31","GUERBET","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NONIONIC CONTRAST AGENT","AGENT DE CONTRASTE NON IONIQUE","",""
"6230","01-05-09","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6231","01-05-07","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISIONS TO THE LABELLING RELATED TO MIXING DIRECTIONS FOR USE","RÉVISIONS À L'ÉTIQUETTAGE RELIÉES AUX DIRECTIVES DE MÉLANGE","ANTICOCCIDIAL, GROWTH PROMOTANT","ANTICOCCIDIEN, AUGMENTE LE GAIN PONDÉRAL","",""
"6232","01-04-20","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE NONSTÉROÏDIEN, ANALGÉSIQUE","",""
"6233","01-04-12","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6234","05-02-10","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ELOCOM OINTMENT 0.1%","SCHERING CANADA INC.","CANADA","CANADA","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"6235","05-02-11","PENDOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"6236","05-02-07","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CANESTEN 3 VAGINAL TABLET COMBI-PAK","MODIFICATION DU NOM DU PRODUIT DE CANESTEN 3 VAGINAL TABLET COMBI-PAK","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"6237","05-02-07","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CANESTEN 1 VAGINAL TABLET COMBI-PAK","MODIFICATION DU NOM DU PRODUIT DE CANESTEN 1 VAGINAL TABLET COMBI-PAK","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"6238","05-02-07","ZLB BEHRING LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BLOOD COAGULATION PRODUCT","FACTEUR DE COAGULATION SANGUIN","",""
"6239","01-04-02","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC, GROWTH PROMOTANT","ANTIBIOTIQUE, AUGMENTE LE GAIN PONDÉRAL","",""
"6240","01-04-02","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC, GROWTH PROMOTANT","ANTIBIOTIQUE, AUGMENTE LE GAIN PONDÉRAL","",""
"6241","01-04-02","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC, GROWTH PROMOTANT","ANTIBIOTIQUE, AUGMENTE LE GAIN PONDÉRAL","",""
"6242","01-04-02","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6243","01-04-02","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6244","01-04-02","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"6245","01-04-02","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6246","01-03-27","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TREATMENT OF EQUINE LARVAL CYATHOSTOMOSIS INDUCED BY ENCYSTED LARVAE (THIRD AND FOURTH STAGE) OF CYATHOSTOMES","POUR LE TRAITEMENT DE LA CYATHOSTOMOSE LARVAIRE ÉQUINE CAUSÉE PAR LES LARVES ENKYSTÉES (DU TROISIÈME ET QUATRIÈME STADE) DE CYATHOSTOMES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6247","01-03-27","CHANELLE PHARMACEUTICALS MANUFACTURING LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE ANALGESIC","SÉDATIF ANALGÉSIQUE","",""
"6248","01-03-09","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6249","01-03-05","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE NONSTÉROÏDIEN, ANALGÉSIQUE","",""
"6250","01-03-05","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE NONSTÉROÏDIEN, ANALGÉSIQUE","",""
"6251","01-03-05","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE NONSTÉROÏDIEN, ANALGÉSIQUE","",""
"6252","01-03-05","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE NONSTÉROÏDIEN, ANALGÉSIQUE","",""
"6253","01-02-16","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6254","01-02-16","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6255","01-02-01","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6256","01-01-22","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6257","00-12-29","ECOLAB CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"6258","00-12-29","BIO AGRI MIX 1998 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ABTICOCCIDIAL","ANTICOCCIDIEN","",""
"6259","00-12-29","ECOLAB CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"6260","00-11-16","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6261","00-10-31","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6262","00-10-31","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6263","96-08-14","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY CORTICOSTEROID","CORTICOSTÉROÏDE ANTI-INFLAMMATOIRE","",""
"6264","96-08-16","SCHERING-PLOUGH ANIMAL HEALTH DIVISION OF SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE, CHANGE IN PACKAGING, NEW EXPIRATION DATE","NOUVEL EMPLACEMENT DE FABRICATION, NOUVEL EMBALLAGE, NOUVELLE DATE LIMITE D'UTILISATION","ANTIBIOTIC","ANITIBIOTIQUE","",""
"6265","00-10-13","PEPTECH ANIMAL HEALTH PTY LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN EXPIRY DATE AND CHANGE IN SPECIFICATIONS","CHANGEMENT DE LA DATE LIMITE ET CHANGEMENT DE SPÉCIFICATION","OVULATORY INDUCTION AGENT","INDUCTEUR DE L'OVULATION","",""
"6266","00-10-13","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"6267","00-10-13","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANABOLIC STEROID","STÉROÏDE ANABOLISANT","",""
"6268","00-10-13","CHEMINEX ANIMAL HEALTH, A DIVISION OF PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"6269","00-10-13","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","IONOPHORE ANTIBIOTIC","ANTIBIOTIQUE IONOPHORE","",""
"6270","00-10-13","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6271","00-10-04","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6272","00-10-04","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6273","00-09-28","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6274","00-09-28","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6275","00-09-28","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"6276","00-09-28","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6277","00-09-21","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6278","00-09-12","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6279","00-09-12","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"6280","05-02-16","ZLB BEHRING GMBH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"6281","05-02-16","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION: PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE (CHD)","NOUVELLE INDICATION : PATIENTS PÉDIATRIQUES AVEC MALADIES CARDIAQUES CONGÉNITALES","PASSIVE IMMUNIZING AGENT (HUMANIZED MONOCLONAL ANTIBODY)","AGENT D'IMMUNISATION PASSIVE (ANTICORPS MONOCLONAL HUMANISÉ)","",""
"6282","05-02-17","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6283","05-02-14","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE","",""
"6284","05-02-15","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","VITAMIN AND MINERAL SUPPLEMENT","SUPPLÉMENT DE VITAMINE ET DE MINÉRAL","",""
"6285","05-02-14","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","THYROID HORMONE","HORMONE THYROÏDIENNE","",""
"6286","05-02-18","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"6287","05-02-14","IVAX PHARMACEUTICALS INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMBIVENT","BOEHRINGER INGELHEIM LTD.","CANADA","CANADA","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"6288","05-02-14","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN FOR ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS","NOUVELLE POSOLOGIE POUR LE TRAITEMENT DE L'EXACERBATION BACTÉRIENNE DE LA BRONCHITE CHRONIQUE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"6289","05-02-18","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PHARMACOKINETIC DATA","AJOUT DE DONNÉES PHARMACOCINÉTIQUES","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"6290","05-02-18","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"6291","05-02-25","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"6292","05-02-22","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR (ANTI-HYPERCALCEMIC AGENT)","RÉGULATEUR DU MÉTABOLISME OSSEUX (AGENT ANTIHYPERCALCÉMIQUE)","",""
"6293","05-02-22","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT PHARMA INC.","CANADA","CANADA","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"6294","05-02-22","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"6295","00-08-15","SCHEIN PHARMACEUTICAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM STERILE CEFUROXIME SODIUM USP","MODIFICATION DU NOM DU PRODUIT DE STERILE CEFUROXIME SODIUM USP","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6296","05-03-02","BAKER CUMMINS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO, MERCK FROSST CANADA & CIE","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"6297","05-03-02","BAKER CUMMINS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOWELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"6298","05-03-02","BAKER CUMMINS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"6299","05-03-03","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"6300","05-02-28","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOVENOX","AVENTIS PHARMA INC.","CANADA","CANADA","0","","","ANTICOAGULANT, ANTITHROMBOTIC AGENT","ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"6301","05-03-02","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE OF REPAGLINIDE IN COMBINATION WITH ROSIGLITAZONE","NOUVELLE INDICATION: USAGE COMBINÉ DU RÉPAGLINIDE ET DE LA ROSIGLITAZONE","ORAL ANTIDIABETIC AGENT","ANTIDIABÉTIQUE ORAL","",""
"6302","05-02-28","PALADIN LABS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","ESTROGEN SUPPLEMENT","OESTROGÈNE","",""
"6303","05-02-28","JOHNSON & JOHNSON INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","COMEDOLYTIC AGENT","AGENT COMÉDOLYTIQUE","",""
"6304","05-03-03","RHOXALPHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEORAL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","ADDITIONAL STRENGTHS","CONCENTRATIONS ADDITIONNELLES","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"6305","05-03-02","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL","ANTIVIRAL","",""
"6306","05-03-02","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL MANUFACTURING SITE FOR THE MEDICINAL INGREDIENT","FABRICANT SUPPLÉMENTAIRE POUR L'INGRÉDIENT MÉDICINAL","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6307","05-03-10","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"6308","05-03-10","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHYROID AGENT","ANTITHYROÏDIEN","",""
"6309","05-03-10","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH FOR PEDIATRIC USE","NOUVELLE CONCENTRATION POUR USAGE PÉDIATRIQUE","ANTIMALARIAL AGENT","ANTIPALUDÉEN","",""
"6310","05-03-10","ORYX PHARMACEUTICALS INC., A SUBSIDIARY OF FILIALE D'ARROW PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"6311","05-03-08","PENDOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE POUR LE TRACTUS GASTRO-INTESTINAL INFÉRIEUR","",""
"6312","05-03-10","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHYROID AGENT","ANTITHYROÏDIEN","",""
"6313","05-03-10","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"6314","05-03-04","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF 5 MG DOSAGE AND UPDATED SAFETY INFORMATION","ADDITION DE LA DOSE DE 5 MG ET MISE À JOUR DE L'INFORMATION CONCERNANT LA NOCIVITÉ","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"6315","05-03-10","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"6316","05-03-10","PERRIGO INTERNATIONAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL EXTRA STRENGTH CAPLETS","WHITEHALL-ROBINS INC.","CANADA","CANADA","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"6317","05-03-07","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"6318","05-03-07","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"6319","99-03-02","GLAXO WELLCOME INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH, REVISED DOSAGE REGIMEN","NOUVELLE CONCENTRATION, SCHÉMA POSOLOGIQUE RÉVISÉ","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"6320","05-03-07","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"6321","05-03-07","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6322","05-03-07","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6323","05-03-07","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6324","05-03-10","PENDOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"6325","96-11-28","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6326","05-03-15","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"6327","05-03-15","BAXTER CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEVORANE AF","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"6328","05-03-15","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH RELATED TO DOSAGE ADJUSTMENT FOR PATIENTS WITH SEVERE RENAL IMPAIRMENT","LES RÉVISIONS DE LA MONOGRAPHIE DE PRODUIT QUI SONT RELIÉES À L'AJUSTEMENT DE LA DOSE POUR LES PATIENTS AYANT UNE INSUFFISANCE RÉNALE SÉVÈRE","ANTICOAGULANT, ANTITHROMBOTIC AGENT","ANTICOAGULANT, ANTITHROMBOTIQUE","",""
"6329","96-10-25","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PRESENTATIONS","NOUVELLES PRÉSENTATIONS","ANTI-DIABETIC AGENT","ANTIDIABÉTIQUE","",""
"6330","96-07-23","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6331","96-08-06","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INOTROPIC","INOTROPIQUE","",""
"6332","96-07-15","SANOFI WINTHROP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INOTROPIC","INOTROPIQUE","",""
"6333","96-12-09","CIBA-GEIGY CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6334","96-12-09","CIBA-GEIGY CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6335","96-12-09","CIBA-GEIGY CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6336","96-12-09","CIBA-GEIGY CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6337","96-11-13","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6338","96-09-17","CIBA-GEIGY CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6339","96-09-17","CIBA-GEIGY CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6340","96-09-17","CIBA-GEIGY CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6341","96-09-17","CIBA-GEIGY CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6342","96-09-04","THE UPJOHN COMPANY - ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6343","96-09-04","THE UPJOHN COMPANY - ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6344","05-03-23","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW CLAIMS: NON-DROWSY, LETS YOU STAY ALERT AND PERFORM NORMALLY, AND CAN BE USED WHILE DRIVING","NOUVELLE RÉCLAMATION : SANS SOMNOLENCE, VOUS PERMET DE RESTER VIGILANT ET DE POURSUIVRE VOS ACTIVITÉS ET PEUT ÊTRE UTILISÉ SI VOUS CONDUISEZ","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1","",""
"6345","05-03-23","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERMAX","DRAXIS HEALTH INC.","CANADA","CANADA","1","","","DOPAMINE AGONIST","AGONISTE DE LA DOPAMINE","",""
"6346","05-03-23","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAVELBINE","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"6347","96-08-07","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6348","96-08-07","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6349","94-05-27","VET A MIX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE ANALGESIC","SÉDATIF ANALGÉSIQUE","",""
"6350","94-06-22","OHMEDA PHARMACEUTICAL PRODUCTS, DIVISION OF BOC CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GAS INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"6351","94-06-06","NORBROOK LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6352","95-01-24","RHÔNE MÉRIEUX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON STEROIDAL ANTIINFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"6353","95-01-24","RHÔNE MÉRIEUX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON STEROIDAL ANTIINFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"6354","95-01-24","RHÔNE MÉRIEUX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"6355","95-01-24","RHÔNE MÉRIEUX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"6356","95-05-19","SYNDEL LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC","ANESTHÉSIQUE","",""
"6357","95-09-14","NORBROOK LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6358","94-01-10","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE ROUTE OF ADMINISTRATION IN CATTLE","VOIE D'ADMINISTRATION ALTERNATIVE CHEZ LES BOVINS","ANTIBIOTIC ANTIBACTERIAL","ANTIBIOTIQUE ANTIBACTÉRIEN","",""
"6359","95-10-20","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE FORMULATION","MODIFICATION DE LA PRÉPARATION","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6360","95-11-03","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6361","94-03-17","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","IONOPHORE ANTIBIOTIC","ANTIBIOTIQUE IONOPHORE","",""
"6362","94-03-25","CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SOURCE OF ACTIVE INGREDIENT","NOUVELLE SOURCE DE PRINCIPE ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6363","94-03-25","CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SOURCE OF ACTIVE INGREDIENT","NOUVELLE SOURCE DE PRINCIPE ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6364","94-03-25","H.B. FULLER COMPANY - MONARCH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TEAT DIP","BAIN DE TRAYON","",""
"6365","94-03-25","CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SOURCE OF ACTIVE INGREDIENT","NOUVELLE SOURCE DE PRINCIPE ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6366","96-01-30","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6367","94-03-25","CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SOURCE OF ACTIVE INGREDIENT","NOUVELLE SOURCE DE PRINCIPE ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6368","94-04-15","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","IONOPHORE ANTIBIOTIC","ANTIBIOTIQUE IONOPHORE","",""
"6369","96-05-16","RHÔNE MÉRIEUX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION, CHANGE IN PACKAGING","MODIFICATION DE LA PRÉPARATION, NOUVEL EMBALLAGE","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"6370","05-03-31","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"6371","05-11-23","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURALITH","JANSSEN-ORTHO INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTI-MANIC AGENT","ANTIMANIAQUE","",""
"6372","05-03-31","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RITALIN SR","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"6373","05-03-31","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMBIVENT UDV","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"6374","05-03-31","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","CANADA","CANADA","1","CHANGE IN MANUFACTURING PROCESS","CHANGEMENT AU PROCÉDÉ DE FABRICATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"6375","05-03-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE: A) NEWLY REPORTED CLINICAL DATA FROM DOUBLE BLIND RANDOMIZED TRIALS, OPEN-LABEL EXTENSION STUDIES TO MONOTHERAPY, COMBINATION WITH METFORMIN AND COMBINATION WITH SULFIONYLUREAS; B) STORAGE CONDITIONS UPDATED TO REFLECT A COMPLETED FREEZE THAW STUDY","MISE À JOUR DE LA MONOGRAPHIE : A) PUBLICATION DE NOUVELLES DONNÉES CLINIQUES PROVENANT D'ESSAIS RANDOMISÉS À DOUBLE INSU, D'ÉTUDES SUBSÉQUENTES AVEC ÉTIQUETAGE EN CLAIR D'UNE MONOTHÉRAPIE, D'UNE ASSOCIATION AVEC LA METFORMINE ET D'UNE ASSOCIATION AVEC LES SULFONYLURÉES; B) CONDITIONS DE CONSERVATION MISES À JOUR POUR TENIR COMPTE DES RÉSULTATS D'UNE ÉTUDE AVEC CONGÉLATION-DÉCONGÉLATION","ANTIDIABETIC AGENT, INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE, AGENT INSULINOSENSIBILISATEUR","",""
"6376","05-03-31","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH WITH INCLUSION OF FOUR YEAR SAFETY DATA","MISE À JOUR DE LA MONOGRAPHIE AVEC INCLUSION DE DONNÉES RELATIVES À L'INNOCUITÉ SUR UNE PÉRIODE DE QUATRE ANS","TYPE I AND II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPES I ET II","",""
"6377","05-03-30","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BLENOXANE","BRISTOL LABORATORIES OF CANADA","CANADA","CANADA","1","","","ANTINEOPLASTIC, ANTIBIOTIC","ANTINÉOPLASIQUE, ANTIBIOTIQUE","",""
"6378","05-03-31","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACCUTANE ROCHE","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","NODULAR/INFLAMMATORY AND CONGLOBATE ACNE THERAPY","TRAITEMENT DE L'ACNÉ NODULAIRE/INFLAMMATOIRE ET DE L'ACNE CONGLOBATA","",""
"6379","05-03-31","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH TO REFLECT THE MOST CURRENT SAFETY INFORMATION, AS PER NEW MEDICAL DATA AND AN APRIL 10, 2003 DEAR HEALTH CARE PROFESSIONAL LETTER AND SAFETY ADVISORY","MISE À JOUR DE LA MONOGRAPHIE POUR TENIR COMPTE DES RENSEIGNEMENTS LES PLUS RÉCENTS SUR L'INNOCUITÉ, COMME L'INDIQUENT LES NOUVELLES DONNÉES MÉDICALES, LA LETTRE DU 10 AVRIL 2003 ADRESSÉE AUX PROFESSIONNELS DE LA SANTÉ ET L'AVIS SUR L'INNOCUITÉ","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"6380","05-04-01","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POST MENOPAUSAL WOMEN WHO HAVE RECEIVED PRIOR STANDARD ADJUVANT TAMOXIFEN THERAPY","NOUVELLE INDICATION : POUR LE TRAITEMENT ADJUVANT PROLONGÉ DU CANCER DU SEIN DÉBUTANT CHEZ LES FEMMES MÉNOPAUSÉES QUI ONT DÉJÀ REÇU UN TRAITEMENT ADJUVANT STANDARD AU TAMOXIFÈNE","NON-STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESIS; ANTITUMOR AGENT","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN, INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES, ANTINÉOPLASIQUE","",""
"6381","05-03-30","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ANECATE INJECTION","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","BENZODIAZEPINE ANTAGONIST","ANTAGONISTE DES BENZODIAZÉPINES","",""
"6382","05-03-31","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"6383","05-03-31","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"6384","05-03-30","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PIPRACIL","WYETH CANADA","CANADA","CANADA","1","NEW STRENGTH AND VIAL SIZE","NOUVELLE CONCENTRATION ET NOUVEAU FORMAT DE FIOLE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6385","05-03-31","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"6386","05-03-31","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION AS MONOTHERAPY FOR THE MANAGEMENT OF ACUTE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER","NOUVELLEMENT INDIQUÉ EN GUISE DE MONOTHÉRAPIE POUR LE TRAITEMENT DES CRISES AIGUËS ASSOCIÉES AU TROUBLE BIPOLAIRE DE TYPE I","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"6387","05-03-31","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN D ANALOG","ANALOGUE DE LA VITAMINE D","",""
"6388","05-03-31","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN - ONCE DAILY","NOUVELLE POSOLOGIE - UNE FOIS PAR JOUR","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"6389","05-03-31","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6390","05-03-31","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6391","05-03-29","SBL VACCIN AB","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING FACILITY","MODIFICATIONS À L'ÉTABLISSEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"6392","05-03-31","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"6393","96-08-29","DEPRENYL ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXPIRY DATE EXTENSION","NOUVELLE DATE LIMITE D'UTILISATION","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'HYPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6394","05-04-08","ASTELLAS PHARMA CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"6395","05-04-08","BAKER CUMMINS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"6396","05-04-08","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"6397","05-04-08","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM - EXTENDED RELEASE CAPSULES","NOUVELLE FORME POSOLOGIQUE - CAPSULES À LIBÉRATION PROLONGÉE","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"6398","05-04-07","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION AS MONOTHERAPY FOR THE MANAGEMENT OF PATIENTS (ADULTS AND CHILDREN SIX YEARS AND OLDER) WITH NEWLY DIAGNOSED EPILEPSY","NOUVELLE INDICATION À TITRE DE MONOTHÉRAPIE DANS LA PRISE EN CHARGE DE PATIENTS (ADULTES ET ENFANTS DE SIX ANS ET PLUS) AYANT REÇU RÉCEMMENT UN DIAGNOSTIC D'ÉPILEPSIE","ANTI-EPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"6399","96-05-31","NORBROOK LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6400","96-08-29","DEPRENYL ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PACKAGING","NOUVEL EMBALLAGE","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'HYPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6401","96-08-29","DEPRENYL ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PACKAGING","NOUVEL EMBALLAGE","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'HYPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6402","96-08-29","DEPRENYL ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'HYPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6403","96-08-29","DEPRENYL ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'YPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6404","96-08-29","DEPRENYL ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PACKAGING","NOUVEL EMBALLAGE","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'YPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6405","96-09-04","WILDLIFE LABORATORIES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","REVERSAL AGENT FOR XYLAZINE","AGENT DE RENVERSEMENT DE LA XYLAZINE","",""
"6406","96-09-18","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANICOCCIDIEN","",""
"6407","96-11-13","DEPRENYL ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'YPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6408","96-11-13","DEPRENYL ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'HYPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6409","96-12-16","JANSSEN","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE EN INHALATION","",""
"6410","97-01-13","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6411","97-01-13","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6412","97-01-13","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6413","97-01-13","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6414","97-02-10","DEPRENYL ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'HYPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6415","97-02-10","DEPRENYL ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'HYPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6416","97-02-10","DEPRENYL ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'HYPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6417","97-02-10","DEPRENYL ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'HYPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6418","97-02-10","DEPRENYL ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","AGENT FOR PITUITARY DEPENDENT HYPERADRENOCORTICISM","TRAITEMENT DE L'HYPERCORTICISME DE DÉPENDANCE PITUITAIRE","",""
"6419","97-02-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6420","97-02-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6421","97-02-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6422","05-04-13","VITA HEALTH PRODUCTS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"6423","05-04-12","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6424","05-04-11","ASTELLAS PHARMA CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"6425","05-04-13","BAKER CUMMINS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"6426","05-04-13","BAKER CUMMINS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","0","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"6427","05-04-11","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET-REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"6428","05-04-11","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"6429","05-04-15","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH - 37.5MG","NOUVELLE CONCENTRATION - 37.5MG","SELECTIVE SEROTONIN REUPTAKE INHIBITOR","INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA SÉROTONINE","",""
"6430","05-04-12","ASTELLAS PHARMA CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"6431","05-04-12","ASTELLAS PHARMA CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL IMMUNOMODULATOR","IMMUNOMODULATEUR TOPIQUE","",""
"6432","05-04-11","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISPOTIN SR","SEARLE CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"6433","05-04-15","GW PHARMA LIMITED","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CANNABINOID ANALGESIC","ANALGÉSIQUE CANNABINOÏDE","",""
"6434","05-04-15","DENTSPLY CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"6435","94-06-07","HOECHST CANADA (1996) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6436","94-08-02","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL MANUFACTURING SITES","EMPLACEMENTS DE FABRICATION SUPPLÉMENTAIRES","IONOPHORE ANTIBIOTIC","ANTIBIOTIQUE IONOPHORE","",""
"6437","94-08-18","H.B. FULLER COMPANY - MONARCH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TEAT SPRAY","VAPORISATEUR DE TRAYON","",""
"6438","94-11-09","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6439","94-12-30","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6440","94-12-30","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6441","94-12-30","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6442","94-12-30","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6443","94-12-30","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6444","94-12-30","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6445","95-02-14","H.B. FULLER COMPANY - MONARCH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TEAT DIP","BAIN DE TRAYON","",""
"6446","95-03-16","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","IONOPHORE ANTIBIOTIC","ANTIBIOTIQUE IONOPHORE","",""
"6447","95-03-28","CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: FOR THE PREVENTION OF NECROTIC ENTERITIS CAUSED BY CLAUSTRIDIUM PERFINGENS","NOUVELLE INDICATION: POUR LA PRÉVENTION D'ENTÉRITE NÉCROSANTE CAUSÉ PAR LE CLOSTRIDIUM PERFINGENS","ANTIBIOTIC, ANTIBACTERIAL","ANTIBIOTIQUE, ANTIBACTÉRIEN","",""
"6448","95-03-28","CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: FOR THE PREVENTION OF NECROTIC ENTERITIS CAUSED BY CLAUSTRIDIUM PERFINGENS","NOUVELLE INDICATION: POUR LA PRÉVENTION D'ENTÉRITE NÉCROSANTE CAUSÉ PAR LE CLOSTRIDIUM PERFINGENS","ANTIBIOTIC, ANTIBACTERIAL","ANTIBIOTIQUE, ANTIBACTÉRIEN","",""
"6449","95-03-28","CYANAMID CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: FOR THE PREVENTION OF NECROTIC ENTERITIS CAUSED BY CLAUSTRIDIUM PERFINGENS","NOUVELLE INDICATION: POUR LA PRÉVENTION D'ENTÉRITE NÉCROSANTE CAUSÉ PAR LE CLOSTRIDIUM PERFINGENS","ANTIBIOTIC, ANTIBACTERIAL","ANTIBIOTIQUE, ANTIBACTÉRIEN","",""
"6450","95-05-01","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW ROUTE OF ADMINISTRATION","NOUVELLE VOIE D'ADMINISTRATION","IONOPHORE ANTIBIOTIC","ANTIBIOTIQUE IONOPHORE","",""
"6451","95-05-10","SYNTEX ANIMAL HEALTH, DIVISION OF SYNTEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SOURCE OF ACTIVE INGREDIENT","NOUVELLE SOURCE DE PRINCIPE ACTIF","ANTHELMINTIC AND BOTICIDE","ANTHELMINTHIQUE ET OESTICIDE","",""
"6452","97-02-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"6453","97-02-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6454","97-05-08","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6455","97-05-08","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6456","97-05-08","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6457","97-05-08","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6458","97-05-15","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6459","97-07-11","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6460","97-07-11","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6461","00-08-03","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6462","00-05-12","NORBROOK LABORATORIES LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA COMPOSITION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6463","00-08-08","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6464","00-08-14","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6465","00-08-14","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6466","00-09-01","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6467","00-04-06","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6468","00-09-08","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL INDICATION: GINGIVITIS ASSOCIATED WITH PERIODONTAL INFECTIONS DUE TO SUSCEPTIBLE STRAINS OF AEROBIC AND ANAEROBIC BACTERIA","INDICATION ADDITIONNELLE : GINGIVITE ASSOCIÉE AUX INFECTIONS PÉRIODONTIQUES DUES À DES SOUCHES SENSIBLES DE BACTÉRIES AÉROBIES ET ANAÉROBIES","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6469","96-12-03","PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"6470","97-06-20","RHÔNE MÉRIEUX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES: CATTLE","ESPÈCE ADDITIONNELLE: BOVINS","NONSTEROIDAL ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE NON STÉROÏDIEN, ANALGÉSIQUE","",""
"6471","96-04-10","GLAXO WELLCOME INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"6472","00-09-08","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL INDICATION: GINGIVITIS ASSOCIATED WITH PERIODONTAL INFECTIONS DUE TO SUSCEPTIBLE STRAINS OF AEROBIC AND ANAEROBIC BACTERIA","INDICATION ADDITIONNELLE : GINGIVITE ASSOCIÉE AUX INFECTIONS PÉRIODONTIQUES DUES À DES SOUCHES SENSIBLES DE BACTÉRIES AÉROBIES ET ANAÉROBIES","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6473","96-03-11","THE UPJOHN COMPANY OF CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"6474","00-09-08","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL INDICATION: GINGIVITIS ASSOCIATED WITH PERIODONTAL INFECTIONS DUE TO SUSCEPTIBLE STRAINS OF AEROBIC AND ANAEROBIC BACTERIA","INDICATION ADDITIONNELLE : GINGIVITE ASSOCIÉE AUX INFECTIONS PÉRIODONTIQUES DUES À DES SOUCHES SENSIBLES DE BACTÉRIES AÉROBIES ET ANAÉROBIES","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6475","00-09-08","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL INDICATION: GINGIVITIS ASSOCIATED WITH PERIODONTAL INFECTIONS DUE TO SUSCEPTIBLE STRAINS OF AEROBIC AND ANAEROBIC BACTERIA","INDICATION ADDITIONNELLE : GINGIVITE ASSOCIÉE AUX INFECTIONS PÉRIODONTIQUES DUES À DES SOUCHES SENSIBLES DE BACTÉRIES AÉROBIES ET ANAÉROBIES","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6476","00-09-01","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6477","00-08-02","CHEMINEX ANIMAL HEALTH, A DIVISION OF PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6478","00-07-04","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","CICATRIZING AGENT","CICATRISANT","",""
"6479","00-02-14","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"6480","00-08-02","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","FIVE ADDITIONAL CLAINS FOR PERSISTENT EFFECT AGAINST: HAEMATOBIA IRRITANS, TRICHOSTRONGLYLUS AXEI, OESOPHAGOSTOMUM RADIATUM, SOLENOPOTES CAPILLATUS AND DAMALINIA (BOVICOLA) BOVIS; AND DELETION OF RAIN CAUTIONARY STATEMENT","CINQ NOUVELLES INDICATIONS POUR EFFET PERSISTANT CONTRE : HAEMATOBIA IRRITANTS, TRICHOSTRONGLYLUS AXEI, OESOPHAGOSTOMUM RADIATUM, SOLENOPOTES CAPILLATUS ET DAMINALINIA (BOVICOLA) BOVIS; ET ÉLIMINATION DE LA PRÉCAUTION RELATIVE À L'EFFET DE LA PLUIE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6481","00-07-21","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6482","00-07-21","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6483","00-07-21","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6484","00-07-10","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6485","00-03-16","PHARMACIA & UPJOHN ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA COMPOSITION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6486","00-07-11","CITADEL ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HAEMATINIC","HÉMATINIQUE","",""
"6487","00-02-14","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"6488","00-09-01","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6489","00-04-06","PHARMACIA & UPJOHN ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","USE OF MGA-100 IN PELLETED FEEDS CONTAINING A LIGNIN SULFONATE BINDING AGENT","USAGE DE MGA-100 DANS LES ALIMENTS GRANULÉS, Y COMPRIS LES FORMULATIONS QUI CONTIENNENT UN AGENT LIANT DES GRANULÉS À BASE DE LIGNOSULFONATE","GROWTH PROMOTANT - SUPPRESSION OF ESTRUS","PROMOTEUR DE CROISSANCE - SUPPRESSION DE L'OESTRUS","",""
"6490","00-04-05","CITADEL ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE, CHANGE IN FORMULATION, CHANGES IN MANUFACTURING","NOUVEAU SITE DE FABRICATION, MODIFICATION DE LA COMPOSITION, MODIFICATIONS DE LA FABRICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6491","00-08-30","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6492","00-08-30","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN EXPIRATION DATE TO 42 MONTHS (25GM PACKAGE), 36 MONTHS (290GM PACKAGE); CHANGE IN MANUFACTURING SITE","CHANGEMENT DE LA DATE LIMITE D'UTILISATION À 42 MOIS (25GM EMBALLAGE), 36 MOIS (290GM EMBALLAGE); NOUVEL EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6493","00-08-30","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6494","00-04-24","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6495","00-08-30","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"6496","00-07-10","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PACKAGING","MODIFICATION DU CONDITIONNEMENT","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6497","00-04-06","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6498","00-04-06","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6499","00-04-06","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6500","00-04-06","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6501","00-04-06","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6502","00-04-06","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6503","00-02-14","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN DE POIDS","",""
"6504","00-02-14","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN DE POIDS","",""
"6505","00-02-02","PROVEL, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","AS AN AID IN THE PREVENTION OF COCCIDIOSIS CAUSED BY EIMERIA ZUERNII AND E. BOVIS IN CATTLE WEIGHING UP TO 350KG","POUR AIDER À PRÉVENIR LA ZUERNII ET E. BOVIS CHEZ LES BOVINS PESANT AU PLUS 350KG","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6506","00-06-27","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN EXPIRATION DATE TO 36 MONTHS","CHANGEMENT DE LA DATE LIMITE D'UTILISATION À 36 MOIS","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6507","00-01-25","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6508","00-02-01","HOECHST ROUSSEL VET CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN EXPIRATION DATE TO 42 MONTHS (25GM PACKAGE) AND 36 MONTHS (290GM PACKAGE); CHANGE IN MANUFACTURING SITE","CHANGEMENT DE LA DATE LIMITE D'UTILISATION À 42 MOIS (25GM EMBALLAGE) ET 36 MOIS (290GM EMBALLAGE); NOUVEL EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6509","00-02-01","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6510","00-08-30","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6511","96-03-19","DISPENSAPHARM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"6512","00-09-01","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6513","00-08-03","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6514","96-10-08","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ANTI-DIABETIC AGENT","ANTIDIABÉTIQUE","",""
"6515","00-04-17","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6516","00-09-01","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6517","00-02-29","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"6518","00-02-29","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"6519","96-07-02","ZENECA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6520","00-06-27","BIO AGRI MIX 1998 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6521","00-06-22","DOMINION VETERINARY LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIFUNGAL","FONGICIDE","",""
"6522","96-05-03","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"6523","00-02-15","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"6524","00-04-06","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6525","96-05-03","WYETH-AYERST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"6526","00-08-02","JANSSEN","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEROTONIN S2 RECEPTOR ANTAGONIST","ANTISÉROTONINE (RÉCEPTEUR S2)","",""
"6527","99-05-12","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6528","99-05-04","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6529","99-07-26","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR FLEXIBLE LABELLING","POUR UN ÉTIQUETAGE SOUPLE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6530","99-07-26","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR FLEXIBLE LABELLING","POUR UN ÉTIQUETAGE SOUPLE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6531","99-07-26","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR FLEXIBLE LABELLING","POUR UN ÉTIQUETAGE SOUPLE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6532","99-07-26","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR FLEXIBLE LABELLING","POUR UN ÉTIQUETAGE SOUPLE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6533","99-07-26","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR FLEXIBLE LABELLING","POUR UN ÉTIQUETAGE SOUPLE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6534","99-07-06","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"6535","99-05-12","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6536","99-02-08","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6537","99-02-08","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6538","99-02-08","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6539","99-07-06","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6540","05-04-22","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXPANSION OF INFORMATION REGARDING PEDIATRIC SAFETY.  UPDATE TO DOSAGE AND ADMINISTRATION FOR ADULTS.","INFORMATION SUPPLÉMENTAIRE SUR L'INNOCUITÉ CHEZ LES ENFANTS.  MISE À JOUR DE LA POSOLOGIE CHEZ LES ADULTES.","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"6541","05-04-22","ALTANA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"6542","05-04-18","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"6543","05-04-22","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN COMBINATION WITH PREDNISONE (OR PREDNISOLONE) FOR THE TREATMENT OF PATIENTS WITH ANDROGEN-INDEPENDENT (HORMONE-REFRACTORY) METASTATIC PROSTATE CANCER","NOUVELLE INDICATION : EN COMBINAISON AVEC LA PREDNISONE (OU LA PREDNISOLONE) POUR LE TRAITEMENT DES PATIENTS ATTEINTS D'UN CANCER DE LA PROSTATE MÉTASTATIQUE ANDROGÉNO-INDÉPENDANT (HORMONO-RÉSISTANT)","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"6544","05-04-18","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL ÉTABLISSEMENT DE FABRICATION","SPECIFIC ANTIBODY FOR DIGOXIN","ANTICORPS SPÉCIFIQUE DE LA DIGOXINE","",""
"6545","99-08-19","VETREPHARM CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"6546","99-07-29","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE USE OF THE NEW DRUG IN LACTATING DAIRY CATTLE, WITHOUT ANY WITHHOLDING TIME FOR MILK AFTER TREATMENT","POUR PERMETTRE L'ADMINISTRATION DE CE MÉDICAMENT AUX VACHES LAITIÈRES EN LACTATION, SANS PÉRIODE D'ATTENTE RELATIVEMENT À L'UTILISATION DU LAIT À LA SUITE DU TRAITEMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6547","99-06-28","JANSSEN","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO ALLOW THE USE OF THE NEW DRUG AS A PROPHYLACTIC ANTICOCCIDIAL IN AN ADDITIONAL ANIMAL SPECIES: GROWING TURKEYS","POUR PERMETTRE L'ADMINISTRATION À TITRE D'ANTICOCCIDIEN PROPHYLACTIQUE CHEZ UNE ESPÈCE ANIMALE ADDITIONNELLE: DINDONS EN CROISSANCE","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6548","99-03-17","PHARMACIA & UPJOHN ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE USE AS A PROPHYLACTIC ANTICOCCIDIAL IN AN ADDITIONAL ANIMAL SPECIES: GROWING TURKEYS","POUR PERMETTRE L'ADMINISTRATION À TITRE D'ANTICOCCIDIEN PROPHYLACTIQUE CHEZ UNE ESPÈCE ANIMALE ADDITIONNELLE: DINDONS EN CROISSANCE","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6549","99-02-08","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6550","99-02-08","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6551","99-02-08","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6552","99-02-08","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6553","99-02-08","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6554","99-07-06","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NUTRITIONAL SUPPLEMENT","SUPPLÉMENT NUTRITIONNEL","",""
"6555","99-07-06","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NUTRITIONAL SUPPLEMENT","SUPPLÉMENT NUTRITIONNEL","",""
"6556","99-05-04","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","CESTOCIDE","CESTOCIDE","",""
"6557","99-07-22","VETREPHARM CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"6558","98-02-04","ALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6559","98-06-26","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6560","98-07-09","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6561","98-06-26","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","MONOAMINE OXIDASE B INHIBITOR","INHIBITEUR DE LA MONO-AMINE-OXYDASE B","",""
"6562","98-06-26","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","MONOAMINE OXIDASE B INHIBITOR","INHIBITEUR DE LA MONO-AMINE-OXYDASE B","",""
"6563","98-06-26","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","MONOAMINE OXIDASE B INHIBITOR","INHIBITEUR DE LA MONO-AMINE-OXYDASE B","",""
"6564","98-06-26","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","MONOAMINE OXIDASE B INHIBITOR","INHIBITEUR DE LA MONO-AMINE-OXYDASE B","",""
"6565","98-06-26","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","MONOAMINE OXIDASE B INHIBITOR","INHIBITEUR DE LA MONO-AMINE-OXYDASE B","",""
"6566","98-07-27","PHARMACIA & UPJOHN ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","PROVIDES FOR THE TREATMENT IN CATS OF INFECTED WOUNDS, ABSCESSES AND DENTAL INFECTIONS","POUR PERMETTRE LE TRAITEMENT CHEZ LE CHAT DES PLAIES INFECTÉES, DES ABCÈS OU DES INFECTIONS DENTAIRES","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6567","98-04-15","ORION CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ALPHA2 ADRENERGIC ANTAGONIST","ADRÉNERGIQUE ALPHA2","",""
"6568","99-03-19","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE PACKAGING: BLISTER PACKAGING","MODIFICATION DE L'EMBALLAGE: PLAQUETTE THERMOFORMÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","ENZYME DE CONVERSION DE L'ANGIOTENSINE (ECA)","",""
"6569","99-03-19","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE PACKAGING: BLISTER PACKAGING","MODIFICATION DE L'EMBALLAGE: PLAQUETTE THERMOFORMÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","ENZYME DE CONVERSION DE L'ANGIOTENSINE (ECA)","",""
"6570","99-03-19","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE PACKAGING: BLISTER PACKAGING","MODIFICATION DE L'EMBALLAGE: PLAQUETTE THERMOFORMÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","ENZYME DE CONVERSION DE L'ANGIOTENSINE (ECA)","",""
"6571","99-03-19","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE PACKAGING: BLISTER PACKAGING","MODIFICATION DE L'EMBALLAGE: PLAQUETTE THERMOFORMÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","ENZYME DE CONVERSION DE L'ANGIOTENSINE (ECA)","",""
"6572","99-03-19","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE PACKAGING: BLISTER PACKAGING","MODIFICATION DE L'EMBALLAGE: PLAQUETTE THERMOFORMÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","ENZYME DE CONVERSION DE L'ANGIOTENSINE (ECA)","",""
"6573","98-09-15","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE PACKAGING","NOUVEL EMBALLAGE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6574","99-11-12","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ANABOLIC STEROID","STÉROÏDE ANABOLISANT","",""
"6575","99-08-13","WOODCHEM CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PARASITICIDE AND FUNGICIDE","ANTIPARASITAIRE ET FONGICIDE","",""
"6576","99-07-06","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6577","99-07-12","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR ADDITIONAL CLAIMS REGARDING THE PERSISTENCY OF EFFECT OF THIS DRUG","POUR AJOUTER CERTAINES INDICATIONS RELATIVES À L'EFFET PERSISTANT DE CE MÉDICAMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6578","99-09-03","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA COMPOSITION","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"6579","99-06-28","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"6580","99-06-04","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR A CHANGE IN THE WITHHOLDING TIME FOR MILK FROM 12 HOURS TO ZERO","CHANGEMENT À LA PÉRIODE DE RETRAIT POUR LE LAIT: AUCUNE AU LIEU DE 12 HEURES","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6581","99-05-20","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING OF ACTIVE INGREDIENT AND ADDITIONAL SOURCE OF ACTIVE INGREDIENT","MODIFICATION DE LA FABRICATION DE L'INGRÉDIENT ACTIF ET VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"6582","99-05-07","DIVERSEY LEVER CANADA, A DIVISION OF UL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","DISINFECTANT","DÉSINFECTANT","",""
"6583","99-07-26","NORBROOK LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6584","99-03-31","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITION OF A SUBCUTANEOUS ROUTE OF ADMINISTRATION","VOIE D'ADMINISTRATION ADDITIONNELLE: SOUS-CUTANÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6585","99-06-17","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6586","99-06-04","NEO-DYNAMICS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"6587","99-04-21","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6588","99-09-03","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GENERAL ANESTHETIC","ANESTHÉSIQUE GÉNÉRAL","",""
"6589","99-06-22","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROGESTIN","PROGESTATIF","",""
"6590","99-05-12","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6591","99-07-06","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6592","99-03-30","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"6593","99-03-30","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"6594","99-03-30","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"6595","99-04-02","SYNTEX ANIMAL HEALTH, DIVISION OF SYNTEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ESTRUS SYNCHRONIZATION","SYNCHRONISATION DE L'OESTRUS","",""
"6596","99-07-06","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6597","99-12-09","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING OF ACTIVE INGREDIENT","MODIFICATION DE LA FABRICATION DE L'INGRÉDIENT ACTIF","SEDATIVE","SÉDATIF","",""
"6598","99-03-31","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6599","99-03-31","HOECHST ROUSSEL VET CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGES IN FORMULATION, MANUFACTURING AND PACKAGING; ALTERNATE MANUFACTURING SITE; CHANGE IN EXPIRATION DATE","MODIFICATION DE LA COMPOSITION, FABRICATION ET CONDITIONNEMENT; AUTRE EMPLACEMENT DU SITE DE FABRICATION; CHANGEMENT DE LA DATE LIMITE D'UTILISATION","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6600","99-03-31","HOECHST ROUSSEL VET CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","96 HOUR MILK WITHDRAWAL WHEN ADMINISTERED TO LACTATING DAIRY CATTLE","PÉRIODE D'ATTENTE DE 96 HEURES APRÈS L'ADMINISTRATION AUX VACHES LAITIÈRES EN LACTATION","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6601","99-07-22","VETOQUINOL N.-A. INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES: CATS","ESPÈCE ADDITIONNELLE: CHATS","ANTI-INFLAMMATORY, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"6602","99-06-07","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL CLAIM AS AN AID IN THE PREVENTION OF PORCINE PROLIFERATIVE ENTEROPATHY","POUR PERMETTRE UNE INDICATION ADDITIONNELLE POUR AIDER À PRÉVENIR L'ENTÉROPATHIE PROLIFÉRATIVE PORCINE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6603","99-06-07","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL CLAIM AS AN AID IN THE PREVENTION OF PORCINE PROLIFERATIVE ENTEROPATHY","POUR PERMETTRE UNE INDICATION ADDITIONNELLE POUR AIDER À PRÉVENIR L'ENTÉROPATHIE PROLIFÉRATIVE PORCINE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6604","99-02-10","NORBROOK LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6605","99-12-30","MACLEOD PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6606","99-07-29","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE USE OF THE NEW DRUG IN LACTATING DAIRY CATTLE, WITHOUT ANY WITHHOLDING TIME FOR MILK AFTER TREATMENT","POUR PERMETTRE L'ADMINISTRATION DE CE MÉDICAMENT AUX VACHES LAITIÈRES EN LACTATION, SANS PÉRIODE D'ATTENTE RELATIVEMENT À L'UTILISATION DU LAIT À LA SUITE DU TRAITEMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6607","99-05-29","SERGEANT'S OF CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6608","99-05-03","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANALGESIC, SEDATIVE","ANALGÉSIQUE, SÉDATIF","",""
"6609","99-12-30","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6610","99-12-30","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6611","99-12-30","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6612","99-12-30","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6613","99-07-22","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6614","97-10-28","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6615","97-10-24","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6616","97-07-23","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6617","97-08-13","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6618","00-07-10","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR TWO ADDITIONAL CLAIMS: 49-DAY PERSISTENT EFFECT AGAINST DAMALINIA (BOVICOLA) BOVIS AND LINOGNATHUS VITULI","POUR AJOUTER DEUX NOUVELLES INDICATION : EFFET PERSISTANT DE 49 JOURS CONTRE DAMALINIA (BOVICOLA) BOVIS ET LINOGNATHUS VITULI","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6619","00-04-11","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6620","05-04-26","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH FOR THE TREATMENT OF MODERATE ACTIVE ULCERATIVE COLITIS","NOUVEAU DOSAGE POUR LE TRAITEMENT DE LA COLITE ULCÉREUSE ACTIVE MODÉRÉE","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DE LA PARTIE BASSE DU TUBE DIGESTIF","",""
"6621","05-04-26","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC","ANXIOLYTIQUE","",""
"6622","05-04-25","VALEANT CANADA LIMITÉE/LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RIVOTRIL","HOFFMANN-LA ROCHE INC.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"6623","05-04-25","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICYCLIC ANTIDEPRESSANT","ANTIDÉPRESSEUR TRICYCLIQUE","",""
"6624","05-04-25","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"6625","05-04-25","VALEANT CANADA LIMITÉE/LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL LABORATORIES OF CANADA","CANADA","CANADA","1","","","ANTI-ARRHYTHMIC","ANTIARYTHMIQUE","",""
"6626","05-04-25","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN T TOPICAL SOLUTION","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6627","05-04-25","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"6628","05-04-25","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"6629","05-04-27","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING PROCESS","NOUVELLE MÉTHODE DE FABRICATION","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE DE L'ÉRYTHROPOÏÈSE","",""
"6630","05-04-27","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE DE L'ÉRYTHROPOÏÈSE","",""
"6631","05-04-29","CHIRON BEHRING GMBH & CO KG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"6632","05-04-25","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISION TO PRODUCT MONOGRAPH","RÉVISION DE LA MONOGRAPHIE DE PRODUIT","ANTITHROMBOTIC AGENT","ANTITHROMBOTIQUE","",""
"6633","05-04-25","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING PROCESS","MODIFICATION DE LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"6634","05-04-28","PR PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6635","97-12-05","3M CANADA COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"6636","97-06-20","VETREPHARM CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF EXPIRY DATE","PROLONGATION DE LA DATE LIMITE D'UTILISATION","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6637","97-05-30","ALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CAUTION STATEMENT MODIFIED","MODIFICATION À L'ÉNONCÉ DE PRÉCAUTION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6638","97-04-13","LES PRODUITS AGRO-B INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TEAT DIP","BAIN DE TRAYON","",""
"6639","97-03-18","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6640","97-02-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6641","97-03-07","CROSS VETPHARM GROUP LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6642","97-03-21","WILDLIFE LABORATORIES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6643","05-05-03","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE OF THE PRODUCT MONOGRAPHS FOR THIS CLASS OF DRUGS","MISE À JOUR DU LIBELLÉ DES MONOGRAPHIES DE CETTE CLASSE DE DROGUES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"6644","05-05-03","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE OF THE PRODUCT MONOGRAPHS FOR THIS CLASS OF DRUGS","MISE À JOUR DU LIBELLÉ DES MONOGRAPHIES DE CETTE CLASSE DE DROGUES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"6645","05-05-02","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF165 INHIBITOR) FOR AGE-RELATED MACULAR DEGENERATION","INHIBITEUR DU FACTEUR DE CROISSANCE ENDOTHÉLIALE VASCULAIRE (INHIBITEUR DU VEGF165), INDIQUÉ POUR LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE","",""
"6646","05-05-03","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE OF THE PRODUCT MONOGRAPHS FOR THIS CLASS OF DRUGS","MISE À JOUR DU LIBELLÉ DES MONOGRAPHIES DE CETTE CLASSE DE DROGUES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"6647","05-05-06","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING THE INDICATION FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION","MISE À JOUR DE L'INDICATION POUR LE TRAITEMENT DE L'HYPERTENSION ESSENTIELLE LÉGÈRE OU MODÉRÉE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","INHIBITEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"6648","05-05-02","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING THE INDICATION FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION","MISE À JOUR DE L'INDICATION POUR LE TRAITEMENT DE L'HYPERTENSION ESSENTIELLE LÉGÈRE OU MODÉRÉE","ANTIHYPERTENSIVE-ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"6649","97-10-14","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF EXPIRY DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6650","97-09-12","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","LOCAL ANAESTHETIC","ANESTHÉSIQUE LOCAL","",""
"6651","05-05-05","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","BIOVAIL PHARMACEUTICALS","CANADA","CANADA","1","","","BETA-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"6652","97-06-20","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6653","05-05-03","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE OF THE PRODUCT MONOGRAPHS FOR THIS CLASS OF DRUGS","MISE À JOUR DU LIBELLÉ DES MONOGRAPHIES DE CETTE CLASSE DE DROGUES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"6654","05-05-02","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"6655","97-05-23","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6656","05-05-05","AXCAN PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MODIFICATIONS À LA MONOGRAPHIE DU PRODUIT","CHOLESTATIC LIVER DISEASES","MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"6657","05-05-03","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE OF THE PRODUCT MONOGRAPHS FOR THIS CLASS OF DRUGS","MISE À JOUR DU LIBELLÉ DES MONOGRAPHIES DE CETTE CLASSE DE DROGUES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"6658","05-05-05","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW CLAIM: THERAPEUTIC INTERPRETATION OF THE TERM COMFORTAB","NOUVELLE ALLÉGATION : INTERPRÉTATION THÉRAPEUTIQUE DU TERME COMFORTAB","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"6659","97-05-15","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6660","05-05-06","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6661","97-05-12","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6662","05-05-06","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DOSING","POSOLOGIE ALTERNATIVE","BILOGOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"6663","05-05-06","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"6664","05-05-02","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE DE L'ÉRYTHROPOÏÈSE","",""
"6665","97-04-18","LEO LABORATORIES CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6666","97-03-07","IVY LAB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","ACTIVATEUR DE CROISSANCE","",""
"6667","97-03-07","IVY LAB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","ACTIVATEUR DE CROISSANCE","",""
"6668","97-03-07","IVY LAB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","ACTIVATEUR DE CROISSANCE","",""
"6669","97-02-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6670","97-12-23","ALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6671","97-10-21","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6672","97-09-12","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6673","97-09-12","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6674","97-07-11","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6675","97-06-20","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC, ANTI-INFLAMMATORY","ANTIBIOTIQUE, ANTI-INFLAMMATOIRE","",""
"6676","97-06-26","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES: SWINE","ESPÈCE ADDITIONNELLE: PORCS","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6677","97-04-14","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6678","97-07-14","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6679","97-07-14","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6680","97-07-14","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6681","97-07-14","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6682","97-05-15","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6683","97-03-07","SOLVAY ANIMAL HEALTH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF JOINT DISFUNCTION","TRAITEMENT DU DISFONCTIONNEMENT DE L'ARTICULATION CARPIENNE","",""
"6684","97-10-14","NORBROOK LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6685","97-09-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HEART FAILURE","TRAITEMENT DE L'INSUFFISANCE CARDIAQUE","",""
"6686","97-09-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HEART FAILURE","TRAITEMENT DE L'INSUFFISANCE CARDIAQUE","",""
"6687","97-11-05","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF THE EXPIRY DATE","PROLONGATION DE LA DATE LIMITE D'UTILISATION","GONADOTROPHIN RELEASING HORMONE","GONADOLIBÉRINE","",""
"6688","97-06-06","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ANTI-INFLAMMATORY CORTICOSTEROID","ANTI-INFLAMMATOIRE CORTICOSTÉROÏDE","",""
"6689","97-10-24","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6690","97-05-15","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE, THE FORMULATION AND PACKAGING","NOUVEL EMPLACEMENT DE FABRICATION, MODIFICATION DE LA PRÉPARATION ET NOUVEL EMBALLAGE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6691","98-10-27","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO ALLOW THE CONCURRENT USE OF SEMDURAMICIN (25PPM) AND BACITRACIN METHYLENE DISALICYLATE (55PPM) IN MEDICATED FEEDS FOR BROILER CHICKENS","POUR PERMETTRE L'ADMINISTRATION CONCOMITANTE DE SENDURAMICINE (25PPM) ET DE DISALICYLATE MÉTHYLÈNE DE BACITRACINE (55PPM) DANS LES MOULÉES MÉDICAMENTEUSES DESTINÉES AUX POULETS DE GRIL","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6692","98-07-17","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6693","98-02-26","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6694","98-01-16","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL CANADIAN FEED MANUFACTURER, TO PREPARE MINERAL-VITAMIN MIXES MEDICATED WITH BOVATEC MEDICATED PREMIX FOR USE IN PASTURED CATTLE","ADDITION D'UN FABRICANT CANADIEN D'ALIMENTS DU BÉTAIL POUVANT UTILISER LE PRÉMÉLANGE MÉDICAMENTEUX BOVATEC DANS LA PRÉPARATION DE MÉLANGES MINÉRAUX MÉDICAMENTÉS POUR LES BOVINS DE PÂTURAGE","IONOPHORE ANTIBIOTIC","IONOPHORE ANTIBIOTIQUE","",""
"6695","98-03-06","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL AND VITAMIN","ANTIBACTÉRIEN ET VITAMINE","",""
"6696","97-06-06","GP ASSOCIATES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","INTRA-ARTICULAR INJECTION FOR NON-INFECTIOUS JOINT DYSFUNCTION","TRAITEMENT INTRA-ARTICULAIRE DU DYSFONCTIONNEMENT ARTICULAIRE NON INFECTIEUX","",""
"6697","98-10-15","LEO VET, DIVISION OF/DE LEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL, ANTIFUNGAL, ANTI-INFLAMMATORY","ANTIBACTÉRIEN, ANTIFONGIQUE, ANTI-INFLAMMATOIRE","",""
"6698","97-08-19","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6699","97-08-19","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6700","98-04-17","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6701","97-08-19","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6702","97-08-19","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6703","98-12-11","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIDEPRESSANT AND SEROTONIN RE-UPTAKE INHIBITOR","ANTIDÉPRESSEUR ET INHIBITEUR DU RECAPTAGE DE LA SÉROTONINE","",""
"6704","98-12-11","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIDEPRESSANT AND SEROTONIN RE-UPTAKE INHIBITOR","ANTIDÉPRESSEUR ET INHIBITEUR DU RECAPTAGE DE LA SÉROTONINE","",""
"6705","98-12-11","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIDEPRESSANT AND SEROTONIN RE-UPTAKE INHIBITOR","ANTIDÉPRESSEUR ET INHIBITEUR DU RECAPTAGE DE LA SÉROTONINE","",""
"6706","97-12-23","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6707","98-05-01","IVY LABORATORIES, DIVISION OF IVY ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6708","98-05-29","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPRURITIC, ANTI-INFLAMMATORY","ANTIPRURIGINEUX, ANTI-INFLAMMATOIRE","",""
"6709","97-12-23","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6710","98-02-04","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE, ALTERNATE PACKAGE TYPE, CHANGES IN FORMULATION","NOUVEL EMPLACEMENT DE FABRICATION, AUTRE TYPE D'EMBALLAGE, MODIFICATION DE LA PRÉPARATION","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6711","98-03-20","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6712","98-06-26","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGES IN MANUFACTURING AND AN ALTERNATE MANUFACTURING SITE","MODIFICATION DE LA FABRICATION ET AUTRE EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6713","98-02-04","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIMS","ALLÉGATIONS ADDITIONNELLES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6714","97-10-14","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6715","97-04-04","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6716","97-11-17","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6717","97-12-23","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6718","97-10-14","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6719","97-08-19","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"6720","97-08-19","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6721","97-08-19","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6722","97-08-19","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6723","97-07-11","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6724","97-07-11","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6725","05-05-10","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADENOCARD","FUJISAWA CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"6726","05-05-13","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - NOSOCOMIAL PNEUMONIA WITH PROPOSED DOSAGE REGIMEN","NOUVELLE INDICATION - PNEUMONIE NOSOCOMIALE AVEC POSOLOGIE PROPOSÉE","ANTIBIOTIC, ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE, INHIBITEUR DE ß-LACTAMASES","",""
"6727","05-05-13","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"6728","05-05-12","BIOGEN IDEC CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION AND NEW STRENGTH","NOUVELLE INDICATION ET NOUVEAU DOSAGE","IMMUNOMODULATORY AGENT","IMMUNOMODULATEUR","",""
"6729","05-05-13","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","POLYPEPTIDE PROTEINASE INHIBITOR / HEMOSTATIC AGENT","INHIBITEUR POLYPEPTIDE PROTÉINASE / AGENT HÉMOSTATIQUE","",""
"6730","05-05-10","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","THERAPEUTIC RADIOPHARMACEUTICAL","RADIOPHARMACEUTIQUE THÉRAPEUTIQUE","",""
"6731","98-11-23","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO APPROVE A 42-DAY PERSISTENCY OF EFFECT AGAINST THE SUCKING LICE, LINOGNATHUS VITULI","POUR APPROUVER UNE PERSISTANCE D'ACTIVIT, DE 42 JOURS CONTRE LES INFECTIONS ATTIBUABLES LINOGNATHUS VITULI","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6732","98-11-24","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"6733","98-06-26","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"6734","98-06-26","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANGIOTENSINE CONVERTING ENZYME INHIBITOR (ACEI)","INHIBITEUR DE L'ENZYME DE CONVERSION DFE L'ANGIOTENSINE","",""
"6735","98-06-26","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"6736","98-06-26","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"6737","98-06-26","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"6738","98-05-07","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6739","98-07-22","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6740","98-05-07","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6741","98-02-26","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"6742","98-02-18","PHARMACIA & UPJOHN ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM FOR USE IN LAMBS, FOR THE TREATMENT OF RESPIRATORY DISEASE 9PNEUMONIA) ASSOCIATED WITH PASTEURELLA HAEMOLYTICA","NOUVELLE ALLÉGATION : TRAITEMENT DES MALADIES RESPIRATOIRES (PNEUMONIE), CHEZ L'AGNEAUX, ASSOCIÉES À PASTEURELLA HAEMOLYTICA","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6743","98-07-16","PHARMACIA & UPJOHN ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN STORAGE CONDITION","CHANGEMENT DES CONDITIONS D'ENTREPOSAGE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6744","98-12-23","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6745","98-05-15","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SYNTHETIC LUTEINIZING HORMONE-RELEASING HORMONE","HORMONE SYNTHÉTIQUE DE LIBÉRATION DE L'HORMONE LUTÉINISANTE","",""
"6746","98-12-11","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HAEMATINIC","HÉMATINIQUE","",""
"6747","98-12-13","LEO VET, DIVISION OF/DE LEO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6748","98-11-10","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6749","98-05-01","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN EXPIRY DATE, CHANGE IN MANUFACTURING SITE, CHANGE IN FORMULATION","CHANGEMENT DE LA DATE LIMITE D'UTILISATION, NOUVEL EMPLACEMENT DE FABRICATION, MODIFICATION DE LA COMPOSITION","ANTIBIOTIC, ANTI-INFLAMMATORY","ANTIBIOTIQUE, ANTI-INFLAMMATOIRE","",""
"6750","98-10-21","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6751","98-10-21","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6752","98-10-21","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6753","98-02-04","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6754","98-02-04","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6755","98-02-04","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6756","98-10-01","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6757","98-10-01","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6758","98-02-04","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6759","98-02-04","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6760","98-02-04","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6761","98-08-14","BEXCO PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","INTRA-ARTICULAR INJECTION FOR NON-INFECTIOUS JOINT DYSFUNCTION ASSOCIATED WITH EQUINE OSTEARTHRITIS","LE TRAITEMENT INTRA-ARTICULAIRE DU DYSFONCTIONNEMENT DE L'ARTICULATION ASSOCIÉ À L'ARTHOSE ÉQUINE","",""
"6762","98-12-23","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6763","98-11-27","P.V.U., DIVISION OF J. WEBSTER LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6764","98-09-15","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES","NOUVELLE ESPÈCE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6765","98-09-15","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES","NOUVELLE ESPÈCE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6766","98-09-15","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES","NOUVELLE ESPÈCE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6767","98-09-15","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL SPECIES","NOUVELLE ESPÈCE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6768","98-03-06","SCHEIN PHARMACEUTICAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANAESTHETIC","ANESTHÉSIQUE","",""
"6769","98-06-26","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC","ANESTHÉSIQUE","",""
"6770","98-01-30","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6771","98-10-21","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIMS REGARDING THE PERSISTENCY OF EFFECT OF THE NEW DRUG","NOUVELLES ALLÉGATIONS CONCERNANT LA PERSISTENCE DE L'ACTIVITÉ ANTHELMINTIQUE CONTRE LES INFECTIONS","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6772","98-10-21","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6773","98-05-14","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO MODIFY THE CAUTIONARY STATEMENT RELATING TO CATTLE GRUBS.  TO DELETE THE NOTIFICATION STATEMENT RELATING TO MANGE MITES","POUR MODIFIER LA PRÉCAUTION RELATIVE AUX HYPODERMES.  POUR ANNULER LA DÉCLARATION RELATIVE À LA GALE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6774","98-05-14","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6775","98-06-26","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6776","98-05-08","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAINS AGAINST THE THREADWORM","INDICATIONS ADDITIONNELLES CONTRE LE VER FILIFORME","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6777","98-12-18","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANAESTHETIC","ANESTHÉSIQUE","",""
"6778","97-05-09","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6779","97-05-09","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6780","97-05-09","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6781","97-05-09","BIO AGRI MIX LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6782","97-03-21","BIO AGRI MIX LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6783","97-05-15","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6784","97-05-15","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBITIQUE","",""
"6785","97-05-15","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6786","97-07-14","DIVERSEY LEVER CANADA, A DIVISION OF UL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","DISINFECTANT","DÉSINFECTANT","",""
"6787","97-06-26","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6788","97-06-20","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT, SUPPRESSION OF ESTRUS","ACTIVATEUR DE CROISSANCE, SUPPRESSION DE L'OESTRUS","",""
"6789","97-02-27","PROVEL, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SPECIES CLAIM","ALLÉGATION CONCERNANT UNE AUTRE ESPÈCE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6790","97-10-06","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6791","97-05-15","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6792","97-05-16","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF EXPIRY DATE","NOUVELLE DATE LIMITE D'UTILISATION","LACRIMOMIMETIC, ANTI-INFLAMMATORY","LACRYMOMIMÉTIQUE, ANTI-INFLAMMATOIRE","",""
"6793","97-11-24","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6794","97-09-12","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6795","97-09-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6796","97-09-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6797","97-09-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6798","97-09-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6799","97-09-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6800","97-09-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6801","97-09-05","VIRBAC INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF SEBORRHEIC DERMATITIS","TRAITEMENT DES DERMATITES SÉBORRHÉIQUES","",""
"6802","97-08-13","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"6803","97-08-13","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL, ANTIFUNGAL, ANTI-INFLAMMATORY","ANTIBACTÉRIEN, ANTIFONGIQUE, ANTI-INFLAMMATOIRE","",""
"6804","05-05-18","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE-OXYDASE","",""
"6805","05-05-16","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"6806","05-05-18","VALEANT PHARMACEUTICALS INTERNATIONAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BENZODIAZEPINE ANTICONVULSANT","ANTICONVULSIVANT, BENZODIAZÉPINE","",""
"6807","05-05-19","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM GEN-LEVOTHYROXINE","MODIFICATION DU NOM DU PRODUIT DE GEN-LEVOTHYROXINE","THYROID HORMONE","HORMONE THYROÏDIENNE","",""
"6808","05-05-18","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ANEXATE INJECTION","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","BENZODIAZEPINE ANTAGONIST","ANTAGONISTE DES BENZODIAZÉPINES","",""
"6809","05-05-16","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"6810","05-05-20","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO UPDATE DILUTION RECOMMENDATION FOR INJECTION OF AMPOULES USED FOR MYOCARDIAL PERFUSION IMAGING","MISE À JOUR DE LA RECOMMANDATION SUR LA DILUTION DU PRODUIT SOUS FORME D'AMPOULES LORSQUE CELUI-CI EST ADMINISTRÉ PAR INJECTION POUR LA SCINTIGRAPHIE MYOCARDIQUE DE PERFUSION","CORONARY VASODILATOR","VASODILATATEUR CORONARIEN","",""
"6811","05-05-18","RANBAXY PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"6812","05-05-18","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC., HEALTHCARE DIVISION","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"6813","05-05-18","RANBAXY PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"6814","05-05-18","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK SHARP AND DOHME","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"6815","05-05-18","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"6816","05-05-18","IVAX LABORATORIES INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"6817","05-05-16","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"6818","05-05-16","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","INCLUSION OF NEW DRUG INTERACTION STUDIES; REVISION OF PEDIATRIC DOSAGE AND ADMINISTRATION","AJOUT DE NOUVELLES ÉTUDES SUR LES INTERACTIONS DE MÉDICAMENTS; MODIFICATION DE LA POSOLOGIE CHEZ LES ENFANTS","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"6819","05-05-20","WESTFALIA-SURGE, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"6820","05-05-20","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SPECIES, NEW CLINICAL CLAIMS","NOUVELLES ESPÈCES, NOUVELLES RÉCLAMATION CLINIQUES","HORMONE","HORMONE","",""
"6821","05-05-18","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","IMMUNOMODULATORY AGENT","AGENT IMMUNOMODULATEUR","",""
"6822","05-05-18","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ALPHA 1-ANTITRYPSIN REPLENISHER","AGENT DE RECHARGE EN ALPHA 1-ANTITRYPSINE","",""
"6823","97-08-13","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL, ANTIFUNGAL, ANTI-INFLAMMATORY","ANTIBACTÉRIEN, ANTIFONGIQUE, ANTI-INFLAMMATOIRE","",""
"6824","97-05-15","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6825","97-11-24","PROVEL, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6826","97-07-08","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6827","97-04-25","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","THE COMPATIBILITY WITH THE THIXOTROPE LIQUID SUPPLEMENT: HCS, NUTRENA FEEDS, CARGILL LIMITED","LA COMPATIBILITÉ AVEC LE SUPPLÉMENT LIQUIDE THIXOTROPE: HCS, NUTRENA FEEDS, CARGILL LIMITED","ANTICOCCIDIAL, GROWTH PROMOTANT","ANTICOCCIDIEN, ACTIVATEUR DE CROISSANCE","",""
"6828","05-05-27","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT NASAL","",""
"6829","05-05-27","DURAMED PHARMACEUTICALS, INC., A SUBSIDIARY OF BARR PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRESCRIPTION TO NON-PRESCRIPTION SWITCH","PASSAGE DE PRODUIT D'ORDONNANCE À PRODUIT EN VENTE LIBRE","EMERGENCY CONTRACEPTION","CONTRACEPTIC D'URGENCE","",""
"6830","05-05-20","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO REDUCE THE SLAUGHTER WITHDRAWAL DOWN TO 15 DAYS AFTER THE LAST TREATMENT","RÉDUCTION DE LA PÉRIODE D'ATTENTE À 15 JOURS ENTRE LE MOMENT DE L'ABATTAGE ET CELUI DU DERNIER TRAITEMENT","ANTAPARASITIC","ANTIPARASITAIRE","",""
"6831","05-05-20","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO REDUCE THE SLAUGHTER WITHDRAWAL DOWN TO 15 DAYS AFTER THE LAST TREATMENT","RÉDUCTION DE LA PÉRIODE D'ATTENTE À 15 JOURS ENTRE LE MOMENT DE L'ABATTAGE ET CELUI DU DERNIER TRAITEMENT","ANTAPARASITIC","ANTIPARASITAIRE","",""
"6832","05-05-27","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","ADDITION OF A NEW STRENGTH","AJOUT D'UNE NOUVELLE CONCENTRATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"6833","05-05-27","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"6834","97-10-24","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","THE COMPATIBILITY WITH THIXOTROPE LIQUID SUPPLEMENT: HCS, NUTRENA FEEDS, CARGILL LIMITED","LA COMPATIBILITÉ AVEC LE SUPPLÉMENT LIQUIDE THIXOTROPE: HCS, NUTRENA FEEDS, CARGILL LIMITED","ANTICOCCIDIAL, GROWTH PROMOTANT","ANTICOCCIDIEN, ACTIVATEUR DE CROISSANCE","",""
"6835","97-10-24","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","THE ADDITION OF A CONTINUOUS 33PPM FEEDING PROGRAM","L'AJOUT DE L'ADMINISTRATION CONTINUELLE - 33PPM POUR L'AMÉLIORATION DE L'INDICE DE CONVERSION ALIMENTAIRE","ANTICOCCIDIAL, GROWTH PROMOTANT","ANTICOCCIDIEN, ACTIVATEUR DE CROISSANCE","",""
"6836","98-07-27","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL ROUTE OF ADMINISTRATION IN CATTLE: SUBCUTANEOUS INJECTION","NOUVELLE VOIE D'ADMINISTRATION POUR LES BOVINS : INJECTION SOUS-CUTANÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6837","98-12-11","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6838","98-10-13","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6839","98-10-13","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6840","98-04-23","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE AND CHANGE IN FORMULATION","NOUVEL EMPLACEMENT DE FABRICATION ET MODIFICATION DE LA PRÉPARATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6841","98-04-06","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6842","98-03-25","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6843","97-05-12","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL, GROWTH PROMOTANT","ANTICOCCIDIEN, ACTIVATEUR DE CROISSANCE","",""
"6844","98-10-01","PROVEL, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE DELETION OF THE WEIGTH RESTRICTION IN CALVES LESS THAN 70 KG BODY WEIGHT","POUR ENLEVER LA RESTRICTION AU POIDS CHEZ LES VEAUX DE MOINS DE 70 KG DE POIDS CORPOREL","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6845","98-06-04","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL CLAIM FOR INCREASED RATE OF WEIGHT GAIN AND IMPROVED FEED EFFICIENCY IN GROWING AND FINISHING SWINE","POUR AMÉLIORER LE GAIN DE POIDS ET L'EFFICACITÉ ALIMENTAIRE CHEZ LES PORCS EN CROISSANCE ET EN FINITION","ANTIBIOTIC, ANTICOCCIDIAL","ANTIBIOTIQUE, ANTICOCCIDIEN","",""
"6846","98-04-17","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"6847","97-04-25","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","THE ADDITION OF A CONTINUOUS 33PPM FEEDING PROGRAM","L'AJOUT DE L'ADMINISTRATION CONTINUELLE - 33PPM POUR L'AMÉLIORATION DE L'INDICE DE CONVERSION ALIMENTAIRE","ANTICOCCIDIAL, GROWTH PROMOTANT","ANTICOCCIDIEN, ACTIVATEUR DE CROISSANCE","",""
"6848","98-04-20","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE AND CHANGE IN FORMULATION","NOUVEL EMPLACEMENT DE FABRICATION ET MODIFICATION DE LA PRÉPARATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6849","97-05-09","HOECHST CANADA (1996) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6850","97-03-07","HOECHST CANADA (1996) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6851","97-02-27","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6852","98-09-02","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN EXTENSION IN THE CLAIM: FOR THE TREATMENT OF BOVINE RESPIRATORY DISEASE COMPLEX, ALSO CALLED SHIPPING FEVER, ASSOCIATED WITH PASTEURELLA HAEMOLYTICA, PASTEURELLA MULTOCIDA AND HAEMOPHILUS SOMNUS","POUR LE TRAITEMENT DU COMPLEX RESPIRATOIRE BOVIN, AUSSI APPELÉ FIÈVRE DU TRANSPORT ASSOCIÉ À PASTEURELLA HAEMOLYTICA, PASTEURELLA MULTOCIDA ET HAEMOPHILUS SOMNUS","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6853","98-11-23","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANALGESIC SEDATIVE","SÉDATIF ANALGÉSIQUE","",""
"6854","97-07-30","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6855","97-07-30","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6856","97-07-30","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6857","97-07-30","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6858","98-11-23","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANALGESIC SEDATIVE","SÉDATIF ANALGÉSIQUE","",""
"6859","97-04-04","HOECHST CANADA (1996) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6860","98-07-17","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6861","98-07-17","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6862","97-01-14","HOECHST CANADA (1996) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6863","97-01-23","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC AND GROWTH PROMOTANT","ANTIBIOTIQUE ET ACTIVATEUR DE CROISSANCE","",""
"6864","98-07-17","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6865","98-07-17","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6866","98-07-17","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6867","98-07-17","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6868","97-01-23","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC AND GROWTH PROMOTANT","ANTIBIOTIQUE ET ACTIVATEUR DE CROISSANCE","",""
"6869","98-07-17","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6870","98-07-17","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6871","97-01-23","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC AND GROWTH PROMOTANT","ANTIBIOTIQUE ET ACTIVATEUR DE CROISSANCE","",""
"6872","98-12-11","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6873","97-07-11","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6874","98-04-06","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6875","98-04-06","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6876","98-04-06","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6877","98-02-26","PEPTECH ANIMAL HEALTH PTY LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","OVULATORY INDUCTION AGENT","AGENT D'INDUCTION DE L'OVULATION","",""
"6878","98-03-24","CITADEL ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6879","97-01-28","BABSON BROTHERS COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TEAT DIP","BAIN DE TRAYONS","",""
"6880","98-05-07","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6881","98-09-02","P.V.U., DIVISION OF J. WEBSTER LABORATORIES INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL SPECIES (SWINE) FOR THE TRATEMENT OF INFECTIONS CAUSED BY PENICILLIN SUSCEPTIBLE STREPTOCOCCUS SUIS","ALLÉGATION CONCERNANT UNE AUTRE ESPÈCE (PORCS) POUR LE TRAITEMTN D'INFECTIONS CAUSÉES PAR STREPTOCOCCUS SUIS SENSIBLES À LA PÉNICILLINE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6882","97-03-18","JANSSEN","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIC, ANTIFUNGAL AND ANTI-INFLAMMATORY","ANTIBIOTIQUE, ANTIFONGIQUE ET ANTI-INFLAMMATOIRE","",""
"6883","98-09-18","EKA CHEMICALS INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"6884","97-08-13","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6885","98-03-06","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"6886","98-06-01","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6887","98-06-01","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6888","97-12-23","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM","NOUVELLE ALLÉGATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6889","98-02-04","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE, ALTERNATE PACKAGE TYPE, CHANGES IN FORMULATION","NOUVEL EMPLACEMENT DE FABRICATION, AUTRE TYPE D'EMBALLAGE, MODIFICATION DE LA PRÉPARATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6890","98-09-02","A.P.A., DIVISION OF J. WEBSTER LABORATORIES INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR AN ADDITIONAL SPECIES (SWINE) FOR THE TREATMENT OF INFECTIONS CAUSED BY PENICILLIN SUSCEPTIBLE STREPTOCOCCUS SUIS","ALLÉGATION CONCERNANT UNE AUTRE ESPÈCE (PORCS) POUR LE TRAITEMENT D'INFECTIONS CAUSÉES PAR STREPTOCOCCUS SUIS SENSIBLES À LA PÉNICILLINE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6891","98-03-04","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6892","98-03-04","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6893","98-10-27","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6894","98-10-27","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6895","98-10-27","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6896","98-10-27","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6897","98-11-27","A.P.A., DIVISION OF J. WEBSTER LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6898","98-09-16","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6899","98-09-16","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6900","98-09-16","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6901","98-12-11","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6902","98-05-25","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6903","98-02-16","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC","ANESTHÉSIQUE","",""
"6904","98-02-04","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6905","98-01-19","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6906","98-02-26","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6907","98-10-27","HOECHST ROUSSEL VET CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6908","98-10-27","HOECHST ROUSSEL VET CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO CHANGE THE MILK WITHHOLDING PERIOD FROM 96 HOURS TO ZERO","POUR RÉDUIRE LA PÉRIODE D'ATTENTE RELATIVE AU LAIT DE 96 HEURES À ZÉRO","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6909","98-03-03","BIO AGRI MIX LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6910","97-12-23","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR A ZERO-DAY WITHDRAWAL PERIOD","NOUVELLE PÉRIODE DE RETRAITE DE ZÉRO","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6911","97-12-23","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM","NOUVELLE ALLÉGATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6912","97-12-23","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR A ZERO-DAY WITHDRAWAL PERIOD","NOUVELLE PÉRIODE DE RETRAITE DE ZÉRO","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6913","97-12-03","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6914","97-07-23","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6915","97-07-23","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6916","97-06-17","VET A MIX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6917","97-06-17","VET A MIX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6918","97-06-17","VET A MIX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6919","97-05-09","VETOQUINOL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"6920","97-05-09","VETOQUINOL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"6921","97-04-04","VET A MIX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6922","97-04-04","VET A MIX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6923","98-10-13","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6924","98-03-20","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6925","98-02-16","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL EFFICACY CLAIN AGAINST THE COMMON ADULT TAPEWORM OF HORSES, ANOPLOCEPHALA PERFOLIATA","UNE INDICATION ADDITIONNELLE CONTRE LA FORME ADULTE DU VER PLAT COMMUN, ANOPLOCEPHALA PERFOLIATA","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6926","98-03-25","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6927","98-07-02","J. WEBSTER LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6928","98-10-01","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6929","98-10-01","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR ORAL ADMINISTRATION IN CATTLE","POUR PERMETTRE L'ADMINISTRATION ORALE CHEZ LES BOVINS","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6930","98-02-18","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6931","98-06-26","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6932","98-05-01","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6933","98-06-26","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"6934","98-05-27","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE AND CHANGE IN FORMULATION","NOUVEL EMPLACEMENT DE FABRICATION ET MODIFICATION DE LA PRÉPARATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6935","98-02-26","BIMEDA-MTC ANIMAL HEALTH INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6936","98-10-27","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"6937","98-06-01","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"6938","98-02-04","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6939","98-01-19","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6940","98-02-04","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6941","98-02-04","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6942","98-02-16","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6943","98-02-16","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6944","97-04-04","VET A MIX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6945","97-04-04","VET A MIX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HYPOTHYROIDISM","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"6946","98-02-16","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6947","98-02-26","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6948","98-02-18","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6949","97-04-04","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF EXPIRY DATE","EXTENSION POUR LA DATE DE PÉREMPTION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6950","98-02-18","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6951","98-02-18","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6952","98-02-23","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6953","97-08-19","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROGESTOGEN","PROGESTOGÈNE","",""
"6954","98-02-16","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6955","97-06-26","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANABOLIC STEROID","STÉROÏDE ANABOLISANT","",""
"6956","98-03-06","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6957","98-02-16","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6958","97-06-26","PHARMACIA & UPJOHN ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANABOLIC STEROID","STÉROÏDE ANABOLISANT","",""
"6959","98-11-27","P.V.U., DIVISION OF J. WEBSTER LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6960","97-04-18","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6961","98-12-18","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6962","98-11-23","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPRURITIC, ANTI-INFLAMMATORY","ANTIPRURIGINEUX, ANTI-INFLAMMATOIRE","",""
"6963","98-06-26","AYERST VETERINARY LABORATORIES","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGES IN MANUFACTURING AND AN ALTERNATE MANUFACTURING SITE","MODIFICATION DE LA FABRICATION ET AUTRE EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6964","98-03-03","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6965","98-03-06","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE, ANALGESIC","SÉDATIF, ANALGÉSIQUE","",""
"6966","98-05-12","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE, ANALGESIC","SÉDATIF, ANALGÉSIQUE","",""
"6967","98-05-07","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6968","96-05-03","ALPHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6969","96-07-16","ALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CONCURRENT USE WITH MAXIBAN PREMIX","USAGE SIMULTANÉ AVEC MAXIBAN PREMIX","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6970","96-07-23","ALPHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6971","96-04-09","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6972","96-05-23","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC ANTIBACTERIAL VITAMIN","ANTIBIOTIQUE ANTIBACTÉRIEN VITAMINE","",""
"6973","96-06-06","JANSSEN","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION, CHANGE IN MANUFACTURING","MODIFICATION DE LA PRÉPARATION, MODIFICATION DE LA FABRICATION","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6974","96-01-23","HOECHST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","AUTRE SOURCE ÉQUIVALENTE DE PRINCIPE ACTIF","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"6975","96-03-19","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6976","96-07-05","FERMENTA ANIMAL HEALTH COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6977","96-03-21","RHONE-POULENC CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"6978","96-07-04","FERMENTA ANIMAL HEALTH COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6979","96-03-21","ALFA LAVAL AGRI","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","DISINFECTANT, TEAT DIP","DÉSINFECTANT, BAIN DE TRAYONS","",""
"6980","96-01-30","DAVIS AND LAWRENCE CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"6981","96-10-10","THE UPJOHN COMPANY - ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM","NOUVELLE ALLÉGATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6982","96-06-06","THE UPJOHN COMPANY - ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6983","96-05-24","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HEART FAILURE","TRAITEMENT DE L'INSUFFISANCE CARDIAQUE","",""
"6984","96-05-24","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TREATMENT OF HEART FAILURE","TRAITEMENT DE L'INSUFFISANCE CARDIAQUE","",""
"6985","05-06-03","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT NASAL","",""
"6986","05-06-03","3M PHARMACEUTICALS, A DIVISION OF 3M CANADA COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FINAL ANALYSES FROM A LONG TERM FOLLOW-UP OBSERVATIONAL STUDY THAT EVALUATED SUSTAINED ACTINIC KERATOSIS CLEARANCE AFTER ONE YEAR","ANALYSES FINALES EFFECTUÉES DANS LE CADRE D'UNE ÉTUDE OBSERVATIONNELLE DE SUIVI À LONG TERME VISANT À ÉVALUER LA DISPARITION COMPLÈTE DE LA KÉRATOSE SÉNILE APRÈS UN AN","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE IMMUNITAIRE","",""
"6987","05-06-02","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: HEART FAILURE NYHA CLASS II AND III","NOUVELLE INDICATION : DÉCOMPENSATION CARDIAQUE NYHA CLASSES II ET III","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"6988","05-06-02","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"6989","05-06-02","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"6990","96-01-30","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"6991","05-05-31","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"6992","05-06-02","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST, DIURETIC","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II, DIURÉTIQUE","",""
"6993","05-06-02","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"6994","05-05-30","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PAEDIATRIC INFORMATION TO THE PRODUCT MONOGRAPH","AJOUT DE RENSEIGNEMENTS D'ORDRE PÉDIATRIQUE À LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"6995","05-06-03","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"6996","05-05-31","SABEX INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOPRESOR","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BETA-ADRENERGIC RECEPTOR-BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"6997","05-06-02","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOVANTRONE","WYETH CANADA","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"6998","05-05-31","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK SHARP & DOHME LIMITED","UNITED KINGDOM","ROYAUME-UNI","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"6999","05-06-02","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR, DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE, DIURÉTIQUE","",""
"7000","05-06-02","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TYPE II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"7001","05-06-02","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TYPE II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"7002","05-05-31","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TWO ADDITIONAL STRENGTHS AND REFORMULATION OF THE 2MG TABLET","DEUX DOSAGES ADDITIONNELS ET REFORMULATION DU COMPRIMÉ DE 2MG","ANTIPSYCHOTIC AGENT","AGENT ANTISPYCHOTIQUE","",""
"7003","96-03-21","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7004","96-03-21","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7005","96-02-29","GP ASSOCIATES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PACKAGING","NOUVEL EMBALLAGE","INTRA-ARTICULAR INJECTION FOR NON-INFECTIOUS JOINT DYSFUNCTION ASSOCIATED WITH EQUINE OSTEO-ARTHRITIS","TRAITEMENT INTRA-ARTICULAIRE DU DISFONCTIONNEMENT DE L'ARTICULATION CARPIENNE ET DU BOULET DES CHEVAUX CAUSÉ PAR UNE SYNOVITE NON-INFECTIEUSE","",""
"7006","96-01-12","GP ASSOCIATES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","INTRA-ARTICULAR INJECTION FOR NON-INFECTIOUS JOINT DYSFUNCTION ASSOCIATED WITH EQUINE OSTEO-ARTHRITIS","TRAITEMENT INTRA-ARTICULAIRE DU DISFONCTIONNEMENT DE L'ARTICULATION CARPIENNE ET DU BOULET DES CHEVAUX CAUSÉ PAR UNE SYNOVITE NON-INFECTIEUSE","",""
"7007","96-02-07","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7008","96-02-07","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7009","96-02-07","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7010","96-02-07","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7011","96-05-03","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC","ANESTHÉSIQUEKETAS","",""
"7012","96-01-03","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANABOLIC STEROID","STÉROÏDE ANABOLISANT","",""
"7013","96-02-12","BIO AGRI MIX LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC COMBINATION","ANTIBIOTIQUE COMBINÉ","",""
"7014","96-01-29","THE UPJOHN COMPANY - ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7015","96-02-02","STERIVET, DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANABOLIC STEROID","STÉROÏDE ANABOLISANT","",""
"7016","96-12-18","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7017","96-12-18","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7018","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7019","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7020","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7021","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7022","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7023","96-01-30","STERIVET, DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HEMORRHEOLOGIC, VASODILATOR","HÉMORRÉOLOGIQUE, VASODILATATEUR","",""
"7024","95-09-19","CROSS VETPHARM GROUP LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7025","95-08-29","A.L. LABORATORIES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7026","95-10-20","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","IONOPHORE ANTIBIOTIC","ANTIBIOTIQUE IONOPHORE","",""
"7027","95-11-03","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7028","95-11-03","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7029","95-10-27","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTIBIOTIC AND GROWTH PROMOTANT","ANTIBIOTIQUE ET PROMOTION DE LA CROISSANCE","",""
"7030","95-10-27","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTIBIOTIC AND GROWTH PROMOTANT","ANTIBIOTIQUE ET PROMOTION DE LA CROISSANCE","",""
"7031","95-10-27","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTIBIOTIC AND GROWTH PROMOTANT","ANTIBIOTIQUE ET PROMOTION DE LA CROISSANCE","",""
"7032","95-10-27","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTIBIOTIC AND GROWTH PROMOTANT","ANTIBIOTIQUE ET PROMOTION DE LA CROISSANCE","",""
"7033","95-09-15","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7034","95-09-15","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7035","95-06-29","THE UPJOHN COMPANY - ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"7036","95-01-20","ROGAR/STB INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7037","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"7038","95-09-15","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GONADOTROPHIN RELEASING HORMONE","HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"7039","95-11-20","FERMENTA ANIMAL HEALTH COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: CONCURRENT USE WITH CHLORTETRACYCLINE IN SWINE FEED","NOUVELLE INDICATION : USAGE SIMULTANÉ AVEC LE CHLORTÉTRACYCLINE DANS L'ALIMENTATION PORCINE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7040","95-06-01","VIRBAC INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"7041","96-04-03","SCHERING-PLOUGH ANIMAL HEALTH DIVISION OF SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7042","96-06-18","PEPTIDE TECHNOLOGY LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","OVULATORY INDUCTION AGENT","AGENT D'INDUCTION DE L'OVULATION","",""
"7043","96-04-03","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7044","96-01-30","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7045","96-01-30","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7046","96-01-30","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7047","96-01-30","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7048","96-01-30","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7049","96-01-16","THE UPJOHN COMPANY - ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC, ANTIBACTERIAL","ANTIBIOTIQUE, ANTIBACTÉRIEN","",""
"7050","96-01-30","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7051","96-06-12","MTC PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7052","96-05-06","MTC PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7053","96-08-07","NORBROOK LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7054","96-01-30","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"7055","96-01-30","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"7056","96-07-16","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","ACTIVATEUR DE CROISSANCE","",""
"7057","96-06-13","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","GROWTH PROMOTANT, ANTICOCCIDIAL","ACTIVATEUR DE CROISSANCE, ANTICOCCIDIEN","",""
"7058","96-03-21","WESTAGRO CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","DISINFECTANT, TEAT DIP","DÉSINFECTANT, BAIN DE TRAYONS","",""
"7059","96-01-16","HOECHST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7060","96-01-30","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7061","96-02-28","FERMENTA ANIMAL HEALTH COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7062","96-02-28","FERMENTA ANIMAL HEALTH COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7063","96-07-05","RHÔNE MÉRIEUX, CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7064","96-12-04","MALLINCKRODT VETERINARY, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7065","96-05-10","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"7066","96-07-04","DANIELS PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HYPOKALEMIA TREATMENT","TRAITEMENT DE L'HYPOKALIÉMIE","",""
"7067","96-07-04","DANIELS PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HYPOKALEMIA TREATMENT","TRAITEMENT DE L'HYPOKALIÉMIE","",""
"7068","96-01-30","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7069","96-03-19","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7070","96-03-21","BIO AGRI MIX LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7071","05-06-10","WYETH CONSUMER HEALTHCARE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, NASAL DECONGESTANT, ANTIHISTAMINE","ANALGÉSIQUE, DÉCONGERSTIONNANT NASAL ET ANTIHISTAMINIQUE","",""
"7072","05-06-07","PHARMAQ AS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7073","05-06-03","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GONADOTROPIN","GONADOTROPHINE","",""
"7074","05-06-08","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPIE PASSIVE","",""
"7075","05-06-08","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPIE PASSIVE","",""
"7076","05-06-08","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPIE PASSIVE","",""
"7077","05-06-08","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPIE PASSIVE","",""
"7078","05-06-08","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPIE PASSIVE","",""
"7079","05-06-08","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPIE PASSIVE","",""
"7080","05-06-08","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPIE PASSIVE","",""
"7081","05-06-08","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","IMMUNOTHÉRAPIE PASSIVE","",""
"7082","05-06-08","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"7083","05-06-08","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"7084","05-06-10","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","PROGESTIN","PROGESTATIF","",""
"7085","05-06-08","ENCYSIVE PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHROMBOTIC","ANTITHROMBOTIQUE","",""
"7086","05-06-07","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7087","05-06-07","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7088","05-06-07","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II","",""
"7089","05-06-08","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"7090","05-06-08","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"7091","05-06-10","SABEX 2002 INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GARAMYCIN","SCHERING CANADA LTD.","CANADA","CANADA","1","NEW CONCENTRATION FOR PAEDIATRIC USE","NOUVELLE CONCENTRATION POUR USAGE PÉDIATRIQUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7092","05-06-09","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MIGRAINE THERAPY","ANTIMIGRAINEUX","",""
"7093","05-06-10","PREMPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","NAPROSYN E","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC, ANTI-PYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"7094","05-06-08","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","POTASSIUM SUPPLEMENT","SUPPLÉMENT DE POTASSIUM","",""
"7095","05-06-17","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHELATING AGENT","CHÉLATEUR","",""
"7096","05-06-17","DUCHESNAY INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION AND HUMAN SAFETY DATA SUPPLIED FOR NEW FORMULATION","NOUVELLE FORMULATION ER DONNÉES CONCERNANT L'INNOCUITÉ DE CETTE FORMULATION","ANTINAUSEANT AGAINST NAUSEA AND VOMITING OF PREGNANCY","ANTINAUSÉEUX CONTRE LES NAUSÉES ET VOMISSEMENTS DE LA GROSSESSE","",""
"7097","05-06-17","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"7098","05-06-14","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PAEDIATRIC INFORMATION TO THE PRODUCT MONOGRAPH","AJOUT DE RENSEIGNEMENTS D'ORDRE PÉDIATRIQUE À LA MONOGRAPHIE DU PRODUIT","ANTIHYPERTENSIVE-ANTIANGINAL AGENT","ANTIHYPERTENSEUR-ANTIANGINEUX","",""
"7099","05-06-17","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"7100","05-06-17","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"7101","95-05-31","ORION CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","SEDATIVE/ANALGESIC","SÉDATIF/ANALGÉSIQUE","",""
"7102","95-09-19","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7103","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7104","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7105","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7106","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7107","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7108","95-11-03","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7109","95-07-28","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO ADD MILD TO CLAIMS, INDICATIONS AND LABEL","NOUVELLE RÉCLAME, NOUVELLE INDICATION: AJOUTER DOUX AUX RÉCLAMES, INDICATIONS, ÉTIQUETTES","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7110","95-07-28","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO ADD MILD TO CLAIMS, INDICATIONS, LABEL","NOUVELLE RÉCLAME, NOUVELLE INDICATION: AJOUTER DOUX AUX RÉCLAMES, INDICATIONS, ÉTIQUETTES","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7111","95-07-28","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO ADD MILD TO CLAIMS, INDICATIONS AND LABEL","NOUVELLE RÉCLAME, NOUVELLE INDICATION: AJOUTER DOUX AUX RÉCLAMES, INDICATIONS, ÉTIQUETTES","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7112","95-07-28","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO ADD MILD TO CLAIMS, INDICATIONS, LABEL","NOUVELLE RÉCLAME, NOUVELLE INDICATION: AJOUTER DOUX AUX RÉCLAMES, INDICATIONS, ÉTIQUETTES","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7113","95-07-28","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO ADD MILD TO CLAIMS, INDICATIONS, LABEL","NOUVELLE RÉCLAME, NOUVELLE INDICATION: AJOUTER DOUX AUX RÉCLAMES, INDICATIONS, ÉTIQUETTES","ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACEI)","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7114","95-02-24","VIRBAC INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ASTRINGENT AND ANTIINFLAMMATORY AGENT FOR OTITIS EXTERNA","ASTRINGENT/ANTI-INFLAMMATOIRE (OTITE EXTERNE)","",""
"7115","95-09-15","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7116","95-09-15","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7117","95-09-15","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7118","95-07-13","VETREPHARM CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL MANUFACTURING SITE FOR DILUENT","EMPLACEMENT DE FABRICATION ADDITIONNEL","SUPEROVULATORY AGENT","AGENT SUPEROVULATAIRE","",""
"7119","95-09-15","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7120","05-06-22","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE L'ANGIOTENSINE","",""
"7121","05-06-22","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7122","95-09-15","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7123","05-06-22","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"7124","05-06-22","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONDEPOLARIZING NEUROMUSCULAR ANTAGONIST","ANTAGONISTE NEUROMUSCULAIRE NON DÉPOLARISANT","",""
"7125","05-06-22","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"7126","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7127","05-06-22","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7128","05-06-22","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT, SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA","ANTICONVULSIVANT, SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU","",""
"7129","95-09-27","GP ASSOCIATES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF THE EXPIRY DATING FROM 9 TO 18 MONTHS","NOUVELLE DATE LIMITE D'UTILISATION","INTRA-ARTICULAR INJECTION FOR NON-INFECTIOUS JOINT DYSFUNCTION ASSOCIATED WITH EQUINE OSTEO-ARTHRITIS","DYSFONCTION ARTICULAIRE NON-INFECTUEUSE ASSOCIÉE À L'ARTHROSE CHEVALINE","",""
"7130","05-06-23","SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION AS AN ADJUNCT FOR EXCESSIVE DAYTIME SLEEPINESS DUE TO SLEEP APNEA","NOUVELLE INDICATION COMME MÉDICAMENT D'APPOINT DANS LE TRAITEMENT DE L'HYPERSOMNIE ATTRIBUABLE À L'APNÉE DU SOMMEIL","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"7131","95-02-16","LUITPOLD PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","INTRA-ARTICULAR INJECTION FOR NON-INFECTIOUS JOINT DYSFUNCTION ASSOCIATED WITH EQUINE OSTEO-ARTHRITIS","TRAITEMENT DU DYSFONCTIONNEMENT INFLAMMATOIRE NON-INFECTIEUX DES ARTICULATIONS CAUSÉ PAR L'ARTHRITE ET L'ARTHROSE","",""
"7132","05-06-22","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7133","05-06-22","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7134","05-06-22","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7135","05-06-22","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7136","05-06-22","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7137","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"7138","95-01-13","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO EXTEND THE INDICATIONS OF THE NEW DRUG TO DOGS OVER TWO WEEKS OF AGE AND GREATER THAN ONE KILOGRAM OF BODY WEIGHT.","ETIQUETTE REVISÉE","BROAD SPECTRUM ANTHELMINTIC","ANTIPARASITAIRE","",""
"7139","95-01-13","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO EXTEND THE INDICATIONS OF THE NEW DRUG TO DOGS OVER TWO WEEKS OF AGE AND GREATER THAN ONE KILOGRAM OF BODY WEIGHT","ETIQUETTE REVISÉE","BROAD SPECTRUM ANTHEMINTIC","ANTIPARASITAIRE","",""
"7140","95-01-13","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO EXTEND THE INDICATIONS OF THE NEW DRUG TO DOGS TWO WEEKS OF AGE AND GREATER THAN ONE KILOGRAM OF BODY WEIGHT","ETIQUETTE REVISÉE","BROAD SPECTRUM ANTHELMINTIC","ANTIPARASITAIRE","",""
"7141","95-01-13","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO EXTEND THE INDICATIONS OF THE NEW DRUG TO DOGS OVER TWO WEEKS OF AGE AND GREATER THAN ONE KILOGRAM OF BODY WEIGHT","ETIQUETTE REVISÉE","BROAD SPECTRUM ANTHELMINTIC","ANTIPARASITAIRE","",""
"7142","95-03-30","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO SUPPORT NEW CLAIMS FOR EFFICACY","ETIQUETTE REVISÉE","BRAOD SPECTRUM ANTIPARASITIC","ANTIPARASITAIRE","",""
"7143","95-11-01","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO EXTEND THE BODY WEIGHT RANGE OF CATTLE TO BE TREATED FROM THE CURRENT 100-300KG TO 100-400KG AT THE TIME OF ADMINISTRATION","ETIQUETTE REVISÉE","BROAD SPECTRUM ANTIPARASITIC","ANTIPARASITAIRE","",""
"7144","95-10-02","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO SUPPORT THE USE OF THIS NEW DRUG IN BREEDING SOWS AND BOARS; IN ADDITION, TO CONFIRM ITS EFFICACY IN BREEDING PIGS; FINALLY, TO REMOVE THE DOG DISCLAIMER","ETIQUETTE REVISÉE","BROAD SPECTRUM ANTIPARASITIC","ANTIPARASITAIRE","",""
"7145","95-06-05","THE UPJOHN COMPANY - ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7146","95-06-05","THE UPJOHN COMPANY - ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR A LABELLING CHANGE IN THE DRUG WITHDRAWAL PERIOD FOR SWINE, FROM 0 TO 48 HOURS, WHEN TREATED WITH LINCOMYCIN HYDROCHLORIDE AT 110 OR 220 PPM IN COMPLETE FEED","ETIQUETTE REVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7147","95-06-05","THE UPJOHN COMPANY - ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR A LABELLING CHANGE IN THE DRUG WITHDRAWAL PERIOD FOR SWINE, FROM 0 TO 48 HOURS, WHEN TREATED WITH LINCOMYCIN HYDROCHLORIDE AT 110 OR 220PPM IN COMPLETE FEED","ETIQUETTE REVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7148","95-06-05","CHEMINEX ANIMAL HEALTH, A DIVISION OF PHARMACIA & UPJOHN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7149","95-06-05","CHEMINEX ANIMAL HEALTH, A DIVISION OF PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR A LABELLING CHANGE IN THE DRUG WITHDRAWAL PERIOD FOR SWINE, FROM 0 TO 48 HOURS, WHEN TREATED WITH LINCOMYCIN HYDROCHLORIDE AT 110 OR 220 PPM IN COMPLETE FEED","ETIQUETTE REVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7150","95-06-05","CHEMINEX ANIMAL HEALTH, A DIVISION OF PHARMACIA & UPJOHN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR A LABELLING CHNAGE IN THE DRUG WITHDRAWAL PERIOD FOR SWINE, FROM 0 TO 48 HOURS, WHEN TREATED WITH LINCOMYCIN HYDROCHLORIDE AT 110 OR 220 PPM IN COMPLETE FEED","ETIQUETTE REVISÉE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7151","95-03-17","ROGAR/STB INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC, ANTIBACTERIAL","ANTIBIOTIQUE, ANTIBACTÉRIEN","",""
"7152","95-05-10","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR A CHANGE IN THE MANUFACTURER OF THE ACTIVE INGREDIENT TRICHLORFON","NOUVELLE SOURCE DE PRINCIPE ACTIF","ANTHELMINTIC AND BOTICIDE","VERMIFUGE ET BOTICIDE","",""
"7153","95-01-24","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR USE IN SOWS WITH A DELAYED RETURN TO ESTRUS FOLLOWING WEANING","NOUVELLE INDICATION","FOLLICLE STIMULATING HORMONE","HORMONE FOLLICULSTIMULANTE","",""
"7154","95-01-27","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"7155","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","INSECTICIDE","INSECTICIDE","",""
"7156","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","INSECTICIDE","INSECTICIDE","",""
"7157","95-11-14","CIBA-GEIGY CANADA LTD, ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7158","95-01-31","MALLINCKRODT VETERINARY, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR USE IN SUCKLING HEIFER CALVES FROM ONE MONTH OF AGE TO WEANING","ETIQUETTE REVISÉE","GROWTH PROMOTANT","PROMOTION DE LA CROISSANCE","",""
"7159","95-10-12","AYERST VETERINARY LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE, ANALGESIC","SÉDATION ACCOMPAGNÉ D'UNE ANALGÉSIE DE COURTE DURÉE","",""
"7160","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE, ANALGESIC","SÉDATIF, ANALGÉSIQUE","",""
"7161","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE, ANALGESIC","SÉDATIF, ANALGÉSIQUE","",""
"7162","95-03-17","DANIELS PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HYPOTHYROIDISM","HORMONE THYROÏDIENNE DE REMPLACEMENT","",""
"7163","95-03-17","DANIELS PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HYPOTHYROIDISM","HORMONE THYROÏDIENNE DE REMPLACEMENT","",""
"7164","95-03-17","DANIELS PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HYPOTHYROIDISM","HORMONE THYROÏDIENNE DE REMPLACEMENT","",""
"7165","95-03-17","DANIELS PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HYPOTHYROIDISM","HORMONE THYROÏDIENNE DE REMPLACEMENT","",""
"7166","95-03-17","DANIELS PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HYPOTHYROIDISM","HORMONE THYROÏDIENNE DE REMPLACEMENT","",""
"7167","95-09-15","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7168","95-09-15","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7169","95-10-23","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7170","95-10-02","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7171","95-10-02","P.V.U., DIVISION OF RHONE-MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7172","95-02-03","JANSSEN PHARMACEUTICA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE A NEW INDICATION","ETIQUETTE REVISÉE","ANTIFUNGAL, ANTIBACTERIAL, ANTI-INFLAMMATORY","AGENT ANTIFONGIQUE, ANTIBACTÉRIEN, ANTI-INFLAMMATOIRE","",""
"7173","95-01-24","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7174","95-11-24","VET A MIX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","XYLAZINE ANTAGONIST AND REVERSING AGENT","AGENT D'INVERSION DE LA XYLAZINE ET ANTIDOTE POUR CHEVAUX","",""
"7175","95-12-20","W.K. BUCKLEY LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"7176","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7177","95-11-28","MALLINCKRODT VETERINARY, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE AND PACKAGING; NEW DOSAGE REGIMEN","NOUVEL EMPLACEMENT DE FABRICATION ET EMBALLAGE, NOUVEAU SCHÉMA","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7178","95-01-24","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7179","95-01-24","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7180","95-01-24","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7181","95-01-24","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7182","95-01-24","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7183","95-01-24","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7184","95-01-24","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7185","95-01-24","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7186","95-01-24","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7187","95-01-24","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7188","95-02-16","FERMENTA ANIMAL HEALTH COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE, ANALGESIC","SÉDATIF, ANALGÉSIQUE","",""
"7189","95-04-04","DAVIS AND LAWRENCE CO.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC, ANTIBACTERIAL","ANTIBIOTIQUE, ANTIBACTÉRIEN","",""
"7190","05-06-23","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"7191","05-06-27","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRESERVATIVE-FREE FORMULATION","PRÉPARATION SANS AGENT DE CONSERVATION","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"7192","05-06-27","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"7193","05-06-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DE MÉTABOLISME OSSEUX","",""
"7194","05-06-28","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"7195","05-06-24","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","GONADOTROPHIN","GONADOTROPHINE","",""
"7196","05-06-30","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCESS","MODIFICATIONS AU PROCESSUS DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7197","05-06-28","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ALPHA1 ANTITRYPSIN REPLENISHER","AGENT DE RECHARGE EN ALPHA1-ANTITRYPSINE","",""
"7198","05-06-28","ZLB BEHRING GMBH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"7199","05-06-29","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING PROCESS","MODIFICATIONS AU PROCESSUS DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7200","05-06-29","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING PROCESS","MODIFICATIONS AU PROCESSUS DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7201","05-06-15","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH - DOSING RECOMMENDATION FOR PATIENTS UNDERGOING HEMODIALYSIS AND CONTINUOUS AMBULATORY PERITONEAL DIALYSIS","MONOGRAPHIE DE PRODUIT RÉVISÉE - POSOLOGIE RECOMMANDÉE POUR LES PATIENTS QUI REÇOIVENT DES TRAITEMENTS D'HÉMODIALYSE OU DE DIALYSE PÉRITONÉALE CONTINUE AMBULATOIRE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"7202","05-06-22","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO THE APPROVED COMMUNITY ACQUIRED PNEUMONIA INDICATION TO INCLUDE ADDITIONAL PATHOGENS AND REVISED TREATMENT DURATION","CHANGEMENTS À L'INDICATION APPROUVÉE POUR LE TRAITEMENT DE LA PNEUMONIE COMMUNAUTAIRE AFIN D'INCLURE DES AGENTS PATHOGÈNES ADDITIONNELS ET UNE DURÉE DE TRAITEMENT RÉVISÉE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"7203","05-07-06","RANBAXY PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"7204","05-07-06","ASTELLAS PHARMA CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORONARY VASODILATOR","VASODILATATEUR CORONARIEN","",""
"7205","05-07-06","BARRIER THERAPEUTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AGENT FOR THE TREATMENT OF SOLAR LENTIGINES AND RELATED HYPERPIGMENTED LESIONS","AGENT DESTINÉ AU TRAITEMENT DES LENTIGINES SOLAIRES ET DES LÉSIONS HYPERPIGMENTÉES CONNEXES","",""
"7206","05-07-06","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"7207","05-07-05","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7208","05-07-07","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: SAFETY INFORMATION ON RECENT STUDY FINDINGS IN THE POTENTIAL EFFECT ON BONE MINERAL DENSITY (BMD) IN ADULT AND ADOLESCENT FEMALES","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT: RENSEIGNEMENTS SUR L'INNOCUITÉ DU PRODUIT, À LA LUMIÈRE DES RÉSULTATS D'UNE ÉTUDE RÉCENTE SUR LES EFFETS POSSIBLES SUR LA TENEUR MINÉRALE DE L'OS CHEZ LES FEMMES ET LES ADOLESCENTES","PROGESTOGEN","PROGESTATIF","",""
"7209","05-07-07","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","5 MG AND 10 MG: NEW FORMULATION, RAPIDLY DISSOLVING TABLETS","5 MG ET 10 MG: NOUVELLE FORMULATION, COMPRIMÉS À LIBÉRATION RAPIDE","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"7210","05-07-05","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST INFECTIONS CAUSED BY PNEUMOCOCCI","AGENT D'IMMUNISATION ACTIVE CONTRE LES INFECTIONS SYSTÉMIQUES À PNEUMOCOQUES","",""
"7211","05-07-07","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR","INHIBITEUR DE L'ACTIVITÉ TYROSINE-KINASE DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE","",""
"7212","05-07-05","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","BETA-ADRENERGIC AGONIST/GROWTH PROMOTANT","AGONISTES-BETA-ADRÉNERGIQUES/STIMULANT DE LA CROISSANCE","",""
"7213","05-07-05","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","BETA-ADRENERGIC AGONIST/GROWTH PROMOTANT","AGONISTES-BETA-ADRÉNERGIQUES/STIMULANT DE LA CROISSANCE","",""
"7214","05-07-06","QLT USA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMICROBIAL AGENT FOR PERIODONTITIS","ANTIMICROBIEN POUR LA PÉRIODONTITE","",""
"7215","05-07-05","ETHYPHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"7216","05-07-08","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HORMONE REPLACEMENT THERAPY","THÉRAPIE HORMONALE DE REMPLACEMENT","",""
"7217","05-07-06","WATSON LABORATORIES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOG","HORMONE DE LIBÉRATION DE L'HORMONE LUTÉINISANTE","",""
"7218","05-07-06","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VIRAL ENTRY BLOCKING AGENT","INHIBITEUR DE LA PÉNÉTRATION VIRALE","",""
"7219","94-12-30","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7220","94-11-09","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7221","94-07-20","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA PRÉPARATION","GROWTH PROMOTANT, ANTIBACTERIAL","PROMOUVOIR LA CROISSANCE, ANTIBACTÉRIEN","",""
"7222","94-07-20","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE OF FORMULATION","MODIFICATION DE LA PRÉPARATION","GROWTH PROMOTANT, ANTIBACTERIAL","PROMOUVOIR LA CROISSANCE, ANTIBACTÉRIEN","",""
"7223","94-11-09","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"7224","94-06-22","FRANCODEX LAB INC, SUBSIDIARY OF VIRBAC INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","EPIDERMAL ASTRINGENT","ASTRINGENT ÉPIDERMIQUE","",""
"7225","94-11-09","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","CESTOCIDE","CESTOCIDE","",""
"7226","94-05-17","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7227","94-05-17","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7228","05-07-15","SOLVAY PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7229","05-07-14","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"7230","05-07-14","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"7231","05-07-14","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"7232","05-07-14","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"7233","05-07-12","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"7234","05-07-12","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"7235","05-07-12","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"7236","05-07-12","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PARENTERAL GENERAL ANESTHETIC","ANESTHÉSIQUE GÉNÉRAL PARENTÉRAL","",""
"7237","05-07-12","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMANIC AGENT","ANTIMANIAQUE","",""
"7238","05-07-12","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7239","05-07-15","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7240","05-07-12","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"7241","05-07-12","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"7242","05-07-14","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"7243","05-07-20","WYETH CONSUMER HEALTHCARE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH AND DOSAGE FORM (ORAL SUSPENSION) FOR THE COMBINATION PRODUCT OF IBUPROFEN, PSEUDOEPHEDRINE HYDROCHLORIDE, AND CHLORPHENIRAMINE MALEATE FOR USE IN CHILDREN FROM 6-12 YEARS OF AGE","NOUVELLE CONCENTRATION ET NOUVELLE FORME POSOLOGIQUE (SUSPENSION ORALE) POUR CE PRODUIT ASSOCIANT IBUPROFÈNE, CHLORHYDRATE DE PSEUDOÉPHÉDRINE ET MALÉATE DE CHLORPHÉNIRAMINE ET DESTINÉ AUX ENFANTS DE 6 À 12 ANS","ANALGESIC, ANTIPYRETIC, NASAL DECONGESTANT, ANTIHISTAMINE","ANALGÉSIQUE, ANTIPYRÉTIQUE, DÉCONGESTIONNANT NASAL, ANTIHISTAMINIQUE","",""
"7244","05-07-18","BIOGEN IDEC CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"7245","05-07-20","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7246","05-07-20","TALECRIS BIOTHERAPEUTICS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING FACILITY","MODIFICATION À L'UNITÉ DE PRODUCTION","ALPHA1-ANTITRYPSIN REPLENISHER","RECHARGEUR ALPHA1-ANTITRYPSINASE","",""
"7247","05-07-20","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST HEPATITIS A VIRUS","AGENT D'IMMUNISATION ACTIF CONTRE LE VIRUS DE L'HÉPATITE A","",""
"7248","05-07-20","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT AGAINST VARICELLA","AGENT D'IMMUNISATION ACTIF CONTRE LA VARICELLE","",""
"7249","05-07-19","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR - EXPECTORANT","BRONCHODILATATEUR - EXPECTORANT","",""
"7250","05-07-19","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SALURETIC - DIURETIC AGENT","SALIDIURÉTIQUE - DIURÉTIQUE","",""
"7251","05-07-20","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 45 MG (6-MONTH). NEW DOSAGE REGIMEN: ADMINISTERED ONCE EVERY 6 MONTHS","NOUVELLE CONCENTRATION: 45 MG (6 MOIS). NOUVELLE POSOLOGIE: ADMINISTRÉ UNE FOIS PAR 6 MOIS","LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ANALOG","HORMONE DE LIBÉRATION DE L'HORMONE LUTÉINISANTE","",""
"7252","05-07-19","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY AGENT FOR CLOSURE OF PATENT DUCTUS ARTERIOSUS","ANTI-INFLAMMATOIRE NON STÉROÏDIEN POUR LA FERMETURE DU CANAL ARTÉRIEL PERSISTANT","",""
"7253","05-07-18","FOURNIER PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION: NANOCRYSTAL","NOUVELLE FORMULATION: NANOCRYSTAL","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7254","05-07-20","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"7255","05-07-20","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRALLY ACTING ANALGESIC","ANALGÉSIQUE CENTRAL","",""
"7256","05-07-19","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7257","05-07-20","GILEAD SCIENCES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REPLACES THE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON MARCH 18, 2003","REMPLACE L'AVIS DE CONFORMITÉ AVEC CONDITIONS DÉLIVRÉ LE 18 MARS 2003","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"7258","05-07-18","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF NON-LIMB THREATENING DIABETIC FOOT INFECTIONS","NOUVELLE INDICATION: TRAITEMENT DES INFECTIONS DU PIED DIABÉTIQUE SANS RISQUE D'ATTEINTE DES MEMBRES","ANTIBACTERIAL AGENT","ANITBACTÉRIEN","",""
"7259","05-07-28","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"7260","05-07-26","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW CLAIMS: NON-DROWSY.  LETS YOU STAY ALERT AND PERFORM NORMALLY.  CAN BE USED WHILE DRIVING.","NOUVELLES ALLÉGATIONS : NE CAUSE PAS DE SOMNOLENCE.  VOUS DEMEUREZ ALERTE ET FONCTIONNEZ NORMALEMENT.  NE NUIT PAS À LA CONDUITE AUTOMOBILE.","HISTAMINE H1 RECEPTOR ANTAGONIST, SYMPATHOMIMETIC AMINE","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE, AMINE SYMPATHOMIMÉTIQUE","",""
"7261","05-07-28","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DOSING SCHEDULE","PLAN POSOLOGIQUE ALTERNATIF","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7262","05-07-27","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF ADOLESCENTS TO INDICATIONS","ADDITION DES ADOLESCENTS AUX INDICATIONS","CNS STIMULANT","STIMULANT DU SNC","",""
"7263","05-07-25","GLAXOSMITHKLINE SHIRE BIOCHEM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"7264","05-07-27","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMARYL","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONYLURÉE)","",""
"7265","05-08-03","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","DOSING REDUCTION WHEN CO-ADMINISTERED WITH TENOFOVIR DISOPROXIL FUMARATE","RÉDUCTION DE LA POSOLOGIE LORSQUE LE PRODUIT EST ADMINISTRÉ EN MÊME TEMPS QUE LE FUMARATE DISOPROXIL DE TÉNOFOVIR","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"7266","05-08-03","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC","ANESTHÉSIQUE","",""
"7267","05-08-03","DELAVAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"7268","05-08-05","ORPHAN MEDICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM DEPRESSANT","DÉPRESSEUR DU SYSTÈME NERVEUX CENTRAL","",""
"7269","05-08-05","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"7270","05-08-05","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"7271","05-07-28","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE AS SINGLE AGENT THERAPY FOR TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS","NOUVELLE INDICATION : UTILISATION EN MONOTHÉRAPIE POUR LE TRAITEMENT DES INFECTIONS COMPLIQUÉES DE LA PEAU ET DES STRUCTURES CUTANÉES","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7272","05-08-08","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIMS","INDICATIONS SUPPLÉMENTAIRES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7273","05-08-08","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"7274","05-08-08","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST AND ANTACID","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2 ET ANTIACIDES","",""
"7275","05-08-08","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"7276","05-08-08","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"7277","05-08-08","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7278","05-08-08","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"7279","05-08-08","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"7280","05-08-08","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"7281","05-08-08","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"7282","05-08-08","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"7283","05-08-09","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR, DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE, DIURÉTIQUE","",""
"7284","05-08-08","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: CONTROLLED-RELEASE TABLET","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉ À LIBÉRATION CONTRÔLÉE","A SELECTIVE ANTAGONIST OF ALPHA 1A/1D ADRENOCEPTOR SUBTYPES IN THE PROSTATE AND BLADDER","ANTAGONISTE SÉLECTIF DES SOUS-TYPES 1A ET 1D DES RÉCEPTEURS ALPHA-ADRÉNERGIQUES DES CELLULES DE LA PROSTATE ET DE LA VESSIE","",""
"7285","05-08-09","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIROPTIC","THERAMED CORPORATION","CANADA","CANADA","1","","","TOPICAL ANTIVIRAL AGENT","ANTIVIRAL TOPIQUE","",""
"7286","02-10-28","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR ADDITIONAL EFFICACY CLAIMS AGAINST ROUNDWORM INFECTIONS (TOXOCARA CANIS) AND TICK INFESTATIONS (RHIPICEPHALUS SANGUINEUS, DERMACENTOR VARIABILIS) IN DOGS, AND FLEA LARVAE (CTENOCEPHALIDES CANIS, C. FELIS) IN THE IMMEDIATE ENVIRONMENT OF THE INTENDED SPECIES (DOGS AND CATS)","POUR AJOUTER CERTAINES INDICATIONS RELATIVES AUX INFECTIONS D'ASCARIDES (TOXOCARA CANIS) ET AUX INFESTATIONS DE TIQUES (RHIPICEPHALUS SANGUINEUS, DERMACENTOR VARIABILIS) CHEZ LE CHIEN, AINSI QU'AUX LARVES DE PUCES (CTENOCEPHALIDES CANIS, C. FELIS) PRÉSENTES DANS L'ENVIRONNEMENT DES CHIENS ET DES CHATS","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7287","05-08-11","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","WARNING ON INTERACTION WITH ORAL CONTRACEPTIVES","MISE EN GARDE CONCERNANT AVEC DES PRODUITS ANTICONCEPTIONNELS","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"7288","05-08-11","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PLASMA SUBSTITUTE AND PLASMA PROTEIN FRACTION","SUBSTITUT DE PLASMA ET FRACTION DE PROTÉINE DE PLASMA","",""
"7289","05-08-17","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GARAMYCIN","SCHERING CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7290","05-08-17","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIHISTAMINE AGENT","ANXIOLYTIQUE, ANTIHISTAMINIQUE","",""
"7291","05-08-17","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"7292","05-08-17","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","URINARY ANTIBACTERIAL","ANTIBIOTIQUE URINAIRE","",""
"7293","05-08-17","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","SITE DE FABRICATION SUPPLÉMENTAIRE","GONADOTROPINS","GONADOTROPHINES","",""
"7294","05-08-18","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","THYROID HORMONE","HORMONE THYROÏDIENNE","",""
"7295","05-08-18","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","ANTI-NEOPLASTIC RADIOIMMUNOTHERAPEUTIC","ANTINÉOPLASIQUE RADIOIMMUNOTHÉRAPEUTIQUE","",""
"7296","05-08-19","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7297","05-08-19","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DOSAGE FORM AND NEW FORMULATION","NOUVELLE FORME POSOLOGIQUE ET NOUVELLE FORMULATION","GONADOTROPIN","GONADOTROPHINE","",""
"7298","05-08-18","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANXIOLYTIC","ANTIDÉPRESSEUR, ANXIOLYTIQUE","",""
"7299","05-08-18","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"7300","05-08-18","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTATIONAL AGENT","AGENT PROGESTATIF","",""
"7301","05-08-18","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","SYNTHETIC LONG-ACTING ß1-24 CORTICOTROPIN PEPTIDE","ß1-24 CORTICOTROPHINE SYNTHÉTIQUE À ACTION PROLONGÉE","",""
"7302","05-08-19","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR UPDATED HUMAN CLINICAL STUDIES, NEW DOSING REGIMEN, AND DESCRIPTION OF NEW ANIMAL CARCINOGENICITY AND DRUG INTERACTION STUDIES","PRÉVOIT DES ÉTUDES CLINIQUES À JOUR CHEZ LES HUMAINS, UN NOUVEAU SCHÉMA POSOLOGIQUE ET UNE DESCRIPTION DES NOUVELLES ÉTUDES ANIMALES SUR LA CANCÉROGÉNICITÉ ET LES INTERACTIONS MÉDICAMENTEUSES","AZAPEPTIDE INHIBITOR OF HIV-1 PROTEASE","INHIBITEUR AZAPEPTIDE DE LA PROTÉASE VIH-1","",""
"7303","05-08-22","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","NONCARDIOSELECTIVE ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR NON CARDIOSÉLECTIF DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"7304","05-08-22","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"7305","05-08-22","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOFRACORT","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANTIBIOTIC, CORTICOSTEROID","ANTIBIOTIQUE, CORTICOSTÉROÏDE","",""
"7306","05-08-22","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HAEMATINIC, IRON SUPPLEMENT","HÉMATINIQUE, SUPPLÉMENT DE FER","",""
"7307","05-08-22","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE","ANTIHYPERTENSEUR","",""
"7308","05-08-22","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GARASONE","SCHERING CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID, ANTIBIOTIC","CORTICOSTÉROÏDE TOPIQUE, ANTIBIOTIQUE","",""
"7309","05-08-18","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF EXTENSIVE SAFETY INFORMATION TO THE PRODUCT MONOGRAPH","ADDITION D'IMPORTANTS RENSEIGNEMENTS TOUCHANT L'INNOCUITÉ À LA MONOGRAPHIE DU PRODUIT","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"7310","05-08-23","SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR D'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7311","05-08-23","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL LABORATORIES OF CANADA","CANADA","CANADA","1","","","ANTI-ARRHYTHMIC","ANTIARYTHMIQUE","",""
"7312","05-08-23","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RIVOTRIL","HOFFMANN-LA ROCHE INC.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTIVCONVULSIVANT","",""
"7313","05-08-23","PROTEIN DESIGN LABS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"7314","05-08-24","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOWELLCOME INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT DE LA MIGRAINE","",""
"7315","05-08-24","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT DE LA MIGRAINE","",""
"7316","05-08-24","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLQAXOSMITHKLINE INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT DE LA MIGRAINE","",""
"7317","05-08-24","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT DE LA MIGRAINE","",""
"7318","05-08-24","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXO CANADA INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT DE LA MIGRAINE","",""
"7319","05-08-24","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXO CANADA INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT DE LA MIGRAINE","",""
"7320","05-08-24","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"7321","05-08-24","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT DE LA MIGRAINE","",""
"7322","05-08-24","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7323","05-08-24","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","THYROID HORMONE","HORMONE THYROÏDIENNE","",""
"7324","05-08-25","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTICHOLINERGIC, ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"7325","05-08-25","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE TO INCLUDE CLINICAL DATA FROM DOUBLE-BLIND RANDOMIZED TRIALS AND OPEN-LABEL EXTENSION STUDIES, FOR MONOTHERAPY WITH ROSIGLITAZONE, AND COMBINATION WITH METFORMIN","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT POUR INCLURE DES DONNÉES CLINIQUES PROVENANT D'ESSAIS RANDOMISÉS À DOUBLE INSU ET D'ÉTUDES D'EXTENSION À ÉTIQUETAGE EN CLAIR POUR LA MONOTHÉRAPIE À LA ROSIGLITAZONE ET LE TRAITEMENT COMBINÉ À LA METFORMINE","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"7326","05-08-25","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN-C PHOSPHATE","UPJOHN CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7327","05-08-25","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEBCIN","ELI LILLY INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7328","05-08-25","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"7329","05-08-25","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETOPIC","ALCON CANADA INC.","CANADA","CANADA","1","","","ANTIGLAUCOMA AGENT (OPHTHALMIC)","AGENT POUR LE TRAITEMENT DU GLAUCOME (OPHTALMIQUE)","",""
"7330","05-08-25","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"7331","05-08-25","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FENTANYL CITRATE INJECTION","ABBOTT LABORATORIES","CANADA","CANADA","1","","","OPIOID ANALGESIC, ADJUNCT TO ANAESTHESIA","ANALGÉSIQUE OPIOÏDE, ADJUVANT ANESTHÉSIQUE","",""
"7332","05-08-26","ALTANA PHARMA AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH REFLUX ESOPHAGITIS AND THE RAPID RESOLUTION OF SYMPTOMS ASSOCIATED WITH REFLUX ESOPHAGITIS, SUCH AS HEARTBURN, REGURGITATION AND DYSPEPSIA","POUR LE TRAITEMENT D'ENTRETIEN DU REFLUX GASTRO-OESOPHAGIEN ET LA RÉSOLUTION RAPIDE DES SYMPTÔMES ASSOCIÉS AU REFLUX GASTRO-OESOPHAGIEN TELS QUE BRÛLEMENTS D'ESTOMAC, RÉGURGITATION ET DYSPEPSIE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"7333","05-08-29","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 5 MG TABLETS","NOUVELLE CONCENTRATION : COMPRIMÉS DE 5MG","IMMUNOSUPPRESSIVRE AGENT","IMMUNOSUPPRESSEUR","",""
"7334","05-08-29","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 2 MG TABLETS","NOUVELLE CONCENTRATION : COMPRIMÉS DE 2 MG","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"7335","05-08-29","ALTANA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REFORMULATION TO INCLUDE A CHELATING AGENT - EDTA FORMULATION","REFORMULATION POUR INCORPORER UN AGENT DE CHÉLATION - FORMULATION CONTENANT DU EDTA","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"7336","05-08-31","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7337","05-08-31","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING PROCESS","MÉTHODE DE FABRICATION ALTERNATIVE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"7338","05-08-31","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTI-DIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"7339","05-08-30","AMERSHAM HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN SUPPLIER OF DRUG SUBSTANCE","CHANGEMENT AU FOURNISSEUR DE LA SUBSTANCE MÉDICAMENTEUSE","DIAGNOSTIC IMAGING AGENT","AGENT D'IMAGERIE DIAGNOSTIQUE","",""
"7340","05-08-31","NOVO NORDISK A/S","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTI-DIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"7341","05-08-30","ORYX PHARMACEUTICALS INC., A SUBSIDIARY OF FILIALE D'ARROW PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7342","05-09-02","ORYX PHARMACEUTICALS INC., A SUBSIDIARY OF FILIALE D'ARROW PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT DE LA MIGRAINE","",""
"7343","05-09-01","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE SYMPTOMATIC RELIEF OF PANIC DISORDER","NOUVELLE INDICATION POUR LE TRAITEMENT SYMPTOMATIQUE DU TROUBLE PANIQUE","ANTIDEPRESSANT, ANXIOLYTIC","ANTIDÉPRESSEUR, ANXIOLYTIQUE","",""
"7344","05-09-01","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW LOWER 40 MG STRENGTH AND NEW INDICATION FOR TREATMENT FOLLOWING MYOCARDIAL INFARCTION","NOUVELLE CONCENTRATION PLUS FAIBLE DE 40 MG ET NOUVELLE INDICATION POUR LE TRAITEMENT DES PATIENTS APRÈS UN INFARCTUS DU MYOCARDE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"7345","05-09-02","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIROSACEA AGENT","AGENT ANTIROSACÉE","",""
"7346","05-09-02","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ELCOM 0.1% OINTMENT","SCHERING CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"7347","05-09-02","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYCLOCORT","STIEFEL CANADA INC.","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"7348","05-09-02","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOPRESOR","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ß-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"7349","05-09-02","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT DE LA MIGRAINE","",""
"7350","05-09-02","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"7351","05-09-02","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"7352","05-09-02","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7353","05-09-02","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"7354","05-09-07","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"7355","05-09-02","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7356","05-09-09","IMCLONE SYSTEMS INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"7357","05-09-09","HOFFMANN-LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"7358","05-09-09","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7359","05-09-14","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"7360","05-09-14","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"7361","05-09-14","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"7362","05-09-14","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO-MCNEIL PHARMACEUTICALS INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DE PRODUIT RÉVISÉE","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"7363","05-09-14","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"7364","05-09-14","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"7365","05-09-14","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO-MCNEIL PHARMACEUTICALS INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"7366","05-09-14","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"7367","05-09-14","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"7368","05-09-14","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RIMSO-50","ROBERTS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","INTRAVESICAL INSTILLATION FOR THE TREATMENT OF INTERSTITIAL CYSTITIS","INSTILLATION INTRAVÉSICALE POUR LE TRAITEMENT DE LA CYSTITE INTERSTITIELLE","",""
"7369","05-09-14","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ANEXATE","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","BENZODIAZEPINE ANTAGONIST","ANTAGONISTE DES BENZODIAZÉPINES","",""
"7370","05-09-14","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"7371","05-09-14","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACRIUM","BURROUGHS WELLCOME INC.","CANADA","CANADA","1","","","SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE","",""
"7372","05-09-14","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM INJECTABLE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"7373","05-09-14","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, ANTIHISTAMINE AGENT","ANXIOLYTIQUE, ANTIHISTAMINIQUE","",""
"7374","05-09-14","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"7375","05-09-14","ERFA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"7376","05-09-15","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"7377","05-09-15","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC, ANTIEMETIC","NEUROLEPTIQUE, ANTIÉMÉTIQUE","",""
"7378","05-09-15","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMIKIN","BRISTOL MYERS SQUIBB","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7379","05-09-15","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PRESENTATION","NOUVELLE PRÉSENTATION","URICOLYTIC AGENT","AGENT URICOLYTIQUE","",""
"7380","05-09-16","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: TO INCLUDE RECENT STUDY FINDINGS PRESENTING THE POTENTIAL OEEFECT ON BONE MINERAL DENSITY IN ADULT WOMEN AND ADOLESCENTS","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT : POUR INCLURE LES DONNÉES RÉCENTES ISSUES D'UNE ÉTUDE ÉVALUANT L'EFFET ÉVENTUEL DU PRODUIT SUR LA DENSITÉ MINÉRALE OSSEUSE CHEZ LES FEMMES ET LES ADOLESCENTES","PROGESTIN","PROGESTATIF","",""
"7381","94-03-25","BIOPHARM AUSTRALIA PTY LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY, ANTI-ARTHRITIC","ANTI-INFLAMMATOIRE, ANTI-ARTHRITIQUE","",""
"7382","05-09-16","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN THE OBESITY MANAGEMENT OF ADOLESCENT PATIENTS AGED 12 TO 16 YEARS","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'OBÉSITÉ CHEZ LES JEUNES DE 12 À 16 ANS","ANTI-OBESITY AGENT, GASTROINTESTINAL LIPASE INHIBITOR","AGENT ANTI-OBÉSITÉ, INHIBITEUR DES LIPASES GASTRO-INTESTINALES","",""
"7383","05-09-16","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","VACCINE FOR IMMUNIZATION AGAINST HEPATITIS B VIRUS","VACCIN POUR L'IMMUNISATION CONTRE L'HÉPATITE B","",""
"7384","94-01-21","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","COCCIDIOSTAT","COCCIDIOSTAT","",""
"7385","94-03-25","PVU DIVISION SANOFI","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","AUTRE EMPLACEMENT DE FABRICATION","GONADOTROPHIN RELEASING HORMONE","GONADOLIBÉRINE","",""
"7386","94-05-02","BAYVET, DIVISION OF CHEMAGRO LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTHELMINTIC","VERMIFUGE","",""
"7387","94-05-02","BAYVET, DIVISION OF CHEMAGRO LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTHELMINTIC","VERMIFUGE","",""
"7388","94-03-25","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7389","94-02-12","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTHIC","VERMIFUGE","",""
"7390","94-02-21","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTHIC","VERMIFUGE","",""
"7391","94-08-02","PROVEL, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7392","94-11-09","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"7393","94-06-06","THE UPJOHN COMPANY - ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SPECIES CLAIM","ALLÉGATION CONCERNANT UNE AUTRE ESPÈCE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7394","05-09-20","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO THE PRODUCT MONOGRAPH IN RESPONSE TO TPD LETTER OF DECEMBER 17, 2004","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT CONCERNANT L'INNOCUITÉ EN RÉPONSE À LA LETTRE DE LA DPT DATANT DU 17 DÉCEMBRE 2004","ANALGESIC, ANTI-INFLAMMATORY AGENT","ANALGÉSIQUE, ANTI-INFLAMMATOIRE","",""
"7395","94-02-15","HOECHST CANADA (1996) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SPECIES CLAIM","ALLÉGATION CONCERNANT UNE AUTRE ESPÈCE","PRODUCTION ENHANCEMENT ANTIBIOTIC","ANTIBIOTIQUE POUR L'AMÉLIORATION DE LA PRODUCTION","",""
"7396","94-05-04","GP ASSOCIATES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","JOINT DYSFUNCTION ASSOCIATED WITH EQUINE OSTEO-ARTHRITIS","DYSFONCTIONNEMENT DES ARTICULATIONS ASSOCIÉ À L'ARTHROSE CHEVALINE","",""
"7397","94-06-07","PHARMACIA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","JOINT DYSFUNCTION ASSOCIATED WITH EQUINE OSTEO-ARTHRITIS","DYSFONCTIONNEMENT DES ARTICULATIONS ASSOCIÉ À L'ARTHROSE CHEVALINE","",""
"7398","05-09-20","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TORADOL","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","NSAID ANALGESIC AGENT","ANALGÉSIQUE AINS","",""
"7399","94-11-09","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"7400","05-09-20","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","UPPER GI MOTILITY MODIFIER, ANTIEMETIC","MODIFICATEUR DE LA MOTILITÉ DE LA PROTION SUPÉRIEURE DU TRACTUS GASTRO-INTESTINAL, ANTIÉMÉTIQUE","",""
"7401","05-09-20","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KETALAR","PFIZER CANADA INC.","CANADA","CANADA","1","","","GENERAL ANESTHETIC","ANESTHÉSIQUE GÉNÉRAL","",""
"7402","05-09-20","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRANDATE","ROBERTS PHARMACEUTICAL CANADA","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"7403","05-09-20","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATIVAN","WYETH AYERST CANADA INC.","CANADA","CANADA","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"7404","05-09-20","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","",""
"7405","05-09-20","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"7406","05-09-20","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR INJECTION","SANOFI WINTHROP","CANADA","CANADA","1","","","INOTROPE, VASODILATOR","INOTROPE, VASODILATATEUR","",""
"7407","05-09-20","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTICHOLINERGIC","ANTICHOLINERGIQUE","",""
"7408","05-09-20","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY AND NEW PRESENTATION","NOUVEL EMPLACEMENT DE FABRICATION ET NOUVELLE PRÉSENTATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7409","94-11-21","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7410","94-11-21","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7411","94-11-21","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7412","94-11-21","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7413","05-09-22","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN PRODUCT NAME FROM CHRONOVERA","MODIFICATION DU NOM DU PRODUIT DE CHRONOVERA","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"7414","05-09-23","INO THERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PULMONARY VASODILATOR","VASODILATATEUR PULMONAIRE","",""
"7415","94-11-09","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF INDICATION","PROLONGATION DE L'INDICATION","BROAD SPECTRUM ANTHELMINTIC","VERMIFUGE À LARGE SPECTRE","",""
"7416","94-11-09","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF INDICATION","PROLONGATION DE L'INDICATION","BROAD SPECTRUM ANTHELMINTIC","VERMIFUGE À LARGE SPECTRE","",""
"7417","94-11-09","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF INDICATION","PROLONGATION DE L'INDICATION","BROAD SPECTRUM ANTHELMINTIC","VERMIFUGE À LARGE SPECTRE","",""
"7418","94-11-09","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF INDICATION","PROLONGATION DE L'INDICATION","BROAD SPECTRUM ANTHELMINTIC","VERMIFUGE À LARGE SPECTRE","",""
"7419","94-11-09","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF INDICATION","PROLONGATION DE L'INDICATION","BROAD SPECTRUM ANTHELMINTIC","VERMIFUGE À LARGE SPECTRE","",""
"7420","94-11-09","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF INDICATION","PROLONGATION DE L'INDICATION","BROAD SPECTRUM ANTHELMINTIC","VERMIFUGE À LARGE SPECTRE","",""
"7421","94-11-09","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF INDICATION","PROLONGATION DE L'INDICATION","BROAD SPECTRUM ANTHELMINTIC","VERMIFUGE À LARGE SPECTRE","",""
"7422","94-11-09","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION OF INDICATION","PROLONGATION DE L'INDICATION","BROAD SPECTRUM ANTHELMINTIC","VERMIFUGE À LARGE SPECTRE","",""
"7423","94-01-04","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7424","94-01-04","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7425","94-01-04","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7426","94-01-04","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7427","94-09-19","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7428","94-09-19","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7429","94-10-11","MERCK AGVET, DIVISION OF MERCK FROSST CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO MODIFY THE LABELLING COMPONENTS","POUR MODIFIER LES COMPOSANTS DE L'ÉTIQUETAGE","BROAD SPECTRUM ANTIPARASITIC","ANTIPARASITAIRE À LARGE SPECTRE","",""
"7430","94-08-04","BIO AGRI MIX LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC ANTIBACTERIAL MEDICATED FEED MIX","MÉLANGE ALIMENTAIRE ANTIBIOTIQUE, ANTIBACTÉRIEN","",""
"7431","94-05-04","BIO AGRI MIX LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC ANTIBACTERIAL MEDICATED FEED MIX","MÉLANGE ALIMENTAIRE ANTIBIOTIQUE, ANTIBACTÉRIEN","",""
"7432","94-07-15","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","ANTIBIOTIC FEED PREMIX","NOURRITURE ANTIBIOTIQUE PRÉMÉLANGÉE","",""
"7433","94-07-15","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","ANTIBIOTIC FEED PREMIX","NOURRITURE ANTIBIOTIQUE PRÉMÉLANGÉE","",""
"7434","94-08-04","BIO AGRI MIX LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC ANTIBACTERIAL MEDICATED FEED MIX","MÉLANGE ALIMENTAIRE ANTIBIOTIQUE, ANTIBACTÉRIEN","",""
"7435","05-09-26","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"7436","05-09-26","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"7437","05-09-26","TARO PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"7438","05-09-26","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEUROMUSCULAIRE NON DÉPOLARISANT","",""
"7439","05-09-26","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAVELBINE","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"7440","05-09-26","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VASODILATOR","VASODILATATEUR","",""
"7441","05-09-26","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"7442","05-09-26","ABBOTT LABORATORIES, LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","THYROID HORMONE","HORMONE THYROÏDIENNE","",""
"7443","05-09-26","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"7444","05-09-26","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO THE PRODUCT MONOGRAPH: NEW DOSAGE SCHEDULE FOR RENALLY IMPAIRED PATIENTS","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT CONCERNANT L'INNOCUITÉ : NOUVELLE POSOLOGIE DANS LE CAS DES PATIENTS ATTEINTS D'INSUFFISANCE RÉNALE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7445","05-09-26","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"7446","05-09-26","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT DE LA MIGRAINE","",""
"7447","05-09-26","BARRIER THERAPEUTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HAIR GROWTH INHIBITOR","INHIBITEUR DE LA POUSSE DE CHEVEUX","",""
"7448","05-09-26","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"7449","05-09-26","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SUFENTA","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC, ADJUNCT TO ANESTHESIA","ANALGÉSIQUE OPIOÏDE, ADJUVANT ANESTHÉSIQUE","",""
"7450","05-09-26","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INDERAL","WYETH-AYESRT","CANADA","CANADA","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"7451","03-07-31","TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"7452","94-02-24","DIVERSEY INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","DISINFECTANT","DÉSINFECTANT","",""
"7453","94-01-31","PROVEL, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIBIOTIQUE","ANTIBIOTIQUE","",""
"7454","94-03-25","H.B. FULLER COMPANY - MONARCH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TEAT DIP","BAIN DE TRAYON","",""
"7455","94-08-18","H.B. FULLER COMPANY - MONARCH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TEAT SPRAY","VAPORISATEUR DE TRAYON","",""
"7456","94-11-21","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7457","94-10-31","SMITHKLINE BEECHAM ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7458","94-10-31","SMITHKLINE BEECHAM ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7459","94-10-31","SMITHKLINE BEECHAM ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7460","94-10-31","SMITHKLINE BEECHAM ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7461","94-11-21","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","LACRIMOMIMETIC, ANTI-INFLAMMATORY","LACRIMOMIMÉTIQUE, ANTI-INFLAMMATOIRE","",""
"7462","05-09-28","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMONUMODULATION","",""
"7463","05-09-29","DRAXIMAGE, A DIVISION OF DRAXIS SPECIALTY PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","RADIODIAGNOSTIC KIT","TROUSSE RADIODIAGNOSTIQUE","",""
"7464","05-09-29","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL ÉTABLISSEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"7465","05-09-29","NOVO NORDISK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"7466","94-11-09","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ESTRUS PREVENTION","PRÉVENTION DE L'OESTRUS","",""
"7467","94-11-09","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"7468","94-10-11","ECOLAB INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TEAT DIP","BAIN DE TRAYON","",""
"7469","05-09-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7470","05-09-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7471","05-09-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7472","05-09-30","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN COMBINATION WITH PACLITAXEL FOR PATIENTS WITH UNRESECTABLE, LOCALLY RECURRENT OR METASTATIC BREAST CANCER, WHO HAVE GOOD PERFORMANCE STATUS AND HAVE RELAPSED FOLLOWING ADJUVANT ANTHRACYCLINE-BASED CHEMOTHERAPY.","NOUVELLE INDICATION : ADMINISTRATION EN ASSOCIATION AVEC LE PACLITAXEL AUX PATIENTES ATTEINTES D'UN CANCER DU SEIN NON RÉSÉCABLE, RÉCIDIVANT LOCALEMENT OU MÉTASTATIQUE, QUI ONT UN BON INDICE FONCTIONNEL ET ONT CONNU UNE RECHUTE APRÈS UNE CHIMIOTHÉRAPIE ADJUVANTE À BASE D'ANTHRACYCLINES.","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"7473","94-12-30","HOECHST CANADA (1996) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW CLAIM","NOUVELLE ALLÉGATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7474","94-07-13","WESTERN CHEMICAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","FUNGICIDE, EXTERNAL PARASITICIDE","FONGICIDE, ANTIPARASITAIRE EXTERNE","",""
"7475","94-11-14","BIO AGRI MIX LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7476","94-10-28","SANOFI SANTE ANIMALE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7477","94-11-09","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"7478","94-10-28","SANOFI SANTE ANIMALE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7479","94-11-09","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","INSECTICIDE","INSECTICIDE","",""
"7480","94-11-09","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","INSECTICIDE","INSECTICIDE","",""
"7481","94-10-27","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION ","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7482","94-10-27","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7483","94-10-27","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7484","94-10-27","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW EXPIRATION DATE","NOUVELLE DATE LIMITE D'UTILISATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7485","94-11-21","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7486","94-11-21","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7487","94-11-21","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7488","94-11-21","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REVISED LABELLING","ÉTIQUETTE RÉVISÉE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7489","94-04-19","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7490","94-04-19","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7491","94-04-19","CIBA-GEIGY CANADA LTD., ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7492","94-04-19","CIBA PHARMACEUTICALS, DIVISION OF CIBA GEIGY CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7493","05-10-03","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANTAGONIST","ANTAGONISTE DES OPIOÏDES","",""
"7494","94-11-09","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"7495","94-11-09","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"7496","94-11-09","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANAESTHETIC","ANESTHÉSIQUE","",""
"7497","94-07-06","COOPERS AGROPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC","ANESTHÉSIQUE","",""
"7498","94-03-08","ROUSSEL UCLAF","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","ACTIVATEUR DE CROISSANCE","",""
"7499","94-04-22","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW DOSAGE REGIMEN","NOUVEAU SCHÉMA POSOLOGIQUE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7500","94-06-07","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE, ANALGESIC","SÉDATIF, ANALGÉSIQUE","",""
"7501","94-06-02","MILES CANADA INC. - AGRIC., DIVISION OF ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE, ANALGESIC","SÉDATIF, ANALGÉSIQUE","",""
"7502","94-03-25","PROVEL, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","IONOPHORE ANTIBIOTIC, ANTI-BLOAT AGENT","ANTIBIOTIQUE IONOPHORE, AGENT ANTI-BALLONNEMENT","",""
"7503","94-12-30","HOECHST CANADA (1996) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW CLAIM","NOUVELLE ALLÉGATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7504","94-01-31","HOECHST CANADA (1996) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7505","94-11-09","MALLINCKRODT VETERINARY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","STEROID ANAESTHETIC","ANESTHÉSIQUE STÉROÏDIEN","",""
"7506","94-03-31","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SEDATIVE","SÉDATIF","",""
"7507","94-08-10","AUSA INTERNATIONAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ENDOCRINE DRUG","MÉDICAMENT ENDOCRINIEN","",""
"7508","94-09-28","SYNTEX ANIMAL HEALTH, DIVISION OF SYNTEX INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PACKAGING","NOUVEL EMBALLAGE","ANTHELMINTIC","VERMIFUGE","",""
"7509","94-03-02","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7510","94-02-08","ROGAR/STB INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7511","94-09-30","AVANT SALES, DIVISION OF ROLF C. HAGEN INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","VERMIFUGE","",""
"7512","95-11-24","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC","ANESTHÉSIQUE","",""
"7513","95-02-16","RHONE-POULENC CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7514","95-01-17","CYANAMID CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7515","95-01-17","CYANAMID CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7516","95-01-17","CYANAMID CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7517","95-03-10","MTC PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC","ANESTHÉSIQUE","",""
"7518","95-02-24","SMITHKLINE BEECHAM ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW PACKAGING","NOUVEL EMBALLAGE","ANAESTHETIC","ANESTHÉSIQUE","",""
"7519","95-02-14","H.B. FULLER COMPANY - MONARCH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","TEAT DIP","BAIN DE TRAYON","",""
"7520","95-06-21","BAYER INC., AGRICULTURE DIVISION, ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7521","95-03-16","PEPTIDE TECHNOLOGY LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","OVULATORY INDUCTION AGENT","IMPLANT HORMONAL","",""
"7522","95-02-01","OXIS INTERNATIONAL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"7523","95-01-05","SMITHKLINE BEECHAM ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING","MODIFICATION DE LA FABRICATION","GROWTH PROMOTANT, ANTIBIOTIC","ACTIVATEUR DE CROISSANCE, ANTIBIOTIQUE","",""
"7524","95-10-27","BIO AGRI MIX LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","GRANULATION OF THE PREMIX","GRANULATION DU PRÉMÉLANGE","ANTIBIOTIC, GROWTH PROMOTANT","ANTIBIOTIQUE, ACTIVATEUR DE CROISSANCE","",""
"7525","95-02-21","A.P.A., DIVISION OF VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7526","95-09-15","A.P.A., DIVISION OF RHONE MERIEUX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"7527","95-04-12","SYNTEX ANIMAL HEALTH, DIVISION OF SYNTEX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONAL GROWTH PROMOTANT","ACTIVATEUR DE LA CROISSANCE HORMONALE","",""
"7528","95-04-04","RHONE-POULENC CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITION OF CLAIM: FOR THE PREVENTION OF NECROTIC ENTERITIS IN CHICKENS","NOUVELLE ALLÉGATION: POUR LA PRÉVENTION DE L'ENTÉRITE NÉCROSANTE (POULETS)","ANTIBIOTIC, ANTIBACTERIAL","ANTIBIOTIQUE, ANTIBACTÉRIEN","",""
"7529","05-10-05","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DOBUTREX","ELI LILLY CANADA","CANADA","CANADA","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"7530","05-10-05","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","PREMEDICANT, SEDATIVE, ANAESTHETIC AGENT","PRÉMÉDICATION, SÉDATIF, ANESTHÉSIQUE","",""
"7531","05-10-05","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"7532","05-10-05","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC FOR INTRAVENOUS INFUSION","DIURÉTIQUE POUR INFUSION INTRAVEINEUSE","",""
"7533","05-10-06","UNITED THERAPEUTICS CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW ROUTE OF ADMINISTRATION - INTRAVENOUS","NOUVELLE VOIE D'ADMINISTRATION - INTRAVEINEUSE","VASODILATOR","VASODILATATEUR","",""
"7534","05-10-06","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOWELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"7535","05-10-06","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYKLOKAPRON","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","ANTIFIBRINOLYTIC AGENT","AGENT ANTIFIBRINOLYTIQUE","",""
"7536","05-10-07","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"7537","05-10-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALFENTA","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC, ADJUNCT TO ANESTHESIA","ANALGÉSIQUE OPIOÏDE, ADJUVANT À L'ANESTHÉSIE","",""
"7538","05-10-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBREX","ALCON CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7539","05-10-07","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT : CHANGEMENTS APPORTÉS À LA SECTION POSOLOGIE ET ADMINISTRATION","ORAL HYPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONYLURÉE)","",""
"7540","05-10-11","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"7541","05-10-11","MDS NORDION, A DIVISION OF MDS (CANADA) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","NEW MANUFACTURING PROCESS","NOUVELLE MÉTHODE DE FABRICATION","N/A","S/O","",""
"7542","05-10-11","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MANUFACTURING CHANGES AND NEW PRESENTATION","CHANGEMENTS DANS LA FABRICATION ET NOUVELLE PRÉSENTATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"7543","05-10-11","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MANUFACTURING CHANGES AND NEW PRESENTATION","CHANGEMENTS DANS LA FABRICATION ET NOUVELLE PRÉSENTATION","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"7544","05-10-12","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR THE USE IN THE TREATMENT OF CANDIDEMIA AND OTHER FORMS OF INVASIVE CANDIDIASIS","INDIQUÉ POUR LE TRAITEMENT DE LA CANDIDÉMIE ET D'AUTRES FORMES DE CANDIDOSE INVASIVE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"7545","05-10-12","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ONCE-DAILY 800MG/200MG DOSING REGIMEN OF LOPINAVIR/RITONAVIR (KALETRA) TO BE ADMINISTERED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN ANTIRETROVIRAL NAIVE PATIENTS INFECTED WITH HIV","SCHÉMA POSOLOGIQUE DE 800MG/200MG DE LOPINAVIR/RITONAVIR (KALETRA) UNE FOIS PAR JOUR À ADMINISTRER EN ASSOCIATION AVEC D'AUTRES AGENTS ANTIRÉTROVIRAUX À DES PATIENTS INFECTÉS PAR LE VIH NAÏFS AUX ANTIRÉTROVIRAUX","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"7546","05-10-11","AVENTIS PASTEUR SA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MÉTHODE DE FABRICATION AMÉLIORÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7547","05-10-11","AVENTIS PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MÉTHODE DE FABRICATION AMÉLIORÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7548","05-10-11","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MÉTHODE DE FABRICATION AMÉLIORÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7549","05-10-11","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MÉTHODE DE FABRICATION AMÉLIORÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7550","05-10-11","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MÉTHODE DE FABRICATION AMÉLIORÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7551","05-10-14","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG, ANALGESIC, ANTIPYRETIC AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"7552","05-10-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","GROWTH HORMONE RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR DE L'HORMONE DE CROISSANCE","",""
"7553","05-10-21","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIAZAC","CRYSTAAL CORPORATION, A DIVISION OF BIOVAIL CORPORATION","CANADA","CANADA","1","","","ANTIHYPERTENSIVE, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"7554","05-10-20","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR CHRONIC IDIOPATHIC CONSTIPATION","NOUVELLE INDICATION POUR LE TRAITEMENT DE LA CONSTIPATION IDIOPATHIQUE CHRONIQUE","5-HT4 RECEPTOR PARTIAL AGONIST","AGONISTE PARTIEL DES RÉCEPTEURS 5-HT4","",""
"7555","05-10-24","SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","SELECTIVE IMMUNOMODULATING AGENT","AGENT IMMUNOMODULATEUR SÉLECTIF","",""
"7556","05-10-24","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANAFLEX","ELAN PHARMACEUTICALS INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTISPASTIC AGENT","AGENT ANTISPASMODIQUE","",""
"7557","05-10-24","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DOSING DELIVERY SYSTEM","AUTRE MODE D'ADMINISTRATION DE LA POSOLOGIE","ANTI-DIABETIC AGENT","ANTIDIABÉTIQUE","",""
"7558","05-10-25","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PRODUCT MONOGRAPH FORMAT","NOUVEAU MODE DE PRÉSENTATION DE LA MONOGRAPHIE DE PRODUIT","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"7559","05-10-25","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMBIVENT","BOEHRINGER INGELHEIM LTD.","CANADA","CANADA","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"7560","05-10-28","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA DUE TO MULTI DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE","NOUVELLE INDICATION : TRAITEMENT DE LA PNEUMONIE EXTRAHOSPITALIÈRE À STREPTOCOCCUS PNEUMONIAE MULTIRÉSISTANT","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"7561","05-10-28","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXY-IR","PURDUE PHARMA INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"7562","05-10-28","MONARCH PHARMACEUTICALS IRELAND LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"7563","05-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7564","05-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTOGEN, ANTINEOPLASTIC, ANTIANOREXIC, ANTICACHECTIC","PROGESTATIF, ANTINÉOPLASIQUE, ANTIANOREXIQUE, ANTICACHECTIQUE","",""
"7566","05-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antipsychotic","Antipsychotique","",""
"7567","05-10-28","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"7568","05-10-28","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MUCOMYST","ROBERTS PHARMACEUTICAL CANADA INC.","CANADA","CANADA","1","","","MUCOLYTIC, ANTIDOTE FOR ACETAMINOPHEN POISONING","AGENT MUCOLYTIQUE, ANTIDOTE CONTRE LES INTOXICATIONS PAR L'ACÉTAMINOPHÈNE","",""
"7569","05-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"7570","05-10-28","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPO-MEDROL","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"7571","05-10-28","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL STEROID","STÉROÏDE TOPIQUE","",""
"7572","05-10-28","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7573","05-10-28","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7574","05-10-28","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7575","05-10-28","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOTHERAPEUTIC AGENT","AGENT IMMUNOTHÉRAPEUTIQUE","",""
"7576","05-10-28","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7577","05-10-28","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7578","05-10-28","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7579","05-10-28","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7580","05-10-28","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7581","05-10-28","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7582","05-10-28","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7583","05-11-01","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7584","05-11-01","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7585","05-11-01","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7586","05-11-01","ASTRAZENECA CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE - ATAC-5 YEAR TREATMENT COMPLETION ANALYSIS - POST-APPROVAL COMMITMENT AS PER LETTER OF UNDERTAKING DATED JUNE 30, 2004","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT - ANALYSE DES DONNÉES RECUEILLIES À LA FIN DU TRAITEMENT DE 5 ANS (ÉTUDE ATAC) - ENGAGEMENT APRÈS L'HOMOLOGATION CONFORMÉMENT À LA LETTRE D'ENGAGEMENT DU 30 JUIN 2004","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON-STÉROÏDIEN","",""
"7587","05-11-02","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"7588","05-11-02","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7589","05-11-02","RHOXALPHARMA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7590","05-11-04","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MÉTHODE DA FABRICATION AMÉLIORÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7591","05-11-04","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MÉTHODE DE FABRICATION AMÉLIORÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7592","05-11-04","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7593","05-11-04","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYTIQUE NEUROMUSCULAIRE","",""
"7594","05-11-07","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","IMDUR","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"7595","05-11-07","VITA HEALTH PRODUCTS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL","WHITEHALL-ROBINS INC.","CANADA","CANADA","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"7596","05-11-08","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONYLURÉE)","",""
"7597","05-11-08","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7598","05-11-08","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7599","05-11-08","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7600","05-11-08","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7601","05-11-08","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7602","05-11-08","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7603","05-11-08","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7604","05-11-08","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"7605","05-11-08","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7606","05-11-10","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"7607","05-11-10","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7608","05-11-10","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"7609","05-11-10","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"7610","05-11-14","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCARINIC M3 SELECTIVE RECEPTOR ANTAGONIST","ANTAGONISTE SÉLECTIF DES RÉCEPTEURS MUSCARINIQUES M3","",""
"7611","05-11-14","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIHYPERTENSIVE, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"7612","05-11-14","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - TREATMENT OF FISTULIZING CROHN'S DISEASE, IN ADULT PATIENTS, WHO HAVE NOT RESPONDED DESPITE A FULL AND ADEQUATE COURSE OF THERAPY WITH CONVENTIONAL TREATMENT","NOUVELLE INDICATION - TRAITEMENT DES FISTULES CHEZ LES PATIENTS ADULTES AYANT UNE MALADIE DE CROHN QUI N'ONT PAS RÉPONDU AU TRAITEMENT STANDARD D'UNE DURÉE APPROPRIÉE","BIOLOGICAL RESPONSE MODIFIER","MODULATEUR DES RÉACTIONS BIOLOGIQUES","",""
"7613","05-11-15","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH: SAFETY UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT EN MATIÈRE D'INNOCUITÉ","NON-STEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"7614","05-11-17","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE ANTIANGINAL AGENT AND LIPID METABOLISM REGULATOR","ANTIHYPERTENSEUR ANTIANGINEUX ET RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"7615","05-11-21","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-PEPTIDIC PROTEASE INHIBITOR (NPPI)","INHIBITEUR DE LA PROTÉASE NON PEPTIDIQUE (IPNP)","",""
"7617","05-11-21","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND HYPERTENSION WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE, BUT WITH OTHER RISK FACTORS SUCH AS AGE GREATER THAN OR EQUAL TO 55 YEARS, RETINOPATHY, ALBUMINURIA OR SMOKING","NOUVELLE INDICATION POUR LA RÉDUCTION DU RISQUE D'INFARCTUS DU MYOCARDE ET D'ACCIDENT VASCULAIRE CÉRÉBRAL CHEZ LES PATIENTS ADULTES QUI SOUFFRENT D'UN DIABÈTE SUCRÉ DE TYPE 2 ET D'HYPERTENSION SANS MANIFESTER DE SIGNES CLINIQUES ÉVIDENTS DE CORONAROPATHIE, MAIS QUI PRÉSENTENT D'AUTRES FACTEURS DE RISQUE TELS QUE LE FAIT D'ÊTRE ÂGÉ DE 55 ANS OU PLUS, UNE RÉTINOPATHIE, UNE ALBUMINURIE OU LE TABAGISME","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"7618","05-11-21","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RESTORIL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"7619","05-11-21","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING PROCESS OF THE DRUG PRODUCT","CHANGEMENT DANS LE PROCÉDÉ DE FABRICATION DU PRODUIT PHARMACEUTIQUE","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"7620","05-11-21","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PRESENTATION: 21 DAY PACKAGE; CHANGE TO NEW PRODUCT MONOGRAPH FORMAT","NOUVELLE PRÉSENTATION : EMBALLAGE DE 21 JOURS; CHANGEMENT APPORTÉ AU MODE DE PRÉSENTATION DE LA MONOGRAPHIE DE PRODUIT","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"7621","05-11-21","GILEAD SCIENCES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"7622","05-11-23","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMARYL","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONYLURÉE)","",""
"7623","05-11-23","GENMED, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"7624","05-11-23","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT, FOLIC ACID DERIVATIVE","ANTINÉOPLASIQUE, DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"7625","05-11-23","GENMED, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT ANTIHYPERLIPIDÉMIQUE","",""
"7626","05-11-23","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT ANTIHYPERLIPIDÉMIQUE","",""
"7627","05-11-24","RHOXALPHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIAZAC","CRYSTAAL CORPORATION (A DIVISION OF BIOVAIL CORPORATION)","CANADA","CANADA","1","","","ANTIHYPERTENSIVE, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"7628","05-11-25","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: HEALING OF NSAID'S-ASSOCIATED GASTRIC ULCERS AND RISK REDUCTION OF NSAID'S-ASSOCIATED GASTRIC ULCERS","NOUVELLE INDICATION: CICATRISATION DES ULCÈRES GASTRIQUES ASSOCIÉS AUX AINS ET RÉDUCTION DU RISQUE D'ULCÈRES GASTRIQUES ASSOCIÉS AUX AINS","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"7629","05-11-28","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOTENSIN","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7630","05-11-29","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7631","05-11-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7632","05-12-01","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7633","05-12-01","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"7634","05-12-01","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"7635","05-12-01","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"7636","05-12-01","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","CRYSTAAL, DIVISION OF BIOVAIL CORPORATION","CANADA","CANADA","1","","","ß-Adrenoceptor Blocking Agent","Inhibiteur des récepteurs ß-Adrénergiques","",""
"7637","05-12-01","PURDUE PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIQUE, ANTISPASMODIC","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"7638","05-11-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, AGENT ANTIOBSESSIONNEL","",""
"7639","05-11-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPROBAY","BAYER AG","GERMANY","ALLEMAGNE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"7640","05-11-30","GENZYME CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"7641","05-12-02","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"7642","05-12-05","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7643","05-12-05","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7644","05-12-06","NORBROOK LABORATORIES LTD.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","IVOMEC (IVERMECTIN) POUR-ON FOR CATTLE","MERIAL CANADA INC.","CANADA","CANADA","1","ADDITIONAL INDICATIONS","INDICATIONS SUPPLÉMENTAIRES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7645","05-12-07","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR & LIPID METABOLISM REGULATOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE ET RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7646","05-12-07","SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","INFORMATION FROM THE WHI TRIAL FOR ESTRACE AND NEW PM FORMAT","INFORMATION TIRÉE DE L'ÉTUDE SUR LA SANTÉ DES FEMMES (WHI) RELATIVEMENT À ESTRACE ET NOUVEAU FORMAT DE PM (MONOGRAPHIE DE PRODUIT)","ESTROGEN","OESTROGÈNE","",""
"7647","05-12-08","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7648","05-12-07","HOFFMANN-LA ROCHE LIMITED","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE ADJUVANT TREATMENT OF PATIENTS WITH STAGE III (DUKES' STAGE C) COLON CANCER","INDIQUÉ COMME TRAITEMENT ADJUVANT CHEZ LES PATIENTS ATTEINTS D'UN CANCER DU CÔLON AU STADE III (STADE C SELON LA CLASSIFICATION DE DUKE)","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"7649","05-12-09","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7650","05-12-09","AMGEN CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","KERATINOCYTE GROWTH FACTOR","FACTEUR DE CROISSANCE KERATINOCYTE","",""
"7651","05-12-12","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM CYCLESSA","MODIFICATION DU NOM DU PRODUIT DE CYLCESSA","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"7652","05-12-14","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAMPTOSAR","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"7653","05-12-12","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION - TREATMENT OF CHRONIC HEPATITIS C IN HIV/HCV CO-INFECTION PATIENTS WITH STABLE HIV DISEASE WITH OR WITHOUT ANTIRETROVIRAL THERAPY","NOUVELLE INDICATION - LE TRAITEMENT DE L'HÉPATITE C CHRONIQUE CHEZ LES PATIENTS ATTEINTS D'UNE CO-INFECTION VIH/VHC, DONT LES PARAMÈTRES ASSOCIÉS À L'ÉVOLUTION DE L'INFECTION PAR LE VIH SONT STABLES","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"7654","05-12-12","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION - TREATMENT OF CHRONIC HEPATITIS C IN HIV/HCV CO-INFECTION PATIENTS WITH STABLE HIV DISEASE WITH OR WITHOUT ANTIRETROVIRAL THERAPY","NOUVELLE INDICATION - LE TRAITEMENT DE L'HÉPATITE C CHRONIQUE CHEZ LES PATIENTS ATTEINTS D'UNE CO-INFECTION VIH/VHC, DONT LES PARAMÈTRES ASSOCIÉS À L'ÉVOLUTION DE L'INFECTION PAR LE VIH SONT STABLES","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"7655","05-12-16","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7656","05-12-16","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"7657","05-12-16","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER PLUS ANTIVIRAL AGENT","AGENT D'IMMUNOMODULATION ET AGENT ANTIVIRAL","",""
"7658","05-12-19","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7659","05-12-19","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"7660","05-12-19","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7661","05-12-20","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","ADDITIONAL INDICATION FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED STAGE III/IV FOLICULAR, CD20 POSITIVE, B-CELL NON-HODGKIN'S LYMPHOMA IN COMBINATION WITH CVP (CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISOLONE) CHEMOTHERAPY","INDICATION ADDITIONNELLE POUR LE TRAITEMENT DES PATIENTS ATTEINTS D'UN LYMPHOME NON HODGKINIEN FOLLICULAIRE DE TYPE B, CD20 POSITIF, DE STADE III/IV AUPARAVANT NON TRAITÉS, EN ASSOCIATION AVEC UN PROTOCOLE CHIMIOTHÉRAPIE CVP (CYCLOPHOSPHAMIDE, VINCRISTINE, ET PREDNISOLONE)","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"7662","05-12-21","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT, SUPPRESSION OF ESTRUS","PROMOTEUR DE CROISSANCE, SUPPRESSION DE L'OESTRUS","",""
"7663","05-12-20","PIERRE FABRE PHARMA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"7664","05-12-20","GALDERMA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PROVIDES FOR A NEW STRENGTH","FOURNIS POUR UNE NOUVELLE CONCENTRATION","TREATMENT OF ACNE VULGARIS","TRAITEMENT ANTIACNÉIQUE","",""
"7665","05-12-20","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - TREATMENT OF CHRONIC PLAQUE PSORIASIS / NEW FORMULATION / NEW STRENGTH","NOUVELLE INDICATION - LE TRAITEMENT DU PSORIASIS EN PLAQUE CHRONIQUE / NOUVELLE FORMULATION / NOUVEAU DOSAGE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"7666","05-12-21","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MODIFICATIONS À LA MONOGRAPHIE DU PRODUIT","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"7667","05-12-22","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE: ADDITIONAL SAFETY INFORMATION AND NEW FORMAT","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT : INFORMATION ADDITIONNELLE SUR L'INNOCUITÉ ET NOUVELLE PRÉSENTATION","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"7668","05-12-22","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC, ANTIHYPERTENSIVE","DIURÉTIQUE, ANTIHYPERTENSEUR","",""
"7670","05-12-23","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMARYL","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONYLURÉE)","",""
"7671","05-12-29","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","POST APPROVAL COMMITMENT #1 IN ACCORDANCE WITH LETTER OF UNDERTAKING DATED DECEMBER 22, 2004-GIST; UPDATE TO THE PRODUCT MONOGRAPH","ENGAGEMENT NO 1 À TRANSMETTRE LES RÉSULTATS OBTENUS APRÈS L'APPROBATION, CONFORMÉMENT À LA LETTRE D'ENGAGEMENT DU 22 DÉCEMBRE 2004 - TSGI; MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"7672","05-12-29","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7673","06-01-03","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7674","06-01-06","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING THE INDICATION FOR THE TREATMENT OF ESSENTIAL OR RENOVASCULAR HYPERTENSION","MISE À JOUR DES INDICATIONS POUR LE TRAITEMENT DE L'HYPERTENSION ARTÉRIELLE ESSENTIELLE OU RÉNO-VASCULAIRE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7675","06-01-06","GILEAD SCIENCES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"7676","06-01-06","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AGRYLIN","SHIRE BIOCHEM INC.","CANADA","CANADA","1","","","PLATELET REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"7677","06-01-10","ORYX PHARMACEUTICALS INC., A SUBSIDIARY OF FILIALE D'ARROW PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC AGENT","AGENT ANTICHOLINERGIQUE","",""
"7678","06-01-11","VIRCO PHARMACEUTICALS (CANADA) CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIOTONIC GLYCOSIDE","GLYCOSIDE CARDIOTONIQUE","",""
"7679","06-01-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIBOULIMIQUE","",""
"7680","06-01-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"7681","06-01-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","INHIBITOR OF PLATELET FUNCTION","AGENT ANTIPLAQUETTAIRE","",""
"7682","06-01-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPAKENE","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"7683","06-01-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOECHST MARION ROUSSEL","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"7684","06-01-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7685","06-01-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIVELLE 100","CIBA PHARMACEUTICALS","CANADA","CANADA","1","","","ESTROGEN THERAPY","OESTROGÈNE","",""
"7686","06-01-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"7687","06-01-11","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"7688","06-01-12","ACTELION PHARMACEUTICALS LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR PULMONARY HYPERTENSION SECONDARY TO HUMAN IMMUNODEFICIENCY VIRUS IN PATIENTS WHO DID NOT RESPOND ADEQUATELY TO CONVENTIONAL THERAPY","NOUVELLE INDICATION POUR LE TRAITEMENT DE L'HYPERTENSION PULMONAIRE SECONDAIRE À UNE INFECTION PAR LE VIRUS DE L'IMMUNODÉFICIENCE HUMAINE CHEZ LES PATIENTS QUI NE RÉPONDENT PAS ADÉQUATEMENT AU TRAITEMENT CLASSIQUE","ENDOTHELIN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"7689","06-01-16","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW ONCE DAILY FORMULATION","NOUVELLE FORME À PRENDRE UNE FOIS PAR JOUR","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7690","06-01-17","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7691","06-01-17","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7692","06-01-17","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR THE 35 MG ONCE-A-WEEK TABLETS","NOUVELLE INDICATION: PRÉVENTION DE L'OSTÉOPOROSE POSTMÉNOPAUSIQUE POUR LE COMPRIMÉ DE 35 MG PRIS 1 FOIS PAR SEMAINE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7693","06-01-17","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7694","06-01-17","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"7695","06-01-18","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7696","06-01-20","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7697","06-01-20","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"7698","06-01-19","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"7699","06-01-24","AVENTIX ANIMAL HEALTH CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC / ANTI-INFLAMMATORY","ANTIBIOTIQUE / ANTI-INFLAMMATOIRE","",""
"7700","06-01-26","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATIONS: FENTANYL TRANSDERMAL SYSTEM","NOUVELLES FORMULATIONS: SYSTÈME TRANSDERMIQUE DE FENTANYL","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"7701","06-01-26","WARNER CHILCOTT COMPANY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"7702","06-01-26","WARNER CHILCOTT COMPANY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"7703","06-01-26","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"7704","06-01-26","THREE RIVERS PHARMACEUTICALS, LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","FONGICIDE","",""
"7705","06-01-26","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7706","06-01-26","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7707","06-01-23","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","HEMATOPOIETIC AGENT","AGENT HÉMATOPOÏÉTIQUE","",""
"7708","06-01-25","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE PM WITH LONG TERM EXTENSION STUDY RESULTS","MISE À JOUR DE LA MP EN INCLUANT DES RÉSULTATS D'ÉTUDE D'EXTENSION SUR UNE LONGUE PÉRIODE","ANDROGENIC HORMONE","HORMONE ANDROGÉNIQUE","",""
"7709","06-01-26","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVENOUS NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"7710","06-01-26","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVENOUS FLUID, NUTRITIVE AND ELECTROLYTE SUPPLEMENT","FLUIDE INTRAVEINEUX, SUPPLÉMENT NUTRITIF ET ÉLECTROLYTE","",""
"7711","06-01-27","WARNER CHILCOTT COMPANY, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN-PROGESTIN COMBINATION","COMBINAISON OESTROGÈNE-PROGESTATIF","",""
"7712","06-01-27","PHARMACEUTICAL PARTNERS OF CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAVELBINE","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"7713","06-01-27","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAMBOCOR","3M PHARMACEUTICALS, A DIVISION OF 3M CANADA COMPANY","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARYTHMIQUE","",""
"7714","06-01-27","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AGRYLIN","SHIRE CANADA INC.","CANADA","CANADA","1","","","PLATELET REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"7715","06-01-27","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMARYL","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONYLURÉE)","",""
"7716","06-01-30","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","INCLUSION OF A 14-DAY WITHDRAWAL PERIOD FOR THE SUBJECT PRODUCT ADMINISTERED TO BREEDING SOWS","INCLUSION D'UNE PÉRIODE D'ATTENTE DE 14 JOURS LORSQUE CE PRODUIT EST ADMINISTRÉ AUX TRUIES REPRODUCTRICES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7717","06-01-27","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","MASTITIS CONTROL","CONTRÔLE DE LA MAMMITE","",""
"7718","06-01-30","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7719","06-01-30","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7720","06-01-30","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7721","06-01-30","GENMED, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7722","06-01-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"7723","06-01-31","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM","INDICATION ADDITIONNELLE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7724","06-01-31","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM","INDICATION ADDITIONNELLE","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7725","06-01-31","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS MAINTENANCE TREATMENT","NOUVELLE INDICATION: POUR LE TRAITEMENT DE PATIENTS NOUVELLEMENT ATTEINTS D'UN GLIOBLASTOME MULTIFORME EN ASSOCIATION AVEC LA RADIOTHÉRAPIE ET ENSUITE COMME TRAITEMENT D'ENTRETIEN","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"7726","06-02-01","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF THE INDICATION OF PROPHYLAXIS AGAINST INFLUENZA IN CHILDREN AGED 1-12 YEARS","AJOUT DE L'INDICATION DE PROPHYLAXIE ANTIGRIPPALE CHEZ LES ENFANTS ÂGÉS DE 1 À 12 ANS","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"7727","06-02-01","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATIVE MANUFACTURNG FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"7728","06-01-31","BIMEDA-MTC ANIMAL HEALTH INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","EQVALAN ORAL PASTE FOR HORSES","MERIAL CANADA INC.","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7729","06-02-02","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIOTONIC GLYCOSIDE","GLUCOSIDE CARDIOTONIQUE","",""
"7730","06-02-02","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIOTONIC GLYCOSIDE","GLUCOSIDE CARDIOTONIQUE","",""
"7731","06-02-01","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","LABEL CHANGE","MODIFICATION DE L'ÉTIQUETTE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"7732","06-02-02","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7733","06-02-02","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE THE PRODUCT MONOGRAPH FORMAT AND TO PROVIDE A LABEL UPDATE ON THE CONCOMITANT USE OF CANCIDAS AND CYCLOSPORINE A","METTRE À JOUR LE MODE DE PRÉSENTATION DE LA MONOGRAPHIE DE PRODUIT ET FOURNIR UNE MISE À JOUR DE L'ÉTIQUETTE PORTANT SUR L'UTILISATION CONCOMITANTE DE CANCIDAS ET DE CYCLOSPORINE A","ANTIFUNGAL","ANTIFONGIQUE","",""
"7734","06-02-03","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7735","06-02-03","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMBIVENT","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"7736","06-02-03","PERRIGO INTERNATIONAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL EXTRA STRENGTH CAPLETS","WHITEHALL ROBINS INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"7737","06-02-06","BIMEDA-MTC ANIMAL HEALTH INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC (IVERMECTIN) INJECTION FOR CATTLE, SWINE AND SHEEP","MERIAL CANADA INC.","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7738","06-02-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"7739","06-02-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"7740","06-02-07","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"7741","06-02-07","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"7742","06-02-08","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXTENDED INDICATION - TREATMENT OF PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH METHOTREXATE","INDICATION SUPPLÉMENTAIRE - TRAITEMENT DES FORMES MODÉRÉES OU GRAVES DE LA POLYARTHRITE RHUMATOIDE CHEZ LES PATIENTS QUI N'ONT PAS ÉTÉ TRAITÉS ANTÉRIEUREMENT AU MÉTHOTREXATE","SELECTIVE IMMUNOSUPPRESSIVE AGENT","AGENT IMMUNOSUPPRESSEUR SÉLECTIF","",""
"7743","06-02-08","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH FOR QT PROLONGATION DATA","MONOGRAPHIE DE PRODUIT RÉVISÉE EN CE QUI A TRAIT AUX DONNÉES SUR L'ALLONGEMENT DE L'INTERVALLE QT","ANTICHOLINERGIC, ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"7744","06-02-08","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH FOR QT PROLONGATION DATA","MONOGRAPHIE DE PRODUIT RÉVISÉE EN CE QUI A TRAIT AUX DONNÉES SUR L'ALLONGEMENT DE L'INTERVALLE QT","ANTICHOLINERGIC, ANTISPASMODIC AGENT","ANTICHOLINERGIQUE, ANTISPASMODIQUE","",""
"7745","06-02-09","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","INCLUSION OF THE STATEMENT: NOT INCLUDED FOR THE PROPHYLACTIC THERAPY OF MIGRAINE, IN THE PRODUCT MONOGRAPH","INCLUSION DE LA DÉCLARATION : N'EST PAS INDIQUÉ POUR LE TRAITEMENT PROPHYLACTIQUE DE LA MIGRAINE, DANS LA MONOGRAPHIE DU PRODUIT","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"7746","06-02-13","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","INCLUSION OF STATEMENT <NOT INTENDED FOR THE PROPHYLACTIC THERAPY OF MIGRAINE> IN THE PRODUCT MONOGRAPH","INCLUSION DE LA DÉCLARATION <N'EST PAS INDIQUÉ POUR LE TRAITEMENT PROPHYLACTIQUE DE LA MIGRAINE> DANS LA MONOGRAPHIE DU PRODUIT","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"7747","06-02-13","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: CHANGE TO THE DOSAGE AND ADMINISTRATION LABELLING INSTRUCTIONS","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT : MODIFICATION APPORTÉE AUX INSTRUCTIONS DE L'ÉTIQUETAGE RELATIVES À LA POSOLOGIE ET À L'ADMINISTRATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7748","06-02-13","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: ADDITION OF CLINICAL REFERENCES AND SAFETY DATA","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT : AJOUT DE RÉFÉRENCES CLINIQUES ET DE DONNÉES SUR L'INNOCUITÉ","SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM)","MODULATEUR SÉLECTIF DES RÉCEPTEURS ESTROGÉNIQUES (MSRE)","",""
"7749","06-02-13","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","INCLUSION OF STATEMENT <NOT INTENDED FOR THE PROPHYKACTIC THERAPY OF MIGRAINE> IN THE PRODUCT MONOGRAPH","INCLUSION DE LA DÉCLARATION <N'EST PAS INDIQUÉ POUR LE TRAITEMENT PROPHYLACTIQUE DE LA MIGRAINE> DANS LA MONOGRAPHIE DU PRODUIT","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"7750","06-02-13","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH BASED ON INFORMATION FROM PROSTATE CANCER PREVENTION TRIAL","MONOGRAPHIE DE PRODUIT RÉVISÉE À LA LUMIÈRE DES DONNÉES D'UN ESSAI DE PRÉVENTION DU CANCER DE LA PROSTATE","TYPE II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"7752","06-02-14","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - GROWTH FAILURE IN PATIENTS SMALL FOR GESTATIONAL AGE","NOUVELLE INDICATION - ABSENCE DE CROISSANCE CHEZ LES PATIENTS PETITS POUR LEUR ÂGE GESTATIONNEL","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"7753","06-02-13","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - MALE INFERTILITY","NOUVELLE INDICATION - INFERTILITÉ MASCULINE","HUMAN GONADOTROPIN","GONADOTROPHINE HUMAINE","",""
"7754","06-02-14","SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SYMPTOMATIC TREATMENT OF EXCESSIVE SLEEPINESS IN SHIFT WORK SLEEP DISORDER (SWSD)","NOUVELLE INDICATION : TRAITEMENT SYMPTOMATIQUE DES TROUBLES DU SOMMEIL RELIÉS AU TRAVAIL PAR QUARTS","CNS STIMULANT","STIMULANT DU SNC","",""
"7755","06-02-15","METHAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","CHOLINERGIC, DIAGNOSTIC AID (BRONCHIAL ASTHMA)","CHOLINERGIQUE, AUXILIAIRE DIAGNOSTIQUE (ASTHME BRONCHIQUE)","",""
"7756","06-02-16","AUROBINDO PHARMA LIMITED (UNIT III)","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRAMIL","H. LUNDBECK A/S (DENMARK)","UNITED KINGDOM","ROYAUME-UNI","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7757","06-02-17","GENZYME CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING FACILITY","CHANGEMENTS À L'EMPLACEMENT DE FABRICATION","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"7758","06-02-17","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PRESENTATION - OPTISET","NOUVELLE PRÉSENTATION - OPTISET","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"7759","06-02-16","BERNA BIOTECH LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING PROCESS","CHANGEMENTS À LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7760","06-02-17","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"7761","06-02-17","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDRONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR, ANTI-PAGETIC AGENT, ANTI-HYPERCALCEMIC AGENT","RÉGULATEUR DU MÉTABOLISME OSSEUX, AGENT ANTIPAGÉTIQUE, AGENT ANTIHYPERCALCÉMIQUE","",""
"7762","06-02-17","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOWELLCOME INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"7763","06-02-17","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOACTIVE AGENT","AGENT VASO-ACTIF","",""
"7764","06-02-17","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"7765","06-02-17","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEORAL","NOVARTIS PHARMACEUTICALS","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"7766","06-02-17","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"7767","06-02-17","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC","HYPOGLYCÉMIANT ORAL","",""
"7768","06-02-17","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT ORAL","",""
"7769","06-02-17","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"7770","06-02-20","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","CORTICOSTEROID FOR ORAL INHALATION","CORTICOSTÉROÏDE POUR INHALATION ORALE","",""
"7771","06-02-16","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"7773","06-02-21","VIRBAC AH, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7774","06-02-20","ASTELLAS PHARMA CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY ANTISPASMODIC","ANTISPASMODIQUE DES VOIES URINAIRES","",""
"7775","06-02-20","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","BRONCHODILATOR (BETA2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT DES RÉCEPTEURS ß2-ADRÉNERGIQUES)","",""
"7776","06-02-20","CIPHER PHARMACEUTICALS LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL SUPRA","LABORATOIRES FOURNIER S.A.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7777","06-02-17","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - THE LONG-TERM TREATMENT OF SHORT STATURE ASSOCIATED WITH TURNER SYNDROME","NOUVELLE INDICATION - TRAITEMENT À LONG-TERME DU RETARD DE CROISSANCE ASSOCIÉ AU SYNDROME TURNER","GROWTH HORMONE","HORMONE DE CROISSANCE","",""
"7778","06-02-22","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE L'INFORMATION SUR L'INNOCUITÉ DANS LA MONOGRAPHIE DE PRODUIT","CNS STIMULANT","STIMULANT DU SNC","",""
"7779","06-02-22","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE L'INFORMATION SUR L'INNOCUITÉ DANS LA MONOGRAPHIE DE PRODUIT","CNS STIMULANT","STIMULANT DU SNC","",""
"7780","06-02-22","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE L'INFORMATION SUR L'INNOCUITÉ DANS LA MONOGRAPHIE DE PRODUIT","CNS STIMULANT","STIMULANT DU SNC","",""
"7781","06-02-22","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","PROGESTIN","PROGESTATIF","",""
"7782","06-02-27","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MÉTHODE DE FABRICATION AMÉLIORÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7783","06-02-27","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"7784","06-02-27","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AND ANTICONVULSANT","HYPNOTIQUE ET ANTICONVULSIVANT","",""
"7785","06-02-27","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE AND NEW FILL VOLUME","SITE DE FABRICATION ALTERNATIF ET NOUVEAU VOLUME DE REMPLISSAGE","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"7786","06-02-27","STIEFEL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","THE PROPHYLAXIS AND TREATMENT OF DANDRUFF OR THE TREATMENT OF SEBORRHOEIC DERMATITIS IN WHICH THE YEAST MALASSEZIA FURFUR IS INVOLVED","LA PROPHYLAXIE ET LE TRAITEMENT DES PELLICULES OU LE TRAITEMENT DE LA DERMATITE SEBORRHÉIQUE ASSOCIÉE À LA LEVURE MALASSEZIA FURFUR","TOPICAL ANTIFUNGAL","ANTIFONGIQUE TOPIQUE","",""
"7787","06-02-27","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"7788","06-03-01","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID WITH ANTIBACTERIAL, ANTIFUNGAL AGENT","CORTICOSTÉROÏDE TOPIQUE, ANTIBACTÉRIEN, ANTIFONGIQUE","",""
"7789","06-03-01","LUNDBECK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","MAINTENANCE OF ANTIDEPRESSANT RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)","MAINTIEN DE LA RÉPONSE ANTIDÉPRESSIVE CHEZ LES PATIENTS AVEC TROUBLE DÉPRESSIF SÉVÈRE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7790","06-03-01","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL, ANTIFUNGAL AGENT WITH TOPICAL CORTICOSTEROID","ANTIBACTÉRIEN, ANTIFONGIQUE, CORTICOSTÉROÏDE TOPIQUE","",""
"7791","06-03-01","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RECTAL ANTI-INFLAMMATORY CORTICOSTEROID FOAM","CORTICOSTÉROÏDE ANTI-INFLAMMATOIRE RECTAL","",""
"7792","06-03-01","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRHEUMATIC AGENT","ANTIRHUMATISMAL","",""
"7793","06-03-01","GENMED, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"7794","06-03-03","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITION OF CLINICAL DATA","L'ADDITION D'INFORMATION CLINIQUE","HEMATOPOIETIC AGENT","AGENT HÉMATOPOÏÉTIQUE","",""
"7795","06-03-02","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"7796","06-03-02","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN THE MANUFACTURING PROCESS FOR THE DRUG PRODUCT","CHANGEMENT DANS LA MÉTHODE DE FABRICATION POUR LE PRODUIT MÉDICAMENTEUX","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"7797","06-03-03","TALECRIS BIOTHERAPEUTICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"7798","06-03-03","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY / ANALGESIC","ANTI-INFLAMMATOIRE TOPIQUE / ANALGÉSIQUE","",""
"7799","06-03-03","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"7800","06-03-03","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7801","06-03-03","LABORATOIRE RIVA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"7802","06-03-03","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"7803","06-03-06","AVENTIX ANIMAL HEALTH CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL, ANTIFUNGAL, ANTI-INFLAMMATORY","ANTIBACTÉRIEN, ANTIFONGIQUE, ANTI-INFLAMMATOIRE","",""
"7804","06-03-07","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON-STÉROÏDIEN","",""
"7805","06-03-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIAZAC","CRYSTAAL CORPORATION (A DIVISION OF BIOVAIL CORPORATION)","CANADA","CANADA","1","","","Antihypertensive, Antianginal Agent","Antihypertenseur, Antiangineux","",""
"7806","06-03-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"7807","06-03-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE ANXIEUX SOCIAL), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"7808","06-03-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7809","06-03-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"7810","06-03-07","TRANSKARYOTIC THERAPIES INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITIES AND CHANGES TO MANUFACTURING PROCESS","NOUVEAUX EMPLACEMENTS DE FABRICATION ET MODIFICATIONS AU PROCESSUS DE FABRICATION","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"7811","06-03-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7812","06-03-06","CHANELLE PHARMACEUTICALS MANUFACTURING LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","ANTIROBE CAPSULES 25 MG","PHARMACIA ANIMAL HEALTH","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7813","06-03-06","CHANELLE PHARMACEUTICALS MANUFACTURING LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","ANTIROBE CAPSULES 75 MG","PHARMACIA ANIMAL HEALTH","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7814","06-03-06","CHANELLE PHARMACEUTICALS MANUFACTURING LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","ANTIROBE CAPSULES 150 MG","PHARMACIA ANIMAL HEALTH","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7815","06-03-08","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING THE INDICATION FOR THE TREATMENT OF ESSENTIAL HYPERTENSION IN PATIENTS FOR WHOM THIS COMBINATION THERAPY IS APPROPRIATE","MISE À JOUR DE L'INDICATION DU TRAITEMENT DE L'HYPERTENSION ARTÉRIELLE ESSENTIELLE CHEZ LES PATIENTS POUR QUI UNE ASSOCIATION MÉDICAMENTEUSE EST APPROPRIÉE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"7816","06-03-09","LABORATOIRE RIVA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"7817","06-03-09","MGI PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"7818","06-03-09","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"7819","06-03-10","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION - TREATMENT OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY","NOUVELLE INDICATION - TRAITEMENT DES FORMES MODÉRÉES OU GRAVES DE COLITE ULCÉREUSE CHEZ LES PATIENTS DONT LA RÉPONSE AU TRAITEMENT STANDARD N'EST PAS SATISFAISANTE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"7820","06-03-10","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7821","06-03-10","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","CGMP-Specific Phosphodiesterase Type 5 Inhibitor","Inhibiteur de la phosphodiestérase de type 5 spécifique du GMPC","",""
"7822","06-03-10","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE (LHRH)","",""
"7823","06-03-10","FRESENIUS KABI DEUTSCHLAND GMBH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLASMA VOLUME EXPANDER","SOLUTÉ DE REMPLISSAGE PLASMATIQUE","",""
"7824","06-03-10","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH REGARDING LONG TERM SAFETY/EFFICACY DATA, AND CHANGES TO CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, AND DRUG-DRUG INTERACTIONS, INCLUDING THE ADDITION OF IMMUNE RECONSTITUTION SYNDROME","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT EN CE QUI CONCERNE LES DONNÉES SUR L'INNOCUITÉ/EFFICACITÉ À LONG TERME ET CHANGEMENTS APPORTÉS AUX CONTRE-INDICATIONS, MISES EN GARDE ET PRÉCAUTIONS AINSI QU'AUX INTERACTIONS MÉDICAMENT-MÉDICAMENT, Y COMPRIS L'AJOUT DU SYNDROME DE RECONSTITUTION IMMUNITAIRE","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"7825","06-03-13","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"7826","06-03-13","F.H. FAULDING & CO LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"7827","06-03-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMATINE","SHIRE CANADA INC.","CANADA","CANADA","1","","","VASOPRESSOR","VASOPRESSEUR","",""
"7828","06-03-15","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7829","06-03-15","JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL PERIODONTAL AGENT","AGENT PÉRIODONTIQUE ANTIBACTÉRIEN","",""
"7830","06-03-17","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","APO-DOMPERIDONE","APOTEX INC.","CANADA","CANADA","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"7831","06-03-17","ALCON CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN F2ALPHA ANALOGUE AND BETA-ADRENERGIC RECEPTOR BLOCKER","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA ET INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"7832","06-03-17","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"7833","06-03-17","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONYLURÉE)","",""
"7834","06-03-17","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"7835","06-03-21","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH","MISE À JOUR DE L'INNOCUITÉ DE LA MONOGRAPHIE DU PRODUIT","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"7836","06-03-21","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT / ANTITHROMBOTIC","ANTICOAGULANT / ANTITHROMBOTIQUE","",""
"7837","06-03-21","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"7838","06-03-21","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7839","06-03-21","SANOFI-AVENTIS CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGLUTAMATE","ANTIGLUTAMATE","",""
"7840","06-03-20","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","LACRIMOMIMETIC-ANTIINFLAMMATORY","LACRIMOMIMÉTIQUE-ANTIINFLAMMATOIRE","",""
"7841","06-03-27","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PRESERVATIVE-FREE FORMULATION FOR A SINGLE DOSE UNIT","NOUVELLE FORMULATION","ANTI-ALLERGY AGENT","AGENT ANTIALLETGIQUE","",""
"7842","06-03-28","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR","INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA NORÉPINÉPHRINE","",""
"7843","06-03-28","PURDUE PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SNC","",""
"7844","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL - ANTIPROTOZOAL","ANTIBACTÉRIEN - ANTIPROTOZOAIRE","",""
"7845","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","URICOLYTIC AGENT","AGENT URICOLYTIQUE","",""
"7846","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITUSSIVE - ANTIHISTAMINE","ANTITUSSIF - ANTIHISTAMINIQUE","",""
"7847","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1-RECEPTOR ANTAGONISTE / SYMPATHOMIMETIC AMINE","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE / AMINE SYMPATHOMIMÉTIQUE","",""
"7848","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC","ANALGÉSIQUE NARCOTIQUE","",""
"7849","06-03-29","COBALT PHARMACEUTICALS INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMBIVENT","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","BRONCHODILATOR","BRONCHODILATATEUR","",""
"7850","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ANALOG","ANALOGUE AGONISTE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE","",""
"7851","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT","ANOREXIGÈNE","",""
"7852","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER / DIURETIC","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II / DIURÉTIQUE","",""
"7853","06-03-29","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE REMOVAL OF THE LABELLING CAUTION STATEMENT: COBAN PREMIX SHOULD NOT BE FED TO TURKEYS OVER 10 WEEKS OF AGE.","FAIRE EN SORTE QUE LA MENTION LE PRÉMÉLANGE COBAN NE DOIT PAS ÊTRE ADMINISTRÉ AUX DINDONS DE PLUS DE 10 SEMAINES PRÉSENTE DANS LA SECTION PRÉCAUTIONS SOIT ENLEVÉE DE L'ÉTIQUETTE","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"7854","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7855","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"7856","06-03-29","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"7857","06-03-29","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST MEDIUM","AGENT DE CONTRASTE","",""
"7858","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"7859","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPTOMATIC TREATMENT OF BENIGN PRSTATIC HYPERPLASIA (BPH) - ADJUNCTIVE THERAPY IN ACUTE URINARY RETENTION (AUR)","TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE - TRAITEMENT ADJUVANT DE LA RÉTENTION URINAIRE AIGUË","",""
"7860","06-03-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-BACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"7861","06-03-30","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION TO RECOMMEND NOT INITIATING TREATMENT TO PATIENTS 65 YEARS AND OLDER","RÉVISION DE LA MONOGRAPHIE DE PRODUIT POUR RECOMMANDER DE NA PAS ADMINISTRER LE TRAITEMENT À DES PATIENTS DE 65 ANS ET PLUS","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"7862","06-03-31","GENZYME CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXPAND INDICATION TO INCLUDE TYPE 3 GAUCHER DISEASE","MODIFICATION DE L'INDICATION POUR INCLURE LA MALADIE DE GAUCHER DE TYPE 3","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"7863","06-03-31","ZLB BEHRING GMBH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","PRODUCTION PROCESS MODIFICATIONS","MODIFICATION DE LA MÉTHODE DE FABRICATION","FIBRINOLYTIC AGENT","SGENT FIBRINOLYTIQUE","",""
"7864","06-03-31","PROTEIN DESIGN LABS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITES AND PRODUCTION PROCESS MODIFICATIONS","NOUVEAUX EMPLACEMENTS DE FABRICATION ET MODIFICATIONS DE LA MÉTHODE DE FABRICATION","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"7865","06-03-31","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMARYL","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONYLURÉE)","",""
"7866","06-03-31","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW 500 MG TABLET AND ADDITIONAL DOSING REGIMEN","NOUVEAU COMPRIMÉ DE 500 MG ET RÉGIME POSOLOGIQUE ADDITIONEL","HIV PROTEASE INHIBITOR/ANTIRETROVIRAL AGENT","INHIBITEUR VIH PROTÉASE/AGENT ANTIRÉTROVIRAL","",""
"7867","06-04-03","VIRBAC AH, INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","EQVALAN (IVERMECTIN) ORAL PASTE FOR HORSES","MERIAL CANADA INC.","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"7868","06-03-31","SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"7869","06-04-05","PDL BIOPHARMA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"7870","06-04-07","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"7871","06-04-07","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"7872","06-04-07","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"7874","06-04-07","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","HEMATOPOIETIC AGENT","AGENT HÉMATOPOÏÉTIQUE","",""
"7875","06-04-07","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","HEMATOPOIETIC AGENT","AGENT HÉMATOPOÏÉTIQUE","",""
"7876","06-04-10","AVENTIS PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW ADMINISTRATION SCHEME","NOUVEAU PLAN POSOLOGIQUE","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"7877","06-04-11","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISION TO PRODUCT MONOGRAPH SUPPORTING THE USE OF MORE THAN FIVE DOSES OF PALIVIZUMAB WITHIN A SINGLE RESPIRATORY SYNCYTIAL VIRUS SEASON","RÉVISION DE LA MONOGRAPHIE DU PRODUIT POUR INCLURE L'USAGE DE PLUS DE CINQ DOSES DE PALIVIZUMAB PENDANT LA SAISON DES INFECTIONS PAR LE VIRUS RESPIRATOIRE SYNCYTIAL","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"7878","06-04-11","OPI S.A.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","CYTOSTATIC","AGENT CYTOSTATIQUE","",""
"7879","06-04-12","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MÉTHODE DE FABRICATION AMÉLIORÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7880","06-04-12","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","REPLACEMENT THERAPY FOR IMMUNODEFICIENCIES","TRAITEMENT SUBSTITUTIF DE L'IMMUNODÉFICIENCE","",""
"7881","06-04-12","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"7882","06-04-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE FORMULATION AND MANUFACTURING METHOD","AUTRE MÉTHODE DE FABRICATION ET FORMULATION","5-HT4 RECEPTOR PARTIAL AGONIST","AGONISTE PARTIEL DES RÉCEPTEURS 5-HT4","",""
"7883","06-04-18","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PITUITARY GONADOTROPIN INHIBITOR","INHIBITEUR DES GONADOTROPHINES HYPOPHYSAIRES","",""
"7884","06-04-18","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","",""
"7885","06-04-18","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V.","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"7886","06-04-18","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"7887","06-04-18","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"7888","06-04-18","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OVULATORY AGENT","AGENT OVULATOIRE","",""
"7889","06-04-18","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ION EXCHANGE RESIN","RÉSINE ÉCHANGEUSE D'IONS","",""
"7890","06-04-18","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AGENT","AGENT HYPNOTIQUE","",""
"7891","06-04-18","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7892","06-04-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO-MCNEIL PHARMACEUTICAL INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEPILEPTIC / MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE / PROPHYLAXIE DE LA MIGRAINE","",""
"7893","06-04-19","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"7894","06-04-19","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"7895","06-04-19","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXO WELCOME GMBH & CO.","GERMANY","ALLEMAGNE","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"7896","06-04-19","OMEGA LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE LTD.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"7897","06-04-19","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"7898","06-04-19","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"7899","06-04-19","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"7900","06-04-19","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE UK LTD.","UNITED KINGDOM","ROYAUME-UNI","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"7901","06-04-21","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL SUPRA","LABORATOIRES FOURNIER S.A.","CANADA","CANADA","1","ADDITIONAL DOSAGE FORMS","FORME POSOLOGIQUE ADDITIONELLE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"7902","06-04-19","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN EXPIRATION DATE TO 24 MONTHS, CHANGE IN MANUFACTURING SITE, CHANGE IN FORMULATION, CHANGES IN MANUFACTURING AND ADDITIONAL PACKAGE SIZE - 100ML","CHANGEMENT DE LA DATE LIMITE D'UTILISATION À 24 MOIS, AUTRE EMPLACEMENT DU SITE DE FABRICATION, MODIFICATION DE LA COMPOSITION, MODIFICATION DANS LA FABRICATION ET EMBALLAGE ADDITIONEL - 100ML","PROSTAGLANDIN","PROSTAGLANDINE","",""
"7903","06-04-13","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7904","06-04-24","JANSSEN-ORTHO INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF PROGRESSIVE MULTIPLE MYELOMA IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY AND WHO HAVE ALREADY UNDERGONE OR ARE UNSUITABLE FOR STEM CELL TRANSPLANTATION","NOUVELLE INDICATION : POUR LE TRAITEMENT DU MYÉLOME MULTIPLE EN PROGRESSION CHEZ LES PATIENTS QUI ONT REÇU AU MOINS UN TRAITEMENT ANTÉRIEUR ET QUI ONT DÉJÀ BÉNÉFICIÉ D'UNE GREFFE DE MOELLE OSSEUSE OU NE SONT PAS ADMISSIBLES À UNE TELLE GREFFE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"7905","06-04-19","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"7906","06-04-18","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC","NEUROLEPTIQUE","",""
"7907","06-04-25","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"7908","06-04-25","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"7909","06-04-26","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7910","06-04-26","LUNDBECK CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE POUR LE TRACTUS GASTRO-INTESTINAL INFÉRIEUR","",""
"7911","06-04-28","ELAN PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION POSOLOGIE ET MODE D'ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT","ANTISPASTIC AGENT","ANTISPASMODIQUE","",""
"7912","06-04-27","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","HORMONE","HORMONE","",""
"7913","06-05-01","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7914","06-05-01","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","URSO","AXCAN PHARMA INC.","CANADA","CANADA","1","","","CHOLESTATIC LIVER DISEASES","MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"7915","06-05-01","VITA HEALTH PRODUCTS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL EXTRA STRENGTH CAPLETS","WYETH CONSUMER HEALTHCARE INC.","CANADA","CANADA","1","","","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"7916","06-05-02","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"7917","06-05-02","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","FIXED POLYSORBATE 80 FORMULATION","FORMULATION AVEC UNE CONCENTRATION FIXE DE POLYSORBATE 80","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"7918","06-05-02","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"7919","06-05-03","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIDIABETIC AGENT/LONG-ACTING RECOMBINANT HUMAN INSULIN ANALOGUE","AGENT ANTIDIABÉTIQUE","",""
"7920","06-05-03","ASTRAZENECA CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH AND REVISED INDICATION","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT ET DE L'INDICATION","EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI)","INHIBITEUR DE LA TYROSINE KINASE DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE","",""
"7921","06-05-03","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR PEDIATRIC USE","NOUVELLE INDICATION POUR USAGE CHEZ LES ENFANTS","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7922","06-05-04","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7923","06-05-03","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"7924","06-05-04","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTI-ALLERGIC AGENT","ANTIALLERGIQUE ORAL","",""
"7925","06-05-04","NOVARTIS CONSUMER HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"7926","06-05-04","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLAXIS OF SYMPTOMS OF BRONCHIAL ASTHMA","PROPHYLAXIE DE L'ASTHME BRONCHIQUE","",""
"7927","06-05-04","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7928","06-05-04","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"7929","06-05-04","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"7930","06-05-04","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUTEINIZING HORMONE-RELEASING HORMONE (LH-RH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE (LH-RH)","",""
"7931","06-05-04","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"7932","06-05-05","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERGIL SOLTAB","ORGANON GMBH","GERMANY","ALLEMAGNE","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7933","06-05-05","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCAEMIC","HYPOGLYCÉMIANT ORAL","",""
"7934","06-05-05","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","BACTROBAN OINTMENT 2%","GLAXOSMITHKLINE INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"7935","06-05-09","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"7936","06-05-11","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"7937","06-05-11","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"7938","06-05-11","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"7939","06-05-11","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC REAGENT (FOR THE PREPARATION OF RADIOLABELLED PHARMACEUTICALS)","RÉACTIF RADIODIAGNOSTIQUE (POUR LA PRÉPARATION DE MÉDICAMENTS RADIOMARQUÉS)","",""
"7940","06-05-11","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"7941","06-05-11","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"7942","06-05-11","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT (MEASUREMENT OF BILE ACID POOL LOSS)","AGENT RADIODIAGNOSTIQUE (MESURE DE LA PERTE DES RÉSERVES D'ACIDE BILIAIRE)","",""
"7943","06-05-11","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","URINARY ANTIBACTERIAL","ANTIBACTÉRIEN DES VOIES URINAIRES","",""
"7944","06-05-11","PENDOPHARM, DIVISION OF/DE PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ALLERGIC AGENT","ANTIALLERGIQUE","",""
"7945","06-05-11","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLUCOCORTICOID / ANTI-INFLAMMATORY","GLUCOCORTICOÏDE / ANTI-INFLAMMATOIRE","",""
"7946","06-05-11","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"7947","06-05-11","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANOREXIANT","ANOREXIGÈNE","",""
"7948","06-05-11","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"7949","06-05-11","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI ANGINAL AGENT","ANTIANGINEUX","",""
"7950","06-05-11","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTIANDROGEN","AGENT ANTIANDROGÈNE NON STÉROÏDIEN","",""
"7951","06-05-11","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"7952","06-05-11","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROLEPTIC","NEUROLEPTIQUE","",""
"7953","06-05-11","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"7954","06-05-11","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOACTIVE AGENT","AGENT VASO-ACTIF","",""
"7955","06-05-12","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERC","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTI-VERTIGO AGENT","AGENT ANTI-VERTIGINEUX","",""
"7956","06-05-12","PERRIGO INTERNATIONAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CHILDREN'S MOTRIN SUSPENSION","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","","","ANALGESIC, ANTIPYRETIC","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"7957","06-05-12","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"7958","06-05-12","SANOFI-SYNTHELABO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH 300/25 MG (IRBESARTAN/HYDROCHLOROTHIAZIDE)","NOUVELLE CONCENTRATION 300/25 MG (IRBÉSARTAN/HYDROCHLOROTHIAZIDE)","ANGIOTENSIN II AT1 RECEPTOR BLOCKER / DIURETIC","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II / DIURÉTIQUE","",""
"7959","06-05-12","PFIZER CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ADJUVANT TREATMENT OF EARLY BREAST CANCER","NOUVELLE INDICATION : TRAITEMENT ADJUVANT DU CANCER DU SEIN À UN STADE PRÉCOCE","AROMATASE INACTIVATOR; ANTI-TUMOUR AGENT","INACTIVATEUR DE L'AROMATASE; ANTITUMORAL","",""
"7960","06-05-15","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"7961","06-05-15","AUXILIUM PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANDROGENIC HORMONE","HORMONE ANDROGÈNE","",""
"7962","06-05-16","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7963","06-05-15","JOHNSONDIVERSEY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"7964","06-05-16","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF INDICATIONS FOR THE FOLLOWING: TREATMENT OF CEREBRAL EDEMA ASSOCIATED WITH HEAD TRAUMA; TREATMENT OF ACUTE SPINAL CORD INJURY","SUPPRESSION DES INDICATIONS SUIVANTES : TRAITEMENT DE L'OEDÈME CÉRÉBRAL ASSOCIÉ À UN TRAUMATISME CRÂNIEN; TRAITEMENT D'UNE LÉSION AIGUË DE LA MOELLE ÉPINIÈRE","GLUCOCORTICOID","GLUCOCORTICOÏDE","",""
"7965","06-05-16","VITA HEALTH PRODUCTS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"7966","06-05-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MEDICAL TREATMENT OF OTOSPONGIOSIS","TRAITEMENT DE L'OTOSPONGIOSE","",""
"7967","06-05-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CATION-EXCHANGE RESIN","RÉSINE POUR ÉCHANGE CATIONIQUE","",""
"7968","06-05-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY - ANTIMALARIAL","ANTI-INFLAMMATOIRE - ANTIPALUDÉEN","",""
"7969","06-05-16","AVENTIX ANIMAL HEALTH CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7970","06-05-18","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXTENSION OF AGE INDICATION TO INCLUDE INFANTS FROM 12 TO 23 MONTHS","CHANGEMENT À L'ÂGE INDIQUÉ (INCLUSION DES ENFANTS DE 12 À 23 MOIS)","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"7971","06-05-17","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RISEDRONATE: BONE METABOLISM REGULATOR; CALCIUM: CALCIUM SUPPLEMENT","RISÉDRONATE: RÉGULATEUR DU MÉTABOLISME OSSEUX; CALCIUM: SUPPLÉMENT CALCIQUE","",""
"7972","06-05-17","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICHOMONACIDE - MONILIACIDE","TRICHOMONACIDE - MONILIACIDE","",""
"7973","06-05-17","ALTANA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"7974","06-05-18","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"7975","06-05-18","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7976","06-05-18","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CALCIUM REGULATOR","RÉGULATEUR DE CALCIUM","",""
"7977","06-05-19","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING PROCESS","CHANGEMENTS AU PROCESSUS DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","AGENT IMMUNOMODULATEUR","",""
"7978","06-05-19","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING PROCESS","CHANGEMENTS AU PROCESSUS DE FABRICATION","ANTIVIRAL AGENT PLUS BIOLOGICAL RESPONSE MODIFIER","ANTIVIRAL AVEC AGENT IMMUNOMODULATEUR","",""
"7979","06-05-19","GENMED, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE - ANTIANGINAL AGENT","ANTIHYPERTENSEUR - ANTIANGINEUX","",""
"7980","06-05-19","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MODIFICATION TO THE APPROVED LABELLING FOR ENBREL IN THE TREATMENT OF PSORIATIC ARTHRITIS","CHANGEMENT À L'ÉTIQUETAGE APPROUVÉ D'ENBREL POUR LE TRAITEMENT DE LA POLYARTHRITE PSORIASIQUE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"7981","06-05-19","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NOTICE OF COMPLIANCE TO REPLACE NOTICE OF COMPLIANCE WITH CONDITIONS ISSUED ON FEBRUARY 12, 1999","AVIS DE CONFORMITÉ QUI REMPLACE L'AVIS DE CONFORMITÉ AVEC CONDITIONS ÉMIS LE 12 FÉVRIER 1999","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"7982","06-05-26","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CGMP Specific Phosphodiesterase Type 5 Inhibitor","Inhibiteur de la phosphodiestérase de type 5 spécifique du GMPC","",""
"7983","06-05-26","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA TYROSINE KINASE","",""
"7984","06-05-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"7985","06-05-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICYCLIC ANTIDEPRESSANT","ANTIDÉPRESSEUR TRICYCLIQUE","",""
"7986","06-05-29","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"7987","06-05-30","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCESS","CHANGEMENT AU PROCESSUS DE FABRICATION","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"7988","06-05-30","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC - ANTIEMETIC","ANTIPSYCHOTIQUE - ANTIÉMÉTIQUE","",""
"7989","06-05-30","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"7990","06-05-30","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITUBERCULOUS ANTIBIOTIC","ANTIBIOTIQUE ANTITUBERCULEUX","",""
"7991","06-05-30","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL","ANTIPALUDÉEN","",""
"7992","06-05-30","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC RADIOGRAPHIC CONTRAST MEDIUM","AGENT DIAGNOSTIQUE OPACIFIANT NON IONIQUE","",""
"7993","06-05-30","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM PRANDASE","MODIFICATION DU NOM DU PRODUIT DE PRANDASE","ORAL ANTIDIABETIC AGENT / ALPHA-GLUCOSIDASE INHIBITOR","ANTIDIABÉTIQUE ORAL / INHIBITEUR DES ALPHA-GLUCOSIDASES","",""
"7994","06-05-30","ETHYPHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"7995","06-05-30","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"7996","06-05-31","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW 1.25 MG STRENGTH","NOUVELLE CONCENTRATION: 1.25 MG","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"7997","06-06-01","ASTELLAS PHARMA CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","SELECTIVE IMMUNOMODULATING ANTIPSORIATIC AGENT","AGENT ANTIPSORIASIQUE IMMUNOMODULATEUR SÉLECTIF","",""
"7998","06-06-01","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","REAGENT FOR PREPARATION OF A RADIODIAGNOSTIC AGENT","RÉACTIF POUR LA PRÉPARATION D'UN AGENT RADIODIAGNOSTIQUE","",""
"7999","06-06-01","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","THERAPEUTIC RADIOPHARMACEUTICAL","THÉRAPEUTIQUE RADIOPHARMACEUTIQUE","",""
"8000","06-06-01","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"8001","06-06-01","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"8002","06-06-02","GENMED, A DIVISION OF PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8003","06-06-01","LES LABORATOIRES NOVICHEM","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8004","06-06-01","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUE H2","",""
"8005","06-06-01","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEGRETOL CR","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT / SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA / ANTIMANIC","ANTICONVULSIVANT / SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU / ANTIMANIAQUE","",""
"8006","06-06-01","LES LABORATOIRES NOVICHEM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"8007","06-06-01","LES LABORATOIRES NOVICHEM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC / SEDATIVE","ANXIOLYTIQUE / SÉDATIF","",""
"8008","06-06-01","GENMED, A DIVISION OF PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIHYPERLIPIDEMIC AGENT","AGENT HYPOLIPIDÉMIANT","",""
"8009","06-06-02","GENMED, A DIVISION OF PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIDEPRESSANT / ANTIPANIC / ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR / ANTIPANIQUE / ANTIOBSESSIONNEL","",""
"8010","06-06-02","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW 15 MG STRENGTH","NOUVEAU DOSAGE : 15 MG","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8011","06-06-05","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"8012","06-06-05","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING THE INDICATION FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION","MISE À JOUR DE L'INDICATION DU TRAITEMENT DE L'HYPERTENSION ESSENTIELLE LÉGÈRE À MODÉRÉE","ANGIOTENSIN II RECEPTOR (AT1) ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS (AT1) DE L'ANGIOTENSINE II","",""
"8013","06-06-07","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DOSING IN THE ADULT ONCOLOGY SETTING","NOUVEAU CHOIX DE RÉGIME POSOLOGIQUE EN ONCOLOGIE CHEZ LES ADULTES","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE DE L'ÉRYTHROPOÏÈSE","",""
"8014","06-06-07","ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8015","06-06-07","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATIONS: 1) REDUCTION OF SIGNS AND SYMPTOMS, INDUCTION OF MAJOR CLINICAL RESPONSE, INHIBITION OF THE PROGRESSION OF STRUCTURAL DAMAGE OF ACTIVE ARTHRITIS, AND IMPROVEMENT IN PHYSICAL FUNCTION IN PATIENTS WITH PSORIATIC ARTHRITIS. 2) TREATMENT OF ADULT PATIENTS WITH CHRONIC MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATE FOR SYSTEMIC THERAPY","NOUVELLES INDICATION : 1) DIMINUTION DES SIGNES ET DES SYMPTÔMES, INDUCTION D'UNE IMPORTANTE RÉPONSE CLINIQUE, INHIBITION DE LA PROGRESSION DES DOMMAGES STRUCTURAUX ASSOCIÉS À L'ARTHRITE EN PHASE ACTIVE ET AMÉLIORATION DES CAPACITÉS FONCTIONNELLES CHEZ LES PATIENTS ATTEINTS DE RHUMATISME PSORIASIQUE. 2) TRAITEMENT DES PATIENTS ADULTES ATTEINTS D'UNE FORME MODÉRÉE OU GRAVE DE PSORIASIS EN PLAQUES ET CANDIDATS À UN TRAITEMENT SYSTÉMIQUE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8016","06-06-07","SOPHERION THERAPEUTICS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW SOURCE OF BULK ACTIVE INGREDIENT; CHANGE TO THE MANUFACTURING SOURCE AND FORMULATION OF THE ACTIVE PHARMACEUTICAL INGREDIENT","NOUVELLE SOURCE D'APPROVISIONNEMENT EN INGRÉDIENT ACTIF EN VRAC; NOUVEAU FABRICANT ET NOUVELLE FORMULATION DE L'INGRÉDIENT PHARMACEUTIQUE ACTIF","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8017","06-06-09","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8018","06-06-12","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LANOXIN","VIRCO PHARMACEUTICALS (CANADA) INC.","CANADA","CANADA","1","","","CARDIOTONIC GLYCOSIDE","GLUCOSIDE CARDIOTONIQUE","",""
"8019","06-06-09","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8020","06-06-13","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"8021","06-06-13","RANBAXY PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"8022","06-06-13","GENMED, A DIVISION OF PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM GMD-AZITHROMYCIN","MODIFICATION DU NOM DU PRODUIT DE GMD-AZITHROMYCIN","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8023","06-06-13","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE & NEW PRODUCT MONOGRAPH FORMAT","MISE À JOUR DE L'INNOCUITÉ ET NOUVEAU FORMAT DE LA MONOGRAPHIE DU PRODUIT","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"8024","06-06-13","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RESPIRATORY ANTIBIOTIC","ANTIBIOTIQUE RESPIRATOIRE","",""
"8025","06-06-13","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL STEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"8026","06-06-13","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS","NOUVELLE INDICATION : TRAITEMENT DES INFECTIONS INTRA-ABDOMINALES COMPLIQUÉES","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"8027","06-06-13","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE VULGARIS THERAPY","TRAITEMENT DE L'ACNÉ VULGAIRE","",""
"8028","06-06-15","QLT USA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ACNE THERAPY","TRAITEMENT ANTIACNÉ","",""
"8029","06-06-15","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8030","06-06-15","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"8031","06-06-15","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8032","06-06-15","RANBAXY PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"8033","06-06-16","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC / COMPONENT TO BALANCED ANESTHESIA","ANALGÉSIQUE","",""
"8034","06-06-16","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TRACE ELEMENT","ÉLÉMENT TRACE","",""
"8035","06-06-16","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TRACE ELEMENT","ÉLÉMENT TRACE","",""
"8036","06-06-16","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT MULTI-TRACES","",""
"8037","06-06-16","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT MULTI-TRACES","",""
"8038","06-06-16","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTIPLE VITAMINS FOR TOTAL PARENTERAL NUTRITION","VITAMINES MULTIPLES POUR ALIMENTATION PARENTÉRALE TOTALE","",""
"8039","06-06-16","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AGRYLIN","SHIRE BIOCHEM INC.","CANADA","CANADA","1","","","PLATELET REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"8040","06-06-16","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AGRYLIN","SHIRE BIOCHEM INC.","CANADA","CANADA","1","","","PLATELET REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"8041","06-06-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRHEUMATIC / IMMUNOMODULATOR AGENT","ANTIRHUMATISMAL / IMMUNOMODULATEUR","",""
"8042","06-06-16","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL","ANTIVIRAL","",""
"8043","06-06-16","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH, POST APPROVAL COMMITMENT 1 & 2 (NEWLY DIAGNOSED CML) AND POST APPROVAL COMMITMENT #17 (2ND LINE CML)","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT, ENGAGEMENT APRÈS L'HOMOLOGATION NOS 1 ET 2 (LMC NOUVELLEMENT DIAGNOSTIQUÉE) ET ENGAGEMENT APRÈS L'HOMOLOGATION NO 17 (TRAITEMENT DE DEUXIÈME INTENTION DE LA LMC)","PROTEIN TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"8044","06-06-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ROSACEA AGENT","AGENT ANTIROSACÉE","",""
"8045","06-06-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"8046","06-06-16","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"8047","06-06-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"8048","06-06-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY . ANALGESIC AGENT","ANTI-INFLAMMATOIRE / ANALGÉSIQUE","",""
"8049","06-06-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"8050","06-06-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"8051","06-06-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICYCLIC ANTIDEPRESSANT","ANTIDÉPRESSEUR TRICYCLIQUE","",""
"8052","06-06-16","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"8053","06-06-16","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"8054","06-06-16","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION: RITUXAN IN COMBINATION WITH METHOTREXATE IS INDICATED TO REDUCE SIGNS AND SYMPTOMS IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TUMOUR NECROSIS FACTOR (TNF) INHIBITOR THERAPIES","NOUVELLE INDICATION : LE RITUXAN, EN COMBINAISON AVEC LE MÉTHOTREXATE, EST INDIQUÉ POUR LA RÉDUCTION DES SIGNES ET DES SYMPTÔMES DE LA POLYARTHRITE RHUMATOÏDE CHEZ DES PATIENTS CHEZ QUI L'ÉVOLUTION DE LA MALADIE EST DE MODÉRÉE À RAPIDE ET QUI ONT EU UNE RÉPONSE INADÉQUATE OU UNE INTOLÉRANCE À UN OU PLUSIEURS TRAITEMENTS AVEC UN INHIBITEUR DU FACTEUR DE NÉCROSE DES TUMEURS","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8055","06-06-19","VÉTOQUINOL N.-A. INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"8056","06-06-20","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: REDUCING THE SIGNS AND SYMPTOMS OF ACTIVE ARTHRITIS IN ADULT PSORIATIC ARTHRITIS PATIENTS.  HUMIRA CAN BE USED IN COMBINATION WITH METHOTREXATE IN PATIENTS WHO DO NOT RESPOND ADEQUATELY TO METHOTREXATE ALONE","NOUVELLE INDICATION : RÉDUCTION DES SIGNES ET DES SYMPTÔMES DE L'ACTIVITÉ ARTHRITIQUE CHEZ LES PATIENTS ADULTES ATTEINTS DE RHUMATISME PSORIASIQUE.  HUMIRA PEUT ÊTRE UTILISÉ EN COMBINAISON AVEC LE MÉTHOTREXATE CHEZ LES PATIENTS QUI ONT UNE RÉPONSE INADÉQUATE AU MÉTHOTREXATE EN MONOTHÉRAPIE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8057","06-06-20","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXTENSION OF INDICATION: TO TREAT RECENTLY DIAGNOSED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH METHOTREXATE","AJOUT D'UNE INDICATION POUR LE TRAITEMENT DES PATIENTS ATTEINTS DE POLYARTHRITE RHUMATOÏDE AYANT ÉTÉ DIAGNOSTIQUÉS RÉCEMMENT ET DONT L'ÉVOLUTION EST DE MODÉRÉE À RAPIDE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8058","06-06-20","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXTENSION OF INDICATION: FOR THE CLAIM OF IMPROVEMENT OF PHYSICAL FUNCTION IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS","AJOUT D'UNE INDICATION POUR L'AFFIRMATION D'UNE AMÉLIORATION DE LA CAPACITÉ FONCTIONNELLE CHEZ LES PATIENTS ADULTES ATTEINTS DE POLYARTHRITE RHUMATOÏDE DONT L'ÉVOLUTION EST DE MODÉRÉE À RAPIDE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8059","06-06-20","LES LABORATOIRES NOVICHEM","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC / MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE / PROPHYLAXIE DE LA MIGRAINE","",""
"8060","06-06-20","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8061","06-06-20","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8062","06-06-20","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8063","06-06-20","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8064","06-06-20","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE INDICATIONS AND CLINICAL USE, WARNINGS AND PRECAUTIONS AND ADVERSE REACTIONS SECTIONS OF THE PRODUCT MONOGRAPH","MISE À JOUR DE L'INDICATION ET UTILISATION CLINIQUE, MISES EN GARDE ET PRÉCAUTIONS ET EFFETS INDÉSIRABLES DE LA MONOGRAPHIE DU PRODUIT","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"8065","06-06-21","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXO CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","5-HT1 RECEPTOR AGONIST MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 ANTIMIGRAINEUX","",""
"8066","06-06-21","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN - 150","PFIZER CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIFUNGAL AGENT","AGENT ANTIFONGIQUE","",""
"8067","06-06-22","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"8068","06-06-22","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INJECTION RATE","DÉBIT D'INJECTION RÉVISÉ","PARAMAGNETIC, INTRAVASCULAR, CONTRAST AGENT FOR MAGNETIC RESONNANCE IMAGING (MRI)","PRODUIT DE CONTRASTE PARAMAGNÉTIQUE INTRAVASCULAIRE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"8069","06-06-22","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIMS FOR CATTLE","INDICATIONS ADDITIONNELLES POUR LES BOVINS","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"8070","06-06-22","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"8071","06-06-22","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 REEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"8072","06-06-22","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8073","06-06-23","SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING THE PRODUCT MONOGRAPH WITH INFORMATION RELEVANT TO DRUG SAFETY IN SUBJECTS WITH HEPATIC IMPAIRMENT","MISE À JOUR DE LA MONOGRAPHIE CONCERNANT LA SÉCURITÉ DU PRODUIT CHEZ LES SUJETS SOUFFRANT D'INSUFFISANCE HÉPATIQUE","PLATELET-REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"8074","06-06-26","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH INCLUDING HRT CLASS LABELLING TEXT AND MODIFICATIONS TO THE INDICATIONS","MISES À JOUR DE L'INFORMATION SUR L'INNOCUITÉ DANS LA MONOGRAPHIE DE PRODUIT, Y COMPRIS LE TEXTE FIGURANT SUR L'ÉTIQUETTE CLASSE POUR LE THS ET LES MODIFICATIONS AUX INDICATIONS","ESTROGENIC HORMONES / PROGESTIN","HORMONES OESTROGÈNES / PROGESTATIF","",""
"8075","06-06-26","ASTRAZENECA CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","STUDY - 1SEL AND SIGN CLINICAL STUDY REPORTS TO COMPLY WITH NOC/C COMMITMENT; AND REVISED PRODUCT MONOGRAPH","ÉTUDE - RAPPORTS D'ÉTUDE CLINIQUE 1SEL ET SIGN VISANT À ASSURER LE RESPECT DE L'ENGAGEMENT EN MATIÈRE D'ACC; MONOGRAPHIE DE PRODUIT RÉVISÉE","EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKI)","INHIBITEUR DE TYROSINE KINASE DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE","",""
"8076","06-06-22","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"8077","06-06-27","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATIONS","INDICATIONS SUPPLÉMENTAIRES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8078","06-06-27","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATIONS","INDICATIONS SUPPLÉMENTAIRES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8079","06-06-27","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATIONS","INDICATIONS SUPPLÉMENTAIRES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8080","06-06-27","BAYER INC., BAYER HEALTHCARE, ANIMAL HEALTH DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATIONS","INDICATIONS SUPPLÉMENTAIRES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8081","06-06-22","ZLB BEHRING CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"8082","06-06-22","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCESS","CHANGEMENT DANS LA MÉTHODE DE FABRICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8083","06-06-29","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","SELECTIVE CO-STIMULATION MODULATOR","MODULATEUR SÉLECTIF DE LA CO-STIMULATION","",""
"8084","06-06-29","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SEASONAL ALLERGIC RHINITIS FOR PATIENTS 15 YEARS OLD OR OLDER WHEN OTHER MEDICATIONS ARE NOT EFFECTIVE/NOT TOLERATED","NOUVELLE INDICATION : RHINITE ALLERGIQUE SAISONNIÈRE CHEZ LES PATIENTS ÂGÉS DE 15 AND ET PLUS LORSQUE D'AUTRES MÉDICAMENTS NE SONT PAS EFFICACES OU TOLÉRÉS","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"8085","06-06-30","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN-150","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8086","06-06-30","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC / ANTIHYPERTENSIVE","DIURÉTIQUE / ANTIHYPERTENSEUR","",""
"8087","06-06-30","ABRAXIS ONCOLOGY, A DIVISION OF PHARMACEUTICAL PARTNERS OF CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8088","06-06-30","JAZZ PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-HOMOCYSTEINE AGENT","AGENT ANTI-HOMOCYSTÉINE","",""
"8089","06-06-30","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC / ANTIHYPERTENSIVE","DIURÉTIQUE / ANTIHYPERTENSEUR","",""
"8090","06-06-30","PDL BIOPHARMA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8091","06-06-30","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","FACILITY UPGRADES","MISES À NIVEAU D'INSTALLATIONS","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8092","06-06-30","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PRODUCTION AREA","NOUVELLE AIRE DE FABRICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8093","06-06-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH","MISE À JOUR DE L'INNOCUITÉ DE LA MONOGRAPHIE DU PRODUIT","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"8094","06-06-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH","MISE À JOUR DE L'INNOCUITÉ DE LA MONOGRAPHIE DU PRODUIT","BRONCHODILATOR AND CORTICOSTEROID","BRONCHODILATATEUR ET CORTICOSTÉROÏDE","",""
"8095","06-06-30","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE POULENC RORER CANADA","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"8096","06-06-30","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"8097","06-06-30","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8098","06-06-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8099","06-06-30","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE, TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"8100","06-06-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING AGENT","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8101","06-06-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8102","06-06-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8103","06-06-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8104","06-06-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8105","06-06-30","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"8106","06-06-30","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"8107","06-06-30","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"8108","06-06-30","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"8109","06-06-30","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO CHANGE THE MILK WITHHOLDING PERIOD FROM 96 HOURS TO ZERO IN LACTATING DAIRY CATTLE","POUR ÉLIMINER LA PÉRIODE D'ATTENTE RELATIVE À L'UTILISATION DU LAIT APRÈS LE DERNIER TRAITEMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8110","06-07-04","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"8111","06-07-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8112","06-07-05","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8113","06-07-05","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8114","06-07-05","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8115","06-07-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL ORAL SOLUTION","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTISPYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8116","06-07-05","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8117","06-07-05","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8118","06-07-05","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8119","06-07-05","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8120","06-07-05","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8121","06-07-05","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8122","06-07-06","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE RÉPONSE BIOLOGIQUE","",""
"8123","06-07-06","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"8124","06-07-06","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"8125","06-07-06","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR TREATMENT OF DIABETIC FOOT INFECTIONS","NOUVELLE INDICATION POUR LE TRAITEMENT DES INFECTIONS LIÉES AU PIED DIABÉTIQUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8126","06-07-06","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: PRESERVATIVE FREE SOLUTION FOR INJECTION","NOUVELLE FORME POSOLOGIQUE : SOLUTION POUR INJECTION SANS AGENT DE CONSERVATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8127","06-07-07","FERRING INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","GONADOTROPINS FOR INFERTILITY","GONADOTROPHINES POUR L'INFERTILITÉ","",""
"8128","06-07-10","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"8129","06-07-10","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISPASMODIC / ANTICHOLINERGIC","ANTISPASMODIQUE / ANTICHOLINERGIQUE","",""
"8130","06-07-10","ACTELION PHARMACEUTICALS LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE","NOUVELLE INDICATION : TRAITEMENT DE L'HYPERTENSION ARTÉRIELLE PULMONAIRE ASSOCIÉE À DES MALFORMATIONS CONGÉNITALES CARDIAQUES","ENDOTHELIN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"8131","06-07-13","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","DRUG SUBSTANCE MANUFACTURING PROCESS CHANGE","CHANGEMENT AU PROCESSUS DE FABRICATION DE LA SUBSTANCE MÉDICAMENTEUSE","ANTI-DIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8132","06-07-13","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","DRUG SUBSTANCE MANUFACTURING PROCESS CHANGE","CHANGEMENT AU PROCESSUS DE FABRICATION DE LA SUBSTANCE MÉDICAMENTEUSE","ANTI-DIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8133","06-07-14","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TRACE ELEMENT","ÉLÉMENT TRACE","",""
"8134","06-07-14","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TRACE ELEMENT","ÉLÉMENT TRACE","",""
"8135","06-07-14","JAZZ PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYTHETIC ALCOHOL DEHYDROGENASE INHIBITOR","INHIBITEUR SYNTHÉTIQUE DE L'ALCOOL DÉSHYDROGÉNASE","",""
"8136","06-07-17","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATIVE MANUFACTURING FACILITY","AIRE DE FABRICATION SUPPLÉMENTAIRE","HEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"8137","06-07-17","IPSEN LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGROWTH HORMONE","INHIBITEUR DE L'HORMONE DE CROISSANCE","",""
"8138","06-07-14","METHAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW PACKAGING FORMAT","NOUVELLE PRÉSENTATION","CHOLINERGIC/DIAGNOSTIC AID (BRONCHIAL ASTHMA)","CHOLINERGIQUE/AUXILIAIRE DIAGNOSTIQUE (ASTHME BRONCHIQUE)","",""
"8139","06-07-17","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8140","06-07-13","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR PLUS DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE ET DIURÉTIQUE","",""
"8141","06-07-13","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","POST APPROVAL COMMITMENTS: REVISION OF ONCOLOGY INDICATIONS ACCORDING TO CURRENT MEDICAL STANDARD OF CARE; REVIEW OF ASSOCIATION WITH ARTERIAL AND VENOUS THROMBOEMBOLIC EVENTS; AND REVIEW OF CASES OF FATALITY","ENGAGEMENTS APRÈS L'APPROBATION: RÉVISION DES INDICATIONS ONCOLOGIQUES CONFORMÉMENT À LA NORME DE PRATIQUE MÉDICALE EN VIGUEUR; EXAMEN DES ASSOCIATIONS AVEC LES ÉVÉNEMENTS THROMBOEMBOLIQUES VEINEUX ET ARTÉRIELS; EXAMEN DES CAS DE DÉCÈS","PROGESTOGEN","PROGESTATIF","",""
"8142","06-07-10","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8143","06-07-12","BIO AGRI MIX LP","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","LINCOMIX 44 PREMIX","PFIZER CANADA INC., ANIMAL HEALTH GROUP","CANADA","CANADA","1","CHANGE IN WITHDRAWAL PERIOD","CHANGEMENT DANS LA PÉRIODE DE RETRAIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8144","06-07-12","BIO AGRI MIX LP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN WITHDRAWAL PERIOD","CHANGEMENT DANS LA PÉRIODE DE RETRAIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8145","06-07-12","BIO AGRI MIX LP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN WITHDRAWAL PERIOD","CHANGEMENT DANS LA PÉRIODE DE RETRAIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8146","06-07-12","BIO AGRI MIX LP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN WITHDRAWAL PERIOD","CHANGEMENT DANS LA PÉRIODE DE RETRAIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8147","06-07-12","BIO AGRI MIX LP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN WITHDRAWAL PERIOD","CHANGEMENT DANS LA PÉRIODE DE RETRAIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8148","06-07-14","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","METHOTREXATE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","",""
"8149","06-07-17","VIRBAC AH, INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC (IVERMECTIN) POUR-ON FOR CATTLE","MERIAL CANADA INC.","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8150","06-07-18","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIOTONIC GLYCOSIDE","GLUCOSIDE CARDIOTONIQUE","",""
"8151","06-07-18","ASTRAZENECA CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKI)","INHIBITEUR DE LA TYROSINE KINASE DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE (EGFR)","",""
"8152","06-07-18","LES LABORATOIRES NOVICHEM","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AGRYLIN","SHIRE BIOCHEM INC.","CANADA","CANADA","1","","","PLATELET REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"8153","06-07-18","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8154","06-07-18","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","VITAMIN SUPPLEMENT","SUPPLÉMENT VITAMINIQUE","",""
"8155","06-07-18","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION POSOLOGIE ET ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT","CNS STIMULANT","STIMULANT DU SNC","",""
"8156","06-07-18","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT MULTI TRACES","",""
"8157","06-07-19","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"8158","06-07-19","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"8159","06-07-20","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMAN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8160","06-07-21","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITION OF ALTERNATE MANUFACTURING FACILITY","ADDITION D'UNE INSTALLATION DE FABRICATION ALTERNATIVE","GONADOTROPIN","GONADOTROPHINE","",""
"8161","06-07-21","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITION OF TWO NEW CONCENTRATIONS","ADDITION DE DEUX NOUVELLES CONCENTRATIONS","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"8162","06-07-21","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLUDARA","BERLEX CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8163","06-07-24","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW IMMUNIZING AGENT","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8164","06-07-24","OMRIX BIOPHARMACEUTICALS LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HAEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"8165","06-07-24","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","DOSE RECOMMENDATIONS FOR RENAL IMPAIRED PATIENTS","DOSES RECOMMANDÉES CHEZ LES PATIENTS AUX FONCTIONS RÉNALES DÉTÉRIORÉES","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8166","06-07-24","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANTIRHEUMATIC, IMMUNOMODULATOR AGENT","ANTIRHUMATISMAUX, AGENT IMMUNOMODULATEUR","",""
"8167","06-07-24","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH - 2 YEAR EFFICACY AND SAFETY RESULTS FROM STUDIES IN AGE-RELATED MACULAR DEGENERATION","MONOGRAPHIE DE PRODUIT RÉVISÉE - RÉSULTATS D'ÉTUDES D'EFFICACITÉ ET D'INNOCUITÉ DE 2 ANS PORTANT SUR LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE","ANTI-VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF 165 INHIBITOR) FOR AGE-RELATED MACULAR DEGENERATION","INHIBITEUR DU FACTEUR DE CROISSANCE DE L'ENDOTHÉLIUM VASCULAIRE (INHIBITEUR DU VEGF165) POUR LE TRAITEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE","",""
"8168","06-07-25","COBALT PHARMACEUTICALS INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"8169","06-07-25","HUVEPHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"8170","06-07-25","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8171","06-07-26","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"8172","06-07-27","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATIVE MANUFACTURING FACILITY","AIRE DE FABRICATION SUPPLÉMENTAIRE","HEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"8173","06-07-28","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","THE MAINTENANCE TREATMENT OF PATIENTS WITH FOLLICULAR NON-HODGKIN'S LYMPHOMA WHO HAVE RESPONDED TO INDUCTION THERAPY WITH EITHER CHOP OR CHOP PLUS RITUXIMAB","LE TRAITEMENT D'ENTRETIEN DES PATIENTS PRÉSENTANT LE LYMPHOME FOLLICULAIRE NON-HODGKINIEN QUI ONT RÉPONDU À LA THÉRAPIE D'INDUCTION AVEC CHOP OU CHOP PLUS RITUXIMAB","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8174","06-07-27","IPET PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","PRODUIT RADIOPHARMACEUTIQUE DIAGNOSTIQUE","",""
"8175","06-07-27","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","DOSE RECOMMENDATIONS FOR RENAL IMPAIRED PATIENTS","DOSES RECOMMANDÉES CHEZ LES PATIENTS AUX FONCTIONS RÉNALES DÉTÉRIORÉES","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8176","06-07-27","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8177","06-07-27","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8178","06-07-27","CIPHER PHARMACEUTICALS LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL SUPRA","LABORATOIRES FOURNIER S.A.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM FENOFIBRATE CAPSULES","MODIFICATION DU NOM DU PRODUIT DE FENOFIBRATE CAPSULES","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8179","06-07-28","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TRACE ELEMENT","ÉLÉMENT TRACE","",""
"8180","06-07-27","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: 80 MG AND 100 MG","NOUVELLE CONCENTRATIONS : 80MG ET 100MG","SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR","INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA NORÉPINÉPHRINE","",""
"8181","06-07-28","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: REDUCTION OF DEEP VEIN THROMBOSIS (DVT) IN HOSPITALIZED PATIENTS WITH SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS","NOUVELLE INDICATION : DIMINUTION DU RISQUE THROMBOSE VEINEUSE PROFONDE CHEZ LES PATIENTS HOSPITALISÉS DONT LA MOBILITÉ EST GRANDEMENT RESTREINTE PENDANT UNE MALADIE","ANTICOAGULANT / ANTITHROMBOTIC AGENT","ANTICOAGULANT / ANTITHROMBOTIQUE","",""
"8182","06-07-28","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HIV PROTEASE INIHBITOR","INHIBITEUR VIH PROTÉASE","",""
"8183","06-07-28","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MULTIKINASE INHIBITOR / ANTINEOPLASTIC AGENT","INHIBITEUR DE LA MULTIKINASE / AGENT ANTINÉOPLASIQUE","",""
"8184","06-07-31","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","TO PROPOSE A NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH A SINGLE DEMYELINATING EVENT ACCOMPANIED BY AT LEAST TWO CLINICALLY SILENT LESIONS TYPICAL OF MULTIPLE SCLEROSIS (MS) ON MAGNETIC RESONANCE IMAGING, TO DELAY PROGRESSION TO DEFINITE MS.  BEFORE INITIATING TREATMENT WITH BETASERON, ALTERNATE DIAGNOSES SHOULD FIRST BE EXCLUDED.","UNE NOUVELLE UTILISATION CLINIQUE : LE BETASERON EST INDIQUÉ POUR LE TRAITEMENT DES PATIENTS AYANT UN ÉPISODE UNIQUE DE DÉMYÉLINISATION ACCOMPAGNÉ D'AU MOINS DEUX LÉSIONS SILENCIEUSES CARACTÉRISTIQUES DE SCLÉROSE EN PLAQUES (SP) EN IMAGERIE PAR RÉSONANCE MAGNÉTIQUE, POUR RETARDER LA PROGRESSION VERS UN DIAGNOSTIQUE DÉFINIT DE SP.  AVANT D'INITIER UN TRAITEMENT AVEC BETASERON, LES ALTERNATIVES DIAGNOSTIQUES DOIVENT ÊTRE EXCLUES.","IMMUNOMODULATORY AGENT","AGENT IMMUNOMODULATEUR","",""
"8185","06-07-31","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRILEPTAL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"8186","06-07-31","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"8187","06-07-31","BAXTER HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"8188","06-08-01","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8189","06-08-02","TAP PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW ADMINISTRATION OPTIONS: - PREVACID FASTTAB: DISPERSED IN WATER AND ADMINISTERED VIA SYRINGE ORALLY OR INTO A NASOGASTRIC TUBE - PREVACID: DISPERSED IN APPLE JUICE OR WATER AND ADMINISTERED VIA SYRINGE INTO A NASOGASTRIC TUBE","NOUVELLES POSSIBILITÉS D'ADMINISTRATION : PREVACID FASTAB : DISPERSÉ DANS L'EAU ET ADMINISTRÉ AU MOYEN D'UNE SERINGUE DANS LA BOUCHE OU DANS UNE SONDE NASOGASTRIQUE; PREVACID : DISPERSÉ DANS LE JUS DE POMME OU L'EAU ET ADMINISTRÉ AU MOYEN D'UNE SERINGUE DANS UNE SONDE NASOGASTRIQUE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"8190","06-08-02","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH 5 MG USED FOR DOSE TITRATION","NOUVELLE CONCENTRATION DE 5 MG UTILISÉE POUR LE TITRAGE DE LA DOSE","ANTICHOLINERGIC - ANTISPASMODIC","ANTICHOLINERGIQUE - ANTISPASMODIQUE","",""
"8191","06-08-03","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"8192","06-08-03","GENZYME CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXPANDED INDICATION - LONG-TERM ENZYME REPLACEMENT THERAPY IN PATIENTS WITH A CONFIRMED DIAGNOSIS OF FABRY DISEASE","INDICATION SUPPLÉMENTAIRE - THÉRAPIE À LONG TERME DE REMPLACEMENT D'ENZYMES CHEZ DES PATIENTS PRÉSENTANT UN DIAGNOSTIC CONFIRMÉ DE LA MALADIE DE FABRY","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"8193","06-08-04","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RENEDIL / PLENDIL","AVENTIS PHARMA INC. / ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"8194","06-08-04","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMARYL","AVENTIS CANADA INC.","CANADA","CANADA","1","","","ORAL HYPOGLYCAEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONLURÉE)","",""
"8195","06-08-10","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"8196","06-08-10","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","URSO","AXCAN PHARMA INC.","CANADA","CANADA","1","","","CHOLESTATIC LIVER DISEASES","MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"8197","06-08-10","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"8198","06-08-10","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"8199","06-08-10","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8200","06-08-10","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","URSO","AXCAN PHARMA INC.","CANADA","CANADA","1","","","CHOLESTATIC LIVER DISEASES","MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"8201","06-08-10","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB CANADA","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8203","06-08-14","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE D'ANXIÉTÉ SOCIALE), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"8204","06-08-14","GENZYME CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"8205","06-08-14","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY / ANALGESIC AGENT / PLATELET AGGREGATION INHIBITOR","ANTI-INFLAMMATOIRE NON STÉROÏDIEN, ANALGÉSIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"8206","06-08-15","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PATIENT POPULATION - INCLUSION OF PATIENTS LESS THAN FIVE YEARS OF AGE FOR THE MANAGEMENT OF CYSTIC FIBROSIS","NOUVELLE POPULATION DE PATIENTS - INCLUSION DE PATIENTS ÂGÉS DE MOINS DE 5 ANS POUR LA GESTION DE LA FIBROSE KYSTIQUE","ENZYME","ENZYME","",""
"8207","06-08-15","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","AIRE DE FABRICATION SUPPLÉMENTAIRE","HEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"8208","06-08-16","HUVEPHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"8209","06-08-15","HUVEPHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8210","06-08-17","PFIZER CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA OF CLEAR CELL HISTOLOGY AFTER FAILURE OF CYTOKINE-BASED THERAPY OR IN PATIENTS WHO ARE CONSIDERED LIKELY TO BE INTOLERANT OF SUCH THERAPY","NOUVELLE INDICATION POUR LE TRAITEMENT DE L'ADÉNOCARCINOME RÉNAL MÉTASTATIQUE À CELLULES CLAIRES CHEZ LES PATIENTS QUI N'ONT PAS RÉPONDU À LA THÉRAPIE À BASE DE CYTOKINES OU QUI RISQUENT D'ÊTRE INTOLÉRANTS À UNE TELLE THÉRAPIE.","TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA TYROSINE KINASE","",""
"8211","06-08-17","TEVA PHARMACEUTICALS INDUSTRIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"8212","06-08-17","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"8213","06-08-17","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8214","06-08-17","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"8215","06-08-17","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8216","06-08-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE PLUS","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ANZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"8217","06-08-22","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8218","06-08-23","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8219","06-08-23","SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO MANUFACTURING PROCESS AND ADDITION OF ALTERNATE MANUFACTURING FACILITIES","CHANGEMENTS AU PROCESSUS DE FABRICATION ET L'ADDITION D'INSTALLATIONS DE FABRICATION ALTERNATIVES","GONADOTROPIN","GONADOTROPHINE","",""
"8220","06-08-25","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DRUG PRODUCT MANUFACTURING SITE","SITE DE FABRICATION ALTERNATIF POUR LE PRODUIT MÉDICAMENTEUX","GONADOTROPIN","GONADOTROPINE","",""
"8221","06-08-25","QLT INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH TO INCLUDE LONG-TERM SAFETY AND EFFICACY DATA","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT POUR INCLURE DES DONNÉES SUR L'INNOCUITÉ ET L'EFFICACITÉ À LONG TERME","PHOTOSENSITIZING AGENT FOR PHOTODYNAMIC THERAPY OF CHOROIDAL NEOVASCULARIZATION","SUBSTANCE SENSIBILISANTE POUR LA THÉRAPIE PHOTODYNAMIQUE DE LA NÉOVASCULARISATION CHOROÏDIENNE","",""
"8222","06-08-25","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"8223","06-08-25","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"8224","06-08-25","BIMEDA-MTC ANIMAL HEALTH INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE AND CHANGE IN METHOD OF STERILIZATION","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION ET VARIATION DANS LA MÉTHODE DE STÉRILISATION","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8225","06-08-25","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE: INCLUSION OF NEW CLINICAL DATA","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT : INCLUSION DE NOUVELLES DONNÉES CLINIQUES.","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"8226","06-08-25","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8227","06-08-25","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8228","06-08-25","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8229","06-08-25","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8230","06-08-25","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8231","06-08-25","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8232","06-08-25","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8233","06-08-25","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8234","06-08-25","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8235","06-08-28","STERIMAX INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8236","06-08-28","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSTIN VR STERILE SOLUTION","PFIZER CANADA INC.","CANADA","CANADA","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"8237","06-08-29","LES LABORATOIRES NOVICHEM","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8238","06-08-31","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8239","06-08-31","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","B-ADRENERGIC RECEPTOR BLOCKING AGENT","ANTAGONISTE DES RÉCEPTEURS ADRÉNERGIQUES BÊTA","",""
"8240","06-09-01","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LITHOLYTIC AGENT","AGENT DE DISSOLUTION DE CALCULS BILIAIRES","",""
"8241","06-09-05","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"8242","06-09-05","BIONICHE PHARMA (CANADA) LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF INTERSTITIAL CYSTITIS","TRAITEMENT DE LA CYSTITE INTERSTITIELLE","",""
"8243","06-09-05","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"8244","06-09-05","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM TIMOLOL MALEATE OPHTHALMIC GEL-FORMING SOLUTION","MODIFICATION DU NOM DU PRODUIT DE TIMOLOL MALEATE OPHTHALMIC GEL-FORMING SOLUTION","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"8245","06-09-06","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: 200 / 50 MG (LOPINAVIR / RITONAVIR) TABLET","NOUVELLE FORME POSOLOGIQUE : COMPRIMÉ DE 200 / 50 MG (LOPINAVIR / RITONAVIR)","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"8246","06-09-06","SANDOZ CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","DIURETIC, SALURETIC","DIURÉTIQUE, SALIDIURÉTIQUE","",""
"8247","06-09-07","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING FACILITY","MODIFICATION DE L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8248","06-09-07","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","NONAGONIST ESTROGEN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES OESTROGÈNES NON AGONISTE","",""
"8249","06-09-08","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SYMPTOMATIC TREATMENT OF MODERATE TO SEVERE IDIOPATHIC RESTLESS LEGS SYNDROME","NOUVELLE INDICATION: LE TRAITEMENT SYMPTOMATIQUE DU SYNDROME DES JAMBES SANS REPOS IDIOPATHIQUE MODÉRÉ À SÉVÈRE","ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST","ANTIPARKINSONIEN / AGONISTE DOPAMINERGIQUE","",""
"8250","06-09-08","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF DRUG INTERACTION INFORMATION WITH TOPAMAX","ADDITION D'UNE INTERACTION AVEC TOPAMAX","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8251","06-09-08","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF DRUG INTERACTION INFORMATION WITH TOPAMAX","ADDITION D'UNE INTERACTION AVEC TOPAMAX","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8252","06-09-08","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION, NEW FORM IN RAPIDLY DISSOLVING TABLET","CHANGEMENT DANS LA FORMULATION, NOUVELLE FORME DANS UN COMPRIMÉ À DISSOLUTION RAPIDE","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"8253","06-09-11","BERLEX CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH IN ACCORDANCE WITH TPD'S GUIDANCE OF NON CONTRACEPTIVE ESTROGEN/PROGESTIN CONTAINING PRODUCTS","MONOGRAPHIE DE PRODUIT RÉVISÉE CONFORMÉMENT À LA LIGNE DIRECTRICE DE LA DPT INTITULÉE MONOGRAPHIES DES PRODUITS CONTRACEPTIFS CONTENANT DES OESTROGÈNES ET DES PROGESTATIFS","ESTROGEN","OESTROGÈNE","",""
"8254","06-09-11","ALTANA PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR ORAL INHALATION","CORTICOSTÉROÏDE POUR INHALATION ORALE","",""
"8255","06-09-12","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","RISEDRONATE: BONE METABOLISM REGULATOR / CALCIUM: CALCIUM SUPPLEMENT","RISÉDRONATE : RÉGULATEUR DU MÉTABOLISME OSSEUX / CALCIUM : SUPPLÉMENT CALCIQUE","",""
"8256","06-09-13","LABORATOIRE HRA PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","EMERGENCY CONTRACEPTION","CONTRACEPTIF D'UREGNCE","",""
"8257","06-09-12","VALEO PHARMA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN-T","UPJOHN COMPANY","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8258","06-09-12","OVATION PHARMACEUTICALS LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACTINOMYCIN ANTIBIOTIC / ANTINEOPLASTIC","ACTINOMYCINE ANTIBIOTIQUE / ANTINÉOPLASIQUE","",""
"8259","06-09-12","COLGATE-PALMOLIVE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTICARIES / ANTIPLAQUE / ANTIGINGIVITIS / ANTICALCULUS","ANTICARIES / ANTIPLAQUE / ANTIGINGIVITE / ANTICALCULS","",""
"8260","06-09-06","NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8261","06-09-13","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION - HUMATROPE IS INDICATED FOR THE LONG-TERM TREATMENT OF IDIOPATHIC SHORT STATURE DEFINED BY: NORMAL BIRTH WEIGHT; CAREFUL DIAGNOSTIC EVALUATION THAT EXCLUDES OTHER KNOWN CAUSES OF SHORT STATURE THAT SHOULD BE EITHER OBSERVED OR TREATED BY OTHER MEANS; HEIGHT AT LEAST 2.25 STANDARD DEVIATION SCORES (SDS) BELOW THE MEAN FOR AGE AND SEX; HEIGHT VELOCITY BELOW THE 25TH PERCENTILE FOR BONE AGE AND SEX OVER 12 MONTHS OF OBSERVATION AND UNLIKELY TO PERMIT ATTAINMENT OF ADULT HEIGHT IN THE EXPECTED RANGE. HUMATROPE TREATMENT FOR IDIOPATHIC SHORT STATURE SHOULD BE PRESCRIBED ONLY FOR THOSE PATIENTS WHOSE EPIPHYSES ARE NOT CLOSED AND SHOULD BE MANAGED BY PHYSICIANS WHO HAVE SUFFICIENT KNOWLEDGE OF IDIOPATHIC SHORT STATURE AND THE EFFICACY/SAFETY PROFILE OF HUMATROPE","NOUVELLE INDICATION - HUMATROPE EST INDIQUÉ POUR LE TRAITEMENT PROLONGÉ DU RETARD STATURAL IDIOPATHIQUE DÉFINI DE LA FAÇON SUIVANTE : POIDS NORMAL À LA NAISSANCE; ÉVALUATION DIAGNOSTIQUE SOIGNEUSE EXCLUANT D'AUTRES CAUSES CONNUES DE RETARD STATURAL QUI DEVRAIENT ÊTRE SURVEILLÉES ET TRAITÉES PAR D'AUTRES MOYENS; TAILLE D'AU MOINS 2.25 ÉCARTS-TYPES SOUS LA MOYENNE POUR L'ÂGE ET LE SEXE; VÉLOCITÉ STATURALE AU-DESSOUS DU 25E PERCENTILE POUR L'ÂGE OSSEUX ET LE SEXE APRÈS 12 MOIS D'OBSERVATION ET PEU SUSCEPTIBLE DE PERMETTRE D'ATTEINDRE LA TAILLE ADULTE (PLAGE NORMALE).  UN TRAITEMENT PAR HUMATROPE DEVRAIT ÊTRE PRESCRIT POUR LE RETARD STATURAL IDIOPATHIQUE UNIQUEMENT DANS LE CAS DES PATIENTS DONT LES ÉPIPHYSES NE SONT PAS SOUDÉES ET DEVRAIT ÊTRE PRIS EN CHARGE PAR DES MÉDECINS QUI CONNAISSENT BIEN CE TROUBLE ET LE PROFIL D'EFFICACITÉ/INNOCUITÉ DE HUMATROPE","GROWTH STIMULANT","STIMULANT DE CROISSANCE","",""
"8262","06-09-12","DOPHARMA B.V.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","BORGAL INJECTION","INTERVET CANADA LTD.","CANADA","CANADA","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8263","06-09-14","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"8264","06-09-14","OVATION PHARMACEUTICALS LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ALKYLATING AGENT","AGENT ALCOYLANT","",""
"8265","06-09-14","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TETRACYCLINE ANTIBIOTIC","ANTIBIOTIQUE TÉTRACYCLINE","",""
"8266","06-09-15","RATIOPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"8267","06-09-15","SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATING THE PRODUCT MONOGRAPH WITH INFORMATION RELEVANT TO FOOD-DRUG INTERACTIONS AND PHARMACOKINETIC INFORMATION IN PEDIATRIC AND RENAL IMPAIRED PATIENTS","MISE À JOUR DE LA MONOGRAPHIE QUANT AUX INTERACTIONS ENTRE LES ALIMENTS ET LE MÉDICAMENT, LES DONNÉES PHARMACOCINÉTIQUES CHEZ LES ENFANTS ET CHEZ LES PATIENTS QUI SOUFFRENT D'INDUFFISANCE RÉNALE","PLATELET-REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"8268","06-09-18","HUVEPHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"8269","06-09-20","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHIN","HOFFMANN-LA ROCHE","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8270","06-09-20","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH RE: USE IN CHILDREN 4 TO 12 YEARS OF AGE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT POUR L'UTILISATION CHEZ LES ENFANTS ÂGÉS DE 4 À 12 ANS","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR USAGE NASAL","",""
"8271","06-09-20","HEALTHPOINT CANADA ULC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","TOPICAL ENZYMATIC DEBRIDING AGENT","TRAITEMENT FIBRINOLYTIQUE PAR ENZYMES","",""
"8272","06-09-20","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RECEPHIN","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8273","06-09-21","COBALT PHARMACEUTICALS INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM CO RANITIDINE","MODIFICATION DU NOM DU PRODUIT DE CO RANITIDINE","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"8274","06-09-21","GENMED, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"8275","06-09-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"8276","06-09-21","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","NEW INDICATION: THALLOUS CHLORIDE TI 201 IS INDICATED FOR SCINTIGRAPHIC IMAGING OF THE MYOCARDIUM TO IDENTIFY CHANGES IN PERFUSION INDUCED BY PHARMACOLOGIC STRESS (WITH ADENOSINE OR DIPYRIDAMOLE) IN PATIENTS WITH KNOWN OR SUSPECTED CORONARY ARTERY DISEASE AND WHO CANNOT EXERCISE ADEQUATELY","NOUVELLE INDICATION : LE CHLORURE DE THALLIUM TI 201 EST ÉGALEMENT INDIQUÉ EN IMAGERIE SCINTIGRAPHIQUE DU MYOCARDE POUR IDENTIFIER LES CHANGEMENTS DANS LA PERFUSION INDUITS PAR LE STRESS PHARMACOLOGIQUES (AVEC ADÉNOSINE OU DIPYRIDAMOLE) CHEZ LES CAS CONNUS OU SUSPECTS DE CORONAROPATHIE QUI NE PEUVENT FAIRE SUFFISAMMENT D'EXERCICE","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"8277","06-09-22","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"8278","06-09-22","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDEPRESSEUR","",""
"8279","06-09-22","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR, MINERAL SUPPLEMENT, VITAMIN SUPPLEMENT","RÉGULATEUR DU MÉTABOLISME OSSEUX, SUPPLÉMENT MINÉRAL, SUPPLÉMENT VITAMINIQUE","",""
"8280","06-09-22","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOVANTRONE","WYETH CANADA","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"8281","06-09-22","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN THE PRE-SLAUGHTER WITHDRAWAL PERIOD (PIGS)","MODIFICATION DU DÉLAI ENTRE LE TRAITEMENT ET L'ABATAGE (PORCS)","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8282","06-09-28","BIOGEN IDEC CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","SELECTIVE ADHESION MOLECULE INHIBITOR","INHIBITEUR SÉLECTIF DE MOLÉCULES D'ADHÉSION","",""
"8283","06-09-28","PURDUE PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"8284","06-09-29","GE HEALTHCARE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","TO REGISTER A REPLACEMENT MANUFACTURER OF THE DRUG SUBSTANCE, METHYLENE DIPHOSPHORIC ACID (MDP), AND TO CHANGE THE OVERALL SPECIFICATION OF THE MDP DRUG SUBSTANCE","ENREGISTRER LE NOUVEAU FABRICANT DE LA SUBSTANCE PHARMACEUTIQUE, ACIDE MÉTHYLÈNE DIPHOSPHORIQUE (MDP), ET MODIFIER LA SPÉCIFICATION GÉNÉRALE DE CETTE SUBSTANCE","DIAGNOSTIC RADIOPHARMACEUTICAL","PRODUIT RADIOPHARMACEUTIQUE SERVANT AU DIAGNOSTIC","",""
"8285","06-09-29","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY; MANUFACTURING CHANGES","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION; CHANGEMENTS À LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8286","06-09-29","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY; MANUFACTURING CHANGES","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION; CHANGEMENTS À LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8287","06-09-29","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY; MANUFACTURING CHANGES","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION; CHANGEMENTS À LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8288","06-09-29","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"8289","06-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS, DIVISION OF WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"8290","06-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8291","06-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"8292","06-10-02","OVATION PHARMACEUTICALS LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"8293","06-10-02","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOLU-MEDROL","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","GLUCOCORTICOID / ANTI-INFLAMMATORY","GLUCOCORTICOÏDE / ANTI-INFLAMMATOIRE","",""
"8294","06-10-02","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"8295","06-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8296","06-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"8297","06-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANTIOBESSSIONAL / ANTIBULIMIC","ANTIDÉPRESSEUR / ANTIOBSESSIONNEL / ANTIBOULIMIQUE","",""
"8298","06-10-02","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"8299","06-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST / MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 / ANTIMIGRAINEUX","",""
"8300","06-10-02","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"8301","06-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"8302","06-10-02","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"8303","06-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"8304","06-10-02","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","LIPID METABOLIMS REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8305","06-10-03","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM CANADA LTD.","CANADA","CANADA","1","","","SELECTIVE ANTAGONIST OF ALPHA 1A ADRENORECEPTOR SUBTYPE IN THE PROSTATE","ANTAGONISTE SÉLECTIF DES RÉCEPTEURS ALPHA 1A-ADRÉNERGIQUES DE LA PROSTATE","",""
"8306","06-10-03","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8307","06-10-04","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"8308","06-10-02","GE HEALTHCARE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","TO REGISTER A REPLACEMENT MANUFACTURER OF THE DRUG SUBSTANCE, METHYLENE DIPHOSPHORIC ACID (MDP), AND TO CHANGE THE OVERALL SPECIFICATION OF THE MDP DRUG SUBSTANCE","ENREGISTRER LE NOUVEAU FABRICANT DE LA SUBSTANCE PHARMACEUTIQUE ACIDE MÉTHYLÈNE DIPHOSPHERIQUE (MDP), ET MODIFIER LA SPÉCIFICATION GÉNÉRALE DE CETTE SUBSTANCE","DIAGNOSTIC RADIOPHARMACEUTICAL","PRODUIT RADIOPHARMACEUTIQUE SERVANT AU DIAGNOSTIC","",""
"8309","06-10-05","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISIONS TO PRODUCT MONOGRAPH: - CHANGE IN AGE INDICATION - THE SAFETY OF ADACEL WHEN CONCURRENTLY ADMINISTERED WITH INACTIVATED INFLUENZA VACCINE","MODIFICATION À LA MONOGRAPHIE DU PRODUIT : - CHANGEMENT À L'INDICATION DE L'ÂGE - LA SÉCURITÉ D'ADACEL LORSQU'ADMINISTRÉ SIMULTANÉMENT AVEC LE VACCIN D'INFLUENZA INACTIVÉ","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8310","06-10-05","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO-MCNEIL PHARMACEUTICALS INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEPILEPTIC / MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE / PROPHYLAXIE DE LA MIGRAINE","",""
"8311","06-10-06","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER. FULFILMENT OF COMMITMENT #1C OUTLINED IN LETTER OF UNDERTAKING DATED APRIL 1, 2005 FOR THE EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POST MENOPAUSAL WOMEN WHO HAVE RECEIVED PRIOR STANDARD ADJUVANT TAMOXIFEN THERAPY","NOUVELLE INDICATION : POUR LE TRAITEMENT ADJUVANT DU CANCER DU SEIN DÉBUTANT À RÉCEPTEURS HORMONAUX POSITIFS CHEZ LES FEMMES MÉNOPAUSÉES.  RESPECT DE L'ENGAGEMENT NO 1C DÉCRIT DANS LA LETTRE D'ENGAGEMENT DATÉE DU 1ER AVRIL 2005 POUR LE TRAITEMENT ADJUVANT AU LONG COURS DU CANCER DU SEIN DÉBUTANT CHEZ LES FEMMES MÉNOPAUSÉES QUI ONT DÉJÀ REÇU UN TRAITEMENT ADJUVANT TYPE AU TAMOXIFÈNE","NON-STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESIS; ANTI-TUMOUR AGENT","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN; INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES; ANTINÉOPLASIQUE","",""
"8312","06-10-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANXIOLYTIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE","",""
"8313","06-10-06","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX DF","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","NEW DF FORMULATION","NOUVELLE FORMULATION/COMPOSITION DF","5-HT1 RECEPTOR AGONIST","AGONISTE DES RÉCEPTEURS 5-HT1","",""
"8314","06-10-11","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8315","06-10-11","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: COVERSYL HAS BEEN DEMONSTRATED TO REDUCE THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND CARDIAC ARREST IN MILD OR MODERATELY HYPERTENSIVE PATIENTS WITH STABLE CORONARY ARTERY DISEASE, OR IN PATIENTS PREVIOUS (>3 MONTHS AGO) MYOCARDIAL INFARCTION AND STABLE CORONARY ARTERY DISEASE, WHEN ADMINISTERED AS AN ADD-ON TO CONVENTIONAL TREATMENT, SUCH AS PLATELET INHIBITORS, BETA BLOCKERS, LIPID-LOWERING AGENTS, NITRATES, CALCIUM CHANNEL BLOCKERS OR DIURETICS","NOUVELLE INDICATION : IL A ÉTÉ ÉTABLI QUE S'IL EST ADMINISTRÉ EN COMPLÉMENT À UN TRAITEMENT CLASSIQUE, TEL QUE DES INHIBITEURS DE L'AGRÉGATION PLAQUETTAIRE, DES BÊTA-BLOQUANTS, DES AGENTS HYPOLIPÉMIANTS, DES NITRATES, DES BLOQUEURS DES CANAUX CALCIQUES OU DES DIURÉTIQUES, COVERSYL RÉDUIT LE RISQUE DE MORTALITÉ CARDIOVASCULAIRE, D'INFARCTUS DU MYOCARDE NON MORTEL ET D'ARRÊT CARDIAQUE CHEZ LES PATIENTS SOUFFRANT D'HYPERTENSION LÉGÈRE À MODÉRÉE ATTEINTS D'UNE MALADIE CORONARIENNE STABLE OU CHEZ LES PATIENTS AYANT DES ANTÉCÉDENTS (IL Y A 3 MOIS?) D'INFARCTUS DU MYOCARDE ET DE MALADIE CORONARIENNE STABLE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8316","06-10-16","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN SITE OF MANUFACTURE","MODIFICATION DU LIEU DE FABRICATION","MUSCARINIC M3 SELECTIVE RECEPTOR ANTAGONIST","ANTAGONISTE SÉLECTIF DES RÉCEPTEURS MUSCARINIQUES M3","",""
"8317","06-10-16","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE INTRAVENOUS","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8318","06-10-16","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADENOCARD","FUJISAWA CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8319","06-10-13","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"8320","06-10-16","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","","","1","UPDATE TO THE PRODUT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"8321","06-10-16","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"8322","06-10-16","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"8323","06-10-16","ABRAXIS ONCOLOGY, A DIVISION OF ABRAXIS BIOSCIENCE, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8324","06-10-17","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: REDUCING THE SIGNS AND SYMPTOMS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY","NOUVELLE INDICATION : RÉDUCTION DES SIGNES ET DES SYMPTÔMES CHEZ LES PATIENTS ATTEINTS DE SPONDYLARTHRITE ANKYLOSANTE ACTIVE QUI N'ONT PAS RÉPONDUS DE FAÇON ADÉQUATE À LA THÉRAPIE CONVENTIONNELLE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8325","06-10-17","VITA HEALTH PRODUCTS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD AND SINUS CAPLETS","WHITHALL-ROBINS INC.","CANADA","CANADA","1","","","ANALGESIC / ANTIPYRETIC / NASAL DECONGESTANT","ANALGÉSIQUE / ANTIPYRÉTIQUE / DÉCONGESTIONNANT NASAL","",""
"8326","06-10-17","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOSPHATE BINDER","CHÉLATEUR DE PHOSPHORE","",""
"8327","06-10-18","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","THE TREATMENT OF PATIENTS WITH EARLY STAGE BREAST CANCER WHOSE TUMOURS OVEREXPRESS HER2 FOLLOWING SURGERY AND AFTER CHEMOTHERAPY","LE TRAITEMENT DES PATIENTES ATTEINTES DE CANCER DU SEIN AU STADE PRÉCOCE DONT LES TUMEURS SUR-EXPRIMENT HER2 SUIVANT LA CHIRURGIE ET APRÈS CHIMIOTHÉRAPIE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8328","06-10-18","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"8329","06-10-18","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TORADOL IM","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE AINS","",""
"8330","06-10-18","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8331","06-10-18","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8332","06-10-18","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IRON CHELATING AGENT","AGENT CHÉLATEUR DU FER","",""
"8333","06-10-18","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE TO WITHDRAWAL PERIOD","CHANGEMENT DANS LA PÉRIODE DE RETRAIT","HORMONE","HORMONE","",""
"8334","06-10-18","NORBROOK LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8335","06-10-20","ECOLAB CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"8336","06-10-20","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT MERCK PHARMA INC.","CANADA","CANADA","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTICOAGULANT","ANTICOAGULATN","",""
"8337","06-10-23","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","CONTRACEPTIVE VAGINAL RING","ANNEAU VAGINAL CONTRACEPTIF","",""
"8338","06-10-23","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANTIPANIC / ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR / ANTIPANIQUE / ANTIOBSESSIONNEL","",""
"8339","06-10-24","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TRACE ELEMENT","ÉLÉMENT TRACE","",""
"8340","06-10-24","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FORANE","ZENECA PHARMA INC.","CANADA","CANADA","1","","","INHALATION ANAESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"8341","06-10-24","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PIPRACIL","WYETH AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8342","06-10-24","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IFEX","BRISTOL MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8343","06-10-24","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ISOVUE","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE","",""
"8344","06-10-24","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ANEXATE INJECTION","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","BENZODIAZEPINE ANTAGONIST","ANTAGONISTE DES BENZODIAZÉPINES","",""
"8345","06-10-24","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN INJECTION","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8346","06-10-24","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8347","06-10-24","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLEXERIL","MERCK FROSST CANADA INC.","CANADA","CANADA","1","","","SKELETAL PRODUCT NAME","MYORELAXANT","",""
"8348","06-10-24","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT / ANTISPASTICITY AGENT","RELAXANT MUSCULAIRE / ANTISPASMODIQUE","",""
"8349","06-10-24","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC / ANTIHYPERTENSIVE AGENT","DIURÉTIQUE / ANTIHYPERTENSEUR","",""
"8350","06-10-24","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID IV","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"8351","06-10-25","GILEAD SCIENCES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"8352","06-10-25","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","AGENT HYPOGLYCÉMIANT ORAL","",""
"8353","06-10-25","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH TO REFLECT DISCONTINUATION OF FORTOVASE (SAQUINAVIR) IN THE GLOBAL MARKET PLACE","MISES À JOUR APPORTÉES À LA MONOGRAPHIE DE PRODUIT AFIN DE TENIR COMPTE DU RETRAIT DE FORTOVASE (SAQUINAVIR) DU MARCHÉ MONDIAL","HIV PROTEASE INHIBITOR / ANTIRETROVIRAL AGENT","INHIBITEUR DE LA PROTÉASE DU VIH / ANTIRÉTROVIRAL","",""
"8354","06-10-26","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","REDUCTION OF SIGNS AND SYMPTOMS AND INDUCTION AND MAINTENANCE OF CLINICAL REMISSION IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY","RÉDUCTION DES SIGNES ET DES SYMPTÔMES ET INDUCTION ET MAINTENANCE DE LA RÉMISSION CLINIQUE DE LA MALADIE CROHN MODÉRÉE À SÉVÈRE CHEZ LES PATIENTS PÉDIATRIQUES QUI N'ONT PAS RÉPONDU DE MANIÈRE ADÉQUATE AU TRAITEMENT STANDARD","BIOLOGIC RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8355","06-10-27","GILEAD SCIENCES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","AGANT ANTIRÉTROVIRAL","",""
"8356","06-10-27","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8357","06-10-27","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"8358","06-10-27","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"8359","06-10-27","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORCURON","ORGANON CANADA INC.","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEURO-MUSCULAIRE NON DÉPOLARISANT","",""
"8360","06-10-27","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8361","06-10-27","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","BENZODIAZEPINE - PREMEDICANT / SEDATIVE / ANAESTHETIC AGENT","BENZODIAZÉPINES - PRÉMÉDICATION / DÉDATIF / ANESTHÉSIQUE","",""
"8362","06-10-27","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAVELBINE","GLAXOSMITHKLINE INC,","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8363","06-10-27","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8364","06-10-27","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8365","06-10-27","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEGRETOL CR","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTICONVULSANT / SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA / ANTIMANIC","ANTICONVULSIVANT / SOULAGEMENT SYMPTOMATIQUE DE LA NÉVRALGIE DU TRIJUMEAU / ANTIMANIAQUE","",""
"8366","06-10-27","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC / ANTIPANIC","ANXIOLYTIQUE / ANTIPANIQUE","",""
"8367","06-10-27","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEBCIN","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8368","06-10-27","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8369","06-10-27","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","UROMITEXAN","BRISTOL-MYERS SQUIBB CANADA","CANADA","CANADA","1","","","UROPROTECTOR","UROPROTECTEUR","",""
"8370","06-10-27","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","THYROID HORMONE","HORMONE THYROÏDIENNE","",""
"8371","06-10-27","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8372","06-10-31","BERLEX CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"8373","06-10-31","ASTELLAS PHARMA CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING HEART TRANSPLANTS","NOUVELLE INDICATION : POUR LA PRÉVENTION DU REJET D'ORGANE CHEZ LES PATIENTS QUI SUBISSENT UNE TRANSPLANTATION CARDIAQUE","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"8374","06-10-31","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE AND NEW PRODUCT MONOGRAPH FORMAT","MISE À JOUR DE L'INNOCUITÉ ET NOUVEAU FORMAT DE LA MONOGRAPHIE DU PRODUIT","ALDOSTERONE ANTAGONIST","ANTAGONISTE DE L'ALDOSTÉRONE","",""
"8375","06-11-01","BERNA BIOTECH LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE TO THE MANUFACTURING PROCESS","MODIFICATION DE LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8376","06-11-01","TALECRIS BIOTHERAPEUTICS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","AIRE DE FABRICATION ALTERNATIVE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"8377","06-11-02","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8378","06-11-03","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE FROM PRESCRIPTION TO OVER THE COUNTER STATUS","PASSAGE DE PRODUIT D'ORDONNANCE À PRODUIT EN VENTE LIBRE","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"8379","06-11-03","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC / MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE / PROPHYLAXIE DE LA MIGRAINE","",""
"8380","06-11-03","ZLB BEHRING CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"8381","06-11-02","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","COX-2 INHIBITOR","INHIBITEUR DE LA COX-2","",""
"8382","06-11-06","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"8383","06-11-06","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZINACEF","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8384","06-11-06","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CALCIJEX","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","VITAMIN D3 METABOLITE","MÉTABOLITE DE LA VITAMINE D3","",""
"8385","06-11-06","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANCEF","SMITHKLINE BEECHAM","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8386","06-11-06","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8387","06-11-06","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8388","06-11-06","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8389","06-11-06","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZINACEF","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8390","06-11-06","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERSANTINE","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","CORONARY VASODILATOR","VASODILATATEUR CORONARIEN","",""
"8391","06-11-06","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING SITE","SITE DE FABRICATION ALTERNATIF","BIOLOGIC RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8392","06-11-07","GW PHARMA LIMITED","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE","CANNABINOID ANALGESIC","ANALGÉSIQUE CANNABINOÏDE","",""
"8393","06-11-07","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 RECEPTOR AGONIST - MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 - TRAITEMENT ANTIMIGRAINEUX","",""
"8394","06-11-07","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATED PRODUCT MONOGRAPH INCLUDING INDICATION, TREATMENT DURATION, PHARMACOKINETICS AND SAFETY INFORMATION","NOUVELLE MONOGRAPHIE DE PRODUIT, COMPRENANT UNE MISE À JOUR DES INDICATIONS, DE LA DURÉE DU TRAITEMENT, DES PROPRIÉTÉS PHARMACOCINÉTIQUES ET DES DONNÉE D'INNOCUITÉ","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"8395","06-11-08","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BLENOXANE","BRISTOL LABORATORIES OF CANADA","CANADA","CANADA","1","","","ANTINEOPLASTIC / ANTIBIOTIC","ANTINÉOPLASIQUE / ANTIBIOTIQUE","",""
"8396","06-11-08","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT MULTI-TRACES","",""
"8397","06-11-08","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT MULTI-TRACES","",""
"8398","06-11-08","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR","SANOFI WINTHROP INC.","CANADA","CANADA","1","","","INOTROPE / VASODILATOR","AGENT INOTROPE / VASODILATATEUR","",""
"8399","06-11-08","SIGMA-TAU PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION FOR USE IN COMBINATION WITH OTHER ANTICANCER AGENTS FOR THE TREATMENT OF STAGE III AND IV HODGKIN'S DISEASE","INDICATION RÉVISÉE POUR L'UTILISATION EN COMBINAISON AVEC D'AUTRES AGENTS ANTICANCÉREUX POUR LE TRAITEMENT DE LA MALADIE DE HODGKIN AUX STADES III ET IV","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8400","06-11-08","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","FOR A RANGE DOSAGE APPROVAL FROM 110 PPM TO 150 PPM FOR THE INDICATION OF NECROTIC ENTERITIS (NE) CAUSED BY CLOSTRIDIUM PERFRINGENS IN BROILER CHICKENS","POUR UNE APPROBATION DE DOSAGE ALLANT DE 110 PPM JUSQU'À 150 PPM POUR L'INDICATION DE L'ENTÉRITE NÉCROTIQUE CAUSÉE PAR C. PERFRINGENS CHEZ LES POULETS À GRILLER","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8401","06-11-09","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO DRUG PRODUCT BATCH SIZE, MANUFACTURE, IN-PROCESS LIMITS, PRESENTATION AND SPECIFICATIONS, RELEASE AND END OF SHELF-LIFE PH SPECIFICATION","CHANGEMENTS APPORTÉS À LA TAILLE DES LOTS DU PRODUIT MÉDICAMENTEUX, À LA FABRICATION, AUX LIMITES EN COURS DE FABRICATION, À LA PRÉSENTATION ET AUX SPÉCIFICATIONS RELATIVES AU PH LORS DE LA MISE EN CIRCULATION ET À LA LIMITE DE LA DURÉE DE CONSERVATION","ANTIDIABETIC","ANTIDIABÉTIQUE","",""
"8402","06-11-10","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REGISTRATION OF AN ADDITIONAL MANUFACTURING SITE FOR THE DRUG PRODUCT NOVORAPID AND A SCALE-UP OF BATCH SIZE TO 3000L AT THE NEW MANUFACTURING SITE ONLY","QUALIFICATION D'UN NOUVEAU SITE DE FABRICATION POUR LE PRODUIT MÉDICAMENTEUX DE NOVORAPID ET AUGMENTATION DE LA TAILLE À 3000L À CE MÊME SITE","ANTI-DIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8403","06-11-10","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA FORMULATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8404","06-11-10","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANTIRHEUMATIC, IMMUNOMODULATOR AGENT","ANTIRHUMATISMAL, IMMUNOMODULATEUR","",""
"8405","06-11-10","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"8406","06-11-10","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC RADIOGRAPHIC CONTRAST MEDIUM","AGENT DE CONTRASTE RADIOLOGIQUE NON IONIQUE","",""
"8407","06-11-14","VETOQUINOL N.-A. INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION AND THE ADDITION OF A NEW ROUTE OF ADMINISTRATION (SUBCUTANEOUS) FOR CATTLE","CHANGEMENT DE FORMULATION ET ADDITION D'UNE NOUVELLE VOIE D'ADMINISTRATION (SOUS-CUTANÉE) CHEZ LE BOVIN","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8408","06-11-15","GENMED, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8409","06-11-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"8410","06-11-15","TEVA PHARMACEUTICALS INDUSTRIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"8411","06-11-17","OVATION PHARMACEUTICALS, INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC / ANTINEOPLASTIC","ANTIBIOTIQUE / ANTINÉOPLASIQUE","",""
"8413","06-11-17","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FAMVIR","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"8414","06-11-20","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DRUG SUBSTANCE MANUFACTURING PROCESS","NOUVEAU PROCESSUS DE FABRICATION DE LA SUBSTANCE MÉDICAMENTEUSE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8415","06-11-20","BRACCO DIAGNOSTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","DIAGNOSTIC ULTRASOUND CONTRAST AGENT","AGENT DE CONTRASTE POUR ÉCHOGRAPHIE","",""
"8416","06-11-20","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8417","06-11-21","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","HORMONAL CONTRACEPTIVE","CONTRACEPTIF HORMONAL","",""
"8418","06-11-22","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING SITES","SITES DE FABRICATION ADDITIONNELS","IGE NEUTRALISING ANTIBODY","SITES DE FABRICATION ADDITIONNELS","",""
"8419","06-11-23","COIN PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"8420","06-11-23","RANBAXY PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8421","06-11-23","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR INITIAL TREATMENT OF SEVERE HYPERTENSION","NOUVELLE INDICATION POUR LE TRAITEMENT INITIAL DE L'HYPERTENSION ARTÉRIELLE SÉVÈRE","ANGIOTENSIN II RECEPTOR ANTAGONIST AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"8422","06-11-23","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYNTHETIC ALCOHOL DEHYDROGENASE INHIBITOR","INHIBITEUR SYNTHÉTIQUE DE L'ALCOOL DÉSHYDROGÉNASE","",""
"8423","06-11-24","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH - NEW FORMAT AND UPDATED SAFETY INFORMATION","RÉVISION DE LA MONOGRAPHIE DU PRODUIT - NOUVEAU FORMAT ET MISE À JOUR DE L'INFORMATION SUR L'INNOCUITÉ DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8424","06-11-24","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","A NEW INDICATION FOR THE TREATMENT OF NASAL POLYPS IN ADULTS 18 YEARS OF AGE AND OLDER","UNE NOUVELLE INDICATION POUR LE TRAITEMENT DES POLYPES NASALES CHEZ LES ADULTES DE 18 ANS ET PLUS","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"8425","06-11-27","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8426","06-11-27","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB INC.","CANADA","CANADA","1","CHANGE IN FORMULATION","CHANGEMENT DANS LA FORMULATION","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"8427","06-11-27","COLGATE-PALMOLIVE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH AND LABELLING","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT ET DE L'ÉTIQUETAGE","ANTICARIES, ANTIPLAQUE, ANTIGINGIVITIS AND ANTICALCULUS","ANTICARIES, ANTIPLAQUE, ANTIGINGIVITE ET ANTICALCULS","",""
"8428","06-11-23","NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIVE","",""
"8429","06-11-28","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"8430","06-11-28","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8431","06-11-28","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW LABEL CLAIM ON 10 MG TABLET PACKAGE","NOUVELLE ALLÉGATION SUR L'EMBALLAGE DU COMPRIMÉ DE 10 MG","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"8432","06-11-28","ALCON CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH REGARDING HEPATIC INSUFFICIENCY, RENAL INSUFFICIENCY, AND EFFECTS ON CARDIAC REPOLARIZATION (QTC)","MISE À JOUR DE L'INFORMATION SUR L'INNOCUITÉ DANS LA MONOGRAPHIE DE PRODUIT, CONCERNANT L'INSUFFISANCE HÉPATIQUE, L'INSUFFISANCE RÉNALE ET LES EFFETS SUR LA REPOLARISATION CARDIAQUE (QTC)","ANTI-ALLERGY AGENT","AGENT ANTIALLERGIQUE","",""
"8433","06-10-25","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8434","06-11-29","LUNDBECK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: GENERALIZED ANXIETY DISORDER","NOUVELLE INDICATION : TROUBLE D'ANXIÉTÉ GÉNÉRALISÉE","ANTIDEPRESSANT / ANXIOLYTIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE","",""
"8435","06-12-01","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE DRUG DELIVERY SYSTEM - HUMIRA PEN","SYSTÈME D'ADMINISTRATION ALTERNATIF DE MÉDICAMENTS - HUMIRA STYLO","BIOLOGIC RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8436","06-11-30","METHAPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 1600 MG POWDER FOR DILUTION PER 50 ML VIAL, AND OTHER CHANGES TO THE PRODUCT MONOGRAPH","NOUVELLE PRÉPARATION POUR DILUTIONS: 1600 MG DE POUDRE PAR FLACON DE 50 ML, ET AUTRES CHANGEMENTS DANS LA MONOGRAPHIE DE PRODUIT","CHOLINERGIC / DIAGNOSTIC AID (BRONCHIAL ASTHMA)","CHOLINERGIQUE / AUXILIAIRE DIAGNOSTIQUE (ASTHME BRONCHIQUE)","",""
"8437","06-12-01","RANBAXY PHARMACEUTICALS CANADA INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8438","06-12-01","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM FOR SWINE","INDICATION ADDITIONNELLE POUR PORCS","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8439","06-12-01","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM FOR SWINE","INDICATION ADDITIONNELLE POUR PORCS","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8440","06-12-04","GE HEALTHCARE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE","",""
"8441","06-12-04","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANXIOLYTIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE","",""
"8442","06-12-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST","AGENT ANTIPARKINSONIEN / AGONISTE DOPAMINERGIQUE","",""
"8443","06-12-06","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIEN AGENT / DOPAMINE AGONIST","AGENT ANTIPARKINSONIEN / AGONISTE DOPAMINERGIQUE","",""
"8444","06-12-07","TAP PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO SPECIAL HANDLING INSTRUCTIONS SECTION AS WELL AS OTHER SECTIONS OF THE PRODUCT MONOGRAPH","RÉVISION DE LA SECTION SUR LES INSTRUCTIONS PARTICULIÈRES DE MANIPULATION DE MÊME QUE D'AUTRES SECTIONS DE LA MONOGRAPHIE DE PRODUIT","GONADOTROPIN-RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"8445","06-12-11","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW CONTRAINDICATION FOR THE USE IN PATIENTS WITH SEVERE RENAL IMPAIRMENT, UPDATES TO THE CLINICAL TRIALS SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE CONTRE-INDICATION DE L'USAGE CHEZ LES PATIENTS AVEC DÉFICIENCES RÉNALES SÉVÈRES; LA MISE À JOUR DE LA SECTION DES ESSAIS CLINIQUES ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANTICOAGULANT / ANTITHROMBOTIC","ANTICOAGULANT / ANTITHROMBOTIQUE","",""
"8446","06-12-11","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF OSTEOPOROSIS IN MEN, TO IMPROVE BONE MINERAL DENSITY","NOUVELLE INDICATION : TRAITEMENT DE L'OSTÉOPOROSE CHEZ L'HOMME, POUR AMÉLIORER LA DENSITÉ MINÉRALE OSSEUSE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"8448","06-12-12","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SPECIES","NOUVELLE ESPÈCE","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8449","06-12-12","SCHERING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8450","06-12-12","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8451","06-12-12","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8452","06-12-12","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8453","06-12-12","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8454","06-12-13","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8455","06-12-13","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SECTRAL","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"8456","06-12-13","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","IMMUNOMODULATORY AGENT","AGENT D'IMMUNOMODULATION","",""
"8457","06-12-13","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","KERATINOCYTE GROWTH FACTOR","FACTEUR DE CROISSANCE KÉTARINOCYTE","",""
"8458","06-12-14","SANOFI-AVENTIS CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TAXOTERE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER","NOUVELLE INDICATION : TAXOTERE ADMINISTRÉ EN ASSOCIATION AVEC LA DOXORUBICINE ET LA CYCLOPHOSPHAMIDE DANS LE TRAITEMENT ADJUVANT DES PATIENTES ATTEINTES D'UN CANCER DU SEIN AVEC ATTEINTE GANGLIONNAIRE OPÉRABLE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8459","06-12-14","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8460","06-12-15","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8461","06-12-15","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8462","06-12-15","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8463","06-12-15","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHIN","HOFFMAN-LAROCHE LIMITED","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8464","06-12-15","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PURIFICATION FACILITY","NOUVELLE INSTALLATION DE PURIFICATION","ANTIDIABETIC","ANTIDIABÉTIQUE","",""
"8465","06-12-15","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MODIFICATIONS TO DOSAGE AND ADMINISTRATION","MODIFICATIONS DE LA POSOLOGIE ET L'ADMINISTRATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8466","06-12-15","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 320 MG TABLET AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE CONCENTRATION : COMPRIMÉS DE 320 MG ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"8467","06-12-15","LUITPOLD PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","USE IN THE TREATMENT OF IRON DEFICIENCY ANEMIA IN NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE PATIENTS AND IN PERITONEAL DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE PATIENTS","UTILISATION POUR LE TRAITEMENT DES PATIENTS ANÉMIQUES ATTEINTS D'INSUFFISANCE RÉNALE CHRONIQUE NON DÉPENDANTE À LA DIALYSE OU DÉPENDANTE À LA DIALYSE PÉRITONÉALE","HEMATINIC","HÉMATINIQUE","",""
"8468","06-12-18","MERCK FROSST/SCHERING PHARMA GP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: EZETROL ADMINISTERED IN COMBINATION WITH FENOFIBRATE IN PATIENTS WITH MIXED HYPERLIPIDEMIA AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION : EZETROL ADMINISTRÉ EN COMBINAISON AVEC FÉNOFIBRATE CHEZ LES PATIENTS ATTEINTS D'HYPERLIPIDÉMIE DE TYPE MIXTE, ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","CHOLESTEROL ABSORPTION INHIBITOR","INHIBITEUR DE L'ABSORPTION DU CHOLESTÉROL","",""
"8469","06-12-19","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8470","06-12-19","NORBROOK LABORATORIES LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC PREMIX FOR SWINE","MERIAL CANADA INC.","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8471","06-12-19","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","INDICATION SUPPLÉMENTAIRE","ANTI-INFLAMMATORY, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"8472","06-12-19","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY CORTICOSTEROID","ANTI-INFLAMMATOIRE CORTICOSTÉROÏDE","",""
"8473","06-12-19","SCHERING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW CLAIM FOR CATTLE","NOUVELLE INDICATION POUR BOVINS","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8474","06-12-20","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8475","06-12-20","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8476","06-12-19","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","FOR THE APPROVAL OF THE CONCURRENT USE OF AVATEC MEDICATED PREMIX (LASALOCID SODIUM) WITH ALBAC 110P (ZINC BACITRACIN PREMIX)","POUR L'APPROBATION DE L'UTILISATION CONCOMITANTE D'AVATEC PRÉMÉLANGE MÉDICAMENTÉ DE LASALOCIDE SODIQUE AVEC LE PRÉMÉLANGE ALBAC 110P PRÉMÉLANGE DE BACITRACINE DE ZINC","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"8477","06-12-20","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8478","06-12-20","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8479","06-12-20","OVATION PHARMACEUTICALS, INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY AGENT FOR CLOSURE OF PATENT DUCTUS ATERIOSUS","ANTI-INFLAMMATOIRE NON STÉROÏDIEN POUR LA FERMETURE DU CANAL ARTÉRIEL PERSISTANT","",""
"8480","06-12-20","PENDOPHARM, DIVISION OF/DE PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"8481","06-12-20","PENDOPHARM, DIVISION OF/DE PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC.","CANADA","CANADA","1","","","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC, PLATELET AGGREGATION INHIBITOR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"8482","06-12-21","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION, DRUG INTERACTIONS, AND WARNINGS AND PRECAUTIONS SECTIONS OF THE PRODUCT MONOGRAPH","RÉVISION DES SECTIONS POSOLOGIE ET ADMINISTRATION, INTERACTIONS MÉDICAMENTEUSES ET MISES EN GARDE ET PRÉCAUTIONS DE LA MONOGRAPHIE DU PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8483","06-12-21","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SYMBICORT MAINTENANCE AND RELIEVER THERAPY: SYMBICORT IS TAKEN AS REGULAR MAINTENANCE THREATMENT AND AS NEEDED IN RESPONSE TO SYMPTOMS; AND REVISION TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION : SYMBICORT POUR LE TRAITEMENT D'ENTRETIEN ET DE DÉPANNAGE : SYMBICORT EST UTILISÉ RÉGULIÈREMENT DANS L'ENTRETIEN ET AU BESOIN POUR LE SOULAGEMENT DES SYMPTÔMES D'ASTHME; ET RÉVISION À LA MONOGRAPHIE DE PRODUIT","CORTICOSTEROID AND BRONCHODILATOR FOR INHALATION","CORTICOSTÉROÏDE ET BRONCHODILATATEUR POUR INHALATION","",""
"8484","06-12-21","ECOLAB CO.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GERMICIDE","GERMICIDE","",""
"8485","06-12-21","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8486","06-12-21","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE ACTION AND CLINICAL PHARMACOLOGY: PHARMACOKINETICS SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISES À JOUR SUR L'ACTION ET PHARMACOLOGIE CLINIQUE : LA SECTION DE PHARMACOCINÉTIQUE, ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"8487","06-12-21","BAYER INC., CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM - CHEWABLE TABLET AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE PRÉSENTATION : COMPRIMÉ CROQUABLE; ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC AND PLATELET AGGREGATION INHIBITEUR","ANALGÉSIQUE, ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE ET INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"8488","06-12-22","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8489","06-12-22","OVATION PHARMACEUTICALS, INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ALKYLATING AGENT","ALCOYLANT","",""
"8490","06-12-22","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8491","06-12-22","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8492","06-12-22","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC / ANTIHYPERTENSIVE","DIURÉTIQUE / ANTIHYPERTENSEUR","",""
"8493","06-12-22","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR THE INDICATION OF PROPHYLAXIS OF INFLUENZA IN PERSONS 7 YEARS OLD AND ABOVE","INDICATION DE PROPHYLAXIE ANTIGRIPPALE CHEZ LES PERSONNES ÂGÉES DE 7 ANS ET PLUS","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"8494","06-12-28","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST","AGENT ANTIPARKINSONIEN / AGONISTE DOPAMINERGIQUE","",""
"8495","07-01-02","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOTENSIN","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","ADDITION OF TWO NEW STRENGTHS","AJOUT DE DEUX NOUVELLES CONCENTRATIONS","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8496","07-01-02","HILL DERMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"8497","07-01-05","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8498","07-01-05","HAMILTON HEALTH SCIENCES CORP.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","PRODUIT RADIOPHARMACEUTIQUE DIAGNOSTIQUE","",""
"8499","07-01-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE","AUTRE EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8500","07-01-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE","AUTRE EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8501","07-01-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE","AUTRE EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8502","07-01-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE","AUTRE EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8503","07-01-05","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FAMVIR","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"8504","07-01-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN EXPIRATION PERIOD; CHANGE IN PACKAGING; CHANGE IN DRUG PRODUCT SPECIFICATIONS","CHANGEMENT DE LA DATE LIMITE D'UTILISATION; MODIFICATION DU CONDITIONNEMENT; CHANGEMENT DES SPÉCIFICATIONS DU MÉDICAMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8505","07-01-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN EXPIRATION PERIOD; CHANGE IN PACKAGING; CHANGE IN DRUG PRODUCT SPECIFICATIONS","CHANGEMENT DE LA DATE LIMITE D'UTILISATION; MODIFICATION DU CONDITIONNEMENT; CHANGEMENT DES SPÉCIFICATIONS DU MÉDICAMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8506","07-01-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN EXPIRATION PERIOD; CHANGE IN PACKAGING; CHANGE IN DRUG PRODUCT SPECIFICATIONS","CHANGEMENT DE LA DATE LIMITE D'UTILISATION; MODIFICATION DU CONDITIONNEMENT; CHANGEMENT DES SPÉCIFICATIONS DU MÉDICAMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8507","07-01-05","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN EXPIRATION PERIOD; CHANGE IN PACKAGING; CHANGE IN DRUG PRODUCT SPECIFICATIONS","CHANGEMENT DE LA DATE LIMITE D'UTILISATION; MODIFICATION DU CONDITIONNEMENT; CHANGEMENT DES SPÉCIFICATIONS DU MÉDICAMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8508","07-01-08","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"8509","07-01-08","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"8510","07-01-09","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN FORMULATION: REMOVAL OF SORBIC ACID, REPLACEMENT OF YELLOW DYE AND IMPLEMENTATION OF PHARMACOPEIA EUROPA MONOGRAPH TESTING FOR ALL EXCIPIENTS","MODIFICATION DE LA FORMULATION PHARMACEUTIQUE: RETRAIT DE L'ACIDE SORBIQUE, CHANGEMENT DU COLORANT JAUNE ET MISE EN APPLICATION DE LA MONOGRAPHIE DE LA PHARMACOPÉE EUROPÉENNE POUR TOUS LES EXCIPIENTS","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8511","07-01-08","PALADIN LABS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIANE-35","BERLEX CANADA INC.","CANADA","CANADA","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"8512","07-01-09","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"8513","07-01-09","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8514","07-01-10","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REDUCING SIGNS AND SYMPTOMS, INDUCING AND MAINTAINING CLINICAL REMISSION, INDUCING AND MAINTAINING MUCOSAL HEALING, AND REDUCING OR ELIMINATING CORTICOSTEROID USE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY","RÉDUCTION DES SIGNES ET DES SYMPTÔMES, INDUCTION ET MAINTENANCE DE LA RÉMISSION CLINIQUE, INDUCTION ET MAINTENANCE DE LA CICATRISATION DES MUQUEUSES ET RÉDUCTION OU ÉLIMINATION DE L'USAGE DES CORTICOSTÉROÏDES CHEZ LES PATIENTS ATTEINTS DE COLITE ULCÉREUSE D'INTENSITÉ MODÉRÉE À GRAVE N'AYANT PAS RÉPONDU ADÉQUATEMENT AU TRAITEMENT STANDARD","BIOLOGIC RESPONSE MODIFIER","AGENT D'IMMUNOMODUATION","",""
"8515","07-01-10","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE INDICATIONS AND CLINICAL USE SECTION OF THE PRODUCT MONOGRAPH","RÉVISIONS À LA SECTION DE L'INDICATION ET L'USAGE CLINIQUE DE LA MONOGRAPHIE DU PRODUIT","ANGIOTENSIN II AT1 RECEPTOR BLOCKER/DIURETIC","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II, DIURÉTIQUE","",""
"8516","07-01-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"8517","07-01-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL SUPRA","LABORATOIRES FORUNIER S.A.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8518","06-12-12","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8519","07-01-11","MAYNE PHARMA INTERNATIONAL PTY LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"8520","07-01-11","VALEANT CANADA LIMITÉE/LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CNS DEPRESSANT","DÉPRESSEUR DU SYSTÈME NERVEUX CENTRAL","",""
"8521","07-01-11","ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MONOTHERAPY AS A TREATMENT OPTION FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER PRIOR CHEMOTHERAPY","NOUVELLE INDICATION : EN MONOTHÉRAPIE COMME TRAITEMENT  POUR LES PATIENTS ATTEINTS D'UN CANCER DU POUMON NON À PETITES CELLULES LOCALEMENT AVANCÉ OU MÉTASTATIQUE APRÈS UNE CHIMIOTHÉRAPIE ANTÉRIEURE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8522","07-01-12","ZLB BEHRING CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"8523","07-01-12","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY / IMPROVED MANUFACTURING PROCESS","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION / MODIFICATION DE LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8524","07-01-12","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY / IMRPOVED MANUFACTURING PROCESS","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION / MODIFICATION DE LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8525","07-01-12","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY / IMPROVED MANUFACTURING PROCESS","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION / MODIFICATION DE LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8526","07-01-12","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY / IMPROVED MANUFACTURING PROCESS","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION / MODIFICATION DE LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8527","07-01-12","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF INFORMATION ON THE DRUG INTERACTION WITH MEMANTINE INTO THE PRODUCT MONOGRAPH","ADDITION DE L'INFORMATION SUR L'INTERACTION AVEC MÉMANTINE DANS LA MONOGRAPHIE DU PRODUIT","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"8528","07-01-15","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE CLINICAL TRIALS SECTION, DOSAGE AND ADMINISTRATION SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DES ÉTUDES CLINIQUES, DE LA SECTION DE DOSAGE ET D'ADMINISTRATION, AINSI QUE D'AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8529","07-01-15","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"8530","07-01-19","NOVO NORDISK A/S","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING SITE","SITE DE FABRICATION ADDITIONNEL","ANTI-DIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8531","07-01-19","NOVO NORDISK A/S","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING SITE","SITE DE FABRICATION ADDITIONNEL","ANTI-DIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8532","07-01-19","GENZYME CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH AND PRESENTATION","NOUVEAU DOSAGE ET NOUVELLE PRÉSENTATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8533","07-01-19","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING PROCESS AND PRODUCTION AREA","PROCESSUS DE FABRICATION ET ZONE DE PRODUCTION ALTERNATIFS","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8534","07-01-19","CANGENE CORPORATION","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"8535","07-01-22","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DDAVP TABLETS","FERRING INC.","CANADA","CANADA","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"8536","07-01-22","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DDAVP","FERRING PHARMACEUTICALS LTD.","UNITED KINGDOM","ROYAUME-UNI","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"8537","07-01-23","MERIDIAN MEDICAL TECHNOLOGIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"8538","07-01-23","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"8539","07-01-23","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIEMETIC AGENT","ANTIÉMÉTIQUE","",""
"8540","07-01-23","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC / ANTIPYRETIC / NASAL DECONGESTANT","ANALGÉSIQUE / ANTIPYRÉTIQUE / DÉCONGESTIONNANT NASAL","",""
"8541","07-01-23","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST / SYMPATHOMIMETIC AMINE","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE / AMINE SYMPATHOMIMÉTIQUE","",""
"8542","07-01-23","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC / ANTIPYRETIC / NASAL DECONGESTANT","ANALGÉSIQUE / ANTIPYRÉTIQUE / DÉCONGESTIONNANT NASAL","",""
"8543","07-01-23","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"8544","07-01-23","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"8545","07-01-23","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"8546","07-01-23","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"8547","07-01-23","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"8548","07-01-23","JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HAIR REGROWTH TREATMENT FOR MEN","STIMULANT POUR LA POUSSE DES CHEVEUX POUR LES HOMMES","",""
"8549","07-01-23","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN API MANUFACTURING SITE","NOUVEL EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8550","07-01-23","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN API MANUFACTURING SITE","NOUVEL EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8551","07-01-23","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN API MANUFACTURING SITE","NOUVEL EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8552","07-01-23","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN API MANUFACTURING SITE","NOUVEL EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8553","07-01-23","VALEANT PHARMACEUTICALS INTERNATIONAL","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW ADJUSTABLE DELIVERY SYSTEM.  REVISIONS TO THE INDICATIONS AND CLINICAL USE AND DOSAGE AND ADMINISTRATION SECTIONS, AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVEAU DISPOSITIF D'ADMINISTRATION RÉGLABLE, RÉVISIONS AUX SECTIONS D'INDICATION, DE POSOLOGIE ET D'ADMINISTRATION, ET AUTRES RÉVISIONS DE LA MONOGRAPHIE","BENZODIAZEPINE ANTICONVULSANT","ANTICONVULSIVANT À BASE DE BENZODIAZÉPINE","",""
"8554","07-01-23","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO INTRODUCE A NEW INDICATION: FOR THE TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME","NOUVELLE INDICATION CLINIQUE: TRAITEMENT DE L'HYPERSÉCRÉTION PATHOLOGIQUE INCLUANT LE SYNDROME DE ZOLLINGER-ELLISON","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"8555","07-01-23","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"8556","07-01-24","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"8557","07-01-24","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"8558","07-01-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMAN LA-ROCHE LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8559","07-01-25","PENDOPHARM, DIVISION OF/DE PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOWELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"8560","07-01-25","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS","NOUVELLE INDICATION CLINIQUE : TRAITEMENT DES INFECTIONS COMPLIQUÉES DE LA PEAU ET DES ANNEXES CUTANÉES","Antibacterial Agent","Antibactérien","",""
"8561","07-01-26","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"8562","07-01-26","GENMED, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8563","07-01-26","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE ADVERSE REACTIONS SECTION AND THE CLINICAL TRIALS SECTION OF THE PRODUCT MONOGRAPH AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DES EFFETS INDÉSIRABLES ET DE LA SECTION DES ÉTUDES CLINIQUES DE LA MONOGRAPHIE DU PRODUIT; AINSI QUE D'AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","BRONCHODILATOR","BRONCHODILATATEUR","",""
"8564","07-01-29","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NIGHTTIME SLEEP-AID","AIDE-SOMMEIL","",""
"8565","07-01-29","NOVARTIS CONSUMER HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"8566","07-01-30","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTOGEN","PROGESTATIF","",""
"8567","07-02-01","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COVERSYL","SERVIER CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8568","07-02-02","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR PATIENTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX HAS BEEN SHOWN TO REDUCE THE RATE OF AN ENDPOINT OF ALL-CAUSE MORTALITY AND THE RATE OF A COMBINED ENDPOINT OF DEATH, RE-INFARCTION OR STROKE AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION : POUR LES PATIENTS AVEC L'INFARCTUS DU MYOCARDE AIGU ACCOMPAGNÉ D'UNE ÉLÉVATION DU SEGMENT ST, IL A ÉTÉ DÉMONTRÉ QUE PLAVIX RÉDUIT LE TAUX DE MORTALITÉ RELIÉ À TOUTES CAUSES AINSI QUE LA COMBINAISON DE CAS DE MORTS, REINFARCTUS ET ACCIDENTS CÉRÉBROVASCULAIRES AINSI QUE D'AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"8569","07-02-05","ORCHID HEALTHCARE (A DIVISION OF ORCHID CHEMICALS & PHARMACEUTICALS LTD.)","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFOXITIN FOR INJECTION, USP","NOVOPHARM LTD.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8570","07-02-05","SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS FOR ADULT AND FOR ADOLESCENT PATIENT POPULATIONS AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLES INDICATIONS POUR LES POPULATIONS ADULTES ET ADOLESCENTES ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","CNS STIMULANT","STIMULANT DU SNC","",""
"8571","07-02-06","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","FOR THE ADDITION OF ANOTHER CANADIAN FEED MILL, LANDMARK FEEDS INC., TO PREPARE A MINERAL-VITAMIN MIX MEDICATED WITH BOVATEC MEDICATED PREMIX","AJOUT DE LANDMARK FEEDS INC. À LA LISTE DES PROVENDERIES CANADIENNES AUTORISÉES À PRÉPARER UN MÉLANGE DE VITAMINES ET MINÉRAUX ADDITIONNÉ DE BOVATEC PRÉMÉLANGE MÉDICAMENTEUX","ANTIBIOTIC, ANTICOCCODIAL","ANTIBIOTIQUE, ANTICOCCIDIEN","",""
"8572","07-02-06","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","FOR THE ADDITION OF ANOTHER CANADIAN FEED MILL, GRANDE PRAIRIE FEED SERVICE (1971) LTD., TO PREPARE A MINERAL-VITAMIN MIX MEDICATED WITH BOVATEC MEDICATED PREMIX","AJOUT DE GRANDE PRAIRIE FEED SERVICE (1971) LTD. À LA LISTE DES PROVENDERIES CANADIENNES AUTORISÉES À PRÉPARER UN MÉLANGE DE VITAMINES ET MINÉRAUX ADDITIONNÉ DE BOVATEC PRÉMÉLANGE MÉDICAMENTEUX","ANTIBIOTIC, ANTICOCCODIAL","ANTIBIOTIQUE, ANTICOCCIDIEN","",""
"8573","07-02-06","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"8574","07-02-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE LTD.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"8575","07-02-06","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION FOR THE 10ML VIAL PRESENTATION / PROCESS MODIFICATIONS","LA NOUVELLE FORMULATION POUR LE 10ML PRÉSENTATION DE FIOLE / MODIFICATION DE LA MÉTHODE DE FABRICATION","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8576","07-02-07","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTO IV","ALTANA PHARMA INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"8577","07-02-08","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"8578","07-02-08","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLACTIC MANAGEMENT OF VASCULAR HEADACHES","TRAITEMENT PROPHYLACTIQUE DES CÉPHALÉES VASCULAIRES","",""
"8579","07-02-09","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PEDIATRIC ASTHMA PROPHYLACTIC AND ANTIALLERGIC AGENT","AGENT PROPHYLACTIQUE DE L'ASTHME INFANTILE ET AGENT ANTIALLERGIQUE","",""
"8580","07-02-09","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTICOAGULANT","ANTICOAGULANT ORAL","",""
"8581","07-02-12","KING PHARMA CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8582","07-02-12","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIDIARRHEAL AGENT","ANTIDIARRHÉIQUE","",""
"8583","07-02-08","BAYER HEALTHCARE LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8584","07-02-15","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","IMPROVED MANUFACTURING PROCESS","MODIFICATION DE LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8585","07-02-14","SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE CLINICAL TRIALS SECTION OF THE PRODUCT MONOGRAPH AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DES ÉTUDES CLINIQUES DANS LA MONOGRAPHIE DU PRODUIT ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"8586","07-02-14","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE","AUTRE EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8587","07-02-14","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE","AUTRE EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8590","07-02-15","PENDOPHARM, DIVISION OF/DE PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL","WHITEHALL-ROBINS INC.","CANADA","CANADA","1","","","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"8591","07-02-15","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE RECOMMENDATION FOR SPECIAL POPULATIONS IN THE WARNING AND PRECAUTIONS SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS AUX SECTIONS DE PRÉCAUTIONS ET MISE EN GARDE SUR LA RECOMMANDATION SUR LES DOSAGES POUR LES POPULATIONS SPÉCIALES, ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8592","07-02-16","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"8593","07-02-16","FRESENIUS KABI CANADA A DIVISION OF CALEA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLASMA VOLUME EXPANDER","SOLUTÉ DE REMPLISSAGE PLASMATIQUE","",""
"8594","07-02-16","GENMED, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"8595","07-02-16","GENMED, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR - TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DU GMPC - TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"8596","07-02-19","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL M-TAB","JANSSEN-ORTHO INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"8597","07-02-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FAMVIR","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"8598","07-02-20","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID / NSAID COMBINATION ANALGESIC","OPIOÏDES / ANALGÉSIQUE AINS","",""
"8599","07-02-20","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","AGENT ANTIARYTHMIQUE","",""
"8600","07-02-15","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE","AUTRE EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8601","07-02-15","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE","AUTRE EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8602","07-02-21","FRESENIUS MEDICAL CARE NORTH AMERICA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOSPHATE BINDER","CHÉLATEUR DES PHOSPHATES","",""
"8603","07-02-21","GERMIPHENE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGINGIVITIS ORAL RINSE","RINCE-BOUCHE ANTI-GINGIVITE","",""
"8604","07-02-21","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8605","07-02-21","ACTAVIS GROUP PTC EHF","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"8606","07-02-21","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8607","07-02-21","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8608","07-02-22","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MANAGEMENT OF UNSTABLE ANGINA OR NON-ST SEGMENT ELEVATION MYOCARDIAL INFARCTION (UA/NSTEMI) FOR THE PREVENTION OF DEATH AND SUBSEQUENT MYOCARDIAL INFARCTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLES INDICATIONS, SOIT LA PRISE EN CHARGE DE L'ANGINE INSTABLE OU DE L'INFARCTUS DU MYOCARDE SANS ÉLÉVATION DU SEGMENT ST (AI/IM SANS ÉLÉVATION ST) POUR LA PRÉVENTION DU DÉCÈS ET DE LA RÉCIDIVE DE L'INFARCTUS MYOCARDIQUE, ET AUTRES MODIFICATIONS APPORTÉES À LA MONOGRAPHIE DE PRODUIT","SYNTHETIC ANTITHROMBOTIC","ANTITHROMBOTIQUE SYNTHÉTIQUE","",""
"8609","07-02-23","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR (ANTI-HYPERCALCEMIC AGENT)","RÉGULATEUR DU MÉTABOLISME OSSEUX (AGENT ANTIHYPERCALCÉMIQUE)","",""
"8610","07-02-23","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","PRODUIT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"8611","07-02-23","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"8612","07-02-23","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHIN","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8613","07-02-23","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8614","07-02-23","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST","AGENT ANTIPARKINSONIEN / AGONISTE DOPAMINERGIQUE","",""
"8615","07-02-23","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PRE-SLAUGHTER WITHDRAWAL PERIOD (BROILER CHICKENS)","MODIFICATION DU DÉLAI REQUIS AVANT L'ABATTAGE (POULETS À GRILLER)","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8616","07-02-26","OVATION PHARMACEUTICALS, INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT FOR ADJUNCTIVE THERAPY","ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT","",""
"8617","07-02-26","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO ACTION AND CLINICAL PHARMACOLOGY AND DETAILED PHARMACOLOGY SECTIONS OF THE PRODUCT MONOGRAPH","RÉVISIONS DES SECTIONS MODE D'ACTION ET PHARMACOLOGIE CLINIQUE, ET DE LA PHARMACOLOGIE DÉTAILLÉE DE LA MONOGRAPHIE DU PRODUIT","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8618","07-02-26","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","NEW FORM OF DRUG SUBSTANCE","NOUVELLE PRÉSENTATION DE LA SUBSTANCE MÉDICAMENTEUSE","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"8619","07-02-27","BAYER HEALTHCARE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","FIXED POLYSORBATE 80 FORMULATION","FORMULATION AVEC UNE CONCENTRATION FIXE DE POLYSORBATE 80","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8620","07-02-27","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MANAGEMENT OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) FOR THE PREVENTION OF DEATH AND MYOCARDIAL RE-INFARCTION, NEW INTRAVENOUS ROUTE OF ADMINISTRATION, AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION : PRISE EN CHARGE DE L'INFARCTUS DU MYOCARDE AVEC SUS-DÉCALAGE DU SEGMENT ST POUR PRÉVENIR LE DÉCÈS ET LA RÉCIDIVE D'INFARCTUS DU MYOCARDE, NOUVEAU MODE D'ADMINISTRATION (PAR VOIE INTRAVEINEUSE) ET AUTRES MODIFICATIONS APPORTÉES À LA MONOGRAPHIE DE PRODUIT","SYNTHETIC ANTITHROMBOTIC","ANTITHROMBOTIQUE SYNTHÉTIQUE","",""
"8621","07-02-27","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF INFORMATION REGARDING USE IS PEDIATRIC POPULATION","COMPLÉMENT D'INFORMATION CONCERNANT L'USAGE DU MÉDICAMENT CHEZ LES ENFANTS","VITAMIN D ANALOG","ANALOGUE DE LA VITAMINE D","",""
"8622","07-02-28","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","FOR THE PRESCRIPTION TO NON-PRESCRIPTION STATUS OF FAMOTIDINE AT THE 20 MG STRENGTH TO TREAT HEARTBURN, ACID INDIGESTION AND SOUR UPSET STOMACH","CHANGEMENT DU STATUT DU MÉDICAMENT SOUS ORDONNANCE, FAMOTIDINE, FORMULATION 20 MG POUR TRAITER LES BRÛLURES D'ESTOMAC, L'INDIGESTION ACIDE ET LES AIGREURS À L'ESTOMAC, POUR DEVENIR UN MÉDICAMENT EN VENTE LIBRE","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"8623","07-02-28","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRESCRIPTION TO NON-PRESCRIPTION SWITCH","PASSAGE DE PRODUIT D'ORDONNANCE À PRODUIT EN VENTE LIBRE","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"8624","07-02-28","BARRIER THERAPEUTICS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8625","07-02-28","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"8626","07-02-28","NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8627","07-03-01","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: THE TREATMENT OF PEDIATRIC PATIENTS WITH TYPE 1 DIABETES MELLITUS WHO REQUIRE A LONG-ACTING (BASAL) INSULIN FOR THE CONTROL OF HYPERGLYCEMIA.  THE SAFETY AND EFFICACY OF LEVEMIR HAS NOT BEEN STUDIED IN CHILDREN BELOW THE AGE OF 6 YEARS","NOUVELLE INDICATION : INDIQUÉ DANS LE TRAITEMENT DES ENFANTS ATTEINTS DE DIABÈTE DE TYPE 1 QUI NÉCESSITENT UNE INSULINE À ACTION PROLONGÉE POUR LE CONTRÔLE D'HYPERGLYCÉMIE.  L'INNOCUITÉ ET L'EFFICACITÉ DE LEVEMIR N'ONT PAS ÉTÉ ÉTUDIÉES CHEZ LES ENFANTS DE MOINS DE SIX ANS","ANTIDIABETIC","ANTIDIABÉTIQUE","",""
"8628","06-12-08","CIPLA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","LUNG SURFACTANT (BOVINE)","SURFACTANT PULMONAIRE (BOVINE)","",""
"8629","07-03-01","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE DRUG INTERACTIONS SECTION OF THE PRODUCT MONOGRAPH AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION INTERACTIONS MÉDICAMENTEUSES DE LA MONOGRAPHIE DE PRODUIT ET AUTRES MODIFICATIONS APPORTÉES À LA MONOGRAPHIE DE PRODUIT","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"8630","07-03-01","SOLVAY PHARMA INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","ANTIPARKINSONIEN","",""
"8631","07-03-02","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STRENGTH","NOUVEAU DOSAGE","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8632","07-03-05","GILEAD SCIENCES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH WITH LONG TERM DATA FROM STUDY GS-98-438 REGARDING AN ASSESSMENT OF THE SAFETY AND EFFICACY OF HEPSERA IN THE TREATMENT OF CHRONIC HEPATITIS B IN HBEAG-NEGATIVE PATIENTS","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT À PARTIR DES DONNÉES À LONG TERME TIRÉES DE L'ÉTUDE GS-98-438 PORTANT SUR L'ÉVALUATION DE L'INNOCUITÉ ET DE L'EFFICACITÉ D'HEPSERA DANS LE TRAITEMENT DE L'HÉPATITE B CHRONIQUE CHEZ DES PATIENTS NÉGATIFS POUR L'ANTIGÈNE E DE L'HÉPATITE B (HBEAG)","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"8633","07-03-05","GILEAD SCIENCES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH WITH LONG TERM DATA FROM STUDY GS-98-435 REGARDING AN ASSESSMENT OF THE SAFETY AND EFFICACY OF HEPSERA IN HEPATITIS B PATIENTS BOTH PRE- AND POST-LIVER TRANSPLANTATION","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT À PARTIR DES DONNÉES À LONG TERME TIRÉES DE L'ÉTUDE GS-98-435 PORTANT SUR L'ÉVALUATION DE L'INNOCUITÉ ET DE L'EFFICACITÉ D'HEPSERA CHEZ LES PATIENTS ATTEINTS D'HÉPATITE B À LA FOIS AVANT ET APRÈS UNE GREFFE DU FOIE","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"8634","07-03-04","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT LABELLING","MISE À JOUR DE L'ÉTIQUETTE DU PRODUIT","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8635","07-03-04","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH - REMOVAL OF CHRONIC INDICATION AND SAFETY UPDATES","MODIFICATIONS APPORTÉES À LA MONOGRAPHIE DE PRODUIT - SUPPRESSION DE L'INDICATION CHRONIQUE ET MISES À JOUR SUR L'INNOCUITÉ","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE","",""
"8636","07-03-07","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8637","07-03-08","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE AS A SINGLE AGENT FOR INDUCTION PHASE THERAPY IN ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL); AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY PH+ALL AS MONOTHERAPY","NOUVELLE INDICATION : UTILISATION COMME AGENT UNIQUE LORS DE LA PHASE D'INDUCTION DU TRAITEMENT DE PATIENTS ADULTES ATTEINTS D'UNE LEUCÉMIE LYMPHOBLASTIQUE AIGUË AVEC CHROMOSOME PHILADELPHIE (LLA PH+) NOUVELLEMENT DIAGNOSTIQUÉE; COMME MONOTHÉRAPIE POUR LE TRAITEMENT DE LA LLA PH+ RÉCIDIVANTE OU RÉFRACTAIRE CHEZ LES PATIENTS ADULTES","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"8638","07-03-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CABADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8639","07-03-09","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","THERAPEUTIC RADIOPHARMACEUTICAL","RADIOPHARMACEUTIQUE THÉRAPEUTIQUE","",""
"8640","07-03-08","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIANE-35","BERLEX CANADA INC.","CANADA","CANADA","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"8641","07-03-08","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"8642","07-03-08","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8643","07-03-14","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8644","07-03-13","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: COZAAR IS ALSO INDICATED IN PATIENTS WITH ESSENTIAL HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY; THE INCLUSION OF THE LIFE STUDY AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH.","NOUVELLE INDICATION: COZAAR EST AUSSI INDIQUÉ POUR LES PATIENTS AYANT L'HYPERTENSION ESSENTIELLE AVEC L'HYPERTROPHIE VENTRICULAIRE; L'INCLUSION DE L'ÉTUDE LIFE ET AUTRES RÉVISIONS DANS LA MONOGRAPHIE DU PRODUIT","ANGIOTENSIN II RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II","",""
"8645","07-03-14","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SPECIES - CATS","NOUVELLE ESPÈCE - CHATS","HORMONE","HORMONE","",""
"8646","07-03-15","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ANTIHYPERTENSIVE / ANTIANGINAL AGENT","ANTIHYPERTENSEUR / ANTIANGINEUX","",""
"8647","07-03-16","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE TO THE MANUFACTURING FACILITY","CHANGEMENT À L'INSTALLATION DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"8648","07-03-16","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE TO THE MANUFACTURING FACILITY","CHANGEMENT À L'INSTALLATION DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER PLUS ANTIVIRAL AGENT","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE PLUS AGENT ANTIVIRAL","",""
"8649","07-03-15","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE CLINICAL TRIALS SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DES ÉTUDES CLINIQUES ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"8650","07-03-16","ORCHID HEALTHCARE DIVISION OF ORCHID CHEMICALS & PHARMACEUTICALS LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHIN","HOFFMAN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8651","07-03-16","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8652","07-03-16","PREMPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ALCOHOL ABSTINENCE AID","AIDE À L'ABSTINENCE DE L'ALCOOL","",""
"8653","07-03-16","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","REMOVAL OF AN OBSOLETE WARNING STATEMENT THAT PREVENTED THIS PREMIX FROM BEING USED IN LACTATING DAIRY CATTLE","RETRAIT D'UN ÉNONCÉ DE MISE EN GARDE OBSOLÈTE STIPULANT QUE CE PRÉMÉLANGE NE PEUT ÊTRE UTILISÉ CHEZ LES VACHES LAITIÈRES EN LACTATION","ANTICOCCIDIAL, GROWTH PROMOTANT","ANTICOCCIDIEN, AUGMENTE LE GAIN PONDÉRAL","",""
"8654","07-03-16","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","PROVIDE FOR THE ADDITION OF A NEW INDICATION AS AN AID IN THE PREVENTION OF COCCIDIOSIS CAUSED BY EIMERIA OVINOIDALIS AND E. OVINA IN LAMBS BEING FED IN CONFINEMENT","AJOUT D'UNE NOUVELLE INDICATION DU PRODUIT COMME ADJUVANT DANS LA PRÉVENTION DE LA COCCIDIOSE CAUSÉE PAR E. OVINOIDALIS ET E. OVINA CHEZ LES AGNEAUX NOURRIS EN CLAUSTRATION","ANTICOCCIDIAL, GROWTH PROMOTANT","ANTICOCCIDIEN, AUGMENT LE GAIN PONDÉRAL","",""
"8655","07-03-16","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8656","07-03-16","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PHTHALATE-FREE TO BE ADDED TO THE LABEL AND PRODUCT MONOGRAPH","SANS PHTALATE À ÊTRE AJOUTÉ À L'ÉTIQUETTE ET À LA MONOGRAPHIE DU PRODUIT","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"8657","07-03-20","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8658","07-03-20","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"8659","07-03-20","PROVAL PHARMA DIVISION OF SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8660","07-03-20","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"8661","07-03-20","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8662","07-03-22","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW INDICATION: REDUCE TO QUIT","NOUVELLE INDICATION : RÉDUCTION EN VUE DE LA CESSATION","STOP SMOKING AID","AIDE POUR CESSER DE FUMER","",""
"8663","07-03-23","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8664","07-03-23","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","PRODUIT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"8665","07-03-23","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: USE IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF ORGAN REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS","NOUVELLE INDICATION : UTILISATION EN ASSOCIATION AVEC LA CYCLOSPORINE POUR PRÉVENIR LE REJET D'ORGANE CHEZ LES GREFFÉS DU REIN À RISQUE ÉLEVÉ","IMMUNOSUPPRESSIVE AGENT","AGENT IMMUNISUPPRESSEUR","",""
"8666","07-03-23","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC.","CANADA","CANADA","1","NEW STRENGTH AND NEW DOSAGE FORM","NOUVELLE CONCENTRATION ET NOUVELLE FORME POSOLOGIQUE","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"8667","07-03-23","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE CLINICAL TRIALS SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DES ÉTUDES CLINIQUES ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"8668","07-03-23","NORBROOK LABORATORIES LTD.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","IVOMEC POUR-ON","MERIAL CANADA INC.","CANADA","CANADA","1","ADDITION OF PERSISTENT EFFECT INDICATIONS","INDICATIONS ADDITIONNELLES RELATIVES AUX EFFETS RÉMANENTS DU MÉDICAMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8669","07-03-26","CSL BEHRING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8670","07-03-26","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","INTRAVENOUS CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"8671","07-03-26","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANDROGEN","ANTIANDROGÈNE","",""
"8672","07-03-26","BRISTOL-MYERS SQUIBB CANADA","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROTEIN-TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"8673","07-03-26","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC / ANTIPYRETIC AGENT","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"8674","07-03-26","SCHERING-PLOUGH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8675","07-03-27","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8676","07-03-27","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIROSACEA AGENT","AGENT ANTIROSACÉE","",""
"8677","07-03-27","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8678","07-03-27","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"8679","07-03-27","LUNDBECK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE ACTION & CLINICAL PHARMACOLOGY SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DE L'ACTION ET PHARMACOLOGIE CLINIQUE ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","ANTIDEPRESSANT / ANXIOLYTIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE","",""
"8680","07-03-28","NORBROOK LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTIQUE","",""
"8681","07-03-29","ORYX PHARMACEUTICALS INC., A SUBSIDIARY OF FILIALE DARROW PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: 750/20 MG AND 1000/40 MG, NEW MAXIMUM DAILY DOSE: 2000/40 MG AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLES FORCES (PRÉSENTATIONS) : 750/20 MG ET 100/40 MG, NOUVELLE DOSE JOURNALIÈRE MAXIMALE, ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8682","07-03-30","CSL BEHRING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"8683","07-03-30","CSL BEHRING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"8684","07-03-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8685","07-03-30","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8686","07-03-30","SERVIER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANGIOTENSIN CONVERTING ENZYME INHIBITOR - DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE - DIURÉTIQUE","",""
"8687","07-03-30","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION, WITH OTHER MINOR CHANGES TO PART I, II AND III OF THE PRODUCT MONOGRAPH TO ALLOW FOR AN ON-DEMAND TREATMENT REGIMEN FOR NONEROSIVE REFLUX DISEASE","MODIFICATIONS DE LA SECTION POSOLOGIE ET ADMINISTRATION ET CHANGEMENTS MINEURS AUX PARTIES I, II ET III DE LA MONOGRAPHIE DE PRODUIT POUR REFLÉTER UN NOUVEAU RÉGIME POSOLOGIQUE POUR LE TRAITEMENT SUR DEMANDE DU REFLUX GASTRO-OESOPHAGIEN NON-ÉROSIF","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"8688","07-04-02","RATIOPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC.","CANADA","CANADA","1","NEW SUPPLIER","NOUVEAU FOURNISSEUR","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"8689","07-04-02","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FOR THE TREATMENT OF ACUTE SINUSITIS WITH A DOSAGE REGIMEN OF 750 MG ONCE DAILY FOR 5 DAYS","POUR LE TRAITEMENT DE LA SINUSITE AIGUE AVEC UNE POSOLOGIE DE 750 MG, EN UNE SEULE DOSE POUR 5 JOURS","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"8690","07-04-03","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","THE REMOVAL OF A STATEMENT FROM WARNING AND PRECAUTIONS AND CONTRAINDICATION SECTIONS AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","SUPPRESSION D'UNE INFORMATION DANS LA SECTION DE MISE EN GARDE ET PRÉCAUTIONS AINSI QUE LA SECTION DE CONTRE-INDICATION ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DE PRODUIT","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"8691","07-02-27","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PURIFICATION AREA","NOUVELLE AIRE DE PURIFICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8692","07-04-05","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8693","07-04-05","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8694","07-04-05","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"8695","07-04-10","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE TO THE MANUFACTURING FACILITY","CHANGEMENT À L'INSTALLATION DE FABRICATION","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8696","07-04-05","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","DOSE ADJUSTMENT IN PATIENTS WITH RENAL IMPAIRMENT","ADAPTATION DE LA POSOLOGIE PROPOSÉE CHEZ LES INSUFFISANTS RÉNAUX","ANTIVIRAL","ANTIVIRAL","",""
"8697","07-04-10","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIPARKINSONIAN AGENT, DOPAMINE AGONIST","ANTIPARKINSONIEN, AGONISTE DOPAMINERGIQUE","",""
"8698","07-04-10","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8699","07-04-10","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8700","07-04-12","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE CLINICAL TRIALS SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DES ÉTUDES CLINIQUES ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","ANGIOTENSIN II AT1 RECEPTOR BLOCKER / DIURETIC","INHIBITEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II / DIURÉTIQUE","",""
"8701","07-04-12","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE DOSAGE AND ADMINISTRATION AND DRUG INTERACTIONS SECTIONS AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DES SECTIONS DE POSOLOGIE ET ADMINISTRATION ET D'INTERACTIONS MÉDICAMENTEUSES ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","ANTIEPILEPTIC, MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE, PROPHYLAXIE DE LA MIGRAINE","",""
"8702","07-04-12","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE DOSAGE AND ADMINISTRATION SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DE POSOLOGIE ET ADMINISTRATION ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"8703","07-04-13","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REPLACEMENT OF HUMAN SERUM ALBUMIN WITH RECOMBINANT ALBUMIN","REMPLACEMENT DE L'ALBUMINE SÉRIQUE HUMAINE PAR UNE ALBUMINE RECOMBINANTE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8704","07-04-12","GENPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8705","07-04-12","MAYNE PHARMA (CANADA) INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLUDARA","BERLEX CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8706","07-04-13","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REFORMULATION, NEW DOSAGE STRENGTH, QUALIFICATION OF A NEW FACILITY","NOUVELLE FORMULATION, NOUVEAU DOSAGE, QUALIFICATION D'UN NOUVEL EMPLACEMENT","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8707","07-04-16","GRACEWAY PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR ORAL INHALATION","CORTICOSTÉROÏDE POUR INHALATION ORALE","",""
"8708","07-04-16","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY / ANALGESIC","ANTI-INFLAMMATOIRE / ANALGÉSIQUE","",""
"8709","07-04-16","GRACEWAY PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE IMMUNITAIRE","",""
"8710","07-04-16","GRACEWAY PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR / BETA2-ADRENERGIC STIMULANT","BRONCHODILATEUR / STIMULANT DES B2-ADRÉNERGIQUES","",""
"8711","07-04-16","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN FORMULATION, NEW MANUFACTURING FACILITY","NOUVELLE FORMULATION, NOUVEL EMPLACEMENT DE FABRICATION","ANTICOAGULANT","ANTICOAGULANT","",""
"8712","07-04-13","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8713","07-04-13","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8714","07-04-17","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","QUALIFICATION OF 200L FERMENTERS","QUALIFICATION DE NOUVEAU FERMENTEUR 200L","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8715","07-04-17","DURAMED PHARMACEUTICALS, INC., A SUBSIDIARY OF BARR PHARMACEUTICALS, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSING REGIMEN: TWO TABLETS OF PLAN B (LEVONORGESTREL 0.75MG) TO BE TAKEN TOGETHER, ORALLY, AS SOON AS POSSIBLE BUT WITHIN 72 HOURS AFTER UNPROTECTED INTERCOURSE","NOUVELLE POSOLOGIE : PRISE ORALE DE DEUX COMPRIMÉS DE PLAN B (LEVONORGESTREL 0.75MG) AUSSITÔT QUE POSSIBLE DURANT LES 72 HEURES SUIVANT UNE RELATION SEXUELLE NON-PROTÉGÉE","EMERGENCY CONTRACEPTION","CONTRACEPTIF D'URGENCE","",""
"8716","07-04-17","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE D'ANXIÉTÉ SOCIALE), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"8717","07-04-18","BRACCO DIAGNOSTICS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MAGNETIC RESONANCE ANGIOGRAPHY (MRA)","NOUVELLE INDICATION : ANGIOGRAPHIE PAR RÉSONANCE MAGNÉTIQUE (ARM)","DIAGNOSTIC CONTRAST AGENT FOR MRI AND MRA","AGENT DE CONTRASTE DIAGNOSTIQUE POUR L'IRM ET L'ARM","",""
"8718","07-04-18","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION TO REDUCE THE RISK OF MYOCARDIAL INFARCTION IN PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION : POUR RÉDUIRE LE RISQUE D'INFARCTUS DU MYOCARDE CHEZ LES PATIENTS AYANT LES ÉVIDENCES CLINIQUES DE MALADIE CORONARIENNE CARDIAQUE; ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"8719","07-04-18","4349121 CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8720","07-04-18","GRACEWAY PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"8721","07-04-18","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8722","07-04-18","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTIN - ESTROGEN","PROGESTATIF - OESTROGÈNE","",""
"8723","07-04-18","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","DIMERIC NON-IONIC RADIOGRAPHIC CONTRAST MEDIUM FOR INTRAVASCULAR USE","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE DIMÉRIQUE","",""
"8724","07-04-18","PROVAL PHARMA, DIVISION OF SERVIER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPOGLYCEMIC SULFONYLUREA / ORAL ANTIDIABETIC AGENT","HYPOGLYCÉMIANT SULFONYLURÉE / ANTIDIABÉTIQUE ORAL","",""
"8725","07-04-18","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8726","07-04-18","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC IODINATED RADIOGRAPHIC CONTRAST MEDIUM","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON IONIQUE IODÉE","",""
"8727","07-04-18","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN & PROGESTIN","OESTROGÈNE & PROGESTATIF","",""
"8728","07-04-18","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","DIMERIC NON-IONIC RADIOGRAPHIC CONTRAST MEDIUM FOR MYELOGRAPHY","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON-IONIQUE DIMÉRIQUE POUR LA MYÉLOGRAPHIE","",""
"8729","07-04-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8730","07-04-23","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE CLINICAL TRIALS SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DES ÉTUDES CLINIQUES ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","INHIBITEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"8731","07-04-23","GRACEWAY PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL","ANTIANGINEUX","",""
"8732","07-04-24","GRACEWAY PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8733","07-04-24","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"8734","07-04-24","KING PHARMA CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPOTHYROIDISM THERAPY","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"8735","07-04-24","BRADLEY PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TREATMENT OF ACTINIC KERATOSES","TRAITEMENT DES KÉRATOSES D'ORIGINE ACTINIQUE","",""
"8736","07-04-24","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGIC RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8737","07-04-25","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL SITE","SITE ADDITIONNEL","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8738","07-04-25","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE TO NSAID GUIDANCE","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT POUR TENIR COMPTE DES RECOMMANDATIONS RELATIVES AUX AINS","NON-STEROIDAL ANTI-INFLAMMATORY DRUG","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"8739","07-04-25","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE TO NSAID GUIDANCE","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT POUR TENIR COMPTE DES RECOMMANDATIONS RELATIVES AUX AINS","NON-STEROIDAL ANTI-INFLAMMATORY DRUG","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"8740","07-04-25","RAINBOW PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"8741","07-04-24","BAYER HEALTHCARE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PURIFICATION AREA","NOUVELLE AIRE DE PURIFICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8742","07-04-24","BAYER HEALTHCARE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN THE MANUFACTURING PROCESS","CHANGEMENT DANS LA MÉTHODE DE FABRICATION","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8743","07-04-26","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","Selective Antagonist of Alpha 1A Adrenoceptor Subtype in the Prostate","Antagoniste sélectif des récepteurs Alpha 1A adrénergiques de la prostate","",""
"8744","07-04-26","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8745","07-04-27","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSCOPAN","BOEHRINGER INGELHEIM","CANADA","CANADA","1","","","ANTISPASMODIC","ANTISPASMODIQUE","",""
"8746","07-04-27","TOLMAR INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMICROBIAL AGENT FOR PERIODONTITIS","ANTIMICROBIEN POUR LA PÉRIODONTITE","",""
"8747","07-05-01","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8748","07-05-01","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"8749","07-05-01","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC / SEDATIVE","ANXIOLYTIQUE / SÉDATIF","",""
"8750","07-05-01","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","LEDERLE CYANAMID CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8751","07-05-01","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC AGENT","HYPNOTIQUE","",""
"8752","07-05-02","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MODIFICATIONS TO MANUFACTURING FACILITY / MANUFACTURING CHANGES","MODIFICATIONS À L'EMPLACEMENT DE FABRICATION / CHANGEMENTS À LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8753","07-05-02","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MODIFICATIONS TO MANUFACTURING FACILITY / MANUFACTURING CHANGES","MODIFICATIONS À L'EMPLACEMENT DE FABRICATION / CHANGEMENTS À LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8754","07-05-02","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MODIFICATIONS TO MANUFACTURING FACILITY / MANUFACTURING CHANGES","MODIFICATIONS À L'EMPLACEMENT DE FABRICATION / CHANGEMENTS À LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8755","07-05-02","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MODIFICATIONS TO MANUFACTURING FACILITY / MANUFACTURING CHANGES","MODIFICATIONS À L'EMPLACEMENT DE FABRICATION / CHANGEMENTS À LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8756","07-05-02","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MODIFICATIONS TO MANUFACTURING FACILITY / MANUFACTURING CHANGES","MODIFICATIONS À L'EMPLACEMENT DE FABRICATION / CHANGEMENTS À LA FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8757","07-05-02","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTIHEMORRHAGICS, BLOOD COAGULATION FACTORS IX, II, VII, X IN COMBINATION","ANTIHÉMORRAGIQUES, ASSOCIATION DES FACTEURS DE COAGULATION SANGUINS IX, II, VII, X","",""
"8758","07-05-02","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH - 300MG CAPSULE","NOUVELLE CONCENTRATION - CAPSULE DE 300MG","AZAPEPTIDE INHIBITOR OF HIV-1 PROTEASE","INHIBITEUR AZAPEPTIDE DE LA PROTÉASE VIH-1","",""
"8759","07-05-02","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8761","07-05-02","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8762","07-05-02","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8763","07-05-03","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8764","07-05-04","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN (2 X 500 MG AND DAILY FOR 5 DAYS)","NOUVELLE POSOLOGIE : 500 MG 2 FOIS PAR JOUR, PENDANT 5 JOURS","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8765","07-05-08","AMGEN CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF MONITORING INSTRUCTIONS TO THE PRODUCT MONOGRAPH","AJOUT D'INSTRUCTIONS RELATIVES À LA SURVEILLANCE DANS LA MONOGRAPHIE DE PRODUIT","CALCIMIMETIC AGENT","AGENT CALCIMIMÉTIQUE","",""
"8766","07-05-04","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","ADDITION OF INDICATIONS: NASAL CONGESTION, ALONG WITH ITCHY NOSE AND THROAT; ALL AS PART OF THE SYMPTOM CONSTELLATION","ADDITION D'INDICATIONS CLINIQUES : OBSTRUCTION NASALE, AVEC DÉMANGEAISONS DU NEZ ET DE LA GORGE, FAISANT PARTIE D'UNE CONSTELLATION DE SYMPTÔMES","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"8767","07-05-04","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLONASE","GLAXOSMITHKLINE INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"8768","07-05-08","CSL BEHRING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT IMMUNISANT PASSIF","",""
"8769","07-05-08","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERTS CANADA INC.","CANADA","CANADA","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8770","07-05-08","BIOMED 2002 INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC","DIURÉTIQUE","",""
"8771","07-05-08","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM CANADA LTD.","CANADA","CANADA","1","","","SELECTIVE ANTAGONIST OF ALPHA 1A ADRENOCEPTOR SUBTYPE IN THE PROSTATE","ANTAGONISTE SÉLECTIF DES RÉCEPTEURS ALPHA 1A ADRÉNERGIQUES DE LA PROSTATE","",""
"8772","07-05-08","PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT ORAL","",""
"8773","07-05-08","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8774","07-05-08","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8775","07-05-10","VÉTOQUINOL N.-A. INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN WITHDRAWAL PERIOD","CHANGEMENT DANS LA PÉRIODE DE RETRAIT","HORMONE","HORMONE","",""
"8776","07-05-09","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH - CORRECTION TO INFORMATION FOR PEDIATRIC PATIENTS","MONOGRAPHIE DE PRODUIT RÉVISÉE - CORRECTION APPORTÉE À L'INFORMATION RELATIVE AUX ENFANTS","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8777","07-05-11","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM - CHEWABLE TABLETS","NOUVELLE FORME POSOLOGIQUE - COMPRIMÉS À CROQUER","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"8778","07-05-11","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION IN ADULTS - COLORECTAL SURGICAL PROPHYLAXIS","NOUVELLE INDICATION POUR ADULTES - PROPHYLAXIE POUR CHIRURGIE COLORECTALE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8779","07-05-11","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SPECIES","NOUVELLES ESPÈCES","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"8780","07-05-14","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8781","07-05-14","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MINERALOCORTICOID FOR ADRENAL INSUFFICIENCY","MINÉRALOCORTICOÏDE POUR L'INSUFFISANCE SURRÉNALE`","",""
"8782","07-05-14","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"8783","07-05-14","GENZYME CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN D ANALOGUE","ANALOGUE DE LA VITAMINE D","",""
"8784","07-05-14","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","SELECTIVE ANTAGONIST OF ALPHA 1A ADRENOCEPTOR SUBTYPE IN THE PROSTATE","ANTAGONISTE SÉLECTIF DES RÉCEPTEURS ALPHA 1A ADRÉNERGIQUES DE LA PROSTATE","",""
"8785","07-05-14","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAPROSYN E","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY AGENT WITH ANALGESIC AND ANTI-PYRETIC PROPERTIES","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"8786","07-05-16","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOMODULATTORY AGENT","AGENT IMMUNOMODULATEUR","",""
"8787","07-05-16","COBALT PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8788","07-05-16","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF USE WITH SPACER DEVICES SUBSECTION TO THE DOSAGE AND ADMINISTRATION SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","L'AJOUT D'UNE SOUS SECTION SUR L'UTILISATION AVEC LES DISPOSITIFS ADAPTEURS À LA SECTION DE POSOLOGIE ET ADMINISTRATION, ET AUTRES RÉVISIONS DE LA MONOGRAPHIE","BRONCHODILATOR AND CORTICOSTEROID FOR ORAL INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE EN INHALATION","",""
"8789","07-05-16","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMARYL","AVENTIS PHARMA","CANADA","CANADA","1","","","ORAL HYPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONYLURÉE)","",""
"8790","07-05-16","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE MANUFACTURING SITE","SITE DE FABRICATION ALTERNATIF","EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA TYROSINE KINASE DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE","",""
"8791","07-05-16","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AVALIDE IS ALSO INDICATED AS INITIAL THERAPY IN PATIENTS WITH SEVERE ESSENTIAL HYPERTENSION FOR WHOM THE BENEFIT OF A PROMPT BLOOD PRESSURE REDUCTION EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION: AVALIDE PEUT AUSSI ÊTRE ADMINISTRÉ COMME TRAITEMENT INITIAL DANS LES CAS D'HYPERTENSION SÉVÈRE LORSQUE LES BÉNÉFICES D'UNE RÉDUCTION RAPIDE DE LA PRESSION ARTÉRIELLE EXCÈDENT LES RISQUES D'INITIER UNE THÉRAPIE ASSOCIANT PLUSIEURS MÉDICAMENTS; ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANGIOTENSIN II AT1 RECEPTOR BLOCKER / DIURETIC","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II / DIURÉTIQUE","",""
"8792","07-05-16","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE TOXICOLOGY SECTION OF THE PRODUCT MONOGRAPH AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISION DE LA SECTION DE TOXICOLOGIE ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SNC","",""
"8793","07-05-17","GENZYME CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","THYROID STIMULATING HORMONE","HORMONE THYRÉOTROPE","",""
"8794","07-05-17","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC / ANTIPYRETIC / DECONGESTANT","ANALGÉSIQUE / ANTIPYRÉTIQUE / DÉCONGESTIONNANT","",""
"8795","07-05-18","SCHERING-PLOUGH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PARTIAL OPIATE AGONIST & OPIATE ANTAGONIST","AGONISTE DES OPIOÏDES ET ANTAGONISTE DES OPIOÏDES PARTIELS","",""
"8796","07-05-22","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH AS WELL AS OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MODIFICATIONS APPORTÉES À LA SECTION POSOLOGIE ET ADMINISTRATION AINSI QU'À D'AUTRES SECTIONS DE LA MONOGRAPHIE DE PRODUIT","LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE (LH-RH)","",""
"8797","07-05-22","ASTELLAS PHARMA CANADA, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"8798","07-05-25","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","BETA-ADRENERGIC AGONIST/GROWTH PROMOTANT","AGONISTES-BÊTA-ADRÉNERGIQUES/STIMULANT DE LA CROISSANCE","",""
"8799","07-05-23","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8800","07-05-24","CANGENE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"8801","07-05-24","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE, CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE","NOUVELLE INDICATION : POUR LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE CHRONIQUE (LMC) À CHROMOSOME PHILADELPHIE POSITIF EN PHASE CHRONIQUE RÉCEMMENT DIAGNOSTIQUÉE CHEZ LES ENFANTS","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"8802","07-05-25","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ALCOHOL DEHYDROGENASE INHIBITOR","INHIBITEUR SYNTHÉTIQUE DE L'ALCOOL","",""
"8803","07-05-29","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTITHROMBOTIC","ANTITHROMBOTIQUE","",""
"8804","07-05-30","NORBROOK LABORATORIES LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8805","07-05-30","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"8806","07-05-30","ENCYSIVE PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ENDOTHELIN RECEPTOR ANTAGONIST","ANTAGONISTES DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"8807","07-06-01","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"8808","07-06-01","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM VICOPROFEN","MODIFICATION DU NOM DU PRODUIT DE VICOPROFEN","OPIOID / NSAID COMBINATION ANALGESIC","OPIOÏDES / ANALGÉSIQUE AINS","",""
"8809","07-06-01","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM APO-ONDANSETRON","MODIFICATION DU NOM DU PRODUIT DE APO-ONDANSETRON","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"8810","07-06-04","PALADIN LABS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH 10 MG AND 20 MG TABLETS AND REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE CONCENTRATION: COMPRIMÉS DE 10 MG ET 20 MG ET RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANTI-THYROID AGENT","ANTITHYROÏDIEN","",""
"8811","07-06-04","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO THE PRODUCT MONOGRAPH TO REFLECT SAFETY-RELATED UPDATES","MODIFICATIONS DE LA MONOGRAPHIE DU PRODUIT POUR UNE MISE-À-JOUR DES RENSEIGNEMENTS SUR L'INNOCUITÉ DU MÉDICAMENT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8812","07-06-04","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"8813","07-06-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC / ANTIMANIC AGENT","ANTIPSYCHOTIQUE / ANTIMANIAQUE","",""
"8814","07-06-06","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH TO INCLUDE 96 WEEK SAFETY AND EFFICACY DATA","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT EN FONCTION DES DONNÉES SUR L'INNOCUITÉ ET L'EFFICACITÉ À LA 96E SEMAINE","ANTIVIRAL","ANTIVIRAL","",""
"8815","07-06-06","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC.","CANADA","CANADA","1","REVISIONS TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIPSYCHOTIC / ANTIMANIC AGENT","ANTIPSYCHOTIQUE / ANTIMANIAQUE","",""
"8816","07-06-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"8817","07-06-06","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","SWITCH FROM PRESCRIPTION TO NON-PRESCRIPTION STATUS FOR LIMITED INDICATIONS","CHANGEMENT DE MÉDICAMENT SUR ORDONNANCE À MÉDICAMENT EN VENTE LIBRE, POUR CERTAINES INDICATIONS","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"8818","07-06-06","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","SWITCH FROM PRESCRIPTION TO NON-PRESCRIPTION STATUS FOR LIMITED INDICATIONS","CHANGEMENT DE MÉDICAMENT SUR ORDONNANCE À MÉDICAMENT EN VENTE LIBRE, POUR CERTAINES INDICATIONS","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"8819","07-06-07","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8820","07-06-07","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"8821","07-06-07","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8822","07-06-07","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACRIUM","BURROUGHS WELLCOME INC.","CANADA","CANADA","1","","","INTRAVENOUS SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE ADMINISTRÉ PAR VOIE INTRAVEINEUSE","",""
"8823","07-06-07","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR VOIE NASALE","",""
"8824","07-06-07","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8825","07-06-08","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DRUG INTERACTIONS SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA SECTION D'INTERACTIONS MÉDICAMENTEUSES ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"8826","07-06-08","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"8827","07-06-11","BARR LABORATORIES INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIN-OVRAL 21 AND MIN-OVRAL 28","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"8828","07-06-13","BAYER HEALTHCARE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","QUALIFICATION OF 200L FERMENTER","QUALIFICATION DE FERMENTEUR 200L","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8829","07-06-12","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DTIC","BAYER INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8830","07-06-12","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8831","07-06-12","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NARCOTIC ANALGESIC, ADJUNCT TO ANESTHESIA","ANALGÉSIQUE NARCOTIQUE, ADJUVANT ANESTHÉSIQUE","",""
"8832","07-06-12","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID I.V.","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"8833","07-06-12","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"8834","07-06-12","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8835","07-06-12","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8836","07-06-12","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE CLINICAL PHARMACOLOGY AND THE INDICATION SECTIONS, AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS DES SECTIONS PHARMACOLOGIE CLINIQUE ET INDICATION ET, AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","PROLACTIN INHIBITOR, GROWTH HORMONE SUPPRESSANT IN ACROMEGALY, ADJUNCTIVE MEDICATION IN PARKINSON'S DISEASE","INHIBITEUR DE LA PROLACTINE, INHIBITEUR DE L'HORMONE DE CROISSANCE DANS L'ACROMÉGALIE, ADJUVANT DANS LA MALADIE DE PARKINSON","",""
"8837","07-06-12","SHIRE BIOCHEM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO THE DOSAGE AND ADMINISTRATION SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISION À LA SECTION DE POSOLOGIE ET ADMINISTRATION ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"8838","07-06-12","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"8839","07-06-12","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHIN","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8840","07-06-12","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DESFERAL","NOVARTIS CANADA INC.","CANADA","CANADA","1","","","IRON AND ALUMINUM CHELATING AGENT","CHÉLATEUR DU FER ET DE L'ALUMINIUM","",""
"8841","07-06-12","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8842","07-06-13","SHIRE HUMAN GENETIC THERAPIES, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYME","",""
"8843","07-06-14","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAMPTOSAR","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8844","07-06-14","ASTELLAS PHARMA CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXTENDED RELEASE CAPSULES FOR ONCE A DAY DOSING FOR THE PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC KIDNEY TRANSPLANTS","CAPSULES À LIBÉRATION PROLONGÉE À PRENDRE UNE FOIS PAR JOUR POUR PRÉVENIR LE REJET D'ORGANE CHEZ LES PATIENTS QUI REÇOIVENT UNE GREFFE DU REIN ALLOGÈNE","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"8845","07-06-15","SANOFI-AVENTIS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8846","07-06-15","LABOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"8847","07-06-20","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANALGESIC, ANTIPYRETIC AGENT","ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"8848","07-06-21","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLUDARA","BERLEX CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8849","07-06-21","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAVELBINE","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8850","07-06-21","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PIPRACIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8851","07-06-21","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"8852","07-06-21","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOVANTRONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8853","07-06-21","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPRIVAN","ZENECA PHARMA CANADA INC.","CANADA","CANADA","1","","","ANESTHETIC / SEDATIVE","ANESTHÉSIQUE / SÉDATIF","",""
"8854","07-06-21","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8855","07-06-21","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"8856","07-06-21","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8857","07-06-21","RARE DISEASE THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-HOMOCYSTEINE AGENT","AGENT ANTI-HOMOCYSTÉINE","",""
"8858","07-06-21","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT / SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)","ANTIHYPERTENSEUR / TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP)","",""
"8859","07-06-22","CSL BEHRING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"8860","07-06-20","CSL BEHRING CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"8861","07-06-22","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARASITIC AGENT","ANTIPARASITAIRE","",""
"8862","07-06-26","PENDOPHARM, DIVISION OF/DE PHARMASCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"8863","07-06-26","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH CHANGES REGARDING PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT","MODIFICATIONS APPORTÉES À LA MONOGRAPHIE DU PRODUIT RELATIVES AUX PATIENTS ATTEINTS D'INSUFFISANCE RÉNALE OU HÉPATIQUE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8864","07-06-26","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH CHANGES REGARDING PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT","MODIFICATIONS APPORTÉES À LA MONOGRAPHIE DU PRODUIT RELATIVES AUX PATIENTS ATTEINTS D'INSUFFISANCE RÉNALE OU HÉPATIQUE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8865","07-06-26","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MODIFICATIONS TO DOSAGE AND ADMINISTRATION","MODIFICATIONS DE LA POSOLOGIE ET L'ADMINISTRATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8866","07-06-26","NOVARTIS OPHTHALMICS, NOVARTIS PHARMACEUTICALS (CANADA) INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTI-NEOVASCULARISATION AGENT","AGENT ANTI-NÉOVASCULARISATION","",""
"8867","07-06-26","GENPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","HYPNOTIC AND SEDATIVE","HYPNOTIQUE ET SÉDATIF","",""
"8868","07-06-26","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SYMPTOMATIC TREATMENT OF PATIENTS WITH SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE","NOUVELLE INDICATION : TRAITEMENT SYMPTOMATIQUE DE PATIENTS ATTEINTS DE DÉMENCE SÉVÈRE DU TYPE ALZHEIMER","Cholinesterase Inhibitor","Inhibiteur de la cholinestérase","",""
"8869","07-06-27","LILLY ICOS LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS 2.5MG AND 5MG TABLETS TO BE USED AS ONCE A DAY","LES NOUVEAUX COMPRIMÉS DE 2,5 MG ET DE 5 MG DOIVENT ÊTRE ADMINISTRÉS UNE FOIS PAR JOUR","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE LA GMPC","",""
"8870","07-06-28","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE AND ANTIRHEUMATIC","ANTIMÉTABOLITE ET ANTIRHUMATISMAL","",""
"8871","07-06-28","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE AND ANTIRHEUMATIC","ANTIMÉTABOLITE ET ANTIRHUMATISMAL","",""
"8872","07-06-28","BAYER INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"8873","07-06-29","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"8874","07-06-29","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8875","07-06-29","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8876","07-07-04","DURAMED PHARMACEUTICALS, INC., A SUBSIDIARY OF BARR PHARMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"8877","07-07-04","JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8878","07-07-04","JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8879","07-07-04","JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8880","07-07-04","JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8881","07-07-04","JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8882","07-07-04","JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"8883","07-07-03","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DOPAMINE AGONIST","AGONISTE DE LA DOPAMINE","",""
"8884","07-07-05","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAXOL","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"8885","07-07-05","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8886","07-07-05","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE; CHANGE IN PACKAGING","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION; MODIFICATION DU CONDITIONNEMENT","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8887","07-07-05","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURER OF THE ACTIVE INGREDIENT","MODIFICATION DU FABRICANT DE L'INGRÉDIENT ACTIF","CARDIOVASCULAR (MYOCARDIAL STIMULANT)","CARDIOVASCULAIRE (STIMULANT DU MYOCARDE)","",""
"8888","07-07-05","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURER OF THE ACTIVE INGREDIENT","MODIFICATION DU FABRICANT DE L'INGRÉDIENT ACTIF","CARDIOVASCULAR (MYOCARDIAL STIMULANT)","CARDIOVASCULAIRE (STIMULANT DU MYOCARDE)","",""
"8889","07-07-05","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURER OF THE ACTIVE INGREDIENT","MODIFICATION DU FABRICANT DE L'INGRÉDIENT ACTIF","CARDIOVASCULAR (MYOCARDIAL STIMULANT)","CARDIOVASCULAIRE (STIMULANT DU MYOCARDE)","",""
"8890","07-07-05","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: REDUCING SIN=GNS AND SYMPTOMS AND INDUCING AND MAINTAINING CLINICAL REMISSION IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY, INCLUDING CORTICOSTEROID AND/OR IMMUNOSUPPRESSANTS","NOUVELLE INDICATION : RÉDUIRE LES SIGNES ET SYMPTÔMES ET INDUIRE ET MAINTENIR LA RÉMISSION CLINIQUE CHEZ LES PATIENTS ADULTES AYANT UNE MALADIE DE CROHN MODÉRÉE À SÉVÈRE ET DONT LA RÉPONSE AU TRAITEMENT CONVENTIONNEL INCLUANT LES CORTICOSTÉROÏDES ET/OU IMMUNOSUPPRESSEUR N'A PAS ÉTÉ SATISFAISANTE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8891","07-07-05","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","HUMIRA IS INDICATED FOR REDUCING SIGNS AND SYMPTOMS AND INDUCING CLINICAL REMISSION IN THESE PATIENTS IF THEY HAVE ALSO LOST RESPONSE TO OR ARE INTOLERANT TO INFLIXIMAB","HUMIRA EST INDIQUÉ POUR RÉDUIRE LES SIGNES ET SYMPTÔMES ET INDUIRE LA RÉMISSION CLINIQUE CHEZ CES PATIENTS LORSQU'ILS NE RÉPONDENT PLUS OU TOLÈRENT MAL LE TRAITEMENT PAR INFLIXIMAB","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8892","07-07-06","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH CANADA INC.","CANADA","CANADA","1","NEW FORMULATION","NOUVELLE FORMULATION","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"8893","07-07-06","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 0.125MG","NOUVELLE DOSE : 0.125MG","ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST","ANTIPARKINSONIEN / AGONISTE DOPAMINERGIQUE","",""
"8894","07-07-06","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT - ANTIOBSESSIONAL - ANTIPANIC - ANXIOLYTIC AGENT - SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER) - POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR - ANTIOBSESSIONNEL - ANTIPANIQUE - ANXIOLYTIQUE - TRAITMENT DE LA PHOBIE SOCIALE (ANGOISSE SOCIALE) - TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"8895","07-07-06","ORCHID HEALTHCARE DIVISION OF ORCHID CHEMICALS & PHARMACEUTICALS LTD.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFAZOLIN FOR INJECTION","NOVOPHARM LIMITED","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8896","07-07-09","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"8897","07-07-09","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH RE: SAFETY AND EFFICACY DATA; DRUG INTERACTIONS; CONCOMITANT THERAPY","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT CONCERNANT : LES DONNÉES SUR L'INNOCUITÉ ET L'EFFICACITÉ; LES INTERACTIONS MÉDICAMENTEUSES; LA THÉRAPIE CONCOMITANTE","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"8898","07-07-09","COBALT PHARMACEUTICALS INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","CHANGE IN FORMULATION","MODIFICATION DE LA FORMULATION","ANTIEPILEPTIC / MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE / PROPHYLAXIE DE LA MIGRAINE","",""
"8899","07-07-10","RARE DISEASE THERAPEUTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: CHANGES TO DOSAGE AND ADMINISTRATION FOR PEDIATRIC PATIENTS","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT : MODIFICATIONS DE L'INFORMATION CONCERNANT LA SECTION DE LA POSOLOGIE ET ADMINISTRATION CHEZ LES ENFANTS","ANTI-HOMOCYSTEINE AGENT","AGENT ANTI-HOMOCYSTÉINE","",""
"8900","07-07-10","ORYX PHARMACEUTICALS INC., A SUBSIDIARY OF FILIALE DARROW PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR USE AS AN ANTICOAGULANT IN PATIENTS WITH OR AT RISK OF HEPARIN INDUCED THROMBOCYTOPAENIA / THROMBOCYTOPAENIA SYNDROME (HIT/TS) UNDERGOING CARDIAC SURGERY, AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION POUR UTILISER COMME ANTICOAGULANT CHEZ LES PATIENTS QUI ONT OU AYANT DES ANTÉCÉDENTS DE THROMBOCYTOPÉNIE INDUITE PAR HÉPARINE / SYNDROME DE THROMBOCYTOPÉNIE (TIH/ST) DURANT LA CHIRURGIE CARDIAQUE; ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","DIRECT THROMBIN INHIBITOR","INHIBITEUR DIRECT DE LA THROMBINE","",""
"8901","07-07-11","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST","AGENT ANTIPARKINSONIEN / AGONISTE DOPAMINERGIQUE","",""
"8902","07-07-12","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8903","07-07-12","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8904","07-07-12","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITOR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"8905","07-07-12","INTERVET CANADA LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTHIC","ANTHELMINTHIQUE","",""
"8906","07-07-13","SHIRE BIOCHEM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE POUR LE TRACTUS GASTRO-INTESTINAL INFÉRIEUR","",""
"8907","07-07-13","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8908","07-07-17","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"8909","07-07-17","BIOGEN IDEC CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","SELECTIVE ADHESION MOLECULE INHIBITOR","INHIBITEUR SÉLECTIF DE MOLÉCULES D'ADHÉSION","",""
"8910","07-07-16","PHARMASCIENCE INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","SWITCH FROM PRESCRIPTION TO NON-PRESCRIPTION STATUS","RECLASSIFICATION D'UN MÉDICAMENT DE PRESCRIPTION À UN MÉDICAMENT VENDU SANS ORDONNANCE","Histamine H2-Receptor Antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"8911","07-07-17","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF ADULTS WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY","NOUVELLE INDICATION : POUR LE TRAITEMENT DES ADULTES ATTEINTS DE LEUCÉMIE LYMPHOBLASTIQUE AIGUË (LLA) POSITIVE POUR LE CHROMOSOME PHILADELPHIE (PH+) ET ASSOCIÉE À UNE RÉSISTANCE OU À UNE INTOLÉRANCE AUX TRAITEMENTS ANTÉRIEURS","PROTEIN-TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"8912","07-07-17","PROCTER & GAMBLE PHARMACEUTICALS CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSING RECOMMENDATION AND NEW STRENGTH TABLET, 75 MG, ON TWO CONSECUTIVE DAYS PER MONTH","NOUVEAU DOSAGE RECOMMANDÉ ET COMPRIMÉ À NOUVELLE TENEUR, 75MG, SUR DEUX JOURS CONSÉCUTIFS PAR MOIS","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"8913","07-07-18","GALDERMA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NOUVELLE CONCENTRATION","","ANTI-ROSACEA AGENT","AGENT ANTIROSACÉE","",""
"8914","07-07-18","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"8915","07-07-18","SQUIRE PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"8916","07-07-18","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"8917","07-07-18","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE AND ANTIRHEUMATIC","ANTIMÉTABOLITE ET ANTIRHUMATISMAL","",""
"8918","07-07-19","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION TO INCLUDE LONG-TERM TREATMENT OF ANGINA PECTORIS DUE TO ISCHEMIC HEART DISEASE AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISION DE L'INDICATION POUR INCLURE LE TRAITEMENT À LONG TERME DE L'ANGINE DE POITRINE CAUSÉE PAR L'ISCHÉMIE CARDIAQUE; ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","B-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"8919","07-07-20","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIQUE","ANTIÉPILEPTIQUE","",""
"8920","07-07-20","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE","GREECE","GRÈCE","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"8921","07-07-20","ORCHID HEALTHCARE DIVISION OF ORCHID CHEMICALS & PHARMACEUTICALS LTD.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFOXITIN FOR INJECTION, USP","NOVOPHARM LTD.","CANADA","CANADA","1","CHANGE TO VIAL LABELS AND PRODUCT NAME CHANGE","CHANGEMENT À L'ÉTIQUETTE DU FLACON ET CHANGEMENT DE NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8922","07-07-20","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"8923","07-07-20","ALTANA PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXTENDED INDICATION: PROPHYLACTIC MANAGEMENT OF STEROID-RESPONSIVE BRONCHIAL ASTHMA IN ADOLESCENTS 12 YEARS OF AGE AND OLDER AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE INCLUANT L'EXTENSION DU TRAITEMENT PROPHYLACTIQUE DE L'ASTHME BRONCHIQUE AUX ADOLESCENTS DE 12 ANS ET PLUS","CORTICOSTEROID FOR ORAL INHALATION","CORTICOSTÉROÏDE POUR INHALATION ORALE","",""
"8924","07-07-20","NYCOMED CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"8925","07-07-20","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE MANAGEMENT OF CHRONIC STABLE ANGINA (EFFORT-ASSOCIATED ANGINA) WITHOUT EVIDENCE OF VASOSPASM IN PATIENTS WHO REMAIN SYMPTOMATIC DESPITE ADEQUATE DOSES OF BETA-BLOCKERS AND/OR ORGANIC NITRATES OR WHO CANNOT TOLERATE THOSE AGENTS.  TIAZAC XC MAY BE TRIED IN COMBINATION WITH BETA-BLOCKERS IN CHRONIC STABLE ANGINA IN PATIENTS WITH NORMAL VENTRICULAR FUNCTION.  WHEN SUCH CONCOMITANT THERAPY IS INTRODUCED, THESE PATIENTS MUST BE MONITORED CLOSELY (SEE WARNING AND PRECAUTIONS). AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH.","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ANGINE CHRONIQUE STABLE (ANGINE ASSOCIÉ À L'EFFORT) SANS PREUVE DE SPASME VASCULAIRE CHEZ LES PATIENTS QUI DEMEURENT SYMPTOMATIQUES EN DÉPIT DE DOSES ADÉQUATES DE BÊTA-BLOQUANTS ET/OU DE DÉRIVÉS NITRÉS, OU QUI NE TOLÈRENT AUCUN DE CES AGENTS.  TIAZAC XC PEUT ÊTRE ESSAYÉ EN ASSOCIATION AVEC UN BÊTA-BLOQUANT POUR TRAITER LES PATIENTS ATTEINTS D'ANGINE CHRONIQUE STABLE DONT L'ACTIVITÉ VENTRICULAIRE EST NORMALE.  LORSQUE DE TELLES ASSOCIATIONS SONT INTRODUITES, LES PATIENTS DOIVENT ÊTRE ÉTROITEMENT SURVEILLÉS (VOIR MISES EN GARDE ET PRÉCAUTIONS); AINSI QUE LES AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANTIHYPERTENSIVE / ANTIANGINAL AGENT","ANTIHYPERTENSEUR / ANTIANGINEUX","",""
"8926","07-07-20","NYCOMED CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"8927","07-07-20","NYCOMED CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"8928","07-07-23","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","SELECTIVE CO-STIMULATION MODULATOR","MODULATEUR SÉLECTIF DE LA CO-STIMULATION","",""
"8929","07-07-23","BAXTER HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","HEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"8930","07-07-23","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF OSTEOARTHRITIS IN ADULTS","NOUVELLE INDICATION : POUR LE TRAITEMENT DES SIGNES ET DES SYMPTÔMES DE L'ARTHROSE CHEZ L'ADULTE","NONSTEROIDAL ANTI-INFLAMMATORY AGENT","AGENT ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"8931","07-07-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8932","07-07-26","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8933","07-07-26","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8934","07-05-01","CARESTREAM HEALTH CANADA COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LOCAL ANAESTHETIC FOR DENTAL USE","ANESTHÉSIQUE LOCAL","",""
"8935","07-07-25","SCHERING-PLOUGH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE FOR THE DRUG SUBSTANCE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION POUR L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8936","07-07-25","SCHERING-PLOUGH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURER SITE FOR DRUG SUBSTANCE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION POUR L'INGRÉDIENT ACTIF","ANTIBIOTIC; GLUCOCORTICOID","ANTIBIOTIQUE, GLUCOCORTICOÏDE","",""
"8937","07-07-25","SCHERING-PLOUGH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE FOR THE DRUG SUBSTANCE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION POUR L'INGRÉDIENT ACTIF","ANTIBIOTIC; GLUCOCORTICOID","ANTIBIOTIQUE; GLUCOCORTICOÏDE","",""
"8938","07-07-25","SCHERING-PLOUGH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE FOR THE DRUG SUBSTANCE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION POUR L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8939","07-07-26","SCHERING-PLOUGH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURER SITE FOR DRUG SUBSTANCE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION POUR L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8940","07-07-26","SCHERING-PLOUGH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURER SITE FOR DRUG SUBSTANCE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION POUR L'INGRÉDIENT ACTIF","ANTIBIOTIC; GLUCOCORTICOID","ANTIBIOTIQUE; GLUCOCORTICOÏDE","",""
"8941","07-07-26","SCHERING-PLOUGH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE FOR THE DRUG SUBSTANCE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION POUR L'INGRÉDIENT ACTIF","ANTIBIOTIC, ANTI-INFLAMMATORY, ANTIFUNGAL","ANTIBIOTIQUE, ANTI-INFLAMMATOIRE, ANTIFONGIQUE","",""
"8942","07-07-26","SCHERING-PLOUGH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE FOR THE DRUG SUBSTANCE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION POUR L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8943","07-07-27","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"8944","07-07-27","AUXILIUM PHARMACEUTICALS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH REVISION - CLASS LABELLING FOR TESTOSTERONE REPLACEMENT THERAPY","RÉVISION DE LA MONOGRAPHIE DE PRODUIT - CLASSE INDIQUÉE POUR UN TRAITEMENT DE REMPLACEMENT DE LA TESTOSTÉRONE","ANDROGENS","ANDROGÈNES","",""
"8945","07-07-27","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"8946","07-07-27","ARROW OTC INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"8947","07-07-27","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RESTORIL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC","HYPNOTIQUE","",""
"8948","07-07-30","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8949","07-07-30","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC / SEDATIVE","ANXIOLYTIQUE / SÉDATIF","",""
"8950","07-07-30","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO THE ACTION AND CLINICAL PHARMACOLOGY SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS DES SECTIONS DE L'ACTION ET PHARMACOLOGIE CLINIQUE ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","BRONCHODILATOR","BRONCHODILATATEUR","",""
"8951","07-07-30","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS AUX SECTIONS DE L'ADMINISTRATION  ET DOSAGE ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"8952","07-07-30","PHARMEL INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIDIARRHEAL","ANTIDIARRHÉIQUE","",""
"8953","07-07-30","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"8954","07-08-01","GW PHARMA LIMITED","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MAY BE USEFUL AS ADJUNCTIVE ANALGESIC TREATMENT IN ADULT PATIENTS WITH ADVANCED CANCER WHO EXPERIENCE MODERATE TO SEVERE PAIN DURING THE HIGHEST TOLERATED DOSE OF STRONG OPIOID THERAPY FOR PERSISTENT BACKGROUND PAIN, AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION : PEUT ÊTRE UTILE POUR LE TRAITEMENT ANALGÉSIQUE D'APPOINT CHEZ LES ADULTES ATTEINTS DE CANCER AVANCÉ QUI PRÉSENTENT UNE DOULEUR MODÉRÉE OU GRAVE PENDANT UN PUISSANT TRAITEMENT OPIOÏDE ADMINISTRÉ À LA PLUS FORTE DOSE TOLÉRÉE CONTRE UNE DOULEUR DE FOND PERSISTANTE ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","CANNABINOID ANALGESIC","ANALGÉSIQUE CANNABINOÏDE","",""
"8955","07-08-01","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"8956","07-08-02","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","RELOCATION AND UPGRADE TO THE MANUFACTURING PROCESS AND FACILITIES","DÉMÉNAGEMENT ET MISE À JOUR DES INSTALLATIONS ET DU PROCESSUS DE FABRICATION","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"8957","07-08-02","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANXIOLYTIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE","",""
"8958","07-08-02","LABOPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"8959","07-08-02","STRIDES ARCOLAB LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"8960","07-08-03","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOLU-MEDROL","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","GLUCOCORTICOID, ANTI-INFLAMMATORY","GLUCOCORTICOÏDE, ANTI-INFLAMMATOIRE","",""
"8961","07-08-07","GE HEALTHCARE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","ALTERNATE MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","RADIODIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"8962","07-08-07","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO THE MANUFACTURING PROCESS","CHANGEMENTS DANS LE PROCÉDÉ DE FABRICATION","ANTIARRHYTHMIC AGENT","AGENT ANTIARYTHMIQUE","",""
"8963","07-08-08","OSCIENT PHARMACEUTICAL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH - ALIGN WITH THE LATEST APPROVED VERSION OF THE USPI","MODIFICATIONS À LA MONOGRAPHIE DU PRODUIT - HARMONISATION AVEC LA PUS RÉCENTE VERSION DU FEUILLET D'INFORMATION AMÉRICAIN","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"8964","07-08-08","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"8965","07-08-10","SCHERING-PLOUGH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE FOR THE DRUG SUBSTANCE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION POUR L'INGRÉDIENT ACTIF","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8966","07-08-10","PARNELL LABORATORIES (AUST) PTY LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"8967","07-08-10","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE FOR THE DRUG SUBSTANCE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION DE L'INGRÉDIENT ACTIF","NON-STEROIDAL ANTI-INFLAMMATORY DRUG","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"8968","07-08-10","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"8969","07-08-10","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE CLINICAL TRIALS AND ADVERSE REACTIONS SECTIONS AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE, ESSAIS CLINIQUES ET EFFETS INDÉSIRABLES","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"8970","07-08-10","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 100MG/12.5MG (LOSARTAN POTASSIUM/HYDROCHLOROTHIAZIDE) AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVEAU DOSAGE: 100MG/12.5MG (LOSARTAN POTASSIQUE/HYDROCHLOROTHIAZIDE) ET AUTRES RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANGIOTENSIN II RECEPTOR ANTAGONIST AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"8971","07-08-13","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL FILLING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE RÉPARTITION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8972","07-08-14","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"8973","07-08-14","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 12.5 MG/VIAL AND OTHER RELATED REVISIONS TO THE PRODUCT MONOGRAPH","NOUVEAU DOSAGE : 12.5MG/FLOCON ET AUTRES MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8974","07-08-14","NYCOMED CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid for oral inhalation","Corticostéroïde pour inhalation orale","",""
"8975","07-08-16","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","SELECTIVE ANTAGONIST OF ALPHA1A ADRENOCEPTOR SUBTYPE IN THE PROSTATE","ANTAGONISTE SÉLECTIF DES RÉCEPTEURS ALPHA1A-ADRÉNERGIQUES DE LA PROSTATE","",""
"8976","07-08-17","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","GONADOTROPIN","GONADOTROPHINE","",""
"8977","07-08-10","NOVARTIS ANIMAL HEALTH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE FOR THE DRUG SUBSTANCE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION DE L'INGRÉDIENT ACTIF","NON-STEROIDAL ANTI-INFLAMMATORY DRUG","DROGUE ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"8978","07-08-17","BARR LABORATORIES INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALESSE 21 AND ALESSE 28","WYETH CANADA","CANADA","CANADA","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"8979","07-08-17","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANXIOLYTIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE","",""
"8980","07-08-20","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","GONADOTROPINS FOR FERTILITY","GONADOTROPHINES POUR L'INFERTILITÉ","",""
"8981","07-08-17","CENTOCOR INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","SHORTENED INFUSION FOR RHEUMATOID ARTHRITIS PATIENTS","PERFUSION DE PLUS COURTE DURÉE POUR LES PATIENTS ATTEINTS DE POLYARTHRITE RHUMATOÏDE","BIOLOGIC RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"8982","07-08-20","NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MODIFICATIONS TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8983","07-08-21","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY AND NEW PRESENTATION","INSTALLATION DE FABRICATION ADDITIONNELLE ET NOUVELLE PRÉSENTATION","BIOLOGIC RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"8984","07-08-21","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DRUG IDENTIFICATION NUMBER FOR THE INITIAL DOSING PACK","NOUVELLE IDENTIFICATION NUMÉRIQUE DE DROGUE POUR LA TROUSSE DE DÉPART","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"8985","07-08-21","ORGANON CANADA LTD./LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DE PRODUIT RÉVISÉE","ANDROGEN","ANDROGÈNE","",""
"8986","07-08-22","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA FORMULATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"8987","07-08-22","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANALGESIC, ANTIPYRETIC AGENT FOR CHILDREN","ANALGÉSIQUE, ANTIPYRÉTIQUE POUR ENFANTS","",""
"8988","07-08-23","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"8989","07-08-23","GENZYME CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALDURAZYME IS INDICATED FOR ENZYME REPLACEMENT THERAPY IN PEDIATRIC PATIENTS (5 MONTHS TO 18 YEARS OF AGE) WITH MUCOPOLYSACCHARIDOSIS I (MPSI;ALPHA-L-IDURONIDASE DEFICIENCY) TO TREAT NON-CENTRAL NERVOUS SYSTEM MANIFESTATIONS OF THE DISEASE","ALDURAZYME EST INDIQUÉ COMME TRAITEMENT ENZYMATIQUE SUBSTITUTIF DES MANIFESTATIONS NON NEUROLOGIQUES DE LA MALADIE CHEZ LES ENFANTS (DE 6 MOIS À 18 ANS) ATTENTIS DE MUCOPOLYSACCHARIDOSE DE TYPE I (MPS I; DÉFICIT EN ALPHA-L-IDURONIDASE)","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"8990","07-08-24","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8991","07-08-24","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROKININ 1 RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR DE LA NEUROKININE 1","",""
"8992","07-08-24","ALLERGAN INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITIONAL CLAIMS IN INDICATIONS AND CLINICAL USE AND UPDATE TO THE SAFETY INFORMATION IN REVISED PM IN NEW FORMAT","PROPRIÉTÉS ADDITIONNELLES DANS LA SECTION INDICATIONS ET UTILISATION CLINIQUE ET MISE À JOUR DE L'INFORMATION SUR L'INNOCUITÉ DANS LA MONOGRAPHIE DU PRODUIT (NOUVEAU FORMAT)","ELEVATED INTRAOCULAR PRESSURE THERAPY","THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"8993","07-08-27","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITION OF DRUG SUBSTANCE MANUFACTURING SITE","AJOUT D'UN SITE DE FABRICATION D'UNE SUBSTANCE MÉDICAMENTEUSE","NON-STEROIDAL ANTI-INFLAMMATORY DRUG","MÉDICAMENT ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"8994","07-08-27","INTERVET CANADA LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITION OF DRUG SUBSTANCE MANUFACTURING SITE","AJOUT D'UN SITE DE FABRICATION D'UNE SUBSTANCE MÉDICAMENTEUSE","NON-STEROIDAL ANTI-INFLAMMATORY DRUG","MÉDICAMENT ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"8995","07-08-27","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"8996","07-08-28","NOVO NORDISK A/S","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ANTI-DIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"8997","07-08-29","NOVARTIS ANIMAL HEALTH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"8998","07-08-29","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"8999","07-08-29","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"9000","07-08-29","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE REMOVAL OF THE LABELLING CAUTION STATEMENT - RUMENSIN PREMIX SHOULD NOT BE FED TO TURKEYS OVER 10 WEEKS OF AGE","FAIRE EN SORTE QUE LA MENTION - LE PRÉMÉLANGE RUMENSIN NE DOIT PAS ÊTRE ADMINISTRÉ AUX DINDONS DE PLUS DE 10 SEMAINES PRÉSENTE DANS LA SECTION PRÉCAUTIONS SOIT ENLEVÉE DE L'ÉTIQUETTE DU PRODUIT","ANTIBIOTIC / ANTICOCCIDIAL","ANTIBIOTIQUE / ANTICOCCIDIEN","",""
"9001","07-08-29","PHARMASCIENCE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH CLASS LABELLING UPDATE","MISE À JOUR DE LA CLASSE DES TRAITEMENTS DANS LA MONOGRAPHIE DE PRODUIT RÉVISÉE","ANDROGENS","ANDROGÈNES","",""
"9002","07-08-30","SOLVAY PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH, CLASS LABELLING UPDATE","MISE À JOUR DE LA CLASSE DES TRAITEMENTS DANS LA MONOGRAPHIE DE PRODUIT RÉVISÉE","ANDROGENIC HORMONE","HORMONE ANDROGÉNIQUE","",""
"9003","07-08-28","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ACNE THERAPY","NOUVELLE INDICATION: TRAITEMENT CONTRE  L'ACNÉ","ORAL CONTRACEPTION","CONTRACEPTIF ORAL","",""
"9004","07-08-30","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DE PRODUIT RÉVISÉE","PDE5 INHIBITOR, TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PDE5, TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"9005","07-08-31","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"9006","07-08-31","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9007","07-09-06","EMD SERONO CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGNET AND FOLIC ACID DERIVATIVE","ANTINÉOPLASIQUE ET DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"9008","07-09-06","ATON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHELATING AGENT","CHÉLATEUR","",""
"9009","07-09-06","VITA HEALTH PRODUCTS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"9010","07-09-06","VITA HEALTH PRODUCTS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"9011","07-09-07","BRISTOL-MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","THE TRANSFER OF THE MANUFACTURING OF THE FINAL INTERMEDIATE USED IN THE MANUFACTURE OF NEUROLITE TO A NEW SITE","TRANSFERT D'UNE NOUVELLE INSTALLATION DE PRODUCTION INTERMÉDIAIRE FINAL SERVANT À FABRIQUER LE PRODUIT NEUROLITE","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"9012","07-09-07","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE ACTION AND CLINICAL PHARMACOLOGY SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DE MODE D'ACTION ET PHARMACOLOGIE CLINIQUE ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9013","07-09-07","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE L'INNOCUITÉ ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"9014","07-09-10","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING SITE, REPLACEMENT OF STERILITY TEST WITH PARAMETRIC PROCESS RELEASE, AND UPDATE TO DRUG PRODUCT SPECIFICATIONS","MODIFICATION DU SITE DE FABRICATION, SUBSTITUTION D'UN TEST DE STÉRILITÉ PAR UN PROCÉDÉ DE LIBÉRATION EN FONCTION DE PARAMÈTRES, ET UNE MISE À JOUR DES SPÉCIFICATIONS DU PRODUIT","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9015","07-09-11","GILEAD SCIENCES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","STREAMLINED AND ALTERED POSITION OF SOME ADVERSE EVENTS IN WARNINGS AND PRECAUTIONS AND ADVERSE EVENTS SECTIONS OF PRODUCT MONOGRAPH.  ADDITION OF DRUG INTERACTION INFORMATION WITH RESPECT TO COADMINISTRATION OF TENOFOVIR DISOPROXIL FUMARATE (TDF) WITH DIDANOSINE (DDL).  UPDATES ADDED TO THE POSTMARKETING ADVERSE DRUG REACTION SECTION OF PRODUCT MONOGRAPH","UNIFORMISATION ET MODIFICATION DE LA POSITION DE CERTAINS EFFETS SECONDAIRES DANS LES SECTIONS MISE EN GARDE ET PRÉCAUTIONS ET EFFETS INDÉSIRABLES DE LA MONOGRAPHIE DE PROUDIT.  AJOUT D'INFORMATION SUR LES INTERACTIONS MÉDICAMENTEUSES LORS DE LA COADMINISTRATION DU FUMARATE DE TÉNOFOVIR DISOPROXIL (FTD) ET DE LA DIDANOSINE (DDL).  MISES À JOUR AJOUTÉES DANS LA SECTION PHARMACOVIGILANCE DE LA MONOGRAPHIE DE PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9016","07-09-11","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FULFILMENT OF CONFIRMATORY COMMITMENTS","SATISFACTION DES ENGAGEMENTS RELATIFS À LA CONFIRMATION","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"9017","07-09-11","GILEAD SCIENCES, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION TO PRODUCT MONOGRAPH OF DRUG INTERACTION INFORMATION WITH RESPECT TO COADMINISTRATION OF TENOFOVIR DISOPROXIL FUMARATE (TDF) WITH DIDANOSINE (DDL)","AJOUT DANS LA MONOGRAPHIE DE PRODUIT D'INFORMATION SUR LES INTERACTIONS MÉDICAMENTEUSES LORS DE LA COADMINISTRATION DU FUMARATE DE TÉNOFOVIR DISOPROXIL (FTD) ET DE LA DIDANOSINE (DDL)","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9018","07-09-11","SCHERING-PLOUGH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"9019","07-09-11","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR / TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE LA GMPC / TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"9020","07-09-12","NOVARTIS PHARMACEUTICALS CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO PRODUCT MONOGRAPH SECTIONS WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, CLINICAL TRIALS, ACTION AND CLINICAL PHARMACOLOGY; POST APPROVAL COMMITMENT #1 & 2 (NEWLY DIAGNOSED CML) AND POST APPROVAL COMMITMENT # 18 (2ND LINE CML)","RÉVISION DES SECTIONS DE LA MONOGRAPHIE DU PRODUIT : MISES EN GARDE ET PRÉCAUTIONS, EFFETS INDÉSIRABLES, POSOLOGIE ET ADMINISTRATION, ESSAIS CLINIQUES, MODE D'ACTION ET PHARMACOLOGIE CLINIQUE; ENGAGEMENT APRÈS L'HOMOLOGATION RELATIF AUX POINTS 1 ET 2 (LMC NOUVELLEMENT DIAGNOSTIQUÉE) ET AU POINT 18 (TRAITEMENT DE 2E INTENTION DE LA LMC)","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"9021","07-09-12","JANSSEN-ORTHO INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA SECTION DE L'ADMINISTRATION ET DOSAGE ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9022","07-09-13","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","H+, K+-ATPASE Inhibitor","Inhibiteur de l'H+, K+-ATPASE","",""
"9023","07-09-14","GE HEALTHCARE CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - USE IN MAGNETIC RESONANCE ANGIOGRAPHY FOR THE DETECTION AND LOCALIZATION OF STENOSIS IN VESSELS SUPPLYING AN ORGAN AND VESSELS WITH TURBULENT FLOW","NOUVELLE INDICATION - UTILISATION DANS LES ANGIOGRAPHIES PAR RÉSONANCE MAGNÉTIQUE POUR LA DÉTECTION ET LA LOCALISATION DE LA STÉNOSE DES VAISSEAUX ALIMENTANT DES ORGANES ET DES VAISSEAUX OÙ L'ÉCOULEMENT EST TURBULENT","CONTRAST ENHANCEMENT AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"9024","07-09-14","LABORATOIRE RIVA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC / ANTISPASMODIC AGENT","ANTICHOLINERGIQUE / ANTISPASMODIQUE","",""
"9025","07-09-14","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9026","07-09-17","GALDERMA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: SOLUTION (SPRAY)","NOUVELLE FORME POSOLOGIQUE: SOLUTION (VAPORISATEUR)","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"9027","07-09-17","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SYMPTOMATIC TREATMENT OF PATIENTS WITH IDIOPATHIC PARKINSON'S DISEASE, AND MILD TO MODERATE DEMENTIA, WITH ONSET AT LEAST 2 YEARS AFTER THE INITIAL DIAGNOSIS OF PARKINSON'S DISEASE, AND IN WHOM OTHER CAUSES OF DEMENTIA HAVE BEEN RULED OUT, AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION : « TRAITEMENT SYMPTOMATIQUE DES PATIENTS ATTEINTS DE LA MALADIE DE PARKINSON IDIOPATHIQUE ET DE DÉMENCE D'INTENSITÉ LÉGÈRE  À MODÉRÉE, LAQUELLE EST APPARUE AU MOINS DEUX ANS APRÈS LE DIAGNOSTIC DE LA MALADIE DE PARKINSON, ET CHEZ QUI LES AUTRES CAUSES POSSIBLES DE DÉMENCES ONT ÉTÉ EXCLUES » ET AUTRES MODIFICATIONS À LA MONOGRAPHIE DU PRODUIT","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"9028","07-09-17","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","BIOVAIL PHARMACEUTICALS CANADA","CANADA","CANADA","1","NEW STRENGTH - 100 MG TABLETS","NOUVELLE CONCENTRATION: COMPRIMÉS DE 100 MG","ANTI-DEPRESSANT","ANTIDÉPRESSEUR","",""
"9029","07-09-20","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"9030","07-09-20","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-EMETIC","ANTI-ÉMÉTIQUE","",""
"9031","07-09-20","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-EMETIC","ANTI-ÉMÉTIQUE","",""
"9032","07-09-20","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-EMETIC","ANTI-ÉMÉTIQUE","",""
"9033","07-09-20","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-EMETIC","ANTI-ÉMÉTIQUE","",""
"9034","07-09-20","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-EMETIC","ANTI-ÉMÉTIQUE","",""
"9035","07-09-20","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","CLAVAMOX TABLETS 62.5MG","PFIZER CANADA INC., ANIMAL HEALTH GROUP","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9036","07-09-20","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","CLAVAMOX TABLETS 125 MG","PFIZER CANADA INC., ANIMAL HEALTH GROUP","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9037","07-09-20","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","CLAVAMOX TABLETS 250 MG","PFIZER CANADA INC., ANIMAL HEALTH GROUP","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9038","07-09-20","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","CLAVAMOX TABLETS 375 MG","PFIZER CANADA INC., ANIMAL HEALTH GROUP","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9039","07-09-24","EMD SERONO CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN MANUFACTURING PROCESS AND NEW PRODUCT FORMULATION","CHANGEMENT AU PROCESSUS DE FABRICATION ET NOUVELLE FORMULATION","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"9040","07-09-24","CUBIST PHARMACEUTICALS, INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED STAPHYLOCOCCUS AUREUS INFECTIVE ENDOCARDITIS (NATIVE VALVE) CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT STRAINS","NOUVELLE INDICATION : INFECTIONS DU SANG (BACTÉRIÉMIES) À STAPHYLOCOCCUS AUREUS, Y COMPRIS L'ENDOCARDITE INFECTIEUSES DROITE (VALVE NATURELLE) À STAPHYLOCOCCUS AUREUS, CAUSÉES PAR LES SOUCHES SENSIBLES À LA MÉTHICILLINE ET LES SOUCHES RÉSISTANTES À LA MÉTHICILLINE","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9041","07-09-24","CUBIST PHARMACEUTICALS, INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9042","07-09-22","GLAXOSMITHKLINE INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9043","07-09-21","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CCR5 ANTAGONIST","INHIBITEUR DU CCR5","",""
"9044","07-09-21","SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, ADJUNCTIVE THERAPY IN ACUTE URINARY RETENTION","TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE, TRAITEMENT ADJUVANT DE LA RÉTENTIO URINAIRE AIGUË","",""
"9045","07-09-21","ORYX PHARMACEUTICALS INC., A SUBSIDIARY OF FILIALE DARROW PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9046","07-09-24","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"9047","07-09-24","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL DOSAGE AND INDICATION IN CATTLE","POSOLOGIE ET INDICATION SUPPLÉMENTAIRES CHEZ LES BOVINS","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"9048","07-09-24","VIRBAC AH, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO ALLOW ADMINISTRATION TO BREEDING MARES","PERMETTRE L'ADMINISTRATION AUX JUMENTS REPRODUCTRICES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"9049","07-09-24","PALADIN LABS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION","ALCOHOL DEHYDROGENASE INHIBITOR","INHIBITEUR SYNTHÉTIQUE DE L'ALCOOL","",""
"9050","07-09-24","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC/ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE/INHIBITEUR DE BÊTA-LACTAMASES","",""
"9051","07-09-24","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: LESCOL/LESCOL XL ARE INDICATED AS AN ADJUNCT TO DIET FOR THE REDUCTION OF ELEVATED TOTAL CHOLESTEROL (TOTAL-C) LDL-C AND APO B LEVELS IN CHILDREN AND ADOLESCENTS AGED 10 YEARS AND OLDER WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION :« LESCOL ET LESCOL XL SONT INDIQUÉS COMME TRAITEMENT D'APPOINT À LA DIÈTE POUR ABAISSER LES TAUX ÉLEVÉS DE CHOLESTÉROL TOTAL, DE CHOLESTÉROL À LIPOPROTÉINES À BASSE DENSITÉ ET D'APOLIPOPROTÉINES B (APO B) CHEZ LES ADOLESCENTS ET LES ENFANTS ÂGÉS DE 10 ANS ET PLUS SOUFFRANT D'HYPERCHOLESTÉROLÉMIE FAMILIALE HÉTÉROZYGOTE » ET AUTRES MODIFICATIONS À LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"9052","07-09-24","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9053","07-09-26","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE TO DRUG SUBSTANCE IN-PROCESS CONTROLS","CHANGEMENT DANS LES CONTRÔLES DES PROCÉDÉS EN COURS DE FABRICATION DE LA SUBSTANCE MÉDICAMENTEUSE","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"9054","07-09-26","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SANDOSTATIN","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"9055","07-09-26","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"9056","07-09-26","JANSSEN-ORTHO INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9057","07-09-27","ASTRAZENECA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PSYCHOTROPIC AGENT","PSYCHOTROPE","",""
"9058","07-09-26","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"9059","07-09-28","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN-400","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","ADDITIONAL STRENGTH","CONCENTRATION ADDITIONNELLE","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE BÊTA-LACTAMASES","",""
"9060","07-09-28","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SELECTIVE COX-2 ENZYME INHIBITING-CLASS NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN DE LA CLASSE DES INHIBITEURS SÉLECTIFS DE L'ENZYME COX-2","",""
"9061","07-09-28","MERIAL CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SELECTIVE COX-2 ENZYME INHIBITING-CLASS NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN DE LA CLASSE DES INHIBITEURS SÉLECTIFS DE L'ENZYME COX-2","",""
"9062","07-09-26","CSL BEHRING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REDUCED VOLUME FORMULATION","PRÉPARATION DE VOLUME DE PRODUIT RÉDUITE","COAGULATION THERAPY","THÉRAPIE DE COAGULATION","",""
"9063","07-10-01","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION AND NEW PEDIATRIC INDICATION FOR USE IN PEDIATRIC PATIENTS 1-11 YEARS","NOUVELLE FORMULATION PHARMACEUTIQUE ET NOUVELLE INDICATION PÉDIATRIQUE POUR UTILISATION CHEZ LES PATIENTS PÉDIATRIQUES ÂGÉS DE 1-11 ANS","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9064","07-10-01","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ORAL ANTIHYPERGLYCEMIC AGENT","AGENT ANTIHYPERGLYCÉMIANT ORAL","",""
"9065","07-10-01","SCHERING-PLOUGH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"9066","07-10-01","SCHERING-PLOUGH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"9067","07-10-01","SCHERING-PLOUGH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"9068","07-10-02","ALBERTA CANCER BOARD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"9069","07-10-02","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION - AS AN AID IN REDUCING THE SEVERITY OF PORCINE POLYSEROSITIS AND ARTHRITIS ASSOCIATED WITH HAEMOPHILUS PARASUIS (GLASSER'S DISEASE) WHEN FED TO PIGS APPROXIMATELY 7 DAYS PRIOR TO ANTICIPATED OUTBREAK","NOUVELLE INDICATION - POUR AIDER À RÉDUIRE LA GRAVITÉ DE LA POLYSÉROSITE ET DE L'ARTHRITE PORCINES ASSOCIÉES À HAEMOPHILUS PARASUIS (MALADIE DE GLASSER) LORSQU'ADMINISTRÉ AUX PORCS ENVIRON 7 JOURS AVANT L'ÉCLOSION ANTICIPÉE DE LA MALADIE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9070","07-10-03","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ANTIHYPERTENSIVE EFFECTS OF COZAAR HAVE BEEN DEMONSTRATED IN HYPERTENSIVE PEDIATRIC PATIENTS AGED 6 TO 16 YEARS.  USE OF COZAAR IN THESE AGE GROUPS IS SUPPORTED BY EVIDENCE FROM ADEQUATE AND WELL-CONTROLLED STUDIES OF COZAAR IN PEDIATRIC PATIENTS, AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION : LES EFFETS ANTIHYPERTENSIFS DU COZAAR ONT ÉTÉ DÉMONTRÉS CHEZ LES PATIENTS HYPERTENDUS ÂGÉS DE 6 À 16 ANS.  L'UTILISATION DE COZAAR DANS CE GROUPE D'ÂGE EST SUPPORTÉE PAR LES ÉTUDES APPROPRIÉES ET BIEN CONTRÔLÉES CHEZ LES PATIENTS PÉDIATRIQUES; AINSI QUE D'AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANGIOTENSIN II RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II","",""
"9071","07-10-03","HILL DERMACEUTICALS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY, ANTIPRURITIC AND VASOCONSTRICING AGENT","ANTI-INFLAMMATOIRE, ANTIPRURIGINEUX ET VASOCONSTRICTIF","",""
"9072","07-10-05","AUROBINDO PHARMA LIMITED (UNIT III)","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON RD","ORGANON CANADA LTD.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9073","07-10-05","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","ESTROGEN","OESTROGÈNE","",""
"9074","07-10-05","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH: USE IN COMBINATION WITH A SULFONYLUREA SHOULD NOT EXCEED 4 MG DAILY","RÉVISION DE LA SECTION POSOLOGIE ET ADMINISTRATION DE LA MONOGRAPHIE DE PRODUIT : LA DOSE QUOTIDIENNE NE DOIT PAS EXCÉDER 4 MG LORSQUE LE PRODUIT EST UTILISÉ EN ASSOCIATION AVEC UNE SULFONYLURÉE","ANTIDIABETIC AGENT / INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE / AGENT INSULINOSENSIBILISATEUR","",""
"9075","07-10-05","FOURNIER PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: LIPIDIL EZ, ADMINISTERED IN COMBINATION WITH EZETIMIBE, IS INDICATED FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON HDL-C PATIENTS WITH MIXED HYPERLIPIDEMIA AND OTHER CHANGES TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION : LIPIDIL EZ, QUAND ADMINISTRÉ EN COMBINAISON AVEC EZETIMIBE, EST INDIQUÉ POUR LA RÉDUCTION DU TAUX ÉLEVÉ DU CHOLESTÉROL TOTAL (TOTAL C), DU CHOLESTÉROL DES LDL (LDL-C), D'APOLIPOPROTÉINE B (APO B) ET DU CHOLESTÉROL DES NON HDL (NON HDL -C) CHEZ LES PATIENTS AVEC L'HYPERLIPIDÉMIE DE TYPE MIXTE AINSI QUE D'AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"9076","07-10-09","CSL BEHRING CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","TRANSFER OF MANUFACTURING AND FILLING","NOUVEL EMPLACEMENT DE FABRICATION ET DE RÉPARTITION","PASSIVE IMMUNIZATION AGENT","AGENT D'IMMUNISATION PASSIF","",""
"9077","07-10-09","GLAXOSMITHKLINE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9078","07-10-09","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","FLAVOUR FORMULATION CHANGE","CHANGEMENT DE FORMULATION SAVEUR","SMOKING CESSATION AID","AIDE PUR CESSER DE FUMER","",""
"9079","07-10-11","LEO PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","AMEND INDICATION TO REMOVE COMBINATION USE WITH PHOTOTHERAPY","MODIFICATION DES INDICATIONS : RETIRER L'ASSOCIATION AVEC LA PHOTOTHÉRAPIE","NON-STEROIDAL ANTIPSORIATIC AGENT","AGENT ANTIPSORIASIQUE NON STÉROÏDIEN","",""
"9080","07-10-12","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATIONS: (1) AS AN AID IN THE TREATMENT OF NECROTIC ENTERITIS CAUSED BY CLOSTRIDIUM PERFRINGENS IN BROILER CHICKENS (2) AS AN AID IN THE TREATMENT OF PROCINE PROLIFERATIVE ENTEROPATHY (PPE) OR ILEITIS ASSOCIATED WITH LAWSONIA INTRACELLULARIS WHEN USED FOLLOWING TREATMENT WITH ELANCO TYLAN SOLUBLE","INDICATIONS NOUVELLES : (1) POUR AIDER À TRAITER L'ENTÉRITE NÉCROTIQUE CAUSÉE PAR CLOSTRIDIUM PERFRINGENS CHEZ LES POULETS À GRILLER (2) COMME ADJUVANT AU TRAITEMENT DE L'ENTÉROPATHIE PROLIFÉRATIVE PORCINE, OU ILÉITE, CAUSÉE PAR LAWSONIA INTRACELLULARIS LORSQU'UTILISÉ À LA SUITE D'UN TRAITEMENT AVEC LE TYLAN SOLUBLE ELANCO","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9081","07-10-12","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATIONS: (1) AS AN AID IN THE TREATMENT OF NECROTIC ENTERITIS CAUSED BY CLOSTRIDIUM PERFRINGENS IN BROILER CHICKENS (2) AS AN AID IN THE TREATMENT OF PROCINE PROLIFERATIVE ENTEROPATHY (PPE) OR ILEITIS ASSOCIATED WITH LAWSONIA INTRACELLULARIS WHEN USED FOLLOWING TREATMENT WITH ELANCO TYLAN SOLUBLE","INDICATIONS NOUVELLES : (1) POUR AIDER À TRAITER L'ENTÉRITE NÉCROTIQUE CAUSÉE PAR CLOSTRIDIUM PERFRINGENS CHEZ LES POULETS À GRILLER (2) COMME ADJUVANT AU TRAITEMENT DE L'ENTÉROPATHIE PROLIFÉRATIVE PORCINE, OU ILÉITE, CAUSÉE PAR LAWSONIA INTRACELLULARIS LORSQU'UTILISÉ À LA SUITE D'UN TRAITEMENT AVEC LE TYLAN SOLUBLE ELANCO","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9082","07-10-12","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATIONS: (1) AS AN AID IN THE TREATMENT OF NECROTIC ENTERITIS CAUSED BY CLOSTRIDIUM PERFRINGENS IN BROILER CHICKENS (2) AS AN AID IN THE TREATMENT OF PROCINE PROLIFERATIVE ENTEROPATHY (PPE) OR ILEITIS ASSOCIATED WITH LAWSONIA INTRACELLULARIS WHEN USED FOLLOWING TREATMENT WITH ELANCO TYLAN SOLUBLE","INDICATIONS NOUVELLES : (1) POUR AIDER À TRAITER L'ENTÉRITE NÉCROTIQUE CAUSÉE PAR CLOSTRIDIUM PERFRINGENS CHEZ LES POULETS À GRILLER (2) COMME ADJUVANT AU TRAITEMENT DE L'ENTÉROPATHIE PROLIFÉRATIVE PORCINE, OU ILÉITE, CAUSÉE PAR LAWSONIA INTRACELLULARIS LORSQU'UTILISÉ À LA SUITE D'UN TRAITEMENT AVEC LE TYLAN SOLUBLE ELANCO","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9083","07-10-12","JOHNSON & JOHNSON INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","COMEDOLYTIC AGENT","AGENT COMÉDOLYTIQUE","",""
"9084","07-10-12","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT LABELLING","RÉVISION DE L'ÉTIQUETTE DU PRODUIT","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9085","07-10-16","FERRING INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","GONADOTROPINS FOR INFERTILITY","GONADOTROPHINES POUR L'INFERTILITÉ","",""
"9086","07-10-16","SCHERING-PLOUGH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN FACILITY INFORMATION","CHANGEMENT À L'INFORMATION CONCERNANT L'INSTALLATION","BIOLOGICAL RESPONSE MODIFIER","AGENT IMMUNOMODULATEUR","",""
"9087","07-10-16","SCHERING-PLOUGH CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGE IN FACILITY INFORMATION","CHANGEMENT À L'INFORMATION CONCERNANT L'INSTALLATION","ANTIVIRAL AGENT PLUS BIOLOGICAL RESPONSE MODIFIER","ANTIVIRAL AVEC AGENT IMMUNOMODULATEUR","",""
"9088","07-10-15","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"9089","07-10-15","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION, ACTION AND CLINICAL PHARMACOLOGY SECTIONS AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS DES SECTIONS POSOLOGIE ET MODE D'ADMINISTRATION, MODE D'ACTION ET PHARMACOLOGIE CLINIQUE, ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DE PRODUIT","ANTICOAGULATN / ANTITHROMBOTIC","ANTICOAGULANT / ANTITHROMBOTIQUE","",""
"9090","07-10-15","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT LABELLING","ÉTIQUETAGE DU PRODUIT RÉVISÉ","ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE ET DIURÉTIQUE","",""
"9091","07-10-15","BRISTOL-MYERS SQUIBB AND GILEAD SCIENCES, LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9092","07-10-15","ASTELLAS PHARMA CANADA, INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM PROGRAF XL","MODIFICATION DU NOM DU PRODUIT DE PROGRAF XL","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"9093","07-10-16","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER","TROUBLE DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ","",""
"9094","07-10-16","PALADIN LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANDROGENS","ANDROGÈNES","",""
"9095","07-10-16","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE POUR LE TRACTUS GASTRO-INTESTINAL INFÉRIEUR","",""
"9096","07-10-16","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET-REDUCING AGENT","RÉDUCTEUR PLAQUETTAIRE","",""
"9097","07-10-16","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"9098","07-10-16","SHIRE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOSPHATE BINDER","CHÉLATEUR DE PHOSPHORE","",""
"9099","07-10-16","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"9100","07-10-16","IROKO INTERNATIONAL LP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9101","07-10-17","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM APO-LISINOZIDE","MODIFICATION DU NOM DU PRODUIT DE APO-LISINOZIDE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9102","07-10-17","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASERETIC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9103","07-10-17","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN CONVERTING EZYME INHIBITOR AND DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE ET DIURÉTIQUE","",""
"9104","07-10-17","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINIVIL / ZESTRIL","MERCK, SHARP & DOHME CANADA / ICI PHARMA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9105","07-10-17","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9106","07-10-17","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9107","07-10-17","TARO PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9108","07-10-17","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9109","07-10-17","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9110","07-10-17","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINIVIL / ZESTRIL","MERCK FROSST CANADA & CO. / ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9111","07-10-17","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9112","07-10-17","RATIOPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINIVIL","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9113","07-10-17","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9114","07-10-17","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9115","07-10-17","RANBAXY PHARMACEUTICALS CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9116","07-10-17","PHARMEL INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9117","07-10-17","RATIOPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINIVIL","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","A CHANGE IN MANUFACTURING PROCESS AND A CHANGE IN PRODUCT NAME","CHANGEMENT AU PROCESSUS DE FABRICATION ET CHANGEMENT DU NOM DU PRODUIT","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","A CHANGE IN MANUFACTURING PROCESS AND A CHANGE IN PRODUCT NAME","",""
"9118","07-10-18","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH TO BE CONSISTENT WITH CANADIAN ASTHMA CONSENSUS GUIDELINES (DECEMBER 2004) BY EMPHASIZING THAT LABA-CONTAINING PRODUCTS SHOULD BE USED ONLY AS ADDITIONAL THERAPY FOR PATIENTS NOT ADEQUATELY CONTROLLED ON LOW-TO MEDIUM-DOSE INHALED CORTICOSTEROIDS, AND TO FURTHER DESCRIBE THE RESULTS OF THE SALMETEROL MULTI-CENTER ASTHMA RESEARCH TRIAL","RÉVISIONS DE LA MONOGRAPHIE POUR QU'ELLE SOIT COMPATIBLE AUX LIGNES DIRECTRICES DE LA SOCIÉTÉ CANADIENNE DE L'ASTHME (CONSENSUS DE DÉCEMBRE 2004) SOULIGNANT QUE LES PRODUITS CONTENANT DES BÉTABLOQUANTS À LONGUES DURÉE D'ACTION NE DOIVENT ÊTRE PRESCRITS QU'AUX PATIENTS QUI NE SONT PAS ADÉQUATEMENT CONTRÔLÉS PAR GLUCOCORTICOÏDES ADMINISTRÉS PAR INHALATION À DES DOSES FAIBLES OU MODÉRÉES, ET, POUR DÉCRIRE LES RÉSULTATS DE L'ÉTUDE SALMETEROL MULTI-CENTER ASTHMA RESEARCH TRIAL (SMART)","BRONCHODILATOR (ß2-ADRENERGIC STIMULANT)","BRONCHODILATATEUR (STIMULANT ß2-ADRÉNERGIQUES)","",""
"9119","07-10-18","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH TO BE CONSISTENT WITH CANADIAN ASTHMA CONSENSUS GUIDELINES (DECEMBER 2004) BY EMPHASIZING THAT LABA-CONTAINING PRODUCTS SHOULD BE USED ONLY AS ADDITIONAL THERAPY FOR PATIENTS NOT ADEQUATELY CONTROLLED ON LOW-TO MEDIUM-DOSE INHALED CORTICOSTEROIDS, AND TO FURTHER DESCRIBE THE RESULTS OF THE SALMETEROL MULTI-CENTER ASTHMA RESEARCH TRIAL","RÉVISIONS DE LA MONOGRAPHIE POUR QU'ELLE SOIT COMPATIBLE AUX LIGNES DIRECTRICES DE LA SOCIÉTÉ CANADIENNE DE L'ASTHME (CONSENSUS DE DÉCEMBRE 2004) SOULIGNANT QUE LES PRODUITS CONTENANT DES BÉTABLOQUANTS À LONGUES DURÉE D'ACTION NE DOIVENT ÊTRE PRESCRITS QU'AUX PATIENTS QUI NE SONT PAS ADÉQUATEMENT CONTRÔLÉS PAR GLUCOCORTICOÏDES ADMINISTRÉS PAR INHALATION À DES DOSES FAIBLES OU MODÉRÉES, ET, POUR DÉCRIRE LES RÉSULTATS DE L'ÉTUDE SALMETEROL MULTI-CENTER ASTHMA RESEARCH TRIAL (SMART)","BRONCHODILATOR AND CORTICOSTEROID FOR ORAL INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE POUR INHALATION ORALE","",""
"9120","07-10-18","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH TO BE CONSISTENT WITH CANADIAN ASTHMA CONSENSUS GUIDELINES (DECEMBER 2004) BY EMPHASIZING THAT LABA-CONTAINING PRODUCTS SHOULD BE USED ONLY AS ADDITIONAL THERAPY FOR PATIENTS NOT ADEQUATELY CONTROLLED ON LOW-TO MEDIUM-DOSE INHALED CORTICOSTEROIDS, AND TO DESCRIBE THE RESULTS OF THE SALMETEROL MULTI-CENTER ASTHMA RESEARCH TRIAL","RÉVISIONS DE LA MONOGRAPHIE POUR QU'ELLE SOIT COMPATIBLE AUX LIGNES DIRECTRICES DE LA SOCIÉTÉ CANADIENNE DE L'ASTHME (CONSENSUS DE DÉCEMBRE 2004) SOULIGNANT QUE LES PRODUITS CONTENANT DES BÉTABLOQUANTS À LONGUES DURÉE D'ACTION NE DOIVENT ÊTRE PRESCRITS QU'AUX PATIENTS QUI NE SONT PAS ADÉQUATEMENT CONTRÔLÉS PAR GLUCOCORTICOÏDES ADMINISTRÉS PAR INHALATION À DES DOSES FAIBLES OU MODÉRÉES, ET, POUR DÉCRIRE LES RÉSULTATS DE L'ÉTUDE SALMETEROL MULTI-CENTER ASTHMA RESEARCH TRIAL (SMART)","BRONCHODILATOR","BRNCHODILATATEUR","",""
"9121","07-10-18","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH TO BE CONSISTENT WITH CANADIAN ASTHMA CONSENSUS GUIDELINES (DECEMBER 2004) BY EMPHASIZING THAT LABA-CONTAINING PRODUCTS SHOULD BE USED ONLY AS ADDITIONAL THERAPY FOR PATIENTS NOT ADEQUATELY CONTROLLED ON LOW-TO MEDIUM-DOSE INHALED CORTICOSTEROIDS, AND TO DESCRIBE THE RESULTS OF THE SALMETEROL MULTI-CENTER ASTHMA RESEARCH TRIAL","RÉVISIONS DE LA MONOGRAPHIE POUR QU'ELLE SOIT COMPATIBLE AUX LIGNES DIRECTRICES DE LA SOCIÉTÉ CANADIENNE DE L'ASTHME (CONSENSUS DE DÉCEMBRE 2004) SOULIGNANT QUE LES PRODUITS CONTENANT DES BÉTABLOQUANTS À LONGUES DURÉE D'ACTION NE DOIVENT ÊTRE PRESCRITS QU'AUX PATIENTS QUI NE SONT PAS ADÉQUATEMENT CONTRÔLÉS PAR GLUCOCORTICOÏDES ADMINISTRÉS PAR INHALATION À DES DOSES FAIBLES OU MODÉRÉES, ET, POUR DÉCRIRE LES RÉSULTATS DE L'ÉTUDE SALMETEROL MULTI-CENTER ASTHMA RESEARCH TRIAL (SMART)","CORTICOSTEROID AND BRONCHODILATOR FOR INHALATION","CORTICOSTÉROÏDE ET BRONCHODILATATEUR POUR INHALATION","",""
"9122","07-10-18","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH TO BE CONSISTENT WITH CANADIAN ASTHMA CONSENSUS GUIDELINES (DECEMBER 2004) BY EMPHASIZING THAT LABA-CONTAINING PRODUCTS SHOULD BE USED ONLY AS ADDITIONAL THERAPY FOR PATIENTS NOT ADEQUATELY CONTROLLED ON LOW-TO MEDIUM-DOSE INHALED CORTICOSTEROIDS, AND TO DESCRIBE THE RESULTS OF THE SALMETEROL MULTI-CENTER ASTHMA RESEARCH TRIAL","RÉVISIONS DE LA MONOGRAPHIE POUR QU'ELLE SOIT COMPATIBLE AUX LIGNES DIRECTRICES DE LA SOCIÉTÉ CANADIENNE DE L'ASTHME (CONSENSUS DE DÉCEMBRE 2004) SOULIGNANT QUE LES PRODUITS CONTENANT DES BÉTABLOQUANTS À LONGUES DURÉE D'ACTION NE DOIVENT ÊTRE PRESCRITS QU'AUX PATIENTS QUI NE SONT PAS ADÉQUATEMENT CONTRÔLÉS PAR GLUCOCORTICOÏDES ADMINISTRÉS PAR INHALATION À DES DOSES FAIBLES OU MODÉRÉES, ET, POUR DÉCRIRE LES RÉSULTATS DE L'ÉTUDE SALMETEROL MULTI-CENTER ASTHMA RESEARCH TRIAL (SMART)","BRONCHODILATOR","BRONCHODILATATEUR","",""
"9123","07-10-17","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9124","07-10-17","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINIVIL / ZESTRIL","MERCK SHARP & DOHME CANADA / ICI PHARMA CANADA INC. (ZENECA PHARMA)","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9125","07-10-17","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9126","07-10-17","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9127","07-10-19","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9128","07-10-19","RATIOPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"9129","07-10-22","HOFFMANN-LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MANUFACTURING PROCESS MODIFICATION FOR THE DRUG SUBSTANCE","MODIFICATION DU PROCESSUS DE FABRICATION POUR LA SUBSTANCE MÉDICAMENTEUSE","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9130","07-06-29","ATON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SALURETIC - DIURETIC AGENT","SALIDIURÉTIQUE","",""
"9131","07-07-25","ATON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SALURETIC - DIURETIC AGENT","SALIDIURÉTIQUE","",""
"9132","07-10-24","PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN MANUFACTURING SITE","CHANGEMENT DE L'EMPLACEMENT DU SITE DE FABRICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9133","07-10-24","PHIBRO ANIMAL HEALTH LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTHELMINTIC","ANTHELMINTIQUE","",""
"9134","07-10-24","P.V.U., DIVISION OF VETOQUINOL N.-A. INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SPECIES AND INDICATION FOR BROILER CHICKENS, AS AN AID IN REDUCING SYMPTOMS ASSOCIATED WITH NECROTIC ENTERITIS CAUSED BY PENICILLIN SUSCEPTIBLE CLOSTRIDIUM PERFRINGENS WHEN ADMINISTERED AT THE BEGINNING OF AN OUTBREAK IN A FLOCK","NOUVELLES ESPÈCES ET INDICATION POUR POULETS À GRILLER, POUR AIDER À RÉDUIRE LES SYMPTÔMES D'ENTÉRITE NÉCROTIQUE CAUSÉE PAR CLOSTRIDIUM PERFRINGENS SENSIBLE À LA PÉNICILLINE LORSQUE ADMINISTRÉ AU MOMENT OÙ LA MALADIE SE DÉCLARE DANS UN TROUPEAU","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9135","07-10-24","A.P.A., DIVISION OF VÉTOQUINOL N.-A. INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW SPECIES AND INDICATION FOR BROILER CHICKENS, AS AN AID IN REDUCING SYMPTOMS ASSOCIATED WITH NECROTIC ENTERITIS CAUSED BY PENICILLIN SUSCEPTIBLE CLOSTRIDIUM PERFRINGENS WHEN ADMINISTERED AT THE BEGINNING OF AN OUTBREAK IN A FLOCK","NOUVELLES ESPÈCES ET INDICATION POUR POULETS À GRILLER, POUR AIDER À RÉDUIRE LES SYMPTÔMES D'ENTÉRITE NÉCROTIQUE CAUSÉE PAR CLOSTRIDIUM PERFRINGENS SENSIBLE À LA PÉNICILLINE LORSQUE ADMINISTRÉ AU MOMENT OÙ LA MALADIE SE DÉCLARE DANS UN TROUPEAU","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9136","07-10-25","LABORATOIRE RIVA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERION DE L'ANGIOTENSINE","",""
"9137","07-10-25","PHARMASCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","IMDUR","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"9138","07-10-26","ELANCO, DIVISION OF ELI LILLY CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","LABELLING UPDATE: POTENTIAL ANTI-INFLAMMATORY EFFECT (MODE OF ACTION)","MISE À JOUR DE L'ÉTIQUETTAGE : EFFET ANTI-INFLAMMATOIRE POSSIBLE (MODE D'ACTION)","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9139","07-10-29","ZYMCAN PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"9140","07-10-29","ZYMCAN PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"9141","07-10-29","NOVARTIS PHARMACEUTICALS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: ONCE-YEARLY INTRAVENOUS INFUSION FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN TO REDUCE THE INCIDENCE OF HIP, VERTEBRAL AND NON-VERTEBRAL FRACTURES","NOUVELLE INDICATION : ADMINISTRÉ UNE FOIS PAR AN EN PERFUSION INTRAVEINEUSE POUR LE TRAITEMENT DE L'OSTÉOPOROSE POST-MÉNOPAUSIQUE AFIN DE RÉDUIRE LA FRÉQUENCE DES FRACTURES DE LA HANCHE, DES FRACTURES VERTÉBRALES ET DES FRACTURES NON VERTÉBRALES","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9142","07-10-30","GENZYME CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXTEND INDICATION: RENAGEL IS INDICATED FOR: THE CONTROL OF HYPERPHOSPHATEMIA IN PATIENTS WITH END-STAGE RENAL DISEASE (ESRD) UNDERGOING DIALYSIS AND OTHER REVISION TO THE PRODUCT MONOGRAPH","INDICATION SUPPLÉMENTAIRE : RENAGEL EST INDIQUÉE POUR LA MAÎTRISE DE L'HYPERPHOSPHORÉMIE CHEZ LES PATIENTS DIALYSÉS SOUFFRANT D'UNE INSUFFISANCE RÉNALE TERMINALE, ET AUTRES RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","PHOSPHATE BINDER","CHÉLATEUR DE LA PHOSPHATE","",""
"9143","07-10-30","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC / ANTIMANIC AGENT","ANTIPSYCHOTIQUE / ANTIMANIAQUE","",""
"9144","07-10-31","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH REGARDING PEDIATRIC USE","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT CONCERNANT L'UTILISATION CHEX LES ENFANTS","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9145","07-10-31","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION TO SUPPORT THE USE OF PRINZIDE AS INITIAL TREATMENT OF ESSENTIAL HYPERTENSION FOR WHOM COMBINATION THERAPY IS APPROPRIATE; AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS DE L'INDICATION POUR SUPPORTER L'UTILISATION DE PRINZIDE DANS LE TRAITEMENT INITIAL DE L'HYPERTENSION ESSENTIELLE CHEZ LES PATIENTS POUR QUI CETTE COMBINAISON MÉDICAMENTEUSE EST JUGÉE APPROPRIÉE; ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9146","07-10-31","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED INDICATION TO SUPPORT THE USE OF LISINOPRIL AS INITIAL TREATMENT OF ESSENTIAL HYPERTENSION; AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISION DE L'INDICATION POUR SUPPORTER L'UTILISATION DE LISINOPRIL DANS LE TRAITEMENT INITIAL DE L'HYPERTENSION ESSENTIELLE; ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9147","07-11-01","BAXTER CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"9148","07-11-01","PHARMACEUTICAL PARTNERS OF CANADA, A DIVISION OF ABRAXIS BIOSCIENCE INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"9149","07-11-01","PALADIN LABS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW 325 MG STRENGTH OF ACETYLSALICYLIC ACID CO-PACKAGE WITH PRAVASTATIN SODIUM SODIUM (10MG, 20MG AND 40MG) AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE POSOLOGIE : ACIDE ACÉTYLSALICYLIQUE 325 MG ET PRAVASTATINE SODIQUE (10MG, 20MG, ET 40MG); ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","PLATELET AGGREGATION INHIBITOR AND LIPID METABOLISM REGULATOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE ET RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"9150","07-11-01","RANBAXY PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9151","07-11-01","COBALT PHARMACEUTICALS INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DOSTINEX","PFIZER CANADA INC.","CANADA","CANADA","1","","","DOPAMINE RECEPTOR AGONIST","AGONISTE DES RÉCEPTEURS DE LA DOPAMINE","",""
"9152","07-11-05","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SHORT TERM TREATMENT (<8 WEEKS) OF GERD IN PEDIATRIC PATIENTS 12-17 YEARS OF AGE","INDICATION CLINIQUE ADDITIONNELLE : TRAITEMENT À COURT-TERME (MOINS DE 8 SEMAINES) DU REFLUX GASTROOESOPHAGIEN SYMPTOMATIQUE DES PATIENTS PÉDIATRIQUES (12-17 ANS)","H+, K+-ATPase Inhibitor","Inhibiteur de L'H+, K+-ATPase","",""
"9153","07-11-06","VETOQUINOL N A INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION; CHANGE IN OWNERSHIP; DELETION OF PACKAGE INSERT","CHANGEMENT DE FORMULATION; CHANGEMENT DE PROPRIÉTAIRE; RETRAIT DU FEUILLET D'EMBALLAGE","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9154","07-11-06","VETOQUINOL N A INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION","CHANGEMENT DE FORMULATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9155","07-11-07","VETOQUINOL N A INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION","CHANGEMENT DE FORMULATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9156","07-11-07","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SUPPLIER OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"9157","07-11-07","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SUPPLIER OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"9158","07-11-07","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SUPPLIER OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"9159","07-11-07","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SUPPLIER OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"9160","07-11-07","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SUPPLIER OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉDOÏDIEN","",""
"9161","07-11-07","PFIZER CANADA INC., ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SUPPLIER OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"9162","07-11-07","ASTRAZENECA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REQUESTED STUDIES RE MAINTENANCE OF REMISSION OF CROHN'S DISEASE","ÉTUDES REQUISES SUR LE MAINTIEN DE LA RÉMISSION DE LA MALADIE DE CROHN","GLUCOCORTICOSTEROID","GLUCOCORTICOSTÉROÏDE","",""
"9163","07-11-01","ELI LILLY CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT / ANALGESIC","ANTIDÉPRESSEUR / ANALGÉSIQUE","",""
"9164","07-11-09","PFIZER CANADA INC.","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MAY BE USEFUL IN THE MANAGEMENT OF CENTRAL NEUROPATHIC PAIN; AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","NOUVELLE INDICATION : PEUT ÊTRE UTILE DANS LE MANAGEMENT DE LA DOULEUR NEUROPATHIQUE CENTRALE, ET AUTRES RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANALGESIC AGENT","ANALGÉSIQUE","",""
"9165","07-11-13","SCHERING-PLOUGH CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","POTASSIUM SUPPLEMENT","SUPPLÉMENT POTASSIQUE","",""
"9166","07-11-13","NYCOMED GMBH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9167","07-11-13","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9168","07-11-13","ATON PHARMA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO PRODUCT MONOGRAPH SECTIONS INDICATIONS AND CLINICAL USE AND ADVERSE DRUG REACTIONS","MISE À JOUR DES SECTIONS INDICATIONS ET USAGE CLINIQUE ET RÉACTIONS INDÉSIRABLES DE LA MONOGRAPHIE DE PRODUIT","CHELATING AGENT","CHÉLATEUR","",""
"9169","07-11-14","BRISTOL-MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"9170","07-11-14","NOVARTIS PHARMACEUTICALS CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RENIN INHIBITOR","INHIBITEUR DE LA RÉNINE","",""
"9171","07-11-14","PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9172","07-11-14","GENPHARM INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW 25MG STRENGTH","NOUVELLE CONCENTRATION DE 25MG","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"9173","07-11-09","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","INTRODUCTION OF AN ADDITIONAL DRUG SUBSTANCE PURIFICATION LINE TO INCREASE PRODUCTION CAPACITY","AJOUT D'UNE LIGNE DE PURIFICATION POUR LA SUBSTANCE MÉDICAMENTEUSE AFIN D'AUGMENTER LA CAPACITÉ DE PRODUCTION","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"9174","07-11-09","NOVO NORDISK CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","INTRODUCTION OF AN ADDITIONAL DRUG SUBSTANCE PURIFICATION LINE TO INCREASE PRODUCTION CAPACITY","AJOUT D'UNE LIGNE DE PURIFICATION POUR LA SUBSTANCE MÉDICAMENTEUSE AFIN D'AUGMENTER LA CAPACITÉ DE PRODUCTION","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"9175","07-11-20","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"9176","07-11-19","BAYER INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW 2000 IU PRESENTATION","NOUVELLE PRÉSENTATION DE 2000 UI","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"9177","07-11-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9178","07-11-21","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","CHANGE IN PRODUCT NAME AND TO INCLUDE ADDITIONAL STRENGTHS","CHANGEMENT DE NOM DU PRODUIT ET AJOUT DE CONCENTRATIONS SUPPLÉMENTAIRES","ANGIOTENSIN-CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9179","07-11-21","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9180","07-11-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9181","07-11-21","BOEHRINGER INGELHEIM (CANADA) LTD./LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE CLINICAL TRIALS SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION ESSAIS CLINIQUES ET AUTRES RÉVISIONS DE LA MONOGRAPHIE","BRONCHODILATOR","BRONCHODILATATEUR","",""
"9182","07-11-21","PHARMEL INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9183","07-11-21","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9184","07-11-22","PHIBRO ANIMAL HEALTH LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBIOTIC, GROWTH PROMOTANT","ANTIBIOTIQUE, AUGMENTE LE GAIN DE POIDS","",""
"9185","07-11-22","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINZIDE","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9186","07-11-22","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: CAPSULES (WITH ASSOCIATED INDICATION)","NOUVELLE FORME POSOLOGIQUE : CAPSULES (ET INDICATIONS AFFÉRENTES)","Vitamin D Analog","Analogue de la vitamine D","",""
"9187","07-11-22","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONIST DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"9188","07-11-08","JANSSEN-ORTHO INC.","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","RECOMBINANT HUMAN B-TYPE NATRIURETIC PEPTIDE (RHBNP)","PEPTIDE NATRIURÉTIQUE DE TYPE B HUMAIN RECOMBINANT (RHBNP)","",""
"9189","07-11-23","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW DRUG PRODUCT MANUFACTURING SITE","NOUVEAU SITE DE FABRICATION POUR LE PRODUIT MÉDICAMENTEUX","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"9190","07-11-23","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXPANDED INDICATION TO INCLUDE PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER","INDICATION ÉTENDUE AUX ENFANTS DE SIX ANS ET PLUS","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9191","07-11-23","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PHARMORUBICIN RDF","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9192","07-11-23","GENPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"9193","07-11-23","RATIOPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA INC.","CANADA","CANADA","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT","ANTIDEPRESSANT / ANXIOLYTIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE","",""
"9194","07-11-23","CANGENE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW LIQUID FORMULATION","NOUVELLE PRÉSENTATION EN FORMAT LIQUIDE","PASSIVE IMMUNIZATION AGENT","AGENT D'IMMUNISATION PASSIF","",""
"9195","07-11-26","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","BIOLOGIC RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"9196","07-11-26","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9197","07-11-27","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO MODIFY THE FREQUENCY OF ADMINISTRATION IN PUPPIES BETWEEN 6 AND 12 WEEKS OF AGE","MODIFICATION DE LA FRÉQUENCE D'ADMINISTRATION CHEZ LES CHIOTS ÂGÉS DE 6 À 12 SEMAINES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"9198","07-11-27","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO MODIFY THE FREQUENCY OF ADMINISTRATION IN PUPPIES BETWEEN 6 AND 12 WEEKS OF AGE","MODIFICATION DE LA FRÉQUENCE D'ADMINISTRATION CHEZ LES CHIOTS ÂGÉS DE 6 À 12 SEMAINES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"9199","07-11-27","MERIAL CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO MODIFY THE FREQUENCY OF ADMINISTRATION IN PUPPIES BETWEEN 6 AND 12 WEEKS OF AGE","MODIFICATION DE LA FRÉQUENCE D'ADMINISTRATION CHEZ LES CHIOTS ÂGÉS DE 6 À 12 SEMAINES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"9200","07-11-27","MERCK FROSST CANADA LTD., MERCK FROSST CANADA LTÉE","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HIV INTEGRASE STRAND TRANSFER INHIBITOR","INHIBITEUR DE TRANSFERT DE BRIN DE L'INTÉGRASE DU VIH","",""
"9201","07-11-27","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MS CONTIN","PURDUE PHARMA","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"9202","07-11-27","PALADIN LABS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PACKAGING AND DILUTION INSTRUCTION","MODIFICATION DU CONDITIONNEMENT ET LES DIRECTRICES POUR LA DILUTION","ALCOHOL DEHYDROGENASE INHIBITOR","INHIBITEUR DE L'ALCOOL DÉSHYDROGÉNASE","",""
"9203","07-11-27","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE INDICATIONS AND CLINICAL USE, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, AND ACTION AND CLINICAL PHARMACOLOGY SECTIONS OF THE PRODUCT MONOGRAPH","RÉVISION DES INDICATIONS ET DE L'UTILISATION CLINIQUE.  SECTIONS EFFETS INDÉSIRABLES, POSOLOGIE ET ADMINISTRATION ET MODE D'ACTION ET PHARMACOLOGIE CLINIQUE DE LA MONOGRAPHIE DE PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9204","07-11-27","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","BIOVAIL PHARMACEUTICALS","CANADA","CANADA","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"9205","07-11-28","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXTENSION OF INDICATION: FOR THE CLAIM OF INHIBITION OF PROGRESSION OF STRUCTURAL DAMAGE AND IMPROVEMENT IN PHYSICAL FUNCTION IN ADULT PATIENTS WITH PSORIATIC ARTHRITIS","AJOUT À L'INDICATION POUR INCLURE : INHIBITION DE L'ÉVOLUTION DES LÉSIONS STRUCTURELLES ET AMÉLIORATION DES CAPACITÉS PHYSIQUES FONCTIONNELLES CHEZ LES PATIENTS ADULTES ATTEINTS DE RHUMATISME PSORIASIQUE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"9206","07-11-28","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9207","07-11-28","GLAXOSMITHKLINE INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9208","07-11-29","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FULFILMENT OF COMMITMENT TO CONDUCT THE CONFIRMATORY STUDY AS PER PROTOCOL ATTACHED TO THE LETTER OF UNDERTAKING DATED AUGUST 2, 2000 FOR THE TREATMENT OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)","EXÉCUTION DE L'ENGAGEMENT D'ENTREPRENDRE L'ÉTUDE CONFIRMATOIRE REQUISE SELON LE PROTOCOLE MENTIONNÉ DANS LA LETTRE D'ENGAGEMENT DATÉE LE 2 AOÛT 2000 POUR LE TRAITEMENT DES PATIENTS AVEC LA SCLÉROSE LATÉRALE AMYOTROPHIQUE","ANTIGLUTAMATE","ANTIGLUTAMATE","",""
"9209","07-11-29","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"9210","07-11-29","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH - CLASS LABELLING FOR NSAIDS","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT - ÉTIQUETAGE DES AINS EN FONCTION DE LA CLASSE DE MÉDICAMENT","NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"9211","07-11-29","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"9212","07-11-29","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH SECTIONS: WARNINGS AND PRECAUTIONS; AND DOSAGE AND ADMINISTRATION","MISE À JOUR DES SECTIONS SUIVANTES DE LA MONOGRAPHIE DE PRODUIT : MISES EN GARDE ET PRÉCAUTIONS; POSOLOGIE ET ADMINISTRATION","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"9213","07-11-30","ASTRAZENECA CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FULFILMENT OF COMMITMENTS III AND IV OUTLINED IN LETTER OF UNDERTAKING DATED JULY 13, 2006 FOR THE THIRD LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF TWO PRIOR CHEMOTHERAPY REGIMENS (PLATINUM-BASED AND DOCETAXEL)","RÉALISATION DES CONDITIONS III ET IV ÉNONCÉES DANS LA LETTRE D'ENGAGEMENT DU 13 JUILLET 2006 À L'ÉGARD DU TRAITEMENT DE TROISIÈME LIGNE DES PATIENTS ATTEINTS D'UN CANCER PULMONAIRE NON À PETITES CELLULES LOCALISÉ AVANCÉ OU MÉTASTATIQUE APRÈS L'ÉCHEC DE DEUX SCHÉMAS CHIMIOTHÉRAPEUTIQUES (À BASE DE PLATINE ET AU DOCÉTAXEL)","EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI)","INHIBITEUR DE LA TYROSINE KINASE DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE (EGFR)","",""
"9214","07-11-30","ALLERGAN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ALLERGIC","ANTIALLERGIQUE","",""
"9215","07-12-03","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"9216","07-12-03","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE MANUFACTURING SITE","VARIATION DE L'EMPLACEMENT DU SITE DE FABRICATION","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"9217","07-11-30","PHARMEL INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","SEARLE CANADA INC.","CANADA","CANADA","1","PRODUCT NAME CHANGE FROM RIVA-VERAPAMIL SR","MODIFICATION DU NOM DU PRODUIT DE RIVA-VERAPAMIL SR","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"9218","07-12-03","LUNDBECK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE ACTIONS AND CLINICAL PHARMACOLOGY SECTION OF THE PRODUCT MONOGRAPH","RÉVISIONS DE LA SECTION MODE D'ACTION ET PHARMACOLOGIE CLINIQUE DE LA MONOGRAPHIE","ANTIDEPRESSANT/ANXIOLYTIC","ANTIDÉPRESSEUR/ANXIOLYTIQUE","",""
"9219","07-12-04","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH SECTIONS: INDICATIONS AND CLINICAL USE, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION, DOSAGE FORM, ADMINISTRATION AND PACKAGING","MISE À JOUR DES SECTIONS SUIVANTES DE LA MONOGRAPHIE DE PRODUIT : INDICATIONS ET UTILISATION CLINIQUE, CONTRE-INDICATIONS, MISES EN GARDE ET PRÉCAUTIONS, POSOLOGIE ET ADMINISTRATION, FORME POSOLOGIQUE, ADMINISTRATION ET CONDITIONNEMENT","ORAL HYPOGLYCEMIC","HYPOGLYCÉMIANT ORAL","",""
"9220","07-12-04","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL/ANTIBULIMIC","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"9221","07-12-04","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9222","07-12-05","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTI-DIABETIC AGENT/INSULIN RESISTANCE REDUCING AGENT","AGENT ANTI-DIABÉTIQUE/AGENT INSULINOSENSIBILISATEUR","",""
"9223","07-12-05","SPECIFAR S A","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTI-DIABETIC AGENT/INSULIN RESISTANCE REDUCING AGENT","AGENT ANTI-DIABÉTIQUE/AGENT INSULINOSENSIBILISATEUR","",""
"9224","07-12-05","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTI-DIABETIC AGENT/INSULIN RESISTANCE REDUCING AGENT","AGENT ANTI-DIABÉTIQUE/AGENT INSULINOSENSIBILISATEUR","",""
"9225","07-12-05","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTI-DIABETIC AGENT/INSULIN RESISTANCE REDUCING AGENT","AGENT ANTI-DIABÉTIQUE/AGENT INSULINOSENSIBILISATEUR","",""
"9226","07-12-05","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTI-DIABETIC AGENT/INSULIN RESISTANCE REDUCING AGENT","AGENT ANTI-DIABÉTIQUE/AGENT INSULINOSENSIBILISATEUR","",""
"9227","07-12-05","GENPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTI-DIABETIC AGENT/INSULIN RESISTANCE REDUCING AGENT","AGENT ANTI-DIABÉTIQUE/AGENT INSULINOSENSIBILISATEUR","",""
"9228","07-12-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTI-DIABETIC AGENT/INSULIN RESISTANCE REDUCING AGENT","AGENT ANTI-DIABÉTIQUE/AGENT INSULINOSENSIBILISATEUR","",""
"9229","07-12-05","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTI-DIABETIC AGENT/INSULIN RESISTANCE REDUCING AGENT","AGENT ANTI-DIABÉTIQUE/AGENT INSULINOSENSIBILISATEUR","",""
"9230","07-12-06","RATIOPHARM INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MS CONTIN SR","PURDUE PHARMA INC.","CANADA","CANADA","1","NEW MANUFACTURING SITE AND CHANGE IN TABLET MARKING","NOUVEL ÉTABLISSEMENT PRODUCTEUR ET MODIFICATION AU MARQUAGE DES COMPRIMÉS","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"9231","07-12-06","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE DOSAGE AND ADMINISTRATION SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MODIFICATIONS APPORTÉES À LA SECTION « POSOLOGIE ET ADMINISTRATION » DE LA MONOGRAPHIE DU PRODUIT ET AUTRES MODIFICATIONS À LA MONOGRAPHIE DU PRODUIT","SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)","INHIBITEUR SÉLECTIF DU RECAPTAGE DE LANORADRÉNALINE DANS LE TRAITEMENT DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ (TDAH)","",""
"9232","07-12-07","CSL BEHRING CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","QUALIFICATION OF AN ALTERNATE DRUG SUBSTANCE INTERMEDIATE","QUALIFICATION D'UNE SUBSTANCE MÉDICAMENTEUSE INTERMÉDIAIRE ADDITIONNELLE","PASSIVE IMMUNIZATION AGENT","AGENT D'IMMUNISATION PASSIF","",""
"9233","07-12-07","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","REPLACEMENT THERAPY FOR IMMUNODEFICIENCIES","THÉRAPIES POUR PATIENT ATTEINT D'IMMUNODÉFICIENCE","",""
"9234","07-12-10","GENPHARM INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC MAXIMUM STRENGTH NON-PRESCRIPTION","PFIZER CANADA INC.","CANADA","CANADA","1","SEEKING APPROVAL OF OTC INDICATION FOR 150 MG STRENGTH","DEMANDE D'APPROBATION POUR LA VENTE LIBRE DE COMPRIMÉS D'UNE CONCENTRATION DE 150 MG","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"9235","07-12-10","NYCOMED CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR INHALATION ORALE","",""
"9236","07-12-11","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, ACTION AND CLINICAL PHARMACOLOGY, CLINICAL TRIALS","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT : MISES EN GARDE ET PRÉCAUTIONS, EFFETS INDÉSIRABLES, ACTION ET PHARMACOLOGIE CLINIQUE, ESSAIS CLINIQUES","ORAL ANTIDIABETIC AGENT; ALPHA-GLUCOSIDASE INHIBITOR","ANTIDIABÉTIQUE ORAL; INHIBITEUR DES ALPHA-GLUCOSIDASES","",""
"9237","07-12-11","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORETIC","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"9238","07-12-12","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"9239","07-12-12","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION DE L'ORIGINE DE L'INGRÉDIENT ACTIF","ANTI-INFLAMMATORY, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"9240","07-12-11","BIOVAIL PHARMACEUTICALS CANADA DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE FROM GLUMETZA (AQ) / GLUMETZA","MODIFICATION DU NOM DU PRODUIT DE GLUMETZA (AQ) / GLUMETZA","ORAL ANTIHYPERGLYCEMIC AGENT","AGENT ANTIHYPERGLYCÉMIANT ORAL","",""
"9241","07-12-13","OVATION PHARMACEUTICALS INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","INDICATION REVISED TO THE FOLLOWING: MUSTARGEN, ADMINISTERED INTRAVENOUSLY, IS INDICATED FOR THE PALLIATIVE TREATMENT OF HODGKIN'S DISEASE (STAGES III AND IV) AS PART OF THE MOPP CHEMOTHERAPY COMBINATION (MECHLORETHAMINE, VINCRISTINE, PROCARBAZINE AND PREDNISONE).  REVISIONS TO THE PRODUCT MONOGRAPH.","MODIFICATION DES INDICATIONS : MUSTARGEN, ADMINISTRÉ PAR VOIE I.V., EST INDIQUÉ POUR LE TRAITEMENT PALLIATIF DE LA MALADIE DE HODGKIN (STADES III ET IV) DANS LE PROTOCOLE DE CHIMIOTHÉRAPIE MOPP (MÉCHLORÉTHAMINE, VINCRISTINE, PROCARBAZINE ET PREDNISONE). RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ALKYLATING AGENT","ALCOYLANT","",""
"9242","07-12-13","NYCOMED CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH REFLUX ESOPHAGITIS AND THE RAPID RESOLUTION OF SYMPTOMS ASSOCIATED WITH REFLUX ESOPHAGITIS SUCH AS HEARTBURN, REGURGITATION AND DYSPEPSIA","INDICATION CLINIQUE RÉVISÉE : POUR LE TRAITEMENT D'ENTRETIEN DES PATIENTS PRÉSENTANT UN REFLUX OESOPHAGIEN ET RÉSOLUTION RAPIDE DES SYMPTÔMES ASSOCIÉS AU REFLUX OESOPHAGIEN, BRÛLEMENTS D'ESTOMAC, RÉGURGITATIONS ET DYSPEPSIE","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9243","07-12-13","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"9244","07-12-13","GENPHARM INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW 25 MG STRENGTH","NOUVEAU COMPRIMÉ : 25 MG","ANTIHYPERTENSIVE / ANTI-ANGINAL AGENT","ANTIHYPERTENSEUR / ANTIANGINEUX","",""
"9245","07-12-14","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT; DPP-4 INHIBITOR; INCRETIN ENHANCER","AGENT ORAL D'ANTIHYPERGLYCÉMIC; INHIBITEUR DPP-4; RENFORCEUR D'INCRETIN","",""
"9246","07-12-17","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT/ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR/AGENT ANTIOBSESSIONNEL","",""
"9247","07-12-18","ALK ABELLO AS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ALLERGENIC EXTRACT","EXTRAIT ALLERGÉNIQUE","",""
"9248","07-12-18","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL AND LEUCOVORIN AS ADJUVANT TREATMENT OF PATIENTS WITH STAGE III (DUKE'S C) COLON CANCER AFTER COMPLETE RESECTION OF PRIMARY TUMOR","NOUVELLE INDICATION : EN ASSOCIATION AVEC LE 5-FLUOROURACILE ET LA LEUCOVORINE ADMINISTRÉS EN PERFUSION, COMME ADJUVANT DANS LE TRAITEMENT DE PATIENTS ATTEINTS D'UN CANCER COLORECTAL DE STADE III (DUKE C) APRÈS RÉSECTION COMPLÈTE DE LA TUMEUR PRIMAIRE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9249","07-12-18","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO THE BLOOD MONITORING FREQUENCY IN THE PRODUCT MONOGRAPH","RÉVISION DE LA MONOGRAPHIE : FRÉQUENCE DE SURVEILLANCE DE LA FORMULE SANGUINE","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9250","07-12-19","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTIDEPRESSANT","ANTIDÉPRESSEUR INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA SÉROTONINE","",""
"9251","07-12-19","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9252","07-12-19","LUNDBECK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE ADVERSE REACTIONS SECTION OF THE PRODUCT MONOGRAPH","RÉVISIONS À LA SECTION D'EFFETS INDÉSIRABLES DE LA MONOGRAPHIE","ANTIDEPRESSANT/ANXIOLYTIC","ANTIDÉPRESSEUR/ANXIOLYTIQUE","",""
"9253","07-12-20","BRISTOL MYERS SQUIBB CANADA","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","STUDY: COMMITMENT #3 OF THE LETTER OF UNDERTAKING DATED MARCH 13, 2007 - RESULTS OF SEGMENT 1 OF STUDY CA 180021.  REVISED PRODUCT MONOGRAPH: CHANGES TO WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS, DOSAGE AND ADMINISTRATION","ÉTUDE : ENGAGEMENT NO 3 DE LA LETTRE D'ENGAGEMENT DATÉE DU 13 MARS 2007 - RÉSULTAT DU SEGMENT 1 DE L'ÉTUDE CA 180021.  MONOGRAPHIE DU PRODUIT RÉVISÉ : MODIFICATION DES MISES EN GARDE ET DES PRÉCAUTIONS, DES INTERACTIONS MÉDICAMENTEUSES, DE LA POSOLOGIE ET DE L'ADMINISTRATION","PROTEIN-TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"9254","07-12-21","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9255","07-12-20","3M CANADA COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIGINGIVITIS ORAL RINSE","RINCE-BOUCHE ANTIGINGIVITE","",""
"9256","07-12-20","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9257","07-12-20","ZYMCAN PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"9258","07-12-20","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"9259","07-12-20","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","SEARLE CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"9260","07-12-20","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH - CLASS LABELLING FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT - ÉTIQUETAGE DES ANTI-INFLAMMATOIRES NON STÉROÏDIENS (AINS) EN FONCTION DE LA CLASSE DE MÉDICAMENT","NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"9261","07-12-20","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH - CLASS LABELLING FOR NSAIDS","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT - ÉTIQUETAGE DES AINS EN FONCTION DE LA CLASSE DE MÉDICAMENT","NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"9262","07-12-20","UCB PHARMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE POUR LE TRACTUS GASTRO-INTESTINAL INFÉRIEUR","",""
"9263","07-12-21","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MTOR KINASE INHIBITOR - ANTINEOPLASTIC AGENT","INHIBITEUR DE LA MTOR - ANTINÉOPLASIQUE","",""
"9264","07-12-21","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","NEW STRENGTHS","NOUVELLES CONCENTRATIONS","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9265","07-12-21","BARR LABORATORIES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRIPHASIL","WYETH CANADA","CANADA","CANADA","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"9266","07-12-24","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9267","07-12-28","VETOQUINOL N A INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION AND ADDITION OF A 1000 ML PACKAGE SIZE","CHANGEMENT DE FORMULATION ET ADDITION D'UN CONTENANT DE 1000 ML","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9268","07-12-31","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"9269","08-01-02","BAYER INC CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN PRODUCT NAMES AND MODIFICATIONS TO CURRENT LABELLING","MODIFICATIONS AUX NOMS DES PRODUITS ET DE L'ÉTIQUETAGE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9270","08-01-02","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - FIRST LINE THERAPY","INDICATION ADDITIONNELLE : TRAITEMENT DE PREMIÈRE INTENTION","ELEVATED INTRAOCULAR PRESSURE THERAPY","THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"9271","08-01-03","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CONVERSION OF SINGLE-PRODUCT FACILITY TO MULTI-PRODUCT FACILITY; IMPROVED MANUFACTURING PROCESS","CONVERSION DE LA FACILITÉ DE PRODUIT SIMPLE À LA FACILITÉDE MULTIPRODUIT; MODIFICATION DE LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9272","08-01-04","SERVIER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE CLINICAL TRIALS SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DES ÉTUDES CLINIQUES ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9273","08-01-07","INTERVET CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","OXYMYCINE LP","WYETH ANIMAL HEALTH","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9274","07-12-27","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","UPDATE TO THE MANUFACTURING OPERATIONS AS WELL AS A CHANGE IN MANUFACTURING AREA","MISE À JOUR DES OPRÉRATIONS DE FABRICATION AINSI QU'UN CHANGEMENT DE LA ZONE DE FABRICATION","DIAGNOSTIC RADIOPHARMACEUTICAL","RADIOPHARMACEUTIQUE À USAGE DIAGNOSTIC","",""
"9275","08-01-07","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","VASCULAR STABILIZER FOR THE TREATMENT OF MENOPAUSAL FLUSHING","STABILISATEUR VASCULAIRE POUR LE TRAITEMENT DES BOUFFÉES DE CHALEUR DE LA MÉNOPAUSE","",""
"9276","08-01-08","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY AND MANUFACTURING PROCESS","MODIFICATION À L'EMPLACEMENT DE FABRICATION ET PROCESSUS DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9277","08-01-07","BIOVAIL PHARMACEUTICALS CANADA DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE GRADE OF EXCIPIENT IN DRUG PRODUCT","EXCIPIENT DE QUALITÉ DIFFÉRENTE DANS LE MÉDICAMENT","ORAL ANTIHYPERGLECEMIC AGENT","AGENT ANTIHYPERGLYCÉMIQUE ORAL","",""
"9278","08-01-07","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN, ONDANSETRON 8 MG TABLETS","GLAXOSMITHKLINE INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"9279","08-01-07","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE CLINICAL TRIALS SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION DES ÉTUDES CLINIQUES ET AUTRES RÉVISIONS DE MONOGRAPHIE DU PRODUIT","BRONCHODILATOR AND CORTICOSTEROID FOR ORAL INHALATION","BRONCHODILATATEUR ET CORTICOSTÉROÏDE EN INHALATION","",""
"9280","08-01-10","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING PROCESS","MODIFICATION DE LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9281","08-01-09","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","EXPANDED AGE INDICATION TO 4 YEARS OF AGE AND OLDER","INDICATION D'ÂGE AUGMENTÉE À 4 ANS ET PLUS","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9282","08-01-09","CSL BEHRING CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"9283","08-01-10","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9284","08-01-10","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: CONTROL OF POSTOPERATIVE PAIN FOLLOWING ORTHOPEDIC AND SOFT TISSUE SURGERY","NOUVELLE INDICATION : MAÎTRISE DE LA DOULEUR POSTOPÉRATOIRE SUIVANT UNE CHIRURGIE ORTHOPÉDIQUE OU DE TISSUS MOUS","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"9285","08-01-10","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: CONTROL OF POSTOPERATIVE PAIN FOLLOWING ORTHOPEDIC AND SOFT TISSUE SURGERY","NOUVELLE INDICATION : MAÎTRISE DE LA DOULEUR POSTOPÉRATOIRE SUIVANT UNE CHIRURGIE ORTHOPÉDIQUE OU DE TISSUS MOUS","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"9286","08-01-10","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: CONTROL OF POSTOPERATIVE PAIN FOLLOWING ORTHOPEDIC AND SOFT TISSUE SURGERY","NOUVELLE INDICATION : MAÎTRISE DE LA DOULEUR POSTOPÉRATOIRE SUIVANT UNE CHIRURGIE ORTHOPÉDIQUE OU DE TISSUS MOUS","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"9287","08-01-10","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: CONTROL OF POSTOPERATIVE PAIN FOLLOWING ORTHOPEDIC AND SOFT TISSUE SURGERY","NOUVELLE INDICATION : MAÎTRISE DE LA DOULEUR POSTOPÉRATOIRE SUIVANT UNE CHIRURGIE ORTHOPÉDIQUE OU DE TISSUS MOUS","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"9288","08-01-10","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: CONTROL OF POSTOPERATIVE PAIN FOLLOWING ORTHOPEDIC AND SOFT TISSUE SURGERY","NOUVELLE INDICATION : MAÎTRISE DE LA DOULEUR POSTOPÉRATOIRE SUIVANT UNE CHIRURGIE ORTHOPÉDIQUE OU DE TISSUS MOUS","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"9289","08-01-10","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION: CONTROL OF POSTOPERATIVE PAIN FOLLOWING ORTHOPEDIC AND SOFT TISSUE SURGERY","NOUVELLE INDICATION : MAÎTRISE DE LA DOULEUR POSTOPÉRATOIRE SUIVANT UNE CHIRURGIE ORTHOPÉDIQUE OU DE TISSUS MOUS","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"9290","08-01-10","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: FOR THE TREATMENT OF: ADULT PATIENTS WITH MYELODYSPLASTIC/MYELOPROLIFERATIVE DISEASES (MDS/MPD) ASSOCIATED WITH PLATELET-DERIVED GROWTH FACTOR RECEPTOR GENE REARRANGEMENTS; ADULT PATIENTS WITH AGGRESSIVE SUB-TYPES OF SYSTEMIC MASTOCYTOSIS (ASM AND SM-AHNMD) WITHOUT THE D816V C-KIT MUTATION. IF C-KIT MUTATIONAL STATUS IN PATIENTS WITH ASM OR SM-AHNMD IS NOT KNOWN OR UNAVAILABLE, TREATMENT WITH GLEEVEC MAY BE CONSIDERED IF THERE IS NO SATISFACTORY RESPONSE TO OTHER THERAPIES; ADULT PATIENTS WITH ADVANCED HYPEREOSINOPHILIC SYNDROME (HES) AND/OR CHRONIC EOSINOPHILIC LEUKEMIA (CEL) WITH FIP1L1-PDGFR REARRANGEMENT; AND ADULT PATIENTS WITH UNRESECTABLE, RECURRENT AND/OR METASTATIC DERMATOFIBROSARCOMA PROTUBERANS (DFSP)","NOUVELLES INDICATIONS : POUR LE TRAITEMENT DE : PATIENTS ADULTES ATTEINTS DES SYNDROMES MYÉLODYSPLASIQUES/MYÉLOPROLIFÉRATIFS (SMD/SMP) ASSOCIÉS AUX RÉARRANGEMENTS DE GÈNE DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DÉRIVÉ DES PLAQUETTES; PATIENTS ADULTES ATTEINTS DE FORMES AGGRESSIVES DE LA MASTOCYTOSE SYSTÉMIQUE (ASM ET SM-AHNMD) SANS LA MUTATION D816V DU C-KIT.  SI L'ON IGNORE LE STATUT D'UN PATIENT ATTEINT D'ASM OU DE SM-AHNMD À L'ÉGARD DE LA MUTATION DU C-KIT, ON PEUT ENVISAGER LE TRAITEMENT PAR GLEEVEC EN L'ABSENCE DE RÉPONSE SATISFAISANTE AUX AUTRES TRAITEMENT; PATIENTS ADULTES ATTEINTS DU SYNDROME HYPERÉOSINOPHILIQUE (HES) À UN STADE AVANCÉ ET/OU DE LEUCÉMIE CHRONIQUE À ÉOSINOPHILES (LCE) ASSOCIÉS À UN RÉARRANGEMENT DU F1P1L1-PDGFR; ET LES PATIENTS ADULTES ATTEINTS D'UN DERMATOFIBROSARCOME DE DARIER-FERRAND NON RÉSÉCABLE, RÉCIDIVANT ET/OU MÉTASTATIQUE","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE KINASE","",""
"9291","08-01-11","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN DRUG SUBSTANCE SPECIFICATIONS; NEW MANUFACTURING SITE AND REPLACEMENT TEST FOR STERILITY TESTING","MODIFICATIONS DES SPÉCIFICATIONS DES COMPOSANTES DE DROGUES, NOUVEAU SITE DE FABRICATION ET NOUVEAUX TESTS DE STÉRILITÉ","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9292","08-01-11","MEDEXUS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","METHOTREXATE INJECTION","MAYNE PHARMA (CANADA) INC.","CANADA","CANADA","1","","","ANTIMETABOLITE AND ANTIRHEUMATIC","ANTIMÉTABOLITE ET ANTIRHUMATISMAL","",""
"9293","08-01-15","INTERVET CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9294","08-01-15","INTERVET CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9295","08-01-15","CAN VET ANIMAL HEALTH SUPPLIES LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"9296","08-01-15","BIO AGRI MIX LP","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","RUMENSIN PREMIX","ELANCO, DIVISION OF ELI LILLY CANADA INC.","CANADA","CANADA","1","NEW INDICATIONS IN LACTATING DAIRY COWS: (1) REDUCTION OF MILK FAT PERCENTAGE (2) MINIMIZING LOSS OF BODY CONDITION DURING LACTATION (3) IMPROVING FEED EFFICIENCY OF MILK PROTEIN PRODUCTION","NOUVELLES INDICATIONS CHEZ LES VACHES LAITIÈRES LACTANTES : (1) RÉDUIRE LA TENEUR EN MATIÈRES GRASSES DU LAIT (2) MINIMISER LA PERTE D'ÉTAT DE CHAIR DURANT LA LACTATION (3) AMÉLIORER L'EFFICACITÉ ALIMENTAIRE POUR LA PRODUCTION DE PROTÉINE DU LAIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9297","08-01-15","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","UPDATE TO THE CLINICAL TRIALS SECTION IN PART 2 OF THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION ESSAIS CLINIQUES DANS LA PARTIE 2 DE LA MONOGRAPHIE DE PRODUIT","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"9298","08-01-15","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DDAVP","FERRING INC.","CANADA","CANADA","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"9299","08-01-15","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW CAPSULES STRENGTHS","CAPSULES DE CONCENTRATIONS DIFFÉRENTES","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"9300","08-01-15","JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW CLAIM - DAYTIME USE","NOUVELLE ALLÉGATION - UTILISATION PENDANT LA JOURNÉE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9301","08-01-16","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITION OF V-S FEED AND AGRI SUPPLIES LTD. FOR THE MANUFACTURING OF BOVATEC FC PASTURE CATTLE MINERAL 200","ADDITION DE V-S FEED AND AGRI SUPPLIES LTD. POUR LA FABRICATION DE BOVATEC FC PASTURE CATTLE MINERAL 200","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9302","08-01-17","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE","",""
"9303","08-01-17","CELGENE","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT, IMMUNOMODULATORY AGENT","AGENT ANTINÉOPLASIQUE, AGENT IMMUNOMODULATEUR","",""
"9304","08-01-17","GILEAD SCIENCES INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9305","08-01-17","GILEAD SCIENCES INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9306","08-01-18","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9307","08-01-18","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9308","08-01-18","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"9309","08-01-22","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","IMMUNOSUPPRESSANT","AGENT IMMUNOSUPPRESSEUR","",""
"9310","08-01-23","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: TREATMENT OF ADULT PATIENTS WITH CHRONIC MODERATE TO SEVERE PSORIASIS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY.  FOR PATIENTS WITH CHRONIC MODERATE PLAQUE PSORIASIS, HUMIRA SHOULD BE USED AFTER PHOTOTHERAPY HAS BEEN SHOWN TO BE INEFFECTIVE OR INAPPROPRIATE","NOUVELLE INDICATION : TRAITEMENT DU PSORIASIS CHRONIQUE D'INTENSITÉ MODÉRÉE À GRAVE CHEZ LES PATIENTS ADULTES CANDIDATS À UN TRAITEMENT SYSTÉMATIQUE.  CHEZ LES PATIENTS ATTEINTS DE PSORIASIS CHRONIQUE EN PLAQUES D'INTENSITÉ MODÉRÉE, HUMIRA NE DEVRAIT ÊTRE UTILISÉ QUE LORSQUE LES TRAITEMENTS PAR PHOTOTHÉRAPIE S'AVÈRENT INEFFICACES OU INAPPROPRIÉS","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"9311","08-01-23","INO THERAPEUTICS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE TOXICOLOGY SECTION OF THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION TOXICOLOGIE DE LA MONOGRAPHIE DU PRODUIT","PULMONARY VASODILATOR","VASODILATATEUR PULMONAIRE","",""
"9312","08-01-23","GENPHARM ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9313","08-01-24","EURO PHARM INTERNATIONAL CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMANIC AGENT","ANTIMANIAQUE","",""
"9314","08-01-24","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"9315","08-01-24","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic, Anti-inflammatory, Antipyretic, Platelet Aggregation Inhibitor","Analgésique, Anti-inflammatoire, Antipyrétique, Inhibiteur d'agglomération des plaquettes","",""
"9316","08-01-24","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE CLINICAL TRIALS SECTION OF THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION SUR LES ESSAIS CLINIQUES DE LA MONOGRAPHIE DE PRODUIT","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"9317","08-01-24","INTERVET CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PACKAGING; CHANGE IN STORAGE TEMPERATURE","CHANGEMENT DU CONTENANT; CHANGEMENT DE LA TEMPÉRATURE D'ENTREPOSAGE","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"9318","08-01-24","INTERVET CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PACKAGING; CHANGE IN STORAGE TEMPERATURE","CHANGEMENT DU CONTENANT; CHANGEMENT DE LA TEMPÉRATURE D'ENTREPOSAGE","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"9319","08-01-24","INTERVET CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PACKAGING; CHANGE IN STORAGE TEMPERATURE","CHANGEMENT DU CONTENANT; CHANGEMENT DE LA TEMPÉRATURE D'ENTREPOSAGE","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"9320","08-01-24","INTERVET CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN PACKAGING; CHANGE IN STORAGE TEMPERATURE","CHANGEMENT DU CONTENANT; CHANGEMENT DE LA TEMPÉRATURE D'ENTREPOSAGE","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"9321","08-01-25","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","RESTRICTION OF INDICATION: FOR USE ONLY IN PATIENTS WITH CHRONIC KIDNEY DISEASE WHO ARE RECEIVING DIALYSIS","RESTRICTION D'INDICATION : POUR UTILISATION SEULEMENT CHEZ LES PATIENTS ATTEINTS D'UNE MALADIE RÉNALE CHRONIQUE QUI SONT DIALYSÉS","CALCIMIMETIC AGENT","AGENT CALCIMIMÉTIQUE","",""
"9322","08-01-25","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","ANTIDEPRESSANT AND ANXIOLYTIC","ANTIDÉPRESSEUR ET ANXIOLYTIQUE","",""
"9323","08-01-25","RANBAXY PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9324","08-01-28","PHARMALOGIC PET SERVICES OF MONTREAL COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"9325","08-01-28","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)","NOUVELLE INDICATION : TRAITEMENT DES PATIENTS ATTEINTS D'UN CARCINOME HÉPATOCELLULAIRE (CHC) NON RÉSÉCABLE","MULTIKINASE INHIBITOR, ANTINEOPLASTIC AGENT","INHIBITEUR DE LA MULTIKINASE, AGENT ANTINÉOPLASIQUE","",""
"9326","08-01-29","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9327","08-01-29","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PIPRACIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9328","08-01-29","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF A BREAKABILITY STATEMENT (FOR THE 400 MG TO SUPPORT THE 200 MG BID DOSING SCHEDULE)","ADDITION D'UNE NOTICE SUR LA FRAGMENTATION DU COMPRIMÉ DE 400 MG QUI POURRAIT ÊTRE UTILISÉ POUR LA POSOLOGIE DE 200 MG B.I.D.","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9329","08-01-29","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DRUG SUBSTANCE VENDOR; CHANGE IN MANUFACTURING SITE OF DRUG PRODUCT; REPLACEMENT OF STERILITY TESTING WITH PRODUCT PARAMETRIC RELEASE","NOUVEAU FOURNISSEUR DE LA SUBSTANCE MÉDICAMENTEUSE, MODIFICATION DU SITE DE FABRICATION DU MÉDICAMENT; ÉLIMINATION DES ÉPREUVES DE STÉRIITÉ PAR UN PROCÉDÉ DE LIBÉRATION EN FONCTION DE PARAMÈTRES","REPLACEMENT PREPARATION","PRÉPARATION DE REMPLACEMENT","",""
"9330","08-01-29","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DRUG SUBSTANCE VENDOR; CHANGE IN MANUFACTURING SITE OF DRUG PRODUCT; REPLACEMENT OF STERILITY TESTING WITH PRODUCT PARAMETRIC RELEASE","NOUVEAU FOURNISSEUR DE LA SUBSTANCE MÉDICAMENTEUSE; MODIFICATION DU SITE DE FABRICATION DU MÉDICAMENT; ÉLIMINATION DES ÉPREUVES DE STÉRIITÉ PAR UN PROCÉDÉ DE LIBÉRATION EN FONCTION DE PARAMÈTRES","REPLACEMENT PREPARATION","PRÉPARATION DE REMPLACEMENT","",""
"9331","08-01-30","BEXCO PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL ROUTE OF ADMINISTRATION: INTRAVENOUS","VOIE D'ADMINISTRATION ADDITIONNELLE: INTRAVEINEUSE","ANTIARTHRITIC","ANTIARTHRITIQUE","",""
"9332","08-01-30","WYETH ANIMAL HEALTH DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9333","08-01-30","WYETH ANIMAL HEALTH DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9334","08-01-30","WYETH ANIMAL HEALTH DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9335","08-01-30","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ACE INHIBITOR","INHIBITEUR DE L'ECA","",""
"9336","08-01-30","NOVARTIS ANIMAL HEALTH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION; CHANGES IN MANUFACTURING PROCESS; NEW PACKAGING","CHANGEMENT DE FORMULATION; MODIFICATIONS DE LA MÉTHODE DE FABRICATION; NOUVEL EMBALLAGE","ACE INHIBITOR","INHIBITEUR DE L'ECA","",""
"9337","08-01-30","NOVARTIS ANIMAL HEALTH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN FORMULATION; CHANGES IN MANUFACTURING PROCESS; NEW PACKAGING","CHANGEMENT DE FORMULATION; MODIFICATIONS DE LA MÉTHODE DE FABRICATION; NOUVEL EMBALLAGE","ACE INHIBITOR","INHIBITEUR DE L'ECA","",""
"9338","08-01-30","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9339","08-01-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAMPTOSAR","PFIZER","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9340","08-01-30","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE (TROUBLE D'ANXIÉTÉ SOCIALE), TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"9341","08-01-30","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BLENOXANE","BRISTOL LABORATORIES OF CANADA","CANADA","CANADA","1","","","ANTINEOPLASTIC, ANTIBIOTIC","ANTINÉOPLASIQUE, ANTIBIOTIQUE","",""
"9342","08-01-30","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IFEX","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9343","08-01-30","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9344","08-01-30","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLORANE","ZENECA PHARMA INC.","CANADA","CANADA","1","","","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"9345","08-01-30","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CALCIJEX","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","VITAMIN D3 METABOLITE","MÉTABOLITE DE LA VITAMINE D3","",""
"9346","08-01-30","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","UROMITEXAN","BRISTOL-MYERS SQUIBB CANADA","CANADA","CANADA","1","","","UROPROTECTOR","UROPROTECTEUR","",""
"9347","08-01-30","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","PREMEDICANT, SEDATIVE, ANESTHETIC AGENT","PRÉMÉDICATION, SÉDATIF, ANESTHÉSIQUE","",""
"9348","08-01-30","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANCEF","SMITHKLINE BEECHAM","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9349","08-01-31","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"9350","08-02-04","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"9351","08-02-04","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE INTRAVENOUS","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"9352","08-02-04","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"9353","08-02-04","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADENOCARD","FUJISAWA CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"9354","08-02-04","HUVEPHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"9355","08-02-05","UCB INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE ACTIONS AND CLINICAL PHARMACOLOGY SECTION OF THE PRODUCT MONOGRAPH","RÉVISIONS DE LA SECTION MODE D'ACTION ET PHARMACOLOGIE CLINIQUE DE LA MONOGRAPHIE","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"9356","08-02-06","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING PROCESS","MODIFICATION DE LA MÉTHODE DE FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9357","08-02-08","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC.","CANADA","CANADA","1","","","RELATIVELY SELECTIVE ALPHA2-ADRENOCEPTOR AGONIST, ELEVATED INTRAOCULAR PRESSURE THERAPY","AGONISTE ALPHA2-ADRÉNOCEPTEUR RELATIVEMENT SÉLECTIF, THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"9358","08-02-08","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"9359","08-02-11","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN INJECTION","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9360","08-02-11","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID IV","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","",""
"9361","08-02-11","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9362","08-02-11","ABRAXIS ONCOLOGY A DIVISION OF PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9363","08-02-12","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERSANTINE","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","CORONARY VASODILATOR","VASODILATATEUR CORONARIEN","",""
"9364","08-02-12","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ANEXATE INJECTION","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","BENZODIAZEPINE ANTAGONIST","ANTAGONISTE DES BENZODIAZÉPINES","",""
"9365","08-02-12","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VEPESID","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9366","08-02-12","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","THYROID HORMONE","HORMONE THYROÏDIENNE","",""
"9367","08-02-12","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TORADOL IM","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","ANALGÉSIQUE AINS","",""
"9368","08-02-12","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPATHOMIMETIC","SYMPATHOMIMÉTIQUE","",""
"9369","08-02-12","BIOVAIL PHARMACEUTICALS CANADA DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES","NOUVELLE INDICATION : PRÉVENTION D'ÉPISODES DÉPRESSIVES RELIÉE AUX SAISONS","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9370","08-02-12","SEPTODONT INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MARCAINE 0.5% AND EPINEPHRINE 1:200,000 LIQ","KODAK","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANAESTHETIC","ANESTHÉSIQUE","",""
"9371","08-02-12","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9372","08-02-12","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9373","08-02-13","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF CHRONIC HEART FAILURE","NOUVELLE INDICATION : TRAITEMENT DE L'INSUFFISANCE CARDIAQUE CHRONIQUE","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"9374","08-02-14","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9375","08-02-15","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","","","",""
"9376","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9377","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"9378","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZINACEF","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9379","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZINACEF","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9380","08-02-14","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE PAIN IN ADULTS","NOUVELLE INDICATION : SOULAGEMENT DE LA DOULEUR D'INTENSITÉ MODÉRÉE OU GRAVE CHEZ L'ADULTE","CENTRALLY ACTING ANALGESIC","ANALGÉSIQUE À ACTION CENTRALE","",""
"9381","08-02-14","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"9382","08-02-15","SBL VACCIN AB","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9383","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHIN","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9384","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT MULTI-TRACES","",""
"9385","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","MULTI-TRACE ELEMENT","ÉLÉMENT MULTI-TRACES","",""
"9386","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TRACE ELEMENT","ÉLÉMENT TRACE","",""
"9387","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORCURON","ORGANON CANADA INC.","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEURO-MUSCULAIRE NON DÉPOLARISANT","",""
"9388","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR","SANOFI WINTHROP INC.","CANADA","CANADA","1","","","INOTROPE / VASODILATOR","INOTROPE / VASODILATATEUR","",""
"9389","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEVELBINE","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9390","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOVANTRONE","WYETH CANADA","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9391","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9392","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEBCIN","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9393","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9394","08-02-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9395","08-02-18","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-PARKINSONIAN DOPAMINERGIC AGENT","AGENT DOPAMINERGIQUE ANTI-PARKINSONIEN","",""
"9396","08-02-15","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATES TO THE PRODUCT MONOGRAPH AND MIGRATION TO NEW FORMAT","MISES À JOUR DES RENSEIGNEMENTS SUR L'INNOCUITÉ DANS LA MONOGRAPHIE DE PRODUIT ET NOUVEAU FORMAT DE PRÉSENTATION DE LA MONOGRAPHIE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9397","08-02-18","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISED PRODUCT MONOGRAPH: DOSAGE AND ADMINISTRATION, ACTION AND CLINICAL PHARMACOLOGY AND LABELLING","MISE À JOUR DE LA MONOGRAPHIE : RÉVISION AUX SECTION DE POSOLOGIE ET ADMINISTRATION, DE PHARMACOLOGIE CLINIQUE ET DE L'ÉTIQUETAGE","COMBINATION ANTIPLATELET AGENT","INHIBITEUR DE L'ADHÉSION ET DE L'AGGRÉGATION PLAQUETTAIRE","",""
"9398","08-02-19","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE TO PRODUCT MONOGRAPH","CHANGEMENT À LA MONOGRAPHIE DE PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9399","08-02-19","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FAMVIR","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"9400","08-02-18","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE REGIMEN FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS","POSOLOGIE ADDITIONNELLE POUR LE TRAITEMENT DES INFECTIONS COMPLIQUÉES DES VOIES URINAIRES ET PYÉLONÉPHRITE AIGUE","ANTI-BACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9401","08-02-22","SYNDEL LABORATORIES LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","","","IODOPHOR DISINFECTANT","DÉSINFECTANT D'IODOPHORE","",""
"9402","08-02-22","SERVIER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: REDUCTION OF CARDIOVASCULAR RISK IN PATIENTS WITH HYPERTENSION OR POST-MYOCARDIAL INFARCTION AND STABLE CORONARY DISEASE","NOUVELLE INDICATION : DIMINUTION DE RISQUES D'ÉVÉNEMENTS CARDIO-VASCULAIRES CHEZ DES PATIENTS SOIT HYPERTENSIFS OU SOIT POST-INFARCTUS DU MYOCARDE ET CORONOPATHIE ISCHÉMIQUE STATIONNAIRE","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9403","08-02-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC XE 0.5%","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE LA PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"9404","08-02-22","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"9405","08-02-25","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN","GEIGY (CANADA) INC.","CANADA","CANADA","1","","","ANTI-INFLAMMATORY - ANALGESIC","ANTI-INFLAMMATOIRE - ANALGÉSIQUE","",""
"9406","08-02-25","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANTIOBSESSIONAL / ANTIBULIMIC","ANTIDÉPRESSEUR / ANTIOBSESSIONNEL / ANTIBOULIMIQUE","",""
"9407","08-02-27","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9408","08-02-28","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANTI-BACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"9409","08-02-29","FERRING INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-BACTERIAL","ANTIBACTÉRIEN","",""
"9410","08-02-29","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR, PLATELET AGGREGATION INHIBITOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE, INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"9411","08-02-29","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED PRODUCT MONOGRAPH","MONOGRAPHIE DU PRODUIT RÉVISÉE","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"9412","08-03-03","BAYER INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, ACTION AND CLINICAL PHARMACOLOGY SECTIONS OF THE PRODUCT MONOGRAPH","MODIFICATIONS APPORTÉES AUX SECTIONS SUIVANTES DE LA MONOGRAPHIE DU PRODUIT : MISES EN GARDE ET PRÉCAUTIONS, EFFETS INDÉSIRABLES, POSOLOGIE ET ADMINISTRATION, MODE D'ACTION ET PHARMACOLOGIE CLINIQUE","MULTIKINASE INHIBITOR - ANTINEOPLASTIC AGENT","INHIBITEUR DE LA MULTIKINASE - AGENT ANTINÉOPLASIQUE","",""
"9413","08-03-03","MERIAL CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","UPDATED MANUFACTURING PROCESS","MISE À JOUR DE LA MÉTHODE DE FABRICATION","ANTIMYCOTIC","ANTIMYCOSIQUE","",""
"9414","08-03-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9415","08-03-07","BIO AGRI MIX LP","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC POUR-ON FOR CATTLE","MERIAL CANADA INC.","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITIQUE","",""
"9416","08-03-06","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9417","08-03-07","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIVIRAL AGENT","ANTIVIRAL","",""
"9418","08-03-11","STRIDES CANADA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","","","ANTIBIOTIC / ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE / INHIBITEUR DE ß-LACTAMASES","",""
"9419","08-03-11","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","","","ANTIBIOTIC / ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE / INHIBITEUR DE ß-LACTAMASES","",""
"9420","08-03-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTO IV","ALTANA PHARMA INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9421","08-03-12","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HEMORRHEOLOGIC","HÉMORRÉOLOGIQUE","",""
"9422","08-03-13","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 100MG/VIAL","NOUVELLE CONCENTRATION : 100MG/VIAL","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9424","08-03-13","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9425","08-03-13","BAUSCH & LOMB INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"9426","08-03-14","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9427","08-03-14","LABORATOIRE RIVA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","SANOFI-AVENTIS CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9428","08-03-19","BIMEDA MTC ANIMAL HEALTH INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","BANAMINE","SCHERING-PLOUGH CANADA INC.","CANADA","CANADA","1","FOR THE CONTROL OF PYREXIA ASSOCIATED WITH BOVINE RESPIRATORY DISEASE, AND THE CONTROL OF PYREXIA AND INFLAMMATION ASSOCIATED WITH ENDOTOXEMIA, IN BEEF CATTLE AND NON-LACTATING DAIRY CATTLE; ALTERNATE SOURCE OF ACTIVE INGREDIENT","POUR LE CONTRÔLE DE LA FIÈVRE ASSOCIÉE AU COMPLEXE RESPIRATOIRE BOVIN, ET LE CONTRÔLE DE LA FIÈVRE ET DE L'INFLAMMATION LORS D'ENDOTOXÉMIE, CHEZ LES BOVINS DE BOUCHERIE ET LES BOVINS LAITIÈRES NON ALLAITANTES; VARIATION D'ORIGINE DE L'INGRÉDIENT ACTIF","NON STEROIDAL ANTI-INFLAMMATORY, ANTIPYRETIC, ANALGESIC","NON STÉROÏDIEN ANTI-INFLAMMATOIRE, ANTIPYRÉTIQUE, ANALGÉSIQUE","",""
"9429","08-03-19","NORBROOK LABORATORIES LTD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","BANAMINE","SCHERING-PLOUGH CANADA INC.","CANADA","CANADA","1","FOR THE CONTROL OF PYREXIA IN BOVINE RESPIRATORY DISEASE, AND THE CONTROL OF PYREXIA AND INFLAMMATION ASSOCIATED WITH ENDOTOXEMIA, IN BEEF CATTLE AND NON-LACTATING DAIRY CATTLE","POUR LE CONTRÔLE DE LA FIÈVRE ASSOCIÉE AU COMPLEXE RESPIRATOIRE BOVIN, ET LE CONTRÔLE DE LA FIÈVRE ET DE L'INFLAMMATION LORS D'ENDOTOXÉMIE, CHEZ LES BOVINS DE BOUCHERIE ET LES BOVINS LAITIÈRES NON ALLAITANTES","ANTI-INFLAMMATORY, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"9430","08-03-19","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9431","08-03-25","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITION OF FEDERATED CO-OPERATIVES LTD. FOR THE MANUFACTURING OF CO-OP BOVATEC PASTURE CATTLE MINERAL","ADDITION DE FEDERATED CO-OPERATIVES LTD. POUR LA FABRICATION DE CO-OP BOVATEC PASTURE MINERAL","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9433","08-03-20","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ENDOTHELIN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"9434","08-03-25","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO THE DOSAGE AND ADMINISTRATION SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISION À LA SECTION DE POSOLOGIE ET ADMINISTRATION ET AUTRES RÉVISIONS DE LA MONOGRAPHIE","CNS STIMULANT","STIMULANT DU SNC","",""
"9435","08-03-25","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH: PRECAUTIONS AND TOXICOLOGY","MISE À JOUR DE LA MONOGRAPHIE : PRÉCAUTIONS ET TOXICOLOGIE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"9436","08-03-27","JANSSEN ORTHO INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR","INHIBITEUR NON-NUCLÉOSIDIQUE DE LA RÉVERSE TRANSCRIPTASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"9437","08-03-27","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V. MINI BAGS","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"9438","08-03-27","BAXTER CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V. MINI BAGS","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"9439","08-03-27","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V. MINI BAGS","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"9440","08-03-27","ACS DOBFAR INFO SA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V. MINI BAGS","BAYER INC.","CANADA","CANADA","1","","","Antibacterial Agent","Agent Antibactérien","",""
"9441","08-03-27","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE CLINICAL TRIALS SECTION OF THE PRODUCT MONOGRAPH AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION SUR LES ESSAIS CLINIQUES ET AUTRES MODIFICATIONS APPORTÉES À LA MONOGRAPHIE DE PRODUIT","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9442","08-03-27","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V. MINI BAGS","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9443","08-03-27","CLARIS LIFESCIENCES LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V. MINI BAGS","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9444","08-03-27","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)","NOUVELLE INDICATION : TRAITEMENT DE L'INFARCTUS DU MYOCARDE AVEC ÉLÉVATION DU SEGMENT ST À LA PHARSE AIGUË","ANTICOAGULANT/ANTITHROMBOTIC","ANTICOAGULANT/ANTITHROMBOTIQUE","",""
"9445","08-03-28","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","µ-OPIOID RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR OPIOÏDE-µ","",""
"9446","08-03-28","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTO I.V.","ALTANA PHARMA INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9447","08-03-28","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTO I.V.","ALTANA PHARMA INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9448","08-03-28","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL M-TAB","JANSSEN-ORTHO INC.","CANADA","CANADA","1","NEW DOSAGE FORM - ORALLY DISINTEGRATING TABLET","NOUVELLE FORME POSOLOGIQUE - COMPRIMÉ À LIBÉRATION RETARD","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9449","08-03-28","PHARMEL INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL M-TAB","JANSSEN-ORTHO INC.","CANADA","CANADA","1","NEW DOSAGE FORM - ORALLY DISINTEGRATING TABLET","NOUVELLE FORME POSOLOGIQUE - COMPRIMÉ À LIBÉRATION RETARD","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9450","08-03-28","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN, ONDANSETRON 8MG TABLETS","GLAXOSMITHKLINE INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"9451","08-03-28","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","PRODUCT MONOGRAPH REVISED","MONOGRAPHIE DU PRODUIT RÉVISÉE","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9452","08-03-28","ELANCO DIVISION OF ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SSRI (SELECTIVE SEROTONIN REUPTAKE INHIBITOR)","ISRS (INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA SÉROTONINE)","",""
"9453","08-03-28","ELANCO DIVISION OF ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SSRI (SELECTIVE SEROTONIN REUPTAKE INHIBITOR)","ISRS (INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA SÉROTONINE)","",""
"9454","08-03-28","ELANCO DIVISION OF ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SSRI (SELECTIVE SEROTONIN REUPTAKE INHIBITOR)","ISRS (INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA SÉROTONINE)","",""
"9455","08-03-28","ELANCO DIVISION OF ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SSRI (SELECTIVE SEROTONIN REUPTAKE INHIBITOR)","ISRS (INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA SÉROTONINE)","",""
"9456","08-03-28","ABBOTT LABORATORIES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANESTHETIC AGENT","AGENT ANESTHÉSIQUE","",""
"9457","08-03-28","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"9458","08-03-31","LUNDBECK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: MAINTENANCE OF EFFICACY IN GENERALIZED ANXIETY DISORDER FOR UP TO 6 MONTHS","NOUVELLE INDICATION : LA MAINTENANCE DE L'EFFICACITÉ JUSQU'À SIX MOIS CHEZ LES PATIENTS AVEC LE DÉSORDRE D'ANXIÉTÉ GÉNÉRALISÉ","ANTIDEPRESSANT / ANXIOLYTIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE","",""
"9459","08-03-31","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ALTERNATE MANUFACTURING AREA","ZONE DE FABRICATION ALTERNATIVE","REPLACEMENT THERAPY FOR IMMUNODEFICIENCIES","TRAITEMENT SUBSTITUTIF DE L'IMMUNODÉFICIENCE","",""
"9460","08-04-01","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"9461","08-03-31","HOFFMANN LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ERYTHROPOIESIS STIMULATING AGENT","AGENT STIMULANT DE L'ÉRYTHROPOÏÈSE","",""
"9462","08-04-02","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION - FOR RELIEF OF SYMPTOMS ASSOCIATED WITH ANKYLOSING SPONDYLITIS","NOUVELLE INDICATION : SOULAGEMENT DES SYMPTÔMES DE LA SPONDYLARTHRITE ANKYLOSANTE","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"9463","08-04-02","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC/ANTIMANIC AGENT","ANTIPSYCHOTIQUE/ANTIMANIAQUE","",""
"9464","08-04-03","AMGEN CANADA INC","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9465","08-04-04","BAYER HEALTHCARE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW 2000 IU PRESENTATION","NOUVELLE PRÉSENTATION DE 2000 UI","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"9466","08-04-03","SHIRE CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASOPRESSOR","VASOPRESSEUR","",""
"9467","08-04-03","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9468","08-04-03","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","BLOVAIL PHARMACEUTICALS","CANADA","CANADA","1","","","BETA-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"9469","08-04-03","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO IV MINI BAGS","BAYER INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9470","08-04-03","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9471","08-04-03","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","NEW SOURCE OF DRUG SUBSTANCE / NEW MANUFACTURING PROCESS AND INGREDIENTS","NOUVELLE SOURCE DE SUBSTANCES MÉDICAMENTEUSES / NOUVEAUX INGRÉDIENTS ET NOUVEAU PROCESSUS DE FABRICATION","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9473","08-04-04","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHIN","HOFFMAN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9474","08-04-08","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9475","08-04-08","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITION OF NEW-LIFE MILLS LIMITED FOR THE MANUFACTURING OF BOVATEC FC PASTURE MINERAL","ADDITION DE NEW-LIFE MILLS LIMITED POUR LA FABRICATION DE BOVATEC FC PASTURE MINERAL","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9476","08-04-09","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"9477","08-04-09","BRISTOL MYERS SQUIBB AND GILEAD SCIENCES LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9478","08-04-09","NOVARTIS CONSUMER HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"9479","08-04-09","MINRAD INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEVORANE AF","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"9480","08-04-10","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDROCAL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9481","08-04-10","NOVARTIS CONSUMER HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","",""
"9482","08-04-10","NOVARTIS CONSUMER HEALTH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","REVISED INNER AND OUTER LABELS","ÉTIQUETTES INTERNES ET EXTERNES RÉVISÉES","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"9483","08-04-10","GENPHARM ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDROCAL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9484","08-04-11","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC., CANADA/ALTANA PHARMA AG","GERMANY","ALLEMAGNE","1","","","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"9485","08-04-11","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAFORAN","HOECHST-ROUSSEL CANADA INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9486","08-04-11","NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES IN MANUFACTURING PROCESS","MODIFICATIONS AUX MÉTHODES DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9487","08-04-15","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS (>18 YEARS OF AGE).","NOUVELLE INDICATION : TRAITEMENT DU TROUBLE DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ (TDAH) CHEZ LES ADULTES (>18 ANS).","CNS STIMULANT","STIMULANT DU SNC","",""
"9488","08-04-15","ORGANON CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE AND NEW PRODUCT MONOGRAPH FORMAT.","MISE À JOUR DE L'INNOCUITÉ ET NOUVEAU FORMAT DE LA MONOGRAPHIE DU PRODUIT.","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9489","08-04-15","ORGANON CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE AND NEW PRODUCT MONOGRAPH FORMAT.","MISE À JOUR DE L'INNOCUITÉ ET NOUVEAU FORMAT DE LA MONOGRAPHIE DU PRODUIT.","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9490","08-04-17","EUSA PHARMA SAS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTILEUKEMIC AGENT","AGENT ANTILEUCÉMIQUE","",""
"9491","08-04-17","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PENLAC","DERMIK LABORATORIES CANADA INC.","CANADA","CANADA","1","","","TOPICAL ANTIFUNGAL AGENT","ANTIFONGIQUE TOPIQUE","",""
"9492","08-04-17","ALCON CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"9493","08-04-18","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ESTROGENIC HORMONES / PROGESTIN","HORMONES OESTROGÈNES / PROGESTATIF","",""
"9494","08-04-18","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFAZOLIN INJECTION USP","NOVOPHARM INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9495","08-04-18","ORYX PHARMACEUTICALS INC A SUBSIDIARY OF FILIALE DARROW PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW FORMULATION FOR 1000 MG TABLET AND INTERCHANGEABILITY WITH 2 X 500 MG TABLETS. CHANGE IN TRADE NAME.","NOUVELLE FORMULATION DES COMPRIMÉS DE 1000 MG MAINTENANT INTERCHANGEABLE AVEC DEUX COMPRIMÉS DE 500 MG. LE NOM DE LA MARQUE A ÉTÉ CHANGÉ.","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"9496","08-04-18","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACCUTANE","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","NODULAR/INFLAMMATORY AND CONGLOBATE ACNE THERAPY","TRAITEMENT DE L'ACNÉ NODULAIRE/INFLAMMATOIRE ET DE L'ACNÉ CONGLOBATA","",""
"9497","08-04-18","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9498","08-04-18","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","BIOVAIL PHARMACEUTICALS CANADA","CANADA","CANADA","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"9499","08-04-18","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","BIOVAIL PHARMACEUTICALS CANADA","CANADA","CANADA","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"9500","08-04-21","S C JOHNSON AND SON LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","DISINFECTANT","DÉSINFECTANT","",""
"9501","08-04-22","ODAN LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9502","08-04-22","ODAN LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN (ONDANSETRON 8MG TABLETS)","GLAXOSMITHKLINE INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"9503","08-04-23","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY, NEW MANUFACTURING PROCESS, NEW 2000 IU PRESENTATION, NAME CHANGE FROM REFACTO TO XYNTHA","NOUVEL EMPLACEMENT DE FABRICATION, NOUVELLE MÉTHODE DE FABRICATION, NOUVELLE PRÉSENTATION DE 2000 UI, CHANGEMENT DU NOM DE REFACTO À XYNTHA","ANTIHEMOPHILIC FACTOR (RECOMBINANT)","FACTEUR ANTIHÉMOPHILIQUE (RECOMBINANT)","",""
"9504","08-03-20","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGES TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTICOAGULANT","ANTICOAGULANT","",""
"9505","08-04-24","HUVEPHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"9506","08-04-24","HUVEPHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"9507","08-04-24","HUVEPHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"9508","08-04-23","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","IMDUR","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"9509","08-04-23","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","IMDUR","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"9510","08-04-23","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"9511","08-04-23","PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CARDIOTONIC GLYCOSIDE","GLUCOSIDE CARDIOTONIQUE","",""
"9512","08-04-23","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9513","08-04-23","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9514","08-04-23","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH: REMOVAL OF REFERENCES TO ORAL FORMULATION","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT : SUPPRESSION DES RÉFÉRENCES À LA PRÉPARATION ORALE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9515","08-04-24","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO SEEK MARKET APPROVAL FOR A PRODUCT LINE EXTENSION FOR TWO NEW STRENGTHS","POUR OBTENIR L'AUTORISATION DE MISE EN MARCHÉ DE DEUX NOUVELLES CONCENTRATIONS S'AJOUTANT À UNE GAMME DE PRODUITS","ANGIOTENSIN II AT1 RECEPTOR BLOCKER AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II - DIURÉTIQUE","",""
"9517","08-04-25","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIANE 35","BERLEX CANADA INC.","CANADA","CANADA","1","","","ACNE THERAPY","TRAITEMENT DE L'ACNÉ","",""
"9518","08-04-28","SIGMA TAU PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE DOSAGE AND AMINISTRATION SECTION AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA SECTION POSOLOGIE ET ADMINISTRATION ET AUTRES MODIFICATIONS APPORTÉES À LA MONOGRAPHIE DE PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9520","08-04-28","AXXESS PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9521","08-04-28","ABRAXIS BIOSCIENCE CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9522","08-04-28","RATIOPHARM INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) / ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS) / ANALGÉSIQUE, ANTIPYRÉTIQUE","",""
"9523","08-04-29","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST / SYMPATHOMIMETIC AMINE","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE / AMINE SYMPATHOMIMÉTIQUE","",""
"9524","08-04-29","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9525","08-04-29","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMANN-LA ROCHE LTD.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9526","08-04-29","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANTIRHEUMATIC / IMMUNOMODULATOR AGENT","ANTIRHUMATISMAL / IMMUNOMODULATEUR","",""
"9527","08-04-29","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC.","CANADA","CANADA","1","","","ANTIRHEUMATIC / IMMUNOMODULATOR AGENT","ANTIRHUMATISMAL / IMMUNOMODULATEUR","",""
"9528","08-04-30","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTI-NEOVASCULARISATION AGENT","AGENT ANTI-NÉOVASCULARISATION","",""
"9529","08-04-30","EUSA PHARMA SAS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","CYTOSTATIC","CYTOSTATIQUE","",""
"9530","08-05-01","BIOGEN IDEC CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MODIFICATIONS TO THE MANUFACTURING PROCESS","MODIFICATIONS À LA MÉTHODE DE FABRICATION","IMMUNOMODULATING AGENT","AGENT IMMUNOMODULATEUR","",""
"9531","08-05-01","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALERTEC","SHIRE BIOCHEM INC.","CANADA","CANADA","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"9532","08-05-01","PFIZER CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) OF CLEAR CELL HISTOLOGY.","NOUVELLE INDICATION : POUR LE TRAITEMENT DE L'ADÉNOCARCINOME RÉNAL MÉTASTATIQUE (ARM) À CELLULES CLAIRES.","TYROSINE KINASE INHIBITOR, ANTI-TUMOUR AGENT","INHIBITEUR DE LA TYROSINE KINASE, ANTINÉOPLASIQUE","",""
"9533","08-05-01","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN-150","PFIZER CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9534","08-05-01","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9535","08-05-01","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH TO REFLECT THE DISCONTINUATION OF CAPSULES","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT À LA SUITE DU RETRAIT DE CAPSULES","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"9536","08-05-01","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DU PRODUIT","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"9537","08-05-01","SQUIRE PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTISPASTIC AGENT","ANTISPASMODIQUE","",""
"9538","08-05-01","PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY STEROID","STÉROÏDE ANTI-INFLAMMATOIRE TOPIQUE","",""
"9539","08-05-02","GENPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDRONEL","PROCTOR AND GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR, ANTI-PAGETIC AGENT, ANTI-HYPERCALCEMIC AGENT","RÉGULATEUR DU MÉTABOLISME OSSEUX, AGENT ANTIPAGÉTIQUE, AGENT ANTIHYPERCALCÉMIQUE","",""
"9540","08-05-07","GENPHARM ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9541","08-05-08","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MANUFACTURING CHANGES","CHANGEMENT DANS LA MÉTHODE DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9542","08-05-09","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANXIOLYTIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE","",""
"9543","08-04-25","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM: NEW PRESENTATION FOR BREVIBLOC INJECTION 10MG/ML IN A 250 ML PREMIXED BAG (2500MG/250ML)","NOUVELLE FORME POSOLOGIQUE : BREVIBLOC, SOLUTION POUR PERFUSION, 10MG/ML, PRÉALABLEMENT MIS EN SOLUTION DANS UNE POCHE DE 250 ML (2 500 MG/250 ML)","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"9544","08-05-09","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9545","08-05-13","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9546","08-05-14","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTIDIABETIC AGENT / INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE / AGENT INSULINOSENSIBILISATEUR","",""
"9547","08-05-14","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","DRUG PRODUCT MANUFACTURING CHANGE","CHANGEMENT À LA FABRICATION DU PRODUIT MÉDICAMENTEUX","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"9548","08-05-14","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","DRUG PRODUCT MANUFACTURING CHANGE","CHANGEMENT À LA FABRICATION DU PRODUIT MÉDICAMENTEUX","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"9549","08-05-14","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"9550","08-05-15","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE","CANADA","CANADA","1","","","ANTIVIRAL","ANTIVIRAL","",""
"9551","08-05-15","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DU PRODUIT","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"9552","08-05-15","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH, NIACIN DOSE CAP REMOVAL","MISE À JOUR DE LA SECTION DE POSOLOGIE ET ADMINISTRATION DE LA MONOGRAPHIE DU PRODUIT : DÉPLAFONNEMENT DE LA DOSE DE NIACIN","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"9553","08-05-16","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANXIOLYTIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE","",""
"9555","08-05-21","SQUIRE PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF ALTERNATIVE DOSING REGIMEN","AJOUT D'UN AUTRE SCHÉMA POSOLOGIQUE","TOPICAL ANTI-INFLAMMATORY, ANALGESIC","ANTI-INFLAMMATOIRE, ANALGÉSIQUE","",""
"9556","08-05-21","ASTELLAS PHARMA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIFUNGAL","ANTIFONGIQUE","",""
"9557","08-05-21","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"9558","08-05-21","PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID / NSAID COMBINATION ANALGESIC","OPIOÏDES / ANALGÉSIQUE AINS","",""
"9559","08-05-20","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE FOR DRUG PRODUCT","NOUVEAU SITE DE FABRICATION POUR LE PRODUIT MÉDICAMENTEUX","BIOLOGIC RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"9560","08-05-22","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"9561","08-05-22","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V.","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9562","08-05-22","PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PREVENTION OF SEASONAL ALLERGIC RHINITIS","PROPHYLAXIE DE LA RHINITE SAISONNIÈRE - ANTIALLERGIQUE","",""
"9563","08-05-23","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH SECTIONS: CONTRAINDICATIONS; WARNINGS AND PRECAUTIONS; ADVERSE REACTIONS; AND DOSAGE AND ADMINISTRATION","MISE À JOUR DES SECTIONS SUIVANTES DE LA MONOGRAPHIE DE PRODUIT : CONTRE-INDICATIONS, MISES EN GARDE, PRÉCAUTIONS, EFFETS INDÉSIRABLES, POSOLOGIE ET ADMINISTRATION","PROGESTOGEN","PROGESTATIF","",""
"9564","08-05-23","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"9565","08-05-27","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","UCB PHARMA INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"9566","08-05-28","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH TO INCLUDE UPDATED ANALYSIS RESULTS OF 49 MONTHS FOR EXTENDED ADJUVANT THERAPY.","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT EN FONCTION DE LA DERNIÈRE ANALYSE DES RÉSULTATS D'UNE PÉRIODE DE 49 MOIS D'UNE ÉTUDE SUR LE TRAITEMENT ADJUVANT PROLONGÉ.","NON-STEROIDAL AROMATASE INHIBITOR / INHIBITOR OF ESTROGEN BIOSYNTHESIS / ANTITUMOR AGENT","INHIBITEUR DE L'AROMATASE NON-STÉROÏDIEN / INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES / ANTINÉOPLASIQUE","",""
"9567","08-05-29","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 32 MG TABLET.","NOUVELLE CONCENTRATION : COMPRIMÉ DE 32 MG.","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"9568","08-05-29","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: SEROQUEL XR IS INDICATED AS MONOTHERAPY FOR THE ACUTE MANAGEMENT OF MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER.","NOUVELLE INDICATION : SEROQUEL XR EST INDIQUÉ COMME MONOTHÉRAPIE POUR LA PRISE EN CHARGE DE LA PHASE AIGÜE ASSOCIÉE À UNE AFFECTION BIPOLAIRE.","PSYCHOTROPIC AGENT","PSYCHOTROPE","",""
"9569","08-05-30","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V. MINIBAGS","BAYER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9570","08-05-30","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9571","08-06-02","WYETH CONSUMER HEALTHCARE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","DECLARATION OF MEDICINAL INGREDIENT.","DÉCLARATION D'INGRÉDIENT MÉDICINAL.","ANALGESIC / ANTIPYRETIC AND NASAL DECONGESTANT","ANALGÉSIQUE / ANTIPYRÉTIQUE ET DÉCONGESTIONNANT NASAL","",""
"9572","08-06-02","WYETH CONSUMER HEALTHCARE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","DECLARATION OF MEDICINAL INGREDIENT.","DÉCLARATION D'INGRÉDIENT MÉDICINAL.","ANTIPYRETIC / ANALGESIC","ANTIPYRÉTIQUE / ANALGÉSIQUE","",""
"9573","08-06-02","WYETH CONSUMER HEALTHCARE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","DECLARATION OF MEDICINAL INGREDIENT.","DÉCLARATION D'INGRÉDIENT MÉDICINAL.","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"9574","08-06-02","ACTAVIS GROUP PTC EHF","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","KERATINIZATION DISORDER THERAPY","TRAITEMENT DES TROUBLES DE LA KÉRATINISATION","",""
"9575","08-06-02","OTSUKA PHARMACEUTICAL CO. LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9576","08-06-02","ACTAVIS GROUP PTC EHF","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"9577","08-06-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9578","08-06-03","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRILEPTAL","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"9579","08-06-03","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCAL ANALGESIC","ANALGÉSIQUE LOCAL","",""
"9580","08-06-03","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC., CANADA / ALTANA PHARMA AG, GERMANY","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9581","08-06-03","GENPHARM ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9582","08-06-03","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9583","08-06-03","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9584","08-06-04","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON MR","SERVIER CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM.","NOUVELLE FORME POSOLOGIQUE.","HYPOGLYCEMIC SULFONYLUREA / ORAL ANTIDIABETIC AGENT","HYPOGLYCÉMIANT SULFONYLURÉE / ANTIDIABÉTIQUE ORAL","",""
"9585","08-06-04","VALEANT CANADA LIMITÉE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 0.25 MG.","NOUVELLE CONCENTRATION : 0.25 MG.","ANTIEMETIC AGENT","ANTIÉMÉTIQUE","",""
"9586","08-06-04","SERVIER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","HARMONIZATION OF THE PRODUCT MONOGRAPH FROM THAT OF PERINDOPRIL ARGININE.","RÉVISION DE LA MONOGRAPHIE POUR CONCORDANCE AVEC CELLE DU PERINDOPRIL ARGININE.","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9587","08-06-04","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V. MINIBAGS 2MG/ML","BAXTER INC.","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9588","08-06-03","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC., CANADA / ALTANA PHARMA AG, GERMANY","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9589","08-06-05","QLT USA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DE PRODUIT","ANTI-ACNE THERAPY","TRAITEMENT ANTIACNÉ","",""
"9590","08-06-06","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","TO REGISTER PARAMETRIC PROCESS RELEASE (PPR) AT AN ALTERNATE DRUG PRODUCT MANUFACTURING FACILITY","IDENTIFIER UN PROCÉDÉ DE LIBÉRATION EN FONCTION DE PARAMÈTRES DANS UN SITE ALTERNATIF DE FABRICATION DU MÉDICAMENT","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"9591","08-06-06","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9592","08-06-09","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","REVISED INDICATION FOR GROWTH HORMONE DEFICIENCY IN ADULT PATIENTS. NEW INDICATION: HUMATROPE IS INDICATED FOR THE TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX-CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED.","RÉVISION DE L'INDICATION DU SUJET ADULTE AYANT UN DÉFICIT EN HORMONE DE CROISSANCE. NOUVELLE INDICATION : HUMATROPE EST INDIQUÉ DANS LE TRAITEMENT DES PATIENTS AYANT UN RETARD DE CROISSANCE ASSOCIÉ À UN DÉFICIT DU GÈNE SHOX (SHORT STATURE HOMEOBOX-CONTAINING GENE) ET DONT LES ÉPIPHYSES NE SONT PAS SOUDÉES.","GROWTH STIMULANT","STIMULANT DE CROISSANCE","",""
"9593","08-06-06","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ALLERGY AGENT","AGENT ANTIALLERGIQUE","",""
"9594","08-06-06","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H1 ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"9595","08-06-06","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-INFLAMMATORY ANALGESIC AGENT","ANTI-INFLAMMATOIRE / ANALGÉSIQUE","",""
"9596","08-06-06","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FULFILMENT OF CONFIRMATORY COMMITMENTS","SATISFACTION DES ENGAGEMENTS RELATIFS À LA CONFIRMATION","AROMATASE INACTIVATOR / ANTI-TUMOUR AGENT","INACTIVATEUR DE L'AROMATASE / ANTINÉOPLASIQUE","",""
"9597","08-06-09","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RELAPSED OR WERE REFRACTORY TO AT LEAST ONE PRIOR THERAPY","NOUVELLE INDICATION : POUR LE TRAITEMENT DE PATIENTS ATTEINTS D'UN LYMPHOME CENTROCYTIQUE RÉCIDIF OU RÉFRACTAIRE À AU MOINS UN TRAITEMENT ANTÉRIEUR.","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9598","08-06-10","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9599","08-06-10","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9600","08-06-10","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9601","08-06-10","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE MANUFACTURING FACILITY","MODIFICATION À L'EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9602","08-06-10","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PURIFICATION FACILITY","NOUVELLE INSTALLATION DE PURIFICATION","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"9603","08-06-10","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW TABLET FORMULATION FOR PEDIATRIC USE","NOUVELLE PRÉPARATION DU COMPRIMÉ POUR USAGE PÉDIATRIQUE","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"9604","08-06-10","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"9605","08-06-10","VALEO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSTIN VR STERILE SOLUTION","PFIZER CANADA INC.","CANADA","CANADA","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"9606","08-06-10","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"9607","08-06-10","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE L'INNOCUITÉ DANS LA MONOGRAPHIE DE PRODUIT","CONTRAST ENHANCING IMAGING AGENT","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE","",""
"9608","08-06-12","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9609","08-06-12","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9610","08-06-12","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON STEROIDAL ANTI-INFLAMMATORY AGENT","NON STÉROÏDIEN ANTI-INFLAMMATOIRE","",""
"9611","08-06-12","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-RHEUMATIC / ANTIMALARIAL","ANTIRHUMATISMAL / ANTIPALUDÉEN","",""
"9612","08-06-12","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9613","08-06-11","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIACALCIN NS","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9614","08-06-11","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURICEF","BRISTOL-MYERS SQUIBB INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9615","08-06-11","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT PHARMA INC.","CANADA","CANADA","1","","","ANTICOAGULANT","ANTICOAGULANT","",""
"9616","08-06-11","RATIOPHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9617","08-06-11","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","AGENT ANTIPARKINSONIEN","",""
"9618","08-06-13","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIEPILEPTIC / MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE / PROPHYLAXIE DE LA MIGRAINE","",""
"9619","08-06-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","IMDUR","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"9620","08-06-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","CIBA GEIGY CANADA LTD","CANADA","CANADA","1","","","ANTI-INFLAMMATORY / ANALGESIC","ANTI-INFLAMMATOIRE / ANALGÉSIQUE","",""
"9621","08-06-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"9622","08-06-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFTIN","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9623","08-06-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARBOLITH","ICN CANADA LTD.","CANADA","CANADA","1","","","ANTIMANIC AGENT","ANTIMANIAQUE","",""
"9624","08-06-13","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATIONS: TREATMENT OF PERENNIAL ALLERGIC RHINITIS AND ITS ASSOCIATED SYMPTOMS IN PATIENTS 12 YEARS OF AGE AND OLDER.  TREATMENT OF SEASONAL ALLERGIC RHINITIS IN CHILDREN FROM 2 TO 11 YEARS OF AGE.","NOUVELLES INDICATIONS : TRAITEMENT DES RHINITES ALLERGIQUES NON-SAISONNIÈRES ET LEURS SYMPTOMES CHEZ LES ENFANTS DE 12 ANS ET PLUS.  TRAITEMENT DES RHINITES ALLERGIQUES SAISONNIÈRES CHEZ LES ENFANTS DE 2 À 11 ANS.","CORTICOSTEROID","CORTISCOSTÉROÏDE","",""
"9625","08-06-13","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9626","08-06-16","CARESTREAM HEALTH CANADA COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MARCAINE 0.5% AND EPINEPHRINE 1:200,000 LIQ","KODAK","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LOCAL ANAESTHETIC FOR DENTAL USE","ANESTHÉSIQUE LOCAL","",""
"9627","08-06-16","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC.","CANADA","CANADA","1","","","DIURETIC / ANTIHYPERTENSIVE AGENT","DIURÉTIQUE / ANTIHYPERTENSEUR","",""
"9628","08-06-16","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","",""
"9629","08-06-18","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: 140 MG AND 180 MG","NOUVELLES CONCENTRATIONS : 140 MG ET 180 MG","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9630","08-06-18","JANSSEN ORTHO INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"9631","08-06-18","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAMPTOSAR IV SOLUTION","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9632","08-06-18","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DESTINÉ AU TRAITEMENT DES MALADIES INTESTINALES","",""
"9633","08-06-19","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9634","08-06-18","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"9635","08-06-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"9636","08-06-20","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH, INCLUDING WARNINGS AND PRECAUTIONS AND OVERDOSAGE SECTIONS","MISE À JOUR DE LA MONOGRAPHIE DONT LES SECTIONS DES MISES EN GARDE ET PRÉCAUTIONS, ET DU SURDOSAGE","ANTIDEPRESSANT / ANXIOLYTIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE","",""
"9637","08-06-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","","","ANTIBIOTIC / BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE / INHIBITEUR DE BÊTA-LACTAMASES","",""
"9638","08-06-26","FERRING INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF INDICATION: FOR THE SHORT-TERM MANAGEMENT OF NOCTURNAL ENURESIS IN PATIENTS 5 YEARS OF AGE AND OLDER WHO HAVE NORMAL ABILITY TO CONCENTRATE URINE","SUPPRESSION DE L'INDICATION SUIVANTE: POUR LE TRAITEMENT À COURT TERME DE L'ÉNURÉSIE NOCTURNE CHEZ LES PATIENTS ÂGÉS DE 5 ANS ET PLUS AYANT UNE CAPACITÉ NORMALE DE CONCENTRER L'URINE","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"9639","08-06-25","BAXTER HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW 2000 IU PRESENTATION","NOUVELLE PRÉSENTATION DE 2000 UI","COAGULANT","COAGULANT","",""
"9640","08-06-26","JANSSEN ORTHO INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9641","08-06-26","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMINYL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"9642","08-06-26","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","SUPER STRENGTH MOTRIN IB","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) / ANALGESIC / ANTIPYRETIC AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS) / ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"9643","08-06-26","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SUPER STRENGTH MOTRIN IB","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) / ANALGESIC / ANTIPYRETIC AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS) / ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"9644","08-06-26","RATIOPHARM INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC.","CANADA","CANADA","1","NEW STRENGTH: 12mcg/h","NOUVELLE CONCENTRATION : 12mcg/h","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"9645","08-06-30","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING PROCESS","NOUVEAU PROCESSUS DE FABRICATION","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"9646","08-07-02","GENPHARM ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","SANOFI-AVENTIS CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9647","08-07-02","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE NEW PRODUCT MONOGRAPH FORMAT","MISE À JOUR DU NOUVEAU FORMAT DE LA MONOGRAPHIE DU PRODUIT","VITAMIN D3 METABOLITE","MÉTABOLITE DE LA VITAMINE D3","",""
"9648","08-07-02","RHOXALPHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9649","08-07-03","NYCOMED CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9650","08-07-03","NYCOMED GMBH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9651","08-07-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9652","08-07-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"9653","08-07-02","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON RD","ORGANON CANADA LTD","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9654","08-07-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9655","08-07-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","SEARLE CANADA INC.","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"9656","08-07-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC.","CANADA","CANADA","1","","","HYPNOTIC AGENT","HYPNOTIQUE - SÉDATIF","",""
"9657","08-07-02","BIOVAIL PHARMACEUTICALS CANADA DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO THE INDICATION FROM PAIN OF MODERATE SEVERITY TO MODERATE TO MODERATELY SEVERE PAIN","RÉVISION DE L'INDICATION : DE DOULEUR D'INTENSITÉ MODÉRÉE À DOULEUR MODÉRÉE À INTENSE","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"9658","08-07-02","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO THE INDICATION FROM PAIN OF MODERATE SEVERITY TO MODERATE TO MODERATELY SEVERE PAIN","RÉVISION DE L'INDICATION : DE DOULEUR D'INTENSITÉ MODÉRÉE À DOULEUR MODÉRÉE À INTENSE","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"9659","08-07-02","LABOPHARM INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO THE INDICATION FROM PAIN OF MODERATE SEVERITY TO MODERATE TO MODERATELY SEVERE PAIN","RÉVISION DE L'INDICATION : DE DOULEUR D'INTENSITÉ MODÉRÉE À DOULEUR MODÉRÉE À INTENSE","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"9660","08-07-07","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9661","08-07-07","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION: FOR THE TREATMENT OF OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY IN MEN AN WOMEN WHO ARE AT INCREASED RISK FOR FRACTURE","NOUVELLE INDICATION: POUR TRAITER L'OSTÉOPOROSE ASSOCIÉE AU TRAITEMENT SYSTÉMIQUE PROLONGÉ PAR GLUCOCORTICOÏDES CHEZ LES HOMMES ET LES FEMMES PRÉSENTANT UN RISQUE ACCRU DE FRACTURES","BONE FORMATION AGENT","AGENT OSTÉOFORMATEUR","",""
"9662","08-07-08","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA ADJUNCTIVE THERAPY IN ACUTE URINARY RETENTION","TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP) - TRAITEMENT ADJUVANT DE LA RÉTENTION URINAIRE AIGUË (RUA)","",""
"9663","08-07-09","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC.","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT CONTRE L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"9664","08-07-08","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9665","08-07-08","EUSA PHARMA SAS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","MANUFACTURING PROCESS AND EQUIPMENT CHANGES","CHANGEMENTS AU PROCESSUS DE FABRICATION ET À L'ÉQUIPEMENT","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"9666","08-07-10","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","AUTHORIZATION OF ANCESTIM DRUG SUBSTANCE VALIDATION LOTS FOR COMMERCIAL USE","AUTORISATION DES LOTS DE VALIDATION DE LA SUBSTANCE MÉDICAMENTEUSE ANCESTIM À DES FINS COMMERCIALES","HEMATOPOIETIC AGENT","AGENT HÉMATOPOIÉTIQUE","",""
"9667","08-07-09","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS, DIVISION OF WARNER LAMBERT CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"9668","08-07-09","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST","ANTIPARKINSONIEN / AGONISTE DOPAMINERGIQUE","",""
"9669","08-07-09","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST","ANTIPARKINSONIEN / AGONISTE DOPAMINERGIQUE","",""
"9670","08-07-09","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA / ALTANA PHARMA INC.","CANADA","CANADA","1","","","H+, K+ -ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+ -ATPASE","",""
"9671","08-07-09","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL SUPRA","LABORATOIRE FOURNIER S.A.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"9672","08-07-09","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA / ALTANA PHARMA INC.","CANADA","CANADA","1","","","H+, K+ -ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+ -ATPASE","",""
"9673","08-07-11","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ORENCIA IS INDICATED FOR REDUCING SIGNS AND SYMPTOMS OF MODERATELY TO SEVERELY ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS/JUVENILE RHEUMATOID ARTHRITIS IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WHO HAVE HAD AN INADEQUATE RESPONSE TO ONE OR MORE DMARDS, SUCH AS METHOTREXATE (MTX). ORENCIA HAS NOT BEEN STUDIED IN CHILDREN LESS THAN 6 YEARS OF AGE.","ORENCIA EST INDIQUÉ POUR ATTÉNUER LES SIGNES ET LES SYMPTÔMES DES FORMES ÉVOLUTIVES, MODÉRÉES OU GRAVES, DE LA POLYARTHRITE IDIOPATHIQUE JUVÉNILE ET DE L'ARTHRITE RHUMATOÏDE JUVÉNILE CHEZ LES ENFANTS DE 6 ANS ET PLUS QUI N'ONT PAS RÉPONDU ADÉQUATEMENT À UN OU À PLUSIEURS AGENTS ANTIRHUMATISMAUX MODIFICATEURS DE LA MALADIE (ARMM), TELS QUE LE MÉTHOTREXATE (MTX). ORENCIA N'A PAS ÉTÉ ÉTUDIÉ CHEZ LES ENFANTS DE MOINS DE 6 ANS.","SELECTIVE CO-STIMULATION MODULATOR","MODULATEUR SÉLECTIF DE LA CO-STIMULATION","",""
"9674","08-07-11","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9675","08-07-11","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT AND PLATELET AGGREGATION INHIBITOR","ANTIHYPERTENSEUR ET INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"9676","08-07-11","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"9677","08-07-11","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CHANGE IN MANUFACTURING PROCESS AND SITE FOR DRUG SUBSTANCE AND PRODUCT WITH BIOEQUIVALENCE STUDY","CHANGEMENT DE PROCÉDÉ ET DE LIEU DE FABRICATION DE LA SUBSTANCE ET DU PRODUIT MÉDICAMENTEUX AVEC ÉTUDE DE BIOÉQUIVALENCE","ANTICONVULSANT","ANTICONVULSIVANT","",""
"9678","08-07-14","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMARYL","AVENTIS PHARMA INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ORAL HYPOGLYCAEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONYLURÉE)","",""
"9679","08-07-15","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN P","ALLERGAN INC.","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE L'HYPERTENSION INTRA-OCULAIRE","",""
"9680","08-07-15","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS DE LA MONOGRAPHIE DU PRODUIT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9681","08-07-16","ELANCO DIVISION OF ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM","INDICATION ADDITIONNELLE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9682","08-07-17","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","TRANSFER OF DRUG SUBSTANCE MANUFACTURING SITE","TRANSFER DU SITE DE FABRICATION DE LA SUBSTANCE MÉDICAMENTEUSE","URICOLYTIC AGENT","AGENT URICOLYTIQUE","",""
"9683","08-07-17","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE PLUS","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9684","08-07-17","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS DIVISION OF WARNER LAMBERT CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"9685","08-07-18","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DU PRODUIT","BRONCHODILATOR AND CORTISOSTEROID FOR ORAL INHALATION","BRONCHODILATATEUR - CORTICOSTÉROÏDE EN INHALATION","",""
"9686","08-07-22","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOTRIN","UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) / ANALGESIC / ANTIPYRETIC AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS) / ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"9687","08-07-23","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADD DESCRIPTION OF 5 CLINICAL TRIALS PREVIOUSLY REVIEWED BY HEALTH CANADA","DESCRIPTION DE CINQ ESSAIS DÉJÀ REVUE PAR SANTÉ CANADA","OPIOID - NSAID COMBINATION ANALGESIC","ANALGÉSIQUE OPIOÏDE - AINS","",""
"9688","08-07-23","GW PHARMA LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO THE DOSAGE AND ADMINISTRATION SECTION OF THE PRODUCT MONOGRAPH","RÉVISION À LA SECTION DE POSOLOGIE ET ADMINISTRATION DE LA MONOGRAPHIE DE PRODUIT","CANNABINOID ANALGESIC","ANALGÉSIQUE CANNABINOÏDE","",""
"9689","08-07-21","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DE PRODUIT","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE / ANALGÉSIQUE","",""
"9690","08-07-23","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC / MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE / PROPHYLAXIE DE LA MIGRAINE","",""
"9691","08-07-23","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ISOVUE","BRISTOL-MYERS SQUIBB","CANADA","CANADA","1","","","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON IONIQUE","",""
"9692","08-07-23","SANTHERA PHARMACEUTICALS SWITZERLAND LIMITED","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ATP PRODUCTION MODULATOR","MODULATEUR DE PRODUCTION D'ATP","",""
"9693","08-07-29","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE INDICATIONS AND CLINICAL USE AND WARNINGS AND PRECAUTIONS SECTIONS OF THE PRODUCT MONOGRAPH","RÉVISION DES SECTIONS INDICATIONS ET USAGE CLINIQUE ET MISES EN GARDE ET PRÉCAUTIONS DE LA MONOGRAPHIE DE PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9694","08-07-29","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISION À LA MONOGRAPHIE DE PRODUIT","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9695","08-07-29","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9696","08-07-30","INTERVET CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR THE USE IN FEEDLOT STEERS","POUR L'USAGE CHEZ LES BOUVILLONS D'ENGRAISSEMENT EN PARC","GROWTH PROMOTANT","AUGMENTE LE GAIN PONDÉRAL","",""
"9697","08-07-29","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"9698","08-07-30","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADD CLINICAL TRIALS SECTION TO THE PRODUCT MONOGRAPH","ADDITION DE LA SECTION ESSAIS CLINIQUES À LA MONOGRAPHIE DE PRODUIT","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"9699","08-07-31","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","PREMEDICANT / SEDATIVE / ANAESTHETIC AGENT","PRÉMÉDICATION / SÉDATIF / ANESTHÉSIQUE","",""
"9700","08-08-01","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9701","08-08-01","INTERVET CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGES IN MANUFACTURING","MODIFICATIONS DE LA FABRICATION","FOLLICLE STIMULATING HORMONE","HORMONE FOLLICULO-STIMULANTE","",""
"9702","08-08-01","NORBROOK LABORATORIES LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","CHANGE IN WITHDRAWAL PERIOD","CHANGEMENT DU DÉLAI D'ATTENTE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9703","08-08-06","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 70mg/140mcg","NOUVELLE CONCENTRATION : 70mg/140mcg","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9704","08-08-08","WYETH ANIMAL HEALTH DIVISION OF WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL INDICATIONS","INDICATIONS SUPPLÉMENTAIRES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"9705","08-08-08","WYETH ANIMAL HEALTH DIVISION OF WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL INDICATIONS","INDICATIONS SUPPLÉMENTAIRES","ANTIPARASITIC","ANTIPARASITAIRE","",""
"9706","08-08-08","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9707","08-08-11","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","PRODUCT MONOGRAPH REVISED","MONOGRAPHIE DE PRODUIT RÉVISÉE","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"9708","08-08-08","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","RE-INTRODUCTION OF ORAL SUSPENSION DOSAGE FORM TO THE PRODUCT MONOGRAPH","RÉ-INSERTION DE LA SUSPENSION ORALE DANS LA MONOGRAPHIE DE PRODUIT","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9709","08-08-12","BRISTOL MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9710","08-08-08","PURDUE PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"9711","08-08-08","PURDUE PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"9712","08-08-12","HEALTHPOINT CANADA ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ENZYMATIC DEBRIDING AGENT","AGENT DE DÉBRIDEMENT ENZYMATIQUE","",""
"9713","08-08-12","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW ALTERNATE FRACTIONATION FACILITY","NOUVEL ÉTABLISSEMENT ALTERNATIF DESTINÉ AU FRACTIONNEMENT","REPLACEMENT THERAPY FOR IMMUNODEFICIENCIES","TRAITEMENT SUBSTITUTIF DE L'IMMUNODÉFICIENCE","",""
"9714","08-08-13","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD/LTÉE","CANADA","CANADA","1","","","ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST","ANTIPARKINSONIEN / AGONISTE DOPAMINERGIQUE","",""
"9715","08-08-13","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9716","08-08-14","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-OBESITY","ANTI-OBÉSITÉ","",""
"9717","08-08-15","LABORATOIRE RIVA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"9718","08-08-15","ZYMCAN PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ß-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS ß-ADRÉNERGIQUES","",""
"9719","08-08-19","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIMOPTIC XE 0.25%","MERCK FROSST CANADA LTD","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE L'HYPERTENSION INTRA-OCULAIRE","",""
"9720","08-08-18","MERIAL CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","NEW INDICATION","INDICATION NOUVELLE","PROTON PUMP INHIBITOR","INHIBITEUR DE LA POMPE À PROTONS","",""
"9721","08-08-18","MERIAL CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM","INDICATION SUPPLÉMENTAIRE","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"9722","08-08-18","MERIAL CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM","INDICATION SUPPLÉMENTAIRE","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"9723","08-08-19","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-CILAG LTD.","UNITED KINGDOM","ROYAUME-UNI","1","","","ANTIEPILEPTIC / MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE / PROPHYLAXIE DE LA MIGRAINE","",""
"9724","08-08-18","CENTOCOR B V","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITIONAL MANUFACTURING FACILITY","ADDITION D'UN NOUVEL EMPLACEMENT DE FABRICATION","ANTIPLATELET ANTIBODY","ANTICORPS ANTIPLAQUETTAIRE","",""
"9725","08-08-20","OVATION PHARMACEUTICALS INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF INDICATIONS: 1) COSMEGEN, AS PART OF A COMBINATION THERAPY AND/OR MULTI-MODALITY TREATMENT REGIMEN INDICATED FOR TREATMENT OF METASTATIC, NONSEMINOMATOUS TESTICULAR CANCER. 2) COSMEGEN, AS A COMPONENT OF REGIONAL PERFUSION IN COMBINATION WITH MELPHALAN, INDICATED FOR PALLIATIVE AND/OR ADJUNCTIVE TREATMENT OF LOCALLY RECURRENT OR LOCOREGIONAL SOLID MALIGNANCIES. REVISION TO THE PRODUCT MONOGRAPH SECTIONS: WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, AND CLINICAL TRIALS","ÉLIMINATION DES INDICATIONS : 1) COSMEGEN, DANS LE CADRE D'UN TRAITEMENT EN ASSOCIATION ET/OU D'UN RÉGIME THÉRAPEUTIQUE À PLUSIEURS MODALITÉS INDIQUÉ POUR TRAITER LE CANCER DES TESTICULES MÉTASTATIQUE ET NON SÉMINOMATEUX. 2) COSMEGEN, EN PERFUSION LOCALE EN ASSOCIATION AVEC LE MELPHALAN, INDIQUÉ POUR LE TRAITEMENT PALLIATIF ET/OU D'APPOINT DE TUMEURS LOCALEMENT RÉCIDIVANTES OU DE TUMEURS SOLIDES LOCORÉGIONALES.  CHANGEMENTS APPORTÉS AUX SECTIONS DE LA MONOGRAPHIE DE PRODUIT : MISES EN GARDE ET PRÉCAUTIONS, RÉACTIONS INDÉSIRABLES, POSOLOGIE ET ADMINISTRATION, ET ESSAIS CLINIQUES.","ACTINOMYCIN ANTIBIOTIC / ANTINEOPLASTIC","ACTINOMYCINE ANTIBIOTIQUE / ANTINÉOPLASIQUE","",""
"9726","08-08-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XATRAL","SANOFI-AVENTIS CANADA INC.","CANADA","CANADA","1","","","SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / ADJUNCTIVE THERAPY IN ACUTE URINARY RETENTION (AUR)","TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP) / TRAITEMENT ADJUVANT DE LA RÉTENTION URINAIRE AIGUË (RUA)","",""
"9727","08-08-22","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9728","08-08-22","BAYER HEALTHCARE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITION OF A NEW MODE OF ADMINISTRATION (CONTINUOUS INFUSION)","AJOUT D'UN NOUVEAU MODE D'ADMINISTRATION (ADMINISTRATION CONTINUE)","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"9729","08-08-22","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","ADDITION OF A NEW MODE OF ADMINISTRATION (CONTINUOUS INFUSION)","AJOUT D'UN NOUVEAU MODE D'ADMINISTRATION (ADMINISTRATION CONTINUE)","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"9730","08-08-22","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: THE ACUTE MANAGEMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I AND BIPOLAR II DISORDER.","NOUVELLE INDICATION : PRISE EN CHARGE DES ÉPISODES DÉPRESSIFS ASSOCIÉS AUX TROUBLES BIPOLAIRES I ET II.","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9731","08-08-22","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: THE ACUTE MANAGEMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I AND BIPOLAR II DISORDER.","NOUVELLE INDICATION : PRISE EN CHARGE DES ÉPISODES DÉPRESSIFS ASSOCIÉS AUX TROUBLES BIPOLAIRE I ET II.","PSYCHOTROPIC AGENT","PSYCHOTROPE","",""
"9732","08-08-25","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"9733","08-08-25","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"9734","08-08-25","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS DE LA MONOGRAPHIE DE PRODUIT","ANTIBIOTIC / ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE / INHIBITEUR DE ß-LACTAMASES","",""
"9735","08-08-22","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REDUCED TABLET SIZE FOR 400 MG TABLET","NOUVEAU FORMAT RÉDUIT POUR LE COMPRIMÉ DE 400 MG","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9736","08-08-26","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9737","08-08-26","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9738","08-08-27","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH SECTIONS: CLINICAL TRIALS, WARNINGS AND PRECAUTIONS, ADVERSE DRUG REACTIONS, DRUG-DRUG INTERACTIONS","MODIFICATIONS APPORTÉES AUX SECTIONS SUIVANTES DE LA MONOGRAPHIE DE PRODUIT : ESSAIS CLINIQUES, MISES EN GARDE ET PRÉCAUTIONS, EFFETS INDÉSIRABLES, ET INTERACTIONS MÉDICAMENTEUSES.","TYPE I AND II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DES TYPES I ET II","",""
"9739","08-08-27","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"9740","08-08-28","BAYER INC BAYER HEALTHCARE ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"9741","08-08-28","BAYER INC BAYER HEALTHCARE ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"9742","08-08-28","BAYER INC BAYER HEALTHCARE ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"9743","08-08-28","INTERVET CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","CYSTORELIN","MERIAL CANADA INC.","CANADA","CANADA","1","","","HORMONE","HORMONE","",""
"9744","08-08-28","LUNDBECK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER AND MAINTENANCE OF ANTI-OBSESSIVE RESPONSE FOR UP TO 6 MONTHS AND OTHER REVISIONS TO THE PRODUCT MONOGRAPH","TRAITEMENT DU TROUBLE OBSESSIF COMPULSIF ET POUR LE MAINTIEN DE LA RÉPONSE ANTI-OBSESSIONNELLE POUR UNE PÉRIODE ALLANT JUSQU'À 6 MOIS, AINSI QUE D'AUTRES RÉVISIONS À LA MONOGRAPHIE DE PRODUIT","ANTIDEPRESSANT / ANXIOLYTIC /ANTIOBSESSIONAL","ANTIDÉPRESSEUR / ANXIOLYTIQUE / ANTIOBSESSIONNEL","",""
"9745","08-08-29","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","CHANGE IN FORMULATION","MODIFICATION DE LA FORMULATION","ANTIDIARRHEAL / ANTIFLATULENT","ANTIDIARRHÉIQUE / ANTIFLATULENT","",""
"9746","08-08-29","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","PRODUCT MONOGRAPH UPDATE","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"9747","08-09-02","CENTOCOR INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT","BIOLOGIC RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"9748","08-09-02","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9749","08-09-02","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9750","08-09-02","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: AS PART OF COMBINATION THERAPY FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA WHO ARE UNSUITABLE FOR STEM CELL TRANSPLANTATION","NOUVELLE INDICATION : DANS LE CADRE D'UN TRAITEMENT EN ASSOCIATION, POUR TRAITER LES PATIENTS ANTÉRIEUREMENT ATTEINTS D'UN MYÉLOME MULTIPLE NON TRAITÉ CHEZ QUI LA TRANSPLANTATION DE CELLULES SOUCHES N'EST PAS INDIQUÉE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9751","08-09-02","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: IN COMBINATION WITH CISPLATIN THERAPY IS INDICATED FOR THE INITIAL TREATMENT OF GOOD PERFORMANCE STATUS PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER OTHER THAN PREDOMINANTLY SQUAMOUS CELL HISTOLOGY","NOUVELLE INDICATION : EN ASSOCIATION AVEC LE CISPLATINE, POUR LE TRAITEMENT INITIAL DE PATIENTS EN BON ÉTAT GÉNÉRAL ATTEINTS D'UN CANCER DU POUMON NON À PETITES CELLULES LOCALEMENT AVANCÉ OU MÉTASTATIQUE DONT L'HISTOLOGIE EST PRINCIPALEMENT NON SQUAMEUSE","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9752","08-09-02","SQUIRE PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NIGHTTIME SLEEP AID","AIDE-SOMMEIL","",""
"9753","08-09-02","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MOTRIN","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY / ANALGESIC / ANTIPYRETIC AGENT","NON STÉROÏDIEN ANTI-INFLAMMATOIRE / ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"9754","08-09-02","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"9755","08-09-03","GILEAD SCIENCES INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR TREATMENT OF CHRONIC HEPATITIS B IN ADULTS","INDICATION NOUVELLE POUR LE TRAITEMENT DES PATIENTS ADULTES ATTEINTS D'HÉPATITE B CHRONIQUE","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9756","08-09-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANTIOBSESSIONAL / ANTIBULIMIC","ANTIDÉPRESSEUR / ANTIOBSESSIONNEL / ANTIBOULIMIQUE","",""
"9757","08-09-04","GENPHARM ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9758","08-09-04","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9759","08-09-04","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9760","08-09-04","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9761","08-09-04","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9762","08-09-04","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9763","08-09-04","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9764","08-09-04","RATIOPHARM INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9765","08-09-04","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9766","08-09-04","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","5-HT3 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS 5-HT3","",""
"9767","08-09-04","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9768","08-09-05","INTERVET CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9769","08-09-05","INTERVET CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9770","08-09-05","INTERVET CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9771","08-09-05","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT / TUMOR IMAGING AGENT","AGENT RADIODIAGNOSTIQUE / AGENT POUR L'IMAGERIE DES CANCERS","",""
"9772","08-09-08","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE FOLLOWING SECTIONS OF THE PRODUCT MONOGRAPH: WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, OVERDOSAGE, AND CONSUMER INFORMATION","MODIFICATIONS APPORTÉES AUX SECTIONS SUIVANTES DE LA MONOGRAPHIE DE PRODUIT : MISES EN GARDE ET PRÉCAUTIONS À PRENDRE, EFFETS INDÉSIRABLES, POSOLOGIE ET ADMINISTRATION, SURDOSAGE ET RENSEIGNEMENTS POUR LE CONSOMMATEUR","BONE METABOLISM REGULATOR (ANTI-HYPERCALCEMIC AGENT)","RÉGULATEUR DU MÉTABOLISME OSSEUX (AGENT ANTIHYPERCALCÉMIQUE)","",""
"9773","08-09-08","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REACTINE","PFIZER CANADA INC.","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"9774","08-09-08","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"9775","08-09-08","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ISOVUE","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","NON-IONIC RADIOGRAPHIC CONTRAST AGENT","SUBSTANCE DE CONTRASTE RADIOGRAPHIQUE NON IONIQUE","",""
"9776","08-09-08","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR TABLETS","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9777","08-09-08","BAYER INC CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","REVISIONS OF PACKAGING LABELS TO INCLUDE DRUG IDENTIFICATION NUMBERS","CHANGEMENTS APPORTÉS AUX ÉTIQUETTES D'EMBALLAGE POUR INCLURE LES NUMÉROS D'IDENTIFICATION DE MÉDICAMENT","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9778","08-09-09","NOVARTIS PHARMACEUTICALS CANADA INC","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROTEIN-TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"9779","08-09-09","SERVIER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9780","08-09-10","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","ADMINISTRATIVE CHANGE IN PRODUCT NAME","MODIFICATION ADMINISTRATIVE APPORTÉE AU NOM DU PRODUIT","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"9781","08-09-11","IMCLONE SYSTEMS INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION: ERBITUX (CETUXIMAB) IS INDICATED IN COMBINATION WITH RADIATION THERAPY FOR THE INITIAL TREATMENT OF LOCALLY OR REGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK","NOUVELLE INDICATION : ERBITUX (CETUXIMAB) EST INDIQUÉ EN ASSOCIATION AVEC LA RADIOTHÉRAPIE POUR LE TRAITEMENT INITIAL DES PATIENTS PRÉSENTANT UN CARCINOME ÉPIDERMOÏDE LOCALEMENT AVANCÉ DE LA TÊTE ET DU COU","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9782","08-09-12","ASTELLAS PHARMA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION FOR THE TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS","ADDITION D'UNE INDICATION CLINIQUE POUR LE TRAITEMENT DE LA CANDIDÉMIE ET DE LA CANDIDOSE INVASIVE","ANTIFUNGAL","ANTIFONGIQUE","",""
"9783","08-09-12","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"9784","08-09-12","INTERVET CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALTERNATE SOURCE OF ACTIVE INGREDIENT","VARIATION D'ORIGINE DE L'INGRÉDIENT ACTIF","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"9785","08-09-15","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIRECT FACTOR XA INHIBITOR","INHIBITEUR DIRECT DU FACTEUR XA","",""
"9786","08-09-16","INTERVET CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR USE IN FEEDLOT HEIFERS","POUR L'USAGE CHEZ LES GÉNISSES EN PARC D'ENGRAISSEMENT","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"9787","08-09-19","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","PRODUCT MONOGRAPH UPDATE","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"9788","08-09-22","INTERVET CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","TO PROVIDE FOR USE IN PASTURE HEIFERS","POUR L'USAGE CHEZ LES GÉNISSES D'ENGRAISSEMENT AU PÂTURAGE","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"9789","08-09-23","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9790","08-09-19","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERIDEX","PROCTOR & GAMBLE INC.","CANADA","CANADA","1","","","ANTIGINGIVITIS ORAL RINSE","RINCE-BOUCHE ANTIGINGIVITE","",""
"9791","08-09-19","JANSSEN ORTHO INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"9792","08-09-23","JANSSEN PHARMACEUTICA N.V.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIFUNGAL","ANTIFONGIQUE","",""
"9793","08-09-23","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9794","08-09-24","INTERVET CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","STIMULANT DE LA CROISSANCE","",""
"9795","08-09-24","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 150 MG TABLET AND NEW DOSING REGIMEN","NOUVELLE CONCENTRATION : COMPRIMÉ DE 150 MG ET NOUVEAU SCHÉMA POSOLOGIQUE","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9796","08-09-24","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTI-DIABETIC AGENT / INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE / AGENT RÉDUCTEUR DE L'INSULINORÉSISTANCE","",""
"9797","08-09-24","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE L'INNOCUITÉ DANS LA MONOGRAPHIE DE PRODUIT","ANTITUBERCULOUS ANTIBIOTIC","ANTIBIOTIQUE ANTITUBERCULEUX","",""
"9798","08-09-25","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9799","08-09-25","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9800","08-09-25","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9801","08-09-25","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9802","08-09-26","RAINBOW PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REMOVAL OF INDICATION","REMOVAL OF INDICATION *TRADUCTION FRANÇAISE À SUIVRE*","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"9803","08-09-29","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","IMDUR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"9804","08-09-29","VIRBAC AH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","EPIDERMAL ASTRINGENT","ASTRINGENT ÉPIDERMIQUE","",""
"9805","08-09-29","LANTHEUS MI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRAST ENHANCING IMAGING AGENT","AGENT DE REHAUSSEMENT DE CONTRASTE POUR L'IMAGERIE","",""
"9806","08-09-29","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN","OESTROGÈNE","",""
"9807","08-09-29","BARR LABORATORIES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MARVELON","ORGANON CANADA LTD","CANADA","CANADA","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"9808","08-09-30","BRISTOL MYERS SQUIBB CANADA","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSING REGIMEN FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML): 100 MG OF SPRYCEL (DASATINIB) ADMINISTERED ONCE DAILY (OD), EITHER IN THE MORNING OR EVENING AND REVISIONS TO THE PRODUCT MONOGRAPH","NOUVEAU SCHÉMA POSOLOGIQUE POUR LA LEUCÉMIE MYÉLOÏDE CHRONIQUE (LMC) EN PHASE CHRONIQUE : 100 MG DE SPRYCEL (DASATINIB) ADMINISTRÉS UNE FOIS PAR JOUR (OD), SOIT LE MATIN OU LE SOIR. RÉVISIONS DE LA MONOGRAPHIE DE PRODUIT.","PROTEIN-TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-TYROSINE KINASE","",""
"9809","08-10-01","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS DE LA MONOGRAPHIE DE PRODUIT","AZAPEPTIDE INHIBITOR OF HIV-1 PROTEASE","INHIBITEUR AZAPEPTIDIQUE DE LA PROTÉASE DU VIH-1","",""
"9810","08-10-01","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9811","08-10-03","CELGENE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTHS: 15 MG AND 25 MG. NEW INDICATION: IN COMBINATION WITH DEXAMETHASONE, FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY.","NOUVELLES CONCENTRATIONS : 15 MG ET 25 MG. NOUVELLE INDICATION : EN ASSOCIATION AVEC LE DEXAMÉTHASONE, POUR LE TRAITEMENT DES PATIENTS ATTEINTS DE MYÉLOME MULTIPLE QUI ONT DÉJÀ REÇU AU MOINS UN TRAITEMENT.","ANTINEOPLASTIC AGENT / IMMUNOMODULATORY AGENT","ANTINÉOPLASIQUE / IMMUNOMODULATEUR","",""
"9812","08-10-06","GILEAD SCIENCES INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","SAFETY UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE L'INNOCUITÉ DANS LA MONOGRAPHIE DE PRODUIT","ANTIVIRAL AGENT","ANTIVIRAL","",""
"9813","08-10-07","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DDAVP SPRAY","FERRING INC","CANADA","CANADA","1","REMOVAL OF INDICATION","SUPPRESSION DE L'INDICATION","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"9814","08-10-08","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW STOCK SEED","NOUVEAU STOCK DE SEMENCE DE CELLULES","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9815","08-10-09","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL CLAIM","INDICATION SUPPLÉMENTAIRE","ANTI-INFLAMMATORY / ANALGESIC / ANTIPYRETIC","ANTI-INFLAMMATOIRE / ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"9816","08-10-09","TAKEDA PHARMACEUTICALS AMERICA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HELICOBACTER PYLORI ERADICATION THERAPY","TRAITEMENT D'ÉRADICATION DE H. PYLORI","",""
"9817","08-10-09","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9818","08-10-09","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9819","08-10-09","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9820","08-10-09","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9821","08-10-09","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9822","08-10-09","WELLSPRING PHARMACEUTICAL CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9823","08-10-09","TAKEDA PHARMACEUTICALS AMERICA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9824","08-10-09","ALCON CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ELEVATED INTRAOCULAR PRESSURE THERAPY - PROSTAGLANDIN F2ALPHA ANALOGUE","TRAITEMENT DE L'HYPERTENSION OCULAIRE ÉLEVÉ - ANALOGUE DE LA PROSTAGLANDINE F2ALPHA","",""
"9825","08-10-10","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT","SELECTIVE CO-STIMULATION MODULATOR","MODULATEUR SÉLECTIF DE LA CO-STIMULATION","",""
"9826","08-10-10","TALECRIS BIOTHERAPEUTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","NEW INDICATION: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY","NOUVELLE INDICATION : POLYNEUROPATHIE INFLAMMATOIRE CHRONIQUE DÉMYÉLINISANTE","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"9827","08-10-10","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"9828","08-10-10","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZEMURON","ORGANON CANADA LTD","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","AGENT DE BLOCAGE NEURO-MUSCULAIRE NON DÉPOLARISANT","",""
"9829","08-10-14","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, SPECIAL HANDLING INSTRUCTIONS, CLINICAL TRIALS, REFERENCES, AND PART III: CONSUMER INFORMATION SECTIONS OF THE PRODUCT MONOGRAPH","MODIFICATIONS APPORTÉES AUX SECTIONS MISES EN GARDE ET PRÉCAUTIONS, EFFETS INDÉSIRABLES, INSTRUCTIONS SPÉCIALES DE MANIPULATION, ESSAIS CLINIQUES, RÉFÉRENCES, ET À LA PARTIE III : RENSEIGNEMENTS POUR LE PATIENT, DE LA MONOGRAPHIE DE PRODUIT.","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9830","08-10-14","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of alternate manufacturing site for the finished product","Ajout d'un autre lieu de fabrication pour le produit fini","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"9831","08-10-14","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","CHANGE IN MANUFACTURING - NEW FACILTIY","NOUVEL EMPLACEMENT DE FABRICATION","THERAPEUTIC RADIOPHARMACEUTICAL","RADIOPHARMACEUTIQUE THÉRAPEUTIQUE","",""
"9832","08-10-15","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DE PRODUIT","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9833","08-10-15","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"9834","08-10-15","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9835","08-10-15","BRISTOL MYERS SQUIBB CANADA","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","COMMITMENT #1 OF THE LETTER OF UNDERTAKING DATED MARCH 13, 2007: FINAL CLINICAL STUDY REPORT CA180002.","ENGAGEMENT NO. 1 DE LA LETTRE D'ENGAGEMENT DU 13 MARS 2007 : RAPPORT FINAL DE L'ÉTUDE CLINIQUE CA180002.","PROTEIN-TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-TYROSINE KINASE","",""
"9836","08-10-15","PHARMETICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) / ANALGESIC / ANTIPYRETIC","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS) / ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"9837","08-10-16","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC / ANTIPYRETIC / ANTI-INFLAMMATORY","ANALGÉSIQUE / ANTIPYRÉTIQUE / ANTI-INFLAMMATOIRE","",""
"9838","08-10-17","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW INDICATION","NOUVELLE INDICATION","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"9839","08-10-17","BIOGEN IDEC CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","SELECTIVE ADHESION MOLECULE INHIBITOR","INHIBITEUR SÉLECTIF DE MOLÉCULES D'ADHÉSION","",""
"9840","08-10-20","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9841","08-10-20","GLAXOSMITHKLINE SHIRE BIOCHEM","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9842","08-10-20","GLAXOSMITHKLINE SHIRE BIOCHEM","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9843","08-10-20","EMD SERONO CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PRESENTATIONS","NOUVELLES PRÉSENTATIONS","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"9844","08-10-22","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRAMIL","H. LUNDBECK A/S DENMARK","UNITED KINGDOM","ROYAUME-UNI","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9845","08-10-22","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","REMOVAL OF INDICATION","SUPPRESSION DE L'INDICATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9846","08-10-23","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION AND FORMULATION CHANGE TO INCREASE SHELF LIFE FROM 18 TO 24 MONTHS","INDICATION CLINIQUE ADDITIONNELLE ET CHANGEMENT DE LA FORMULATION PHARMACEUTIQUE POUR ACCROITRE LA PÉRIODE DE STABILITÉ DE 18 À 24 MOIS","TETRACYCLINE ANTIBIOTIC","ANTIBIOTIQUE DE LA CLASSE TÉTRACYCLINES","",""
"9847","08-10-23","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PHARMORUBICIN PFS","PHARMACIA & UPJOHN INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9848","08-10-23","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PHARMORUBICIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9849","08-10-23","DABUR ONCOLOGY PLC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PHARMORUBICIN PFS","PFIZER INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9850","08-10-23","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"9851","08-10-23","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9852","08-10-23","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","FULFILLMENT OF COMMITMENTS AS PER THE LETTER OF UNDERTAKING DATED DECEMBER 7, 2005 FOR USE IN THE ADJUVANT TREATMENT OF PATIENTS WITH STAGE III (DUKE'S STAGE C) COLON CANCER","RESPECT DES ENGAGEMENTS ÉTABLIS DANS LA LETTRE D'ENGAGEMENT DU 7 DÉCEMBRE 2005 RELATIVEMENT À L'UTILISATION DU PRODUIT DANS LE TRAITEMENT ADJUVANT DU CANCER DU CÔLON DE STADE III (STADE C DE DUKES)","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9853","08-10-24","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"9854","08-10-24","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZEMURON","ORGANON CANADA LTD","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","BLOQUEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"9855","08-10-24","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Gonadotropin-Releasing Hormone Analog","Analogue de l'hormone de libération de la gonatrophine","",""
"9856","08-10-24","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GONADOTROPIN-RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONATROPHINE","",""
"9857","08-10-24","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GONADOTROPIN-RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONATROPHINE","",""
"9858","08-10-24","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC","CANADA","CANADA","1","NEW DOSAGE FORM","NOUVELLE FORME POSOLOGIQUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9859","08-10-27","IMCLONE SYSTEMS INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHEMISTRY AND MANUFACTURING UPDATES","MISE À JOUR DE LA CHIMIE ET DE LA FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9860","08-10-27","NYCOMED CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9861","08-10-28","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"9862","08-10-28","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of alternate manufacturing site for the finished product","Ajout d'un autre lieu de fabrication pour le produit fini","SYMPATHOMIMETIC AGENT","SYMPATHOMIMÉTIQUE","",""
"9863","08-10-28","SERVIER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9864","08-10-29","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF PHYSICIAN SAMPLE LABELLING, AND CHANGES TO THE PRODUCT MONOGRAPH IN PART III ONLY","ÉTIQUETAGE DES ÉCHANTILLONS DE MÉDICAMENTS REMIS AUX MÉDECINS, ET CHANGEMENTS APPORTÉS UNIQUEMENT À LA PARTIE III DE LA MONOGRAPHIE DE PRODUIT","ANTIHYPERTENSIVE AGENT AND PLATELET AGGREGATION INHIBITOR","ANTIHYPERTENSEUR ET INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"9865","08-10-30","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE INDICATIONS AND CLINICAL USE SECTION OF THE PRODUCT MONOGRAPH","RÉVISION À LA SECTION DE L'INDICATION ET DE L'USAGE CLINIQUE DE LA MONOGRAPHIE DE PRODUIT","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9866","08-10-30","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW STRENGTH: 80 MG/25 MG","NOUVELLE POSOLOGIE : 80 MG/25 MG","ANGIOTENSIN II AT1 RECEPTOR BLOCKER / DIURETIC","INHIBITEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II / DIURÉTIQUE","",""
"9867","08-11-04","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"9868","08-11-04","ALLERGAN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-ACNE THERAPY","TRAITEMENT ANTIACNÉ","",""
"9869","08-11-04","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","SUPER STRENGTH MOTRIN IB","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG / ANALGESIC / ANTIPYRETIC","ANTI-INFLAMMATOIRE NON STÉROÏDIEN / ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"9870","08-11-05","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY","CANADA","CANADA","1","NEW PRESENTATION","NOUVELLE PRÉSENTATION","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9871","08-11-06","LEO PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIPSORIATIC AGENT, VITAMIN D ANALOGUE, CORTICOSTEROID","AGENT ANTIPSORIASIQUE, ANALOGUE DE LA VITAMINE D, CORTICOSTÉROÏDE","",""
"9872","08-11-06","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9873","08-11-06","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"9874","08-11-06","LEO PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE INDICATIONS AND CLINICAL USE, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, AND CLINICAL TRIALS SECTIONS OF THE PRODUCT MONOGRAPH","MODIFICATIONS APPORTÉES AUX SECTIONS INDICATIONS ET UTILISATION CLINIQUE, MISES EN GARDE ET PRÉCAUTIONS, EFFETS INDÉSIRABLES, POSOLOGIE ET ADMINISTRATION, ET ESSAIS CLINIQUES DE LA MONOGRAPHIE DE PRODUIT","TOPICAL ANTIPSORIATIC AGENT, VITAMIN D ANALOGUE, CORTICOSTEROID","AGENT ANTIPSORIASIQUE TOPIQUE, ANALOGUE DE LA VITAMINE D, CORTICOSTÉROÏDE","",""
"9875","08-11-07","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"9876","08-11-07","EMD SERONO CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL EMPLACEMENT DE FABRICATION","GONADOTROPIN","GONADOTROPINE","",""
"9877","08-11-07","LANTHEUS MI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","RADIOPHARMACEUTIQUE POUR USAGE DIAGNOSTIQUE","",""
"9878","08-11-07","LANTHEUS MI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"9879","08-11-07","LANTHEUS MI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"9880","08-11-07","LANTHEUS MI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"9881","08-11-07","LANTHEUS MI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL FOR DIAGNOSTIC USE","RADIOPHARMACEUTIQUE POUR USAGE DIAGNOSTIQUE","",""
"9882","08-11-07","LANTHEUS MI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC AGENT FOR INTRAVENOUS USE","AGENT DIAGNOSTIQUE POUR USAGE INTRAVEINEUX","",""
"9883","08-11-10","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"9885","08-11-07","LANTHEUS MI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"9886","08-11-10","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"9887","08-11-10","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ENDOTHELIN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"9888","08-11-10","EMD SERONO CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","THYROID HORMONE","HORMONE THYROÏDIENNE","",""
"9889","08-11-13","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"9890","08-11-13","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"9891","08-11-13","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"9892","08-11-14","GENPHARM ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","ANTIRHEUMATIC IMMUNOMODULATOR AGENT","ANTIRHUMATISMAL IMMUNOMODULATEUR","",""
"9893","08-11-10","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DE PRODUIT","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9894","08-11-13","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","DELETION OF CLINICAL TRIAL SECTION AND CONVERSION OF THE PRODUCT MONOGRAPH TO THE NEW FORMAT","LA SECTION DES ESSAIS CLINIQUES A ÉTÉ SUPPRIMÉE ET LE NOUVEAU FORMAT DE LA MONOGRAPHIE DE PRODUIT EST MISE EN PLACE","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"9895","08-11-13","FRESENIUS KABI CANADA A DIVISION OF CALEA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","TO REMOVE SODIUM CHLORIDE FROM THE LIST OF ACTIVE INGREDIENTS IN THE CERTIFIED PRODUCT INFORMATION DOCUMENT AND PRODUCT MONOGRAPH","RETRAIT DU CHLORURE DE SODIUM DE LA LISTE DES INGRÉDIENTS ACTIFS DANS LE DOCUMENT CERTIFIÉ D'INFORMATION SUR LE PRODUIT ET LA MONOGRAPHIE DE PRODUIT","PLASMA VOLUME EXPANDER","SOLUTÉ DE REMPLISSAGE PLASMATIQUE","",""
"9896","08-11-17","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH","RÉVISIONS À LA MONOGRAPHIE DE PRODUIT","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9897","08-11-19","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL MANUFACTURER FOR THE MANUFACTURING OF MEDICATED MINERALS USING BOVATEC","FABRICANT ADDITIONNEL POUR LA FABRICATION DE MINÉRAUX MÉDICAMENTÉS UTILISANT LE BOVATEC","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9898","08-11-19","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL MANUFACTURER FOR THE MANUFACTURING OF MEDICATED MINERALS USING BOVATEC","FABRICANT ADDITIONEL POUR LA FABRICATION DE MINÉRAUX MÉDICAMENTÉS UTILISANT LE BOVATEC","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9899","08-11-19","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ADDITIONAL MANUFACTURER FOR THE MANUFACTURING OF MEDICATED MINERALS USING BOVATEC","FABRICANT ADDITIONNEL POUR LA FABRICATION DE MINÉRAUX MÉDICAMENTÉS UTILISANT LE BOVATEC","ANTIMICROBIAL","ANTIMICROBIEN","",""
"9900","08-11-19","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM CANADA LTD","CANADA","CANADA","1","","","SELECTIVE ANTAGONIST OF ALPHA 1A ADRENORECEPTOR SUBTYPE IN THE PROSTATE","ANTAGONISTE SÉLECTIF DES SOUS-TYPES DES RÉCEPTEURS ALPHA 1A ADRÉNERGIQUES DE LA PROSTATE","",""
"9901","08-11-20","MODERN VETERINARY THERAPEUTICS LLC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Priority","Priorité","Veterinary","Vétérinaire","DOPRAM-V","WYETH ANIMAL HEALTH, DIVISION OF WYETH CANADA","CANADA","CANADA","1","","","RESPIRATORY STIMULANT","STIMULANT RESPIRATOIRE","",""
"9902","08-11-20","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, ACTION AND CLINICAL PHARMACOLOGY AND CLINICAL TRIALS SECTIONS OF THE PRODUCT MONOGRAPH","MODIFICATIONS APPORTÉES AUX SECTIONS SUIVANTES DE LA MONOGRAPHIE DE PRODUIT: MISES EN GARDE ET PRÉCAUTIONS, EFFETS INDÉSIRABLES, MODE D'ACTION ET PHARMACOLOGIE CLINIQUE ET ESSAIS CLINIQUES","ANTIDIABETIC AGENT / INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE / AGENT INSULINOSENSIBILISATEUR","",""
"9903","08-11-20","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA INC","CANADA","CANADA","1","UPDATE TO THE PRODUCT MONOGRAPH TO BE IN LINE WITH CRP","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT POUR QU'ELLE CORRESPONDE À CELLE DU PRODUIT DE RÉFÉRENCE CANADIEN","ANTIBIOTIC / BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE / INHIBITEUR DE BÊTA-LACTAMASES","",""
"9904","08-11-21","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER / DIURETIC","INHIBITEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II / DIURÉTIQUE","",""
"9905","08-11-21","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO DOSAGE AND ADMINISTRATION AND PART III: CONSUMER INFORMATION SECTIONS OF THE PRODUCT MONOGRAPH","MODIFICATIONS APPORTÉES À LA SECTION POSOLOGIE ET ADMINISTRATION ET À LA PARTIE III : RENSEIGNEMENTS POUR LE PATIENT, DE LA MONOGRAPHIE DE PRODUIT","THYROID HORMONE","HORMONE THYROÏDIENNE","",""
"9906","08-11-25","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"9907","08-11-25","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","UPDATE IN PRODUCT MONOGRAPH TO BE IN LINE WITH CRP","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT POUR QU'ELLE CORRESPONDE À CELLE DU PRODUIT DE RÉFÉRENCE CANADIEN","ANTIBIOTIC / BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE / INHIBITEUR DE BÊTA-LACTAMASES","",""
"9908","08-11-27","JANSSEN PHARMACEUTICA N.V.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTHELMINTIC","ANTHELMINTHIQUE","",""
"9909","08-11-27","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"9910","08-11-27","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO","CANADA","CANADA","1","NEW STRENGTH","NOUVELLE CONCENTRATION","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"9911","08-11-28","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PRODUCT NAME CHANGE","MODIFICATION DU NOM DU PRODUIT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9912","08-11-28","EKR THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","THROMBOLYTIC AGENT","AGENT THROMBOLYTIQUE","",""
"9913","08-12-01","VALESCO PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9914","08-12-01","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM","HOECHST MARION ROUSSEL INC","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT / ANTIANGINAL AGENT","ANTIHYPERTENSEUR / ANTIANGINEUX","",""
"9915","08-12-01","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO A DRUG SUBSTANCE MANUFACTURING FACILITY","CHANGEMENTS À L'INSTALLATION DE FABRICATION DE LA SUBSTANCE MÉDICAMENTEUSE","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"9916","08-12-01","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CHANGES TO THE DRUG SUBSTANCE MANUFACTURING FACILITY","CHANGEMENTS À L'INSTALLATION DE FABRICATION DE LA SUBSTANCE MÉDICAMENTEUSE","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"9917","08-12-01","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","SELECTIVE ANTAGONIST OF ALPHA 1A ADRENOCEPTOR SUBTYPE IN THE PROSTATE","ANTAGONISTE SÉLECTIF DE SOUS-TYPES DES RÉCEPTEURS ALPHA 1A ADRÉNERGIQUES DE LA PROSTATE","",""
"9918","08-12-02","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXY-IR","PURDUE PHARMA","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"9919","08-12-03","AUROBINDO PHARMA LIMITED UNIT III","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"9920","08-12-02","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW MANUFACTURING SITE","NOUVEL EMPLACEMENT DE FABRICATION","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9921","08-12-03","STRAGEN INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAXOL","BRISTOL MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9922","08-12-04","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEUSTATIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ANTINEOPLASTIC / CHEMOTHERAPEUTIC AGENT","ANTINÉOPLASIQUE / AGENT CHIMIOTHÉRAPIE","",""
"9923","08-12-04","STIEFEL CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AGENT FOR THE TREATMENT OF SOLAR LENTIGINES AND RELATED HYPERPIGMENTED LESIONS","AGENT DESTINÉ AU TRAITEMENT DES LENTIGINES SOLAIRES ET DES LÉSIONS HYPERPIGMENTÉES CONNEXES","",""
"9924","08-12-04","STIEFEL CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HAIR GROWTH INHIBITOR","INHIBITEUR DE LA POUSSE DE CHEVEUX","",""
"9925","08-12-04","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","EXPANDED INDICATION TO INCLUDE PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER","INDICATION ÉTENDUE AUX ENFANTS DE SIX ANS ET PLUS","AZAPEPTIDE INHIBITOR OF HIV-1 PROTEASE","INHIBITEUR AZAPEPTIDIQUE DE LA PROTÉASE DU VIH-1","",""
"9926","08-12-04","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PHARMORUBICIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9927","08-12-04","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAXOL","BRISTOL MYERS SQUIBB","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9928","08-12-02","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfilment of commitments as per the Letter of Undertaking dated May 7, 2004 for use in the adjuvant treatment of postmenopausal women with hormone receptive positive early breast cancer.","Respect des obligations énoncées dans la lettre d'engagement du 7 mai 2004 concernant l'utilisation du produit pour le traitement adjuvant du cancer du sein précoce à récepteurs hormonaux positifs chez les patientes ménopausées.","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"9929","08-12-05","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","Revised Product Monograph as requested by TPD.","Monographie de produit révisée suite à la demande de DPT.","ANTIBIOTIC / BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE / INHIBITEUR DE BÊTA-LACTAMASES","",""
"9930","08-12-09","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the Product Monograph.","Mise à jour de la monographie de produit.","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"9931","08-12-09","BRISTOL MYERS SQUIBB CANADA","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength: 100 mg Tablet.","Nouvelle concentration : comprimé de 100 mg.","PROTEIN-TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA PROTÉASE-TYROSINE KINASE","",""
"9932","08-12-10","VALEANT CANADA LIMITÉE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","PM update as per TPD's request.","Monographie de produit révisée suite à la demande de DPT.","ORAL ANTIHYPERGLYCEMIC AGENT","AGENT ANTIHYPERGLYCÉMIQUE ORAL","",""
"9933","08-12-12","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRI-CYCLEN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"9934","08-12-12","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYCLEN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"9935","08-12-12","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Dosage & Administration section and other revisions to the Product Monograph.","Révision à la section de Posologie et Administration et autres révisions à la monographie de produit.","CNS STIMULANT","STIMULANT DU SNC","",""
"9936","08-12-12","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Class labelling (updates to indication section).","Classe des traitements (mises à jour de la section de l'indication).","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"9937","08-12-12","JANSSEN ORTHO INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","SELECTIVE IMMUNOMODULATING AGENT","AGENT IMMUNOMODULATEUR SÉLECTIF","",""
"9938","08-12-15","BRACCO DIAGNOSTICS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","New manufacturing facility.","Nouvel emplacement de fabrication.","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"9939","08-12-15","INTERVET CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Alternate manufacturing site.","Variation d'emplacement du site de fabrication.","FOLLICLE STIMULATING HORMONE","HORMONE FOLLICULE-STIMULANTE","",""
"9940","08-12-15","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional clinical claims","Indications cliniques supplémentaires","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9941","08-12-15","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9942","08-12-15","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9943","08-12-11","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9944","08-12-12","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"9945","08-12-18","JHP PHARMACEUTICALS LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","DÉCONTRACTANT DES MUSCLES STRIÉS","",""
"9946","08-12-18","JHP PHARMACEUTICALS LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","DÉCONTRACTANT DES MUSCLES STRIÉS","",""
"9947","08-12-17","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Alternate drug product manufacturing facility","Nouvel établissement de fabrication pour le produit médicamenteux","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9948","08-12-18","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph revised","Monographie de produit révisée","ANTI-NEOVASCULARISATION AGENT","AGENT ANTI-NÉOVASCULARISATION","",""
"9949","08-12-18","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Manufacturing site change and change in non-functional coating","Changement d'un emplacement de fabrication et changement d'un pelliculage non fonctionnel","VASOACTIVE AGENT","AGENT VASOACTIF","",""
"9950","08-12-18","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: use in adults and children 12 years of age and older in the treatment of symptoms associated with mild to moderate uncomplicated acute rhinosinusitis where signs or symptoms of bacterial infection are not present.","Nouvelle indication : usage chez les adultes et enfants de plus de 12 ans pour le traitement de symptômes associés à une rhinosinusite aiguë, bénigme ou modérée, en l'absence de signes et symptômes d'infection bactérienne.","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"9951","08-12-18","STRIDES CANADA","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","Update to the Product Monograph to be in line with CRP","Mise à jour de la monographie de produit pour qu'elle corresponde à celle du produit de référence canadien","ANTIBIOTIC / BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE / INHIBITEUR DE BÊTA-LACTAMASES","",""
"9952","08-12-19","ASTRAZENECA CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph sections: Clinical Pharmacology; Warnings; Adverse Reactions; Toxicology; and Information for the Patient.","Mise à jour des sections suivantes de la monographie de produit : Pharmacologie clinique, Mises en garde, Effets indésirables, Toxicologie et Renseignements pour le consommateur.","EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKI)","INHIBITEUR DE LA TYROSINE KINASE DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE (EGFR)","",""
"9953","08-12-19","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"9954","08-12-19","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Class labelling","Classe des traitements","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"9955","08-12-19","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Class labelling","Classe des traitements","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"9956","08-12-19","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Class labelling","Classe des traitements","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"9957","08-12-19","CENTOCOR INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product monograph revised","Monographie de produit révisée","BIOLOGIC RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"9958","08-12-22","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"9959","08-12-22","MEDEXUS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","METHOTREXATE INJECTION USP","MAYNE PHARMA (CANADA) INC.","CANADA","CANADA","1","Addition of new strengths","Ajout de nouvelles concentrations","ANTIMETABOLITE / ANTIRHEUMATIC","ANTIMÉTABOLITE / ANTIRHUMATISMAL","",""
"9960","08-12-22","GW PHARMA LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Safety updates to various sections of the product monograph","Des mises à jour sur l'innocuité dans les diverses sections de la monographie de produit","CANNABINOID ANALGESIC","ANALGÉSIQUE CANNABINOÏDE","",""
"9961","08-12-23","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: treatment of bipolar mania","Nouvelle indication : traitement de manie bipolaire","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"9962","08-12-23","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of 500 IU beside the heading of the brand name on the product label and carton","Ajout de 500 UI à côté du nom du produit sur l'étiquette et le carton","ANTIHEMORRHAGICS, BLOOD COAGULATION FACTORS IX, II, VII, X IN COMBINATION","ANTIHÉMORRAGIQUES, ASSOCIATION DES FACTEURS DE COAGULATION SANGUINS IX, II, VII, X","",""
"9963","08-12-23","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL CONTRACEPTIVE / ACNE THERAPY","CONTRACEPTIF ORAL / TRAITEMENT DE L'ACNÉ","",""
"9964","08-12-23","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"9965","08-12-23","BIOVAIL PHARMACEUTICALS CANADA DIVISION OF BIOVAIL CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MONOAMINE DEPLETING AGENT","AGENT DE DÉPLÉTION DES MONOAMINES","",""
"9966","08-12-23","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARAPLATIN-AQ","BRISTOL-MYERS SQUIBB CANADA","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9967","08-12-23","BAUSCH & LOMB INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"9968","08-12-24","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Class labelling","Classe des traitements","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"9969","08-12-24","GLAXOSMITHKLINE SHIRE CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"9970","08-12-24","GLAXOSMITHKLINE SHIRE CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9971","08-12-24","GLAXOSMITHKLINE SHIRE CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9972","08-12-24","GLAXOSMITHKLINE SHIRE CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9973","08-12-24","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Class labelling","Classe des traitements","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"9974","08-12-24","GLAXOSMITHKLINE SHIRE CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"9975","08-12-23","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional indications","Indications supplémentaires","ANTIBIOTIC","ANTIBIOTIQUE","",""
"9976","08-12-22","MACLEOD PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"9977","08-12-29","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"9978","08-12-30","GENPHARM ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADALAT XL","BAYER INC","CANADA","CANADA","1","","","ANTIANGINAL / ANTIHYPERTENSIVE AGENT","ANTIANGINEUX / ANTIHYPERTENSEUR","",""
"9979","08-12-31","AUROBINDO PHARMA LIMITED UNIT III","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"9980","08-12-31","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Clinical Trials section of the Product Monograph","Révisions à la section Essais cliniques de la monographie de produit","SYNTHETIC OCTAPEPTIDE ANALOGUE OF SOMATOSTATIN","OCTAPEPTIDE SYNTHÉTIQUE ANALOGUE DE LA SOMATOSTATINE","",""
"9981","09-01-02","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Indications and Clinical Use section of the Product Monograph","Révisions à la section Indications et utilisation clinique de la monographie de produit","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9982","09-01-06","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANDROGEN / ANABOLIC","ANDROGÈNE / ANABOLISANT","",""
"9983","09-01-05","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANDROGEN","ANDROGÈNE","",""
"9984","09-01-06","CSL BEHRING CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of Canadian plasma as the starting material for the manufacturing of Privigen","Ajout de plasma canadien comme substance de départ à la fabrication de Privigen","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"9985","09-01-08","CSL BEHRING CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Indication in von Willebrand disease: To prevent excessive bleeding during and after surgery in adult and pediatric patients","Nouvelle indication dans la maladie de von Willebrand : Prévention des saignements excessifs durant et après la chirurgie chez les patients adultes et enfants","COAGULATION THERAPY","THÉRAPIE DE COAGULATION","",""
"9986","09-01-09","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC AGENT","HYPOGLYCÉMIANT","",""
"9987","09-01-09","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength: 150 mg","Nouvelle concentration : 150 mg","PSYCHOTROPIC AGENT","PSYCHOTROPE","",""
"9988","09-01-06","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New formulation: 100mg/vial powder for solution for injection","Nouvelle formulation : poudre pour solution injectable en flacon de 100 mg","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"9989","09-01-12","SERVIER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength: 8mg/2.5mg","Nouvelle concentration : 8mg/2.5mg","ANGIOTENSIN CONVERTING ENZYME INHIBITOR / DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE / DIURÉTIQUE","",""
"9990","09-01-13","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"9991","09-01-13","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","BIOVAIL PHARMACEUTICALS CANADA","CANADA","CANADA","1","","","BETA-ADRENOCEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"9992","09-01-13","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA TYROSINE KINASE DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE (EGFR)","",""
"9993","09-01-13","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"9994","09-01-13","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication for use of Reyataz, boosted with Ritonavir, in treatment-naïve HIV-infected patients","Nouvelle indication pour l'usage de Reyataz, potentialisé par le ritonavir, dans le traitement des patients infectés par le VIH qui n'ont jamais été traités (naïfs)","AZAPEPTIDE INHIBITOR OF HIV-1 PROTEASE","INHIBITEUR AZAPEPTIDIQUE DE LA PROTÉASE DU VIH-1","",""
"9995","09-01-14","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE POULENC RORER CANADA INC","CANADA","CANADA","1","","","HYPNOTIC AGENT","HYPNOTIQUE / SÉDATIF","",""
"9996","09-01-15","NYCOMED CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Extended indication: prophylactic management of steroid-responsive bronchial asthma in children 6-11 years of age","L'extension du traitement prophylactique de l'asthme bronchique aux enfants de 6-11 ans","COTICOSTEROID FOR ORAL INHALATION","COTICOSTÉROÏDE POUR INHALATION BUCCALE","",""
"9997","09-01-16","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTI-DIABETIC AGENT / INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE / AGENT RÉDUCTEUR DE L'INSULINORÉSISTANCE","",""
"9998","09-01-16","IMCLONE SYSTEMS INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the Clinical Trials section in Part 2 of the Product Monograph","Mise à jour de la section Essais Cliniques dans la partie 2 de la monographie de produit","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"9999","09-01-15","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC. / ALTANA PHARMA AG","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"10000","09-01-16","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To replace sterility test with Process Parametric Release","Le test de stérilité sera remplacé par une autorisation de libération en fonction des paramètres","INTRAVENOUS NUTRIENT SUPPLEMENT","SUPPLÉMENT NUTRITIF INTRAVEINEUX","",""
"10001","09-01-20","BAUSCH & LOMB INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"10002","09-01-21","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"10003","09-01-23","BAYER HEALTHCARE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Indication: When used as a regular prophylactic treatment, HELIXATE FS is also indicated to prevent the occurrence of spontaneous hemorrhagic episodes and to prevent joint damage in children with no pre-existing joint damage","Nouvelle Indication : HELIXATE FS utilisé comme traitement prophylactique est aussi indiqué pour prévenir les hémorragies spontanées ainsi que les dommages articulaires chez les enfants qui n'ont pas de dommages articulaires pré-existants","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"10004","09-01-22","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in site of manufacture of the drug product","Changement de l'emplacement de fabrication","MUSCARINIC M3 SELECTIVE RECEPTOR ANTAGONIST","ANTAGONISTE SÉLECTIF DES RÉCEPTEURS MUSCARINIQUES M3","",""
"10005","09-01-23","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Indication: When used as a regular prophylactic treatment, KOGENATE FS is also indicated to prevent the occurrence of spontaneous hemorrhagic episodes and to prevent joint damage in children with no pre-existing joint damage","Nouvelle Indication : KOGENATE FS utilisé comme traitement prophylactique est aussi indiqué pour prévenir les hémorragies spontanées ainsi que les dommages articulaires chez les enfants qui n'ont pas de dommages articulaires pré-existants","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"10006","09-01-26","BIOVITRUM AB (PUBL)","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","KERATINOCYTE GROWTH FACTOR","FACTEUR DE CROISSANCE KÉRATINOCYTE","",""
"10007","09-01-26","BIOVITRUM AB (PUBL)","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HEMATOPOIETIC AGENT","AGENT HÉMATOPOÏÉTIQUE","",""
"10008","09-01-26","BIOVITRUM AB (PUBL)","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOMODULATORY AGENT","AGENT D'IMMUNOMODULATION","",""
"10009","09-01-27","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","ORAL CONTRACEPTIVE / ACNE THERAPY","CONTRACEPTIF ORAL / TRAITEMENT DE L'ACNÉ","",""
"10010","09-01-27","LUNDBECK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Dosage & Administration section and other revisions to the Product Monograph","Révisions à la section de Posologie et Administration et autres révisions à la monographie de produit","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"10011","09-01-27","GENZYME CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New indication: for the treatment of patients with previously untreated progressive B-cell chronic lymphocytic leukemia (B-CLL)","Nouvelle indication : traitement de patients présentant une leucémie lymphoïde chronique B (LLC B) progressive non traitée précédemment","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"10012","09-01-28","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","LOWER GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DE LA PARTIE BASSE DU TUBE DIGESTIF","",""
"10013","09-01-28","ALEXION PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","COMPLEMENT INHIBITOR","INHIBITEUR DU COMPLÉMENT","",""
"10014","09-01-29","NU PHARM INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New formulation","Nouvelle formulation","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"10015","09-01-29","DRAXIMAGE A DIVISION OF DRAXIS SPECIALTY PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOPHARMACEUTICAL","PRODUIT RADIOPHARMACEUTIQUE","",""
"10016","09-01-30","DECHRA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-CORTICOSTEROID","ANTI-CORTICOSTÉROÏDE","",""
"10017","09-01-30","DECHRA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-CORTICOSTEROID","ANTI-CORTICOSTÉROÏDE","",""
"10018","09-01-30","DECHRA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-CORTICOSTEROID","ANTI-CORTICOSTÉROÏDE","",""
"10019","09-01-30","DECHRA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-CORTICOSTEROID","ANTI-CORTICOSTÉROÏDE","",""
"10020","08-11-07","LANTHEUS MI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","RADIOPHARMACEUTIQUE POUR USAGE DIAGNOSTIQUE","",""
"10021","09-02-03","TALECRIS BIOTHERAPEUTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Indication: chronic inflammatory demyelinating polyneuropathy","Nouvelle indication : polyneuropathie inflammatoire chronique démyélinisante","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"10022","09-02-04","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"10023","98-11-01","DUPONT PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE","",""
"10024","09-02-04","UMAN PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PHARMORUBICIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"10025","09-02-04","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTITHROMBOTIC","ANTITHROMBOTIQUE","",""
"10026","09-02-04","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"10027","09-02-04","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","New indication: For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii","Nouvelle indication : Pour le traitement du piétin (nécrobacillose interdigitée) associé à Fusobacterium necrophorum et Porphyromonas levii","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"10028","09-02-05","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPO-PROVERA","PFIZER CANADA INC","CANADA","CANADA","1","","","PROGESTOGEN","PROGESTATIF","",""
"10029","09-02-06","HOFFMANN LA ROCHE LIMITED","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Indication: Avastin (bevacizumab) in combination with paclitaxel is indicated for the treatment of patients with metastatic HER2-negative breast cancer and who are ECOG Class 0-1","Nouvelle Indication : Avastin (bevacizumab) est indiqué en association avec le paclitaxel pour le traitement des patients atteints de cancer du sein métastatique HER2 négatif et ayant un indice fonctionnel ECOG de 0 ou 1","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"10030","09-02-04","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HUMAN GONADOTROPIN","GONADOTROPHINE HUMAINE","",""
"10031","09-02-06","DRAXIMAGE A DIVISION OF DRAXIS SPECIALTY PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","CARDIOLITE","LANTHEUS MI CANADA INC","CANADA","CANADA","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"10032","09-02-09","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FAMVIR","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"10033","09-02-09","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FAMVIR","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"10034","09-02-10","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"10035","09-02-10","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","HORMONAL CONTRACEPTIVE","CONTRACEPTIF HORMONAL","",""
"10036","09-02-11","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDRIOL","ORGANON CANADA LTD","CANADA","CANADA","1","","","ANDROGEN","ANDROGÈNE","",""
"10037","09-02-11","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfillment of commitments","Satisfaction des engagements","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"10038","09-02-13","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XATRAL","SANOFI-SYNTHELABO CANADA INC","CANADA","CANADA","1","","","SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / ADJUNCTIVE THERAPY IN ACUTE URINARY RETENTION (AUR)","TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE (HBP) / TRAITEMENT ADJUVANT DE LA RÉTENTION URINAIRE AIGUË (RUA)","",""
"10039","09-02-16","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXIPIME","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10040","09-02-18","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product monograph update","Mise à jour de la monographie de produit","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"10041","09-02-18","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To extend the currently approved duration of treatment of enoxaparin for prevention of venous thromboembolic disease following hip replacement surgery for up to 35 days","Augmentation de la durée du traitement de prévention de thromboses veineuses jusqu'à 35 jours dans les cas de prothèse de la hanche","ANTICOAGULANT / ANTITHROMBOTIC AGENT","ANTICOAGULANT / ANTITHROMBOTIQUE","",""
"10042","09-02-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KYTRIL","ROCHE LABORATORIES INCORPORATED (USA)","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEMETIC / 5-HT3 RECEPTOR ANTAGONIST","ANTIÉMÉTIQUE / ANTAGONISTE DES RÉCEPTEURS 5-HT3","",""
"10043","09-02-19","SHIRE CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER","STIMULANT DU SYSTÈME NERVEUX CENTRAL POUR LE TROUBLE DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ","",""
"10044","09-02-19","LABORATOIRE HRA PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New dose regimen","Nouveau schéma posologique","EMERGENCY CONTRACEPTION","CONTRACEPTIF D'URGENCE","",""
"10045","09-02-20","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KYTRIL","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"10046","09-02-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KYTRIL","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"10047","09-02-19","AMGEN CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","THROMBOPOIESIS-STIMULATING PROTEIN","PROTÉINE STIMULANT LA THROMBOPOÏÈSE","",""
"10048","09-02-20","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"10049","09-02-20","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"10050","09-02-20","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"10051","09-02-23","ACS DOBFAR INFO SA","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V. MINI BAGS","BAYER INC","CANADA","CANADA","1","Replace the sterility test with process parametric release in the drug product specifications","Substitution des épreuves de stérilité par un procédé de libération en fonction de paramètres dans les spécifications du produit","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10052","09-02-23","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PHARMORUBICIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"10053","09-02-24","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KYTRIL","HOFFMAN-LA ROCHE","CANADA","CANADA","1","","","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"10054","09-02-24","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","SELECTIVE ANTAGONIST OF ALPHA 1A ADRENORECEPTOR SUBTYPE IN THE PROSTATE","ANTAGONISTE SÉLECTIF DE SOUS-TYPES DES RÉCEPTEURS ALPHA 1A ADRÉNERGIQUES DE LA PROSTATE","",""
"10055","09-02-24","SEPRACOR PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"10056","09-02-24","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CONTRACEPTIVE VAGINAL RING","ANNEAU VAGINAL CONTRACEPTIF","",""
"10057","09-02-24","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"10058","09-02-24","JOHNSON & JOHNSON INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","AGENT FOR THE TREATMENT OF PHOTODAMAGED SKIN","AGENT POUR LE TRAITEMENT DE LA PEAU ENDOMMAGÉE SUITE À UNE EXPOSITION AU SOLEIL OU À LA LUMIÈRE ULTRAVIOLETTE","",""
"10059","09-02-24","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"10060","09-02-24","BRISTOL MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"10061","09-02-26","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: Generalized Anxiety Disorder","Nouvelle indication : Trouble d'anxiété généralisée","ANTIDEPRESSANT / ANXIOLYTIC / ANALGESIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE / ANALGÉSIQUE","",""
"10062","09-02-26","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Drug-drug interaction and safety update","Interactions médicamenteuses et mise à jour de l'innocuité du produit","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"10063","09-02-26","JANSSEN PHARMACEUTICA N.V.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIOBESITY","ANTI-OBÉSITÉ","",""
"10064","09-02-26","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ALDOSTERONE ANTAGONIST","ANTAGONISTE DE L'ALDOSTÉRONE","",""
"10065","09-02-26","GALDERMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"10066","09-03-02","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","AZAPEPTIDE INHIBITOR OF HIV-1 PROTEASE","INHIBITEUR AZAPEPTIDIQUE DE LE PROTÉASE DU VIH-1","",""
"10067","09-03-03","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing site","Nouveau lieu de fabrication","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"10068","09-03-04","ORBUS PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFTIN","GLAXOSMITHKLINE CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10069","09-03-04","IMCLONE SYSTEMS INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing site / New vial size","Nouvel emplacement de fabrication / Nouvelle grandeur de fiole","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"10070","09-03-04","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfilment of commitments","Satisfaction des engagements","HIV INTEGRASE STRAND TRANSFER INHIBITOR","INHIBITEUR DE TRANSFERT DE BRIN DE L'INTÉGRASE DU VIH","",""
"10071","09-03-04","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Management of pain associated with fibromyalgia","Nouvelle indication : Contrôle de la douleur associée à la fibromyalgie","ANALGESIC AGENT","ANALGÉSIQUE","",""
"10072","09-03-05","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"10073","09-03-04","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New intermediate strengths: 15 mg, 30 mg, 60 mg, 120 mg","Nouvelles doses : 15 mg, 30 mg, 60 mg, 120 mg","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"10074","09-03-05","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"10075","09-03-05","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIPYRETIC","ANTIPYRÉTIQUE","",""
"10076","09-03-09","GLAXOSMITHKLINE SHIRE CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of score to currently approved tablet","Ajout d'une rainure au comprimé déjà approuvé","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"10077","09-03-09","NORBROOK LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","RIMADYL CAPLETS","PFIZER CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"10078","09-03-09","NORBROOK LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","RIMADYL CAPLETS","PFIZER CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"10079","09-03-09","NORBROOK LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","RIMADYL CAPLETS","PFIZER CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"10080","09-03-04","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: The treatment to increase bone mineral density in men with osteoporosis, as a once-yearly infusion","Nouvelle indication : Le traitement, administré par perfusion une fois par année, vise à accroître la densité minérale osseuse chez les hommes souffrant d'ostéoporose","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"10081","09-03-10","BAYER HEALTHCARE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New sterile fill facility","Nouvel établissement de remplissage stérile","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"10082","09-03-10","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New sterile fill facility","Nouvel établissement de remplissage stérile","COAGULATION FACTOR","FACTEUR DE COAGULATION","",""
"10083","09-03-11","GRACEWAY PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE IMMUNITAIRE","",""
"10084","09-03-11","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the product monograph; addition of 48 week data","Mises à jour de la monographie de produit; ajouts des résultats obtenus à 48 semaines","CCR5 ANTAGONIST","ANTAGONISTE DU CCR5","",""
"10085","09-03-12","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"10086","09-03-11","ELANCO DIVISION ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","New capsule design","Nouvelle conception de capsule","ANTI-KETOGENIC AGENT","AGENT ANTI-CÉTOGÉNIQUE","",""
"10087","09-03-12","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication for treatment naive adults, new 400 mg and 600 mg tablets, and new once daily dosage regimen","Indication clinique additionnelle pour le traitement des patients naïfs aux antirétroviraux, nouveaux comprimés de 400 mg et 600 mg et nouvelle posologie d'une dose quotidienne","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"10088","09-03-13","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIANGINAL / ANTIHYPERTENSIVE AGENT","ANTIANGINEUX / ANTIHYPERTENSEUR","",""
"10089","09-03-13","COBALT PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"10090","09-03-13","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"10091","09-03-13","NORBROOK LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","CLAVAMOX TABLETS","PFIZER CANADA INC., ANIMAL HEALTH GROUP","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10092","09-03-13","NORBROOK LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","CLAVAMOX TABLETS","PFIZER CANADA INC., ANIMAL HEALTH GROUP","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10093","09-03-13","NORBROOK LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","CLAVAMOX TABLETS","PFIZER CANADA INC., ANIMAL HEALTH GROUP","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10094","09-03-13","NORBROOK LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","CLAVAMOX TABLETS","PFIZER CANADA INC., ANIMAL HEALTH GROUP","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10095","09-03-13","MERZ PHARMACEUTICALS GMBH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","NEUROMUSCULAR PARALYTIC AGENT","AGENT PARALYSANT DU FUSEAU NEUROMUSCULAIRE","",""
"10096","09-03-12","GENPHARM ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADALAT XL","BAYER INC","CANADA","CANADA","1","Product name change. Revisions to the product monograph","Modification du nom du produit. Révisions à la monographie de produit","ANTIANGINAL / ANTIHYPERTENSIVE AGENT","ANTIANGINEUX / ANTIHYPERTENSEUR","",""
"10097","09-03-16","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"10098","09-03-17","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of a new compounding and filling site for EPREX pre-filled syringes","L'addition d'un nouveau site pour le malaxage et le remplissage des seringues pré-remplies d'Eprex","ERYTHROPOIESIS REGULATING HORMONE","HORMONE RÉGULATRICE DE L'ÉRYTHROPOÏÈSE","",""
"10099","09-03-18","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","BETA-ADRENERGIC AGONIST","AGONISTE BÊTA-ADRÉNERGIQUE","",""
"10100","09-03-18","JUROX PTY LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GABAA RECEPTOR BLOCKER","INHIBITEUR DES RÉCEPTEURS GABAA","",""
"10101","09-03-18","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in manufacturing and formulation","Changement d'un emplacement de fabrication et de la formulation","ANTIANGINAL / ANTIHYPERTENSIVE AGENT","ANTIANGINEUX / ANTIHYPERTENSEUR","",""
"10102","09-03-19","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternative site of administration - deltoid muscle","Site d'administration alternatif; muscle deltoïde","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"10103","09-03-19","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","The addition of new physician sample labelling","Nouvelle étiquette des échantillons destinés aux médecins","DIRECT FACTOR XA INHIBITOR","INHIBITEUR DIRECT DU FACTEUR XA","",""
"10104","09-03-18","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: The treatment and prevention of glucocorticoid-induced osteoporosis, to increase bone mineral density, as a once-yearly intravenous infusion","Nouvelle indication : Utilisé pour le traitement et la prévention de l'ostéoporose induite par des glucocorticoïdes, ce médicament vise à augmenter la densité minérale osseuse et est administré par perfusion intraveineuse annuelle","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"10105","09-03-19","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Safety update to the product monograph","Mise à jour de l'innocuité dans la monographie de produit","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"10106","09-03-20","RECKITT BENCKISER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HARD SURFACE DISINFECTANT","DÉSINFECTANT POUR SURFACES DURES","",""
"10107","09-03-20","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDROCAL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"10108","09-03-20","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PHARMORUBICIN PFS","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"10109","09-03-23","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Safety and efficacy updates to the product monograph based on 104 week data","Mises à jour basées sur les données obtenues sur 104 semaines, de l'information relative à l'innocuité et l'efficacité de la monographie de produit","ANTIVIRAL AGENT","ANTIVIRAL","",""
"10110","09-03-23","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOWELLCOME INC","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"10111","09-03-23","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CIE / MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"10112","09-03-23","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VINCRISTINE SULPHATE INJECTION","NOVOPHARM LIMITED","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"10113","09-03-20","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"10114","09-03-20","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"10115","09-03-23","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"10116","09-03-24","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Warnings & Precautions, Clinical Trials and Part III: Consumer Information sections of the product monograph","Modifications apportées aux sections Mises en garde et précautions, Essais cliniques, et à la partie III : Renseignements pour le patient, de la monographie de produit","ANTIDIABETIC AGENT / INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE / AGENT INSULINOSENSIBILISATEUR","",""
"10117","09-03-24","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"10118","09-03-25","WYETH ANIMAL HEALTH DIVISION OF WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","New manufacturing site","Nouvel emplacement de fabrication","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10119","09-03-24","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"10120","09-03-25","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Contraindications, Warnings & Precautions, Adverse Reactions, Drug Interactions, Overdosage, Clinical Trials, and Part III: Consumer Information sections of the product monograph","Modifications apportées aux sections Contre-indications, Mises en garde et précautions, Effets indésirables, Interactions médicamenteuses, Surdosage, Essais cliniques, et à la partie III : Renseignements pour le patient, de la monographie de produit","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"10121","09-03-25","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Contraindications, Warnings & Precautions, Overdosage, Clinical Trials and Part III: Consumer Information sections of the product monograph","Modifications apportées aux sections Contre-indications, Mises en garde et précautions, Surdosage, Essais cliniques, et à la partie III : Renseignements pour le patient, de la monographie de produit","ANTIDIABETIC AGENT","ANTIDIABÉTIQUE","",""
"10122","09-03-27","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","New Indication: Avastin, in combination with carboplatin/paclitaxel chemotherapy regimen, is indicated for treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer","Nouvelle indication : Avastin, en combinaison avec un régimen de chimiothérapie à base de carboplatine et de paclitaxel, est indiqué chez les patients atteints d'un cancer du poumon non à petites cellules (non squameux) et non résécable avancé, métastatique ou récurrent","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"10123","09-03-27","INSITE VISION INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MACROLIDE ANTIBIOTIC","ANTIBIOTIQUE MACROLIDE","",""
"10124","09-03-30","BIO AGRI MIX LP","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","DENAGARD SOLUBLE POWDER","NOVARTIS ANIMAL HEALTH CANADA INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10125","09-03-31","BIONICHE ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SYNOVIAL FLUID SUBSTITUTE","SUBSTITUT DE LIQUIDE SYNOVIAL","",""
"10126","09-03-30","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EVISTA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","SELECTIVE ESTROGEN RECEPTOR MODULATOR","MODULATEUR SÉLECTIF DES RÉCEPTEURS ESTROGÉNIQUES","",""
"10127","09-03-31","CARIDIANBCT INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","RED BLOOD CELL STORAGE SOLUTION","SOLUTION D'ENTREPOSAGE POUR LE CULOT GLOBULAIRE","",""
"10128","09-03-31","BIO AGRI MIX LP","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","TYLAN SOLUBLE","ELANCO, DIVISION ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10129","09-04-01","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NEUROKININ 1 (NK1) RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE LA NEUROKININE (NK1)","",""
"10130","09-04-02","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","ANTIHYPERTENSIVE AGENT AND PLATELET AGGREGATION INHIBITOR","ANTIHYPERTENSEUR ET INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"10131","09-04-03","INTERVET CANADA CORP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Alternate manufacturing site","Variation d'emplacement du site de fabrication","HORMONE","HORMONE","",""
"10132","09-04-06","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"10133","09-04-07","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product monograph update","Mise à jour de la monographie de produit","LUNG SURFACTANT","SURFACTANT PULMONAIRE","",""
"10134","09-04-08","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"10135","09-04-07","CENTOCOR INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","TUMOR NECROSIS FACTOR ALPHA INHIBITOR","INHIBITEUR DU FACTEUR NÉCROSE TUMORALE ALPHA","",""
"10136","09-04-08","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10137","09-04-08","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"10138","09-04-08","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","KNOLL PHARMA INC","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"10139","09-04-08","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID / NSAID COMBINATION ANALGESIC","OPIOÏDES / ANALGÉSIQUE AINS","",""
"10140","09-04-08","SEPRACOR PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"10141","09-04-08","SEPRACOR PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"10142","09-04-08","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC","ANALGÉSIQUE","",""
"10143","09-04-09","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SNC","",""
"10144","09-04-09","HUVEPHARMA AD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"10145","09-04-09","HUVEPHARMA AD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"10146","09-04-14","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EVISTA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","SELECTIVE ESTROGEN RECEPTOR MODULATOR","MODULATEUR SÉLECTIF DES RÉCEPTEURS ESTROGÉNIQUES","",""
"10147","09-04-09","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New formulation","Nouvelle formulation","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"10148","09-04-09","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to Indication and Clinical Use, Dosage and Administration, and Consumer Information sections of the Product Monograph: Eligard should be administered by a health care professional","Modification apportée aux sections Indications et utilisation clinique, Posologie et administration et Renseignements pour le patient, de la monographie de produit : Eligard devrait être administré par un professionel de la santé","LUTEINIZING HORMONE-RELEASING HORMONE ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE","",""
"10149","09-04-14","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MOTRIN","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","Update to the Product Monograph","Mise à jour de la monographie de produit","ANALGESIC / ANTIPYRETIC AGENT","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"10150","09-04-15","TEVA PHARMACEUTICALS INDUSTRIES LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Treatment of patients with Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis","Traitement des patients présentant un syndrome clinique isolé, évocateur de la sclérose en plaques","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"10151","09-04-15","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength","Nouvelle concentration","ELEVATED INTRAOCULAR PRESSURE THERAPY","THÉRAPIE POUR RÉDUIRE LA PRESSION INTRAOCULAIRE","",""
"10152","09-04-15","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","URSO (250 MG) AND URSO DS (500 MG)","AXCAN PHARMA INC","CANADA","CANADA","1","","","CHOLESTATIC LIVER DISEASE","MALADIES HÉPATIQUES CHOLESTATIQUES","",""
"10153","09-04-15","AMDIPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10154","09-04-15","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional drug product manufacturing facility, changes to drug product batch size, manufacturing process and in-process controls","Addition d'un emplacement de fabrication du produit médicamenteux, changements apportés à la taille des lots du produit médicamenteux, à la fabrication et aux limites en cours de fabrication","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"10155","09-04-15","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional drug product manufacturing facility, changes to drug product batch size, manufacturing process and in-process controls","Addition d'un emplacement de fabrication du produit médicamenteux, changements apportés à la taille des lots du produit médicamenteux, à la fabrication et aux limites en cours de fabrication","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"10157","09-04-17","THREE RIVERS PHARMACEUTICALS LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","AGENT D'IMMUNOMODULATION","",""
"10158","09-04-15","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional drug product manufacturing facility, changes to drug product batch size, manufacturing process and in-process controls","Addition d'un emplacement de fabrication du produit médicamenteux, changements apportés à la taille des lots du produit médicamenteux, à la fabrication et aux limites en cours de fabrication","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"10159","09-04-17","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID / NSAID COMBINATION ANALGESIC","OPIOÏDES / ANALGÉSIQUE AINS","",""
"10160","09-04-17","SEPRACOR PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"10161","09-04-17","MCNEIL CONSUMER HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC / ANTIPYRETIC / NASAL DECONGESTANT","ANALGÉSIQUE / ANTIPYRÉTIQUE / DÉCONGESTIONNANT NASAL","",""
"10162","09-04-17","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","LACRIMOMIMETIC, ANTI-INFLAMMATORY","LACRIMOMIMÉTIQUE, ANTI-INFLAMMATOIRE","",""
"10163","09-04-20","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the following sections in the Product Monograph: Warnings and Precautions, Clinical Trial Adverse Drug Reactions, and Clinical Trials","Modifications apportées aux sections suivantes de la monographie de produit : Mises en garde et précautions, Effets indésirables du médicament observés au cours des essais cliniques, et Essais cliniques","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"10164","09-04-20","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Dosage and Administration section and other revisions to the Product Monograph","Mise à jour de la section de posologie et administration et autres révisions de la monographie de produit","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"10165","09-04-21","HUVEPHARMA AD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"10166","09-04-21","PHIBRO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10167","09-04-15","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional drug product manufacturing facility, changes to drug product batch size, manufacturing process and in-process controls","Addition d'un emplacement de fabrication du produit médicamenteux, changements apportés à la taille des lots du produit médicamenteux, à la fabrication et aux limites en cours de fabrication","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"10168","09-04-22","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"10169","09-04-21","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing area","Nouvelle zone de fabrication","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"10170","09-04-22","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: Children 17 years & younger","Indication additionnelle : pour les enfants de 17 ans et moins","ANTIFUNGAL","ANTIFONGIQUE","",""
"10171","09-04-22","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing site, modification of the manufacturing process","Addition d'un nouveau site de fabrication, modification au processus de fabrication","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIF","",""
"10172","09-04-23","CANGENE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Indication: HepaGam B is indicated for the treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg positive persons and household exposure to persons with acute HBV infection (collectively known as post-exposure prophylaxis)","Nouvelle Indication : HepaGam B est indiqué dans le traitement de l'exposition aiguë à du sang contenant l'antigène HBs, de l'exposition en phase périnatale de nouveau-nés dont la mère est porteuse de l'antigène HBs, de rapports sexuels avec une personne porteuse de l'antigène HBs ou de l'exposition dans un milieu où vit une  personne ayant une infection aiguë au VHB (collectivement appelé prophylaxie post-exposition)","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"10173","09-04-23","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTI-ANGINAL AGENT","ANTIANGINEUX","",""
"10174","09-04-23","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY / ANALGESIC","ANTI-INFLAMMATOIRE TOPIQUE / ANALGÉSIQUE","",""
"10175","09-04-20","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"10176","09-04-23","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength","Nouvelle concentration","ESTROGEN","OESTROGÈNE","",""
"10177","09-04-24","BAYER INC CONSUMER CARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"10178","09-04-28","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"10179","09-04-28","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANTIOBSESSIONAL / ANTIPANIC / ANXIOLYTIC AGENT / SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER / POSTRAUMATIC STRESS DISORDER) THERAPY","ANTIDÉPRESSEUR / ANTIOBSESSIONNEL / ANTIPANIQUE / ANXIOLYTIQUE / TRAITEMENT DE LA PHOBIE SOCIALE / TRAITEMENT DE L'ÉTAT DE STRESS POST-TRAUMATIQUE","",""
"10180","09-04-29","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10181","09-04-24","BAYER INC CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Proposed label for one caplet professional sample; revisions to the Product Monograph","Étiquette proposée pour l'échantillon d'un comprimé destiné aux professionnels; révisions à la monographie de produit","ANALGESIC / ANTIPYRETIC / ANTI-INFLAMMATORY","ANALGÉSIQUE / ANTIPYRÉTIQUE / ANTI-INFLAMMATOIRE","",""
"10182","09-04-30","4349121 CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10183","09-04-30","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Safety update to the Product Monograph","Mise à jour de l'innocuité dans la monographie de produit","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10184","09-04-30","SEPRACOR PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIRECT THROMBIN INHIBITOR","INHIBITEUR DIRECT DE LA THROMBINE","",""
"10185","09-04-30","ORGANON CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Clinical Trials section of the Product Monograph and other revisions to the PM","Mise à jour de la section des études cliniques et autres révisions à la monographie de produit","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","BLOQUEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"10186","09-05-01","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTI-INFLAMMATORY / ANALGESIC / ANTIPYRETIC","ANTI-INFLAMMATOIRE / ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"10187","09-04-30","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Changes to the manufacturing facility","Modification à l'emplacement de fabrication","IGE-NEUTRALIZING ANTIBODY","ANTICORPS NEUTRALISANT LES IGE","",""
"10188","09-05-01","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","New strength","Nouvelle concentration","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"10189","09-05-01","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Label update as per DHPL dated January 2, 2009","Mise à jour de la monographie d'après l'avis aux professionnels de la santé du 2 janvier 2009","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"10190","09-05-01","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MOTRIN","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","Name change, addition of indication, warnings and non-medicinal ingredients to container labels","Changement de nom, ajout d'indications, de mise en garde et d'ingrédients non-médicinaux aux étiquettes de conditionnement","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) / ANALGESIC / ANTIPYRETIC AGENT","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS) / ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"10191","09-05-01","DENTSPLY CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANESTHETIC FOR PERIDONTAL USE","POUR USAGE PARODONTAL","",""
"10192","09-05-06","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"10193","09-05-06","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS, DIV. OF WARNER-LAMBERT CANADA INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"10194","09-05-06","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE","BAYER INC.","CANADA","CANADA","1","Product name change","Modification du nom du produit","PLATELET AGGREGATION INHIBITOR","INHIBITEUR D'AGGLOMÉRATION DES PLAQUETTES","",""
"10195","09-05-07","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"10196","09-05-07","STRAGEN INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHIN","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10197","09-05-07","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXY-IR","PURDUE PHARMA INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"10198","09-05-08","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDRIOL","ORGANON CANADA LTD","CANADA","CANADA","1","Product name change","Modification du nom du produit","ANDROGEN","ANDROGÈNE","",""
"10199","09-05-07","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form: 30 mg/tab","Nouvelle forme posologique : 30 mg/tab","CALCIUM CHANNEL BLOCKING AGENT","INHIBITEUR DES CANAUX CALCIQUES","",""
"10200","09-05-11","ALBERTA HEALTH SERVICES","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","RADIOPHARMACEUTIQUE À USAGE DIAGNOSTIQUE","",""
"10201","09-05-11","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New indication: fixation of autologous skin grafts and skin flaps and adjunct to hemostatis on subcutaneous tissue surfaces to treat burns in adult and pediatric patients, additional viral inactivation step, introduction of synthetic aprotinin, introduction of frozen liquid presentation","Nouvelle indication : fixation d'autogreffes cutanées et de greffons de peau et adjuvant à l'hémostase des tissus sous-cutanés pour traiter les brûlures chez l'adulte et l'enfant, étape additionnelle d'inactivation virale, présentation d'aprotinine synthétique et nouvelle formulation liquide congelée","HEMOSTATIC AGENT","AGENT HÉMOSTATIQUE","",""
"10202","09-05-12","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"10203","09-05-12","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","ANTIEPILEPTIC / MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE / PROPHYLAXIE DE LA MIGRAINE","",""
"10204","09-05-12","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"10205","09-05-12","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"10206","09-05-12","ZYMCAN PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"10207","09-05-12","ZYMCAN PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SKELETAL MUSCLE RELAXANT","RELAXANT MUSCULAIRE SQUELETTIQUE","",""
"10208","09-05-12","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"10209","09-05-12","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Removal of contraindication Congestive heart failure requiring pharmacologic treatment","Retrait de la contre-indication insuffisance cardiaque congestive nécessitant un traitement pharmacologique","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"10210","09-05-13","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","New package size","Nouveau format d'emballage","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"10211","09-05-13","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: Prevention of Venous Thromboembolic Events (VTE) in cancer patients undergoing abdominal surgery","Nouvelle indication : Prévention d'évènements thrombo-emboliques chez les cancéreux subissant une chirurgie abdominale","SYNTHETIC ANTITHROMBOTIC","ANTITHROMBOTIQUE SYNTHÉTIQUE","",""
"10212","09-05-14","ZYMCAN PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"10213","09-05-14","GENPHARM ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Indications and Clinical Use, Warnings, Precautions, Adverse Reactions, Dosage and Administration and Information for the Patient sections of the Product Monograph","Modifications apportées aux sections de la monographie de produit suivantes : Indications et utilisation clinique, Mises en garde et précautions, Effets indésirables, Posologie et administration et Renseignements pour le patient","ANTI-INFLAMMATORY AGENT WITH ANALGESIC PROPERTIES","ANTI-INFLAMMATOIRE AVEC DES PROPRIÉTÉS ANALGÉSIQUES","",""
"10214","09-05-15","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MINERALCORTICOID FOR ADRENAL INSUFFICIENCY","MINÉRALOCORTICOÏDE POUR L'INSUFFISANCE SURRÉNALE","",""
"10215","09-05-15","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NIGHTTIME SLEEP AID","AIDE-SOMMEIL","",""
"10216","09-05-15","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"10217","09-05-15","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"10218","09-05-20","GILEAD SCIENCES CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"10219","09-05-20","GILEAD SCIENCES CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"10220","09-05-20","GILEAD SCIENCES CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"10221","09-05-20","GILEAD SCIENCES CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"10222","09-05-20","TAKEDA PHARMACEUTICALS NORTH AMERICA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-DIABETIC AGENT / INSULIN RESISTANCE REDUCING AGENT","ANTIDIABÉTIQUE / AGENT RÉDUCTEUR DE L'INSULINORÉSISTANCE","",""
"10223","09-05-22","RANBAXY PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New formulation","Nouvelle formulation","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"10224","09-05-22","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Clinical Trials section and revisions to the Product Monograph","Mise à jour de la section sur les essais cliniques et modifications apportées à la monographie de produit","LUTEINIZING HORMONE / RELEASING HORMONE (LHRH) ANALOG","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉOSTIMULINE (ANALOGUE DE LA LH-RH)","",""
"10225","09-05-25","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Dosage and Administration section and other revisions to the Product Monograph","Révision à la section de Posologie et administration et autres révisions à la monographie de produit","SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)","INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA NORADRÉNALINE POUR LE TROUBLE DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ (TDAH)","",""
"10226","09-05-25","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10227","09-05-27","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Major depressive disorder","Nouvelle indication : Dépression majeure","PSYCHOTROPIC AGENT","PSYCHOTROPE","",""
"10228","09-05-29","WYETH ANIMAL HEALTH DIVISION OF WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Alternate source of active ingredient","Variation d'origine de l'ingrédient actif","ANTI-INFLAMMATORY CORTICOSTEROID","ANTI-INFLAMMATOIRE CORTICOSTÉROÏDE","",""
"10229","09-06-01","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC AGENT FOR BLADDER INSTILLATION","ANTINÉOPLASIQUE","",""
"10230","09-06-03","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","TAP PHARMACEUTICALS INC","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","",""
"10231","09-06-03","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","METHOTREXATE SODIUM INJECTION USP","MAYNE PHARMA (CANADA) INC","CANADA","CANADA","1","","","ANTIMETABOLITE / ANTIRHEUMATIC AGENT","ANTIMÉTABOLITE / ANTIRHUMATISMAL","",""
"10232","09-06-03","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTICOAGULANT","ANTICOAGULANT ORAL","",""
"10233","09-05-28","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosing regimen: The ZINECARD dose should be reduced by 50% in patients with creatinine clearance values < 40 ml/min. In patients with moderate to severe renal dysfunction, the recommended dosage ratio of ZINECARD:doxorubicin is 5:1","Nouveau schéma posologique : La dose ZINECARD devrait être réduite de 50% chez les patients dont la clairance de la créatinine est < 40 ml/min. Chez les patients présentant une insuffisance rénale modérée ou grave, le rapport ZINECARD:doxorubicine recommandé est 5:1","CARDIOPROTECTIVE AGENT","AGENT CARDIOPROTECTEUR","",""
"10234","09-06-03","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID WITH ANTIBACTERIAL - ANTIFUNGAL AGENT","CORTICOSTÉROÏDE TOPIQUE AVEC ANTIBACTÉRIEN ET ANTIFONGIQUE","",""
"10235","09-06-03","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the product monograph - addition of 48/96 week data","Mise à jour de la monographie de produit - ajouts des résultats obtenus à 48/96 semaines","NON-PEPTIDIC PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE NON PEPTIDIQUE","",""
"10236","09-06-03","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"10237","09-06-03","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC.","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"10238","09-06-04","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","New indication","Nouvelle indication","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"10239","09-06-05","AMDIPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10240","09-06-05","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROSTAGLANDIN","PROSTAGLANDINE","",""
"10241","09-06-05","ACTELION PHARMACEUTICALS LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To extend the currently approved indication to include the treatment of pulmonary arterial hypertension in patients with WHO functional class II","Pour élargir l'indication actuelle aux patients atteints d'hypertension artérielle pulmonaire de classe fonctionnelle II selon la classification de l'OMS","ENDOTHELIN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"10242","09-06-08","EMD SERONO CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Updated Product Monograph","Monographie de produit révisée","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"10243","09-06-09","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT CONTRE L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"10244","09-06-09","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST - MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 - ANTIMIGRAINEUX","",""
"10245","09-06-05","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indications: For the reduction of hypercalcemia in patients with parathyroid carcinoma and for the reduction of clinically significant hypercalcemia, as defined by relevant treatment guidelines, in patients with primary HPT for whom parathyroidectomy is not clinically appropriate or is contraindicated","Nouvelles indications : Réduction de l’hypercalcémie chez les patients atteints d’un cancer parathyroïdien et réduction de l’hypercalcémie cliniquement significative, telle qu’elle est définie dans des directives de traitement pertinentes, chez les patients atteints d’hyperparathyroïdie primaire chez lesquels une parathyroïdectomie est contre-indiquée ou non indiquée","CALCIMIMETIC AGENT","AGENT CALCIMIMÉTIQUE","",""
"10246","09-06-11","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTONE DEACETYLASE INHIBITOR / ANTINEOPLASTIC AGENT","INHIBITEUR D'HISTONE DÉACÉTYLASE / ANTINÉOPLASIQUE","",""
"10247","09-06-12","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE / ANTIANGINAL AGENT","ANTIHYPERTENSEUR / ANTIANGINEUX","",""
"10248","09-06-12","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"10249","09-06-12","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC / ANTIMANIC AGENT","ANTIPSYCHOTIQUE / ANTIMANIAQUE","",""
"10250","09-06-12","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST","ANTIPARKINSONIEN / AGONISTE DOPAMINERGIQUE","",""
"10251","09-06-12","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfilment of commitments as per the Letter of Undertaking dated July 24, 2006 for the treatment of locally advanced / metastatic renal cell carcinoma in patients who failed or are intolerant to prior systemic therapy","Respect des engagements de la lettre datée du 24 juillet 2006 relativement au traitement de l'hypernéphrone localement avancé/métastatique chez les patients chez lesquels un traitement général a échoué ou ne convenait pas","MULTIKINASE INHIBITOR / ANTINEOPLASTIC AGENT","INHIBITEUR DE LA MULTIKINASE / ANTINÉOPLASIQUE","",""
"10253","09-06-16","WYETH ANIMAL HEALTH DIVISION OF WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Alternate source of active ingredient","Variation d'origine de l'ingrédient actif","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10254","09-06-16","TYCO HEALTHCARE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","CARDIOLITE","LANTHEUS MI CANADA INC","CANADA","CANADA","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIC","",""
"10256","09-06-17","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST / SYMPATHOMIMETIC AMINE","INHIBITEUR DES RÉCEPTEURS H1 DE L'HISTAMINE / AMINE SYMPATHOMIMÉTIQUE","",""
"10257","09-06-17","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Adverse Reactions, Dosage and Administration (maintenance dose) and Clinical Trials section","Modifications apportées aux sections suivantes de la monographie de produit : Effets indésirables, Posologie et administration (dose d'entretien) et Essais cliniques","IRON CHELATING AGENT","CHÉLATEUR DU FER","",""
"10258","09-06-18","BRISTOL MYERS SQUIBB CANADA","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Study: Commitment # 4 of the Letter of Undertaking dated March 13, 2007 - final results of a pharmacokinetic study of SPRYCEL in subjects with hepatic impairment. Revised Product Monograph: Changes to Warnings and Precautions, Dosage and Administration, Action and Clinical Pharmacology","Étude : Engagement 4 de la lettre datée du 13 mars 2007 - résultats finaux d'une étude pharmacocinétique de Sprycel chez des sujets souffrant d'insuffisance hépatique. Monographie de produit révisée : Modifications apportées aux sections Mises en garde et précautions, Posologie et administration, Mode d'action et pharmacologie clinique","PROTEIN-TYROSINE KINASE INHIBITOR","INHIBITEUR DE LA PROTÉASE-TYROSINE KINASE","",""
"10259","09-06-18","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAVELBINE","PIERRE FABRE PHARMA CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"10260","09-06-19","BAYER INC CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"10261","09-06-19","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10262","09-06-19","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Process parametric release","Identifier un procédé de libération en fonction de paramètres","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"10263","09-06-19","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Process parametric release","Identifier un procédé de libération en fonction de paramètres","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"10264","09-06-19","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Process parametric release","Identifier un procédé de libération en fonction de paramètres","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"10265","09-06-19","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Process parametric release","Identifier un procédé de libération en fonction de paramètres","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"10266","09-06-19","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Process parametric release","Identifier un procédé de libération en fonction de paramètres","NUTRITIVE SUPPLEMENT","SUPPLÉMENT NUTRITIF","",""
"10267","09-06-22","HUVEPHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Change in the manufacturer of the drug substance and drug product","Modification à l'emplacement de fabrication de l'ingrédient actif et du produit médicament","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"10268","09-06-22","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Dosage and Administration Section and other revisions to the Product Monograph","Révisions à la section de Posologie et Administration et autres révisions à la monographie de produit","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SNC","",""
"10269","09-06-23","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"10270","09-06-24","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10271","09-06-24","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10272","09-06-24","PHARMEL INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10273","09-06-24","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN TABLETS","JANSSEN-ORTHO INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10274","09-06-24","GENPHARM ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10275","09-06-24","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10276","09-06-24","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10277","09-06-24","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10278","09-06-24","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN (LEVOFLOXACIN)","ORTHO-MCNEIL PHARMACEUTICALS INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10279","09-06-24","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10280","09-06-24","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10281","09-06-15","LANTHEUS MI CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","An alternate source of Molybdenum Mo99","Source alternative de Molybdène Mo99","DIAGNOSTIC RADIOPHARMACEUTICAL","RADIOPHARMACEUTIQUE POUR USAGE DIAGNOSTIC","",""
"10282","09-06-24","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10283","09-06-24","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10284","09-06-24","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","Product name change from Apo-Levoflox","Modification du nom du produit de Apo-Levoflox à Apo-Levofloxacin","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"10285","09-06-23","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT3 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS 5-HT3","",""
"10286","09-06-24","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: for the management of pain associated with fibromyalgia","Nouvelle indication : Contrôle de la douleur associée à la fibromyalgie","ANTIDEPRESSANT / ANXIOLYTIC / ANALGESIC","ANTIDÉPRESSEUR / ANXIOLYTIQUE / ANALGÉSIQUE","",""
"10287","09-06-24","BIMEDA MTC ANIMAL HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC POUR-ON FOR CATTLE","MERIAL CANADA INC.","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITIQUE","",""
"10288","09-06-24","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL / ANTIFUNGAL AGENT WITH TOPICAL CORTICOSTEROID","ANTIBACTÉRIEN / ANTIFONGIQUE / CORTICOSTÉROÏDE TOPIQUE","",""
"10289","09-06-24","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROPHYLACTIC MANAGEMENT OF VASCULAR HEADACHES","TRAITEMENT PROPHYLACTIQUE DES CÉPHALÉES VASCULAIRES","",""
"10290","09-06-24","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"10291","09-06-24","ALCON CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: First line therapy in treating patients with open-angle glaucoma or ocular hypertension","Nouvelle indication : Traitement de première ligne pour des patients atteints de glaucome à angle ouvert ou d'hypertension oculaire","ELEVATED INTRAOCULAR PRESSURE THERAPY PROSTAGLANDIN F2ALPHA","TRAITEMENT DE L'HYPERTENSION OCULAIRE ÉLEVÉE - PROSTAGLANDINE F2ALPHA","",""
"10292","09-06-24","VALEO PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"10293","09-06-24","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"10294","09-06-24","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID WITH ANTIBACTERIAL / ANTIFUNGAL AGENT","CORTICOSTÉROÏDE TOPIQUE / ANTIBACTÉRIEN / ANTIFONGIQUE","",""
"10295","09-06-24","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"10296","09-06-24","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATATEUR","",""
"10297","09-06-25","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"10298","09-06-25","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITEUR DES RÉCEPTEURS BÊTA-ADRÉNERGIQUES","",""
"10299","09-06-25","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"10300","09-06-25","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"10301","09-06-25","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","DIURETIC / ANTIHYPERTENSIVE AGENT","DIURÉTIQUE / ANTIHYPERTENSEUR","",""
"10302","09-06-26","GENPHARM ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT","",""
"10303","09-06-26","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","Indication revision. Product Monograph revision.","Révision de l'indication. Révision de la monographie de produit.","Enzyme replacement therapy","Thérapie de remplacement d'enzymes","",""
"10304","09-06-26","SOLSTICE NEUROSCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New master cell bank","Nouvelle banque de cellules primaire","Neuromuscular Blocking Agent","Agent bloquant neuromusculaire","",""
"10305","09-06-29","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anthelmintic","Anthelmintique","",""
"10306","09-06-29","ALPHARMA CANADA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antimicrobial","Antimicrobien","",""
"10307","09-06-29","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic","Antiparasitique","",""
"10308","09-06-26","NEXT GENERATION PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antidepressant","Antidépresseur","",""
"10309","09-06-29","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10310","09-06-29","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Anti-Diabetic Agent / Insulin Resistance Reducing Agent","Antidiabétique / Agent réducteur de l'insulinorésistance","",""
"10311","09-06-29","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Selective Antagonist of Alpha1A-Adrenoreceptor Subtype in the Postate","Antagoniste sélectif des sous-types des récepteurs alpha1A-adrénergiques de la prostate","",""
"10312","09-06-29","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC","CANADA","CANADA","1","","","H+, K+-ATPase Inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10313","09-06-29","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C","PHARMACIA & UPJOHN INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10314","09-06-29","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Corticosteroid","Corticostéroïde topique","",""
"10315","09-06-29","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAPROSYN E","HOFFMAN-LA ROCHE LIMITED","CANADA","CANADA","1","","","Non-Steroidal Anti-Inflammatory Drug","Anti-inflammatoire non stéroïdien (AINS)","",""
"10316","09-06-29","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Alcohol Abstinence Aid","Aide à l'abstinence de l'alcool","",""
"10317","09-06-29","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid for Nasal Use","Corticostéroïde pour voie nasale","",""
"10318","09-06-29","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Corticosteroid","Corticostéroïde topique","",""
"10319","09-06-30","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"10320","09-06-30","DRAXIMAGE A DIVISION OF DRAXIS SPECIALTY PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","Alternate raw material supplier","Fournisseur alternatif de la matière première","Radiopharmaceutical Diagnostic Agent","Agent diagnostique radiopharmaceutique","",""
"10321","09-07-02","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PMS-HYDROCHLOROTHIAZIDE","BIOMED 2002 INC","CANADA","CANADA","1","","","Antihypertensive","Antihypertenseur","",""
"10322","09-07-02","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor / Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine / Diurétique","",""
"10323","09-07-02","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anxiolytic / Antipanic","Anxiolytique / Antipanique","",""
"10324","09-07-02","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB CANADA","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"10325","09-07-02","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du métabolisme osseux","",""
"10326","09-07-02","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10327","09-07-02","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RIVOTRIL","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","Anticonvulsant","Anticonvulsivant","",""
"10328","09-07-02","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme lipidique","",""
"10329","09-07-02","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYDREA","SQUIBB CANADA INC","CANADA","CANADA","1","","","Antineoplastic Agent","Antinéoplasique","",""
"10330","09-07-02","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACCUTANE ROCHE","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Nodular / Inflammatory and Conglobate Acne Therapy","Traitement de l'acné nodulaire/inflammatoire et de l'acné conglobata","",""
"10331","09-07-02","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiarrhythmic","Antiarythmique","",""
"10332","09-07-02","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiviral Agent / Antiparkinsonian Agent","Agent antiviral / Antiparkinsonien","",""
"10333","09-07-02","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-2","ASTRA PHARMA INC","CANADA","CANADA","1","","","Antihypertensive Agent / Symptomatic Treatment of Benign Prostatic Hyperplasia","Antihypertenseur / Traitement symptomatique de l'hyperplasie bénigne de la prostate (HBP)","",""
"10334","09-07-06","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MARVELON 28","ORGANON CANADA","CANADA","CANADA","1","","","Oral Contraceptive","Contraceptif oral","",""
"10335","09-07-07","BAYER HEALTHCARE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Revision to the Product Monograph","Révision à la monographie de produit","Coagulation Factor","Facteur de coagulation","",""
"10336","09-07-07","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Revision to the Product Monograph","Révision à la monographie de produit","Coagulation Factor","Facteur de coagulation","",""
"10337","09-07-07","NOVARTIS ANIMAL HEALTH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Addition of a 75 mg tablet size","Addition d'un comprimé de 75 mg","COX-2 Inhibitor / Non-Steroidal Anti-Inflammatory","Inhibiteur COX-2 / Anti-inflammatoire non stéroïdien","",""
"10338","09-07-07","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength: 37.5 mg capsules","Nouvelle concentration : comprimés de 37.5 mg","Tyrosine Kinase Inhibitor / Anti-Tumour Agent","Inhibiteur de la tyrosine kinase / Agent anti-tumeur","",""
"10339","09-07-07","ELANCO DIVISION ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","To provide for the use of Optaflexx 100 in beef liquid feed supplements to be incorporated into complete rations in cattle","Pour permettre l'ajout du Optaflexx 100 à des suppléments liquides pour bovins de boucherie destinés à être incorporés dans les aliments complets des bovins","Beta-Adrenergic Agonist / Growth Promotant","Agoniste bêta-adrénergique / Stimulant de la croissance","",""
"10340","09-07-08","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTO I.V.","NYCOMED CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase Inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10341","09-07-08","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Non-Steroidal Antiandrogen","Antiandrogène non stéroïdien","",""
"10342","09-07-08","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10343","09-07-08","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic","Hypnotique","",""
"10344","09-07-08","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Anti-Diabetic Agent / Insulin Resistance Reducing Agent","Antidiabétique / Agent réducteur de l'insulinorésistance","",""
"10345","09-07-08","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDRONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone Metabolism Regulator / Anti-Pagetic Agent / Anti-Hypercalcemic Agent","Régulateur du métabolisme osseux / Agent antipagétique / Agent antihypercalcémique","",""
"10346","09-07-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"10347","09-07-09","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC TABLETS","PFIZER CANADA & CO","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"10348","09-07-09","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"10349","09-07-09","GENPHARM ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"10350","09-07-09","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"10351","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic Agent / Social Phobia (Social Anxiety Disorder) / Posttraumatic Stress Disorder Therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"10352","09-07-09","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"10353","09-07-09","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"10354","09-07-10","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"10355","09-07-10","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"10356","09-07-10","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"10357","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC","CANADA","CANADA","1","","","Antiarrhythmic Agent","Antiarythmique","",""
"10358","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT MERCK PHARMA INC","CANADA","CANADA","1","","","Anticoagulant","Anticoagulant","",""
"10359","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS, DIVISION OF WARNER-LAMBERT CANADA INC","CANADA","CANADA","1","","","Antiepileptic Agent","Antiepileptique","",""
"10360","09-07-09","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bronchodilator","Bronchodilateur","",""
"10361","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"10362","09-07-09","FERRING INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Gonadotropins for Infertility","Gonadotropins pour l'infertilité","",""
"10363","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEGRETOL CR","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Anticonvulsant / Symptomatic Relief of Trigeminal Neuralgia / Antimanic","Anticonvulsivant / Soulagement symptomatique de la névralgie du trijumeau / Antimaniaque","",""
"10364","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE POULENC RORER CANADA INC","CANADA","CANADA","1","","","Hypnotic and Sedative","Hypnotique et sédatif","",""
"10365","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Non-Steroidal Anti-Inflammatory Drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"10366","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Antirheumatic / Immunomodulator Agent","Antirhumatismal / Immunomodulateur","",""
"10367","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","Inhibitor of Platelet Function","Agent antiplaquettaire","",""
"10368","09-07-10","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10369","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10370","09-07-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10371","09-07-09","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bronchodilator","Bronchodilateur","",""
"10372","09-07-09","BRISTOL MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antipsychotic","Antipsychotique","",""
"10373","09-07-10","CSL BEHRING CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Increased infusion rate to a maximum of 12mg/kg/min, when tolerated by the patient","Augmentation de la vitesse de perfusion à un maximum de 12 mg/kg/min, si tolérée par le patient","Passive immunizing agent","Agent d'immunisation passif","",""
"10374","09-07-10","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive - antianginal agent","Antihypertenseur - antiangineux","",""
"10375","09-07-15","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage regimen - once a day 800/200 mg","Posologie additionnelle - une fois par jour 800/200 mg","Human immunodeficiency virus (HIV) protease inhibitor","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH)","",""
"10376","09-07-15","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Addition of new dosing regimen for combination treatment with 2mg Nicorette Gum","Addition de deux nouvelles posologies pour polythérapie avec gomme Nicorette 2 mg","Smoking cessation aid","Aide pour cesser de fumer","",""
"10377","09-07-15","WYETH CONSUMER HEALTHCARE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"10378","09-07-15","WYETH CONSUMER HEALTHCARE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"10379","09-07-15","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme lipidique","",""
"10380","09-07-16","GENZYME CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent","Antinéoplasique","",""
"10381","09-07-15","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral antihyperglycemic agent","Agent antihyperglycémique oral","",""
"10382","09-07-15","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Rectal anti-inflammatory corticosteroid foam","Corticostéroïde anti-inflammatoire rectal","",""
"10383","09-07-15","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid","Corticostéroïde topique","",""
"10384","09-07-16","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Pediatric asthma prophylactic / Antiallergic agent","Agent prophylactique de l'asthme infantile / Agent antiallergique","",""
"10385","09-07-15","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antirheumatic agent","Antirhumatismal","",""
"10386","09-07-15","WYETH CONSUMER HEALTHCARE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"10387","09-07-16","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antispastic agent","Antispasmodique","",""
"10388","09-07-17","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","NITROLINGUAL SPRAY","RHONE-POULENC RORER INC","CANADA","CANADA","1","","","Anti-anginal agent","Antiangineux","",""
"10389","09-07-17","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADALAT XL","BAYER INC","CANADA","CANADA","1","","","Antianginal / Antihypertensive agent","Antiangineux / Antihypertenseur","",""
"10390","09-07-17","ZYMCAN PHARMACEUTICALS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10391","09-07-17","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Antiviral agent","Agent antiviral","",""
"10392","09-07-17","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE","GREECE","GRÈCE","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (Antagoniste des récepteurs 5-HT3)","",""
"10393","09-07-20","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10394","09-07-20","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10395","09-07-20","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticonvulsant","Anticonvulsivant","",""
"10396","09-07-20","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic","Antinéoplasique","",""
"10397","09-07-20","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme lipidique","",""
"10398","09-07-20","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihyperlipidemic agent","Agent antihypolipidémiant","",""
"10399","09-07-20","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO-MCNEIL PHARMACEUTICAL INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"10400","09-07-20","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral hypoglycemic agent","Hypoglycémiant","",""
"10401","09-07-20","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABOTT LABORATORIES LTD","CANADA","CANADA","1","","","Anticonvulsant","Anticonvulsivant","",""
"10402","09-07-20","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New tablet formulation","Nouvelle formulation","Cardiotonic glycoside","Glucoside cardiotonique","",""
"10403","09-07-20","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"10404","09-07-20","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anticoccidial","Anticoccidien","",""
"10405","09-07-20","ELANCO DIVISION ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional warning statement","Ajout d'une déclaration de mise en garde","Anti-ketogenic agent","Agent anti-cétogénique","",""
"10406","09-07-21","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Elevated intraocular pressure therapy","Thérapie pour réduire la pression intraoculaire","",""
"10407","09-07-21","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLEXERIL","MERCK FROSST CANADA INC","CANADA","CANADA","1","","","Skeletal muscle relaxant","Relaxant des muscles squelettiques","",""
"10408","09-07-21","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10409","09-07-21","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT1 Receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"10410","09-07-21","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"10411","09-07-21","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","APO-DOMPERIDONE","APOTEX INC","CANADA","CANADA","1","","","Modifier of upper gastrointestinal motility","Modificateur de la motilité des voies digestives supérieures","",""
"10412","09-07-21","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10413","09-07-21","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antipanic / Antiobsessional agent","Antidépresseur / Antipanique / Antiobsessionnel","",""
"10414","09-07-21","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","Antineoplastic","Antinéoplasique","",""
"10415","09-07-21","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidiabetic agent / Insulin resistance reducing agent","Antidiabétique / Agent réducteur de l'insulinorésistance","",""
"10416","09-07-21","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Anti-diabetic agent / Insulin resistance reducing agent","Antidiabétique / Agent réducteur de l'insulinorésistance","",""
"10417","09-07-21","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FAMVIR","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"10418","09-07-21","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidiabetic agent / Insulin resistance reducing agent","Antidiabétique / Agent réducteur de l'insulinorésistance","",""
"10419","09-07-21","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANAFLEX","ELAN PHARMACEUTICALS INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antispastic agent","Antispasmodique","",""
"10420","09-07-22","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10421","09-07-22","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10422","09-07-22","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10423","09-07-21","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immunosuppressive agent","Agent immunosuppresseur","",""
"10424","09-07-21","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10425","09-07-21","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bronchodilator","Bronchodilatateur","",""
"10426","09-07-21","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Muscle relaxant / Antispasticity agent","Relaxant musculaire / Antispasmodique","",""
"10427","09-07-21","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antipanic / Antiobsessional agent","Antidépresseur / Antipanique / Antiobsessionnel","",""
"10428","09-07-21","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"10429","09-07-21","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RHINOCORT AQ NASAL SPRAY","ASTRA PHARMA CANADA INC","CANADA","CANADA","1","","","Glucocorticosteroid spray for the treatment of seasonal and perennial rhinitis and nasal polyposis","Glucocorticostéroïde","",""
"10430","09-07-22","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Opioid analgesic","Analgésique opioïde","",""
"10431","09-07-22","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme lipidique","",""
"10432","09-07-22","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"10433","09-07-22","AMDIPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10434","09-07-22","AMDIPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10435","09-07-22","AMDIPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10436","09-07-22","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10437","09-07-22","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC","CANADA","CANADA","1","","","Antiepileptic agent","Antiépileptique","",""
"10438","09-07-22","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10439","09-07-22","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength: 300 mg","Nouvelle concentration : 300 mg","Platelet aggregation inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"10440","09-07-20","ORGANON CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product monograph update to the new format, update to be in line with global labelling","Monographie de produit mise à jour selon la nouvelle présentation à des fins de conformité à l'étiquette mondiale","Oral contraceptive","Contraceptif oral","",""
"10441","09-07-23","CHIEF MEDICAL SUPPLIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC POUR-ON FOR CATTLE","MERIAL CANADA INC","CANADA","CANADA","1","","","Antiparasitic","Antiparasitaire","",""
"10442","09-07-23","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibacterial","Antibactérien","",""
"10443","09-07-23","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Prostaglandin","Prostaglandine","",""
"10444","09-07-24","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate manufacturing facility","Autre emplacement de fabrication","CNS stimulant","Stimulant du SNC","",""
"10445","09-07-27","GENZYME CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Antineoplastic","Antinéoplasique","",""
"10446","09-07-28","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BUSPAR","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Anxiolytic","Anxiolytique","",""
"10447","09-07-28","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10448","09-07-28","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiparkinsonian agent","Antiparkinsonien","",""
"10449","09-07-28","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral hypoglycemic agent","Hypoglycémiant","",""
"10450","09-07-28","AMDIPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10451","09-07-28","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10452","09-07-28","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New presentation without solvent","Nouvelle présentation sans solvant","Antifungal agent","Antifongique","",""
"10453","09-07-29","STERIMAX INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Reactivation of DINs","Réactivation des DIN","Anorexiant","Anorexigène","",""
"10454","09-07-29","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN","SEARLE CANADA INC.","CANADA","CANADA","1","","","Antianginal / Antiarrhythmic / Antihypertensive agent","Antiangineux / Antiarythmique / Antihypertenseur","",""
"10455","09-07-29","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10456","09-07-29","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA INC.","CANADA","CANADA","1","New strength","Nouvelle concentration","Antibiotic / B-lactamase inhibitor","Antibiotique / Inhibiteur de Bêta-lactamases","",""
"10457","09-07-29","JANSSEN ORTHO INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"10458","09-07-31","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX (SUMATRIPTAN SUCCINATE) SOLUTION FOR INJECTION","GLAXOSMITHKLINE CANADA INC","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"10459","09-07-30","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic / Non-steroidal anti-inflammatory","Antibiotique / Anti-inflammatoire non stéroïdien","",""
"10460","09-07-31","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength: 1.5 mg","Nouvelle concentration : 1.5 mg","Antipsychotic agent","Antipsychotique","",""
"10461","09-08-04","GENPHARM ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC DELAYED-RELEASE CAPSULE","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10462","09-08-05","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAQUENIL","SANOFI-WINTHROP CANADA INC","CANADA","CANADA","1","","","Anti-rheumatic / Antimalarial","Antirhumatismal / Antipaludéen","",""
"10463","09-08-05","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Platelet-reducing agent","Réducteur plaquettaire","",""
"10464","09-08-05","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2-receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"10465","09-08-05","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive / Anti-anginal agent","Antihypertenseur / Antiangineux","",""
"10466","09-08-05","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10467","09-08-05","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema","Nouvelle indication : traitement d'entretien de broncho-pneumopathie chronique obstructive modérée et sévère incluant la bronchite chronique et l'emphysème","Corticosteroid / Bronchodilator for inhalation","Corticostéroïde / Bronchodilatateur pour inhalation","",""
"10468","09-08-06","IMCLONE LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Antineoplastic","Antinéoplasique","",""
"10469","09-08-05","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10470","09-08-06","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing process","Nouvelle méthode de fabrication","Erythropoiesis regulating hormone","Hormone de régulation d'érythropoïèse","",""
"10471","09-08-06","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the product monograph","Mises à jour de la monographie de produit","Antiretroviral agent, non-nucleoside reverse transcriptase inhibitor with activity against human immunodeficiency virus type 1 (HIV-1)","Antirétroviral, inhibiteur non-nucléoside de la reverse-transcriptase contre le virus de l'immunodéficience humaine de type 1 (VIH-1)","",""
"10472","09-08-06","BRISTOL MYERS SQUIBB CANADA","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Commitment #1 and part of commitment #2 of the Letter of Undertaking dated March 13, 2007 - final results of CA180005, CA180006, CA180013, CA180015 and CA180017. Revised Product Monograph: Changes to Warnings and Precautions, Adverse Reactions and Clinical Trials.","Engagement 1 et partie de l'engagement 2 de la lettre d'engagement datée du 13 mars 2007 - résultats finaux des études CA180005, CA180006, CA180013, CA180015 et CA180017. Monographie de produit révisée : Modification des sections « Mises en garde et précautions », « effets indésirables » et « essais cliniques ».","Protein-tyrosine kinase inhibitor","Inhibiteur de la protéase-tyrosine kinase","",""
"10473","09-08-07","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","New indication: Rituxan (Rituximab) is indicated for the treatment of patients with previously untreated B-cell chronic lymphocytic leukemia (B-CLL), stage B or C, in combination with Fludarabine and Cyclophosphamide","Nouvelle indication : Rituxan (Rituximab) est indiqué pour le traitement des patients atteints de la leucémie lymphoïde chronique B (LLC-B) de stade B ou C, auparavant non traités en combinaison avec la fludarabine et la cyclophosphamide","Antineoplastic","Antinéoplasique","",""
"10474","09-08-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"10475","09-08-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM PHARMA INC","CANADA","CANADA","1","","","Nonsteroidal anti-inflammatory agent","Anti-inflammatoire non stéroïdien","",""
"10476","09-08-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BERLEX CANADA INC","CANADA","CANADA","1","","","Antiandrogen","Antiandrogène","",""
"10477","09-08-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"10478","09-08-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10479","09-08-07","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength","Nouvelle concentration","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10480","09-08-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLUANXOL DEPOT INJECTION","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antipsychotic","Antipsychotique","",""
"10481","09-08-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antibulimic","Antidépresseur / Antiobsessionnel / Antiboulimique","",""
"10482","09-08-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDROCAL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"10483","09-08-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10484","09-08-07","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","COATED ASPIRIN DAILY LOW DOSE 81 MG","BAYER INC","CANADA","CANADA","1","Product name change","Modification du nom du produit","Platelet aggregation inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"10485","09-08-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLOZARIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10486","09-08-07","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antipsychotic agent","Antipsychotique","",""
"10487","09-08-11","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10488","09-08-11","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme lipidique","",""
"10489","09-08-11","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-depolarizing skeletal neuromuscular blocking agent","Bloqueur neuromusculaire squelettique non dépolarisant","",""
"10490","09-08-11","SEPRACOR PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant, Antiobsessional","Antidépresseur, Antiobsessionnel","",""
"10491","09-08-11","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10492","09-08-11","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10493","09-08-11","GENZYME CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic","Antinéoplasique","",""
"10494","09-08-11","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Antiepileptic","Antiepileptique","",""
"10495","09-08-11","SANOFI AVENTIS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiarrhythmic agent","Antiarythmique","",""
"10496","09-08-11","GENZYME CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic","Antinéoplasique","",""
"10497","09-08-11","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC","CANADA","CANADA","1","","","Antiepileptic agent","Antiépileptique","",""
"10498","09-08-12","UCB CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Biological response modifier","Modificateur de la réponse biologique","",""
"10499","09-08-13","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10500","09-08-13","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10501","09-08-13","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Oral antihyperglycemic agent","Antihyperglycémiant","",""
"10502","09-08-13","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive agent","Antihypertenseur","",""
"10503","09-08-13","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Diuretic / Antihypertensive","Diurétique / Antihypertenseur","",""
"10504","09-08-13","ALCON CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Elevated intraocular pressure therapy","Thérapie pour réduire la pression intraoculaire","",""
"10505","09-08-13","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Maintenance therapy in major depressive disorder","Nouvelle indication : Pour le maintien de la réponse suite à un épisode dépressif majeur","Antidepressant / Anxiolytic / Analgesic","Antidépresseur / Anxiolytique / Analgésique","",""
"10506","09-08-14","ASTELLAS PHARMA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of new strength","Ajout d'une nouvelle concentration","Immunosuppressant","Agent immunosuppresseur","",""
"10507","09-08-14","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the product monograph","Mises à jour de la monographie de produit","Antiviral","Antiviral","",""
"10508","09-08-14","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"10509","09-08-18","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10510","09-08-19","AGRIMIN LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Trace mineral supplement","Supplément minéral de trace","",""
"10511","09-08-19","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme lipidique","",""
"10512","09-08-19","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10513","09-08-19","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC DELAYED RELEASE CAPSULE","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10514","09-08-19","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"10515","09-08-19","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"10516","09-08-19","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10517","09-08-19","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10518","09-08-20","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10519","09-08-20","LUNDBECK INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Actinomycin antibiotic, Antineoplastic","Actinomycine antibiotic, Antinéoplasique","",""
"10520","09-08-20","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"10521","09-08-20","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10522","09-08-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","Antidepressant / Anxiolytic","Antidépresseur / Anxiolytique","",""
"10523","09-08-20","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10524","09-08-20","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10525","09-08-20","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme lipidique","",""
"10526","09-08-21","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10527","09-08-21","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10528","09-08-21","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM CANADA LTD","CANADA","CANADA","1","","","Selective antagonist of alpha1A adrenoceptor subtype in the prostate","Antagoniste sélectif des sous-types des récepteurs alpha1A-adrénergiques de la prostate","",""
"10529","09-08-24","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic","Antiparasitaire","",""
"10530","09-08-24","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic","Antiparasitaire","",""
"10531","09-08-24","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic","Antiparasitaire","",""
"10532","09-08-24","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic","Antiparasitaire","",""
"10533","09-08-24","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic","Antiparasitaire","",""
"10534","09-08-21","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Treatment of perennial allergic rhinitis in pediatrics (2 years to < 12 years of age)","Nouvelle indication : traitement des rhinites allergiques non-saisonnières chez les enfants de 2 à 11 ans","Corticosteroid","Corticostéroïde","",""
"10535","09-08-21","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRA PHARMA INC","CANADA","CANADA","1","New indication: new PM format","Nouvelle indication : nouveau format de MP","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10536","09-08-24","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme lipidique","",""
"10537","09-08-24","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC","CANADA","CANADA","1","","","Antiepileptic agent","Antiépileptique","",""
"10538","09-08-24","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"10539","09-08-24","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10540","09-08-24","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10541","09-08-24","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Class labelling","Classe des traitements","Antihypertensive - Antianginal agent & lipid metabolism regulator","Antihypertenseur - Antiangineux et régulateur du métabolisme des lipides","",""
"10542","09-08-25","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic/glucocorticoid","Antibiotique/glucocorticoïde","",""
"10543","09-08-25","DECHRA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anti-hyperthyroid","Anti-hyperthyroïdien","",""
"10544","09-08-25","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the product monograph","Mise à jour de la monographie de produit","Antiviral agent","Agent antiviral","",""
"10545","09-08-26","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10546","09-08-27","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLUANXOL DEPOT","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antipsychotic","Antipsychotique","",""
"10547","09-08-27","COBALT PHARMACEUTICALS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM CANADA LTD","CANADA","CANADA","1","Product monograph update","Mise à jour de la monographie de produit","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10548","09-08-27","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Dosage and Administration section of the product monograph","Révision à la section de Posologie et administration de la monographie de produit","Opioid analgesic","Analgésique opioïde","",""
"10549","09-08-27","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Dosage and Administration section of the product monograph","Révision à la section de Posologie et administration de la monographie de produit","Opioid analgesic","Analgésique opioïde","",""
"10550","09-08-27","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Dosage and Administration section of the product monograph","Révision à la section de Posologie et administration de la monographie de produit","Opioid analgesic","Analgésique opioïde","",""
"10551","09-08-27","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Dosage and Administration section of the product monograph","Révision à la section de Posologie et administration de la monographie de produit","Opioid analgesic","Analgésique opioïde","",""
"10552","09-08-27","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Dosage and Administration section of the product monograph","Révision à la section de Posologie et administration de la monographie de produit","Opioid analgesic","Analgésique opioïde","",""
"10553","09-08-27","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Dosage and Administration section of the product monograph","Révision à la section de Posologie et administration de la monographie de produit","Opioid analgesic","Analgésique opioïde","",""
"10554","09-08-28","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New indication","Nouvelle indication","Thyroid stimulating hormone","Hormone thyréotrope","",""
"10555","09-08-28","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Revision to the product monograph","Révision à la monographie de produit","Antiviral agent plus biological response modifier","Antiviral avec agent immunomodulateur","",""
"10556","09-08-31","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"10557","09-08-31","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"10558","09-08-31","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"10559","09-09-01","RANBAXY PHARMACEUTICALS CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","New strength 125mg / 5ml","Nouvelle concentration 125mg/ 5ml","Antibiotic","Antibiotique","",""
"10560","09-09-02","JANSSEN ORTHO INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial agent","Antibactérien","",""
"10561","09-09-02","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10562","09-09-02","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10563","09-09-02","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10564","09-09-02","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10565","09-09-02","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10566","09-09-02","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10567","09-09-01","MERIAL CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Addition of a claim: for the control of post-operative pain and inflammation associated with orthopedic surgery in dogs","Indication supplémentaire : pour le contrôle de la douleur et de l'inflammation postopératoires associés à une chirurgie orthopédique chez le chien","Non-steroidal anti-inflammatory","Anti-inflammatoire non stéroïdien","",""
"10568","09-08-31","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibacterial","Antibactérien","",""
"10569","09-09-01","HUVEPHARMA AD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","TYLAN SOLUBLE","ELANCO, DIVISION ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10570","09-09-01","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Extension of duration of action from 4-5 hours to 8-10 hours","Prolongation de la durée d'action de 4-5 heures à 8-10 heures","cGMP-specific phosphodiesterase type 5 inhibitor","Inhibiteur de la phosphodiestérase de type 5 spécifique de la GMPC","",""
"10571","09-09-03","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10572","09-09-04","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of new strengths: 32mg/12.5mg and 32mg/25mg","Ajout de nouvelles concentrations : 32mg/12.5mg et 32mg/25mg","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"10573","09-09-04","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Renin inhibitor / Diuretic","Inhibiteur de la rénine / Diurétique","",""
"10574","09-09-08","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERC","SOLVAY PHARMA INC","CANADA","CANADA","1","","","Anti-Vertigo Agent","Agent antivertigineux","",""
"10575","09-09-08","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10576","09-09-11","WYETH CONSUMER HEALTHCARE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Removal of the dosing for children under 6 years of age","L'enlèvement de la posologie pour les enfants de moins de 6 ans","Analgesic, antipyretic and nasal decongestant","Analgésiques, antipyrétique et décongestionnant nasal","",""
"10577","09-09-11","GILEAD SCIENCES CANADA INC","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10578","09-09-11","BANNER PHARMACAPS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL EXTRA STRENGTH LIQUI-GELS","WYETH CONSUMER HEALTHCARE INC.","CANADA","CANADA","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"10579","09-09-11","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2 receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"10580","09-09-11","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticholinergic / Antispasmodic agent","Anticholinergique / Antiparkinsonien","",""
"10581","09-09-11","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"10582","09-09-11","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive agent","Antihypertenseur","",""
"10583","09-09-14","CSL BEHRING CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of canadian plasma as the starting material","Ajout de plasma canadien comme substance de départ","Coagulation Therapy","Facteur de coagulation","",""
"10584","09-09-11","SEPRACOR PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant/Antiobsessional/Antibulimic","Antidépresseur/Antiobsessionnel/Antiboulimique","",""
"10585","09-09-14","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Action and clinical pharmacology section of the product monograph","Mise à jour de la section Mode d'action et pharmacologie clinique de la monographie de produit","Renin inhibitor","Inhibiteur de la rénine","",""
"10586","09-09-08","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","PRIORIX-TETRA (combined measles, mumps, rubella and varicella vaccine, live, attenuated) is indicated for active immunization against measles, mumps, rubella and varicella in individuals from 9 months to 6 years of age. Efficacy has not been evaluated in subjects above 6 years of age. PRIORIX-TETRA may be used in individuals up to 12 years of age based upon previous experience with the separate component vaccines, PRIORIX (combined measles, mumps and rubella  vaccine, live attenuated) and VARILRIX [varicella virus vaccine, live, attenuated (Oka-strain)]","PRIORIX-TETRA (vaccin associé rougeole-oreillons-rubéole-varicelle à virus vivants, atténués) est indiqué pour l'immunisation active des sujets âgés de 9 mois à 6 ans contre la rougeole, les oreillons, la rubéole et la varicelle. L'efficacité du vaccin n'a pas été évaluée chez les sujets âgés de plus de 6 ans. PRIORIX-TETRA peut être administré jusqu'à l'âge de 12 ans selon les réactions observées dans le passé avec les composantes distinctes des vaccins PRIORIX (vaccin associé rougeole-oreillons-rubéole à virus vivants, atténués) et VARILRIX [vaccin contre la varicelle, à virus vivant, atténué (souche Oka)]","Active immunizing agent","Agent de l'immunisation actif","",""
"10587","09-09-15","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibacterial","Antibactérien","",""
"10588","09-09-15","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibacterial","Antibactérien","",""
"10589","09-09-14","LUNDBECK INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Alkylating agent","Alcoylant","",""
"10590","09-09-14","BIOVAIL PHARMACEUTICALS CANADA DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the product monograph: deletion of the contraindication for use in patients with congestive heart failure","Mise à jour de la monographie de produit: suppression de la contre-indication relative à l'utilisation chez les patients ayant une insuffisance cardiaque congestive","Oral Antihyperglycemic Agent","Agent antihyperglycémiant oral","",""
"10591","09-09-11","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Warnings and Precautions section of the Product Monograph","Mise à jour de la section Mises en garde et précautions de la monographie de produit","Platelet aggregation inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"10592","09-09-17","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic, glucocorticoid","Antibiotique, glucocorticoïde","",""
"10593","09-09-17","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibacterial","Antibactérien","",""
"10594","09-09-15","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the product monograph - class labelling as per TPD letter of September 10, 2008","Mise à jour de la monographie de produit - Étiquetage selon la classe de médicament, conformément aux directives émises dans la lettre de la Direction des produits thérapeutiques du 10 septembre 2008","Nonsteroidal anti-inflammatory drug with a mucosal protective agent","Anti-inflammatoire non stéroïdien contenant un protecteur de la muqueuse","",""
"10595","09-09-16","UMAN PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","METHOTREXATE SODIUM INJECTION","MAYNE PHARMA CANADA INC.","CANADA","CANADA","1","","","Antimetabolite / Antirheumatic","Antimétabolite / Antirhumatismal","",""
"10596","09-09-16","UMAN PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VINCRISTINE SULFATE INJECTION","NOVOPHARM LIMITED","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"10597","09-09-17","NOVO NORDISK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Hyperglycemic agent","Agent hyperglycémiant","",""
"10598","09-09-16","TARO PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ELOCOM LOTION","SHERING CANADA INC.","CANADA","CANADA","1","","","Corticosteroid","Corticostéroïde","",""
"10599","09-09-14","BRISTOL MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral Antihyperglycemic Agent, DPP-4 Inhibitor, Incretin Enhancer","Agent oral d'antihyperglycémic; inhibiteur DPP-4; renforceur d'incretin","",""
"10600","09-09-21","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph - Class Labelling as per TPD letter of September 10, 2008","Mise à jour de la monographie de produit - Étiquetage selon la classe de médicament, conformément aux directives émises dan la lettre de la Direction des produits thérapeutiques du 10 septembre 2008","Nonsteroidal Anti-Inflammatory Drug","Anti-inflammatoire non stéroïdien","",""
"10601","09-09-18","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph - Class Labelling as per TPD letter of September 10, 2008","Mise à jour de la monographie de produit - Étiquetage selon la classe de médicament, conformément aux directives émises dans la lettre de la Direction des produits thérapeutiques du 10 septembre 2008","Nonsteroidal Anti-Inflammatory Drug","Anti-inflammatoire non stéroïdien","",""
"10602","09-09-17","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the clinical trials section on the product monograph: Beneficial effect maintained over 1 year follow-up period in treatment of acute STEMI.","Mise à jour de la section Essais cliniques de la monographie de produit: effets bénéfiques maintenus au cours d'un suivi d'une année suite au traitement de la STEMI aiguë","Anticoagulant/Antithrombotic Agent","Anticoagulant et antithrombotique","",""
"10603","09-09-17","BIOGEN IDEC CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Alternative drug substance manufacturing process","Processus de fabrication alternatif de la substance médicamenteuse","Selective adhesion molecule inhibitor","Inhibiteur sélectif de molécules d'adhésion","",""
"10604","09-09-22","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10605","09-09-21","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme lipidique","",""
"10606","09-09-23","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph; ACTION AND CLINICAL PHARMACOLOGY regarding dysbetalipoproteinemia","Révisions à la monographie: MODE D'ACTION ET PHARMACOLOGIE CLINIQUE au sujet de la dysbêtalipoprotéinémie","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"10607","09-09-24","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral Antihyperglycemic Agent; DPP-4 inhibitor; Incretin Enhancer","Agent oral d'antihyperglycémic; inhibiteur DPP-4; renforceur d'incretin","",""
"10608","09-09-24","TRITON PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","Selective antagonist of alpha1A adrenoreceptor subtype in the prostate","Antagoniste sélectif des sous-types des récepteurs alpha1A-adrénergiques de la prostate","",""
"10609","09-09-24","LUNDBECK INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal anti-inflammatory","Anti-inflammatoire non stéroïdien","",""
"10610","09-09-22","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAVULIN","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHLINE BEECHAM INC.","CANADA","CANADA","1","","","Antibiotic / Beta-lactamase inhibitor","Antibiotique / Inhibiteur de bêta-lactamases","",""
"10611","09-09-24","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Nouveau nom du produit","Elevated intraocular pressure therapy / Prostamide analogue","Thérapie pour réduire la pression intraoculaire / Protamide analogue","",""
"10612","09-09-24","LANTHEUS MI CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Intravenous Contrast Enhancement Agent for Magnetic Resonance Imaging (MRI)","Agent de rehaussement de contrast pour l'imagerie par résonance magnétique (IRM) intraveineuse","",""
"10613","09-09-25","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10614","09-09-25","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10615","09-09-28","ORION CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Sedative / Analgesic","Sédatif / Analgésique","",""
"10616","09-09-29","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Prostaglandin","Prostaglandine","",""
"10617","09-09-29","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","Additional indication","Indication additionnelle","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10618","09-09-29","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10619","09-09-29","ASTELLAS PHARMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10620","09-09-30","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Antidiabetic agent","Agent antidiabétique","",""
"10621","09-09-30","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10622","09-09-30","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antipanic / Antiobsessional agent","Antidépresseur / Antipanique / Antiobsessionnel","",""
"10623","09-09-30","PRO DOC LIMITÉE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC","CANADA","CANADA","1","Additional strength","Concentration additionnelle","Antidepressant","Antidépresseur","",""
"10624","09-09-30","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10625","09-09-30","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10626","09-09-30","NOVO NORDISK AS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Anti-diabetic agent","Agent antidiabétique","",""
"10627","09-10-01","NOVO NORDISK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Growth hormone","Hormone de croissance","",""
"10628","09-10-01","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"10629","09-09-21","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10630","09-10-02","FERRING INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Progestin","Progestatif","",""
"10631","09-10-04","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: The prevention of postmenopausal osteoporosis in women with osteopenia as a single intravenous infusion","Nouvelle indication : Prévention de l'ostéoporose postménopausique chez les femmes atteintes d'ostéopénie comme perfusion intraveineuse unique","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"10632","09-10-04","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO-MCNEIL PHARMACEUTICALS INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"10633","09-10-04","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10634","09-10-04","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CILOXAN","ALCON CANADA INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"10635","09-10-05","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX FOR INTRAVENOUS INJECTION","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10636","09-10-05","MM THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10637","09-10-05","MM THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antipsychotic agent","Antipsychotique","",""
"10638","09-10-05","MM THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2 receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"10639","09-10-05","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic, anti-inflammatory, antifungal","Antibiotique, anti-inflammatoire, antifongique","",""
"10640","09-10-05","MM THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10641","09-10-05","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Growth promotant","Augmente le gain pondéral","",""
"10642","09-10-05","MM THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"10643","09-10-05","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Non-steroidal anti-inflammatory","Anti-inflammatoire non-stéroïdien","",""
"10644","09-10-06","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Change in the manufacturing process","Changement au processus de fabrication","Biologic response modifier","Modificateur de la réponse biologique","",""
"10645","09-10-06","LUNDBECK INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiepileptic","Antiépileptique","",""
"10646","09-10-06","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMBIVENT","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Bronchodilator","Bronchodilatateur","",""
"10647","09-10-06","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10648","09-10-06","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10649","09-10-06","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10651","09-10-06","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of long term safety and efficacy data of Isentress in combination with other antiretroviral therapy in HIV-infected treatment-naive patients","Données additionnelles sur l'efficacité et l'innocuité, obtenues à long terme, pour le traitement de l'infection au VIH chez les patients naifs aux antirétroviraux","Human immunodeficiency virus integrase strand transfer inhibitor","Inhibiteur de transfert de brin d'intégrase du virus de l'immunodéficience humaine","",""
"10652","09-10-07","4501128 CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10653","09-10-09","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anesthetic","Anesthésique","",""
"10654","09-10-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimaniac agent","Agent antipsychotique / Antimaniaque","",""
"10655","09-10-09","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","Antipsychotic agent / Antimaniac agent","Antipsychotique / Antimaniaque","",""
"10656","09-10-13","ZYMCAN PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional strength","Concentration additionnelle","Antidepressant","Antidépresseur","",""
"10657","09-10-13","CHARLOTTE PRODUCTS LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Hard surface disinfectant","Désinfectant pour surfaces dures","",""
"10658","09-10-14","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimanic agent","Antipsychotique / Antimaniaque","",""
"10659","09-10-14","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Selenium and vitamin E","Sélenium et de vitamine E","",""
"10660","09-10-14","NORBROOK LABORATORIES LTD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","BANAMINE","INTERVET CANADA CORP.","CANADA","CANADA","1","Additional claims","Indications supplémentaires","Anti-inflammatory, analgesic, antipyretic","Anti-inflammatoire, analgésique, antipyrétique","",""
"10661","09-10-14","MODERN VETERINARY THERAPEUTICS LLC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","DORMOSEDAN","ORION CORPORATION","FINLAND","FINLANDE","1","","","Sedative, analgesic","Sédatif, analgésique","",""
"10662","09-10-14","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT1 receptor agonist, migraine therapy","Agoniste des récepteurs 5-HT1, antimigraineux","",""
"10663","09-10-14","CSL BEHRING CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","Passive immunizing agent","Agent d'immunisation passive","",""
"10664","09-10-15","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimanic agent","Antipsychotique / Antimaniaque","",""
"10665","09-10-15","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"10666","09-10-16","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional indication","Indication supplémentaire","Antibacterial","Antibactérien","",""
"10667","09-10-16","MCNEIL CONSUMER HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"10668","09-10-16","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"10669","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10670","09-10-16","ZYMCAN PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypercholesterolemic and antidiarrheal","Hypocholestérolémiant et antidiarrhéique","",""
"10671","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10672","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"10673","09-10-16","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"10674","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA INC.","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10675","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINIVIL / ZESTRIL","MERCK FROSST CANADA & CO. / ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10676","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10677","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RENEDIL / PLINDIL","AVENTIS PHARMA INC. / ASTRAZENECA CANADA INC.","CANADA","CANADA","1","","","Antihypertensive agent","Antihypertenseur","",""
"10678","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC.","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10679","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","CRYSTAAL, DIVISION OF BIOVAIL CORPORATION","CANADA","CANADA","1","","","ß-adrenoceptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"10680","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10681","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10682","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10683","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LUVOX","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","Antidepressant / Antiobsessional agent","Antidépresseur / Agent antiobsessionnel","",""
"10684","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA INC.","CANADA","CANADA","1","","","Antidepressant / Anxiolytic","Antidépresseur / Anxiolytique","",""
"10685","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","Antidiabetic agent / Insulin resistance reducing agent","Agent antidiabétique / Agent diminuant la résistance à l'insuline","",""
"10686","09-10-16","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZEMURON","SCHERING-PLOUGH CANADA INC.","CANADA","CANADA","1","Labelling update","Mise à jour de l'étiquetage","Non-depolarizing skeletal neuromuscular blocking agent","Agent de blocage neuro-musculaire non dépolarisant","",""
"10687","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Antirheumatic / Immunomodulator agent","Antirhumatismal / Immunomodulateur","",""
"10688","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXO WELLCOME GMBH & CO.","GERMANY","ALLEMAGNE","1","","","Antiemetic (5-HT3-receptor antagonist)","Antiémétique (Antagoniste des récepteurs 5-HT3)","",""
"10689","09-10-16","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10690","09-10-16","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic Agent / Social Phobia (Social Anxiety Disorder) / Posttraumatic Stress Disorder Therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"10691","09-10-21","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"10692","09-10-21","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","New strength","Nouvelle concentration","Antibacterial agent","Antibactérien","",""
"10693","09-10-20","GILEAD SCIENCES CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","96 week data for the treatment of chronic hepatitis B (CHB) infection in patients 18 years of age and older","Données obtenues à 96 semaines pour le traitement des patients âgés de 18 ans et plus qui sont atteints de l'hépatite B chronique","Antiretroviral agent","Antirétroviral","",""
"10694","09-10-21","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimanic agent","Antipsychotique / Antimaniaque","",""
"10695","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10696","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10697","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10698","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10699","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10700","09-10-21","MEDA AB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"10701","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10702","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPROBAY","BAYER AG","GERMANY","ALLEMAGNE","1","","","Antibacterial agent","Antibactérien","",""
"10703","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEORAL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Immunosuppressive agent","Agent immunosuppresseur","",""
"10704","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10705","09-10-21","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"10706","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antibulimic","Antidépresseur / Antiobsessionnel / Antiboulimique","",""
"10707","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH AYERST CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic agent","Antiarythmique","",""
"10708","09-10-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXO WELLCOME INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"10709","09-10-21","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Perservative free formulation","Préparation sans agent de conservation","Active immunizing agent","Agent d'immunisation actif","",""
"10710","09-10-23","BAUSCH & LOMB INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial (ophthalmic)","Antibactérien (ophtalmique)","",""
"10711","04-07-08","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Non-steroidal anti-inflammatory","Anti-inflammatoire non stéroïdien","",""
"10712","09-10-26","MM THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10713","09-10-26","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor / Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine / Diurétique","",""
"10714","09-10-23","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Histamine H2-receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"10715","09-10-23","CELGENE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent / Pyrimidine analogue","Antinéoplasique / Analogue de pyrimidine","",""
"10716","09-10-26","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-diabetic agent / Insulin resistance reducing agent","Antidiabétique / Agent réducteur de l'insulinorésistance","",""
"10717","09-10-27","MICROBIX BIOSYSTEMS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Fibrinolytic agent","Agent fibrinolytique","",""
"10718","09-10-27","MICROBIX BIOSYSTEMS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Fibrinolytic agent","Agent fibrinolytique","",""
"10719","09-10-27","ENDO PHARMACEUTICALS SOLUTIONS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Cytotoxic antineoplastic anti-cancer agent","Antinéoplasique cytotoxique","",""
"10720","09-10-27","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To replace sterility test with process parametric release","Le test de stérilité sera remplacé par une autorisation de libération en fonction des paramètres","Contrast agent for magnetic resonance imaging","Produit de contraste pour l'imagerie par résonance magnétique","",""
"10721","09-10-29","RATIOPHARM INC","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","N-methyl-D-aspartate (NMDA) receptor antagonist","Antagoniste du récepteur N-méthyl-D-asparte","",""
"10722","09-10-29","NU PHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic","Hypnotique","",""
"10723","09-10-29","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXY-IR","PURDUE PHARMA INC","CANADA","CANADA","1","","","Opioid analgesic","Analgésique opioïde","",""
"10724","09-10-29","NU PHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10725","09-10-29","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"10726","09-10-29","NU PHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10727","09-10-29","INTERCELL AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immusation actif","",""
"10728","09-10-30","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C CAPSULES","PHARMACIA & UPJOHN INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10729","09-10-30","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Antirheumatic agent","Antirhumatismal","",""
"10730","09-10-30","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DDAVP SPRAY","FERRING INC","CANADA","CANADA","1","","","Antidiuretic","Antidiurétique","",""
"10731","09-10-30","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT PHARMA INC","CANADA","CANADA","1","","","Anticoagulant","Anticoagulant","",""
"10732","09-10-30","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"10733","09-11-02","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10734","09-11-02","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10735","09-10-29","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Removal of dosage forms from Product Monograph: Oral, suspension, 40mg/5ml and Intravenous, solution, 10mg/ml","Suppression de formes posologiques de la monographie de produit : Poudre pour suspension buvable 40mg/5ml et Solution intraveineuse 10mg/ml","Histamine H2 receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"10736","09-11-02","GE HEALTHCARE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To replace sterility test with process parametric release","Remplacement des épreuves de stérilité par un procédé de libération en fonction des paramètres","Non-ionic radiographic contrast media","Substance de contraste radiographique non ionique","",""
"10737","09-11-02","ELANCO DIVISION ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional swine indication","indication supplémentaire de porcs","Antimicrobial","Antimicrobien","",""
"10738","09-11-02","MERIAL CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Change in indication","Changement dans l'indication","Antiparasitic","Antiparasitaire","",""
"10739","09-10-30","GE HEALTHCARE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To replace sterility test with process parametric release","Remplacement des épreuves de stérilité par un procédé de libération en fonction des paramètres","Non-ionic radiographic contrast media","Substance de contraste radiographique non ionique","",""
"10740","09-11-04","PHARMASCIENCE INC","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","N-methyl-D-aspartate (NMDA) receptor antagonist","Antagoniste du récepteur N-méthyl-D-asparte","",""
"10741","09-11-04","NU PHARM INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER S.C.A.","CANADA","CANADA","1","New strength","Nouvelle concentration","Lipid metabolism regulator","Régulateur du métabolisme lipidique","",""
"10742","09-11-04","NU PHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Xanthine oxidase inhibitor","Inhibiteur de la xanthine-oxydase","",""
"10743","09-11-04","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10744","09-11-02","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10745","09-11-04","BAXTER HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional dose strength of 3000 IU/vial for final drug product and increase the upper limit of the Factor VIII potency specification from 2400 IU/vial to 3600 IU/vial","L'ajout d'une dose supplémentaire de 3000 UI/ampoule de produit final avec une limite supérieure de spécification d'activité du facteur VIII allant de 2400 UI/ampoule à 3600 UI/ampoule","Coagulant","Coagulant","",""
"10746","09-11-04","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLONASE","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Corticosteroid for nasal use","Corticostéroïde pour voie nasale","",""
"10747","09-11-04","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","CIBA-GEIGY CANADA LTD","CANADA","CANADA","1","","","Anti-inflammatory / Analgesic","Anti-inflammatoire / Analgésique","",""
"10748","09-11-04","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"10749","09-11-04","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10750","09-11-04","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic agent","Antiarythmique","",""
"10751","09-11-04","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","BIOVAIL PHARMACEUTICALS","CANADA","CANADA","1","","","Beta-adrenoceptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"10752","09-11-04","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Cardiotonic glycoside","Glucoside cardiotonique","",""
"10753","09-11-05","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor / Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine / Diurétique","",""
"10754","09-11-05","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10755","09-11-05","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFTIN","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10756","09-11-05","NU PHARM INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form: ophthalmic solution","Nouvelle forme posologique : solution ophtalmique","Topical anti-inflammatory agent","Agent anti-inflammatoire topique","",""
"10757","09-11-05","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON TABLETS","SERVIER CANADA INC","CANADA","CANADA","1","","","Oral hypoglycemic agent","Hypoglycémiant","",""
"10758","09-11-05","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","AERIUS","SCHERING CANADA INC","CANADA","CANADA","1","","","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"10759","09-11-06","MODERN VETERINARY THERAPEUTICS LLC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","ANTISEDAN","ORION CORPORATION","FINLAND","FINLANDE","1","","","Medetomidine reversing agent","Agent d'inversion de la médétomidine","",""
"10760","09-11-06","MODERN VETERINARY THERAPEUTICS LLC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","DOMITOR","ORION CORPORATION","FINLAND","FINLANDE","1","","","Sedative / Analgesic","Sédatif / Analgésique","",""
"10761","09-11-06","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of new clinical data to the Pegetron Product Monograph","Ajout de nouvelles données cliniques à la monographie de produit du Pegetron","Antiviral agent plus biological response modifier","Antiviral avec agent immunomodulateur","",""
"10762","09-11-06","NU PHARM INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","KNOLL PHARMA INC","CANADA","CANADA","1","New strengths","Nouvelles concentrations","Antihypertensive agent","Antihypertenseur","",""
"10763","09-11-06","NU PHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Analgesic / Anti-inflammatory agent","Analgésique / Anti-inflammatoire","",""
"10764","09-11-06","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PMS-HYDROCHLOROTHIAZIDE","BIOMED 2002 INC","CANADA","CANADA","1","","","Diuretic / Antihypertensive","Diurétique / Antihypertenseur","",""
"10765","09-11-06","NU PHARM INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength","Nouvelle concentration","Diuretic / Antihypertensive agent","Diurétique / Antihypertenseur","",""
"10766","09-11-06","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","ORTHO MCNEIL PHARMACEUTICALS INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antibacterial agent","Antibactérien","",""
"10767","09-11-06","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Non-steroidal antiandrogen","Antiandrogène non stéroïdien","",""
"10768","09-11-06","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10769","09-11-06","NU PHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antifungal agent","Antifongique","",""
"10770","09-11-06","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAQUENIL","SANOFI CANADA INC","CANADA","CANADA","1","","","Anti-rheumatic / Antimalarial","Antirhumatismal / Antipaludéen","",""
"10771","09-11-06","NU PHARM INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form - enteric coated tablets","Nouvelle forme posologique - comprimé entéro-soluble","Anti-inflammatory agent with analgesic and antipyretic properties","Anti-inflammatoire avec des propriétés analgésiques et antipyrétiques","",""
"10772","09-10-06","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","Update to Product Monograph: Indications and clinical use","Mise à jour de la monographie de produit : indications et utilisation clinique","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10773","09-11-06","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTO IV","NYCOMED CANADA INC","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10774","09-11-06","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","AERIUS","SCHERING CANADA INC","CANADA","CANADA","1","","","Histamine H1-receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"10775","09-11-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Centrally acting analgesic","Analgésique à action centrale","",""
"10776","09-11-09","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10777","09-11-10","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Change to the manufacturing facility and equipment in addition to a change in the container closure system","Changement à l'usine de fabrication et à l'équipement en plus d'un changement au système récipient-fermeture","Antineoplastic","Antinéoplasique","",""
"10778","09-11-12","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph with respect to pharmacokinetic differences in the elderly compared to the non-elderly with anagrelide exposure","Mises à jour de la monographie de produit concernant les différences pharmacocinétiques d'exposition à l'anagrélide chez les patients âgés comparés aux patients plus jeunes","Platelet-reducing agent","Réducteur plaquettaire","",""
"10779","09-11-12","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IDAMYCIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"10780","09-11-13","BASILEA PHARMACEUTICALS CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immunomodulator / Anti-inflammatory agent","Immunomodulateur / Anti-inflammatoire","",""
"10781","09-11-13","MM THERAPEUTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional formulation and additional manufacturing site","Formulation additionnelle et emplacement de fabrication additionnel","Antibiotic","Antibiotique","",""
"10782","09-11-13","NU PHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"10783","09-11-13","SEPRACOR PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antispasmodic","Antispasmodique","",""
"10784","09-11-16","FERRING INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Gonadotropin-releasing hormone receptor antagonist","Antagoniste des récepteurs de l'hormone de libération de la gonadotrophine","",""
"10785","09-11-17","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10786","09-11-18","JANSSEN ORTHO INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid analgesic","Analgésique opioïde","",""
"10787","09-11-18","ROUGIER PHARMA DIVISION OF RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ROBAX PLATINUM","WYETH CANADA","CANADA","CANADA","1","","","Muscle relaxant / Analgesic","Relaxant musculaire / Analgésique","",""
"10788","09-11-18","ICPBIO REPRODUCTION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Hormone","Hormone","",""
"10789","09-11-18","LABORATOIRES SOGEVAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antipyretic","Antipyrétique","",""
"10790","09-11-19","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfilment of commitments as per the Letter of Undertaking, dated March 13, 2007 for the treatment of adults with chronic, accelerated, or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate","Respect des obligations énoncées dans la lettre d’engagement du 13 mars 2007 pour ce qui concerne le traitement des adultes atteints d’une leucémie myéloïde chronique (LMC) en phase chronique, en phase d’accélération ou en crise blastique, associée à une résistance ou à une intolérance au traitement antérieur, y compris celui par le mésylate d’imatinib","Protein-tyrosine kinase inhibitor","Inhibiteur de la protéase-tyrosine kinase","",""
"10791","09-11-20","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strengths: 75mg/18.75mg/200mg and 125mg/31.25mg/200mg","Nouvelles concentrations : 75mg/18.75mg/200mg et 125mg/31.25mg/200mg","Anti-parkinsonian dopaminergic agent","Agent dopaminergique anti-parkinsonien","",""
"10792","09-11-23","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MERIDIA","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Anorexiant / Antiobesity agent","Anorexigène / Agent anti-obésité","",""
"10793","09-11-23","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MERIDIA","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","Anorexiant / Antiobesity agent","Anorexigène / Agent antiobésité","",""
"10794","09-11-24","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive / Acne therapy","Contraceptif oral / Traitement de l'acné","",""
"10795","09-11-24","NU PHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10796","09-11-24","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive / Acne therapy","Contraceptif oral / Traitement de l'acné","",""
"10797","09-11-24","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immunosuppressive agent","Agent immunosuppresseur","",""
"10798","09-11-20","BRISTOL MYERS SQUIBB AND GILEAD SCIENCES LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to Clinical Trials section for treatment-experienced patients","Mises à jour des données de la partie Essais cliniques sur les patients traités précédemment aux antirétroviraux","Antiretroviral agent","Antirétroviral","",""
"10799","09-11-23","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Use in combination with Tamsulosin for the treatment of moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH) in men with enlarged prostates","Nouvelle indication : Utiliser en association avec la tamsulosine pour traiter l'hyperplasie bénigne de la prostate (HBP) modérément ou sévèrement symptomatique","Type I and II 5-alpha reductase inhibitor","Inhibiteur de la 5 alpha-réductase des types I et II","",""
"10800","09-11-24","JUROX PTY LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","ESTRUMATE (DIN 02137658)","INTERVET CANADA CORP.","CANADA","CANADA","1","","","Prostaglandin","Prostaglandine","",""
"10801","09-11-24","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Selenium-Vitamin E supplement","Supplément de sélénium et de vitamine E","",""
"10802","09-11-25","ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","cGMP-specific phosphodiesterase type 5 inhibitor","Inhibiteur de la phosphodiestérase de type 5 spécifique de la GMPC","",""
"10803","09-11-25","WATSON LABORATORIES INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Luteinizing hormone-releasing hormone (LHRH) analog","Analogue de l'hormone de libération de la lutéinostimuline (LH-RH)","",""
"10804","09-11-25","COBALT PHARMACEUTICALS INC","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","N-methyl-D-aspartate (NMDA) receptor antagonist","Antagoniste du récepteur N-méthyl-D-asparte","",""
"10805","09-11-25","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Risk reduction of cardiovascular morbidity in patients intolerant to angiotensin converting enzyme inhibitors","Nouvelle indication : Réduction des risques de morbidité cardiovasculaire chez les patients intolérants aux inhibiteurs de l'enzyme de conversion de l'angiotensine","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine","",""
"10806","09-11-26","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Antimetabolite / Antirheumatic","Antimétabolite / Antirhumatismal","",""
"10807","09-11-26","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","Product Monograph update","Mise à jour de la monographie de produit","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10808","09-11-26","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent / Antimanic agent","Antipsychotique / Antimaniaque","",""
"10809","09-11-26","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"10810","09-11-26","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC","CANADA","CANADA","1","","","Congestive heart failure agent","Agent contre l'insuffisance cardiaque congestive","",""
"10811","09-11-26","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Commitment 3 as per Letter of Undertaking: Clinical study report (A2116) for patients with hepatic impairment.  Also provided clinical study report A2103 (Pgp interactions) and Pre-Clinical study 901168 (oral pre and postnatal study in rat)","Troisième engagement conformément à la lettre d’engagement : rapport d’essai clinique (A2116) chez les patients atteints d’insuffisance hépatique. Le rapport d’essai clinique A2103 (interactions avec la Pgp) et l’étude préclinique 901168 (portant  sur l'administration par voie orale prénatale et postnatale chez le rat) ont également été fournis","Protein-tyrosine kinase inhibitor","Inhibiteur de la protéase-tyrosine kinase","",""
"10812","09-11-27","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Immunomodulator","Immunomodulateur","",""
"10813","09-11-27","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Immunomodulator","Immunomodulateur","",""
"10814","09-11-30","SERVIER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form: orally disintegrating tablets","Nouvelle forme posologique : comprimé orodispersible","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10815","09-11-30","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC","CANADA","CANADA","1","Additional strength","Concentration additionnelle","Antidepressant","Antidépresseur","",""
"10816","09-11-30","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10817","09-11-30","NOVARTIS CONSUMER HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"10818","09-11-26","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","Update to the Product Monograph to match innovator","Mise à jour de la monographie de produit","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10819","09-11-26","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Update to the Product Monograph to match innovator","Mise à jour de la monographie de produit","Anti-fungal agent","Antifongique","",""
"10820","09-12-01","MM THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Cardiotonic glycoside","Glucoside cardiotonique","",""
"10821","09-12-01","GALDERMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical non-steroidal antipsoriatic agent","Agent antipsoriatique non stéroïdien topique","",""
"10822","09-12-02","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMERGE","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"10823","09-12-02","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMERGE","GLAXOSMITHKLINE CANADA INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"10824","09-12-01","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","","","Antineoplastic","Antinéoplasique","",""
"10825","09-12-03","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Bronchodilator","Bronchodilatateur","",""
"10826","09-12-04","PHARMEL INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic Agent / Social Phobia (Social Anxiety Disorder) / Posttraumatic Stress Disorder Therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"10827","09-12-04","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic Agent / Social Phobia (Social Anxiety Disorder) / Posttraumatic Stress Disorder Therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"10828","09-12-04","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10829","09-12-04","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10830","09-12-04","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","Antipsychotic agent","Antipsychotique","",""
"10831","09-12-04","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10832","09-12-04","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10833","09-12-04","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Changes to the Product Monograph","Modifications apportées à la monographie de produit","Antibacterial agent","Antibactérien","",""
"10834","09-12-04","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Thyroid hormone","Hormone thyroïdienne","",""
"10835","09-12-07","NOVOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bronchodilator","Bronchodilatateur","",""
"10836","09-12-02","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Bipolar Disorder, Risperdal Consta is indicated as monotherapy maintenance treatment in patients with bipolar 1 disorder to delay occurrence of manic episodes","Nouvelle indication: Trouble bipolaire: Risperdal Consta est indiqué en monothérapie de maintien pour retarder l'apparition d'épisode maniaque chez les patients atteints d'un trouble bipolaire 1","Antipsychotic agent","Antipsychotique","",""
"10837","09-12-03","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: In combination with Oxaliplatin for the treatment of metastatic colorectal cancer following failure of Irinotecan-containing combination chemotherapy","Nouvelle indication : En association avec l’oxaliplatine pour le traitement du cancer colorectal métastatique à la suite de l’échec de la chimiothérapie d’association à base d’irinotecan","Antineoplastic agent","Antinéoplasique","",""
"10838","09-12-08","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMINYL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10839","09-12-09","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"10840","09-12-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10841","09-12-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10842","09-12-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10843","09-12-09","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph: Clinical Pharmacology","Mise à jour de la monographie de produit : Pharmacologie clinique","Bronchodilator","Bronchodilatateur","",""
"10844","09-12-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","SANOFI-AVENTIS CANADA INC.","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10845","09-12-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C","PHARMACIA & UPJOHN INC.","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"10846","09-12-10","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10847","09-12-10","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10848","09-12-10","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10849","09-12-10","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE POULENC RORER CANADA INC","CANADA","CANADA","1","","","Hypnotic and sedatif","Hypnotique et sédatif","",""
"10850","09-12-10","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic Agent / Social Phobia (Social Anxiety Disorder) / Posttraumatic Stress Disorder Therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"10851","09-12-11","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Diuretic glucocorticoid","Diurétique glucocorticoïde","",""
"10852","09-12-02","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication for pediatrics and a new 75mg tablet for the pediatric patient population","Nouvelle indication pour les enfants et nouveau comprimé de 75mg pour la population pédiatrique","Human Immunodeficiency Virus (HIV) protease inhibitor","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH)","",""
"10853","09-12-09","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Alpha2-adrenergic agonist","Agoniste adrénergique alpha2","",""
"10854","09-12-10","GENPHARM ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph to comply with Basic Product Monograph Information for NSAIDS, effective date November 23, 2006 and Product Monograph, effective date October 1, 2004, guidance documents","Modifications à la monographie de produit afin de respecter les lignes directrices Information de base sur la 		monographie des anti-inflammatoires non stéroïdiens (AINS),  en vigueur depuis le 23 novembre 2006, et 	Monographies de produit, en vigueur depuis le 1er octobre 2004 ","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non-stéroïdien (AINS)","",""
"10855","09-12-14","DR REDDYS LABORATORIES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10856","09-12-14","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility and change to manufacturing","Nouvel emplacement de fabrication et modification de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"10857","09-12-14","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility and change to manufacturing","Nouvel emplacement de fabrication et modification de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"10858","09-12-14","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility and change to manufacturing","Nouvel emplacement de fabrication et modification de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"10859","09-12-14","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility and change to manufacturing","Nouvel emplacement de fabrication et changement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"10860","09-12-14","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent (mTOR kinase inhibitor)","Antinéoplasique (Inhibiteur de la mTOR kinase)","",""
"10861","09-12-14","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"10862","09-12-10","FERRING INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change to formulation of the drug product","Modification à la formulation du produit","Antihemorrhagic","Antihémorragique","",""
"10863","09-12-15","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"10864","09-12-15","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"10865","09-12-11","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph updates","Mises à jour de la monographie de produit","Active immunizing agent","Agent d'immunisation actif","",""
"10866","09-12-16","PURDUE PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid analgesic / Opioid Antagonist","Analgésique opioïde / Antagoniste des opioïdes","",""
"10867","09-12-15","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Coagulation factor","Facteur de coagulation","",""
"10868","09-12-15","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10869","09-12-15","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Monotherapy - as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus and for whom metformin is inappropriate due to contraindications or intolerance","Nouvelle indication : Monothérapie - en complément à une diète et à l’exercice, pour un meilleur contrôle de la glycémie chez les sujets adultes atteints de diabète sucré de type 2 pour qui la metformine n’est pas appropriée en raison de contre-indications ou d’une intolérance ","Oral antihyperglycemic agent / DPP-4 inhibitor / Incretin enhancer","Antihyperglycémiant oral / Inhibiteur DPP-4 / Renforceur d'incretin","",""
"10870","09-12-18","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"10871","09-12-18","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"10872","09-12-18","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"10873","09-12-21","WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"10875","09-12-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMINYL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10876","09-12-21","PIERREL S.P.A.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","SEPTANEST N AND SEPTANEST SP","SEPTODONT","CANADA","CANADA","1","","","Local anaesthetic for dental use","Anesthésique local pour usage dentaire","",""
"10877","09-12-15","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph: Addition of 96 week data for treatment-Naive patients","Modifications de la monographie de produit : Données additionnelles à 96 semaines de traitement chez les patients n'ayant pas reçu d'antirétroviraux","Azapeptide inhibitor of HIV-1 protease","Inhibiteur azapeptidique de la protéase du VIH-1","",""
"10878","09-12-18","OTSUKA PHARMACEUTICAL CO. LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Removal of breast cancer and ovarian cancer from the Indications and Clinical Use and Clinical Trials sections of the Product Monograph","Retrait du cancer du sein et du cancer de l’ovaire des sections suivantes de la monographie de produit : Indications et utilisation clinique; Essais cliniques ","Antineoplastic","Antinéoplasique","",""
"10879","09-12-21","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10880","09-12-21","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CCR5 antagonist","Antagoniste du CCR5","",""
"10881","09-12-22","JOHNSON & JOHNSON INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antifungal agent","Antifongique","",""
"10882","09-12-21","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"10883","09-12-21","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"10884","09-12-21","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"10885","09-12-18","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: For the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK","Nouvelle indication : Pour le traitement de première ligne des patients atteints d’un cancer du poumon non à petites cellules localisé et avancé (impossible à guérir par un traitement curatif) ou métastatique, qui ont des mutations activatrices de la tyrosine kinase du récepteur du facteur de croissance épidermique (EGFR-TK)","Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)","Inhibiteur de la tyrosine kinase du récepteur du facteur de croissance épidermique (EGFR)","",""
"10886","09-12-22","NORBROOK LABORATORIES LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"10887","09-12-22","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","New indication","Nouvelle indication","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10888","09-12-23","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10889","09-12-23","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10890","09-12-23","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC DELAYED RELEASE CAPSULE","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"10891","09-12-24","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10892","09-12-24","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN-150","PFIZER CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"10893","09-12-24","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"10894","09-12-24","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN-150","PFIZER CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"10895","09-12-30","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LABETALOL HYDROCHLORIDE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antihypertensive agent","Antihypertenseur","",""
"10896","09-12-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRUSOPT","MERCK FROSST CANADA INC","CANADA","CANADA","1","","","Elevated Intraocular pressure therapy (Topical carbonic anhydrase inhibitor)","Thérapie pour réduire la pression intraoculaire (Inhibiteur de l'anhydrase carbonique topique)","",""
"10897","09-12-22","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: For the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST ","Nouvelle indication : Concernant le traitement adjuvant des patients adultes qui sont entre le stade intermédiaire et le stade à risque élevé d’une rechute à la suite de la résection totale de la tumeur stromale gastro-intestinale du c-kit (CD117)","Protein kinase inhibitor","Inhibiteur de la protéine kinase","",""
"10898","09-12-31","GRACEWAY PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","1. New strength; 2. Product name change","1) Nouvelle concentration; 2) Modification du nom du produit","Immune response modifier","Modificateur de la réponse immunitaire","",""
"10899","10-01-04","SANOFI AVENTIS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hematinic","Hématinique","",""
"10900","10-01-04","IROKO CARDIO (UK) LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Platelet aggregation inhibitor","Inhibiteur de l'aggrégation plaquettaire","",""
"10901","10-01-06","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of the 12mcg/h strength. Updated inner & outer label","Ajout de la concentration 12mcg/h. Mise à jour des étiquettes internes et externes","Opioid analgesic","Analgésique opioïde","",""
"10902","10-01-08","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Improved manufacturing process and facilities","Modification de la méthode de fabrication et de l'emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"10903","10-01-11","SEPRACOR PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Direct thrombin inhibitor","Inhibiteur direct de la thrombine","",""
"10904","10-01-08","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Alternative manufacturing facility","Aire de fabrication supplémentaire","Hemostatic agent","Agent hémostatique","",""
"10905","10-01-11","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New formulation","Nouvelle formulation","Active immunizing agent","Agent d'immunisation actif","",""
"10906","10-01-12","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10907","10-01-12","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"10908","10-01-12","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Anti-diabetic agent / Insulin resistance reducing agent","Agent antidiabétique / Agent réducteur de l'insulinorésistance","",""
"10909","10-01-12","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10910","10-01-12","LUNDBECK INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticonvulsant for adjunctive therapy","Anticonvulsivant comme traitement adjuvant","",""
"10911","10-01-12","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hair growth inhibitor","Inhibiteur de la pousse de cheveux","",""
"10912","10-01-12","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Gonadotropin-releasing hormone (GnRH) antagonist","Antagoniste de l'hormone de libération de la gonatrophine (GnRH)","",""
"10913","10-01-12","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticoagulant / Antithrombotic agent (heparinoid)","Anticoagulant / Antithrombotique (héparinoïde)","",""
"10914","10-01-12","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"10915","10-01-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiviral agent","Antiviral","",""
"10916","10-01-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral hypoglycemic","Hypoglycémiant oral","",""
"10917","10-01-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticonvulsant","Anticonvulsivant","",""
"10918","10-01-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"10919","10-01-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","KNOLL PHARMA INC","CANADA","CANADA","1","","","Antihypertensive agent","Antihypertenseur","",""
"10920","10-01-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antifungal agent","Antifongique","",""
"10921","10-01-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Skeletal muscle relaxant","Relaxant musculaire squelettique","",""
"10922","10-01-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Muscle relaxant / Antispastic agent","Relaxant musculaire / Antispasmodique","",""
"10923","10-01-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiarrhythmic","Antiarythmique","",""
"10924","10-01-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10925","10-01-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Modifier of upper gastrointestinal motility","Modificateur de la motilité des voies digestives supérieures","",""
"10926","10-01-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC","CANADA","CANADA","1","","","Congestive heart failure agent","Agent contre l'insuffisance cardiaque congestive","",""
"10927","10-01-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10928","10-01-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antianginal / Antiarrhythmic / Antihypertensive agent","Antiangineux / Antiarythmique / Antihypertenseur","",""
"10929","10-01-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Immunosuppressive agent","Agent immunosuppresseur","",""
"10930","10-01-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Anticonvulsant","Anticonvulsivant","",""
"10931","10-01-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC","CANADA","CANADA","1","","","Diuretic / Antihypertensive agent","Diurétique / Antihypertenseur","",""
"10932","10-01-13","UCB CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiepileptic","Antiépileptique","",""
"10933","10-01-13","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Opioid analgesic","Analgésique opioïde","",""
"10934","10-01-14","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Contrast enhancement agent for magnetic resonance imaging","Agent de rehaussement de contraste pour l'imagerie par résonance magnétique","",""
"10935","10-01-14","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiparkinson agent","Agent antiparkinsonien","",""
"10936","10-01-14","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form: solution for injection","Nouvelle forme posologique : solution pour injection","cGMP-specific phosphodiesterase type 5 inhibitor","Inhibiteur de la phosphodiestérase de type 5 spécifique de la GMPC","",""
"10937","10-01-15","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"10938","10-01-15","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10939","10-01-15","ALLERGAN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antispasmodic","Antispasmodique","",""
"10940","10-01-15","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive agent / Symptomatic treatment of benign prostatic hyperplasia (BPH)","Antihypertenseur / Traitement symptomatique de l'hypertrophie bénigne de la prostate (HBP)","",""
"10941","10-01-15","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID analgesic agent","Analgésique AINS","",""
"10942","10-01-15","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10943","10-01-15","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"10944","10-01-15","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive and anti-anginal agent","Antihypertenseur et antiangineux","",""
"10945","10-01-18","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATORIES FOURNIER S.C.A.","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10946","10-01-18","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10947","10-01-20","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CONCERTA","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","CNS stimulant","Stimulant du CNS","",""
"10948","10-01-22","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Clinical Trials section of the Product Monograph","Révisions de la section sur les essais cliniques de la monographie de produit","Antidepressant / Anxiolytic / Analgesic","Antidépresseur / Anxiolytique / Analgésique","",""
"10949","10-01-21","PHIBRO ANIMAL HEALTH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anticoccidial","Anticoccidien","",""
"10950","10-01-21","PHIBRO ANIMAL HEALTH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anticoccidial","Anticoccidien","",""
"10951","10-01-22","NU PHARM INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product Monograph update to match innovator's Product Monograph","Mise à jour de la monographie de produit pour égaler la monographie de produit de l'innovateur","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"10952","10-01-22","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM CANADA LTD","CANADA","CANADA","1","Update to the Product Monograph to match the innovator's Product Monograph","Mise à jour de la monographie de produit pour égaler la monographie de produit de l'innovateur","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"10953","10-01-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS, USA (CAPSULES) / PFIZER CANADA INC, CANADA (TABLETS)","CANADA","CANADA","1","","","Antiepileptic agent","Antiépileptique","",""
"10954","10-01-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antipanic / Antiobsessional agent","Antidépresseur / Antipanique / Antiobsessionnel","",""
"10955","10-01-26","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"10956","10-01-26","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"10957","10-01-26","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10958","10-01-26","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antipanic / Antiobsessional agent","Antidépresseur / Antipanique / Antiobsessionnel","",""
"10959","10-01-26","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"10960","10-01-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10961","10-01-26","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10962","10-01-26","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Antiobsessional agent","Antidépresseur / Antiobsessionnel","",""
"10963","10-01-26","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic and sedative","Hypnotique et sédatif","",""
"10964","10-01-26","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Nonsteroidal anti-inflammatory with a mucosal protective agent","Anti-inflammatoire non stéroïdien contenant un protecteur de la muqueuse","",""
"10965","10-01-26","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin converting enzyme inhibitor / Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine / Diurétique","",""
"10966","10-01-26","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"10967","10-01-26","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic agent / Social phobia (social anxiety disorder) / Posttraumatic stress disorder therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"10968","10-01-26","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMINYL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"10969","10-01-26","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"10970","10-01-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"10971","10-01-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic agent / Social phobia (social anxiety disorder) / Posttraumatic stress disorder therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"10972","10-01-26","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Antiobsessional / Antibulimic agent","Antidépresseur / Antiobsessionnel / Antiboulimique","",""
"10973","10-01-26","ACTAVIS GROUP PTC EHF","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in drug product manufacturing site","Changement de l'emplacement de fabrication","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"10974","10-01-26","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","Bone formation agent","Agent ostéoformateur","",""
"10975","10-01-25","PHIBRO ANIMAL HEALTH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anthelmintic","Anthelmintique","",""
"10976","10-01-26","PHIBRO ANIMAL HEALTH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"10977","10-01-27","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"10978","10-01-28","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in manufacturing site and changes in formulation","Changement du lieu de fabrication et modification de la formulation","Anticonvulsant","Anticonvulsivant","",""
"10979","10-01-27","BAYER HEALTHCARE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New fill size 3000 IU","Nouveau volume de remplissage de 3000 UI","Coagulation factor","Facteur de coagulation","",""
"10980","10-01-27","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New fill size 3000 IU","Nouveau volume de remplissage de 3000 UI","Coagulation factor","Facteur de coagulation","",""
"10981","10-01-29","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimanic agent","Antipsychotique / Antimaniaque","",""
"10982","10-01-29","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur 5-alpha réductase du type II","",""
"10983","10-01-29","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic","Antipsychotique","",""
"10984","10-01-29","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"10985","10-01-29","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PEPCID TABLETS","MERCK FROSST CANADA LTD","CANADA","CANADA","1","Product Monograph update to match the innovator's Product Monograph","Mise à jour de la monographie de produit pour égaler la monographie de produit de l'innovateur","Histamine H2 receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"10987","10-01-29","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimanic agent","Antipsychotique / Antimaniaque","",""
"10988","10-01-29","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"10989","10-02-01","LUNDBECK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to Clinical Trials section of the Product Monograph","Modifications apportées à la section Essais cliniques de la monographie de produit","Antidepressant / Anxiolytic / Antiobsessional","Antidépresseur / Anxiolytique / Antiobsessionnel","",""
"10990","10-02-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","Antidepressant / Anxiolytic","Antidépresseur / Anxiolytique","",""
"10991","10-02-02","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE HCT","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor plus diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine avec diurétique","",""
"10992","10-02-03","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"10993","10-02-03","RECKITT BENCKISER HEALTHCARE (UK) LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Opioid analgesic","Analgésique d'opioïde","",""
"10994","10-02-03","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"10995","10-02-03","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CONCERTA","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Central nervous system stimulant","Stimulant du système nerveux central","",""
"10996","10-02-03","WYETH ANIMAL HEALTH DIVISION OF WYETH CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anesthetic","Anesthésie","",""
"10997","10-02-03","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph: Indication, Warnings & Precautions, Post-Market Adverse Drug Reaction and Dosage & Administration sections","Mise à jour de la monographie de produit : sections de l’indication, des mises en garde et précautions, des effets indésirables des médicaments connus après la mise en marché et de la posologie et l’administration","Progestogen","Progestatif","",""
"10998","10-02-03","IMCLONE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","New indication","Nouvelle indication","Antineoplastic","Antinéoplasique","",""
"10999","10-02-04","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Xanthine oxidase inhibitor","Inhibiteur de la xanthine-oxydase","",""
"11000","10-02-04","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11001","10-02-04","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUMETZA","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","CANADA","CANADA","1","","","Oral anti-hyperglycemic agent","Antihyperglycémiant oral","",""
"11002","10-02-05","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2 receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"11003","10-02-05","ROUGIER PHARMA DIVISION OF RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ROBAX PLATINUM","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Muscle relaxant / Analgesic","Relaxant musculaire / Analgésique","",""
"11004","10-02-05","ROUGIER PHARMA DIVISION OF RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ROBAX PLATINUM","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Muscle relaxant / Analgesic","Relaxant musculaire / Analgésique","",""
"11005","10-02-05","ROUGIER PHARMA DIVISION OF RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ROBAX PLATINUM","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Muscle relaxant / Analgesic","Relaxant musculaire / Analgésique","",""
"11006","10-02-05","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimanic agent","Antipsychotique / Antimaniaque","",""
"11007","10-02-05","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS, DIVISION OF WARNER LAMBERT CANADA INC","CANADA","CANADA","1","","","Antiepileptic agent","Antiépileptique","",""
"11008","10-02-05","XEDITON PHARMACEUTICALS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antirheumatic agent","Antirhumatismal","",""
"11009","10-02-05","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ROBAX PLATINUM","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Muscle relaxant / Analgesic","Relaxant musculaire / Analgésique","",""
"11010","10-02-05","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA / ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimanic","Antipsychotique / Antimaniaque","",""
"11011","10-02-05","NOVARTIS VACCINES AND DIAGNOSTICS GMBH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"11012","10-02-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","AERIUS","SCHERING CANADA INC","CANADA","CANADA","1","","","Histamine H1-receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11013","10-02-05","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"11014","10-02-05","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immunosuppressive agent","Agent immunosuppresseur","",""
"11015","10-02-05","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRA PHARMA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11016","10-02-05","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11017","10-02-05","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TICLID","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Inhibitor of platelet function","Agent antiplaquettaire","",""
"11018","10-02-05","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimanic agent","Antipsychotique / Antimaniaque","",""
"11019","10-02-05","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-2","ASTRA PHARMA INC","CANADA","CANADA","1","","","Antihypertensive agent / Symptomatic treatment of benign prostatic hyperplasia (BPH)","Antihypertenseur / Traitement symptomatique de l'hyperplasie bénigne de la prostate (HBP)","",""
"11020","10-02-05","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELAFEN","SMITHKLINE BEECHAM PHARMA INC","CANADA","CANADA","1","","","Nonsteroidal anti-inflammatory agent","Anti-inflammatoire non stéroïdien","",""
"11021","10-02-08","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiparkinsonian agent / Antiviral agent","Antiparkinsonien / Antiviral","",""
"11022","10-02-08","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticonvulsant","Anticonvulsivant","",""
"11023","10-02-08","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYDREA","SQUIBB CANADA INC","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"11024","10-02-08","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC","CANADA","CANADA","1","","","Antiarrhythmic agent","Antiarythmique","",""
"11025","10-02-09","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Extension of the maximum treatment period from 18 months to 24 months","Prolongation de la durée maximale du traitement de 18 mois à 24 mois","Bone formation agent","Agent ostéoformateur","",""
"11026","10-02-10","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"11027","10-02-10","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"11028","10-02-10","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11029","10-02-10","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11030","10-02-10","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"11031","10-02-10","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"11032","10-02-10","NT PHARMA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11033","10-02-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Drug product manufacturing site change","Changement de l'emplacement de fabrication","Selective serotonin reuptake inhibitor","Inhibiteur sélectif du recaptage de la sérotonine","",""
"11034","10-02-10","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"11035","10-02-10","ANGITA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antidepressant","Antidépresseur","",""
"11036","09-12-17","EMD SERONO CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New formulation and product monograph update","Nouvelle formulation et mise à jour de la monographie de produit","Gonadotropin","Gonadotrophine","",""
"11037","10-02-12","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Carbonic anhydrase inhibitor and beta-adrenergic blocking agent","Inhibiteur de l'anhydrase carbonique et inhibiteur des récepteurs bêta-adrénergiques","",""
"11038","10-02-12","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to Contraindications, Warnings and Precautions, Adverse Reactions,  Drug Interactions, Dosage and Administration, Overdosage, Clinical Pharmacology, Toxicology and References sections of the Product Monograph ","Révisions apportées aux sections suivantes de la monographie de produit :  contre-indications, mises en garde et précautions, effets indésirables, interactions médicamenteuses, posologie et administration, surdosage, pharmacologie clinique, toxicologie et références","Oral contraceptive","Contraceptif oral","",""
"11039","10-02-15","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11040","10-02-15","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLEXERIL","MERCK FROSST CANADA INC","CANADA","CANADA","1","","","Skeletal muscle relaxant","Relaxant musculaire squelettique","",""
"11041","10-02-15","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONITAN","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11042","10-02-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11043","10-02-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11044","10-02-15","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTIVA","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Opioid component to anesthesia","Composant narcotique d'anésthésique","",""
"11045","10-02-15","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"11046","10-02-15","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOWELLCOME INC","CANADA","CANADA","1","","","Histamine H2-receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"11047","10-02-15","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11048","10-02-15","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11049","10-02-15","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11050","10-02-15","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"11051","10-02-15","STIEFEL CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid therapy","Corticostéroïde topique","",""
"11052","10-02-15","TALECRIS BIOTHERAPEUTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Modified manufacturing process and name change","Modification du processus de fabrication et du nom du produit","Alpha-1 antitrypsin replenisher","Agent de recharge en alpha1-antitrypsine","",""
"11053","10-02-15","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11054","10-02-15","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","DUPONT MERCK PHARMA INC","CANADA","CANADA","1","","","Anticoagulant","Anticoagulant","",""
"11055","10-02-17","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Extension of the adult rheumatoid arthritis indication: When used as first-line treatment in recently diagnosed patients who have not been previously treated with metothrexate (MTX), Orencia should be given in combination with MTX","Ajout à l'indication de polyarthrite rhumatoïde chez les adultes : Lorsqu'il est utilisé comme traitement de première intention chez des patients dont le diagnostic est récent et qui n'étaient préalablement pas sous méthotrexate (MTX), Orencia doit être administré en association avec le MTX","Selective co-stimulation modulator","Modulateur de co-stimulation sélectif","",""
"11056","10-02-17","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Muscle relaxant / Antispastic agent","Relaxant musculaire / Antispastique","",""
"11057","10-02-18","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral hypoglycemic agent","Hypoglycémiant oral","",""
"11058","10-02-18","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"11059","10-02-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11060","10-02-19","BIMEDA MTC ANIMAL HEALTH INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","BANAMINE","INTERVET CANADA CORP","CANADA","CANADA","1","Additional indication","Indication additionnelle","Anti-inflammatory, analgesic, antipyretic","Anti-inflammatoire, analgésique, antipyrétique","",""
"11061","10-02-18","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC.","CANADA","CANADA","1","Update Product Monograph to match the innovator's Product Monograph","Mise à jour de la monographie de produit pour égaler la monographie de produit de l'innovateur","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11062","10-02-18","WARNER CHILCOTT CANADA CO","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11063","10-02-17","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RYTHMOL","KNOLL PHARMA INC","CANADA","CANADA","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Antiarrhythmic agent","Antiarythmique","",""
"11064","10-02-19","WARNER CHILCOTT CANADA CO","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Urinary tract antibacterial","Antibactérien des voies urinaires","",""
"11065","10-02-18","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antibulimic","Antidépresseur / Antiobsessionnel / Antiboulimique","",""
"11066","10-02-18","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Diuretic","Diurétique","",""
"11067","10-02-18","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"11068","10-02-19","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"11069","10-02-19","MELIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticonvulsant","Anticonvulsivant","",""
"11070","10-02-19","MELIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticonvulsant","Anticonvulsivant","",""
"11071","10-02-19","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, A DIVISION OF SMITHKLINE BEECHAM INC","CANADA","CANADA","1","","","Congestive heart failure agent","Agent contre l'insuffisance cardiaque congestive","",""
"11072","10-02-19","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Hypnotic and sedative","Hypnotique et sédatif","",""
"11073","10-02-19","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","","","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11074","10-02-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHÔNE-POULENC RORER CANADA INC","CANADA","CANADA","1","","","Hypnotic and sedative","Hypnotique et sédatif","",""
"11075","10-02-19","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"11076","10-02-18","WARNER CHILCOTT CANADA CO","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bone metabolism regulator / Vitamin and mineral supplement","Régulateur du métabolisme osseux / Supplément minéral / Supplément vitaminique","",""
"11077","10-02-18","WARNER CHILCOTT CANADA CO","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bone metabolism regulator / Mineral supplement","Régulateur du métabolisme osseux / Supplément minéral","",""
"11078","10-02-22","WARNER CHILCOTT CANADA CO","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11079","10-02-22","WARNER CHILCOTT CANADA CO","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lower gastrointestinal anti-inflammatory","Anti-inflammatoire de la partie basse du tube digestif","",""
"11080","10-02-22","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Gardasil is indicated in boys and men 9 through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11","Gardasil est indiqué chez les garçons et les hommes de 9 à 26 ans pour la prévention de l'infection par les virus du papillome humain (VPH) des types 6, 11, 16 et 18 et des verrues génitales causées par les VPH des types 6 et 11","Active immunizing agent","Agent d'immunisation actif","",""
"11081","10-02-23","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","Anti-hypertensive agent / Symptomatic treatment of benign prostatic hyperplasia (BPH)","Antihypertenseur / Traitement symptomatique de l'hypertrophie bénigne de la prostate (HBP)","",""
"11082","10-02-23","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","Product monograph update","Mise à jour de la monographie de produit","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11083","10-02-23","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New dosing and extension of indication: Treatment of adult patients (18 years of age and older) with chronic hepatitis C who have compensated liver disease and are positive for HCV-RNA, including patients who have not received previous treatment or who failed prior treatment with Interferon Alpha (pegylated or non-pegylated) and Ribavirin combination therapy","Nouveau dosage et prolongation d'indication : Traitement de patients adultes (c.-à-d. 18 ans et plus) atteints d'hépatite C chronique, qui présentent un hépatopathie compensée et qui sont porteurs de l'ARN du VHC, y compris les patients qui n'ont pas reçu de traitement antérieur par Interféron Alpha (pégylé ou non pégylé) et Ribavirine en bithérapie ou qui n'ont pas répondu à ce traitement","Antiviral agent plus biological response modifier","Antiviral avec agent immunomodulateur","",""
"11084","10-02-22","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic / Anti-inflammatory / Antifungal","Antibiotique / Anti-inflammatoire / Antifongique","",""
"11085","10-02-24","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","Uricolytic agent","Agent uricolytique","",""
"11086","10-02-24","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine Therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"11087","10-02-24","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"11088","10-02-24","VALEO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STERILE VANCOMYCIN HYDROCHLORIDE USP","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11089","10-02-24","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Opioid analgesic","Analgésique opioïde","",""
"11090","10-02-24","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FAMVIR","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"11091","10-02-24","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","Antidepressant / Anxiolytic","Antidépresseur / Anxiolytique","",""
"11092","10-02-25","AUROBINDO PHARMA LIMITED (UNIT VI)","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11093","10-02-25","PHARMEL INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11094","10-02-25","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11095","10-02-25","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11096","10-02-25","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11097","10-02-26","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Fulfill a commitment included in Notice of Compliance with Conditions issued on April 3, 2008","Répondait à un engagement inclus dans l'avis de conformité avec conditions émis le 3 avril 2008","Antineoplastic","Antinéoplasique","",""
"11098","10-02-26","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Antipsychotic agent","Antipsychotique","",""
"11099","10-02-26","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL","CANADA","CANADA","1","New strength","Nouvelle concentration","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11100","10-02-26","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAMPTOSAR","PFIZER CANADA INC.","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"11101","10-02-25","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph in response to May 6, 2009 Advisement Letter","Mise à jour de la monographie de produit en réponse à la lettre d'avis du 6 mai 2009","Non steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11102","10-02-26","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","Immunomodulatory agent - a selective interleukin-1 beta (IL-1beta) inhibitor","Agent immunomodulateur, un inhibiteur sélectif de l'interleukine-1 bêta (IL-1bêta)","",""
"11103","10-03-02","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA & CO","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11104","10-03-02","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALERTEC","SHIRE BIOCHEM INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Central nervous system stimulant","Stimulant du système nerveux central","",""
"11105","10-03-02","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Concomitant use with angiotensin II ATI receptor blockers","Nouvelle indication : usage concomitant des antagonistes du récepteur type 1 de l'angiotensine II","Renin inhibitor","Inhibiteur de la rénine","",""
"11106","10-03-04","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial agent","Antibactérien","",""
"11107","10-03-04","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"11108","10-03-05","ZYMCAN PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional strength","Concentration additionnelle","Anticonvulsant","Anticonvulsivant","",""
"11109","10-03-05","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic / Decongestant","Analgésique / Antipyrétique / Décongestionnant","",""
"11110","10-03-05","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DOSTINEX","PFIZER CANADA INC","CANADA","CANADA","1","","","Dopamine receptor agonist","Agoniste des récepteurs de la dopamine","",""
"11111","10-03-05","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11112","10-03-05","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC., HEALTH DIVISION","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"11113","10-03-02","VIIV HEALTHCARE ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Modify pediatric oral dosing recommendations and related changes to the Product Monograph","Modifier les doses orales recommendées chez les enfants et réviser la monographie de produit en conséquence","Antiretroviral agent","Antirétroviral","",""
"11114","10-03-05","PURDUE PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid analgesic","Analgésique opioïde","",""
"11115","10-03-05","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph revised","Monographie de produit révisée","Biologic response modifier","Modificateur de la réponse biologique","",""
"11116","10-03-08","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOLAN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Vasodilator","Vasodilatateur","",""
"11117","10-03-08","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Lipid emulsion for intravenous nutrition","Émulsion lipidique pour alimentation par voie intraveineuse","",""
"11118","10-03-09","BAYER INC CONSUMER CARE DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antifungal agent","Agent antifongique","",""
"11119","10-03-09","BAYER INC CONSUMER CARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Revised labelling and Product Monograph","Révision de l'étiquetage et de la monographie de produit","Antifungal agent","Antifongique","",""
"11120","10-03-09","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","DIFLUCAN-150","PFIZER CANADA INC","","","1","Revisions to the Product Monograph - Prescription to Over the Counter (OTC)","Révisions à la monographie de produit - médicament vendu sous ordonnance à médicament en vente libre","Antifungal agent","Antifongique","",""
"11121","10-03-09","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","DIFLUCAN-150","PFIZER CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph - Prescription to Over the Counter (OTC)","Révisions à la monographie de produit - médicament vendu sous ordonnance à médicament en vente libre","Antifungal agent","Antifongique","",""
"11122","10-03-09","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","DIFLUCAN-150","PFIZER CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph - Prescription to Over the Counter (OTC)","Révisions à la monographie de produit - médicament vendu sous ordonnance à médicament en vente libre","Antifungal agent","Antifongique","",""
"11123","10-03-09","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","DIFLUCAN","PFIZER CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph - Prescription to Over the Counter (OTC)","Révisions à la monographie de produit - médicament vendu sous ordonnance à médicament en vente libre","Antifungal agent","Antifongique","",""
"11124","10-03-09","BAYER INC CONSUMER CARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antifungal agent","Agent antifongique","",""
"11125","10-03-09","BAYER INC CONSUMER CARE DIVISION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Revised labelling and Product Monograph. Change in product name from CanesOral Duo-Pak to CanesOral Combi-Pak","Révision de l'étiquetage et de la monographie de produit. Modification du nom du produit de CanesOral Duo-Pak à CanesOral Combi-Pak","Antifungal agents","Agents antifongiques","",""
"11126","10-03-04","ACTELION PHARMACEUTICALS LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: To slow the progression of some of the neurological manifestations in patients with Niemann-Pick Type C disease","Nouvelle indication : Pour ralentir la progression de certaines manifestations neurologiques de la maladie de Niemann-Pick de type C","Glucosyceramide synthase inhibitor","Inhibiteur de la glucosyceramide synthase","",""
"11127","10-03-10","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","DIFLUCAN 150","PFIZER CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph and new product name","Révisions à la monographie de produit et nouveau nom du produit","Antifungal agent","Antifongique","",""
"11128","10-03-09","CUBIST PHARMACEUTICALS INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternative method of administration 2 minute bolus intravenous injection, 500mg/vial","Autre méthode d'administration (en deux minutes) d'un bolus intraveineux, 500mg/fiole","Antibacterial agent","Antibactérien","",""
"11129","10-03-09","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revised indication: Prevention of nausea and vomiting in women due to treatment with moderately emetogenic cancer chemotherapy","Indication révisée : Prévention, chez les femmes, des nausées et des vomissements consécutifs à l'administration d'une chimiothérapie anticancéreuse modérément émétisante","Neurokinin 1 (NK1) receptor antagonist","Antagoniste des récepteurs de la neurokinine (NK1)","",""
"11130","10-03-09","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revised indication: Prevention of nausea and vomiting in women due to treatment with moderately emetogenic cancer chemotherapy","Indication révisée : Prévention, chez les femmes, des nausées et des vomissements consécutifs à l'administration d'une chimiothérapie anticancéreuse modérément émétisante","Neurokinin 1 (NK1) receptor antagonist","Antagoniste des récepteurs de la neurokinine (NK1)","",""
"11131","10-03-11","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Dosage recommendation in patients with end stage renal disease (ESRD) who are receiving regular haemodialysis","Posologie recommandée chez les patients atteints d'insuffisance rénale en phase terminale recevant des traitements réguliers d'hémodialyse","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"11132","10-03-11","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: To reduce the risk of non-fatal myocardial infarction or stroke, or coronary revascularization in patients without documented cardiovascular events but with at least two risk factors for cardiovascular disease","Nouvelle indication : Pour réduire le risque d'infarctus du myocarde ou accident vasculaire cérébral non-fatal, ou revascularisation coronaire chez des patients sans accident cardiovasculaire préalable mais présentant au moins deux facteurs de risque","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11133","10-03-12","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph - Clinical Trial information regarding lower back pain","Mise à jour de la monographie de produit - Informations sur un essai clinique concernant les douleurs lombaires","Opioid analgesic","Analgésique opioïde","",""
"11134","10-03-16","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"11135","10-03-16","AGNES PHARMACEUTICAL PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiemetic","Antiémétique","",""
"11136","10-03-16","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"11137","10-03-16","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Hypnotic and sedative","Hypnotique et sédatif","",""
"11138","10-03-16","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11139","10-03-16","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11140","10-03-17","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR TABLET","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur 5-alpha réductase du type II","",""
"11141","10-03-16","TORRENT PHARMACEUTICALS LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO-MCNEIL NEUROLOGICS, INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiepileptic, Migraine prophylaxis","Antiépileptique, Prophylaxie de la migraine","",""
"11142","10-03-17","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur 5-alpha réductase du type II","",""
"11143","10-03-16","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11144","10-03-16","MELIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihyperglycemic agent","Antihyperglycémiant","",""
"11145","10-03-16","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"11146","10-03-16","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE POULENC RORER CANADA INC","CANADA","CANADA","1","","","Hypnotic agent","Hypnotique","",""
"11147","10-03-16","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"11148","10-03-16","MELIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenoceptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11149","10-03-16","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"11150","10-03-16","CRUCELL SWITZERLAND LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"11151","10-03-16","DENTSPLY CANADA LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Product name change","Modification du nom du produit","Local anesthetic","Anesthésique local","",""
"11152","10-03-17","NOVARTIS VACCINES AND DIAGNOSTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent for the prevention of influenza","Agent immunisant actif pour la prévention de la grippe","",""
"11153","10-03-18","AUROBINDO PHARMA LIMITED UNIT III","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"11154","10-03-18","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DOSTINEX","PFIZER CANADA INC","CANADA","CANADA","1","","","Dopamine receptor agonist","Agoniste des récepteurs de la dopamine","",""
"11155","10-03-18","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11156","10-03-19","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"11157","10-03-19","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Anxiolytic, Sedative","Anxiolytique, Sédatif","",""
"11158","10-03-19","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"11159","10-03-18","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New room temperature stable formulation with new solvent","Nouvelle formulation stable à la température de la pièce avec un nouveau solvent","Coagulation factor","Facteur de coagulation","",""
"11160","10-03-19","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strengths: 20 mg, 40 mg and 60 mg","Nouvelles concentrations : 20 mg, 40 mg et 60 mg","Central nervous system stimulant for attention deficit hyperactivity disorder","Stimulant du système nerveux central pour le trouble déficitaire de l'attention avec hyperactivité","",""
"11161","10-03-19","MELIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihyperglycemic agent","Antihyperglycémiant","",""
"11162","10-03-18","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New formulation: grape flavoured sugar free","Nouvelle préparation sans sucre et à saveur de raisin","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11163","10-03-25","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MS CONTIN","PURDUE PHARMA","CANADA","CANADA","1","","","Opioid analgesic","Analgésique opioïde","",""
"11164","10-03-25","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Modifier of upper gastrointestinal motility","Modificateur de la motilité des voies digestives supérieures","",""
"11166","10-03-25","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11167","10-03-25","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenoceptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11168","10-03-25","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral hypoglycemic","Hypoglycémiant oral","",""
"11169","10-03-25","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"11170","10-03-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALERTEC","SHIRE BIOCHEM INC","CANADA","CANADA","1","","","Central nervous system stimulant","Stimulant du système nerveux central","",""
"11171","10-03-25","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"11172","10-03-25","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticholinergic, Antispasmodic agent","Anticholinergique, Antispasmodique","",""
"11173","10-03-25","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","Antihypertensive agent, Symptomatic treatment of benign prostatic hyperplasia (BPH)","Antihypertenseur, Traitement symptomatique de l'hypertrophie bénigne de la prostate (HBP)","",""
"11174","10-03-25","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product Monograph to match innovator's Product Monograph","Mise à jour de la monographie de produit pour égaler la monographie de produit de l'innovateur","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"11175","10-03-26","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDRONEL","PROCTER AND GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator / Anti-pagetic agent / Anti-hypercalcemic agent","Régulateur du métabolisme osseux / Agent antipagétique / Agent antihypercalcémique","",""
"11176","10-03-26","ALKOPHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anorexiant","Anorexigène","",""
"11177","10-03-29","MERIAL CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11178","10-03-29","4513347 CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11179","10-03-29","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11180","10-03-29","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO-MCNEIL PHARMACEUTICAL INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","Update to Product Monograph","Mise à jour de la monographie de produit","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"11181","10-03-29","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anxiolytic, Sedative","Anxiolytique, Sédatif","",""
"11182","10-03-29","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PMS-CARVEDILOL","PHARMASCIENCE INC","CANADA","CANADA","1","","","Congestive heart failure agent","Agent contre l'insuffisance cardiaque congestive","",""
"11183","10-03-29","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"11184","10-03-29","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Aldosterone antagonist","Antagoniste de l'aldostérone","",""
"11185","10-03-29","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"11186","10-03-29","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New route of administration","Nouvelle voie d'administration","Active immunizing agent","Agent de l'immunisation actif","",""
"11187","10-03-30","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"11188","10-03-30","TEVA WOMEN S HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"11189","10-03-30","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11190","10-03-30","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOECHST-ROUSSEL CANADA INC","CANADA","CANADA","1","","","Anticonvulsant","Anticonvulsivant","",""
"11191","10-03-30","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2 receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"11192","10-03-30","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11193","10-03-30","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"11194","10-03-30","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDROCAL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11195","10-03-30","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA","CANADA","CANADA","1","New formulation","Nouvelle formulation","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11196","10-03-24","LUNDBECK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision of the dosing recommendations in renal impairment and creation of a Consumer Information Leaflet","Modification des recommendations relatives au dosage pour les cas de déficience rénale et création d'un feuillet d'information à l'intention des consommateurs","N-methyl-D-aspartate (NMDA) receptor antagonist","Antagoniste du récepteur N-méthyl-D-asparte","",""
"11197","10-03-30","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic","Hypnotique","",""
"11198","10-03-30","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDRONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator / Anti-pagetic agent / Anti-hypercalcemic agent","Régulateur du métabolisme osseux / Agent antipagétique / Agent antihypercalcémique","",""
"11199","10-03-31","SIGMA TAU PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antifungal","Antifongique","",""
"11200","10-03-30","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11201","10-03-30","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antipanic / Antiobessional agent","Antidépresseur / Antipanique / Antiobsessionnel","",""
"11202","10-03-31","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11203","10-03-30","COBALT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DRIDROCAL","PROCTER AND GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11204","10-03-30","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate drug product manufacturing site","Changement de l'emplacement de fabrication","Anticholinergic / Antispasmodic agent","Anticholinergique / Antispasmodique","",""
"11205","10-03-30","DENTSPLY CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Local anesthetic","Anesthésique local","",""
"11206","10-03-30","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM CANADA LTD","CANADA","CANADA","1","Approval for additional strengths. Update to the Product Monograph","Approbation de concentrations additionnelles. Mise à jour de la monographie de produit","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"11207","10-03-31","DELAVAL INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Manufacturing change","Modification de la fabrication","Antiseptic","Antiseptique","",""
"11208","10-04-01","NORBROOK LABORATORIES LTD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","BANAMINE","INTERVET CANADA CORP","CANADA","CANADA","1","New indication","Nouvelle indication","Anti-inflammatory, analgesic, antipyretic","Anti-inflammatoire, analgésique, antipyrétique","",""
"11209","10-03-31","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES INC","CANADA","CANADA","1","Update to Product Monograph","Mise à jour de la monographie de produit","Anticonvulsant","Anticonvulsivant","",""
"11210","10-03-31","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11211","10-03-31","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","New indication","Nouvelle indication","Hormone","Hormone","",""
"11212","10-04-07","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur 5-alpha réductase du type II","",""
"11213","10-04-07","SANDOZ CANADA INCORPORATED","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11214","10-04-07","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid therapy","Corticostéroïde topique","",""
"11215","10-04-01","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11216","10-04-01","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"11217","10-04-01","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11218","10-04-01","SORRES PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihyperglycemic agent","Antihyperglycémiant","",""
"11219","10-04-01","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ISOPTIN SR","SEARLE CANADA INC","CANADA","CANADA","1","","","Antihypertensive agent","Antihypertenseur","",""
"11220","10-04-01","SORRES PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Skeletal muscle relaxant","Relaxant musculaire squelettique","",""
"11221","10-04-01","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic","Antiarythmique","",""
"11222","10-04-01","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lower gastrointestinal anti-inflammatory","Anti-inflammatoire de la partie basse du tube digestif","",""
"11223","10-04-01","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","BIOVAIL PHARMACEUTICALS CANADA","CANADA","CANADA","1","","","Beta-adrenoceptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11224","10-04-01","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"11225","10-04-01","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11226","10-04-08","OMRIX BIOPHARMACEUTICALS LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Change to manufacturing process and name","Changement du processus de la fabrication et du nom","Hemostatic agent","Agent hémostatique","",""
"11227","10-04-08","WYETH CONSUMER HEALTHCARE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Muscle relaxant / Analgesic","Relaxant musculaire / Analgésique","",""
"11228","10-04-08","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Histamine H2-receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"11229","10-04-08","ZYMCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (Antagoniste des récepteurs 5-HT3)","",""
"11230","10-04-08","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Diuretic","Diurétique","",""
"11231","10-04-08","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DDAVP SPRAY","FERRING INC","CANADA","CANADA","1","","","Antidiuretic","Antidiurétique","",""
"11232","10-04-08","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Xanthine oxidase inhibitor","Inhibiteur de la xanthine-oxydase","",""
"11233","10-04-08","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant, Anxiolytic agent","Antidépresseur, Anxiolytique","",""
"11234","10-04-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRILEPTAL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"11235","10-04-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON MR","SERVIER CANADA INC","CANADA","CANADA","1","","","Hypoglycemic sulfonylurea / Oral antidiabetic agent","Hypoglycémiant sulfonylurée / Antidiabétique oral","",""
"11236","10-04-09","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11237","10-04-09","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11238","10-04-09","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Non-steroidal antiandrogen","Antiandrogène non stéroïdien","",""
"11239","10-04-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KYTRIL","ROCHE LABORATORIES INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiemetic / 5-HT3 receptor antagonist","Antiémétique / Antagoniste des récepteurs 5-HT3","",""
"11240","10-04-09","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic agent","Antiarythmique","",""
"11241","10-04-09","VIIV HEALTHCARE ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Use in treatment-naive patients infected with CCR5-tropic HIV-1","Nouvelle indication : Traitement de l'infection par le VIH-1 à tropisme CCR5 chez des patients n'ayant jamais reçu de traitement","CCR5 antagonist","Antagoniste du CCR5","",""
"11242","10-04-07","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Extension of the indication to include paediatric population:  Apidra [insulin glulisine (rDNA origin)] is a recombinant human insulin analogue indicated for: - the treatment of adult patients with diabetes mellitus where treatment with insulin is required. - the treatment of pediatric patients with type 1 diabetes mellitus who require short acting insulin. There is insufficient clinical data on the use of Apidra in children below the age of 6 years","Ajout à l'indication pour inclure la population pédiatrique: Apidra (insuline glulisine [ADN recombiné]) est un analogue recombiné de l'insuline humaine indiqué pour: - le traitement des adultes atteints de diabète devant prendre de l'insuline. - le traitement des enfants atteints de diabète de type 1 devant prendre de l'insuline à action rapide. On ne dispose pas suffisamment de données cliniques relativement à l'emploi d'Apidra chez les enfants de moins de 6 ans","Antidiabetic agent","Antidiabétique","",""
"11243","10-03-25","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New drug product presentation, new drug product manufacturing facility","Nouvelle présentation de produit médicamenteux, nouvel emplacement de fabrication pour le produit médicamenteux","Selective immunomodulating agent","Agent immunomodulateur sélectif","",""
"11244","10-03-24","HOFFMANN LA ROCHE LIMITED","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New indication: Avastin (bevacizumab) is indicated as a single agent, for the treatment of patients with glioblastoma after relapse or disease progression, following prior therapy","Nouvelle indication : Avastin (bevacizumab) est indiqué en monothérapie pour le traitement des patients atteints d'un glioblastome, à la suite d'une rechute ou d'une progession de la maladie après un traitement préalable","Antineoplastic","Antinéoplasique","",""
"11245","10-04-07","ALEXION PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional drug product manufacturing site","Nouveau site de fabrication du produit médicamenteux","Complement inhibitor","Inhibiteur du complément","",""
"11246","10-04-08","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic agent","Antiarythmique","",""
"11247","10-04-14","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"11248","10-04-16","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11249","10-04-16","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11250","10-04-16","SANDOZ CANADA INCORPORATED","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","N-methyl-D-aspartate (NMDA) receptor antagonist","Antagoniste du récepteur N-méthyl-D-asparte","",""
"11251","10-04-16","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FAMVIR","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"11252","10-04-16","ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Platelet aggregation inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"11253","10-04-15","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent immunisant actif","",""
"11254","10-04-19","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORETIC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antihypertensive agent","Antihypertenseur","",""
"11255","10-04-19","VALEANT CANADA LIMITÉE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid","Corticostéroïde topique","",""
"11256","10-04-19","ABBOTT PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiemetic","Antiémétique","",""
"11257","10-04-19","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"11258","10-04-12","VIIV HEALTHCARE ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Dosage recommendations for patients with severe hepatic impairment","Posologies recommandées pour les patients atteints d'une insuffisance hépatique grave","Antiretroviral agent","Antirétroviral","",""
"11259","10-04-20","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional manufacturer for the manufacturing of medicated minerals using Bovatec","Fabricant additionnel pour la fabrication de minéraux médicamentés utilisant Bovatec","Antimicrobial","Antimicrobien","",""
"11260","10-04-20","SORRES PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypercholesterolemic / Antidiarrheal","Hypocholestérolémiant / Antidiarrhéique","",""
"11261","10-04-20","SEPRACOR PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11262","10-04-20","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","IMDUR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antianginal agent","Antiangineux","",""
"11263","10-04-20","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"11264","10-04-20","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAPOTEN","SQUIBB CANADA","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11265","10-04-20","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic Agent / Social Phobia (Social Anxiety Disorder) / Posttraumatic Stress Disorder Therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"11266","10-04-20","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","Antidepressant / Anxiolytic","Antidépresseur / Anxiolytique","",""
"11267","10-04-20","SORRES PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenoceptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11268","10-04-20","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS DIVISION OF WARNER LAMBERT CANADA","CANADA","CANADA","1","","","Antiepileptic agent","Antiépileptique","",""
"11269","10-04-20","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of Clinical Trial Data","Ajout de données à la section des Essais cliniques","Central nervous system stimulant for attention deficit hyperactivity disorder","Stimulant du système nerveux central pour le trouble déficitaire de l'attention avec hyperactivité","",""
"11270","10-04-20","ABBOTT PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Androgens","Androgène","",""
"11271","10-04-21","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal anti-inflammatory drug","Anti-inflammatoire non stéroïdien","",""
"11272","10-04-21","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Oral antidiarrheal / Antiflatulent agent","Antidiarrhéique oral / Antiflatulent","",""
"11273","10-04-21","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph: Clinical Trials section","Révisions à la monographie de produit : section des Essais cliniques","Corticosteroid for nasal use","Corticostéroïde pour voie nasale","",""
"11274","10-04-21","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Nonsteroidal anti-inflammatory drug","Anti-inflammatoire non stéroïdien","",""
"11275","10-04-21","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Nonsteroidal anti-inflammatory drug","Anti-inflammatoire non stéroïdien","",""
"11276","10-04-22","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","DIFLUCAN","PFIZER CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"11277","10-04-22","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Progestogen / Antineoplastic / Antianorexic / Anticachectic","Progestatif / Antinéoplasique / Antianoréxique / Anticachetique","",""
"11278","10-04-22","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAMBOCOR","3M PHARMACEUTICALS, A DIVISION OF 3M CANADA COMPANY","CANADA","CANADA","1","","","Antiarrhythmic agent","Antiarythmique","",""
"11279","10-04-22","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Immunosuppressive agent","Agent immunosuppresseur","",""
"11280","10-04-22","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Antirheumatic agent","Antirhumatismal","",""
"11281","10-04-22","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MODULON","AXCAN PHARMA INC","CANADA","CANADA","1","","","Lower gastrointestinal tract motility regulator","Régulateur de la motilité du tractus gastro-intestinal inférieur","",""
"11282","10-04-22","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"11283","10-04-22","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOTENSIN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11284","10-04-22","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anxiolytic / Sedatif","Anxiolytique / Sédatif","",""
"11285","10-04-22","ELANCO DIVISION ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional claim","Indication supplémentaire","Anti-ketogenic agent, anti-bloat agent, anti-coccidial agent","Agent anti-cétogénique, agent anti-ballonnement, agent anticoccidial","",""
"11286","10-04-23","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADALAT XL","BAYER INC","CANADA","CANADA","1","New strength","Nouvelle concentration","Antianginal / Antihypertensive agent","Antiangineux / Antihypertenseur","",""
"11287","10-04-23","UCB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate drug manufacturing process","Autre procédé de fabrication","Antiepileptic","Antiépileptique","",""
"11288","10-04-23","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYTOTEC","SEARLE CANADA","CANADA","CANADA","1","","","Mucosal protective agent","Agent protecteur de la muqueuse","",""
"11289","10-04-23","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PENLAC","DERMIK LABORATORIES CANADA INC","CANADA","CANADA","1","","","Topical antifungal agent","Antifongique topique","",""
"11290","10-04-23","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMATINE","SHIRE CANADA INC","CANADA","CANADA","1","","","Vasopressor","Vasopresseur","",""
"11291","10-04-23","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LARIAM","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Antimalarial agent","Antipaludéen","",""
"11292","10-04-23","JANSSEN ORTHO INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid analgesic","Analgésique opioïde","",""
"11293","10-04-23","HUVEPHARMA AD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","PULMOTIL PREMIX (DIN 02240124)","ELANCO DIVISION ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antibacterial","Antibactérien","",""
"11294","10-04-27","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antibulimic","Antidépresseur / Antiobsessionnel / Antiboulimique","",""
"11295","10-04-27","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"11296","10-04-27","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"11297","10-04-27","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC","CANADA","CANADA","1","","","Hypnotic","Hypnotique","",""
"11298","10-04-27","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Congestive heart failure agent","Agent contre l'insuffisance cardiaque congestive","",""
"11299","10-04-27","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Selective antagonist of alpha1A adrenoreceptor subtype in the prostate","Antagoniste sélectif des sous-types des récepteurs alpha1A-adrénergiques de la prostate","",""
"11300","10-04-23","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfilment of commitments as per the Letter of Undertaking dated July 28, 2006 and April 30, 2008 for the treatment of metastatic renal cell carcinoma (MRCC) of clear cell histology, as well as an update to the Product Monograph with overall survival data for the gastrointestinal stromal tumour indication after failure of Imatinib Mesylate treatment due to resistance or intolerance","Respect des obligations énoncées dans la lettre d’engagement du 28 juillet 2006 et du 30 avril 2008 au sujet du traitement de l’adénocarcinome rénal métastatique caractérisé par la présence de cellules claires, et mise à jour de la monographie par l’ajout de données sur la survie globale relative à l’indication de traitement d’une tumeur stromale gastro-intestinale à la suite d’un échec au traitement par le mésylate d’imatinib causé par une résistance ou une intolérance","Tyrosine kinase inhibitor / Anti-tumour agent","Inhibiteur de la tyrosine kinase / Antinéoplasique","",""
"11301","10-04-27","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","GEIGY PHARMACEUTICALS, CIBA GEIGY CANADA LTD","CANADA","CANADA","1","","","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11302","10-04-27","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"11303","10-04-28","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11304","10-04-28","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11305","10-04-28","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11306","10-04-28","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11307","10-04-28","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11308","10-04-28","NOVOPHARM LIMITED","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11309","10-04-28","TEVA CANADA LIMITED","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11310","10-04-28","COBALT PHARMACEUTICALS INC","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11311","10-04-28","GENERIC MEDICAL PARTNERS","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor, Inhibitor of estrogen biosynthesis, Antitumor agent","Inhibiteur de l'aromatase non stéroïdien, Inhibiteur de la biosynthèse des oestrogènes, Antinéoplasique","",""
"11312","10-04-28","ACCORD HEALTHCARE INC","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11313","10-04-28","MYLAN PHARMACEUTICALS ULC","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11314","10-04-28","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Non-steroidal anti-inflammatory","Anti-inflammatoire non stéroïdien","",""
"11315","10-04-28","SIGMACON LIFESCIENCES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11316","10-04-28","ORPHAN EUROPE SARL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-homocysteine agent","Agent anti-homocystéine","",""
"11317","10-04-28","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Histamine H2-receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"11318","10-04-22","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to Drug Resistance, and Post-Market Adverse Events","Mises à jour concernant la résistance aux médicaments, et évènements indésirables signalés après la commercialisation","Antifungal","Antifongique","",""
"11319","10-04-29","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: use in pediatric patients 10-17 years old with heterozygous familial hypercholesterolemia","Nouvelle indication : usage chez les enfants de 10-17 ans atteints d'hypercholestérolémie familiale hétérozygote","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11320","10-04-29","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Tricyclic antidepressant","Antidépresseur tricyclique","",""
"11321","10-04-29","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticholinergic / Antispasmodic agent","Anticholinergique / Antispasmodique","",""
"11322","10-04-29","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Anti-hypertensive agent / Symptomatic treatment of benign prostatic hyperplasia (BPH)","Antihypertenseur / Traitement symptomatique de l'hypertrophie bénigne de la prostate (HBP)","",""
"11323","10-04-29","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral hypoglycemic","Hypoglycémiant oral","",""
"11324","10-04-29","NU PHARM INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11325","10-04-29","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Modifier of upper gastrointestinal motility","Modificateur de la motilité des voies digestives supérieures","",""
"11326","10-04-29","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"11327","10-04-29","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11328","10-04-29","PUBLIC BENEFITS PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11329","10-04-29","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11330","10-04-29","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Opioid analgesic","Analgésique opioïde","",""
"11331","10-04-29","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC, HEALTHCARE DIVISION","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"11332","10-04-29","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"11333","10-04-29","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MS CONTIN","PURDUE FREDERICK","CANADA","CANADA","1","","","Opioid analgesic","Analgésique opioïde","",""
"11334","10-04-29","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA / ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"11335","10-04-30","BIONICHE ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Veterinary hormone","Hormone vétérinaire","",""
"11336","10-04-30","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11337","10-04-30","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11338","10-04-30","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11339","10-04-30","PUBLIC BENEFITS PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Modifier of upper gastrointestinal motility","Modificateur de la motilité des voies digestives supérieures","",""
"11340","10-04-30","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC.","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11341","10-04-30","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","Antidepressant / Anxiolytic","Antidépresseur / Anxiolytique","",""
"11342","10-04-30","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenoceptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11343","10-04-30","BIOMARIN PHARMACEUTICAL INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Enzyme activator","Activateur d'enzyme","",""
"11344","10-04-30","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-rosacea","Agent antirosacée","",""
"11345","10-04-30","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"11346","10-04-30","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","APO-CYCLOBENZAPRINE","APOTEX INC","CANADA","CANADA","1","","","Skeletal muscle relaxant","Relaxant musculaire squelettique","",""
"11347","10-04-30","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC","CANADA","CANADA","1","Product name change","Modification du nom du fabricant","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11348","10-04-30","HOFFMANN LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Interleukin receptor inhibitor","Inhibiteur du récepteur de l'interleukine","",""
"11349","10-04-29","EMD CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New liquid formulation","Nouvelle formulation liquide","Human growth hormone","Hormone de croissance humaine","",""
"11350","10-05-05","ELANCO DIVISION ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional indications","Indications supplémentaires","Growth promotant","Augmente le gain pondéral","",""
"11351","10-05-05","ALLERGAN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Eyelash growth enhancer","Stimulateur de croissance pour les cils","",""
"11352","10-05-05","MEDA AB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid analgesic","Analgésique opioïde","",""
"11353","10-04-27","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph: use in hypertensive pediatric patients","Modifications apportées à la monographie de produit : utilisation chez les patients pédiatriques hypertendus","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11354","10-05-06","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MS CONTIN","PURDUE PHARMA","CANADA","CANADA","1","","","Opioid analgesic","Analgésique opioïde","",""
"11355","10-05-06","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11356","10-05-06","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11357","10-05-06","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11358","10-05-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (Antagoniste des récepteurs 5-HT3)","",""
"11359","10-05-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN P","ALLERGAN INC","CANADA","CANADA","1","","","Elevated intraocular pressure therapy","Thérapie pour réduire la pression intraoculaire","",""
"11360","10-05-06","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Bronchodilator","Bronchodilatateur","",""
"11361","10-05-07","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical acne therapy","Traitement de l'acné topique","",""
"11362","10-05-05","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition to the indication for Chronic Lymphocytic Leukemia (CLL)","Addition à l'indication de Leucémie lymphoïde chronique (LLC)","Antineoplastic","Antinéoplasique","",""
"11363","10-05-07","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Changes to the adhesive component of the patch and the drug product specification","Changements à l'élément adhésif du timbre et aux spécifications du produit médicamenteux","Hormonal contraceptive","Contraceptif hormonal","",""
"11364","10-05-11","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","Anti-diabetic agent / Insulin resistance reducing agent","Agent antidiabétique / Agent diminuant la résistance à l'insuline","",""
"11365","10-05-11","ACCORD HEALTHCARE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","Removal of indication","Suppression de l'indication","Anti-diabetic agent / Insulin resistance reducing agent","Agent antidiabétique / Agent diminuant la résistance à l'insuline","",""
"11366","10-05-12","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROPECIA","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"11367","10-05-12","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROPECIA","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"11368","10-05-12","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Manufacturing scale-up at a new manufacturing facility","Nouvelle échelle de production au nouveau site de fabrication","Enzyme replacement therapy","Traitement enzymatique substitutif","",""
"11369","10-05-13","TALECRIS BIOTHERAPEUTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of subcutaneous route of administration","L'ajout de la voie d'administration sous-cutanée","Passive immunizing agent","Agent d'immunisation passive","",""
"11370","10-05-13","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Antihypertensive agent / Symptomatic treatment of benign prostatic hyperplasia (BPH)","Antihypertenseur / Traitement symptomatique de l'hyperplasie bénigne de la prostate (HBP)","",""
"11371","10-05-13","LABORATOIRE RIVA INC","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","N-methyl-D-aspartate (NMDA) receptor antagonist","Antagoniste du récepteur N-méthyl-D-aspartate","",""
"11372","10-05-13","JANSSEN ORTHO INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent","Antinéoplasique","",""
"11373","10-05-11","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: treatment of idiopathic menorrhagia following appropriate diagnostic investigation in women accepting the contraceptive effect of Mirena","Nouvelle indication : traitement de la ménorragie idiopathique après investigation diagnostique appropriée chez les femmes acceptant l'effet contraceptif de Mirena","Progestogen","Progestatif","",""
"11374","10-05-11","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Maintenance treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer, in a good performance status patients without disease progression immediately following four cycles of first-line platinum doublet chemotherapy, excluding pemetrexed","Nouvelle indication : Traitement d'entretien du cancer du poumon non à petites cellules non squameux au stade local avancé ou métastatique chez les patients présentant une bonne capacité fonctionnelle dont le cancer ne progresse pas immédiatement après quatre cycles de bichimiothérapie de première intention à base de platine associé à un agent autre que le pémétrexed","Antineoplastic agent","Antinéoplasique","",""
"11375","10-05-18","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouveau site de fabrication","Antineoplastic","Antinéoplasique","",""
"11376","10-05-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR TABLETS","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11377","10-05-19","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11378","10-05-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11379","10-05-19","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR TABLETS","PFIZER CANADA INC","CANADA","CANADA","1","Change in drug substance. Change in formulation of drug product.","Modification de la substance médicamenteuse. Modification de la formulation du médicament.","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11380","10-05-19","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11381","10-05-14","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Januvia is indicated in combination with metformin and a sulfonylurea in adult patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise, and dual therapy with these agents, do not provide adequate glycemic control","Nouvelle indication : Januvia est indiqué en association avec la metformine et une sulfonylurée chez les adultes atteints de diabète de type 2 pour améliorer l'équilibre glycémique lorsque le régime alimentaire et l'exercise, jumelés au traitement au moyen de ces agents, ne procurent pas un équilibre glycémique adéquat","Oral antihyperglycemic agent / DPP-4 inhibitor / Incretin enhancer","Antihyperglycémiant oral / Inhibiteur DPP-4 / Renforceur d'incrétin","",""
"11382","10-05-19","PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11383","10-05-19","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11384","10-05-19","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11385","10-05-19","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11386","10-05-19","COBALT PHARMACEUTICALS COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revised Product Monograph","Révisions à la monographie de produit","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11387","10-05-19","COBALT PHARMACEUTICALS COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11388","10-05-19","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11389","10-05-19","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11390","10-05-19","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"11391","10-05-19","MELIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11392","10-05-19","DOMINION PHARMACAL","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Product Monograph","Révision à la monographie de produit","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11393","10-05-20","RANBAXY PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11394","10-05-20","RANBAXY PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11395","10-05-20","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLUDARA","BERTEX CANADA INC","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"11396","10-05-20","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical antibiotic","Antibiotique topique","",""
"11397","10-05-20","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid / Keratolytic","Corticostéroïde topique / Kératolytique","",""
"11398","10-05-20","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMAXIN","MERCK FROSST CANADA LIMITED","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11399","10-05-19","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Extension of treatment duration for the prevention of CMV disease and addition of Pediatric, Pharmacokinetic data","Prolongation de la durée de traitement pour la prévention de l'infection à cytomégalovirus et ajout de données pharmacocinétiques pédiatriques","Antiviral agent","Antiviral","",""
"11400","10-05-20","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","An alternate source of Molybdenum Mo99","Source alternative de Molybdéne Mo99","Diagnostic radiopharmaceutical","Agent diagnostique radiopharmaceutique","",""
"11401","10-05-20","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical antifungal","Antifongique topique","",""
"11402","10-05-20","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11403","10-05-25","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"11404","10-05-25","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC","CANADA","CANADA","1","Removal of strength","Suppression d'une concentration","Antifungal agent","Antifongique","",""
"11405","10-05-25","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"11406","10-05-25","SORRES PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11407","10-05-21","NOVO NORDISK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Human glucagon like peptide-1 (GLP-1)","Peptide humain apparenté au glucagon 1 (GLP-1)","",""
"11408","10-05-20","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Revised Product Monograph","Monographie de produit révisée","Active immunizing agent","Agent d'immunisation actif","",""
"11409","10-05-26","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anxiolytic / Sedative","Anxiolytique / Sédatif","",""
"11410","10-05-26","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11411","10-05-26","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2 receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"11412","10-05-26","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","GEIGY PHARMACEUTICALS / CIBA GEIGY CANADA LTD.","CANADA","CANADA","1","","","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11413","10-05-26","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Diuretic","Diurétique","",""
"11414","10-05-26","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Antirheumatic agent","Antirhumatismal","",""
"11415","10-05-26","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lower gastrointestinal anti-inflammatory","Anti-inflammatoire pour le tractus gastro-intestinal inférieur","",""
"11416","10-05-26","PUBLIC BENEFITS PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical anti-inflammatory steroid","Stéroïde anti-inflammatoire topique","",""
"11417","10-05-26","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN CILAG LTD","UNITED KINGDOM","ROYAUME-UNI","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"11418","10-05-26","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADALAT XL","BAYER INC.","CANADA","CANADA","1","","","Antianginal / Antihypertensive agent","Antiangineux / Antihypertenseur","",""
"11419","10-05-26","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC.","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11420","10-05-21","SANOFI PASTEUR LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"11421","10-05-26","PUBLIC BENEFITS PHARMA","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINIVIL","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11422","10-05-26","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO-MCNEIL NEUROLOGICS INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"11423","10-05-27","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical acne therapy","Traitement topique de l'acné","",""
"11424","10-05-27","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"11425","10-05-27","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid","Corticostéroïde","",""
"11426","10-05-27","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEPTAZANE","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Carbonic anhydrase inhibitor (Ocular pressure lowering therapy)","Inhibiteur de l'anhydrase carbonique (Thérapie pour réduire la pression intraoculaire)","",""
"11427","10-05-27","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11428","10-05-27","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BERLEX CANADA INC.","CANADA","CANADA","1","","","Antiandrogen","Antiandrogène","",""
"11429","10-05-27","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMATINE","SHIRE CANADA INC.","CANADA","CANADA","1","","","Vasopressor","Vasopresseur","",""
"11430","10-05-27","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DDAVP SPRAY","FERRING INC.","CANADA","CANADA","1","","","Antidiuretic","Antidiurétique","",""
"11431","10-05-27","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (antagoniste des récepteurs 5-HT3)","",""
"11432","10-05-27","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","Anti-diabetic agent / Insulin resistance reducing agent","Antidiabétique / Agent réducteur de l'insulinorésistance","",""
"11433","10-05-27","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOTENSIN","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11434","10-05-28","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"11435","10-05-27","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11436","10-05-28","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC-MAT","JANSSEN-ORTHO INC","CANADA","CANADA","1","Revise the Product Monograph","Révisions à la monographie de produit","Opioid analgesic","Analgésique opioïde","",""
"11437","10-05-28","RATIOPHARM INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC-MAT","JANSSEN-ORTHO INC","CANADA","CANADA","1","Revise the Product Monograph","Révisions à la monographie de produit","Opioid analgesic","Analgésique opioïde","",""
"11438","10-05-28","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LARIAM","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Antimalarial agent","Antipaludique","",""
"11439","10-05-28","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical acne therapy","Traitement topique de l'acné","",""
"11440","10-05-27","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC.","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11441","10-05-28","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Platelet inhibitory agent / Uricosuric agent","Angent antiplaquettaire / Agent uricorusique","",""
"11442","10-05-28","ABBOTT PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-vertigo Agent","Antivertige","",""
"11443","10-05-28","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Safety updates to the Product Monograph","Mise à jour de l'innocuité dans la monographie de produit","Smoking cessation aid","Aide pour cesser de fumer","",""
"11444","10-05-28","AUROBINDO PHARMA LIMITED (UNIT VI)","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLAFORAN","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Beta-lactam antibiotic","Antibiotique bêta-lactamase","",""
"11445","10-05-25","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update package labels to approved indication","Actualiser les étiquettes des emballages pour y inclure l'indication approuvée","Renin inhibitor","Inhibiteur de la rénine","",""
"11446","10-05-27","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent","Antinéoplasique","",""
"11447","10-05-31","ABBOTT PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent for the prevention of Influenza","Agent immunisant actif pour la prévention de la grippe","",""
"11448","10-05-28","CENTOCOR ORTHO BIOTECH INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Biologic response modifier","Agent d'immunomodulation","",""
"11449","10-06-01","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11450","10-06-01","WARNER CHILCOTT CANADA CO","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Estrogen-progestin combination","Combinaison oestrogène-progestatif","",""
"11451","10-06-01","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHIN","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11452","10-06-01","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFAZOLIN FOR INJECTION","NOVOPHARM LIMITED","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11453","10-06-01","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11454","10-06-01","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical acne therapy","Traitement topique de l'acné","",""
"11455","10-06-01","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC","CANADA","CANADA","1","","","Antidepressant, Antiobsessional, Antipanic, Anxiolytic agent, Social phobia (social anxiety disorder), Posttraumatic stress disorder therapy","Antidépresseur, Antiobsessionnel, Antipanique, Anxiolytique, Traitement de la phobie sociale, Traitement de l'état de stress post-traumatique","",""
"11456","10-06-01","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical acne therapy","Traitement topique de l'acné","",""
"11457","10-06-01","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11458","10-06-01","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11459","10-05-31","CSL BEHRING CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Serine protease inhibitor","Inhibiteur de protéase de sérine","",""
"11460","10-06-01","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic agent","Antiarythmique","",""
"11461","10-06-02","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYTOTEC","SEARLE CANADA","CANADA","CANADA","1","","","Mucosal protective agent","Agent protecteur de la muqueuse","",""
"11462","10-06-02","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Progestogen, Antineoplastic, Antianorexic, Anticachectic","Progestatif, Antinéoplasique, Antianorexique, Anticachectique","",""
"11463","10-06-02","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antifungal agent","Antifongique","",""
"11464","10-06-02","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Product name change","Modification du nom du produit","Antifungal agent","Antifongique","",""
"11465","10-06-02","ABBOTT PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Antiobsessional agent","Antidépresseur / Antiobsessionnel","",""
"11466","10-05-27","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Update Product Monograph for safety changes","Mise à jour de l'innocuité dans la monographie de produit","Topical anesthetic for dermal analgesia","Anesthésique topique pour analgésie dermique","",""
"11467","10-06-02","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic","Hypnotique","",""
"11468","10-06-02","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid","Corticostéroïde topique","",""
"11469","10-06-02","PIRAMAL CRITICAL CARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEVORANE AF","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Inhalation anesthetic","Anesthésique par inhalation","",""
"11470","10-06-02","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial agent","Antibactérien","",""
"11471","10-06-02","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anxiolytic / Sedative","Anxiolytique / Sédatif","",""
"11472","10-06-02","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SIBELIUM","JANSSEN PHARMACEUTICA","CANADA","CANADA","1","","","Selective calcium-entry blocker","Inhibiteur calcique sélectif","",""
"11473","10-06-02","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAMBOCOR","3M PHARMACEUTICALS, A DIVISION OF 3M CANADA COMPANY","CANADA","CANADA","1","","","Antiarrhythmic agent","Antiarythmique","",""
"11474","10-06-02","ABBOTT PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II receptor (AT1) antagonist / Diuretic","Antagoniste des récepteurs (AT1) de l'angiotensine II / Diurétique","",""
"11475","10-06-02","ABBOTT PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II receptor (AT1) antagonist","Antagoniste des récepteurs (AT1) de l'angiotensine II","",""
"11476","10-06-04","CROSS VETPHARM GROUP LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","BANAMINE (DIN 00465305)","INTERVET CANADA CORP.","CANADA","CANADA","1","","","Non steroidal anti-inflammatory / Analgesic / Antipyretic","Anti-inflammatoire non stéroïdien / Analgésique / Antipyrétique","",""
"11477","10-06-03","HAMILTON HEALTH SCIENCES CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","1) New automated manufacturing method; 2) Modifications to the manual manufacturing method","1) Nouvelle méthode de fabrication automatisée; 2) Modifications à la méthode de fabrication manuelle","Diagnostic radiopharmaceutical","Produit radiopharmaceutique diagnostique","",""
"11478","10-06-04","PHIBRO ANIMAL HEALTH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic / Growth promotant","Antibiotique / Augmente le gain de poids","",""
"11479","10-06-04","PHIBRO ANIMAL HEALTH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic / Growth promotant","Antibiotique / Promotant de croissance","",""
"11480","10-06-04","PHIBRO ANIMAL HEALTH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antimicrobial","Antimicrobien","",""
"11481","10-06-04","BAXTER HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouveau site de fabrication","Coagulant","Coagulant","",""
"11482","10-06-04","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosing administration: once daily dosing in antiretroviral treatment-experienced patients","Nouvelle posologie : une dose par jour chez les patients pré traités aux antirétroviraux","Human Immunodeficiency Virus (HIV) protease inhibitor","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH)","",""
"11483","10-06-07","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC DELAYED RELEASE CAPSULE","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11484","10-06-07","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11485","10-06-09","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MODULON","AXCAN PHARMA INC.","CANADA","CANADA","1","","","Lower gastrointestinal tract motility regulator","Régulateur de la motilité du tractus gastro-intestinal inférieur","",""
"11486","10-06-09","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","Selective antagonist of alpha1A adrenoreceptor subtype in the prostate","Antagoniste sélectif des sous-types des récepteurs alpha1A-adrénergiques de la prostate","",""
"11487","10-06-09","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"11488","10-06-09","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-inflammatory / Analgesic agent","Anti-inflammatoire / analgésique","",""
"11489","10-06-09","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Tricyclic antidepressant","Antidépresseur tricyclique","",""
"11490","10-06-04","ALCON CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Removal of preservative formulation from the Canadian market","Retrait du marché canadien de la formulation contenant un agent de conservation","Elevated intraocular pressure therapy / Prostaglandin F2alpha analogue","Traitement de l'hypertension oculaire élevée / Analogue de la prostaglandine F2alpha","",""
"11491","10-06-08","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REVATIO","PFIZER CANADA INC","CANADA","CANADA","1","","","cGMP-specific phosphodiesterase type 5 inhibitor / Treatment of pulmonary arterial hypertension","Inhibiteur de la phosphodiestérase de type 5 spécifique de la GMPc / Traitement de l'hypertension artérielle pulmonaire","",""
"11492","10-06-09","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTO IV","NYCOMED CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11493","10-06-09","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD","CANADA","CANADA","1","Revision to the Product Monograph","Révision à la monographie de produit","Antidepressant","Antidépresseur","",""
"11494","10-06-09","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC-MAT","JANSSEN-ORTHO INC","CANADA","CANADA","1","Revision to the Product Monograph","Révision à la monographie de produit","Opioid analgesic","Analgésique opioïde","",""
"11495","10-06-08","VITA HEALTH PRODUCTS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD & SINUS CAPLETS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Analgesic / Antipyretic / Nasal decongestant","Analgésique / Antipyrétique / Décongestionnant nasal","",""
"11496","10-06-10","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Diuretic / Glucocorticoid","Diurétique / Glucocorticoïde","",""
"11497","10-06-10","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic","Antiparasitaire","",""
"11498","10-06-11","TARO PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PENLAC","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Topical antifungal agent","Antifongique topique","",""
"11499","10-06-11","MYLAN PHARMACEUTICALS ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Product Monograph","Révision à la monographie de produit","Oral hypoglycemic agent","Hypoglycémiant oral","",""
"11500","10-06-11","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin converting enzyme inhibitor / Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine / Diurétique","",""
"11501","10-06-11","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11502","10-05-21","NOVARTIS VACCINES AND DIAGNOSTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"11503","10-06-10","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Revisions to the Product Monograph - Response to TPD notification regarding the Food and Drug Regulations - project # 1597 - Schedule F","Modifications apportées la monographie de produit - En réponse à l'avis de la DPT concernant le Règlement sur les aliments et drogues - projet 1597 - annexe F","Antifungal agent","Antifongique","",""
"11504","10-06-10","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Alternate manufacturing site","Addition d'un nouveau site de fabrication","Growth stimulant","Stimulant de la croissance","",""
"11505","10-06-16","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Agent for the treatment of photodamaged skin","Traitement de la peau photoaltérée","",""
"11506","10-06-16","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Agent for the treatment of solar lentigines and related hyperpigmented lesions","Agent destiné au traitement des lentigines solaires et des lésions hyperpigmentées connexes","",""
"11507","10-06-16","GENMED A DIVISION OF PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON RD","ORGANON CANADA LTD","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"11508","10-06-16","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Anti-inflammatory agent with analgesic and antipyretic properties","Anti-inflammatoire, analgésique, antipyrétique","",""
"11509","10-06-16","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Non-steroidal anti-inflammatory / Analgesic agent","Anti-inflammatoire non stéroïdien / Analgésique","",""
"11510","10-06-16","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11511","10-06-16","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional dosage form","Forme posologique additionnelle","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11512","10-06-16","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid therapy","Corticostéroïde topique","",""
"11513","10-06-16","GENMED A DIVISION OF PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"11514","10-06-16","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"11515","10-06-16","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11516","10-06-16","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11517","10-06-16","GENMED A DIVISION OF PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"11518","10-06-16","OMRIX BIOPHARMACEUTICALS LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Extension of indication: For use as supportive treatment in surgery where standard techniques are insufficient, for improvement of hemostasis. Evidence of efficacy and safety has been demonstrated in the following clinical trials: liver surgery such as liver resection and reduced-size live transplantation, orthopedic surgery such as total hip replacement and total knee replacement, retroperitoneal / intra-abdominal surgery, and vascular surgery","Extension de l'indication : Le produit peut être utilisé comme traitement de soutien en chirurgie où les techniques standards sont insuffisantes pour l'amélioration de l'hémostase. La preuve de l'efficacité et de la sécurité a été démontrée dans les essais cliniques suivants : la chirurgie du foie comme la résection du foie, la transplantation de taille réduite du foie, la chirurgie orthopédique comme le remplacement total de la hanche ou le remplacement total du genou, la chirurgie rétropéritonéale / intra-abdominale et la chirurgie vasculaire","Hemostatic agent","Agent hémostatique","",""
"11519","10-06-16","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to Adverse Reactions and Clinical Trials section based on 96 week data","Mises à jour de la section Effets indésirables et essais cliniques en fonction de données portant sur une période de 96 semaines","Human immunodeficiency virus (HIV) protease inhibitor","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH)","",""
"11520","10-06-16","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Asthma prophylaxis","Prophylaxie de l'asthme","",""
"11521","10-06-16","TEVA WOMEN S HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"11522","10-06-16","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11523","10-06-16","TEVA WOMEN S HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Emergency contraception","Contraceptif d'urgence","",""
"11524","10-06-16","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11525","10-06-16","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"11526","10-06-16","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC. HEALTHCARE DIVISION","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"11527","10-06-17","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11528","10-06-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"11529","10-06-17","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEXIUM","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11530","10-06-14","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Use in pediatric patients 10-17 years old with heterozygous familial hypercholesterolemia","Nouvelle indication : usage chez les enfants de 10 à 17 ans atteints d'hypercholestérolémie familiale hétérozygote","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11531","10-06-18","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","TAP PHARMACEUTICALS INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11532","10-06-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"11533","10-06-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11534","10-06-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOWELLCOME INC","CANADA","CANADA","1","","","Histamine H2-receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"11535","10-06-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REQUIP","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"11536","10-06-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"11537","10-06-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDROCAL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11538","10-06-18","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Xanthine oxidase inhibitor","Inhibiteur de la xanthine-oxydase","",""
"11539","10-06-18","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","AERIUS","SCHERING CANADA INC","CANADA","CANADA","1","Revision to the Product Monograph","Révision à la monographie de produit","Histamine H1-receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11540","10-06-18","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to Action and Clinical Pharmacology section of the Product Monograph","Modifications apportées à la section mode d'action et pharmacologie clinique de la monographie de produit","Anticholinergic / Antispasmodic","Anticholinergique / Antispasmodique","",""
"11541","10-06-18","SHIRE HUMAN GENETIC THERAPIES INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing site","Nouveau site de fabrication","Enzyme replacement therapy","Enzymothérapie de remplacement","",""
"11542","10-06-21","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-anginal agent","Antiangineux","",""
"11543","10-06-21","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"11544","10-06-21","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11545","10-06-21","INSPIRE PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Macrolide antibiotic","Antibiotique macrolide","",""
"11546","10-06-21","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IDARAC","SANOFI WINTHROP","CANADA","CANADA","1","","","Anti-inflammatory / Analgesic","Anti-inflammatoire / Analgésique","",""
"11547","10-06-21","IMMUNEX CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing process","Nouvelle procédure de fabrication","Biologic response modifier","Modificateur de la réponse biologique","",""
"11548","10-06-21","RANBAXY PHARMACEUTICALS CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","Revised Product Monograph","Monographie de produit révisée","Opioid analgesic","Analgésique opioïde","",""
"11549","10-06-14","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph to reflect new study information for patients with moderate liver impairment","Mise à jour de la monographie de produit afin qu'elle rende compte de nouvelles données de recherche chez les patients atteints de troubles hépatiques modérés","Synthetic antithrombotic","Antithrombotique synthétique","",""
"11550","10-06-21","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Updated manufacturing process, product name change, new 50 ml fill size","Méthode de fabrication actualisée, changement de nom du produit, nouveau volume de remplissage de 50 ml","Hemostatic agent","Agent hémostatique","",""
"11551","10-06-17","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfilment of commitments as per the Letter of Undertaking dated 15 May, 2006 for the treatment of adult patients with newly diagnosed, Philadelphia-chromosome-positive, chronic myeloid leukemia (CML) in chronic phase","Respect des obligations énoncées dans la lettre d'engagement du 15 mai 2006 au sujet du traitement d'adultes atteints d'une leucémie myéloïde chronique (LMC) à chromosome Philadelphie positif en phase chronique nouvellement diagnostiquée","Protein kinase inhibitor","Inhibiteur de la protéine kinase","",""
"11552","10-06-24","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Hormone","Hormone","",""
"11553","10-06-24","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11554","10-06-22","ASTRAZENECA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Influenza vaccine","Vaccin contre la grippe","",""
"11555","10-06-24","EISAI LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic","Antinéoplasique","",""
"11556","10-06-25","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROLOPRIM","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"11557","10-06-25","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-inflammatory agent","Anti-inflammatoire","",""
"11558","10-06-25","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid","Corticostéroïde topique","",""
"11559","10-06-25","WATSON PHARMA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Luteinizing hormone-releasing hormone (LHRH) analog","Analogue de l'hormone de libération de la lutéinostimuline (LH-RH)","",""
"11560","10-06-25","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antimicrobial / Anti-inflammatory","Antimicrobien / Anti-inflammatoire","",""
"11561","10-06-28","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (antagoniste des récepteurs 5-HT3)","",""
"11562","10-06-28","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (antagoniste des récepteurs 5-HT3)","",""
"11563","10-06-28","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (antagoniste des récepteurs 5-HT3)","",""
"11564","10-06-28","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (antagoniste des récepteurs 5-HT3)","",""
"11565","10-06-28","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antidepressant; Anxiolytic","Antidépresseur; Anxiolytique","",""
"11566","10-06-28","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAQUENIL","SANOFI-WINTHROP CANADA INC","CANADA","CANADA","1","New indication","Nouvelle indication","Anti-inflammatory / Antimalarial","Anti-inflammatoire / Antipaludéen","",""
"11567","10-06-28","BAXTER CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Intravenous nutritive supplements","Suppléments nutritifs intraveineux","",""
"11568","10-06-29","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form","Nouvelle forme posologique","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"11569","10-06-30","JANSSEN ORTHO INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antipsychotic agent","Antipsychotique","",""
"11570","10-06-30","TORRENT PHARMACEUTICALS LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST PHARMACEUTICALS INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antidepressant","Antidépresseur","",""
"11571","10-07-02","CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Diagnostic radiopharmaceutical","Produit radiopharmaceutique diagnostique","",""
"11572","10-07-02","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Opioid analgesic","Analgésique opioïde","",""
"11573","10-07-02","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Coronary vasodilator","Vasodilatateur coronarien","",""
"11574","10-07-02","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE HCT TABLETS","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor / Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine / Diurétique","",""
"11575","10-06-29","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfilment of commitments as per the Letter of Undertaking dated September 17, 2007 for the treatment of neuropathic pain associated with spinal cord injury","Respect des obligations énoncées dans la lettre d'engagement du 17 septembre 2007 au sujet du traitement de la douleur neuropathique associée aux traumatismes médullaires","Analgesic agent","Analgésique","",""
"11576","10-07-02","CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Radiodiagnostic agent","Agent radiodiagnostique","",""
"11577","10-07-07","GENZYME CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Phosphate binder","Chélateur des phosphates","",""
"11578","10-06-28","STRIDES ARCOLAB LTD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","New preservative containing formulation in a multi-dose vial.","Nouvelle formulation contenant un agent de préservation dans un flacon à multi dose.","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (antagoniste des récepteurs 5-HT3)","",""
"11579","10-07-09","EUSA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Therapeutic radiopharmaceutical","Produit radiopharmaceutique thérapeutique","",""
"11580","10-07-12","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11581","10-07-13","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New indication: HUMATROPE is indicated for the treatment of growth failure in children born small for gestational age (birth weight and/or length below -2 SD) and who fail to achieve catch-up growth by 2 to 4 years or later","Nouvelle indication: HUMATROPE est indiqué dans le traitement du retard de croissance chez les enfants nés petits pour l'âge gestationnel avec un poids et/ou une taille de naissance inférieure à - 2 DS et n'ayant pas rattrapé leur retard de croissance 2 à 4 ans plus tard","Growth stimulant","Stimulant de croissance","",""
"11582","10-07-13","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11583","10-07-05","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfillment of commitment #4 as per the Letter of Undertaking dated July 10, 2008, and other revisions to the product monograph","Respect de l'obligation no 4 énoncée dans la lettre d'engagement du 10 juillet 2008, et autres corrections apportées à la monographie de produit","Protein tyrosine kinase inhibitor","Inhibiteur de la protéase-tyrosine kinase","",""
"11584","10-07-09","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the following sections of the product monograph: indications, contraindications, warnings and precautions, special populations, adverse reactions, drug interactions, action and clinical pharmacology, clinical trials and part III: consumer information","Modifications apportées aux sections suivantes de la monographie de produit: indications, contre-indications, mises en garde et précautions, populations spéciales, effets indésirables, interactions médicamenteuses, mode d'action et pharmacologie clinique et essais cliniques, ainsi qu'à la partie III: renseigements pour le consommateur","Chelating agent","Chélateur du fer","",""
"11585","10-07-15","ABBOTT PRODUCTS INC","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiparkinson agent","Antiparkinsonien","",""
"11586","10-07-15","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial agent","Antibactérien","",""
"11587","10-07-15","BIOVAIL PHARMACEUTICALS CANADA DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in manufacturing site for 1000 mg tablets","Changement relatif au site de fabrication pour comprimés de 1000 mg","Antihyperglycemic agent","Agent antihyperglycémiant","",""
"11588","10-07-15","WINSTON LABORATORIES INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical analgesic","Analgésique topique","",""
"11589","10-07-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PENNSAID","PALADIN LABS INC.","CANADA","CANADA","1","","","Topical anti-inflammatory, analgesic","Anti-inflammatoire topique, analgésique","",""
"11590","10-07-16","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Antimanic agent","Antimaniaque","",""
"11591","10-07-16","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","","","Type II 5-alpha-reductase inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"11592","10-07-16","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALERTEC","SHIRE CANADA INC.","CANADA","CANADA","1","Removal of indication","Suppression de l'indication","Central nervous system stimulant","Stimulant du système nerveux central","",""
"11593","10-07-16","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","New strength, change in formulation","Nouvelle concentration, modification de la formulation pour la concentration de 500 mg","Antiviral","Antiviral","",""
"11594","10-07-16","MYLAN PHARMACEUTICALS ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to product monograph","Révisions à la monographie de produit","Beta-adrenergic receptor blocking agent","Inhibiteurs des récepteurs bêta-adrénergiques","",""
"11595","10-07-16","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteurs des récepteurs bêta-adrénergiques","",""
"11596","10-07-16","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADALAT XL","BAYER INC.","CANADA","CANADA","1","","","Antianginal, antihypertensive agent","Antiangineux, antihypertenseur","",""
"11597","10-07-16","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Anticonvulsant, symptomatic relief of trigeminal neuralgia, antimanic","Anticonvulsivant, soulagement de la névralgie du trijumeau, antimaniaque","",""
"11598","10-07-14","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC.","CANADA","CANADA","1","Update to the product monograph to match the innovator","La mise à jour de la monographie du produit, pour égaler la monographie du produit de l'innovateur","Non-steroidal antiandrogen","Antiandrogène non stéroïdien","",""
"11599","10-07-19","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product monograph update for action and clinical pharmacology, special populations and conditions","Mise à jour de la monographie du produit pour mode d'action et pharmacologie clinique, populations particulières et états pathologiques","Anticoagulant / Antithrombotic agent","Anticoagulant / Antithrombotique","",""
"11600","10-07-19","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11601","10-07-19","SEPRACOR PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid metabolism regulator","Régulateur du métabolisme lipidique","",""
"11602","10-07-19","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11603","10-07-20","PHIBRO ANIMAL HEALTH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anthelmintic","Anthelmintique","",""
"11604","10-07-20","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11605","10-07-20","INTERVET CANADA CORP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Change in starting dose for dogs and cats","Changement de la dose de départ pour les chiens et les chats","Hormone","Hormone","",""
"11606","10-07-20","ABBOTT PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Gastrointestinal calcium antagonist","Antagoniste calcique gastro-intestinal","",""
"11607","10-07-15","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to product monograph to include use in pediatric populations (term neonates - 3 months old)","La mise à jour de la monographie du produit comprendra l'utilisation dans les populations pédiatriques (naissances à terme - 3 mois)","Non-depolarizing skeletal neuromuscular blocking agent","Bloqueur neuromusculaire squelettique non dépolarisant","",""
"11608","10-07-20","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Safety update relating to the risks of myopathy and rhabdomyolysis associated with the use of the 80 mg dose of the product","Mise à jour sur l'innocuité du produit concernant les risques de myopathie et de rhabdomyolyse associés à la dose de 80 mg","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11609","10-07-22","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Proton pump inhibitor","Inhibiteur de la pompe à protons","",""
"11610","10-07-22","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: For the treatment of chronic phase Philadelphia chromosome positive chronic myeloid leukemia (CML) in adult patients resistant to or intolerant of at lease one prior therapy including imatinib","Nouvelle indication: Traitement de la leucémie myéloïde chronique (LMC) à chromosome Philadelphie positif en phase chronique chez des patients adultes qui ne répondent pas ou qui sont intolérants à au moins un traitement antérieur comprenant l'imatinib","Protein-tyrosine kinase inhibitor","Inhibiteur de la protéase-tyrosine kinase","",""
"11611","10-07-20","PHIBRO ANIMAL HEALTH CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anti-bloat surfactant","Surfactant contre le ballonnement","",""
"11612","10-07-21","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH-AYERST CANADA INC.","CANADA","CANADA","1","","","Antidepressant / anxiolytic","Antidépresseur / anxiolytique","",""
"11613","10-07-21","MYLAN PHARMACEUTICALS ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","Elevated intraocular pressure therapy","Thérapie pour réduire la pression intraoculaire","",""
"11614","10-07-22","SANDOZ CANADA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the product monograph","Mises à jour de la monographie de produit","Neuroleptic, antiemetic","Neuroleptique, antiémétique","",""
"11615","10-07-21","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Updated product monograph to reflect revisions made to the vaccination schedule for the third dose of FSME-IMMUN as well as inclusion of the rapid immunization schedule","La monographie de produit a été mise à jour afin de refléter les révisions effectuées au calendrier de vaccination pour la troisième dose de FSME-IMMUN ainsi que l'inclusion du calendrier de vaccination rapide","Active immunizing agent","Agent d'immunisation actif","",""
"11616","10-07-26","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCONORM","NOVO NORDISK CANADA INC.","CANADA","CANADA","1","","","Antidiabetic agent","Antidiabétique oral","",""
"11617","10-07-26","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCONORM","NOVO NORDISK CANADA INC.","CANADA","CANADA","1","PM update to reflect innovator","La mise à jour de la monographie du produit pour égaler la monographie du produit de l'innovateur","Antidiabetic agent","Antidiabétique oral","",""
"11618","10-07-26","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KYTRIL","ROCHE LABORATORIES INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiemetic / 5-HT3 receptor antagonist","Antiémétique / Antagoniste des récepteurs 5-HT3","",""
"11619","10-07-26","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCONORM","NOVO NORDISK CANADA INC.","CANADA","CANADA","1","","","Oral antidiabetic agent","Antidiabétique oral","",""
"11620","10-07-26","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC.","CANADA","CANADA","1","Revised product monograph","Monographie de produit révisée","Opioid analgesic","Analgésique opioïde","",""
"11621","10-07-27","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11622","10-07-27","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11623","10-07-27","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11624","10-07-27","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antipanic / Antiobsessional agent","Antidépresseur / Antipanique / Antiobsessionnel","",""
"11625","10-07-28","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTOR AND GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11626","10-07-28","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTOR AND GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11627","10-07-28","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTOR AND GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Additional strength","Concentration additionnelle","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11628","10-07-28","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTOR AND GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11629","10-07-28","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTOR AND GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11630","10-07-28","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTOR AND GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11631","10-07-28","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antidepressant","Antidépresseur","",""
"11632","10-07-28","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"11633","10-07-28","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11634","10-07-28","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New formulation","Nouvelle formulation","Analgesic","Analgésique","",""
"11635","10-07-28","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","WARNER-LAMBERT","CANADA","CANADA","1","","","Antiepileptic agent","Antiépileptique","",""
"11636","10-07-29","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition to the Rheumatoid Arthritis (RA) indication: Rituxan in combination with Methotrexate has been shown to reduce the rate of progression of joint damage as measured by x-ray","Addition  à l'indication de polyarthrite rhumatoïde (PR) : Il a été démontré que Rituxan, en association avec le méthotrexate, ralentit l'évolution des lésions articulaires, telle que mesurée par radiographie","Antineoplastic","Antinéoplasique","",""
"11637","10-07-29","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Expansion of the conditions for use to pediatrics aged 2-17 years of age","Inclusion des patients pédiatriques de 2 à 17 ans dans le groupe cible","Contrast enhancement agent for magnetic resonance imaging (MRI)","Produit de contraste pour l'imagerie par résonance magnétique (IRM)","",""
"11638","10-07-29","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New formulation and new dosage form","Nouvelle formulation et nouvelle forme posologique","Progestogen","Progestatif","",""
"11639","10-07-30","NU PHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11640","10-08-03","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"11641","10-08-03","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11642","10-08-03","BANNER PHARMACAPS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL LIQUI-GELS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"11643","10-08-03","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"11644","10-08-04","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","New indication: Herceptin in combination with capecitabine or intravenous 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.  Herceptin should only be administered to patients with metastatic gastric cancer whose tumours have HER2 overexpression as defined by IHC2+ confirmed by FISH+ or IHC 3+ as determined by an accurate and validated assay.","Nouvelle indication : Herceptin en association avec la capécitabine ou le 5-fluoro-uracil i.v. et le cisplatine, est indiqué dans le traitement des patients atteints d'un adénocarcinome gastrique ou de la jonction oeso-gastrique métastatique, HER2-positif, n'ayant pas reçu de traitement anticancéreux préalable pour leur maladie métastatique.  Herceptin ne doit être administré qu'aux patients atteints d'un cancer gastrique métastatique en présence d'une surexpression de HER2 définie par un score IHC2+ confirmé par FISH+, ou un score IHC 3+ determiné par une méthode précise et validée.","Antineoplastic","Antinéoplasique","",""
"11645","10-08-04","CELGENE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immunomodulatory agent","Agent immunomodulateur","",""
"11646","10-08-05","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimanic agent","Antipsychotique / Antimaniaque","",""
"11647","10-08-09","EURO PHARM INTERNATIONAL CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CHILDREN'S MOTRIN SUSPENSION","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"11648","10-08-09","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CISPLATIN INJECTION","MAYNE PHARMA INC","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"11649","10-08-06","AMGEN CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Human monoclonal antibody to RANKL: Bone metabolism regulator","Anticorps monoclonal humain au ligand RANK : régulateur du métabolisme osseux","",""
"11650","10-08-09","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11651","10-08-09","TALECRIS BIOTHERAPEUTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of subcutaneous route of administration","L'ajout de la voie d'administration sous-cutanée","Passive immunizing agent","Agent d'immunisation passive","",""
"11652","10-08-10","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11653","10-08-13","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"11654","10-08-13","ACCORD HEALTHCARE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","Removal of indication","Suppression de l'indication","Antineoplastic agent","Antinéoplasique","",""
"11655","10-08-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anxiolytic / Sedative","Anxiolytique / Sédatif","",""
"11656","10-08-13","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic","Hypnotique","",""
"11657","10-08-11","GW PHARMA LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Sativex is useful as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy","Nouvelle indication : Sativex peut être utilisé comme traitement auxiliaire pour le soulagement des symptômes relatifs à l’hypertonie spastique chez les patients adultes atteints de sclérose en plaques (SEP) qui n’ont pas répondu adéquatement à d’autres thérapies et qui ont montré une amélioration importante dans le cadre d’un premier essai du traitement","Cannabinoid analgesic","Analgésique cannabinoïde","",""
"11658","10-08-13","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Reformulation of chewable tablets","Reformulation des comprimés croquables","Histamine H2-receptor antagonist / Antacid","Antagoniste des récepteurs H2 de l'histamine / Antiacide","",""
"11659","10-08-13","MISSION PHARMACAL COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength: 10 mEq","Nouvelle concentration : 10 mEq","Renal stone treatment in patients with hypocitraturia or uric acid lithiasis","Traitement des calculs rénaux chez les patients présentant une hypocitraturie ou une lithiase urique","",""
"11660","10-08-12","GILEAD SCIENCES CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revised indication: Viread is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in patients 12 years of age and older","Indication révisée : Viread est indiqué pour le traitement de l'infection par le VIH-1 en association avec d'autres agents antirétroviraux chez les patients agés de 12 ans et plus","Antiretroviral agent","Antirétroviral","",""
"11661","10-08-17","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product name change","Changement du nom de produit","Hemostatic agent","Agent hémostatique","",""
"11662","10-08-18","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","Lower gastrointestinal anti-inflammatory","Anti-inflammatoire de la partie basse du tube digestif","",""
"11663","10-08-18","VIIV HEALTHCARE SHIRE CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"11664","10-08-18","VIIV HEALTHCARE SHIRE CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"11665","10-08-18","VIIV HEALTHCARE SHIRE CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiviral agent","Antiviral","",""
"11666","10-08-18","VIIV HEALTHCARE SHIRE CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"11667","10-08-18","VIIV HEALTHCARE SHIRE CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent","Antirétroviral","",""
"11668","10-08-19","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of pediatric kinetic data","Ajout de données sur la cinétique chez l'enfant","Antidepressant / Anxiolytic / Analgesic","Antidépresseur / Anxiolytique / Analgésique","",""
"11669","10-08-19","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph: pharmacokinetics","Mise à jour de la monographie de produit : pharmacocinétiques","Histamine H1-antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11670","10-08-19","GILEAD SCIENCES CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph: Clinical Efficacy in patients with class A or B decompensated liver disease","Révisions à la monographie de produit : Efficacité clinique chez les patients atteints d'une maladie hépatique décompensée de type A ou B","Antiretroviral agent","Antirétroviral","",""
"11671","10-08-20","BAYER INC BAYER HEALTHCARE ANIMAL HEALTH DIVISION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Veterinary","Vétérinaire","","","","","1","","","Anticoccidial","Anticoccidien","",""
"11672","10-08-19","JANSSEN ORTHO INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Dosage and Administration section and other revisions to the Product Monograph","Révision à la section Posologie et administration et autres révisions à la monographie de produit","Human immunodeficiency virus (HIV) non-nucleoside reverse transcriptase inhibitor","Inhibiteur non-nucléosidique de la réverse transcriptase du virus de l'immunodéficience humaine (VIH)","",""
"11673","10-08-19","ALLERGAN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-inflammatory / Immunomodulator","Anti-inflammatoire / Immunomodulateur","",""
"11674","10-08-20","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate manufacturing site for the finished product and change in formulation of the drug product","Autre lieu de fabrication pour le produit fini et modification de la formulation du produit","Antiparkinson agent","Antiparkinsonien","",""
"11675","10-08-20","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL MYERS SQUIBB COMPANY","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11676","10-08-20","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11677","10-08-23","VITA HEALTH PRODUCTS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","","","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11678","10-08-24","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Endectocide","Endectocide","",""
"11679","10-08-24","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11680","10-08-25","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11681","10-08-25","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2-receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"11682","10-08-25","GENMED A DIVISION OF PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11683","10-08-25","DOMINION PHARMACAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11684","10-08-25","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11685","10-08-25","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"11686","10-08-25","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Xanthine oxidase inhibitor","Inhibiteur de la xanthine-oxydase","",""
"11687","10-08-25","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anxiolytic / Sedative","Anxiolytique / Sédatif","",""
"11688","10-08-27","ORION CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Sedative","Sédatif","",""
"11689","10-08-27","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Gonadotrophins","Gonadotrophines","",""
"11690","10-08-27","WYETH CONSUMER HEALTHCARE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Sleep aid","Analgésique / Aide-sommeil","",""
"11691","10-08-27","PHARMASCIENCE INC","Y","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11692","10-08-27","MM THERAPEUTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Antibiotic","Antibiotique","",""
"11693","10-08-27","FERRING INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Reactivation of the 3.2 mg strength","Réactivation de la concentration 3.2 mg","Ovulatory agent","Agent ovulatoire","",""
"11694","10-08-30","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAROPIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Local anaesthetic","Anesthésique local","",""
"11695","10-08-30","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","NAROPIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Local anaesthetic","Anesthésique local","",""
"11696","10-08-27","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Dosing adjustment when co-administered with CYP3A inducing agents","Changement de la posologie lorsque le produit est co-administré avec les inducteurs du CYP3A","Human immunodeficiency virus (HIV) protease inhibitor","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH)","",""
"11697","10-08-31","ERFA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Reactivation of DIN","Réactivation du DIN","Progestin","Progestatif","",""
"11698","10-08-31","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11699","10-09-01","VITA HEALTH PRODUCTS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC","CANADA","CANADA","1","Product name change","Modification du nom du produit","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11700","10-09-01","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN ORTHO INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11701","10-09-01","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIDAMOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Antikaliuretic agent with diuretic properties","Antikaliurétique, diurétique","",""
"11702","10-09-01","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFOXITIN FOR INJECTION USP","NOVOPHARM LIMITED","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11703","10-09-01","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Histamine H2 receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"11704","10-09-01","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Antihypertensive agent / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11705","10-09-02","WYETH CONSUMER HEALTHCARE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"11706","10-09-07","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CLOZARIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Update to the Product Monograph to match the innovator","Mise à jour de la monographie de produit pour égaler la monographie de produit de l'innovateur","Antipsychotic agent","Antipsychotique","",""
"11707","10-09-09","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11708","10-09-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LIMITED","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"11709","10-09-09","SERVIER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength: 60 mg and update to the Product Monograph","Nouvelle concentration : 60 mg et mise à jour de la monographie de produit","Hypoglycemic sulfonylurea / Oral antidiabetic agent","Hypoglycémiant sulfonylurée / Antidiabétique oral","",""
"11710","10-09-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCONORM","NOVO NORDISK CANADA INC","CANADA","CANADA","1","","","Oral antidiabetic agent","Antidiabétique oral","",""
"11711","10-09-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Alternate dosing schedule","Plan posologique alternatif","Active immunizing agent","Agent d'immunisation actif","",""
"11712","10-09-13","IPSEN BIOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antigrowth hormone","Inhibiteur de l'hormone de croissance","",""
"11713","10-09-16","MM THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypercholesterolemic / Antidiarrheal","Hypocholestérolémiant / Antidiarrhéique","",""
"11714","10-09-16","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective norepinephrine reuptake inhibitor for attention-deficit / Hyperactivity disorder (ADHD)","Inhibiteur sélectif du recaptage de la noradrénaline pour le trouble déficitaire de l'attention avec hyperactivité (TDAH)","",""
"11715","10-09-16","SEPRACOR PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate manufacturing site for the finished product","Autre lieu de fabrication pour le produit fini","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11716","10-09-16","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to indication for tablets: delay in clinical worsening for PAH patients already stabilised on epoprostenol therapy","Révision de l'indication des comprimés: retardement d'une détérioration clinique chez les patients avec hypertension artérielle pulmonaire déjà stabilisés avec l'époprosténol","cGMP-specific phosphodiesterase 5 inhibitor","Inhibiteur de la phosphodiestérase de type 5 spécifique de la GMPc","",""
"11717","10-09-17","WYETH CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage format and new manufacturing site","Nouveau format posologique et nouvel emplacement de fabrication","mcg-opioid receptor antagonist","Antagoniste du récepteur opioïde-mcg","",""
"11718","10-09-21","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11719","10-09-21","PATRIOT A DIVISION OF JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"11720","10-09-21","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Estrogen","Oestrogène","",""
"11721","10-09-21","SEPTA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antidepressant","Antidépresseur","",""
"11722","10-09-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective norepinephrine reuptake inhibitor for attention-deficit / hyperactivity disorder (ADHD)","Inhibiteur sélectif du recaptage de la noradrénaline pour le trouble déficitaire de l'attention avec hyperactivité (TDAH)","",""
"11723","10-09-21","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"11724","10-09-21","VITA HEALTH PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Hair regrowth treatment","Stimulant pour la pousse des cheveux","",""
"11725","10-09-21","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Estrogen","Oestrogène","",""
"11726","10-09-21","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Estrogen","Oestrogène","",""
"11728","10-09-21","PALADIN LABS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in formulation","Modification de la formulation","Pediatric asthma prophylactic / Anti-allergic agent","Agent prophylactique de l'asthme infantile / Agent antiallergique","",""
"11729","10-09-15","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of long term safety and efficacy data of Isentress in combination with other antiretroviral therapy in HIV-infected treatment-naive patients","Données additionnelles sur l'innocuité et l'efficacité à long terme d'Isentress lorsque utilisé en association avec d'autres antirétroviraux pour le traitement de l'infection au VIH des patients non-traités précédemment","Human immunodeficiency virus integrase strand transfer inhibitor","Inhibiteur de transfert de brin d'intégrase du virus de l'immunodéficience humaine","",""
"11730","10-09-22","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Xanthine oxidase inhibitor","Inhibiteur de la xanthine-oxydase","",""
"11731","10-09-22","FRESENIUS KABI CANADA, A DIVISION OF CALEA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Plasma volume expander","Soluté de remplissage plasmatique","",""
"11732","10-09-23","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11733","10-09-24","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO MCNEIL PHARMACEUTICAL INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"11734","10-09-24","MM THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Collagenase inhibitor for periodontal use","Inhibiteur de la collagénase pour usage périodontique","",""
"11735","10-09-24","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antibulimic","Antidépresseur / Antiobsessionnel / Antiboulimique","",""
"11736","10-09-24","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Xanthine oxidase inhibitor","Inhibiteur de la xanthine oxidase","",""
"11737","10-09-24","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form","Nouvelle forme posologique","Topical anti-inflammatory / Analgesic","Anti-inflammatoire topique / Analgésique","",""
"11738","10-09-24","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC.","CANADA","CANADA","1","","","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11739","10-09-24","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"11740","10-09-24","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC","CANADA","CANADA","1","","","Hypnotic / Sedative","Hypnotique / Sédatif","",""
"11741","10-09-24","JAMP PHARMA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Skeletal muscle relaxant","Relaxant des muscles squelettiques","",""
"11742","10-09-24","JAMP PHARMA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenoceptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11743","10-09-27","SERVIER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength","Nouvelle concentration","Angiotensin converting enzyme inhibitor / Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine / Diurétique","",""
"11744","10-09-27","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCONORM","NOVO NORDISK CANADA INC","CANADA","CANADA","1","","","Oral antidiabetic agent","Antidiabétique oral","",""
"11745","10-09-27","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New tablet formulation","Nouvelle formulation : comprimés","Human immunodeficiency virus (HIV) protease inhibitor","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH)","",""
"11746","10-09-27","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New sulfite free formulation","Nouvelle formulation sans sulfite","Nutritive supplement","Supplément nutritif","",""
"11747","10-09-23","HILL DERMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revised indication: Treatment of moderate to severe atopic dermatitis in children 3 months to 12 years. It may be used for a maximum duration of 4 weeks on the body. It is not indicated for use on the face or in the diaper or anogenital areas. Derma-Smoothe/FS topical oil should not be used on infants under the age of 3 months.","Indication révisée : Traitement de la dermatite atopique de modérée à sévère chez les enfants de 3 mois à 12 ans.  Il peut être utilisé pour une durée maximale de 4 semaines sur le corps.   Il n'est pas indiqué pour utilisation sur le visage, sur la région sous la couche ou sur la région anogénitale. L'huile topique Derma-Smoothe/FS ne devrait pas être utilisée chez les nourrissons de moins de 3 mois.","Topical corticosteroid","Corticostéroïde topique","",""
"11748","10-09-29","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"11749","10-09-29","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Non-steroidal antiandrogen","Antiandrogène non stéroïdien","",""
"11750","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antimetabolite","Antimétabolite","",""
"11751","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anxiolytic / Sedative","Anxiolytique / Sédatif","",""
"11752","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","mcg-opioid receptor antagonist","Antagoniste du récepteur opioïde-mcg","",""
"11753","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"11754","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"11755","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiarrhythmic agent","Antiarythmique","",""
"11756","10-09-29","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11757","10-09-29","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11758","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Estrogenic hormones / Progestin","Hormones oestrogènes / Progestatif","",""
"11759","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Folic acid derivative","Dérivé de l'acide folique","",""
"11760","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","mtor kinase inhibitor / Antineoplastic agent","Inhibiteur de la mtor/ Antinéoplasique","",""
"11761","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic / Beta-lactamase inhibitor","Antibiotique / Inhibiteur de bêta-lactamases","",""
"11762","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Anxiolytic","Antidépresseur / Anxiolytique","",""
"11763","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"11764","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"11765","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11766","10-09-29","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11767","10-09-30","UCB CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiepileptic agent","Antiépileptique","",""
"11768","10-09-30","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER AND GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11769","10-09-29","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Tetracycline antibiotic (glycylcycline derivative)","Antibiotique tétracycline (dérivé de glycylcycline)","",""
"11770","10-10-01","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"11771","10-10-01","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic","Hypnotique","",""
"11772","10-10-01","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"11773","10-10-01","CELGENE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Product Monograph to update the content related to the RevAid controlled distribution program","Modification à la monographie de produit afin de mettre à jour le contenu lié au programme de distribution contrôlée RevAid","Antineoplastic agent / Immunomodulatory agent","Antinéoplasique / Agent immunomodulateur","",""
"11774","10-10-01","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Progestagen / Progestational steroid","Progestatif / Stéroïde progestative","",""
"11775","10-10-01","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"11776","10-10-01","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST PHARMACEUTICALS INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antidepressant","Antidépresseur","",""
"11777","10-10-01","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"11778","10-10-01","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMAXIN","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11779","10-10-01","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"11780","10-09-30","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: In combination with letrozole for the treatment of post-menopausal patients with hormone receptor positive metastatic breast cancer, whose tumours over express the ErbB2 (HER2) receptor, and who are suitable for endocrine therapy ","Nouvelle indication : En association avec le létrozole pour le traitement des patientes ménopausées atteintes d'un cancer du sein métastatique exprimant des récepteurs hormonaux avec surexpresssion tumorale des récepteurs ErbB2 (HER2), et pour qui un traitement endocrinien est approuvé","Antineoplastic","Antinéoplasique","",""
"11781","10-10-01","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"11782","10-10-01","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Estrogenic hormones / Progestin","Hormones oestrogènes / Progestatif","",""
"11783","10-10-01","SHIRE HUMAN GENETIC THERAPIES INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Enzyme replacement therapy","Traitement de remplacement d'enzymes","",""
"11784","10-10-01","GENMED A DIVISION OF PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Revisions to the Product Monograph - Response to TPD notification regarding the Food and Drugs Regulations - project # 1597 - Schedule F and correction to product name","Modifications apportées à la monographie de produit - En réponse à l'avis de la DPT concernant le Règlement sur les aliments et drogues - projet 1597 - annexe F et correction au nom du produit  ","Antifungal agent","Antifongique","",""
"11785","10-10-05","MELIAPHARM INC.","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","N-methyl-D-aspartate (NMDA) receptor antagonist","Antagoniste du récepteur N-méthyl-D-aspartate","",""
"11786","10-10-06","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate manufacturing site for the finished product and change in formulation of the drug product","Autre lieu de fabrication pour le produit fini et modification de la formulation du produit","Antiparkinson agent","Antiparkinsonien","",""
"11787","10-10-06","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","Aldosterone antagonist with a diuretic","Antagoniste de l'aldostérone avec un diurétique","",""
"11788","10-10-06","ASTELLAS PHARMA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of a maintenance indication","Ajout d'une indication de maintenance","Topical calcineurin inhibitor","Inhibiteur topique de la calcineurine","",""
"11789","10-10-06","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11790","10-10-07","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antipanic / Antiobsessional agent","Antidépresseur / Antipanique / Antiobsessionnel","",""
"11791","10-10-07","VITA HEALTH PRODUCTS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL LIQUI-GELS AND ADVIL EXTRA STRENGTH LIQUI-GELS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"11792","10-10-07","CENTRAL SALES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiarthritic","Antiarthritique","",""
"11793","10-10-07","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"11794","10-10-07","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"11795","10-10-07","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"11796","10-10-08","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC MAXIMUM STRENGTH NON-PRESCRIPTION","PFIZER CANADA INC","CANADA","CANADA","1","","","Histamine H2-receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"11797","10-10-08","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC","CANADA","CANADA","1","Product name change","Modification du nom du produit","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11798","10-10-08","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXOWELLCOME INC","CANADA","CANADA","1","","","Histamine H2-receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"11799","10-10-08","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11800","10-10-08","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immunosuppressive agent","Agent immunosuppresseur","",""
"11801","10-10-08","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral hypoglycemic","Hypoglycémiant oral","",""
"11802","10-10-08","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Antiobsessional / Antibulimic","Antidépresseur / Antiobsessionnel / Antiboulimique","",""
"11803","10-10-08","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11804","10-10-08","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"11805","10-10-08","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 receptor blocker and diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II et diurétique","",""
"11806","10-10-13","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DDAVP","FERRING INC","CANADA","CANADA","1","","","Antidiuretic","Antidiurétique","",""
"11807","10-10-13","RATIOPHARM INC","Y","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","New indication","Nouvelle indication","N-methyl-D-aspartate (NMDA) receptor antagonist","Antagoniste du récepteur N-méthyl-D-aspartate","",""
"11808","10-10-08","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph based on information from a Warfarin interaction study","Mise à jour de la monographie de produit basée sur une étude d'interaction avec Warfarin","Antidepressant / Anxiolytic / Analgesic","Antidépresseur / Anxiolytique / Analgésique","",""
"11809","10-10-14","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Additional indications","Indications additionnelles","Histamine H1-receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11810","10-10-14","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11811","10-10-14","LEO PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Issuance of DINs for different package sizes of unit dose","Emissions d'identifications numériques de drogue pour les différentes tailles d'emballage à dose unitaire","Anticoagulant / Antithrombotic","Anticoagulant / Antithrombotique","",""
"11812","10-10-15","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","New indication","Nouvelle indication","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11813","10-10-15","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Post-approval commitment","Engagement post-approbation","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"11814","10-10-19","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Post-approval commitment","Engagement post-approbation","Renin inhibitor / Diuretic","Inhibiteur de la rénine / Diurétique","",""
"11815","10-10-20","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMAXIN","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11816","10-10-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRUSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Elevated intraocular pressure therapy (Topical carbonic anhydrase inhibitor)","Thérapie pour réduire la pression intraoculaire (Inhibiteur de l'anhydrase carbonique topique)","",""
"11817","10-10-26","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication and new strength","Nouvelle indication et nouvelle concentration","Anticoagulant","Anticoagulant","",""
"11818","10-10-26","BIOVAIL PHARMACEUTICALS CANADA DIVISION OF BIOVAIL CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Manufacturing site change","Changement de l'emplacement de fabrication","Antihypertensive agent / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11819","10-10-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Elevated intraocular pressure therapy","Thérapie pour réduire la pression intraoculaire","",""
"11820","10-10-26","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON MR","SERVIER CANADA INC","CANADA","CANADA","1","","","Hypoglycemic sulfonylurea / Oral antidiabetic agent","Hypoglycémiant sulfonylurée / Antidiabétique oral","",""
"11821","10-10-26","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Safety update","Mise à jour de l'innocuité","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11822","10-10-28","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New dosage form","Nouvelle forme posologique","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"11823","10-10-27","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph, regarding action and clinical pharmacology","Mise à jour de la monographie de produit, concernant le mode d'action et la pharmacologie clinique","Central nervous system stimulant for attention deficit hyperactivity disorder","Stimulant du système nerveux central pour le trouble déficitaire de l'attention avec hyperactivité","",""
"11824","10-10-29","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11825","10-11-01","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIDROCAL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11826","10-11-01","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical anti-inflammatory corticosteroid","Anti-inflammatoire corticostéroïde topique","",""
"11827","10-11-02","SANIS HEALTH INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Lower gastrointestinal anti-inflammatory","Anti-inflammatoire de la partie basse du tube digestif","",""
"11828","10-11-02","BASILEA MEDICAL LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immunomodulator / Anti-inflammatory agent","Immunomodulateur / Anti-inflammatoire","",""
"11829","10-11-01","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiemetic","Antiémétique","",""
"11830","10-11-01","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Pediatric asthma prophylactic / Antiallergic agent","Agent prophylactique de l'asthme infantile / Agent antiallergique","",""
"11831","10-11-02","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"11832","10-11-02","SANIS HEALTH INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","GEIGY PHARMACEUTICALS, CIBA GEIGY CANADA LTD","CANADA","CANADA","1","Product name change","Modification du nom du produit","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11833","10-11-01","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective norepinephrine reuptake inhibitor for attention-deficit / hyperactivity disorder (ADHD)","Inhibiteur sélectif du recaptage de la noradrénaline pour le trouble déficitaire de l'attention avec hyperactivité (TDAH)","",""
"11834","10-11-02","SANIS HEALTH INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11835","10-11-01","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antipanic / Antiobsessional agent","Antidépresseur / Antipanique / Antiobsessionnel","",""
"11836","10-11-02","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","UNIPHYL","PURDUE PHARMA","CANADA","CANADA","1","","","Bronchodilator","Bronchodilatateur","",""
"11837","10-11-02","TRITON PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New formulation, manufacturing procedure and manufacturing site","Nouvelle formulation, nouveau procédé de fabrication et nouveau lieu de fabrication","Immunosuppressive agent","Agent immunosuppresseur","",""
"11838","10-11-02","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","DIFLUCAN-150","PFIZER CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"11839","10-11-02","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Non-steroidal antiandrogen","Antiandrogène non stéroïdien","",""
"11840","10-11-02","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Vascular stabilizer for the treatment of menopausal flushing (0.025 mg tablet) / Antihypertensive (0.1 and 0.2 mg tablets)","Stabilisateur vasculaire pour le traitement des bouffées de chaleur de la ménopause (comprimé de 0.025 mg) / Antihypertenseur (comprimés de 0.1 et 0.2 mg)","",""
"11841","10-11-02","SANIS HEALTH INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Antibiotic","Antibiotique","",""
"11842","10-11-02","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Immunosuppressive agent","Agent immunosuppresseur","",""
"11843","10-11-03","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB COMPANY","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11844","10-11-03","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA INC., DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11845","10-11-03","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EVISTA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective estrogen receptor modulator","Modulateur sélectif des récepteurs estrogéniques","",""
"11846","10-11-03","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the following sections of the Product Monograph: Indications and Clinical Use, Adverse Reactions, Dosage and Administration, Clinical Trials, References and Part III: Consumer Information","Révisions des sections suivantes de la monographie de produit: Indications et utilisation clinique, Réactions indésirables, Dosage et administration, Essais cliniques, Références et Partie III : Renseignements à l'intention des clients","Type I and II 5-alpha reductase inhibitor","Inhibiteur de type I et II de la 5-alpha réductase","",""
"11847","10-10-29","GILEAD SCIENCES CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph: changes based on 144 week safety and efficacy data for studies GS-US-174-0102 and GS-US-174-0103 to further support the CHB indication","Mises à jour de la monographie de produit : changements basés sur les données obtenues à 144 semaines, de l’information relative à l’innocuité et l’efficacité, pour les études GS-US-174-0102 et GS-US-174-0103, afin de supporter davantage l’indication concernant l’hépatite B chronique","Antiretroviral","Antirétroviral","",""
"11848","10-11-04","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EVISTA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective estrogen receptor modulator","Modulateur sélectif des récepteurs estrogéniques","",""
"11849","10-11-05","CSL BEHRING CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Blood coagulation factors II, VII, IX, and X combination","Combinaisons des facteurs II, VII, IX et X de la coagulation sanguine","",""
"11850","10-11-05","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Elevated intraocular pressure therapy","Thérapie pour réduire la pression intraoculaire","",""
"11851","10-11-05","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"11852","10-11-08","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11853","10-11-08","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product monograph update","Mise à jour de la monographie de produit","Endothelin receptor antagonist","Antagoniste des récepteurs de l'endothéline","",""
"11854","10-11-08","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN ORTHO INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11855","10-11-10","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Changes to rFVlla drug substance manufacturing scale","Modification de l'échelle de fabrication de la substance rFVlla","Coagulation factor","Facteur de coagulation","",""
"11856","10-11-10","SEPTA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11857","10-11-10","MM THERAPEUTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form","Nouvelle forme posologique","Cardiotonic glycoside","Glucoside cardiotonique","",""
"11858","10-11-10","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","N.V. ORGANON OSS","NETHERLANDS","PAYS-BAS","1","","","Antidepressant","Antidépresseur","",""
"11859","10-11-10","WARNER CHILCOTT CANADA CO","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Estrogen-progestin combination","Combinaison oestrogène-progestatif","",""
"11860","10-11-10","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Clinical Trials section of the Product Monograph","Révisions à la section des essais cliniques de la monographie de produit","Antineoplastic agent","Antinéoplasique","",""
"11861","10-11-12","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11862","10-11-10","SERVIER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11863","10-11-10","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product Monograph update","Mise à jour de la monographie de produit","Central nervous system stimulant","Stimulant du système nerveux central","",""
"11864","10-11-12","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMINYL ER CAPSULES","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Cholinesterase inhibitor","Inhibiteur de la cholinestérase","",""
"11865","10-11-12","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antipanic / Antiobsessional agent","Antidépresseur / Antipanique / Antiobsessionnel","",""
"11866","10-11-12","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN ORTHO INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"11867","10-11-12","NEXMED USA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Treatment of male erectile dysfunction","Traitement de la dysfonction érectile","",""
"11868","10-11-15","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11869","10-11-15","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11870","10-11-16","AUROBINDO PHARMA LIMITED UNIT III","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIRAMUNE","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Antiretroviral agent / Non-nucleoside reverse transcriptase inhibitor with activity against Human Immunodeficiency Virus type 1 (HIV-1)","Antirétroviral / Inhibiteur non-nucléoside de la reverse transcriptase contre le virus de l'immunodéficience humaine de type 1 (VIH-1)","",""
"11871","10-11-16","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIRAMUNE","BOEHRINGER INGELHEIM (CANADA) LIMITED","CANADA","CANADA","1","","","Antiretroviral agent / Non-nucleoside reverse transcriptase inhibitor with activity against Human Immunodeficiency Virus type 1 (HIV-1)","Antirétroviral / Inhibiteur non-nucléoside de la reverse transcriptase contre le virus de l'immunodéficience humaine de type 1 (VIH-1)","",""
"11872","10-11-15","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to safety, drug-drug interactions and drug-food interactions","Mises à jour de l’innocuité, interactions médicament-médicament et interactions médicament-aliment","Antihypertensive / Antianginal agent / Lipid metabolism regulator","Antihypertenseur / Antiangineux / Régulateur du métabolisme des lipides","",""
"11873","10-11-17","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","The addition of a 4.5 mg and 9 mg strength. Update to the Product Monograph","Nouvelles concentrations de 4.5 mg et 9 mg. Mise à jour de la monographie de produit","Opioid analgesic","Analgésique opioïde","",""
"11874","10-11-18","MEDICAL FUTURES INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Osmotic laxative","Laxatif osmotique","",""
"11875","10-11-19","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURALITH","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antimanic agent","Antimaniaque","",""
"11876","10-11-18","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"11877","10-11-19","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHIN","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"11878","10-11-18","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"11879","10-11-19","NOVARTIS ANIMAL HEALTH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Manufacturing changes","Modification de la fabrication","Antibiotic","Antibiotique","",""
"11880","10-11-23","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to Action and Clinical Pharmacology and other sections of the Product Monograph","Mise à jour de la section Mode d'action et pharmacologie clinique ainsi qu'à d'autres sections de la monographie de produit","Tyrosine kinase inhibitor / Anti-tumour agent","Inhibiteur de la tyrosine kinase / Antinéoplasique","",""
"11881","10-11-23","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product Monograph update to the Warning and Precautions for patients with hepatic impairment","Mise à jour de la monographie de produit: section des mises en gardes et précautions pour les patients atteints d'une insuffisance hépatique","Human immunodeficiency virus (HIV) protease inhibitor / Antiretroviral agent","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH) / Antirétroviral","",""
"11882","10-11-23","NYCOMED CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Phosphodiesterase 4 (PDE4) inhibitor","Inhibiteur de la phosphodiestérase 4 (PDE4)","",""
"11883","10-11-25","VITA HEALTH PRODUCTS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD & SINUS CAPLETS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","Product name change","Modification du nom du produit","Analgesic / Antipyretic / Nasal decongestant","Analgésique / Antipyrétique / Décongestionnant nasal","",""
"11884","10-11-25","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"11885","10-11-25","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM","HOECHST MARION ROUSSEL","CANADA","CANADA","1","","","Antiarrhythmic","Antiarythmique","",""
"11886","10-11-25","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11887","10-11-25","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticonvulsant / Symptomatic relief of trigeminal neuralgia / Antimanic","Anticonvulsivant / Soulagement de la névralgie du trijumeau / Antimaniaque","",""
"11888","10-11-25","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Expansion of the indication to include adolescents and adults","Extension de l'indication pour inclure les adolescents et les adultes","Central nervous system stimulant for attention deficit hyperactivity disorder","Stimulant du système nerveux central pour le trouble déficitaire de l'attention avec hyperactivité","",""
"11889","10-11-26","CRUCELL SWEDEN AB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"11890","10-11-26","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","Product name change and removal of indication","Modification du nom du produit et suppression de l'indication","Antineoplastic agent","Antinéoplasique","",""
"11891","10-11-26","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Antiepileptic","Antiépileptique","",""
"11892","10-11-26","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"11893","10-11-29","VITA HEALTH PRODUCTS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD AND SINUS PLUS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Analgesic / Nasal decongestant / Antihistamine","Analgésique / Décongestionnant nasal / Antihistaminique","",""
"11894","10-11-30","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision of Indication: Treatment of schizophrenia and related psychotic disorders","Révision de l'indication : Traitement de la schizophrénie et des troubles psychotiques apparentés","Antipsychotic agent","Antipsychotique","",""
"11895","10-12-02","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","The addition of a 75 mg and 100 mg strength","Ajout des concentrations suivantes : 75 mg et 100 mg","Opioid analgesic","Analgésique opioïde","",""
"11896","10-10-20","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Antihemorrhagic blood coagulation factor VIII","Facteur VIII de coagulation antihémorragique","",""
"11897","10-12-02","JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid analgesic","Analgésique opioïde","",""
"11898","10-11-10","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"11899","10-11-10","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"11900","10-12-07","VALEANT CANADA LIMITÉE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antimicrobial and keratolytic","Antimicrobien et kératolytique","",""
"11901","10-12-08","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial agent","Antibactérien","",""
"11902","10-12-08","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antianginal agent","Antiangineux","",""
"11903","10-12-08","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antileukemic","Antileucémique","",""
"11904","10-12-08","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINIVIL / ZESTRIL","MERCK SHARP & DOHME / ZENECA PHARMA","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11905","10-12-08","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINIVIL / ZESTRIL","MERCK SHARP & DOHME / ZENECA PHARMA","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11906","10-12-08","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Elevated intraocular pressure therapy","Thérapie pour réduire la pression intraoculaire","",""
"11907","10-12-08","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent","Antinéoplasique","",""
"11908","10-12-08","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antileukemic agent","Antileucémique","",""
"11909","10-12-08","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11910","10-12-08","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Analgesic","Analgésique","",""
"11911","10-12-08","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN ORTHO INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"11912","10-12-08","SANOFI AVENTIS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical analgesic","Analgésique topique","",""
"11913","10-12-08","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic / Nasal decongestant","Analgésique / Antipyrétique / Décongestionnant nasal","",""
"11914","10-12-08","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINZIDE","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"11915","10-12-08","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic (alkylating) agent","Antinéoplasique (alkylant)","",""
"11916","10-12-08","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic / Nasal decongestant","Analgésique / Antipyrétique / Décongestionnant nasal","",""
"11917","10-12-08","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Nasal decongestant / Antihistamine","Analgésique / Décongestionnant nasal / Antihistaminique","",""
"11918","10-12-08","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic / Nasal decongestant / Antihistamine","Analgésique / Antipyrétique / Décongestionnant nasal / Antihistaminique","",""
"11919","10-12-10","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Nonsteroidal anti-inflammatory drug","Anti-inflammatoire non stéroïdien","",""
"11920","10-12-09","APOTEX INCORPORATED","Y","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11921","10-12-10","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Revised Product Monograph","Monographie de produit révisée","Enzyme replacement therapy","Thérapie de remplacement d'enzymes","",""
"11922","10-12-10","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Analgesic agent","Analgésique","",""
"11923","10-12-10","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Anxiolytic","Antidépresseur / Anxiolytique","",""
"11924","10-12-10","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"11925","10-12-10","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","UNIPHYL","PURDUE PHARMA","CANADA","CANADA","1","","","Bronchodilator","Bronchodilatateur","",""
"11926","10-12-10","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MS CONTIN","PURDUE FREDERICK","CANADA","CANADA","1","","","Opioid analgesic","Analgésique opioïde","",""
"11927","10-12-10","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Aromatase inactivator / Anti-tumour agent","Inactivateur de l'aromatase / Antitumoral","",""
"11928","10-12-13","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAXOL","BRISTOL-MYERS SQUIBB CANADA","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"11929","10-12-13","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC","CANADA","CANADA","1","Update Product Monograph to match the innovator's Product Monograph","Mise à jour de la monographie de produit pour égaler la monographie de produit de l'innovateur	","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11930","10-12-13","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","TAP PHARMACEUTICALS INC","CANADA","CANADA","1","Alternate manufacturing site. Change in manufacturing process","Autre lieu de fabrication. Changement dans le procédé de fabrication","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11931","10-12-15","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Muscle relaxant / Analgesic","Relaxant musculaire / Analgésique","",""
"11932","10-12-16","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Antihypertensive agent / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11933","10-12-16","FRESENIUS KABI ONCOLOGY PLC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Non-steroidal antiandrogen","Antiandrogène non stéroïdien","",""
"11934","10-12-16","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX DF","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT1 receptor agonist; Migraine therapy","Agoniste des récepteurs 5-HT1; Antimigraineux","",""
"11935","10-12-17","EMD CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidote","Antidote","",""
"11936","10-12-17","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","Additional strength","Concentration additionnelle","Antipsychotic agent","Antipsychotique","",""
"11937","10-09-29","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","Change in manufacturing process and release testing procedures","Changement dans la procédure de fabrication et dans la procédure de libération du produit","Diagnostic radiopharmaceutical agent","Agent diagnostique radiopharmaceutique","",""
"11938","10-07-21","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph revised","Monographie de produit révisée","Active immunizing agent","Agent d'immunisation actif","",""
"11939","10-12-20","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"11940","10-03-23","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","Change in the release testing procedures","Changement dans la procédure de libération du produit","Diagnostic radiopharmaceutical agent","Agent diagnostique radiopharmaceutique","",""
"11941","10-03-23","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","Change to manufacturing process","Changement dans la procédure de libération du produit","Diagnostic radiopharmaceutical agent","Agent diagnostique radiopharmaceutique","",""
"11942","10-03-23","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","Change in the release testing procedures","Changement dans la procédure de libération du produit","Diagnostic radiopharmaceutical agent","Agent diagnostique radiopharmaceutique","",""
"11943","10-03-23","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","Change in the release testing procedures","Changement dans la procédure de libération du produit","Diagnostic radiopharmaceutical agent","Agent diagnostique radiopharmaceutique","",""
"11944","10-12-17","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfillment of commitments as per the Letters of Undertaking dated April 1, 2005 and September 18, 2006 for the extended adjuvant treatment  of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy and for the adjuvant treatment  of postmenopausal women with hormone receptor positive early breast cancer, respectively ","La satisfaction des responsabilités conformément aux lettres d’engagement en date du 1er avril 2005 et du 18 septembre 2006 pour le traitement adjuvant prolongé du cancer du sein au stade précoce chez les femmes ménopausées qui ont déjà reçu un traitement adjuvant standard par le tamoxifène et pour le traitement adjuvant des femmes ménopausées atteintes d’un cancer du sein au stade précoce avec récepteurs hormonaux positifs, respectivement","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"11945","10-03-30","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Antineoplastic agent for bladder instillation","Antinéoplasique","",""
"11946","10-12-21","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVANDAMET","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidiabetic agent","Antidiabétique","",""
"11947","10-12-22","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FUROSEMIDE SPECIAL","SANDOZ CANADA INC","CANADA","CANADA","1","","","Diuretic","Diurétique","",""
"11948","10-12-22","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FUROSEMIDE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Diuretic","Diurétique","",""
"11949","10-12-22","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Vascular stabilizer for the treatment of menopausal flushing (0.025 mg tablet) / Antihypertensive (0.1 and 0.2 mg tablets)","Stabilisateur vasculaire pour le traitement des bouffées de chaleur de la ménopause (comprimé de 0.025 mg) / Antihypertenseur (comprimés de 0.1 et 0.2 mg)","",""
"11950","10-12-22","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYTRIN","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","Anti-hypertensive agent / Symptomatic treatment of benign prostatic hyperplasia (BPH)","Antihypertenseur / Traitement symptomatique de l'hypertrophie bénigne de la prostate (HBP)","",""
"11951","10-12-22","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Non-steroidal antiandrogen","Antiandrogène non stéroïdien","",""
"11952","10-12-22","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Immunosuppressive agent","Agent immunosuppresseur","",""
"11953","10-12-22","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"11954","10-12-22","MM THERAPEUTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antipsychotic","Antipsychotique","",""
"11955","10-12-23","SWEDISH ORPHAN BIOVITRUM AB (PUBL)","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Keratinocyte growth factor","Facteur de croissance kératinocyte","",""
"11956","10-12-23","SWEDISH ORPHAN BIOVITRUM AB (PUBL)","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Immunomodulatory agent","Agent d'immunomodulation","",""
"11957","10-12-24","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEVAQUIN","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"11958","10-12-24","COREPHARMA LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antimalarial","Antipaludéen","",""
"11959","10-12-24","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"11960","10-12-29","UNIVERSITY OF OTTAWA HEART INSTITUTE - NATIONAL CARDIAC PET CENTRE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Diagnostic radiopharmaceutical","Agent diagnostique radiopharmaceutique","",""
"11961","10-12-29","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC., CANADA / ALTANA PHARMA AG, GERMANY","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11962","10-12-30","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"11963","10-12-30","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC., CANADA / ALTANA PHARMA AG, GERMANY","CANADA","CANADA","1","","","H+,K+-ATPase inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"11964","10-12-29","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC., CANADA / ALTANA PHARMA AG, GERMANY","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"11965","10-12-24","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product monograph updates","Mises à jour de la monographie de produit","Active immunizing agent","Agent d'immunisation actif","",""
"11966","10-12-31","JUBILANT DRAXIMAGE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Diagnostic","Diagnostique","",""
"11967","10-12-31","JUBILANT DRAXIMAGE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Diagnostic","Diagnostique","",""
"11968","10-12-31","JUBILANT DRAXIMAGE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Therapeutic radiopharmaceutical","Radiopharmaceutique thérapeutique","",""
"11969","10-12-31","JUBILANT DRAXIMAGE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Diagnostic","Diagnostique","",""
"11970","10-12-31","JUBILANT DRAXIMAGE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Radiodiagnostic agent (Myocardial imaging)","Agent radiodiagnostique de l'infarctus myocardique","",""
"11971","10-12-31","JUBILANT DRAXIMAGE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Diagnostic","Diagnostique","",""
"11972","10-12-31","JUBILANT DRAXIMAGE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Agent for the study of pulmonary function and cerebral blood flow","Agent pour l'évaluation de fonction pulmonaire et de débit sanguin cérébral","",""
"11973","11-01-04","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"11974","11-01-04","JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent","Antinéoplasique","",""
"11975","11-01-04","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Antiobsessional agent","Antidépresseur / Antiobsessionnel","",""
"11976","11-01-04","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II receptor (AT1) antagonist","Antagoniste des récepteurs (AT1) de l'angiotensine II","",""
"11977","11-01-04","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiemetic","Antiémétique","",""
"11978","11-01-04","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Gastrointestinal calcium antagonist","Antagoniste calcique gastro-intestinal","",""
"11979","11-01-04","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Androgens","Androgènes","",""
"11980","11-01-04","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-vertigo agent","Antivertige","",""
"11981","11-01-04","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II receptor (AT1) antagonist / Diuretic","Antagoniste des récepteurs (AT1) de l'angiotensine II / Diurétique","",""
"11982","11-01-04","AXCAN PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Helicobacter pylori eradication therapy in conjunction with omeprazole","Traitement d'éradication de l'helicobacter pylori en utilisant parallèlement l'oméprazole","",""
"11983","11-01-04","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strengths: 80 mg and 140 mg tablets","Nouvelles concentrations : comprimés de 80 mg et de 140 mg","Protein-tyrosine kinase inhibitor","Inhibiteur de la protéase-tyrosine kinase","",""
"11984","11-01-04","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor, Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine, Diurétique","",""
"11985","11-01-04","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINZIDE","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor, Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine, Diurétique","",""
"11986","11-01-04","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX CR","BOEHRINGER INGELHEIM CANADA LTD","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","Selective antagonist of alpha 1a/1d adrenoreceptor subtypes in the prostate and bladder","Antagoniste sélectif des sous-types 1a et 1d des récepteurs alpha-adrénergiques des cellules de la prostate et de la vessie","",""
"11987","11-01-04","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AGRYLIN","SHIRE BIOCHEM INC","CANADA","CANADA","1","","","Platelet reducing agent","Réducteur plaquettaire","",""
"11988","10-12-30","ALCON CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Elevated intraocular pressure therapy","Thérapie pour réduire la pression intraoculaire","",""
"11989","10-12-23","PROTHERICS INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Specific antibody for digoxin","Anticorps spécifiques de la digoxine","",""
"11990","11-01-06","CHIESI FARMACEUTICI S P A","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal anti-inflammatory / Analgesic agent","Anti-inflammatoire non stéroïdien / Analgésique","",""
"11991","11-01-06","CENTOCOR ORTHO BIOTECH INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Tumor necrosis factor alpha inhibitor","Inhibiteur du facteur nécrose tumorale alpha","",""
"11992","11-01-10","MERZ PHARMACEUTICALS GMBH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Revised indications","Révisions des indications","Neuromuscular paralytic agent","Agent paralysant du fuseau neuromusculaire","",""
"11993","11-01-06","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in wet granulation equipment for drug product manufacturing and concomitant minor changes to the manufacturing process parameters","Changement au niveau d'équipement de granulation par voie humide pour la fabrication du produit pharmaceutique et modifications concomitantes mineures des paramètres du processus de fabrication","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"11994","11-01-11","WATSON LABORATORIES INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Selective antagonist for alpha1A adrenoreceptor subtype in the prostate and bladder","Antagoniste sélectif des sous-types des récepteurs alpha1A-adrénergiques de la prostate et de la vessie","",""
"11995","11-01-11","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid / Long-acting beta2-agonist","Corticostéroïde / Agoniste bêta2 à action prolongée","",""
"11996","11-01-12","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Thrombopoietin receptor agonist","Agoniste du récepteur thrombopoïèse","",""
"11997","11-01-13","ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihyperglycemic agent","Antihyperglycémiant","",""
"11998","11-01-13","ASTRAZENECA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non steroidal anti-inflammatory drug (NSAID) / H+, K+-ATPase inhibitor","Anti-inflammatoire non stéroïdien (AINS) / Inhibiteur de l'H+, K+-ATPase","",""
"11999","11-01-14","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CAMPTOSAR","PFIZER CANADA INC","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"12000","11-01-14","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"12001","11-01-14","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12002","11-01-14","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","SQUIBB CANADA, DIVISION OF BRISTOL MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12003","11-01-14","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New drug substance manufacturing process","Nouveau processus de fabrication de la substance médicamenteuse","Anti-diabetic agent","Agent antidiabétique","",""
"12004","11-01-17","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"12005","11-01-17","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Vascular stabilizer for the treatment of menopausal flushing (0.025 mg tablet) / Antihypertensive (0.1 and 0.2 mg tablets)","Stabilisateur vasculaire pour le traitement des bouffées de chaleur de la ménopause (comprimé de 0.025 mg) / Antihypertenseur (comprimés de 0.1 et 0.2 mg)","",""
"12006","11-01-18","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Hormone","Hormone","",""
"12007","11-01-18","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiparkinsonian agent","Antiparkinsonien","",""
"12008","11-01-18","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROVERA","THE UPJOHN COMPANY OF CANADA","CANADA","CANADA","1","","","Progestin","Progestatif","",""
"12009","11-01-18","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC.","CANADA","CANADA","1","","","Anti-diabetic agent / Insulin resistance reducing agent","Antidiabétique / Agent réducteur de l'insulinorésistance","",""
"12010","11-01-20","NOVARTIS ANIMAL HEALTH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Manufacturing changes","Changements de fabrication","Antibiotic","Antibiotique","",""
"12011","11-01-19","ORAPHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial periodontal agent","Agent périodontique antibactérien","",""
"12012","11-01-19","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"12013","11-01-19","LABOPHARM INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12014","11-01-20","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","","","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"12015","11-01-20","SUN PHARMA GLOBAL FZE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT1 receptor agonist","Agoniste des récepteurs 5-HT1","",""
"12016","11-01-20","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","Additional strength","Concentration additionnelle","Antipsychotic agent","Antipsychotique","",""
"12017","11-01-20","VITA HEALTH PRODUCTS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ROBAX PLATINUM","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Muscle relaxant / Analgesic","Relaxant musculaire / Analgésique","",""
"12018","11-01-21","ALCON CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-allergy agent","Agent antiallergique","",""
"12019","11-01-21","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LIMITED","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12020","11-01-07","NOVO NORDISK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Anti-diabetic agent","Agent antidiabétique","",""
"12021","11-01-24","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORETIC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antihypertensive agent","Antihypertenseur","",""
"12022","11-01-24","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Modifier of upper gastrointestinal motility","Modificateur de la motilité des voies digestives supérieures","",""
"12023","11-01-24","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiviral agent","Antiviral","",""
"12024","11-01-24","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"12025","11-01-24","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive and anti-anginal agent","Antihypertenseur / Antiangineux","",""
"12026","11-01-24","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenoceptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"12027","11-01-24","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2-receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"12028","11-01-24","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Modifier of upper gastrointestinal motility","Modificateur de la motilité des voies digestives supérieures","",""
"12029","11-01-24","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN","UPJOHN CANADA","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12030","11-01-24","RATIOPHARM INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Antiepileptic","Antiépileptique","",""
"12031","11-01-24","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH AYERST CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic agent","Antiarythmique","",""
"12032","11-01-24","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"12033","11-01-24","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","1) Replacement of 250 mg dose regimen with 500 mg dose regimen. 2) Indication revision: Hormonal treatment of locally advanced or metastatic breast cancer in postmenopausal women, regardless of age, who have disease progression following prior anti-estrogen therapy. ","1) Remplacement du schéma posologique d'une dose de 250 mg à celui d'une dose de 500 mg. 2) Révision de l’indication : Traitement hormonal du cancer du sein localement avancé ou métastatique chez les femmes ménopausées, peu importe leur âge, qui présentent une progression de la maladie après avoir reçu un traitement antioestrogénique.","Nonagonist estrogen receptor antagonist","Antagoniste des récepteurs des oestrogènes non agonistes","",""
"12034","11-01-17","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To extend the use of the once-daily administration of DRV/rtv to early treatment - experienced patients","Extension de l'indication du Darunavir/Ritonavir au traitement en dose unique quotidienne des patients prétraités aux antirétroviraux, spécifiquement à ceux n'ayant pas de mutations DRV ou IP","Human immunodeficiency virus (HIV) protease inhibitor","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH)","",""
"12035","11-01-25","BAYER INC CONSUMER CARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New dosage form: 220 mg capsules","Nouvelle forme posologique : capsule de 220 mg","Non-steroidal anti-inflammatory drug / Analgesic / Antipyretic","Anti-inflammatoire non stéroïdien / Analgésique / Antipyrétique","",""
"12036","11-01-27","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADENOCARD","FUJISAWA CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Antiarrhythmic","Antiarythmique","",""
"12037","11-01-27","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form: solution for injection","Nouvelle forme posologique : solution pour injection","Antihypertensive agent","Antihypertenseur","",""
"12039","11-01-28","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Prevention of exercise-induced bronchospasm in patients four years of age and older","Nouvelle indication : la prévention du bronchospasme induit par l'effort chez les patients de 4 ans et plus","Bronchodilator","Bronchodilatateur","",""
"12040","11-01-31","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph updates","Mises à jour de la monographie de produit","Active immunizing agent","Agent d'immunisation actif","",""
"12041","11-01-27","NOVARTIS VACCINES AND DIAGNOSTICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"12042","11-02-01","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX CR","BOEHRINGER INGELHEIM CANADA LTD","CANADA","CANADA","1","","","Selective antagonist of alpha 1a/1d adrenoreceptor subtypes in the prostate and bladder","Antagoniste sélectif des sous-types de récepteurs alpha 1a/1d-adrénergiques de la prostate et de la vessie","",""
"12043","11-02-03","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA INC","CANADA","CANADA","1","New indication","Nouvelle indication","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12044","11-02-03","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength","Nouvelle concentration","Smoking cessation aid","Aide pour cesser de fumer","",""
"12045","11-02-03","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective norepinephrine reuptake inhibitor for attention-deficit / hyperactivity disorder (ADHD)","Inhibiteur sélectif du recaptage de la noradrénaline pour le trouble déficitaire de l'attention avec hyperactivité (TDAH)","",""
"12046","11-02-07","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS INC.","CANADA","CANADA","1","","","Antiepileptic agent","Antiépileptique","",""
"12047","11-02-07","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS, DIVISION OF WARNER LAMBERT CANADA INC.","CANADA","CANADA","1","","","Antiepileptic agent","Antiépileptique","",""
"12048","11-02-07","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional manufacturer for the manufacturing of medicated minerals using Avatec 20","Fabricant additionnel pour la fabrication de minéraux médicamentés utilisant le Avatec 20","Anticoccidial","Anticoccidien","",""
"12049","11-02-07","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional manufacturer for the manufacturing of medicated minerals using Avatec 20","Fabricant additionnel pour la fabrication de minéraux médicamentés utilisant le Avatec 20","Anticoccidial","Anticoccidien","",""
"12050","11-02-07","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional manufacturer for the manufacturing of medicated minerals using Bovatec 20","Fabricant additionnel pour la fabrication de minéraux médicamentés utilisant le Bovatec 20","Anticoccidial","Anticoccidien","",""
"12051","11-02-07","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional manufacturer for the manufacturing of medicated minerals using Bovatec 20","Fabricant additionnel pour la fabrication de minéraux médicamentés utilisant le Bovatec 20","Anticoccidial","Anticoccidien","",""
"12052","11-02-08","VITA HEALTH PRODUCTS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD + SINUS CAPLETS","WYETH CONSUMER HEALTHCARE INC.","CANADA","CANADA","1","","","Analgesic / Antipyretic / Nasal decongestant","Analgésique / Antipyrétique / Décongestionnant nasal","",""
"12053","11-02-08","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","Congestive heart failure agent","Agent contre l'insuffisance cardiaque congestive","",""
"12054","11-02-10","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Contraceptive vaginal ring","Anneau vaginal contraceptif","",""
"12055","11-02-10","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"12056","11-02-10","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid analgesic","Analgésique opioïde","",""
"12057","11-02-10","ALLERGAN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid","Corticostéroïde","",""
"12058","11-02-10","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"12059","11-02-11","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12060","11-02-11","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"12061","11-02-11","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Smoking cessation aid","Aide pour cesser de fumer","",""
"12062","11-02-10","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ALEVE","BAYER INC CONSUMER CARE DIVISION","CANADA","CANADA","1","","","Non-steroidal anti-inflammatory drug / Analgesic / Antipyretic","Anti-inflammatoire non stéroïdien / Analgésique / Antipyrétique","",""
"12063","11-02-11","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"12064","11-02-11","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antianginal agent","Antiangineux","",""
"12065","11-02-11","LUNDBECK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Antipsychotic agent","Antipsychotique","",""
"12066","11-02-11","PIERREL S.P.A.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","SEPTANEST N AND SEPTANEST SP","SEPTODONT","CANADA","CANADA","1","","","Local anaesthetic for dental use","Anesthésique local pour usage dentaire","",""
"12067","11-02-15","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12068","11-02-15","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal antiandrogen","Antiandrogène non stéroïdien","",""
"12069","11-02-15","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Injectable glucocorticoid","Glucocorticoïde injectable","",""
"12070","11-02-15","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12071","11-02-15","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Androgen","Androgène","",""
"12072","11-02-08","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","1. New strength: 150 mg/vial.  2. Revision to the Dosage and Administration section of the Product Monograph.","1. Nouvelle concentration : 150 mg/fiole. 2. Révision de la section Posologie et administration de la monographie de produit.","Neurokinin 1 (NK1) receptor antagonist","Antagoniste des récepteurs de la neurokinine (NK1)","",""
"12073","11-02-15","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"12074","11-02-16","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12075","11-02-16","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12076","11-02-16","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12077","11-02-16","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12078","11-02-16","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12079","11-02-16","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN-HCT","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12080","11-02-16","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12081","11-02-16","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN-HCT","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12082","11-02-16","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN-HCT","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12083","11-02-16","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Estrogen","Oestrogène","",""
"12084","11-02-16","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent","Antinéoplasique","",""
"12085","11-02-16","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Gonadotropin-releasing hormone (GnRH) antagonist","Antagoniste de l'hormone de libération de la gonatrophine (GnRH)","",""
"12086","11-02-16","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-inflammatory / Analgesic agent","Anti-inflammatoire / Analgésique","",""
"12087","11-02-16","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Diuretic, Antihypertensive Agent","Diurétique, Antihypertenseur","",""
"12088","11-02-16","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC., CANADA / ALTANA PHARMA AG, GERMANY","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"12089","11-02-17","VITA HEALTH PRODUCTS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ASPIRIN 81 MG","BAYER INC.","CANADA","CANADA","1","","","Analgesic / Anti-inflammatory / Antipyretic / Platelet aggregation inhibitor","Analgésique / Anti-inflammatoire / Antipyrétique / Inhibiteur d'agglomération des plaquettes","",""
"12090","11-02-17","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL PLUS CALCIUM","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator / Mineral supplement","Régulateur du métabolisme osseux / Supplément minéral","",""
"12091","11-02-17","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid analgesic","Analgésique opioïde","",""
"12092","11-02-18","ALPHARMA CANADA CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","COXISTAC 12% (DIN 02237631)","PHIBRO ANIMAL HEALTH CORPORATION","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","Manufacturing changes","Changements de fabrication","Anticoccidial","Anticoccidien","",""
"12093","11-02-18","ORION CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional indication","Indication supplémentaire","Sedative / Analgesic","Sédatif / Analgésique","",""
"12094","11-02-18","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic / Antibacterial / Antifungal / Anti-inflammatory","Antiparasitaire / Antibactérien / Antifongique / Anti-inflammatoire","",""
"12095","11-02-18","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"12096","11-02-18","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12097","11-02-18","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral contraceptive","Contraceptif oral","",""
"12098","11-02-18","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid","Corticostéroïde","",""
"12099","11-01-31","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updated dosing information for immunocompromised patients","Posologie révisée pour les patients immunodéficients","Antiviral agent","Antiviral","",""
"12100","11-02-04","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Contraindications, Overdosage and Toxicology sections of the Product Monograph","Révisions des sections Contre-indications, Surdosage et Toxicologie de la monographie de produit","Antiandrogen","Antiandrogène","",""
"12101","11-02-22","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid / Keratolytic","Corticostéroïde topique / Kératolytique","",""
"12102","11-02-24","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic / Antihistamine","Analgésique / Antipyrétique / Antihistaminique","",""
"12103","11-02-24","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic / Beta-lactamase inhibitor","Antibiotique / Inhibiteur de bêta-lactamases","",""
"12104","11-02-25","HOSPIRA HEALTHCARE CORPORATION","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent","Antinéoplasique","",""
"12105","11-02-25","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic / Sedative","Hypnotique / Sédatif","",""
"12106","11-02-25","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid","Corticostéroïde topique","",""
"12107","11-02-25","PHARMA STRIDES CANADA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (antagoniste des récepteurs 5-HT3)","",""
"12108","11-02-25","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antianginal agent","Antiangineux","",""
"12109","11-02-08","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Extension of indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis","Extension de l'indication pour inclure le traitement de la rémission clinique et endoscopique (restauration muqueuse) chez les patients atteints de colite ulcéreuse","Lower gastrointestinal anti-inflammatory","Anti-inflammatoire de la partie basse du tube digestif","",""
"12110","11-02-25","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Muscle relaxant / Analgesic","Relaxant musculaire / Analgésique","",""
"12111","11-02-25","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor / Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine / Diurétique","",""
"12113","11-02-25","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINZIDE","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor / Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine / Diurétique","",""
"12114","11-02-25","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12115","11-02-25","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"12116","11-02-25","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"12117","11-02-25","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXO WELLCOME GMBH & CO","GERMANY","ALLEMAGNE","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (antagoniste des récepteurs 5-HT3)","",""
"12118","11-02-25","PHARMA STRIDES CANADA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LABETALOL HYDROCHLORIDE INJECTION, USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antihypertensive agent","Antihypertenseur","",""
"12119","11-02-25","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTORETIC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor / Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine / Diurétique","",""
"12120","11-02-25","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"12121","11-02-25","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CEFZIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12122","11-02-28","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC","CANADA","CANADA","1","","","Antiepileptic agent","Antiépileptique","",""
"12123","11-02-28","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-hypertensive agent / Anti-anginal agent / Lipid metabolism regulator","Anti-hypertenseur / Antiangineux / Régulateur du métabolisme des lipides","",""
"12124","11-02-28","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hormone replacement therapy","Thérapie hormonale de remplacement","",""
"12125","11-02-16","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: patients with atrial fibrillation","Nouvelle indication : patients souffrant de fibrilation auriculaire","Platelet aggregation inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12126","11-03-02","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New presentation","Nouvelle présentation","Active immunizing agent","Agent d'immunisation actif","",""
"12127","11-03-03","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antifungal agent","Antifongique","",""
"12128","11-03-04","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral hypoglycemic","Hypoglycémiant oral","",""
"12129","11-03-04","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"12130","11-03-04","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2-receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"12131","11-03-07","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-steroidal antiandrogen","Antiandrogène non stéroïdien","",""
"12132","11-03-07","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Platelet aggregation inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12133","11-03-08","COLGATE PALMOLIVE CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Anticaries / Antiplaque / Antigingivitis / Anticalculus","Anticaries / Antiplaque /  Antigingivite / Anticalculs","",""
"12134","11-03-08","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE UK LTD","UNITED KINGDOM","ROYAUME-UNI","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (antagoniste des récepteurs 5-HT3)","",""
"12135","11-03-08","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK SHARP & DOHME CANADA","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"12136","11-03-08","CENTOCOR ORTHO BIOTECH INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouveau site de fabrication","Tumor necrosis factor alpha inhibitor","Inhibiteur du facteur nécrose tumorale alpha","",""
"12137","11-03-08","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New drug substance manufacturing process","Nouveau processus de fabrication de la substance médicamenteuse","Biological response modifier","Agent d'immunomodulation","",""
"12138","11-03-09","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","PLAN B","DURAMED PHARMACEUTICALS INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Emergency contraception","Contraception d'urgence","",""
"12139","11-03-09","CSL BEHRING CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Transfer of manufacturing activities","Transfert d'activités de fabrication","Passive immunization agent","Agent d'immunisation passif","",""
"12140","11-03-11","JANSSEN PHARMACEUTICA N.V.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Serotonin S2 receptor antagonist","Antisérotonine (récepteur S2)","",""
"12141","11-03-11","JANSSEN PHARMACEUTICA N.V.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anticoccidial","Anticoccidien","",""
"12142","11-03-11","JANSSEN PHARMACEUTICA N.V.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antifungal / Antibacterial / Anti-inflammatory","Antifongique / Antibactérien / Anti-inflammatoire","",""
"12143","11-03-11","JANSSEN PHARMACEUTICA N.V.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antifungal","Antifongique","",""
"12144","11-03-11","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication:  As monotherapy for maintenance treatment in patients with locally advanced or metastatic  non-small cell lung cancer with stable disease after 4 cycles of standard platinum-based first-line chemotherapy ","Nouvelle indication : En monothérapie comme traitement d’entretien chez les patients atteints du cancer du poumon non à petites cellules localement  avancé ou métastatique dont l’état pathologique est stable après 4 cycles de chimiothérapie habituelle de première intention à base de platine ","Epidermal growth factor receptor tyrosine kinase inhibitor","Inhibiteur de la tyrosine kinase du récepteur du facteur de croissance épidermique","",""
"12145","11-03-11","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"12146","11-03-11","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMERGE","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Migraine therapy","Antimigraineux","",""
"12147","11-03-11","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON","SERVIER CANADA INC","CANADA","CANADA","1","","","Oral hypoglycemic agent","Hypoglycémiant oral","",""
"12148","11-03-11","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Muscle relaxant / Antispastic agent","Relaxant musculaire / Antispastique","",""
"12149","11-03-11","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Skeletal muscle relaxant","Relaxant des muscles squelettiques","",""
"12150","11-03-11","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiarrhythmic","Antiarythmique","",""
"12151","11-03-11","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"12152","11-03-11","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic / Sedative","Hypnotique / Sédatif","",""
"12153","11-03-14","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph update and change to preparation of infusion solution","Mise à jour de la monographie de produit et changement du mode de préparation de la solution de perfusion","Enzyme replacement therapy","Thérapie de remplacement d'enzymes","",""
"12154","11-03-14","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hyperglycemic agent","Agent hyperglycémiant","",""
"12155","11-03-14","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","BIOVAIL PHARMACEUTICALS","CANADA","CANADA","1","","","Beta-adrenoceptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"12156","11-03-14","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12157","11-03-14","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"12158","11-03-11","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Antineoplastic agent for bladder instillation","Antinéoplasique","",""
"12159","11-03-15","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAQUENIL","SANOFI CANADA INC","CANADA","CANADA","1","","","Anti-rheumatic / Antimalarial","Antirhumatismal / Antipaludéen","",""
"12160","11-03-15","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"12161","11-03-15","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Antiobsessional agent","Antidépresseur / Antiobsessionnel","",""
"12162","11-03-15","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","","","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"12163","11-03-15","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"12164","11-03-15","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PMS-HYDROCHLOROTHIAZIDE","BIOMED 2002 INC","CANADA","CANADA","1","","","Diuretic / Antihypertensive","Diurétique / Antihypertenseur","",""
"12165","11-03-15","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Diuretic / Antihypertensive","Diurétique / Antihypertenseur","",""
"12166","11-03-15","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antianginal agent","Antiangineux","",""
"12167","11-03-15","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"12168","11-03-15","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticholinergic / Antispasmodic agent","Anticholinergique / Antispasmodique","",""
"12169","11-03-17","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antifungal agent","Antifongique","",""
"12170","11-03-17","ALCON CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRUSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Elevated Intraocular pressure therapy / Topical carbonic anhydrase inhibitor","Thérapie pour réduire la pression intraoculaire / Inhibiteur de l'anhydrase carbonique topique","",""
"12171","11-03-17","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12172","11-03-17","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical antifungal and corticosteroid agent","Antifongique et corticostéroïde topique","",""
"12173","11-03-17","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Progestin","Progestatif","",""
"12174","11-03-17","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid","Corticostéroïde topique","",""
"12175","11-03-17","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical antibiotic","Antibiotique topique","",""
"12176","11-03-17","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Safety update to the Product Monograph","Mise à jour de l'innocuité dans la monographie de produit","Type I and II 5-alpha reductase inhibitor","Inhibiteur de type I et II de la 5-alpha réductase","",""
"12177","11-03-17","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic agent","Antiarythmique","",""
"12178","11-03-17","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12179","11-03-18","BAXTER HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Reconstitution in 2ml sterile water","Reconstitution dans 2ml d'eau stérile","Coagulant","Coagulant","",""
"12180","11-03-18","ASTELLAS PHARMA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antifungal","Antifongique","",""
"12181","11-03-18","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Removal of intravenous dosage form","Suppression de la forme posologique intraveineuse","Anticoagulant","Anticoagulant","",""
"12182","11-03-18","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Muscle relaxant / Analgesic","Relaxant musculaire / Analgésique","",""
"12183","11-03-21","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12184","11-03-21","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12185","11-03-21","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12186","11-03-21","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor antagonist","Antagoniste des récepteurs AT1 de l'angiotensine II","",""
"12187","11-03-21","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-SYNTHELABO CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12188","11-03-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Essential Hypertension / Angiotensin II AT1 receptor blocker","Hypertension essentielle / Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12189","11-03-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12190","11-03-21","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12191","11-03-21","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-SYNTHELABO CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12192","11-03-21","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-SYNTHELABO CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12193","11-03-21","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12194","11-03-21","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Cholesterol absorption inhibitor","Inhibiteur de l'absorption du cholestérol","",""
"12195","11-03-21","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Potassium supplement","Supplément potassique","",""
"12196","11-03-21","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"12197","11-03-21","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid","Corticostéroïde","",""
"12198","11-03-21","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Congestive heart failure agent","Agent contre l'insuffisance cardiaque congestive","",""
"12199","11-03-18","GRACEWAY PHARMACEUTICALS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immune response modifier","Modificateur de la réponse immunitaire","",""
"12200","11-03-18","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RIVOTRIL","HOFFMANN-LA ROCHE","CANADA","CANADA","1","","","Anticonvulsant","Anticonvulsivant","",""
"12201","11-03-18","ACCEL PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"12202","11-03-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"12203","11-03-21","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical corticosteroid and antibiotic","Corticostéroïde et antibiotique topique","",""
"12204","11-03-21","GALDERMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Acne therapy","Traitement de l'acné","",""
"12205","11-03-22","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Antiviral agent plus biological response modifier","Antiviral avec agent immunomodulateur","",""
"12206","11-03-22","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph update","Mise à jour de la monographie de produit","Human glucagon like peptide-1 (GLP-1)","Peptide humain apparenté au glucagon 1 (GLP-1)","",""
"12207","11-03-22","SANOFI PASTEUR INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent","Agent d'immunisation actif","",""
"12208","11-03-09","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Sphingosine 1-phosphate receptor modulator","Modulateur du récepteur de la sphingosine 1-phosphate","",""
"12209","11-03-23","ORION CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Alpha2 adrenergic antagonist","Antiadrénergique alpha2 de synthèse","",""
"12210","11-03-23","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Non-depolarizing skeletal neuromuscular blocking agent","Bloqueur neuromusculaire squelettique non dépolarisant","",""
"12211","11-03-23","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid","Corticostéroïde","",""
"12212","11-03-24","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Diuretic / Antihypertensive agent","Diurétique / Antihypertenseur","",""
"12213","11-03-24","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HALOPERIDOL INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"12214","11-03-24","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12215","11-03-24","SEPRACOR PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing site","Nouveau site de fabrication","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12216","11-03-24","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Manufacturing site change","Modification du site de fabrication","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"12217","11-03-03","VIIV HEALTHCARE ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revised dosing instructions for patients with renal impairment based on the result from study A4001075","La modification des instructions sur la posologie chez les patients avec insuffisance rénale basée sur les résultats de l’étude A4001075","CCR5 antagonist","Antagoniste du CCR5","",""
"12218","11-03-25","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antipsychotic agent","Antipsychotique","",""
"12219","11-03-25","SANIS HEALTH INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","New indication","Nouvelle indication","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12220","11-03-25","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","New indication","Nouvelle indication","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12221","11-03-25","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Human gonadotropin","Gonadotrophine humaine","",""
"12222","11-03-28","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"12223","11-03-24","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Biological response modifier","Modificateur de la réponse biologique","",""
"12224","11-03-29","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Register two additional sites for manufacture of starting material","Enregistrement de deux sites additionnels pour fins de fabrication du matériel de départ","Anticoagulant / Antithrombotic","Anticoagulant / Antithrombotique","",""
"12225","11-03-29","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"12226","06-06-29","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","VACCINE","VACCIN","",""
"12227","11-03-30","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARBOPLATIN INJECTION","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"12228","11-03-30","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12229","11-03-31","JANSSEN PHARMACEUTICA N.V.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antifungal","Antifongique","",""
"12230","11-03-31","JANSSEN PHARMACEUTICA N.V.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Sedative, tranquilizer","Sédatif, tranquillisant","",""
"12231","11-03-31","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic / Decongestant","Analgésique / Antipyrétique / Décongestionnant","",""
"12232","11-04-01","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Respiratory antibiotic","Antibiotique respiratoire","",""
"12233","11-04-01","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic agent","Antiarythmique","",""
"12234","11-04-01","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Modifier of upper gastrointestinal motility","Modificateur de la motilité des voies digestives supérieures","",""
"12235","11-04-01","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antipanic / Antiobsessional agent","Antidépresseur / Antipanique / Antiobsessionnel","",""
"12236","11-04-01","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12237","11-04-01","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"12238","11-04-01","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12239","11-04-01","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATORIES FOURNIER S.C.A.","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12240","11-03-31","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication for the maintenance of an antidepressant response for up to 12 months in patients who have shown initial treatment response","Nouvelle indication pour le maintien, jusqu'à 12 mois, d'une réponse antidépressive chez les patients qui ont montré une réponse au traitement initial","Antidepressant / Anxiolytic / Analgesic","Antidépresseur / Anxiolytique / Analgésique","",""
"12241","11-04-04","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C","PHARMACIA & UPJOHN INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12242","11-04-04","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDURA-2","ASTRA PHARMA INC","CANADA","CANADA","1","","","Antihypertensive agent / Symptomatic treatment of benign prostatic hyperplasia (BPH)","Antihypertenseur / Traitement symptomatique de l'hyperplasie bénigne de la prostate (HBP)","",""
"12243","11-04-04","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC","CANADA","CANADA","1","","","Diuretic / Antihypertensive agent","Diurétique / Antihypertenseur","",""
"12244","11-04-04","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Diuretic","Diurétique","",""
"12245","11-04-06","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"12246","11-04-06","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenoceptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"12247","11-04-11","EISAI LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Reactivation of Drug Identification Number (DIN). Updates to the Product Monograph","Réactivation du numéro d'identification d'un médicament (DIN). Mises à jour de la monographie de produit","Antineoplastic","Antinéoplasique","",""
"12248","11-04-11","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Antiobsessional / Antibulimic agent","Antidépresseur / Antiobsessionnel / Antiboulimique","",""
"12249","11-04-11","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-inflammatory agent with analgesic and antipyretic properties","Anti-inflammatoire, analgésique, antipyrétique","",""
"12250","11-04-11","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antianginal / Antiarrhythmic / Antihypertensive agent","Antiangineux / Antiarythmique / Antihypertenseur","",""
"12251","11-04-11","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12252","11-04-11","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"12253","11-04-11","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Monoamine depleting agent","Agent de déplétion des monoamines","",""
"12254","11-04-11","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication for the management of chronic low back pain","Nouvelle indication pour la prise en charge de douleur associée à la lombalgie chronique","Antidepressant / Anxiolytic / Analgesic","Antidépresseur / Anxiolytique / Analgésique","",""
"12255","11-04-12","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVANDIA","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidiabetic agent / Insulin resistance reducing agent","Agent antidiabétique / Agent diminuant la résistance à l'insuline","",""
"12256","11-04-12","GENMED A DIVISION OF PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRAMIL","H LUNDBECK A/S DENMARK","GREAT BRITAIN","GRANDE BRETAGNE","1","","","Antidepressant","Antidépresseur","",""
"12257","11-04-12","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic agent / Social phobia (social anxiety disorder) / Posttraumatic stress disorder therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"12258","11-04-13","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Biological response modifier","Modificateur de la réponse biologique","",""
"12259","11-04-13","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Biological response modifier plus antiviral agent","Modificateur de la réponse biologique plus agent antiviral","",""
"12260","11-04-13","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVANDIA","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidiabetic agent / Insulin resistance reducing agent","Agent antidiabétique / Agent diminuant la résistance à l'insuline","",""
"12261","11-04-13","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVANDIA","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidiabetic agent / Insulin resistance reducing agent","Agent antidiabétique / Agent diminuant la résistance à l'insuline","",""
"12262","11-04-13","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVANDIA","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidiabetic agent / Insulin resistance reducing agent","Agent antidiabétique / Agent diminuant la résistance à l'insuline","",""
"12263","11-04-13","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVANDIA","GLAXOSMITHKLINE INC","CANADA","CANADA","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Antidiabetic agent / Insulin resistance reducing agent","Agent antidiabétique / Agent diminuant la résistance à l'insuline","",""
"12264","11-04-13","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12265","11-04-14","DELAVAL INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiseptic","Antiseptique","",""
"12266","11-04-14","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New indication","Nouvelle indication","Active immunizing agent","Agent d'immunisation actif","",""
"12267","11-04-14","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Anticoagulant / Antithrombotic agent (Heparinoid)","Anticoagulant / Agent antithrombotique (Héparinoïde)","",""
"12268","11-04-14","JUBILANT DRAXIMAGE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Radiopharmaceutical diagnostic imaging agent / Therapeutic radiopharmaceutical agent","Agent radiopharmaceutique pour imagerie diagnostique / Agent radiopharmaceutique pour usage thérapeutique","",""
"12269","11-04-15","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"12270","11-04-15","THE MEDICINES COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive agent","Antihypertenseur","",""
"12271","11-04-15","HOSPIRA HEALTHCARE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Intravenous nutrient supplement","Supplément nutritif intraveineux","",""
"12272","11-04-15","WATSON LABORATORIES INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticholinergic / Antispasmodic","Anticholinergique / Antispasmodique","",""
"12273","11-04-18","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Removal of intravenous injection dosage form","Suppression de l'injection intraveineuse comme forme posologique","Antiemetic","Antiémétique","",""
"12274","11-04-19","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CISPLATIN INJECTION BP","MAYNE PHARMA CANADA INC","CANADA","CANADA","1","","","Antineoplastic agent","Antinéoplasique","",""
"12275","11-04-20","ELANCO DIVISION ELI LILLY CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","REVALOR 200 (DIN 02254026)","INTERVET CANADA CORP.","CANADA","CANADA","1","","","Growth promotant","Augmente le gain pondéral","",""
"12276","11-04-20","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Growth promotant","Augmente le gain pondéral","",""
"12277","11-04-21","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph revised","Monographie de produit révisée","Active immunizing agent","Agent d'immunisation actif","",""
"12278","11-01-13","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Active immunizing agent for the prevention of Influenza","Agent immunisant actif pour la prévention de la grippe","",""
"12279","11-04-21","RANBAXY PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revised Product Monograph","Monographie de produit révisée","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12280","11-04-21","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"12281","11-04-21","COBALT PHARMACEUTICALS COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revised Product Monograph","Monographie de produit révisée","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12282","11-04-21","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"12283","11-04-21","LUNDBECK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Clinical Trials section of the Product Monograph","Modifications apportées à la section des Essais cliniques de la monographie de produit","Antidepressant, Anxiolytic, Antiobsessional","Antidépresseur, Anxiolytique, Antiobsessionnel","",""
"12284","11-04-26","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12285","11-04-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12286","11-04-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC","CANADA","CANADA","1","","","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"12287","11-04-26","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiemetic (5-HT3 receptor antagonist)","Antiémétique (antagoniste des récepteurs 5-HT3)","",""
"12288","11-04-26","TARO PHARMACEUTICALS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ELOCOM CREAM","SCHERING CANADA INC","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","Corticosteroid","Corticostéroïde","",""
"12289","11-04-26","RB PHARMACEUTICALS LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Partial opiate agonist and opiate antagonist","Agoniste des opioïdes et antagoniste des opioïdes partiels","",""
"12290","11-04-27","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","Additional strength","Concentration additionnelle","Antipsychotic agent","Antipsychotique","",""
"12291","11-04-27","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12292","11-04-27","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Anti-diabetic agent / Insulin resistance reducing agent","Antidiabétique / Agent réducteur de l'insulinorésistance","",""
"12293","11-04-27","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent / Antibiotic","Antinéoplasique / Antibiotique","",""
"12294","11-04-27","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA / ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimanic agent","Antipsychotique / Antimaniaque","",""
"12295","11-04-28","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic","Antiparasitaire","",""
"12296","11-04-28","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anesthetic","Anesthésique","",""
"12297","11-04-21","LUNDBECK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Removal of commitments as per the Letter of Undertaking dated October 14, 2004 for the symptomatic treatment of patients with moderate to severe dementia of the Alzheimer's type","Retrait des obligations énoncées dans la lettre d'engagement du 14 octobre 2004 au sujet du traitement symptomatique de la démence de type Alzheimer d'intensité modérée à sévère","N-methyl-D-aspartate (NMDA) receptor antagonist","Antagoniste du récepteur N-méthyl-D-aspartate","",""
"12298","11-05-02","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph: new strength","Révisions à la monographie de produit : nouvelle concentration","Antipsychotic agent","Antipsychotique","",""
"12299","11-05-02","RATIOPHARM INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM CANADA LTD","CANADA","CANADA","1","Revision to the Product Monograph","Révision à la monographie de produit","Selective antagonist of alpha1A adrenoreceptor subtype in the prostate","Antagoniste sélectif des sous-types des récepteurs alpha1A-adrénergiques de la prostate","",""
"12300","11-05-02","TARO PHARMACEUTICALS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEGRETOL SUSPENSION","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","Anticonvulsant / Symptomatic relief of trigeminal neuralgia / Antimanic","Anticonvulsivant / Soulagement de la névralgie du trijumeau / Antimaniaque","",""
"12301","11-05-02","AXCAN PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","Lower gastrointestinal tract anti-inflammatory","Anti-inflammatoire de la partie basse du tube digestif","",""
"12302","11-05-02","AXCAN PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","Lower gastrointestinal tract anti-inflammatory","Anti-inflammatoire de la partie basse du tube digestif","",""
"12303","11-05-02","AXCAN PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","Lower gastrointestinal tract anti-inflammatory","Anti-inflammatoire de la partie basse du tube digestif","",""
"12304","11-05-02","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antimetabolite","Antimétabolite","",""
"12305","11-05-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-SYNTHELABO CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12306","11-05-02","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12307","11-05-03","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Oral hypoglycemic agent","Hypoglycémiant oral","",""
"12308","11-05-02","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","Revision to the Product Monograph","Révision à la monographie de produit","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12309","11-05-02","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing sites","Nouveaux sites de fabrication","Immunomodulator","Immunomodulateur","",""
"12310","11-05-03","BIO AGRI MIX LP","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","LINCOMIX 44 PREMIX (00813559)","PFIZER CANADA INC., ANIMAL HEALTH GROUP","CANADA","CANADA","1","Additional indication","Indication supplémentaire","Antibiotic","Antibiotique","",""
"12311","11-05-04","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","Enzyme replacement therapy","Thérapie de remplacement d'enzymes","",""
"12312","11-05-03","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid","Corticostéroïde","",""
"12313","11-05-05","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Product name change","Modification du nom du produit","Oral antidiarrheal Agent","Antidiarrhéique oral","",""
"12314","11-05-06","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiparkinson agent","Antiparkinsonien","",""
"12315","11-05-05","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","Revision to the Product Monograph","Révision à la monographie de produit","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12316","11-05-06","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN ORTHO INC","CANADA","CANADA","1","","","Antiepileptic / Migraine prophylaxis","Antiépileptique / Prophylaxie de la migraine","",""
"12317","11-05-06","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Diuretic / Antihypertensive","Diurétique / Antihypertenseur","",""
"12318","11-05-06","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form: 400 mg extended-release tablet","Nouvelle forme posologique : comprimé à effet prolongé de 400 mg","Antiretroviral agent / Non-nucleoside reverse transcriptase inhibitor with activity against Human Immunodeficiency Virus type 1 (HIV-1)","Antirétroviral / Inhibiteur non-nucléoside de la reverse transcriptase contre le virus de l'immunodéficience humaine de type 1 (VIH-1)","",""
"12319","11-05-06","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anxiolytic / Sedative","Anxiolytique / Sédatif","",""
"12320","11-05-06","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic agent","Antipsychotique","",""
"12321","11-05-06","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12322","11-05-09","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12323","11-05-09","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12324","10-12-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12325","10-12-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12326","10-12-10","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional purification facility","Addition d'un nouvel emplacement de purification","Active immunizing agent","Agent d'immunisation actif","",""
"12327","11-05-09","BTG INTERNATIONAL INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Specific antibody for digoxin","Anticorps spécifiques de la digoxine","",""
"12328","10-12-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12329","11-05-10","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"12330","11-05-10","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTIVA","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Opioid component to anesthesia","Composant narcotique d'anésthésique","",""
"12331","11-05-10","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12332","11-05-10","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NOROXIN","MERCK SHARP & DOHME CANADA","CANADA","CANADA","1","","","Antibacterial agent","Antibactérien","",""
"12333","11-05-03","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Acute treatment of migraine headache pain in patients 12-17 years of age who have a history of migraine attacks with or without aura usually lasting 4 hours or longer (when untreated)","Nouvelle indication : Traitement aigu de la douleur associée à la migraine chez les patients âgés de 12 à 17 ans ayant déjà subis des crises de migraine avec ou sans aura durant, en général, au moins 4 heures si elles ne sont pas traitées","5-HT1 receptor agonist migraine therapy","Agoniste des récepteurs 5-HT1 antimigraineux","",""
"12334","11-05-10","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Nonsteroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"12335","10-12-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12336","11-05-10","AMGEN CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Human monoclonal antibody to RANKL: Bone metabolism regulator","Anticorps monoclonal humain au ligand RANK : régulateur du métabolisme osseux","",""
"12337","10-12-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12338","11-05-11","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA","CANADA","CANADA","1","Revision to the Product Monograph","Révision de la monographie de produit","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"12339","11-05-11","LABORATOIRE RIVA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Skeletal muscle relaxant","Relaxant des muscles squelettiques","",""
"12340","11-05-11","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12341","11-05-11","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12342","10-12-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12343","11-05-11","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12344","11-05-12","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZEMURON","ORGANON CANADA LTD","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Non-depolarizing skeletal neuromuscular blocking agent","Bloqueur neuromusculaire squelettique non dépolarisant","",""
"12345","11-05-12","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New dosage form","Nouvelle forme posologique","Histamine H1 receptor antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"12346","11-05-13","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Histamine H2 receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"12347","11-05-13","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12348","11-05-13","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12349","11-05-13","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New drug substance manufacturing process","Nouveau processus de fabrication de la substance médicamenteuse","Antidiabetic agent","Agent antidiabétique","",""
"12350","11-05-13","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 receptor blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"12351","11-05-13","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12352","11-05-17","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN-HCT","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","New strengths","Nouvelles concentrations","Angiotensin II AT1 receptor blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"12353","11-05-17","ALEXION PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouveau site de fabrication","Complement inhibitor","Inhibiteur du complément","",""
"12354","11-05-17","STRIDES ARCOLAB LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12355","11-05-17","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph: Drug-drug interaction with proton pump inhibitors","Révisions à la monographie de produit : Interaction médicamenteuse avec les inhibiteurs des pompes à protons","Platelet aggregation inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12356","11-05-17","VITA HEALTH PRODUCTS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL IBUPROFEN CAPLETS, ADVIL EXTRA STRENGTH CAPLETS, ADVIL IBUPROFEN TABLETS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"12357","10-12-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12358","11-05-19","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"12359","10-12-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12360","10-12-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12361","11-05-20","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"12362","11-05-20","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"12363","11-05-20","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bronchodilator","Bronchodilatateur","",""
"12364","10-12-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12365","11-05-24","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXOSMITHKLINE INC","CANADA","CANADA","1","Revisions to the Product Monograph. New product name","Révisions à la monographie de produit. Nouveau nom du produit","Histamine H2 receptor antagonist","Antagoniste des récepteurs H2 de l'histamine","",""
"12366","11-05-25","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","Thyroid stimulating hormone","Hormone thyréotrope","",""
"12367","11-05-25","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","TAP PHARMACEUTICALS INC","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"12368","11-05-24","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Extension to indication to include anal cancer and anal intraepithelial neoplasia (AIN) grades 1, 2, 3","Extension de l'indication pour inclure cancers de l'anus et neoplasies intraépithéliales anales (AIN) de grade 1, 2 et 3","Active immunizing agent","Agent d'immunisation actif","",""
"12369","11-05-27","CSL BEHRING CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Alternate facility for drug substance manufacturing","Installation alternative pour la fabrication de la substance médicamenteuse","Passive immunization agent","Agent d'immunisation passive","",""
"12370","11-05-30","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","For the immunization of adults 50 years of age and older for the prevention of herpes zoster (shingles)","Pour l'immunisation des adultes âgés de 50 ans et plus pour la prévention d'herpes zoster (zona)","Active immunizing agent","Agent d'immunisation actif","",""
"12371","11-05-27","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"12372","11-05-27","JAMP PHARMA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"12373","11-05-30","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX CR","BOEHRINGER INGELHEIM CANADA LTD","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","Selective antagonist of alpha 1a/1d adrenoreceptor subtypes in the prostate and bladder","Antagoniste sélectif des sous-types 1a et 1d des récepteurs alpha-adrénergiques des cellules de la prostate et de la vessie","",""
"12374","11-05-30","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM CANADA LTD","CANADA","CANADA","1","","","Selective antagonist of alpha1A adrenoreceptor subtype in the prostate","Antagoniste sélectif des sous-types des récepteurs alpha1A-adrénergiques de la prostate","",""
"12375","11-05-30","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC","CANADA","CANADA","1","","","Hypnotic / Sedative","Hypnotique / Sédatif","",""
"12376","11-05-30","ASTRAZENECA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Platelet aggregation inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12377","11-05-30","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antifungal agent","Antifongique","",""
"12378","11-05-31","MINT PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"12379","11-05-31","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent","Antinéoplasique","",""
"12380","11-05-31","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-inflammatory / Analgesic agent","Anti-inflammatoire / Analgésique","",""
"12381","11-05-31","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"12382","11-06-01","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Change to withdrawal period","Modification du délai d'attente","Hormone","Hormone","",""
"12383","11-06-01","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Growth promotant","Stimulant de croissance","",""
"12384","11-06-01","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic","Antiparasitaire","",""
"12385","11-05-31","JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form: Aerosol foam. New strength: 50 mg/g (5% w/w)","Nouvelle forme posologique : Aérosol moussant. Nouvelle concentration : 50 mg/g (5% w/w)","Hair regrowth treatment for men","Stimulant pour la pousse des cheveux pour hommes","",""
"12386","11-06-02","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Emergency contraception","Contraception d'urgence","",""
"12387","11-06-02","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"12388","11-06-02","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"12389","11-06-02","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MS CONTIN","PURDUE PHARMA","CANADA","CANADA","1","","","Opioid analgesic","Analgésique opioïde","",""
"12390","11-06-02","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-acne therapy","Traitement antiacné","",""
"12391","11-06-02","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","H. LUNDBECK A/S","UNITED KINGDOM","ROYAUME-UNI","1","","","N-methyl-D-aspartate (NMDA) receptor antagonist","Antagoniste du récepteur N-méthyl-D-aspartate","",""
"12392","11-06-02","NOVARTIS VACCINES AND DIAGNOSTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Active immunizing agent","Agent d'immunisation actif","",""
"12393","11-06-03","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Growth promotant","Stimulant de croissance","",""
"12394","11-06-03","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Growth promotant","Stimulant de croissance","",""
"12395","11-06-03","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Growth promotant","Stimulant de croissance","",""
"12396","11-06-03","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Growth promotant","Stimulant de croissance","",""
"12397","11-06-03","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Analgesic","Analgésique","",""
"12398","11-06-03","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anesthetic","Anesthésique","",""
"12399","11-06-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"12400","11-06-07","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"12401","11-06-07","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG RAPIMELT","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"12402","11-06-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG RAPIMELT","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"12403","11-06-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"12404","11-06-07","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Migraine therapy / 5-HT1 receptor agonist","Antimigraineux / Agoniste des récepteurs 5-HT1","",""
"12405","11-06-07","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG RAPIMELT","ASTRAZENECA CANADA INC","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","Migraine therapy / 5-HT1 receptor agonist","Antimigraineux / Agoniste des récepteurs 5-HT1","",""
"12406","11-06-07","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG RAPIMELT","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"12407","11-06-07","RATIOPHARM INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"12408","11-06-03","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: With norethindrone acetate 5 mg daily is indicated for the initial management of endometriosis and for management of recurrence of symptoms","Nouvelle indication : Avec l’acétate de noréthindrone, une dose quotidienne de 5 mg est indiquée pour le traitement initial d’endométriose et pour le traitement lors de la récurrence de symptômes","Gonadotropin-releasing hormone analog","Analogue de l'hormone de libération de la gonatrophine","",""
"12409","11-06-08","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Elevated intraocular pressure therapy","Thérapie pour réduire la pression intraoculaire","",""
"12410","11-05-05","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of clinical trial data from HIV infected pregnant women. Updates to the Post-Market Data, and the Antiretroviral Pregnancy Registry","Ajout de données obtenues lors d'essais cliniques chez les femmes enceintes infectées par le VIH. Mises-à-jour des données de post-commercialisation et du Registre des Antirétroviraux utilisés durant la grossesse","Azapeptide inhibitor of HIV-1 protease","Inhibiteur azapeptidique de la protéase du VIH-1","",""
"12411","11-05-17","GILEAD SCIENCES CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To fulfill the conditions of the NOC/C and obtain full NOC without Conditions","Pour remplir des conditions inclues dans l'Avis de Conformité avec Conditions et obtenir un Avis de Conformité sans Conditions","Antibiotic","Antibiotique","",""
"12412","11-05-12","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: To use as cotherapy with lithium or divalproex sodium for maintaining clinical improvement for up to 1 year in patients with manic or mixed episodes associated with Bipolar I Disorder","Nouvelle Indication : À utiliser en association avec le lithium ou le divalproex sodique pour le maintien d’une amélioration clinique 			jusqu'à 1 ans chez les patients avec des épisodes maniaques ou mixtes associés aux troubles bipolaires de type I","Antipsychotic","Antipsychotique","",""
"12413","11-06-08","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouveau site de fabrication","Antineoplastic","Antinéoplasique","",""
"12414","11-06-08","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA INC","CANADA","CANADA","1","","","Antidepressant / Anxiolytic","Antidépresseur / Anxiolytique","",""
"12415","11-06-08","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Removal of a dosage form and indication in its entirety (Fludara IV) and removal of package size (Fludara oral tablets 100s)","Le retrait d'une forme posologique et indication dans sa totalité (Fludara IV) et le retrait d'un format d'emballage (Fludara 100 comprimés oraux)","Antineoplastic","Antinéoplasique","",""
"12416","10-12-10","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","Active immunizing agent","Agent d'immunisation actif","",""
"12417","11-06-09","MERIAL CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Change in withdrawal period","Modification du délai d'attente","Gonadotropin-releasing hormone","Hormone de libération de la gonatrophine","",""
"12418","11-06-10","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE HCT","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","Additional strength","Concentration additionnelle","Angiotensin converting enzyme inhibitor / Diuretic","Inhibiteur de l'enzyme de conversion de l'angiotensine / Diurétique","",""
"12419","11-06-10","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC, CANADA / ALTANA PHARMA AG, GERMANY","CANADA","CANADA","1","","","H+, K+-ATPase inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"12420","11-06-10","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral agent / Non-nucleoside reverse transcriptase inhibitor with activity against Human Immunodeficiency Virus type 1 (HIV-1)","Antirétroviral / Inhibiteur non-nucléoside de la reverse transcriptase contre le virus de l'immunodéficience humaine de type 1 (VIH-1)","",""
"12421","11-06-09","JANSSEN PHARMACEUTICA N.V.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Changes in manufacturing","Modifications de la fabrication","Serotonin S2 receptor antagonist","Antisérotonine (récepteur S2)","",""
"12422","11-06-14","GENERIC MEDICAL PARTNERS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"12423","11-06-14","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XATRAL","SANOFI-SYNTHELABO CANADA INC","CANADA","CANADA","1","","","Symptomatic treatment of benign prostatic hyperplasia (BPH) / Adjunctive therapy in acute urinary retention (AUR)","Traitement symptomatique de l'hyperplasie bénigne de la prostate (MBP) / Traitement adjuvant de la rétention urinaire aiguë (RUA)","",""
"12424","11-06-14","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiviral agent","Antiviral","",""
"12425","11-06-14","ALCON CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Visualization agent","Agent de visualisation","",""
"12426","11-06-14","PURE BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Hard surface disinfectant","Désinfectant pour surfaces dures","",""
"12427","11-06-14","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic agent / Social phobia (social anxiety disorder) / Posttraumatic stress disorder therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"12428","11-06-14","MELIAPHARM INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic agent / Social phobia (social anxiety disorder) / Posttraumatic stress disorder therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"12429","11-06-14","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antipanic / Anxiolytic agent / Social phobia (social anxiety disorder) / Posttraumatic stress disorder therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"12430","11-06-14","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Warnings and Precautions section of the Product Monograph","Mise à jour de la section Mises en garde et précautions de la monographie de produit","Antineoplastic agent","Antinéoplasique","",""
"12431","11-06-15","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New dosage form","Nouvelle forme posologique","Antiemetic agent","Antiémétique","",""
"12432","11-06-15","ALLERGAN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical non-steroidal anti-inflammatory agent","Anti-inflammatoire non stéroïdien topique","",""
"12433","11-06-14","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12434","11-06-14","PURE BIOSCIENCE INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Hard surface disinfectant","Désinfectant pour surfaces dures","",""
"12435","11-06-14","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Elevated intraocular pressure therapy","Thérapie pour réduire la pression intraoculaire","",""
"12436","11-06-15","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","Change in formulation and change to the manufacturing process","Modification à la formulation et au procédé de fabrication","Antihypertensive / Antianginal agent","Antihypertenseur / Antiangineux","",""
"12437","11-06-16","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC","CANADA","CANADA","1","","","Congestive heart failure agent","Agent contre l'insuffisance cardiaque congestive","",""
"12438","11-06-16","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic","Antiarythmique","",""
"12439","11-06-16","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","ORGANON CANADA LTD","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"12440","11-06-16","QD PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral antihyperglycemic agent","Antihyperglycémiant oral","",""
"12441","11-06-16","SEPTA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Beta-adrenergic receptor blocking agent","Inhibiteur des récepteurs bêta-adrénergiques","",""
"12442","11-06-16","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"12443","11-06-16","SANOFI AVENTIS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic agent / Taxane","Antinéoplasique / Taxane","",""
"12444","11-06-17","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Change to the manufacturing facility and equipment in addition to a change in the container closure system","Changement à l'usine de fabrication et à l'équipement en plus d'un changement au système récipient-fermeture","Fibrinolytic agent","Agent fibrinolytique","",""
"12445","11-06-17","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Gastro-duodenal cytoprotective agent","Agent cytoprotecteur gastro-duodénal","",""
"12446","11-06-17","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Non-steroidal antiandrogen","Antiandrogène non stéroïdien","",""
"12447","11-06-17","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-inflammatory / Analgesic","Anti-inflammatoire / Analgésique","",""
"12448","11-06-17","VITA HEALTH PRODUCTS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD AND SINUS PLUS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Analgesic / Antipyretic / Nasal decongestant / Antihistamine","Analgésique / Antipyrétique / Décongestionnant nasal / Antihistaminique","",""
"12449","11-06-22","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","Enzyme replacement therapy","Thérapie de remplacement d'enzymes","",""
"12450","11-06-22","INTERVET CANADA CORP","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Change in withdrawal period","Modification du délai d'attente","",""
"12451","11-06-22","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Immunological","Immunologique","",""
"12452","11-06-23","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New information on concomitant use of DETROL LA with alpha-blockers","Nouveau renseignements sur l'utilisation concomitante de DETROL LA avec des alphabloquants","Anticholinergic / Antispasmodic Agent","Anticholinergique / Antispasmodique","",""
"12453","11-06-22","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength: 150mg capsule New indication: For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (PH+CML) in chronic phase","Nouvelle force: capsule de 150mg Nouvelle indication: pour le traitement des patients adultes porteurs du chromosome Philadelphie qui ont récemment reçu un diagnostic de leucémie myéloïde chronique (PH+LMC) en phase chronique","Protein-tyrosine kinase inhibitor","Inhibiteur de la protéase-tyrosine kinase","",""
"12454","11-06-22","EISAI LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiepileptic","Antiépileptique","",""
"12455","11-06-22","JAMP PHARMA CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Modifier of upper gastrointestinal motility","Modificateur de la motilité des voies digestives supérieures","",""
"12456","11-06-22","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"12457","11-06-24","CENTOCOR ORTHO BIOTECH INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the product monograph","Mise à jour à la monograpie de produit","Tumor necrosis factor alpha inhibitor","Inhibiteur du facteur nécrose tumorale alpha","",""
"12458","11-06-27","HUVEPHARMA AD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","DENAGARD LIQUID CONCENTRATE","NOVARTIS ANIMAL HEALTH CANADA INC.","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12459","11-06-27","HUVEPHARMA AD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","PULMOTIL PREMIX","ELANCO, DIVISION ELI LILLY CANADA INC.","CANADA","CANADA","1","Manufacturing change(s)","Modification(s) de la fabrication","Antibacterial","Antibactérien","",""
"12460","11-06-24","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","Revisions to the product monograph","Révisions à la monographie de produit","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"12461","11-06-24","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC.","CANADA","CANADA","1","Revisions to the product monograph","Révisions à la monographie de produit","Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"12462","11-06-23","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCONORM","NOVO NORDISK CANADA INC.","CANADA","CANADA","1","","","Oral antidiabetic agent","Antidiabétique oral","",""
"12463","11-06-28","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Aldosterone antagonist","Antagoniste de l'aldostérone","",""
"12464","11-06-28","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Aldosterone antagonist with a diuretic","Antagoniste de l'aldostérone avec un diurétique","",""
"12465","11-06-28","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC.","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","iNHIBITEUR DE L'H+, K+-ATPASE","",""
"12466","11-06-28","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIOLID","SYNTEX INC.","CANADA","CANADA","1","","","Inhibitor of platelet function","Agent antiplaquettaire","",""
"12467","11-06-28","PHARMA STRIDES CANADA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","","","ANTIBIOTIC / ß-LACTAMASE INHIBITOR","ANTIBIOTIQUE / INHIBITEUR DE ß-LACTAMASES","",""
"12468","11-06-30","ROUGIER PHARMA, DIVISION OF TEVA CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","AERIUS","SCHERING-PLOUGH CANADA INC.","CANADA","CANADA","1","","","Histamine H1-Receptor Antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"12469","11-06-30","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: For the treatment of patients with unresectable locally advanced or metastic, well differentiated pancreatic neuroendocrine tumours (pancreatic NET), whose disease is progressive","Nouvelle indication : pour le traitement de patients atteints de tumeurs neuroendocriniennes du pancréas (TNE du pancréas) inopérables et bien différenciées, localement avancées ou métastatiques, dont la maladie est évolutive","Tyrosine kinase inhibitor / Anti-tumour agent","Inhibiteur de la tyrosine kinase / Antinéoplasique","",""
"12470","11-06-28","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX / IMITREX DF","GLAXOSMITHKLINE INC.","CANADA","CANADA","1","","","5-HT1 Receptor agonist / Migraine therapy","Agoniste des récepteurs 5-HT1 / Antimigraineux","",""
"12471","11-06-30","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New potency assay","Nouvel essai de détermination de l'activité","Neuromuscular paralytic agent","Agent neuromusculaire paralysant","",""
"12472","11-06-30","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New potency assay","Nouvel essai de détermination de l'activité","Neuromuscular paralytic agent","Agent neuromusculaire paralysant","",""
"12473","11-07-05","EUSA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Radiodiagnostic agent / Tumor imaging agent","Agent radiodiagnostique / Agent d'imagerie de tumeur","",""
"12474","11-06-30","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Clinical Trials and Warnings and Precautions sections of the Product Monograph based on the CONDOR study results","Les modifications apportées aux essais cliniques et aux articles de mises en garde et précautions de la monographie du produit, fondées sur les résultats de l'étude CONDOR","Non-steroidal anti-inflammatory drug (NSAID)","Anti-inflammatoire non stéroïdien (AINS)","",""
"12475","11-06-30","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Removal of progestogen and antineoplatic indications due to the discontinuation of tablet presentation from the Product Monograph","Le retrait des indications progestogène et antinéoplasique en vue de l'abandon de la présentation de comprimés de la monographie du produit","Antianorexic, Anticachectic","Antianorexique, Anticachexique","",""
"12476","11-06-30","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: For the treatment of patients 3 years of age or older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) that have demonstrated serial growth, who are not candidates for surgical resection and for whom immediate surgical intervention is not required, at a starting dose of 2.5mg, 5mg or 7.5mg once per day","Nouvelle indication : pour les patients âgés de 3 ans ou plus atteints de l'astrocytome sous-épendymaire à cellules géantes liées à la sclérose tubéreuse de Bourneville, qui ont subi une croissance consécutive, et qui ne sont pas admissibles à la résection chirurgicale et qui ne nécessitent pas une intervention chirurgicale immédiate, le traitement sera une dose initiale de 2,5mg, 5mg ou 7,5mg, une fois par jour","Antineoplastic agent (mTOR kinase inhibitor)","Antinéoplasique (Inhibiteur de la mTOR kinase)","",""
"12477","11-07-11","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product monograph revised","Monographie du produit révisée","Active immunizing agent","Agent d'immunisation actif","",""
"12478","11-07-11","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product monograph revised","Monographie du produit révisée","Active immunizing agent","Agent d'immunisation actif","",""
"12479","11-07-11","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New indication: single-agent maintenance treatment of previously untreated patients with advanced follicular non-Hodgkin's lymphoma with high tumour burden and who have responded to induction therapy with either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus rituximab or CVP (cyclophosphamide, vincristine and prednisolone) plus rituximab","Nouvelle indication : monothérapie d'entretien des patients atteints d'un lymphome non hodgkinien folliculaire avancé non traité auparavant qui ont une forte charge tumorale et qui ont répondu à un traitement d'induction soit par CHOP (cyclophosphamide, doxorubicine, vincristine et prednisone) plus rituximab our par CVP (cyclosphosphamide, vincristine et prednisolone) plus rituximab","Antineoplastic","Antinéoplasique","",""
"12480","11-07-11","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC.","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"12481","11-07-07","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength","Nouvelle concentration","Human immunodeficiency virus (HIV) protease inhibitor","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH)","",""
"12482","11-07-06","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Immunosuppressant","Immunosuppresseur","",""
"12483","11-07-05","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin-converting enzyme inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"12484","11-07-05","ACTAVIS GROUP PTC EHF","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN ORTHO INC.","CANADA","CANADA","1","","","Opioid analgesic","Analgésique opioïde","",""
"12485","11-06-27","CENTOCOR ORTHO BIOTECH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Monoclonal antiplatelet antibody","Anticorps monoclonal antiplaquettaire","",""
"12486","11-06-21","NOVARTIS VACCINES AND DIAGNOSTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Extension to indication to include children aged 2 to 10 years","Extension de l'indication aux enfants âgés de 2 à 10 ans","Active immunizing agent","Agent d'immunisation actif","",""
"12487","11-07-11","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","Revision of the product monograph Addition of a new indication","Révision à la monographie de produit Ajout d'une nouvelle indication","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"12488","11-07-13","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the product monograph","Mise à jour à la monographie de produit","Immunomodulator","Immunomodulateur","",""
"12489","11-07-06","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial (Ophthalmic)","Antibiotique (Ophtalmique)","",""
"12490","11-07-14","ACCORD HEALTHCARE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC.","CANADA","CANADA","1","New strength","Nouvelle concentration","Antineoplastic Agent","Antinéoplasique","",""
"12491","11-07-12","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD.","CANADA","CANADA","1","","","Antiparkinsonian agent / Dopamine agonist","Antiparkinsonien / Agoniste dopaminergique","",""
"12492","11-07-14","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: For the treatment of patients with metastatic liposarcoma or leiomyosarcoma after failure of prior anthracycline and ifosfamide chemotherapy","Nouvelle indication : pour le traitement des patients souffrant d'un liposarcome métastatique ou d'un léiomyosarcome après l'échec d'une chimiothérapie antérieure par anthracycline et ifosfamide","Antineoplastic Agent","Antinéoplasique","",""
"12493","11-07-15","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of a manufacturing site","Lieu de fabrication additionnel","Estrogen","Oestrogène","",""
"12494","11-07-18","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST & CIE, MERCK FROSST CANADA & CO","CANADA","CANADA","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"12495","11-07-19","BRISTOL MYERS SQUIBB CANADA","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: For the Treatment of adults with newly diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML) in Chronic Phase","Nouvelle Indication: Pour Traiter des Adultes Chez qui on Vient de Diagnostiquer une Leucémie myéloïde Chronique (LMC) et qui son Porteurs du Chromosome de Philadelphie (Ph+)","Protein-tyrosine Kinase Inhibitor","Inhibiteur de la protéase-tyrosine kinase","",""
"12496","11-07-27","WARNER CHILCOTT CANADA CO","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Dosage Form: Delayed-Release Tablet","Nouvelle forme posologique: Comprimés à libération progressive,","Bone Metabolism Regulator","Régulateur du métabolisme osseux","",""
"12497","11-07-19","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Topical Antifungal Agent","ANTIFONGIQUE","",""
"12498","11-07-19","MEDA AB","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic Agent","Agent Hypnotique","",""
"12499","11-07-20","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic / Antipyretic","Analgésique / Antipyrétique","",""
"12500","11-07-27","ALCON CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-inflammatory Analgeic Agent","ANTI-INFLAMMATOIRE / ANALGÉSIQUE","",""
"12501","11-07-20","PRO DOC LIMITÉE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Nonsteroidal Anti-Inflammatory Drug (NSAID)","Anti-inflammatoire non stéroïdien","",""
"12502","11-07-21","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the Product Monograph","Mise à jour de la Monographie du Produit","Biological Response Modifier","Agent d'Immunomodulation","",""
"12503","11-07-21","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing process","Nouveau processus de fabrication","Interleukin Receptor Inhibitor","Inhibiteur du récepteur de l'interleukine","",""
"12504","11-07-22","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","TAP PHARMACEUTICALS INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"12505","11-07-27","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","Revisions to the Product Monograph - New Strength","Révisions à la monographie de produit - Nouvelle Concentration","Antidepressant","Antidépresseur","",""
"12506","11-07-19","HEALTHPOINT CANADA ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Manufacturing Site","Nouveau Site de Fabrication","Enzymic Debriding Agent","Agent de Débridement Enzymatique","",""
"12507","11-07-29","GENZYME CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Hematopoietic Growth Factor","Facteur de croissance hématopoïétique","",""
"12508","11-07-29","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouveau site de fabrication","Growth hormone receptor antagonist","Antagoniste du récepteur de l'hormone de croissance","",""
"12509","11-07-29","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","Human gonadotropin","Gonadotrophine humaine","",""
"12510","11-08-02","MERZ PHARMACEUTICALS GMBH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of new manufacturing facility, addition of a dosage form or change in the formulation","Ajout d'un établissement responsable de la fabrication, ajout d'une forme posologique ou un changement à la formulation","Neuromuscular paralytic agent","Agent paralysant du fuseau neuromusculaire","",""
"12511","11-07-28","OTSUKA PHARMACEUTICAL CO. LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Indications, Drug-Drug Interactions, Adverse Reactions, Clinical Trials and Bibliography sections of the Product Monograph","Mises à jour aux indications, interactions médicament - médicament, effets indésirables, essais clinique et sections de la bibliographie de la monographie du produit","Antineoplastic","Antinéoplasique","",""
"12512","11-07-27","AXCAN PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph","Révisions à la monographie de produit","Cholestatic liver diseases","Maladies hépatiques cholestatiques","",""
"12513","11-07-13","CSL BEHRING CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Passive Immunizing Agent","Agent d'immunisation passif","",""
"12514","11-07-26","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC.","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12515","11-07-25","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"12516","11-07-25","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: Lucentis (ranibizumab) is indicated for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO)","Nouvelle indication : Lucentis (ranibizumab) est indiqué pour le traitement de la déficience visuelle due à un cedème maculair secondaire à une occlusion veineuse rétinienne (OVR)","Anti-neovascularisation agent","Agent anti-nèovascularisation","",""
"12517","11-07-29","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Manufacturing Facility","Nouvel Emplacement de Fabrication","Replacement Therapy for Immunodeficiencies","Thérapie pour Patient Attaint d'Immounodéficience","",""
"12518","11-07-28","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral Antihyperglycemic Agent: DPP-4 Inhibitor: Incretin Enhancer","Antihyperglycémiant oral / Inhibiteur DPP-4 / Renforceur d'incrétin","",""
"12519","11-07-27","JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Androgen Biosynthesis Inhibitor","Inhibiteur de la biosynthèse androgénique","",""
"12520","11-08-08","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REACTINE","MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC","CANADA","CANADA","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Histamin H1 Receptor Antagonist","Antagoniste des récepteurs H1 de l'histamine","",""
"12521","11-08-05","JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Tumour Necrosis Factor Alpha Inhibitor","Inhibiteur du Facteur Nécrose Tumorale Alpha","",""
"12522","11-08-05","JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Biological Response Modifier","Agent d'Immunomodulation","",""
"12523","11-08-05","BIO AGRI MIX LP","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","POT-PEN","VÉTOQUINOL N.-A. INC","CANADA","CANADA","1","Additional Claim","Indication Supplémentaire","Antiiotic","Antibiotique","",""
"12524","11-08-05","PERRIGO INTERNATIONAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","PLAN B","DURAMED PHARMACEUTICALS INC, A SUBSIDIARY OF BARR PHARMACEUTICALS INC","CANADA","CANADA","1","","","Emergency Contraception","Contraceptif d'urgence","",""
"12525","11-08-05","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph to Include 500 mg/Vial, 1 g/Vial and 2 g/Vial with Reactivated Drug Identification Numbers","Mettre à Jour la Monographie Pour Inclure 500 mg/Flacon, 1 g/Flacon et 2 g/Flacon avec les Identifications Numériques aux Médicaments Réactivées","Antileukemic Agent","Antileucémique","",""
"12526","11-08-05","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Manufacturing Facility","nouveau Site de Fabrication","Selective Immunomodulating Agent","Agent Immunomodulateur Sélectif","",""
"12527","11-08-03","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker, Diuretic","Bloqueur des récepteurs AT1 de l'Angiotensine II, Diurétique","",""
"12528","11-08-03","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOVIRAX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiviral Agent","Antiviral","",""
"12529","11-08-03","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 Receptor Blocker / Clacium Channel Blocker","Antagoniste des Récepteurs AT1 de l'Angiotensine II / Bloqueurs des Canaux calciques","",""
"12530","11-08-02","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du métabolisme osseux","",""
"12531","11-08-02","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidepressant, Antiobsessional, Antipanic, Anxiolytic Agent, SOcial Phobia (Social Anxiety Disiorder), Posttraumatic Stress Disorder Therapy","ANTIDÉPRESSEUR, ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIAL","",""
"12532","11-08-02","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL M-TAB","JANSSEN-ORTHO INC","CANADA","CANADA","1","New Strengths; Revisions to the Product Monograph","Nouvelle Concentrations; Révisions à la Monographie de Produit","Antipsychotic Agent","Antipsychotique","",""
"12533","11-08-02","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CORPORATION","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Non-Steroidal Aromatase Inhibitor; Inhibitor of Estrogen Biosynthesis; Antitumour Agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"12534","11-08-02","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERON","NV ORGANON OSS","NETHERLANDS","PAYS-BAS","1","","","Antidepressant","Antidépresseur","",""
"12535","11-07-29","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hepatitis C Virus (HCV) Protease Inhibitor","Inhibiteur de la protéase du virus de l'Hépatite C","",""
"12536","11-07-25","OTSUKA PHARMACEUTICAL CO. LTD.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Vasopressin V2-Receptor Antagonist","Antagoniste des récepteurs Vasopressin V2","",""
"12537","11-08-09","TRITON PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Indications and Clinical Use and the Dosage and Administration Sections of the Product Monograph","Révisions des Directives et de l'Utilisation Clinique, ainsi que les Sections sur la Posologie et l'Administration de la Monographie de Produit","Estrogen","Oestrogène","",""
"12538","11-08-10","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiviral Agent","Antiviral","",""
"12539","11-08-08","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic","Antipsychotique","",""
"12540","11-08-03","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-SYNTHELABO CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Bloqueur des récepteurs AT1 de l'angiotensine II","",""
"12541","11-08-15","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Antihypertensive Agent - Antianginal Agent","Antihypertenseur - Antiangineux","",""
"12542","11-08-16","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph Revised","Monographie du Produit Révisée","Active Immunizing Agent","Agent d'Immunisation Actif","",""
"12543","11-08-16","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLEXERIL","MERCK FROSST CANADA INC","CANADA","CANADA","1","","","Skeletal Muscle Relaxant","MYORELAXANT","",""
"12544","11-08-16","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL MYERS SQUIBB CANADA","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"12545","11-08-16","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSENN-ORTHO INC","CANADA","CANADA","1","","","Antiepileptic / Migraine Prophylaxis","Antiépileptique / Prophylaxie de la Migraine","",""
"12546","11-08-16","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC","CANADA","CANADA","1","","","Congestive Heart Failure Agent","AGENT POUR L'INSUFFISANCE CARDIAQUE CONGESTIVE","",""
"12547","11-08-16","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Muscle Relaxant / Antispastic Agent","Relaxant musculaire / Antispasmodique","",""
"12548","11-08-16","THREE RIVERS PHARMACEUTICALS LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Manufacturing Facility","Nouveau Site de Fabrication","Biological Response Modifier","Modificateur de la Réponse Biologique","",""
"12549","11-08-16","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Preservative Free Formulation","Preparation sans Agent de Conservation","Active Immunizing Agent","Agent d'Immunisation Actif","",""
"12550","11-08-16","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Preservative Free Formulation","Preparation sans Agent de Conservation","Active Immunizing Agenr","Agent d'Immunisation Actif","",""
"12551","11-08-15","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Type I and II Alpha-Reductase Inhibitor (Dutasteride) and Alpha-Adrenoreceptor Antagonist (Tamsulosin Hydrochloride)","Inhibitor Alpha-Réductase de Type I et II (Dutastéride) et Adréno-Récepteur Antagoniste (Chlorhydrate de Tamsulosine)","",""
"12552","11-08-12","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"12553","11-08-12","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypothyroidism Therapy","TRAITEMENT DE L'HYPOTHYROÏDIE","",""
"12554","11-08-11","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","Product Name Change","Modification du nom du produit","Type II 5 Alpha-Redutcase Inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"12555","11-08-11","MERUS LABS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"12556","11-08-11","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin Converting Enzyme Inhibiter","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"12557","11-08-11","RATIOPHARM INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","Removal of Commitments as per the letter of Undertaking dated August 12, 2009 for the Symptomatic Treatment of Patients with Moderate to Severe Dementia of the Alzheimer's Type.","Retrait des obligations énoncées dans la lettre d'engagement du 12 Août 2009 au sujet du traitement symptomatique de la démence de type Alzheimer d'intensité modérée à sévère","N-Methyl-D-Aspartate (NMDA) Receptor Antagonist","Antagoniste du récepteur N-méthyl-D-aspartate","",""
"12558","11-08-11","VALEO PHARMA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STERILE VANCOMYCIN HYDROCHLORIDE USP","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","Product Name Change","Modification du nom du produit","Antibiotic","Antibiotique","",""
"12559","11-08-08","MELIAPHARM INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"12560","11-08-11","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Revisions to Product Monograph - Change in Age Indication - Update to Immunogenicity and Safety Data","Modifications à la Monographie du Produit - Changement à l'Indication de L'àge - Mise à Jour de Donnàes d'Immunogénicité et de Sécurité","Active Immunizing Agent","Agent d'immunisation actif","",""
"12561","11-08-10","EMD SERONO A DIVISION OF EMD INC CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Presentation","Nouvelle Présentation","Gonadotropin","Gonadotropine","",""
"12562","11-08-03","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiemetic (5-HT3) Receptor Antagonist","ANTIÉMÉTIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"12563","11-08-03","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EVISTA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective Estrogen Reeptor Modulator","MODULATEUR SÉLECTIF DES RÉCEPTEURS ESTROGÉNIQUES","",""
"12564","11-08-18","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfillment of Commitment #1 as per the Letter of Undertaking dated July 10, 2008 for the treatment of accelerated phase Philadelphia chromosome positive myelogenous leukemia (CML) in adult patients resistant to or tolerant of at least one prior therapy including imatinib; and other revisions to the Product Monograph.  Fulfillment of Commitments as per the Letters of Undertaking dated July 10, 2008 and June 21, 2010 for the treatment of chronic phase Phiadelphia chromosome positive chronic myelogenous leukemia (CML) in patients resistant to or intolerant of at least one prior therapy including imatinib.","Le respect de l'engagement # 1 conformemément à la lettre d'engagement du 10 juillet 2008 relative au traitment de la leucémie myéloïde chronique (LMC) avec chromosome Philadelphie positive en phase accélérée (PA) chez les patients adultes résistants ou intolérants à au moins un traitement antérieur inculant l'imatinib; et autres révisions de la monographie de produits.  Le respect des engagements conformément aux lettres d'engagement du 10 juillet 2008 et du 21 juin 2010 relatives au traitment de la leucémie myéloïde chronique (LMC) à chromosome Philadelphie positive en phasee accélérée (PA) chez les patients adultes résistants ou intolérants à au moins un traitment antérieur incluant l'imatinib.","Protein-tyrosine Kinase Inhibitor","Inhibiteur de la protéase-tyrosine kinase","",""
"12565","11-08-16","ACCORD HEALTHCARE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Non-steroidal Aromatase Inhibitor; Inhibitor of Estrogen Biosynthesis; Anti-Tumour Agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"12566","11-08-15","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressanat / Antipanic / Antiobsessional Agent","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONNEL","",""
"12567","11-08-15","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant / Antiobsessional / Antibulimic","ANTIDÉPRESSEUR/ANTIOBSESSIONNEL/ANTIBOULIMIQUE","",""
"12568","11-08-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XALATAN","PFIZER CANADA INC","CANADA","CANADA","1","","","Prostaglandin F2alpha Analogue","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA","",""
"12569","11-07-21","JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Human Immunodeficiency Virus (HIV) Non-nNucleoside Reverse Transcriptasee Inhibitor","Inhibiteur non nucléosidique de la transcriptase inverse","",""
"12571","11-08-23","BIMEDA MTC ANIMAL HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","POT PEN","VÉTOQUINOL N.-A. INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12573","11-08-18","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Cyclic GMP-Specific Phosphodiesterase Type 5 Inhibitor","Inhibiteur de la phosphodiestérase de type 5 spécifique de la GMPC","",""
"12574","11-08-22","ANGITA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-Adrenergic Receptor Blocking Agent","Inhibiteur des Récepteurs Béta-adrénergigues","",""
"12575","11-08-22","ANGITA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive - Antianginal Agent","Antihypertenseur - Antiangineux","",""
"12576","11-08-22","ANGITA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"12578","11-08-25","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additiona of Multi-Dose Vials Containing Benzyl-Alcohol and updating Relevant Sections of the Product Monograph","Ajout de Flacons Multidoses Contenant de l'Alcool Benzylique et mise à Jour des Sections Pertinentes à la mOnographie de Produit","Uroprotector","Uroprotecteur","",""
"12579","11-08-25","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XALATAN","PHARMACIA & UPKOHN INC","CANADA","CANADA","1","","","Prostaglandin F2Alpha Analogue","Ananlogue de la Prostaglandine F2Alpha","",""
"12580","11-08-24","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"12581","11-08-22","ANGITA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiemetic (5-HT3 Receptor Antagonist)","Antiémétique (Antagoniste des Récepteurs 5-HT3)","",""
"12582","11-08-16","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph","Mise à Jour de la Monographie de Produit","Contrast Enhancement Agent for Magnetic Resonance Imaging (MRI)","Produit de contraste pour l'imagerie par résonance magnétique (IRM)","",""
"12583","11-08-22","PURDUE PHARMA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid Analgesic","Analgésique Opioïdes","",""
"12584","11-08-31","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","Extension of the Ulcerative Colitis Indication to the Pediatric Population:  Reproduction of signs and symptoms, induction and maintenance of c linical remission, and induction of mucosal healing in pediatric patients with moderate to severely active ulcerative colitis who have had an inadequate response to conventional therapy (i.e. aminosalicylate and/or corticosteroid and/or an immunosuppressant). The safety and efficacy of Remicade have not been established in patients less than 6 years of age.","Ajout à l'Indication de la Colite Ulcéreuse pour Inclure la Population Pédiatrique:  Pour la réduction des signes et des symptômes des poussées évolutives des formes modérées à graves de la colite ulcéreuse, ainsi que pour l'induction et le maintien de la rémission clinique et l'induction de la guérison de la muqueuse chez les enfants dont la réponse au traitment standard (c. à-d. aminosalicylate et (ou) corticostéroïde et (ou) immunosuppresseur n'est pas satisfaisante. Chez L'enfant de moins 6 ans, l'innocuité et l'efficacité de Remicade n'ont pas été démonstratrées.","Biological Response Modifier","Agent d'Immunomodulation","",""
"12585","11-08-31","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Manufacturing Facility","Nouvelle Emplacement de Fabrication","Interleukin Receptor Inhibitor","Inhibiteur du récepteur de l'interleukine","",""
"12586","11-08-30","DELAVAL INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiseptic","Antiseptique","",""
"12587","11-08-29","JAMP PHARMA CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","New Strength","Nouvelle concentration","Antidepressant","Antidépresseur","",""
"12588","11-08-29","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"12589","11-08-26","BAYER INC CONSUMER CARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic, Antipyretic","Analgésique, Antipyrétique","",""
"12590","11-08-31","MINT PHARMACEUTICALS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","New Strength","Nouvelle Concentration","Antidepressant","Antidépresseur","",""
"12591","11-08-31","NT PHARMA CANADA LTD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMERGIL SOLTAB","ORGANON GMBH","GERMANY","ALLEMAGNE","1","New Dosage Form - Orally Disintegrating Tablets","Nouvelle forme posologique - Comprimés à Désintégration Orale","Antidepressant","Antidépresseur","",""
"12592","11-08-31","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"12593","11-09-02","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Warnings and Precautions, Dosage and ADministration, and the Action and Clinical Pharmacology Sections of the Product Monograph","Mise à Jour de la Section Mises en Garde et Précautions, de la Section Posologie et Administration, et de la Section Action et Pharmacologie Clinique, de la Monographie de Prodcuit","Antineoplastic Agent","Antinéoplastique","",""
"12594","11-08-31","AA PHARMA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SIBELIUM","JANSSEN PHARMACEUTICA","CANADA","CANADA","1","Change in Drug Manufacturing Process","Changement dans le procédé de fabrication du Produit","Selective Calcium-Entry Blocker","INHIBITEUR CALCIQUE SÉLECTIF","",""
"12595","11-09-01","MERCK FROSST CANADA LTD MERCK FROSST CANADA LTÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: In Combination with a Sulfonylurea (i.e, Triple Combination Therapy) as an Adjuct to Diet and Exercise to Improve Glycemic Control in Adult Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and a Sulfonylurea.","Nouvelle Indication: En Association avec une Sulfonylurée (c'est-à-dir une Trithérapie) Comme un Médicament d'appoint à l'Alimentation et à l'Exercise pour Amliorer le Contrôle Glycémique Chez de Patients ADultes dont le Diabète de Type 2 est Insuffisamment Maîtrise avec la Metformine et une Sulfonylurée.","Oral Antihyperglycemic Agent / DPP-4 Inhibitor / Incretin Enhancer","Agent oral d'antihyperglycémic; inhibiteur DPP-4; renforceur d'incretin","",""
"12596","11-09-06","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication","Nouvelle Indication","Anti-Neovasularisation Agent","Agnet Anti-Néovasulrisation","",""
"12597","11-09-02","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anti-Inflammatory","Anti-inflammatoire","",""
"12598","11-09-02","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anti-inflammatory","ANti-inflammatoire","",""
"12599","11-09-02","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"12600","11-09-07","IPSEN BIOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph Related to the Unsupervised Injection","Révisions de la Monographie de Produit Concernant les Injections non Supervisées","Antigrowth Hormone","Inhibiteur de l'hormone de croissance","",""
"12601","11-09-06","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATOIRES LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12602","11-09-06","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12603","11-09-06","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de Conversion de l'angiotensine","",""
"12604","11-09-06","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiviral Agent","Antiviral","",""
"12605","11-09-02","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX CR","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Selective Antagonist of Alpha 1A/1D Adrenoreceptor Subtypes in the Prostate and Bladder","Anatagoniste Sélectif Des Sous-tpes 1A et 1D Des Récepteurs Alpha-Adrénergiques des Celleuse de la Prostate et de la  Vessie","",""
"12606","11-09-06","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC / ALTANA PHARMA AG","GERMANY","ALLEMAGNE","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"12607","11-09-06","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Non-Steroidal Antiandrogen","Antiandrogène non Steroïdien","",""
"12608","11-09-06","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOWELLCOME INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist - Migraine Therapy","Agoniste des Récepteurs 5-HT1, Antimigraineux","",""
"12609","11-09-01","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","Removal of commitments as per the Letter of Undertaking dated August 28, 2009 for the symptomatic treatment of patients with moderate to severe dementia of the Alzheimer's Type.","Retrait des obligations énoncées dans la lettre d'engagement du 28 Août 2009 au sujet du traitement symptomatique de la démence de type Alzheimer d'intensité modérée à sévère","N-Methyl-D-Aspartate (NMDA) Receptor Antagonist","Antagoniste du récepteur N-méthyl-D-aspartate","",""
"12610","11-08-30","CIPHER PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid Analgesic","Analgésique Opioïdes","",""
"12611","11-09-07","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiemetic (5-HT3 Receptor Antagonist)","Antiémtique (Antagoniste des Récepteurs 5-HT3)","",""
"12612","11-09-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CORPORATION","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Non-steroidal Aromatose Inhibitor / Inhibitor of Estrogen Biosynthesis / Antitumour Agent","Inhibiteur de l'Aromatase non Stéroïdien / Inhibiteur de la Biosynthèse des Oestrogènes / Antinéoplastique","",""
"12613","11-09-07","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"12614","11-09-07","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme Lipidique","",""
"12615","11-09-07","QD PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-Adrenergic Receptor Blocking Agent","Inhibiteur des Récepteurs Béta-adrénergiques","",""
"12616","11-08-22","ANGITA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Beta-Adrenergic Receptor Blocking Agent","Inhibiteur des Récepteurs Bêta-adrénergiques","",""
"12617","11-09-09","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'Enzyme de Conversion de l'Angiotensine","",""
"12618","11-09-09","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL ORAL SOLUTION","JANSSEN ORTHO INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"12619","11-09-08","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"12620","11-09-08","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"12621","11-09-13","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"12622","11-09-08","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidiabetic Agent","Antidiabétique","",""
"12623","11-09-09","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Beta-Adrenergic Receptor Blocking Agent","Inhibiteur des Récepteurs Béta-adrénergiques","",""
"12624","11-09-09","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive / Antianginal Agent","Antihypertenseur / Antiangineux","",""
"12625","11-09-13","MARCAN PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-Adrenergic Receptor Blocking Agent","Inhibiteur des Récepteurs Béta-adrénergiques","",""
"12626","11-09-07","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid","Corticosteroïde","",""
"12627","11-09-12","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCONORM","NOVO NORDISK CANADA INC","CANADA","CANADA","1","","","Oral Antidiabetic Agent","Antidiabétique Oral","",""
"12628","11-09-13","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTED","CANADA","CANADA","1","","","Antiparkisonian Agent / Dopamine Agonist","Agent Antiparkinsonien / Agoniste Dopaminergique","",""
"12629","11-09-13","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 Alpha-reductase Inhibitor","Inhibiteur de la 5 Alpha-réductase de Type II","",""
"12630","11-09-14","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial Agent","Antibactérien","",""
"12631","11-09-14","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO-MCNEIL PHAMRACEUITCALS INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiepileptic / Migraine Prophylaxis","Antiépileptique / Prophylaxie de la Migraine","",""
"12632","11-09-13","SUN PHARMA GLOBAL FZE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antineoplastic Agent","Antinéoplastique","",""
"12633","11-09-14","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","1. To align th Product Monograph with the Reference Safety Information (RSI) as per the Therapeutic Products Directorate's Advisement Letter dated February 8, 2010 2. To Update the Product Monograph to the new Format","1. Harmoniser la Monographie du Produit aux Références des Renseignements sur l'Innocuité (RRI), Conformément la Lettre d'Avis de la Direction des Produits Thérapeutiques, datée su 8 Février 2010. 2. Mettre à Jour la Monographie du Produit au Nouveau Format","Antineoplastic Agent","Antinéoplastique","",""
"12634","11-09-16","ECO ANIMAL HEALTH LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"12635","11-09-20","JUBILANT DRAXIMAGE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Diagnostic Radiopharmaceutical","Agent Diagnostique Radiopharmaceutique","",""
"12636","11-09-20","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Presentation; New Dosage Strength 3000 IU; New Drug Product Manufacturing Facility","Nouvelle Présentation; Nouvelle Concentration de 2000 IU; Nouvel Emplacement de Fabrication pour les Produits Médicamenteux","Antihemorrhagic Blood Coagulation Factor VIII","Facteur VIII de Coagulation Antihémorragique","",""
"12637","11-09-14","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Manufacturing Site for the Drug Product","Nouvel emplacement de fabrication pour les Produits Médicamenteux","Antihypertensive Agent","Antihypertenseur","",""
"12638","11-09-20","COLGATE PALMOLIVE CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Anticaries; Antiplaque; Antigingivitis; Anticalculus; Anti-Sensitivity","Anticarie; Antiplaque; Antigingivite; Anticalcul; Antisensibilité","",""
"12639","11-09-21","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"12640","11-09-21","PALADIN LABS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIANE-35","BERLEX CANADA INC","CANADA","CANADA","1","","","Acne Therapy","Traitement de l'Acné","",""
"12641","11-09-21","MEDIAM","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Radiodiagnostic Agent","Agent Radiodiagnostique","",""
"12642","11-09-15","SORRES PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"12643","11-09-20","TAKEDA CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate Manufacturing Site for Mixed Granules-L","Autre lieu de fabrication pour les Granules-L Melangé","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"12644","11-09-21","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Expanded Indication - Rheumatoid Arthritis (RA) - Simponi in COmbination with Methotrexate (MTX) is idicated for: Reducing Signs and Symptoms and Improving Physical Function in Adult Patients with Moderately to Severe Active Rheumatoid Arthritis. Inhibiting the Progression of Strutural Damage in Adult Patients with Moderate to Severely Active Rheumatoid Arthritis who had not Previously been Treated with MTX.","Indication Énlargie - Polyarthrite Rhumatoïde Simponi en Association aven le Méthotrexate (MTX) est Indique: Pour la Réduction des Signes et des Symptômes, et l'Amélioration du Fonctionnement des Patients Adultes Présentant des Poussées Évolutives de Formes Modérées à Graves de Polyarthrite Rhumatoïde. Réduction de la Progression de Dommages Struturels des Articulations des Patients Adultes Souffrant de Polyarthrite Rheumatoïde Active Modérée ou Grave qui n'on pas été Traités avec le MTX.","Tumor Necrosis Factor Alpha Inhibitor","Inhibiteur du Facteur Nécrose Tumorale Alpha","",""
"12645","11-09-22","GENZYME CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bile Acid Sequestrant","Chélateur des Acides Bilaires","",""
"12646","11-09-22","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CORPORATION","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Non-Steroidal Aromitase Inhibitor / Inhibitor of Estrogen Biosynthesis / Antitumour Agent","Inhibituer non Stéroïdien de l'Aromatase / Inhibiteur de la Biosynthèse des Oestogènes / Agent Antinéoplastique","",""
"12647","11-09-22","QD PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"12648","11-09-22","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"12649","11-09-22","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","AERIUS","SCHERING CANADA INC","CANADA","CANADA","1","","","Histamine H1 Receptor Antagonist","Antagoniste des Récepteurs H1 de l'Histamine","",""
"12650","11-09-22","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du métabolisme osseux","",""
"12651","11-09-22","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Antifungal Agent","Antifongique","",""
"12652","11-09-23","VITA HEALTH PRODUCTS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ASPIRIN 81 MG","BAYER INC","CANADA","CANADA","1","","","Platelet Aggregation Inhibitor","Inhibiteur de l'Aggrégation Plaquettaire","",""
"12653","11-09-23","GILEAD SCIENCES CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiretroviral","Antirétroviral","",""
"12654","11-09-27","NORBROOK LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC POUR-ON","MERIAL CANADA INC","CANADA","CANADA","1","","","Anthelmintic","Anthelmintique","",""
"12655","11-09-23","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Removal of the 25 mg Strength from the PRoduct monograph","Suppression de la Conentration 25 mg du Monographie de Produit","5-HT1 Receptor Agonist","Antagoniste des Récepteurs 5-HT1","",""
"12656","11-09-26","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du Métabolisme Osseux","",""
"12657","11-09-26","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","TAP PHARMACEUTICALS INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"12658","11-09-27","G POHL BOSKAMP GMBH & CO KG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Pediculicide","Pédiculicide","",""
"12659","11-09-27","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antidepressant","Antidépresseur","",""
"12660","11-09-27","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive - Antianginal Agent","Antihypertenseur - Antiangineux","",""
"12661","11-09-27","MANDA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive - Antianginal Agent","Antihypertenseur - Antiangineux","",""
"12662","11-09-27","MANDA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FORES LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antidepressant","Antidépresseur","",""
"12663","11-09-27","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN-HCT","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker and diuretic","Antagoniste des Récepteurs AT1 de L'Angiotensin II - Diurétique","",""
"12664","11-09-28","DR REDDYS LABORATORIES INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA INC","CANADA","CANADA","1","","","Antidepressant - Anxiolytic","Antidépresseur - Anxiolytique","",""
"12665","11-09-29","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Prostaglandin F2a Analogue and Beta-adrenergic Receptor Block","Analogue de la Prostaglandine F2a et Inhibiteur des Récepteurs Beta-adrenergiques","",""
"12666","11-09-29","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Prostagglandin F2a Analogue","Analogue de la Prostaglandine F2a","",""
"12667","11-09-29","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CORPORATION","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Non-steroidal Aromatase Inhibitor / Inhibitor of Estrogen Biosynthesis / Antitumour Agent","Inhibiteur Non-steroïdien de l'Aromatase / Inhibiteur de la Biosynthèse des Oestrogènes / Agent Antinéoplastique","",""
"12668","11-09-28","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"12669","11-09-29","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MOTRIN","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","","","Non-steroidal Anti-inflammatory Drug / Analgesic / Antipyretic Agent","Non-Stéroïdien Anti-inflammatoire / Analgésique / Antipyrétique","",""
"12670","11-09-30","SUNOVION PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antispasmodic","Antispasmodique","",""
"12671","11-09-30","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"12672","11-09-29","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Beta-Adrenergic Receptor Blocker","Inhibiteur des Récepteurs Beta-adrénergiques","",""
"12673","11-09-29","RANBAXY PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic Receptor Blocking Agent","Inhibiteur des Récepteurs Beta-adrénergiques","",""
"12674","11-10-03","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","non-steroidal Anti-inflammatory","Non Stéroïdien Anti-inflammatoire","",""
"12675","11-09-30","RANBAXY PHARMACEUTICALS CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","New Indication / Update Product Monograph to Match Innovator","Nouvelle indication / Mise à jour de la monographie de produit pour égaler la monographie de produit de l'innovateur	","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"12676","11-10-04","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TIAZAC","CRYSTAAL CORPORATION, DIVISION OF BIOVAIL CORPORATION","CANADA","CANADA","1","","","Antihypertensive - Antianginal Agent","Antihypertenseur - Antiangineux","",""
"12677","11-10-04","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CORPORATION","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Non-Steroidal Aromatase Inhibitor / Inhibitor of Estrogen Biosynthesis / Antitumour Agent","Inhibiteur de l'Aromatase non Stéroïdien / Inhibiteur de la Biosynthèse des Oestrogènes / Antinéoplastique","",""
"12678","11-10-04","RANBAXY PHARMACEUTICALS CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"12679","11-10-04","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immunosuppressive Agent","Agent Immunosuppresseur","",""
"12680","11-10-04","SUNOVION PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bone Metabolism Regulator","Régulateur du Meétabolisme Osseux","",""
"12681","11-10-05","GRACEWAY PHARMACEUTICALS","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Dosage and ADministration and clinical Trials Sections of the PRoduct onograph","Mise à jour des Sections de Posologie et Administration et Essais Clinique de la Monographie de Produit","Immune Response Modifier","Modificateur de la Réponse Immunitaire","",""
"12682","11-10-05","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing Site for the Finished PRoduct","Nouveau lieu de fabrication pour le produit fini","Antiparkinsonian Agent","Agent Antiparkinsonien","",""
"12683","11-09-30","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH AYERST CANADA INC","CANADA","CANADA","1","New Dosage Form / New API Supplier and Drug Product Manufacturing Site","Nouvelle forme posologique / Nouvelle source de l'IPA et lieu de Fabrication pour le Produit","Antiarrhythmic Agent","Antiarythmique","",""
"12684","11-10-04","DIVERSEY INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiseptic","Antiseptique","",""
"12685","11-10-07","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SERC","SOLVAY PHARMA INC","CANADA","CANADA","1","","","Anti-vertigo Agent","ANtivertige","",""
"12686","11-10-07","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of a two-dose Primary Series for Infants 6 Weeks to 6 Months of age and use in Children up to 5 Years of Age","Changement du Calendrier de Primovaccination pour les Nourrisons âgés de 6 Semaines à 6 mois à Deux Doses et l'Addition de l'Utilisation de Synflorix Chez les Enfants jusqu'à 5 ans","Active Immunizing Agent","Agent d'Immunisation Actif","",""
"12687","11-10-07","INTERCELL AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of Booster Dose; Updates to Product Monograph","Addition d'une Injection de Rappel; Mis à Jour de la Monographie du Produit","Active Immunizing Agent","Agent Immunisation Actif","",""
"12688","11-10-11","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leucotriènes","",""
"12689","11-10-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Anatagoniste des Récepteurs des Leucotriènes","",""
"12690","11-10-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leucotriènes","",""
"12691","11-10-11","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leucotriènes","",""
"12692","11-10-11","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leucotriènes","",""
"12693","11-10-11","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","New Dosage Form and Strength","Nouvelle Forme Posologique et Concentration","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leucotriènes","",""
"12694","11-10-11","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des récepteurs des leucotriènes","",""
"12695","11-10-11","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leucotriènes","",""
"12696","11-10-11","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leucotriènes","",""
"12697","11-10-12","EMD SERONO A DIVISION OF EMD INC CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Manufacturing Site","Nouvel emplacement de fabrication","Immunomodulator","immunomodulateur","",""
"12698","11-10-11","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Non-steroidal Anti-inflammatory","Non Stéroïdien Anti-infllatoire","",""
"12699","11-10-05","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"12700","11-10-07","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antipsychotic Agent","Antipsychotique","",""
"12701","11-10-12","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Progestin","Progestatif","",""
"12702","11-10-14","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker; Diuretic","Bloquer des Récepteurs AT1 de l'Angiotensine II; Diurétique","",""
"12703","11-10-14","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-SYNTHELABO CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Bloquer des Récepteurs AT1 de l'Angiontensine II","",""
"12704","11-10-14","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC DELAYED RELEASE CAPSULE","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibtor","Inhibituer de l'H+,K+-ATPase","",""
"12705","11-10-14","WATSON LABORATORIES INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lteinizing Hormone-releasing Hormone (LHRH) Analog","Analogue de l'Hormone de Libération de la Lutéinostimuline (LHRH)","",""
"12706","11-10-14","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Anti-diabetic Agent","Agent Anti-dibétique","",""
"12707","11-10-14","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"12708","11-10-14","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant / Antiobsessional / Antibulimic","Antidépresseur / Antiobsessionnel / Antiboulimique","",""
"12709","11-10-14","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MANERIX","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"12710","11-10-18","VETOQUINOL N A INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","KETASET","PFIZER CANADA INC., ANIMAL HEALTH GROUP","CANADA","CANADA","1","","","Anaesthetic","Anesthésique","",""
"12711","11-10-18","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Prophylaxis fo Headaches in Adults with Chronic Migraine","Prophylaxie des Céphalées chez l'Adulte Atteint de Migraine Chronique","Neuromuscular Paralytic Agent","Agent Neuromusculaire Paralysant","",""
"12712","11-10-19","SUNOVION PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"12713","11-10-19","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOZIDE","SERVIER CANADA INC","CANADA","CANADA","1","","","Diuretic - Antihypertensive Agent","Diurétique - Antihypertenseur","",""
"12714","11-10-19","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","Update to the PRoduct Monograph","Mise à Jour de la Monographie de Produit","Histamine H1 Receptor ANtagonist","Inhibituer des Récepteurs H1 de l'Histamine","",""
"12715","11-10-19","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive - Antianginal Agent","Antihypertenseur - Antiangineux","",""
"12716","11-10-19","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12717","11-10-19","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antianginal and Antihypertensive Agent","Agent Antiangineux et Antihypertenseur","",""
"12718","11-10-19","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive","Antihypertenseur","",""
"12719","11-10-19","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2 Receptor Antagonist","Antagoniste des Récepteurs H2 de l'Histamine","",""
"12720","11-10-19","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"12721","11-10-18","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MACRODANTIN","NORWICH EATON CANADA INC, A PROCTER & GAMBLE COMPANY","CANADA","CANADA","1","","","Urinary Tract Antibacterial","Antibactérien des Voies Urinaires","",""
"12722","11-10-18","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA INC","CANADA","CANADA","1","Update to the Product Monograph","Mise à Jour de la Monographie de Produit","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"12723","11-10-20","DIVERSEY INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiseptic","Antiseptique","",""
"12724","11-10-20","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Expansion of the Rheumatoid Arthritis Indication: reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who have inadequate response to one or more disease modifying anti-rheumatic drugs (DMARDs) and/or tumour necrosis factor (TNF) antagonists. ACTEMRA in combination with methotrexate has been shown to reduce the rate of progression of radiographic joint damage at Week 52","Ajout à l'indication de polyarthrite rhumatoïde: réduire les signes et symptômes de la polyarthrite rhumatoïde évolutive moderée ou grave chez des adultes ayant obtenu une réponse inadéquate à un ou plusieurs antirhumatismaux modificateurs de la maladie (ARMM) ou à des inhibteurs du facteur de nécrose tumorale (TNF). À la semaine 52, il a été montré qu'ACTEMRA, en association avec le méthotrexate, réduit le taux de progression des lésions articulaires mesuré par radiographie","Interleukin Receptor Inhibitor","Inhibiteur du récepteur d'interleukine","",""
"12725","11-10-21","GENZYME CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Manufacturing Facility","Nouvel Emplacement de Fabrication","Enzyme Replacement Therapy","Thérapie de Remplacement d'Enzymes","",""
"12726","11-10-14","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Master Seed Lot (MSL) and Working Seed Lot (WSL) for Streptococcus Pneumoniae Type 7F","Nouveau lot de Semence Primare (LSP) et lot de Semence de Travail (LST) pour Strtococcus Pneumoniae de Type 7F","Active Immuniaing Agent","Agent d'Immunisation Actif","",""
"12727","11-10-24","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Manufacturing Process and Facilities","Nouveau Processus et Nouveaux sites de Fabrication","Growth Hormone Receptor Antagonist","Antagonists du Récepteur de l'Hormone de Croissance","",""
"12728","11-10-21","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Antiviral Agent","Antiviral Topique","",""
"12729","11-10-17","LANTHEUS MI CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Providing Results of Post Market Commitments Regarding the Safe use of Definity, and Resulting Updates to the Product Monograph","Présentation des Résulats Obtenus des Engagements Pos-commercialisation Concernant l'Usage Sécutiaire du Definity et Mise-à-jour de la Monographie qui en on Résulté","Contrast Enhancing Imaging Agent","Agent de Rehaussement de Contraste pour l'Imagerie","",""
"12730","11-10-25","BIONICHE ANIMAL HEALTH CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","LEGEND","BAYER INC., BAYER HEALTHCARE ANIMAL HEALTH","CANADA","CANADA","1","","","Anti-inflammatory","ANti-inflammatoire","",""
"12731","11-10-14","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic Receptor Blocking Agent","Inhibiteur des Récepeurs Bét-adrenergiques","",""
"12732","11-10-25","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"12733","11-10-25","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant - Antipanic - Antiobsessional Agent","Antidépresseur - Antipanique - Antiobsessionnel","",""
"12734","11-10-25","ANGITA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Nonsteroidal Antiandrogen","Antiandrogène non Stéroïdien","",""
"12735","11-10-25","ANGITA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 Alpha-reductase Inhibitor","Inhibiteur de la 5 Alpha-réductase de Type II","",""
"12736","11-10-21","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","Update to the Product Monograph","Mise à Jour de la Monographie de Produit","Histamine H1 Receptor Antagonist","Inhibiteur des récepteurs H1 de l'histamine","",""
"12737","11-10-25","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Antipsychotic","Antipsychotique","",""
"12738","11-10-27","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antitussive","Antitussive","",""
"12739","11-10-27","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antitussive","Antitussive","",""
"12740","11-08-16","VERTEX PHARMACEUTICALS (CANADA) INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiviral Agent","Antiviral","",""
"12741","11-10-26","SUN PHARMA GLOBAL FZE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal Aromitase Inhibitor; Inhibitor of Estrogen Biosynthesis; Anti-tumour Agent","Inhibiteur de l'aromatase non stéroïdien; Inhibiteur de la biosynthèse des oestrogènes; Antinéoplasique","",""
"12742","11-10-26","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","","","Antibiotic; Beta-lactamase Inhibitor","Antibiotique; Inhibiteur de Beta-lactimase","",""
"12743","11-10-28","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate Manufacturing Site for the Drug Substance and Drug Product","Autre Site de Fabrication de la Substance Médicamenteuse et du Produit Pharmaceutique","Progestin","Progestatif","",""
"12744","11-10-31","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Refrigerator-stable Formulation","Formulation Stable au Refrigerateur","Active Immunizing Agent","Agent d'Immunisation Actif","",""
"12745","11-11-01","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic; Antielminitic","Anti-parasitaire; Antihelminthique","",""
"12746","11-11-01","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","","","",""
"12747","11-11-01","ELANCO DIVISION ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional Claims and Concurrent use with Monensin Sodium","Indications Supplémentaires et Utilisation Concomitante avec le Monensin Sodique","Anibiotic","Antibiotique","",""
"12748","11-10-28","RB PHARMACEUTICALS LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opiate Agonist-Antagonist","Agoniste-Antagoniste des Opiacés","",""
"12749","11-10-24","ANGITA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CORPORATION","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Non-steroidal Aromatase Inhibitor; Inhibitor of Estrogen Biosynthesis; Antitumour Agent","Inhibiteur de l'Aromatse non Stéroïdien; Inhibiteur de la Biosynthèse des Oestrogènes; Antinéoplastique","",""
"12750","11-10-27","GILEAD SCIENCES CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph Based on Data from two Long Term (192 weeks) Studies to Support the CHB Indication","Mises à Jour de la Monographie de Produit Basés sur les Données Obtenues à deux études à Longe Terme (192 Semaines) afin de Supporter Davantage l'Indication Concernant l'Hépatite B Chronique","Antiretroviral","Antirétroviral","",""
"12751","10-10-20","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Coagulation Factor","Facteur de Coagulation","",""
"12752","11-11-02","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XATRAL","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH) / Adjunctive Therapy in Acute Urinary Retention (UAR)","TRAITEMENT SYMPTOMATIQUE DE L'HYPERPLASIE BÉNIGNE DE LA PROSTATE, TRAITEMENT ADJUVANT DE LA RÉTENTION URINAIRE AIGUË","",""
"12753","11-11-02","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRA PHARMA INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"12754","11-11-02","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du Métabolisme Osseux","",""
"12755","11-11-03","BIO AGRI MIX LP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional Clain","Indication Supplémentaire","Antibiotic","Antibiotique","",""
"12756","11-11-03","BIO AGRI MIX LP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional Claim","Indication Supplémentaire","Antibiotic","Antibiotique","",""
"12757","11-11-03","BIO AGRI MIX LP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional Claim","Indication Supplémentaire","Antibiotic","Antibiotique","",""
"12758","11-11-04","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Non-steroidal Anti-inflammatory","Anti-inflammatoire non stéroïdien","",""
"12759","11-11-03","LUNDBECK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in Formulation; Updates to the Product Monograph and labels","Modification de la formulation; Mise à Jour de la Monographie du Produite et les étiquettes","Antipsychotic Agent","Antipsychotique","",""
"12760","11-11-04","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC","CANADA","CANADA","1","","","Antidepressant; Antiobsessional; Antipanic; Anxiolytic Agent; Social Phobia (Social Anxiety Disorder; Posttraumatic Stress Disorder Therapy","Antidépresseur / Antiobsessionnel / Antipanique / Anxiolytique / Traitement de la phobie sociale / Traitement de l'état de stress post-traumatique","",""
"12761","11-11-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADRIAMYCIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","Antineoplastic Agent","Antinéoplastique","",""
"12762","11-11-04","VITA HEALTH PRODUCTS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD & SINUS CAPLETS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","New Presentation","Nouvelle présentation","Analgesic; Antipyretic; Nasal Decongestant","Analgésique; Antipyrétique; Décongestionnanat Nasal","",""
"12763","11-11-03","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Warnings Section of the Product Monograph - Implicit Safety Claim; Congenital Malformations after Assisted Reproduction Technologies (ART)","Modification à la Section de Mises en Garde de la Monographie de Produit - Allégation Relative à l'Innocuité Implicite: Malformations Congéitales à la suite des Technologies de Reproduction Assistée","Gonadotropin-releasing Hormone (GmRH) Antagonist","Antagoniste de l'hormone de libération de la gonatrophine (GnRH)","",""
"12764","11-11-09","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Change in Manufacturing Process","Changement au Processus de Fabrication","Passive Immunizing Agent","Agen d'Immunisation Passif","",""
"12765","11-11-10","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New 2.5 mg Strength for Once Daily use in Patients with Moderate or Severe Renal Impairment","Une Nouvelle Concentration de 2,3 mg une foiss par Jour pour les Patients Atteints d'une Insufficance Rénale Modérée ou Sévère,","Oral Antihyperglycemic Agent; DPP-4 Inhibitor; Incretin Enhancer","Agent oral d'antihyperglycémic; inhibiteur DPP-4; renforceur d'incretin","",""
"12766","11-11-04","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"12767","11-10-26","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antiepiliptic","Antiépileptique","",""
"12768","11-11-15","DIVERSEY INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiseptic","Antiseptique","",""
"12769","11-11-16","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-SYNTHELABO CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Bloquer des Récepteurs AT1 de l'Angiotensine II","",""
"12770","11-11-16","ANGITA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Anti-diabetic Agent; Insulin Resistance Reducing Agent","Agent Antidiabétique' Agent Réducteur de l'Insulinoréistance","",""
"12771","11-11-16","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker; Diuretic","Bloqeur des Récepteurs AT1 de l'Angiontensine II; Diurétique","",""
"12772","11-11-16","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme Lipidique","",""
"12773","11-11-16","PHARMEL INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGERLHEIM (CANADA) LTD","CANADA","CANADA","1","","","Antiparkinsonian Agent; Dopamine Agonist","Agent Antiparkinsonien; Agoniste Dopaminergique","",""
"12774","11-11-16","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker; Diuretic","Bloqueur des Rcepteurs AT1 de l'Antiotensine II; Diuretique","",""
"12775","11-11-16","ANGITA PHARMA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","New Strength","Nouvelle Conentration","Antidepressant","Antidépresseur","",""
"12776","11-11-16","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"12777","11-11-15","ALKERMES GAINESVILLE LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Nonsteroidal Anti-inflammatory Drug","Anti-inflammatoire non Stéroïdien","",""
"12778","11-11-16","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI SYNTHELABO CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Bloqueur des Récepteurs AT1 de l'Angiontensine II","",""
"12779","11-11-14","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Strength","Nouvelle concentration","Human Immunodeficiency Virus (HIV) Non-nucleoside Reverse Transcriptase Inhibitor","Inhibiteur de la Protéase du Virus de l'immunodéficience Humaine (VIH)","",""
"12780","11-11-14","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New Dosage Form","Nouvelle forme posologique","Oral Antidiarrheal Agent","Antidiarrhéique oral","",""
"12781","11-11-14","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immunosuppressant","Immunosuppresseur","",""
"12782","11-11-14","GALDERMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-rosacea","Agent antirosacée","",""
"12783","11-11-16","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12784","11-11-08","EMD SERONO A DIVISION OF EMD INC CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To Register an Additional Fill Volume","Pour Enrigistrée une Volume de Remplit Addtionelle","Antidote","ANtidote","",""
"12785","11-11-17","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the Product monograph","Mise à Jour à la Monographie de Produit","Antidiabetic Agent","Agent Antidiabétique","",""
"12786","11-11-17","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","","","Histamine H1 Receptor Antagonist","Antagoniste des récepteurs de l'histamine H1","",""
"12787","11-11-16","STERIMAX INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"12788","11-11-18","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Expanded Indication: Psoriatic Arthritis (PsA); Reducing signs and symptoms, inhibiting the progresssion of structural damage and improving physical function in adult patients with moderately to severely active psoriatic arthritis. Simpponi can be used in combination with MTX in patients who do not respond adequately to MTX alone.","Indication Ékargue; Rhumatisme Psoriasique (RP); la réduction des signes et des symptômes, l'inhibition des lésions structurelles, et l'amélioration de la fonction physique chez les patients adultes atteints de rhumatisme psoriasique actif, modéré à sévère. Simponi peut être utilisé en association avec le MTX chez des patients qui ne répondent pas de façon adéquate au traitement par le MTX employé seul.","Tumour Necrosis Factor Alpha Inhibitor","Inhibiteur du Facteur Nécrose Tumorale Alpha","",""
"12789","11-11-21","PINNACLE BIOLOGICS, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic Photosensitizing agent","Photosensibilisant ANtinéoplastique","",""
"12790","11-11-21","PRO DOC LIMITÉE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Révisions à la Monographie de Produit","Non-sterodial Anti-inflammatory Drug","Anti-inflammatiore no Stéroïdien","",""
"12791","11-11-21","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"12792","11-11-21","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication for the treatment of schizophrenia in adolescents 15-17 years of age","Nouvelle indication: traitement de la schizophrénie dans les adolescents à l'age de 15-17 ans","Antipsychotic AAgent","Antipsychotique","",""
"12793","11-11-22","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Antiparkinsonian Agent / Dopamine Agonist","Agent Antiparkinsonien ' Agoniste de Dopamine","",""
"12794","11-11-23","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"12795","11-11-23","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMOXIL","WYTH-AYERST CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotque","",""
"12796","11-11-23","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'Enzyme de Conversion de l'Angiotensine","",""
"12797","11-11-28","LLOYD INC OF IOWA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Analgesic; Sedative","Analgésique; Sédatif","",""
"12798","11-11-28","LLOYD INC OF IOWA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Analgesic; Sedative","Analgésique; Sédatif","",""
"12799","11-11-28","LLOYD INC OF IOWA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Xylazine Reversing Agent and Antagonist","Agent d'Inversion de Xylazine et Antidote","",""
"12800","11-11-29","VIRBAC AH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Glucocorticoid","Glucocorticoïde","",""
"12801","11-11-25","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMTHKLINE BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC","CANADA","CANADA","1","","","Congestive Heart Failure Agent","Agent pour l'Isuffisance Cardique Congestive","",""
"12802","11-11-28","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"12803","11-11-25","GALDERMA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Dosage Form - Lotion","Nouvelle forme posologique - Lotion","Acne Therapy","Traitement Antiacnéique","",""
"12804","11-11-21","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic; Sleep Aid","Analgésique; Aide-sommeil","",""
"12805","11-11-29","ALVEDA PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Nonselective Cyclooxygenase Inhibitor / Nonsteroidal Anti-inflammatory Drug","Inhibiteur Nonsélectif de Cyclooxygénase / Anti-inflammatoire non Stéroïdien","",""
"12806","11-11-29","APTALIS PHARMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Helicobacter Pylori Eradication Therapy in Conjuction with Omeprazole","Traitement d'éradication de l'Helicobacter Pylori en Utilisant Parallèlement l'Omeprazole","",""
"12807","11-11-20","APTALIS PHARMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lower Gastrointestinal Tract Motility Regulator","Régulateur de la Motilité du Tracius Gasto-intestinal Inférieur","",""
"12808","11-11-29","APTALIS PHARMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Cholestatic Liver Diseases","Maladies Hépatiques Cholestatiques","",""
"12810","11-11-30","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPRIVAN","ZENECA PHARMA CANADA INC","CANADA","CANADA","1","New Formulation","Nouvelle formulation","Anaesthetic; Sedative","Anesthésique","",""
"12811","11-11-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","CLARITIN","SCHERING CANADA INC","CANADA","CANADA","1","","","Histamine H1 Receptor Antagonist","Antagoniste des Récepteurs H1 de l'Histamine","",""
"12812","11-11-30","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fullfilment of the final commitment as per the Letter of Undertaking dated July 10, 2008 for the treatment of accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or not toleant of at lease one prior therapy including imatinib; and other revisions to the product monograph","Le respect de l'engagement final conformément à la lettre d'engagement du 10 juillet 2008 releative au traitement de la leucémie myéloïde chronique (LMC) ace chromosome Philadelphie positive en phase accélérée (PA) chez les patients adultes résistants ou intolérants à au moins un tratement antrieur incluant l'imatinib; et autres révisions de la monographie de produits","Protein-tyrosine Kinase Inhibitor","Inhibiteur de la protéase-tyrosine kinase","",""
"12813","11-11-30","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppressive Agent","Immunosuppresseur","",""
"12814","11-11-30","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HAFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppressive Agent","Immunosuppresseur","",""
"12815","11-11-30","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppresive Agent","Immunosuppresseur","",""
"12816","11-11-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppressive Agent","Immunosuppresseur","",""
"12817","11-11-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppressive Agent","Immunosuppresseur","",""
"12818","11-11-30","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppressive Agent","Immunosuppresseur","",""
"12819","11-11-30","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppressive Agent","Immunosuppresseur","",""
"12820","11-11-30","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL LIQUI-GELS; ADVIL EXTRA STRENGTH LIQUI-GELS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Analgesic; Antipyretic","Analgésique; Antipyrétique","",""
"12821","11-11-30","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Bl;ocker; Diuretic","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II / DIURÉTIQUE","",""
"12822","11-12-01","FERRING INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Estrogens","Oestrogène","",""
"12823","11-12-01","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC","CANADA","CANADA","1","","","Hypnotic and Sedative","hypnotique et Sédatif","",""
"12824","11-12-01","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Type II 5 Alpha-reductase Inhibitor","Inhibiteur de la 5 Alpha-réductase de Type II","",""
"12825","11-12-01","APTALIS PHARMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lower Gastroinestinal Trant Anti-inflammatory","Anti-inflammatoire du Tratus Gasto-intestinal Inférieur","",""
"12826","11-11-30","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"12827","11-12-02","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Rvisions à la Monographie du Produit","Nonbo-steroidal Aromitase Inhibitor; Inhibitor of Estrogen Biosynthesis; Anti-tumor Agent","Inhibiteur non Stéroïdien de l'Aromitase; Inhibiteur de la Biosynthèse des Oestrogènes; Agnet Antinéplastique","",""
"12828","11-12-02","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Histamin H2 Receptor Antagonist","Antiagoniste des Rcepteurs Histaminiques H2","",""
"12829","11-12-02","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Histamine H2 Receptor Antagonist","Antagoniste des Récepteurs histaminiques H2","",""
"12830","11-12-05","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph Revised","Monographie du Produit Révisée","Acitve Immunizing Agent","Agent d'Immunisation Actif","",""
"12831","11-12-06","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Histamine H2 Receptor Antagonist","Antagoniste des Récepteurs Histaminiques H2","",""
"12832","11-12-02","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Calcneurin Inhibitor","Inhibiteur Topique de la Calcineurine","",""
"12833","11-11-29","APTALIS PHARMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Gastro-duodenal Cytoprotective Agent","Agent Cytoprotecteur Gastro-duodénal","",""
"12834","11-12-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","BRISTLOL MAYERS SQUIBB / SANOFI-SYNTHLEABO CANADA INC","CANADA","CANADA","1","","","Platelet Aggregation Inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12835","11-12-07","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI AVENTIS CANADA INC","CANADA","CANADA","1","","","Platelet Aggregatioin Inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12836","11-12-06","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","BRISTOL-MYERS SQUIBB / SANOFI-PHARMACEUTICALS PARTNERSHIP","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Platelet Aggregation Inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12837","11-12-06","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-SYNTHELABO","CANADA","CANADA","1","","","Platelet aggregation inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12838","11-12-06","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Platelet Aggregation Inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12839","11-12-06","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XALATAN","PFIZER CANADA INC","CANADA","CANADA","1","","","Prostaglandin F2 (Alpha) Analogue","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA","",""
"12840","11-12-06","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Long-Acting Beta2 Agonist","Agoniste à Duration Prolongée de Beta2","",""
"12841","11-12-07","JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Enterokinetic Agent","Agent Enterokinetique","",""
"12842","11-12-08","INSIGHT PHARMACEUTICALS CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antifungal Agent","Antifongique","",""
"12843","11-12-08","INSIGHT PHARMACEUTICALS CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antifungal Agent","Antifongique","",""
"12844","11-12-08","INSIGHT PHARMACEUTICALS CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antifungal Agent","Antifongique","",""
"12845","11-12-08","INSIGHT PHARMACEUTICALS CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antifungal Agent","Antifongique","",""
"12846","11-12-06","DR REDDYS LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Cholinesterase Inhibitor","Inhibiteur de la Cholinestérase","",""
"12847","11-12-06","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Muscle Relaxant; Analgesic","Relaxant Musculaire; Analgésique","",""
"12848","11-12-06","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE  INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs 5-HT1; Antimigraineux","",""
"12849","11-12-08","GENZYME CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hematopoitic Agent","Agent Hématopoitique","",""
"12850","11-12-06","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme Lipidique","",""
"12851","11-12-06","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Histamine h2 Receptor Antagonist and Antacid","Antagoniste des Récepteurs Histaminiques H2 et Antacide","",""
"12852","11-12-06","GENMED A DIVISION OF PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to Clinical Trials and the Warnings and Precautions sections of the Product Monograph based on the CONDOR study Results","Les Modifications Apportées aux essaies Cliniques et aux Articles de Mises en Garde et Précautions de la Monographie du Produit, Fondées sur les Résultats de l'Etude CONDOR","Non-steroidal Anti-inflammatory Drug (NSAID)","Anti-inflammatoire non Stéroïdien (AINS)","",""
"12853","11-12-09","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph- Change in Wording of Indication from Beast Cancer to Metastatic Breast Cancer","Mise à Jour de la Monographie du Produit - Changement de Cancer du Sein à Cancer du Sein Métastatique Apportée à la Formulation de l'indication","Cardioprotective Agent","Agent Cardioprotectif","",""
"12854","11-12-09","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 Alpha-reductase Inhibitor","Inhibiteur de la 5 Alpha-réductase de Type II","",""
"12855","11-12-09","SUNOVION PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12856","11-12-09","1466406 ONTARIO LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Non-steroidal Anti-inflammatory Drug, Analgesic, Antipyretic Agent","Non Stéroïdien Anti-inflammatoire, Analgésique, Antipyrétique","",""
"12857","11-12-09","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Histamine H1 Receptor Antagonist; Sympathomimetic Amine","Antagoniste des Recepteurs de l'Histamine H1; Amine Sympathomimétique","",""
"12858","11-12-09","CEVA SANTÉ ANIMALE S.A.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Hormone","Hormone","",""
"12859","11-12-12","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: RITUXAN in combiination with glucocorticoids is indicated for the induction of remission in adult patients with severely active Granulomatosis with Polyangitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangitis (MPA). Consideration should be given to current treatment guidelines for vasculitis","Nouvelle Indication: RITUXAN en association aux corticoïdes est indiqué chez les adultes comme traitement d'induction de la rémission de la granulomatose ave polyangéite (GPA aussi connue sous le nom de granulomatose de Wegener) et la polyangéite microscopique (PAM) actives et graves. Considération devrait être accordée aux directives thérapeutiques actuelles des vascularites","Antineoplastic","Antinoplastique","",""
"12860","11-12-08","MYLAN PHARMACEUTICALS ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Update to the Product Monograph","Mise à Jour de la Monographie du Produit","Histamine H2 Recepter Antagonist","Antagoniste des Récepteurs de l'Histamine H2","",""
"12861","11-12-08","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hematinic","Hématinique","",""
"12862","11-12-14","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN-HCT","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker and Diuretic","Antagoniste des Récepteurs AT1 de l'angiotensin II et Diurétique","",""
"12863","11-12-14","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","BRISTOL MYERS SQUIBB/SANOFI-SYNTHLABO CANADA INC","CANADA","CANADA","1","","","Platelet Aggregation Inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12864","11-12-14","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-SYNTHELABO CANADA INC","CANADA","CANADA","1","","","Platelet Aggregation Inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12865","11-12-12","SEPTA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiemetic","Antiémétique","",""
"12866","11-12-12","SEPTA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme Lipidique","",""
"12867","11-12-12","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINEMET","MERCK SHAPRE & DOHME","CANADA","CANADA","1","","","Antiparkinson Agnet","Agent Antipsrkinsonien","",""
"12868","11-12-14","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Changes to the Drug Substance Manufacturing Process","Changements au Processus de Fabrication de la Substance Médicamenteuse","Erythropoiesis Regulating Hormone","Hormone Régulatrice de l'erythropoïèse","",""
"12869","11-11-30","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"12870","11-12-12","BAUSCH & LOMB INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Contact Lens Disinfectant","Désinfectant pour les Lentille de Conatact","",""
"12871","11-12-14","EISAI LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic","Antinéoplastique","",""
"12872","11-12-15","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New Presentation","Nouvelle Presentation","Anticoagulant, Antithrombotic Agent","Anticoagulant, Antithrombotique","",""
"12873","11-12-14","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Antirheumatic, Immunomodulator Agent","Antirhumatismal, Immunomodulateur","",""
"12874","11-12-14","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MOTRIN","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","","","Non-steroidal Anti-inflammatory Drug; Analgesic; Antipyretic","Anti-inflammatoire nonstéroïdien; Analgésique; Antipyrétique","",""
"12875","11-12-19","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Name Change","modification de nom du Produit","Plasma Substitute and Plasma Protein Fraction","SUBSTITUT DE PLASMA ET FRACTION DE PROTÉINE DE PLASMA","",""
"12876","11-12-16","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Expanded indication for Crohn's Disease; reduction of signs and syptoms, induction and maintenance of clinical remission and mucosal healing and reduction of corticosteroid use in adult patients with moderately to severely active Crohn's disease who have had an inadequate respone to a corticosteroid and/or aminoslicylate, REMICADE can be used alone or in combination with conventional therapy","Indication élargie pour la maladie de Crohn: Pour la réduction des signes et des symptômes, ainsi que pour l'indication et le maintien de la rémission clinique et de la guérison de la muquese eet la réduction du recours aux corticoïdes chez les adultes atteints de la forme modérée à grave et active de la maladie de Crohn ne répondant pas adéquatement aux corticoïdes et/ou à l'aminosalicylate. REMICADE puet être utilisé seul ou en assotiation avec le traitement standard.","Biological Response Modifier","Agent d'immunomodulation","",""
"12877","11-12-20","LLOYD INC OF IOWA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Alpha-2 Adrenergic Receptor Antagonist","Antagoniste du Récepteur Adrénergique Alpha-2","",""
"12878","11-12-19","COSTWIN TECHNOLOGIES LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiseptic","Antiseptique","",""
"12879","11-12-20","AMG MEDICAL INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Disinfectant","Désinfectant","",""
"12880","11-12-16","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product monograph","Mise à jour de la monographie de produit","Smoking Cessation Aid","Aide pour cesser de fumer","",""
"12881","11-12-16","BRISTOL MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticoagulant","Anticoagulant","",""
"12882","11-12-21","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: For the treatment of urinary incontinence due to neurogenic detrusor overactivity resulting from neurogenic bladder associated with multiple sclerosis or subcervical spinal cord injury in adults who had an inadequate respone to or are intolerant of anticholinergic medications","Nouvelle indication: Pour le traitement de l'incontinence urinaire due à une hyperactivité détrusorienne neurogénique qui est entrainée par une vessie neurogène associée à la sclérose en plaques ou les blessures médullaires sous cervicales chez les adultes qui n'ont pas répendu adéquatement ou qui sont intolérants aux médicaments anticholinergiques.","Neuromuscular Paralytic Agent","Agent Neuromusculaire Paralysant","",""
"12883","11-12-20","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","Removal of commitments as per the Letter of Undertaking dated November 3, 2009 for the symptomatic treatment of patients with moderate to severe dementia of the ALzheimer's type","Retrait des obligations énoncées dans la lettre d'engagement du 3 Novembre 2009 au sujet du traitement symptomatique de la démence de type Alzheimer d'intensité modeérée à sévère.","N-methyl-D-aspartate Receptor Antagonist","Antagoniste du Récepteur N-méthyl-aspartate","",""
"12884","11-12-20","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI AVENTIS CANADA INC","CANADA","CANADA","1","","","Platelet Aggregation Inhibtor","Inhibiteur de l'agrégation Plaquettaire","",""
"12885","11-12-20","NT PHARMA CANADA LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product Name Change","Changement de nom du Produit","Antidepressant; Antiobsessional; Antibulimic","Antidépresseur; Antiobsessionnel; Antiboulimique","",""
"12886","11-12-20","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VANCOCIN","IROKO INTERNATIONAL LP","CANADA","CANADA","1","New Dosage Form","Nouvelle forme posologique","Antibiotic","Antibiotique","",""
"12887","11-12-28","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bile Acid Sequestrant","Chélateur des Acides Bilaires","",""
"12888","11-12-23","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","METHOTREXATE INJECTION USP","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","","","ANTIMETABOLITE / ANTIRHEUMATIC AGENT","ANTIMÉTABOLITE / ANTIRHUMATISMAL","",""
"12889","11-12-28","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone metabolism regulator","Régulateur du métabolisme osseux","",""
"12890","11-12-22","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the product monograph","Mise à jour de la monographie de produit","Intravenous nutritive supplements","Suppléments nutritifs intraveineux","",""
"12891","11-12-22","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the product monograph","Mise à jour de la monographie de produit","Lipid emulsion for intravenous nutrition","Émulsion lipidique pour alimentation par voie intraveineuse","",""
"12892","11-12-21","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD.","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leucotriènes","",""
"12893","11-12-21","STERIMAX INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","New presentation","Nouvelle présentation","Antibiotic / Beta-lactamase Inhibitor","Antibiotique / Inhibiteur de bêta-lactamases","",""
"12894","11-12-21","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12895","11-12-21","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA & CO.","CANADA","CANADA","1","","","Type II 5 alpha-reductase inhibitor","Inhibiteur de la 5 alpha-réductase de type II","",""
"12896","11-12-21","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXO WELLCOME INC.","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"12897","11-12-21","MELIAPHARM INC.","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC.","CANADA","CANADA","1","Removal of commitments as per the Letter of Undertaking dated March 23, 2010 for the symptomatic treatment of patients with moderate to severe dementia of the Alzheimer's type","Retrait des obligations énoncées dans la lettre d'engagement du 22 mars 2010 au sujet du traitement symptomatique de la démence de type Alzheimer d'intensité modérée à sévère","N-methyl-D-aspartate receptor antagonist","Antagoniste du récepteur N-méthyl-D-aspartate","",""
"12898","11-12-22","OMEGA LABORATORIES LTD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V. MINIBAGS","BAYER INC.","CANADA","CANADA","1","Product name change","Changement du nom du produit","Antibacterial Agent","Antibactérien","",""
"12899","11-12-22","PATRIOT A DIVISION OF JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opoid Analgesic","Analgésique opioïde","",""
"12900","11-12-22","SUNOVION PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme lipidique","",""
"12901","12-01-03","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Oral Antihyperglycemic Agent","Antihyperglycémiant oral","",""
"12902","11-12-30","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Mise à Jour de la Mongraphie du Produit","Platelet Aggregation Inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"12903","12-01-03","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPROBAY","BAYER AG","GERMANY","ALLEMAGNE","1","Revisions to the PRoduct monograph","Mise à Jour de la Monographie du Produit","Antibacterial Agent","Antibactérien","",""
"12904","11-12-30","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs 5-HT1; Antimigraineux","",""
"12905","12-01-03","CEPHALON FRANCE SAS","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Central Nervous System Stimulant","Stimulant du Système Nerveux Central","",""
"12906","11-12-30","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Anti-diabetic Agent; Insulin Resistance Reducing Agent","Agent Antidiabétique; Agent Réducteur de l'insulinorésistance","",""
"12907","12-01-06","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMINYL ER","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Cholinesterase Inhibitor","Inhibiteur de la Cholinestérase","",""
"12908","12-01-04","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Drug-Drug Interactions, Warnings and Precautions, Adverse Reactions and References sections of the Product Monograph regarding tumour lysis syndrome and interactions with acetaminophen.","Mise à jour sur les interactions médicamentmédicament, les mises en garde et précautions, les sections Effets indésirables et Références, la monographie du produit au sujet du syndrome de lyse tumorale et les interactions avec de lacétaminophène","Protein Kinase Inhibitor","Inhibiteur de la protéine kinase","",""
"12909","12-01-03","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Inhibiteur des récepteurs AT1 de l'angiotensine","",""
"12910","12-01-06","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Oral Antihyperglycemic Agent","Antihyperglycémiant Oral","",""
"12911","12-01-06","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Reeptor Blocker","Inhibiteur des récepteurs AT1 de l'angiotensine","",""
"12912","12-01-09","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Inhibiteur des récepteurs AT1 de l'angiotensine","",""
"12913","12-01-05","PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Muscle Relaxant; Analgesic","Relaxant Musculaire; Analgésique","",""
"12914","12-01-09","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STERILE VANCOMYCIN HYDROCHLORIDE, USP","PHARMACEUTICAL PARTNERS OF CANADA INC","CANADA","CANADA","1","New Presentation; New Manufacturing Site","Nouvelle Prsentation; Nouvel Emplacement de Fabrication","Antibiotic","Antibiotique","",""
"12915","12-01-12","NOVARTIS ANIMAL HEALTH CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Non-steroidal Anti-inflammatory","Anti-inflammatoire Non-stéroïdien","",""
"12916","12-01-06","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","Revisisons to the Product Monograph","Révisions à la monographie de produit","Angiotensin II AT1 Receptor Blocker","Inhibiteur des récepteurs AT1 de l'angiotensine","",""
"12917","12-01-11","SUNOVION PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Direct Thrombin Inhibitor","Inhibiteur Direct de la Thrombine","",""
"12918","11-10-07","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Labelling update to reflect the two sunscreens as active ingredients","Mise à jour de l'étiquetage du produit pour indiquer la présence de deux écrans solaires comme ingrédients actifs","Anti-rosacea Agent","Agent antirosacée","",""
"12919","11-10-04","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product monograph: Addition of 192 week safety and efficacy data for treatment-naïve patients; label changes made to the Comapany Core Data Sheet of December 2010","Mise à jour de la monographie du produit: ajout de données d'efficacité et d'innocuité obtenues après 192 semaines de traitement des patients naifs, changements de l'étiquettage du produit basés sur les données essentielles recueillies par le fabricant","Human Immunodeficiency Virus (HIV) Protease Inhibitor","Inhibiteur de la protéase du virus de l'immunodéficience humaine (VIH)","",""
"12920","12-01-12","STASON PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal Aromatase Inhibitor; Inhibitor or Estrogen Biosynthesis; Anti-tumour Agent","Inhibiteur de l'aromatase non stéroïdien / Inhibiteur de la biosynthèse des oestrogènes / Antinéoplasique","",""
"12921","12-01-12","ASTRAZENECA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Receptor Tyrosine Kinase Inhibitor","Inhibiteur des Récepteurs de Tyrosine Kinase","",""
"12922","11-01-11","AVANSTRA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","Change in formulation and change to the manufacturing process","Modification à la formulation et au procédé de fabrication","Antihypertensive; Antianginal Agent","Antihypertenseur; Antiangineux","",""
"12923","12-01-13","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Indication for adults aged 50 years or older","Indication pour adultes âgées de 50 ans ou plus","Active Immunizing Agent","Agent d'immunisation Actif","",""
"12924","12-01-16","NOVARTIS ANIMAL HEALTH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional manufacturing facility and nds packaging","Addition d'un amplacement de fabrication et nouvel emballage","Antiparasitic","Antiparasitique","",""
"12925","12-01-12","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Replacement of sterility test with process parametric release","Substitution des épreuves de stérilité par un procédé de libération en fonction de paramètres","Electrolyte Replenisher","Réapprovisionnement d'électrolyte","",""
"12926","12-01-13","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMERGE","GLXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs 5-HT1; Antimigreaineux","",""
"12927","12-01-13","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CONCERTA","JANSSEN ORTHO INC","CANADA","CANADA","1","","","CNS Stimulant","Stimulant du SNC","",""
"12928","12-01-16","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Agent Antipsychotique","",""
"12929","12-01-16","Q-GEN PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"12930","12-01-16","Q-GEN PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive; Antianginal Agent","Antihypertenseue; Antiangineux","",""
"12931","12-01-16","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12932","12-01-16","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"12933","12-01-17","IMCLONE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing site and process","Nouveau site et processus de fabrication","Antineoplastic","Antinéoplastique","",""
"12934","12-01-16","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form and new indication forf the management of moderate to severe acute pain in adults","Nouvelle formw posologique et nouvelle indication pour le soulangement de la douleur aigüe d'intensité","Opioid Analgesic","Analgésique Opioïdes","",""
"12935","12-01-19","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with one or more non steroidal anti-inflammatory drugs and systemic corticosteroids","Nouvelle indication: ACTEMRA est indiqué dans le traitement de l'arthrite juvénile idiopathique systémique évolutive chez les patients âgés de 2 ans et plus qui n'ont pas répondu adéquatement à un traitement antérieur par un ou plusieurs anti-inflammatoires non stéroïdiens et des corticostéroïdes à action générale","Interleukin Receptor Inhibitor","Inhibiteur du récepteur de l'interleukine","",""
"12936","12-01-19","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anti-inflammatory Corticosteroid","Anti-inflammatoire Corticostéroïde","",""
"12937","12-01-20","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional drug product manufacturing facility","Addition d'un emplacement de fabrication du produit médicamentaux","Antidiabetic Agent","Agent Antidiabétique","",""
"12938","12-01-20","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional drug product manufacturing facility","Addition d'un emplacement de fabrication du produit médicamentaux","Antidiabetic Agent","Agent Antidiabétique","",""
"12939","12-01-19","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticholinergic - Antispasmodic Agent","Anticholinergique - Antispasmodique","",""
"12940","12-01-19","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I.V","BAYER INC","CANADA","CANADA","1","","","Antibacterial Agent","Antibactérien","",""
"12941","12-01-19","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticholinergic - Antispasmodic Agent","Anticholinergique - Antispasmodique","",""
"12942","12-01-19","ALKERMES GAINESVILLE LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive Agent","Antihypertenseur","",""
"12943","12-01-18","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des récepteurs des leucotriènes","",""
"12944","12-01-19","PERRIGO INTERNATIONAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ALEVE","BAYER INC, CONSUMER CARE DIVISION","CANADA","CANADA","1","","","Non-steroidal Anti-inflammatory Drug; Analgesic; Antipyretic","Anti-inflammatoire non Stéroïdien; Analgésique; Antipyretique","",""
"12945","12-01-19","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication","Nouvel indication","Corticosteroid","Corticostéroïde","",""
"12946","12-01-25","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR DS","MERCK FROSST  CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist and Diuretic","Antagoniste des Récepteurs de l'angiotensine II et Diurétique","",""
"12947","12-01-20","ANGELINI LABOPHARM LIMITED LIABILITY COMPANY (LLC)","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"12948","12-01-25","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR DS","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist and Diuretic","Antagoniste des Récepteurs de l'angiotensin II et Diurétique","",""
"12949","12-01-25","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR DS","MERCK FROSST CANADA & CO","CANADA","CANADA","1","New Strength","Nouvell concentration","Angiotensin II Receptor Antagonist and Diuretic","ANtagoniste des écepteur de l'angiotensin II et Diurétique","",""
"12950","12-01-25","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist","Antagonist des Récepteurs de l'angiotensine II","",""
"12951","12-01-25","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","Angiotensin II Receptor Antagonist","Antagoniste des Récepteurs de l'angiotensine II","",""
"12952","12-01-25","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist","ANtagoniste des Récepteurs de l'angiotensine II","",""
"12953","12-01-25","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA INC","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist","Antiagoniste des Récepteurs de l'angiotensine II","",""
"12954","12-01-23","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Platelet Aggregation Inhibitor","Inhibiteur de l'Aggrégation Plaquettaire","",""
"12955","12-01-19","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic; Antipyretic","Analgésique; Antipyrétique","",""
"12956","12-01-17","PERRIGO INTERNATIONAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ALEVE","BAYER INC  CONSUMER CARE DIVISION","CANADA","CANADA","1","","","Non-steroidal ANti-inflammatory Drug; Analgesic; Antipyretic","Anti-inflammatoire non Stéroïdien; Analgésique; Antipyrétique","",""
"12957","12-01-17","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppressive Agent","Immunosuppresseur","",""
"12958","12-01-20","SANOFI AVENTIS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antimitotic Agent","Agent Antimitotique","",""
"12959","12-01-20","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"12960","12-01-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist","Antagoniste des Récepteurs de l'Angiotensine II","",""
"12961","12-01-25","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist","Antagoniste des Récepteurs de l'Angiotensine II","",""
"12962","12-01-25","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Antiotensin II Receptor Antagonist","Antagoniste des Récepteurs de l'Angiotensine II","",""
"12963","12-01-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist and Diuretic","Antagoniste des Récepteurs de l'Angiotensine II et Diurétique","",""
"12964","12-01-25","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist and Diuretic","Antagoniste des Récepteurs de l'Angiotensine II et Diurétique","",""
"12965","12-01-24","OTSUKA PHARMACEUTICAL CO. LTD.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Expanding the package insert in order to provide additonal imformation to the clinicians","Agrandir la notice d'accompagnement du produit afin d'y inclure d'autres renseignements à l'intention des cliniciens","Antineoplastic","Antinéoplastique","",""
"12966","12-01-16","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: prevention of stroke and systemic embolism in patients with arterial fibrillation:  New strengths 15mg, 20mg","Nouvelle indication: la prévention de l'accident vasculaire cérébral et de l'embolie systémique chez les patients atteints de fibrallation auriculaire. Nouvelles concentrations, 15mg, 20 mg","Anticoagulant","Anticoagulant","",""
"12967","11-11-21","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the indications: Treatment of patients with paroxysmal or persistent atrial fibrillation who are in sinus rhythm or who are intended to be cardioverted to reduce the risk of cardiovascular hospitalization due to arterial fibrillation. Multaq should only be prescribed after alternative treatment options have been considered.","Modifications apportées aux indications: traitement des patients atteints de fibrillation auriculaire paroxystique ou persistante qui sont en rythme sinusal ou chez qui ona l'intention de procéder à une cardioversion, afin de réduire le risque d'hospitalisation pour cause d'affection cardiovasculaire attribuable à la fibrillation auriculaire. Multaq ne devrait être prescit qu'après avoir envisageé les auttres options thérapeutique","Antiarrhythmic Agent","Antiarythmique","",""
"12968","12-01-26","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MERREM","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antibiiotic","Antibiotique","",""
"12969","12-01-26","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective Norepinephrine Reuptake Inhibitor for Attemtion-Deficit/Hyperactivity Sidorder (ADHD)","Inhibiteur Sélectif du Recaptage de la Noradrénalin Pour le Trouble LE Déficitaire de l'Attention Avec Hyperactivité (TDAH)","",""
"12970","12-01-27","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XALATAN","PFIZER CANADA INC","CANADA","CANADA","1","","","Prosataglandin F2a Analogue","Analogue de la Prostaglandine F2a","",""
"12971","12-01-27","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XALATAN","PFIZER CANADA INC","CANADA","CANADA","1","","","Prostaglandin F2a Analogue","Analogue de la Prostaglandine F2a","",""
"12972","12-01-30","VITA HEALTH PRODUCTS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ALEVE","BAYER INC, CONSUMER CARE DIVISION","CANADA","CANADA","1","","","Non-steroidal Anti-inflammatory Drug; Analgesic; Antipyretic","Non-stéroïdien Anti-inflammatoire; Analgésique; Antipyretique","",""
"12973","12-01-27","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist","Antagoniste des Récepeurs de l'Angiotensine II","",""
"12974","12-01-27","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist","Antagoniste des Récepteurs de l'Angiotensine II","",""
"12975","12-01-30","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT RPD","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","5-HT1 Receptor Agonist, Migraine Therapy","Agoniste des récepteurs de la 5-HT1, Antimigraineux","",""
"12976","12-01-30","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral Contraceptive","Contraceptif Orale","",""
"12977","12-01-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT LINGUA","MSD SHARPE & DOHME GMBH","GERMANY","ALLEMAGNE","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs 5-HT1: Antimigraineux","",""
"12978","12-01-30","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT RPD","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Migraine Therapy","Antimigraineux","",""
"12979","12-01-30","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT","MERCK & CO INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs 5-HT1: Antimigraineux","",""
"12980","12-01-30","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT","MERK FROSST CANADA LTD","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs 5-HT1: Antimigraineux","",""
"12981","12-01-25","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial Agent","Antibactérien","",""
"12982","12-01-30","GRIFOLS THERAPEUTICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Passive Immunizing Agent","Agent d'Immunisation Passive","",""
"12983","12-01-30","GRIFOLS THERAPEUTICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Passive Immunizing Agent","Agnet d'Immunisation Passive","",""
"12984","12-01-30","GRIFOLS THERAPEUTICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Anticoagulant","Anticoagulant","",""
"12985","12-02-01","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du Méetabolisme Osseux","",""
"12986","12-01-31","MYLAN PHARMACEUTICALS ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXOSMITHKLINE INC","CANADA","CANADA","1","New manufacturing facilities","Nouvel emplacement de fabrication","Histamine H2-Receptor Antagonist","Antagoniste des Récepteurs H2 de l'Histamine","",""
"12987","12-02-01","BRISTOL MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Antineoplastic","Antinéoplastique","",""
"12988","12-01-30","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA","CANADA","CANADA","1","","","ANtidepressant; Antiobsessional; Antipanic; Anxiolytic Agent; Social Phobia (Social Anxiety Disorder)Therapy; Posttraumatic Stress Disorder Therapy","ANtidépresseur; Antiobsessionnel; Antipanique; Anxiolytique; Traitement de la Phobie Social et Traitement de l'état de Stress Post-Traumatique","",""
"12989","12-02-02","GRIFOLS THERAPEUTICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Alpha1-Antitrypsin Replenisher","Agent de Recharge en Alpha1-Antitrypsine","",""
"12990","12-02-02","GRIFOLS THERAPEUTICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Passive Immunizint Agent","Immunothérapie Passive","",""
"12991","12-02-02","GRIFOLS THERAPEUTICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Passive Immunizing Agent","Immunothérapie Passive","",""
"12992","12-02-02","GRIFOLS THERAPEUTICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Passive Immunizing Agent","Immunothérapie Passive","",""
"12993","12-02-02","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","BIOVAIL PHARMACEUTICALS CANADA, DIVISION OF BIOVAIL CORPORATION","CANADA","CANADA","1","New Manufacturing Site","Nouvel emplacement de fabrication","Antidepressant","Antidépresseur","",""
"12994","12-02-02","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","Product name change","Changement du nom du produit","Immunosuppressive Agent","Immunosuppresseur","",""
"12995","12-02-02","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ALEVE","BAYER INC, CONSUMER CARE DIVISION","CANADA","CANADA","1","","","Non-steroidal Anti-inflammatory Drug; Analgesic; Antipyretic","Anti-inflammatoire non stéroïdien; Analgésique; Antipyretique","",""
"12996","12-02-03","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRUSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Elevated Intraocular Pressure Therapy (Topical Carbonic Anhydrase Inhibitor)","Traitement d'une Pression Intraoculaire élevée (Inhibiteur Topique de l'anhydrase Carbonique)","",""
"12997","12-02-02","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 Alpha-Reductase Inhibitor","Inhibiteur de la 5 Alpha-Réductae de Type II","",""
"12998","12-02-02","AA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALERTEC","SHIRE BIOCHEM INC","CANADA","CANADA","1","","","Central Nervous System Stimulant","Stimulant du Système Nerveux Central","",""
"13000","12-02-01","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial Agent","Antibactérien","",""
"13001","12-02-01","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Oral Antidiarrheal Agent","Antidiarrhétique Oral","",""
"13002","12-02-01","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR DS","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist and Diuretic","Antagoniste des Récepteurs de l'Angiotensine II et Diurétique","",""
"13003","12-02-03","GRIFOLS THERAPEUTICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Alpha-1 Antitrypsin Replenisher","Agent de Recharge en Alpha-1 Antitrypsine","",""
"13004","12-02-03","GRIFOLS THERAPEUTICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Passive Immunizing Agent","Agent d'Immunisation Passive","",""
"13005","12-02-03","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","For issuance of DINS for Unit Dose pre-filled syringes","Emission de DIN pour les seringues pré-remplis à dose unitaire","Anticoagulant - Antithrombotic Agent","Anticoagulant et Antithrombotique","",""
"13006","12-02-03","GRIFOLS THERAPEUTICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Passive Immunizing Agent","Agent d'Immunisation Passive","",""
"13007","12-02-03","GRIFOLS THERAPEUTICS INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Passive Immunizing Agent","Agent d'mmunisation Passive","",""
"13008","12-02-03","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR DS","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist and Diuretic","Antagoniste de Récepteur de l'Angiotensine II et Diurétique","",""
"13009","12-02-03","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Blocquer de Récepteur AT1 de l'Angiotensine II","",""
"13010","12-02-06","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGGELHEIM (CANADA) LTD","CANADA","CANADA","1","New Strength","Nouvelle concentration","Angiotensin II AT1 Receptor Blocker / Diuretic","Inhibiteur des Récepteurs AT1 de l'Angiontensine II; Diurétique","",""
"13011","12-02-06","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGELEHIM (CANADA) LTD","CANADA","CANADA","1","","","ANgiotensin II AT1 REceptor Blockerl Diuretic","Inhibiteur des Récepteurs AT1 de l'Angiontensine II; Diurétique","",""
"13012","12-02-02","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Inhibiteur des Récepteurs AT1 de l'Angiotensine II","",""
"13013","12-02-03","SALIX PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","mcg-Opioid Receptor Antagonist","Antagoniste du récepteur opioïde-mcg","",""
"13014","12-02-02","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: for the treatment of progressive neuroendocrine tumours of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease ","Nouvelle indication: pour le traitement des tumeurs neuroenocrines (TNE) d-origine pancréatique et de nature évolutive chez les patients atteints d'une maladie nonrésécable localement ou métastatique","Antineoplastic Agent (mTOR Kinase Inhibitor)","Antinéoplasique (Inhibiteur de la mTOR kinase)","",""
"13015","12-02-03","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To align the Product Monograph with the Company Core Safety Information (CCSI) and convert from old to new format according to the requirements, as per Health Canada Product Monograph Guidance","Harmoniser la monographie du produit avec l'information de base de l'entreprise sur son innocuité et convertir l'ancien format au nouveau, comme le prescrit la ligne directrice sur les monographies de produit de Santé Canada","Antineoplastic Agent","Antinéoplastique","",""
"13016","12-02-07","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Recpetor Blocker","Antagoniste des Récepteurs AT1 de l'Angiotensine II","",""
"13017","12-02-07","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker; Diuretic","Antagoniste des Récepteurs AT1 de l'Angiotensine II; Diurétique","",""
"13018","12-02-09","ECOLAB CO","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional Claim","Indication Supplémentaire","Antiseptic","Antiseptique","",""
"13019","12-02-09","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anticholinergic; Antispasmodic Agent","Anticholinergique; Antispasmodique","",""
"13020","12-02-10","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","Product name change","Changement du nom  du produit","Angiotensin II AT1 Receptor Blocker","Inhibiteur des récepteurs AT1 de l'angiotensine II","",""
"13021","12-02-10","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Oral Antihyperglycemic Agent","Antihyperglycémiant Oral","",""
"13022","12-02-10","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Oral Antihyperglycemic Agent","Antihyperglycémiant Oral","",""
"13023","12-02-10","INSIGHT PHARMACEUTICALS LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antifungal Agent","Antifongique","",""
"13024","12-02-10","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2 Receptor Antagonist","ANtagoniste des Récepteurs H2 à l'Histamine","",""
"13025","12-02-10","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EVISTA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective Estrogen Receptor Modulator","Modulateur Sélectif des Récepteurs Estrogéniques","",""
"13026","12-02-10","AVANSTRA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2 Receptor Antagonist","ANtagoniste des Récepteurs H2 de l'Histamine","",""
"13027","12-02-10","ODAN LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme Lipidique","",""
"13028","12-02-10","BIOGEN IDEC CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Potassium Channel Blocker","Blocquer du Canal de Potassium","",""
"13029","12-02-10","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Histamine H1 Receptor Antagonist","Antagoniste des Récepteurs H1 de l'Histamine","",""
"13030","12-02-10","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Modify wording of the indication on the inner and outer labels from Cures Athlete's Foot to Kills Athlete;s Foot Fungus","Remplacement le texte de l'indication Guérit le pied d'athlete sur les étiquettes intérieures et extérieures par Tue les champignons du peid d'athlete","Topical Antifungal Agent","Antifongique Topique","",""
"13031","12-02-13","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppresive AAgent","Immunosuppresseur","",""
"13032","12-02-13","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL EXTRA STRENGTH LIQUI-GELS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Analgesic; Antipyretic","Analgésique; Antipyretique","",""
"13033","12-02-14","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leukotriènes","",""
"13034","12-02-13","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la Monographie du Produit","Antineoplastic","Antinéoplastique","",""
"13035","12-02-13","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Passive Immunizing Agent","Agent d'Immunisation Passif","",""
"13036","12-02-14","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"13037","12-02-14","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph","Mise à jour de la Monographie du Produit","Inhalation Anaesthetic","Anesthésique par Inhalation","",""
"13038","10-02-14","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"13039","12-02-15","HOFFMANN LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Protein Kinase Inhibitor","Inhibiteur de la protéine kinase","",""
"13040","12-02-17","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","Antidepressant / Anxiolytic","Antidépresseur / Anxiolytique","",""
"13041","12-02-15","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB COMPANY","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13042","12-02-15","BAXTER HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New indication: routine prophylaxis to prevent or reduce frequency of bleeding episodes in adults and children with Haemophilia A","Nouvelle indication: prophylaxie de routine visant la prévention et la réduction des épisodes hémorragiques chez les adultes et enfants atteints d'hemophilie A","Coagulation Agent","Agent de Coagulation","",""
"13043","12-02-15","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antineoplastic Agent","Antinéoplastique","",""
"13044","12-02-15","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: treatment of deep vein thrombosis (DVT) without symptomatic pulmonary emoblism (PE)","Nouvell indiaction: le traitement de la thrombose veineuse profonde (TVP) sans embolie pumonaire symptomatique","Anticoagulant","Anticoagulant","",""
"13045","12-02-17","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","To remove metastatic breast cancer indication","Retirer l'indication sur le cancer du sein métastatique","Antineoplastic","Antinéoplasique","",""
"13046","12-02-15","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of long term safety and efficacy data - 156 - of raltegravir in combination with other antiretroviral therapy in HIV-infected treatment naïve adult patients","Ajout de sonnées sur l'innocuité et l'efficacité à lon terme - 156 semaines - du raltegravir lorsqu'administré en association avec une autre thérapie antirétrovirale à des adultes infectés par le VIH et n'ayant jamais reçu un traitement antirétroviral.","Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor","Inhibiteur de transfert de brin d'intégrase du virus de l'immunodéficience humaine","",""
"13047","12-02-21","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional claim","Indication supplémentaire","Non-steroidal Anti-inflammatory","Anti-inflammatoire non stéroïdien","",""
"13048","12-02-21","CSL BEHRING CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Change in manufacturing process","Changement au processus de fabrication","Serine Protease Inhibitor","Inhibiteur de Protéase de Sérine","",""
"13049","12-02-21","TORRENT PHARMACEUTICALS LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","UCB CANADA INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"13050","12-02-21","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALternate manufacturing site","Variation d'emplacement du site de fabrication","Anesthetic","Anesthésique","",""
"13051","12-02-22","BIO AGRI MIX LP","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","TYLAN 40 PREMIX","ELANCO, DIVISION OF ELI LILLY CANAD INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13052","12-02-22","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT","MERCK & CO","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Antagoniste des Récepteurs de la 5-HT1: Antimigraineux","",""
"13053","12-02-22","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial Agent","Antibactérien","",""
"13054","12-02-22","ACTAVIS GROUP PTC EHF","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13055","12-02-22","BENTEC PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13056","12-02-22","SEPTA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial Agent","Antibactérien","",""
"13057","12-02-21","IPSEN BIOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revised method of manufacturing of drug substance and drug product","Procédé révisé de fabrication de la substance et du produit pharmaceutiques","Antigrowth Hormone","Inhibiteur de l'hormone de croissance","",""
"13058","12-02-24","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant; Antiobssessional; Antibulimic","Antidépresseur; Antiobsessionnel; Antibulimique","",""
"13059","12-02-24","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph","Mise à jour de la monographie du produit","Beta-Adrenergic Receptor Blocking Agent","Inhibiteur des Récepteurs Bêta-Adrénergique","",""
"13060","12-02-24","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","Leukotriene Receptor Antagoniste","Antagoniste des Récepteurs des Leukotrienes","",""
"13061","12-02-27","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph revised","Monographie du Produit révisée","Active Immunizing Agent","Agent d'immunisation Actif","",""
"13062","12-02-27","JANSSEN BIOTECH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Monoclonal Antiplatelet Antibody","Anticorps Monoclonal Antiplaquettaire","",""
"13063","12-02-28","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","New Strength","Nouvelle concentration","Angiotensin II Receptor Antagonist","Antagonistes des Récepteurs de l'Angiotensine","",""
"13064","12-02-28","MODERN VETERINARY THERAPEUTICS LLC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","VENTIPULMIN","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Bronchodilator","Bronchodilateur","",""
"13065","12-02-29","SUNOVION PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Nwe indication: treatment of patients with acute coronary syndromes due to ST-segment elevation myocardial infacrtion (STEMI) undergoing percutanious coronary intervention (PCI)","Traitement de patients atteints de syndromes coronariens aigus des suites d'un infarctus du myocarde, indiqué par un sus-décalage du segment ST, et qui subissent une angioplastie coronaire transluminale percutanée (ACTP)","Direct Thrombin Inhibitor","Inhibiteur Direct de la Thrombine","",""
"13066","12-02-29","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New dosage form and strength","Nouvelle forme posologique et concentration","Histamine H1 Receptor Antagonist","Antagoniste des Récepteurs H1 de l'Histamine","",""
"13067","12-02-29","SHIRE HUMAN GENETIC THERAPIES INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing site","Nouveau site de fabrication","Enzyme Replacement Therapy","Enzymothérapie de Remplacement","",""
"13068","12-03-01","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MALARONE","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antimalarial Agent","Antipaludéen","",""
"13069","12-03-01","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ETOPOSIDE INJECTION","NOVOPHARM LIMITED","CANADA","CANADA","1","","","Antineoplastic Agent","Antinéoplastique","",""
"13070","12-03-05","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Oral Antihyperglycemic Agent","Antihyperglycémiant Oral","",""
"13071","12-03-05","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Antifungal Agent","Antifongique Topique","",""
"13072","12-03-05","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Corticosteroid","Corticostéroïde Topique","",""
"13073","12-03-05","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Acne Vulgaris Therapy","Traitement de l'Acne Vulgaire","",""
"13074","12-03-05","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-Rosacea Agnet","Agent Anti-rosacée","",""
"13075","12-03-02","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB COMPANY","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Lipid Metabollism Regulator","Régulateur du Métabolisme des Lipides","",""
"13076","12-03-02","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Oral Antihyperglycemic Agent","Antihyperglycémiant Oral","",""
"13077","12-03-02","SEPTA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Oral Antihyperglycemic Agent","Antihyperglycémiant Oral","",""
"13078","12-03-06","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"13079","12-03-06","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antifungal, Antibacterial, Anti-inflammatory","Antifongique, Antibactérien, Anti-inflammatoire","",""
"13080","12-03-07","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Acne Therapy","Traitement de l'acné","",""
"13081","12-03-07","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","AGONISTE DES RÉCEPTEURS 5-HT1, ANTIMIGRAINEUX","",""
"13082","12-03-07","ODAN LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive - Antianginal Agent","Antihypertenseur et Antiangineux","",""
"13083","12-03-07","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Clinical Trials and Overdosage sections of the Product Monograph","Mise à jour des sections de la Monographie du Produit portant sur les essais cliniques et le surdosage","Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor","Inhibiteur de la tyrosine kinase du récepteur du facteur de croissance épidermique (EGFR)","",""
"13084","12-03-05","IPSEN BIOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product Monograph revisions related to an extended dosing interval","Modifications à la monographie du produit liées à un espacement des doses prolongé","Antigrowth Hormone","Inhibiteur de l'Hormone de Croissance","",""
"13085","12-03-06","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Warnings and Precautions and Drug-Drug Interactions sections of the Product Monograph","Mise à jour des sections de la monographie du produit portant sur les mise en garde et les mesures de précaution ainsi que les interactions médicamenteuses","Bone Metabolism Regulator","Régulateur du Métabolisme Osseux","",""
"13086","12-02-21","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update the PRoduct Monograph to comply with the newly updated Company Core Data Sheet for Magnevist","Mettre à jour la monographie de Magnevist afin qu'elle soit conforme aux données de base de l'enterprise récemment mises à jour pour ce produit","Contrast agent for Magentic Resonance Imaging","Produit de contraste pour l'imagerie par résonance magnétique","",""
"13087","12-03-07","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppressive Agent","Immunosuppresseur","",""
"13088","12-03-08","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 Receptor Blocker","Inhibiteur des Récepteurs AT1 de l'Angiotensine II","",""
"13089","12-03-09","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"13090","12-03-09","GLAXOSMITHKLINE INC","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Antineoplastic Agent","Agent Antinéoplastique","",""
"13091","12-03-09","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New route: subcutaneous injection","Nouvelle voie: injection sou-cutané","Antineoplastic Agent","Antinéoplastique","",""
"13092","12-03-12","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anticoccidial","Anticoccidien","",""
"13093","12-03-12","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","New strength","Nouvelle concentration","Antiviral Agent","Antiviral","",""
"13094","12-03-13","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication for the acute treatment of manic or mixed episodes in bipolar 1 disorder as monotherapy in adolescent patients 13-17 years of age","Nouvelle indication pour le traitement aigu des épisodes maniaques ou mixtes associeés aux troubles bipolaires des type 1 en monothérapie chez des patients adolescents âgées de 13 à 17 ans","Antipsychotic","Antipsychotique","",""
"13095","12-03-14","EISAI LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-emetic (5-HT3 Receptor Antagonist)","Antiémetique (Antagoniste des récepteurs 5-HT3","",""
"13096","12-03-13","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","New indication","Nouvell indication","Antineoplastic Agent","Antinéoplastique","",""
"13097","12-03-13","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"13098","12-03-14","TRIBUTE PHARMACEUTICALS CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Nonsteroidal Anti-inflammatory Drug (NSAID)","ANti-inflammatoire non Stéroïdien (AINS)","",""
"13099","12-03-15","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","N-methyl-D-aspartate Receptor Antagonist","ANtagoniste du Récepteur N-methyl-D-aspartate","",""
"13101","12-03-15","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"13102","12-03-15","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid MEtabolism Regulator","Régulateur du métabolisme des lipides","",""
"13104","12-03-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"13105","12-03-15","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"13106","12-03-15","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"13107","12-03-15","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"13108","12-03-15","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du Métabolisme Osseux","",""
"13109","12-03-15","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial Agent","Antibactérien","",""
"13110","12-03-15","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypercholesterolemic and Antidiarrheal","Antihypercholestérolémiant et Antidiarrheique","",""
"13111","12-03-15","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Collagenase Inhibitor for Periodontal use","Inhibiteur de la Collagénase pour Usage Parodontal","",""
"13112","12-03-15","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Oral Antihyperglycemic Agent","Antihyperglycémiant Oral","",""
"13113","12-03-15","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","BRISTOL-MYERS SQUIBB/SANOFI SYNTHELABO CANAD INC","CANADA","CANADA","1","","","Platelet Aggregation Inhibitor","Inhibiteur de l'aggregation Plaquettaire","",""
"13114","12-03-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG RAPIMELT","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs 5-HT1; Antimigraineux","",""
"13115","12-03-15","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Allergenic Substance","Substance Allergénique","",""
"13116","12-03-16","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product process modifications","Modification de la méthode de fabrication","Active Immunizing Agent","Agent d'immunisation Actif","",""
"13117","12-03-16","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","New manufacturing process","Nouveua procédé de fabrication","Radiotherapeutic Agent","Agent Radiothérpeutique","",""
"13118","12-03-19","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Antifungal Agnet","Antifongique Topique","",""
"13119","12-03-19","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT","MERCK & CO INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des récepteurs de la 5HT1; Antimigraineux","",""
"13120","12-03-16","MANDA PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial Agent","Antibactérien","",""
"13121","12-03-16","MEDICIS PHARMACEUTICAL CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immune Response Modifier","Modificateur de la réponse Immunitaire","",""
"13122","12-03-16","MEDICIS PHARMACEUTICAL CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immune Response Modifier","Modificateur de la Réponse Immunitaire","",""
"13123","12-03-16","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective Norepinephrine Reuptake Inhibitor for Attention Deficit/Hyperactivity Disorder (ADHD)","Inhibiteur sélectif du recaptage de la noradrénaline pour la trouble déficitaire de l'attention avec hyperactivité (TDAH)","",""
"13124","12-03-16","MEDICIS PHARMACEUTICAL CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid for Oral Inhalation","Corticostéroîde pour Inhalation Orale","",""
"13125","12-03-16","MEDICIS PHARMACEUTICAL CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Immune Response Modifier","Modificateur de la Réponse Immunitaire","",""
"13126","12-03-19","PALADIN LABS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New tablet formulation","Nouvelle formulation pour le comprimé","Opioid Analgesic","Analgésique Opiacé","",""
"13127","12-03-20","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","ANtagoniste des récepteurs des Leucotriènes","",""
"13128","12-03-20","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","","","Histamine H1 Receptor Antagonist","Antagoniste des Récepteurs H1 de l'histamine","",""
"13129","12-03-20","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Acne Therapy","Traitement TOpique de l'acné","",""
"13130","12-03-20","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Topical Sterdoid","Corticostéroïde Topique","",""
"13131","12-03-20","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiparasitic","Antiparasitaire","",""
"13132","12-03-20","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph regarding pediatric use","Mise à jour de la Monographie du Produit concernant l'utilisation pédiatrique","Antipsychotic Agent; Antidepressant","Antipsychotique; Antidépresseur","",""
"13133","12-03-20","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional drug product manufacturing site","Site de fabrication additionnel pour le produit médicamenteux","Antineoplastic","Antinéoplasique","",""
"13134","12-03-21","AGRISAN SPECIALTY CHEMICAL & PHARMACEUTICAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","THERAPEUTIC PRE & POST ANTISEPTIC TEAT DIP","WESTFALIA SURGE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antidseptic Teat Dip","Bain de Trayons Antiseptique","",""
"13135","12-03-23","ACCORD HEALTHCARE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE CANADA INC","CANADA","CANADA","1","New formulation","Nouvelle formulation","5-HT3 Receptor Antagonist, Antiemetic Agent","Antagoniste des Récepteurs 5-HT3, Antiémétique","",""
"13136","12-03-23","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZEMURON","SCHERING-PLOUGH CANADA INC","CANADA","CANADA","1","","","Non-depolarizing Skeletal Neuromuscular Blocking Agent","Bloqueur Neuromusculaire Squelettique nonDépolarisant","",""
"13137","12-03-26","ALVEDA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NALOXONE HYDROCHLORIDE INJECTION","SANDOZ CANADA INC","CANADA","CANADA","1","","","OPIOID ANTAGONIST","ANTAGONISTE DES OPIOÏDES","",""
"13138","12-03-26","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIDAZOLAM INJECTION","SANDOZ CANADA INC","CANADA","CANADA","1","","","BENZODIAZEPINE - PREMEDICANT - SEDATIVE - ANAESTHETIC AGENT","BENZODIAZÉPHINE - PRÉMÉDICATION - SÉDATIF - ANESTHÉSIQUE","",""
"13139","12-03-22","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal Aromatase Inhibitor; Inhibitor of Estrogen Biosynthesis; Anti-tumor Agent","Inhibiteur de l'aromatase non Stéroïdien; Inhibitor de la Biosynthèse des Oestrogénes; Antinéoplastique","",""
"13140","12-03-23","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADRIAMYCIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","Antineoplastic Agent","Antinéoplastique","",""
"13141","12-03-23","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","Remooval of the commitments as per the Letter of Undertaking dated November 3, 2009 for the symptomatic treatment of patients with moderate to severe dementia of the alzheimer'x type.","Retrait des obligations énoncées dans la lettre d'engagement du 3 novembre 2009 au sujet du traitement symptomatique de la démence de type Alzheimer d'intensité modérée à sévère","N-Methyl-D-Aspartate (NMDA) Receptor Inhibitor","Antagoniste du récepteur N-méthyl-D-asparte","",""
"13142","12-03-26","MEDICIS PHARMACEUTICAL CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Brochodilator; Beta2-adrenergic Stimulant","Bronchodilateur; Stimulant des Récepteurs B2-adrèdergiques","",""
"13143","12-03-26","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Saluretic - Diuretic Agent","Saldiurétique","",""
"13144","12-03-26","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Chelating Agent","Chélateur","",""
"13145","12-03-26","CELGENE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic Agent","Antinéoplastique","",""
"13146","12-03-26","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial Agent","Agent Antibactérien","",""
"13147","12-03-22","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic Receptor Blocking Agent","Inhibiteur des Récepteurs Beta-adrenergiques","",""
"13148","12-03-22","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","","","Histamine H1 Receptor Antagonist","Antagoniste des Récepteurs de l'histamine H1","",""
"13149","12-03-25","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CESAMET","VALEANT CANADA LTD","CANADA","CANADA","1","","","Antiemetic","Antiémétique","",""
"13150","12-03-23","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Alternate dosing schedule","Plan posoligique alternatif","Immunological","Immunologique","",""
"13151","12-03-26","LUNDBECK INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph regarding pediatric use","Mise à jour de la monographie du produit concernant l'utilisation pédiatrique","Antiepileptic","Antiépileptique","",""
"13152","12-03-26","MEDICIS PHARMACEUTICAL CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial Agent","Agent Antibactérien","",""
"13153","12-03-26","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Cardiotonic Glycoside","Glycoside Cardiotonique","",""
"13154","12-03-27","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antifungal Agent","Antifongique","",""
"13155","12-03-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métablisme des Lipides","",""
"13156","12-03-28","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG, ZOMIG RAPIMELT","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist - Migraine Therapy","Agoniste des Récepteurs 5-HT1; Antimigraineux","",""
"13157","12-03-28","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leucotriènes","",""
"13158","12-03-28","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NURONTIN TABLETS / NEURONTIN CAPSULES","PFIZER CANADA INC / PARKE-DAVIS (USA)","CANADA","CANADA","1","","","Antiepileptic Agent","Antiépileptique","",""
"13159","12-03-28","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leukotriènes","",""
"13160","12-03-28","SANDOZ CANADA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing site","Nouvel emplacement de fabrication","Opioid Antagonist","Antagoniste des Opioïdes","",""
"13161","12-03-28","SANDOZ CANADA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LASIX","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","New manufacturing site","Nouvel emplacement de fabrication","Diuretic","Diurétique","",""
"13162","12-03-28","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DILAUDID-HP","PURDUE PHARMA INC.","CANADA","CANADA","1","","","Opioid Analgesic","Analgésique opioïde","",""
"13163","12-03-28","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional primary and secondary packaging site; additional container closure system","Site de conditionnement primaire et secondaire supplémentaire; système récipient=fermeture supplémentaire","Antineoplastic","Antinéoplastique","",""
"13164","12-03-30","NOVOCOL PHARMACEUTICAL OF CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Local Anaesthetic for Dental Use","Anesthésique Local pour Usage Dentaire","",""
"13165","12-03-29","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMTAN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Adjunct to Levodopa and DDC Inhibitor / COMT Inhibitor","Traitement d'appoint à la Lévodopa et Inhibiteur de la DDC /  COMT","",""
"13166","12-03-29","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMTAN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Adjuct to Levodopa and DDC Inhibitor / COMT Inhibitor","Traitement d'appoint à la Lévodopa et Inhibiteur de la DDC /  COMT","",""
"13167","12-03-30","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT","MERCK & CO INC.","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs de la 5-HT1; Antimigraineux","",""
"13168","12-03-30","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Name change","Changement du nom","Histamine H1 Receptor Antagonist","Antagoniste des Récepteurs H1 de l'Histamine","",""
"13169","12-03-30","AVANSTRA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leucotriènes","",""
"13170","12-03-30","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Safety Updates to the Product Monograph","Mise à jour de la monographie du produit","Synthetic Antithrombotic","Antithrombotique synthétique","",""
"13171","12-03-30","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZEMURON","ORGANON CANADA LTD","CANADA","CANADA","1","New indication","Nouvelle indication","Non-depolarizing Skeletal Neuromuscular Blocking Agent","Bloqueur neuromusculaire squelettique non dépolarisant","",""
"13172","12-03-30","PHARMA STRIDES CANADA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBRAMYCIN INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13173","12-03-29","MEDICIS PHARMACEUTICAL CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antianginal","Antiangineux","",""
"13174","12-03-30","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revised indication: Forane (Isoflurane) is indicated for induction and maintenance of gerneal anesthesia. Revisions to the Product Monograph","IndicationréviséeL le médicament Forane (Isoflurane) est administré pour l'induction et le maintien de l'anesthésie générale. Révisions de la monographie de produit","Inhalation Anesthetic","Anesthétique par Inhalation","",""
"13175","12-03-30","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","Revisions to the PRoduct Monograph","Révisions à la monographie de produit","Angiotensin II Receptor Antagonist","ANtagoniste des Récepteurs de l'angiotensine II","",""
"13176","12-03-30","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Adjuct to Levodopa and DDC Inhibitor - COMT Inhibitor","Adjuvant à la L1?vodopa et Inhibteur de la DDC - Inhibieur de la COMT","",""
"13177","12-03-30","LABORATOIRES THEA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-Allery Agent","Agent Antiallergique","",""
"13178","12-03-30","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du métabolisme des lipides","",""
"13179","12-03-30","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial Agent","Agent Antibactérien","",""
"13180","12-03-30","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic / Antimanic","Antipsychotique / Antimaniaque","",""
"13181","12-04-03","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMANN-LA ROCHE CANADA LTD","CANADA","CANADA","1","New manufacturing site","Nouvel emplacement de fabrication","Benzodiazepine, Premedicant-Sedative-Anesthetic Agent","Benzodiazépine, Prémédicament-Sédatif-Anesthétique","",""
"13182","12-04-03","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBRAMYCIN INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13183","12-04-03","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","GLYCOPYRROLATE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Anticholiergic","Anticholinergique","",""
"13184","12-04-03","OMEGA LABORATORIES LTD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","GLYCOPYRROLATE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","New formulation","Nouvell formulation","Anticholinergic","Anticholinergique","",""
"13185","12-03-30","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN-HCT","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker and Diuretic","Antagoniste des Récepteurs At1 d l'Angiotensin II et Diurétique","",""
"13186","12-04-03","JUBILANT DRAXIMAGE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","Alternate raw material supplier / New formulation","Fournisseur alternatif de la matière première / Nouvelle formulation","Radiopharmaceutical","Produit Radiopharmaceutique","",""
"13187","12-04-04","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM","HOESCHT MARION ROUSSEL CANADA","CANADA","CANADA","1","","","Antiarrhythmic","Antiarythmique","",""
"13188","12-04-04","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","New manufacturing process","Nouveau procédé de fabrication","Radiotherapeutic Agent","Angent Radiothérapeutique","",""
"13189","12-04-04","VETOQUINOL N A INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anticonvulsant","Anticonsulsivant","",""
"13190","12-04-05","ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Androgen","Androgène","",""
"13191","12-04-05","INSIGHT PHARMACEUTICALS LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antifungal Agent","Antifongique","",""
"13192","12-04-04","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","New Strength","Nouvell Concentration","N-Methyl-D-Aspartate (NMDA) Receptor Antagonist","Antagoniste du récepteur N-méthyl-D-aspartate","",""
"13193","12-04-10","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Immunosuppressant; Calincurin Inhibitor","Immunosuppresseur; Inhibiteur de la Calcineurine","",""
"13194","12-04-10","VETOQUINOL N A INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","New Indication","Nouvelle Indication","Antihelmintic","Antihelmintique","",""
"13195","12-04-02","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of the 6 mg/mL strength. Updated to the PRoduct Monograph; extemporaneous preparation of oral suspension from capsules","Ajout de la concentration de 6 mg/mL. Mise à jour de la monographie du produit; péparation magistrale d'une suspension orale à partir de capsules","Antiviral Agent","Antiviral","",""
"13196","12-04-04","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Strength of the benzoyl peroxide component in a preservative free formulation. Changes to the drug substance which applies to both the currently approved Clindoxyl Gel as well as the new Clindoxyl Adv Gel. Conversion of the Product Monograph to the new format which now includes Information for the Consumer","Nouvelle concentraiton du composant peroxyde de benzoyle dans ine formulation sans agent de préservation. Modifications à la substance médicamenteuse apportée à la fois au Clindoxyl Gel actuellement approuvé et au nouveau. Conversion de la monographie du produit au nouveau format, qui comprend dorénavant de Resneignements destinés aux patients","Topical Acne Therapy","Traitement de l'acné topique","",""
"13197","12-04-12","MERZ PHARMACEUTICALS GMBH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Muscle Relaxant, Peripherally Acting Agent","Les Relaxants Musculaire, des Agents à Action Péripherique","",""
"13198","12-04-12","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of New Manufacturing Site","Nouvel epmlacement de fabrication","Antihemorrhagics, Blood Coagulation Factors IX, II, VII, X in Combination","Antihémorragiques, Association des Facteurs de Coagulation Sanguins IX, II, VII, X","",""
"13199","12-04-12","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LABETALOL HYDROCHLORIDE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antihypertensive Agent","Antihypertenseur","",""
"13200","12-04-12","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant, Antiobsessional, Antibulimic","Antidépresseur, Antiobsessionnel, Antiboulimique","",""
"13201","12-04-12","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Centrally Acting Analgesic","Analgésique à Action Centrale","",""
"13202","12-04-12","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Platelet Aggregation Inhibitor","Inhibteur de l'Aggregation Plaquettaire","",""
"13203","12-04-16","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'Enzyme de Conversion de l'Angiotensine","",""
"13204","12-04-16","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC","CANADA","CANADA","1","","","Hypnotic and Sedative","Hypnotique et Sédatif","",""
"13205","12-04-16","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"13206","12-04-16","NOVOCOL PHARMACEUTICAL OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","MARCAINE 0.5% AND EPINEPHRINE 1:200,000","KODAK","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Local Anaesthetic for Dental Use","Anesthésique Local à Usage Dentaire","",""
"13207","12-04-17","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Selective Serotonin Reuptake Inhibtor","Inhibiteur Sélectif de Recaptage de la Sérotonine","",""
"13208","12-04-11","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the PRoduct Monograph","Mise à jour de la monographie du produit","Nonionic Iodinated Radiographic Contrast Medium","Substance de Contrate Radiographique non Ionique Iodée","",""
"13209","12-04-17","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Anti-Diabetic Agent","Agent Antidiabétique","",""
"13210","12-04-19","AGILA SPECIALTIES PRIVATE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antipsychotic Agent","Antipsychotique","",""
"13211","12-04-20","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Indication extension: Use of Synflorix in premature infants","Extension de l'indication: l'utilaisation de Synflorix chez les enfants prématurés","Active Immunizing Agent","Agent d'immunisation Actif","",""
"13212","12-04-23","BAYER INC BAYER HEALTHCARE ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","New indications","Nouvelles indications","Antimicrobial","Antimicrobien","",""
"13213","12-04-23","VALEO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AREDIA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du Métabolisme Osseux","",""
"13214","12-04-23","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRIMACOR INJECTION","SANOFI-SYNTHELABO CANADA INC","CANADA","CANADA","1","","","Inotrope; Vasodilator","Inotrope; Vasodilatateur","",""
"13215","12-04-23","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VERSED","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","","","Premedicant, Sedatine, Anesthetic Agent","Prémédication, Sédatif, Anesthésique","",""
"13216","12-04-23","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KYTRIL","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Antiemetic (5-HT3 Receptor Antagtonist","Antiémétique (Antagoniste des Récepteurs 5-HT3)","",""
"13217","12-04-23","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the Warnings and Precautions section of the Product Monograph","Révision à la section de Mises en garde et précautions de la monographie du produit","Progestin; Estrogen","Progestatif; Oestrogène","",""
"13218","12-04-23","ABBOTT LABORATORIES LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Treatment for Male Erectile Dysfunction","Traitement de la Dysfonction Érectile","",""
"13219","12-04-23","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Comedolytic Agent","Agent Comédolytique","",""
"13220","12-04-23","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Agent for the Treatment of Photodamaged Skin","Agent pour le Traitement de la Peau Endommagée suite à une Exposition au Soleil ou à la Lumiere Ultraviolette","",""
"13221","12-04-23","MEDICIS PHARMACEUTICAL CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiarrhythmic Agent","Antiarythmique","",""
"13222","12-04-23","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Comedolytic Agent","Agent Comédolytique","",""
"13223","12-04-20","NO. 0929797 B.C. LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"13224","12-04-20","PATRIOT A DIVISION OF JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"13225","12-04-20","ALVEDA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FUROSEMIDE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Diuretic","Diurétique","",""
"13226","12-04-20","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiemetic (5-HT3 Receptor Antagonist)","Antiémétique (Antagoniste des Récepteurs 5-HT3)","",""
"13227","12-04-20","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FENTANYL CITRATE INJECTION","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","ALternate manufacturing site","Autre lieu de fabrication","Narcotic Analgesic; Adjunct to Anesthesia","Analgésique Narcotique: Adjuvant Anesthésique","",""
"13228","12-04-23","PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic, Anti-inflammatory, Antipyretic, Platelet Aggregation Inhibitor","Analgésique, Anti-inflammatoire, Antipyrétique, Inhibiteur de l'agrégation Plaquettaire","",""
"13229","12-04-23","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","CRYSTAAL, DIVISION OF BIOVAIL CORPORATION","CANADA","CANADA","1","","","Beta-Adrenoceptor Blocking Agent","Inhibiteur des Récepteurs Beta-Adrénergiques","",""
"13230","12-04-23","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Non-steroidal Antiandrogen","Antiandrogène non Stéroïdien","",""
"13231","12-04-23","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"13232","12-04-23","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant; Antiobsessional; Antibulimic","Antidépresseur; Antiobsessionel; Antiboulimique","",""
"13233","12-04-24","TARO PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs 5-HT1; Antimigraineux","",""
"13234","12-04-24","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"13235","12-04-24","TARO PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antineoplastic Agent","Antinéoplastique","",""
"13236","12-04-24","TARO PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal Aromitase Inhibitor; Inhibitor of Estrogen Biosynthesis; Anti-tumour Agent","Inhibitor non Stéroïdien di l'aromitase; Inhibiteur de la Biosynthèse des Oestrogènes; Agent Antinéoplastique","",""
"13237","12-04-26","ZYMCAN PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Skeletal Muscle Relaxant","Relaxant des Muscles Squelettiques","",""
"13238","12-04-27","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN","NOVARITS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Blocquer des Récepteurs AT1 de l'Angiotensine II","",""
"13239","12-04-27","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVIR","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiretroviral Agent","Agent Antirétorviral","",""
"13240","12-04-27","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMBIVIR","GLAXOSMITHKLINE SHIRE BIOCHEM","CANADA","CANADA","1","","","Antiretroviural Agent","Agent Antirétroviral","",""
"13241","12-04-26","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Removal of the indication for concomitant use of Rasilez with angiotensin converting enzyme inhibitors and Angiotensin ii AT1 receptor blockers","Élimination de l'indication de l'utilisation concomitante de Rasilez aven des inhibiteurs de l'enzyme de conversion de l'angiotensine et des antagonistes des récepteurs AT1","Renin Inhibitor","Inhibiteur de la rénine","",""
"13242","12-04-25","PFIZER CANADA INC","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor","Inhibiteur de la Anaplastique Lymphoma Kinase (ALK) Tyrosine Kinase","",""
"13243","12-05-02","CELGENE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional drug product manufacturing site for primary packaging and testing","Lieu de fabrication addtional pour emballage primaire et d-essai du produit","Antineoplastic Agent; Pyrimidine Analogue","Antinéoplasique / Analogue de pyrimidine","",""
"13244","12-04-30","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DOBUTAMINE HYDROCHLORIDE INJECTION USP","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","New manufacturing site","Nouveau endroit de fabrication","Sympathomimetic","Sympathomimétique","",""
"13245","12-04-30","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMANN-LA ROCHE LIMITED","CANADA","CANADA","1","","","Immunosuppressive Agent","Immunosuppresseur","",""
"13246","12-04-30","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph; contraindications, adverse reactions, drug interactions, dosage and administration, overdosage, action and clinical pharmacology, detailed pharmacology and part III consumer informaion","Révisions à la monographie de produit; Contraindicaitons, Réactions Indésirables, interactions médicamenteuses, posologie et administration, action et pharmacologie clinique, pharmacologie, et Partie III, renseignements pour la consummateur","Contrast Enhancement Agent for Magnetic Resonance Imaging (MRI)","Agent de rehaussement de contraste pour l'imagerie par résonance magnétique","",""
"13247","12-05-01","SUNSTAR AMERICAS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PERIDEX ORAL RINSE","3M CANADA COMPANY","CANADA","CANADA","1","","","Antigingivitis Oral RInse","Rince-Bouche Antigingivite","",""
"13248","12-05-01","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBRAMYCIN FOR INJECTION USP","SANDAOZ CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13249","12-04-30","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Prevention of nausea and vomiting in women du to treatment with moderately emetogenic cancer chemotherapy","Nouvelle indication; Prévention chez les femme, des nausées et des vomissement consécutifs à inuits par l'administration d'une chimithérapie anticanéreuse modérement émétisante","Neurikinin 1 (NK1) Receptor Antagonist","Antagoniste des récepteurs de la neurokinine (NK1)","",""
"13250","12-05-02","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD AND SINUS CAPLETS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","Analgesic; Antipyretic; Nasal Decongestant","Analgésique; Antipyrétique; Décongestionnant Nasal","",""
"13251","12-05-02","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LABETALOL HYDROCHLORIDE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antihypertensive Agent","Antihypertenseur","",""
"13252","12-05-02","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CALCIMAR","RHONE-POULENC RORER CANADA INC","CANADA","CANADA","1","","","Calcium Regulator","Régulateur du Calcium","",""
"13253","12-05-02","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MODECATE","SQUIBB CANADA INC","CANADA","CANADA","1","","","Antipsychotic","Antipsychotique","",""
"13254","12-05-02","AGILA SPECIALTIES PRIVATE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Histamine H2 Receptor Antagonist","Antagoniste des Récepteurs Histaminiques H2","",""
"13255","12-05-01","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CESAMAET","VALEANT CANADA LMITÉE/LIMITED","CANADA","CANADA","1","","","Antiemetic","Antiémétique","",""
"13256","12-05-01","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SANDOZ BISOPROLOL","SANDOZ CANADA INC","CANADA","CANADA","1","","","Beta-Adrenoceptor Blocking Agent","Inhibiteur des récepteurs ß-Adrénergiques","",""
"13257","12-05-02","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA INC","CANADA","CANADA","1","","","Antidepressant; Anxiolytic","Antidépresseur; Anxiolytique","",""
"13258","12-05-03","GE HEALTHCARE CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","Diagnostic Radiopharmaceutical","Agent Diagnostique Radiopharmaceutique","",""
"13259","12-04-20","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of a new Clinical Trial to the Product monographL six week maintenance study in adult patients with attention deficit hyperactivity disorder (ADHD)","Addition d'un nouveau essai clinique à la monographie due produit: étude d'entretien de six semaines chez les patients adultes atteints du trouble d'hyperactivité aven déficit de l'attention (THADA)","Central Nervous System Stimulant for Attentions Deficit Hyperactivity Disorder","Stimulant du système nerveux central pour le trouble déficitaire de l'attention avec hyperactivité","",""
"13260","12-05-02","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change of dosing recommendations for patients having hepatic impairment with cirrhosis","Modification des recommendations de dosage en ce qui a trait aux patients atteints d'insuffisance hépatique avec cirrhose","Thrombopoietin Receptor Agonist","Agoniste du récepteur thrombopoïèse","",""
"13261","12-05-07","JAMIESON LABORATORIES LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","New Indications","Nouvelles indications","Antibiotic","Antibiotique","",""
"13262","12-05-04","ALVEDA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAZEPAM, INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Anxiolytic; Sedative","Anxiolytique; Sédatif","",""
"13263","12-05-04","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT RPD","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs de la 5-HT1: Antiminraineux","",""
"13264","12-05-07","ALVEDA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FENTANYL CITRATE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Opioid Analgesic; Adjuct to Anaethesia","Analgésique Opioïde, Adjuvant Anesthétique","",""
"13265","12-05-07","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Scale-up of drug substance manufacturing process","Augmentation de l'échelle de production de la substance Médicamenteuse","Antihemorrhagic Blood Coagulation Factor IX","Facteur IX de Coagulation Antihémorragique","",""
"13266","12-05-07","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","TAKEDA CANADA INC","CANADA","CANADA","1","","","Anti-Diabetic Agent","Antidiabétique","",""
"13267","12-05-07","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KYTRIL","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","New manufacturing facility","Nouvel emplacement de fabrication","Antiemetic","Antiémétique","",""
"13268","12-05-08","ABBOTT LABORATORIES LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Changes to the drug product manufacturing process","Changements au processus de fabrication duu produit médicamenteaux","Biological Response Modifier","Agent d'immunomodulation","",""
"13269","12-05-09","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","Bone Metabolism Regulator","Régulateur du Métabolisme Osseux","",""
"13270","12-05-03","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","New indications","Nouvelles indications","Antibiotic","Antibiotique","",""
"13271","12-05-09","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New strength","Novelle concentration","Analgesic; Antipyretic","Analgésique; Antipyrétique","",""
"13272","12-05-09","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Hypnotic and Sedative","Hypnotique et Sédatif","",""
"13273","12-05-09","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","New Formulation, new manufacturing facility","Nouvell Formulation, Nouvel emplacement de fabrication","Antibiotic","Antibiotique","",""
"13274","12-05-10","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C PHOSPHATE","PFIZER CANADA INC","CANADA","CANADA","1","New manufacturing facility","Nouvel emplacement de fabrication","Antibiotic","Antibiotique","",""
"13275","12-05-11","FRESENIUS BIOTECH GMBH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Antineoplastic Agent","Agent Antinéoplastique","",""
"13276","12-05-14","ALVEDA PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of a new indication: Caldolor (ibuprofen) is indicated for the management of moderate to severe pain as an adjunct to intravenous opioid analgesics","Addition d'une nouvelle indication: Caldolor (ibuprofène) est indiqué pour le soulangement de la douleur d'intensité modér à sévère comme compleément à des analgésiques opioïdes par voie intraveneuse","Nonselective Cyclooxygenase Inhibitor; Nonsteroidal Anti-Inflammatory Drug (NSAID)","Inhibiteur Nonsélectif de Cyclooxygénase / Anti-inflammatoire non Stéroïdien","",""
"13277","12-05-14","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic; Sleep Aid","Analgésique; Aide de Dormir","",""
"13278","12-05-14","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anxiolytic; Sedative","Anxiolytique; Sédative","",""
"13279","12-05-16","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant; Antiobsessional; Antibulimic","Antidépresseur; Antiobsessionnel; Antiboulimique","",""
"13280","12-05-17","WATSON LABORATORIES INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Androgens","Androgène","",""
"13281","12-05-17","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","SMITHKLINE-BEECHAM PHARMA, DIVISION OF SMITHKLINE BEECHAM INC","CANADA","CANADA","1","","","Congestive Heart Failure Agent","Agnet pour l'insuffisance cardiaque congestive","",""
"13282","12-05-17","SIVEM PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 Receptor Blocker","Inhibiteur des Récepteurs AT1 de l'Angiotensin II","",""
"13283","12-05-17","OSIRIS THERAPEUTICS INC","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Allogenic Cellular Therapy","Thérapie Cellulaire Allogénique","",""
"13284","12-05-18","NT PHARMA CANADA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 Receptor Blocker","Inhibiteur des Récepteurs AT1 de l'Angiotensine II","",""
"13285","12-05-18","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","TAKEDA PHARMACEUTICALS AMERICA INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+K+-ATPase","",""
"13286","12-05-22","SIVEM PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Modifier of Upper Gastrointestinal Motility","Modificateur de la Motilité des Voies Digestives Supérieures","",""
"13287","12-05-22","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","ANtagoniste des Récepteurs des Leucotriènes","",""
"13288","12-05-22","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC","CANADA","CANADA","1","","","Antidepressant; Antiobsessional; Antipanic; Anxiolytic Agent; Social Phobia (Social Anxiety Disorder); Posttraumatic Stress Disorder Therapy","Antidépresseur; Antiobsessionel; Antipanique; Anxiolytique; Traitment de la Phobie Sociale et Traitement de l'État de Stresse Post-Trumatique","",""
"13289","12-05-23","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouveau site de fabrication","Selective Immunomodulating Agent","Agent Immunomodulateur Sélectif","",""
"13290","12-05-23","SUNOVION PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","A change in manufacturing process and drug product batch size for 500 mg and 1000 mg strengths","Changement daans le processus de fabrication et la taille des lots du produit pharmaceutique aux concentraitons de 500 mg et de 1000 mg","Lipid Metabolism Regulator","Régulateur du métabolisme lipidique","",""
"13291","12-05-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIRAPEX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Antiparkinsonian Agent; Dopaimine Agonist","Antiparkinsien; Agoniste Dopaminergique","",""
"13292","12-05-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION FOUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de Conversion de l'angiotensine","",""
"13293","12-05-25","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du Métabolisme Osseux","",""
"13294","12-05-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateeur du Métabolisme Osseux","",""
"13295","12-05-24","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","ALEVE","BAYER INC","CANADA","CANADA","1","","","Non-steroidal Anti-inflammatory Drug; Analgesic; Antipyretic","Anti-inflammatoire Non Stéroïdien; Analgésique; Antipyrétique","",""
"13296","12-05-24","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC., CANADA / ALTANA PHARMA AG, GERMANY","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"13298","12-05-24","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","New indication","Nouvelle indication","Type II 5 Alpha -reductase Inhibitor","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"13299","12-05-24","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"13300","12-05-24","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS, DIVISION OF WARNER LABERT CANADA","CANADA","CANADA","1","","","Antiepileptic Agent","Antiépileptique","",""
"13301","12-05-24","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13302","12-05-24","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSSAMAX","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulatuer du Métabolisme Osseux","",""
"13303","12-05-24","SIVEM PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin II AT1 Receptod Blocker and Diuretic","ANtagoniste des Récepteurs AT1 de l'angiotensine II et Diuretique","",""
"13304","12-05-24","LABORATOIRE HRA PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Changes in spcifications, new drug product manufacturing site, change in shelf-life spcifications, changes in the embossing for the finished product","Modification des spécifications, nouveau site de fabrication du produit pharmaceutique, modification des spécifications pour la durée de conservation, modification de l'impression en relief du produit final","Emergeny Contraception","CONTRACEPTIF D'URGENCE","",""
"13305","12-05-24","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Elevated Inmtraocular Pressure Therapy","Traitement d'une pression intraoculaire élevée","",""
"13306","12-05-28","TEVA PHARMACEUTICAL INDUSTRIES LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Confirmation of MAO-B selectivity of Azilect (rasagliline) at the recommended doses","Confirmation de la sélectivité de la MAO-B d'Azilect (rasigiline) aux doses recommendées","Antiparkinsonian Agent","Agent Antiparkinsonien","",""
"13307","12-05-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"13308","12-05-25","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYKLOKAPRON","PFIZER CANADA INC","CANADA","CANADA","1","","","Antifibrinolytic Agent","Agent Antifibrinolytique","",""
"13309","12-05-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC","CANADA","CANADA","1","","","Oral Antihyperglycemic Agent","Antihyperglycémiant Oral","",""
"13310","12-05-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du Métabolisme Osseux","",""
"13311","12-05-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"13312","12-05-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker; Diuretic","Bloquer des Récepteurs AT1 de l'Angiotensine II; Diuretique","",""
"13313","12-05-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"13314","12-05-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMISIL","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antifungal Agent","Antifongique","",""
"13315","12-05-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Bloquer des Récepteurs AT1 de l'Angiotensine II","",""
"13316","12-05-28","QD PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength","Nouvelle concentration","Antidepressant","Antidépresseur","",""
"13317","12-05-31","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZITHROMAX","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antbiotique","",""
"13318","12-05-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA (25, 40, 60, 80 AND 100 MG - USA) (10 AND 18 MG - CANADA)","ELI LILLY AND COMPANY, USA / ELI LILLY CANADA INC., CANADA","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Selective Norepinephrine Reuptake Inhibitor","INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA NORADRÉNALINE POUR LE TROUBLE DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ (TDAH)","",""
"13319","12-05-29","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACLEER","ACTELION PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Endothelin Receptor Antagonist","ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"13320","12-05-29","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACLEER","ACTELION PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Endothelin Receptof Antagonist","ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"13321","12-05-31","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX DF","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Antagoniste des Récepteurs 5-HT1; Antimigraineux","",""
"13322","12-05-31","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH AYERST CANADA INC","CANADA","CANADA","1","","","Antidepressant; Anxiolytic","Antidépresseur; Anxiolytique","",""
"13323","12-05-31","SIVEM PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressantl Antiobsessional; Antibulimic","Antdépresseur; Antiobsessionnel; Antibulimique","",""
"13324","12-05-31","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH-AYERST CANADA INC","CANADA","CANADA","1","","","Antiarrythmic Agent","Agent Anti-arythmique","",""
"13325","12-05-31","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG RAPIMELT","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Rcepteurs 5-HT1; Antimigraineux","",""
"13326","12-06-01","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE-DAVIS INC","CANADA","CANADA","1","","","Antineoplastic Agent","Antinéoplastique","",""
"13327","12-06-02","GENMED A DIVISION OF PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LAMICTAL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiepileptic","Antiépileptique","",""
"13328","12-05-31","TORRENT PHARMACEUTICALS LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Inhibiteur des récepteurs AT1 de l'angiotensine","",""
"13329","12-06-01","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Indications and Clinical Use, Contraindications, Warnings, Precautions, Adverse Drug Reactions, Dosage and ADministration and Pharmacology sections of the PRoduct Monograph; and a new Part III Consumer Information section of the Product Monograph","Mise à jour des sections Indications et usage clinique, Contre-indications, Mises en garde et précautions, Effets indésirables du médicament, Posologie et administration, ainsi que Pharmacologie de la monographie de produit; et nouvelle Partie III, Reseignement pour le consummateur de la monographie de produit","Adrenocorticotropic Hormone","Hormone Adrénocorticotopique","",""
"13330","12-06-01","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Product name change","Modification du nom du produit","Platelet Aggregation Inhibitor","Inhibiteur de l'Aggrégation Plaquettaire","",""
"13331","12-06-04","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"13332","12-06-04","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Product Name Change","Modification du nom du produit","Histamine H2 Receptor Antagonist","Antagoniste des Récepteurs H2 de l'Histamine","",""
"13333","12-06-04","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACLEER","ACTELION PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Endothelin Receptor Antagonist","Antagoniste des Récepteurs de l'Endothéline","",""
"13334","12-06-04","VALEANT CANADA LIMITÉE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid Analgesic","Analgésique Opioïdes","",""
"13335","12-06-01","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing site","Nouvel emplacement de fabrication","Hyperglycemic Agent","Agent Hyperglycémiant","",""
"13336","12-05-30","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Warnings and Precautions, Dosage and ADministration and ACtion and Clinical Pharmacology sections of the Product Monograph","Révisions des sections Mise en garde et précautions, Posologie et administration, ainsi que Mode d'action et pharmacologie clinique de la monographie de produit ","Antineoplastic (mTOR Kinase Inhibitor)","Antinéoplasique (Inhibiteur de la mTOR kinase)","",""
"13337","12-06-04","GENMED A DIVISION OF PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","Antibacterial Agent","Antibactérien","",""
"13338","12-06-04","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACLEER","ACTELION PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Endothelin Receptor Antagonist","Antagoniste des Récepteus de l'Endothéline","",""
"13339","12-06-04","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KETLAR","ERFA CANADA INC","CANADA","CANADA","1","New manufacturing facility","Nouvel emplacement de fabrication","General Parenteral Anesthetic","Anesthésie Parentéral Généale","",""
"13340","12-06-05","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LABETALOL HYDROCHLORIDE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antihypertensive Agent","Antihypertenseur","",""
"13341","12-06-05","SANDOZ CANADA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LASIX","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","New manufacturing site","Nouvel emplacement de fabrication","Diuretic","Diurétique","",""
"13342","12-05-31","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective Norepinephrine Reuptake Inhibitor for Attention Deficit/Hyperactivity Disorder (ADHD)","Inhibiteur Sélectif du Recaptage de la Noradrénaline pour le Troouble Déficitaire de l'Attention avec Hyperactivité (TDAH)","",""
"13343","12-05-23","STERIMAX INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form","Nouvelle forme posologique","Antihypertesive Agent","Antihypertenseur","",""
"13344","12-06-04","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: For use in patients with type 2 diabetes melitus to improve glycemic control in combination with premixed or long/term acting insulin (with or without metformin) whe premixed or long/intermediate acting insulin (with or without metformin) used alone, with diet and exercise do not provide adequate glycemic control","Nouvelle indiaction: Indiqué chez les pateints atteints de diabète de type 2 pour améliorer le contrôle glycémique en association avec l'insuline prémélangée ou à action prolongée ou intermdiaire (avec ou sans metformine) lorsque l'insuline prémélangée ou intermédiaire (aven ou sans metformine) utilisée seule, avec l'alimentation et l'exercise, ne procure pas une maîtrise glycémique adéquate","Oral Antihyperglycemic Agent; DPP-4 Inhibitor; Incretin Enahncer","Agent oral d'antihyperglycémic; inhibiteur DPP-4; renforceur d'incretin","",""
"13345","12-06-05","SIVEM PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiarrythmic","Antiarythmique","",""
"13346","12-06-05","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Modifier of upper gastrointestinal motility","Modificateur de la motilité des voies digestives supérieures","",""
"13347","12-06-05","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antipsychotic","Antipsychotique","",""
"13348","12-06-05","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMBIVIR","GLAXOSMITHKLINE SHIRE BIOCHEM","CANADA","CANADA","1","","","Antiretroviral Agent","Antirétroviral","",""
"13349","12-06-05","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"13350","12-06-05","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepressant; Antipanic; Antiobsessional Agent","ANtidépresseur; Antipanique; Antiobsessionnel","",""
"13351","12-06-05","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"13352","12-06-05","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13353","12-06-05","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"13354","12-06-05","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"13355","12-05-18","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Distinction between Tazocin with/without EDTA (which  is no longer available on the Canadian market) in the Dosage and Administration and Pharmaceutical Information sections of the Product Monograph. Conversion of the Product Monograph to the new format","Disctinction entre Tazocin avev et sans EDTA (qui n'est plus en vente au Canada) dans les sections de la monographie de produit portant sur la posologie et l'administration aise que sur les renseignements pharmaceutiques. Conversion de la monographie de produit au nouveau format","Antibiotic; ß-Lactamase Inhibtor","Antibiotique / Inhibiteur de bêta-lactamases","",""
"13356","12-06-07","EMD SERONO A DIVISION OF EMD INC CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Extension of indication: The treatment of patients who have experienced a single demyelizing event, accompanied by an active inflammatory process and an abnorman MRI scan with lesions typical of MS, who are determined to be at high risk of developing clinically definite multiple sclerosis","Extension d'indication: Le traitement des patients qui ont subi un seul événement démyélinisant, accompagné d'un processus inflammatoire actif et un résultat anormal d'IRM révélant des lésions typiques de la SEP qui présentent un risque élevé d'évoluer vers une sclérose en plaques cliniquement certaine","Immunomodulator","Immunomodulateur","",""
"13357","12-06-06","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","ANtagoniste des Récepteurs AT1 de l'Angiotensine II","",""
"13358","12-06-06","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral Contraceptive","Contraceptif Oral","",""
"13359","12-06-06","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANtidepressant; Antiobsessional; Antibulimic","Antidépresseur; Antiobsessionel; Antibulimmique","",""
"13360","12-06-06","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Strength; New manufacturing facility","Nouvelle concentration; Nouvel emplacement de fabrication","Opioid Analgesic; Opioid Antagonist","Analgésique Opioïdes; Antagoniste Opioïdes","",""
"13361","12-06-06","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppressive Agent","Immunosuppresseur","",""
"13362","12-05-11","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Change in resin for container closure system","Changement de la résine pour la systeme de clôture","Radiopaque Contrast Medium","AGENT DE CONTRASTE RADIOLOGIQUE","",""
"13363","12-06-07","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERK FROSST CANADA LTD","CANADA","CANADA","1","New indication","Nouvelle indication","Type II 5alpha-Reductase Inhibitor","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"13364","12-06-07","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PHARMORUBICIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","Antineoplastic Agent","Antinéoplastique","",""
"13365","12-06-07","OPTIMER LUXEMBOURG 2 S.A R.1.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial Agent","Antibactérien","",""
"13366","12-06-08","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional drug product manufacturing site","Site de fabrication additionel pour le produit médicamenteux","Antineoplastic","Antinéoplatique","",""
"13367","12-06-11","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Revisions to the Product Monograph","Révision de la monographie du produit","Active Immunizing Agent","Agent d'Immunisation Actif","",""
"13368","12-06-08","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme Lipidique","",""
"13369","12-06-08","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MIN-OVRAL","WYETH CANADA","CANADA","CANADA","1","","","Oral Contraceptive","Contraceptif Oral","",""
"13370","12-06-08","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Platelet Aggregation Inhibitor","Inhibiteur de l'Agrégation Plaquettaire","",""
"13371","12-06-08","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH-AYERST CANADA  INC","CANADA","CANADA","1","","","Antidepressant; Anxiolytic","Antidépresseur; Anxiolytique","",""
"13372","12-06-08","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC","CANADA","CANADA","1","","","Hypnotic and Sedative","Hypnotique et Sédatif","",""
"13373","12-06-08","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","MILES CANADA INC","CANADA","CANADA","1","","","Antibacterial Agent","Antibactérien","",""
"13374","12-06-08","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","TPS PHARMACEUTICALS INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"13375","12-06-08","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive; Antianginal Agent","Antihypertenseur et Antiangineux","",""
"13376","12-06-08","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZANTAC","GLAXO WELLCOME INC","CANADA","CANADA","1","","","Histamine H2 Receptor Antagonist","Antagoniste des Récepteurs H2 de l'Histamine","",""
"13377","12-06-08","SIVEM PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'Enzyme de Conversion de l'Angiotensine","",""
"13378","12-06-11","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATERRA","ELI LILLY CANADA  INC","CANADA","CANADA","1","Product Name Change","Changement du nom du produit","Selective Norepinephrine Reuptake Inhibitor for Attention-Deficit Hyperactivity Disorder (ADHD)","Inhibiteur Sélectif du Recaptage de la Noradrénaline pour le Trouble Déicitaire de L'Attention avec Hyperactivité (TDAH)","",""
"13379","12-06-11","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in storage conditions of the drug product","Changement aux conditions d'entreposage du produit pharmaceutique","Synthetic Antithrombotic","Antithrombotique synthétique","",""
"13380","12-06-12","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker; Diuretic","Bloquer des Récepteurs AT1 de l'Angiotensine II; Diurétique","",""
"13381","12-06-12","RAFTER 8 PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anti-bloat Agent","Agent ANti-ballonnement","",""
"13382","12-06-13","SUNOVION PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antipsychotic","Antipsychotique","",""
"13383","12-06-13","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMIODARONE HYDROCHLORIDE FOR INJECTION","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic Agent","Antiarythmique","",""
"13384","12-06-13","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Cholinesterase Inhibitor","Inhibiteur de la Cholinestérase","",""
"13385","12-06-13","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","Alternate manufacturing site for the drug substance","Autre lieu de fabrication pour la substance médicament","H+,K+-ATPase Inhibitor","Inhibituer de l'H+,K+-ATPase","",""
"13386","12-06-14","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Hypnotic and Sedative","Hynotique et Sédatif","",""
"13387","12-06-14","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA & CO","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13388","12-06-14","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"13389","12-06-13","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"13390","12-06-13","SANOFI PASTEUR INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","To expand the label indication to include the administration of 2 single doses at leasat 3 months apart for infants and toddlers from 9 months through we months of age","Étendre les indications de la monographie afin d'inclure l'administration de 2 doses simples au moins à un intervalle de 3 mois pour les nourissons et les tout-petits de 9 mois à 23 mois","Active Immunizing Agent","Agent d'Immunisation Actif","",""
"13391","12-06-18","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AMIODARONE HYDROCHLORIDE FOR INJECTION","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antiarrhythmic Agent","Agent Antiarythmique","",""
"13392","12-06-15","AGILA SPECIALTIES PRIVATE LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LABETALOL HYDROCHLORIDE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","New manufacturing site","Nouvel emplacement de fabrication","Antihypertensive Agent","Antihypertenseur","",""
"13393","12-06-19","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate drug substance manufacturing site; Revisions to the drug substance specifications","Autre site de fabrication de la substance médicamenteuse; Révision aux spécification de la substance médicamenteuse","Muscle Relaxant and Antispastic Agent","Rélaxant Musculataire et Antispasmodique","",""
"13394","12-06-15","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate drug substance manufacturing site","Autre site de fabrication de la substance médicamenteuse; Révision aux spécification de la substance médicamenteuse","Muscle Relaxant and Antispastic Agent","Rélaxant Musculataire et Antispasmodique","",""
"13395","12-06-18","INTERVET CANADA CORP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anti-protozoal","Antiprotozoaire","",""
"13396","12-06-19","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in manufacturing site","Changement d'emplacement de fabrication","Oral Antihyperglycemic Agent","Antihyperglycémiant oral","",""
"13397","12-06-19","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Rgulateur du Métabolisme des Lipides","",""
"13398","12-06-19","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTO IV","NYCOMED CANADA INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"13399","12-06-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALESSE","WYETH CANADA","CANADA","CANADA","1","","","Oral Contraceptive","Contraceptif oral","",""
"13400","12-06-19","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du Métabolisme Osseux","",""
"13401","12-06-20","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIRAMUNE","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Antiretroviral Angent; Non-Nuucleoside Reverse Transcriptase Inhibitor with Activity Against Human Immunodeficiency Virus Type 1 (HIV-1)","Antirétroviral / Inhibiteur non-nucléoside de la reverse transcriptase contre le virus de l'immunodéficience humaine de type 1 (VIH-1)","",""
"13402","12-06-20","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"13403","12-06-21","SUNOVION PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant; Antiobsessional","Antidépresseur; Antiobsessionnel","",""
"13404","12-06-19","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Janus Associated Kinase 1,2 (JAK1,2) Inhibitor","Inhibiteur de la Janus Kinase 1,2 (JAK1,2)","",""
"13405","12-06-20","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Opioid Analgesic","Analgésique Opioïdes","",""
"13406","12-06-21","SEPTA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Hypnotic and Sedative","Hypnotique et Sédatif","",""
"13407","12-06-21","WARNER CHILCOTT CANADA CO","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral Contraceptive","Contraceptif Oral","",""
"13408","12-06-22","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","New indication","Nouvelle indication","Antineoplastic Agent","Antinéoplastique","",""
"13409","12-06-22","NOVARTIS ANIMAL HEALTH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Site transfer of manufacturing, packaging, labelling and testing","Transfert du site de fabrication, emballage, étiquetage et épreuves","Non-steroidal Anti-inflammatory","Anti-inflammatoire non Stéroïdien","",""
"13410","12-06-22","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VASOTEC IC","SANDOZ CANADA INC","CANADA","CANADA","1","","","Angiotensin COnverting Enzyme Inhibitor","Inhibiteur de l'enzyme de Conversion de l'angiotensine","",""
"13411","12-06-22","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC","CANADA","CANADA","1","New manufacturing site","Nouvel emplacement de fabrication","Antifungal Agent","Antifongique","",""
"13412","12-06-21","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"13413","12-06-21","SIVEM PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic Receptor Blocking Agent","Inhibiteur des Récepteurs Béta-adréergiques","",""
"13414","12-06-22","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Opioid Analgesic","Analgésique Opioïdes","",""
"13415","12-06-22","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","New indication - new strength","Nouvelle indication - Nouvelle concentration","Platelet Aggregation Inhibitor","Inhibiteur de l'agrégation plaquettaire","",""
"13416","12-06-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","POLYTRIM OPHTHALMIC SOLUTION","ALLERGAN INC","CANADA","CANADA","1","","","Antibacterial Agent","Agent Antibactérien","",""
"13417","12-06-21","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OCUFLOX","ALLERGAN INC","CANADA","CANADA","1","","","Antibacterial Agent","ANtibactérien","",""
"13418","12-06-21","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid","Corticostéroïde","",""
"13419","12-06-21","SUNOVION PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic","Hypnotique","",""
"13420","12-06-21","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibacterial Agent","Antibactérien","",""
"13421","12-06-21","WARNER CHILCOTT CANADA CO","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral Contraceptive","Contraceptif Oral","",""
"13422","12-06-22","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR","MERCK CANADA INC","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist and Diuretic","Agoniste des Recepteurs II de l'angiotensine et Diuretique","",""
"13423","12-06-12","IPSEN BIOPHARM LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Neuromuscular Blocking Agent","Agent Bloquant Neuromusculaire","",""
"13424","12-06-26","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PARKE DAVIS, DIVISION OF WARNER LAMBERT CANADA","CANADA","CANADA","1","","","Antiepileptic Agent","Antiépileptique","",""
"13425","12-06-26","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SIFROL","BOEHRINGER INGELHEIM INTERNATIONAL GMBH","GERMANY","ALLEMAGNE","1","Change in manufacturing process; New formulation","Changement dans le procédé de fabrication; Nouvelle formulation","Antiparkinsonian Agent; Dopamine Agoniste","Agent Antiparkinsonien; Agoniste dopaminergique","",""
"13426","12-06-26","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","SMITHKLINE BEECHAM PHARMA INC","CANADA","CANADA","1","","","Antidepressant; Antiobsessional; Antipanic; Anxiolytic Agent; Social Phobia (Social Anxiety Disorder), Posttraumatic Stress Disorder Therapy","ANtidépresuer; Antiobsessionnel; Antipanique; Anxiolytique; Traitement de la Phobie Sociale et Traitement de ltat de Stresse Post-Traumatique","",""
"13427","12-06-26","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13428","12-06-26","MEDTECH PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Topical Scabicide","Scabicide Topique","",""
"13429","12-06-26","FAMY CARE LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALESSE","WYETH CANADA","CANADA","CANADA","1","","","Oral Contraceptive","Contraceptif Oral","",""
"13430","12-06-27","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE HCT","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor and Diuretic","Inhibituer de l'enzyme de Conversions de l'angiotensine et Diurétique","",""
"13431","12-06-27","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-SYNTHELABO","CANADA","CANADA","1","","","Platelet Aggregation Inhibitor","Inhibiteur de l'aggregation Plaquettaire","",""
"13432","12-06-27","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","APO-AMOXYL","APOTEX INC","CANADA","CANADA","1","","","Antiobiotic","Antibiotique","",""
"13433","12-06-27","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid","Corticostéroïde","",""
"13434","12-06-27","AGRISAN SPECIALTY CHEMICAL & PHARMACEUTICAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","THERATEC PRE & POST ANTISEPTIC TEAT DIP","WETFALIA SURGE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiseptic Teat Dip","Bain de Trayons Antiseptique","",""
"13435","12-06-26","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Replacement of drug substance manufacturing site; Change in the drug substance specifications and analytical procedures","Remplacement du site de fabrication de la substance médicamenteuse; Modification des spécifications de la substance médecamenteuse et de méthodes d'analyse","Topical Corticosteroide","Cotricostéroïde Topique","",""
"13436","12-06-28","AGRISAN SPECIALTY CHEMICAL & PHARMACEUTICAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antiseptic Teat Dip","Bain de Trayons Antiseptique","",""
"13437","12-06-27","PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Elevated Intraocular Pressure Therapy","Traitement de l'hypertension Intraoculaire","",""
"13438","12-06-27","MEDTECH PRODUCTS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Topical Pediculicide and Ovicide","Pédiculicide et Ovicide Topique","",""
"13439","12-06-27","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"13440","12-06-27","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Corticosteroid for Oral Inhalation","Corticostéroïde pour Inhalation Buccal","",""
"13441","12-06-27","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of an altenrate manufacturing, packaging and testint site","Autre lieu de fabrication, emballage et mise à l'essai","Antineoplastic Agent","Antinéoplastique","",""
"13442","12-06-28","EISAI LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form","Nouvelle forme posologique","Antiepileptic","Antiépileptique","",""
"13443","12-06-28","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BETAGAN","ALLERGAN INC","CANADA","CANADA","1","","","Glaucoma Therapy","Traitement de Glaucome","",""
"13444","12-06-28","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALPHAGAN","ALLERGAN INC","CANADA","CANADA","1","","","Elevated Intraocular Pressure Therapy","Traitement pour réduire la pression Inctraoculaire","",""
"13445","12-06-28","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","SOLVAY PHARMA INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"13446","12-06-29","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur de métabolisme osseux","",""
"13447","12-06-29","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LORAZEPAM INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Anxiolytic; Sedative","Anxiolytique; Sédatif","",""
"13448","12-06-29","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Oral Antihyperglycemic Agent","Antihyperglycémiant Oral","",""
"13449","12-06-05","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Reformulation of the drug product to remove sodium hydrosulfite rendering the product sulfite free","Reformulation du produit pharmaceutique afin d'en retirer toute trace d'hydrosulfite de sodium et d'en faire un produit sans sulfite","Nutirive Supplement","Supplément nutritif","",""
"13450","12-07-03","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13451","12-07-04","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonost and Diuretic","Antagoniste des Récepteurs de l'angiontensine II et Diurétique","",""
"13452","12-07-05","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la monographie du produit","Oral Hypoglyaemic Agent","Agnet Hypoglycémiant Oral","",""
"13453","12-07-05","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bronchdilator","Bronchdilateur","",""
"13454","12-07-05","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist","Antagoniste des Réceptuers de l'angiotensine II","",""
"13455","12-07-05","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","ANtagoniste des Récepteurs AT1 de l'angiotensine II","",""
"13456","12-07-05","PALADIN LABS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Replacement of the drug product manufacturing site","Substitution de lieu de fabrication pour le produit finit","Synthetic Alcohol Dehydrogenase Inhibtor","INHIBITEUR SYNTHÉTIQUE DE L'ALCOOL DÉSHYDROGÉNASE","",""
"13457","12-07-05","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour à la monographie du produit","Biological Response Modifier plus Antiviral Agent","Modificateur de la Réponse Biologique plus Agent Antiviral","",""
"13458","12-06-29","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Alternate manufacturing line, additional container closure system","Ajout d'une chaine de fabrication, ajout au dispositif de fermeture du contenant","Anticoagulant; Antithrombotic","ANticoagulant; Antithrombotique","",""
"13459","12-07-04","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","Bone Formation Agent","Agent Ostéoformateur","",""
"13460","12-07-09","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Extension of duration of protection","Extension de la durée de protection","Active Immunizing Agent","Agent d'immunization Actif","",""
"13461","12-07-09","BRISTOL MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral Antihyperglycemic Agent; DPP-4 Inhibitor; Incretin Enhancer","Agent Antihyperglycémiant; Inhibiteur de DPP-4; Enhanceur de l'incretin","",""
"13462","12-07-05","AUXILIUM PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","Collagenase Clostridium Histolyticum","Collagénase de Clostridium Histolyticum","",""
"13463","12-07-05","FERRING INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Luteinizing Hormone-Releasaing Hormone (LHRH) Ananlog","Analogue de l'hormone de libération de la lutéinostimuline (LH-RH)","",""
"13464","12-07-06","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ANEXATE","HOFFMAN-LA ROCHE LTD","CANADA","CANADA","1","New formulation; Change in manufacturing process","Nouvelle formulation; Changement dans le procédé de fabrication","Benzodiazepine Antagonist","Antagoniste des Benzodiazépines","",""
"13465","12-06-29","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indications 1) Treatment of the signs and symptoms of benign prostatic hyperplasia 2) Treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia","Nouvelles indiactions: 1) Traitement des signes et des symptômes d'hyperplasie béngigne de la prostate 2) Traitement du dysfonction érectile ainsi que des signes et des symptômes d'hyperplasie bénigne de la prostate","cGMP-Specific Phosphodiesterase Type 5 Inhibitor","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE LA GMPC / TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"13466","12-07-10","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Change to the anti-FVII matrix at purification","Changement de la matrice de purification anti-FVII","Coagulation Factor","Facteur de Coagulation","",""
"13467","12-07-11","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Brochodilator","Bronchodiateur","",""
"13468","12-07-11","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Antagoniste des Récepteurs AT1 de l'angiotensine II","",""
"13469","12-07-11","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13470","12-07-11","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabollism Regulator","Régulateur du Métabolisme des Lipides","",""
"13471","12-07-09","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALternate site for the manufacture, primary packaging and testing of Tygacil","AUtre lieu pour le fabrication, embellage primaire et de l'essai de Tygacil","Tetracylcine Antibiotic","Antibiotique tétracycline","",""
"13472","12-07-12","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in dose packaging size","Changement du format d'emballage de la dose","Brochodilator","Bronchodilateur","",""
"13473","12-07-12","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Anaesthetic","Anesthésique","",""
"13474","12-07-12","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: For the treatment of adult patients with selective subtypes of advanced Soft TIssue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Patients were required to have diseasee progression on or after, or be intolerant to, an anthracyline-based regimen in the pivotal pahse III study in STS","Nouvelle indication: Indiqué pour le traitement de patients adultes atteints de certains sous-types de sarcome des tissues mous (STM) avancé ayant reçu précédemmment un traitement de chimothérapie contre une atteinte métastatique ou dont la maladie a progressé au cours des 12 mois suivant un treaitement (néo)adjuvant. Les patients devaient présenter une progression de la maladie penfant ou après avoir suivi un schéma posologique à base d'anthracycline, ou y être intolérant dans le cadre d'une étude pivotale de phase III sur le STM.","Antineoplastic Agent","Antinéoplastique","",""
"13475","12-07-13","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"13476","12-07-12","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Kinase Inhibitor; Anti-Tumour Agent","Inhibiteur de la Kinase; Agent Anti-Tumeur","",""
"13477","12-07-11","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Diuretic","Diurétique","",""
"13478","12-07-12","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blcker; Diuretic","Antagoniste des Récepteurs AT1 de l'angiotensine II; diurétique","",""
"13479","12-07-13","LUPIN LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de Conversion de l'angiotensine","",""
"13480","12-07-16","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Agenet Antipsychotique","",""
"13481","12-07-16","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Luteinizing Hormone-Releasing Hormone (LHRH) Analogue","Analogue de l'hormone de Librératioin de la Luteinostimuline (LHRH)","",""
"13482","12-07-16","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMBIVENT","BOEGRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Bronchodilator","Bronchodilateur","",""
"13483","12-07-13","NT PHARMA CANADA LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotesin II AT1 Receptor Blocker","Antagoniste des Récepteurs AT1 de l'agiotensine II","",""
"13484","12-07-12","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOBI","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Respiratory Antibiotic","Antibiotique Respiratoir","",""
"13485","12-06-29","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New indication; Listing of non-medical ingredients; Revisions to the Product monograph; Larger size bottle","Nouvelle indication; Liste des ingrédients non-medicamaux; révisions à la monographie de produit; addition d'un plus grand flacon","Analgesic; Antipyretic","Analgésique; Antipyrétique","",""
"13486","12-07-17","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of primary packaging for IV injection (2mg/mL)","Addition d'emballage primaire pour l'injection IV (2 mg/mL)","Antibacterial Agent","Agent Antibactérien","",""
"13487","12-07-18","LEO PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in Product Name","Changement de nom du produit","Topical Antipsoriatic Agent; Vitamin D Analogue; Corticosteroid","Agent Antipsoriasique; Analogue de la Vitamine D; Corticostéroïde","",""
"13488","12-07-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","ANtagoniste des Récepteurs AT1 de l'angiotensine II","",""
"13489","12-07-18","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13490","12-07-18","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Antagoniste des Récepteurs AT1 de l'angiotensine II","",""
"13491","12-07-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist","Antagoniste des Récepteurs de l'angiotensine II","",""
"13492","12-07-17","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"13493","12-07-19","NOVO NORDISK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","Coagulation Factor","Facteur du Coagulation","",""
"13494","12-07-20","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Hypnotic","Hypnotique","",""
"13495","12-07-20","PATRIOT A DIVISION OF JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Centrally Acting Analgesic","Analgésique à Action Centrale","",""
"13496","12-07-20","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Antiepileptic - Migraine Prophylaxis","Antiépileptique - Prophylaxie de la Migraine","",""
"13497","12-07-20","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID Analgesic Agent; Topical Anti-inflammatory Agent","Agent Analgésique AINS; Agent Anti-inflammatoire Topique","",""
"13498","12-07-20","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","ORTHO-MCNEIL PHARMACEUTICALS INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiepileptic; Migraine Prophylaxis","Antiépileptique; Prpphylaxie de la Migraine","",""
"13499","12-07-19","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HHOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","Immunosuppressive Agent","Immunosuppresseur","",""
"13500","12-07-20","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anxiolytic; Sedative","Anxiolytique; Sédatif","",""
"13501","12-07-20","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"13502","12-07-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Antagoniste des Récepteurs AT1 de l'angiotensine II","",""
"13503","12-07-23","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Androgen","Androgène","",""
"13504","12-07-23","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant and Anxiolytic","Antidépresseur et Anxiolytique","",""
"13505","12-07-23","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG / ZOMIG RAPIMELT","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Reécepteurs 5-HT1; Antimigraineux","",""
"13506","12-07-23","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Vasoactive Agent","Agent Vasoactif","",""
"13507","12-07-25","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEMODAL","SCHERING-PLOUGH","BELGIUM","BELGIQUE","1","","","Antineoplastic","Antinéoplastique","",""
"13508","12-07-24","TORRENT PHARMACEUTICALS LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker; Diuretic","Antagoniste des Récepteurs AT1 de l'angiotensine II; Diurétique","",""
"13509","12-07-23","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB COMPANY","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13510","12-07-24","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antiemetic (5-HT3 Receptor Antagonist)","Antiémétique (Antagoniste des Récepteurs 5-HT3","",""
"13511","12-07-24","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Elevated Intraocular Pressure Therapy","Traitement d'une Pression Intraoculaire Élevée","",""
"13512","12-07-25","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5 Alpha-reductase Inhibitor","Inhibituer de la Alpha-réductase de Type II 5","",""
"13513","12-07-25","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AROMASIN","PFIZER CANADA INC","CANADA","CANADA","1","","","Aromitase Inactivator; Anti-Tumour Agent","Inactivateur de l'Aromitase; Antinéoplastique","",""
"13514","12-07-25","JUBILANT DRAXIMAGE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","Change in the generator manufacturing proces","Changement dans la méthode de fabrication du générateur","Diagnostic Radiopharmaceutical","Agent Diagnostique Radiopharmaceutique","",""
"13515","12-07-26","CHANELLE PHARMACEUTICALS MANUFACTURING LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","METACAM ORAL SUSPENSION","BOEHRINGER INGELHEIM VETMEDICA","GERMANY","ALLEMAGNE","1","","","Non-steroidal Anti-inflammatory","Anti-inflammatoire non stérodïen","",""
"13516","12-07-26","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALternate manufacturing site","Autre lieu de fabrication","HIV Protease Inhibitor","Inhibiteur de la Protéase de VIH","",""
"13517","12-07-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker; Diuretic","Antagoniste des Récepteurs AT1 de l'angiotensine; Diurétique","",""
"13518","12-07-25","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Antagoniste des Récepteurs AT1 de l'angiotensine II","",""
"13519","12-07-25","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","","","Antibiotic; ß-Lactamase Inhibitor","Antibiotique; Inhibiteur de ß-Lactamase","",""
"13520","12-07-26","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Use in pediatrics (6-16 years of age)","Utilisation en pédiatrie (6 - 16 ans)","Angiotensin II AT1 Receptor Blocker","Antagoniste des Récepteurs AT1 de l'angiotensine II","",""
"13521","12-07-30","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs de la 5-HT1; Antimigraineux","",""
"13522","12-07-30","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN BID","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13523","12-07-30","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13524","12-07-30","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"13525","12-07-30","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COMTAN","NOVARTIS PHARMACETUCIALS CANADA INC","CANADA","CANADA","1","","","ADjunct to Levodopa and DDC Inhibitor; COMT-Inhibitor","TRAITEMENT D'APPOINT À LA LÉVODOPA ET INHIBITEUR DE LA DDC/COMT","",""
"13526","12-07-26","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA UK LTD","FRANCE","FRANCE","1","","","Non-Steroidal Aromitase Inhibitor","Inhibiteur de l'aromitase non Stéroïdien","",""
"13527","12-07-27","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MINOCIN","STIEFEL CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13528","12-07-27","TORRENT PHARMACEUTICALS LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Antipsychotique","",""
"13529","12-07-27","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Warnings and Precautions section of the Product Monograph","M ise à jour de la section des mises en garde et précaution de la Monographe du produit","Progestogen","Progestatif","",""
"13530","12-07-20","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Is indicated as monotherapy for the first-line treatment of patients with locally advanced (stage III b) not amenable to curative therapy) or metastatic (stage IV) nono-mall cell lung cancer (NSCLC) eith EFGR activating mutations","Nouvelle indication: Est indiqué comme monothérapie pour le traitement de première ligne des patients atteints du cancer du poumon non à petites cellules (CPNPC) localement avancé (stade III b) pour lequel il n'existe aucun tratiement curatif) ou métastatique (stage IV) avec mutations activatrices du récepteur du facteur de croissance épidermique (RFCE)","Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor","Inhibiteur de la tyrosine kinase du récepteur du facteur de croissance épidermique","",""
"13531","12-07-31","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antifungal","Antifongique","",""
"13532","12-07-31","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Sedative/Tranquilizer","Sédatif/tranquillisant","",""
"13533","12-08-01","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing site and changes to manufacturing process","Nouveau site de fabrication et changements au processus de fabrication","Human Monoclonal Antibody RANKL: Bone Metabolism Regulator","Aanticorps Monoclonal Humain au Ligand RANK: Régulateur du Métablisme Osseux","",""
"13534","12-08-01","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing site and changes to manufacturing process","Nouveau site de fabrication et changements au processus de fabrication","Human Nomoclonal Antibody to RANKL: Bone Metabolism Regulator","Anticorps Monoclonal Humain au Ligand RANK: Régulateur du Métablisme Osseux","",""
"13535","12-07-31","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KETOROLAC TROMETHAMINE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","NSAID Analgesic Agent","AINS Analgésique","",""
"13536","12-07-31","TAKEDA CANADA INC.","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN ZYDIS LINGUAL","GLAXOSMITHKLINE GMBH AND CO KG","GERMANY","ALLEMAGNE","1","","","Antiemetic","Antiémétique","",""
"13537","12-07-31","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CAMADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Antagoniste des Récepteurs AT1 de l'Angiotensine II","",""
"13538","12-07-31","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Cymbalta is indicated for the management of chronic pain associated with osteoarthritis (OA) of the knee","Nouvell indication: Cymbalta est indiqué pour la prise en charge de la doleur chronique associée à l'arthrose du genou","Analgesic; Antidepressant; Anxiolytic","Analgsique; Antidépresseur; Ansiolytique","",""
"13539","12-07-27","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR DS","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonst and Diuretic","Antagonste des Récepteurs de l'Angiotensine II et Diurétique","",""
"13540","12-08-01","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Antihistamine","Antihistamine","",""
"13541","12-08-02","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL EZ","FOURNIER PHARMA INC","CANADA","CANADA","1","","","Lipid Metaboliism Regulator","Régulateur du Métabolsme des Lipides","",""
"13542","12-08-02","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Revisions to the PRoduct Monograph","Révisions à la monographie de produit","Analgesic; Antipyretic","Analgésique: Antipyrétique","",""
"13543","12-08-03","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Antagoniste des Récepteurs AT1 de l'Angiotansine II","",""
"13544","12-08-08","ELANCO DIVISION ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Manufacturing Changes","Modification de la fabrication","Antibiotic","Antibiotique","",""
"13545","12-08-03","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Is indicated in combination with insulin glargine (with or without metformin) to improve glycemic control in patients with type 2 diabetes mellitus when insulin glargine (with or without metformin) in addition to diet and exercise, does not proveide adequate glycemic control.","Nouvell indication: Indiqué en association avec l'insuline glargine (avec ou sans metformine) pour améliorer le contrôle glycémique chez des patients atteints de diabète de type 2 lorsque l'insuline glargine (avec ou sans metformine) jumelée à un régime alimentaire et à l'activité physique ne procure pas un contrôle glycémique adéquat.","Antihyperglycemic Agent:","Antihyperglycémiant","",""
"13546","12-08-07","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: In combination with premixed or long/intermediate acting insulin as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on metformin, and premixed of lon'intermediate acting insulin","Nouvelle indication: En association avec l'insuline prém1?angée ou à action prolongée ou intermédiaire comme complément un régime alimentaire à l'exercise pour améliorer le contrôle glycémique chez les patients adultes atteints de diabète de type 2 mal contrôlé par la metformine et l'insuline prémélangée ou à action prolongée ou intermdiaire","Oral Antihyperglycemic Agent; DPP-4 Inhibitor/Incretin Enhancer","Agent oral d'antihyperglycémic; inhibiteur DPP-4; renforceur d'incretin","",""
"13547","12-08-03","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph regarding use in severe renal insufficiency and data from final study reports","Révisions apportées à la monographie de produit portant sur l'utilisation dans le cas de l'insuffisance rénale sévère et données provenent de rapports d'étude finaux.","Oral Antihyperglycemic Agent: DPP-4 Inhibitor; Incretin Enhancer","Antihyperglycémiant oral / Inhibiteur DPP-4 / Renforceur d'incrétin","",""
"13548","12-08-08","GENERIC MEDICAL PARTNERS","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BAYER INC","CANADA","CANADA","1","","","Antiandrogen","Antiandrogène","",""
"13549","12-08-07","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: As add-on combination therapy with premixed or long/intermediate acting insulin (with or without metformin) in adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control when diet and exercise, and therapy with premixed or long/intermediate acting insulin (with or without metformin) do not provide adequate glycemic control.","Nouvelle indicationa: Pour le traitement en association avec l'insuline prémélangée ou avec l'insuline à action prolongée ou intermidédiaire (avec ou sans la metformine) chez des patients adultes atteints du diabète de type 2 comme un médicament d'appoint au régime alimentaire et à l'exercise pour améliorer le contrôle flycémique lorsqu'uun régime alimentaire et l'activitéphysique, et le traitement avec l'insuline prémélangé ou avec l'insuline à action prolongée oue intermédiaire (avec ou sans la metformine) ne procurent pas un contrôle glyc1?mique adéquat.","Oral Antihyperglycemic Agentl DPP-4 Inhibitor, Incretin Enhancer","Antihyperglycémiant oral / Inhibiteur DPP-4 / Renforceur d'incrétin","",""
"13550","12-08-10","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13551","12-08-10","UCB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing site and new manufacturing process","Nouveau site de fabrication et nouveau processus de fabrication","Biological Response Modifier","Modificateur de la Réponse Biologique","",""
"13552","12-08-10","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","Antidepessant; Antipanic; Antiobsessional Agent","Antidépresseur; Antipabique; Antiobsessionel","",""
"13553","12-08-10","HOSPIRA HEALTHCARE CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LABELTALOL HYDROHCLORIDE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Antihypertensive Agent","Antihypertenseur","",""
"13554","12-08-10","SCHERING PLOUGH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Change in the product name and update to the labels","Changement du nom de produit et mise à jour de l'etiquettage","Histamine H1 Receptor Antagonist","Antagoniste des Récepteurs de l'Histamine H1","",""
"13555","12-08-15","ALSTOE LTD ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Opioid Analgesic","Analgésique d'Opioïde","",""
"13556","12-08-10","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","Antineoplastic Agent","Antinéoplastique","",""
"13557","12-08-10","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of a new manufacturing site","Addition d'un nouvel emplacement de fabrication","Non-depolarizing Skeletal Neuromuscular Blocking Agent","Bloqueur neuromusculaire squelettique non dépolarisant","",""
"13558","12-08-15","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13559","12-08-15","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZEMURON","ORGANON CANADA LTD","CANADA","CANADA","1","New manufacturing facility","Nouvel emplacement de fabrication","Non-Depolaraizing Skeletal Neuromuscular Blocking Agent","Bloqueur neuromusculaire squelettique non dépolarisant","",""
"13560","12-08-15","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Analgesic; Antipyretic","Analgésique; Antipyrétique","",""
"13561","12-08-14","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"13562","12-08-14","LUNDBECK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant; Anxiolytic; Antiobsessional","Antidérpesseur; Anxiolytique: Antiobsessionel","",""
"13563","12-08-17","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfillment of Post Approval Comitment #1 in accordance with the Letter of Undertaking dated May 10, 2011","Respect de l'obligation no 1 énoncée dans la lettre d'engagement du 19 Mai, 2011","Protein-Tyrosine Kinase Inhibitor","Inhibiteur de la protéase-tyrosine kinase","",""
"13564","12-08-17","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Non-Steroidal Anti-Inflammatory Drug (NSAID)","Anti-inflammatoire non Stéroïdien (AINS)","",""
"13565","12-08-16","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","Antidepressant; Anxiolytic","Antidépresseur; Anxiolytique","",""
"13566","12-08-16","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOCOR","CRYSTAAL, DIVISION OF BIOVAIL CORPORATION","CANADA","CANADA","1","","","ß-Adrenoceptor Blocking Agent","Inhibituer des Récepteurs  ß-Adrénergiques","",""
"13567","12-08-16","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"13568","12-08-16","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","","","Antibiotic; ß-Lacamase Inhibitor","Antibiotique; Inhibiteur de ß-Lqactamases","",""
"13569","12-08-16","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Selective Norepinephrine Reuptake Inhibitor for Attention-Deficit/Hyperactivity Disorder (ADHA)","Inhibiteur Sélectif du Recaptage de la Noradréaline pour le Trouble Déficitaire de l'Attention avec Hyperactivité (TDAH)","",""
"13570","12-08-16","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Leukotriene Receptor Antagonist","Antagoniste des Récepteurs des Leukotriènes","",""
"13571","12-08-17","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strengths: 50 mg for use in patients with moderal renal insufficiency and 25 mg for use in patients with severe renal insufficiency, including those wiht end-stage renal disease on dialysis","Nouvelles concentrations; 50 mg pour le patients présentement une insuffisance rénale modérée et 25 mg pour les patients présentant une insuffisance rénale grave, y compris ceux qui sont atteints d'insuffisance rénale terminale traitée par dialyse","Oral Antihyperglycemic Agent; DPP-4 Inhibitor; Incretin Enhancer","Antihyperglycémiant oral / Inhibiteur DPP-4 / Renforceur d'incrétin","",""
"13572","12-08-23","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph toxicology section","Metter à jour la monographie de produit; section TOxicologie","Brochodilator","Bronchodilateur","",""
"13573","12-08-21","MEDICIS PHARMACEUTICAL CORP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength - 2.5%","Nouvelle concentration - 2.5%","Immune Response Modifier","Modificateur de la réponse Immunitaire","",""
"13574","12-08-20","EISAI LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To reinstate the indication in selected patients with newly-diagnosed high-grade malignant glioma for whom surgical resection is indicated, as an adjunct to surgery and radiation","Rétablir l'indication chez certains patients ayant récemment reçu un diagnostic de gliome malin de haut grade pour qui la résection chirurgicale est indiqée en tant que complément à la chirurgie et é la radiation","Antineoplastic","Antinéoplastique","",""
"13575","12-08-21","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product Monograph update","Mise à jour de lla monographie du produit","Human Monoclonal ANtibody to RANKL; Bone Metabolism Regulator","Anticorps monoclonal humain au ligand RANK; Régulateur du Métabolisme Osseux","",""
"13576","12-08-20","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotrine Receptor Antagonist","Antagoniste des Récepteurs des Leucotriènes","",""
"13577","12-08-20","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13578","12-08-20","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métablisme des Lipides","",""
"13579","12-08-20","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Anti-Allergic Agent","Agent Antiallergique","",""
"13580","12-08-22","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antibiotic","Antibiotique","",""
"13581","12-08-20","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antidepressant","Antidépresseur","",""
"13582","12-08-23","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C","PFIZER CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13583","12-08-24","LUNDBECK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic","Antinéoplastique","",""
"13584","12-08-23","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant; Antiobsessional; Antibulimic","Antidépresseur; Antiobsessionel; Antibulimique;","",""
"13585","12-08-23","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TORADOL IM","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","Alternate drug substance suppliers","Autre source du produit médicamentaire","Non-steroidal Anti-inflammatory Analgesic agent","Non-stroïdien Anti-inflammatoir Agent Analgésique","",""
"13586","12-08-23","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAXOL","BRISTOL-MYERS SQUIBB CANADA","CANADA","CANADA","1","","","Antineoplastic Agent","Antinéoplastique","",""
"13587","12-08-24","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: For the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older","Nouvelle indication: Destiné au traitement de la surcharge chronique en fer chez les patients âgés de 10 ans ou plus atteints des syndromes de thalassémie non dépendante de la transfusion","Iron Chelating Agent","Chélateur du fer","",""
"13588","12-08-27","MEDA AB","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength and patient population: 5 mg tablet )orally disinegrating) for use in the elderly and in patients with hepatic impairment.","Nouvelle concentration et population visée: comprimé (à dissolution orale) de 5 mg destiné aux oersibbes âgés et aux patients atteints d'insuffisance hépatique","Hypnotic Agent","Hypnotique","",""
"13589","12-08-24","AURO PHARMA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","Removal of indications","Révocation d'indications","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de Conversion de l'angiontensine","",""
"13590","12-08-24","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de Conversion de l'angiotensine","",""
"13591","12-08-28","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER LIMITED","UNITED KINGDOM","ROYAUME-UNI","1","","","Antiepileptic Agent","Antiépileptique","",""
"13592","12-08-28","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Antagoniste des Récepteurs AT1 de l'Angiotensine II","",""
"13593","12-08-28","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NSAID Analgesic Agent - Topical Anti-inflammatory","Agent Analgésique AINS - Agent Anit-inflammatoire Topique","",""
"13594","12-08-28","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Type II 5A-reductase Inhibitor","Inhibiteur de la 5A-réductase de Type II","",""
"13595","12-08-29","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Change to age of indication, extension of post-immunization immunogenicity data","Modification de l'âge d'indication, prologement de données d'immunigénicité après la vaccination","Active Immunizing Agent","Agent d'immunisation Actif","",""
"13596","12-08-29","HEALTHPOINT CANADA ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing site","nouveau site de fabrication","Enzymatic Debriding Agent","Agent de Débridement Enzymatique","",""
"13597","12-08-29","NOVARTIS ANIMAL HEALTH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional Claim","Indications Supplémentaire","Non-steroidal Anti-inflammatory","Anti-inflammatoire Non Stéroïdien","",""
"13598","12-08-29","NOVARTIS ANIMAL HEALTH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","New strength","Nouveau dosage","Non-steroidal ANti-inflammatory","Anti-inflammatoire Non Stéroïdien","",""
"13599","12-08-24","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the PRoduct Monograph","Révisions à la monographie de produit","Antineoplastic Agent","Antinéoplastique","",""
"13600","12-08-24","ONCO THERAPIES LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAVELBINE","PIERRE FABRE PHARMA CANADA INC","CANADA","CANADA","1","","","Antineoplastic Agent","Antinéoplasique","",""
"13601","12-08-29","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Antibiotic","Antibiotique","",""
"13602","12-08-29","BIOMED 2002 INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","Antihypertensive - Antianginal Agent","Antihypertenseur - Antiangineux","",""
"13603","12-08-29","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant and Anxiolytic","Antidépresseur et Anxiolytique","",""
"13604","12-08-30","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Oral Contraceptive","Contraceptif Oral","",""
"13605","12-08-29","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhiitor","Inhibiteur de l'enzyme de Conversion de l'angiotensine","",""
"13606","12-08-29","BIOMED 2002 INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","Non-steroidal Aromitase Inhibitor; Inhibitor of Estrogen Function; Anti-tumour Agent","Inhibiteur de l'aromitase non Stéroïdien; Inhibiteur de la Biosynthèse des Oestrogènes; Antinéoplastic","",""
"13607","12-08-30","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: reduce the risk of cardiovascular mortality and hospiitalization for heart failure patients with NYHA class II systolic chronic heart failure and left ventricular systolic dysfunction","Nouvelle indication: diminue le risque de motalité cardiovasculaire et d'hospitalizatioin poour les raisons d'insuffisance cardiaque chez les patients atteints d'insuffisance cardiaque systolique chronique de classe II selon les crité res de la New York Heart Association (NYHA) et de dysfonction systolique ventriculaire gauche","Aldosterone Receptor Antagonist","ANTAGONISTE DE L'ALDOSTÉRONE","",""
"13608","12-08-30","NOVO NORDISK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouveau site de fabrication","Antidiabetic Agent","Agent Antidiabétique","",""
"13609","12-08-30","JUBILANT DRAXIMAGE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","New formulation","Nouvelle formulation","Radiodiagnostic Kit","Trousse Radiodiagnostique","",""
"13610","12-08-30","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROPECIA","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Type II 5alpha-Reductase Inhibitor","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"13611","12-08-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMINYL ER","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Cholinesterase Inhibitor","Inhibiteur de la Cholinésterase","",""
"13612","12-08-30","TORRENT PHARMACEUTICALS LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","NYCOMED CANADA INC","CANADA","CANADA","1","","","H+,K+-ATPase Inhibitor","Inhibiteur de l'H+,K+-ATPase","",""
"13613","12-08-31","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13614","12-08-31","BIOMED 2002 INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Beta-adrenergic Receptor Blocking Agent","Inhibituer des Récepteurs Bêta-adrénergiques","",""
"13615","12-08-31","BIOMED 2002 INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TENORMIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Beta-adrenergic Receptor Blocker","Inhibiteur des Récepteurs Bêta-adrénergiques","",""
"13616","12-08-31","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Hypnotic and Sedative","Hypnotique et Sédatif","",""
"13617","12-08-31","GALDERMA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in product name","Changement de nom du produit","Anti-Rosacea","Anti-rosacée","",""
"13618","12-08-31","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","BIAXIN","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13619","12-09-04","ACTELION PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Collagenase Clostridium Hystolyticum","Collagénase de Clostridium Histolyticum","",""
"13620","12-09-01","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","manufacturing change","Changement de fabrication","Active Immunizing Agent","Agent d'immunisation Actif","",""
"13621","12-09-04","ODAN LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Centrally Acting Analgesic","Analgésique à Action Centrale","",""
"13622","12-09-04","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Prevention of Seasonal Allergic Rhinitis","Prévention de la Rhinite Allergique Seasonière","",""
"13623","12-09-04","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Centrally Acting Analgesic","Analgésique à Action Centrale","",""
"13624","12-09-04","PHARMAPAR INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Centrally Acting Analgesic","Analgésique à Action Centrale","",""
"13625","12-09-04","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-ORHTO INC","CANADA","CANADA","1","","","Centrally Acting Analgesic","Analgésique à Action Centrale","",""
"13626","12-09-04","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur de la Métabolisme Lipidique","",""
"13627","12-09-04","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Centrally Acting Analgesic","Analgésique à Action Centrale","",""
"13628","12-09-04","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Centrally Acting Analgesic","Analgésique à Action Centrale","",""
"13629","12-09-04","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Centrally Acting Analgesic","Analgsique à Action Centrale","",""
"13630","12-09-04","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","Centrally Acting Analgesic","Analgésique à Action Centrale","",""
"13631","12-09-05","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New dosage strength 3000 IU","Nouvelle concentration de 3000 IU","Antihemorrhagic Blood Coagulation Factor IX","Facteur IX de Coagulation Antihémorragique","",""
"13632","12-08-27","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosing regimen for the prevention of chemotherapy induced nausea and vomiting based on results of a QT prolongation study; The maximum intravenous recommended dose is 16 mg over 15 minutes. A single dose greater the 16 mg should not be given.","Nouveau régime posologique pour la prévention des nausées et vomissement associé à la chimiothérapie fondé sur les résultats d'une étude de la prolongation de l'intervalle QT: la dose intraveineuse maximale reommendée est de 16 mg administrés par perfusion durant 15 minnutes. On de doit pas administrer une dose supérieure à 16 mg.","Antiemetic (5-HT-3 Receptor Antagonist)","Antiémétique (Antagoniste des récepteurs de 5-HT-3)","",""
"13633","12-09-06","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing sites","Nouveaux sites de fabrication","Immunomoderator","Immunomodulateur","",""
"13634","12-09-07","GENMED A DIVISION OF PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant; Antiobsessional; Antibulimic","Antidépresseur; Antiobseessionel; Antibulimique","",""
"13635","12-09-07","PALADIN LABS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Changement du nom du produit","Opioid Analgesic","Analgésique Opioïde","",""
"13636","12-09-06","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant; Antiobsessional; Antibulimic","Anridépresseur; Antiobsessionnel; Antibulimique","",""
"13637","12-09-06","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","cGMP Specific Phsophodiesterase Type 5 Inhibitor","Inhibiteur de la Phosphodiestérase de type 5 Spécifique du GMPc","",""
"13638","12-09-06","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Elevated Intraocular Pressure Therapy","Traitement d'une Pression Intraoculaire Élevée","",""
"13639","12-09-06","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive Agent","Agent Antihypertenseur","",""
"13640","12-09-05","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of alternate drug substance supplier","ADdition d'autre source de l'ingrédiant médicinal","Antibiotic","Antibiotique","",""
"13641","12-09-07","TRITON PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Antibiotic","Antibiotique","",""
"13642","12-09-07","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Modification du nom du produit","Anticoagulant","Anticoagulant","",""
"13643","12-09-07","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Prolactin Inhibitor; Growth Hormons Suppressant in Acromegaly, Adjunctive Medication in Parkinson's Disease","Inhibiteur de la Prolactine; Inhibiteur de l'hormone de Croissance dans l'acromégalie; Traitement Adjuvant dans la Maladie de Parkinson","",""
"13644","12-09-07","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antipsychotic Agent","Agnet Antipsychotique","",""
"13645","12-09-07","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Nonsteroidal Anti-inflammatory Drug (NSAID)","Anti-inflammatoire non-stéroïdien (AINS)","",""
"13646","12-09-07","ONCO THERAPIES LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","Antineoplastic Agent","Agent antinéoplasique","",""
"13647","12-09-07","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CESAMET","VALEANT CANADA LIMITÉE/LIMITED","CANADA","CANADA","1","","","Antiemetic","Antiémétique","",""
"13648","12-09-13","CSL BEHRING CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","Coagulation Factor I","Facteur I de la Coagulation","",""
"13649","12-09-14","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Serotonin S2 Receptor Antagonist","Antisérotonine (Récepteur S2)","",""
"13650","12-09-14","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antifungal","Antifongique","",""
"13651","12-09-14","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"13652","12-08-28","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist and Diuretic","Antagoniste des Réceptuers de l'Angiotensine II et Diurétique","",""
"13653","12-09-14","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ULTIVA","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","Opioid Component to Anesthesia","Compsante Opioïde pour l'Anesthésie","",""
"13654","12-09-14","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVIR-HBV","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Antiviral Agent","Agent Antiviral","",""
"13655","12-09-14","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker / Diuretic","Inhibiteur des récepteurs AT1 de l'angiotensine II / Diurétique","",""
"13656","12-09-07","EISAI LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate drug product manufacturing facility involved in the production and testing (release and stability) of a sterile drug product","Autre installation de fabrication d'un produit mdecamenteux qui participe à ;a fabrication et à la mise à essai (libération et stabilité) d'un produit médicamenteux stérile","Antineoplastic","Antinéoplastique","",""
"13657","12-08-27","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Blocker","Antagoniste des Réceptuers de l'Angiotensine II","",""
"13658","12-09-19","NORBROOK LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","RIMADYL CAPLETS","PFIZER CANADA INC","CANADA","CANADA","1","","","Non-steroidal Anti-inflammatory","Anti-inflammatoire Non-stéroïdien","",""
"13659","12-09-20","ELANCO DIVISION ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Add species, new strengthNouveau espèces, nouveau dosage","","Antiparasitic","Antiparasitique","",""
"13660","12-09-18","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate manufacturer for timolol maleate","autre fabricant pour maléate de timolol","Elevated Intraocular Pressure Therapy","Thérapie pour Réduire la Pression Intra-Oculaire","",""
"13661","12-09-17","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker / Diuretic","Bloquer des Récepteurs AT1 de l'Angiotensine II / Diurétique","",""
"13663","12-09-18","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KETALAR","ERFA CANADA INC","CANADA","CANADA","1","New manufacturing facility","Nouveau emplacement de fabrication","General Parenteral Anesthetic","Anesthésique Général","",""
"13664","12-09-24","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing site and changes to the manufacturing process","Nouveau site de fabrication et changements au processus de fabrication","Antineoplastic","Antnéoplastique","",""
"13665","12-09-24","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND PLUS","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker and Diuretic","Antagoniste des Récepteurs AT1 de l'Angiotensine II et Diurétique","",""
"13666","12-09-24","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND PLUS","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker and Diuretic","Antagoniste des Récepteurs AT1 de l'Angiotensine II et Diurétique","",""
"13667","12-09-24","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND PLUS","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker and Diuretic","Antagoniste des Rcepteurs AT1 de l'Angiotensine II et Diurétique","",""
"13668","12-09-24","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New DIN","Nouveau DIN","Erythropoiesis Regulating Hormone","Hormone de Régulation d'Eérythropoïèse","",""
"13669","02-06-17","TYCO HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Radiopaque Contrast Medium","Agent de Contraste Radiologique","",""
"13670","12-09-24","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND PLUS","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Antihypertensive","Antihypertenseur","",""
"13671","12-09-21","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RILUTEK","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Antiglutamate","Antiglutamate","",""
"13672","12-09-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND PLUS","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker and Diuretic","Antagoniste des Recepteurs AT1 de l'Angiotensine II et Diurétique","",""
"13673","12-09-25","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Manufacturing update","Mise à jour du processus de fabrication","Active Immunizing Agent","Agent d'Immunisation Actif","",""
"13674","12-09-25","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional Manufacturing facility","Addition d'un nouveau site de fabrication","Antineoplastic","Antinéoplasique","",""
"13675","12-09-26","PALADIN LABS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Changement du nom du produit","Platelet Aggregation Inhibitor and Lipid Metabolism Regulator","Inhibiteur de l'Agrégation Plaquettaire et Régulateur du Métabolisme des Lipides","",""
"13676","12-09-26","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAPROSYN E","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","Product Monograph update","Mise à jour de la monographie du produit","Non-steroidal Anti-inflammatory Drug (NSAID)","Anti-inflammatoire non Stéroïdien (AINS)","",""
"13677","12-09-26","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antineoplastic","Antinéoplastique","",""
"13678","12-09-26","AA PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antidepressant","Antidépresseur","",""
"13679","12-09-28","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Change in withholding time","Changement de période de retrait","Antibiotic","Antibiotique","",""
"13680","12-09-28","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","Antibiotic","Antibiotique","",""
"13681","12-09-27","UCB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing site","Nouvel emplacement de fabrication","Antiepileptic","Antiépileptique","",""
"13682","12-09-27","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph; use in hypertensive pediatric parents","Modifications apportées à la monographie du produit; utilisation chez les patients pédiatriques hypertendu","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'Enzyme de Conversion de l'Angiotensine","",""
"13683","12-09-27","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CESAMET","VALEANT CANADA LTD","CANADA","CANADA","1","","","Antiemetic","Antiémétique","",""
"13684","12-09-27","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in manufactuirng process","Changement dans le procédé de fabrication","Anxiolytic - Sedative","Anxiolytique - Sédatif","",""
"13685","12-09-27","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT RPD","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs 5-HT1; Antimingraineux","",""
"13686","12-09-28","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker; Diuretic","Antagoniste des Récepteurs AT1 de l'Angiotensine II; Diurétique","",""
"13687","12-09-28","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","NITROLINGUAL PUMPSPRAY","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Antianginal Agent","Antiangineux","",""
"13688","12-09-27","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","Antidepressant; Antiobsessional; Antibulimic","Antidépresseur; Antiobsessionel; Antibulimique","",""
"13689","12-09-27","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","Change in the manufacturing process","Changement dans le procédé de fabrication","Antidepressant; Antiobsessional; Antibulimic","Antidépresseur; Antiobsessionel; Antibulimique","",""
"13690","12-09-27","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MONOPRIL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","Additional drug substance supplier","Autre source du produit Médicamentaire","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'Enzyme de Conversion de l'Angiotensine","",""
"13691","12-09-26","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfilmenmt of final commitment as per amended Letter of Undertaking dated October 16, 2008 for use in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients wieh operable node-positive breast cancer. Revisions to the Product monograph including Indications and clinical use, contreaindications, warnings and precautions, advierse reatcions and clinical trials","Le respect de l'engagement final conformément à la letrtre d'engagement modifie en date du 16 octobre 2008 concernent l'administration combinée du doxorubicine et du cyclophosphamide pour le traitement adjuvant des patientes atteintes d'un cancer du sein opérable avec atteinte ganglionnaire. Les modifications apportées à la monographie touchent les senctions indication set utilisation clinique, contre-indications, mises en garde précautions, effets indésirables et essais cliniques","Antineoplastic Agent","Antinéoplastique","",""
"13692","12-09-27","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT","MERCK & CO INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs 5HT1; Antimigraineux","",""
"13693","12-09-21","TYCO HEALTHCARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Change of resin for container closure system","Changement de la résine pour le conteneur","PARAMAGNETIC, INTRAVASCULAR CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","PRODUIT DE CONTRASTE PARAMAGNÉTIQUE INTRAVASCULAIRE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"13694","12-09-21","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Replace current sterility release parameter in the drug product specification with a parametric release decision","Substitution des épreuves de stérilité par un procédé de libération en fonction de paramètres dans les spécifications du produit","Nonoionic Iodinated Radiographic Contrast Medium","Substance de Contrate Radiographique non Ionique Iodée","",""
"13695","12-10-01","INTERMUNE INTERNATIONAL AG","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-fibrotic; Anti-inflammatory Agent","Anti-fibrotique; Agent anti-inflammatoire","",""
"13696","12-10-03","NORBROOK LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","CLAVAMOX TABLETS","PFIZER CANADA INC , ANIMAL HEALTH GROUP","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13697","12-10-03","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","Antihemorrhaginc Blood Coagulation Factor VIII","Facteur VIII de Coagulation Antihémorragique","",""
"13698","12-10-02","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the Product Monograph","Mise à jour de la monographie du produit","Selective Immunomodulating Agent","Agent Immunomodulateur Sélectif","",""
"13699","12-10-03","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Dosage Format: 800 mg Oral Tablet","Nouvelle forme posologique: Comprimées Orale de 800 mg","Human Immunodeficiency Viras Protease Inhibitor","Inhibiteur de la Protéase du Virus de l'Immunodficience Humaine","",""
"13700","12-10-03","GALDERMA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate manufacturing process for the synthesis of the drug substance","Autre processus de fabrication pour la synthése de la substance thérapeutique","Acne Therapy","Traitement Antiacné","",""
"13701","12-10-03","QD PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Recpeotr Blocker","Bloqueur des Récepteurs AT1 de l'Angiotensine II","",""
"13702","12-10-04","HUVEPHARMA AD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","DENEGARD LIQUID CONCENTRATE","NOVARTIS ANIMAL HEALTH CANADA INC","CANADA","CANADA","1","Change in packaging, change in strength","Changement de contenant, changement de dosage","Antibiotic","Antibiotique","",""
"13703","12-10-03","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de conversion de l'angiotensine","",""
"13704","12-10-03","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13705","12-10-03","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB CANADA","CANADA","CANADA","1","","","Lipid Metabolism Regulator","Régulateur du Métabolisme des Lipides","",""
"13706","12-10-04","GALDERMA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of an alternate drug substance manufacturer and addition of an alternate manufacturing process for the synthesis of the drug substance","Addition d'un autre fabricat de la substance thérapeutique et addition d'un autre processus de fabrication pour la synthèse de la substance thérapeutique","Ance Therapy","Traitement Antiacné","",""
"13707","12-10-04","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER LTD","UNITED KINGDOM","ROYAUME-UNI","1","","","Antiepileptic Agent","Antiépileptique","",""
"13708","12-10-09","NOVOPHARM LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NIZORAL","JANSSEN PHARMACEUTICA, DIVISION OF JANSSEN ORTHO INC","CANADA","CANADA","1","New API manufacturier","Nouveau fabricant de l'IPA","Anti-fungal Agent","Antifongique","",""
"13709","12-10-05","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELPAX","PFIZER CANADA INC","CANADA","CANADA","1","","","5-HT1 Receptor Agonist; Migraine Therapy","Agoniste des Récepteurs 5-HT1; Antimigraineux","",""
"13710","12-10-05","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Modification of specification and testing method before packaging","Modification des spécifications et de la méthode d'essai avant l'ebmallage","Smoking Cessation Aid","Aide pour cesser de fumer","",""
"13711","12-10-01","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: For use in combination with premixed of long/intermediate acting Insulin as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus who are already treated with saxagliptin, metformin and premixed of long/intermediate acting insulin or who are inadequately controlled on metformin and premixed or long'intermediate acting insulin alone","Nouvelle indication: Indiqué en associaiton aven l'insuline prémélangée ou à action prolongée ou intermédiare comme médicament d'appont au régime alimentaire et à l'exercise pour améliorer le contrôle glycémique chez les adultes atteints du diabète de type 2 qui sont déjà traités à l'aide de la saxagliptine de la metformine combinée à l'insuline à action prolongée ou intermédiare, ou dont le diabète est insuffisamment maîtrisé avec la metformine combinée à l'insuline prémélangée, ou avec l'insuline à action prolongée ou intermédiare seule.","Oral Antihyperglycemic Agent; DPP-4 Inhibitor; Incretin Enhancer","Agent Antihyperglycémiant; Inhibiteur de DPP-4; Enhanceur de l'incretin","",""
"13712","12-10-03","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XALACOM","PFIZER CANADA INC","CANADA","CANADA","1","","","Elevated Intraocular Pressure Therapy","Thérapie pour réduire la pression intraoculaire","",""
"13713","12-10-01","TERUMO BCT, INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Red Blood Cell Storage Solution","Solution d'entreposage pour le Culot Globulaire","",""
"13714","12-10-12","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New master seed lot","Nouvelle lot de semence primaires","Active Immunizing Agent","Agent d'immunisation Actif","",""
"13715","12-10-12","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New master seed lot","Nouvelle lot de semence primaires","Acitve Immunizing Agent","Agnet d'immunisation Actif","",""
"13716","12-10-12","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New master seed lot","Nouvelle lot de semence primaires","Active Immunizing Agent","Agnet d'immunisation Actif","",""
"13717","12-10-12","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New master seed lot","Nouvelle lot de semence primaires","Active Immunizing Agent","Agent d'immunisation Actif","",""
"13718","12-10-03","ONCO THERAPIES LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CISPLATIN INJECTION BP","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","","","Antineoplastic Agent","Agent antinéoplasique","",""
"13719","12-10-10","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC","CANADA","CANADA","1","","","Antiepileptic Agent","Antiéipleptique","",""
"13720","12-10-10","ACCORD HEALTHCARE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","New Strength","Nouvelle concentration","Anti-diabetic Agent","Agent antidiabétique","",""
"13721","12-10-12","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin Converting Enzyme Inhibitor","Inhibiteur de l'enzyme de Conversion de l'angiotensine","",""
"13722","12-10-12","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XALACOM","PFIZER CANADA INC","CANADA","CANADA","1","","","Elevated Intraocular Pressure Therapy, Prostaglandin F2A Analogue; Beta-adrenergic Receptor Blocker","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA ET INHIBITEUR DES RÉCEPTEURS BETA-ADRÉNERGIQUES","",""
"13723","12-10-15","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND PLUS","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker and Diuretic","Antagoniste des Recepteurs AT1 de l'angiotensine II et Diurétique","",""
"13724","12-10-15","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND PLUS","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker and Diuretic","Antagoniste des Récepteurs AT1 de l'angiotensine et Diurétique","",""
"13726","12-10-10","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication: In combination with pioglitazone in adult patients with type 2 diabetes mellitus to improve glycemic control when dieat and exercise and dial therapy with metformin and pioglitazone do not provide adequate glycemic control.","Nouvelle indication: En association avec la pioglitazone chez les patients adultes atteints de diabète de type 2 afin d'améliorer le contrôle glycémique lorsque l'alimentation et l'exercise, en plus d'un traitement à double modalité à l'aide de la metformine et de la pioglitazone ne fournissent pas un contrôle glycémique adéquat.","Oral Antihyperglycemic Agent; DPP-4 Inhibitor; Incretin Enhancer","Agent oral d'antihyperglycémic; inhibiteur DPP-4; renforceur d'incretin","",""
"13727","12-10-10","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: In combination with pioglitazone in adult patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise plus pioglitazone do not provide adequate glucemic control. New Indication: In combination with metformin and pioglitazone in adult patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise and dual therapy with these agents do not provide adequate glycemic control.","Nouvelle indication: En association avec la pioglitazone chez les patients adultes atteints de diabète de type 2 afin d'améliorer lo contrôle glycémique lorsque l'alimentation et l'exercise en plus de la pioglitazone ne fournissent pas un contrôle glycémique adéquat. Nouvelle indication: En association avec la metformine et la pioglitazone chez les patients adultes atteints de diabète de type 2 afin d'améliorer le contrôle glycémique lorsque l'alimentation et l'exercise enplus du tritement à double modalité à l'aide de ces agents ne fournissent pas un contrôle glycémique adéquat.","Oral Antihyperglycemic Agent; DPP-4 Inhibitor; Incretin Enhancer","Agent oral d'antihyperglycémic; inhibiteur DPP-4; renforceur d'incretin","",""
"13728","12-10-16","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Anti-allergy Agent","Agent Antiallergique","",""
"13729","12-10-16","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Bronchodilator","Bronchodilateur","",""
"13730","12-10-18","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiepileptic Agent","Antiépileptique","",""
"13731","12-10-23","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Leukotriene Receptor Antagonist","ANTAGONISTE DES RÉCEPTEURS DE LEUKOTRIÈNE","",""
"13732","12-10-19","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional drug substance manufacturing and tesint sight","Endroit additionnelle pour le fabricatione et verification de la produit médicament","Selective Serotonin Reuptake Inhibitor","Inhibiteur Sélectif du Recaptage de la Sérotonine","",""
"13733","12-10-10","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","Angiotensin II AT1 Receptor Blocker","Antagoniste des Récepteurs AT1 de l'Angiotensine II","",""
"13734","12-10-19","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional drug substance manufacturing and testin site","Endroit additionnelle pour la fabrication et verification de la produit médicamentaire","Selective Serotonin Reuptake Inhibitor","Inhibiteur Sélectif du Recaptage de la Sérotonine","",""
"13735","12-10-19","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist","Antagoniste des Récepteurs de l'Angiotensine II","",""
"13736","12-10-22","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RILOTEK","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","Antigultamate","Antiglutamate","",""
"13737","12-10-19","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELEHIM (CANADA) LTD","CANADA","CANADA","1","Removal of indication","Suppression de l'indication","Angiotensin II AT1 Receptor Blocker","Antagoniste des Récepteurs AT1 de l'Angiotensine","",""
"13738","12-10-19","VIROPHARMA BIOLOGICS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Biologic","Biologique","","","","","1","","","Serine Protease Inhibitor","Inhibiteur de Protéase de Sérine","",""
"13739","12-10-22","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYLOPRIM","AA PHARMA INC","CANADA","CANADA","1","","","Xanthine Oxidase Inhibitor","Inhibiteur de la xanthine oxidase","",""
"13740","12-09-11","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYKLOKAPRON","PFIZER CANADA INC","CANADA","CANADA","1","","","Antifibrolytic Agent","Antifibrolytique","",""
"13741","12-09-10","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NALOXONE HYDROCHLORIDE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","","","Opioid Antagonst","Antagoniste Opioïdes","",""
"13742","12-10-22","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP","PHARMACEUTICAL PARTNERS OF CANADA INC","CANADA","CANADA","1","","","Antibiotic","Antibiotique","",""
"13743","12-10-23","PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","Platelet Aggregation Inhibitor","Inhibiteur d'aggloméraiton des Plaquettes","",""
"13744","12-10-23","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND PLUS","ASATRAZEMECA CANADA INC","CANADA","CANADA","1","","","Angiotensin II AT1 Recpeptor Blocker + Diuretic","Antagoniste des écepteurs AT1 de l'Angiotensine II + Diurétique","",""
"13745","12-10-23","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antiepileptic","Antiépileptique","",""
"13746","12-10-23","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR DS","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist and Diuretic","Antagoniste des Récepteurs de l'Angiotensine II et Diurétique","",""
"13747","12-10-23","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Bone Metabolism Regulator","Régulateur du Métabolisme Osseux","",""
"13748","12-10-26","BAUSCH & LOMB INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRUSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","Elevated Intraocular Pressure Therapy","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"13749","12-10-26","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL EXTRA STRENGTH CAPLETS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"13750","12-10-26","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Replacement of drug product manufacturer","Substitution du fabricant de la produit","ANTIBIOTIC","ANTIBIOTIQUE","",""
"13751","12-10-26","SANDOZ CANADA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate manufacturing site for the drug substance","Autre lieu de fabrication pour le sutance médicamentaire","ANTIARRHYTHMIC","ANTIARTHMIQUE","",""
"13752","12-10-26","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","ALEVE","BAYER INC CONSUMER CARE","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-NFLAMMATORY DRUG / ANALGESIC / ANTIPYRETIC","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN / ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"13753","12-10-25","BIOMED 2002 INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13754","12-10-26","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"13755","12-10-25","STASON PHARMACEUTICALS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","Revisions to the product monograph","Révisions à la monographie de produit","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13756","12-10-25","STASON PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13757","12-10-25","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13758","12-10-25","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13759","12-10-25","TARO PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13760","12-10-25","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13761","12-10-25","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13762","12-10-25","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13763","12-10-25","GENERIC MEDICAL PARTNERS","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13764","12-10-25","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"13765","12-10-25","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA PHARMACEUTICALS LP","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"13766","12-10-25","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13767","12-10-29","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","New Indication","Nouvelle indication","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13768","12-10-25","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13769","12-10-25","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEXIUM","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,k=-ATPASE","",""
"13770","12-10-25","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","PLATELET AGGREGATION INHIBTOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"13771","12-10-29","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON STÉROÏDIEN","",""
"13772","12-10-26","KORA HEALTHCARE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SUBACUTE SCLEROSING PANENCEPHALITIS THERAPY","TRAITEMENT DE LA LEUCOENCÉPHAILTE SCLÉROSANTE SUBAIGUË","",""
"13773","12-10-26","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","To harmonize product labelling","Pour harmoniser l'etiquettage","ANALGESIC","ANALGÉSIQUE","",""
"13774","12-10-26","TRITON PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"13775","12-10-29","PALADIN LABS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Replacement of drug substance source and change of manufacturing method","Remplacement de la source de substance médicamenteuse et changement de la méthode de fabrication","ANTISPASTIC AGENT","ANTISPASMODIQUE","",""
"13776","12-10-26","GEA FARM TECHNOLOGIES INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Change in formulation - Change in manufacturer","Changement de formulation - Modification du fabricant","ANTISEPTIC","ANTISEPTIQUE","",""
"13777","12-10-26","GEA FARM TECHNOLOGIES INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Change in formulation","Changement de formulation","ANTISEPTIC","ANTISEPTIQUE","",""
"13778","12-10-29","INTERMUNE CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTI-FIBROTIC; ANTI-INFLAMMATORY AGENT","ANTIFIBROTIQUE; AGENT ANTI-INFALMMATOIRE","",""
"13779","12-10-29","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","SUPER STRENGTH MOTRIN IB","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG, ANALGESIC, ANTIPYRETIC","NON STEROÏDIEN ANTI-INFLAMMATOIRE, ANALGÉSIQUE. ANTIPYRÉTIQUE","",""
"13780","12-10-25","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","Removal of indication","Suppression de l'indication","NON-STEROIDAL AROMITASE INHIBITOR","INHIBITEUR DE L'AROMITASE NON-STÉROÏDIEN","",""
"13781","12-10-25","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"13782","12-10-25","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD AND SINUS PLUS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","ANALGESIC;ANTIPYRETIC;NASAL DECONGESTANT;ANTIHISTAMIN","Analgésique / Antipyrétique / Décongestionnant nasal / Antihistaminique","",""
"13783","12-10-25","TARO PHARMACEUTICALS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON-STÉROÏDIEN","",""
"13784","12-10-31","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","TAKEDA PHARMACEUTICALS AMERICA INC","CANADA","CANADA","1","","","H+, K+-ATPase Inhibitor","Inhibiteur de l'H+, K+-ATPase","",""
"13785","12-11-01","BAUSCH & LOMB INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"13786","12-10-30","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"13787","12-10-30","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND PLUS","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER + DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II + DIURÉTIQUE","",""
"13788","12-10-29","TORRENT PHARMACEUTICALS LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","PLATELET AGGREGATION INHIBTOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"13789","12-11-01","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"13790","12-11-01","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"13791","12-11-01","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Replacement of manufacturer for active pharmaceutical ingredient (API) ethynodiol diacetate","Remplacement du fabricant de l'ingrédient phaarmaceutique actif, le diacétate d'éthyndiol","ORAL CONTRACEPTOVE","CONTRACÉPTIF ORAL","",""
"13792","12-10-25","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND PLUS","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II ATI RECEPTOR BLOCKER AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"13793","12-11-01","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New intermediate seed lots and working seed lot","Nouveau lot de semence intermédiaire et nouoveau lot de travail","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"13794","12-11-01","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New intermediate seed lots and working seed lot","Nouveau loty de semence interméiaire et nouveau lot de travail","ACITVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"13795","12-11-01","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New intermediate seed lots and working seed lot","Nouveau lot de semence intermédiaire et nouveau lot de travail","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"13796","12-11-01","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEMODAL","SCHERING PLOUGH","BELGIUM","BELGIQUE","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"13797","12-11-01","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"13798","12-11-01","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","Product name change","Changement du nom du produit","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"13799","12-11-01","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANDROCUR","BAYER INC","CANADA","CANADA","1","","","ANTIANDROGEN","ANTIANDROGÈNE","",""
"13800","12-11-02","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Update to the Product monograph","Mise à jour à la monographie de produit","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"13801","12-08-24","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph and labels","Mise à jour à la monographie de produit et étiquettage","ACNE THERAPY","TRAITEMENT D'ACNÉ","",""
"13802","12-11-01","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"13803","12-11-01","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"13804","12-11-01","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"13805","12-11-01","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECPEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"13806","12-11-01","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITUER DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"13807","12-11-01","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","JANSSEN-CILAG LTD","UNITED KINGDOM","ROYAUME-UNI","1","","","ANTIEPILEPTIC; MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE; PROPHYLAXIE DE LA MIGRAINE","",""
"13808","12-11-02","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"13809","12-11-02","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INTRAVENOUS SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE INTRAVEINEUSE","",""
"13810","12-11-02","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INTRAVENOUS NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NONDÉPOLARISANT INTRAVEINEUX","",""
"13811","12-11-02","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCLUAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NONDÉPOLARISANT","",""
"13812","12-11-02","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GONADOTROPIN-RELEASING HORMONE ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA GONADOTROPHINE","",""
"13813","12-11-02","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN D ANALOGUE","ANALOGQUE DE LA VITAMINE D","",""
"13814","12-11-02","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in storage temperature for the diluent from refirgerated to room temperature","Msodification de la température d'entreposage du diluent, passant de réfrigérée à température ambiante","MTOR KINASE INHIBITOR; ANTINEOPLASTIC AGENT","INHIBITEIR DE LA MTOR; ANTINÉOPLASTIQUE","",""
"13815","12-11-02","EMD SERONO A DIVISION OF EMD INC CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in the drug substance manufacturer, new manufacturing process, new container closure system for the drug product and the diluent","Modification du fabricant de la substance médicamenteuse, nouveau procédé de fabrication, nouveau système récipient-fermeture pour le product pharmaceutique et le diluant","GNRH ANTAGONIST","GNRH (ANTAGONISTE)","",""
"13816","12-09-27","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT RPD","MERCK FROSSST CANADA LTD","CANADA","CANADA","1","","","MIGRAINE THERAPY","ANTIMIGRAINEUX","",""
"13817","12-11-07","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN D3 METABOLITE","MÉTABOLITE DE LA VITAMINE D3","",""
"13818","12-11-07","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID DOMPONENT TO ANESTHESIA","COMPOSANTE OPIOÏDE POUR L'ANESTHÉSIE","",""
"13819","12-11-07","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBIREUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"13820","12-11-07","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate container system, label change, update to the Product Monograph","Autre systèm de de closure, changement de l'etiquettage, mise à jour de la monographie de produit","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"13821","12-11-07","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALATION ANESTHETIC","ANESTHÉSIQUE PAR INHALATION","",""
"13822","12-11-07","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOCAL ANESTHETIC","ANESTHÉSIQUE LOCAL","",""
"13823","12-10-30","JUBILANT LIFE SCIENCES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK CANADA INC","CANADA","CANADA","1","","","Angiotensin II Receptor Antagonist","Antagoniste des récepteurs de l'angiotensine II","",""
"13824","12-11-05","PALADIN LABS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Major update to the Product Monograph including the Indication, Warnings & Precautions, Dosage and Administration and creation of Part III","Mise à jour majeure de la monographi de produit incluant les sections Indication, Mise en Garde et Précuations, Posologie et Mode d'administration et création d;une Partie III","MIGRAINE PROPHYLAXIS","PROPHYLAXIE DE LA MIGRAINE","",""
"13825","12-10-26","GILEAD SCIENCES CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the PRoduct Monograph","Mise à jour de la monographie de produit","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"13826","12-11-06","WINNIPEG REGIONAL HEALTH AUTHORITY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","FLUGLUCOSCAN INJECTION","ALBERTA HEALTH SERVICES","CANADA","CANADA","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"13827","12-10-31","JUBILANT LIFE SCIENCES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"13828","12-11-08","NOVOPHARM LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","cGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE GMPc, TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"13829","12-11-01","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"13830","12-11-08","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE GMPC","",""
"13831","12-11-08","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE DYSFUNTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE GMPC","",""
"13832","12-11-08","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","C/GMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE GMPC","",""
"13833","12-11-08","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","C/GMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE GMPC","",""
"13834","12-11-08","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","C/GMP-SPECIFIC PHHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE DYSFUNTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE GMPC","",""
"13835","12-11-13","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC.","CANADA","CANADA","1","New presentation; New product name","Nouvelle présentation, nouveau nom du produit","cGMP-Specific Phosphodiesterase Type 5 Inhbitor; Treatment of Erectile Dysfunction","Inhibiteur de la phosphodiestérase de type 5 spécifique de GMPC; Traitement de la dysfonction érectile","",""
"13836","12-11-08","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGARA","PFIZER CANADA INC.","CANADA","CANADA","1","","","cGMP-Specific Phosphodiesterase Type 5 Inhbitor; Treatment of Erectile Dysfunction","Inhibiteur de la phosphodiestérase de type 5 spécifique de GMPC; Traitement de la dysfonction érectile","",""
"13837","12-11-09","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC.","CANADA","CANADA","1","","","cGMP-Specific Phosphodiesterase Type 5 Inhbitor; Treatment of Erectile Dysfunction","Inhibiteur de la phosphodiestérase de type 5 spécifique de GMPC; Traitement de la dysfonction érectile","",""
"13838","12-11-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC.","CANADA","CANADA","1","","","cGMP-Specific Phosphodiesterase Type 5 Inhbitor; Treatment of Erectile Dysfunction","Inhibiteur de la phosphodiestérase de type 5 spécifique de GMPC; Traitement de la dysfonction érectile","",""
"13839","12-11-13","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC.","CANADA","CANADA","1","","","cGMP-Specific Phosphodiesterase Type 5 Inhbitor; Treatment of Erectile Dysfunction","Inhibiteur de la phosphodiestérase de type 5 spécifique de GMPC; Traitement de la dysfonction érectile","",""
"13840","12-11-09","FAMY CARE LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MARVELON 28","ORGANON CANADA LTD.","CANADA","CANADA","1","","","Oral Contraceptive","Contraceptif Oral","",""
"13841","12-11-08","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC.","CANADA","CANADA","1","","","cGMP-Specific Phosphodiesterase Type 5 Inhbitor; Treatment of Erectile Dysfunction","Inhibiteur de la phosphodiestérase de type 5 spécifique de GMPC; Traitement de la dysfonction érectile","",""
"13842","12-11-09","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC.","CANADA","CANADA","1","","","Lipid metabolism regulator","Régulateur du métabolisme des lipides","",""
"13843","12-11-09","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","Antihypertensive agent; Symptomatic Treatment of Benign Prostatic Hyperplasia (BHP)","Antihypertenseur; Traitement symptomatique de l'hypertropie bénigne de la prostate (HBP)","",""
"13844","12-11-14","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","METACAM ORAL SUSPENSION","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","NON-STEROIDAL ANTIINFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STEROÏDIEN (AINS)","",""
"13845","12-11-14","PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAVELBINE","PIERRE FABRE PHARMA CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASTIQUE","",""
"13846","12-11-14","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"13847","12-11-14","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NAVELBINE","PIRRE FABRE PHARMA CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASTIQUE","",""
"13848","12-11-14","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","UCB CANADA INC","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"13849","12-11-14","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TOPAMAX","OTHO-MCNEIL NEUROLOGICS INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEPILEPTIC; MIGRAINE PROPHYLAXIS","ANTIÉPILEPTIQUE; PROPHYLAXIE DE LA MIGRAINE","",""
"13850","12-11-15","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Consumer Information section of the PRoduct Monograph","Mise à jour de la section de rensignements pour la consummateur de la monographie de produit","ADRENOCORTICOTROPIC HORMONE","Hormone Adrénocorticotopique","",""
"13851","12-11-15","VETOQUINOL N A INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","New strength","Nouveau Dosage","ANTIBIOTIC","ANTIBIOTIQUE","",""
"13852","12-10-25","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"13853","12-11-16","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Indication extensin: Herceptin (trastuzumab) is indicated for the treatment of patients with early stage breasta acnacer with ECOG 0-1 status whose romours overexpress HER2 following surgery and after chemotherapy; following adjuvant chemotherapy consisting of socorubicin and cylophosphamide, in combination with paclitaxel or doxetaxel; in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin","Extenison de l'indication: Herceptin (trastuzumab) est indiqué dans la traitement du cancer du sein wu stade précocem en présence  d'une surexpression de HER2 et d'un indice ECOG de 0 à 1; à la suite d'une chirugie et d'une chimiothérapie; à la suite d'une chhimiothérapie adjuvante acomposée de doxorubicine et de cyclophosphamide, en asssociation avev le pacitaxel et le ocetaxel; en assoaition avec une chimiothérapie adjuvante composée de docetaxel et de carboplatine","ANTINEOPLASTIC","ANTINÉOPLASTIQUE","",""
"13854","12-11-16","ACCORD HEALTHCARE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"13855","12-11-16","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIRAMUNE","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"13856","12-11-16","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","TAKEDA CANADA INC","CANADA","CANADA","1","","","ANTI-DIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"13857","12-11-19","CIPHER PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SEVERE NODULAR INFLAMMATORY ACNE; ACNE CONGLOBATE; RECALCITRANT ACNE THERAPY","ACNÉ NODULAIRE INFLAMMATOIRE SÉVERE; ACNÉ CONGLABOTE; TRAITEMENT D'ACNÉ RÉCALCITRANT","",""
"13858","12-11-16","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"13859","12-11-20","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"13860","12-11-20","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Inclusion of pediatric data in the Product Monograph","Ajout de données pour la population pédiatrique dans la monographie de produit","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"13861","12-11-16","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","Alternate drug substance supplier","Autre fabricant de la substance médicamentaire","C-GMP SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DU GMPC","",""
"13862","12-11-20","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDES","",""
"13863","12-11-22","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional species","Especès addtionelles","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"13864","12-11-21","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Chane to Dosage and Administration","Changement à la Posologie et administration","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"13865","12-11-22","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Change to Dosage and ADministration.","Changement à la Posologie et administration","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"13866","12-11-20","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","OSTEOINDUCTIVE AGENT","AGENT OSTÉOINDUCTEUR","",""
"13867","12-11-20","FRESENIUS KABI CANADA, A DIVISION OF CALEA LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","LIPID EMULSION FOR INTRAVENOUS NUTRITION","ÉMULSION LIPIDIQUE POUR LE NUTRITION INTRAVÉNEUSE","",""
"13868","12-11-20","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product Monograph update","Mise à jour de la monographie de produit","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"13869","12-11-20","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New 25 mg tablet; New indication for pediatric patients 6 to <18 years of age","Nouveau comprimé de 25 mg; Nouvell iindication pour les patients pédiatriques à l'age de 6 à <18 ans.","HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR","Inhibiteur de la Protéase du Virus de l'immunodéficience Humaine (VIH)","",""
"13870","12-11-21","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing site","Nouveau site de fabrication","GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"13871","12-11-21","AMGEN CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: treatment to increase bone mass in men with osteoporosis at high risk for fracture","Nouvelle indication: traitement pour augmenter la masse osseuse chez les hommes atteints d'ostéoporose qui sont à risque élevéde fracture","HUMAN MONOCLONAL ANTIBODY RANKL; BONE METABOLISM REGULATOR","ANTICORPS NONOCLONAL HUMAIN AU LIGAND RANK; RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"13872","12-11-22","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PATANOL","ALCON CANADA INC","CANADA","CANADA","1","","","ANTI-ALLERGY AGENT","AGENT ANTIALLERGIQUE","",""
"13873","12-11-22","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT RPD","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST - MIGRAINE THERAPY","AGONISTE DES RÉCEPEURS DE LA 5-HT1 - ANTIMIGRAINEUX","",""
"13874","12-11-22","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYLOPRIM","AA PHARMA INC","CANADA","CANADA","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE OXYDASE","",""
"13875","12-11-22","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","Product name change","Changement du nom du produit","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DU GMPC; TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"13876","12-11-23","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate drug substance manufacturing process","Autre processus pour le fabrication de la substance médicamentaire","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"13877","12-11-22","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","RETROGRADE CYSTOLOGY AND CYSTOURETHROGRAPHY X-RAY CONTRAST MEDIUM","AGENT DE CONTRASTE RADIOLOGIQUE CYSTOGRAPHIE RÉTROGRADE ET CYSTOURÉTROGRAPHIE","",""
"13878","12-11-22","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","PARAMAGNETIC INTRAVASCULAR CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING (MRI)","PRODUIT DE CONTRASTE PARAMAGNÉTIQUE, INTRAVASCULAIRE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE (IRM)","",""
"13879","12-11-22","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASTIQUE","",""
"13880","12-11-22","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ORAL RADIOPAQUE CONTRAST MEDIUM FOR DILUTION","AGENT DE CONTRASTE RADIOLOGIQUE À DILUER POUR ADMINISTRATION ORALE","",""
"13881","12-11-23","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT RPD","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST; MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS DE 5-HT1; ANTIMIGRAINEUX","",""
"13882","12-11-23","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"13883","12-11-23","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIHYPERTENSIVE; ANTIANGINAL AGENT","ANTIHYPERTENSUEUR; ANTIANGINEUX","",""
"13884","12-11-23","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"13885","12-11-23","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"13886","12-11-23","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ATNIVIRAL AGENT","AGENT ANTIVIRAL","",""
"13887","12-11-21","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Indications and Clinical Use; Woarnings and Precautions; CLinical Trials; and Dosage and Administration sections of the Product Monograph","Mise à jour des sections Indication et  emploi clinique; Mises en garde et preécautions; Essais cliniques et Posoligie et administration de la monographie de produit","PHOSPHATE BINDER","CHÉLATEUR DE PHOSPHORE","",""
"13888","12-11-26","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13889","12-11-26","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA INC","CANADA","CANADA","1","Additional Strengths","Concentrations Additionnels","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13890","12-11-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13891","12-11-26","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA","CANADA","CANADA","1","New Strengths","Nouvelle concentrations","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13892","12-11-26","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13893","12-11-26","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13894","12-11-26","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13895","12-11-26","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA","CANADA","CANADA","1","New strength","Nouvelle concentration","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13896","12-11-26","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA","CANADA","CANADA","1","New strengths","Nouvelles concentrations","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13897","12-11-26","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA","CANADA","CANADA","1","New strength","Nouvelle concntration","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13898","12-11-26","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13899","12-11-26","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","OXYCONTIN","PURDUE PHARMA","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIACÉ","",""
"13900","12-11-23","ABBVIE CORPORATION","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","AGENT ANTIPARKINSONIEN","",""
"13901","12-11-23","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XANAX","PHARMACIE & UPJOHN COMPANY, DIVISION OF PFIZER INC","CANADA","CANADA","1","","","ANXIOLYTIC; ANTIPANIC","ANXIOLYTIQUE; ANTIPANIQUE","",""
"13902","12-11-26","BAYER INC CONSUMER CARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Change of product name","Changement duu nom du fabricant","ANALGESIC, ANTI-INFLAMMATORY, ANTIPYRETIC","ANALGÉSIQUE, ANTIINFLAMMATOIRE, ANTIPYRÉTIQUE","",""
"13903","12-11-27","PEGASUS LABORATORIES INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","SYMPATHOMIMETIC AMINE","AMINE SYMPATHOMIMÉTIQUE","",""
"13904","12-11-27","VETOQUINOL N A INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Addition of subcutaneous route of administration","Addition de la voie d'administration sous-cutanée","MINERAL SUPPLEMENT","SUPPLÉMENT MINÉRAL","",""
"13905","12-11-27","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Extension of shelf life of the 300 mcg/100 mg strength when stoored under refirigeration; updateds to the PROduct Monograph","Prolongation de la duré de conservation pour les dosages de 330mcg/100mg lorsque le produit est réfrigéré et mise à jour de la monographie de produit.","TREATMENT OF MALE ERECTILE DYSFUNTCTION","TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"13906","12-11-26","VERTEX PHARMACEUTICALS (CANADA) INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR","RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANE DE LA MUCO-VISCIDOSE","",""
"13907","12-11-26","GILEAD SCIENCES CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRERTOVIRAL AGENT","ANTIRÉTROVIRAL","",""
"13908","12-11-27","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Product Monograph update","Mise à jour de la monographie de produit","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"13909","12-11-28","ABBVIE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication; in combination with methotrexate, for reducing signs and symptons of moderately to severe active polyarticular juvenile idiopathic arthritis in patients 4 to 17 years of age who have ahd ana indadequate response to one or more diseasee-modifying anti-rheumatic drugs (DMARDS). Humira can be used as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is not appropriate. Changes to the manufacturing process","Nouvelle indication; en association avec le méthtrexate, pour aatténuer les signes et les symptômes de la polyarthrite idiopathique juvénile polyarticulaire active modérée à sévère chez les patients de 4 à 17 ans qui ont eu une réponse inadéquate à un ou à plusieurs antirhumatismaux modificatieurs de la malade (ARMM). Humira puet être utilis1? en monothérapie en cas d'intolérance au mthtrexate ou lorsque la poursuite du traitement avec le méthotrexate n'est pas appropriée. Changement au processus de fabrication","BIOLOGICAL RESPONSE MODIFIER","AGEN D'IMMUNOMODULATION","",""
"13910","12-11-28","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"13911","12-11-28","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DE MÉTABOLISME LIPIDIQUE","",""
"13912","12-11-28","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STERILE VANCOMYCIN HYDROCHLORIDE USP","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"13913","12-11-28","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"13914","12-11-28","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)","INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA NORADRÉNALINE POUR LA TROUBLE DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ (TDAH_","",""
"13915","12-11-28","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CISPLATIN INJECTION BP","HOSPIRA HEALTHCARE CORPORAITON","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"13916","12-11-28","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","",""
"13917","12-11-28","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARTHROTEC","PFIZER CANADA INC","CANADA","CANADA","1","","","NSAID with a Mucosal Protective Agent","Anti-inflammatoire non stéroïdien contenant un protecteur de la muqueuse","",""
"13918","12-11-30","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","IONIC, WATER SOLUBLE, RADIOPAQUE CONTRAST MEDIUM FOR INTRAVASCULAR USE","IONIQUE, SUBSTANCE DE CONTRASTE RADIOOPAQUE HYDROSOLUBLE POUR USAGE INTRAVASCULAIRE","",""
"13919","12-11-29","ACTELION PHARMACEUTICALS LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASODILATOR","VASODILATEUR","",""
"13920","12-11-30","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Removal of species; turkey poults","Élimination d'espèce; dindonneaux d'un jour","ANTIBIOTIC","ANTIBIOTIQUE","",""
"13921","12-11-30","ABBVIE CORPORATION","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LUNG SURFACTANT (BOVINE)","SURFACTANT PULMONAIRE (BOVIN)","",""
"13922","12-11-30","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","NON-IONIC, LOW OSMOLALITY, WATER SOLUBLE, RADIOPAQUE CONTRAST MEDIUM FOR INTRAVASCULAR USE","NON-IONIQUE, BASSE OSMOLALITÉ, SUBSTANCE DE CONTRASTE RADIOPAQUE HYDROSOLUBLE POUR USAGE INTRAVASCULAIRE","",""
"13923","12-12-03","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER / THIAZIDE-LIKE DIURETIC","ANTAGONISTE DES RECEPTEURS AT1 DE L'ANGIOTENSINE II / DIURÉTIQUE COMME THIAZIDE","",""
"13924","12-12-06","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"13925","12-12-05","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication for the prevention of stroke and systemic embolism in patients with atrial fibrillation and new strength of 5 mg tablets","NOuvell indiaction de prévention des accident vasculaires cérébraux et des emolies systémiques chez les patients atteints de fibrillation auriculaire, et nouvelle concentration de 5 mg","ANTICOAGULANT","ANTICOAGULANT","",""
"13926","12-12-06","FERRING INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"13927","12-12-06","GALDERMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANESTHETIC FOR DERMAL ANALGESIA","ANESTHÉSIQUE TOPIQUE POUR L'ANALGÉSIE DERMAL","",""
"13928","12-12-06","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication for pediatric and adolescant patients aged 2 to 18 years. New 25 mg and 100 mg tablets","Nouvelle indiacation chez les patients pédiatrique et adolescant agée 2 à 18 ans. Nouvelles comprimes à 25 mg et 100 mg","HUMAN IMMUNODEFICIENCY VIRUS INTEGRASE STRAND TRANSFER INHIBITOR","INHIBITEUR DE TRANSFERT DE BRIN DE L'INTÉGRASE DU VIH","",""
"13929","12-12-07","SWEDISH ORPHAN BIOVITRUM AB (PUBL)","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing site","Nouveau site de fabrication","IMMUNOMODULATORY AGENT","AGENT D'IMMUNOMODULATION","",""
"13930","12-12-07","METHAPHARM INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","CHOLINERGIC/DIAGNOSTIC AID (BRONCHIAL ASTHMA)","CHOLINERGIQUE / AUXILIAIRE DIAGNOSTIQUE (ASTHME BRONCHIQUE)","",""
"13931","12-12-07","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PRINVIL, ZESTRIL","MERCK FROSST CANADA & CO, ASTRAZENECA CANADA","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"13932","12-12-11","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LESCOL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"13933","12-12-11","NOVARTIS PHARMACEUTICALS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RENIN INHIBITOR AND CALCIUM CHANNEL BLOCKER","INHIBITEUR DE RENIN ET BLOQEUR DES CANAUX CALCIQUES","",""
"13934","12-12-11","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIDEPRESSANT / ANTIPANIC / ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR / ANTIPANIQUE / ANTIOBSESSIONEL","",""
"13935","12-12-10","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"13936","12-12-06","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZINACEF","GLAXO WELLCOME INC","CANADA","CANADA","1","Alternate dur substance and drug product manufacturing site","Autre endroit de fabrication pour le produit et substance medicamentaire","ANTIBIOTIC","ANTIBIOTIQUE","",""
"13937","12-12-12","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK CANADA INC","CANADA","CANADA","1","New presentation","Nouvelle présentation","TYPE 11 5A-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5A-RÉDEUCTASE DE TYPE 11","",""
"13938","12-12-13","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC","HYPNOTIQUE","",""
"13939","12-12-17","PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASTIQUE","",""
"13940","12-12-17","PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CISPLATIN INJECTION BP","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGNET ANTINÉOPLASTIQUE","",""
"13941","12-12-14","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of an alternate site for the fabrication, packaging, labelling, testing, storage and distribution of the drug substance","Addition d'autre site pour le fabrication, embellagement, etiquettage, essai, entreposage et distribution de la substance thérapeutique","ANTIBIOTIC; BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE; INHIBITEUR DE BETA-LACTAMASES","",""
"13942","12-12-14","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REMINYL ER","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"13943","12-12-17","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL SUPRA","FOURNIER PHARMA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUES","",""
"13944","12-12-18","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISM DES LIPIDES","",""
"13945","12-12-18","JAMP PHARMA CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTOS","ELI LILLY CANADA INC","CANADA","CANADA","1","New strength","Nouvelle conentration","ANTI-DIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"13946","12-12-18","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","Product name change","Changement du nom du produit","cGMP-Specific Phophodiesterase Type 5 Inhibitor, Treatment of Erectile Dysunction","Inhibiteur de la phosphodiestérase de type 5 spécifique du GMPc, Traitement de la dysfonction érectile","",""
"13947","12-12-20","IMCLONE LLC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: for the treatment of EGFR-expressing K-ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinoteca, 5-fluorouracil, leucovorin) for first-line treatment.","Nouvelle indication: pour le traitement de première intention chez les patients atteints d'un carcinome colorectal métastatique expriment le récepteur du facteur de croissance épidermique (EGFr) et comprtant le gène KRAS type sauvage en association avec FOLFIRI (irinotécan, le 5-fluorouracile, leucovirine)","ANTINEOPLASTIC","ANTINÉOPLASTIQUE","",""
"13948","12-12-19","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the product monograph","Mise à jour de la monographie du produit","SMOKING CESSATION AID","Aide pour cesser de fumer","",""
"13949","12-12-21","AMEDRA PHARMACEUTICALS LLC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMALARIAL","ANTIPALUDÉEN","",""
"13950","12-12-21","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New drug substance manufacturing process. Alternate drug substance manufacturing and release site","Nouveau processus de fabrication de substances pharmaceutiques. Site de recharge pour la fabrication et les essais avant la mise en circulation de substances pharmaceutiques","PROGESTOGEN","PROGESTATIF","",""
"13951","12-12-21","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","DIFLUCAN-150","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","AGENT ANTIFONGIQUE","",""
"13952","12-12-21","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"13953","12-12-21","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"13954","12-12-21","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"13955","12-12-21","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLLISME LIPIDIQUE","",""
"13956","12-12-21","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","LLIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"13957","12-12-21","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"13958","12-12-21","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"13959","12-12-21","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strengths","Nouveaux dosages","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"13960","12-12-21","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"13961","12-12-19","GLAXOSMITHKLINE CONSUMER HEALTHCARE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","TOPICAL ANTIBIOTIC","ANTIBIOTIQUE TOPIQUE","",""
"13962","12-12-21","FOREST LABORATORIES CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"13963","12-12-21","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,k+-ATPSE","",""
"13964","12-12-21","BIOCODEX SA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"13965","12-12-27","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New prophylaxis indication","Nouvelle indication pour la prophylaxie","ANTIHEMORRHAGIC BLOOD COAGULATION FACTOR IX","FACTEUR IX DE COAGULATION ANTIHÉMORRAGIQUE","",""
"13966","12-12-28","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","TETRACYCLINE ANTIBIOTIC","ANTIBIOTIQUE TÉTRACYCLINE","",""
"13967","12-12-03","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Dosage and Administration section of the PRoduct Monograph","Mise à jour de la section de posologie et administration de la monographie de produit","AZAPEPTIDE INHIBITOR OF HIV-1 PROTEASE","INHIBITEUR AZAPEPTIDIQUE DE LE PROTÉASE DU VIH-1","",""
"13968","12-12-28","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph; effectiveness in pediatric population not extablished; updates to the Warnings and Precautions, Dosage and Aministration and Action and CLinical Pharmacology","Révisions à la monographie de produit; efficacité mpm établie dans la population pédiatrique; mise à jour des section Mises en garde et précautions, PPosologie et administration et Action et pharmacologie clinique.","MTOR KINASE INHIBITOR - ANTINEOPLASTIC AGENT","INHIBITEIR DE LA MTOR; ANTINÉOPLASTIQUE","",""
"13969","12-12-21","BAXTER AG","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updated manufacturing process; product name change","Mise à jour de la fabrication; Changement du nom du produit","ANTICOAGULANT","ANTICOAGULANT","",""
"13970","12-12-28","AGRISAN SPECIALTY CHEMICAL & PHARMACEUTICAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","THERATEC PRE & POST ANTISEPTIC TEAT DIP","WETFALIA SURGE","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","TEAT DIP","BAIN DE TRAYONS","",""
"13971","12-12-28","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACLEER","ACTELION PHARMACEUTICALS LTD","CANADA","CANADA","1","","","ENDOTHELIN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"13972","12-12-28","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCONORM","NOVO NORDISK CANADA INC","CANADA","CANADA","1","Revision to specifications","Révision des spcifications","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"13973","13-01-02","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"13974","13-01-02","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","CGMP-SPECIFIC PHOSPHODESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE SYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DU GMPC; TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"13975","13-01-02","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ADJUNT IN THE MANAGEMENT OF AFFECTIVE DISORDERS","ADJUVANT DANS LA TRAITEMENT DES TROUBLES AFFECTIFS","",""
"13976","13-01-02","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"13977","13-01-02","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOSPHDIESTERASE R (PDE4) INHIBITOR","INHIBITEUR DE LA PHOSPHODIESTÉRASE 4 (PDE4)","",""
"13978","13-01-03","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"13979","13-01-03","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"13980","13-01-03","FERRING INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in formulation, method of manufacture and Manufacturing Site","Modifiaction de la formulation, procédé de fabrication et endroit de fabrication","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"13981","13-01-04","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"13982","13-01-04","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"13983","13-01-04","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"13984","13-01-04","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"13985","13-01-04","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"13986","13-01-04","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"13987","13-01-04","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"13988","13-01-04","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"13989","13-01-04","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIODIAGNOSTIC AGENT","AGNET RADIODIAGNOSTIQUE","",""
"13990","13-01-04","MALLINCKRODT CANADA ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","RADIOTHERAPEUTIC AGENT","AGNET RADIOTHÉRAPEUTIQUE","",""
"13991","13-01-03","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New brand Name","Nouveau nom du produit","MUSCLE RELAXANT; ANALGESIC","Relaxant Musculaire; Analgésique","",""
"13992","13-01-03","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition to the manufacturing site; Suspension of eht 50 mg vial production","Addition de l'endroit de fabrication: Suspension de la production des ampoules de 50 mg","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"13993","13-01-07","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph; Warnings and Precautions, Drug Interactions, Overdosage and COnsumer Information","Mises à jour de la monographie de produit: Mise en garde et précautions, Interactions médicamenteuse, Surdosage et information pour la consummateur","HIV PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIH","",""
"13994","13-01-04","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-AVENTIS CANADA","CANADA","CANADA","1","New dosage form","Nouvelle forme posologique","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"13995","13-01-04","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRACLEER","ACTELION PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Addition of a drug substance supplier","Nouveau fournisseur de la substance médicamentaire","ENDOTHELIN RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE","",""
"13996","13-01-07","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"13997","13-01-07","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIHYPERTENSIVE-ANTIANGINAL AGENT","ANTIHYPERTENSUR ET ANTIANGINEUX","",""
"13998","13-01-07","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIHYPERTENSIVE-ANTIANGINAL AGENT","ANTIHYPERTENSUR ET ANTIANGINEUX","",""
"13999","13-01-08","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE ET DIURÉTIQUE","",""
"14000","13-01-08","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDES EN AÉROSOL","",""
"14001","13-01-08","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"14002","13-01-07","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ROBAX PLATINUM","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","MUSCLE RELAXANT; ANALGESIC","RELAXANT MUSCULAIRE; ANALGÉSIQUE","",""
"14003","13-01-08","GENERIC MEDICAL PARTNERS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU METABOLISME DES LIPIDES","",""
"14004","13-01-08","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II","",""
"14005","13-01-08","GENMED A DIVISION OF PFIZER CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSIONS DE L'ANGIOTENSINE","",""
"14006","13-01-08","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPPTEURS DE L'ANGIOTENSINE II","",""
"14007","13-01-08","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIHYPERTENSIVE-ANTIANGINAL AGENT","ANTIHYPERTENSUER ET ANTIANGINEUX","",""
"14008","12-12-20","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"14009","13-01-09","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST; MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS DE 5-HT1; ANTIMIGRAINEUX","",""
"14010","13-01-09","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","INHIBITEUR DES RÉCEPTEURS DE L'ANGIONTENSINE II AT1","",""
"14011","13-01-10","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: The treatment of postmenopausal women with hormone receptor-positive HER2-negative advanced breast cancer in combincaitoin with exemestane after recurrence or progression following treatment with letrozole or anastrozole.","Nouvelle indication: Le traiatement des femmes méopaus1?es atteintes d'un cancer du sein avancé à récepteur hormonal positif et her2-négatif en combination avec l'exémstane après une récidive ou une progression suite à un traitement par létrozole ou anastrozole.","ANTINEOPLASTIC","ANTINÉOPLASTIQUE","",""
"14012","13-01-10","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"14013","13-01-10","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR ADMINISTRATION NASALE","",""
"14014","13-01-10","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","AVENTIS PHARMA INC","CANADA","CANADA","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"14015","13-01-10","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIPANIC, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, ANTIPANIQUE, ANTIOBSESSIONEL","",""
"14016","13-01-10","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"14017","13-01-10","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ROBAX PLATINUM","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","ANALGESIC AND MUSCLE RELAXANT","ANALGÉSIQUE ET RELAXANT MUSCULAIRE","",""
"14018","13-01-11","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","New indication","Nouvelle indication","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14019","13-01-11","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST; MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1; ANTIMIGRAINEUX","",""
"14020","13-01-14","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision of the in-vitro drug release spcifications acceptance criteria","Révision de critères d'acceptation des spécifications de libération du médicament in vitro","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"14021","13-01-14","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC; ANTIPYRETIC; NASAL DECONGESTANT; ANTIHISTAMINE","ANALGÉSIQUE; ANTIPYRÉTIQUE; DÉCONGESTANNANT NASAL; ANTIHISTAMINE","",""
"14022","13-01-16","CHIESI FARMACEUTICI S P A","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Chemistry and manufacturing information update","Mise à jour des informations de chimie et fabrication","LUNG SURFACTANT","SURFACTANT PULMONAIRE","",""
"14023","13-01-15","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate drug product manufacturing, packaging and testing site","autre lieu de fabrication, emballagement et de l'essai pour le produit médicamentaire","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14024","13-01-15","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate drug substance manufacturing testing and release site","Autre lieu de fabrication, d'essai et de libération de la substance médicamentaire","ANTITUBERCULOUS ANTIBIOTIC","ANTIBIOTIQUE ANTITUBERCULEUX","",""
"14025","13-01-16","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the product monograph. Update to the Action and Clinical Pharmacology Section","Révisions à la monographie de produit. Mise à jour de la section Mode d'action et pharmacologie clinicque","LOCAL ANAESTHETIC","ANESTHÉSIQUE LOCAL","",""
"14026","13-01-16","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"14027","13-01-17","AVEVA DRUG DELIVERY SYSTEMS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"14028","12-12-11","UNIMARK REMEDIES LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK SHARP & DOHME LTD","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"14029","12-12-11","UNIMARK REMEDIES LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK SHARP & DOHME LTD","GERMANY","ALLEMAGNE","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"14030","13-01-17","S C JOHNSON AND SON LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HARD SURFACE DISINFECTANT","DÉSINFECTANT POUR LES SURFACES DURS.","",""
"14031","13-01-18","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCKE SHARPE & DOHME LTD","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUKOTRIÈNES","",""
"14032","13-01-18","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK SHARPE & DOHME LTD","GERMANY","ALLEMAGNE","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUKOTRIÈNES","",""
"14033","13-01-22","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Change to manufacturing process","Changement au procédé de fabrication","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"14034","13-01-21","FERRING INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength","Nouvelle concentration","GASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE ENTÉROCOLIQUE","",""
"14035","13-01-23","PATRIOT A DIVISION OF JANSSEN INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITOR","INHIBITEUR DE LA PROTÉASE DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE (VIH)","",""
"14036","13-01-23","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION SE L'ANGIOTENSINE","",""
"14037","13-01-23","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALTACE","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION SE L'ANGIOTENSINE","",""
"14038","13-01-25","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XANAX","PHARMACIA & UPJON COMPANY DIVISION OF PFIZER INC","CANADA","CANADA","1","","","ANXIOLYTIC; ANTIPANIC","ANXIOLYTIQUE; ANTIPANIQUE","",""
"14039","13-01-25","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication for the treatment of adult patients (> 18 years of age) with renal angiomuylopipoma assoricated with tuberous sclerosis complex (TSC) aho do not require immediate surgery","Nouvelle indication pour le traitement des patients adultes (de 18 ans et plus) atteints d'un angiomyolipome rébal associé à une sclérose tub1?reuse de Bourneville qui ne nécessitent pas d'intervention chirurgical immédiate","ANTINEOPLASTIC","ANTINÉOPLASTIQUE","",""
"14040","13-01-28","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","ANAFEN TABLETS","MERIAL CANADA INC","CANADA","CANADA","1","","","NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC","ANALGÉSIQUE ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"14041","13-01-28","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14042","13-01-28","BAUSCH & LOMB INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","CONTACT LENS DISINFECTANT","DÉSINFECTANT POUR LES LENTILLE DE CONTACT","",""
"14043","13-01-29","GRIFOLS THERAPEUTICS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Priority","Priorité","Biologic","Biologique","","","","","1","New indication for Guillain-Barre Syndrome (GBS)","Nouvelle indication pour le Syndrome de Guillain-Barré","PASSIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION PASSIVE","",""
"14044","13-01-29","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANCEF","SMITHKLINE BEECHAM","CANADA","CANADA","1","New format","Nouveau format","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14045","13-01-29","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ANCEF","SMITHKLIINE BEECHAM","CANADA","CANADA","1","Alternate drug substance supplier; Alternate drug product manufacturing site","Autre source  de la substance thérapeutique; autre lieu de fabrication pour le produit thérapeutique","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14046","13-01-29","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VITAMIN D3 METABOLITE","MÉTABOLITE DE LA VITAMINE D3","",""
"14047","13-01-25","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC MAXIMUM  STRENGTH NON-PRESCRIPTION","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","","","HISTAMINE H2-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'HISTAMINE H2","",""
"14048","13-01-31","PFIZER CANADA INC ANIMAL HEALTH GROUP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Labelling update","Étiquetage mise à jour","ANESTHETIC","ANESTHÉSIQUE","",""
"14049","13-01-30","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZADITOR","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","ANTI-ALLERGY AGENT","AGENT ANTIALLERGIQUE","",""
"14050","13-01-30","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARTHROTEC 50 AND ARTHROTEC 75","PFIZER CANADA INC","CANADA","CANADA","1","","","NSAID WITH A MUCOSAL PROTECTIVE AGENT","ANTI-INFLAMMATOIRE ANALGÉSIQUE, AGENT PROTECTEUR DE LA MUQUEUSE","",""
"14051","13-01-30","LEO PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CHEMOPTHERAPEUTIC FOR TOPICAL USE (D06BX02)","CHÉMATHÉRAPEUTIQUE TOPIQUE (D06BX02)","",""
"14052","13-01-31","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CADUET","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTI-HYPERTENSIVE; ANTI-ANGINAL AGENT AND LIPID METABOLISM REGULATOR","ANTIHYPERTENSEUR; ANTIANGIEUX ET RÉGULATEUR DE MÉTABOLISME DES LIPIDES","",""
"14053","13-01-30","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADENOCARD","ASTELLAS PHARMA CANADA","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"14054","13-01-30","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADRIAMYCIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTAIC AGENT","ANTINÉOPLASTIQUE","",""
"14055","13-01-30","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"14056","13-02-01","SEATTLE GENETICS INC","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASTIQUE","",""
"14057","13-01-31","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYKLOKAPRON","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIFIBRINOLYTIC","ANTIFIBRINOLYTIQUE","",""
"14058","12-08-21","ALEXION PHARMACEUTICALS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New drug product manufacturer","Nouvel emplacement de fabrication","COMPLEMENT INHIBITOR","INHIBITOR DU COMPLÉMENT","",""
"14059","13-02-04","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"14060","13-02-05","CORREVIO (UK) LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"14061","13-02-05","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"14062","13-02-07","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","PM update","Mise à jour de la MP","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"14063","13-02-11","PHARMALOGIC PET SERVICES OF MONTREAL","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","","","DIAGNOSTIC RADIOPHARMACEUTICAL","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"14064","13-02-11","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNNISATION ACTIF","",""
"14065","13-02-08","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-OPRTHO INC","CANADA","CANADA","1","","","CENTRALLY ACTING ANALGESIC","ANALGÉSIQUE À ACTION CENTRALE","",""
"14066","13-02-08","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALESSE","WYETH CANADA","CANADA","CANADA","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"14067","13-02-08","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VINBLASTINE SULFATE INJECTION","MAYNE PHARMA (CANADA) INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14068","13-02-08","AURO PHARMA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MOBICOX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","New packaging","Nouveau embellage","NON-SETROIDAL ANTI-INFLAMMATORY DRUG","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN","",""
"14069","13-02-08","ACCORD HEALTHCARE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VINCRISTINE SULPHATE INJECTION","NOVOPHARM LTD","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","ANTINEOPLASTIC AGENT","ANTINÉEOPLASTIQUE","",""
"14070","13-02-08","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL EZ","FOURNIER PHARMA INC","CANADA","CANADA","1","New presentation","Nouveau présentation","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"14071","13-02-11","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DALACIN C CAPSULES","PHARMACIA & UPJOHN INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14072","13-02-11","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"14073","13-02-11","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CARDIZEM CD","HOECHST MARION ROUSSEL CANADA INC","CANADA","CANADA","1","","","ANTIHYPERTENSIVE; ANTIANGINAL AGENT","ANTIHYPERTENSEUR; ANTIANGINEUX","",""
"14074","13-02-11","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"14075","13-02-11","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHDIESTÉRASE DE TYPE 5 SPÉCIFIQUE DU GMPC; TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"14076","13-02-11","TARO PHARMACEUTICALS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMITREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","Product name change","Changement du nom du produit","5-HT1 RECEPTOR AGONIST - MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 - ANTIMIGRAINEUX","",""
"14077","13-02-11","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EPIVAL","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPIEPTIQUE","",""
"14078","13-02-11","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SNOFI-AVENTIS CANAD INC","CANADA","CANADA","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉGATION PLAQuettaire","",""
"14079","13-02-07","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Chemistry & manufacturing updates; New strengths.presentations; new indications for children; revised indication for adults","Mise à jour des informations de chimie et fabrication; nouveaux dosages/présentations; Nouvelles indications chez les enfants; Révision de l'indication chez les adultes","GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"14080","13-02-13","FERRING INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFIBRINOLYTIC AGENT","ANTIFIBRINOLYTIQUE","",""
"14081","13-02-13","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAMAX","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"14082","13-02-13","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","TYPE II 5-ALPHA REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"14083","13-02-13","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"14084","13-02-13","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"14085","13-02-13","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"14086","13-02-13","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"14087","13-02-13","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"14088","13-02-13","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"14089","13-02-13","SIVEM PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14090","13-02-13","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","ANALGESIC AGENT","ANALGÉSIQUE","",""
"14092","13-02-14","PFIZER CONSUMER HEALTHCARE, A DIVISION OF PFIZER CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC; ANTIPYRETIC AND ANTIHISTAMINE; ANTITUSSIVE","ANALGÉSIQUE; ANTIPYRÉTIQUE ET ANTIHISTAMINE; ANTITUSSIF","",""
"14093","13-02-14","MCNEIL CONSUMER HEALTHCARE, DIVISION OF JOHNSON & JOHNSON INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANALGESIC; ANTIPYRETIC AGENT","ANALGÉSIQUE; ANTIPYRÉTIQUE","",""
"14094","13-02-14","ALCON CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate formulation; Alternate manufacturing site","Autre formulation; Autre lieu de fabrication","Elevated Intraocular Pressure Therapy","Thérapie pour réduire la pression intraoculaire","",""
"14095","13-02-14","PRO DOC LIMITÉE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NON-STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESIS; ANTI-TUMOUR AGENT","INHIBITEUR NON STÉROÏDIEN DE L'AROMATASE; INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES; AGENT ANTINÉOPLASTIQUIE","",""
"14096","13-02-14","SANDOZ CANADA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfilment of conditions","Respect des engagements","ANTITUMOUR AGENT","ANTINÉOPLASTIQUE","",""
"14097","13-02-13","SANDOZ CANADA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New drug substance supplier","Nouvelle source de la substance thérapeutique","ANTICHOLINERGIC","ANTICHOLINÉRGIQUE","",""
"14098","13-02-14","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDIQUE","",""
"14099","13-02-14","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","ANALGESIC AGENT","AGENT ANALGÉSIQUE","",""
"14100","13-02-14","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNOMODULATOR; ANTI-INFLAMMATORY AGENT","IMMUNOMODULATEUR. ANTI-INFLAMMATOIRE","",""
"14101","13-02-14","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"14102","13-02-14","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","ANALGESIC AGENT","AGENT ANALGÉSIQUE","",""
"14103","13-02-14","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","ANALGESIC AGENT","AGENT ANALGÉSIQUE","",""
"14104","13-02-14","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTIDEPRESSANT; ANTIOBSESSIONAL; ANTIBULIMIC","ANTIDÉPRESSEUR; ANTIOBSESSIONNEL; ANTIBOULIMIQUE","",""
"14105","13-02-14","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PHOTOSENSITIZING AGENT FOR PHOTODYNAMIC THERAPY OF CHOROIDAL NEOVASCULARIZATION","AGENT PHOTOSENSIBILLISANT POUR LA THÉRAPIE OHOTODYNAMIQUE DE LA NÉOVASCULARISATION CHOROÏDIENNE","",""
"14106","13-02-14","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTBACTÉRIEN","",""
"14107","13-02-14","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOFRAN","GLAXOSMITHKLINE INC","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIEMETIC (5-HT3 RECEPTOR ANTAGONIST)","ANTIÉETIQUE (ANTAGONISTE DES RÉCEPTEURS 5-HT3)","",""
"14108","13-02-14","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIHYPERTENSIVE-  ANTIANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","",""
"14109","13-02-14","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","HYPNOTIC AND SEDATIVE","HYPNOTIQUE ET SÉDATIF","",""
"14110","13-02-14","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL EXTRA STRENGTH CAPLETS 400 MG","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","ANALGESIC - ANTIPYRETIC","ANALGÉSIQUE - ANTIPYRÉTIQUE","",""
"14111","13-02-14","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST; MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1; ANTIMIGRAINEUX","",""
"14112","13-02-15","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","Analgesic Agent","Agent analgésique","",""
"14113","13-02-15","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","Analgesic Agent","Agent analgésique","",""
"14114","13-02-15","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER PHARMACEUTICAL LLC FOR PARKE DAVIS","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","Analgesic Agent","Agent analgésique","",""
"14115","13-02-15","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER PHARMACEUTICAL LLC FOR PARKE-DAVIS","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","New Indication","Nouvelle indication","Analgesic Agent","Agent analgésique","",""
"14116","13-02-15","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER PHARMACEUTICAL LLC FOR PARKE-DAVIS","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","New Indication","Nouvelle indication","Analgesic Agent","Agent analgésique","",""
"14117","13-02-15","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC.","CANADA","CANADA","1","","","Analgesic Agent","Agent analgésique","",""
"14118","13-02-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","Analgesic Agent","Agent analgésique","",""
"14119","13-02-15","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of 96 week data from the ECHO and THRIVE trials","Addition de data de la semaine 96 de les essais ECHO et THRIVE","HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR","Inhibiteur non nucléosidique de la transcriptase inverse","",""
"14120","13-02-15","LEO PHARMA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: for the topical treatment of mild to moderate psoriasis on the body","Nouvelle indication: pour le traitement local du psoriasis léger à modéré sur le corps","TOPICAL ANTIPSORIATIC AGENT; VITAMIN D ANALOGUE; CORTICOSTEROID","Agent Antipsoriasique; Analogue de la Vitamine D; Corticostéroïde","",""
"14121","13-02-15","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Altenrate manufacturing site","Autre lieu de fabrication","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"14122","13-02-15","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"14123","13-02-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DURAGESIC","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDE","",""
"14124","13-02-15","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMATASE INHIBITOR; INHIBITOR OF ESTROGEN BIOSYNTHESIS; ANTI-TMOUR AGENT","INHIBITOEUR NON-STÉROÏDIEN DE L'AROMATASE; INHIBITEUR DE LA BIOSYNTHÈSE DES OESTROGÈNES; ANTINÉOPLASTIQE","",""
"14125","13-02-13","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour de la monographie de produit","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"14126","13-02-08","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Mmonograph","Révision à l monographie de produit","IRON CHELATING AGENT","Chélateur du fer","",""
"14127","13-02-15","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing facility","Nouveau site de fabrication","ANTI-NEOVASCULARISATION AGENT","AGENT ANTI-NÉOVASULARISATION","",""
"14128","13-02-18","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT, ANTIBACTERIAL","STIMULANT DE CROSSANCE, ANTBACTÉRIEN","",""
"14129","13-02-18","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT, ANTIBACTERIAL","STIMULANT DE CROISSANCE, ANTIBACTÉRIEN","",""
"14130","13-02-18","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT, ANTIBACTERIAL","STIMULANT DE CROISSANCE, ANTIBACTÉRIEN","",""
"14131","13-02-18","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","STIMULANT DE CROISSANCE","",""
"14132","13-02-18","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","STIMULANT DE CROISSANCE","",""
"14133","13-02-18","ELANCO DIVISION ELI LILLY CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","STIMULANT DE CROISSANCE","",""
"14134","13-02-18","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT, ANTIBACTERIAL","STIMULANT DE CROISSANCE, ANTIBACTÉRIEN","",""
"14135","13-02-18","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","STUMULANT DE CROISSANCE","",""
"14136","13-02-18","ELANCO DIVISION ELI LILLY CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","STIMULANT DE CROISSANCE","",""
"14137","13-02-18","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT, ANTIBACTERIAL","STIMULANT DE CROISSANCE, ANTIBACTÉRIEN","",""
"14138","13-02-15","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER; DIURETIC","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II; DIURÉTIQUE","",""
"14139","13-02-18","JUBILANT LIFE SCIENCES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","cGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE GMPC; TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"14140","13-02-18","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","Analgesic Agent","Agent analgésique","",""
"14141","13-02-19","DIVERSEY INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"14142","13-02-10","VETOQUINOL N A INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Labelling update","Mise à jour de l'étiquetage","ANESTHETIC","ANESTHÉSIQUE","",""
"14143","13-02-22","GENZYME CANADA, A DIVISION OF SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","ENZYME REPLACEMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"14144","13-02-22","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NITOMAN","VALEANT CANADA LP / VALEANT CANADA S.E.C.","CANADA","CANADA","1","","","MONOAMINE DEPLETING AGENT","AGENT DE DÉPLÉTION DE MONOAMINES","",""
"14145","13-02-20","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph","Mises é jour de la monographie de produit","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"14146","13-02-21","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New formulation for subcutaneous administration","Nouvelle formulation pour administration sous-cutanée","SELECTIVE CO-STIMULATION MODULATOR","MODULATEUR DE CO-STIMULATION SÉLECTIF","",""
"14147","13-02-20","ALLERGAN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Preservative free formulation","formulation sans péservatives","ELEVATED INTRAOCULAR PRESSURE THERAPY","THÉRAPIE POUR RÉDUIRE LA PRESSION INTRA-OCULAIRE","",""
"14148","13-02-22","GENERIC MEDICAL PARTNERS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"14149","13-02-25","BIO AGRI MIX LP","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Addition of API Supplier; update labelling","Ajout d'un distributeur de l'ingédient pharmaceutique actif; mise à jour de l'étiquetage","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14150","13-02-22","JAMP PHARMA CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","New strength","Nouvell concentraiton","ANTIDEPRESSANT; ANTIOBSESSIONAL; ANTIBULIMIC","ANTIDÉPRESSEUR; ANTIOBSESSIONEL; ANTIBOULIMIQUE","",""
"14151","13-02-22","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","AGENT ANTIÉPILEPTIQUE","",""
"14152","13-02-22","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADENOCARD","ASTELLAS PHARMA CANADA INC","CANADA","CANADA","1","","","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"14153","13-02-22","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPROSALIC LOTION","SCHERING CANADA INC","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID AND KERATOLYTIC","CORTICOSTÉROÏDE TOPIQUE ET KERATOLYTIQUE","",""
"14154","13-02-22","ONCO THERAPIES LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYTARABINE IMJECTION","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","","","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"14155","13-02-22","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MALARONE","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTIMALARIAL AGENT","ANTIPALUDÉEN","",""
"14156","13-02-25","APOTEX INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","New product name","Nouveau nom de produit","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","",""
"14157","13-02-26","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"14158","13-02-26","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","AGENT POUR L'INSUFFIANCE CARDIAQUE CONGESTIVE","",""
"14159","13-02-26","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOLOFT","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIDEPRESSANT; ANTIPANIC; ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR; ANTIPANIQUE; ANTIOBSESSIONNEL","",""
"14160","13-02-26","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","RHONE-POULENC RORER CANADA INC","CANADA","CANADA","1","","","HYPNOTIC AND SEDATIVE","HYPNOTIQUE ET SÉDATIF","",""
"14161","13-02-11","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in composition of the dosage form, bacth size and drug product manufacturing process","Changement de la composition de la fomre posologique, la taille de lot et processus de fabrication de la produit médicamentaire","PROGESTIN","PROGESTATIF","",""
"14162","13-02-26","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SALAGEN TABLETS","PFIZER CANADA INC","CANADA","CANADA","1","","","CHOLINOMIMETIC AGENT","AGENT CHOLINOMIMÉTIQUE","",""
"14163","13-02-27","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Drug-drug interactions and safety updates","Interactions drogue-drogue et mise à jour de l'innocuité","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"14164","13-02-27","AMG MEDICAL INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of foor processing, domestic, barn and institutional/industrial uses to the label","Addtion de transformation alimentaire, domestique, agricole et établissement et industries à l'etiquette.","DISINFECTANT","DÉSINFECTANT","",""
"14165","13-02-27","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC","CANADA","CANADA","1","New dosage form","Nouvelle forme posoligique","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14166","13-02-28","HUVEPHARMA AD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","DENAGARD PREMIX","NOVARTIS ANIMAL HEALTH CANADA INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14167","13-02-28","INTERVET CANADA CORP","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","ALternate manufacturing site, labaling update","Autre lieu de fabrication, mise à jour de l'étiquetage","GROWTH PROMOTANT","STIMULANT DE CROISSANCE","",""
"14169","13-02-21","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfillment of conditions as per the Letter of undertaking deated May 17, 2007 for the treatment of paediatric patients with newly diagnosed, Philadelphia chromosome positive chronic myeloid leukemia in chronic phase.  Fulfillment of conditions as pre the Letter of Undertaking dated December 22, 2004 for the treatment of adult patients with KIT (CD117) positive unresectable and/or metastatic malignamt gastrointestinal stromal tumours>","Satisfaction des conditions décrites dans la lettre d'engagement du 17 mai 2007 pour le traitement des patients pédiatriques atteins d'une leucémie myéloïde chronique chromosome Philadephie positive nouvellement diagnostiqu6e et wn phase chronique  Satisfaction des conditions décrites dans la lettre d'engagement du 22 décembre 2004 pouyr le traitement des patienjts adultes atteints de tumeurs stromales gastro0intestinales malignes non résécables ou métastatiques KIT (CD117) positives.","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"14170","13-01-07","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of long term data","Addition de data à long terme","ANTIVIRAL AGENT","ANTIVIRAL","",""
"14171","13-01-17","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Simplification of dosing","Simplification de posologique","AZAPEPTIDE INHIBITOR OF HIV-1 PROTEASE","INHIBITEUR AZAPEPTIDIQUE DE LE PROTÉASE DU VIH-1","",""
"14172","13-01-28","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Use with Boceprevir and Ribavirin","Usage avec boceprevir et ribavirin","HEPATITIS C VIRUS PROTEASE INHIBITOR","Inhibiteur de la protéase du virus de l'Hépatite C","",""
"14173","13-03-04","UCB CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing site","Nouvel emplacement de fabrication","ANTIEPILEPTIC","ANTIÉPILETPTIQUE","",""
"14174","13-03-01","DUCHESNAY INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To change the prescribing information to the new Product Monograph format","Pour changer l'information de préscription au nouveau format de la monographie de produit","RECTAL ANTI-INFLAMMATORY FOAM","TRAITEMENT ANORECTAL","",""
"14175","13-03-01","ALVEDA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14176","13-03-05","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"14177","13-03-05","SANOFI PASTEUR INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional Manufacturing facility","Emplacement de fabrication additionnel","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATIOIN ACTIF","",""
"14178","13-03-05","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"14179","13-03-06","ASTELLAS PHARMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SELECTIVE BETA-3 ANDRENORECEPTOR AGONIST","AGONISTE SÉLECTIF DES ADRÉNORÉCEPTEURS BETA-3","",""
"14180","13-03-06","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in specifications","Changements aux specifications","IMMUNOMODULATOR","IMMUNOMODULATEUR","",""
"14181","13-03-06","ALVEDA PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAZOCIN","WYETH CANADA","CANADA","CANADA","1","","","ANTIBIOTIC; B-LACATAMSE INHIBITEUR","ANTIBIOTIQUE; INHIBITEUR DE BETA-LACTAMASES","",""
"14182","13-03-05","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","ANALGESIC AGENT","AGENT ANALGÉSIQUE","",""
"14183","13-03-01","ALEXION PHARMACEUTICALS INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New indication for the treatment of patients with atypical hemolytic uremic syndrome to reduce complement-mediated thrombotic microangiopathy","Nouvelle indication pour le traitement du syndrome urémique et hémolytique atypique pour réduire la microangiopathie thrombotique causée par le complément","COMPLEMENT INHIBITOR","INHIBITEUR DU COMPLÉMENT","",""
"14184","13-03-07","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","CENTRALLY ACTING ANALGESIC","ANALGÉSIQUE À ACTION CENTRALE","",""
"14185","13-03-07","PRO DOC LIMITÉE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIFLUCAN","PFIZER CANADA INC","CANADA","CANADA","1","Removal of strength","SUpression d'une concentration","ANTIFUNGAL AGENT","AGENT ANTIFONGIQUE","",""
"14186","13-03-07","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"14187","13-03-07","PRO DOC LIMITÉE","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","DIFLUCAN-150","PFIZER CANADA INC","CANADA","CANADA","1","Revised product monograph - prescription to over the counter (OTC)","Révisions à la monographie de produit - médicament vendu sous ordonnance à médicament en vente libre","ANTIFUNGAL AGENT","AGENT ANTIFONGIQUE","",""
"14188","13-03-07","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","BIOLOGICAL RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE BIOLOGIQUE","",""
"14189","13-03-07","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","BIOLOGICA RESPONSE MODIFIER AND ANTIVIRAL AGENT","MODIFICATEUR DE LA RÉPONSE BIOLOOGIQUE PLUS AGNET ANTIVIRAL","",""
"14190","13-03-07","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the Product Monograph; dosing recommendations for missed/delayed second initiation doses","Révision de la monographie de produit; recommandations posologiques en cas d'omission ou de retard de la deuxième dose du traitement","ANTIPSYCHOTIC AGENT","ANTNIPSYCHOTIQUE","",""
"14191","13-03-08","SANOFI PASTEUR LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of building 14","Addition de l'édifice 14","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"14192","13-03-07","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT; DPP-4 INHIBITOR; INCRETIN ENHANCER","Antihyperglycémiant oral / Inhibiteur DPP-4 / Renforceur d'incrétin","",""
"14193","13-03-08","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE IMMUNITAIRE","",""
"14194","13-03-08","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","ANTIANGINAL","ANTIANGINEUX","",""
"14195","13-03-08","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR ORAL INHALATION","CORTICOSTÉROÏDE POUR INHALATION ORALE","",""
"14196","13-03-08","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"14197","13-03-08","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR; BETA2-ADRENERGIC STIMULANT","BRAONCHODILATUER; STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"14198","13-03-08","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE IMMUNAIRE","",""
"14199","13-03-08","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE IMMUNAIRE","",""
"14200","13-03-07","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","For reduced depyrogenation cycle for empty vials prior to filling for the drug product which is manufactured as a lyophilized powder for injection","","THYROID HORMONE","HORMONE THYROÏDIENNE","",""
"14201","13-03-08","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL XR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","New strengths","Nouvelles concentrations","ANTIPSYCHOTIC; ANTIDEPRESSANT","ANTIPSYCHOTIQUE; ANTIDÉPRESSEUR","",""
"14202","13-03-11","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MULTIKINASE INHIBITOR; ANTINEOPLASTIC","INHIBITEUR DES MULTIKINASES; ANTINÉOPLASTIQUE","",""
"14203","13-03-08","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL XR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANTIPSYCHOTIC; ANTIDEPRESSANT","ANTIPSYCHOTIQUE; ANTIDÉPRESSEUR","",""
"14204","13-03-11","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Clinical Trials section of the Product Monograph","Mise à jour de la section Essais cliniques de la monographie de produit","PLATELET AGGREGATION INHIBITOR","INHHIBITEUR DE L'AGRÉGATION PALQUETTAIRE","",""
"14205","13-03-11","MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ESTROGEN AND PROGESTIN","OESTROGEN ET PROGESTIN","",""
"14206","13-03-12","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","TAKEDA PHARMACEUTICALS AMERICA INC","CANADA","CANADA","1","","","H+,K+-ATPASE INHIBITOR","INHIITEUR DE L'H+,K+-ATPASE","",""
"14207","13-03-12","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK SHARPE & DOHME LTD","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUKOTRÈNES","",""
"14208","13-03-12","PHARMASCIENCE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERLIPIDEMIC AGENT","AGENT ANTIHYPOLIIPIÉMIANT","",""
"14209","13-03-12","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ELOCOM","SCHERING CANADA INC","CANADA","CANADA","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"14210","13-03-13","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"14211","13-03-13","BIONICHE ANIMAL HEALTH CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Labelling update","Mise à jour de l'étiquetage","ANESTHETIC","ANESTHÉSIQUE","",""
"14212","13-03-13","ELANCO DIVISION ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","New species - Honey bees; New indication","Nouvelle espèce - Abeilles Mellifères; Noucell indication","ANTIMICROBIAL","ANTIMICROBIEN","",""
"14213","13-03-13","GE HEALTHCARE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","RADIOPHARMACEUTICAL DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"14214","13-03-13","CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","New formulation","Nouvelle formulation","RADIOPHARMACEUTICAL DIAGNOSTIC AGENT","AGENT DIAGNOSTIQUE RADIOPHARMACEUTIQUE","",""
"14215","13-03-14","DUCHESNAY INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional drug product manufacturing site","lieu de fabrication addtionel pour le produit","ANTINAUSEANT AGAINST NAUSEA AND VOMITING OF PREGNANCY","ANTINAUSÉEUX CONTRE LES NAUSÉES ET VOMISSEMENTS DE LA GROSSESSE","",""
"14216","13-03-15","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NASONEX","SCHERING CORPORATION","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"14217","13-03-14","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVANDIA","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTIDIABETIC AGENT","ANTIDIABÉTIAUE","",""
"14218","13-03-15","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSIN II","",""
"14219","13-03-05","GILEAD SCIENCES CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product monograph updates","Mises à jour de la monographie de produit","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"14220","13-03-18","MALLINCKRODT CANADA ULC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","Alternative source of Molybdenum Mo99","Source alternative de Molybdéne Mo99","RADIODIAGNOSTIC AGENT","AGENT RADIODIAGNOSTIQUE","",""
"14221","13-03-15","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CISPLATIN INJECTION","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14222","13-03-15","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","NAROPIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","Additional strength","","LOCAL ANAESTHETIC","ANESTHÉSIQUE LOCAL","",""
"14223","13-03-15","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","APO-DOMPERIDONE","APOTEX INC","CANADA","CANADA","1","","","MODIFIER OF UPPER GASTROINESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"14224","13-03-15","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","ROBAX PLATINUM","PFIZER CONSUMER HEALTHCAREM A DIVISION OF PFIZER CANADA INC","CANADA","CANADA","1","","","MUSCLE RELAXANT; ANALGESIC","RELAXANT MUSCULAIRE; ANALGÉSIQUE","",""
"14225","13-03-18","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DEPPRA","UCB CANADA INC","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","AGENT ANTIÉPILEPTIQUE","",""
"14226","13-03-19","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"14227","13-03-18","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE OXYDASE","",""
"14228","13-03-18","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","ANALGESIC AGENT","AGENT ANALGÉSIQUE","",""
"14229","13-03-19","BAUSCH & LOMB INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Modification of the suture tab","Modification de l'attache de la suture","CORTOCOSTEROID","CORTICOSTÉROÏDE","",""
"14230","13-03-20","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14231","13-03-19","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HYPNOTIC AND SEDATIVE","HYPNOTIQUE ET SÉDATIF","",""
"14232","13-03-19","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","",""
"14233","13-03-19","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LOSEC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","H+,K+-ATPASAE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"14234","13-03-21","UCB CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSONIAN AGENT; DOPAMINE AGONIST","AGENT ANTIPARKINSONIEN; AGONISTE DE DOPAMINE","",""
"14235","13-03-20","NOVARTIS PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To update the Recommended Dose and Dose Adjustment and Pharmacokinetics sections of the Product Monograph based on the results of a food effect study","Mettre à jour les sections Dose recommandée, Modification de la dose et Pharmacocinétique dans la monographie de produit en fonction des résultats d'une étude sur les effets des aliments","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14236","13-03-21","TEVA PHARMA B.V.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME CENTRAL","",""
"14237","13-03-22","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE DYSFUNTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DE GMPC","",""
"14238","13-03-22","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL XR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC; ANTIDEPRESSANT AGENT","ANTIPSYCHOTIQUE; ANTIDÉPRESSEUR","",""
"14239","13-03-25","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FOSAVANCE","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLLSIME OSSEUX","",""
"14240","13-03-21","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New dosage form; solution for injection","Nouvelle forme posologique; solution pour l'injection","ANTILEUKEMIC AGENT","ANTILEUCÉMIQUE","",""
"14241","13-03-21","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTIPURITIC","ANTIPURIGINEUX TOPIQUE","",""
"14242","13-03-26","JUBILANT DRAXIMAGE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Radiopharmaceutical","Radiopharmaceutique","","","","","1","Change in formulation","Changement dans la formulation","THERAPEUTIC RADIOPHARMACEUTICAL","RADIOPHARMACEUTIQUE THÉRAPEUTIQUE","",""
"14243","13-03-25","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","cGMP-Specific Phosphodiesterase Type 5 Inhibitor; Treatment of Erectile Dysfunction","Inhibituer de la phosphodiestérase de type 5 spécifique du GMPc; Traitement de la dysfonction érectile","",""
"14244","13-03-26","SIVEM PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","ANALGESIC","ANALGÉSIQUE","",""
"14245","13-03-26","MARCAN PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","APO-DOMPERIDONE","APOTEX INC","CANADA","CANADA","1","","","MODIFIER OF UPPER GASTROINESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIERURES","",""
"14246","13-03-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"14247","13-03-26","OMEGA LABORATORIES LTD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FUROSEMIDE SPECIAL","SANDOZ CANADA INC","CANADA","CANADA","1","Additional manufacturing site; Revisions to the Product Monograph","Lieu de fabrication additionnel; Révisions à la monographie de produit","DIURETIC","DIURÉTIQUE","",""
"14248","13-03-26","JUBILANT LIFE SCIENCES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER; DIURETIC","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II / DIURÉTIQUE","",""
"14249","13-03-26","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AND CORTICOSTEROID","ANTIVIRAL ET CORTICOSTÉROÏDE","",""
"14250","13-03-26","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COUMADIN","BRISTOL-MYERS SQUIBBB CANADA","CANADA","CANADA","1","Change in formulation; Change in the manufacturing process","Modification de la formulation; Changement dans le procédé de fabrication","ANTICOAGULANT","ANTICOAGULANT","",""
"14251","13-03-26","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CADUET","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTI-HYPERTENSINVE - ANTI-ANGINAL AGENT AND LIPID METABOLISM REGULATOR","ANTIHYPERTENSEUR - ANTIANGINEUX ET RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"14252","13-03-26","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LEUCOVORIN CALCIUM INJECTION USP","NOVOPHARM LTD","CANADA","CANADA","1","","","FOLIC ACID DERIVATIVE","DÉRIVÉ DE L'ACIDE FOLIQUE","",""
"14253","13-02-13","ID BIOMEDICAL CORPORATION OF QUEBEC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Biologic","Biologique","","","","","1","","","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"14254","13-03-28","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Updates to the Product Monograph","Mise à jour à la monographie du produit","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"14255","13-03-28","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK SHARP & DOHME LTD","GERMANY","ALLEMAGNE","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"14256","13-03-27","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing site and process","Nouveau lieu de fabrication et processus","BACTERICIDAL ANTIBIOTIC","ANTIBIOTIQUE BACTÉRICIDIQUE","",""
"14257","13-03-27","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN-ORTHO INC","CANADA","CANADA","1","New formulation","Nouvelle formulation","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"14258","13-04-02","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLEEVEC","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Updates to the Product Monograph","Mises à jour de la monographie de produit","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"14259","13-04-02","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLEEVEC","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Revision of indications","Révision des indications","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"14260","13-03-28","PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New drug substance manufacturer","Nouveau fabricant de la substance thérapeutique","ORAL HYPOGLYCEMIC AGENT","AGENT HYPOGLYCÉMIANT ORAL","",""
"14261","13-04-02","BAUSCH & LOMB INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XALATAN","PFIZER CANADA INC","CANADA","CANADA","1","","","PROSTAGLANDIN F2A ANALOGUE","ANALOGUE DE LA PROSTAGLANDINE F2ALPHA","",""
"14262","13-03-28","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"14263","13-03-28","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COSOPT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT D'UNE PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"14264","13-03-28","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANTIHYPERTENSIVE - ANTIANGINAL AGENT","ANTIHYPERTENSEUR - ANTIANGINEUX","",""
"14265","13-04-02","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLEEVEC","NOVARTIS PHARMACETUCIALS CANADA INC","CANADA","CANADA","1","","","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"14266","13-04-02","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLEEVEC","NOVARTIS PHARMACETUCIALS CANADA INC","CANADA","CANADA","1","","","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"14267","13-04-03","GRIFOLS THERAPEUTICS INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility and process","Nouvel emplacement de fabrication et de procédures","ANTICOAGULANT","ANTICOAGULANT","",""
"14268","13-04-03","BIOGEN IDEC CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OTHER NERVOUS SYSTEM DRUG","AUTRE MÉDICAMENT POUR LE SYSTÈME NERVEUX","",""
"14269","13-04-04","EISAI LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILEPTIC AGENT","AGENT ANTIÉPILEPTIQUE","",""
"14270","13-04-05","FERRING INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in immediate packaging of solvent","CHangement de l'emballage du solvant","GONADOTROPIN RELEASING HORMONE RECEPTOR AGAONIST","Antagoniste des récepteurs de l'hormone de libération de la gonadotrophine","",""
"14271","13-04-10","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New format of the Product Monograph including safety updates","Nouvelle présentation de la monographie de produit qui inclus mise à jour de l'innocuité","ANTI-VERTIGO AGENT","ANTIVERTIGE","",""
"14272","13-04-10","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XALACOM","PFIZER CANADA INC","CANADA","CANADA","1","","","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"14273","13-04-10","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYTOVENE","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","ANTIVIRAL AGENT","ANTIVIRAL","",""
"14274","13-04-08","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II","",""
"14275","13-04-12","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"14276","13-04-12","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA","ELI LILLY CANADA INC","CANADA","CANADA","1","New strengths","Nouvelles concentrations","SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR FOR ATTENION DEFICIT/HYPERACTIVITY DISORDER","Inhibiteur sélectif du recaptage de la noradrénaline pour la trouble déficitaire de l'attention avec hyperactivité (TDAH)","",""
"14277","13-04-12","TORRENT PHARMACEUTICALS LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"14278","13-04-12","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14279","13-04-15","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"14280","13-04-15","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","XANAX","PHARMACIA & UPJOHN COMPANY, DIVISION OF PFIZER CANADA INC","CANADA","CANADA","1","","","ANXIOLYTIC, ANTIPANIC","ANXIOLYTIQUE, ANTIPANIQUE","",""
"14281","13-04-15","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID FOR NASAL USE","CORTICOSTÉROÏDE POUR LA VOIE NASALE","",""
"14282","13-04-12","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","Addition of a drug subsatance supplier","Addition d'un fournisseur de la substance médicamentaire","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"14283","13-04-12","OMEGA LABORATORIES LTD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FUROSOMIDE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","Additional manufacturing site","Lieu de fabrication additionel","DIURETIC","DIURÉTIQUE","",""
"14284","13-04-12","NOVOPHARM LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional manufacturing site","Lieu de fabrication additionel","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14285","13-04-11","SHIRE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of an indication in a combined population of children and adolescents","Ajout d'une indication dans une population comprenant à la fois des enfants et des adolescents","CENTRAL NERVOUS SYSTEM STIMULANT FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER","STIMULANT DU SYSTÈME NERVEUX CENTRAL POUR LE TROUBLE DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ","",""
"14286","13-04-12","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALTREX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"14287","13-04-12","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","RELPAX","PFIZER CANADA INC","CANADA","CANADA","1","","","5HT1 RECEPTOR AGONIST; MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5HT1; ANTIMIGRAINEUX","",""
"14288","13-04-12","HOFFMANN LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASTIQUE","",""
"14289","13-04-16","LABORATOIRE RIVA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANALGESIC AGNET","AGENT ANALGÉSIQUE","",""
"14290","13-04-16","MERUS LABS LUXCO S. A R.L.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCARINIC ME SELECTIVE RECEPTOR ANTAGONIST","ANTAGONISTE SÉELECTIF DES RÉCEPTEURS MUSCARINIQUES M3","",""
"14291","13-04-17","ALBERTA VETERINARY LABORATORIES LTD","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","EQVALAN LIQUID FOR HORSES","MERIAL","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITIQUE","",""
"14292","13-04-17","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SOTACOR","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","",""
"14293","13-04-16","SCHERING PLOUGH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Labelling Only","Étiquetage Seulement","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'HISTAMINE H1","",""
"14294","13-04-18","ABRI PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARTHROTEC","PFIZER CANADA INC","CANADA","CANADA","1","","","NSAID WITH A MUCOSAL PROTECIVE AGENT","AINS ASSOCIÉ À UN AGENT CYTOPROTECTEUR","",""
"14295","13-04-18","ABRI PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","AVENTIS PHARMA INC","CANADA","CANADA","1","","","HYPNOTIC AND SEDATIVE","HYPNOTIQUE ET SÉDATIF","",""
"14296","13-04-18","ABRI PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT RPD","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","MIGRAINE THERAPY","ANTI MIGRAINEUX","",""
"14297","13-04-18","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","GLAUCOMA THERAPY, NONCARDIOESELECTIVE BETA-ADRENOCEPTOR BLOCKING AGENT","TRAITEMENT POUR LE GLAUCOME, INHIBITEUR NON CARDOISÉLECTIF DES RÉCEPTEURS BÉTA-ADRÉNERGIQUES","",""
"14298","13-04-18","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","RELATIVELY SELECTIVE ALPHA2 ADRENOCEPTOR AGONIST, ELEVATED INTRAOCULAR PRESSURE THERAPY","AGONISTE DES RÉCEPTEURS APLPHA2 ADRÉNERGIQUES RELATIVEMENT SÉLECTIF, TRAITEMENT POUR LA PRESSION INTRAOCULAIRE ÉLEVÉE","",""
"14299","13-04-17","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MUSCLE RELAXANT, ANTISPASTIC AGENT","RELAXANT MUSCULAIRE, AGENT ANTISPASTIQUE","",""
"14300","13-04-18","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIAMICRON MR","SERVIER CANADA INC","CANADA","CANADA","1","","","HYPOGLYCEMIC SULFONYLURIA, ORAL ANTIDIABETIC AGENT","HYPOGLYCÉMIANT SULFOYLLURÉE, AGENT ANTIDIABÉTIQUE ORAL","",""
"14301","13-04-16","PALADIN LABS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉEOPLASTIQUE","",""
"14302","13-04-18","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALERTEC","SHIRE BIOCHEM INC","CANADA","CANADA","1","","","CENTRAL NERVOUS SYSTEM STIMULANT","STIMULANT DU SYSTÈME NERVEUX CENTRAL","",""
"14303","13-04-17","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","AERIUS","SCHERING-PLOUGH CANADA INC","CANADA","CANADA","1","","","HISTAMINE H1-RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"14304","13-04-19","GENZYME CANADA, A DIVISION OF SANOFI-AVENTIS CANADA INC.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Changes to the manufacturing facility","Modification a l'emplacement de fabrication","ENZYME REPLACMENT THERAPY","THÉRAPIE DE REMPLACEMENT D'ENZYMES","",""
"14305","13-04-19","UNITED THERAPEUTICS CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of a new manufacturing and packaging site for drug product and a change to the manufacturing process","Addition d'un nouveau emplacement pour le fabrication & embellagement du produit et modifications de la processus de fabrication","VASODILATOR","VASODILATEUR","",""
"14306","13-04-22","ALVEDA PHARMACEUTICALS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FUROSEMIDE INJECTION USP","SANDOZ CANADA INC","CANADA","CANADA","1","Additional drug product manufacturing site","Nouveau lieu de fabrication pour le produit","DIURETIC","DIURÉTIQUE","",""
"14307","13-04-22","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AROMASIN TABLETS","PFIZER CANADA INC","CANADA","CANADA","1","","","AROMATASE INACTIVATOR; ANTI-TUMOUR AGENT","INACTIVATEUR DE L'AROMATASE; ANTINÉOPLASTIQUE","",""
"14308","13-04-22","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FUNGIZONE","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","ANTIFUNGAL AGENT","ANTIFONGIQUE","",""
"14309","13-04-22","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOCOR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"14310","13-04-23","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CYTARABINE INJECTION","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","","","ANTILEUKEMIC AGENT","AGENT ANTILEUCÉMIQUE","",""
"14311","13-04-23","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate manufacturing, packaging, testing and storage site","Autre lieu de fabrication, conditionnement, essai et entreposage","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14312","13-04-24","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","HORMONE","HORMONE","",""
"14313","13-04-18","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: Treatment of pulmonary embolism (PE) and prevention of recurrent deep vein thrombosis (DVT) and PE","Nouvelle indication: Traitement de l'embolie pulmonaire (EP) et prévention des thromboses veineuses profondes (TVP) récidivantes et du l'EP","ANTICOAGULANT","ANTICOAGULANT","",""
"14314","13-04-25","ALCON CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product name change","Changement du nom du produit","ELEVATED INTRAOCULAR PRESSURE THERAPY","TRAITEMENT DE LA PRESSION INTRA-OCULAIRE ÉLEVÉE","",""
"14315","13-04-24","FRESENIUS KABI AB","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Alternative primary packaging material","Autre matériel de l'emballagement primaire","FAT EMULSION FOR INTRAVENOUS NUTRITION","ÉMULSION DE GRAS, ALIMENTATION I.V.","",""
"14316","13-04-25","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIRAMUNE","BOEHRINGER INGELHEIM (CANADA) LTDR","CANADA","CANADA","1","","","ANTIRETROVIRAL AGENT; NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR WITH ACTIVITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)","Antirétroviral / Inhibiteur non-nucléoside de la reverse transcriptase contre le virus de l'immunodéficience humaine de type 1 (VIH-1)","",""
"14317","13-04-29","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVALIDE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","Alternate drug substance manufacturing site","Autre lieu de fabrication pour la substance thérapeutique","ANGIOTENSIN II AT1 RECEPTOR BLOCKER; DIURETIC","BLOQUEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II / DIURÉTIQUE","",""
"14318","13-04-25","NU PHARM INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZORIVAX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","Additional drug substance supplier","Fournisseur additionnel de la substance actif","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"14319","13-04-29","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INTEGRILIN","MERCK CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"14320","13-04-29","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","TYPE II 5 ALPHA REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"14321","13-05-01","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","ANALGESIC AGENT","AGENT ANALGÉSIQUE","",""
"14322","13-05-01","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"14323","13-04-30","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TRICYCLIC ANTIDEPRESSANT","ANTIDÉPRESSEUR TRICYCLIQUE","",""
"14324","13-04-30","SANOFI AVENTIS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASTIQUE","",""
"14325","13-04-30","SANOFI AVENTIS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASTIQUE","",""
"14326","13-05-01","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOCQUER DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"14327","13-04-30","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in the manufacturing process","Changement dans le procédé de fabrication","GASTROINTESTINAL CALCIUM ANTAGONIST","Antagoniste calcique gastro-intestinal","",""
"14328","13-05-01","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","",""
"14329","13-05-01","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","APRESOLINE","STERIMAX INC","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"14330","13-04-29","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INTEGRILIN","SCHERING-PLOUGH CANADA INC","CANADA","CANADA","1","","","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"14331","13-05-06","TEVA CANADA LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional drug substance supplier","Fournisseur addtionel de la substance de drogue","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14332","13-05-06","ALVEDA PHARMACEUTICALS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NALOXONE HYDROCHLORIDE INJECTION","SANDOZ CANADA INC","CANADA","CANADA","1","Additional drug product site","Endriot additionel pour le produit de drogue","OPIOID ANTAGONISTE","ANTAGONISTE DES OPIOÏDES","",""
"14333","13-05-06","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Change of manufacturing equipment","Chengement d'un équipemment de production","ANTIHEMORRHAGICS, BLOOD COAGULATION FACTORS IX II, VII, X IN COMBINATION","CNTIHÉMORRAGIQUES ASSOCIATION DES FACTEURS DE COAGULATION SANGUINS IX, II, VII, X","",""
"14334","13-01-17","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","UCB CANADA INC","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","AGENT ANTIÉPILEPTIQUE","",""
"14335","13-05-07","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"14336","13-05-07","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","ANTIDIABETIC AGENT","AGENT ANTIDIABÉTIQUE","",""
"14337","13-05-06","SANOFI AVENTIS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Biologic","Biologique","","","","","1","","","IMMUNOSUPPRESSANT","IMMUNOSUPPRESSEUR","",""
"14338","13-05-07","FROSST A DIVISION OF MERCK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BONE METABOLISM REGLATOR AND VITAMIN D","RÉGULATOEUR DU MÉTABOLISME OSSEUX ET VITAMINE D","",""
"14339","13-05-06","GUERBET","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","IONIC, LOW OSMOLALLITY , WATER SOLUBLE RADIOPAQUE CONTRAST MEDIUM FOR INTRAVASCULAR USE","PRDUIT DE CONTRASTE RADIO-OPAQUE HYDROCOLUBLE, IONIQUE À FAIBLE OSMOLALITÉ POUR USAGE INTRAVASCULAIRE","",""
"14340","13-05-07","ALBERTA VETERINARY LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","IVOMEC","MERIAL CANADA INC","CANADA","CANADA","1","","","ANTIPARASITIC","ANTIPARASITAIRE","",""
"14341","13-05-07","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON  STÉROÏDIEN (AINS)","",""
"14342","13-05-08","GENMED A DIVISION OF PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Drug-drug interaction and safety update","Interactions drogue-drogue et mise à jour de l'innocuité","ANTIFUNGAL AGENT","AGENT ANTIFONGIQUE","",""
"14343","13-05-08","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","CGMP SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DU CGP; TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"14344","13-05-08","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"14345","13-05-08","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTROGEN, ANTINEOPLASTIC, ANTIANOREXIC, ANTICACHETIC","PROGESTATIF, ANTINÉOPLASTIQUE, ANTIANOREXIQUE, ANTICACHECTIQUE","",""
"14346","13-05-08","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROZAC","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIBULIMIC","ANTIDÉPRESSEUR, ANTIOSESSIONNEL, ANTIBOULIMIQUE","",""
"14347","13-05-08","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLOMAX","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","SELECTIVE ANTAGONIST OF ALPHA 1A ADRENOCEPTOR SUBTYPE IN THE PROSTATE","ANTAGONISTE SÉLECTIF DES SOUS-TYPES DES RÉCEPTEURS ALPHA 1A ADRÉNERGIQUES DES LA PROSTATE","",""
"14348","13-05-08","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO I/V/ MINIBAGS","BAYER INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"14349","13-05-08","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOCARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMATASE INHIBITOR, INHIBITOR OF ESTROGEN BIOSYNTHESIS, ANTI-TUMOR AGENT","INHIBITOR NON STÉDOÏDIEN DE L'AROMATASE, INHIBITEUR DE LA BIOSYNTHÈSE DES OESTOGÈNES, AGENT ANTINÉOPLATIQUE","",""
"14350","13-05-08","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMATASE INHIBITOR, INHIBITOR OF ESTROGEN BIOSYNTHESIS, ANTI-TUMOR AGENT","INHIBITOR NON STÉDOÏDIEN DE L'AROMATASE, INHIBITEUR DE LA BIOSYNTHÈSE DES OESTOGÈNES, AGENT ANTINÉOPLATIQUE","",""
"14351","13-05-08","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FEMARA","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL AROMATASE INHIBITOR, INHIBITOR OF ESTROGEN BIOSYNTHESIS, ANTI-TUMOR AGENT","INHIBITOR NON STÉDOÏDIEN DE L'AROMATASE, INHIBITEUR DE LA BIOSYNTHÈSE DES OESTOGÈNES, AGENT ANTINÉOPLATIQUE","",""
"14352","13-05-08","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL LIQUI-GELS, ANDVIL EXTRA STRENGTH LIQUI-GELS","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","Change in specifications","Modifications des spécifications","ANALGESIC / ANTIPYRETIC","ANALGÉSIQUE / ANTIPYRÉTIQUE","",""
"14353","13-05-08","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACTONEL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","",""
"14354","13-05-08","JUBILANT LIFE SCIENCES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR DS","MERCK CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS II DE L'ANGIOTENSINE ET DIURÉTIQUE","",""
"14355","12-12-19","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","METHOTREXATE INJECTION USP","MAYNE PHARMA (CANADA) INC","CANADA","CANADA","1","","","ANTIMETABOLITE; ANTIRHEUMATIC","ANTIMÉTABOLITE, ANTIRHUMASTISMAL","",""
"14356","13-05-09","THERAKOS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASTIQUE","",""
"14357","13-05-09","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of pediatric pK and clinical data to the Action and Clinical Pharmacology section of the Product Monograph","Ajout de données phmacocinétiques et cliniques dans une popluation pédiatrique dans la section Mode d'action et pharmacologie clinique de la monographie de produit","5-HT1 RECEPTOR AGONIST","AGONISTE DES RÉCEPTEURS 5-HT1","",""
"14358","13-05-10","GLAXOSMITHKLINE INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfill commitment number one (1) of the letter of Undertaking","Satisfaire l'engagement numéro un (1) de la lettre d'engagement","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASTIQUE","",""
"14359","13-05-10","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR, TREATMENT OF ERECTILE DYSUNCTION","iNHIBITEUR DE LA PHOSPHODIESTÉRAE DE TYPE 5 SPÉCIFIQUE DU GMPC; TRIATEMENT DE LA DYSFONCTION ÉRECTILE","",""
"14360","13-05-09","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGISTIVES SUPÉRIEURES","",""
"14361","13-05-10","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ROBAX PLATINUM","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","MUSCLE RELAXANT; ANALGESIC","RELAXANT MUSCULAIRE; ANALGÉSIQUE","",""
"14362","13-05-09","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","COZAAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II","",""
"14363","13-05-10","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPIDIL MICRO","LABORATOIRES FOURNIER S.A.","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"14364","13-05-10","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","STRATTERA","ELI LILLY CANADA INC","CANADA","CANADA","1","","","SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (sdhd)","INHIBITEUR SÉLECTIF DU RECAPTAGE DE LA NORADRÉNALINE POUR LA TROUBLE DÉFICITAIRE DE L'ATTENTION AVEC HYPERACTIVITÉ (TDAH)","",""
"14365","13-05-09","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CIPRO","BAYER INC, HEALTHCARE DIVISION","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","AGENT ANTIBACTÉRIEN","",""
"14366","13-05-10","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","Alternate manufacturing site for the drug substance","Autre emplacement de fabrication de la substance médicamentaire","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"14367","13-05-10","ABBOTT LABORATORIES, LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of a drug product manufacturing site","Ajout d'un site de fabrication de medicament","ANTIEPILEPTIC","ANTIÉPILEPTIQUE","",""
"14368","13-05-13","HUVEPHARMA AD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Veterinary","Vétérinaire","PULMOTIL PREMIX","ELANCO, DIVISION OF ELI LILLY CANADA INC","CANADA","CANADA","1","Addition of species; feedlot cattle","ADdition d'espéces; bovins en parc","ANTIBACTERIAL","ANTIBACTÉRIEN","",""
"14369","13-05-14","CEVA ANIMAL HEALTH","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","ANTISEPTIC","ANTISEPTIQUE","",""
"14370","13-05-13","PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Product name change","Changement du nom du produit","ANTI-ALLERGIC AGENT","AGENT ANTIALLERGIQUE","",""
"14371","13-05-13","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in storage conditions of reconstituted and diluted solution","Modification des conditions d'entreposage de la solution reconstituée et diluée","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASTIQUE","",""
"14372","13-05-14","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in manufacturing process for drug substance containing adhesive copolymer","Modification du procédé de fabrication de la substance pharmaceutique contenant un copolyère adhésif","ANTIANGINAL AGENT","ANTIANGINEUX","",""
"14373","13-05-14","STRIDES ARCOLAB LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VANCOCIN","MERUS LABS INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14374","13-05-09","AMO CANADA COMPANY","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","","","CONCTACT LENS DISINFECTANT","DÉSINFECTANT POUR LES LENTILLE DE CONTACT","",""
"14375","13-05-09","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Extension of Maintenance Therapy- Nonsquamous Non-Small Cell Lung Cancer (NSCLC) - monotherapy indication to permit continuous Alimta maintenance treatment in patients with advanced nonsquamous NSCCLC, immediately following Alimta-containing first-line platinum doublet chemotherapy","Elargissement du traitment d'entretien - concer du poumon non à petities cellules non épidermoïde (CPNPC) - monothérapie indication permettant le traitement d'entretien continu par Alimta chez les patients atteints d'un CPNPC non épidermoïde, immédiatement à la suite d'une chimiothérapie d'association  base platine avec Alimta en première intention.","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASTIQUE","",""
"14376","13-05-15","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","GROWTH STIMULANT","STIMULANT DE CROISSANCE","",""
"14377","13-05-22","SANDOZ CANADA INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","WELLBUTRIN SR","GLAXOSMITHKLINE INC","CANADA","CANADA","1","Alternate manufacturing site","Autre lieu de fabrication","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"14378","13-05-16","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HALOPERIDOL INJECTION","OMEGA LABORATORIES LTD","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","ANTIPSYCHOTIQUE","",""
"14379","13-05-22","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS PLUS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER AND DIURETIC","INHIBITEUR DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II / DIURÉTIQUE","",""
"14380","13-05-16","ONCO THERAPIES LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","FLUDARABINE PHOSPHATE INJECTION","NOVOPHARM LTD","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"14381","13-05-22","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP","PHARMACEUTICAL PARTNERS OF CANADA INC.","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14382","13-05-22","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VINBLASTINE SULFATE INJECTION","MAYNE PHARMA (CANADA) INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASTIQUE","",""
"14383","13-05-22","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"14384","13-05-22","PFIZER ANIMAL HEALTH CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","METACAM ORAL SUSPENSION","BOEHRINGER ONGELHEIM VETMEDICA","GERMANY","ALLEMAGNE","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"14385","13-05-22","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"14386","13-05-22","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"14387","13-05-22","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"14388","13-05-22","NOVARTIS ANIMAL HEALTH CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","NON-STEROIDAL ANTI-INFLAMMATORY (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","",""
"14389","13-05-17","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EFFEXOR XR","WYETH CANADA INC","CANADA","CANADA","1","","","ANTIDEPRESSANT - ANXIOLYTIC","ANTIDÉPRESSEUR - ANSIOLYTIQUE","",""
"14390","13-04-24","BAYER INC CONSUMER CARE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Removing carton (keeping bottle only) for 250 caplet package only. Removing indication statement from bottle due to space limitations","Retirer la boîte (nd garder que le flacon) pour l'embellage de 250 caplets uniquement. Retirer l'énoncé de l'inditation sur le flacon en raison de l'espace limité","ANALGESIC - ANTIPYRETIC","ANALGÉSIQUE - ANTIPYRÉTIQUE","",""
"14391","13-04-19","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To register facility changes made to the Parenterals Business Unit for the manufacturer of sterile drug product","Homologuer les modification touchant les installations apportées à l'unité opérationnelle des médicaments à ussage parentéral pour la fabricxation du produit phamraceutique stérile","ANTIBIOTIC AND BETA LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE ß-LACTAMASES","",""
"14392","13-05-23","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in synthesis of drug substance","Changement de la synthèse de la substance thérapeutique","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"14393","13-05-23","DR REDDYS LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIXTRA","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","SYNTHETIC ANTITHROMBOTIC","ANTITHROMBOTIQUE SYNTHÉTIQUE","",""
"14394","13-05-23","AGILA SPECIALTIES PRIVATE LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NIMBEX","ABBVIE CORPORATION","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"14395","13-05-23","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14396","13-05-24","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ROBAX PLATINUM","WYETH CONSUMER HEALTHCARE INC","CANADA","CANADA","1","","","MUSCLE RELAXANT; ANALGESIC","RELAXANT MUSCULAIRE; ANALGÉSIQUE","",""
"14397","13-05-24","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EBIXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST","ANTAGONISTE DU RÉCEPTEUR N-METHYL-D-ASPARTATE (NMDA)","",""
"14398","13-05-24","APOTEX INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPARKINSON AGENT","AGENT ANTIPARKINSONIEN","",""
"14399","13-05-24","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","REVATIO","PFIZER CANADA INC","CANADA","CANADA","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR; TREATMENT OF PUMMONARY ARTERIAL HYPERTENSION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPECIFIQUE DU GMPC; TRATIEMENT DE L'HYPERTENSION ARTÉRIELLE PULMONAIRE","",""
"14400","13-05-24","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PROSCAR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","TYPE II 5 ALPHA-REDUCTASE INHIBITOR","INHIBITEUR DE LA 5 ALPHA-RÉDUCTASE DE TYPE II","",""
"14401","13-05-24","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL ANTI-INFLAMMATORY STEROID","CORTICOSTÉROÏDE ANTI-INFLAMMATOIRE TOPIQUE","",""
"14402","13-05-23","ASTRAZENECA CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revision to the drug substance design space upper boundary limit and the introduction of two new key process parameters to the design space","Modification de la limite supÉrieure de l''espace de fabrication de la substance mÉdicamenteuse et introduction de deux nouveaux paramètres de procédé essentiels à l'espace de fabrication","PLATELET AGGREGATION INHIBITOR","INHHIBITEUR DE L'AGRÉGATION PLAQUETTAIRE","",""
"14403","13-05-22","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Product Monograph update to align existing cardiovascular warnings in the Warnings and Precautions and Part III sections of the Product Monograph with the USPI and SmPC","Mises à jour de la monographie de produit pour harmoniser les mises en garde cardiovasculaires existantes dans la section Mises en garde et précautions et la partie III aven la notice d'accompagnement de produit américaine (USPI) et le résumé des caractéristiques de produit euroipéan (RCP)","SMOKING CESSATION AID","AIDE POUR CESSER DE FUMER","",""
"14404","13-05-13","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication: for use in patients with type 2 diabetes millitus to improve glycemic control in combination with metformin and sulfonlurea when dual therapy with these two agents, with diet and exercise, does not provide adequate glycemic control","Nouvelle indication: pour les patients atteints d'un diabète sucré (de type 2) dans le but d'améliorer le contrôle glycémique en association avec de la metformine et de la sulfonylurée lorsque cette bithérapie, accompangnée d'un régime alimentaire et d'exercise physique, ne permet pas de contrôler adéquatement la glycémie","ORAL ANTIHYPERGLYCEMIC AGENT, DPP-4 INHIBITOR INCRETIN ENHANCER","Agent oral d'antihyperglycémic; inhibiteur DPP-4; renforceur d'incretin","",""
"14405","13-05-28","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRI-CYCLEN LO","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"14406","11-05-29","BAYER INC BAYER HEALTHCARE ANIMAL HEALTH","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Labelling update","Mise à jour de l'étiquettage","PARASITICIIDE","PARACITICIDE","",""
"14407","13-05-29","ONCO THERAPIES LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASIQUE","",""
"14408","13-05-29","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New indication for the use as an adjunct to antidepressants for the treatment of Major Depressinve Disorder (MDD) in adult patients who had an inadequate reponse to prior antidepressant treatments during the current episode","Nouvell indication pour l'usage comme comlément aux antidépresseurs pour le traitement du trouble dépressif majeur (TDM) chez les patients adultes ayant eu une réponse indéquate aux traitements adtidépresseurs antrieurs pendant l'épisode actuel.","ANTIPHSYCHOTIC","ANTIPSYCHOTIQUE","",""
"14409","13-05-29","ASTELLAS PHARMA CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC ENDOCRINE THERAPY","THÉRAPIE ANTINÉOPLASTIQUE ENDROCRINE","",""
"14410","13-05-28","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New Indication to include ZYTIGA in combination with prednisone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).","Nouvelle indication afin d'inclure l'emploi de ZYTIGA en association avec la prednisone pour le traitement du cancer prostatique métastatique résistant à la castration (CPmRC) chez les patients asymptomatiques ou légérement symptomatique après l'échec d'une hormonothérapie androgénosuppressive (HA)","ANDROGEN BIOSYNTHESIS INHIBITOR","Inhibiteur de la biosynthèse androgénique","",""
"14411","13-05-31","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Changes to the Product Monograph","Changements à la monographie du produit","INTERLEUKIN RECEPTOR INHIBITOR","INHIBITEUR DU RÉCEPTEUR DE L'INTERLEUKINE","",""
"14412","13-05-31","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Addition of manufacturing facility for drug product","Ajout d'un établissement reponsable de la fabrication d'un produit médicamenteux","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"14413","13-05-31","COBALT PHARMACEUTICALS COMPANY","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","YASMIN 21, YASMIN 28","BAYER INC","CANADA","CANADA","1","","","Oral Contraceptive; Acne Therapy","Contraceptif oral; Traitement d'acné","",""
"14414","13-05-31","ALEXION PHARMA INTERNATIONAL SARL","Y","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","COMPLEMENT INHIBITOR","INHIBITEUR DU COMPLÉMENT","",""
"14415","13-05-30","JUBILANT LIFE SCIENCES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KEPPRA","UCB CANADA INC","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","AGENT ANTIÉPILEPTIQUE","",""
"14416","13-05-31","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DDVAP","FERRING PHARMACEUTICALS LTD","UNITED KINGDOM","ROYAUME-UNI","1","","","ANTIDIURETIC","ANTIDIURÉTIQUE","",""
"14417","13-06-04","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change to the manufacturing facility and equipment in addition to a change in the container closure system","Changement à l'usine de fabrication et à l'équipement en plus d'un changement au système récipient-fermeture","FIBRINOLYTIC AGENT","AGENT FIBRINOLYTIQUE","",""
"14418","13-06-04","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","AERIUS","SCHERING CANADA INC","CANADA","CANADA","1","Revisions to the Product Monograph","Révisions à la monographie de produit","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","",""
"14419","13-06-04","GENERIC MEDICAL PARTNERS","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","",""
"14420","13-06-04","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","NITRO-DUR","MERCK CANADA INC","CANADA","CANADA","1","","","ANTIANGINAL AGENT","AGENT ANTIANGINEUX","",""
"14421","13-06-03","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14422","13-06-03","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIARRHYTHMIC, ANTIANGINAL, ANTIHYPERTENSIVE AGENT","ANTIARHYTHMIQUE, ANTIANGINEUX, ANTIHYPERTENSEUR","",""
"14423","13-06-04","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","CHOLINESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"14424","13-06-04","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IMOVANE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","HYPNOTIC AND SEDATIVE","HYPNOTIQUE ET SÉDATIF","",""
"14425","13-06-03","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","EXELON","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","CHOLIESTERASE INHIBITOR","INHIBITEUR DE LA CHOLINESTÉRASE","",""
"14426","13-05-30","PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTILEUKEMIC AGENT","AGENT ANTILEUCÉMIQUE","",""
"14427","13-05-30","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELE LILLY CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT-ANTIPSYCHOTIQUE","",""
"14428","13-05-31","SANDOZ CANADA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New strength","Nouvelle concentration","ANTICONVULSANT, SYMPTOMATIC RELIEF OF TRIGEMINAL NEURALGIA, ANTIMANIC","ANTICONVULSIVANT, SOULANGEMENT SYMPTOMATIQUE DE LA NÉVRAIGIE DU TRIJUMEAU, ANTIMANIAQUE","",""
"14429","13-06-05","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","",""
"14430","13-06-05","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BROCHODILATOR, BETA2-ADRENERGIC STIMULANT","BRONCHODILATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","",""
"14431","13-06-06","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MEVACOR","MERCK FROSST CANADA","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME LIPIDIQUE","",""
"14432","13-06-06","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","Additional Strength","Concentraton additionel","ANALGESIC AGENT","AGENT ANALGÉSIQUE","",""
"14433","13-06-06","PHARMGATE LLC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","CHLOR 100 GRANULAR PREMIX","BIO AGRL MIX LP","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14434","13-06-07","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","Administrative transfer of Drun Ideentification Numbers","Administratif transfert d'identification numérique des drogues"
"14435","13-06-07","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRéTROVIRAL","Administrative trasfer of Drug Identification Numbers","Administratif transfert d'identification numérique des drogues"
"14436","13-06-07","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","rÉGULATEUR DU MÉTABOLISME DES LIPIDES","",""
"14437","13-06-07","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Nonprescription Pharmaceutical","Disponible sans ordonnance","ZANTAC","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","HIDTAMINE H2 RECEPTOR ANTAGONIST","ANGTAGONISTE DES RÉCEPTEURS H2 DE L'HISTAMINE","New manufacturer","Nouveau nom du fabricant"
"14438","13-06-07","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional drug product manufacturing site","Ajout d'un site de fabrication du medicament","ANTIFUNGAL AGENT","AGENT ANTIFONGIQUE","",""
"14439","13-06-07","LUNDBECK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority","Priorité","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC","ANTINÉOPLASTIQUE","",""
"14440","13-06-07","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in synthesis of drug substance","Cnage à la sythèse de la substance médicamentaire","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"14441","13-06-07","TARO PHARMACEUTICALS INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TEGRETOL","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","New strength","Nouvelle concentration","ANTICONVULSANT; FOR SYSTAMATIC RELIEF OF TRIGEMINAL NEURALGIA; ANTIMANIC","Anticonvulsivant, Soulagement symptomatique de la névralgie du trijumeau, Antimaniaque","",""
"14442","13-06-11","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LONG ACTING BETA2 AGONIST","AGONISTE BETA2 À L'ACTION PROLONGÉE","",""
"14444","13-06-07","ACCORD HEALTHCARE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICARDIS","BOEHRINGER INGELHEIM (CANADA) LTD","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUER DES RéCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"14445","13-06-12","ELANCO DIVISION ELI LILLY CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Veterinary","Vétérinaire","","","","","1","","","GROWTH PROMOTANT","STIMULANT DE CROISSANCE","",""
"14446","13-06-06","CELGENE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Fulfilment of conditions as per the letter of Unertaking dated January 15, 2008 indicated for the treatment of patients with transfusion-dependent anemia due to low or intermediate 1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities","Stasifaction des conditions décrites dans la lettre d'engagement du 15 janvier 2008, indiqué pour le traitement des patients atteints d'anémie n¶cessitant des tranfusions du à in syndrome myélodyspasique à risque faible ou intermédiare 1 associé à une anomalie cytogénétique 5q de suppression avec ou sans autre anomalie cytogénétique","ANTINEOPLASTIC AGENT, IMMUNOMODULATING AGENT","ANTINÉOPLASTIQUE, IMMUNOMODULATEUR","",""
"14447","13-06-12","SANDOZ CANADA INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product Monograph","Mise à jour à la monographie de produit","HUMAN GROWTH HORMONE","HORMONE DE CROISSANCE HUMAINE","",""
"14448","13-06-12","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PREVACID","TAP PHARMACEUTICALS","CANADA","CANADA","1","New indication to match innovator","Nouvell indication comme l'innovateur","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"14449","13-06-12","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","ADministrative - licensing agreement between two companies","Administratif - accord de license entre deux socités"
"14450","13-06-13","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PAXIL","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL, ANTIPANIC AGENT, ANXIOLYTIC AGENT, SOCIAL PHOBIA (SOCIAL ANXIETY DISORDER), POSTTRAUMATIC STRESS DISORDER THERAPY","ANTIDÉPRESSEUR ANTIOBSESSIONNEL, ANTIPANIQUE, ANXIOLYTIQUE, TRAITEMENT DE LA PHOBIE SOCIALE ET TRAITEMENT DE L'ÉTAT DE STRESSE POST-TRAUMATIQUE","",""
"14451","13-05-16","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph following the results of the anemia management study (P06086) and results from the ongoing study in previous treatment failures, including null responders (P05514)","Mise à jour de la monographie de produit suite aux résultats de l'étude sur la prise en charge de l'anémie (P06086) et aux résultats de l'étude en cours concernant les checs thérapeutiques antérieurs, y compris les réponses nulles (P05514)","HEPATITIS C VIRUS (HCV) PROTEASE INHIBITOR","Inhibiteur de la protéase du virus de l'Hépatite C","",""
"14452","13-05-23","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Product Monograph following the reults of the anemia management study (P06086) and results from the ongoing study in previous treatment failures including null responders (P05514)","Mise à jour de la monographie de produit suite aux résultats de l'étude sur la prise en charge de l'anémie (P06086) et aux résultats de l'étude en cours concernant les checs thérapeutiques antérieurs, y compris les réponses nulles (P05514)","ANTIVIRAL AGENT","ANTIVIRAL","",""
"14453","13-06-13","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional manufacturer for the manufacturing of medicated minerals using Avatec 20","Fabricant additionnel pour la fabrication de minéreux médicamentés utilisant le Avatec 20","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"14454","13-06-13","ALPHARMA CANADA CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional manufacturers for the manufacturing of medicated minerals using Bovatec 20","Fabricant additionnel pour la fabrication de minéreux médicamentés utilisant le Bovatec 20","ANTICOCCIDIAL","ANTICOCCIDIEN","",""
"14455","13-06-13","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PANTO IV","NYCOMED CANADA INC","CANADA","CANADA","1","","","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"14456","13-06-13","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARAVA","AVENTIS PHARMA INC","CANADA","CANADA","1","","","ANTI-RHEUMATIC","AGENT ANTIRHUMATISMAL","",""
"14457","13-06-13","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GLEEEVEC","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","Removal of an indication","Enlévement d'un indication","PROTEIN KINEASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"14458","13-06-13","PHARMASCIENCE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIPRIVAN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","Additional drug substance manufacturers","Fabricants de la substance médicament additionnel","ANAESTHETIC (SEDATIVE)","ANESTHÉSIQUE (SÉDATIF)","",""
"14459","13-06-13","OMEGA LABORATORIES LTD","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","KYTRIL","HOFFMANN LA-ROCHE LTD","CANADA","CANADA","1","Additional drug product manufacturing site","dite de fabrication du medicament additionnel","ANTIEMETIC","ANTIÉMÉTIQUE","",""
"14460","13-06-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NITOMAN","BIOVAIL PHARMACEUTICALS CANADA","CANADA","CANADA","1","","","MONOAMINE DEPLETING AGENT","Agent de déplétion des monoamines","",""
"14461","13-06-13","LUPIN LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TRAMACET","JANSSEN INC","CANADA","CANADA","1","","","CENTRALLY ACTING ANALGESIC","ANALGÉSIQUE À L'ACTION CENTRALE","",""
"14462","13-06-13","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","ADVIL COLD & SINUS LOQUI-GEL","WYETH CONSUMER HEALTHCARE","CANADA","CANADA","1","","","ANALGESIC; ANTIPYRETIC; NASAL DECONGESTANT","ANALGÉSIQUE; ANTIPYRÉTIQUE; DÉCONGESTIF NASAL","",""
"14463","13-06-14","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIPSYCHOTIC, ANTIDEPPRESSANT AGENT","ANTIPSYCHOTIQUE, ANTIDÉPRESSEUR","Administrative licensing agreement between two companies","Administratif accord de license enttre deux sociétés"
"14464","13-06-14","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC AND BETA-LACTAMASE INHIBITOR","ANTIBIOTIQUE ET INHIBITEUR DE BETA-LACTAMASES","Administrative manufacturer name change","Administratif changement du nom du fabricant"
"14465","13-06-14","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"14466","13-06-14","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHEN","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14467","13-06-14","SANIS HEALTH INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","NORVASC","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIHYPERTENSIVE, ANTIANGINAL AGENT","ANTIHYPERTENSEUR ET ANTIANGINEUX","Administrative licensing agreement between two companies","Administratif accord de license entre duex sociétés"
"14468","13-06-14","ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate drug product manufacturing and testing site","Autre lieu de fabrication et de l'essai pour le médicament","ANALGESIC, ANTIDEPRESSANT, ANXIOLYTIC","ANALGÉSIQUE, ANTIDÉPRESSEUR, ANXIOLYTIQUE","",""
"14469","13-06-14","LUNDBECK CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDES","",""
"14470","13-06-05","VALEANT CANADA LP VALEANT CANADA S.E.C.","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Addition of a 30 mL airless piston controlled delivery (pump) container closure system","Ajout d'un système récipient-fermeture avec administration contrôlée par un piston sans air comprimé (pompe) de 30 ml","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE IMMUNAIRE","",""
"14471","13-06-17","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","Administrative transfer of Drug Identification Numbers","Administratif transfert d'identification numerique de drogue"
"14472","13-06-17","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT, ANTIOBSESSIONAL AGENT","ANTIDÉPRESSEUR, AGENT ANTIOBSESSIONNEL","Administrative manufacturer name change","Administratif chaangement du nom du fabricant"
"14473","13-06-20","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","New strengths","Nouvelles concentrations","ANALGESIC AGENT","ANALGÉSIQUE","",""
"14474","13-06-19","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Additional primary packaging - blisters","Embellage primaire addtionnel -en plaquette","ANTISPASMODIC","ANTISPASMODIQUE","",""
"14475","13-06-18","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate sites for the media bags sterilization","autres endroit pour le stérilisation des sacs","LEUTINIZING HORMONE-RELEASEING HORMONE ANALOGUE","ANALOGUE DE L'HORMONE DE LIBÉRATION DE LA LUTÉINOSTIMULINE","",""
"14476","13-06-18","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","DIOVAN HCT","NOVARTIS PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER AND DIURETIC","BLOQUER DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II ET DIURÉTIQUE","",""
"14477","13-06-19","BAYER INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROGESTOGEN","PROGESTOGEN","",""
"14478","13-06-20","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","LYRICA","PFIZER CANADA INC","CANADA","CANADA","1","","","ANALGESIC AGENT","AGENT ANALGÉSIQUE","",""
"14479","13-06-21","BIO AGRI MIX LP","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Veterinary","Vétérinaire","BMD 110 G","ALPHARMA CANADA CORPORATION","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14480","13-06-21","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","VANCOCIN","MERUS LABS INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","Administrative licensing agreement between two companies","Administratif accord de licence entre deux sociétés"
"14481","13-06-21","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","Administrative transfer of Drug Identification Numbers","Administratif trasfert d'identification numeriques des drogues"
"14482","13-06-21","VIIV HEALTHCARE ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRRÉTROVIRAL","Administrative transfer of Drug Identification Number","Administratif transfert d'identification numerique de drogue"
"14483","13-06-21","NOVARTIS PHARMACEUTICALS CANADA INC","Y","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Updates to the Warnings and Precautions, Adverse Reactions and Drug-Drug Interaction sections of the Product Monograph","Mises à jour des sections Mises en Gardes et Précautions, Effets Indésirable et l'Intéraction drogues-drogues de la monographie de produit","PROTEIN-TYROSINE KINASE INHIBITOR","Inhibiteur de la protéase-tyrosine kinase","",""
"14484","13-06-24","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","Administrative licensing agreement between two companies","Administratif accord de licence entre deux sociétés"
"14485","13-06-20","CADENCE PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC AN ANTIPYRETIC","ANALGÉSIQUE ET ANTIPYRÉTIQUE","",""
"14486","13-06-24","WATSON LABORATORIES INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SELECTIVE PROGESTERONE RECEPTOR MODULATOR","MODULATEUR DES RÉCEPTEURS DE PROGESTÉRONE SÉLECTIF","",""
"14487","13-06-24","BAXTER CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Expansion of manufacturing facility and changes to the manufacture of intermediate","Agrandissement de l'installation de fabrication et changements à la fabrication de l'intermédiaire","REPLACEMENT THERAPY FOR IMMUNODEFICIENCIES","TRAITEMENT DE SUBSTITUTION DES DÉFICITS IMMUNITAIRES","",""
"14488","13-06-24","NOVARTIS VACCINES AND DIAGNOSTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"14489","13-06-24","NOVARTIS VACCINES AND DIAGNOSTICS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Additional manufacturing facility","Addition d'un nouvel emplacement de fabrication","ACTIVE IMMUNIZING AGENT","AGENT IMMUNISANT ACTIF","",""
"14490","13-06-26","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIMETABOLITE","ANTIMÉTABOLITE","Administrative manufacturer name change","Administratif changement du nom du fabricant"
"14491","13-06-26","PRO DOC LIMITÉE","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","TIAZAC","CRYSTAAL CORPORATION (A DIVISION OF BIOVAIL CORPORATION)","CANADA","CANADA","1","","","ANTIHYPERTENSIVE, ANTIANGINAL AGENT","ANTIHYPERTENSEUR, ANTIANGINEUX","Administrative licensing agreement between two companies","Administratif accord de licence entre deux sociétés"
"14492","13-06-26","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICONVULSANT","ANTICONVULSIVANT","Administrative manufacturer and product name change","Administratif changement du nom du fabricatn et du produit"
"14493","13-06-26","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","PMS-VANCOMYCIN","PHARMASCIENCE INC","CANADA","CANADA","1","","","ANTIBIOTIC","ANTIBIOTIQUE","Administrative licensing agreement between two companies","Administratif accord de licence entre deux sociétés"
"14494","13-06-26","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ALDARA CREAM 5%","GRACEWAY PHARMACEUTICALS","CANADA","CANADA","1","","","IMMUNE RESPONSE MODIFIER","MODIFICATEUR DE LA RÉPONSE IMMUNITAIRE","",""
"14495","13-06-24","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revised indication: As part of a medically recognized combination therapy for induction treatment of patients with previously untreated multiple myeloma who are suitable for stem cell transplantation","Indication modifiée: Dans le cadre d'une polythérapie revconnue médicament pour le traitement d'induction des patients atteints d'un myélome multiple jamais traité qui sont candidats à le greffe de cellules souches","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14496","13-06-24","JANSSEN INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Update to the Product MOnograph uner Clinical Trials section, referring to combination therapy for the treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell transplantation. Update to the Product Monograph under Actions and Clinical Pharmacology section","Mise à jour de la section Essais cliniques de la monographie de produit, concernant les polythérapies destinées aux patients atteints d'un myélome multiple jamais traité qui ne sont pas candidats à la greffe de cellules souches. Mis à jour de la section Action et pharmacologie clinique de la monographie de produit.","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14497","13-06-28","OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","New manufacturing site and changes to the manufacturing process","Nouvel emplacement de fabrication et changements aux procédures de fabrication","PLASMA SUBSTITUTE AND PLASMA PROTEIN FRACTIONS","SUBSTITUT DE PLASMA ET FRACTIONS DE PROTéINES DE PLASMA","",""
"14498","13-06-26","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","RISPERDAL","JANSSEN ORTHO INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","Administrative licensing agreement between two companies","Administratif accord de license entre deux sociétés"
"14499","13-06-26","DOMINION PHARMACAL","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","","","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR, TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DU GMPC, TRAITEMENT DE LA DDYSFONCTION ÉRECTILE","",""
"14500","13-06-26","DOMINION PHARMACAL","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VIAGRA","PFIZER CANADA INC","CANADA","CANADA","1","Product name change","Changement du nom de produit","CGMP-SPECIFIC PHOSPHODIESTERASE TYPE 5 INHIBITOR, TREATMENT OF ERECTILE DYSFUNCTION","INHIBITEUR DE LA PHOSPHODIESTÉRASE DE TYPE 5 SPÉCIFIQUE DU GMPC, TRAITEMENT DE LA DYSFONCTION ÉRECTILE","",""
"14501","13-06-27","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in formulation","Modification de la formulation","ESTROGEN AND PROGESTIN","OESTROGEN ET PROGESTIN","",""
"14502","13-07-02","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACCUPRIL","PARKE DAVIS, DIVISION OF WARNER LAMBERT CO","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITUER DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"14503","13-07-02","APOTEX INCORPORATED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACCUPRIL","PFIZER PHARMACEUTICALS LTD","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","Change in formulation and Manufacturing process","Modification de la formulation et le precédé de fabrication","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"14504","13-06-26","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONSTEROIDAL ANTI-INFLAMMATORY ANALGESIC AGENT","AGENT ANALGÉSIQUE ANTIO-INFLAMMATOIRE NON STÉROÏDIEN","",""
"14505","13-06-28","HOSPIRA HEALTHCARE CORPORATION","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate drug product manufacturing site","Autre lieu de fabrication","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14506","13-06-27","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate manufacturing site for the drug substance","Autre lieu de fabrication pour la substance de drogue","DIFFERENTIATION INDUCING AGENT","INDUCTEUR DE DIFFÉRENTIATION","",""
"14507","13-06-28","TAKEDA CANADA INC.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","OPIOID ANALGESIC","ANAGÉSIQUE OPIOÏDES","",""
"14508","13-06-27","ONCO THERAPIES LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","TAXOL","BRISTOL-MYERS SQUIBB CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASIQUE","",""
"14509","13-06-28","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","VALCYTE","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"14510","13-06-28","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NIMBEX","ABBOTT LABORATORIES LTD","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGNET","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","",""
"14511","13-06-28","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ACCURETIC","PFIZER CANADA INC","CANADA","CANADA","1","","","ANGIOTRENSIN CONVERTING ENZYME INHIBITOR, DIURETIC","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE, DIURÉTIQUE","",""
"14512","13-06-28","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","Expansion of pediatric indication; use in children and adolescents 6 to 17 years of age","Extension de l'indication pédiatrique; utilisation chez les enfants et adolscents de 6 ans à 17 ans","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"14513","13-07-03","VALEO PHARMA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","TOPICAL CORTICOSTEROID","CORTICOSTÉROÏDE TOPIQUE","Administrative transfer of Drug Identification Numbers","Administratif transfert d'identification numérique de (s) drogue(s)"
"14515","13-07-04","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTICHOLINERGIC ANTISPASMODIC AGENT","AGENT ANTICHOLINERGIQUE, ANTISPASMODIQUE","Administrative merger buyout","Administratif fusion rachata"
"14516","13-07-04","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","XANTHINE OXIDASE INHIBITOR","INHIBITEUR DE LA XANTHINE OXYDASE","Administrative merger buyout","Administratif fusion - rachat"
"14517","13-07-04","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","LOWER GOASTROINTESTINAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE DE LA PARTIE BASE DU TUBE DIGESTIF","Administrative merger/buyout","Administratif fusion/rachat"
"14518","13-07-03","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","ZYPREXA ZYDIS","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","Administrative licensing agreement between two companies","Administratif accord de licence entre deux socités"
"14519","13-07-03","LABORATOIRE RIVA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","CIRPO","BAYER INC","CANADA","CANADA","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","Administrative licensing agreement between two companies","Administratif accord de licence entre deux sociétés"
"14520","13-07-04","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","HYZAAR DS","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","ANGIOTENSIN II RECEPTOR ANTAGONIST AND DIURETIC","ANTAGONISTE DES RÉCEPTEURS DE L'ANGIOTENSINE II ET DIURÉTIQUE","Administrative licensing agreement between two companies","Administratif accord de licence entre deux sociétés"
"14521","13-07-04","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","VENTOLIN NEBULES PF","GLAXO WELLCOME INC","CANADA","CANADA","1","","","BRONCHODILATOR, BETA2 ADRENERGIC STIMULANT","BRONCHDILATEUR, STIMULANT DES RÉCEPTEURS BETA2-ADRÉNERGIQUES","Administrative merger/buyout","Administratif fusion/rachat"
"14522","13-07-03","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","INHALED CORTICOSTEROID AND BRONCHODILATOR COMBINATION","COMBINATION D'UN CORTICOSTÉROÏDE ET UN BROCHODILATEUR","",""
"14523","13-07-05","SHIRE CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","SELECTIVE ALPHA 2A-ADRENERGIC RECEPTOR AGONIST","AGONISTE SÉLECTIF DES RÉCEPTEURS ADRÉNERGIQUE ALPHA 2A","",""
"14524","13-07-04","THE MEDICINES COMPANY","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Change in drug product formulation, manufacturing site and packaging (sterile product); reduction in drug product shelf life","Modifiation de la formulation du produit pharmaceutique, du site de fabrication et du conditionnement (produit stérile); réduction de la durée d'entreposage du produit pharmaceutique.","ANTIHYPERTENSIVE AGENT","Antihypertenseur","",""
"14525","13-06-28","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","NAROPIN","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","LOCAL ANAESTHETIC","ANESTHÉSIQUE LOCAL","",""
"14526","13-07-10","SANDOZ CANADA INCORPORATED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14527","13-07-08","PFIZER CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Extension of the indication for the maintenance of efficacy in Major Depressive Disorder (MDD) and subsequent modification of the recommended dosing","Extension de l'indication pour le maintien de l'efficacité dans le trouble dépreddive majeur (TDM) et modification subséquante de la dose recommandée","ANTIDEPRESSANT","ANTIDÉPRESSEUR","",""
"14528","13-07-05","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PARIET","JANSSEN-OTHO INC","CANADA","CANADA","1","","","H+,K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+,K+-ATPASE","",""
"14529","13-07-04","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SUBOXONE","SCHERING-PLOUGH CNADA INC","CANADA","CANADA","1","","","PARTIAL OPIATE AGONIST AND OPIATE ANTAGONIST","AGONISTE DES OPIOÏDES ET ANTAGONISTE DES OPIOÏDES PARTIELS","",""
"14530","13-07-10","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Additional claim","Indication supplémentaire","NON-STEROIDAL ANTI-INFLAMMATORY DRUG","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"14531","13-07-05","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MMODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","Administrative merger/buuyout","Administratif fusion/rachat"
"14532","13-07-05","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","Administrative merger/buyout","Administratif fusion/rachat"
"14533","13-07-05","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANXIOLYTIC, SEDATIVE","ANXIOLYTIQUE, SÉDATIF","Administrative merger/buyout","Administratif fusion/rachat"
"14534","13-07-05","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","ZORIVAX","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","Administrative merger/buyout","Administratif fusion/rachat"
"14535","13-07-05","PALADIN LABS INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTISPASTIC AGENT","AGENT ANTISPASMODIQUE","Product name change","Changement du nom du produit"
"14536","13-07-07","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","ORAL ANTIHYPERGLYCEMIC AGNENT","ANTIHYPERGLYCÉMIANT ORAL","Administrative licensing agreement between two companies","Administrif accord de license entre deux sociétés"
"14537","13-07-05","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC (SULFONYLUREA)","HYPOGLYCÉMIANT ORAL (SULFONYLURÉE","Administrive merger/buyout","Administratif fusion/rachat"
"14538","13-07-08","COLGATE PALMOLIVE CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","","","","","1","Line extension","Extension de ligne","ANTICARIES, ANTIPLAQUE, ANTIGINGIVITIS, ANTICALCULUS","Anticarie; Antiplaque; Antigingivite; Anticalcul; Antisensibilité","",""
"14539","13-07-05","MAYNE PHARMA INTERNATIONAL PTY LTD","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Alternate drug substance supplier","Autre fournisseur de la substance pharmacologique","OPIOD ANALGESIC","ANALGÉSIQUE OPIOÏDES","",""
"14540","13-07-11","BIMEDA MTC ANIMAL HEALTH INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Labelling update","Étiquetage mise à jour","ANAESTHETIC","ANESTHÉSIQUE","",""
"14541","13-07-12","SWEDISH ORPHAN BIOVITRUM AB (PUBL)","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","New manufacturing facility","Nouvel emplacement de fabrication","IMMUNOMODULATORY AGENT","AGENT D'IMMUNOMODULATION","",""
"14542","13-07-15","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Administrative change in synthesis of the drug substance","Administreaitf changement de la synthèse de la substance thérapeutique","ORAL CONTRACEPTIVE, ACNE THERAPY","CONTRACEPTIF ORAL, TRAITEMENT DE L'ACNÉ","",""
"14544","13-07-12","RANBAXY PHARMACEUTICALS CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZESTRIL","ASTRAZENECA CANADA INC","CANADA","CANADA","1","New manufacturing facility for the drug substance","Nouvel emplacment de fabrication pour la substance tthérapeutique","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","",""
"14545","13-07-12","AGILA SPECIALTIES PRIVATE LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADENOCARD","ASTELLAS PHARMA CANADA INC","CANADA","CANADA","1","New packaging format","Nouvel format d'emballage","ANTIARRHYTHMIC","ANTIARYTHMIQUE","",""
"14546","13-07-12","HOFFMANN LA ROCHE LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14547","13-07-12","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PLAVIX","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","PLATELET AGGREGATION INHIBITOR","INHIBITEUR DE L'AGRÉFATION PLAQUETTAIRE","",""
"14548","13-07-16","PHARMASCIENCE INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CISPLATIN INJECTION","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASIQUE","",""
"14549","13-07-16","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CISPLATIN INJECTION","HOSPIRA HEALTHCARE CORPORATION","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14550","13-07-16","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","HYCAMTIN","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14551","13-07-16","BOEHRINGER INGELHEIM CANADA LTD LTEE","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","Changes in formulation","Changement de formulation","NONSTEROIDAL ANTI-INFLAMMATORY","ANTI-INFLAMMATOIRE NON STÉROÏDIEN","",""
"14553","13-07-17","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NEURONTIN","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTIEPILEPTIC AGENT","AGENT ANTIÉPILEPTIQUE","",""
"14554","13-07-16","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"14555","13-07-17","COBALT PHARMACEUTICALS COMPANY","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATACAND","ASTRAZENECA CANADA INC","CANADA","CANADA","1","New indication","Nouvel indication","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUER DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE","",""
"14556","13-07-18","RANBAXY PHARMACEUTICALS CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AVAPRO","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","BLOQUER DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","",""
"14557","13-07-18","GLAXOSMITHKLINE INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","PROTEIN KINASE INHIBITOR","INHIBITEUR DE LA PROTÉINE-KINASE","",""
"14558","13-07-17","TEVA CANADA LIMITED","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHIN","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","Alternate manufacturing site, alternate manufacturing process","Autre lieu de fabrication, autre processus de fabrication","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14559","13-07-17","ACCORD HEALTHCARE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC","CANADA","CANADA","1","Additional drug product manufacturing site. Alternate drug substance manufacturing process","Lieu de fabrication additionel pour la produit thérapeutique. Autre processus de fabrication pour la substance thérapeutique","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14560","13-07-22","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","NIMBEX","ABBVIE CORPORATION","CANADA","CANADA","1","","","NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT","INHIBITEUR NEUROMUSCULAIRE SQUELETTIQUE NON DÉPOLARISANT","Administrative licensing agreement between two companies","Administratif accord de license entre deux sociétés"
"14561","13-07-22","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","INHIBACE","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","Administrative merger/buyout","Administratif fusion/rachat"
"14562","13-07-22","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN II AT1 RECEPTOR BLOCKER","ANTAGONISTE DES RÉCEPTEURS AT1 DE L'ANGIOTENSINE II","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14563","13-07-19","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","IMURAN","GLAXO WELLCOME INC","CANADA","CANADA","1","","","IMMUNOSUPPRESIVE AGENT","AGENT IMMUNOSUPPRESSEUR","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14564","13-07-19","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","LIPITOR","PFIZER CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14565","13-07-19","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BETA-ADRENERGIC RECEPTOR BLOCKING AGENT","INHIBITUR DES RÉCEPTEURS BÉTA-ADRÉNERGIQUES","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14566","13-07-19","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","CORDARONE","WYETH AYERST CANADA INC","CANADA","CANADA","1","","","ANTIARRHYTHMIC AGENT","ANTIARYTHMIQUE","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14567","13-07-19","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL HYPOGLYCEMIC","HYPOGLYCÉMIANT ORAL","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14568","13-07-22","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AXERT","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST. MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 - TRAITEMENT ANTIMIGRAINEUX","",""
"14569","13-07-22","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AXERT","MCNEIL CONSUMER HEALTHCARE","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST, MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1, TRAITEMENT ANTIMIGRAINEUX","",""
"14570","13-07-22","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","AXERT","MCNEIL CONSUMER HEALTHCARE CANADA","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST. MIGRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1 - TRAITEMENT ANTIMIGRAINEUX","",""
"14571","13-07-19","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","Revisions to the indiation for renal cell carcinoma to: Indicated for the first line treatment of patients with metastatic renal cell (clear cell) carcinoma (mRCC) and for patients who have received prior treatment with cytokines for metastatic disease","Modification de l'indication pour les carcinomes à cellules rénales: Indiqué pour le traitement de premiere omtemtopm des [atients atteints d'un carcinome à cellules rénales (cellules claires) métastatique et des patients ayant déjà reçu des cytokines pour lutter contre une maldie métastatique.","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14572","13-07-22","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","TENORETIC","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14573","13-07-24","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14574","13-07-24","JAMP PHARMA CORPORATION","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","PANTOLOC","NYCOMED CANADA INC","CANADA","CANADA","1","","","H+, K+-ATPASE INHIBITOR","INHIBITEUR DE L'H+, K+-ATPASE","ADMINISTRATIVE LICENSING AGREEMENT BETWEEN TWO COMPANIES","ADMINISTRTIF ACCORD DE LICENSE ENTRE DEUX SOCIÉTÉS"
"14575","13-07-23","MYLAN PHARMACEUTICALS ULC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANALGESIC AGENT","ANALGÉSIQUE","ADMINISTRATIVE LICENSING AGREEMENT BETWEEN TWO COMPANIES","ADMINISTRATIX ACORD DE LICENSE ENTRE DEUX SOCIÉTÉS"
"14576","13-07-24","INTERNATIONAL PHARMACEUTICAL GENERICS LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","APO-DOMPERIDONE","APOTEX INC","CANADA","CANADA","1","","","MODIFIER OF UPPER GASTROINTESTINAL MOTILITY","MODIFICATEUR DE LA MOTILITÉ DES VOIES DIGESTIVES SUPÉRIEURES","",""
"14577","13-07-23","STERIMAX INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PIPERACILLIN SODIUM/TAZOBACTAM SODIUM FOR INJECTION","SANDOZ CANADA INC","CANADA","CANADA","1","REVISIONS TO THE PRODUCT MONOGRAPH; CHANGE IN SPECIFICATIOS","RÉVISIONS À LA MONOGRAPHIE DE PRODUIT; CHANGMENT DANS LES SPÉCIFICATIONS","ANTIBIOTIC; BETA LACTAMASE INHIBITOR","ANTIBIOTIQUE; INHIBITEUR DE LA BETA LACTAMASE","",""
"14578","13-07-24","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ADRIAMYCIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14579","13-07-24","GENERIC MEDICAL PARTNERS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14580","13-07-23","JUBILANT LIFE SCIENCES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MAXALT","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","5-HT1 RECEPTOR AGONIST","AGONISTE DES RÉCEPTEURS 5-HT1","",""
"14581","13-07-24","MINT PHARMACEUTICALS INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SINGULAIR","MERCK FROSST CANADA LTD","CANADA","CANADA","1","","","LEUKOTRIENE RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS DES LEUCOTRIÈNES","",""
"14582","13-07-24","TEVA CANADA LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW MANUFACTURING FACILITY FOR THE DRUG SUBSTANCE","NOUVEL EMPLACEMENT DE FABRICATION POUR LA SUBSTANCE THÉRAPEUTIQUE","ANTIHYPERTENSIVE AGENT","ANTIHYPERTENSEUR","",""
"14583","13-07-23","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PHARMORUBICIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASTIQUE","",""
"14584","13-07-29","BIOGEN IDEC CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATE TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT","IMMUNOMODULATING AGNET","AGENT IMMUNOMOULATEUR","",""
"14585","13-07-26","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","FLUDARABINE PHOSPHATE INJECTION","NOVOPHARM LTD","CANADA","CANADA","1","","","ANTINEOPLASTIC","ANTINÉOPLASTIQUE","ADMINISTRATIVE LICENSING AGREEMENT BETWEEN TWO COMPANIES","ADMINISTRATIF ACCORD DE LICENSE ENTRE DEUX SOCIÉTÉS"
"14586","13-07-26","AGILA JAMP CANADA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","GEMZAR","ELI LILLY CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","AGENT ANTINÉOPLASTIQUE","ADMINISTRATIVE LICENSING AGREEMENT BETWEEN TWO COMPANIES","ADMINISTRATIF ACCORDE DE LICENSE ENTRE DEUX SOCIÉTÉES"
"14587","13-07-26","NATCO PHARMA (CANADA) INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","FOREST LABORATORIES","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","ADMINISTRATIVE LICENSING AGREEMENT BETWEEN TWO COMPANIES","ADMINISTRATIF ACCORD DE LICENSE ENTRE DEUX SOCIÉTÉS"
"14588","13-07-26","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Nonprescription Pharmaceutical","Disponible sans ordonnance","AERIUS","SCHERING CANADA INC","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","ADMINISTRATIVE LICENSING AGREEMENT NETWEEN TWO COMPANIES","ADMINISTRITF ACCORD DE LICENSE ENTRE DEUX SOCIÉTÉS"
"14589","13-07-26","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Nonprescription Pharmaceutical","Disponible sans ordonnance","REACTINE","PFIZER CANADA INC","CANADA","CANADA","1","","","HISTAMINE H1 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS H1 DE L'HISTAMINE","ADMINISTRATIVE LICENSING AGREEMENT BETWEEN TWO COMPANIES","ADMINISTRIF ACCORD DE LICENSE ENTRE DEUX SOCIÉTÉS"
"14590","13-07-26","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","COREG","GLAXOSMITHKLINE INC","CANADA","CANADA","1","","","CONGESTIVE HEART FAILURE AGENT","TRAITEMENT DE L'INSUFFISANCE CARDIAQUE CONGESTIVE","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRTIF FUSION/RACHAT"
"14591","13-07-26","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","CASODEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","NON-STEROIDAL ANTIANDROGEN","ANTIANDROGÈNE NON STÉROÏDIEN","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14592","13-07-26","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","ADMINISTRATIVE MANUFACTURER AND PRODUCT NAME CHANGE","ADMINISTRIF CHANGEMENT DU NOM DU FABRICANT ET DU PRODUIT"
"14593","13-07-26","GENMED A DIVISION OF PFIZER CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIFIBRINOLYTIC AGENT","AGENT ANTIFIBRINOLYTIQUE","ADMINISTRATIVE LICENSING AGREEMENT BETWEEN TWO COMPANIES","ADMINISTRATIF ACCORD DE LICENSE ENTRE DRUX SOCIÉTÉS"
"14594","13-07-26","SANIS HEALTH INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","ADMINISTRATIVE LICENSING AGREEMENT BETWEEN TWO COMPANIES","ADMINISTRATIF ACCORD DE LICENSE ENTRE DEUX SOCIÉTÉS"
"14595","13-07-25","SUNOVION PHARMACEUTICALS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISION TO THE INDICATION; MANAGEMENT OF THE MANIFESTATIONS OF SCHIZOPHRENIA","RÉVISION DE L'INDICATION PRISE EN CHARGE DES MANIFESTATIONS DE LA SCHIZOPHRÉNIE","ANTIPSYCHOTIC","ANTIPSYCHOTIQUE","",""
"14596","13-07-29","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBIOTIC","ANTIBIOTIQUE","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14597","13-07-29","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","VASULAR STABILIZER FOR THE TREATMENT OF MENOPAUSAL FLUSHING 0.0025 MG; ANTIHYPOPERTENSIV 0.1 MG AND 0.2 MG","STABILISATEUR VASCULAIRE POUR LE TRAITEMENT DES BOUFFÉES DE CHALEUR DE LA MÉNOPAUSE 0.025 MG; ANTYHYPERTENSEUR 0.1 MG ET 0.2 MG","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14598","13-07-29","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","FRISIUM","HOECHST-ROUSSEL CANADA INC","CANADA","CANADA","1","","","ANTICONVULSANT","ANTICONVULSIVANT","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14599","13-07-29","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","CELEXA","LUNDBECK CANADA INC","CANADA","CANADA","1","","","ANTIDEPRESSANT","ANTIDÉPRESSEUR","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14600","13-07-29","PHARMEL INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Nonprescription Pharmaceutical","Disponible sans ordonnance","ALEVE","BAYER INC, CONSUMER CARE DIVISION","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG, ANALGESIC, ANTIPYRETIC","ANTI-INFLAMMATOIRE NON STÉROÏDIEN, ANALGÉSIQUE, ANTIPYRÉTIQUE","ADMINISTRATIVE LICENSING AGREEMENT BETWEEN TWO COMPANIES","ADMINISTRATIF ACCORD DE LICENSE ENTRE DEUX SOCIÉTÉS"
"14601","13-07-25","ACCORD HEALTHCARE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ARIMIDEX","ASTRAZENECA CANADA INC","CANADA","CANADA","1","REVISIONS TO THE PRODUCT MONOGRAPH; ADDITIONAL CONTAINER CLOSURE SYSTEM","RÉVISIONS À LA MONOGRAPHIE DE PRODUIT; SYSTÈME DE FERMETURE ADDITIONNEL","NON-STEROIDAL AROMATASE INHIBITOR","INHIBITEUR DE L'AROMATASE NON STÉROÏDIEN","",""
"14602","13-07-25","VERTEX PHARMACEUTICALS (CANADA) INCORPORATED","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISES À JOUR DE LA MONOGRAPHIE DE PRODUIT","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"14603","13-07-29","ALMIRALL S.A.","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","New Active Substance (NAS)","Nouvelle substance active (NSA)","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","BRONCHODILATOR","BRONCHODILATEUR","",""
"14604","13-07-30","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANGIOTENSIN CONVERTING ENZYME INHIBITOR","INHIBITEUR DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14605","13-07-30","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SUSTIVA","BRISTOL-MYERS SQUIBB CANADA","CANADA","CANADA","1","","","ANTIRETROVIRAL","ANTIRÉTROVIRAL","",""
"14606","13-07-30","MYLAN PHARMACEUTICALS ULC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","SUSTIVA","BRISTOL-MYERS SQUIBB CANADA","CANADA","CANADA","1","","","ANTIRETROVIRAL AGENT","ANTIRÉTROVIRAL","",""
"14607","13-07-26","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ADDITION OF A DRUG ABUSE STUDIES SECTION TO THE PRODUCT MONOGRAPH UNDER ACTION AND CLINICAL PHARMACOLOGY","AJOUT D'UNE SECTION CONCERNANT DES ÉTUDES SUR L'ABUS DE DROGUES DANS LA PARTIE MODE D'ACTION ET PHARMACOLOGIE CLINIQUE","OPIOID ANALGESIC / APIOID ANTAGONIST","ANALGÉSIQU OPIOÏDES / ANTAGONISTE OPIOÏDE","",""
"14608","13-06-14","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISE À JOUR DE LA MONOGRAPHIE DE PRODUIT","ANTIVIRAL AGENT","AGENT ANTIVIRAL","",""
"14609","13-07-22","MERCK CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","To include in the 'clinical trials' section of the PM information related to previously reviewed clinical studies pertaining to both the seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) indications","inclure, dans la section essais cliniques de la monographie de produit, de l'information sur les études cliniques précédemment examinées au sujet des indications de la rhinite allergique saisonnière et de la rhinite allergique apériodique","CORTICOSTEROID","CORTICOSTÉROÏDE","",""
"14610","13-07-31","SANDOZ CANADA INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","SEROQUEL","ASTRAZENECA CANAD INC","CANADA","CANADA","1","","","ANTIPSYCHOTIC AGENT","AGENT ANTIPSYCHOTIQUE","ADMINIATRATIVE LICENSING AGREEMENT BETWEEN TWO COMPANIES","ADMINISTRATIF ACCORD DE LICENSE ENTRE DEUX SOCIÉTÉS"
"14611","13-07-30","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HISTAMINE H2 RECEPTOR ANTAGONIST","ANTAGONISTE DES RÉCEPTEURS HISTAMINIQUES H2","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14612","13-07-30","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","DIDROCAL","PROCTER & GAMBLE PHARMACEUTICALS CANADA INC","CANADA","CANADA","1","","","BONE METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME OSSEUX","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF USION RACHAT"
"14613","13-07-31","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIDEPRESSANT AND ANXIOLYTIC AGENT","ANTIDÉPRESSEUR ET ANXIOLYTIQUE","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14614","13-07-30","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","VOLTAREN RAPIDE","GEIGY PHARMACEUTICALS, CIBA GEIGY CANADA LTD","CANADA","CANADA","1","","","NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON-STÉROÏDIEN (AINS)","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14615","13-07-30","SANOFI AVENTIS CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","HEMATOPOIETIC AGENT","AGENT HÉMATOPOÏÉTIQUE","ADMINISTRATIVE TRANSFER OF DRUG IDENTIFICATION NUMBER","ADMINISTRATIF TRANSFERT D'IDENTIFICATION NUMERIQUE DE DROGUE"
"14616","13-07-30","PHARMACEUTICAL PARTNERS OF CANADA INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ROCEPHEN","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","NEW FORMAT","NOUVEL FORMAT","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14617","13-07-31","ACCEL PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","GLUCOPHAGE","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","ORAL ANTIHYPERGLYCEMIC AGENT","ANTIHYPERGLYCÉMIANT ORAL","ADMINISTRATIVE LICENSING AGREEMENT BETWEEN TWO COMPANIES","ADMINISTRATIF ACCORD DE LICENSE ENTRE DEUX SOCIÉTÉS"
"14618","13-07-31","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","CRESTOR","ASTRAZENECA CANADA INC","CANADA","CANADA","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14619","13-07-31","TEVA CANADA LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","PRAVACHOL","BRISTOL-MYERS SQUIBB COMAPNY","UNITED STATES OF AMERICA","ÉTATS-UNIS D' AMÉRIQUE","1","","","LIPID METABOLISM REGULATOR","RÉGULATEUR DU MÉTABOLISME DES LIPIDES","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14620","13-07-31","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","NONN-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)","ANTI-INFLAMMATOIRE NON STÉROÏDIEN (AINS)","ASMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14621","13-08-02","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CONVERSION OF THE PRODUCT MONOGRAPH TO NEW FORMAT","CONVERSION DE LA MONOGRAPHIE DE PRODUIT À NOUVEAU FORMAT","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"14622","13-08-02","BAYER INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","CONVERSION OF THE PRODUCT MONOGRAPH TO NEW FORMAT","CONVERSION DE LA MONOGRAPHIE DE PRODUIT À NOUVEAU FORMAT","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"14623","13-08-01","BRISTOL MYERS SQUIBB CANADA","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIHYPERGLYCEMIC AGENT","AGENT ANTIHYPERGLYCÉMIANT","",""
"14624","13-08-07","ELANCO DIVISION ELI LILLY CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Veterinary","Vétérinaire","","","","","1","EXTENSION TO DOGS TO THE 90MG","EXTENSION DE CHIENS POUR LE 90MG","ANTIPARASITIC","ANTIPARASITIQUE","",""
"14625","13-08-06","MYLAN PHARMACEUTICALS ULC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ZOMIG RAPIMELT","ASTRAZENECA CANADA INC","CANADA","CANADA","1","NEW PRESENTATION","NOUVELLE PRÉSENTATION","5-HT1 RECEPTOR AGONIST; MIDRAINE THERAPY","AGONISTE DES RÉCEPTEURS 5-HT1; ANTIMIGRAINEUX","",""
"14626","13-08-07","GILEAD SCIENCES CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","UPDATES TO THE PRODUCT MONOGRAPH","MISE Â JOUR DE LA MONOGRAPHIE DE PRODUIT","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"14627","13-08-07","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MARVELON","ORGANON CANADA LTD","CANADA","CANADA","1","","","ORAL CONTRACEPTIVE","CONTRACEPTIF ORAL","",""
"14628","13-08-02","BRISTOL MYERS SQUIBB CANADA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW INDICATION: FOR USE IN COMBINATION WITH A SULFONYLUREA (IE. TRIPLE COMBINATION THERAPY) AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MILLITUS WHO ARE ALREADY TREATED WITH SAXAGLIPTIN, METFORMIN AND A SULFONYLUREA OR WHO ARE INADEQUATELY CONTROLLED ON METFORIN AND A SULFONYLUREA ALONE","NOUVELLE INDICATION: POUR UNE UTILISATION EN ASSOCIATION AVEC UNE SULFONYLURÉE (TRITHÉRAPIE) EN COMPLÉMENT DU RÉGIME ALIMENTAIRE ET DE L'EXERCISE PHYSIQUE DANS LE BUT D'AMÉLIORER LE CONTRÔLE GLYCÉMIQUE CHEZ LES ADULTES ATTEINTS D'UN DIABÈTE SUCRÉ (DE TYPE 2) QUI SUIVENT DÉJÀ UN TRAITEMENT PAR SAXAGLIPTINE, METFORMINE ET UNE SULFONYLURÉE, OU POUR QUI LE TRAITEMENT PARA METFORMINE ET UNE SULFONYLURÉE SEULEMENT OFFRE UN CONTRÔLE INSUFFISANT","ORAL ANTIHYPERGLYCEMIC AGENT, DDP-4 INHIBITOR, INCRETIN ENHANCER","Agent Antihyperglycémiant; Inhibiteur de DPP-4; Enhanceur de l'incretin","",""
"14629","13-08-09","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","CO-ADMINISTRATION OF ENGERIX-B WITH CERAVIX","ADMINISTRATION CONCOMITANTE D'ENGERIX-B AVEC CERAVIS","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"14630","13-08-09","SANOFI AVENTIS CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","NEW MANUFACTURING FACILITY","NOUVEL IMPLACEMENT DE FABRICATION","ANTICOAGULANT AND ANTITHROMBOTIC AGENT","ANTICOAGULANT ET ANTITHROMBOTIQUE","",""
"14631","13-08-08","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIVIRAL AGENT","AGENT ANTIVIRAL","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRATIF FUSION/RACHAT"
"14632","13-08-08","TEVA CANADA LIMITED","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Administrative","Administrative","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIEPILEPTIC AGENT","ANTIÉPILEPTIQUE","ADMINISTRATIVE MERGER/BUYOUT","ADMINISTRIF FUSION/RACHAT"
"14633","13-08-08","PURDUE PHARMA","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","REVISIONS TO THE PRODUCT MONOGRAPH - ACTION AND CLINICAL PHARMACOLOGY","RÉVISIONS À LA MONOGRAPHIE DE PRODUIT - MODE D'ACTION ET PHARMACOLOGIE CLINIQUE","OPIOID ANALGESIC","ANALGÉSIQUE OPIOÏDES","",""
"14634","13-08-08","OMEGA LABORATORIES LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","INTEGRILIN","MERCK CANADA INC","CANADA","CANADA","1","","","PLATELET AGGREGATION INHIBITOR","ANTIAGRÉGANT PLAQUETTAIRE","",""
"14635","13-08-08","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","PENLAC","SANOFI-AVENTIS CANADA INC","CANADA","CANADA","1","","","TOPICAL ANTIFUNGAL AGENT","AGENT ANTIFONGIQUE TOPIQUE","",""
"14636","13-08-08","ONCO THERAPIES LIMITED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","IDAMYCIN PFS","PFIZER CANADA INC","CANADA","CANADA","1","","","ANTINEOPLASTIC AGENT","ANTINÉOPLASTIQUE","",""
"14637","13-08-12","ACCORD HEALTHCARE INC","N","Supplement to an Abbreviated New Drug Submission (SANDS)","Supplément à une présentation abrégée de drogue nouvelle (SPADN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","CELLCEPT","HOFFMANN-LA ROCHE LTD","CANADA","CANADA","1","ADDITION OF A CONTAINER CLOSURE SYSTEM","ADDDITION D'UN SYSTÈME DE FERMATURE","IMMUNOSUPPRESSIVE AGENT","IMMUNOSUPPRESSEUR","",""
"14638","13-08-12","STERIMAX INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","NITOMAN","VALEANT CANADA LP / VALEANT CANADA S.E.C.","CANADA","CANADA","1","","","MONOAMINE DEPLETING AGENT","AGENT DE DÉPLÉTION DE MONOAMINES","",""
"14639","13-08-06","GILEAD SCIENCES CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","ALTERNATE DRUG PRODUCT MANUFACTURING SITE","AUTRE LIEU DE FABRICATION POUR LE PRODUIT DE DROGUE","ANTIBIOTIC","ANTIBIOTIQUE","",""
"14640","13-08-13","AURO PHARMA INC","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","3TC","VIIV HEALTHCARE SHIRE CANADA","CANADA","CANADA","1","","","ANTIRETROVIRAL AGENT","AGENT ANTIRÉTROVIRAL","",""
"14641","13-08-13","ALCON CANADA INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Biologic","Biologique","","","","","1","","","OPHTHALOMOLOGICAL","OPHTHALMOLOGIQUES","",""
"14642","13-08-13","SALIX PHARMACEUTICALS INC","N","New Drug Submission (NDS)","Présentation de drogue nouvelle (PDN)","N","Priority-NAS","Priorité-NSA","Prescription Pharmaceutical","Disponible avec ordonnance","","","","","1","","","ANTIBACTERIAL AGENT","ANTIBACTÉRIEN","",""
"14643","13-08-08","FAMY CARE LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Nonprescription Pharmaceutical","Disponible sans ordonnance","PLAN B","DURAMED PHARMACEUTICALS INC","CANADA","CANADA","1","","","EMERGENCY CONTRACEPTION","CONTRACEPTIF D'URGENCE","",""
"14644","13-08-12","FAMY CARE LTD","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","MICRONOR","JANSSEN-ORTHO INC","CANADA","CANADA","1","","","ORAL CONTRACEPTIVE","CANTRACEPTIF ORAL","",""
"14645","13-08-14","CSL BEHRING CANADA INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW PRESENTATION; CHANGES TO THE MANUFACTURING PROCESS","NOUVELLE PRESENTATION; MODIFICATIONS DE LA MÉTHODE DE FABRICATION","BLOOD COAGULATION FACTORS II, VII, IX, AND X COMBINATION","COMBINATION DES FACTEURS II, VII, IX ET X DE LA COAGULATION","",""
"14646","13-08-14","GLAXOSMITHKLINE INC","N","Supplement to a New Drug Submission (SNDS)","Supplément à une présentation de drogue nouvelle (SPDN)","Y","Other","Autre","Biologic","Biologique","","","","","1","NEW FORMULATION","NOUVELLE FORMULATION","ACTIVE IMMUNIZING AGENT","AGENT D'IMMUNISATION ACTIF","",""
"14647","13-08-14","APOTEX INCORPORATED","N","Abbreviated New Drug Submission (ANDS)","Présentation abrégée de drogue nouvelle (PADN)","N","Other","Autre","Prescription Pharmaceutical","Disponible avec ordonnance","ATIVAN","WYETH CANADA","CANADA","CANADA","1","","","ANXIOLYTIC - SEDATIVE","ANXIOLYTIQUE - SÉDATIF","",""
"14648","13-08-16","HOFFMANN LA ROCHE LIMITED","N","Supplement to a New Drug Submission (SNDS)","Supplément à u